<SEC-DOCUMENT>0001558370-24-003738.txt : 20240322
<SEC-HEADER>0001558370-24-003738.hdr.sgml : 20240322
<ACCEPTANCE-DATETIME>20240322073349
ACCESSION NUMBER:		0001558370-24-003738
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		118
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240322
DATE AS OF CHANGE:		20240322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HOOKIPA Pharma Inc.
		CENTRAL INDEX KEY:			0001760542
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				815395687
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38869
		FILM NUMBER:		24773098

	BUSINESS ADDRESS:	
		STREET 1:		430 EAST 29TH STREET
		STREET 2:		14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		0114318906360

	MAIL ADDRESS:	
		STREET 1:		430 EAST 29TH STREET
		STREET 2:		14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>hook-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.5.0.8 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/22/2024 10:36:29 AM -->
<!-- iXBRL Library version: 1.0.8703.18788 -->
<!-- iXBRL Service Job ID: ed7a1f34-d178-4b7b-a713-c9fe2a6547f9 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:hook="http://www.hookipapharma.com/20231231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" xs:nil="true" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_T7Md-c8SK0aUrChrCIRLXw"/><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" xs:nil="true" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_iMb9OcFSKUijcU0WDSX4sw"/><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_P9wzsTrqDEqqB-FUp3dy7w">http://www.hookipapharma.com/20231231#CollaborationAndLicensingMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_GQ5TUkl_kUi7iAqvXtlLgQ">http://www.hookipapharma.com/20231231#CollaborationAndLicensingMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_xaQq4UotwEeS_tUhTmB-jQ">2399517</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_NoZMJdxkzkmTujJyjYptbQ">2399517</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:DocumentFiscalPeriodFocus" id="Tc_CKcMMs4Hy0qFoZwt02j2QQ_3_1">FY</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_htHehux1wEi6rYPm9TyLvA">52317138</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_H8dP_q76KUqlgTeQjbo2gA">96550590</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_Gv7XN7EYJUGrVUI8-0DE1w">http://www.hookipapharma.com/20231231#CollaborationAndLicensingMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" name="hook:FairValueAssetsLevel1ToLevel2TransfersAmount1" id="Hidden_Lpjoo-HNUkK1Q7dne6IAVQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" name="hook:FairValueAssetsLevel2ToLevel1TransfersAmount1" id="Hidden_9wPB5a7NckWc0o_lT7sjxw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Hidden_L0ges7xDOUOYjlazpNEvlw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_EUaK3Tg6FEeEOqOHWmJvgA">96550590</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_K3IEYYVgEkOcLQ_fmEnbgg">2399517</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_wHXhiF9z3UaARnOvYs1xow">370</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_fN05Sy8hG0-TjqIRvTiFCg">10800</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_HE01NwGMaUaBkBAhb5ZKIA">15268</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" id="Hidden_Eut-pnlYxkmGfE27-Y1kbg">1000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" id="Hidden_x3Vvh87iFkeGHTZK_-BIJg">1000</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityCentralIndexKey" id="Narr_9blnaQpz6U-5VAFAajUEpg">0001760542</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:AmendmentFlag" id="Narr_SRTD79RQL0GOg73FbDkU0g">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="hook-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_l4B2TGYOiE-DNTqDxlQcPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_WqKtPPVwDUSMTGed8PBTnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_1EokcRnMHkWHJTLR_xT8tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_vxWMxth910WYNpMnH4Je_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_K5J3_Ady2kSe1fEoyF_eEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_UtzcBbT1wkeghno1rw2kMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_7YwYjyiTDkSMl_b_qdxauw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_2Z7XTTCdlUG1MXSD_C6hBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_Rai6liu0xUW1EmNBgzCqLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_7xv9iHlOIkCLF2rL0Aa76g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_XsAClSmPLkGgxcjtrxYK8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_b7J_k05VpUCTEauHSsAOvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_cvCbnPylgUKTRN7F1GF4qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_eDyYJl1mAEWF4gZrS_YyCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_qYw6vTRVN0ubcxuWYyT9fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kQUzEzJS40CQZoM-Toa5sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOSFNmfs3EOqv4WZIP0Bvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_uFqE4irDUEqudmnogjdsfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4T_o5zMCE0ug338F1VQDdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_2yyWaG6qFEu8WStCSjJPqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7iTqTo5Mc0yU0G14JpKP1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_klU7bfgmHkO3j4OIlzDcCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_QKv2gv1YAkqr34O2n2MLMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cwRIsmcBbUqKd9OfVFboQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_5_2023_To_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_KDCyo9xrfUm2SNyHUjgpxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-05</xbrli:startDate><xbrli:endDate>2023-06-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_5_2023_To_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_trpEIIU-tU-_tJvtabhPzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-05</xbrli:startDate><xbrli:endDate>2023-06-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_SUI_rRcgM0yn74er9fveIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_f2cWQ1nLsU6e2ugzoaWBEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_BAyUBYYE_0qxHktu111vWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2022_To_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_5F71-AsX2EC4M3MSefmV1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-04</xbrli:startDate><xbrli:endDate>2022-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2022_To_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_sAJY_NDjZEehCI5DuVqezg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-04</xbrli:startDate><xbrli:endDate>2022-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_2mnDHSaTCU-2dD6XGhTvLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_nXIctgCoNU-Gzk42kRTkKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_Lt7jkjnIqEmsokc68MGWDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_VZQQp8bdV0acmmpRV4RXpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CQ02v_YunkKcjWHZFY_DeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_ySK9Z-Ny_k23tpFuUhWeZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbReoX6pl0ebta1Mqf9EfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_4h3ktrQRFk21oF_BuLPDMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_PCu4S2Tjlkac9CaMTmb6UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kkhUGeXDzk62-3EYlJzDVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eADOfy2zHkGdzANuuDMnKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hawa35VgPkm-hhsVFZrIwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy8iNx1CQU-KWT7AIRWsZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qsCzYAIcaEOszR8epDIoZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_p9D5TacsTUuux2uOCCEN0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ht1Iko3ekkKK4bUJJCj6Vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_50aQNcU1rESa1A_NH0ITtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HPm7mnaUk0OFlLY3NbuqlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LfPs5RT700ypYFvEtpSSxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GguYoNHqi02T3cZxSRd0nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lkdWE0tsUkWi1RgazRbc0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CmfM8R1qc0ia9PJJbDvGQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TB8nJkfO206JH4IgeDIJYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eavcYujje0qBEWD0ZLFF4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_cp2qFIiDmE2EuFHtMEm6eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3sxrr_m_10WVU9FJBClJ1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BRiLG2VnwEyMWEgoQSDszQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_tQFbE_DcHkOkMLytg817wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XzMTTAsN-kat0RQ4mLVSsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GpwDSGNgm06tza9uL7YsfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_7Ko22T84I06Il1nncKM6WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_wdQcSZ0gGUG6oC7D9nz3PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_kh4lFA0HYkm_8ou4RKPQ4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kANAvXPJ_0a7gsAvkRIetA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_9_7EqTslY0yqSx5HU_L_qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_9xIbJy1mtE6TWI_wKOUrpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_G59PYeJ12ECeSIQHOayjyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_Xcsey5dkJECXYtbLisOkXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_ZM4WJ3Ojn0quhH4Pn5CYdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_EcSzpwdfREKHNIcL7hVs2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BcR8oItz_UOIQXNtcPyaQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4xGiuYB470aHSLaFha05pA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_XHb2VxbEKkeLgdecA0RSzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_ob0J9wZKyk2iJVWb7ieH0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_y96X3sy35kK-JiMbzDVPjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Cjpb3hF7IEea2TyyB2JGNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_AFyGmgyE8kiyCNQqfpXApA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_vsxwLcmVd0qxvZfveKo1qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_6eU7lu-gYkGX1lF7SujF0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_xnILDkMs_kCjhQ1U1ADU1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_H0tCjW2DHECbxO5klnyB9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aKhFceKN_063s8FrQsNE-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_XF87Kq4bd0-7XFTH2TZbAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_ioKeOQv4MEC7RRwFd806mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_Rc5jKwDFOEqAwiZthnKExQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_XWdzK47-T06jRMxyOKZ3Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_jrD8j5sy7UakHnOm30LdFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">hook:January2024RestructuringPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-29</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_hook_MaltePetersMember_us-gaap_RelatedPartyTransactionAxis_hook_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_PWdmVxfZlkStxnW1wmGGow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hook:MaltePetersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">hook:ConsultingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_X3TmsbLhFku7xpVyRcYkrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Kkn9Mty5DUurhtItxm046g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Y740NWFhXUaA_KiLwpYS-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_oSbIwYv_yE-SfbOG9eEVMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_W1jTBgF7KU6w3PAGk_NZLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_fTi5jMBdM0qbHxQohSMwDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_H9q5fvXIvUyymHn9HgMWCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_d9nAVl9o7USSeTumRsaPVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_n75mKrZ5ykylerI6_Na9ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_DTmiN0Wjdk2iaqY9dIsckQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_eO8goNhRB0-aM5lXAIyMyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_v9vy-6pd6UqP7xZfF6NTog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_2LsuutyUQE6wY7QxmZAn0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_V0f2IgZ-pke_ekfxUL0PFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_OVW8CCm-m0i5lry7fXD5tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Dv-_4sRg6EC65tReOfjV-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_pt9hTzP2p0aDdaGKrVFYZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Pkdmu3XpuUGFFIIVvDmOsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_5_2023_To_6_5_2023_HDaSSSxSpUCGD9FJbOAwcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-05</xbrli:startDate><xbrli:endDate>2023-06-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2022_To_3_4_2022_NTQl-cLtAk6xlttcf3yn2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-04</xbrli:startDate><xbrli:endDate>2022-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_15_2022_To_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_Agf-g2EmxkChN7RAIyPgCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-15</xbrli:startDate><xbrli:endDate>2022-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HHVctDOtV0C6dlcgQy1LxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_unSFbxjx2kSBUd8Oh40Kbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pSYi6VRiEEWiQxkyw445Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_C_IAmN5vm0OXRMTCb5TGJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_AT_yaoK_p7Sukuiq2w5N3spOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6rCpmJmAUk-pthMRELXHZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_AT_3mwjH__tMUma_hkm6Ve5jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_poFM7cMgMUmMG8tthzI0dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AT_nqOGXBicVESvalgSTFcbwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MrV6NCzS0UKVJ_8-CMc7bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qZP9Or45rU2FWGne3bmD7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Yto5HIXmyEG1TJnAO6oOwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_15_2022_srt_OwnershipAxis_hook_GileadSciencesIncMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_IJ87WrWO-k-9t1hFfOiVgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">hook:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_rYOLLftQ0E631s3QNeZC5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">hook:LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeaseForCorporateHeadquartersInNewYorkCityMember_O5rj1qjLx02TAFtZTvjJiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">hook:LeaseForCorporateHeadquartersInNewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeaseForCertainParkingSpacesInViennaOfficeMember_BUA7zVRMSEmA3Ot_9-TINQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">hook:LeaseForCertainParkingSpacesInViennaOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_pNxGgv4tck6OcN9EE9uBvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_xsd7nsH6k0yzM-JYdiLW2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_StatementGeographicalAxis_country_AT_kfxilsmFSkCesBThL4nisw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_AT_hpenzR01Xkuk5j5fUTX0jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AT_c4d1mu2O80qu0WCXkZuWww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AT_3NogJxMRLUKuio1gDYqLrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_f2bozshHvEqDnHPJIfLxkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_5OZpzWR5ZE-g65N3W9mQlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_-Sb_oTNrbE67HtDm8P8UiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_pc7cQA2m-kOSmJHzPEfppQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_qhAXDY6gbUi75WUSONZh_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_igpyXqNHCkeaCiqmtmt_nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACQheD3jekytMJkUUeE47g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_iL34pNGK3UGEaXA4MINluA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_Oo1iK1CDRkCwVRfUUVTjbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_RangeAxis_srt_MaximumMember_G5knO1JxEUipkKfqXVba6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_RangeAxis_srt_MaximumMember_hy3OpU7SA0uUGHTffJQ5fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_InducementAwardsPlanMember_bUvp9git4U6vhtxSXzOaEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:InducementAwardsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_PSUqRWmVfkCw7OQN6sRoGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1LRqYYOuTkW9E0CdbjORBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vp7OjZUKs0qrjBy07u3Rwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kU5iAAu8lUOCuAzHNGZFtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_t6cFMObpAkuRcFhZNL6fUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_q3DFOTCJoUOMsPJyaBQ3Fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AuBlzmENrUa8NdUXnGeaBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sjQ1_m16gUyGeWyA8dpSbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_f7Evnw8lLU6TvXq4xZaF1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_4GN9LMP8E0i2s2spo0zrXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Eytulubnr0ySr_VAROpxiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nivr3y_350aPACUslx3dMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b8VlOcR0O0OmF5emQANTkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3z_KZuEbyUyufSDi6RFYKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e9XlwwWzZUyxUx3pingkdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mzTecP16KUqdKJ51DcbR8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ShuqB9wIDkS3F21xuhUuPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OgNb7067TEG0mtw4IpZ_2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_NoPDm3BqIEaimDdH7xzzAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_qjK-CNSWD0-cN7Yfpf-UAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_lBtbfJCmPUmNKH1HpAUlxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_OohY4lRPq0yPekG2Wk5KZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_37LOdjtI8EWZBGW9I5pzGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_VChA_ldFhkWxOYuQUqtGHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_eFFXVBkbrEeySJMxE-8wLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HivProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HbvProgramMember_3dT06FX4VkCwkIjTV8mikA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HbvProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_eTvVFL_Gb0ihVkFmAe5Ybg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HivProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HbvProgramMember_u76tVQD6oU2TjpnsvGjXJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HbvProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_shcM24-UD0G_87KWD0abFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_12_2023_To_9_12_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_Xd8PFrmLWECYLMz00H-fVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-12</xbrli:startDate><xbrli:endDate>2023-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zch3U472NU6ienNHLQ1xSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_pT4ROzEyWkS4z3OWuisutw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9_5E61jCp0qkRK8pXIBRXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iIx2YHcEt0CG7Jld-YUTtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ZtdYdiFLwEqrZPGSD1c3dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pi9ns7LHMEqJa6iUqFqKqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_7_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember__FwCStMaU0OyzpKGLfbvNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_7_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_I0qOWFNRG0m7UhyFU_5e3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_m8WtQLcukk2yFLSY4g5v3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_IuERzRWMYUO5kK8uAkmuTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_20_2023_To_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_H8YdukywEUa5F4R0wQD4ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-20</xbrli:startDate><xbrli:endDate>2023-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_15_2022_To_2_15_2022_z3PV6PoxAUyoMugmqtg5lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-15</xbrli:startDate><xbrli:endDate>2022-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_0rn22fHyykOFZjGSZjx9-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_DNqYfPgFh0Ck9fuBQnQtWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_AustrianResearchIncentiveProgramMember_Ocbk301LuEKBJ-hS6sdG-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:AustrianResearchIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_r-zd0dtsfkWw5mLU7UMv4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember__7jEylpDhk2E7HBL-QMsuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_4t0j2RLtRUim5ad7YUNdww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_oBjN55Dh4kWdP45kjmc_cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-07</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_t2LLWZ24bUKTQiMbE7AcJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_iLfkqbjLEkO8cY690Z1M_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_LCk-o0XEz0Coe9Nfe-mo4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_AustrianResearchIncentiveProgramMember_b5PBJbDWP0aRQ3y6jpvjFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:AustrianResearchIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_7_2023_To_8_7_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_br4Ybr-YDUajiQqo-HL-lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-07</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_7_2023_To_8_7_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_3at3uPhCo0ShjqrpfD4Klg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-07</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_UsydwOHzwEWlwarT8cPtyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_1Wpbg1kMJkWMHx62rdrnHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4qOs21ojTUO-rUJpz1kUcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6fTsmB6TxUSozaWhvhJ6_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_DRzR59S0e0i1yiiJ_sbKPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HivProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_zfz8LxQPIku68ssP9_JeQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_X56qauEA7k-9t9AFLtndIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_WGiMi9INf02gQAVOw20hGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sSCjg8UmtUy-0Ck5qV73Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_c0SKflh3TEWHuSa8ZwnJiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k1H7ZYJMsU-107bPr2ox5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cXPFzUalKEKzwidBaBnRKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_qRcTFAJpgUSnNR1W3QhRvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_15_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_eliDdZ6mik-1LCK1kA6MqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_15_2024_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_0yA3j7PesESeO_PoZqEkpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760542</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Program_OVVzQkKn40SXnlnbXe7UtA"><xbrli:measure>hook:Program</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg"><xbrli:measure>hook:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_GQrC70uM-UyPQD7KgwAVng"><xbrli:measure>hook:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA"><xbrli:measure>hook:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_JIvkuNcm3UeH8NvB6ulLsQ"><xbrli:measure>hook:employee</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c238b3da_04fa_4d20_a5ae_e3e91dc77b4d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:DocumentType" id="Narr_kghkEG-k8Emlw3X7Z5XJRw"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:DocumentAnnualReport" id="Narr_AwZnrK7N2Em3ia00mQ0CTQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:normal;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;font-weight:normal;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:DocumentPeriodEndDate" id="Narr_lhZ-LaUadUKICoYzxMLpbQ"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:CurrentFiscalYearEndDate" id="Narr_ScvIZVjUUkCNNXzHOSUKtA"><b style="font-size:8pt;font-weight:bold;">December&#160;31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">,&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:DocumentFiscalYearFocus" id="Narr_T2HX96T6eUWZlHyX3bM4kA"><b style="font-size:8pt;font-weight:bold;">2023</b></ix:nonNumeric></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:DocumentTransitionReport" id="Narr_42ZnrQeKuEKCD46TviIK3g"><span style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:normal;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:9pt;font-weight:normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityFileNumber" id="Narr_WZH4S0wzpk-DSwoQ9ycsjw"><b style="font-size:8pt;font-weight:bold;">001-38869</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityRegistrantName" id="Narr_2sfQ4DTZ20uYsx3qbkE64A"><b style="font-weight:bold;">HOOKIPA PHARMA&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_bf00e41e_95ca_4e7e_b718_b937c7f2934c"></a><a id="Tc_0XHhmAmj1EWQsw7NSvBdmA_2_0"></a><a id="Tc_LIVAWVza5UmB-433XYUESw_2_1"></a><a id="Tc_SxFaGnhHy0qTQXt9S5MfnA_4_0"></a><a id="Tc_prFkO8wfrE6FWShXYD6LaA_5_0"></a><a id="Tc_vxEQg6PWE06EA0-E1LE99A_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:2.35pt;padding-right:2.35pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityIncorporationStateCountryCode" id="Tc_CO6JS18iMkuVbjoh5J4i_Q_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityTaxIdentificationNumber" id="Tc_CvVm7IKO-UGE1pb1hRStrQ_1_1"><b style="font-size:8pt;font-weight:bold;">81-5395687</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(State of Other Jurisdiction of incorporation or Organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityAddressAddressLine1" id="Narr_QFeNvQuMNUaAx0l2cJXOFw"><b style="font-size:8pt;font-weight:bold;">350 Fifth Avenue, 72nd Floor, Suite&#160;7240</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"><br/></b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityAddressCityOrTown" id="Narr_KJduekKwCk-s7xe8kpDNEQ"><b style="font-size:8pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityAddressStateOrProvince" id="Narr_PfKTXVJgiEq12L1FZg0ylA"><b style="font-size:8pt;font-weight:bold;">New York</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityAddressPostalZipCode" id="Tc_ro8ATnvK1ketO2Ts-objfA_4_1"><b style="font-size:8pt;font-weight:bold;">10118</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 2.34pt 0pt 2.34pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant's telephone number, including area code: </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:CountryRegion" id="Narr_ExuuUyTJ6UaJZbPU3tB7cA"><b style="font-size:8pt;font-weight:bold;">+43</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:CityAreaCode" id="Narr_gVaTcuSHBkSlq6PgsrT9Gw"><b style="font-size:8pt;font-weight:bold;">1</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:LocalPhoneNumber" id="Narr_BLtql_mUwEmgxIXN95Lr6Q"><b style="font-size:8pt;font-weight:bold;">890 63 60</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_ac58c657_2a31_444a_a1f6_763af3bcc52a"></a><a id="Tc_r6TLRDZ5ekuEYwEtClfeMA_1_2"></a><a id="Tc__wRFCi-fwEGWcU9ObYkeiA_2_0"></a><a id="Tc_EAU5DxtXUEqgt3oXavkgyw_2_1"></a><a id="Tc_eMZT7JJnzkKMp3GVDZniaQ_2_2"></a><a id="Tc_1xqHdXF6d06_dHY1p2xNMQ_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name Of Each Exchange</b></p></td></tr><tr><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of Each Class</b></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">On Which Registered</b></p></td></tr><tr><td style="vertical-align:top;width:39.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:Security12bTitle" id="Tc_Z4tV6j8FYUSDMVrWiuqfTw_3_0"><b style="font-size:8pt;font-weight:bold;">Common Stock, $0.0001 Par Value per Share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:30.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:TradingSymbol" id="Tc__85SdwO-2UaOw_TGbAW1JA_3_1"><b style="font-size:8pt;font-weight:bold;">HOOK</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:30.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">The </b><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:SecurityExchangeName" id="Narr_c5A-M0f_MUCOaW-dmjNCXw"><b style="font-size:8pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> Capital Market</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Securities registered pursuant to Section 12(g) of the Act:  None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_qBrlFqYwP0aLTtlRnKg7Dg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityVoluntaryFilers" id="Narr__lZ20y7MFEuNZc0PJxK71Q"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityCurrentReportingStatus" id="Narr_B5r5LTNS80yQ82n3sO_JHg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the Registrant has submitted electronically; every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.0405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityInteractiveDataCurrent" id="Narr_zwhSP7aHZkij4aRm8pi-jA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Large accelerated filer&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Accelerated filer&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityFilerCategory" id="Narr_yzPnYmEVtUWuLXfs1jBpfQ"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;&#160;</span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntitySmallBusiness" id="Narr_xTc_bzZQ5ku932xlcpo6hA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:21.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:28.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;&#160;</span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityEmergingGrowthCompany" id="Narr_n8s6aJSMk0ekWwAQER3XZg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityExTransitionPeriod" id="Narr_i9MJYi-6-EeB9M3t72clpQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:IcfrAuditorAttestationFlag" id="Narr_hXhi1N54lkOW2K5PugG78A"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_a962A2hJsk6zT8hoqBoq8w"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:EntityShellCompany" id="Narr_36JB9oYcmEizlIVvtAW-ig"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:14.4pt;margin:0pt;">Based on the closing price as reported on the Nasdaq Global Select Market, the aggregate market value of the Registrant's Common Stock held by non-affiliates on June&#160;30,&#160;2023 (the last business day of the Registrant's most recently completed second fiscal quarter) was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2023_qRcTFAJpgUSnNR1W3QhRvw" decimals="-5" name="dei:EntityPublicFloat" id="Narr_hyly7TQHv0Goa_DIQ5YxHA">71.7</ix:nonFraction>&#160;million. Shares of Common Stock held by each executive officer and director and by each shareholder affiliated with a director or an executive officer have been excluded from this calculation because such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. The number of outstanding shares of the Registrant's Common Stock as of March&#160;15,&#160;2024 was <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_15_2024_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_0yA3j7PesESeO_PoZqEkpg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_58U-0IRNqUeCr3JWDEmfhg">96,550,590</ix:nonFraction>&#160;shares and <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_15_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_eliDdZ6mik-1LCK1kA6MqQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_zlv8sxr4AU2TlEB7knEqdg">2,399,517</ix:nonFraction>&#160;shares of Class&#160;A common stock outstanding, each $0.0001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;text-align:center;margin:0pt;">Documents Incorporated by Reference</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If the Registrant&#8217;s Definitive Proxy Statement relating to the 2024 Annual General Meeting of Shareholders (the &#8220;Proxy Statement&#8221;) is filed with the Commission within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, then portions of the Proxy Statement will be incorporated by reference into Part III of this Annual Report on Form 10-K. If the Proxy Statement is not filed within such 120-day period, then the Registrant will file an amendment to this Annual Report within such 120-day period that will contain the information required to be included or incorporated by reference into Part III of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_44ac81d8_54ea_4d39_b355_5886c0a9fdc9"></a><a id="Tc_lOhAXzbRZ0yqGlUVhZNa9A_1_0"></a><a id="Tc_Dk8yjTwAy0a2WgxmWjjhZw_1_2"></a><a id="Tc_VbW_QxaeM0SheEbs7Pqqew_1_3"></a><a id="Tc_a90BVrLYH0ye81vb0xO5aw_1_4"></a><a id="Tc_NHCF2PQXX0iG5EcUtHC9Zw_1_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:92.05%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.88%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.16%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.35%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.69%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2.65pt 0pt 1.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.95%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:19.88%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:2.65pt 0pt 1.5pt 0pt;">Auditor Firm Id: </p></div></div></td><td style="vertical-align:bottom;width:7.16%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2.65pt 0pt 1.5pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:AuditorFirmId" id="Tc_d7PT_zuNW0Cp5tyMk0vgwg_1_1"><span style="font-size:8pt;">1259</span></ix:nonNumeric></p></div></div></td><td style="vertical-align:bottom;width:15.35%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:2.65pt 0pt 1.5pt 0pt;">Auditor Name:</p></div></div></td><td style="vertical-align:bottom;width:24.69%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:2.65pt 0pt 1.5pt 0pt;">PwC Wirtschaftspr&#252;fung GmbH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2.65pt 0pt 1.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.95%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:2.65pt 0pt 1.5pt 0pt;">Auditor Location:</p></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt 2.65pt 0pt 2.65pt;"><div style="height:12pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:2.65pt 0pt 1.5pt 0pt;">Vienna, Austria</p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4663c843_f354_4598_bc13_76979b7a6077"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Table of Contents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">PART I</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Business_108848"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Business_108848"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">6</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#RiskFactors_480000"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#RiskFactors_480000"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">62</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#UnresolvedStaffComments_377193"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#UnresolvedStaffComments_377193"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">119</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item1CCybersecurity_867122"><span style="font-style:normal;font-weight:normal;">Item 1C.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item1CCybersecurity_867122"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">119</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Properties_188239"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Properties_188239"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">121</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt;">PART II</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#LegalProceedings_351583"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#LegalProceedings_351583"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">121</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><a href="#MineSafetyDisclosures_997431"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#MineSafetyDisclosures_997431"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">121</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#MarketforRegistrantsCommon_947933"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#MarketforRegistrantsCommon_947933"><span style="font-style:normal;font-weight:normal;">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">121</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SelectedFinancialData_379980"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SelectedFinancialData_379980"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">122</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ManagementsDiscussionandAnalysis_660301"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ManagementsDiscussionandAnalysis_660301"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">122</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">141</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#FinancialStatementsandSupplementaryData_"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#FinancialStatementsandSupplementaryData_"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">142</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ChangesinandDisagreements_29131"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ChangesinandDisagreements_29131"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">142</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ControlsandProcedures_489690"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ControlsandProcedures_489690"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">142</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#OtherInformation_174221"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#OtherInformation_174221"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">143</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9CDisclosureregardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item&#160;9C.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item9CDisclosureregardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">144</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">PART III</p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#DirectorsExecutiveOfficersandCorporateGo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#DirectorsExecutiveOfficersandCorporateGo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers, and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">145</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ExecutiveCompensation_255286"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#ExecutiveCompensation_255286"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">145</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SecurityOwnershipofCertainBeneficial_240"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#SecurityOwnershipofCertainBeneficial_240"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">145</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#CertainRelationshipsandRelatedTransactio"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#CertainRelationshipsandRelatedTransactio"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">145</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#PrincipalAccountantsFeesandServices_2130"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#PrincipalAccountantsFeesandServices_2130"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">145</p></td></tr><tr style="height:1pt;"><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;">PART IV</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Exhibits_364151"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Exhibits_364151"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">146</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:8.39%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item16Form10KSummary_412517"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:85.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a href="#Item16Form10KSummary_412517"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">150</p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:94.24%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><a href="#SIGNATURES_467"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:5.75%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">151</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7f961461_3737_4e17_9278_401d2c1da6d0"></a><a id="FORWARDLOOKINGSTATEMENTS_927471"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K, including &#8220;Business&#8221; in Part I Item I and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II Item 7, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These statements may be identified by such forward-looking terminology as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success, cost and timing of our product development activities and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, scope or likelihood of regulatory filings and approvals, including timing of Investigational New Drug Application and Biological Licensing Application filings for our current and future product candidates, and final U.S. Food and Drug Administration, European Commission or other foreign regulatory authority approval of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to develop and advance our current product candidates and programs into, and successfully complete, clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our manufacturing, commercialization and marketing capabilities and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of and our ability to maintain our collaboration with Gilead Sciences,</span><span style="font-family:'Times';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inc. and establish or maintain future collaborations or strategic relationships or obtain additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance and clinical utility of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering our non-replicating and replicating technologies and the product candidates based on these technologies, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future agreements with third parties in connection with the commercialization of our product candidates and any other approved product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States and foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of the recent coronavirus pandemic or other emerging global health threats on business and operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive companies, technologies and our industry and the success of competing therapies that are or may become available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract and retain key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of our estimates of our annual total addressable market, future revenue, expenses, capital requirements and needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations about market trends;</span><span style="font-family:'Times';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to comply with Nasdaq listing rules and our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All of our forward-looking statements are as of the date of this Annual Report on Form&#160;10-K only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Annual Report on Form&#160;10-K or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Annual Report on Form&#160;10-K, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Annual Report on Form&#160;10-K that modify or impact any of the forward-looking statements contained in this Annual Report on Form&#160;10-K will be deemed to modify or supersede such statements in this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><a id="_1b61dd48_7c02_4e43_9865_01e1326de047"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Note Regarding Trademarks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This 10-K report includes trademarks and trade names that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this 10-K report appear without the &#174; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, trade names and service marks appearing in 10-K report are the property of their respective owners. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated or the context otherwise requires, all references in this 10-K report to &#8220;HOOKIPA Pharma&#8221;, &#8220;HOOKIPA&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;our&#8221;, &#8220;ours&#8221;, &#8220;us&#8221; or similar terms refer to HOOKIPA Pharma Inc. and our consolidated subsidiaries.</p><a id="_2b9857e8_52b8_40b9_ba69_e5ca595d896f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Summary Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our business is subject to numerous risks and uncertainties, including those described in Item 1A &#8220;Risk Factors&#8221;. These risk factors include, but are not limited to the following:</p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a clinical-stage biopharmaceutical company with no approved products and a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require substantial additional financing and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the U.S. Food and Drug Administration (&#8220;FDA&#8221;), the European Medicines Agency (&#8220;EMA&#8221;), the European Commission, and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory schemes, standards, and other obligations related to data privacy and security (including security incidents) could harm our business. Compliance or the actual or perceived failure to comply with such obligations could increase the costs of our products and services, limit their use or adoption, and otherwise negatively affect our operating results and business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates are based on a novel approach to the treatment of cancer and infectious diseases, which makes it difficult to predict the time and cost of product candidate development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates may cause serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential or result in significant negative consequence.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are fully dependent on our collaboration with Gilead Sciences, Inc. (&#8220;Gilead&#8221;) for the development of our hepatitis B virus program, rely on funding from Gilead for development of our human immunodeficiency virus program, and may depend on Gilead or additional third parties for the development and commercialization of our other programs and future product candidates. Our current and future collaborators may control aspects of our clinical trials, which could result in delays or other obstacles in the commercialization of the product candidates we develop. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of licenses granted to us by others, and, if we fail to comply with our obligations under these arrangements or resolve related disputes, we could lose such intellectual property rights or owe damages to the licensor of such intellectual property.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_44a2eeb0_808c_4764_a2ff_3307b009b9e9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART I</p><a id="Business_108848"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1.&#160;&#160;Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on our proprietary arenavirus platform that is designed to target and amplify T cell and immune responses to fight diseases. Our replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T&#160;cell responses and pathogen-neutralizing antibodies. We believe that our technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by inducing CD8+ T cell response levels previously not achieved by other immune therapy approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are building a proprietary immuno-oncology pipeline utilizing our replicating technology. Our oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: HB-200 and HB-700. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (&#8220;HPV16+&#8221;) head and neck cancers in a Phase&#160;1/2 clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. We also have a third oncology program, HB-300, targeting self-antigens for the treatment of prostate cancer, which the Company paused further development in January&#160;2024, to conserve capital and ensure pipeline success and operational efficiency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategic priority is the development of our oncology portfolio, most importantly the advancement of our HB-200 program, and we expect to initiate a randomized Phase&#160;2/3 trial in 2024. Additionally, we are developing infectious disease therapies in partnership with other companies. Our Hepatitis B (&#8220;HBV&#8221;) program, HB-400, and our Human Immunodeficiency Virus (&#8220;HIV&#8221;) program, HB-500, are being developed in a partnership with Gilead.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2023 Highlights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, we executed on several key areas across our pipeline. The highlights include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Oncology: </i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-200 in combination with pembrolizumab: We presented positive preliminary Phase 2 data in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting in May 2023 and additional patient data in October 2023 at the European Society for Medical Oncology (&#8220;ESMO&#8221;) Congress 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:90pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Data showed 42% objective response rate for 19 evaluable checkpoint inhibitor (&#8220;CPI&#8221;)-na&#239;ve patients. These data represent a doubling of the historical response rate (19 percent) reported for pembrolizumab alone. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:90pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are preparing to start a randomized Phase&#160;2/3 trial of HB-200 in combination with pembrolizumab in the 1st-line setting for patients with R/M HPV16+ head and neck cancers.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-700: We continued Investigational New Drug (&#8220;IND&#8221;) application-enabling activities and we are on track to submit an IND in the second quarter of 2024. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-300: We enrolled the first two dose escalation cohorts in the Phase&#160;1/2 study. The Study Safety Committee deemed that HB-300 was generally safe and well-tolerated in both dose escalation cohorts. However, we paused further development of this program in January 2024 to refocus our capital resources on the advancement of our HB-200 program and Gilead-partnered infectious disease programs.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Infectious Disease: Gilead-Partnered Programs</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-400: In August 2023, the Journal of Infectious Disease published peer-reviewed preclinical data on HB-400. The data showed that HB-400 induced robust, HBV-specific T cell and antibody responses in non-human primates and cleared detectable serum HBV antigens in a mouse model for chronic HBV infection, with near elimination of detectable HBV antigen positive hepatocytes in the liver. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-500: In November 2023, we announced FDA clearance of our IND application for HB-500 for the treatment of HIV. Additionally, Nature Partner Journals published peer-reviewed preclinical data for the program in November 2023. The data showed that HB-500 was well tolerated and generated robust, high-quality and durable immune responses (antigen-specific T cells and antibodies) in non-human primates, and that arenaviral therapeutic vaccination significantly reduced SIV viral load and clinical illness in those animals compared to placebo.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financial Highlights: </i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In January 2023, we received a $5.0&#160;million milestone payment under our HB-400 collaboration agreement with Gilead. The success-based milestone payment reflected our completion and delivery of a regulatory support package for Gilead&#8217;s Phase&#160;1 clinical trial. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In February 2023, we received a $10.0&#160;million milestone payment under our HB-700 collaboration agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively referred to as &#8220;Roche&#8221;). The success-based milestone payment reflected the start of the HB-700 manufacturing process to support a Phase&#160;1 clinical trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In June 2023, we completed a $50.0&#160;million public offering of common stock and non-voting convertible preferred stock. The financing was completed in parallel with the initial Phase&#160;2 data release for HB-200.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In December 2023, we issued 15&#160;million shares of common stock for approximately $21.25&#160;million, at a price of $1.4167 per share, to Gilead under a stock purchase agreement with Gilead (as amended to date, the &#8220;Stock Purchase Agreement&#8221;). We have the right, subject to certain terms and conditions, to sell an additional approximately $8.75&#160;million of common stock to Gilead as pro-rata participation in potential future equity raises.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant Recent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;29,&#160;2024, we provided an update on our business priorities and oncology partnership programs. We announced that we will focus our resources in two strategic areas: (1) the clinical development of a randomized trial for our HB-200 program in HPV16+ head and neck squamous cell carcinoma (&#8220;HNSCC&#8221;) and (2) our two Gilead-partnered infectious disease cure programs for HBV and HIV. As part of our strategic refocus, which we announced in January 2024, we have paused development activities related to HB-300 and most of our preclinical research activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also announced in January&#160;2024 that we received notification from Roche of their decision to terminate the collaboration and licensing agreement for our HB-700 program in KRAS mutated cancers. We have met all go-forward criteria under the agreement and remain eligible for a final milestone payment associated with an IND submission. Effective April 25, 2024, we will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for this program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, we announced a reduction in our workforce by approximately 30% and rebalance in our cost structure in alignment with the reprioritization of our programs, and both are expected to be implemented and substantially completed by the end of the first quarter of 2024. As of December&#160;31,&#160;2023, we had $117.5&#160;million in cash, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:132.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">cash equivalents and restricted cash, and we believe that the planned reductions will help conserve resources and better align our organization in direct support of late-stage clinical development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leadership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are led by a team of highly experienced executives, clinicians, and scientists with focused and translational expertise in oncology, immunology, vaccinology, clinical development, and commercialization. Our Chief Executive Officer, Joern Aldag, was previously the Chief Executive Officer of uniQure, a company that under his leadership pioneered the approval of the first gene therapy product. The fundamental discoveries underlying our arenavirus platform originated with our co-founders, Nobel laureate Rolf Zinkernagel, M.D., and Daniel Pinschewer, M.D., an internationally recognized arenavirus expert who serves as Scientific Advisor to our Chief Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are leveraging our modular arenavirus platform to develop the following product candidates for multiple cancers and infectious diseases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k001.jpg" alt="Graphic" style="display:inline-block;height:131.68pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:472pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our differentiated platform is based on engineered arenaviruses that are designed to activate the natural immune defense mechanism to trigger potent and target-specific T cell and B cell immunity. Arenaviruses have been used for decades as a preclinical tool to study CD8+&#160;T&#160;cell responses. Our co-founder, Rolf Zinkernagel, was awarded a Nobel Prize in Physiology or Medicine for his arenavirus-based work on how CD8+&#160;T&#160;cells recognize virus-infected cells. We believe that arenaviruses have several key advantages that give them the characteristics of an optimal immunotherapy, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to induce a robust CD8+&#160;T&#160;cell response by directly targeting and activating antigen-presenting cells (&#8220;APCs&#8221;), such as dendritic cells, which are the most efficient antigen presenting cells of the body;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ability to induce a robust antibody response to disease-specific target antigens;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced neutralization of vector specific antibodies, which facilitates potential for repeat administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">do not require an adjuvant to stimulate the immune system; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have been observed to be well-tolerated in our preclinical studies and clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We believe we are the first to reengineer arenaviruses for therapeutic purposes. Our systemic and reproduceable approach features two technologies capable of delivering disease-specific antigens for the prevention and treatment of disease. Our non-replicating technology is designed to induce a strong immune response for prophylactic and therapeutic use against infectious disease. Our replicating technology is engineered to produce an even more powerful immune </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">response, which we are currently exploring in oncology indications. In preclinical studies, our replicating technology was able to reprogram the immune system such that more than half of the body&#8217;s CD8+&#160;T&#160;cells focused on a specific cancer self-antigen target without observed serious adverse events. We observed the ability of HB-200 monotherapy to induce robust, high-quality and durable antigen-specific CD8+ T&#160;cell responses in our HB-200 clinical trial in human patients. We have designed our platform to be modular in nature to allow substitution of antigens to target a broad range of infectious diseases and cancers. We have a robust intellectual property portfolio for our suite of arenaviruses with exclusive rights in issued patents and patent applications related to our non-replicating technology and exclusive and joint rights in issued patents and patent applications for our replicating technology. We believe the breadth and depth of our intellectual property portfolio is a strategic asset that has the potential to provide us with a significant competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that our arenavirus platform approach gives us a unique and powerful way to tap into the biology of the immune system and reprogram it by instructing APCs, such as dendritic cells, to express antigens that direct the immune system to the desired targets. Our product candidates are designed to deliver full length proteins to activate T&#160;cells and B&#160;cells to produce a robust immune response through natural means, avoiding the use of artificial <i style="font-style:italic;">ex&#160;vivo</i> constructs such as CAR-T&#160;cells and related approaches that bypass the immune system&#8217;s normal control mechanisms. Although these latter approaches have shown clinical activity, they have the potential to cause life threatening side effects, including cytokine release syndrome. In addition, we believe that our immunotherapy approach is simpler, more straightforward and cost effective to manufacture and administer than CAR-T&#160;cells or other patient derived cellular approaches.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The immune system is designed to protect the human body from infections and cancers. Infections can be generally defined as the proliferation of foreign microorganisms such as bacteria, viruses, and parasites in a patient&#8217;s body resulting in clinical manifestations of disease. Cancer can be generally defined as the uncontrolled proliferation of native cells resulting in disease. In both cases, the immune system recognizes and destroys microorganisms, infected cells and cancers by targeting specific proteins, or antigens, as well as their immunogenic sub parts, which are referred to as epitopes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The innate immune system is the body&#8217;s first line of defense and enables a rapid, short-lived and nonspecific response. In contrast, the adaptive immune system utilizes highly specialized immune cells called lymphocytes that have been selected to recognize specific foreign antigens. Although it takes longer to mobilize, the adaptive immune system is capable of providing long term, more effective immunity against specific pathogens by being able to recall prior antigen exposure and mounting a very powerful and specific response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order for the adaptive immune system to function effectively, the innate immune system must first present disease specific antigens to a subset of lymphocytes called T cells in order to &#8220;instruct&#8221; the T cells as to which antigen they must recognize. The T cell population consists of CD8+ T cells, those that kill virus infected and cancer cells by releasing cytotoxic proteins, and CD4+ T cells that help or stimulate additional parts of the immune system such as B cells that produce antibodies. Antigen presentation to T cells is mediated by APCs, such as dendritic cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Technology Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our proprietary platform is based on engineering arenaviruses to carry and deliver virus-specific or tumor-specific genes to APCs, such as dendritic cells, which are natural activators of CD8+ T&#160;cells. Arenaviruses have been used for decades to stimulate potent CD8+ T&#160;cells responses in preclinical research. Our co-founder, Rolf Zinkernagel, was awarded a Nobel Prize in Physiology or Medicine for his arenavirus-based work on how CD8+ T cells recognize virus infected cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Arenaviruses have several important advantages, which we believe represent the optimal characteristics for an antigen specific immunotherapy. Specifically, they:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the ability to induce a robust CD8+ T cell response by directly targeting and activating APCs, such as dendritic cells, which are the most efficient antigen presenting cells of the body;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the ability to induce a robust antibody response to disease specific target antigens;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are not efficiently neutralized by vector specific antibodies, which may facilitate repeat administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">do not require an adjuvant to stimulate the immune system; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have been observed to be well tolerated in preclinical studies and clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The arenavirus family is comprised of over 30 currently known species, many of which we believe have potential prophylactic and therapeutic applications. We believe we are the first to reengineer arenaviruses for the prevention and treatment of disease. We have created two types of viral technologies capable of delivering disease specific antigens: a replication defective vector, and a replication competent but attenuated vector.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our non-replicating and replicating technologies utilize both a Lymphocytic Choriomeningitis Virus (&#8220;LCMV&#8221;) and a Pichinde Virus (&#8220;PICV&#8221;), two species of arenaviruses, as a backbone of the product candidates we are developing. LCMV is principally carried and secreted by wild mice, with human infection being secondary to such exposure and uncommon. Approximately 2% to 5% of individuals in industrialized countries have circulating antibodies against LCMV, which indicates prior exposure in these individuals. Individuals infected with LCMV typically remain asymptomatic or may present with a nonspecific and self-resolving flu-like illness. PICV is principally carried and secreted by Colombian rice rats (oryzomys albigularis) and is a nonpathogenic virus that does not cause disease in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Replicating Technology Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our proprietary non-replicating technology disables arenavirus replication by substituting one of its four structural genes with the gene for a desired antigen. The modified, non-replicating arenavirus is able to directly infect individual APCs, such as dendritic cells and deliver proteins that serve as antigens to activate the immune system but is not able to replicate and infect additional cells in the body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advantages of Non-Replicating Technology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the preclinical and clinical data that we have generated to date, we believe our non-replicating technology supports the benefits of our arenavirus platform approach. Specifically, in preclinical studies and clinical trials this technology has demonstrated that it is well tolerated and has the following additional benefits:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Robust CD8+ T cell Response as Well as Pathogen Neutralization Response.</i> Our non-replicating technology is designed to induce a robust CD8+ T cell and pathogen neutralizing response to fight disease. We believe our technology results in a prophylactic and immuno-therapeutic approach with potential for greater potency than existing prophylactic treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Immunological Memory and Protection Against Challenge.</i> Our non-replicating technology has shown the ability to trigger a robust and long term CD8+ T cell response of at least 12 months in humans. Furthermore, in various animal models non-replicating vector immunization resulted in protection against infectious challenge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Reduced Neutralization of Vector Specific Antibodies.</i> The reduced neutralization of vector specific antibodies facilitates repeat administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Replicating Technology Overview</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our proprietary replicating technology was designed to provide the beneficial properties of our non-replicating technology but to induce an even more robust immune response. Unlike naturally occurring arenaviruses which have two genomic segments, our replicating constructs were engineered to have three segments to allow for the introduction of genomic space in which to insert additional target antigens of choice. As a result of the larger genome, the virus&#8217; ability to replicate is reduced (attenuated).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advantages of our Replicating Technology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on our preclinical data, we believe our replicating technology shows all the benefits of the non-replicating technology and the following additional benefits:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Quantitatively:</i> <i style="font-style:italic;">Even More Robust CD8+ T Cell Response.</i> In animal studies, our replicating technology has shown to induce a CD8+ T cell response that directs more than 50% of a body&#8217;s T cells, which is approximately ten times greater than the response induced by our non-replicating technology, to focus on a single target of choice. Similar data have been demonstrated in our Phase&#160;1/2 clinical study of HB-200. We believe our technology results in an immunotherapeutic approach with potential for greater potency than existing therapeutic treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">Qualitatively: Immunological Memory and Protection Against Challenge.</i> Our replicating technology has shown the ability to trigger a long term CD8+ T cell response. Furthermore, in various animal models replicating immunization resulted in complete tumor remission after a single treatment and protection against a cancer re-challenge months after primary treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The additional benefits noted above are attributable to our technology&#8217;s ability to replicate. This allows it to infect not only APCs, such as dendritic cells, but also lymphoid stromal cells, which are immune support cells found in lymph nodes and the spleen. Infection of lymphoid stromal cells results in the release of a signaling protein which further drives the proliferation and differentiation of CD8+ T cells. This mechanism has the potential to generate ten fold more antigen specific CD8+ T cells as compared to viral delivery systems that are unable to trigger this pathway. Furthermore, we believe our replicating technologies may also be synergistic with other approved immuno-oncology agents and currently are conducting a clinical trial of our replicating technology in combination with checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In additional preclinical models, including a mouse melanoma model and a cancer testis self-antigen cancer model, we again demonstrated the ability of sequential administration of replicating PICV and LCMV constructs to direct up to 50% of a body&#8217;s T cells to focus on a single target of choice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advantages of sequential administration of replicating PICV and replicating LCMV</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have observed increased antitumor activity and survival of animals that received sequential administration of replicating PICV and replicating LCMV in a preclinical mastocytoma model. In this model, tumor cells expressed a cancer testis self-antigen known as P1A. In the absence of treatment, tumors grew rapidly and most of the mice died by day 25. When given a first dose with a replicating LCMV P1A vector, followed by a second dose with the same vector, there was a delay in tumor growth of approximately ten days and an increase in survival rates, with some mice surviving to almost 100 days (left panel below). In contrast, mice that were treated first with replicating PICV P1A followed by a second dose with a different arenavirus, replicating LCMV P1A, had an average tumor growth delay of approximately 25 days and in 18% of the mice the tumors were eliminated, and they survived beyond the 160 days of the study. Furthermore, and as seen in our other studies, mice with eliminated tumors demonstrated resistance to a tumor rechallenge (right panel below).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:133.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k002.jpg" alt="Graphic" style="display:inline-block;height:133.38pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:474.5pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Figure: Bonilla, W. et al. Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack. journal.ppat. 100209. Cell Reports Medicine</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">HB-200 Program for the Treatment of HPV16+ Cancers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The HB-200 program is our first program in oncology and the first clinical exploration of our replicating arenaviral vector-based technology. The HB-200 program is composed of potential therapeutic agents for people with cancers caused by the Human Papillomavirus (&#8220;HPV&#8221;), specifically HPV16+.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All of our current product candidates are alternating, dual-vector arenaviral immunotherapies. HB-200 is a targeted dual vector arenaviral-based immunotherapy that uses alternating sequential injections of a LCMV vector and a PICV vector, both expressing the E7E6 fusion protein specific to HPV16+ cells. The two components of our HB-200 program are referred to as HB-201 (LCMV) and HB-202 (PICV).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HPV-Positive Cancers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HPV is estimated to cause about 5% of cancers worldwide, including approximately 99% of cervical cancers, up to 60% of HNSCC, 70% of vaginal cancers and 88% of anal cancers. While most infections with HPV are cleared from the body with no lasting consequences, in some cases, HPV DNA becomes integrated into chromosomal DNA. When host cells take up this DNA, they express the HPV E6 and E7 proteins. The expression of these proteins can lead to alterations in cell cycle control, which in turn predisposes these cells to become cancerous.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HPV infection is linked to several cancer types, including HNSCC which is now the 8th most common cancer affecting men in the United States (Siegel et al. 2023). The high incidence rate of HNSCC is largely due to a rising epidemic of oropharyngeal squamous cell carcinoma (&#8220;OPSCC&#8221;) associated with HPV (Price &amp; Cohen 2012). The median overall survival (&#8220;OS&#8221;) for R/M HNSCC remains less than 15 months despite modern chemotherapy, targeted agents, and recent immunotherapy. The high-risk genotype HPV 16 accounts for 88% of HPV+ OPSCC cases in the United States (Chaturvedi et al. 2011) and for more than 50% of HPV+ cases found in other head and neck anatomical locations (Abogunrin et al. 2014; Vokes et al. 2015). In 2023, an estimated 54,540 new cases of head and neck cancers were diagnosed in the United States alone, with anticipated deaths estimated at 11,580 (Siegel et al. 2023).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While there is no T&#160;cell therapy approved for HNSCC, retrospective analyses have shown that patients&#8217; outcomes are improved for those with high levels of CD8+ T&#160;cells in tumors as compared to patients with low levels. In many cases, the survival rate of patients with higher levels is more than double that of patients with lower levels of CD8+ T&#160;cells.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Our Solution: HB-200 Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-200 alternates the administration of both HB-201 (LCMV) and HB-202 (PICV) attenuated viral vectors, which on their own are replicating-based therapeutics expressing a non-oncogenic, but highly antigenic, E7E6 fusion protein from HPV16. We have observed strong immunogenicity and robust antitumor activity in mouse models for LCMV alone as well as for the sequential administration of LCMV and PICV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Relevance of E6 and E7 as Tumor Antigens</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Integration of HPV viral sequences into the genome of a cell can result in the introduction of E6 and E7 oncoproteins. They are present in cells that become cancerous and play a critical role in interfering with cellular processes and interrupting normal tumor suppressor functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Profiling of immune cells isolated from patients with HPV16+ tumors has identified E6 and E7 specific T&#160;cells, indicating that the E6 and E7 proteins are immunogenic, meaning that they trigger antigen specific CD8+ T&#160;cell responses. Because both E6 and E7 are highly expressed in tumor cells and are absent in normal cells, they are ideal candidates for use as targets of tumor directed active immunization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">HB-200 Clinical Trial </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-200 is being evaluated in an ongoing Phase&#160;1/2 clinical trial for the treatment of HPV16+ cancers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This trial is currently enrolling participants in Phase 2, evaluating HB-200 therapy in combination with pembrolizumab in the first line setting of HPV16+ PD-L1+ oropharynx cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Previously, the trial has, in multiple arms, explored several dose levels and administration regimens across multiple HPV16+ cancer indications. The Company has published interim data readouts at key scientific conferences dating back to 2021. Interim data readouts from 2021 to 2022 have shaped further the study design and protocol.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Most recently, there has been data published on two key components of the trial:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;1 evaluation of HB-200 as a monotherapy in second or later-line R/M setting of HPV16+ cancers and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;2 evaluation of HB-200 in combination with pembrolizumab in the first line R/M setting of HPV16+ OPSCC.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical Results: HB-200 Monotherapy in Second or Later-Line Setting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2023, we presented updated Phase&#160;1 monotherapy data for HB-200 in the second or later-line R/M setting of HPV16+ cancer at the Society for Immunotherapy of Cancer annual congress (Abstract #679). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31,&#160;2023, in the Phase 1 portion of the study, 93 patients with any HPV16+ cancer (72 HNSCC and 21 non-HNSCC) were enrolled to receive HB-200 therapy (LCMV 1-vector therapy or PICV/LCMV alternating 2-vector therapy). Patients were heavily pretreated with a median of three prior anticancer systemic therapies (range 1-11). The recommended phase 2 dose (&#8220;RP2D&#8221;) and regimen for HB-200 monotherapy was previously determined to be alternating 2-vector therapy IV at dose level 3 (PICV 1&#215;107 RCV FFU, LCMV 5&#215;107 RCV FFU). The reported efficacy and clinical biomarker data focused on the 41 patients with HPV16+ HNSCC treated with HB-200 alternating 2-vector therapy, especially 29 patients with HPV16+ HNSCC treated with HB-200 alternating 2-vector therapy at the RP2D (DL3) or one dose lower than the RP2D (RP2D-1, DL2).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:99.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Safety and Tolerability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Across all patients treated, the safety profile with HB-200 monotherapy was generally favorable. The majority of reported adverse events (&#8220;AEs&#8221;) were mild to moderate (Grade 1 or Grade 2) with the most common AEs being flu-like symptoms. Across the 93 patients treated in Phase&#160;1, 11.8% of patients reported grade &#8805;3 treatment related adverse events (&#8220;TRAEs&#8221;), 2.2% of patients had treatment discontinuation due to TRAEs, and no treatment-related deaths occurred, as shown below. Safety data were generally comparable to checkpoint inhibitor monotherapy in the later-line HNSCC setting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20231231x10k003.jpg" alt="Graphic" style="display:inline-block;height:99.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical Activity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The intent to treat population (&#8220;ITT&#8221;) of 29 patients with HPV16+ HNSCC were treated at the RP2D and RP2D-1 of HB-200 alternating 2-vector monotherapy, with 27 patients evaluable with &#8805;1 tumor efficacy scan. Importantly, HB-200 demonstrated clinical activity and tumor shrinkage as a monotherapy in a very difficult to treat and immune checkpoint resistant patient population that we believe has the potential to be best-in-class. Among the evaluable patient population, the disease control rate was 44% (1 confirmed partial response &#8220;PR&#8221; and 11 stable disease &#8220;SD&#8221;), and 33% of patients had tumor shrinkage in the target lesions (Figure 1). Overall survival data is still maturing with a median OS of ~13 months and a median follow-up time of 6.3 months for the 29 patients as of August 7, 2023. Two patients (patient #1 and #2) had paired biopsies available. High levels of circulating E6-E7&#8211;specific CD8+ T cells and increased tumor infiltration of CD8+ lymphocytes were seen in these 2 patients, who also demonstrated clinical benefit / disease control (Figures 1-4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:187.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k004.jpg" alt="Graphic" style="display:inline-block;height:26.65pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:439.55pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k005.jpg" alt="Graphic" style="display:inline-block;height:187.3pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:274.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biomarker and Translational Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Augmentation of tumor-specific T cells was observed in 100% of patients tested across all 4 dose levels (N = 35 tested out of 41 HNSCC patients receiving HB-200 alternating 2-vector therapy) (Figure 2B):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Up to 48% of all CD8+ T cells in blood were specific for the tumor antigen (i.e., HPV16 E6 &amp; E7), with a median specificity of 2.0% (Figure 2A).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Figure 2C illustrates one representative patient with HNSCC (Patient #1) from DL3 cohort with tumor-specific CD8+ T cell responses measured by ICS, E6-E7&#8211;specific IFN-&#947;+ CD8+ T cells increasing from 0% at baseline to 10% after 2 doses of HB-200.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k006.jpg" alt="Graphic" style="display:inline-block;height:178.7pt;width:468pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Figure 2. HPV16 E6-E7&#8211;specific T cell responses in HNSCC patients treated with HB-200 alternating 2-vector therapy.</b><br/>A. Baseline and peak IFN-&#947;+ HPV16 E6-E7 T cell response measured by ICS. Peak responses were typically observed post 2 doses of HB-200 (N = 35/41 HNSCC patients receiving HB-200 alternating 2-vector therapy across DL1-4). <br/>B. Box plots are representing IFN-&#947;+ HPV16 E6-E7 T cell response measured by ICS per DL (N = 35/41). Box and whiskers represent minimum, maximum and median. DL1 = PICV 1&#215;106, LCMV 5&#215;106 RCV FFU; DL2 (RP2D-1) = PICV 1&#215;107, LCMV </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:188.1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;">5&#215;106 RCV FFU; DL3 (RP2D) = PICV 1&#215;107, LCMV 5&#215;107 RCV FFU; DL4 = PICV 1&#215;108, LCMV 5&#215;106 RCV FFU. Patients from DL2 &amp; DL3 with available PBMC samples are highlighted (N = 26/29) <br/>C. Representative pseudo-color plots (Patient #1) with the frequencies of double-positive IFN-&#947;+ TNF-&#945;+ cells gated on CD8+ T cells at baseline and post 2 doses of HB-200.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Importantly, HB-200 showcased durability and functionality of tumor-specific CD8+ T cells (N = 35/41 HNSCC patients receiving alternating 2-vector therapy) and infiltration of CD8+ T cells in tumors upon therapy in patients with paired biopsies (N = 13 tested out of 93 patients in Phase 1) (Figure 3):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results showed rapid induction of tumor-specific T cells, sustained for more than 8 months and increasing in polyfunctionality during treatment (Figure 3A).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patients with increased CD8+ T cell influx in tumors during HB-200 treatment tended to show clinical benefit (stable disease vs. progressive disease) (Figure 3B).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k007.jpg" alt="Graphic" style="display:inline-block;height:188.1pt;width:468pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 3.</b><b style="font-weight:bold;"><br/></b>A. Median of circulating E6-E7&#8211;specific T cells over time measured by ELISpot (solid line shows median SFU/1 x 106 PBMCs and dashed lines indicate Patient #1 and #2 in the case report in Figure 4). Pie charts below graph show percentage of tumor-specific T cells expressing the indicated number of cytokines/markers (IFN-&#947;, TNF-a, CD107a, IL-2) measured by ICS in available PBMCs from HNSCC patients undergoing HB-202/HB-201 alternating 2-vector therapy at DL2 &amp; DL3 at the corresponding timepoints (N = 26/29). <br/>B. Percent change in tumor-infiltrating CD8+ T cells pre and post HB-200 treatment in patients with disease control (blue) and progressive disease (red) measured by IF IHC. Mean &#177; SD. Data shown are all patients with available paired biopsies, which includes patients from all groups explored in the study (N = 13 out of 93 total patients enrolled in Phase 1).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Paired tumor biopsies of two HNSCC patients treated with HB-200 2-vector therapy at DL2 or DL3 were available for analysis (pt #1 &amp; pt #2 Figure 3B):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tumor-specific T&#160;cell responses were induced rapidly and remained at high levels throughout therapy in these 2 patients (Figure 3A), both of whom also exhibited clinical benefit (stable disease / disease control) (Figure 4A).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In these patients, HB-200 therapy induced high levels of tumor-specific CD8+ T cells in the circulation (Figure 2A and 3A), as well as elevated CD8+ T cell numbers in tumors (Figure 3B &amp; 4C).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The patients with disease control exhibited only small increases or modest reductions in ctDNA levels (Figure 4B), with respective best percent change in target lesions -29% (pt #1) and -11% (pt #2) (Figure 1).</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:312pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k008.jpg" alt="Graphic" style="display:inline-block;height:311.65pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:468pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 4. Tumor response, HPV16 ctDNA, and TILs in 2 patients with stable disease who received HB-200 alternating 2-vector therapy.</b><b style="font-weight:bold;"><br/></b>A. Percent change in sum of target lesion diameters from baseline over time in Patient #1 and #2.<br/>B. Percent change in circulating HPV16 DNA from baseline in Patient #1 and #2.<br/>C. TILs in tumor tissue from Patient #2 with best overall response of stable disease. Tissues were analyzed by Multiplex IF IHC Vectra&#174; Polaris&#8482; and HALO&#174; Quantification to determine expression of immune markers (CD8, DAPI, and PanCK).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical Results: HB-200 in Combination with Pembrolizumab in the First Line Setting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In October 2023, we presented updated Phase 2 data for HB-200 in combination with pembrolizumab in the first line setting at the ESMO annual congress (Abstract 2212) for the first 20 patients treated with HB-200 and pembrolizumab in the first-line setting (data cut-off August 7, 2023).  The efficacy evaluable data set (&#8805;1 tumor scan post-treatment) consisted of 19 patients, as one patient discontinued prior to tumor scans due to COVID-related death. Baseline characteristics are highlighted in the table below.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:199.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k009.jpg" alt="Graphic" style="display:inline-block;height:199.3pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:301.85pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Safety and Tolerability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The data showed that HB-200 and pembrolizumab was generally well tolerated among the 20 patients treated. The majority of reported AEs were mild to moderate with the most common AEs being flu-like symptoms. Two patients (10%) reported serious adverse events related to the treatment with HB-200 or pembrolizumab. Only one patient (5%) discontinued due to a treatment-related adverse event of checkpoint inhibitor pneumonitis (related to pembrolizumab). The updated safety data adds to the previously reported safety and tolerability data from patients across all arms of the trial who received HB-200 monotherapy or HB-200 in combination with pembrolizumab. This generally favorable tolerability profile highlights the potential of HB-200 &#8211; and arenaviral immunotherapies in general &#8211; to be successfully combined with other immunotherapies where tumor antigen-specific T cell induction is of potential benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="hook-20231231x10k010.jpg" alt="Graphic" style="display:inline-block;height:173.8pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:167.45pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Presented at ESMO 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical Activity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preliminary data showed a 42% confirmed objective response rate (&#8220;ORR&#8221;) and disease control rate (&#8220;DCR&#8221;) of 74% across 19 evaluable patients, doubling the historical 19% ORR for pembrolizumab alone. Best overall response for the evaluable population included one patient with a confirmed complete response, seven patients with confirmed partial responses, and six patients with stable disease. The preliminary data showed sustained disease control in the majority of patients. All efficacy-evaluable patients were alive at the data cutoff (August 7, 2023), and the median follow-up time at DCO was 8.3 months. Median overall survival and progression-free survival data are still maturing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:187.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k011.jpg" alt="Graphic" style="display:inline-block;height:187.25pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:338.5pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k012.jpg" alt="Graphic" style="display:inline-block;height:177.75pt;width:302.95pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biomarker and Translational Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Importantly, the data showed significant activation of antigen-specific CD8+ T&#160;cells, the body&#8217;s primary driver of tumor killing activity. Out of 17 patients with available peripheral blood mononuclear cells (&#8220;PMBC&#8221;) samples, all patients showed an increase of tumor antigen-specific circulating HPV16+ CD8+ T cells. Peak percentage of antigen-specific circulating HPV16+ CD8+ T cells reached up to 31 percent with a median of 3.36%. Max response on treatment vs. before treatment of systemic HPV-16 E7 and E6 specific T&#160;cells measured by ELISPOT showed that the median fold-increase for these patients&#8217; total tumor specific T cells was a 451-fold increase over baseline, with the maximal increase of 4,000-fold.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:171.95pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k013.jpg" alt="Graphic" style="display:inline-block;height:171.95pt;width:224.1pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the data generated in our clinical trials, we believe that HB-200, in combination with standard of care pembrolizumab, has the potential to improve treatment outcomes in persons diagnosed with HPV16+ PD-L1+ R/M OPSCC, and has the potential to be used in the first line setting. We believe that success in developing HB-200 into an effective therapy for HPV16+ OPSCC would suggest the potential of HB-200 to be an effective therapy in all HPV16+ cancers, regardless of the cancer&#8217;s tissue of origin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The totality of the data from our clinical trials of HB-200, both as a monotherapy and in combination with pembrolizumab, give us conviction to proceed with a randomized Phase&#160;2/3 trial to evaluate HB-200 in combination with pembrolizumab in the first line setting for patients with HPV16+ OPSCC. We plan to begin the randomized Phase&#160;2/3 trial in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">HB-700 for Targeting Mutated KRAS in Pancreatic, Colorectal and Lung Cancers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Targeting Shared Neoantigens</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">KRAS is a gene that acts as an on/off switch for cell growth as it is a key regulator of cell proliferation and survival. When there is a mutation, or error, in the gene, cells can grow out of control. KRAS is one of the most frequently mutated proto-oncogenes with respective mutations found in approximately 30% of all human cancers. KRAS mutations are most frequently found in pancreatic cancer (85% to 90%), colorectal cancer (approximately 40%) and lung cancer (approximately 32%). However, the spectrum of mutations mainly target amino acid position 12 (G12D, G12V, G12R, and G12C) and position 13 (G13D), rendering these mutations an attractive target for immunotherapy. We plan to develop our KRAS targeted therapy for patients suffering from pancreatic adenocarcinoma (&#8220;PAAD&#8221;), colorectal cancer (&#8220;CRC&#8221;) and lung adenocarcinoma (&#8220;LUAD&#8221;) and carrying one or more of the five most prevalent G12D, G12V, G12R, and G12C and position 13 G13D mutations. Our arenavirus technology enables us to integrate all five mutations into one single-vector, which allows our product to potentially be a single therapeutic targeting multiple large cancer indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An early proof of concept for targeting KRAS mutations via CD8+ T cells was reported by Tran et al in 2016. Tran targeted a KRAS mutation on position 12 (G12D) in a patient with metastatic CRC by tumor infiltrating lymphocyte (&#8220;TILs&#8221;); Tran demonstrated objective regression of all seven lung metastatic lesions from underlying CRC after the infusion of KRAS G12D-directed tumor infiltrating lymphocytes. More recently, small molecule inhibitors targeting mutated KRAS were developed and have showed promising results in clinical trials. However, those targeted therapies are limited to a single, specific KRAS mutation (KRAS G12C), which is frequently found in LUAD (approximately 50% of the late-stage cancers). However, KRAS G12C is underrepresented in PAAD and CRC when compared to other KRAS mutations such as G12D, G12V, G12R and G13D, which are much more frequently found (greater than 60% and greater than 90% in advanced CRC or PAAD, respectively). Hence, we believe that there is an urgent medical need to develop effective therapies for those patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:140pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pancreatic cancer is considered one of the most lethal malignancies. Overall, approximately 500,000 new cases of pancreatic cancer per year are recorded globally. Incidence, prevalence and mortality for pancreatic cancer has increased by more than 50% during the last 25 years. Pancreatic cancer accounts for 1.8% of all cancers but causes 4.6% of all cancer deaths and pancreatic cancer deaths are expected to double by the year 2060. The high mortality rate can be explained in part as pancreatic cancer typically remains silent, not causing signs or symptoms for a long time. When patients become symptomatic, the cancer has usually reached an advanced and incurable stage. According to the American Cancer Society, the overall 5-year survival rate for pancreatic cancer is approximately 9%. 97% of patients with metastatic cancer (i.e., stage IV) are expected to die within 5 years after diagnosis. Additional effective therapies are therefore urgently needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Colorectal cancer is the third most diagnosed malignancy worldwide and the second leading cause of cancer death. The incidence of colorectal cancer was estimated at 1.9 million cases in 2020, causing 0.9 million deaths worldwide. The incidence is higher in highly developed countries and it is increasing in middle- and low-income countries due to westernization. The death rate from colorectal cancer in 2018 was approximately 55%. The 5-year survival rate of patients with localized stage colorectal cancer is 90%. About 38% of patients are diagnosed at this early stage. If the cancer has spread to surrounding tissues or organs and/or the regional lymph nodes, the 5-year survival rate is 72%. If the cancer has metastasized to distant parts of the body, the 5-year survival rate is less than 15%. The advancements made in understanding colorectal cancer pathophysiology have led to increased treatment options, including endoscopic and surgical excision, radiotherapy, immunotherapy, palliative chemotherapy, targeted therapy, and extensive surgery and local ablative therapies for metastases. These treatments have prolonged overall survival and screening through endoscopy also greatly enhanced the early detection, leading to good prospects of a cure. Although the prospect for colorectal cancer therapy is generally good, the increasing number of cases and rising incidence among younger generations still poses a heavy financial burden and a public health challenge.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Lung cancer is the most common cause of cancer death worldwide, with an estimated 1.6 million deaths annually. Approximately 85% of lung cancer patients suffer from a subgroup called non-small cell lung cancer (&#8220;NSCLC&#8221;), of which LUAD and lung squamous cell carcinoma are the most common subtypes. LUAD represents approximately 40% of NSCLC and is the most common primary lung cancer diagnosed in the United States. Despite new treatments, the 5-year survival rate is only 12% to 15%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Our Solution: HB-700 for KRAS Mutated Cancers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">HB-700 is based on our replicating arenavirus platform and was designed for treatment of cancers encoding mutated KRAS, especially KRAS-mutated pancreatic, colorectal, and lung cancers. HB-700 is a replicating dual-vector therapy that has been engineered to encode fragments encoding multiple KRAS mutations found in these three cancers, specifically KRAS mutations G12D, G12V, G12R, G12C and G13D.  By simultaneously targeting these five most common mutations, we believe HB-700 has the potential to benefit more patients than single mutation inhibitors. Potential coverage of KRAS mutations of important cancer indications by our product candidate HB-700 is illustrated in the following graph:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="hook-20231231x10k014.jpg" alt="Graphic" style="display:inline-block;height:140pt;width:303pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similar to our other immuno-oncology candidate therapies, we can deliver HB-700 by simple infusion; HB-700 is designed to target APCs, such as dendritic cells, without the need for cellular isolation or <i style="font-style:italic;">ex vivo</i> processing. Since induction of KRAS mutation-specific CD8+ T cells is the mode of action of this investigational therapy, and administration of alternating LCMV- and PICV-based vectors have been shown to induce unprecedented tumor antigen-specific CD8+ T cell levels in the context of our HB-200 program, we have designed HB-700 to potentially maximize HB-700-induced CD8+ T cell responses by using replicating vectors based on both LCMV and PICV in a sequential dosing regimen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2022, we announced a strategic collaboration and license agreement with Roche to develop HB-700 for KRAS-mutated cancers. Through the collaboration, we have conducted research and early clinical development for HB-700.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2023, we achieved a $10.0&#160;million milestone payment under our HB-700 collaboration agreement with Roche. The success-based milestone payment reflected the start of the HB-700 manufacturing process to support a Phase&#160;1 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25,&#160;2024, we received written notice from Roche of their decision to terminate the Research Collaboration and License Agreement dated October 18, 2022. Roche&#8217;s decision to terminate the Collaboration Agreement was made according to Roche&#8217;s right to terminate without cause, acknowledging that we had met all go-forward criteria under the Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Collaboration Agreement was entered into to (i) grant Roche an exclusive license to research, develop, manufacture and commercialize the Company's pre-clinical HB-700 cancer program, an arenaviral immunotherapeutic for KRAS-mutated cancers, and (ii) grant Roche an option right to exclusively license for research, development manufacturing and commercialization, a second, novel arenaviral immunotherapeutic program targeting undisclosed cancer antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Collaboration Agreement and the Notice, the Collaboration Agreement will be terminated on April&#160;25,&#160;2024. The Company remains eligible for a final milestone payment associated with an IND submission. The Company plans to submit an IND to the FDA in April 2024. Effective April&#160;25,&#160;2024, the Company will regain full control of the associated intellectual property portfolio and will have full collaboration and licensing rights for the HB-700 program, and we are evaluating a potential new partnership to advance HB-700. After the termination of the Collaboration Agreement, and except as disclosed above, there is no other material relationship between the Company and Roche.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">HB-300 Program for Prostate Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Targeting Self Antigens</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that our viral vectors may be appropriate for any antigen where a T cell response may be therapeutically meaningful. We have shown in multiple preclinical models that replicating product candidates are active in generating robust immune responses to tumor self antigens and that this response results in decreased tumor growth and an increase in survival rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-200 program targets viral antigens associated with tumors induced by HPV16. In these programs, the viral, or non self nature of the antigens, makes them a natural target for an immunotherapy approach. In addition, we are pursuing the development of product candidates based on our arenavirus platform to target self antigens, nonviral antigenic proteins that are highly overexpressed in solid tumors or only minimally expressed in normal cells. Because self antigens are found in certain normal cells as well as tumor cells, the immune system does not typically recognize them as foreign proteins and does not respond to them. This protection of self antigens from immune system attack is known as immune tolerance. The results obtained by earlier generation marketed products such as sipuleucel T, developed as PROVENGE by Dendreon Pharmaceuticals, Inc., have proven that it is possible to overcome immune tolerance and activate the immune system to produce an antitumor response.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:256.7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Our Solution: HB 300 for Prostate Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are developing our most advanced self antigen candidate in this area, HB 300, based on our replicating technology in metastatic, hormone resistant prostate cancer. Prostate cancer provides a unique treatment opportunity for immunotherapy because prostate cancer cells express a number of tumor specific antigens that serve as potential targets. HB-300 is an alternating, dual-vector replicating arenaviral immunotherapy which uses LCV and PCV as arenaviral backbones, with each expressing two well-defined antigens of prostate cancer, prostatic acid phosphatase (&#8220;PAP&#8221;) and prostate specific antigen. Subsequent clinical development may include addition of arenaviral therapeutics expressing a third antigen, prostate specific membrane antigen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Direct evidence for the ability to induce a therapeutically relevant immune response to one of these antigens, PAP, comes from PROVENGE. To create PROVENGE, a personalized treatment, clinicians remove dendritic cells from the body, load them with PAP and then reintroduce them to the patient. The use of PROVENGE has been shown to increase survival in patients with metastatic, hormone resistant prostate cancer and led to its approval in 2010. Other companies are developing dendritic cell therapies similar to PROVENGE by using other tumor antigens. These dendritic cell therapies generally require complex, patient-specific therapeutic manufacturing processes involving isolating cells from patients, loading them ex vivo with tumor antigens and then readministering the cells to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since HB-300 is a replicating-based product candidate, we can deliver it by simple infusion whereby it targets APCs, such as dendritic cells, without the need for cellular isolation or ex vivo processing. We have shown in preclinical experiments and in the HB-200 clinical program that replicating vectors can lead to robust CD8+ T cell responses to the encoded antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k015.jpg" alt="Graphic" style="display:inline-block;height:256.7pt;width:426.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In April 2022, we presented preclinical data at the American Association for Cancer Research Annual Meeting (abstract #3298 and abstract #4198) that showed antitumor activity with a single administration of replicating arenaviral immunotherapy targeting tumor self-antigens. Specifically, the arenaviral immunotherapy was able to overcome immune tolerance, induce potent T cell responses against two different tumor self-antigens and reduce tumor growth in these cancers. Notably, targeting tumor self-antigens can be a challenge because the immune system does not recognize these molecules as foreign. These preclinical data provided further support for the clinical evaluation of our HB-300 candidate for treatment of prostate cancer. The AACR data demonstrated the ability of our arenaviral immunotherapeutic </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">technology to induce potent T cell responses against tissue-specific self-antigens, which is the same type of tumor self-antigens targeted by HB-300.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2022, we announced that the FDA accepted our IND for HB-300 for the treatment of metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;). A Drug Master File was also accepted, which we believe will facilitate reduced cycle time between completion of preclinical studies and clinical entry of our pipeline projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2023, we opened a first-in-human Phase 1/2, multinational, multicenter, open-label study of HB-302/HB-301 alternating dual-vector therapy in participants with mCRPC. This study (NCT05553639) has 2 phases: a Phase&#160;1 dose escalation with an RP2D confirmation and a Phase 2 dose expansion. The Phase 1 dose escalation will evaluate HB-302/HB-301 alternating dual-vector therapy for safety and tolerability, preliminary efficacy and immunogenicity, and determination of a RP2D. The Phase 2 dose expansion will assess HB-302/HB-301 alternating dual-vector therapy at the RP2D defined in the Phase 1 portion of the study. Based on lessons learned from the HB-200 program, HB-302/HB-301 Alternating dual-vector therapy will be administered intravenously every three weeks (Q3W) for the first five doses and every 6 weeks (Q6W) from the fifth dose and onward. HB-302 is to be administered first followed three or six weeks later by HB-301.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2023, we had completed enrollment of the Phase&#160;1 dose escalation cohorts. The Study Safety Committee deemed that HB-300 was generally safe and well-tolerated in both dose escalation cohorts. Initial analysis of target antigen-specific T&#160;cell responses &#8211; using direct ELISPOT without pre-expansion of T&#160;cells &#8211; in ten patients between dose level 1 (N=5) and dose level 2 (N=5) indicated a 15- to 26-fold increase of target antigen specific T&#160;cells in 30% of patients (3/10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In line with our previously announced strategy to prioritize the development of HB 200, we have terminated the Phase&#160;1/2 study of HB-300 and will utilize the associated capital and resources for the advancement of our HB-200 program. We will not proceed to the Phase&#160;2 dose expansion component of this study, but we will keep the IND open to allow the potential for further development of this program in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Next Generation Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A critical advantage of our technology is that it is designed to deliver full length proteins directly to APCs, such as dendritic cells, for endogenous expression and direct presentation to CD8+ T cells. Having APCs, such as dendritic cells, express full-length proteins and present all fragments (epitopes) overcomes the major difficulty of attempting to predict which part of the protein, or epitope, will be presented by the patient&#8217;s individual major histocompatibility complex (&#8220;MHC&#8221;) class&#160;I alleles. This presentation is important in immunotherapy because T cells will only recognize and respond to the antigen when it is bound to the individual&#8217;s MHC class&#160;I molecules, of which several hundred different versions exist in the population. While this approach overcomes the major issue faced by neoepitope-based personalized antigen approaches, it also has limitations in that the repertoire of known tumor-associated proteins that could be used for targets is limited. The best example of full-length proteins that are, to a degree, cancer-specific and immunogenic include the cancer testis antigens, examples of which include NYESO1, MAGE and CAGE. These cancer testis antigens have been known for decades, and many of them are currently being pursued by other companies. For many tumor types the cancer testis type of antigens remains unknown. Furthermore, most of the known tumor associated antigens are not commonly expressed or are not sufficiently specific to tumor tissue, making them suboptimal targets for clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Infectious Disease Pipeline Highlights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our strategic priority is the development of our oncology portfolio, we believe that our platform is also uniquely positioned to provide value from the prophylactic and therapeutic use against infectious diseases. We plan to continue developing infectious disease therapies in partnership with other companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our collaboration with Gilead to develop functional cures for chronic HBV and HIV infections has become our main driver of our infectious disease pipeline progress. We entered into our collaboration and licensing agreement (the &#8220;Gilead Collaboration Agreement&#8221;) with Gilead in June 2018. To date, we have received $46.2&#160;million in upfront and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">milestone payments and $42.2&#160;million of cost reimbursements from Gilead. Both programs have completed preclinical research and the HBV program is currently in a Phase&#160;1 clinical trial. The HIV program is being progressed towards entry into a Phase&#160;1 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2023, we announced the achievement of a $5.0 million milestone payment for the completion and delivery of a regulatory support package for Gilead&#8217;s Phase&#160;1 clinical trial of the HBV therapeutic vaccine developed under the Gilead Collaboration Agreement. The first participant in the Phase 1 clinical trial being conducted by Gilead was dosed in 2023. The preclinical data on the HBV vaccine as a potential component for a curative regimen were presented at the American Association for the Study of Liver Diseases (&#8220;AASLD&#8221;) in November 2022 and was selected by AASLD as a &#8220;Best of the Liver Meeting&#8221; highlight. These data were published in The Journal of Infectious Disease in August of 2023. Gilead is solely responsible for further development and commercialization of the HBV product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2022, we signed an amended and restated collaboration agreement (the &#8220;Restated Gilead Collaboration Agreement&#8221;) which revised the terms only for the HIV program, whereby we took on development responsibilities for the HIV program through a Phase 1b clinical trial and Gilead provides funding through a combination of an initiation payment of $15.0 million, a milestone payment of $5.0&#160;million and equity contributions of up to $35.0 million. In November 2023, we announced FDA clearance of our IND application for the treatment of HIV. Additionally, Nature Partner Journals published peer-reviewed preclinical data for the program. Data show that HB-500 was well tolerated and generated robust, high-quality and durable immune responses (antigen-specific T cells and antibodies) in non-human primates, and arenaviral therapeutic vaccination significantly reduced SIV viral load and clinical illness in those animals compared to placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, we received approximately $26.25 million from Gilead&#8217;s purchases of our common stock under the Stock Purchase Agreement with Gilead entered into in connection with the Restated Gilead Collaboration Agreement. We have the right, subject to certain terms and conditions, to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises. Gilead retains an exclusive right (the &#8220;Option&#8221;) to take back the rights for the HIV program, including further research, development and commercialization. If Gilead elects to exercise the Option, we will be entitled to a $10.0 million program completion fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Infectious Disease: In Collaboration with Gilead</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-400 for the Treatment of HBV</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-400 Preclinical Data Package for Hepatitis B Virus Cure Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In collaboration with Gilead Sciences, Inc. a HBV-specific immunotherapy consisting of 2 non-replicating arenavirus vectors derived from PICV (HB-402) and 2 non-replicating arenavirus vectors derived from LCMV (HB-401) was developed. The immunotherapy is intended to utilize the patient`s own immune system to induce a strong cellular and antibody response against HBV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Arenavirus vectors were constructed to encode three different HBV antigens: HBV Core, Pol (an inactivated version of the HBV polymerase) and HBV surface antigen (&#8220;HBsAg&#8221;). In a preclinical study, conducted in nonhuman primates (&#8220;NHPs&#8221;), animals were immunized with HB-402 and HB-401 in an alternating, sequential manner, which resulted in a robust cellular immune response with HBV-specific CD8+ T-cell responses against all 3 encoded HBV antigens, and induction of high titers of anti-HBsAg antibodies (Figure 1).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:229.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k016.jpg" alt="Graphic" style="display:inline-block;height:229.25pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:263.05pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 1:</b> PICV-LCMV vaccination produces robust antibody and T cell responses in non-human primates. (A) Anti-HBsAg responses induced by monthly dosing with alternating HB-402/GS-2829 and HB-401/GS-6779. Vector dosing timepoints are indicated by red (LCMV vector) or green (PICV vector) arrowheads. (B) Peak anti-HBsAg responses in individual animals. (C) Total HBV-specific ELISpot response kinetics. (D) Peak total HBV-specific T cell responses in individual animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In vivo efficacy of HB-402 and HB-401 was tested in mice transduced with varying amounts of AAV-HBV vector (high: 2x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">9</sup> viral genomes AAV-HBV; low: 5x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">8</sup> viral genomes AAV-HBV) to establish HBV persistence (chronic HBV animal model). It was found that, in mice with low serum HBV surface antigen (HBsAg) levels HB-402/HB-401 vaccination cleared detectable HBsAg in 6 of 8 mice and reduced antigens to just above the limit of detection in the remaining two animals (Figure 2, left panel). HBsAg loss was accompanied by near elimination of detectable HBV+ hepatocytes in liver of those mice (Figure 2, right panel) and significant increases in HBV-specific cellular immune responses in splenocytes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k017.jpg" alt="Graphic" style="display:inline-block;height:39.6pt;width:235.8pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k018.jpg" alt="Graphic" style="display:inline-block;height:115.8pt;width:191.85pt;"/><img src="hook-20231231x10k019.jpg" alt="Graphic" style="display:inline-block;height:133.7pt;width:162.9pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 2:</b> Vaccine efficacy in the AAV-HBV mouse model. C57BL/6 mice were transduced with 5x10<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">8</sup> or 2x10<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">9</sup> viral genomes (vg) of AAV-HBV on day -35. HB-402/GS-2829 and HB-401/GS-6779 or vehicle control immunization were administered every 2 weeks starting on Day 0 (arrows). (Left panel) Plasma HBsAg levels over time. (Right panel) HBV core+ cells in liver immunohistochemistry at day 84. **p &lt; 0.01. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:109.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(Figures from: Schmidt et al., Alternating arenavirus vector immunization generates robust polyfunctional genotype cross-reactive HBV-specific CD8 T cell responses and high anti-hbs titers. The Journal of Infectious Diseases, jiad340, https://doi.org/10.1093/infdis/jiad340).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-400 Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that the results of the preclinical studies, and the association of strong CD8+ T-cell responses and anti-HBsAg antibodies with immune clearance and long-term control of chronic hepatitis B virus (&#8220;CHBV&#8221;) (Boni 2012, Hoogeveen 2022, Yip 2018), provide a strong rationale for clinical development of HB-400. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A phase 1a/1b study (GS-US-642-5670 / NCT05770895) is underway and is designed to evaluate the safety and immunogenicity of HB-402 and HB-401 healthy volunteers and participants with CHB. Gilead Sciences initiated screening in the first quarter of 2023. Enrollment continues as the date of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-500 for the Treatment of HIV </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-500 Preclinical Data Package for HIV Cure Program</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In collaboration with Gilead Sciences, Inc. a preclinical study in a NHP model of HIV infection was conducted. The model uses Simian Immunodeficiency Virus (&#8220;SIV&#8221;) as a surrogate virus for HIV. The study shows that immunization of monkeys with replicating arenavirus vaccine vectors encoding SIV antigens (i.e., SIV Gag, Env, and Pol) is safe, immunogenic, and efficacious. The immunization induced a robust immune response, composed of SIV-specific T-cell responses and SIV Env-binding antibodies, which resulted in a reduction of SIV viral load and clinical illness in monkeys after subsequent SIV challenge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In this study, 24 monkeys were immunized with an alternating, heterologous prime/boost of PICV and LCMV based vectors, encoding the respective SIV antigens. Eight monkeys were treated with a placebo and served as control group (Figure 1). Four weeks after the last vaccination, the monkeys were challenged with a high dose of SIV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="hook-20231231x10k020.jpg" alt="Graphic" style="display:inline-block;height:109.25pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:248.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Figure 1: Schematic of the preclinical monkey study</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The vaccine induced cellular response was determined by IFN&#947; ELISpot, an assay which allows to measure T-cells and other immune cells, which respond to a specific antigen (in this case SIV vaccine antigen) by releasing IFN&#947;. It was found that after vaccination, animals developed robust SIV Gag-, Env-, and Pol-specific cellular responses (median 44-fold increase after each vaccine boost) compared with pre-vaccination (Figure 2).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:144pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k021.jpg" alt="Graphic" style="display:inline-block;height:139.65pt;width:213.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 2:</b> Total SIV-specific IFN-&#947; response measured in peripheral blood mononuclear cells (PBMCs) over weeks 0&#8211;32 of the study; circles on the x-axis indicate the day of vaccination with PICV (closed circles) and LCMV (open circles) with median responses represented by horizontal black lines.<br/>***p &lt; 0.0001<br/>(a p value of 0.05 or less represents statistical significance, meaning that there is a less than 1-in-20 likelihood that the observed results occurred by chance. A p value of 0.01 or less means that there is a less than 1-in-100 likelihood that the observed results occurred by chance).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Four weeks after the last vaccination, animals (24 monkeys in the treatment group and 7 monkeys in the Placebo group) were challenged with a high dose of SIV. Over the course of 40 weeks, SIV viral load in blood as well as signs for clinical illness of the animals was monitored (Figure 3). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Animals which were vaccinated with arenavirus vectors had significant reductions in median SIV viral load (1.45-log10 copies/mL) after SIV challenge compared with placebo (Figure 3, left panel). In addition, clinical illness after SIV infection (which is characterized by a decrease in CD4 T cell counts and body weight, non-resolving diarrhea, anemia, mild edema, loss of appetite, jaundice, lymph node swelling along with an increase in viral load) was monitored for 40 weeks after infection. It was found that vaccination resulted in significant reduction in SIV-induced clinical illness versus the placebo group at 40 weeks after challenge (Figure 3, right panel). Only 2 out of 24 monkeys in the vaccination group showed symptoms of clinical illness (app. 8%), whereas 3 out of 7 monkeys in the Placebo group exhibited signs of clinical illness (app. 42%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="hook-20231231x10k022.jpg" alt="Graphic" style="display:inline-block;height:143.8pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:215.5pt;"/><img src="hook-20231231x10k023.jpg" alt="Graphic" style="display:inline-block;height:143.85pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:200.95pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Figure 3:</b> SIV viral load after challenge with SIV. <br/>Left panel: Kinetics of SIV viral load over weeks 0&#8211;40 after challenge in placebo (closed triangles; n = 7 NHPs) and PICV/LCMV (closed circles; n = 24 NHPs) groups. Data are median &#177; IQR (interquartile range).<br/>Right panel: Clinical disease progression after SIV challenge.<br/>Correlation of (f) peak breadth of Gag-specific T-cell responses at 2 weeks after the third vaccine dose and <br/>*p &lt; 0.05.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(Figures from: Boopathy et al., Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys. npj Vaccines (2023) 8:175 ; https://doi.org/10.1038/s41541-023-00768-x).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-500 Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe, the results of this preclinical monkey study support clinical investigation of arenavirus-based vectors as a central component of therapeutic vaccination for HIV cure. We expect to initiate a Phase&#160;1 clinical study of HB-500 in people with HIV in the second quarter of 2024. Under the collaboration agreement with Gilead, we are eligible for a milestone payment upon dosing the first patient in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends, in part, on our ability to obtain and maintain intellectual property protection for our product candidates, technology and knowhow, to defend and enforce our intellectual property rights, in particular, our patent rights, to preserve the confidentiality of our knowhow and trade secrets, and to operate without infringing the proprietary rights of others. We seek to protect our product candidates and technologies by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. We also rely on trade secrets, knowhow, continuing technological innovation and in-licensing of third-party intellectual property to develop and maintain our proprietary position. We, or our collaborators and licensors, file patent applications directed to our key product candidates in an effort to establish intellectual property positions to protect our product candidates as well as uses of our product candidates for the prevention and/or treatment of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 19, 2024, we are the owner, co-owner or exclusive licensee to 13&#160;issued U.S. patents and 12&#160;pending U.S. patent applications, three pending international Patent Cooperation Treaty (&#8220;PCT&#8221;) applications, two pending U.S. provisional patent applications, and approximately 200 issued foreign patents and approximately 100 foreign patent applications. These patents and patent applications are related to our technologies concerned with the arenavirus-based immunization systems, non-replicating and replicating, our product candidates and various development programs, which are directed to the use of these immunization systems for the treatment and/or prevention of various infectious diseases or cancer, and certain clinical uses of our current or future product candidates in oncology. The issued patents and pending patent applications contain claims directed to various aspects of our work, including compositions of matter, methods of treatment and prevention, methods of producing certain compositions, and use of our product candidates in combination with certain other therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Non-Replicating Technology Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our patent portfolio related to our non-replicating technology includes a patent family exclusively licensed to us from the University of Zurich. This patent family includes five patents granted in the United States and patents granted in Europe (validated in Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom), Canada, China, India, Hong Kong, Macao and Japan. This patent family also includes pending applications in the United States, Europe, and Hong Kong. The granted patents and pending applications related to our non-replicating technology are expected to expire no earlier than 2028, not giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. Our non-replicating technology is being employed or may be employed in one or more of the product candidates or programs described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Replicating Technology Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are the owner or exclusive licensee to proprietary patent positions related to our replicating technology. Our patent portfolio related to our replicating technology includes a patent family exclusively licensed from the University of Geneva. This patent family includes a patent granted in the United States and patents granted in Europe (validated in Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland/LI, The Netherlands, Turkey and the United Kingdom), Australia, Canada, Hong Kong, India and Japan. The European patent in this family (European Patent No. 3218504) was opposed by a third party in April 2021. The opposition was dismissed, and the patent was maintained as granted by the European Patent Office (&#8220;EPO&#8221;) in an oral proceeding on May 9, 2023. This patent family also includes pending applications in the United States, Europe, Australia, Japan, China and Hong Kong. The granted United States patent from the first patent family related to our replicating technology is expected to expire in April 2037 due to patent term adjustment. The granted patents in Europe, Australia, Canada, Hong Kong, India and Japan, and the pending applications are expected to expire in 2035, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. The second patent family in our replicating platform portfolio is jointly owned by us and the University of Basel. The rights of the University of Basel under this patent family are exclusively licensed to us. This second patent family includes patents granted in Australia, China, Hong Kong and Japan. This patent family also includes pending applications in various countries, including in the United States, Europe, Eurasia, Hong Kong, Korea, China, Macao, Australia, New Zealand, Mexico, Japan, Brazil, Singapore, India, and Israel. The granted patents and the pending applications are expected to expire in 2037, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. Our replicating technology is being employed or may be employed in one or more of the product candidates or programs described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Split Vector Technology Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are the owner or exclusive licensee to proprietary patent positions related to a novel molecular strategy to vectorize arenavirus genomes, which we refer to as the Split Vector Technology. Our patent portfolio related to the Split Vector Technology includes a patent family exclusively licensed from the University of Basel. This patent family includes pending applications in the United States, Europe, Hong Kong, Canada, Australia, Japan, India and China. The second patent family related to the Split Vector Technology is jointly owned by us and the University of Basel. The rights of the University of Basel under this patent family are exclusively licensed to us. This second patent family includes pending applications in the United States and Europe. The pending applications related to the Split Vector Technology are expected to expire in November&#160;2040 and May 2042, respectively, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. The Split Vector technology is currently not employed in any of our clinical stage product candidates or late-stage preclinical programs.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Oncology Technology Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">For the application of our non-replicating and replicating technologies in oncology, we own three patent families, one pending international PCT application and one pending U.S. provisional patent application, relating to potential clinical uses of our product candidates, such as combination treatments and modes of administration. One of the patent families includes a patent granted in the United States and patents granted in Europe (validated in Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland/LI, The Netherlands, Turkey and the United Kingdom), Hong Kong, Australia, China, Macao, India  and Japan. This patent family also includes pending applications in the United States, Europe, Canada, Japan, India and Hong Kong. A second patent family includes a patent granted in China and pending applications in the United States, Europe, Australia, Canada, Hong Kong, India and Japan. The third patent family includes pending applications in the United States, Europe, Australia, Canada, China, Hong Kong, India and Japan. The granted patents and pending applications within the three patent families are expected to expire between 2036 and 2038, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. Applications claiming priority to the respective PCT application are expected to expire in February 2043, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-200 (HPV16+ Head and Neck Squamous Cell Carcinoma)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-201 and HB-202, the two components of our HB-200 product candidate, rely on our replicating technology and, depending on their clinical implementation, may relate to one or more applications in our oncology patent portfolio. In addition to the replicating and oncology patent portfolios, we own two patent families that relate more specifically to our HB-200 product candidate. The first patent family includes two patents granted in the United States and patents granted in Australia, China, Macao, India and Japan with claims directed to compositions of matter. This patent family also includes pending applications in the United States, Europe, Australia, Canada, China, India, Japan and Hong Kong. The second patent family includes pending applications in the United States, Europe, Eurasia, Australia, Brazil, Canada, China, Costa Rica, Hong Kong, India, Israel, Japan, Korea, Mexico, New Zealand, Peru, Singapore, South Africa relating to HB-200 treatment regimens. Excluding the replicating and oncology patent portfolios, the granted patents and pending applications specifically related to our HB-200 product candidate are expected to expire in 2036 and 2041, respectively, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HB-700 (KRAS Mutated Tumors)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-700 product candidate relies on our replicating technology and, depending on its clinical implementation, may relate to one or more applications in our oncology patent portfolio. In addition to the replicating and oncology patent portfolios, we currently own one pending international PCT application, one pending application in Taiwan, and one pending application in Argentina that more specifically relate to our HB-700 product candidate. Any patent claiming priority to this pending PCT application specifically related to our HB-700 product candidate is expected to expire in 2042, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-300 (Prostate Cancer)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-300 product candidate relies on our replicating technology and, depending on its clinical implementation, may relate to one or more applications in our oncology patent portfolio. In addition to the replicating and oncology patent portfolios, we currently own one patent family that more specifically relates to our HB-300 product candidate. This patent family includes pending applications in the United States, Europe, Australia, Brazil, Canada, China, India, Israel, Japan, Korea, Mexico, New Zealand, Singapore and South Africa. The pending applications specifically related to our HB-300 product candidate are expected to expire in 2042, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-400 (Hepatitis B Virus)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-400 product candidate, codeveloped with Gilead, is in Phase&#160;1b clinical trial and is being built on our non-replicating technology. In addition to the non-replicating patent portfolio, we own one patent family that relates to the use of our platform technologies for prevention and treatment of HBV. This patent family includes patents granted in the United States, Europe (validated in Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland/LI, The Netherlands, Turkey and the United Kingdom), Australia, China, Hong Kong, Macao, Mexico and Japan. This patent family also includes pending applications in the United States, Europe, Australia, Brazil, Canada, China, India, Israel, Japan, Hong Kong, Korea, Mexico, New Zealand and Singapore. Excluding the non-replicating patent portfolio, the granted patents and pending applications related to the HBV program are expected to expire in 2036, not giving effect to any potential patent term extensions or patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">HB-500 (HIV)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-500 product candidate, codeveloped with Gilead, is in preclinical phase and is being built on our replicating technology. In February 2022, we signed an amended and restated collaboration agreement, wherein we assumed development responsibilities through the end of Phase&#160;1b. In November 2023, our investigational new drug application was cleared by the FDA and we anticipate initiating the Phase&#160;1b trial in the first half of 2024. We currently do not own any patents or patent applications that more specifically relate to an HIV program outside of the replicating patent portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The actual term of any patent that may issue from the above described patent applications claiming one of our product candidates could be longer than described above due to patent term adjustment or patent term extension, if available, or shorter if we are required to file terminal disclaimers. The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20&#160;years from the earliest claimed filing date of a non-provisional patent application in the applicable country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to maintain and solidify our proprietary position for our product candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims once granted. We do not know whether any of our patent applications will result in the issuance of any patents, or what the scope of the claims in any future issued patents may be. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, invalidated, narrowed, rendered unenforceable or circumvented, which could limit our ability to stop competitors from marketing identical or substantially similar products or could reduce the length of term of patent protection that we may have for our products. With respect to patents and patent applications licensed to us, our licensors may have the right to terminate our licenses if we fail to comply with our obligations under the applicable license agreement. In addition, the claims granted in any of our issued patents may not provide us with advantages against competitors with similar products or technology. Furthermore, our competitors may independently develop technologies that are similar or identical to technology developed by us but that do not infringe our patents or other intellectual property. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, by the time that any of our product candidates or those developed by our collaborators can be commercialized, our key patent may have expired or may only continue to remain in force for a short period following commercialization, thereby reducing the usefulness of the patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors and other contractors. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants or contractors use technology or know-how owned by others in their work for us, disputes may arise as to the rights in related inventions. For this and more comprehensive risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gilead Collaboration Agreement and Stock Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;4,&#160;2018, we entered into the Gilead Collaboration Agreement, with Gilead to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating our replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of HBV or HIV, which we refer to, collectively, as the Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Gilead Collaboration Agreement, we granted Gilead an exclusive, worldwide, royalty bearing license to our knowhow and our owned and in-licensed patent rights (including those patent rights in-licensed from the University of Geneva, the University of Basel, and the University of Zurich) that are necessary or reasonably useful for researching, developing, manufacturing or commercializing products that contain a vaccine that uses our replicating or non-replicating technology platforms for expressing one or more HIV or HBV antigens, which foregoing knowhow and patent rights we refer to as the Licensed Technology (and each such product a Licensed Product), for the purpose of researching, developing, manufacturing and commercializing Licensed Products for uses in the Field.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Gilead Collaboration Agreement, we will own all new intellectual property conceived or created out of the activities conducted under the Gilead Collaboration Agreement that specifically relate to the replicating and non-replicating technology platforms. Gilead will own all other intellectual property rights conceived or created out of the activities conducted under the Gilead Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February&#160;15, 2022, we entered into the Restated Gilead Collaboration Agreement, which altered key aspects of the collaboration pertaining to the HIV therapeutic. Specifically, we assumed responsibility for advancing the HIV program through to the end of a Phase&#160;1b clinical program, and Gilead retains an exclusive right, the Option, for further development thereafter. Pursuant to the Option, Gilead has the exclusive right to take back the development rights for such HIV program candidates and to further research, develop, and commercialize such candidates in accordance with the terms and conditions of the Restated Gilead Collaboration Agreement. Gilead may exercise the Option at any time, but no later than 60&#160;days after the receipt of a data package containing pre-clinical, clinical, chemistry and manufacturing control, regulatory and other data specified by the Restated Gilead Collaboration Agreement in return for an option exercise fee of $10.0&#160;million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the Option is not exercised by Gilead during the term of the Option, or if Gilead provides written notice to us of its intention to not exercise the Option, then the terms of the Restated Gilead Collaboration Agreement will be deemed terminated with respect to the HIV Development Plan and HIV Licensed Products (each as defined in the Restated Gilead Collaboration Agreement), and the Field and rights granted under the Restated Gilead Collaboration Agreement will be limited to the HBV indication. Furthermore, if the Option expires or is terminated, the non-competition and right of first negotiations terms contained in the Restated Gilead Collaboration Agreement and summarized below will not be applicable to the development for HIV indications. In the event the Option is not exercised, we and Gilead will work in good faith to enter into a license agreement pursuant to which Gilead will grant us a milestone and/or royalty-bearing license under certain Gilead owned intellectual property necessary or reasonably useful to allow us to research, develop, manufacture and commercialize HIV product candidates as of the date on which the Option is declined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial support from Gilead to us includes a $15.0&#160;million non-refundable initiation fee and $35.0&#160;million equity commitment pursuant to the Stock Purchase Agreement. As of December 31, 2023, we received approximately $26.25&#160;million from Gilead&#8217;s purchases of our common stock under the terms of this equity commitment. In December&#160;2023, the Stock Purchase Agreement was amended. Under the amended terms we have the right to sell an additional $8.75&#160;million of common stock to Gilead as pro-rata participation with an equity financing (either public or private) at the offer price of the financing. Our option to sell these shares to Gilead expires on December 20, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Gilead Collaboration Agreement, in the event we offer a license or other rights to the Licensed Technology to a third party to research, develop, manufacture or commercialize a Licensed Product outside of the Field before June&#160;4,&#160;2028, we are required to offer Gilead a right of first negotiation for the same rights to the Licensed Technology in such field offered to the third party. If the Option expires or is terminated, the right of first negotiations terms contained in the Restated Gilead Collaboration Agreement will not be applicable to the development for HIV indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Financial Terms</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon execution of the Gilead Collaboration Agreement, Gilead paid us a one-time upfront fee of $10.0&#160;million and through to December&#160;31,&#160;2023, we received $21.2&#160;million in milestone payments for the achievement of pre-clinical research milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Upon execution of the Restated Gilead Collaboration Agreement, we became entitled to a program initiation fee of $15.0&#160;million. In addition, we are eligible for up to $140.0&#160;million in developmental milestone payments for the HBV program and $50.0&#160;million in commercialization milestone payments for the HBV program. If Gilead exercises the Option, we are eligible for up to a further $167.5&#160;million in developmental milestone payments for the HIV program, inclusive of the $10.0&#160;million program completion fee payable upon Option exercise, and $65.0&#160;million in commercialization milestone payments for the HIV program. Upon the commercialization of a Licensed Product, if ever, we are eligible to receive tiered royalties of a high single-digit to mid-teens percentage on the worldwide net sales of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">each HBV Licensed Product, and royalties of a mid-single-digit to 10% of worldwide net sales of each HIV Licensed Product, if the Option is exercised. The royalty payments are subject to reduction under specified conditions set forth in the Gilead Collaboration Agreement. In addition, Gilead is obligated to pay us for all out-of-pocket costs incurred by us in connection with the HBV program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, Gilead is obligated to pay us for all out-of-pocket costs incurred by us in connection with the HBV programs, including CMO related costs, to the extent contemplated under the research plans and research budget. In December&#160;2019, Gilead agreed to expand the reimbursement for our resources allocated to the collaboration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Termination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Either party may terminate for the uncured breach of the other party and upon the other party filing for bankruptcy, reorganization, liquidation, or receivership proceedings. On a program-by-program basis, at any time after the expiration or termination of the collaboration term for such program, Gilead may terminate the Restated Gilead Collaboration Agreement with respect to such program or on a product by product or a country-by-country basis upon prior written notice. If the Restated Gilead Collaboration Agreement is not otherwise terminated prior to the expiration of the last to expire royalty term, upon such expiration the license granted to Gilead will continue in effect, but will be fully paid-up, royalty free, perpetual, and irrevocable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Supply Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2020, we entered into a Clinical Supply Agreement with Gilead. Under the terms of the Clinical Supply Agreement, we provide Gilead with drug product for use in proof-of-concept clinical trials associated with the Licensed Products designated under the Gilead Collaboration Agreement. We receive reimbursement at an agreed cost in accordance with the terms of the Restated Gilead Collaboration Agreement. Clinical supply of a potential Phase&#160;3 clinical trial will be regulated in a separate supply agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Restated Gilead Collaboration Agreement, on February&#160;15,&#160;2022, the Effective Date, we entered into the Stock Purchase Agreement with Gilead. Pursuant to, and subject to the terms and conditions of, the Stock Purchase Agreement, Gilead will be required, at our option, to purchase up to $35,000,000 of our common stock, the proceeds of which we intend to use to fund additional research and development activities of our HIV program. On the Effective Date, Gilead purchased an initial amount of 1,666,666 unregistered shares of our common stock in exchange for approximately $5.0&#160;million at a purchase price per share equal to $3.00. On December&#160;20,&#160;2023, the parties amended the terms of the Stock Purchase Agreement and Gilead purchased 15,000,000&#160;shares of our common stock in exchange for approximately $21.25&#160;million in cash at a purchase price per share equal to $1.4167. Pursuant to the terms of the Stock Purchase Agreement, we may require Gilead to purchase the balance of the $8.75&#160;million of common stock as pro-rata participation in potential future equity raises. Our ability to sell shares of our common stock to Gilead are subject to specified limitations, including compliance with Nasdaq Rule 5635(d) and continued compliance with the Nasdaq listing rules. The Stock Purchase Agreement also prohibits Gilead from purchasing shares of our common stock if such purchase would result in Gilead being a beneficial owner of more than 19.9% of the total number of our then-issued and outstanding shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Stock Purchase Agreement may be terminated: (1) by Gilead (a) any time an Event of Default (as defined in the Stock Purchase Agreement) exists or (b) if we suspend, terminate or otherwise cease to perform our obligations under the HIV Development Plan; (2) automatically if Gilead exercises its Option pursuant to the Restated Gilead Collaboration Agreement; (3) by us for any reason; (4) automatically on the date that we sell and Gilead purchases the full $35.0&#160;million of common stock; or (5) automatically on December&#160;20,&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Stock Purchase Agreement, we and Gilead agreed to enter into a registration rights agreement obligating us to file a registration statement on Form S-3 to register for resale any additional purchases of common stock within four months of any additional purchases of common stock by Gilead.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Roche Collaboration Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October&#160;18,&#160;2022, we entered into the Roche Collaboration Agreement, with Roche, to (i) grant Roche an exclusive license to research, develop, manufacture and commercialize our pre-clinical HB-700 cancer program, an arenaviral immunotherapeutic for KRAS-mutated cancers, and (ii) grant Roche an exclusive option right to exclusively license for research, development manufacturing and commercialization, a second, novel arenaviral immunotherapeutic program targeting undisclosed cancer antigens (collectively UCAs or UCA Program). Pursuant to the Roche Collaboration Agreement, we received a non-refundable upfront payment of $25.0&#160;million and have received $10.0&#160;million in milestone payments for the achievement of a GMP manufacturing milestone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25,&#160;2024, Roche terminated the Collaboration Agreement without cause, effective as of April&#160;25,&#160;2024. The Company remains eligible for a final milestone payment associated with an IND submission. The Company plans to submit an IND to the FDA prior to the termination effective date and achieve the milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">University of Geneva License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, we entered into an Exclusive License Agreement with the University of Geneva, the Geneva Agreement. Pursuant to the Geneva Agreement, the University of Geneva granted us a worldwide, exclusive license to use the University of Geneva&#8217;s technology titled &#8220;method for vaccine delivery&#8221; and the patent rights in the subject matter of U.S. Provisional Patent Application No.&#160;62/079,493 and PCT Patent Application No.&#160;PCT/EP2015/076458, each titled &#8220;Tri-Segmented Arenaviruses as Vaccine Vectors,&#8221; including any patents that claim priority thereto, the Geneva Licensed Patent Rights, to make, have made, to use and have used, to sell and have sold, to commercialize and have commercialized products, the manufacture, use, or sale of which would infringe a claim of the Geneva Licensed Patent Rights, each a Geneva Licensed Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Geneva Agreement, we are obligated to use reasonable efforts to develop and make commercially available Geneva Licensed Products. We were also required to provide proof to the University of Geneva that we have filed an IND or an equivalent application for a Geneva Licensed Product within seven years of the effective date of the Geneva Agreement. In June&#160;2019 we informed the University of Geneva about the filing of an IND for a Geneva Licensed Product. The University of Geneva can terminate the Geneva Agreement if we stop the development and/or exploitation of the technology licensed by the University of Geneva to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Starting with the third anniversary of the effective date of the Geneva Agreement, we are required to pay the University of Geneva a nominal annual fee, which is deductible from any milestone payments, royalties or sublicense payments payable by us to the University of Geneva during the same fiscal year. We are required to pay the University of Geneva, subject to the achievement by us of specified development and regulatory milestones, payments aggregating up to CHF&#160;290,000 per Geneva Licensed Product. While the Geneva Agreement remains in effect, we are required to pay the University of Geneva low single digit royalties on aggregate net sales of Geneva Licensed Products sold by us. We must also pay the University of Geneva percentages ranging from the low single digits to 10%, decreasing as a Geneva Licensed Product proceeds through development stages, of any consideration we receive from sublicensees, depending on the timing of such sublicense. We are also responsible for the prosecution and maintenance of the Geneva Licensed Patents Rights, including the costs related thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Geneva Agreement remains in effect until the expiration of the last to expire of the Geneva Licensed Patent Rights. Following the expiry of the Geneva Agreement due to the last to expire of the Geneva Licensed Patent Rights, we will have a fully paid-up, royalty-free right to use, sell and commercialize Geneva Licensed Products. We or the University of Geneva may terminate the Geneva Agreement for the other party&#8217;s breach that remains uncured after 60&#160;days&#8217; notice. We may terminate the Geneva Agreement for convenience upon prior notice. The University of Geneva may terminate the Geneva Agreement if we cease to carry on our business or become insolvent.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">University of Basel License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2017, we entered into an Exclusive License Agreement with the University of Basel, the Basel Agreement. Pursuant to the Basel Agreement, the University of Basel granted us a worldwide, exclusive license under the University of Basel&#8217;s share in U.S. Provisional Patent Application No.&#160;62/338,400, titled &#8220;Tri-segmented Pichinde viruses as vaccine vectors,&#8221; including any patents that claim priority thereto, the Basel Licensed Patent Rights to use the technology titled &#8220;tri-segmented Pichinde viruses as vaccine vectors&#8221; as covered by the Basel Licensed Patent Rights, to make and have made, to use and have used, to sell and have sold, to commercialize and have commercialized products, the manufacture, use, sale, or importation of which would infringe a claim of the Basel Licensed Patent Rights, each a Basel Licensed Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Basel Agreement, we are obligated to use reasonable efforts to develop and make commercially available Basel Licensed Products. Beginning on February&#160;28,&#160;2018, and for as long as we have not effected a first commercial use of a Basel Licensed Product, we are required to provide the University of Basel with an annual report detailing our efforts to develop Basel Licensed Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are required to pay the University of Basel, subject to the achievement of specified development and regulatory milestones, payments aggregating up to CHF&#160;265,000 per Basel Licensed Product. While the Basel Agreement remains in effect, we are required to pay the University of Basel low single digit royalties on net sales of Basel Licensed Products. We must also pay the University of Basel a low to high single digit percentage, decreasing as a Basel Licensed Product proceeds through development stages, of any consideration we receive from sublicensees, depending on the timing of such sublicense. We are also responsible for the prosecution and maintenance of the Basel Licensed Patent Rights, and the costs related thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Basel Agreement remains in effect until the expiration of the last to expire of the Basel Licensed Patent Rights. Following the expiry of the Basel Agreement due to the last to expire of the Basel Licensed Patent Rights, we will have a fully paid-up, royalty-free right to use, sell and commercialize Basel Licensed Products. We or the University of Basel may terminate the agreement for the other party&#8217;s breach that remains uncured after 60&#160;days&#8217; notice. We may terminate the Basel Agreement for convenience upon prior notice. The University of Basel may terminate the Basel Agreement if we cease to pay for the costs associated with prosecution and maintenance of the Basel Licensed Patent Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">University of Basel Split License Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, we entered into an Exclusive License Agreement with the University of Basel, which was subsequently amended in July 2022 and September 2022, hereinafter referred to as the Basel Split Agreement. Pursuant to the Basel Split Agreement, the University of Basel granted us a worldwide, exclusive license to proprietary patent positions related to a novel molecular strategy to vectorize arenavirus genomes (Split Vector Technology as described in the Intellectual Property Section), the Basel Licensed Split Patent Rights, to make or to have made, to develop or have developed, to use, have used, sell, have sold, market, have marketed, offer for sale, distribute, have distributed, import or have imported products, the manufacture, use, sale, or importation of which would infringe a claim of the Basel Licensed Split Patent Rights, each a Basel Licensed Split Product. Pursuant to the Basel Split Agreement, the University of Basel further granted us a worldwide, exclusive license under the University of Basel&#8217;s share in an international PCT application related to certain improvements of the Split Vector Technology, including any patents and patent applications that claim priority thereto, such patents and patent applications are further included in the Basel Licensed Split Patent Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to the terms of the Basel Split Agreement, we are obligated to use commercially reasonable efforts to develop and manufacture Basel Licensed Split Products and make commercially available Basel Licensed Split Products in the United States and at least three major European countries. In addition, we have to reach certain pre-clinical and clinical development milestones within specified time periods. Based on technical difficulties and changing priorities / strategic considerations, we did not meet the first pre-clinical milestone as defined in the original Basel Split Agreement and had to pay a re-scheduling fee of CHF 100,000 to University of Basel. We subsequently agreed with the University of Basel to amend the original Basel Split Agreement and entered into an amendment under which we defined a new </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pre-clinical development plan and pre-clinical development milestones. Under the respective amendment we further agreed to make additional non-material milestone payments upon achievement of the newly defined pre-clinical development milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the amended Basel Split Agreement, we have the right to request postponement of pre-defined pre-clinical or clinical development milestones against payment of rescheduling fees in the range of CHF&#160;250,000 to CHF&#160;1,000,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we fail to perform any of our diligence obligations specified in the Basel Split Agreement, after having exercised all available postponement options, the University of Basel can demand a written development and marketing plan. If we fail to agree with the University of Basel on any amendments to our development and marketing plans based on the procedure specified in the Basel Split Agreement upon such demand for amendments from the University of Basel, the University of Basel has the right to send us a notice of its intention to terminate the Basel Split Agreement. If we are not in agreement, we may request that the matter is assessed by an independent expert arbitrator. If such an expert arbitrator determines that we fail to meet our diligence obligations, the University of Basel may terminate the Basel Split Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Beginning on January&#160;1,&#160;2021 and ending on the date of the first commercial sale of a Basel Licensed Split Products, we are required to provide the University of Basel with an annual report detailing our efforts to develop Basel Licensed Split Products and to obtain governmental approvals necessary for marketing the same, as well as periodic updates relating to the pre-defined pre-clinical milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We paid the University of Basel nominal amounts upon entering into the agreement as well as upon execution of the second amendment in September 2022 and are required to pay a non-material annual maintenance fee, which is deductible from any milestone payments, royalties or sublicense payments payable by us to the University of Basel during the same year. We are required to pay the University of Basel, subject to the achievement of specified development and regulatory milestones, payments aggregating up to CHF&#160;2,000,000 per Basel Licensed Split Product. While the Basel Split Agreement remains in effect, we are required to pay the University of Basel low single digit royalties on net sales of Basel Licensed Split Products. We must also pay the University of Basel a low double digit to low single digit percentage, decreasing as a Basel Licensed Split Product proceeds through development stages, of any consideration we receive from sublicensees, depending on the timing of such sublicense. We are also responsible for the prosecution and maintenance of the Basel Licensed Split Patent Rights, and the costs related thereto. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Basel Split Agreement remains in effect until the expiration of the last to expire of the Basel Licensed Split Patent Rights. Following the expiry of the Basel Split Agreement due to the last to expire of the Basel Licensed Split Patent Rights, we will have a fully paid up, royalty free right to use, sell and commercialize Basel Licensed Split Products. We or the University of Basel may terminate the agreement for the other party&#8217;s breach that remains uncured after 60&#160;days&#8217; notice. We may terminate the Basel Agreement for convenience upon prior notice. The University of Basel may terminate the Basel Split Agreement if we file&#160;a petition for bankruptcy or insolvency or both, or reorganization relating to bankruptcy or insolvency, or in the event of an adjudication that we have become bankrupt or insolvent or both. The University of Basel may further terminate the Basel Split Agreement if we oppose or dispute the validity of any of the Basel Licensed Split Patent Rights or assist a third party to do the same. If we fail to perform any of our diligence obligations specified in the Basel Split Agreement, after having exercised all available postponement options, and if we fail to agree with the University of Basel on any amendments to our development and marketing plans based on the procedure specified in the Basel Split Agreement upon such demand for amendments from the University of Basel, the University of Basel may terminate the Basel Split Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">University of Zurich License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In October&#160;2011, we entered into a License Agreement with the University of Zurich, the Zurich Agreement. Pursuant to the Zurich Agreement, the University of Zurich granted us a worldwide, exclusive license to PCT Patent Application No. PCT/EP/08/010994, titled &#8220;Propagation deficient arenavirus vectors,&#8221; the Zurich Licensed Patent Rights, to make and have made, use, sell, offer for sale, and import products that fall within the scope of the Zurich </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Licensed Patent Rights, each a Zurich Licensed Product and to practice the Zurich Licensed Patent Rights and methods that fall within the scope of the Zurich Licensed Patent Rights, each a Zurich Licensed Method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Zurich Agreement, we are obligated to diligently proceed with the development, manufacture, and sale of, and the obtaining of government approvals for the manufacture, use and sale of, suitable Zurich Licensed Products in the United States, Japan and certain European countries. If we fail to use commercially reasonable efforts to do the foregoing, the University of Zurich can demand a written development and marketing plan. Failure of the parties to agree on a development and marketing plan entitles the University of Zurich to terminate the Zurich Agreement. Beginning on January&#160;1,&#160;2012, and ending on the date of the first commercial sale of a Zurich Licensed Product, we are required to provide the University of Zurich with an annual report detailing our efforts to develop and test Zurich Licensed Products and to use the Zurich Licensed Patent Rights and Zurich Licensed Methods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In consideration for the license granted to us under the Zurich Agreement, we issued 26,744&#160;shares with a nominal value of EUR&#160;2,297 of our common stock to the University of Zurich and agreed to provide them certain antidilution rights, which rights have subsequently expired. We are required to pay the University of Zurich low single digit royalties on net sales of Zurich Licensed Products or Zurich Licensed Methods. We must also pay the University of Zurich percentages ranging from the mid-single digits to 20% of any sublicense fees and consideration we receive from sublicensees, depending on the amount of fees received from sublicensees and the cumulative monetary value of the consideration and fees received from all sublicensees. We are responsible for the prosecution and maintenance of the Zurich Licensed Patent Rights, and the costs related thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Zurich Agreement remains in effect on a country-by-country basis until the expiration of the last to expire of the Zurich Licensed Patent Rights in such country. The University of Zurich may terminate the agreement for our uncured breach of any of the terms of the Zurich Agreement or if we oppose or dispute the validity of any of the Zurich Licensed Patent Rights, or assist a third party to do the same. If we fail to use commercially reasonable efforts to market and develop the Zurich Licensed Products in certain countries, and if we fail to agree with the University of Zurich on any amendments to our development and marketing plans within the time specified in the Zurich Agreement upon such demand for amendments from the University of Zurich, the University of Zurich may terminate the Zurich Agreement. We may terminate the Zurich Agreement for convenience upon prior notice. The Zurich Agreement automatically terminates if we file&#160;a petition for bankruptcy, insolvency, or reorganization relating to bankruptcy or insolvency, or in the event of an adjudication that we have become bankrupt or insolvent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">National Institutes of Health License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2013, we entered into a Biological Materials License Agreement with the National Institutes of Health (&#8220;NIH&#8221;) which was subsequently amended in April&#160;2017, July&#160;2018, January&#160;2021, and May 2021, hereinafter referred to as the NIH Agreement. Pursuant to the NIH Agreement, the NIH granted us a worldwide, nonexclusive license to make, have made, import and use certain cells and cell clones developed at the Vaccine Research Center of the NIH (the &#8220;NIH Licensed Products&#8221;) to manufacture viral vectors based on our proprietary arenavirus-based vectors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the NIH Agreement, we are required to provide the NIH with an annual report which states the number and description of NIH Licensed Products made or otherwise disposed of. We are further responsible for obtaining and maintaining any required third-party license for the background rights for the commercial use of the respective cells and cell clones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In consideration of the license granted to us pursuant to the NIH Agreement, we paid the NIH a low six figure and a mid-five figure issue royalty, upon execution of the NIH Agreement and the first amendment, respectively. We must also pay the NIH 10% of any consideration we receive from sublicensees. We must also pay the NIH low five figure to mid six figure annual royalty payments, increasing as our most developed product candidate manufactured from NIH Licensed Products proceeds through development stages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Unless earlier terminated, the NIH Agreement remains in effect for a term of 20 years from the effective date. We have the option to extend the term of the agreement for additional one year periods, upon prior notice to the NIH. The NIH may terminate the NIH Agreement if we are in default in performing any material obligation under the NIH </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement and do not remedy such default within a specified period upon notice thereof. We may terminate the NIH Agreement for convenience upon prior notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">University of Minnesota License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2022, we entered into a Non-Exclusive License Agreement with the Regents of the University of Minnesota (the &#8220;Minnesota Agreement&#8221;). Pursuant to the Minnesota Agreement, the University of Minnesota granted us a worldwide, non-exclusive license under the University of Minnesota&#8217;s rights in the subject matter of PCT Patent Application No. PCT/US2015/051337 including any patents that claim priority thereto (the &#8220;Minnesota Licensed Patent Rights&#8221;) to make, have made, sell, have sold, offer to sell, have offered to sell, commercialize, have commercialized, import, have imported, export, have exported, use, have used and otherwise exploit products that are covered by a valid claim of the Minnesota Licensed Patent Rights (and simultaneously covered by a claim of the University of Geneva patent related to our replicating technology which is exclusively licensed to us), (each, a &#8220;Minnesota Licensed Product&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We paid the University of Minnesota a low six figure amount upon entering into the agreement and are required to pay a non-material annual maintenance fee, and, upon commercialization of the first Minnesota Licensed Product, an annual minimum royalty which is creditable against royalties payable in the same year. We are required to pay the University of Minnesota, subject to the achievement of specified regulatory and commercial milestones, payments aggregating up to $2,750,000 per Minnesota Licensed Product. While the Minnesota Agreement remains in effect, we are required to pay the University of Minnesota royalties on aggregate net sales of Minnesota Licensed Products, of a generally below single digit percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We must also pay the University of Minnesota low single digit percentages of certain considerations we receive from sublicensees, subject to pre-defined minimum and maximum payments in the range of a mid five figure amount to a mid six figure amount. We further have to pay the University of Minnesota a nominal amount if we assign the Minnesota Agreement as part of a change of control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless earlier terminated, the Minnesota Agreement remains in effect until the expiration of the last to expire of the Minnesota Licensed Patent Rights. Following the expiry of the Minnesota Agreement due to the last to expire of the Minnesota Licensed Patent Rights, we will have a fully paid-up, royalty-free right to use, sell and commercialize Minnesota Licensed Products. We or the University of Minnesota may terminate the Minnesota Agreement for the other party&#8217;s breach that remains uncured after 30 days&#8217; notice. We may terminate the Minnesota Agreement for convenience upon prior notice. The University of Minnesota may terminate the Minnesota Agreement if we cease operations, become insolvent, enter into any bankruptcy, receivership, or similar proceeding, or attempt to use the Minnesota Licensed Patent Rights as collateral for any debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries have made substantial investments in recent years into the rapid development of novel immunotherapies for the treatment of a range of pathologies, including infectious diseases and cancers, making this a highly competitive market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face substantial competition from multiple sources, including large and specialty pharmaceutical, biopharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. Our competitors compete with us on the level of the technologies employed to target various therapeutic areas, such as adoptive cell therapies and active immunization technologies, or on the level of development of product candidates. In addition, many small biotechnology companies have formed collaborations with large, established companies to (i)&#160;obtain support for their research, development and commercialization of products or (ii)&#160;combine several treatment approaches to develop longer lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies and combinations thereof, technologies, and data emerge within the field of immunotherapy and, furthermore, within the treatment of infectious diseases and cancers.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the current standard of care treatments for patients with infectious diseases or cancers, numerous commercial and academic preclinical studies and clinical trials are being undertaken by a large number of parties to assess novel technologies and product candidates in the field of immunotherapy. Results from these studies and trials have fueled increasing levels of interest in the field of immunotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors in the development of product candidates in our lead immunooncology indication of therapies for HPV+ cancers, include, among others, companies such as Cue Biopharma, ISA Pharmaceuticals B.V., Nyode, PDS Biotech, TCR Cure, Transgene and Ultimovacs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Companies developing technology that competes directly or indirectly with our technology include Abalos GmbH, which is developing mammarenavirus vectors for cancer, and companies developing oncolytic viruses, bispecific antibodies, engineered cell therapies, tumor specific antigens, and other active immunization technologies including, among others, Adaptimmune PLC, BioNTech, CureVac AG, Gritstone Bio, Inc., Merck &amp; Co., Moderna, Novartis, Replimune Group, Inc., Roche and Turnstone Biologics Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, the regulatory approval process, and marketing than we do. Mergers and acquisition activity in the pharmaceutical, biopharmaceutical and biotechnology sector is likely to result in greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if one or more of our competitors develop and commercialize products that are safer, more effective, better tolerated, or of greater convenience or economic benefit than our proposed product offering. Our competitors also may be in a position to obtain FDA or other regulatory approval for their products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and treatment cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have been establishing robust manufacturing processes, reliable assays and strong supply agreements for all of the components used in our product candidates to support ongoing and planned clinical trials. These include the components for our non-replicating based and replicating based product candidates. For GMP production and testing we rely on qualified CMOs to produce and test our clinical material. Currently we do not own or operate manufacturing facilities beyond laboratory scale non-GMP production. We require that our CMOs produce bulk drug substances and finished drug products in accordance with cGMP, and all other applicable laws and regulations. Although we plan to establish our own manufacturing facility in the future, we may continue to rely on CMOs for parts of the process, like filling and labelling of our products for commercial sale, to reduce supply risks and cost of goods sold. We continue to build and maintain agreements with manufacturers that include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we made the decision to discontinue our current GMP facility project as part of the Reduction Plan announced in January&#160;2024 we plan to ultimately establish our own manufacturing facility in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, such as those developed from our non-replicating and replicating technologies and any other product candidates we develop. Generally, before a new drug or biologic can be marketed, considerable </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">U.S. Biological Product Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations and biologics under the FDCA, the Public Health Service Act (&#8220;PHSA&#8221;) and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates and any future biological product candidates we develop must be approved by the FDA through a biologics license application (BLA) process before they may be legally marketed in the United States. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity and potency. The FDA review and approval process generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Approval by an Institutional Review Board (IRB) or independent ethics committee at each clinical trial site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and well controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (GCP) requirements and other clinical trial related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of a BLA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A determination by the FDA within 60&#160;days of its receipt of a BLA to accept the filing for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">7.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA preapproval inspection of the manufacturing facility or facilities where the biologic will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, strength, quality and purity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">8.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Potential FDA audit of the clinical trial sites that generated the data in support of the BLA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">9.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA, including, where applicable, consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the biologic in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Preclinical Studies and IND</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well designed and well conducted foreign clinical trial not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials generally are conducted in three sequential phases, known as Phase&#160;1, Phase&#160;2 and Phase&#160;3, and may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;1 clinical trials generally involve a small number of healthy volunteers or disease affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;2 clinical trials involve studies in disease affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Post-approval trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of a BLA. Failure to exhibit due diligence with regard to conducting required Phase&#160;4 clinical trials could result in withdrawal of approval for products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">FDA Review Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. The BLA may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity and potency of the investigational product to the satisfaction of FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Prescription Drug User Fee Act (PDUFA) as amended, each BLA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA reviews all submitted BLAs before it accepts them for filing and may request additional information rather than accepting the BLA for filing. The FDA decides whether to accept a BLA for filing within 60&#160;days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months, from the filing date, in which to complete its initial review of an original BLA and respond to the applicant, and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">six months from the filing date of an original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process is often extended by FDA requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before approving a BLA, the FDA will conduct a preapproval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates a BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data, pivotal Phase&#160;3 clinical trial(s) as well as other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000&#160;individuals in the United States, or more than 200,000&#160;individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Orphan drug designation for a biologic must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union (EU) has similar, but not identical, requirements and benefits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FDA provides programs intended to facilitate and expedite development and review of new products that are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast-track designation, breakthrough therapy designation, priority review, and accelerated approval. These designations are not mutually exclusive, and a product candidate may qualify for one or more of these programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fast-track program is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for fast-track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast-track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a biologic can request the FDA to designate the product for fast-track status any time before receiving BLA approval, but ideally no later than the pre-BLA meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A product that receives fast-track program designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biologic designated for priority review in an effort to facilitate the review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. Under the Food and Drug Omnibus Reform Act of 2022 (FDORA), the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct such studies in a timely manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, unless otherwise informed by the agency, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast-track designation, plus intensive guidance from the FDA to ensure an efficient drug development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Fast-track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Pediatric Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the Pediatric Research Equity Act (PREA), a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the biologic for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Innovation Act (FDASIA) amended the FDCA to require that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (PSP) within 60&#160;days of an end of Phase&#160;2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase&#160;3 or Phase&#160;2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials as well as other clinical development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Post-Marketing Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. Prescription drug and biologic promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the development of additional data or preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy (REMS) to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FDA regulations require that products be manufactured in specific facilities and in accordance with cGMP regulations. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws, including applicable product tracking and tracing requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violations, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of post-approval problems with a product may result in restrictions on a product, manufacturer or holder of an approved BLA, including recall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Other U.S. Healthcare Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), other divisions of the Department of Health and Human Services (HHS), the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufactures to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act (FCA) which may constrain the business or financial arrangements and relationships through which companies sell, market and distribute pharmaceutical products. In addition, transparency laws and patient privacy regulations by federal and state governments and by governments in foreign jurisdictions can apply to the manufacturing, sales, promotion and other activities of pharmaceutical manufactures. These laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:53.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary penalties;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:53.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal civil and criminal false claims laws and civil monetary penalty laws, such as the FCA, which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:53.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:53.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:53.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">privacy, security and transmission of individually identifiable health information, as well as their covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:53.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal transparency requirements under the Affordable Care Act (ACA) including the provision commonly referred to as the Physician Payments Sunshine Act, and its implementing regulations, which requires applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed health care practitioners and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:53.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:53.45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute and FCA, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales representatives. State and foreign laws, including for example the EU General Data Protection Regulation (EU GDPR), also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations with respect to certain laws. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect our business in an adverse way. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ensuring our business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time and resource consuming and can divert a company&#8217;s attention from the business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The failure to comply with any of these laws or regulatory requirements may subject companies to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical company to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are&#8239;found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">U.S. Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower cost biosimilars, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition to coverage under Medicare Part&#160;D for the manufacturer&#8217;s outpatient drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which remain in effect through 2032, absent additional congressional action. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation. The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, on May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives which could limit the amounts that federal and state governments will pay for healthcare products and services and result in reduced demand for certain pharmaceutical products or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Inflation Reduction Act of 2022 (IRA) includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one rare disease designation and for which the only approved indication is for that disease or condition.  If a product receives multiple rare disease designations or has multiple approved indications, it may not qualify for the orphan drug exemption. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The effects of the IRA on our business and the healthcare industry in general is not yet known. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the United States, there has also been a lot of legislative activity at the state level with respect to privacy regulation. For example, in California, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;) (collectively the &#8220;CCPA&#8221;), broadly defines personal information and creates individual privacy rights and protections for California consumers (as defined in the law), places increased privacy and security obligations on entities handling personal data of consumers or households, and provides for civil penalties for violations and a private right of action for data breaches. The CCPA requires covered companies to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. While there is an exception for protected health information that is subject to HIPAA and clinical trial regulations, the CCPA may impact our business activities if we become a "Business" regulated by the scope of the CCPA. Additionally, as of January 1, 2023, the effective date for the CPRA&#8217;s amendments to the CCPA, California has a new state agency that is vested with authority to implement and enforce the CCPA. In addition to the CCPA, numerous other U.S. states &#8211; including Virginia, Colorado, Connecticut, and Utah &#8211; have enacted comprehensive privacy laws that are substantially similar in scope and contain many of the same requirements and exceptions as the CCPA, including exemptions for clinical trial data and limited obligations for entities regulated by HIPAA. In addition, Congress regularly contemplates passing comprehensive privacy legislation at the federal level, reflecting a trend toward more stringent privacy legislation in the U.S., which trend may accelerate in the future. The effects of the CCPA, and other similar state or federal laws, are potentially significant and may require us to modify our data processing practices and policies and to incur substantial costs and potential liability in an effort to comply with such legislation. The existence of comprehensive privacy laws in different states in the country could make </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">U.S. Patent Term Restoration and Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of FDA approval of our product candidates and any future product candidates we develop, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch Waxman Amendments. The Hatch Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office (USPTO) in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. A reference biological product is granted 12&#160;years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods. This six-month exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA issued &#8220;Written Request&#8221; for such a trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Union Drug Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU our future products also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory authorities has been obtained.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. In April 2014, the EU adopted the new Clinical Trials Regulation (EU) No 536/2014 (CTR), which entered into application on January 31, 2022, repealing and replacing the Clinical Trials Directive 2001/20/EC (CTD). The extent to which on-going clinical trials will be governed by the CTR will depend on the duration of the individual clinical trial. For clinical trials in relation to which an application for approval was made on the basis of the CTD before January 31, 2023, the CTD will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The CTR aims to simplify and streamline the approval of clinical trials in the EU, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increase transparency. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System (&#8220;CTIS&#8221;); a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each Member State concerned. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Union Drug Review and Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, medicinal products can only be commercialized after obtaining a marketing authorization (&#8220;MA&#8221;). To obtain an MA for a product in the EU, an applicant must submit a Marketing Authorization Application, or MAA, either under a centralized procedure administered by the European Medicines Agency, or EMA, or one of the procedures administered by the competent authorities of EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The centralized procedure provides for the grant of a single MA is issued by the European Commission, based on the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA, that is valid throughout the entire territory of the European Economic Area (&#8220;EEA&#8221;) (which comprises the 27 EU Member States, Iceland, Liechtenstein and Norway). The centralized procedure is mandatory for certain types of products, such as medicines produced by biotechnological processes, products designated as orphan medicinal products, advanced therapy medicines (i.e. gene therapy, somatic cell therapy or tissue engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance indicated for the treatment of other diseases and products not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who adopts the final decision in relation to a MAA, which is issued within 67 days of receipt of the EMA&#8217;s opinion. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unlike the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human, or CMDh, for review. The subsequent decision of the European Commission is binding on all EU Member States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the MA of a medicinal product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the above-described procedures, before granting the MA, the European Commission or the competent authorities of the EU Member States make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An MA has, in principle, an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the Common Technical Document providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The European Commission may grant a conditional MA for a medicinal product if it is demonstrated that all of the following criteria are met: (i) the benefit-risk balance of the medicinal product is positive; (ii) it is likely that the applicant will be able to provide comprehensive data post-authorization; (iii) the medicinal product fulfils an unmet medical need; and (iv) the benefit of the immediate availability to patients of the medicinal product is greater than the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">risk inherent in the fact that additional data are still required. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA and approved by the European Commission, the MA will cease to be renewed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An MA may also be granted &#8220;under exceptional circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA will be withdrawn if the risk-benefit ratio is no longer favorable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Advanced Therapy Medicinal Products in the European Union</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advanced Therapy Medicinal Products (&#8220;ATMPs&#8221;), include gene therapy products as well as somatic cell therapy products and tissue engineered products. The grant of marketing authorization in the EU for products containing viable human tissues or cells such as gene therapy medicinal products is governed by Regulation (EC) No. 1394/2007 on ATMPs, read in combination with Directive (EC) No. 2001/83 of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation (EC) No. 1394/2007 establishes specific rules concerning the authorization, supervision and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety and efficacy of their products to the EMA which is required to provide an opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cell-based products must also comply with Directive (EC) No. 2004/23 of the European Parliament and of the Council of March 31, 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, or the Tissues and Cells Directive, as well as its technical implementing directives. This Directive describes the conditions and quality requirements which must be applied when sourcing the cells intended for manufacturing of the cell-based medicinal product. The EU Member States have transposed the Tissues and Cells Directive into their national laws. However, various interpretations of the Tissue and Cells Directive have occurred and are reflected in individual EU Member States national implementing legislation which have led to diverging approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Union Pediatric Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EU, Regulation (EC) No 1901/2006 provides that all MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a six-month extension to the Supplementary Protection Certificate (&#8220;SPC&#8221;) if any is </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in effect at the time of authorization or, in the case of orphan medicinal products, a two-year extension of orphan market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Union Data and Market Exclusivities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, innovative medicinal products qualify for eight years of data exclusivity upon grant of an MA and an additional two years of market exclusivity. The data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU, during a period of eight years from the date on which the reference product was first authorized in the EU. During the additional two-year period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be placed on the EU market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are determined to bring a significant clinical benefit in comparison with currently approved therapies. There is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be an innovative medicinal product, and products may not qualify for data exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for MA. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Union Orphan Designation and Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, medicinal products can be designated as an orphan medicinal product by the European Commission, following the opinion of the EMA&#8217;s Committee for Orphan Medicinal Products if the sponsor of a product can establish that: (1) the product is intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (2) either (i) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (ii) it is unlikely that the marketing of the product, without the benefits derived from orphan status, would generate sufficient return in the EU to justify the necessary investment in its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or, if a method exists, the product would be a significant benefit to those affected by that condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An application for the designation of a medicinal product as an orphan medicinal product must be submitted at any stage of development of the medicinal product but before filing of an MAA. An MA for an orphan medicinal product may only include indications designated as orphan. For non-orphan indications treated with the same active pharmaceutical ingredient, a separate marketing authorization has to be sought.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EU, orphan designation entitles a party to financial incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Upon grant of a marketing authorization, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a &#8220;similar product&#8221; and the European Commission cannot grant a marketing authorization for the same indication for a period of ten years. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The market exclusivity period may be reduced to six years if the orphan designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, an MA may be granted to a similar medicinal product with the same orphan indication during the 10 year period if (i) it is established that a similar medicinal product is safer, more </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">effective or otherwise clinically superior to the original orphan medicinal product; (ii) the marketing authorization holder of the authorized orphan product consents to a second original orphan medicinal product application; or (iii) the marketing authorization holder of the authorized orphan product cannot supply enough orphan medicinal product. A company may also voluntarily remove a product from the register of orphan products. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Manufacturing Regulation in the EU</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to an MA, various other requirements apply to the manufacturing and placing on the EU market of medicinal products. The manufacturing of medicinal products in the EU requires a manufacturing authorization and import of medicinal products into the EU requires a manufacturing authorization allowing for import. The manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including EU cGMP standards. Similarly, the distribution of medicinal products within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of EU Member States. Marketing authorization holders and/or manufacturing and import authorization, or MA holders and/or distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of non-compliance with the EU or EU Member States&#8217; requirements applicable to the manufacturing of medicinal products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an MA for a medicinal product in the EU is obtained, the holder of the MA is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (&#8220;PSURs&#8221;).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All new MAAs must include a risk management plan (&#8220;RMP&#8221; describing the risk management system that the Company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk- minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, which may require approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Much like the Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. In addition, payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization as well as the regulatory authorities of the individual EU Member States. Outside the United States, interactions between pharmaceutical companies and health care </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">professionals including the provision of benefits or advantages to physicians , are also governed by strict laws, such as national anti-bribery laws of European countries such as the Bribery Act 2010 in the UK, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aforementioned EU rules are generally applicable in the European Economic Area (EEA) which consists of the EU Member States, plus Norway, Liechtenstein and Iceland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">European Data Collection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The collection and use of personal health data in the EEA is governed by the EU GDPR. The EU GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The EU GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct privacy impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, mandatory data breach notification and &#8220;privacy by design&#8221; requirements, and creates direct obligations on service providers acting as data processors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, further to the United Kingdom&#8217;s exit from the European Union on January 31, 2020, the EU GDPR ceased to apply in the United Kingdom at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the United Kingdom&#8217;s European Union (Withdrawal) Act 2018 incorporated the EU GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the United Kingdom&#8217;s data protection regime, which is independent from but substantially aligned to the European Union&#8217;s data protection regime. Although the EU GDPR and the UK GDPR currently impose substantially similar obligations, it is possible that over time the UK GDPR could become less aligned with the EU GDPR. The UK government has announced plans to reform the data protection legal framework in the UK in the Data Protection and Digital Information Bill. The potential misalignment between future UK laws and regulations and EU laws and regulations could add legal risk, uncertainty, complexity and cost to our handling of EU/UK personal information and our privacy and data security compliance programs and could require us to implement different compliance measures for the UK and the EU. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU GDPR, the EC has issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the United Kingdom to countries not regarded by the United Kingdom as providing adequate protection. The UK government has confirmed that personal data transfers from the United Kingdom to the EEA remain free flowing. To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with EU and UK data protection laws. There are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EU&#8217;s Standard Contractual Clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK Extension thereto (which allows for transfers for relevant U.S.-based organizations who self-certify compliance and participate in the Framework). However, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with the requirements of the EU GDPR or UK GDPR and the related national data protection laws of the EEA Member States may result in fines up to &#8364;20 million or 4% of a company&#8217;s global annual revenues for the preceding financial year, whichever is higher. Moreover, the EU GDPR and UK GDPR grant data subjects the right to claim material and non-material damages resulting from infringement of the EU GDPR or UK GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the EU GDPR and UK GDPR, will require significant time, resources and expense, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Brexit and the Regulatory Framework in the United Kingdom</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The United Kingdom&#8217;s, or UK, withdrawal from the EU on January 31, 2020, commonly referred to as Brexit, has changed the regulatory relationship between the UK and the EU. The Medicines and Healthcare products Regulatory Agency, or MHRA, is now the UK&#8217;s standalone regulator for medicinal products and medical devices.  Great Britain (England, Scotland and Wales) is now a third country to the EU. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules for now. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is derived from the CTD, as implemented into UK national law through secondary legislation. On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials, and which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The UK Government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations will align with the CTR. In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketing authorizations in the UK are governed by the Human Medicines Regulations (SI 2012/1916), as amended. Since January 1, 2021, an applicant for the EU centralized procedure marketing authorization can no longer be established in the UK. As a result, since this date, companies established in the UK cannot use the EU centralized procedure and instead must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain a marketing authorization to market products in the UK. All existing EU marketing authorizations for centrally authorized products were automatically converted or grandfathered into UK marketing authorization, effective in Great Britain only, free of charge on January 1, 2021, unless the marketing authorization holder opted-out of this possibility. Northern Ireland currently remains within the scope of EU authorizations in relation to centrally authorized medicinal products. Accordingly, until the Windsor Framework is implemented in Northern Ireland on January 1, 2025, products falling within the scope of the EU centralized procedure can only be authorized through UK national authorization procedures in Great Britain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The MHRA has also introduced changes to national marketing authorization procedures. This includes introduction of procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment route, a rolling review procedure and the International Recognition Procedure. Since January 1, 2024, the MHRA may rely on the International Recognition Procedure, or IRP, when reviewing certain types of marketing authorization applications. This procedure is available for applicants for marketing authorization who have already received an authorization for the same product from a reference regulator. These include the FDA, the EMA, and national competent authorities of individual EEA countries. A positive opinion from the EMA and CHMP, or a positive end of procedure outcome from the mutual recognition or decentralized procedures are considered to be authorizations for the purposes of the IRP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is no pre-marketing authorization orphan designation for medicinal products in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding marketing authorization application. The criteria are essentially the same as those in the EU, but have been tailored for the market. This includes the criterion that prevalence of the condition in Great Britain, rather than the EU, must not be more than five in 10,000. Upon the grant of a marketing authorization with orphan status, the medicinal product will benefit from up to 10 years of market exclusivity from similar products in the approved orphan indication. The start of this market exclusivity period will be set from the date of first approval of the product in Great Britain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Rest of the World Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For other countries outside of the EU and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. In addition, many jurisdictions outside of Europe are also considering and/or enacting comprehensive data protection legislation. These laws impose stringent requirements applicable to our collection, use and processing of personal data including identifiable health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sales of our products, when and if approved, will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, an agency within the HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug or biological products exists in the United States. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. As a result, coverage determination is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Factors payors consider in determining reimbursement are based on whether the product is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a covered benefit under its health plan; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safe, effective and medically necessary; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">appropriate for the specific patient; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost-effective; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:38.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">neither experimental nor investigational.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of biosimilars for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the HHS as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e.,&#160;new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established the Medicare Part&#160;D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part&#160;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part&#160;A and B, Part&#160;D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part&#160;D prescription drug plan sponsors are not required to pay for all covered Part&#160;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part&#160;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&#160;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&#160;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&#160;D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part&#160;B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although, under the current state of the law, with the exception of children&#8217;s hospitals, these newly eligible entities will not be eligible to receive discounted 340B pricing on orphan drugs. In addition, as 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide coverage and reimbursement. Obtaining coverage and reimbursement for newly approved drugs and biologics is a time consuming and costly process, and coverage may be more limited than the purposes for which a drug is approved by the FDA or comparable foreign regulatory authorities. Assuming coverage is obtained for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require copayments that patients find unacceptably high. Additionally, coverage policies and third-party reimbursement rates may change at any time. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of prescribed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, we, or our collaborators may develop companion diagnostic tests for use with our product candidates. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have not yet developed any companion diagnostic tests for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. In addition, some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies. This Health Technology Assessment, or HTA, process is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the national healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. In December 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA Regulation, was adopted. The HTA Regulation is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. When it enters into application in 2025, the HTA Regulation will be intended to harmonize the clinical benefit assessment of HTA across the European Union. In light of the fact that the United Kingdom has left the EU, Regulation No 2021/2282 on HTA will not apply in the United Kingdom. However, the UK Medicines and Healthcare products Regulation Agency (&#8220;MHRA&#8221;) is working with UK HTA bodies and other national organizations, such as the Scottish Medicines Consortium (&#8220;SMC&#8221;), the National Institute for Health and Care Excellence (&#8220;NICE&#8221;), and the All-Wales Medicines Strategy Group, to introduce new pathways supporting innovative approaches to the safe, timely and efficient development of medicinal products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Capital Resources</p><a id="_Hlk129176541"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February&#160;29,&#160;2024, we had 151&#160;full-time employees and 28&#160;part-time employees. Of our 179&#160;full and part-time employees, 42, or 23.5%, have Ph.D. or M.D. degrees and 140, or 78.2%, are engaged in research and development activities. Pursuant to Austrian law, all of our Austrian employees are covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. To further drive attraction and retention of our high-quality, experienced, and diverse workforce, we invest in the physical, emotional, and financial well-being of our employees. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of stock-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate History</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were originally incorporated as Hookipa Biotech AG under the laws of Austria in 2011. In February&#160;2017, we reorganized to become a corporation under the laws of the State of Delaware as Hookipa Biotech,&#160;Inc., which was a wholly-owned subsidiary of Hookipa Biotech AG. In June&#160;2018, Hookipa Biotech,&#160;Inc. changed its name to HOOKIPA Pharma&#160;Inc. and acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech&#160;GmbH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Facilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located in New York, New York, pursuant to a lease that expires in August&#160;2026. Our European research and preclinical development operations are located in Vienna, Austria, where we lease and occupy approximately 30,681&#160;square feet of office and laboratory space. Our first facility is leased pursuant to two operating leases, comprised of (i)&#160;a lease of unlimited duration for approximately 15,239&#160;square feet of office and laboratory space and (ii)&#160;a lease set to expire in September 2028 and with no option to extend for approximately 2,367&#160;square feet of storage space. In 2019, we entered into a lease for a second facility located in Vienna, Austria that is set to expire in February&#160;2029, where we occupy approximately&#160;15,440&#160;square feet of office and laboratory space. In May 2021 we signed an agreement to purchase a parcel of land in the north of Vienna and have received building permission to build a GMP manufacturing plant. We have completed the detailed engineering phase, but decided to discontinue the construction project of a GMP manufacturing facility, which was written-off in the year ended December&#160;31,&#160;2023. Furthermore, we decided to divest all assets associated with this project, including, but not limited to the parcel of land. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We were recently a party to a patent proceeding opposing European Patent No. 3218504 (the &#8220;EP &#8217;504 Patent&#8221;), which was granted to the University of Geneva in July 2020 and is exclusively licensed to us. In a decision that has become final, the Opposition Division of the European Patent Office (&#8220;EPO&#8221;) dismissed the opposition in an oral proceeding on May&#160;9,&#160;2023, and maintained the patent as granted. We are not currently a party to any material legal proceedings. From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk34056236"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements, and other information, including amendments and exhibits to such reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, are available free of charge on our website located at www.hookipapharma.com, as soon as reasonably practicable after they are filed with or furnished to the SEC. These reports are also available at the SEC&#8217;s Internet website at www.sec.gov. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A copy of our Corporate Governance Guidelines, Code of Conduct and the charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are posted on our website, www.hookipapharma.com, under the heading &#8220;Corporate Governance.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5b0d9027_058f_4272_ba9b_ad2931bfd8cd"></a><a id="RiskFactors_480000"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Capital Needs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company with no approved products and a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage biopharmaceutical company with no approved products and a limited operating history. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of our product candidates, securing related intellectual property rights and conducting discovery, research and development activities for our programs. As a result, we are not profitable and have incurred losses in each period since our inception in 2011. For the years ended December&#160;31,&#160;2022 and 2023, we reported a net loss of $64.9&#160;million and $81.6&#160;million, respectively. As of December&#160;31,&#160;2023, we had an accumulated deficit of $369.3&#160;million. We expect to continue to incur significant losses for the foreseeable future. We anticipate that our expenses will increase substantially if, and as, we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue the clinical and preclinical development of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage our technologies to advance product candidates into preclinical and clinical development;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for product candidates that successfully complete clinical trials, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract, hire, and retain additional clinical, quality control and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish our manufacturing capabilities through third parties or by ourselves and scale-up manufacturing to provide adequate supply for clinical trials and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other product candidates and technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates and we may never generate revenue that is significant or large enough to achieve profitability. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Accordingly, our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will require substantial additional financing and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our non-replicating and replicating technologies and our product candidates derived from these technologies. Preclinical studies and clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current product candidates and programs, any future product candidates we may choose to pursue, when we begin to develop our own manufacturing capabilities and other corporate uses. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing and supply, as well as marketing and selling any products approved for sale. Our expenses could increase beyond our current expectations if other unanticipated costs arise or if the FDA, the EMA, or other comparable foreign regulatory authorities requires us to perform clinical trials and other studies in addition to those that we currently anticipate. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our current or future product candidates. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or terminate our research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2023, we had $117.5&#160;million in cash, cash equivalents and restricted cash. Based on our research and development plans, we expect that our existing cash and cash equivalents at December&#160;31,&#160;2023, together with the payment we expect to receive prior to the termination of the Roche Collaboration Agreement in April 2024, will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">enable us to fund our operating expenses and capital expenditure requirements for at least the next 12&#160;months. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur beyond our control that would cause us to consume our available capital before that time, including changes in and progress of our development activities and changes in regulation. Our future capital requirements depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of researching and developing our current and future product candidates and programs, and of conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other product candidates that we may pursue, and other indications for our current product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve efficiencies and expected cost reductions in connection with our recent strategic refocus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the stability, scale and yields of our future manufacturing process as we scaleup production and formulation of our product candidates for later stages of development and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining regulatory and marketing approvals and developing our ability to establish sales and marketing capabilities, if any, for our current and future product candidates we develop if clinical trials are successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our collaborations with Gilead;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements. For example, in January 2024 Roche notified us of their decision to terminate their collaboration agreement with us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of commercialization activities for our current and future product candidates that we may develop, whether alone or with a collaborator;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or royalties on, our future products, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing oncology and infectious disease therapies and other adverse market developments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other than the Stock Purchase Agreement and our collaboration agreements with Gilead, we do not have any committed external source of funds or other support for our development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements and grant funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we raise additional capital through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ownership interest will be diluted. For example, in December 2023 we entered into an Amended and Restated Stock Purchase Agreement with Gilead pursuant to which we issued and sold 15,000,000 shares of unregistered common stock to Gilead for approximately $21.25 million, and we may require Gilead to purchase up to approximately $8.75 million of additional share of common stock. In addition, in May 2023 we completed a public offering in which we issued and sold 22,900,768 shares of common stock and 15,268 shares of Series A-2 convertible preferred stock, which are convertible into common stock on a 1,000 to one basis, pursuant to our shelf registration statement on Form S-3 (File No. 333-266104) for net proceeds of $46.3 million. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, reduce or terminate our product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders if we issue equity securities, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may evaluate various acquisitions and strategic partnerships, including acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased operating expenses and cash requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the assumption of additional indebtedness or contingent liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of our equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, if we undertake acquisitions, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have obtained funding from an agency of the Austrian government that contains certain covenants that may restrict our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the past, we have contracted numerous funding agreements with an agency of the Austrian government to partially finance our research and development programs, such as personnel costs, material costs, third-party services, travel expenses and research and development infrastructure use. These funding agreements include both below market rate loans and grants, which are subject to various criteria linked to certain terms and conditions as well as certain costs attributable to the respective funded research and development program. We have committed to reporting obligations and to obtain the approval for significant changes in the cost structure of the funded research and development programs. If we were to breach these contractual obligations, we may be held liable by the agency of the Austrian government for damages incurred by such agencies resulting from the breach of contract and we could be required to reimburse in full the funding granted by such agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, pursuant to the general terms of each grant, the agency is entitled to re-evaluate the funding granted to us in case of a fundamental change in our ownership structure if such change no longer ensures that the purpose of the funding can be achieved. Any such re-evaluation could negatively impact the funding that we receive or have received from the agency or that we may receive in the future from other agencies of the Austrian government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All of our product candidates are in early stages of development, including our lead product candidate, HB-200, which is currently in a Phase 1/2 clinical trial, and as such will require extensive preclinical and clinical testing. We cannot predict with any certainty if or when we might submit an IND, or BLA, or comparable foreign applications, for regulatory approval for any of our product candidates or whether any such IND or BLA, or comparable foreign applications, will be accepted for review by the FDA or comparable foreign regulatory authority, or subsequently whether any such IND will go into effect or BLA will be approved upon review, or whether comparable foreign applications will fulfill the related milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. For example, we recently announced a strategic refocus to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease and to pause development activities related to HB-300 and most other preclinical research activities. In connection with this strategic refocus, we implemented an approximately 30% reduction in our workforce and discontinued our GMP manufacturing facility project. In addition, in January 2024 Roche notified us of their decision to terminate the collaboration and licensing agreement for HB-700 in KRAS mutated cancers, despite acknowledging we had met all go-forward criteria under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate product revenues, which we do not expect to occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of the product candidates we develop, which may never occur. Before we are able to generate any revenues from product sales, our current product candidates, and any future product candidates we develop, will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other markets, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization, and substantial investment and significant marketing efforts. The success of our current and future product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of INDs and comparable foreign applications for our planned clinical trials or future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment and completion of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful data from our clinical program that support an acceptable risk-benefit profile of our product candidates in the intended populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scale-up of our manufacturing processes and formulation of our product candidates for later stages of development and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing our own manufacturing capabilities or agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entry into collaborations to further the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully launching commercial sales of our product candidates, if and when approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the product candidate&#8217;s benefits and uses, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse events experienced with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the product candidates following approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">qualifying for, maintaining, enforcing and defending intellectual property rights and claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory approval processes of the FDA, the EMA and the European Commission and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The time required to obtain approval from the FDA, the European Commission and other comparable foreign regulatory authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that none of our current or future product candidates will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, the EMA or other comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or the European Commission or other comparable foreign regulatory authorities that a product candidate is safe, pure and potent or effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA and the European Commission or other comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, the EMA or the European Commission or other comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA, or similar foreign submission to the EMA or other comparable foreign regulatory authority, or to obtain approval in the United States, the European Union or elsewhere;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of materials for product candidates we develop or other materials necessary to conduct clinical trials may be insufficient or inadequate;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, the EMA the European Commission, competent authorities of EU Member States or other comparable foreign regulatory authorities may, as applicable, find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA, the EMA and the European Commission or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have conducted, and intend to conduct, clinical trials of certain of our product candidates outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA, including compliance with all applicable U.S. laws and regulations. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCP, including review and approval by an independent ethics committee and informed consent from subjects. The study population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. There can be no assurance the FDA will accept data from trials </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">conducted outside of the United States. Comparable risks apply abroad in relation to the data that was generated in the United States which we intend to leverage for purposes of obtaining regulatory authorizations abroad. There can be no assurance that foreign regulatory authorities will accept data from trials conducted outside of their territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA, the EMA and the European Commission and other comparable foreign regulatory authorities have discretion in the approval process and determining when or whether regulatory approval will be obtained for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the European Commission or any other comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, including HB-200, HB-400, HB-500, HB-700 and any other future product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and, because our product candidates are in an early stage of development, there is a high risk of failure and we may never succeed in developing marketable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future drug sales and regulatory and commercialization milestones. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring comparable products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA, the EMA and the European Commission, or other comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA, the EMA and the European Commission or other comparable foreign regulatory authorities will view our product candidates as having efficacy even if positive results are observed in our clinical trials. To the extent that the results of the trials are not satisfactory to the FDA, the EMA and the European Commission or other comparable foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our preclinical programs may experience delays or our product candidates may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of our product candidates and all of our next generation product candidates are still in the preclinical development stage, and the risk of failure of preclinical programs is high. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies to obtain regulatory clearance to initiate human clinical trials, including based on INDs in the United States and clinical trial applications in Europe. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA, the competent authorities of EU Member States or other regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our product candidates. As a result, we cannot be sure that submission of INDs or similar applications will result in the FDA, the competent authorities of EU Member States or other comparable foreign regulatory authorities allowing clinical trials to begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have in the past, and may in the future, encounter challenges in collecting, transporting and analyzing clinical blood samples, which could cause delays or prevent the approval of our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim, top line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to regulatory audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publish interim, top line or preliminary data from our clinical trials. We may decide to conduct an interim analysis of the data after a certain number or percentage of patients have been enrolled, or after only a part of the full follow-up period but before completion of the trial. Similarly, we may report top line or preliminary results of primary and key secondary endpoints before the final trial results are completed. Preliminary, top line and interim data from our clinical trials may change as more patient data or analyses become available. Preliminary, top line or interim data from our clinical trials are not necessarily predictive of final results and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, more patient data become available, and we issue our final clinical trial report. These data also remain subject to verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary, interim and top line data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our interim, topline or preliminary analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of earlier studies and trials of our product candidates may not be predictive of future trial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Even if we are able to commence clinical trials, issues may arise that could suspend or terminate such clinical trials. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we cannot be certain that we will not face similar setbacks. In addition, the results of our preclinical animal studies, including our oncology mouse studies and animal studies, may not be predictive of the results of outcomes in human clinical trials. For example, our oncology product candidates that are in preclinical development may demonstrate different chemical and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">biological properties in patients than they do in laboratory animal studies or may interact with human biological systems in unforeseen or harmful ways.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our replicating technology is early in clinical development and could therefore prove to be unsafe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our replicating technology is an attenuated viral vector technology which is in a Phase&#160;1/2 clinical trial. If our ongoing Phase&#160;1/2 clinical trial for HB-200 causes unexpected side effects that are not tolerable in the treatment of the relevant patient group, the further development of the product candidate and any other potential products based on the replicating technology may be significantly limited or become impossible. Although clinical trials of onco-viral therapies have supported their role as a potential treatment for cancer, there is the risk of uncontrolled replication in vivo and possible transmission to patients' contacts, such as other patients and health care workers. In recent years, clinical trials to address these concerns have been conducted. Any such transmission by our product candidates or a competitor would have an adverse impact on our future research and development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concentrated all of our research and development efforts on product candidates based on our non-replicating and replicating technologies, and our future success depends on the successful development of this therapeutic approach. Our non-replicating and replicating technologies utilize arenaviruses to activate CD8+ T&#160;cells and induce pathogen-neutralizing antibodies. There are no approved products that utilize the arenavirus. Because our non-replicating and replicating technologies are novel, regulatory agencies may lack experience with product candidates which may lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates. We have not yet succeeded and may not succeed in demonstrating safety and efficacy for any of our product candidates in ongoing or late-stage clinical trials or in obtaining marketing approval thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our vectors are live, gene-modified organisms for which the FDA, the EU and other comparable foreign regulatory authorities and other public health authorities, such as the Centers of Disease Control and Prevention and hospitals involved in clinical studies, have established additional safety and contagion rules and procedures, which could establish additional hurdles for the development, manufacture or use of our vectors. These hurdles may lead to delays in the conduct of clinical trials or in obtaining regulatory approvals for further development, manufacturing or commercialization of our product candidates. We may also experience delays in transferring our process to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Since the number of patients that we plan to dose in some of our planned clinical trials is small, the results from such clinical trials, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder our efforts to obtain regulatory approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A trial design that is considered appropriate for regulatory approval includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. In the Phase&#160;2 portion of our Phase&#160;1/2 trial for HB&#8209;200 in combination with pembrolizumab, we expect to enroll two groups of 10 to 20 patients each. Future trials for HB&#8209;200 or other product candidates may similarly enroll a small number of patients although some trials will require the enrollment of more patients. The preliminary results of trials with smaller sample sizes can be disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, making the trial results less reliable than trials with a larger number of patients. As a result, there may be less certainty that such product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials, we may not achieve a statistically significant result or the same level of statistical significance, if any, that would have been possible to achieve in a larger trial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential or result in significant negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities, including IRBs or ethics committees, to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the European Commission or other comparable foreign regulatory authorities. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the drug. Because of our dose escalation design for our clinical trials, undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Additionally, results of our trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. If we do observe severe side effects in our clinical trials, our ongoing clinical trials may be halted or put on clinical hold prior to completion if there is an unacceptable safety risk for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our trials or the FDA, the competent authorities of EU Member States or other comparable foreign regulatory authorities, or local regulatory authorities such as IRBs or ethics committees, could order us to cease clinical trials. Competent national health authorities, such as the FDA or the European Commission, could also deny approval of our product candidates for any or all targeted indications. Even if the side effects presented do not preclude the product from obtaining or maintaining marketing approval, treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates, if approved, to understand the side effect profile of these technologies for both our planned clinical trials and upon any commercialization of any product candidates, if approved. Inadequate training in recognizing or managing the potential side effects of our technologies could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the novel nature of the technology underlying our product candidates which may not be known to or be negatively perceived by clinical trial investigators or patients;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before the manufacturing and infusion of our product candidates or trial completion; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current or potential pandemics that may limit patients, principal investigators or staff or clinical site availability (e.g. the recent COVID-19 pandemic).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates or similar areas, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for the treatment of infectious diseases and cancers, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic stem cell transplantation, rather than enroll patients in any future clinical trial. Additionally, because some of our clinical trials will be in patients with relapsed or refractory cancer, the patients are typically in the late stages of the disease and may experience disease progression independent from our product candidates, making them unevaluable for purposes of the trial and requiring additional enrollment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these trials and adversely affect our ability to advance the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have limited experience as a company conducting clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited experience as a company in conducting clinical trials. In part because of this lack of experience, we cannot be certain that our ongoing clinical trials will be completed on time or if our planned clinical trials will begin at all. Large scale trials would require significant additional financial and management resources and reliance on third-party clinical investigators, contract research organizations (CROs), or consultants. Relying on third-party clinical investigators or CROs may force us to encounter delays that are outside of our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for our oncology product candidates may be limited to those patients who are ineligible for or have failed prior treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cancer therapies are characterized as first line, second line, or third line, and the FDA and comparable foreign regulatory authorities often approve new therapies initially only for a particular line of use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, antibody drugs, tumor-targeted small molecules, hormone therapy, radiation therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules, or a combination of these. Third line therapies can include hematopoietic stem cell transplantation in certain cancers, chemotherapy, antibody drugs, and small molecule tumor-targeted therapies, more invasive forms of surgery, and new revolutionary technologies. We expect to initially seek approval of our product candidates in most instances at least as a third line therapy, for use in patients with relapsed or refractory metastatic cancer. Subsequently, for those product candidates that prove to be sufficiently safe and beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved as a third or subsequent line of therapy, would be approved for an earlier line of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If the market opportunities for our product candidates are smaller than we believe they are, even assuming approval of a drug candidate, our business may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our projections of both the number of people who have the infectious diseases and cancers we are targeting, as well as the subset of people with these infectious diseases and cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, commissioned reports, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new therapies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates within our addressable patient population, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as first or second line therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The use of an arenavirus for the treatment of infectious diseases and tumors is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. Various factors will influence whether our product candidates, if approved, are accepted in the market, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived advantages of our product candidates over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects for virus-based therapeutic products, in particular, other prime-boost therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of our product candidates as well as competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing efforts.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, although we are not utilizing fully replication competent live virus vectors, our replicating technology uses a replication attenuated vector and adverse publicity due to the ethical and social controversies surrounding the therapeutic use of such technologies, and reported side effects from any clinical trials using these technologies or the failure of such trials to demonstrate that these therapies are safe and effective may limit market acceptance of our product candidates. If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers, third-party payors or others in the medical community, we will not be able to generate significant revenue and we may not become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we, or any future collaborators, are able to commercialize any product candidate that we, or they, develop, the product may become subject to unfavorable pricing laws, regulations or third-party payor coverage and reimbursement policies, any of which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. These third-party payors decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford many types of treatments. Sales of these or other product candidates that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. See &#8220;Item 1. Business &#8211; Government Regulation &#8211; Coverage and Reimbursement.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price (ASP), and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, we, or our collaborators may develop companion diagnostic tests for use with our product candidates. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have not yet developed any companion diagnostic tests for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, the requirements governing drug pricing vary widely from country to country. In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by the manufacturer or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Many EU Member States also periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, in order to obtain reimbursement for our products in some European countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. This Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We cannot predict whether we will receive reimbursement from third-party payors for any product we may successfully commercialize in the future. Any reimbursement we may receive might not be adequate for use to generate significant revenue and we may not become profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are developing, and in the future may develop, other product candidates, in combination with other therapies, which exposes us to additional risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HB-200 program is being developed to be used in combination with or without an approved checkpoint inhibitor, a currently approved cancer therapy. In the future, we may develop other product candidates to be used with one or more currently approved cancer therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially. In addition, if the results from our combination trials are not significantly better than results from the existing therapy that we are combining with, then regulatory authorities, clinical investigators, physicians and patients may perceive our product candidates negatively, which could adversely affect enrollment in our clinical trials, approval by regulatory authorities or commercial adoption of our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also evaluate our future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Negative developments in the field of immuno-oncology and virus-based therapies could damage public perception of any of our product candidates and negatively affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The commercial success of product candidates based on our replicating technology will depend in part on public acceptance of the use of cancer immunotherapies. Adverse events in the HB-200 program or our other product candidates based on our replicating technology or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments in the field of immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for any product candidates based on our replicating technology that we may develop. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our therapies or those of our competitors, our product candidates may not </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our clinical trials. In addition, responses by national or state governments to negative public perception may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, prospects and results of operations and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. As a result, we may not be able to continue or may be delayed in conducting our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates consist of a modified virus. Adverse developments in clinical trials of other immunotherapy products based on viruses, like oncolytic viruses, may result in a disproportionately negative effect for our non-replicating and replicating technologies as compared to other products in the field of infectious disease and immuno-oncology that are not based on viruses. Future negative developments in the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in our efforts to identify and successfully commercialize additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Part of our strategy involves identifying novel product candidates. We have developed a pipeline of product candidates and intend to pursue clinical development of additional product candidates utilizing our non-replicating and replicating technologies. The process by which we identify product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may not be effective in treating their targeted diseases or symptoms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the regulatory pathway for a potential product candidate is highly complex and difficult to navigate successfully or economically.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Developing, obtaining regulatory approval for and commercializing additional product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you with any assurance that we will be able to successfully advance any of these additional product candidates through the development process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may choose to focus our efforts on and allocate resources to a potential product candidate that ultimately proves to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we are unable to evaluate the commercial potential or target market for a particular product candidate, identify and successfully commercialize additional suitable product candidates, this would adversely impact our business strategy and our financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other products or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In immuno-oncology for HPV16+ cancers, we face competition from companies such as BioNtech AG, Cue Biopharma, Inc., ISA Pharmaceuticals B.V., in collaboration with Regeneron Pharmaceuticals, Inc., Kite Pharma, a Gilead company, and PDS Biotechnology Corporation. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. In addition, other immuno-oncology companies are developing the following technologies, including, but not limited to, neoantigens, bispecific antibodies, engineered cell therapies and tumor specific antigens in areas outside of HPV16+ cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to commercialize any product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates or products that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reputational damage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants and inability to continue clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exhaustion of any available insurance and our capital resources; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decline in our share price.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. In the future, we may be unable to maintain this insurance coverage, or we may not be able to obtain additional or replacement insurance at a reasonable cost, if at all. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A variety of risks associated with operating our business internationally could materially adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Many of our employees and a significant portion of our operations are located outside the United States, including in Vienna, Austria. In addition, we plan to seek regulatory approval of our product candidates outside of the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">United States and, accordingly, we expect that we, and any potential collaborators in those jurisdictions, will be subject to additional risks related to operating in foreign countries, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing regulatory requirements in foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign taxes, including withholding of payroll taxes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential liability under the Foreign Corrupt Practices Act of 1977 (FCPA), Office of Foreign Assets Control Anti-Money Laundering Program as required by the Bank Secrecy Act and its implementing regulations, or comparable foreign laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These and other risks associated with our planned international operations may materially adversely affect our ability to attain or maintain profitable operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Natural disasters, geopolitical unrest, war, terrorism, public health issues or other catastrophic events could disrupt the supply, delivery or demand of products and reduce our ability to access capital, which could negatively affect our operations and performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to the risk of disruption by earthquakes, floods and other natural disasters, fire, power shortages, geopolitical unrest, war, terrorist attacks and other hostile acts, public health issues, epidemics or pandemics and other events beyond our control and the control of the third parties on which we depend. Any of these catastrophic events, whether in the United States, Europe or abroad, may have a strong negative impact on the global economy, our employees, facilities, partners, suppliers, distributors or customers, and could decrease demand for our products, create delays and inefficiencies in our supply chain and make it difficult or impossible for us to continue preclinical studies or clinical trials, seek and receive approval for any of our product candidates by the FDA and comparable foreign regulatory authorities, or deliver products to our customers. Further, disruption of global financial markets and a recession or market correction, including as a result of any resurgence of the coronavirus pandemic, the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, any escalation of the conflict in Israel and the Gaza Strip, and other global macroeconomic factors, could reduce our ability to access capital, which could, in the future, negatively affect our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business may be adversely affected by a pandemic, epidemic or outbreak of an infectious disease, such as the recent coronavirus pandemic or other emerging global health threats on business and operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:21.3pt;margin:0pt;">Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business activities and could cause significant disruption in the operations of third-party contract manufacturers and contract research organizations upon whom we rely, as well as our ability to recruit patients for our clinical trials. For example, the recent coronavirus pandemic had unpredictable impacts on global societies, economies, financial markets, and business practices around the world, and caused temporary delays and disruptions in our clinical development operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:21.3pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have no sales, marketing or distribution capabilities and have no experience in marketing products. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of product candidates, securing related intellectual property rights and conducting discovery, research and development activities for our programs. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other biotechnology and pharmaceutical companies to recruit, hire, train and retain marketing and sales personnel. There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In addition, there can be no assurance that we will be able to develop inhouse sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, property, umbrella, and directors&#8217; and officers&#8217; insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also expect that firming of the insurance market will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Exchange rate fluctuations may materially affect our results of operations and financial conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the U.S. dollar and the euro, may adversely affect us. Although we are incorporated in Delaware in the United States, we have significant research and development operations in Austria, and source third-party manufacturing, consulting and other services in the European Union. As a result, our business and the price of our common stock may be affected by fluctuations in foreign exchange rates, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are fully dependent on our collaboration with Gilead for the development of our HBV programs, rely on funding from Gilead for development of our human immunodeficiency virus program, and may depend on Gilead or additional third parties for the development and commercialization of our other programs and future product candidates. Our current and future collaborators may control aspects of our clinical trials, which could result in delays or other obstacles in the commercialization of the product candidates we develop. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are currently party to collaborations with Gilead to help expand and advance our pipeline of candidates. In the future, we may form or seek other strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our current collaborations pose, and potential future collaborations involving our product candidates may pose, the following risks to us:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, including technology we in-license, products that compete directly or indirectly with our products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">invalidate our intellectual property or proprietary information or expose us to potential litigation, or other intellectual property proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may restrict our right to independently pursue new product candidates. For example, under the Gilead Collaboration Agreement, we are prohibited from, directly or indirectly, researching, developing, manufacturing or commercializing product candidates targeted to HBV and with respect to HIV so long as Gilead&#8217;s option for the program has not expired; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated by the collaborator (such as the termination of the Roche Collaboration Agreement by Roche), and, if terminated, we may suffer reputational harm, find it more difficult to attract new collaborators and be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result, if we enter into additional collaboration agreements and strategic partnerships, or license our intellectual property, products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development and commercialization of our other product candidates, which would harm our business prospects, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our programs, we may decide to collaborate with additional biotechnology and pharmaceutical companies with respect to development and potential commercialization. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. We cannot predict the success of any collaboration that we have entered into or will enter into. For example, in January 2024 Roche notified us of their decision to terminate the Roche Collaboration Agreement despite acknowledging we had met all go-forward criteria under the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. For example, under the Restated Gilead Collaboration Agreement, we have granted worldwide exclusive rights to Gilead for using our technologies to develop treatments for HBV, and during the term of the agreement we will be restricted from granting similar rights to other parties. This exclusivity could limit our ability to enter into strategic collaborations with future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations or do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We depend and will continue to depend upon independent investigators and collaborators, such as medical institutions, CROs, CMOs and strategic partners to conduct our preclinical studies and clinical trials under agreements with us. We expect to have to negotiate budgets and contracts with CROs, trial sites and CMOs which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. As a result, we have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under current good manufacturing practices (cGMP) regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and we may rely on third parties for at least a portion of the manufacturing process of our product candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of clinical product supplies or product candidates or fail to do so at acceptable quality levels or prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and must currently rely on outside vendors to manufacture our product candidates. We have not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to do so for any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The manufacture of biological drug products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up or out, validating the production process and assuring high reliability of the manufacturing process, including the absence of contamination. These problems include logistics and shipping, difficulties with production costs and yields, quality control, including lot consistency, stability of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. We have encountered problems with our third party manufacturers in the past, including delays and low yields, and there can be no assurance that we will not encounter similar or other difficulties in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability failures or other issues relating to the manufacture of our product candidates will not occur in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our reliance on a limited number of third-party manufacturers exposes us to the following risks:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the production process for our product candidates is complex and requires specific know-how that only a limited number of CMOs can provide, as a result, we compete with other companies in the field for the scarce capacities of these organizations and may not be able to secure sufficient manufacturing capacity when needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA and comparable foreign regulatory authorities must inspect any manufacturers for cGMP compliance as part of our marketing application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of our product candidates;</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a change in manufacturers or certain changes in manufacturing processes/procedures will require that we conduct a manufacturing comparability study to verify that any new manufacturer or manufacturing process/procedure will produce our product candidate according to the specifications previously submitted to the FDA or other regulatory authority, to which we may be unsuccessful; </span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers may have little or no experience with viral vector products and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers may not perform as agreed, may not devote sufficient resources to our product candidates or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state and foreign regulatory authorities to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards, of which we have limited control over;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers could breach or terminate their agreements with us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available timely or may not be suitable or acceptable for use due to material or component defects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers and critical suppliers may be subject to risks related to cyber-attacks that could cause disruptions in manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers and critical suppliers may be subject to inclement weather, as well as natural or manmade disasters; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturers may have unacceptable or inconsistent product quality success rates and yields, and we have no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA and comparable foreign regulatory authorities, result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA and comparable foreign regulatory authorities could place significant restrictions on our company until deficiencies are remedied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Despite our efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">including shutdown of the third-party vendor or invalidation of drug product lots or processes, fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products, if approved,  and significantly harm our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a (REMS) in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Comparable foreign regulatory authorities may impose similar requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, under the Food and Drug Omnibus Reform Act of 2022 (FDORA), sponsors of approved drugs and biologics must provide six months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#8217;s ability to be marketed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, if the FDA, the European Commission or another comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for any such approved product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or our or our distributors&#8217;, licensees&#8217; or co-marketers&#8217; failure to comply with changes to regulatory requirements, may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning or untitled letters or holds on clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA, the European Commission or other comparable foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, refusal to permit the import or export of our product candidates, or request that we initiate a product recall;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties or monetary fines; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s, the EMA&#8217;s and the European Commission and other comparable foreign regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. As an example, the regulatory landscape related to clinical trials in the EU has evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. The CTR permits trial sponsors to make a single submission to both the competent authority and an ethics committee in each EU Member State, leading to a single decision for each EU Member State. The assessment procedure for the authorization of clinical trials has been harmonized as well, including a joint assessment of some elements of the application by all EU Member States in which the trial is to be conducted, and a separate assessment by each EU Member State with respect to specific requirements related to its own territory, including ethics rules. Each EU Member State&#8217;s decision is communicated to the sponsor through a centralized EU portal, the Clinical Trial Information System, or CTIS. The CTR provides a three-year transition period. The extent to which ongoing clinical trials will be governed by the CTR varies. For clinical trials in relation to which an application for approval was made on the basis of the Clinical Trials Directive before January 31, 2023, the CTD will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025. In light of the entry into application of the CTR on January 31, 2022, we may be required to transition clinical trials for which we have obtained regulatory approvals in accordance with the CTD to the regulatory framework of the CTR by October 31, 2024. A transitioning application will need to be submitted to the competent authorities of E.U. Member States through the Clinical Trials Information Systems and related regulatory approval obtained to continue the clinical trial past January 30, 2025. This will require financial, technical and human resources. If we are unable to transition our clinical trials in time, the conduct of those clinical trials may be negatively impacted. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of these events occurs, our ability to commercialize such product candidate may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, and may adversely affect our business model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of our collaborators, to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">additional downward pressure on the price that we, or our collaborators, may receive for any approved products. See &#8220;Business &#8211; Other U.S. Healthcare Laws.&#8221; We cannot predict the initiatives that may be adopted in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may adversely affect:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the demand for any of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to set a price that we believe is fair for any of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate revenues and achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of taxes that we are required to pay; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of capital.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2021, Regulation No 2021/2282 on HTA amending Directive 2011/24/EU, was adopted in the EU. This Regulation, which entered into force in January 2022 and will apply as of January 2025, is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation foresees a three-year transitional period and will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected. In light of the fact that the United Kingdom has left the EU, Regulation No 2021/2282 on HTA will not apply in the United Kingdom. However, the UK Medicines and Healthcare products Regulation Agency (&#8220;MHRA&#8221;) is working with UK HTA bodies and other national organizations, such as the Scottish Medicines Consortium (&#8220;SMC&#8221;), the National Institute for Health and Care Excellence (&#8220;NICE&#8221;), and the All-Wales Medicines Strategy Group, to introduce new pathways supporting innovative approaches to the safe, timely and efficient development of medicinal products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation. If adopted in the form proposed, the recent European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity opportunities for our product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical and biologic products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. Compliance with new requirements may increase our operational expenses and impose significant administrative burdens. As a result of these and other new proposals, we may need to change our current manner of operation, which could have a material adverse effect on our business, financial condition, and results of operations. Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Legislative and regulatory proposals may also </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">impact our regulatory and commercial prospects, expand post-approval requirements, and restrict sales and promotional activities. We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments, whether regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. Such future price controls or other changes in pricing regulation or negative publicity related to the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our future products, which would adversely affect our anticipated revenue and results of operations. See &#8220;Business &#8211; U.S. Healthcare Reform.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The FDA or comparable foreign regulatory authorities could require the clearance, CE marking or approval of a companion diagnostic device as a condition of approval for our product candidates. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our drug development strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success may depend, in part, on the development and commercialization of companion diagnostic tests to select patients for our drug candidates. If safe and effective use of any of our product candidates depends on an in vitro diagnostic that is not otherwise commercially available, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates. The process of obtaining or creating such diagnostic is time consuming and costly. Foreign regulatory authorities may impose comparable requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and require separate regulatory approval from therapeutic approval prior to commercialization. The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to a product candidate to obtain pre-market approval (PMA), simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of preclinical and clinical data and the submission and review by the FDA, can take several&#160;years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting. We will be subject to additional obligations and regimes with respect to such companion diagnostic tests with regulators outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the EEA, companion diagnostics are deemed to be in vitro diagnostic medical devices, or IVDs, and are governed by Regulation 2017/746, or IVDR, which entered into application on May 26, 2022, repealing and replacing Directive 98/79/EC. The IVDR defines a companion diagnostic as a device which is essential for the safe and effective use of a corresponding medicinal product to: (a) identify, before and/or during treatment, patients who are most likely to benefit from the corresponding medicinal product; or (b) identify, before and/or during treatment, patients likely to be at increased risk of serious adverse reactions as a result of treatment with the corresponding medicinal product. The IVDR and its associated guidance documents and harmonized standards govern, among other things, device design and development, preclinical and clinical or performance testing, premarket conformity assessment, registration and listing, manufacturing, labeling, storage, claims, sales and distribution, export and import and post-market surveillance, vigilance, and market surveillance. IVDs, including companion diagnostics, must conform with the general safety and performance requirements, or GSPR, of the IVDR. Compliance with these requirements is a prerequisite to be able to affix the CE mark to devices, without which they cannot be marketed or sold in the EEA. To demonstrate compliance with the GSPR laid down in Annex I to the IVDR, and obtain the right to affix the CE mark, IVD manufacturers must </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">conduct a conformity assessment procedure, which varies according to the type of IVD and its classification. Companion diagnostics must undergo a conformity assessment by a Notified Body. Depending on the relevant conformity assessment procedure, the Notified Body audits and examines the technical documentation and the quality system for the manufacture, design and final inspection of the medical devices. The Notified Body issues a CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the GSPRs. If the related medicinal product has, or is in the process of, been authorized through the centralized procedure for the authorization of medicinal products, the notified body will, before it can issue a CE Certificate of Conformity, be required to seek a scientific opinion from the EMA on the suitability of the companion diagnostic for use in relation to the medicinal product concerned. For medicinal products that have or are in the process of authorization through any other route provided in EU legislation, the Notified Body must seek the opinion of the national competent authority of an EU Member State. The CE Certificate of Conformity and the related conformity assessment process entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Given our limited experience in developing and commercializing diagnostics, we do not plan to develop companion diagnostics internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for these companion diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval or CE marking for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval or CE marking the companion diagnostics could delay or prevent approval of our product candidates. In addition, we, our collaborators or third parties may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the medical community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales, if any, of any product candidate for which we obtain approval and that requires a companion diagnostic test. In addition, any companion diagnostic collaborator or third party with whom we contract may decide not to commercialize or to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates, or our relationship with such collaborator or third party may otherwise terminate. We may not be able to enter into arrangements with another provider to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may pursue breakthrough therapy designation from the FDA for our product candidates but such designation may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that our product candidates will receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may in the future seek breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For compounds that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for accelerated approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. We cannot be sure that any evaluation we may make of our product candidates as qualifying for breakthrough therapy designation will meet the FDA&#8217;s expectations. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek Fast Track Designation by the FDA for a product candidate that we develop, and we may be unsuccessful. If we are successful, the designation may not actually lead to a faster development or regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may seek Fast Track Designation for the product candidates we develop. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, as we have for HB-200 in combination with pembrolizumab, for the treatment of first-line advanced/metastatic HPV16+ HNSCC, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek Orphan Drug Designation for product candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our business strategy, we may seek Orphan Drug Designation for any product candidates we develop, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similarly, in Europe, the European Commission may grant orphan designation after receiving the opinion of the EMA Committee for Orphan Medicinal Products on an orphan designation application. Orphan designation is intended to promote the development of drugs that are intended (i) for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions, (ii) either the conditions affect no more than 5 in 10,000 persons in the EU or without the benefits derived from orphan status, it is unlikely that sales of the product in the EU would be sufficient to justify the necessary investment in developing the product, and (iii) there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition. In the EU, orphan designation entitles a party to a number of incentives, such as protocol assistance, access to the centralized marketing authorization procedure, and potential fee reductions or waivers depending on the status of the sponsor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, if a drug with an orphan designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. Similarly, the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication. The applicable period is seven years in the United States and ten years in the EU. The EU exclusivity period can be reduced to six years if, at the end of the fifth year, a drug no longer meets the criteria on the basis of which it received orphan designation, including where it can be demonstrated on the basis of available evidence that the drug is sufficiently profitable such that market exclusivity is no longer justified or where the prevalence of the condition has increased above the threshold.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different therapies can be approved for the same condition and the same therapies can be approved for different conditions but used off-label. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. Similar considerations apply abroad. While we may seek Orphan Drug Designation for applicable indications for our current and any future product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal, state and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we do not currently have any products on the market, if we obtain FDA approval for our product candidates, and begin commercializing those products in the United States, our operations may be directly, or indirectly through our prescribers, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws, federal health data privacy laws, and the Physician Payments Sunshine Act and regulations. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our current business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Finally, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by comparable foreign regulatory authorities in jurisdictions in which we conduct our business that may affect our ability to operate. See &#8220;Business &#8211; Other U.S. Healthcare Laws.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource- consuming and can divert a company&#8217;s attention from the business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental and regulatory authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the delay, reduction, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">termination or curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, interactions between pharmaceutical companies and health care professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is not permitted in the countries that form part of the European Union. Some European Union Member States, and the United Kingdom, through the United Kingdom Bribery Act 2010, have enacted laws explicitly prohibiting the provision of these types of benefits and advantages. Infringements of these laws can result in substantial fines and imprisonment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments made to physicians in certain European Union Member States (e.g., France or Belgium) must be publicly disclosed. Moreover, agreements with physicians may be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the European Union Member State national laws, industry codes (e.g. the European Federation of Pharmaceutical Industries and Associations Disclosure and Healthcare Professionals Codes) or professional codes of conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining regulatory approval of a product candidate in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval for that product candidate in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, in order to market and sell our drugs in the European Union and many other jurisdictions, we, and any collaborators we may have in the future, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for reimbursement before the drug can be approved for sale in that country. In some cases, the price that we intend to charge for our products is also subject to regulatory approval. We, and any collaborators we may have in the future, may not obtain approvals from regulatory authorities outside of the United States on a timely basis, if at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">European data collection and processing is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The collection, use, storage, disclosure, transfer or other processing of personal data, including personal health data regarding individuals in the EEA is governed by the EU GDPR. The EU GDPR is wide ranging in scope and imposes several requirements on companies that process personal data, including requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. Failure to comply with the requirements of the EU GDPR and the related national data protection laws of the EU Member States may result in fines and other administrative penalties, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater, for breach or non-compliance.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, further to the UK&#8217;s exit from the EU on January 31, 2020, the EU GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK&#8217;s European Union (Withdrawal) Act 2018 incorporated the EU GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the EU GDPR and the UK GDPR currently impose substantially similar obligations, it is possible that over time the UK GDPR could become less aligned with the EU GDPR. The UK government has announced plans to reform the data protection legal framework in the UK in its Data Protection and Digital Information Bill. The potential misalignment between future UK laws and regulations and EU laws and regulations could add legal risk, uncertainty, complexity and cost to our handling of EU/UK personal information and our privacy and data security compliance programs and could require us to implement different compliance measures for the UK and the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The EU GDPR also imposes strict rules on the transfer of personal data out of the EEA, including to the United States. Although the UK is regarded as a third country under the EU GDPR, the EC has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with EU and UK data protection laws. There are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EU&#8217;s Standard Contractual Clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK Extension thereto (which allows for transfers for relevant U.S.-based organizations who self-certify compliance and participate in the Framework). However, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The EU GDPR and UK GDPR also confer a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the EU GDPR and UK GDPR. The EU GDPR and UK GDPR regulations may impose additional responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms ensuring compliance with these and/or new data protection rules. This may be onerous and adversely affect our business, financial condition, prospects and results of operations. Compliance with the EU GDPR and UK GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice (DOJ) and the Securities and Exchange Commission, (SEC) is involved with enforcement of the books and records provisions of the FCPA and may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Recently the SEC and DOJ have increased their FCPA enforcement activities with respect to pharmaceutical companies. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to utilize our foreign net operating loss carryforwards may be limited by GILTI taxation introduced through the tax reform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred substantial losses during our operating history. We do not anticipate generating revenue from sales of products for the foreseeable future, if ever, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. The tax reform legislation introduced section&#160;951A, a new tax on so-called &#8220;global intangible low-taxed income,&#8221; or GILTI. GILTI applies to income of a controlled foreign corporation (CFC) that is not otherwise subpart&#160;F income. Our Austrian subsidiary is expected to be treated as a CFC and GILTI taxation may therefore apply when use of foreign net operating loss carryforwards reduce our foreign income tax to a low level. Tax benefits from the use of our foreign net operating loss carryforwards could be partially offset by U.S. GILTI taxation, which could have an adverse effect on our future results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes to section 174 capitalization rules through the tax reform may impact our ability to immediately deduct research and development expenses, leading to higher taxable income and effective income tax payments even before reaching profitability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The tax reform legislation also altered section 174, by requiring that, beginning with the year 2022, research and development expenses be capitalized and amortized over five years for expenditures incurred in the U.S. and 15 years for expenditures incurred outside the U.S. Therefore, our ability to use research and development expenses to offset revenue in the coming years, may be limited, and we may be required to record taxable income while our business is actually still loss-making. The resulting tax payments could have an adverse effect on our future results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of licenses granted to us by others, and, if we fail to comply with our obligations under these arrangements or resolve related disputes, we could lose such intellectual property rights or owe damages to the licensor of such intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. We license patents related to our non-replicating and replicating technologies and certain other intellectual property rights from third parties, including from the University of Geneva, the University of Basel, the University of Zurich and the University of Minnesota and expect in the future to be party to other material license or collaboration agreements. These agreements typically impose numerous obligations, such as diligence and payment obligations, including in relation to revenues we may receive from any sublicenses we grant in respect of the licensed patents. If we fail to comply with our obligations under these agreements, our licensors may have the right to terminate our licenses, in which event we might not be able to develop, manufacture or market any product that is covered by the intellectual property we in-license from such licensor and may face other adverse consequences. These licenses do and future licenses may also include provisions that impose obligations and restrictions on us that could delay or otherwise negatively impact a transaction that we may wish to enter into.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Disputes may also arise between us and our licensors regarding the license agreements we have with them, including with respect to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proper interpretation of the license agreement terms, including with respect to our right to sublicense patent rights and any other intellectual property rights to third parties and the amount of fees owed to the licensors as a result of such sublicenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how created by us and our partners using a combination of our own intellectual property and that licensed from our licensors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If disputes arise that prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely upon a combination of patents, confidentiality agreements, trade secret protection and license agreements to protect the intellectual property related to our technologies. Such means may afford only limited protection of our intellectual property and may not: (i)&#160;prevent our competitors from duplicating our technology or product candidates; (ii)&#160;prevent our competitors from gaining access to our proprietary technology; or (iii)&#160;permit us to gain or maintain a competitive advantage. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by the third parties to which we grant access to such intellectual property, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. These third parties also may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property-related proceedings that could jeopardize or invalidate our proprietary information and intellectual property. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends in large part on our ability to obtain and maintain patent protection with respect to our non-replicating technology, our replicating technology, including our HB-200 and HB-700 product candidates, the vaccine product candidates we are developing with Gilead for HBV (HB-400) and HIV (HB-500), and other proprietary product candidates. Although we own or license from others certain patents and patent applications that cover some of the foregoing technologies and product candidates, we do not currently own or license from others issued patents covering all of the foregoing technologies and product candidates. Our reliance on patent applications carries certain risks associated with pending patent applications prior to the issuance of patents, as described below. If we do not adequately obtain and protect our intellectual property rights, competitors may be able to erode, negate or preempt any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States and abroad related to our product candidates that are important to our business. The patent application and approval process is expensive and time-consuming and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We cannot predict:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if and when patents will issue from our patent applications;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and range of protection any patents that we obtain will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we will need to initiate litigation or administrative proceedings related to obtaining, protecting or enforcing our patents, which may be costly whether we win or lose.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the USPTO or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered patentable by courts in the United States or foreign countries. Certain of our issued patents and pending applications are method of use patents, which protect the use of a product for a specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may induce or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights may be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if patents do successfully issue from such applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. If our patents are rendered invalid or unenforceable, or narrowed in scope, the patent coverage afforded our products could be impaired. Such impairment could significantly impede our ability to market our products, negatively affect our competitive position and harm our business and operating results. In addition, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various jurisdictions, including significant commercial markets such as Europe, restrict the patentability of methods of treatment of the human body more than United States law does. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our patent protection. No assurances can be given that third parties will not create new products or methods that achieve similar results without infringing upon patents we own. If these developments were to occur, it could have an adverse effect on our sales or market position. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we enter into additional collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced and could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. It is also possible for third parties to file observations with various patent offices during the patent application process. Various post grant review proceedings, such as inter partes review and post grant review in the United States and opposition proceedings at the EPO, are available for any interested third party to challenge the patentability of claims issued in patents to us. Some of these procedures are relatively new and can be unpredictable. For example, the EP &#8217;504 Patent, which is owned by the University of Geneva and is exclusively licensed to us, was opposed by a third-party at the EPO. The Opposition Division of the EPO eventually dismissed the opposition and maintained the patent as granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we seek to rely on trade secret protection, confidentiality agreements, and license agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, reexamination, <i style="font-style:italic;">inter partes</i> review and post grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and certain other development activities in the United States is not considered an act of infringement. If and when any of our product candidates are approved by the FDA, a third party may then seek to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">enforce its patent by filing a patent infringement lawsuit against us. While we are aware of certain third-party patents and applications that relate to similar subject matter as our technologies, we do not believe that any patent claims that could otherwise materially adversely affect commercialization of our product candidates, if approved, are valid and enforceable. We may be incorrect in this belief, or we may not be able to prove it in a litigation. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be third-party patents of which we are currently unaware which cover materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license, which may not be available on commercially reasonable terms, if at all, or until such patent expires or is determined to be invalid or unenforceable. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Presently we have rights to certain intellectual property, through licenses from third parties and under patents and/or patent applications that we own or will own, related to HB-200, HB-700, HB-400, HB-500 and certain other product candidates. Because additional product candidates may require the use of proprietary rights held by third parties, such as the rights to use certain antigens that are, specific to future disease targets, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, while we have patent rights directed to certain non-replicating and replicating technologies we may not be able to obtain intellectual property to all uses of non-replicating and replicating technologies. Our product candidates may also require specific formulations to work effectively and efficiently and rights to such formulations may be held by others. Similarly, efficient production or delivery of our product candidates may also require specific compositions or methods, and the rights to these compositions or methods may be owned by third parties. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. Even if we are able to obtain a license to use such intellectual property, it may be non-exclusive, which would not restrict the licensor party from giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. Moreover, the specific antigens that will be used with our product candidates may be covered by the intellectual property rights of others.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For certain of our in-licensed patent rights, such as patent rights in-licensed from the University of Geneva, the University of Basel and the University of Zurich, we may not have the right to file a lawsuit for infringement and may have to rely on a licensor to enforce these rights for us. If we are not able to directly assert our licensed patent rights against infringers or if a licensor does not vigorously prosecute any infringement claims on our behalf, we may have difficulty competing in certain markets where such potential infringers conduct their business, and our commercialization efforts may suffer as a result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Post-grant proceedings, including interference proceedings, provoked by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patents or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not agree to a license on commercially reasonable terms or at all. Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will be due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of our patents and/or patent applications and any patent rights we may obtain in the future. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that such patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, <i style="font-style:italic;">inter partes</i> review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidate. Such a loss of patent protection could have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology or pharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States continues to adapt to wide-ranging patent reform legislation that became effective starting in 2012. Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Furthermore, the specific content of patents and patent applications that are necessary to support and interpret patent scope is highly uncertain due to the complex nature of the relevant legal, scientific, and factual issues. Changes in either patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Changes in the laws and regulations governing patents in other jurisdictions could similarly have an adverse effect on our ability to obtain and effectively enforce our patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For example, the Biden administration recently indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to COVID-19 vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and other foreign governments could have a material adverse effect on our competitive position, business, financial condition and results of operations. For example, recent decisions raise questions regarding the award of patent term adjustment (PTA) for patents in families where related patents have been issued without PTA. Thus, it cannot be said with certainty how PTA will or will not be viewed in the future and whether patent expiration dates may be impacted. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. For example, in Europe, a new unitary patent system took effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have less robust intellectual property rights in certain foreign jurisdictions and may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain of our key patent families have been filed in the United States, as well as in numerous jurisdictions outside the United States. However, our intellectual property rights in certain jurisdictions outside the United States may be less robust. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. A portion of our patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by an employee, consultant, or contractor, as applicable, in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. We may face claims by third parties that our agreements with employees, contractors or consultants obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such intellectual property. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. We may be subject to claims that former collaborators or other third parties have an ownership interest in our patents or other intellectual property, including our in-licensed patent rights. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time-consuming. If we are unsuccessful, we could lose valuable rights in intellectual property that we regard as our own.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers or our consultants&#8217; or contractors&#8217; current or former clients or customers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees from their normal responsibilities. If we are not successful, in addition to paying monetary damages, we could lose access or exclusive access to valuable intellectual property and personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technologies, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pending patent applications that we own or license may not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents, should they issue, that we own or license, may not provide us with any competitive advantages, or may be challenged and held invalid or unenforceable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology but that is not covered by our owned or in-licensed patents, should any such patents issue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our licensors, might not have been the first to make the inventions covered by a pending patent application that we own or license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our licensors, might not have been the first to file patent applications covering a particular invention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may assert an ownership interest in our intellectual property, including our in-licensed patent rights, and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop or in-license additional proprietary technologies that are patentable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could significantly harm our business and results of operation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Employee Matters, Managing Our Growth and Other Risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The contractual obligations of Daniel Pinschewer to the University of Basel may present conflicts of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Daniel Pinschewer, M.D., Founder and Chief Scientific Officer until March&#160;2020, who serves as our Scientific Advisor to the Chief Executive Officer, provides research services to us pursuant to a consulting agreement. Dr.&#160;Pinschewer is also an employee of the University of Basel where he engages in, among other activities, academic research related to arenaviruses and our technology platform. Pursuant to a separate research service agreement with the University of Basel, the university provides us with on-going services with respect to our technologies, and employs the services of Dr.&#160;Pinschewer to perform some of these services. As an employee of the University of Basel, Dr.&#160;Pinschewer is subject to the university&#8217;s rules of conduct, such as confidentiality, academic objectivity and transparency of research with respect to his academic research. As a result of Dr.&#160;Pinschewer&#8217;s obligations to the University of Basel and his current role as our Scientific Advisor to the Chief Executive Officer, circumstances may arise that could create or appear to create conflicts of interest when, we, the University of Basel or Dr.&#160;Pinschewer are faced with decisions that could have different implications for the University of Basel and our company. Additionally, we would not automatically obtain rights to inventions that are developed by Dr.&#160;Pinschewer unless the inventions were made in the course of his consulting services to us. Furthermore, other research being conducted by the University of Basel may receive higher priority than research and services related to our technology platform. Any potential disagreement or dispute that may arise with the University of Basel relating to the ownership of Dr.&#160;Pinschewer&#8217;s inventions, conflicts of interest or otherwise may result in a delay or termination of the research, development or commercialization of our product candidates or may have other negative consequences for our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on members of our executive team, including our Chief Executive Officer, Joern Aldag. Although we have formal employment agreements with our executive officers, any of our executive officers could leave our employment at any time, or within a contractual termination period that is too short to find an adequate replacement. We currently do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the services of our executive officers or other key employees may adversely impact the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our success. We primarily conduct our operations at our facility in Vienna, Austria. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To induce valuable employees to join and remain at our company, in addition to salary and cash incentives, we have provided, and intend to continue to provide, stock options that vest over time. The value of these equity grants that vest over time to our employees may be significantly affected by movements in the fair market value of our capital stock that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, many of our employees have become or will soon become vested in a substantial amount of our common stock or a number of common stock options. Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accordingly, our future success depends on our ability to continue to attract and retain current and additional executive officers and other key employees. The inability to recruit, or the loss of services of certain executives, key </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our strategic refocus and the associated workforce reduction announced in January 2024 may not result in anticipated cost savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2024, we announced a reduction in workforce by approximately 30% in connection with the strategic refocus of our business to prioritize and focus on our lead assets. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our operating structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our results of operation and financial condition would be adversely affected. We expect to incur additional costs as we recognize one-time employee termination-related charges. We also cannot guarantee that we will not have to undertake additional workforce reductions or restructuring activities in the future. Furthermore, our strategic Restructuring Plan may be disruptive to our operations. For example, our workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale. If employees who were not affected by the reduction in force seek alternate employment, this could result in us seeking contract support which may result in unplanned additional expense or harm our productivity. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific, and clinical personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing our product candidates in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may need to grow or contract our organization, and we may experience difficulties in managing this growth or contraction, which could disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the risks associated with a reduction in force, as our finances, development and commercialization plans and strategies evolve, we may choose to expand or contract our employee base for managerial, operational, manufacturing, financial and other resources. Future growth or additional contraction would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing either growth or contraction activities. We may not be able to effectively manage our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage such growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any such growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we recently implemented an approximately 30% reduction in our workforce and discontinued our GMP manufacturing facility project as part of our recent strategic refocus, as our research, development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations. Future growth would impose significant added responsibilities on members of management, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving our operational, financial and management controls, reporting systems and procedures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. Due to our limited financial resources and the limited experience of some members of our management team in managing a public company, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may also lead to significant costs. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including substantially all aspects of regulatory approval, clinical trial management and manufacturing. Our independent organizations, advisors and consultants may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Ownership of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">An active trading market for our common stock may not be sustainable, and you may not be able to resell your shares of our common stock at or above the purchase price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An active trading market for our shares may not be sustained. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. As a result of these and other factors, it may be difficult for our stockholders to resell their shares of our common stock at or above the prices at which they acquired their shares or sell their shares at the time they would like to sell. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we fail to satisfy the continued listing requirements of The Nasdaq Capital Market, such as the minimum closing bid price requirement, The Nasdaq Stock Market, LLC (Nasdaq) may take steps to delist our common stock. Under Nasdaq rules, the closing bid price for our common stock must remain at or above $1.00 per share to comply with Nasdaq&#8217;s minimum bid requirement for continued listing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On August&#160;3,&#160;2023, we received a letter from the Listing Qualifications Department of Nasdaq notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Requirement). Under Nasdaq Listing Rule 5810(c)(3)(A), we have been granted a 180 calendar day grace period, or until January&#160;30,&#160;2024, to regain compliance with the Minimum Bid Price </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Requirement. The Minimum Bid Price Requirement will be met if our common stock has a minimum closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the 180 calendar day grace period. However, we failed to regain compliance prior to January&#160;30,&#160;2024. Accordingly, on January 18, 2024, we applied for and on January 31, 2024 were granted by the Listing Qualifications Department of Nasdaq the right to list our common stock on the Capital Market and to have an additional 180 calendar days, or until June 29, 2024, to regain compliance with the Minimum Bid Price Requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are monitoring the closing bid price of our common stock; however, there can be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The delisting of our common stock from Nasdaq may make it more difficult for us to raise capital on favorable terms in the future. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. Further, if we were to be delisted from Nasdaq, our common stock would cease to be recognized as covered securities and we would be subject to regulation in each state in which we offer our securities. Moreover, there is no assurance that any actions that we take to restore our compliance with the Minimum Bid Price Requirement would stabilize the market price or improve the liquidity of our common stock, prevent our common stock from falling below the minimum bid price required for continued listing again or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our stock may be volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading price of our common stock could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commencement, enrollment or results of the clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse developments concerning our manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to establish collaborations if needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated serious safety concerns related to the use of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products or services offered by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to effectively manage our growth or concentration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of our initial cancer target markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully treat additional types of cancers or at different stages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated variations in quarterly operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overall performance of the equity markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our stockholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ineffectiveness of our internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general political and economic conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which are beyond our control.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our principal stockholders and management own a significant percentage of our stock and exert significant influence over matters subject to stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Class A common stock has no voting rights. As a result, all matters submitted to our stockholders are decided by the vote of holders of our common stock. Our executive officers, directors, and 5% stockholders beneficially own approximately 40% of our outstanding voting stock. These stockholders may be able to determine many matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under current and any potential future license and collaboration agreements and, if approved, sales of our product candidates. These upfront and milestone payments may vary significantly from period to period and any variance could cause a significant fluctuation in our operating results from one period to the next.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which will change from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcomes of clinical trials for our current and any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing our current and any future product candidates, which may vary depending on FDA guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to adequately support our future growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential unforeseen business disruptions that increase our costs or expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future accounting pronouncements or changes in our accounting policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the changing and volatile global economic environment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. The price of our common stock could decline even when we have met any previously publicly stated revenue and/or earnings guidance we may provide.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to continue to incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after we are no longer an emerging growth company, as defined in the JOBS Act, we will incur significant legal, accounting and other expenses that we did not incur as a private company. Our status as an &#8220;emerging growth company&#8221; will end on December&#160;31,&#160;2024, at the latest. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will continue to need to hire additional accounting, finance, and other personnel in connection with our efforts to comply with the requirements of being, a public company and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We are continuously evaluating these rules and regulations which are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act (SOX Section 404) we are required to furnish a report by our management on our internal control over financial reporting with our Annual Report on Form 10-K with the SEC. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. After no longer qualifying as an emerging growth company, we may, under certain conditions, still qualify as a &#8220;smaller reporting company&#8221; and benefit from similar exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. To achieve compliance with SOX Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by SOX Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock, which may never occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that special meetings of stockholders be called only by our board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement of approval of (i)&#160;not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action and (ii)&#160;the majority of the outstanding shares of our voting stock to amend specific provisions of our certificate of incorporation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for state law claims for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees to us or our stockholders, (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, or other employees or stockholders arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, (iv)&#160;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws, or (v)&#160;any action asserting a claim against us or any of our current or former directors or officers or other employees that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the jurisdiction. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated certificate of incorporation or amended and restated bylaws inapplicable to, or unenforceable in respect of, one </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or more of the specified types of actions or proceedings, we may incur additional costs, which could have a material adverse effect on our business, financial condition or results of operation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of our initial public offering in April 2019, we became subject to the periodic reporting requirements of the Exchange Act. We are continuing to refine our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Pursuant to Section 404 of Sarbanes-Oxley, our management is required to report upon the effectiveness of our internal control over financial reporting. When we lose our status as an &#8220;emerging growth company&#8221; and if we do not qualify as a &#8220;smaller reporting company&#8221; at such time, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">General Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect the Company&#8217;s current and projected business operations and its financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, such as the failure of Silicon Valley Bank and various regional banks in 2023, have in the past and may in the future lead to market-wide liquidity problems. If any of our lenders or counterparties to any such instruments were to be placed into receivership, we may be unable to access such funds. In addition, if any of our customers, suppliers or other parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">financial institution, such parties&#8217; ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Heightened inflation and increases in interest rates may increase our labor costs, costs to conduct clinical trials and other operational costs, or adversely affect our ability to obtain additional funding on attractive terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Although inflation has not had a material impact on our business or operating results historically, inflation, has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to conduct clinical trials and other operational costs. Inflationary costs could adversely affect our business, financial condition and results of operations. Increased interest rates may adversely affect our borrowing rate and our ability to obtain, or the terms under which we can obtain, any potential additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the regulations of the FDA and other comparable foreign regulatory bodies, provide true, complete and accurate information to the FDA and other comparable foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws and regulations will increase significantly, and our costs associated with compliance with such laws and regulations are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee and other third-party misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Violations of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that could have a material adverse effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve the use of potentially hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We could incur substantial costs as a result of violations of or liabilities under environmental requirements in connection with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party claims. Although we generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of changes to applicable laws and regulations and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, clinical trial data and financial information (collectively, sensitive data).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws).  For example, the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information. For more information regarding risks associated with HIPAA, please refer to the section above that discusses risks associated with U.S. healthcare laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;) (collectively, &#8220;CCPA&#8221;), applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws may impact (possibly significantly) our business activities depending on how it is interpreted, should we become subject to the CCPA in the future. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments may further complicate compliance efforts and increase legal risk and compliance costs for us and the third parties upon whom we rely. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, EU GDPR and the UK GDPR impose strict requirements for processing personal data. For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be subject to new laws governing the privacy of consumer health data, including reproductive, sexual orientation, and gender identity privacy rights. For example, Washington&#8217;s My Health My Data Act (&#8220;MHMD&#8221;) broadly defines consumer health data, places restrictions on processing consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law. Other states are considering and may adopt similar laws. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our employees and personnel use generative artificial intelligence (&#8220;AI&#8221;) technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations.  Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits.  If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some EU regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the EU GDPR&#8217;s cross-border data transfer limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to data privacy and security laws, we are bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We also publish privacy policies, marketing materials, and other statements regarding data privacy and security and if these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations.  Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data (including clinical trial data); and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cybersecurity risks and the failure to maintain the security, confidentiality, integrity, and availability of our information technology systems or data, and those maintained on our behalf, could result in adverse consequences that materially affect our business, including without limitation regulatory investigations or actions, a material disruption of the development programs of our product candidates, damage to our reputation and/or subject us to costs, loss of customers or sales, fines and penalties or lawsuits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we collect and store sensitive data, and, as a result, we and the third parties upon which we rely face a variety of evolving threats that could cause security incidents. We manage and maintain our applications and data utilizing on-site systems and outsourced vendors. These applications and data encompass a wide variety of business critical information, including research and development information, commercial information and business and financial information. Because information systems, networks and other technologies are critical to many of our operating activities, shutdowns or service disruptions at our company or vendors that provide information systems, networks or other services to us pose increasing risks. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to computer hacking, phishing attacks and social engineering (including through deep fakes, which may be increasingly more difficult to identify as fake), supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, ransomware, dissemination of malware, computer viruses, worms and other destructive or disruptive software, denial of service attacks and other malicious activity, credential stuffing, credential harvesting, personnel misconduct or error as well as power outages, telecommunications failures, natural disasters (including extreme weather), terrorist attacks or other similar events. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Such events could have an adverse impact on us and our business, including loss of data and damage to equipment and data. In addition, system redundancy may be ineffective or inadequate, and our disaster recovery planning may not be sufficient to cover all eventualities. If such events were to occur and cause interruptions in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our operations, it could result in a material disruption of our development programs and our business operations, such as the loss of clinical trial data from completed or future clinical trials. Such loss could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we may not have adequate insurance coverage to compensate for any losses associated with such events. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. We may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation the manufacture of our product candidates and to conduct clinical trials. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences, including the unauthorized access, disclosure and use of sensitive data, including information from our patient registry or other patient information, which is protected by HIPAA, and other laws. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, damage to our reputation and the further development and commercialization of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of our suppliers are affected by a man-made or natural disaster or other business interruption. Damage or extended periods of interruption to our third-party collaborators&#8217;, including Gilead&#8217;s, corporate, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause them to cease or delay development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As we outsource more of our information systems to vendors, engage in more electronic transactions with payors and patients, and rely more on cloud-based information systems, the related security risks will increase and we will need to expend additional resources to protect our technology and information systems. In addition, there can be no assurance that our internal information technology systems or those of our third-party contractors, or our consultants&#8217; efforts to implement adequate security and control measures, will be sufficient to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a cyber-attack, security breach, industrial espionage attacks or insider threat attacks which could result in financial, legal, business or reputational harm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We also take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may expend significant resources or modify our business activities to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data. Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may prevent or cause customers to stop using our services, deter new customers from using our services, and negatively impact our ability to grow and operate our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data of the Company or our customers could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_a986d39a_e4e1_4377_af81_5bbf12776de2"></a><a id="UnresolvedStaffComments_377193"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1B.&#160;&#160;Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2673c6f_c76b_48b6_b310_67bf7ab7643c"></a><a id="Item1CCybersecurity_867122"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1C.&#160;&#160;Cybersecurity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cybersecurity Risk Management and Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have implemented and maintain various cybersecurity processes, technologies, and controls to aid in our efforts to assess, identify, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data (&#8220;Information Systems and Data&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cybersecurity function, led by our Head of DevSecOps and supported by our Head of IT and third-party service providers, identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example: maintaining manual and automated tools, subscribing to reports and services that identify cybersecurity threats, conducting scans of our threat environment, evaluating our and our industry&#8217;s cybersecurity risk profile, evaluating threats reported to us, completing internal and external cybersecurity audits, completing third-party cybersecurity threat assessments, conducting vulnerability assessments, leveraging external intelligence feeds, and completing third-party red/blue team exercises and tabletop incident response exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depending on the environment, we implement and maintain technical, physical, and organizational measures, processes, standards, practices, and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. These measures, processes, standards, practices, and policies address, for example: incident detection and response, risk assessments, security certifications, encryption, network security controls, data segregation, access controls, physical security, asset management (such as tracking and disposal), systems monitoring, employee cybersecurity awareness training, and systems monitoring. We also have cybersecurity insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our process for identifying and assessing material risks from cybersecurity threats operates alongside our broader overall enterprise risk assessment process. We have a cybersecurity-specific risk assessment process designed to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assess identified material risks from cybersecurity threats. This process is designed to help us manage our material risks from cybersecurity threats and protect against, detect, and respond to cybersecurity incidents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example cybersecurity software providers and cybersecurity consultants that provide threat intelligence, managed cybersecurity, forensic, and penetration testing services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, we use third-party service providers to perform a variety of functions throughout our business, such as software-as-a-service providers, data hosting companies, contract research organizations, and contract manufacturing organizations. We have certain vendor management processes designed help to manage cybersecurity risks associated with our use of these providers. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management processes may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider, including, for example, security questionnaires and the imposition of contractual obligations related to cybersecurity on the provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a description of the cybersecurity risks and related impacts that may materially affect the Company and how they may do so, see our risk factors in Part I, Item 1A of this Annual Report on Form 10-K, including &#8220;Cybersecurity risks and the failure to maintain the security, confidentiality, integrity, and availability of our information technology systems or data, and those maintained on our behalf, could result in adverse consequences that materially affect our business, including without limitation regulatory investigations or actions, a material disruption of the development programs of our product candidates, damage to our reputation and/or subject us to costs, loss of customers or sales, fines and penalties or lawsuits.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Cybersecurity Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board of Directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. Our Audit Committee is responsible for the oversight of risks from cybersecurity threats and data breaches. On a quarterly basis, the Audit Committee receives an overview from our Head of IT regarding our cybersecurity threat risk management and strategy processes, which may include, for example, covering topics such as data security posture, results from third-party assessments, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks. The Chair of the Audit Committee periodically updates our Board of Directors on its oversight of cybersecurity and data breach risk management and strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our executive management team, with regulatory and governance oversight from our Audit Committee, are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Our Digital and IT Steering Committee is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cybersecurity function, led by our Head of DevSecOps and supported by our Head of IT and third-party service providers, is responsible for our cybersecurity risk management and strategy processes. Our Head of IT, who is a Certified Information Security Manager (CISM ISACA) and a Certified Information Systems Auditor (CISA ISACA), and our Head of DevSecOps, collectively have significant prior work experience in various roles involving managing information security, developing cybersecurity strategy and implementing effective information and cybersecurity programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our cybersecurity incident response plan provides for escalation of certain cybersecurity incidents to members of management depending on the circumstances, including our CFO, COO, and CEO. Management works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. Our incident response team also reports material cybersecurity incidents to the Chair of the Audit Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_832f2c2c_2db7_4567_8679_f57e9bb4fd56"></a><a id="Properties_188239"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 2.&#160;&#160;Properties</p><a id="_Hlk98840454"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our principal executive offices are located in New York, New York, pursuant to a lease that expires in August&#160;2026. Our European research and preclinical development operations are located in Vienna, Austria, where we lease and occupy approximately 30,681&#160;square feet of office and laboratory space. Our first facility is leased pursuant to two operating leases, comprised of (i)&#160;a lease of unlimited duration for approximately 15,239&#160;square feet of office and laboratory space and (ii)&#160;a lease set to expire in September&#160;2028 and with no option to extend for approximately 2,367&#160;square feet of storage space. In 2019, we entered into a lease for a second facility located in Vienna, Austria that is set to expire in February&#160;2029, where we occupy approximately&#160;15,440&#160;square feet of office and laboratory space. In May 2021 we purchased a parcel of land in the north of Vienna and have received building permission to build a GMP manufacturing plant of approximately 48,440&#160;square feet. In January 2024 our Board decided to implement a Restructuring Plan, which included the discontinuation of the GMP manufacturing project and the divestment of all associated assets, including the parcel of land. Strategic considerations preceding the adoption of the Restructuring Plan resulted in the impairment of the full carrying value of the GMP manufacturing facility project in the year ended December&#160;31,&#160;2023. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7cc284ca_2ebf_42ca_9be2_b2dff4af57a6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II&#8212;OTHER INFORMATION</p><a id="LegalProceedings_351583"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2021, a third party opposed European Patent No.&#160;3218504 (the &#8220;EP &#8217;504 Patent&#8221;) which was granted to the University of Geneva in July&#160;2020 and is exclusively licensed to us. The patent is directed to our replicating arenavirus platform technology and is part of our strategy to protect current product candidates based on this platform technology, including our lead oncology product candidate HB-200. In a decision that has become final, the Opposition Division of the European Patent Office (&#8220;EPO&#8221;) dismissed the opposition in an oral proceeding on May&#160;9,&#160;2023, and maintained the patent as granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">From time to time, we may become involved in other litigation or legal proceedings relating to claims arising from the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_85d1b756_9610_4762_9cbe_ca05ad2af476"></a><a id="MineSafetyDisclosures_997431"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;Mine Safety Disclosures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dbab2a73_2adb_440f_bb8b_e9ed904c965e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART II</p><a id="MarketforRegistrantsCommon_947933"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5.&#160;&#160;Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity</b><b style="font-weight:bold;"> Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Certain Information Regarding the Trading of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock trades under the symbol &#8220;HOOK&#8221; on The Nasdaq Capital Market and has been publicly traded since April&#160;18,&#160;2019. Prior to this time, there was no public market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Holders of Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of March&#160;22,&#160;2024, there were four holders of record of shares of our common stock, which does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name, and two holders of record of shares of our Class A common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not paid any cash dividends on our common stock since inception and do not anticipate paying cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part II of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_67458b54_ac22_4db3_911a_0a497f908b82"></a><a id="SelectedFinancialData_379980"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 6.&#160;&#160;[Reserved]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_c663ed27_61d7_4abf_bb4b_b3e8c3983bef"></a><a id="ManagementsDiscussionandAnalysis_660301"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;Management&#8217;s Discussion&#160;and&#160;Analysis&#160;of&#160;Financial&#160;Condition&#160;and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><a id="_Hlk64378034"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on our proprietary arenavirus platform that is designed to target and amplify T&#160;cell and immune responses to fight diseases. Our replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. We believe that our technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by inducing CD8+ T&#160;cell response levels previously not achieved by other immune therapy approaches. </p><a id="_Hlk64378634"></a><a id="_Hlk64378441"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are building a proprietary immuno-oncology pipeline utilizing our replicating technology. Our oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: HB-200 and HB-700. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (&#8220;HPV16+&#8221;) head and neck cancers in a Phase&#160;1/2 clinical trial. HB-700, which has been partnered with F.&#160;Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively referred to as &#8220;Roche&#8221;), is in preclinical development for the treatment of KRAS mutated cancers, including, lung, colorectal and pancreatic cancers. Our third oncology program, HB-300, targeting self-antigens for the treatment of prostate cancer, was paused for further development in January 2024.</p><a id="_Hlk64379414"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategic priority is the development of our oncology portfolio, most importantly the advancement of our HB-200 program, and we expect to initiate a randomized Phase&#160;2/3 trial in 2024. Additionally, we are developing infectious disease therapies in partnership with other companies. Our Hepatitis B (&#8220;HBV&#8221;) program, HB-400, and our Human Immunodeficiency Virus (&#8220;HIV&#8221;) program, HB-500, are developed in a partnership with Gilead Sciences Inc. (&#8220;Gilead&#8221;).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">2023 Highlights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, we executed on several key areas across our pipeline. The highlights include: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Oncology: </i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-200 in combination with pembrolizumab: We presented positive preliminary Phase 2 data in patients with recurrent/metastatic (&#8220;R/M&#8221;) HPV16+ head and neck cancers in the first line setting in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology (ESMO) Congress 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:90pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Data showed 42% objective response rate for 19 evaluable checkpoint inhibitor (&#8220;CPI&#8221;)-na&#239;ve patients. These data represent a doubling of the historical response rate (19%) reported for pembrolizumab alone. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:90pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are preparing to start a randomized Phase&#160;2/3 trial of HB-200 in combination with pembrolizumab in the 1st-line setting for patients with R/M HPV16+ head and neck cancers.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-700: We continued Investigational New Drug (&#8220;IND&#8221;) application-enabling activities. We are on track to submit an IND in the second quarter of 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-300: We have enrolled the first two dose escalation cohorts in the Phase&#160;1/2 study. The Study Safety Committee deemed that HB-300 was generally safe and well-tolerated in both dose escalation cohorts. However, we paused further development of this program in January 2024 to refocus our capital resources on the advancement of our HB-200 program and Gilead-partnered infectious disease programs. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Infectious Disease: Gilead-Partnered Programs</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-400: In August, the Journal of Infectious Disease published peer-reviewed preclinical data on HB-400. The data showed that HB-400 induced robust, HBV-specific T cell and antibody responses in non-human primates and cleared detectable serum HBV antigens in a mouse model for chronic HBV infection, with near elimination of detectable HBV antigen positive hepatocytes in the liver. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HB-500: In November 2023, we announced FDA clearance of our IND application for HB-500 for the treatment of HIV. Additionally, Nature Partner Journals published peer-reviewed preclinical data for the program in November 2023. The data showed that HB-500 was well tolerated and generated robust, high-quality and durable immune responses (antigen-specific T cells and antibodies) in non-human primates, and arenaviral therapeutic vaccination significantly reduced SIV viral load and clinical illness in those animals compared to placebo.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have funded our operations to date primarily from public offerings of common stock and convertible preferred stock, including our initial public offering, as well as private placements of our redeemable convertible preferred stock, grant funding and loans from an Austrian government agency, and upfront, milestone and initiation payments from Gilead and Roche in connection with our respective collaboration and license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not expect to generate revenue from any product candidates that we develop until we obtain regulatory approval for one or more of such product candidates, if at all, and commercialize our products or enter into additional collaboration agreements with third parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk64379547"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All of our product candidates, including our most advanced oncology product candidate, HB-200, will require substantial additional development time and resources before we would be able to apply for and receive regulatory approvals and begin generating revenue from product sales. Before launching our first products, if approved, we plan to establish our own manufacturing facility to reduce or eliminate our reliance on contract manufacturing organizations (&#8220;CMOs&#8221;) which will require substantial capital expenditures and cause additional operating expenses. We currently have no marketing and sales organization and have no experience in marketing products; accordingly, we will incur significant expenses to develop a marketing organization and sales force in advance of generating any commercial product sales. As a result, we will need substantial additional capital to support our operating activities. In addition, we expect to continue to incur legal, accounting and other expenses in operating our business, including the costs associated with operating as a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently anticipate that we will seek to fund our operations through equity or debt financings or other sources, such as government grants and additional collaboration agreements with third parties. Adequate funding may not be available to us on acceptable terms, or at all. If sufficient funds on acceptable terms are not available when needed, we will be required to significantly reduce our operating expenses and delay, reduce the scope of, or eliminate one or more of our development programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;29,&#160;2024, we announced our decision to prioritize the clinical development of our HB-200 program for the treatment of HPV16+ head and neck cancers and our two Gilead-partnered infectious disease programs and to pause development activities related to HB-300 and most of our preclinical research activities. In connection with this strategic refocus, our Board of Directors approved a plan to reduce our workforce by 55&#160;fulltime employees, or approximately 30% of the then-current employee base, and to rebalance our cost structure in alignment with the new prioritization of research and development programs. The prioritization of our HB-200 program and our two Gilead-partnered programs also includes the discontinuation of our GMP manufacturing facility project. We expect the restructuring to be implemented and substantially completed by the end of the first quarter of 2024. In connection with the Restructuring Plan, we estimate that we will incur cash charges of approximately $1.6&#160;million for severance and other personnel and restructuring related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also announced in January&#160;2024 that we received notification from Roche of their decision to terminate the collaboration and licensing agreement for our HB-700 program in KRAS mutated cancers. We have met all go-forward criteria under the agreement and remain eligible for a final milestone payment associated with an IND submission. Effective April 25, 2024, we will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for this program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred net losses each&#160;year since our inception in 2011, including net losses of $81.6&#160;million for the year ended December&#160;31,&#160;2023 and $64.9&#160;million for the year ended December&#160;31,&#160;2022. As of December&#160;31,&#160;2023, we had an accumulated deficit of $369.3&#160;million and we do not expect positive cash flows from operations in the foreseeable future, if ever. We expect to continue to incur net operating losses for at least the next several&#160;years as we advance our product candidates through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, continue our research and development efforts and invest to establish further commercial manufacturing capacity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that our cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements at least through the next 12&#160;months from the issuance date of the consolidated financial statement. See &#8220;&#8212;Liquidity and Capital Resources.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impacts of Coronavirus and Market Conditions on Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have been actively monitoring the coronavirus pandemic situation and its impact globally. We believe our financial results for the years ended December&#160;31,&#160;2023, 2022 and 2021 were not significantly impacted by any lingering effects of the recent coronavirus pandemic. Further, disruption of global financial markets and a recession or market correction, including as a result of any resurgence of the coronavirus pandemic, the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia, any escalation of the conflict in Israel and the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Gaza Strip, and other global macroeconomic factors, could reduce our ability to access capital, which could, in the future, negatively affect our business and the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Effects of Inflation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not believe that inflation has had a material impact on our business or operating results during the periods presented. However, inflation, has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to conduct clinical trials and other operational costs. Inflationary costs could adversely affect our business, financial condition and results of operations. In addition, increased inflation has had, and may continue to have, an effect on interest rates. Increased interest rates may adversely affect our borrowing rate and our ability to obtain, or the terms under which we can obtain, any potential additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue from collaboration and licensing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenue from product sales and do not expect to do so in the near future, if at all. All of our revenue to date has been derived from research collaboration and license agreements with Gilead and Roche.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Gilead Collaboration Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;4,&#160;2018, we entered into the Gilead Collaboration Agreement to evaluate potential vaccine products using or incorporating our replicating technology and non-replicating technology for the treatment, cure, diagnosis or prevention of HBV and HIV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Collaboration Agreement, we granted Gilead an exclusive, royalty-bearing license to our technology platform for researching, developing, manufacturing and commercializing products for HIV or HBV. We received a non-refundable $10.0&#160;million upfront payment upon entering the Gilead Collaboration Agreement. In February&#160;2022, we signed an amended and restated collaboration agreement (the &#8220;Restated Gilead Collaboration Agreement&#8221;) which revised the terms only for the HIV program, whereby we will take on development responsibilities for the HIV program candidate through a Phase&#160;1b clinical trial. Pursuant to the Restated Gilead Collaboration Agreement, Gilead will retain an exclusive right, the Option, to take back the development responsibilities, thus keeping the rights for the HIV program, including further development and commercialization in return for an option exercise payment of $10.0&#160;million. Pursuant to the Restated Gilead Collaboration Agreement, we are eligible for up to $140.0&#160;million in developmental milestone payments for the HBV program and $50.0 million in commercialization milestone payments. If Gilead exercises the Option, we are eligible for up to $172.5&#160;million in developmental milestone payments for the HIV program, inclusive of the $10.0&#160;million Option exercise payment, and $65.0&#160;million in commercialization milestone payments for the HIV program. Upon the commercialization of a product, we are eligible to receive tiered royalties of a high single-digit to mid-teens percentage on the worldwide net sales of each HBV product, and royalties of a mid-single-digit to 10% of worldwide net sales of each HIV product. Gilead is obligated to reimburse us for our costs, including all benefits, travel, overhead, and any other expenses, relating to performing research and development activities under the Restated Gilead Collaboration Agreement with respect to the HBV program, and if the Option is exercised, any manufacturing costs related to the HIV program. Through December&#160;31,&#160;2023, we have received a non-refundable upfront payment of $10.0&#160;million, a program initiation fee of $15.0&#160;million and $21.2&#160;million in milestone payments for the achievement of pre-clinical research milestones from Gilead. In addition, we have recognized $42.2&#160;million of cost reimbursements for research and development services performed under the Restated Gilead Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We determined that our performance obligations under the terms of the original Gilead Collaboration Agreement included one combined performance obligation for each of the HBV and HIV research programs, comprised of the transfer of intellectual property rights and providing research and development services. Accordingly, we recognized these amounts as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours for each of the performance obligations. The terms of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the Restated Gilead Collaboration Agreement added an additional performance obligation to us to perform research and development work for the HIV program. We recognize the amounts of revenue allocated to the performance obligation resulting from the Restated Gilead Collaboration Agreement on a percent of completion basis over the performance period, using total estimated research and development costs as the measure of progress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">Roche Collaboration Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October&#160;18,&#160;2022, we entered into the Roche Collaboration Agreement to (i) grant Roche an exclusive license to research, develop, manufacture and commercialize our pre-clinical HB-700 cancer program, an arenaviral immunotherapeutic for KRAS-mutated cancers, and (ii) grant Roche an exclusive option right to exclusively license for research, development manufacturing and commercialization, a second, novel arenaviral immunotherapeutic program targeting undisclosed cancer antigens. In January&#160;2024, Roche provided us with written notice of the termination of the collaboration and licensing agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the terminated Roche Collaboration Agreement, we granted Roche an exclusive, royalty-bearing license to our technology platforms for KRAS-mutated cancers, and an option right to exclusively license a second, novel arenaviral immunotherapeutic program targeting undisclosed cancer antigens. Pursuant to the terms of the Roche Collaboration Agreement, following the termination notice, the Roche Collaboration Agreement will be terminated on April&#160;25,&#160;2024. We remain eligible for a final milestone payment associated with an IND submission. Effective April&#160;25,&#160;2024, we will regain full control of the associated intellectual property portfolio and will have full collaboration and licensing rights for the KRAS program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Through December&#160;31,&#160;2023, we have received from Roche the non-refundable upfront payment of $25.0&#160;million and $10.0&#160;million in milestone payments for the achievement of a GMP manufacturing milestone under the HB-700 program. In addition, we have recognized $0.5&#160;million of cost reimbursements for research and development activities related to a first human trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We determined that our performance obligations under the terms of the Roche Collaboration Agreement included one combined performance obligation for the transfer of intellectual property rights (licenses) and providing research and development services for the HB-700 program, and a second, separate performance obligation during the UCA Option period to perform research and development services with respect to the UCA Program. Accordingly, we allocated the non-refundable upfront payment of $25.0&#160;million between the two performance obligations. Milestone payments that are contingent on future events will be added to the transaction price when the triggering event has become probable. The consideration allocated to a performance obligation has been recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development costs for each of the performance obligations. Milestone payments, or parts thereof, that relate to completed services will be reflected via a cumulative catch up for past performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At December&#160;31,&#160;2023, $26.8&#160;million of non-refundable upfront and milestone payments received from Roche were still recorded as deferred revenue and will be early recognized as revenue as a result of the termination in the first half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operating expenses since inception have only consisted of research and development costs and general administrative costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since our inception, we have focused significant resources on our research and development activities, including establishing our arenavirus platform, conducting preclinical studies, developing a manufacturing process, conducting Phase&#160;1 and Phase&#160;2 clinical trials, including the ongoing HB-200 Phase&#160;1/2 trial, and progressing investigational new drug (&#8220;IND&#8221;) applications, including for HB-500 and HB-700. Research and development activities </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">account for a significant portion of our operating expenses. Research and development costs are expensed as incurred. These costs include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in connection with the preclinical development of our programs and clinical trials of our product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations (</span><span style="font-family:'Times';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CROs</span><span style="font-family:'Times';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing drug products for use in clinical trials, including under agreements with third parties, such as CMOs, consultants and contractors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">laboratory costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party license fees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The majority of our research and development costs are external costs, which we track on a program-by-program basis. We do not track our internal research and development expenses on a program-by-program basis as they primarily relate to shared costs deployed across multiple projects under development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expenses to increase substantially in the future as we advance our existing and future product candidates into and through clinical trials and pursue regulatory approval. The process of conducting the necessary clinical studies to obtain regulatory approval is costly and time-consuming. Clinical trials generally become larger and more costly to conduct as they advance into later stages and, in the future, we will be required to make estimates for expense accruals related to clinical trial expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any product candidates that we develop from our programs. We are also unable to predict when, if ever, material net cash inflows will commence from sales of product candidates we develop, if at all. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of INDs for our planned clinical trials or future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment and completion of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful data from our clinical program that support an acceptable risk-benefit profile of our product candidates in the intended populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scaleup of our manufacturing processes and formulation of our product candidates for later stages of development and commercialization;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing our own manufacturing capabilities or agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidate is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entry into collaborations to further the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully launching commercial sales of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the product candidates benefits and uses, if approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of adverse events experienced with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the product candidates following approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">qualifying for, maintaining, enforcing and defending intellectual property rights and claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses by product candidate or program (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HB-200 program</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,301</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,409</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HB-300 program</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,654</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,938</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gilead partnered programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,529</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roche partnered programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other and earlier-stage programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,946</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,815</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other unallocated research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,316</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,954</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 86,424</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 68,645</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other unallocated research and development expenses include stock-based compensation expense, certain lease expenses and other operating expenses that we do not track on a program-by-program basis, since our research and development employees and infrastructure resources are utilized across our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our general and administrative expenses consist primarily of personnel costs in our executive, finance and investor relations, business development and administrative functions. Other general and administrative expenses include consulting fees and professional service fees for auditing, tax and legal services, lease expenses related to our offices, premiums for directors and officers liability insurance, intellectual property costs incurred in connection with filing and prosecuting patent applications, depreciation and other costs. We expect our general and administrative expenses to continue to increase in the future as we expand our operating activities and prepare for potential commercialization of our current and future product candidates, increase our headcount and investor relations activities and maintain compliance with requirements of the Nasdaq Capital Market and the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Impairment expenses consist of non-cash impairment charges relating to long-lived assets. Impairments are determined using management&#8217;s judgment about the anticipated performance of our business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets and their effects based on information available as of the date of these consolidated financial statements. Management disposes of fixed assets during the regular course of business due to damage, obsolescence, strategic shifts, and loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to future undiscounted net cash flows expected to be generated by the assets. If the carrying amount of an asset group exceeds its estimated undiscounted net future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset group exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><a id="_Hlk64379675"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have received grants from the Austrian Research Promotions Agency, either under funding agreements or under research incentive programs. In addition, we have received loans under funding agreements that bear interest at below market interest rate. We account for the grants received as other income and for the imputed benefits arising from the difference between a market rate of interest and the rate of interest as additional grant income, and record interest expense for the loans at a market rate of interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We participate in a research incentive program provided by the Austrian government under which we are entitled to reimbursement of a percentage of qualifying research and development expenses and capital expenditures incurred in Austria. Submissions for reimbursement under the program are submitted annually. Incentive amounts are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">generally paid out during the calendar year that follows the year of the expenses but remain subject to subsequent examinations by the responsible authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we participated in the life sciences research and development program provided by the New York State government under which we were entitled to reimbursement of a percentage of qualifying research and development expenses in New York State up to $0.5 million per year for the years 2019 to 2021. Submissions for reimbursement under the program were submitted in the fourth quarter of 2023 and certificates of tax credits were received. Incentive amounts are generally paid out six to nine months after amended tax returns including a certificate of tax credit issued by Empire State Development are filed. We account for the grants received as other income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also participate in the New York City biotechnology tax credit program, according to which certain expenses for business in the biotechnology field in New York City limited to $0.25 million per year for three consecutive years from January 1, 2023 to December 31, 2025 are incentivized. We account for the grants received as other income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest income results of interest earned on our cash, cash equivalents, and restricted cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expense results primarily from loans under funding agreements with the Austrian Research Promotion Agency, recorded at a market rate of interest. The difference between interest payments payable pursuant to the loans, which rates are at below market interest rates, and the market interest rate, is accounted for as grant income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income tax expense results from U.S. federal and state income tax as well as foreign minimum income tax and profit on a legal entity basis. The losses that we have incurred since inception result primary from the losses of our Austrian subsidiary. As of December&#160;31,&#160;2023, we had a deferred tax asset of $94.4&#160;million primarily resulting from foreign net operating loss carryforwards of $378.1&#160;million with no expiry date. We have considered that, at this point in time, it is uncertain whether we will ever be able to realize the benefits of the deferred tax asset, and accordingly, have established a full valuation allowance as of December&#160;31,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of Years Ended December&#160;31,&#160;2023 and 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes our results of operations for the years ended December&#160;31,&#160;2023 and 2022 (in thousands). Discussions of 2021 items and year-to-year comparisons between 2022 and 2021 that are not included in this Annual Report on Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Results of Operations&#8221; Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31,&#160;2022 filed with the SEC on March&#160;15,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Revenue from collaboration and licensing </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 20,129</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 14,249</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 5,880</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Operating expenses:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Research and development </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (86,424)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (68,645)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (17,779)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">General and administrative </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (18,633)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (18,759)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 126</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Impairment expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (12,766)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (12,766)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="color:#231f20;">Total operating expenses </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (117,823)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (87,404)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (30,419)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Loss from operations </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (97,694)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (73,155)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (24,539)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Other income (expense):</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Grant income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 11,193</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 7,916</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 3,277</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Interest income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 5,293</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 1,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 3,660</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Interest expense </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (317)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (687)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 370</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Other income and expenses, net </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 313</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (392)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 705</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="color:#231f20;">Total other income (expense), net </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 16,482</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 8,470</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> 8,012</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Net loss before tax </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (81,212)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (64,685)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (16,527)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="color:#231f20;">Income tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (368)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (230)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (138)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (81,580)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (64,915)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;"> (16,665)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue from Collaboration and Licensing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue was $20.1&#160;million for the year ended December&#160;31,&#160;2023, compared to $14.2&#160;million for the year ended December&#160;31,&#160;2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The increase of $5.9&#160;million for the year ended December&#160;31,&#160;2023 compared to the year ended December&#160;31,&#160;2022 was primarily due to higher partial recognition of the upfront and milestone payments under the Gilead and Roche collaborations, partially offset by lower aggregate cost reimbursements received under these collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2023 and 2022, revenue included $1.9 million and $5.2 million, respectively, from reimbursement of research and development expenses, and $18.2 million and $4.0 million, respectively, from partial recognition of milestone and initiation payments that were initially recorded as deferred revenue. In addition, revenue for the year ended December 31, 2022 included $5.0 million that were recognized upon the achievement of a research milestone related to the Restated Gilead Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December&#160;31,&#160;2023, revenue included $8.5&#160;million related to the Restated Gilead Collaboration Agreement, of which $1.4&#160;million resulted from reimbursement of research and development expenses, and $7.1&#160;million from partial recognition of milestone and initiation payments that were initially recorded as deferred revenue. In addition, revenue included $11.6&#160;million related to the Roche Collaboration Agreement, of which $11.1&#160;million resulted from partial recognition of milestone and initiation payments that were initially recorded as deferred revenue, and $0.5&#160;million from reimbursement of expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For the year ended December&#160;31,&#160;2022, revenue included $13.9&#160;million related to the Restated Gilead Collaboration Agreement, of which $5.2&#160;million resulted from reimbursement of research and development expenses, $3.7&#160;million from partial recognition of milestone and initiation payments that were initially recorded as deferred revenue and $5.0&#160;million from revenue that was immediately recognized upon the achievement of a research milestone. In the year ended December&#160;31,&#160;2022 we completed the recognition of the deferred revenue related to the $4.0&#160;million milestone payment that we received in 2020 related to the Restated Gilead Collaboration Agreement. In addition, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">revenue included $0.3&#160;million related to the Roche Collaboration Agreement, which resulted from partial recognition of milestone and initiation payments that were initially recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December&#160;31,&#160;2023, our research and development expenses were $86.4&#160;million, compared to $68.6&#160;million, for the year ended December&#160;31,&#160;2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The increase of $17.8&#160;million for the year ended December&#160;31,&#160;2023 compared to the year ended December&#160;31,&#160;2022 was attributable to an increase in direct research and development expenses of $12.4&#160;million, and an increase in indirect research and development expenses of $5.4&#160;million. The increase in direct research and development expenses was primarily driven by higher clinical trial expenses for our HB-200 program, which continued to enroll patients, primarily in the first line combination arm with pembrolizumab, as well as increased spending for our Roche partnered HB-700 program. These increases were partially offset by lower manufacturing expenses, including for our HB-300 program. Indirect research and development expenses increased mainly because of personnel related expenses including stock-based compensation, partially offset by lower expenses for consulting and professional services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the year ended December&#160;31,&#160;2023 were $18.6&#160;million, compared to $18.8&#160;million for the year ended December&#160;31,&#160;2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The decrease was primarily due to a decrease in other expenses of $1.1&#160;million, partially offset by an increase in personnel-related expenses of $0.8&#160;million, and an increase in professional and consulting fees of $0.2&#160;million. The decrease in other expenses was primarily due to lower insurance expenses. The increase in personnel-related expenses resulted from a growth in headcount along with increased salaries in our general and administrative functions as well as expenses for contractors, partially offset by decreased stock compensation expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Impairment expenses for the year ended December&#160;31,&#160;2023 was comprised of $12.8&#160;million of asset write-downs related to our GMP manufacturing facility project. As a result of the strategic considerations preceding the decision to implement a Restructuring Plan, we assessed the recoverability of the long-lived assets related to the GMP manufacturing project at December 31, 2023, and concluded it was more likely than not, that the GMP manufacturing facility project will be discontinued leading to a trigger for the impairment test that ultimately resulted in the write-offs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2023 we recorded grant income of $11.2&#160;million, compared to $7.9&#160;million in the year ended December&#160;31,&#160;2022 from grants, research incentives and imputed benefits from below market interest rates on loans from governmental agencies. The increase of $3.3&#160;million was primarily due to higher income of $2.1&#160;million from Austrian research and development incentives as a result of higher eligible research and development expenses, $1.4&#160;million related to the New York State life sciences research and development program for the years 2019 to 2021, and $0.1&#160;million related to the New York City biotechnology tax credit program, partially offset by lower imputed benefits from below market interest rates on loans from governmental agencies of $0.3&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Income and Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Interest income was $5.3&#160;million for the year ended December&#160;31,&#160;2023, compared to $1.6&#160;million for the year ended December&#160;31,&#160;2022. The increase in interest income of $3.7&#160;million for the year ended December&#160;31,&#160;2023 was a result of the rising U.S. dollar and euro interest rates. Interest income represents interest from cash and cash equivalents held in U.S. dollars and euros resulting from the proceeds from the issuance of common and preferred stock as well as payments received under our Gilead and Roche collaborations. During the year ended December&#160;31,&#160;2023 our cash, cash equivalents and restricted cash were mainly held in dollars at U.S. investment grade financial institutions or in money </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">market funds. In addition, the necessary amounts to cover short-term working capital requirements were held in euros and dollars at our Austrian subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest expenses for loans from government agencies were $0.3&#160;million for the year ended December&#160;31,&#160;2023, compared to $0.7&#160;million for the year ended December&#160;31,&#160;2022. Interest expense was recorded at the market rate of interest, which exceeded the contractual interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income and Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other income was $0.3&#160;million for the year ended December&#160;31,&#160;2023, compared to other expenses of $0.4&#160;million for the year ended December&#160;31,&#160;2022. The change in the year ended December&#160;31,&#160;2023 resulted primarily from exchange rate differences and foreign currency remeasurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2011, we have funded our operations primarily from public offerings and private placements of common stock and convertible preferred stock, including our initial public offering, as well as private placements of our redeemable convertible preferred stock, grant funding and loans from an Austrian government agency, and upfront, milestone and initiation payments from Gilead and Roche in connection with research collaboration agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to our IPO, we raised gross proceeds of approximately $142.5&#160;million from the issuance of our redeemable convertible preferred stock. In April 2019, we completed our IPO in which we issued and sold 6,000,000&#160;shares of our common stock, at $14.00 per share, for gross proceeds of $84.0&#160;million, or net proceeds of $74.6&#160;million. In December&#160;2020, we completed a follow-on public offering in which we issued 3,910,000&#160;shares of our common stock, at $11.75&#160;per share, and 2,978&#160;shares of our Series&#160;A convertible preferred stock, at $11,750.00 per share, for net proceeds of $75.0&#160;million after deducting underwriting discounts and commissions and offering expenses. In March&#160;2022, we completed a follow-on public offering in which we issued 21,700,000&#160;shares of our common stock, at $2.00 per share, and 15,800&#160;shares of our Series&#160;A-1 convertible preferred stock, at $2,000.00 per share, for net proceeds of $70.2&#160;million after deducting underwriting discounts and commissions and offering expenses. In June&#160;2023, we completed a follow-on public offering in which we issued 22,900,768&#160;shares of our common stock, at $1.31 per share, and 15,268&#160;shares of our Series&#160;A-2 convertible preferred stock, at $1,310.00&#160;per share, for net proceeds of $46.2&#160;million after deducting underwriting discounts and commissions and offering expenses. In addition, in February&#160;2022, Gilead purchased 1,666,666&#160;shares of our common stock for $5.0&#160;million, at a purchase price of $3.00 per share, and in December 2023, Gilead purchased 15,000,000&#160;shares of our common stock, at $1.4167 per share, for net proceeds of $21.1&#160;million after deducting offering expenses. Gilead also committed to purchase an additional $8.7&#160;million of common stock as pro-rata participation in potential future equity raises (see &#8220;Note 11. Common stock, Class A common stock and convertible preferred stock&#8221; to our consolidated financial statements appearing elsewhere in this Annual Report). We also received $46.2&#160;million from non-refundable upfront, milestone and initiation payments pursuant to the Restated Gilead Collaboration Agreement and $35.0&#160;million from non-refundable upfront and milestone payments related to the Roche Collaboration Agreement. As of December&#160;31,&#160;2023, we had cash, cash equivalents and restricted cash of $117.5&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July&#160;12,&#160;2022, we filed a registration statement on Form S-3 (the Registration Statement) with the SEC, which was declared effective on July&#160;21,&#160;2022. The Registration Statement registers the offering, issuance and sale of an unspecified amount of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. We simultaneously entered into a Sales Agreement with SVB Securities LLC, as sales agent, to provide for the issuance and sale by us of up to $50.0&#160;million of common stock from time to time in &#8220;at-the-market&#8221; offerings under the Registration Statement and related prospectus filed with the Registration Statement or the ATM Program. As of December&#160;31,&#160;2023, no sales had been made pursuant to the ATM Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We entered into various funding agreements with the Austrian Research Promotion Agency (&#214;sterreichische Forschungsf&#246;rderungsgesellschaft, or &#8220;FFG&#8221;). The loans by FFG (the &#8220;FFG Loans&#8221;), were made on a project-by-project basis and bear interest at a rate of 0.75%&#160;per annum. In the event that the underlying program research results in a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">scientific or technical failure, the principal then outstanding under any loan may be forgiven by FFG and converted to non-repayable grant funding on a project-by-project basis. The FFG Loans contain no financial covenants and are not secured by any of our assets. The remaining debt obligation under the FFG loan is $1.2&#160;million, which is due for repayment upon final maturity in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because the FFG Loans bear interest at below market rates we account for the imputed benefit arising from the difference between an estimated market rate of interest and the contractual interest rate as grant funding from FFG, which is included in grant income. On the date that FFG Loan proceeds are received, we recognize the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income. As of December&#160;31,&#160;2023, the unamortized debt discount related to FFG Loans was $0.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We entered into arrangements with contract manufacturing organizations. As of December&#160;31,&#160;2023, we had total non-cancellable obligations under such contracts of $7.4&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not expect positive cash flows from operations in the foreseeable future, if at all. Historically, we have incurred operating losses as a result of ongoing efforts to develop our arenavirus technology platform and our product candidates, including conducting ongoing research and development, preclinical studies, clinical trials, providing general and administrative support for these operations and developing our intellectual property portfolio. We expect to continue to incur net operating losses for at least the next several&#160;years as we progress clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization of our most advanced oncology product candidate HB-200, continue our research and development efforts relating to our other and future product candidates, and invest in our manufacturing capabilities and our own manufacturing facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have no products approved for commercial sale. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of our product candidates. As a result, we are not profitable and have incurred losses in each period since our inception in 2011. As of December&#160;31,&#160;2023, we had an accumulated deficit of $369.3&#160;million. We expect to continue to incur significant losses for the foreseeable future. We anticipate that our expenses will increase substantially as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue the clinical and preclinical development of our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage our technologies to advance product candidates into preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for product candidates that successfully complete clinical trials, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract, hire and retain additional clinical, quality control and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish our manufacturing capabilities through third parties or by ourselves and scale-up manufacturing to provide adequate supply for clinical trials and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other product candidates and technologies; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional legal, accounting and other expenses in operating our business, including ongoing costs associated with operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will require substantial additional financing and a failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our non-replicating and replicating technologies and our product candidates derived from these technologies. Preclinical studies and clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current product candidates and programs as well as any future product candidates we may choose to pursue, as well as the gradual gaining of control over our required manufacturing capabilities and other corporate uses. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of researching and developing our current and future product candidates and programs, and of conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other product candidates that we may pursue, and other indications for our current product candidates that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the stability, scale and yields of our future manufacturing process as we scale-up production and formulation of our product candidates for later stages of development and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining regulatory and marketing approvals and developing our ability to establish sales and marketing capabilities, if any, for our current and future product candidates we develop if clinical trials are successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our collaboration with Gilead;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of commercialization activities for our current and future product candidates that we may develop, whether alone or with a collaborator;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or royalties on, our future products, if any; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing oncology and infectious disease therapies and other adverse market developments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will need additional funds to meet operational needs and capital requirements associated with such operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have any committed external source of funds or other support for our development efforts. Until we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements as well as grant funding. Based on our research and development plans, we expect that our existing cash and cash equivalents, including the funds received under the Restated Gilead Collaboration Agreement, and the funds received under the Roche Collaboration Agreement, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12&#160;months. These estimates are based on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, the ownership interest of our shareholders will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to obtain additional funding on favorable terms when needed, we may have to delay, reduce the scope of or terminate one or more of our research and development programs or clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a summary of the primary sources and uses of cash (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (57,524)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (19,997)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,159)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,017)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,670</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72,271</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,987</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,257</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2023, cash used in operating activities was $57.5&#160;million, which consisted of a net loss of $81.6&#160;million, adjusted by non-cash charges of $18.8&#160;million and cash provided due to changes in our operating assets and liabilities of $5.3&#160;million. The non-cash charges consisted primarily of restructuring expenses of $12.8&#160;million, resulting from a write-off of our GMP manufacturing facility project, depreciation and amortization expense of $3.6&#160;million, stock-based compensation of $2.3&#160;million and other non-cash items of $0.1&#160;million. The change in our operating assets and liabilities was primarily due to an increase in accounts payable of $6.5&#160;million, a decrease in accounts receivable of $6.2&#160;million, primarily resulting from the collection of a $5.0&#160;million milestone payment and cost reimbursements from Gilead, an increase in other non-current liabilities of $2.7&#160;million, a decrease in prepaid expenses and other current assets of $1.7&#160;million, an increase in accrued expenses and other current liabilities of $0.5&#160;million, and a decrease in other non-current assets of $0.3&#160;million, partially offset by a decrease in deferred revenues of $8.3&#160;million, an increase in receivable research incentives of $2.7&#160;million, and a decrease in operating lease liabilities of $1.6&#160;million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2022, cash used in operating activities was $20.0&#160;million, which consisted of a net loss of $64.9&#160;million, adjusted by non-cash charges of $8.8&#160;million and cash provided due to changes in our operating assets and liabilities of $36.1&#160;million. The non-cash charges consisted primarily of stock-based compensation of $5.0&#160;million, depreciation and amortization expense of $3.6&#160;million, and other non-cash items of $0.2&#160;million. The change in our operating assets and liabilities was primarily due to an increase of deferred revenues current and non-current of $35.5&#160;million, an increase in accrued expenses and other current liabilities of $2.5&#160;million, a decrease in prepaid expenses and other current and non-current assets of $2.5&#160;million, and an increase in other non-current liabilities of $1.5&#160;million, partially offset by a decrease in accounts payable of $2.0&#160;million, an increase in receivable research incentives of $2.0&#160;million, a decrease in operating lease liabilities of $1.6&#160;million, and an increase in accounts receivable of $0.3&#160;million. Changes in deferred revenues were due to upfront and initiation payments related to our collaboration agreements. Changes in research incentives were due to increased receivables under the research incentive program provided by the Austrian government. Changes in prepaid expenses and other current assets, accounts payable and other non-current assets in the year ended December&#160;31,&#160;2022 were generally due to lower research and development expenses and the timing of invoicing and payments. Changes in other current and non-current liabilities were generally related to the advancement of our research programs. Changes in operating lease liabilities in the year ended December&#160;31,&#160;2022 were mainly due to regular lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Used in Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December&#160;31,&#160;2023 and 2022, cash used in investing activities was $4.2&#160;million and $5.0&#160;million, respectively. The decrease of $0.8&#160;million compared to the year ended December&#160;31,&#160;2022 resulted from lower capital expenditures in connection with our GMP manufacturing facility project and lower expenditures for purchase of equipment. Cash used in investing activities in the year ended December&#160;31,&#160;2023 resulted from capital expenditures in connection with our GMP manufacturing facility project and for purchase of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2022, cash used in investing activities resulted primarily from capital expenditures in connection with our GMP manufacturing facility project as well as expenditures for laboratory and office space extension and purchase of equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Provided by Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2023, cash provided by financing activities was $65.7&#160;million, which consisted mainly of net proceeds of $46.3&#160;million from our follow-on public offering in June&#160;2023 and of net proceeds of $21.2&#160;million from Gilead&#8217;s purchase of 15,000,000&#160;shares of our common stock in December&#160;2023, partially offset by principal repayments of loans of $1.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2022, cash provided by financing activities was $72.3&#160;million, which consisted mainly of net proceeds of $70.2&#160;million from our follow-on public offering in March&#160;2022 and of net proceeds of $5.0&#160;million from Gilead&#8217;s purchase of 1,666,666 shares of our common stock in February 2022, partially offset by a repayment of a loan of $2.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property Licenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2011, we entered into a license agreement with University of Zurich for an exclusive, worldwide, royalty-bearing license for a propagation-deficient arenavirus vector. Pursuant to the license agreement, we are obligated to pay the University of Zurich low single-digit royalties on aggregate net sales of products licensed under the agreement, and to pay percentages ranging from the mid-single digits to 20% of the sublicense fees that we may receive from sublicensing, depending on the amount of fees received from sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In January&#160;2017, we entered into a license agreement with University of Basel for an exclusive, worldwide, royalty-bearing license for a tri-segmented Pichinde virus vector. We are required to use reasonable efforts to make commercially available licensed products. Pursuant to the license agreement, we are obligated to pay nominal milestone payments for each licensed product upon the achievement of certain development and regulatory milestones and to pay </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">royalties of low single digits of net sales of licensed products. We are also obligated to pay a low- to high-single digit percentage of the sublicense fees that we may receive from sublicensing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, we entered into a license agreement with the University of Geneva for an exclusive, worldwide, royalty-bearing license for a tri-segmented arenavirus vector. Pursuant to the license agreement, we are obligated to pay the University of Geneva an annual fee which is fully deductible from any milestone, royalty or sublicense payments. We are also obligated to pay milestone nominal payments for each licensed product upon the achievement of certain development and regulatory milestones and to pay low single-digit royalties on aggregate net sales of products licensed under the agreement, and to pay percentages ranging from the low-single digits to 10% of the sublicense fees that we may receive from sublicensing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2013, we entered into a Biological Materials License Agreement with NIH for a worldwide, nonexclusive license to make, have made, import and use certain cells and cell clones developed at the Vaccine Research Center of the NIH, i.e., the NIH Licensed Products, to manufacture viral vectors based on our proprietary arenavirus-based vectors. Pursuant to the terms of the NIH Agreement, we are obligated to pay the NIH low to mid six figure annual royalty payments, increasing as our most developed product candidate manufactured from NIH Licensed Products proceeds through development stages. We must also pay the NIH 10% of any consideration we receive from sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In&#160;October 2020, we entered into a license agreement with the University of&#160;Basel&#160;for an exclusive, worldwide, royalty-bearing license for a tri-segmented arenavirus&#160;Split&#160;vector&#160;technology.&#160;We are required to use reasonable efforts to make commercially available licensed products. Pursuant to the license agreement, we are obligated to pay the University of&#160;Basel&#160;an annual fee which is fully deductible from any milestone,&#160;royalty&#160;or sublicense payments.&#160;We are also obligated to pay&#160;nominal milestone payments for each licensed product upon the achievement of certain development and regulatory milestones and to pay royalties of low single digits of net sales of licensed products. We are also obligated to pay&#160;a low double digit to low single digit percentage&#160;of the sublicense fees that we may receive from sublicensing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2022, we entered into a non-exclusive license agreement with the Regents of the University of Minnesota for a worldwide, non-exclusive license to patent rights related to our replicating technology patent which is exclusively licensed to us by the University of Geneva. We paid the University of Minnesota a low six figure amount upon entering into the agreement and are required to pay a non-material annual maintenance fee, and, upon commercialization of the first Minnesota Licensed Product, an annual minimum royalty which is creditable against royalties payable in the same year. While the Minnesota Agreement remains in effect, we are required to pay the University of Minnesota royalties on aggregate net sales of Minnesota Licensed Products, of a generally below single digit percentage. We must also pay the University of Minnesota low single digit percentages of certain considerations we receive from sublicensees, subject to pre-defined minimum and maximum payments. We further have to pay the University of Minnesota a nominal amount if we assign the Minnesota Agreement as part of a change of control. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2023, we recorded $1.6&#160;million in licensing fees from intellectual property licenses as research and development expenses. At December&#160;31,&#160;2023, no payable from sublicensing fees was included in accrued expenses and other current liabilities. In the year ended December&#160;31,&#160;2022, we recorded $1.0&#160;million in licensing fees from intellectual property licenses as research and development expenses. At December&#160;31,&#160;2022, $1.2&#160;million payables from sublicensing fees were included in accounts payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For additional information on these license agreements, please see &#8220;Business&#8212;Intellectual Property&#8212;License Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with the rules&#160;and regulations of the SEC, and generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our critical accounting policies and the methodologies and assumptions we apply under them have not materially changed as compared to those disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2022, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;15,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recognition of revenue from contracts with customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into the Restated Gilead Collaboration Agreement for the development and commercialization of certain of our product candidates. Our performance obligations under the terms of this agreement include one combined performance obligation for each research program comprised of the transfer of intellectual property rights (licenses) and providing research and development services. Payments by Gilead to us under this agreement included a non-refundable up-front payment, payments for research and development activities, and may include payments based upon the achievement of defined pre-clinical development and commercial milestones and royalties on product sales if certain future conditions are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into the Roche Collaboration Agreement for the development and commercialization of certain of our product candidates. Our performance obligations under the terms of this agreement include one combined performance obligation for the transfer of intellectual property rights (licenses) and providing research and development services for the HB-700 program, and a second, separate performance obligation to perform research and development services and to deliver a specified package of preclinical data and results with respect to targeting undisclosed cancer antigens (&#8220;UCA program&#8221;). Payments by Roche under the Roche Collaboration Agreement included a non-refundable up-front payment, payments based upon the achievement of defined milestones, an additional payment if the option for the UCA program is exercised and royalties on product sales if certain future conditions are met. In January&#160;2024, Roche provided us with written notice of the termination of the collaboration and licensing agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We evaluate our collaboration and licensing arrangements pursuant to Accounting Standards Codification 606 (ASC&#160;606). To determine the recognition of revenue from arrangements that fall within the scope of ASC&#160;606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, we satisfy a performance obligation. We present revenues from collaboration and licensing arrangements separately from other sources of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amounts received by us as non-refundable upfront payment under the Restated Gilead Collaboration Agreement and the Roche Collaboration Agreement as well as success-based milestone payments under the Roche Collaboration Agreement prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in our consolidated balance sheets. Contingent milestone payments related to specified preclinical and clinical development milestones are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC 606. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis for each of the obligations. We measure the progress toward complete satisfaction of the performance obligations based on the total cost of each collaboration program. This method of measuring progress results in recognizing revenue in proportion to the cost incurred during the quarter in relation to total expected cost for the respective program, according to the respective collaboration budget. Reimbursement of costs for our services under the Restated Gilead Collaboration Agreement and the Roche Collaboration Agreement are presented as revenue and not deducted from expenses. The Restated Gilead Collaboration Agreement and the Roche Collaboration Agreement also include certain sales-based milestone and royalty payments upon successful commercialization of a licensed product which we anticipate recognizing if and when sales from a licensed product are generated.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leasing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The determination of whether an arrangement is qualified as a lease is made at contract inception. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. We use the implicit rate when readily determinable and our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as operating lease assets on the consolidated balance sheets. Certain of our arrangements contain lease and non-lease components. We applied an accounting policy choice to separate or not to separate lease payments for the identified assets from any non-lease payments included in the contract by asset class. Operating leases are reflected in operating lease assets, in accrued expenses and other current liabilities and in non-current operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the relating revenue is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We measure all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. We classify stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient's payroll costs are classified. Generally, we issue stock options, with service-only vesting conditions and record expense using the graded-vesting method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We estimate the fair value of each stock option award using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make. As we have only been a public company since 2019, we estimate the expected stock volatility based on the volatility of our own stock as well as the historical volatility of a publicly traded set of peer companies until such time that we have adequate historical data regarding the volatility of our own traded stock price. For options with service-based vesting conditions, the expected term of our stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future. We do not estimate and apply a forfeiture rate as we have elected to account for forfeitures as they occur. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recognition of other income under government grant agreements and research incentives</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recognize income from grants, research incentives and the imputed benefit arising from the difference between an estimated market rate of interest and the contractual interest rate on loans received from Austrian government agencies as well as from New York State and New York City government agencies in the United States. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, we recognize grant and incentive income in an amount equal to the qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant income that we have received in advance of incurring qualifying expenses is recorded in the consolidated balance sheets as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have received loans under funding agreements that bear interest below market rates. We account for the imputed benefit arising from the difference between an estimated market interest rate and the actual interest rate charged on such loans as additional grant income, and record interest expense for the loans at a market interest. On the date that loan proceeds are received, we recognize the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is subsequently recognized as additional grant income over the term of the funding agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our consolidated financial statements appearing in this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status and Smaller Reporting Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As an &#8220;emerging growth company,&#8221; the Jumpstart Our Business Startups Act of 2012 allows us to delay adoption of new or revised accounting standards applicable to public companies until such standards are made applicable to private companies. However, we have irrevocably elected not to avail ourselves of this extended transition period for complying with new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by non-affiliates is less than $700&#160;million and our annual revenue was less than $100 million during our most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250&#160;million or (ii) our annual revenue was less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.</p><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are exposed to market risk from changes in interest rates, foreign exchange rates and inflation. All of these market risks arise in the ordinary course of business, as we do not engage in speculative trading activities. The following analysis provides additional information regarding these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Foreign Currency and Exchange Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are subject to the risk of fluctuations in foreign currency exchange rates, specifically with respect to the euro. Our functional currency is the U.S. dollar and the functional currency of our wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro. Our cash, cash equivalents and restricted cash as of December&#160;31,&#160;2023 included small amounts of cash balances held by Hookipa Biotech GmbH in euro. Assets and liabilities of Hookipa Biotech GmbH are translated into U.S. dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the condensed consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the condensed consolidated Statements of Operations and Comprehensive Loss as incurred. A significant portion of our operating costs are in Austria, which are denominated in the euro. This foreign currency exposure gives rise to market risk associated with exchange rate movements of the U.S. dollar against the euro. Furthermore, we anticipate that a significant portion of our expenses will continue to be denominated in the euro. A hypothetical 10% weakening of the U.S. dollar compared to the euro would have increased our net loss for the year ended December&#160;31,&#160;2023, by approximately $2.8&#160;million and decreased our currency translation adjustment by approximately $0.3&#160;million. A hypothetical 10% strengthening of the U.S. dollar compared to the euro would have an equal and opposite effect on our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Rate Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents and restricted cash of $117.5&#160;million as of December&#160;31,&#160;2023, which included account balances with foreign banks. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, we do not believe that we have any material exposure to changes in the fair value of our investment portfolio as a result of changes in interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Impacts of Inflation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, we do not believe inflation has had a material effect on our historical results of operations and financial condition. However, inflation, has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to conduct clinical trials and other operational costs. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset higher costs through raising funds or other corrective measures, and our inability or failure to do so could adversely affect our business, financial condition, and results of operations. In addition, increased inflation has had, and may continue to have, an effect on interest rates. Increased interest rates may adversely affect our borrowing rate and our ability to obtain, or the terms under which we can obtain, any potential additional funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a159fb73_0709_41ea_83ca_eae6e82c1ab8"></a><a id="FinancialStatementsandSupplementaryData_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">I</b><b style="font-weight:bold;">tem 8.&#160;&#160;Financial Statements and Supplementary Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The financial statements required to be filed pursuant to this Item 8 are appended to this report. An index of those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_55d25771_a448_4e36_b13b_f71dab9f770b"></a><a id="ChangesinandDisagreements_29131"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9.&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8a02317d_3a4f_4a5f_85a5_3a563502db70"></a><a id="ControlsandProcedures_489690"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9A.&#160;&#160;Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2023, management, with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial and Accounting Officer, to allow timely decisions regarding required disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of December&#160;31,&#160;2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Under the supervision of and with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, our management assessed the effectiveness of our internal control over financial report as of December&#160;31,&#160;2023 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#8220;Internal Control-Integrated Framework&#8221; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December&#160;31,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a 15(f) and 15d 15(f) under the Exchange Act) identified that occurred during the quarter ended December&#160;31,&#160;2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_46c16081_1f1a_4004_b3de_c61f11bbdcae"></a><a id="OtherInformation_174221"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9B.&#160;&#160;Other Information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the quarter ended December&#160;31,&#160;2023, none of the Company&#8217;s <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_NEy4PleY-EKyp5VZmhghpQ">directors</ix:nonNumeric> or <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_0dH-VAXUMkmMVOseA69efQ">officers</ix:nonNumeric> (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_jSsGL3cvTEGrqix2UYZyiA">terminated</ix:nonNumeric> or <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_02VT2QD-L0aYgYnIXATUQA">modified</ix:nonNumeric> a <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ" format="ixt:booleanfalse" name="hook:Rule10b51ArrangementModified" id="Narr_aFwhrdPbI0iKlBhVEEYDnQ">Rule 10b5-1</ix:nonNumeric> trading arrangement or <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ" format="ixt:booleanfalse" name="hook:NonRule10b51ArrangementModified" id="Narr_QYpDExDQdk-namKWDUT3NA">non-Rule 10b5-1</ix:nonNumeric> trading arrangement (as such terms are defined in Item 408 of Regulation S-K).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9efe6652_519a_4c47_b7c8_da20249feba2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item9CDisclosureregardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9C.&#160;&#160;Disclosure regarding Foreign Jurisdictions that Prevent Inspections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_527586ff_aa4b_4dfb_bfd8_719e1a49d262"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART III</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to file a definitive Proxy Statement for our 2024 Annual Meeting of Stockholders (&#8220;2024 Proxy Statement&#8221;) with the SEC, pursuant to Regulation 14A, not later than 120 days after the end of our fiscal year. Accordingly, certain information required by Part III has been omitted under General Instruction G(3) to Form 10-K. Only those sections of the 2024 Proxy Statement that specifically address the items set forth herein are incorporated by reference.</p><a id="DirectorsExecutiveOfficersandCorporateGo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 10.&#160;&#160;Directors, Executive Officers, and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 10 is incorporated by reference to the sections of the 2024 Proxy Statement under the captions &#8220;Director Biographies,&#8221; &#8220;Executive Officers,&#8221; &#8220;The Board of Directors and its Committees,&#8221; &#8220;Corporate Governance&#8221; and &#8220;Delinquent Section 16(a) Reports&#8221;.</p><a id="_a65fdbfb_6aa4_4b57_a0bc_cc980e391202"></a><a id="ExecutiveCompensation_255286"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 11.&#160;&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information required by this Item 11 is incorporated by reference to the sections of the 2024 Proxy Statement under the captions &#8220;Executive Compensation&#8221; and &#8220;Director Compensation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ab067a98_436a_401e_9955_1bce872d107b"></a><a id="SecurityOwnershipofCertainBeneficial_240"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 12.&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 12 is incorporated by reference to the sections of the 2024 Proxy Statement under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; and &#8220;Equity Compensation Plan Information.&#8221;</p><a id="_a374fb58_886d_4cf5_8146_9ac3ea646b47"></a><a id="CertainRelationshipsandRelatedTransactio"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 13.&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information required by this Item 13 is incorporated by reference to the sections of the 2024 Proxy Statement under the captions &#8220;Certain Relationships and Related Person Transactions&#8221; and &#8220;The Board of Directors and Its Committees &#8211; Board Independence.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c0a76159_b67a_4734_854c_84f742a6742d"></a><a id="PrincipalAccountantsFeesandServices_2130"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 14.&#160;&#160;Principal Accountant&#8217;s Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The information required by this Item 14 is incorporated by reference to the sections of the 2024 Proxy Statement under the caption &#8220;Ratification of the Selection of Independent Registered Public Accounting Firm.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b4009dac_9cb0_4e0b_8f2b_d6d2173bbc04"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Part IV</p><a id="Exhibits_364151"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;15.&#160;&#160;Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">(1) Financial Statements and Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following documents are included on pages F-1 through F-7 attached hereto and are filed as part of this Annual Report on Form 10-K.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.56%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:93.56%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"/><td style="vertical-align:bottom;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTERED_34038"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID 1259)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-1</p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#BALANCESHEETSUNAUDITED_890928"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-2</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#OPERATIONS_814316"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-3</p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#DEFICIT_226113"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-4</p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#CASHFLOWS_176896"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-6</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:93.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#a1Natureofthebusinessandorganization_284"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a0bf25cb_d62f_4214_b073_95b1cb7be53e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">(2) Financial Statement Schedules:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-indent:37.15pt;background:#ffffff;margin:0pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the consolidated financial statements or the notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:18pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">(3) Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;text-indent:37.15pt;margin:0pt;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.15pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.29%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:86.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465922076551/tm2220184d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of the Company (filed as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on July 1, 2022 (File No. 001- 38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465919023112/a19-8744_1ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the Company (filed as Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on April 23, 2019 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Common Stock Certificate (filed as Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465919023112/a19-8744_1ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Shareholders Agreement among HOOKIPA Pharma Inc. and certain of its shareholders, dated February 15, 2019 (filed as Exhibit 4.1. to the Company&#8217;s Current Report on Form 8-K filed on April 23, 2019 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.35pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20231231xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465922073084/tm2218404d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated June 17, 2022, by and between the Company and Gilead Sciences, Inc. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on June 22, 2022 (File No. 001-38869) and incorporated herein by reference)</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">HOOKIPA Pharma Inc. 2018 Stock Option and Grant Plan and forms of awards thereunder (filed as Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 filed on March 22, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000155837023009258/hook-20230331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2019 Stock Option and Incentive Plan (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May&#160;11,&#160;2023 (File No.001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Incentive Stock Option Agreement under the Company&#8217;s 2019 Stock Option and Incentive Plan</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (filed as Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Qualified Stock Option Agreement for Company Employees under the Registrant's 2019 Stock Option and Incentive Plan (filed as Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Qualified Stock Option Agreement for Non-Employee Directors under the Registrant's 2019 Stock Option and Incentive Plan (filed as Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restricted Stock Award Agreement under the Registrant's 2019 Stock Option and Incentive Plan</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (filed as Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.29%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restricted Stock Award Agreement for Company Employees under the Registrant's 2019 Stock Option and Incentive Plan (filed as Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restricted Stock Award Agreement for Non-Employee Directors under the Registrant's 2019 Stock Option and Incentive Plan (filed as Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2019 Employee Stock Purchase Plan</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> (filed as Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465923045006/tm2312420d2_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">HOOKIPA Pharma Inc. 2023 Inducement Plan and form of award agreements thereunder (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 13, 2023 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Director Indemnification Agreement (filed as Exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 filed on</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Officer Indemnification Agreement (filed as Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 filed on</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Joern Aldag and HOOKIPA Biotech GmbH </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(filed as Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919002035/a2238259zex-10_13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Reinhard Kandera and HOOKIPA Biotech GmbH </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(filed as Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed on April 8, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000155837022004211/hook-20211231xex10d15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Klaus Orlinger and HOOKIPA Biotech GmbH, dated January&#160;1,&#160;2022 (filed as Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K filed on March 24, 2021 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000155837023009258/hook-20230331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Christine Baker and the Registrant, dated August&#160;1,&#160;2019 (filed as Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May&#160;11,&#160;2023 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17#</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000155837023018412/hook-20230930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consultancy Service Agreement between Hookipa Biotech GmbH and Malte Peters, effective September 15, 2023 (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 9, 2023 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease by and between HOOKIPA Biotech GmbH and Marxbox Bauprojekt GmbH &amp; Co OG, dated February 3, 2012, as supplemented by the Lease Agreement, dated April 2, 2014 (filed as Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease by and between HOOKIPA Biotech GmbH and W&#252;stenrot Marxbox GmbH &amp; Co KG, dated May 15, 2018 (filed as Exhibit 10.17 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465922028676/tm227839d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Collaboration and License Agreement, by and between Hookipa Biotech GmbH and Gilead Sciences, Inc., dated as of </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">February 15</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 20</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">22  (filed as Exhibit 10.1. to the Company&#8217;s Current Report on Form 8-K/A filed on March 1, 2022 (File No. 001-38869) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.29%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Patent License Agreement, by and between Hookipa Biotech GmbH and the University of Zurich, dated as of October 6, 2011 (filed as Exhibit 10.19 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Patent License Agreement, by and between Hookipa Biotech AG and the University of Basel, dated as of January 16, 2017 (filed as Exhibit 10.20 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_21.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Patent License Agreement, by and between Hookipa Biotech AG and the University of Geneva, dated as of February 8, 2017 (filed as Exhibit 10.21 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">The National Institutes of Health Biological Materials License Agreement, by and between the National Institutes of Health within the Department of Health and Human Services through the Office of Technology Transfer and Hookipa Biotech AG, dated as of September 25, 2013, as amended by the First Amendment, dated April 12, 2017, and the Second Amendment, dated July 11, 2018 (filed as Exhibit 10.22 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Funding Contract, by and between Hookipa Biotech AG and The Austrian Research Promotion Agency, dated August 8, 2012, as extended by the Funding Contract, dated December 17, 2013, and the Funding Contract, dated May 22, 2015 (filed as Exhibit 10.23 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000155837021003176/hook-20201231ex1023d1109.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Funding Contract, by and between Hookipa Biotech AG and The Austrian Research Promotion Agency, dated December 16, 2014, as extended by the Funding Contract, dated October 4, 2016, the Funding Contract, dated February 27, 2018, and the Funded Contract dated October 25, 2019&#160;(filed as Exhibit&#160;10.23 to the Company&#8217;s Annual Report on Form 10-K filed on March&#160;18,&#160;2021 (File No. 001-&#160;38869) and incorporated herein by reference</span></a>)</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.27</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-10_25.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease by and between the Registrant and W&#252;stenrot Marxbox GmbH &amp; Co. KG, dated February 26, 2019 (filed as Exhibit 10.25 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.28</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465923127949/tm2333370d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Stock Purchase Agreement, by and between the Registrant and Gilead Sciences, Inc., dated as of December&#160;20,&#160;2023 </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on December&#160;21,&#160;2023 (File No. 001-38869) and incorporated herein by reference)</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.29&#8224;&#8224;</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000110465922110103/tm2228531d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Research Collaboration and License Agreement, dated October 19, 2022, by and among Hookipa Biotech GmbH, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on October 20, 2022 (File No. 001-38869) and incorporated herein by reference)</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.30</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000155837023003778/hook-20221231xex10d28.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to License Agreement, by and between University of Basel and Hookipa Biotech GmbH, dated July 11, 2022 (filed as Exhibit 10.28 to the Company&#8217;s Annual Report on Form 10-K filed on March&#160;15,&#160;2023 (File No. 001-38869) and incorporated herein by reference).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.31</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000155837023003778/hook-20221231xex10d29.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 2 to License Agreement, by and between University of Basel and Hookipa Biotech GmbH, dated September 15, 2022 (filed as Exhibit 10.29 to the Company&#8217;s Annual Report on Form 10-K filed on March&#160;15,&#160;2023 (File No. 001-38869) and incorporated herein by reference).</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1760542/000104746919001538/a2238048zex-21_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries of the Company (filed as Exhibit 21.1 to the Company&#8217;s Registration Statement on Form S-1 filed on </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">March 22</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2019 (File No. 333-230451) and incorporated herein by reference)</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20231231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">PwC Wirtschaftspr&#252;fung GmbH, Independent Registered Public Accounting Firm</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.29%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20231231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Principal Executive Officer pursuant to Exchange Act Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20231231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Principal Financial Officer pursuant to Exchange Act Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1+</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20231231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2002</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97.1*</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="hook-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Clawback Policy</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:90.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8224; </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Confidential treatment granted as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8224;&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Portions of this document (indicated by &#8220;[***]&#8221; have been omitted because they are not material and are the type that the Company treats as private and confidential.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"># </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Indicates a management contract or any compensatory plan, contract or arrangement required to be filed as an exhibit pursuant to Item 15(a)(3) of Form 10-K.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">* </span></span>Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">+</span></span><span style="display:inline-block;width:18pt;"></span>Furnished herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_40348b0d_743f_4f14_808a_164fbc630d5c"></a><a id="Item16Form10KSummary_412517"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-weight:bold;">Item 16. Form 10-K Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cb5eadc3_3a52_449d_a799_1b0cca409d8c"></a><a id="SIGNATURES_467"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 8pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">HOOKIPA Pharma&#160;Inc.</p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: March&#160;22,&#160;2024</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">POWER OF ATTORNEY AND SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.15pt;margin:0pt;">We, the undersigned directors and officers of HOOKIPA Pharma Inc. (the &#8220;Company&#8221;), hereby severally constitute and appoint Joern Aldag and Reinhard Kandera, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.45pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:37.45pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:44.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title(s)</b></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:24.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joern Aldag</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;22,&#160;2024</p></td></tr><tr><td style="vertical-align:bottom;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joern Aldag</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Reinhard Kandera</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer and Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;22,&#160;2024</p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reinhard Kandera</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jan van de Winkel</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jan van de Winkel, Ph.D.</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;22,&#160;2024</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Terry Coelho</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Terry Coelho</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;22,&#160;2024</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Kaufman</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Kaufman</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;22,&#160;2024</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Malte Peters</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Malte Peters, M.D,</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;22,&#160;2024</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Timothy Reilly</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Timothy Reilly, Ph.D.</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;22,&#160;2024</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Julie O&#8217;Neill</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Julie O&#8217;Neill</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;22,&#160;2024</p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:26.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_833e0956_fb2f_4bab_811a_0dcd5545b57d"></a><a id="REPORTOFINDEPENDENT_704895"></a><a id="REPORTOFINDEPENDENTREGISTERED_34038"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the stockholders and the Board of Directors of HOOKIPA Pharma Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have audited the accompanying consolidated balance sheets of HOOKIPA Pharma Inc. and its subsidiary (the &#8220;Company&#8221;) as of December&#160;31,&#160;2023 and 2022, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and stockholders&#8217; equity (deficit) and of cash flows for each of the three years in the period ended December&#160;31,&#160;2023, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31,&#160;2023 in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emphasis of Matter</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As discussed in Note&#160;2 to the consolidated financial statements, the Company will require additional financing to fund future operations. Management&#8217;s plans in regard to this matter are described in Note&#160;2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:AuditorLocation" id="Narr__KPdqg4jaUS8T_DgwPb_Wg">Vienna, Austria</ix:nonNumeric> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;22,&#160;2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="dei:AuditorName" id="Narr_XWdlar86R0WFn_z0kjCQeA">PwC Wirtschaftspr&#252;fung GmbH</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Gabor Kruepl</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Austrian Certified Public Accountant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company's, or its predecessors, auditor since 2012, which includes periods before the Company became subject to SEC reporting requirements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8e9c3036_3ae9_42ac_a8d9_ad03c997db6d"></a><a id="FINANCIALINFORMATION_402800"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 5pt 0pt;">PART&#160;I&#8212;FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_398446"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 5pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><a id="BALANCESHEETSUNAUDITED_890928"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share </b><b style="font-weight:bold;">amounts</b><b style="font-weight:bold;">)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5a4c391b_9f57_4c9f_b030_61bf23d0dd00"></a><a id="Tc_jEdpMwyinUu718yfQMttyg_1_2"></a><a id="Tc_hWHbAATxKkir40wGl1qgtQ_1_5"></a><a id="Tc_FYPoiPuDIUWgrY6f6gdO9Q_2_2"></a><a id="Tc_j8_v-p46xkGdDhRUP2HMwQ_2_5"></a><a id="Tc__keSWok_K0y4QImbcctvLg_3_0"></a><a id="Tc_SkP2jg386ka3lcNaaDROMQ_4_0"></a><a id="Tc_JNVAY5FSSUGfBOYGiHyZTA_5_0"></a><a id="Tc_qTJ30LY3wE-0j5fMr21w6g_5_2"></a><a id="Tc_9xzRWxbVr0KCqkGDUSsWFw_5_5"></a><a id="Tc_v7OUa8ViQkuumeW8pBg8tA_6_0"></a><a id="Tc_5zgyDpiOoEOCi8OQtV-2Tg_6_3"></a><a id="Tc_yQWzP15cpUyU8oR1TjxkbA_7_0"></a><a id="Tc_Xz5COKQZP0-BJXzf6Ii6Eg_8_0"></a><a id="Tc_w7PPN38HxU2qeOUnwsU2fw_9_0"></a><a id="Tc_3ACmvEJf6UqDHXsXuLWZ1w_10_0"></a><a id="Tc_Z6IJsSX_RU-g9FY8mCPSAw_11_0"></a><a id="Tc_Ql3kcxRX_UqfS1MeOYGnAw_12_0"></a><a id="Tc_0bP9S7IrC0-S-ZpbyxVPQw_13_0"></a><a id="Tc_xULwYvg2kkmk59OTttVYaA_14_0"></a><a id="Tc_vTwHW7qXnkmViFzRKbTejA_15_0"></a><a id="Tc_KW6_rwuykkyzo7JUlSgT4A_16_0"></a><a id="Tc_wb4UouvjwUGoVmio8Bm1Tw_18_0"></a><a id="Tc_Ffmq8xYLBk2uFRZq3oD-qg_18_2"></a><a id="Tc_we0CexmYkkueBBLEsAzwFA_18_5"></a><a id="Tc_yepQPUPi7UeX0hIE8Lzsww_20_0"></a><a id="Tc_h2dZYuZ0aEyI8Eui6RkyzA_21_0"></a><a id="Tc_YjJos9uui06b_ZaGRr6z2w_22_0"></a><a id="Tc_8TzMzHl6Pk23BZgyKuV6Kg_22_2"></a><a id="Tc_9U19btrTBkmNhCJH3BzlFw_22_5"></a><a id="Tc_anoDxJdi9U-XvvPsx_5_4Q_23_0"></a><a id="Tc_hy1NRQaDEEaSJ6AjgQYmlA_24_0"></a><a id="Tc_HiJxbCo-m0e5k65K3BdKWw_25_0"></a><a id="Tc_URgTewTjDUq9QqTNaiqrDg_26_0"></a><a id="Tc_-IVq4KiASE-H2WByiuPXQw_27_0"></a><a id="Tc_QmmBO7SZpkWBmQpwynQmWg_28_0"></a><a id="Tc_5v2M4jiP1EqpIAb5NyifvA_29_0"></a><a id="Tc_Q1E6NS3MB0WllcoeLZP98w_29_3"></a><a id="Tc_0DtLdOl3Kk6JcJZ3cOo2rw_30_0"></a><a id="Tc_wC3OBXwZJEmCIrXZ4uQJlA_31_0"></a><a id="Tc_lR96wo_JL0yluaQUHtl5lg_32_0"></a><a id="Tc_xh9pPgmM0kKSDbCxpZeEeA_33_0"></a><a id="Tc_yg4t94v6ZUy7WqY6dtDUCg_34_0"></a><a id="Tc_-xiWkMcL7Eyv3KnAZX6mWQ_36_0"></a><a id="Tc_gwoLfGawg06Yy7M7LPuy_Q_38_0"></a><a id="Tc_Sno6yfuRkEOmaTlwsrGTNA_39_0"></a><a id="Tc_25Eu0ktNcUK4Q-6kVVIXHQ_40_0"></a><a id="Narr_f8cUaK_sb0214Zlw8-b_0A"></a><a id="Tc_TfTyV0dTE0iN8IZ7Ox7vyg_41_0"></a><a id="Narr_N04hZSZYN0yURmnd9ucDng"></a><a id="_edc27114_2daa_42a4_a9bf_12e1aca21aaf"></a><a id="_edc27114_2daa_42a4_a9bf_12e1aca21aaf_2"></a><a id="_edc27114_2daa_42a4_a9bf_12e1aca21aaf_3"></a><a id="Tc_0eRudbdenUSZmKX4mfMHTQ_42_0"></a><a id="Tc_RA4oNquiWUKWKm7eflPSFQ_43_0"></a><a id="Tc_jBSDDxnH90KIDlqKuoqQsA_44_0"></a><a id="Tc_yxRyjVVdS0WdQGYR8efjtA_45_0"></a><a id="Tc_uyJ_Smp1jkevfaM7nUJ5yg_47_0"></a><a id="Tc_m5cXqD4jtE2lVtZStnmYcg_47_2"></a><a id="Tc_keLZxnUm90amkBKxCVVqDw_47_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_DST_D3uIVESNaN2sa6G5WQ_5_3">117,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_hPNgVUHlbkmAYXpeqSR6fw_5_6">112,488</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_oS9tR_rU80es2y4sQLVetQ_6_6">537</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_QkW7ksOsj0iA-HwL2MRUrA_7_3">511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_Dq9uPhIRZkWvHwS58-zNDg_7_6">6,533</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Receivable research incentives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="3" id="Tc_3YZwXvcvLEiIApIIaF9nqw_8_3">18,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="3" id="Tc_NlRnuVDitE6vMTJtux6XxA_8_6">15,479</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:PrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc__6N_FSVeskWr_qEj0wCSmw_9_3">10,749</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:PrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc_R_b8FkQRNUaOg3ZM7d-oHg_9_6">12,159</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_OAVqJU9UB0aDuIJg_QZM4A_10_3">147,116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_V_9mZ1wI60K_d_OzxaU0TA_10_6">147,196</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_FHL1zHp8x0KTQczdlaszWw_12_3">425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_SG-K1VvMlUuw2MK2ZezgQw_12_6">419</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_utCYo6D3P0GqO2YIvmiFeA_13_3">7,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_QlrMPRHsREuIjRCRjwwDLg_13_6">17,970</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_pi-IERVj7kGwWqu1hzxqTQ_14_3">5,473</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_i9jjh52Xkk-LQGpaewPfMA_14_6">4,006</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_E8MgY-8bHUCD9PmBjoRdZw_15_3">581</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_unncAv_yj0y66lf9fw3EoA_15_6">863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_-4d7Qpo0okS0aJIkyPvAvg_16_3">14,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_Xu_BsbcfgkCREHQZmxL7gA_16_6">23,258</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_e9m3pduNEkq48iiFU2eJuQ_18_3">161,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_KnkyI5DqSkWrnyo8WRFrRA_18_6">170,454</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_42FdwMcU4EaV8fOoE7aX0Q_22_3">12,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_4qVC1GLn80ag3BQQTfGWCQ_22_6">5,488</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Deferred revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_eDj38OkKvUOXqlohQCGrGA_23_3">14,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_XHbu6W7Fn0SyvZgontneIQ_23_6">15,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_qWID4AfJOEq8ysvrgSWAKQ_24_3">1,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ovOJGOahU0-fdgySo5Q1qg_24_6">1,688</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_GdTN3r0SDE-jlIcyFGNUfg_25_3">12,101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_eg6mt7MIrkC3lG2wwB2aoA_25_6">11,178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loans payable, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayableCurrent" scale="3" id="Tc_5hP5oMRlu0e6hzPEX46eMQ_26_3">1,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayableCurrent" scale="3" id="Tc_8Ayig_GBPEeznCcOgALjog_26_6">1,594</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_NaS_bP-kHECMZJqYhYFk_w_27_3">41,988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_cCuGFNOCz0itBfQOOIZqGA_27_6">35,632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Loans payable, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LoansPayable" scale="3" id="Tc_9Vk4nMa4mE-4Yj2opc26rg_29_6">911</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc__8prs3pp60qUwsYyEhQm7A_30_3">3,801</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_8NO1rAACzkyx0p6ZkfGHZA_30_6">2,310</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Deferred revenues, non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_Xm68LceA4kOYf5uN_Xz1dg_31_3">19,674</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_1r7CJNZp_0C6XDlfV4YAdw_31_6">25,664</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_Knv6lZDXYUeUJEYPqve6Mg_32_3">6,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_YN5Nt2s-skSpAnJS1ZESOg_32_6">3,420</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_8cPWYb_TC0yso1ozzGVHUA_33_3">29,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_8Wr6egrLvUqoTmfWcFwZIw_33_6">32,305</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_oHhjLm-uiUKj2QbNlijCvQ_34_3">71,480</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_tfawF3Y2q0mU_tvW8kTFRg_34_6">67,937</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Commitments and contingencies (Note 14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_KyMXhV4bBEmrQ_ZGwhAUpA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_ru1Uub22tUKjAXc7NM5kvg">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_n6sjXuiTdUqYUwHnhyWTxw"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Tqpo4d--hketzZ6xJoVulQ">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; Series A convertible preferred stock, <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember__7jEylpDhk2E7HBL-QMsuA" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_wtTuu5gegUy_e14v34m52g"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_msd8byN0mEqXRB3xnVScgw">2,978</ix:nonFraction></ix:nonFraction> shares designated, <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_8pdzFNCCkUGtkMDvnCH6iQ">370</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember__7jEylpDhk2E7HBL-QMsuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_uV2HIE-GnEyldEvD7FDygQ">1,697</ix:nonFraction> shares outstanding at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; Series A-1 convertible preferred stock, <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_oBjN55Dh4kWdP45kjmc_cA" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_NvkUVhKBhkW9_9y-W2P_Rw"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_3LmZVPmqhEagqrD7c6wgUQ">15,800</ix:nonFraction></ix:nonFraction> shares designated, <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_fZFEVlnlUUeR6n9l-LUr_Q">10,800</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_oBjN55Dh4kWdP45kjmc_cA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_z7YM83TrOEayjv67KpZL0A">15,800</ix:nonFraction> shares outstanding at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; Series A-2 convertible preferred stock, <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_eVFr5tkuoU-HkiBpI6yo8Q">15,268</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_4t0j2RLtRUim5ad7YUNdww" decimals="INF" format="ixt-sec:numwordsen" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_c4x112QAg0mj3cfdsDQbsQ">no</ix:nonFraction> shares designated, and <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_dSXz4I9ZhU-qcWINoF6bjw">15,268</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_4t0j2RLtRUim5ad7YUNdww" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_3ESBU0HX6kyMy7AbH0qlGg">no</ix:nonFraction> shares outstanding at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_x9EhvWpDTkCVOaGm8OUqEw_39_3">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_GFUcUxw25UOJ0ghRBPj5jw_39_6">0</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;">Common stock, </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ybYKs_ACp024qnGdfz6KRw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_R8xznBDkuE66fz968Jb4kA">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_tmTgflD-00a2hDxIGoNGjg"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_m21KIyrIkkKL8OORK19Gtg">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_s0N0BfdcIk-cwMcLKFxVJg">96,550,590</ix:nonFraction></span><span style="font-size:8pt;"> shares and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_kMH1vEEDG0Grm1MR0350AA">52,317,138</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_htHehux1wEi6rYPm9TyLvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_H8dP_q76KUqlgTeQjbo2gA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_KvV-9hjn0kyG7ym9e36MYA_40_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_JWXeub_4dU2PAoPX7y-42Q_40_6">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Class A common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_VppXB1EW_0a15F_RdHFXCA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_meoXHCL4d0OKLv08NuVIcA">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_zjpnsdYEl0an0S7Fcx1eZA"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_lfTMq6-00UabWcS4WkrzDQ">3,900,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_qg3Sbupv5USlxFW_psI2sw"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_LWZmXT520EuJ9WwljIo7SA"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_j0NbpP_q4UiANx0ZC9wi1A">2,399,517</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_RMIVhw-ytUG8UgtzJciTJw_41_3">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_Aw4e8myvNkGdF9d7ReACMA_41_6">0</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_BiGa-qZ2lkqb8jTqrEmfHg_42_3">467,041</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_Rx8cUwtcdkyflQ9sBfcWJw_42_6">397,349</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_2AUV6pzF9kmV2ZgiWYuXtA_43_3">7,933</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_IGFpm7zbJk60mBSI3S1MBw_43_6">7,156</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_J2K0EJUHA0-xhflKsSp3mw_44_3">369,261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_Yk6NE3bkr0mSrNuUcrwHpg_44_6">287,681</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jHNsfg1a4U-CX2ug6Mejnw_45_3">89,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_IH-oYv2Ym0e0zJEBwHDrWw_45_6">102,517</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_xw1Z-6_XqEeS8TTgRCm8gw_47_3">161,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_sL49_84dkUykFBH_-PrNSA_47_6">170,454</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b972a5f2_9e27_4917_8c38_1361649ad8a1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><a id="OPERATIONS_814316"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_869beca8_a29a_4113_aaa3_8ade6285c2c1"></a><a id="_26d1accd_16fb_4f34_beea_b9b7b7ffebbb"></a><a id="Tc_AMTE_4ZvdkaXJnoCNPMNzA_1_2"></a><a id="Tc_guhC9atF7Eio466FgvOGtg_2_2"></a><a id="Tc_yXAU2fQqWkey2vw-SH9i8A_2_5"></a><a id="Tc_kAfauhGRE0S0XjseozXApg_2_8"></a><a id="Tc_9KZA85W44k-Z1xKXC8TlkQ_3_2"></a><a id="Tc_K6WADFJyDkKM-E-tHeBS4g_3_5"></a><a id="Tc_pnV1Dz8JrkalVlUZCCrpSQ_3_8"></a><a id="Tc_N7sl2SB26kCbLPjSo9t20A_4_0"></a><a id="Tc_9AzAYJ2G00Shg7JaV0913Q_5_0"></a><a id="Tc_NeSyJhxVZ0WIsg9_48CZXA_6_0"></a><a id="Tc_fCAVgRL3r0SPOkmcoHjUEw_7_0"></a><a id="Tc_pWYHV3NzHEqwC5LgZeC9_g_7_6"></a><a id="Tc_5eHwUAauZU2MoLMmIMVzMA_7_9"></a><a id="Tc_rkif85B_ckC-63gv6MXxEw_8_0"></a><a id="Tc_HuzugqTIXU2ZVy949IyyHw_9_0"></a><a id="Tc_7rzDs7qAxkiVOiV52-X7dA_10_0"></a><a id="Tc_pTURCCHyBkyrL0OrQjcnEw_11_0"></a><a id="Tc_Hpx08njnD0GEE2kQIv1SQw_11_2"></a><a id="Tc_w9e4t_1L6027S7s8xH6YUA_11_5"></a><a id="Tc_QqseV7oe3EidDnOlwqCKXA_11_8"></a><a id="Tc_RH1HSY_K2UiLl0QU6ZvzQQ_12_0"></a><a id="Tc_5P85bK-cMk-VOd3DCOENQA_13_0"></a><a id="Tc__stYDkZoT026sh4ywqal6w_14_0"></a><a id="Tc_X68T6lSWdkOS45y1TvuzBQ_16_0"></a><a id="Tc_-a-T_vbXRUeaGFc2aDDzJw_18_0"></a><a id="Tc_JMD0UyZWoUWHyXR6Qp2yAw_20_0"></a><a id="Tc_HrRyJVYB70esZ5HeoyitmQ_22_0"></a><a id="Tc_oAUrB3Ezp021OHVEi9RupQ_25_0"></a><a id="Tc_n4iCiyn-MUSR-v7zXzvoqg_26_0"></a><a id="Tc_1hSDPXl56Eeqk5glWrQVdQ_27_0"></a><a id="Tc_gOOWCvucBEGAOJIqUNV-fA_27_2"></a><a id="Tc__JU-rWl2AESHmTC1CwKixQ_27_5"></a><a id="Tc_Tf4gMzj71keqv1DxAw9eJA_27_8"></a><a id="Tc_21uTHtjL4Uy9xiML4J-mww_29_0"></a><a id="Tc_3fZiQw7GmUuvUtehWT00Yg_29_2"></a><a id="Tc_Hg9A4nk6wEaIyYrTfuC9yA_29_5"></a><a id="Tc_JBYB7MvrXk678ZVcdWfeTw_29_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Gv7XN7EYJUGrVUI8-0DE1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Revenue from collaboration and licensing</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_F4pMqNDERk-J-g_0IPc4SQ_3_3">20,129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_VOA1yNLhpkeCvRwsXYFWGg_3_6">14,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_JabPlhAN_EikqnIntHpyqg_3_9">18,448</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_EiVZp8fXmEKAmH2I_v62xQ_5_3">86,424</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Ddhi4o6wREu6IFSa5EJpJw_5_6">68,645</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_eOtfB1GXxE6_FpbuQHeuvQ_5_9">82,853</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_JSrAM117SUuy8j5ivLRjAg_6_3">18,633</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_xxTinr9b7ESUKWcTfmDyXA_6_6">18,759</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_FuSfuk-PwkKlV4GdaGbKcA_6_9">17,269</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="Tc_b00pHIlZe0ehARTrXR8BxA_7_3">12,766</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_xjOc_8wAgE-12Hxyi27zbw_8_3">117,823</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_DoAadr1r30CTYie0iUf6mw_8_6">87,404</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_zE55SOs2HUuhl5J-erRFZg_8_9">100,122</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_rxIC3pDHSEuT6Zd4ynosfg_9_3">97,694</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_S_R7LruLjUq_QYQfze1TuQ_9_6">73,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_AO-xajjuekKzKTyauXCiJw_9_9">81,674</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="hook:GrantIncome" scale="3" id="Tc_SOmXON56NkSfPpUaSchz_w_11_3">11,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="hook:GrantIncome" scale="3" id="Tc_spW_G3dNWUGE7B-igLUhFw_11_6">7,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="hook:GrantIncome" scale="3" id="Tc_QuQRIjwPkkOfA_a93-xkdw_11_9">9,724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_FyxkQICIvkyv6_cJmKQ-SA_12_3">5,293</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_TRXfdRuKUkyoRXSEn0EcAA_12_6">1,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_LhR_BDfLZkKVrFHfpKD0Qw_12_9">27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_-dfPmHvfzEqsssoq5hPYxw_13_3">317</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_YTECRrUHp0Ki1UUISID8lA_13_6">687</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_ml6sHYmFc0W8yfIQUdfJog_13_9">898</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other income and (expenses), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_SwJf71ZI1kqV-VypIWBaqQ_14_3">313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_6GNDPA6sE0q8EPsMsVcXVA_14_6">392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_BCodCMF760eV89iCxc3GfQ_14_9">2,843</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_4FK-2Qmmxk2VHjIMPbcpRA_16_3">16,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_8AkpB8tDrkqs-0p6_3h19A_16_6">8,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_ivhG5I_Eqkud5b_pJY-aMw_16_9">6,010</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_IM7RF3X6zU-kBNA3-wdZZg_18_3">81,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_ECiIIcAX3UG9Ki0e3rY8bA_18_6">64,685</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_p_QJk_R_eEqDsx-SyqHI1Q_18_9">75,664</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_kZTxCEeO40m3FdU2e6eRiw_20_3">368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_ZEG75uK2xkSO0se0jPB-oA_20_6">230</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_gRQlPDrbyUW8hY4ucso_Ag_20_9">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Gnebx4HOc0WNd6Zy_QPvew_22_3">81,580</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XnvPUk4ljkOf_Qf6i41yVQ_22_6">64,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZLxu_Xe9aU2aAWKxW9NgXg_22_9">75,665</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive (loss) income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency translation (loss) gain, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_o6nEWjtwlk2nhWDXbrKhKA_26_3">777</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_P6rbcbwTR0Wk2VAPfEik4w_26_6">2,376</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_havv8U0eYU-zqCM4wq4bzg_26_9">1,287</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_hjv7lBZ0QUKMkr7guoX_Hg_27_3">82,357</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_UUfV6SFyekGa28QgzVwZ4Q_27_6">67,291</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Q70H0Ol_VEm77zxNcwedVA_27_9">74,378</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share &#8212; basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_JjLrPxauRk2JJadJCUSgrg_29_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_JjLrPxauRk2JJadJCUSgrg_29_3_2">0.86</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_RyHUr6WGikCO21r-_irpnw_29_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_RyHUr6WGikCO21r-_irpnw_29_6_2">0.99</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_bPqVXYLNnkiulId2NkTwFw_29_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_bPqVXYLNnkiulId2NkTwFw_29_9_2">2.30</ix:nonFraction></ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9f857be2_047e_4ba6_b034_975009e17cd6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><a id="DEFICIT_226113"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d962d92c_1dee_47b5_9e82_d2f82e5073b0"></a><a id="Tc_L1K1xk_sIkOBE9m4Q_jSXQ_1_20"></a><a id="Tc_rDKOtmYW20C7ijRlk99DYA_2_2"></a><a id="Tc_H-nh0EBGT0C9-zi3Ro3thw_2_7"></a><a id="Tc_d9Oi4ajH5k6uqLrF7ehJKg_2_17"></a><a id="Tc_BnyrI5NsV061c3LeJ714cg_2_20"></a><a id="Tc_7h6VeXVyxUWFIqE_2FAk4g_2_26"></a><a id="Tc_muGF9GVkhk6fxD5tAUFwGA_3_2"></a><a id="Tc_9ip5dfuHAE-r1uKmebemKA_3_7"></a><a id="Tc_y-kMiATwa0mMr7-XXuvsRQ_3_12"></a><a id="Tc_YlBP6EcYaEic5uEOlC5ctQ_3_17"></a><a id="Tc_udywjF-aA029JhgpnuN6kQ_3_20"></a><a id="Tc_GA9eBQDc3kuoHLbr6qUaiQ_3_23"></a><a id="Tc_BBVSL9zU5UqVjahCPWhVqA_3_26"></a><a id="Tc_OIl1rSzKDU-99wWnEaTgjg_4_2"></a><a id="Tc_qUdXO4Ai3EyEcHbHRuVQdQ_4_4"></a><a id="Tc_Mgus2Kls6UaPnjzEtvSZ-g_4_7"></a><a id="Tc_uAp10yY1_E2B7nNTlQTo1g_4_9"></a><a id="Tc_r-sa_9izI0-rocLiT97kZw_4_12"></a><a id="Tc_WnSGXLcuvUGy4MHOc94Fsw_4_14"></a><a id="Tc_IhIyzSvWmECjak7NaatPJA_4_17"></a><a id="Tc_RSzP_9GfBUCLBseOa3FrZg_4_20"></a><a id="Tc_K5PhUwT8bUmvpTawdAwqeQ_4_23"></a><a id="Tc_ARHypPjbW0yossU9jZWNLg_4_26"></a><a id="Tc_IKtb2ihcFEC30dPzLy3wrg_5_0"></a><a id="Tc_lqtvqU_Pf0WnEpyqwzIEdQ_5_4"></a><a id="Tc_XIBvcNDEaU-UA4hTbBA3tg_5_9"></a><a id="Tc_y8eO9lGXkECs7JgEEGP0Ow_5_14"></a><a id="Tc_jIl55TIJQEWztic1b1-b2Q_5_17"></a><a id="Tc_ik7u54ugb0Kjdnee_EjSPw_5_20"></a><a id="Tc_T-FnKoSOFUKpXzNXPJ1u_g_5_23"></a><a id="Tc_W7l2jWnSlUiyTWeFoiUkIg_5_26"></a><a id="Tc_PilV_c_0l0aDHrBoPgduLQ_6_0"></a><a id="Tc_4Uewz3gF3Eyq_6yG9dihtg_6_7"></a><a id="Tc_kyD-H6cqGkagmJkD5hEDzg_6_10"></a><a id="Tc_RtxO9H1ssUCf6fgcUL7kzQ_6_12"></a><a id="Tc_srpvcDIwdkKgmwpBm7maqQ_6_15"></a><a id="Tc_c2pHv5457EmcKV3LgI_PrA_6_21"></a><a id="Tc_e-4zVe34wE2Uv_03HD4qyA_6_24"></a><a id="Tc_LEGFaILXqUOEPfUrtOUK6Q_7_0"></a><a id="Tc_RzclhCwEF0-nTDBFW1Pxhg_7_2"></a><a id="Tc_1QL0gF6FRECiR_jd8O9VaA_7_5"></a><a id="Tc_zx1X921-A0qs1hXPW96R-Q_7_12"></a><a id="Tc_ksrXFEniM0-manvQqJrS_Q_7_15"></a><a id="Tc_smtlUvmGc02Ck7YxY9jF2w_7_21"></a><a id="Tc_oHKyGCigzkSVDnd4MzAqyw_7_24"></a><a id="Tc_9EK7blIxh0Cs_OO-CLjEpg_8_0"></a><a id="Tc_4_4m_cBFWUq34vbvNjs-fw_8_2"></a><a id="Tc_hzrl6qiiDU6ilcYIdYdKbw_8_5"></a><a id="Tc_jd0-E5PfpUepaVvuQL6ZMQ_8_12"></a><a id="Tc_jIzO63SBxUqo08qlIPCD3A_8_15"></a><a id="Tc_kAnOLS9xAU22NNW-D4sJ5Q_8_21"></a><a id="Tc_J6mU0vgd1kC0h7p9XxpDgQ_8_24"></a><a id="Tc_QJ6wT6cV6E-2Zfjk_clQKA_9_0"></a><a id="Tc_jxd0fXr5E0Wg_qNiEZ4Grg_9_12"></a><a id="Tc_emQYrzroeEi-2-Jryg2fbw_9_15"></a><a id="Tc_VW_9x_3J7EGM1qmvznt85w_9_21"></a><a id="Tc_HH4jmZyADUmqBusTFfSPcg_9_24"></a><a id="Tc_MMCR0yAwakCuxaa4MHeUsw_9_27"></a><a id="Tc_XjDopVk4-E6s6X9NqeJ0Jw_10_0"></a><a id="Tc_dZtZAxnmdkSu0Waksxpqxg_10_12"></a><a id="Tc_1ZD_34utTE6nSzFeWURlMA_10_15"></a><a id="Tc_7cy3fLUmL0KCYP_xJWSkfw_10_21"></a><a id="Tc_-AHf5_qo-0urbiBvsnXIwA_10_24"></a><a id="Tc_W318ZkjXmka_FcF19oYpuw_10_27"></a><a id="Tc_tqVxjGqBHEOPa8URqgwNag_11_0"></a><a id="Tc_HHQ0ZIkSs0aA3C0Xf-Mz6Q_11_2"></a><a id="Tc_CfGMRrVhZ06uSH_pqPJcZA_11_5"></a><a id="Tc_Ttw17KINpk6aPZohAQZ5uQ_11_12"></a><a id="Tc_BTySxcEF4UqjpWYyAZkmSg_11_15"></a><a id="Tc_UGVsJ29p40CGzARjpknuMg_11_21"></a><a id="Tc_hjPxVJo8eU-lNfsqfNyS4A_11_24"></a><a id="Tc_I0jXD9cS-EewkVm-OW0B9g_12_0"></a><a id="Tc_5ekEjpnmVUuUAEAQh3dyOg_12_2"></a><a id="Tc_bbaD-60y9kGQAtST34osAQ_12_5"></a><a id="Tc_SXqTE4E5v0KHhM3JGeyLoQ_12_7"></a><a id="Tc_L9GWKqFZ-UCtNlmvhamaYw_12_10"></a><a id="Tc_URoT220sREiWUaGRq5HVFA_12_12"></a><a id="Tc_DEsIWkSgc0egVDJdI7AqjQ_12_15"></a><a id="Tc_eTtYw8_UT0SMGsNVFzVnBA_12_21"></a><a id="Tc_EP2aTivlbUq1x5EQcALURg_12_24"></a><a id="Tc_paPPhaK9QEW_n9KSISC-3Q_13_0"></a><a id="Tc_xHLZyP_urUirqdfYGnrwyA_13_2"></a><a id="Tc_BvdB8hsBR0Glwob6HrpxtA_13_5"></a><a id="Tc_l84BLqg7f0KxF7cLE9NOwQ_13_7"></a><a id="Tc_J3qW-33L0USsxOtsv1hCMg_13_10"></a><a id="Tc_8_wy1Gqwdk28gZ--6fIxMQ_13_12"></a><a id="Tc_2Mmr4l45ckSP-9m6uBG1_w_13_15"></a><a id="Tc_VITBg5vfx0udQGb07IE2iA_13_18"></a><a id="Tc_-EBFuYd7iUiWHLCkLxJo3A_13_24"></a><a id="Tc_M-kgz5MNaUmzMt-S6_7RBw_14_0"></a><a id="Tc_gR620DYbfkao0vh-vM-bsw_14_2"></a><a id="Tc_3RmD34IOTkeaNf4LtJOQww_14_5"></a><a id="Tc_NbcFgYyqtU6BXu2d1zSCug_14_7"></a><a id="Tc_yGW__55Sj0ugK1DMdwhoyQ_14_10"></a><a id="Tc_Z4bJc4zPfk-K3dX5aMIssw_14_12"></a><a id="Tc_3T6B55jgGEeMUv5pa9Tdqw_14_15"></a><a id="Tc_Eesth2wL_0KxxCgpTMFaLQ_14_21"></a><a id="Tc_ucJLh1oV_kilj_2IFQ1y6w_14_24"></a><a id="Tc_9kdhXyeJ102bL-YIZSdPNA_15_0"></a><a id="Tc_q2XbLIEEjUKhT8b61fz0ug_15_2"></a><a id="Tc_pNCnraV_DE-Eyvty5YDGqQ_15_5"></a><a id="Tc_Af_3rEvl00q0W01CvbaRSg_15_7"></a><a id="Tc_J_5lv119lkyK0Cw4N0h_dw_15_10"></a><a id="Tc_lNBlRd2eh0G9TEvhMwS9ww_15_12"></a><a id="Tc_hIDrQO1prUi_Pum4oGcutA_15_15"></a><a id="Tc_sgTjC0CDj0mOuZNaVBQOLQ_15_18"></a><a id="Tc_M_3vaA_ZIUWftKxBpMKZXg_15_21"></a><a id="Tc__GB1WaZB502RxYsjYY7w6w_16_0"></a><a id="Tc_wuAz8NWR0kCCWeBVGTim9w_16_4"></a><a id="Tc_PhnV_X5z50-EuD7nI2bmSg_16_9"></a><a id="Tc_TVDexaRPIUW0ygEDo9Hjcw_16_14"></a><a id="Tc_J-W2HRqTGUWArbQHDzu2xg_16_17"></a><a id="Tc_Z0eBu4HArky3jeMY24493A_16_20"></a><a id="Tc_aAtuL5Ya6EaAxsmB3igKUw_16_23"></a><a id="Tc_ErNXMwy-gUWNQ1pJAPywSQ_16_26"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:29.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class&#160;A&#160;Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_yIF4oRKHIkCrbNmRPsNdEA_5_2">17,497</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OyInEuyrfU2zJp0WCD5w0w_5_5">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_87LveTVC10qUkiTwyixEpQ_5_7">52,317,138</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kBxUGz2seESACoDK67HuOw_5_10">5</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_2M_rNwGl20SqrEf5ovd1bw_5_12">2,399,517</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8eH62hbPP0GyEcozl3_lxg_5_15">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_p9D5TacsTUuux2uOCCEN0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Zmtda8ayQkuwcNjAXouU1w_5_18">397,349</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ht1Iko3ekkKK4bUJJCj6Vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_dZ31jebrWU-HZyLvqx2pog_5_21">7,156</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qsCzYAIcaEOszR8epDIoZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_sPlxubkqOUKsACtwM0duaA_5_24">287,681</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0-VssoLJOE2NV2NbuShr9w_5_27">102,517</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series A-2 convertible preferred stock upon public offering at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_wdQcSZ0gGUG6oC7D9nz3PQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_vYyDdd1ETEiSIcEegp_0kw">1,310</ix:nonFraction> per share for cash, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_NoPDm3BqIEaimDdH7xzzAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_pqR1_49ePUqs6uplRyJcWg">1,471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_SUI_rRcgM0yn74er9fveIA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_bgXPLstu4UKl9ZmFcO3O3w_6_2">15,268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_SUI_rRcgM0yn74er9fveIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_1inJhOpq3U2RZRluYVE10Q_6_5">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_7xv9iHlOIkCLF2rL0Aa76g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc__uS9vmpQQU2tnNcoFn8X0Q_6_18">18,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_NoPDm3BqIEaimDdH7xzzAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_u9fOqoLAuUWn7x1rjYKjkQ_6_27">18,530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon public offering at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kANAvXPJ_0a7gsAvkRIetA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_8GbOO7Wb70i1aHBWK2icdg">1.31</ix:nonFraction> per share for cash, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_lBtbfJCmPUmNKH1HpAUlxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_dnpQ4YXrz0uEdm46jlyMcA">2,207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_BAyUBYYE_0qxHktu111vWw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_UkHTNdDEOkiwFIiPTGpvLQ_7_7">22,900,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_BAyUBYYE_0qxHktu111vWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_nKGnCJA-cE-ap7r2dgvwuw_7_10">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_b7J_k05VpUCTEauHSsAOvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_g9X638BcL0azLylsXk8j4g_7_18">27,791</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_eDyYJl1mAEWF4gZrS_YyCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_y7udfl-aMkGJOsBOI3J5rg_7_27">27,793</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon stock purchase agreement with Gilead at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_kh4lFA0HYkm_8ou4RKPQ4w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_3rWuHRcTtkWrs2uviLaJkg">1.4167</ix:nonFraction> per share for cash, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_qjK-CNSWD0-cN7Yfpf-UAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_Peg_K4I2IkiliRSPJt9rWA">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_f2cWQ1nLsU6e2ugzoaWBEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_CM-h4-uRCEKIDG03lAtJ4g_8_7">15,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_f2cWQ1nLsU6e2ugzoaWBEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_OwJUCk7tbUSU_DUc-TUHjw_8_10">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_XsAClSmPLkGgxcjtrxYK8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_mpWZx_cSY0O_FJzcA1zQPw_8_18">21,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_cvCbnPylgUKTRN7F1GF4qQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_JBSVQQEO7kKrjTkitotBjA_8_27">21,114</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series A convertible preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_ySK9Z-Ny_k23tpFuUhWeZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_JWVkZ7lhSkW0EiEKpc8KcA_9_2">1,327</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_ySK9Z-Ny_k23tpFuUhWeZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_0U9a4pLks0G8wGi9UCFXGQ_9_5">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CQ02v_YunkKcjWHZFY_DeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_FqpKzO263UerByhYacyRHQ_9_7">1,327,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CQ02v_YunkKcjWHZFY_DeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_2t9_I_ONkkqLteQgcokM7A_9_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7iTqTo5Mc0yU0G14JpKP1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_gBWL9oUcBkWG_4k2jq5W-Q_9_18">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series A-1 convertible preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_4h3ktrQRFk21oF_BuLPDMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_FQk6Jpi37kGfZ-mXYLWucQ_10_2">5,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_4h3ktrQRFk21oF_BuLPDMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_dEL1Yn28gkGG3c7_TbInpg_10_5">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbReoX6pl0ebta1Mqf9EfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_4OUCnpGdrEG6cnvZf3xaUA_10_7">5,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbReoX6pl0ebta1Mqf9EfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_OjI4axyZO0WR9B3u8sXn_w_10_10">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_klU7bfgmHkO3j4OIlzDcCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" sign="-" scale="3" id="Tc_W13bHMKlOkisyfMhVqwJAw_10_18">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cwRIsmcBbUqKd9OfVFboQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_qF5rU01eSE-AIVAHQYIlGQ_11_7">5,684</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cwRIsmcBbUqKd9OfVFboQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_6utyp8f_IU6u0n2TKsb1WA_11_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k1H7ZYJMsU-107bPr2ox5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_gC4IwDDGx0ukMdbXyKwryQ_11_18">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_bp91GE752EiqqZeYN13vUw_11_27">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">ATM costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k1H7ZYJMsU-107bPr2ox5A" decimals="-3" format="ixt:numdotdecimal" name="hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" scale="3" id="Tc_TPkzcEdB3Ey9kl9sOivpcg_12_18">86</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" scale="3" id="Tc_mXqdAT4By0eRUl5vnt2iuw_12_27">86</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HHVctDOtV0C6dlcgQy1LxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_I0wTzVzaeEO2x_gHKovDpw_13_21">777</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_7BxzSlxicEi8ERTTbJ_I8w_13_27">777</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k1H7ZYJMsU-107bPr2ox5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_LQ0fI3arhkS5rCntYnQ9Bg_14_18">2,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_jnPtlHKoYEu8SxvTnzQRUg_14_27">2,345</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MrV6NCzS0UKVJ_8-CMc7bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mJ--wKk9YEKFsDDvyd-Wxg_15_24">81,580</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_s95m_8JZAEmxAl5MiWXuxQ_15_27">81,580</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_cp2qFIiDmE2EuFHtMEm6eA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_zivUeMsOg0eqtjm00ETRww_16_2">26,438</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_cp2qFIiDmE2EuFHtMEm6eA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_PPXtofEPBU66g9A1tPNEVw_16_5">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eavcYujje0qBEWD0ZLFF4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_o9P_zYaXs0-qGAOW6qMZsw_16_7">96,550,590</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eavcYujje0qBEWD0ZLFF4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CY2YjWmyLUut5CVdhjoMOA_16_10">10</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TB8nJkfO206JH4IgeDIJYw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_uvRvF45IPUG8MyvQHs4W1Q_16_12">2,399,517</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TB8nJkfO206JH4IgeDIJYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hrFVBrXeLUq2EwXSK8Tf0A_16_15">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hawa35VgPkm-hhsVFZrIwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_iuGPNdI3ckK0JqsdptnXtg_16_18">467,041</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy8iNx1CQU-KWT7AIRWsZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_nYEVCRCshk2hhyu5aGZ8gQ_16_21">7,933</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eADOfy2zHkGdzANuuDMnKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_DUlm38LKFkSLfZv9YBA-vg_16_24">369,261</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_paB0WL4wTUmxAdTPmTNxnQ_16_27">89,857</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_12c409d7_290a_4b50_87a2_2e3fdf8919f1"></a><a id="Tc_HPzwYH1z4kGGp-84-gO1uA_1_20"></a><a id="Tc_Uh-L4bX12kqggP2B5wAg8g_2_7"></a><a id="Tc_PfOcMLXrf0m8aOhZDwzpAg_2_17"></a><a id="Tc_JUyw-utWJ0KpIEQ49S0hGg_2_20"></a><a id="Tc_-oZRrCArkUqM0oz_SffA0w_2_26"></a><a id="Tc_faBQXGk_T0qt9GXmvAQWLw_3_2"></a><a id="Tc_EYSHCvBuo0WOzmOLHs7t_A_3_7"></a><a id="Tc_y6_2F3yKpEO-JEVHfoahTA_3_12"></a><a id="Tc_ex7wObNp0k2sJXkFg0FDJQ_3_17"></a><a id="Tc_4ow8avarvEi40t0dbE5Q-g_3_20"></a><a id="Tc_5nUXIRfFlUSJBqP0KUv_Yg_3_23"></a><a id="Tc_TM3Iu8G-d0exalcVX7rEZw_3_26"></a><a id="Tc_hoXWZXRT-E6wqzRDUS_liA_4_2"></a><a id="Tc_5PkbhXxcH021rlr7E_V_SQ_4_4"></a><a id="Tc_-CrFaVmceke0N6NraEqlRQ_4_7"></a><a id="Tc_JObyyt-8zEGipvhzbmMG2g_4_9"></a><a id="Tc_mxXFA4VMBUWn4gGCscdqaQ_4_12"></a><a id="Tc_XXvKJdPeMkiEBR-w1Zn01A_4_14"></a><a id="Tc_qmCUNvHXUUW1AbkbeKXdNg_4_17"></a><a id="Tc_YrAXlfrGI0KqcugWeXPOHw_4_20"></a><a id="Tc_Mx8xJefyt0isaSJdZMcEtg_4_23"></a><a id="Tc_n1n0eYsFiE2U4W_Ld5wnnw_4_26"></a><a id="Tc_hw-aBq81HEG7ygEjuDq2NA_5_0"></a><a id="Tc_gORp0XUXXEWiR0ZiWJissA_5_4"></a><a id="Tc_AcEMee8eb0elHbl5Nn2_Hg_5_9"></a><a id="Tc_jXMCzxaheUeEB0AcvDJzGA_5_14"></a><a id="Tc_H29tLi6di0qlnlztDhnqrg_5_17"></a><a id="Tc_RU48lU-I-EiIDDEhZlnoUA_5_20"></a><a id="Tc_RvQ_0Ir1aE-EDw2C87HXIg_5_23"></a><a id="Tc_aMUNv14D5kaVH68fy3FRoQ_5_26"></a><a id="Tc_AAKHvqH2iEuIkB0c9mV8Bw_6_0"></a><a id="Tc_FziqlVwILkSaZD4kJ3-RVQ_6_12"></a><a id="Tc_dPNy1QVbHUyhVQA_t1c6YQ_6_15"></a><a id="Tc_oxLZ-DvLQEykCakpJuDStg_6_21"></a><a id="Tc_jWw4qe2HDEWQn2hYpVpEIg_6_24"></a><a id="Tc_dHIFuwyPWEuTFWyD09kgww_6_27"></a><a id="Tc_RcxrAuNuEE6dZ6Tu23oWew_7_0"></a><a id="Tc_W4LNCCUFR0m-rUxXIXZQKA_7_2"></a><a id="Tc_fwQ_bFB2AU6KVhvoK4pGnQ_7_5"></a><a id="Tc_g3_-iiWxK0u-QQD-9mymoQ_7_12"></a><a id="Tc_n7uZ8v4KaUehNI4AY49CJw_7_15"></a><a id="Tc_uazdW7hKi0SIIHh2Ui4x9g_7_21"></a><a id="Tc_d1UvqgOYt0qThNFq9k3_iQ_7_24"></a><a id="Tc_x3ckcMNN-USXCQf_bJbcyQ_8_0"></a><a id="Tc_Pk7mSSeEsEm1xtZ9Mva0Tg_8_2"></a><a id="Tc_4MYuGuhJQE2Aq0WtRZBtiA_8_5"></a><a id="Tc_tjuw6GZQekmb8E6XnVv-cg_8_12"></a><a id="Tc_-d3hGaVP60iDuv5_yJyoqg_8_15"></a><a id="Tc_EG51cpX7IE6u24NOiZtsJw_8_21"></a><a id="Tc_92UnVEaARU-Rq3seXsl8FQ_8_24"></a><a id="Tc_R9Pl-lMGsE6lz6pxCY95Ng_8_27"></a><a id="Tc_esFg6FudOka4zVsjKr8f9Q_9_0"></a><a id="Tc_DmHHhNRwOkO6lrOVDliLKQ_9_2"></a><a id="Tc_VnirQ0dMI0ufMVndXSCujw_9_5"></a><a id="Tc_12qAkQep1U2nf2IhRv48eA_9_7"></a><a id="Tc_VN29hE348k6gHv0tFt5hpg_9_10"></a><a id="Tc_hTmYCvLSSUOSqnnK6sdMhQ_9_12"></a><a id="Tc_s7jOouvbBUS0mqHZPEhMpA_9_15"></a><a id="Tc_MroMyCZMd0yo-khFue1tHw_9_18"></a><a id="Tc_M7_jHv19tE2lu0iWU8MM5A_9_24"></a><a id="Tc_QJKDZw7Fr0qF_XRQ4GvG0Q_10_0"></a><a id="Tc__pan-U8d_kutKdEYrTxBDA_10_2"></a><a id="Tc_vZsafqyp_E6Iq-S4Q0oc0g_10_5"></a><a id="Tc_LZCcMWOUn0WB7sz-QjQ-nQ_10_7"></a><a id="Tc_9BgxzmxEwE2lORv48qagvQ_10_10"></a><a id="Tc_ikrKIdklF0eR0f4lFxK08Q_10_12"></a><a id="Tc_0JA7u57gVEaocaim_pdTvg_10_15"></a><a id="Tc_qleFfGUW3E-LO0DO0s-3nQ_10_21"></a><a id="Tc_qcIr4fMlbkaFYPHR2Jbnvw_10_24"></a><a id="Tc_YFZ3wAyN306TTShJ_AP9zg_11_0"></a><a id="Tc_9JtyS6dCrU2HV9AIIv0mJQ_11_2"></a><a id="Tc_aq0pxbmobEKohxds8vBxqg_11_5"></a><a id="Tc_tbLFxD90mUKnACgf9kpWEg_11_7"></a><a id="Tc_5RB9zQinzk2EgKqtNQBwpA_11_10"></a><a id="Tc_60Z1FlVGXEO8eLzZVPoVuw_11_12"></a><a id="Tc_7tgeVn6Da0ip6mMRtvscyg_11_15"></a><a id="Tc_6HQSNgWC5EWMXu6fT16miw_11_18"></a><a id="Tc_bo3T_4oGSECghcufO7vmlQ_11_21"></a><a id="Tc_R_FI2ATgdU67ZpkseB-p7w_12_0"></a><a id="Tc_C0KSD5TmIUWe3CKVExo4JQ_12_4"></a><a id="Tc_zZzXSUYfW02RkOF20zMe5A_12_9"></a><a id="Tc_Y5dFB3MT6EWOK1XoSBlmww_12_14"></a><a id="Tc_E3Ni-tdNKUeQZVmGhCmJwg_12_17"></a><a id="Tc_RejUoglFx0GLwDkQatqRUw_12_20"></a><a id="Tc_RsoDDbRM7U-GZJwh10XY9A_12_23"></a><a id="Tc_1njuMAqEsUSGH0t3pRmtXg_12_26"></a><a id="Tc_fiS-dCb-2U6DYfNGXQ-KeA_13_0"></a><a id="Tc_-u5xa06CIEiqo1F2vzEEEw_13_7"></a><a id="Tc_YGKK1POLQEq0INV2T4igEQ_13_10"></a><a id="Tc_rXnESooG_kOy_1Gb0I1T_g_13_12"></a><a id="Tc_A4RUW5XukUe8-qrMl2oB7g_13_15"></a><a id="Tc_RCPRkeHuVEODcGTgj8CQeQ_13_21"></a><a id="Tc_JYFYn9w2lkOJ3gpwFSZXBA_13_24"></a><a id="Tc_cjRLAx3N7UOGyAif5uZa8Q_14_0"></a><a id="Tc_WU7K0scAwkOEZaHSNwWVdg_14_2"></a><a id="Tc_HRfhzrFteEu-g2vPM8Qxew_14_5"></a><a id="Tc_lYpmYd_pyE66eXcCQAACXQ_14_12"></a><a id="Tc_WolwV2V3sUiFWEAZonM4zA_14_15"></a><a id="Tc_lKMmjCfZM02ANWfl8FsxTA_14_21"></a><a id="Tc_KbcEM_ouVEaIyw8ylLCEvg_14_24"></a><a id="Tc_AE4mZ06BQUSgpjc4zwSzjA_15_0"></a><a id="Tc_TFbAyTVD9E6c1d9q4whvJg_15_2"></a><a id="Tc_kR33xi1Cd0a4MTfvnpKMqA_15_5"></a><a id="Tc_Iwz9K2R6KE2f5mA62Tfd5Q_15_12"></a><a id="Tc_e_jfhqGd1kKpIKT1JrJHDQ_15_15"></a><a id="Tc_HRXc5S8JYkGN2cNtfF4MZw_15_21"></a><a id="Tc_Pmu3wjzJzkCX3K7lLE9PEQ_15_24"></a><a id="Tc__aKjVoOArk6PcQFy88Ra5A_16_0"></a><a id="Tc_oeyiJny1MUiCCK2jWgMBxg_16_2"></a><a id="Tc_6gKiIjogsESlPF4bA8c0xw_16_5"></a><a id="Tc_ZbnhOPQnQUabbl9jkGnaLg_16_18"></a><a id="Tc_nuOM5Nu7xES1LD2U3tLg2A_16_21"></a><a id="Tc_lp0uv5JBlEajK_Q7ZZS_Rw_16_24"></a><a id="Tc_nxeQ9N-bD0Oa2lfBabp9Jg_16_27"></a><a id="Tc_v7ZqzuOd_ki9vqrwcoJtyQ_17_0"></a><a id="Tc_K80oBB3cB06TgoCw092E0w_17_2"></a><a id="Tc_ZSXYmWhH-kifS85GVcXYUg_17_5"></a><a id="Tc_LkzJLi6OL02ET5wUgi3Y7Q_17_12"></a><a id="Tc_SOUs3GnBskCsPIWfyC2YMQ_17_15"></a><a id="Tc_AMBP0fZYuUSy7x6A_S4ZjA_17_21"></a><a id="Tc_tGUW_XkPV0azoHTlLCn5Jw_17_24"></a><a id="Tc_Mr-fmOOaFk20IRFKRnW2vg_18_0"></a><a id="Tc_pu0aTv2LukSQ3-DzAEoFoA_18_2"></a><a id="Tc_Cg8W_-WOdk6peOPxWfCBYg_18_5"></a><a id="Tc_REdm-j0Rf02v_ZdALHmU_w_18_12"></a><a id="Tc_rL1eOkjZX0-07M7r5FPe4A_18_15"></a><a id="Tc_qeQcUrHhb0SHgT5UwVgC5g_18_21"></a><a id="Tc_hteg6WynlUGKytUkImgJOg_18_24"></a><a id="Tc_1Ck9T4iGIkiiTYOAOrjZqg_18_27"></a><a id="Tc_Cjz6Qq5u0kuTyxS36b2DVg_19_0"></a><a id="Tc_6PNe8q8Wwk-0CRspuc26CQ_19_2"></a><a id="Tc_o4y46dH6vUuTRceqoLGfOw_19_5"></a><a id="Tc_aeaNjWk5GUa4fgeE3GuM6A_19_7"></a><a id="Tc_bDGE4eAnmECYc16t1m7AYg_19_10"></a><a id="Tc_XwkidtK9JkO45CGNsqUnsQ_19_12"></a><a id="Tc_1vNKettYsUSoX2r88-RyXw_19_15"></a><a id="Tc_m_EOOGcsFUKMA9Ee5YVq1Q_19_21"></a><a id="Tc_B9EPcA_FSkKYxjPxtK_mAg_19_24"></a><a id="Tc_WLN-Yh-esE2JPPj9zNTVNQ_20_0"></a><a id="Tc_dlt9EAv490yoQZ1gBgYuyA_20_2"></a><a id="Tc_6g3Q12QcZkGLfOVzAzT57Q_20_5"></a><a id="Tc_DFbkVo84bkWv_h18GrEX0w_20_7"></a><a id="Tc_lOd84Yf9EEeVK0Ydthe6Tw_20_10"></a><a id="Tc_e_XrcMoSCkWasPbk6_Vk-g_20_12"></a><a id="Tc_wVZ8P-AkwEWcYROT5G2R8g_20_15"></a><a id="Tc_IAKnEC_7IUWbjdoIpJxnpg_20_18"></a><a id="Tc_sL0WGFo7tk-H3WYNKmW6Hg_20_24"></a><a id="Tc_iOveEc62XUmLdBYZbIaVvw_21_0"></a><a id="Tc_bcowtYFF7kahaPYnmjSDrw_21_2"></a><a id="Tc_cE9Ak0sElE-Zsxi3rBIpig_21_5"></a><a id="Tc_qRsbEUkMN0S_20UzUn892Q_21_7"></a><a id="Tc__tRtC-ZcwUuknx3oiZ97Pg_21_10"></a><a id="Tc_IsOtS_vEdUiCrCyb_Tlfng_21_12"></a><a id="Tc_NUeiyCiyUU20tABzuFnEEQ_21_15"></a><a id="Tc_w9M9tA224ECeVkfD87-mVQ_21_21"></a><a id="Tc_uZLRmwgz6EKu2j5PDAAgsg_21_24"></a><a id="Tc_GYgOIPLDyEOTVXnAJI3lUQ_22_0"></a><a id="Tc_oxU_Fipe3Ue9JzrU1gcxMQ_22_2"></a><a id="Tc_ofmkAB-sQEWYtlTN_gkUig_22_5"></a><a id="Tc_zRauvk10pkaeF9H0Y-tF2A_22_7"></a><a id="Tc_vJLmQwQo0UiV6RarohSoLw_22_10"></a><a id="Tc_tcTCQOTBfkiSDodEVtWyiA_22_12"></a><a id="Tc_uI80PFN4MEOYDMY57arngw_22_15"></a><a id="Tc_ZA5M2hmxzUOMlgqHi4eoTw_22_18"></a><a id="Tc__tDQcGxB2kqVZp0G_BTEnw_22_21"></a><a id="Tc_NnKY0OEcaEC60xpp09iADA_23_0"></a><a id="Tc_kr8P1Ye5CUe6VmvlMjkgTw_23_4"></a><a id="Tc_aeqNYjX1ikyy3zcGIQ7Mnw_23_9"></a><a id="Tc_jFzb8KAKs0-n5pZknl28yQ_23_14"></a><a id="Tc_hZFWcRGliEy2c85MOuQ_oA_23_17"></a><a id="Tc_lfVNO1csC0GieKlCfeXk3g_23_20"></a><a id="Tc_qQiTrcKBgUujrUbMkf8Cbg_23_23"></a><a id="Tc_nDCiva8jb0WF0Cyd2dZ3sg_23_26"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:29.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class&#160;A&#160;Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income&#160;(Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_7Ko22T84I06Il1nncKM6WQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_xFe3v42wiE200fTgdOA9Ow_5_2">2,978</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_7Ko22T84I06Il1nncKM6WQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9WG4Mtk-JUGU_D3u2hPTfg_5_5">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GpwDSGNgm06tza9uL7YsfA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_8J8LEHIa2UmF1OAbTGECcQ_5_7">25,948,712</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GpwDSGNgm06tza9uL7YsfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZcRRbJfxOUmBb6k8WKHZ8A_5_10">3</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XzMTTAsN-kat0RQ4mLVSsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_WHnCdQgISESoJugm5KfAjA_5_12">3,819,732</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XzMTTAsN-kat0RQ4mLVSsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_FVcj6YeSekCpZjDNjyMGvw_5_15">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lkdWE0tsUkWi1RgazRbc0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7eQ7Qr_sSE28oIgG6bzf6w_5_18">309,288</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CmfM8R1qc0ia9PJJbDvGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_EaVeJMLCFUeFMe9wqr3amg_5_21">6,067</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GguYoNHqi02T3cZxSRd0nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jLPcpT9v10u8GPopiHXKuQ_5_24">147,101</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2020_PSUqRWmVfkCw7OQN6sRoGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_FChepbkUlEijOMDAVOpF8A_5_27">156,123</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series A convertible preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kkhUGeXDzk62-3EYlJzDVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="0" id="Tc_Jn_TJbcNLEy27HNJi8AUcA_6_2">1,281</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kkhUGeXDzk62-3EYlJzDVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_9N96tKp1L0OQKvo6PYyxaA_6_5">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_PCu4S2Tjlkac9CaMTmb6UA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_rifbOpYJP0-ncCDYDLljiQ_6_7">1,281,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_PCu4S2Tjlkac9CaMTmb6UA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_HyGKD4V5AU6LHBspNKqcog_6_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_QKv2gv1YAkqr34O2n2MLMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_aLqt0G4k_UO8lAKoUPEhuA_6_18">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_EmP6GXB1EUWfZ7zOkYfMjw_7_7">110,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_oB9AL5P8QkS5-nV0u0YRZw_7_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zch3U472NU6ienNHLQ1xSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_nng59nWmvU6LuUzwGmPT6w_7_18">203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_XSCI1_1F3kyZsait2Dy8hQ_7_27">203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw" decimals="INF" format="ixt:numdotdecimal" name="hook:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" scale="0" id="Tc_9kG7BoSMiEKba0Ws1NPtpQ_8_7">43,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw" decimals="-3" format="ixt:numdotdecimal" name="hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested" scale="3" id="Tc_nHAM4ZTzREqFjdlk4b_WVA_8_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zch3U472NU6ienNHLQ1xSQ" decimals="-3" format="ixt:numdotdecimal" name="hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested" scale="3" id="Tc_4RCe1MXTo0-USVVzoyeUag_8_18">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pSYi6VRiEEWiQxkyw445Kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_jZ38dKwm8ka2ItlZySgQlw_9_21">1,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="Tc_7mqnAg9WXU-VYd4fZWKdSA_9_27">1,287</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zch3U472NU6ienNHLQ1xSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_nXi0Cjg_LkemRfPGu4XUtQ_10_18">7,644</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_IBiMI77Yj0CLmlB6wclqzw_10_27">7,644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Yto5HIXmyEG1TJnAO6oOwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RRhEBDfEw0yXDNpcv9QcEg_11_24">75,665</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_tJG9m9DPoEOn6LqRAQf9Nw_11_27">75,665</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_tQFbE_DcHkOkMLytg817wQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Bj5KVu7cpki2XTV5XCcJUQ_12_2">1,697</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_tQFbE_DcHkOkMLytg817wQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lsLah2EX-ES_QF1YPrL6AA_12_5">0</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BRiLG2VnwEyMWEgoQSDszQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_oqtqyajkUUCTck28jdeaEQ_12_7">27,383,483</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BRiLG2VnwEyMWEgoQSDszQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NV9T3RFaXkah2KnBUY1Kfw_12_10">3</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3sxrr_m_10WVU9FJBClJ1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_HTZUo9yMFEyHSrV_Q23AQA_12_12">3,819,732</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3sxrr_m_10WVU9FJBClJ1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TsKcNxKY00GaLUZari39Ig_12_15">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HPm7mnaUk0OFlLY3NbuqlQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_v5Ih3fO3JE-uGbiPpGGMgw_12_18">317,135</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LfPs5RT700ypYFvEtpSSxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_M6-ZrOt8Y02myKqFD0_TZg_12_21">4,780</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_50aQNcU1rESa1A_NH0ITtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_diAI_5ZIfEWf9JMQor-yeA_12_24">222,766</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZCUK2TacsUiMUGQTTMgPZQ_12_27">89,592</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series A-1 convertible preferred stock upon public offering at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_Xcsey5dkJECXYtbLisOkXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_uxIpDy3QzEi-KsifyjtZ0A">2,000</ix:nonFraction> per share for cash, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_OohY4lRPq0yPekG2Wk5KZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_9mzZ4w3u30yE9mXjPV2nyg">1,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_Lt7jkjnIqEmsokc68MGWDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_ZrybZflSBUeRmqfcgYYugQ_13_2">15,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_Lt7jkjnIqEmsokc68MGWDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_uK0-rG4EhkChHNvIRwG_CQ_13_5">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOSFNmfs3EOqv4WZIP0Bvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_pyTeFP-mEkqlQ5QWJVVibg_13_18">29,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4T_o5zMCE0ug338F1VQDdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Cfy5HAteAkOhFCUUTGGQDA_13_27">29,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon public offering at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_EcSzpwdfREKHNIcL7hVs2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_rLzC8hKH_0G8dOLPyojNBQ">2.00</ix:nonFraction> per share for cash, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_VChA_ldFhkWxOYuQUqtGHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_aMMFv0YPlEyXK-jJVDPGqA">2,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_nXIctgCoNU-Gzk42kRTkKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_e-ryeT2cV0Gt5ilaPCb0Iw_14_7">21,700,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_nXIctgCoNU-Gzk42kRTkKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_kvd_FiQffk-jEjyE3nv8bQ_14_10">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kQUzEzJS40CQZoM-Toa5sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_cz72siGDDkSoaWEqAcoKWA_14_18">40,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_2yyWaG6qFEu8WStCSjJPqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_C1_ayEsvU0qVCUI4E5qNZg_14_27">40,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon stock purchase agreement with Gilead at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_ZM4WJ3Ojn0quhH4Pn5CYdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_PIB7NXLBqEKINHtqcjttCA">3.00</ix:nonFraction> per share for cash, <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_37LOdjtI8EWZBGW9I5pzGQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Narr_uwyRGVVKOUCYWpiqsH7Vsw">no</ix:nonFraction> issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_2mnDHSaTCU-2dD6XGhTvLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_qY-y-5Yt-0qfRr6kvWKEoQ_15_7">1,666,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_2mnDHSaTCU-2dD6XGhTvLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_46rkEvMBQ0aCaG0Q8n5BnQ_15_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_qYw6vTRVN0ubcxuWYyT9fQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_e7kZnKcsS0aBu2bv2WIbeg_15_18">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_uFqE4irDUEqudmnogjdsfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_vn83meHtsk-wv8ArlgwXYA_15_27">5,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Class A common stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Tc_aChfVnu9C0WmqIDwLUKGvg_16_7">1,420,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="Tc_SuUYbcfXkkqWptUaAya-ig_16_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACQheD3jekytMJkUUeE47g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" sign="-" scale="0" id="Tc_QBuamxIgX0KtrYT6c_fsFQ_16_12">1,420,215</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACQheD3jekytMJkUUeE47g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="Tc_IgHsvxHz00GG_r1cxJLCWQ_16_15">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_0_JrjAryck-RG_xYfRfDxQ_17_7">34,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_6VPohFjUnEauccaMRpMc1Q_17_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9_5E61jCp0qkRK8pXIBRXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_J4ufxDlcPEirA-Y5e_UQRw_17_18">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_Rai6liu0xUW1EmNBgzCqLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_RtpANzF44UiaS3fSM5Iu0A_17_27">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of equity grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q" decimals="INF" format="ixt:numdotdecimal" name="hook:SharesIssuedSharesShareBasedPaymentArrangementVested" scale="0" id="Tc_bU0Nhv8PCk26FG_HrqAChg_18_7">112,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q" decimals="-3" format="ixt:numdotdecimal" name="hook:SharesGrantedValueShareBasedPaymentArrangementVested" scale="3" id="Tc_rDBWsFcpJU6MbdRByse5Ww_18_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9_5E61jCp0qkRK8pXIBRXA" decimals="-3" format="ixt:numdotdecimal" name="hook:SharesGrantedValueShareBasedPaymentArrangementVested" scale="3" id="Tc_iG8HvPyp506VhjPDtUP1gA_18_18">0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">ATM costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cXPFzUalKEKzwidBaBnRKg" decimals="-3" format="ixt:numdotdecimal" name="hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" scale="3" id="Tc_dGNh_3NQZky3TASXT9YCQQ_19_18">142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" scale="3" id="Tc_VoPI0tcRtk6JQTZ77yJyYw_19_27">142</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_unSFbxjx2kSBUd8Oh40Kbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_hhVg98Bzs0KRzZoQ_k4GXA_20_21">2,376</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_fSv2VFVyDUO7ri8PcDguLQ_20_27">2,376</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cXPFzUalKEKzwidBaBnRKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Lkng48l8eEy8VeWnVOrcKw_21_18">5,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_rUBZoUecNEC32aecTaSJbg_21_27">5,043</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qZP9Or45rU2FWGne3bmD7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2U0ratwu2kGAKuoc7JVHnQ_22_24">64,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jHjBozhIQkaQVHEm1sm_HQ_22_27">64,915</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_xStbDAUlcU-rfgSKKkAHiA_23_2">17,497</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_IlV85zDI80u5nkxRGZ7A0w_23_5">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_1BfUNjkqAE2rHWUU4hQYHQ_23_7">52,317,138</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NEnClwUsc0WsLTiZ0pgRig_23_10">5</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_RNgAWBJMlECKWvgmJi2hoQ_23_12">2,399,517</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_angpCfPYxEG1tGCc9m0O5w_23_15">0</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_p9D5TacsTUuux2uOCCEN0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_D-aQx9pSL0qdhB8211YCxw_23_18">397,349</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ht1Iko3ekkKK4bUJJCj6Vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BsfuL9dM8023iqg-3OVOtg_23_21">7,156</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qsCzYAIcaEOszR8epDIoZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_81l8tB3wtU2H33QcEYnKsA_23_24">287,681</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lLaTJbD5HkSnssiAT9Os1Q_23_27">102,517</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_31f84cb2_e0f4_487d_a73b_1a6d92511a33"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 5pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><a id="CASHFLOWS_176896"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><a id="_b6930d0a_5fe4_463b_be7a_d09e41ebc69b"></a><a id="Tc_u6CZFDOCJ0yCYdvI2kXw6A_1_2"></a><a id="Tc_f42uzY935EOZlJ8jCW5ujA_2_2"></a><a id="Tc_Cc8eO2f3LEGZDAEE41WhFw_2_5"></a><a id="Tc_wNEevz5Bd0uLjzNGMlFFBg_2_8"></a><a id="Tc_qZaJgBdXgU6_1fe7cBDX_A_3_0"></a><a id="Tc_YlXL2vhcX0uQqWBOo73gDA_4_0"></a><a id="Tc_kTMnrB-tskOdzUzPfsLHYw_4_2"></a><a id="Tc_COOKne5UHE28PLnCMIV5Yg_4_5"></a><a id="Tc_lZQKpyF2_kuGnXW3SaSUUA_4_8"></a><a id="Tc_vjdQtveJUES5EjnYJqcLWA_5_0"></a><a id="Tc_dMee-pEU80aPbECuXi7q5Q_6_0"></a><a id="Tc_PqVz5BNBPEyU4gAuuiz1ZA_7_0"></a><a id="Tc_vBASivkeb06y5Eh5Ul3yHw_8_0"></a><a id="Tc_K19HHN2dh0u58u3HM0Da3Q_8_6"></a><a id="Tc_a6s4RrorEEOf6mFEOmvZQA_8_9"></a><a id="Tc_7wcuBN1TaE-iRtjC-Ut2uQ_9_0"></a><a id="Tc_Kn2XqmzbeEquv-JoJ7PTxA_10_0"></a><a id="Tc_bK2awF7wZ06Hegd_Jlx41w_11_0"></a><a id="Tc__NEpD2Y7Rkewi-eqOoFUhg_12_0"></a><a id="Tc_36KZ1VFC2kyPPEr9WK1hvg_13_0"></a><a id="Tc_dw7xlrAw2EecAw814SPYdw_14_0"></a><a id="Tc_PRt6Y27n5EeuK8qR5KQSkA_15_0"></a><a id="Tc_cs-u3wdp80uhOXnsc3q1Tg_16_0"></a><a id="Tc_l_YwZp-7y0ePjRjIBIn0dA_17_0"></a><a id="Tc_ESi4WceQKkS-vHgRYBc1fg_18_0"></a><a id="Tc_YeQNwK9qIUS32tE9JtLh4g_19_0"></a><a id="Tc_DCjs9VDCSE6_QDwzl7G8Kw_20_0"></a><a id="Tc_-LJdou51n0mCThR0NtQNXg_22_0"></a><a id="Tc_j6TY_0HbPUKKMxIJT-NKvQ_23_0"></a><a id="Tc_6qgZMXGFxEKhQWrpyRh6wQ_25_0"></a><a id="Tc_WGp2a5-VhUmTTsu2sGyecw_27_0"></a><a id="Tc_0IENBmCe1kODboCdyixBbw_28_0"></a><a id="Tc_0EHHOem7-EGQ471xFzi8jw_28_3"></a><a id="Tc_cEwsO7t6TUiBpR4gDUdYaQ_29_0"></a><a id="Tc_43usg4Xa8EuTJOleLserWw_29_9"></a><a id="Tc_1eIcI9QEB0-CySXjbREsXw_30_0"></a><a id="Tc_WPxLYplPEE6RalDx6qjIJw_31_0"></a><a id="Tc_eTbsTAkrIUG_neqD3NpoOw_31_9"></a><a id="Tc_gLi_NGfcUE2pz72VSUKymg_32_0"></a><a id="Tc_VGdEhrVrd0KXwePiNvV1Vw_32_9"></a><a id="Tc_IqXf5_unFkavhb4PMTwO7w_34_0"></a><a id="Tc_gbml9x-EWUClWwJQGmllCg_36_0"></a><a id="Tc_g_yzfzUp_k-YGlyJu4v9mw_38_0"></a><a id="Tc_KD0gULN2PkWUmB3FYkVRBA_39_0"></a><a id="Tc_mpX75Mh_E0i85sXHoU4IYw_40_0"></a><a id="Tc_CwQbItp4FkuXfMyZsnv8fQ_40_2"></a><a id="Tc_EPud7pg2bk6-IJq3lUwm3g_40_5"></a><a id="Tc_PJEXCsiMQEKBxg5Dq04Utw_40_8"></a><a id="Tc_O6KTQiedjkaanuVykk72vA_42_0"></a><a id="Tc_pVl5jbbezESQfjxGsd9iaQ_43_0"></a><a id="Tc_9kIBhNBDm0Ga15T9s5Ge8A_43_2"></a><a id="Tc_sv_9GRDVXUmZ1cSDxJ4F5w_43_5"></a><a id="Tc_Z6oEF-4Zfk6ROQdMoYsNNw_43_8"></a><a id="Tc_rg1CVRHtOUKLl8RLWiA6PA_44_0"></a><a id="Tc_O4RVI7ki-U6RXSBzR2C3cQ_44_2"></a><a id="Tc_RxK-h_t6kEeoROzn-EMVOQ_44_5"></a><a id="Tc_BZohQaTRmU28kIs6tPwyAg_44_8"></a><a id="Tc_HToe3b7Ew0SxeeEQV0RJ0A_46_0"></a><a id="Tc_TqA4lcIzP0C4Tu2nES6kHQ_47_0"></a><a id="Tc_4vz1Iuo_80Cqzf75UC_Wig_47_2"></a><a id="Tc_F8RpCW7l-UqcCz72-TsR4A_47_5"></a><a id="Tc_z32icMWKkUqbaZWVHaar3w_47_8"></a><a id="Tc_VRaCyZYpVECE5CmyrgXloA_48_0"></a><a id="Tc_V0Ic89T7bke-wFtfKnRRWA_48_2"></a><a id="Tc__8oNfhNRd0mOUBpHgiHg4g_48_5"></a><a id="Tc_RpITBqa0gkqO5yK1nld6zQ_48_8"></a><a id="Tc_5OZ5E-fLake6v6IuKGfHlQ_49_0"></a><a id="Tc_lglWMcZQBUavyOh-TLGQDQ_49_2"></a><a id="Tc_VlYDNedE1Eavv-AMyzY7Rg_49_3"></a><a id="Tc_L_NBaKvGmEeNOk_tHfSJbA_49_5"></a><a id="Tc_V8W-5iuo6Uu1XIKb32_5BA_49_6"></a><a id="Tc_4hfOOXuW2EuRCZIrFQZZ3Q_49_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_I5yXJkI-lUSWOW42JZATcQ_4_3">81,580</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Jb-jf1ifIUOoMqpMNc8P6g_4_6">64,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_ue64QnWoWEK3s6sQa1GKxg_4_9">75,665</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_quZsVMDDrEerO9M-2YH4AA_6_3">2,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_QnjLyH4QrUmgt1oyHtWhmQ_6_6">5,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_qhEiWCfld06bMkAoSp2Rtg_6_9">7,644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_VJOVrk6SakmQ0YOg55owRg_7_3">3,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_HwnTiK19T0S0Go8QUw1SzQ_7_6">3,602</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_DJTICutyt0asnDjxgGj6rA_7_9">4,640</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Impairment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="Tc_8c9G8m8q9k-nPNv7wY4MLg_8_3">12,766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Other non-cash items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_EIAm7UdlhEu_OIqWnA_MuQ_9_3">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_q_tiOxO_ukueKVKx6TFVTA_9_6">160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="3" id="Tc_IJGYqh7qrkS6tRNsBN62Fg_9_9">1,226</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_w0-Tg9W8pUqQKjHBZyNibg_11_3">6,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_EzsBW7ndokK-tFdaQ4_Mqw_11_6">341</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_BcCEboR2_EC_w8CK1SnxcA_11_9">1,943</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Receivable research incentives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInReceivableResearchIncentives" scale="3" id="Tc_CJ2MPvRbT0q1P1Da9syZ6Q_12_3">2,726</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInReceivableResearchIncentives" scale="3" id="Tc_A6gTDeoTOEONjXStpq6TSw_12_6">1,958</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInReceivableResearchIncentives" scale="3" id="Tc_e5lkyueL8EelGtyq3gRsvA_12_9">295</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" sign="-" scale="3" id="Tc_g0E5gtuWr0Occ90YgyTyEA_13_3">1,735</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" sign="-" scale="3" id="Tc_XpK0kDZ0HEe5XKg-4GXLcQ_13_6">2,007</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc_AuyGimrwSU6uDZKUnLpW9Q_13_9">7,091</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_765aLQU5DEWq-M-mqWhZdg_14_3">304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_Xtz5JdP1wUy4MlkwjBkUJQ_14_6">424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_R-6Mck_th0Ws2NERZCRUQA_14_9">416</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_m-4CF5_Fc0utpXkPwY8b5Q_15_3">6,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_OEowA4QUdkWX8xidfBHEFA_15_6">1,999</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_axngcP9O8ECkK0ZFkheYYw_15_9">858</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Deferred revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_e7a18pmaKk6w1Vp41oxUEA_16_3">8,258</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_mDVUd0diokerCUFFvPnlFA_16_6">35,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_cj6yEeHO6E2XSNI8fgpGaw_16_9">1,422</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_cC4zXJ-lpEqH0MgUgU0r4A_17_3">1,622</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_47aJrLZSnECVGBgJKuRXRw_17_6">1,584</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_x3nsY5PfrEupk8hedlUccQ_17_9">1,588</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" scale="3" id="Tc_4KEWwg2nmECsA9MitQY7FQ_18_3">490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" scale="3" id="Tc_ccYHBLmCrUCVJ3N8QrGu-Q_18_6">2,510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" scale="3" id="Tc_5B9suO8KqkOnyOkNvm4e1g_18_9">4,776</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_8d9KDgEkKEGGqSPRn6onEg_19_3">2,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_RYcpfuUaHEqAnXuRWnNTnA_19_6">1,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_qEMdPH73t0C7kjLvwI2pxA_19_9">416</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_ZktwEobvb0WKmH4JYjWCqQ_20_3">57,524</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_l5j4gRDu60WafIY5AwyCmQ_20_6">19,997</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_VgzULa4zfEauZFU1bEUSYQ_20_9">66,016</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_OXXXkXw01Um5Mi1MmnY1qQ_23_3">4,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_xoZ4BZzXikWreyFK0Qm8IA_23_6">5,017</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_9szRd1r9CUGB4VVQuR_uzg_23_9">12,581</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_DnMgweq7Xkiub_PcPd08jQ_25_3">4,159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_2ZxLgIx2CUSW8Dl3qt6ajQ_25_6">5,017</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_cgpLiPQ21UaXCJuDDpah0A_25_9">12,581</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Payments related to finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_UcCjc56IZUyr1yP4tnsnog_28_6">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_dvo147Ls70aPSR8Lq14kSA_28_9">438</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of convertible preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="Tc_CfpCWR_QSkqLVTAt6nNyzw_29_3">18,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="Tc_l87TKpctrEqi1nTgVuJw4A_29_6">29,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_xFfrDvy6yU2o0rW9dexUQw_30_3">49,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_ZdXg3Wvrj0uemZej7tKwPA_30_6">45,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_hWReKAa99kyWnqfUoXVdxg_30_9">203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Payments for deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="3" id="Tc_tdp2Xup-rEC_1Di1ys2p1Q_31_3">149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="3" id="Tc_kBUQZK3KvUK7zTywlbfE5w_31_6">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Repayments of borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_pOeFSdL36kapp47YAwZjKw_32_3">1,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_nNPRrKlygUuFJ7Fw56Doxw_32_6">2,825</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_INOmb49Ao0aCDP-oLeETuw_34_3">65,670</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_GhlzAUUSMU-wGGeJhi6L6w_34_6">72,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_gV8vVGMQjE6RyDAow7KH9g_34_9">235</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net increase (decrease) in cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_-0c-PlREkESjujNF0OK_Zw_36_3">3,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_wweVdrb3jEKlamV7PhCM0g_36_6">47,257</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_Y0aJpm-y-U6ko9bPh5p4Iw_36_9">78,832</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Q2FQvlFY20WV2Q7YOks-Dw_38_3">113,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gU97CZ91skeklvjMZDcskQ_38_6">66,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2020_PSUqRWmVfkCw7OQN6sRoGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_LgBhbmW0SEOs_-elW4O6IQ_38_9">143,177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_zgCosuqVb06DQKrSMyIo5w_39_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_9KwkwSEcgUGeaaW-Hhbw9Q_39_6">725</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Q2NLjDbl10ey4MeoeYfadQ_39_9">2,567</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Tre6XGb4U0CPp2mc0asChg_40_3">117,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_oZUdVAL5ZkG51480xy-Kvw_40_6">113,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_JwRvmpy7yk2JBm3IHd9nkg_40_9">66,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_3UJiTkbctUi_3y6ZAK5N3A_43_3">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_4HJsoIcS9kaNYLfORfxXHg_43_6">32</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_4ql3tslo0kmJO7od4I-qAQ_43_9">48</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_awqZpsTxr0mDpn8kg6UcMg_44_3">403</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_cVcTPiitb0-8Vu7l7Mxwww_44_6">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_wyAZ2nL6XE6MI8nN2uigEw_44_9">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of non-cash financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment additions in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_IO_ez6knZU2_hkr7r30T_w_47_3">34</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_nymgSQ4RCEC_lNJWsznhoA_47_6">56</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_8IcY1O_t_U6wSHzDWBJCFA_47_9">742</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Lease assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc__gZLLBN23kqqA5rKa-e5NA_48_3">2,874</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_avEMQ-5OBEGl_wZVCI--qw_48_6">225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_WhGqOvrCgEWMOVfX1z4xcg_48_9">2,727</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Lease assets derecognized upon lease cancellation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="hook:LeaseAssetsDerecognizedUponLeaseCancellation" scale="3" id="Tc_qik5bQL83k-RmuC88QwKvA_49_9">1,061</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS </p></div><div style="clear:both;max-width:100%;position:relative;"><a id="a1Natureofthebusinessandorganization_284"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:NatureOfOperations" id="Tb_uHfLEoOoPk6CBdL3XO0Zyw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;Nature of the business and organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HOOKIPA Pharma&#160;Inc. (&#8220;HOOKIPA&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body&#8217;s immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the name of Hookipa Biotech,&#160;Inc. under the laws of the State of Delaware in February&#160;2017 as a fully-owned subsidiary of Hookipa Biotech AG. In June&#160;2018, the Company changed its name from Hookipa Biotech,&#160;Inc. to HOOKIPA Pharma&#160;Inc. and in order to effectuate the change of the jurisdiction of incorporation, the Company acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH. HOOKIPA is headquartered in New York, with European research and preclinical development operations headquartered in Vienna, Austria. In April&#160;2019, the Company closed its initial public offering (&#8220;IPO&#8221;) and its common stock started trading on the Nasdaq Global Select Market under the ticker symbol &#8220;HOOK&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities and may not ultimately lead to a marketing approval and commercialization of a product. Even if the Company&#8217;s drug development efforts are successful, it is uncertain if and when the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_zUxLtDPaKUGDlNlpoDWYiw" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;Summary of significant accounting policies</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_K-iM1PahdUuot_zG6JtbcA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:GoingConcernPolicyPolicyTextBlock" id="Tb_24i2poVYSEe3sQxnA2S8tA" continuedAt="Tb_24i2poVYSEe3sQxnA2S8tA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company&#8217;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2023, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_QsvcaFqJUEeNYgyeoqoiGA">81.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_ja2R6ir1YEmfi2q0b1IooQ">64.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_nWoCfJjLh06sM32VsWhgrg">75.7</ix:nonFraction>&#160;million for the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively. As of December&#160;31,&#160;2023, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_tMYPLLZQZEik8ZXXNcb_IQ">369.3</ix:nonFraction>&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;22,&#160;2024, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company will seek additional funding in order to reach its development and commercialization objectives. The Company may seek funds through further equity financings, debt financings, collaborations, strategic alliances and </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont1" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont2"><ix:continuation id="Tb_24i2poVYSEe3sQxnA2S8tA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:UseOfEstimates" id="Tb_k-vjCcVw4Ua5V2gG8YFxpQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards, the valuation of current and non-current loans payable and the impairment of long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_Hdbcl-psr0SOG-_ziBpPDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign currency and currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency for the Company is the United States dollar and the functional currency for the Company's wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_5px0XzcdHkSdZWdFmipnMg" continuedAt="Tb_5px0XzcdHkSdZWdFmipnMg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 the net proceeds from the Company&#8217;s offerings have been deposited in interest-bearing bank accounts with two of the largest investment grade U.S. financial institutions and have been partially invested in money market funds. The money market funds, held in U.S. dollars, are primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, the Company&#8217;s cash and </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont2" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont3"><ix:continuation id="Tb_5px0XzcdHkSdZWdFmipnMg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">cash equivalents included smaller amounts of cash balances held in accounts with regional European banks at the Company&#8217;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively, Gilead Sciences, Inc. (&#8220;Gilead&#8221;) and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together &#8220;Roche&#8221;) accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021 Gilead and Roche accounted for the majority of the Company&#8217;s revenues. Other customers accounted for less than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_ko-ixCQC9UST2ygDxcw3xQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022 cash equivalents consisted of money market funds and short-term deposits.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:DeferredOfferingCostsPolicyPolicyTextBlock" id="Tb_wrmaUWtz9ESnu1c4AlwEjg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred offering costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_EMcRpuTekUebnVbWb4xURA" continuedAt="Tb_EMcRpuTekUebnVbWb4xURA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont3" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont4"><ix:continuation id="Tb_EMcRpuTekUebnVbWb4xURA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;5).</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_DA_TpH1MwUCBxnWPpw77Vw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="Tb_gJaePAoZikamlGMNYZCkQQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">shorter of useful life or term of lease</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Kkn9Mty5DUurhtItxm046g" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_ljmwRFk7uUy-7Ha8khHDaA">2</ix:nonNumeric> - <ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_W1jTBgF7KU6w3PAGk_NZLA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_wGRfmUGNKUKCsuqfVPXVhg">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_X3TmsbLhFku7xpVyRcYkrQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_jINFXzY_Dkya9Bv6dViwsg">2</ix:nonNumeric> - <ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_oSbIwYv_yE-SfbOG9eEVMQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_H4A-ee7zIEOWUOo6F9h7JQ">10 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Y740NWFhXUaA_KiLwpYS-Q" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_k98d4ForMkiUF-AhPsrglw">2</ix:nonNumeric> - <ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_fTi5jMBdM0qbHxQohSMwDw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_lx4EAyvipUCgAOz6SP6G8A">4 years</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_U0N1iec4B0m9UnTH88bSVw" continuedAt="Tb_U0N1iec4B0m9UnTH88bSVw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#8220;ROU&#8221;) assets and lease liabilities in the consolidated balance sheets. For leases with an initial term of 12 months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#8217;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#8220;ASC&#8221;)&#160;360.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont4" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont5"><ix:continuation id="Tb_U0N1iec4B0m9UnTH88bSVw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="Tb_UxaEGXYxXkenJZcLyn3cwA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Capitalized Software Development Cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="Narr_w7lQTu68vE-easOWEWnUsA"><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="Narr_DdbPOR9mY0qHUd7ZT1UsBA">0.1</ix:nonFraction></ix:nonFraction>&#160;million associated with the Company's cloud computing arrangements has been recognized during each of the fiscal years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 (see Note&#160;6). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="Tb_m0Am1ThASUqfIV_MdrnsCw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value (see Note 4. and Note 6.).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_irR8dE7k9k-uAAv1HMsL-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company's resources. The majority of the Company's tangible assets are held in Austria.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_RfIRCYRSc02nmX3FPjF0vw" continuedAt="Tb_RfIRCYRSc02nmX3FPjF0vw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition from contracts with customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized revenue from collaboration and license agreements with Gilead and Roche. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the collaboration and license agreement with Gilead (as amended and restated, the &#8220;Gilead Collaboration Agreement&#8221;), the parties agreed to collaborate with respect to <ix:nonFraction unitRef="Unit_Standard_Program_OVVzQkKn40SXnlnbXe7UtA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="INF" format="ixt-sec:numwordsen" name="hook:CollaborativeArrangementNumberOfPreclinicalResearchPrograms" scale="0" id="Narr_Hd55lHAEJUuDdusP_eWLAQ">two</ix:nonFraction> preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#8220;HBV&#8221;) and the human immunodeficiency virus (&#8220;HIV&#8221;). In February&#160;2022, the parties signed an amended and restated collaboration agreement (the &#8220;Restated Gilead Collaboration Agreement&#8221;), which revised the terms only for the HIV program, whereby the Company took on development responsibilities for the HIV program candidate through a Phase&#160;1b clinical trial. The Company&#8217;s performance obligations under the terms of the original agreement include <ix:nonFraction unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="INF" format="ixt-sec:numwordsen" name="hook:NumberOfCombinedPerformanceObligationForEachResearchProgram" scale="0" id="Narr_kCyOmayJ8E64ob81RrFfWA">one</ix:nonFraction> combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The terms of the Restated Gilead Collaboration Agreement added an additional performance obligation to perform research and development work for the HIV program. The licenses do not </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont5" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont6"><ix:continuation id="Tb_RfIRCYRSc02nmX3FPjF0vw_cont1" continuedAt="Tb_RfIRCYRSc02nmX3FPjF0vw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under the Restated Gilead Collaboration Agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the research collaboration and license agreement with Roche (the &#8220;Roche Collaboration Agreement&#8221;), the Company has agreed to conduct research and early clinical development through Phase&#160;1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. The Roche Collaboration Agreement also includes an obligation of the Company to deliver a specified package of preclinical data and results with respect to a second program, targeting undisclosed cancer antigens (collectively &#8220;UCAs&#8221;) and an option for Roche to license the UCA program. The Company&#8217;s performance obligations under the terms of the Roche Collaboration Agreement include <ix:nonFraction unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="INF" format="ixt-sec:numwordsen" name="hook:NumberOfCombinedPerformanceObligation" scale="0" id="Narr_z07lUc0MzUihimEoDpCReQ">one</ix:nonFraction> combined performance obligation for the transfer of intellectual property rights (licenses) and providing research and development services for the HB-700 program, and a second, separate performance obligation to perform research and development services with respect to the UCA program. The UCA Option provides a right to license the program at the standalone selling price and therefore does not constitute a separate performance obligation. Payments to the Company under the Roche Collaboration Agreement include a non-refundable up-front payment, payments based upon the achievement of defined milestones, an additional payment if the option for the UCA program is exercised and royalties on product sales. In January 2024, Roche provided written notice of the termination of the collaboration and licensing agreement to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC&#160;606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC&#160;606, the Company applies significant judgement to evaluate whether the promises under the collaboration and licensing arrangements, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, the timing of revenue recognition, whether the UCA Option constitutes a material right, and the determination of when milestone payments are probable of being received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Upfront payment and program initiation fee</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-refundable upfront-payment received by the Company upon signing of the Gilead Collaboration Agreement, and milestone payments that were linked to future performance obligations, were initially recorded as deferred revenue and allocated between the <ix:nonFraction unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="INF" format="ixt-sec:numwordsen" name="hook:NumberOfResearchProgramPerformanceObligations" scale="0" id="Narr_aXPo9u7_lEOu979MgBUncg">two</ix:nonFraction> research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The non-refundable program initiation payment received from Gilead upon signing of the Restated Collaboration Agreement was also initially recorded as deferred revenue and is recognized on a percent of completion basis using total estimated research and development costs (input method) for the performance of the obligations. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer, due to the immediate benefit that it adds to the value of </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont6" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont7"><ix:continuation id="Tb_RfIRCYRSc02nmX3FPjF0vw_cont2" continuedAt="Tb_RfIRCYRSc02nmX3FPjF0vw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the customer&#8217;s rights on the program, the short time intervals in which development results are shared and the nature of the work being performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-refundable upfront-payment received by the Company upon signing of the Roche Collaboration Agreement, was initially recorded as deferred revenue and allocated between the HB-700 program and the UCA program. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development costs (input method) for each of the obligations during the initial term of the contract. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reimbursement for services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Collaboration Agreement and the Roche Collaboration Agreement, the Company incurs employee expenses as well as external costs for research, manufacturing and clinical trial activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangements, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues as progress is achieved. Unpaid reimbursement amounts are presented as Accounts Receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development milestones</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gilead Collaboration Agreement and the Roche Collaboration Agreement include contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific uncertainties and the required commitment from Gilead and Roche. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to including the variable consideration associated with these payments within the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales-based milestones and royalty payments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gilead Collaboration Agreement and the Roche Collaboration Agreement also include certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost to fulfill contracts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont7" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont8"><ix:continuation id="Tb_RfIRCYRSc02nmX3FPjF0vw_cont3"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_0LfErrppRESk9V2f8iaS8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" id="Tb_lV_ieuLyLEaWeP_ue5Ua6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and manufacturing contract costs and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" id="Tb_aEgBYL24_k-B5nr4nIMtqg" continuedAt="Tb_aEgBYL24_k-B5nr4nIMtqg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government grant agreements and research incentives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes funding from grants and research incentives received from Austrian government agencies as well as from New York State and New York City government agencies in the United States as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont8" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont9"><ix:continuation id="Tb_aEgBYL24_k-B5nr4nIMtqg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_1X53pN3ZBE6QvKzfy5O0hA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company's common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient's payroll costs are classified or in which the recipient's service payments are classified.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_2oXwA53DU0yWdsPh4PWZjg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss and foreign currency translation adjustments. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 comprehensive loss included $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="6" id="Narr_I2-HeT-WVk6KpgL-a7nUcA">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="6" id="Narr_vYSDTuR_pkONNpUPF8AiuA">2.4</ix:nonFraction>&#160;million, respectively, of foreign currency translation loss adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="Narr_2BadKWuDlECPJu0xeeIxXg">1.3</ix:nonFraction>&#160;million of foreign currency translation gain adjustments.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:EarningsPerSharePolicyPolicyTextBlock" id="Tb_k8gig923ukqfwpLt2N9rHw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2023, 2022 and 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_DvsGYyvFakaLlO7Ff7esdw" continuedAt="Tb_DvsGYyvFakaLlO7Ff7esdw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont9" continuedAt="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont10"><ix:continuation id="Tb_DvsGYyvFakaLlO7Ff7esdw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2017 Tax Cuts and Jobs Act subjects a US shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in the future years or provide for tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize tax expense related to GILTI in the year the tax is incurred.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_K8G3SBroOEqCyQN5inW0JA" continuedAt="Tb_K8G3SBroOEqCyQN5inW0JA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Adopted as of current period</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718) to amend various SEC paragraphs in the Accounting Standards Codification to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. Staff Accounting Bulletin No. 120 provides guidance to companies issuing share-based awards shortly before announcing material, nonpublic information to consider such material nonpublic information to adjust observable market prices if the release of material nonpublic information is expected to affect the share price. The ASU does not provide any new guidance so there is no transition or effective date associated with it and therefore, the Company adopted the ASU with no impact to its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#8220;own stock&#8221; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company adopted this standard with no impact to its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zUxLtDPaKUGDlNlpoDWYiw_cont10"><ix:continuation id="Tb_K8G3SBroOEqCyQN5inW0JA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_M95CQoxRb02QT_2bnDKkUA" continuedAt="Tb_M95CQoxRb02QT_2bnDKkUA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Collaboration and Licensing Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gilead Collaboration and License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2018, the Company entered into the Gilead Collaboration Agreement whereby the Company and Gilead agreed to collaborate with respect to <ix:nonFraction unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA" decimals="INF" format="ixt-sec:numwordsen" name="hook:NumberOfPreclinicalResearchPrograms" scale="0" id="Narr_-uwJqYvwn0qiRAIC5328Qg">two</ix:nonFraction> preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of HBV and HIV. In February&#160;2022, the Company signed the Amended and Restated Collaboration Agreement, which altered key aspects of the collaboration pertaining to the HIV therapeutic. Most importantly, the Amended and Restated Collaboration Agreement allocated additional research and development responsibility to the Company with respect to the Company&#8217;s HIV candidate and provided for additional funding by Gilead of such research and development activities as well as increased later stage development and commercial milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Collaboration Agreement, the Company granted Gilead an exclusive, royalty-bearing license to the Company&#8217;s technology platforms. Upon entering into the agreement in June&#160;2018, the Company received a non-refundable $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromNonRefundableUpFrontPayment" scale="6" id="Narr_x9Gk1mcGhk2JxDjkb8dWdQ">10.0</ix:nonFraction>&#160;million upfront payment from Gilead and upon signing of the Restated Gilead Collaboration Agreement in February&#160;2022, the Company received a program initiation fee of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeAgreementProgramInitiationFees" scale="6" id="Narr_jIA8fdMLT0W0zdibpGqD3w">15.0</ix:nonFraction>&#160;million. Gilead is also obligated to make additional payments to the Company upon the achievement of pre-clinical, development and commercial milestones. The development milestones amount to $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HbvProgramMember_3dT06FX4VkCwkIjTV8mikA" decimals="-6" format="ixt:numdotdecimal" name="hook:TotalMilestoneAmount" scale="6" id="Narr_JQdT3tdhF0S1h3GmtxJ1tw">140.0</ix:nonFraction>&#160;million for the HBV program, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_eFFXVBkbrEeySJMxE-8wLQ" decimals="-5" format="ixt:numdotdecimal" name="hook:TotalMilestoneAmount" scale="6" id="Narr_Kcv6cSDjTkipW-47pVuzhw">172.5</ix:nonFraction>&#160;million for the HIV program, inclusive of a $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_DRzR59S0e0i1yiiJ_sbKPw" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborationArrangementProgramCompletionFeeOnOptionExercise" scale="6" id="Narr_v91eOO82Oky6o1RN05p4yA">10.0</ix:nonFraction>&#160;million program completion fee, payable upon Gilead&#8217;s exercise of the option to pursue further development activities post Phase&#160;1b. The commercial milestones amount to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HbvProgramMember_u76tVQD6oU2TjpnsvGjXJw" decimals="-5" format="ixt:numdotdecimal" name="hook:TotalMilestoneAmount" scale="6" id="Narr__HhAs6P_TEaEHweIypxSng">50.0</ix:nonFraction>&#160;million for the HBV program, and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_eTvVFL_Gb0ihVkFmAe5Ybg" decimals="-5" format="ixt:numdotdecimal" name="hook:TotalMilestoneAmount" scale="6" id="Narr_7X4jgN-j3EehjXHrFISW5w">65.0</ix:nonFraction>&#160;million for the HIV program. Additionally, Gilead is obligated to pay royalties on net sales for each program. Payments from Gilead generally have a <ix:nonNumeric contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA" format="ixt-sec:durday" name="hook:CollaborativeArrangementTermOfRoyaltyPayment" id="Narr_l_899bm0IEmJnt3fZDdeEQ">60</ix:nonNumeric>&#160;day payment term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromNonRefundableUpFrontPayment" scale="6" id="Narr_CZTHnZI9nU-jnXaDlZ9guw">10.0</ix:nonFraction>&#160;million upfront payment, the $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeAgreementProgramInitiationFees" scale="6" id="Narr_USH4f4JWKUu2uEfYzf7cAQ">15.0</ix:nonFraction>&#160;million initiation fee and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromMilestonePayment" scale="6" id="Narr_MpxCLfE4zEel3wAwvYcc8w">8.0</ix:nonFraction>&#160;million in milestone payments were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of December&#160;31,&#160;2023, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_qgezqEplwESt0S26-K-s-A">7.5</ix:nonFraction>&#160;million of such payments were still recorded as a liability in deferred revenues, current and non-current. As of December&#160;31,&#160;2022, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4qOs21ojTUO-rUJpz1kUcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr_EtFKa7nobkOhlH6Q7GkoJg">14.3</ix:nonFraction>&#160;million of upfront and milestone payments were included as a liability in deferred revenues, current and non-current. Approximately <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg" decimals="3" format="ixt:numdotdecimal" name="hook:DeferredRevenuePercentageOfRevenueRecognizedInYearOne" scale="-2" id="Narr_bUFmZFzgOke_91zwJTE8_g">55.2</ix:nonFraction>% of deferred revenue is expected to be recognized as revenue in 2024, <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg" decimals="3" format="ixt:numdotdecimal" name="hook:DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" scale="-2" id="Narr_wBLEB78Z90GSGsoY7rTxtQ">36.8</ix:nonFraction>% in 2025 and the remaining <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg" decimals="3" format="ixt:numdotdecimal" name="hook:DeferredRevenuePercentageOfRevenueRecognizedInYearThree" scale="-2" id="Narr_arO3HLkjN0eL0ldy8r-6zw">8.0</ix:nonFraction>% in 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2023, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_zfz8LxQPIku68ssP9_JeQA" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborationAgreementMilestonePaymentsRevenueRecognized" scale="6" id="Narr_3SoktZlhwEOaFEO0p0384Q">7.1</ix:nonFraction>&#160;million of the milestone and initiation payments that were originally recorded as deferred revenue. Furthermore, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_zfz8LxQPIku68ssP9_JeQA" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" scale="6" id="Narr_claJokb5DkW3qm5_mze0Qg">1.4</ix:nonFraction>&#160;million revenue from cost reimbursements for research and development services. In the year ended December&#160;31,&#160;2022, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_WGiMi9INf02gQAVOw20hGg" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborationAgreementMilestonePaymentsRevenueRecognized" scale="6" id="Narr_CqjMzI4sBUe54qb6w71q3w">3.7</ix:nonFraction>&#160;million of the upfront and milestone payments that were originally recorded as deferred revenue, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_WGiMi9INf02gQAVOw20hGg" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" scale="6" id="Narr_WXn3eAFWPUW5v-OR6tIRwQ">5.2</ix:nonFraction>&#160;million revenue from cost reimbursements for research and development services and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_WGiMi9INf02gQAVOw20hGg" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromMilestonePayments" scale="6" id="Narr_lBiXa8xdM0egJjVBeIl-Kw">5.0</ix:nonFraction>&#160;million revenue from a milestone achieved in December&#160;2022. In the year ended December&#160;31,&#160;2021, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sSCjg8UmtUy-0Ck5qV73Gg" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborationAgreementMilestonePaymentsRevenueRecognized" scale="6" id="Narr_y4w8HFvGu0KMKWeneYwSfQ">2.1</ix:nonFraction>&#160;million of the upfront and milestone payments that were originally recorded as deferred revenue and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sSCjg8UmtUy-0Ck5qV73Gg" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" scale="6" id="Narr_PDI9KVwDrU2UGSaA0QcgVg">16.3</ix:nonFraction>&#160;million revenue from cost reimbursements for research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_M95CQoxRb02QT_2bnDKkUA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the triggering payment is recognized. As of December&#160;31,&#160;2023 and 2022, the contract asset relating to the sublicense payment was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment" scale="6" id="Narr_xrD11VVi8kyKBE5HH4GkrQ">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4qOs21ojTUO-rUJpz1kUcg" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment" scale="6" id="Narr_M_pZ70LEi0yeVXWM8OTZ2w">0.2</ix:nonFraction>&#160;million, respectively, and there was <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4qOs21ojTUO-rUJpz1kUcg" decimals="-5" format="ixt-sec:numwordsen" name="hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" scale="6" id="Narr_HjPqrjRqX0-RdRdzHcvpdg"><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg" decimals="-5" format="ixt-sec:numwordsen" name="hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" scale="6" id="Narr_ima8rb9idEWGFOGpEpNLvQ">no</ix:nonFraction></ix:nonFraction> liability relating to sublicense payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Roche Collaboration and License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2022, the Company entered into the Roche Collaboration Agreement whereby the Company and Roche agreed to collaborate with respect to the development of novel arenaviral immunotherapies for KRAS-mutated cancers and, potentially, a second, novel arenaviral immunotherapeutic program targeting specific undisclosed cancer antigens. In January&#160;2024, Roche provided written notice of the termination of the collaboration and licensing agreement to the Company (see Note 18. &#8220;Subsequent Events&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the terminated Roche Collaboration Agreement, the Company granted Roche an exclusive, royalty-bearing license to the Company&#8217;s technology platforms for KRAS-mutated cancers, and an option right to exclusively license a second, novel arenaviral immunotherapeutic program targeting undisclosed cancer antigens. Pursuant to the terms of the Collaboration Agreement, following the termination notice, the Collaboration Agreement will end on April&#160;25,&#160;2024. The Company remains eligible for a final milestone payment associated with an IND submission. Effective April&#160;25,&#160;2024, the Company will regain full control of the associated intellectual property portfolio and will have full collaboration and licensing rights for the KRAS program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon signing the Roche Collaboration Agreement in October&#160;2022, the Company received a non-refundable upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_r-zd0dtsfkWw5mLU7UMv4g" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromNonRefundableUpFrontPayment" scale="6" id="Narr_74i_nDwl1022TE3mE0dkDg">25.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This upfront payment, and a $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_X56qauEA7k-9t9AFLtndIQ" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromMilestonePayment" scale="6" id="Narr_8MG7LB38eUaQEke6CgJWpw">10.0</ix:nonFraction>&#160;million milestone payment received in the twelve months ended December&#160;31,&#160;2023 were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of December&#160;31,&#160;2023, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_8zSgY1ZsqkikJgqlf-tCqA">26.8</ix:nonFraction>&#160;million of such payments were still recorded as a liability in deferred revenues, current and non-current. As of December&#160;31,&#160;2022, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6fTsmB6TxUSozaWhvhJ6_g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr__-eVjCempkOWCbjw3wvSMw">27.0</ix:nonFraction>&#160;million of the upfront payment was included as a liability in deferred revenues, current and non-current. The deferred revenues related to the $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_r-zd0dtsfkWw5mLU7UMv4g" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromNonRefundableUpFrontPayment" scale="6" id="Narr_yN-wAESy4US062m0SrcDQQ">25.0</ix:nonFraction>&#160;million upfront payment and the $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_X56qauEA7k-9t9AFLtndIQ" decimals="-5" format="ixt:numdotdecimal" name="hook:ProceedsFromMilestonePayment" scale="6" id="Narr_O7Xq9WI1pkKtCridMCgREw">10.0</ix:nonFraction>&#160;million milestone payment are subject to foreign currency exchange rate fluctuations in future accounting periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2023, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_X56qauEA7k-9t9AFLtndIQ" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborationAgreementMilestonePaymentsRevenueRecognized" scale="6" id="Narr_1EYA5r4ohkmzjXI2e4AX-A">11.1</ix:nonFraction>&#160;million of the upfront and milestone payments that were originally recorded as deferred revenue. Furthermore, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" scale="6" id="Narr_slUGazWMWU23YAK2rRo-1w">0.5</ix:nonFraction>&#160;million revenue from cost reimbursements for activities related to the preparation of a first in human trial. In the year ended December&#160;31,&#160;2022, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_IuERzRWMYUO5kK8uAkmuTQ" decimals="-5" format="ixt:numdotdecimal" name="hook:RevenueRecognizedUpfrontPayment" scale="6" id="Narr_-xVGNcdmuU6cO8pDtRGHTQ">0.3</ix:nonFraction>&#160;million of the upfront payment that was originally recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from the triggering payment is recognized. As of December&#160;31,&#160;2023, the contract asset relating to the sublicense payment was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment" scale="6" id="Narr_fC3l7Y5gsE2lb8nRVWYQfA">2.0</ix:nonFraction>&#160;million and there was <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww" decimals="-5" format="ixt-sec:numwordsen" name="hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" scale="6" id="Narr_NDAQ3BHcukmU6Qh_bdyHww">no</ix:nonFraction> liability relating to sublicense payment. As of December&#160;31,&#160;2022 the contract asset and the liability relating to the sublicense payment was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6fTsmB6TxUSozaWhvhJ6_g" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment" scale="6" id="Narr_JPrlqvSc3kCKeInfUZ-pGw">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6fTsmB6TxUSozaWhvhJ6_g" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" scale="6" id="Narr_1N6qNl-XjE-5DE3WD9_oSg">1.2</ix:nonFraction>&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="Tb_fro2EhVtCUaJVouFtxzcGg" continuedAt="Tb_fro2EhVtCUaJVouFtxzcGg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;Impairment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January&#160;29,&#160;2024, the Company announced its decision to prioritize the clinical development of its HB-200 program for the treatment of HPV16+ head and neck cancers and its two Gilead-partnered infectious disease programs and to pause development activities related to HB-300 and most of its preclinical research activities (see Note&#160;18. &#8220;Subsequent Events&#8221;). In connection with this strategic refocus, the Company&#8217;s board of directors approved a Restructuring Plan to rebalance the Company&#8217;s cost structure, which includes a reduction of the Company&#8217;s workforce </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_y197byoxY0elMATn5O95og_1_2"></a><a id="Tc_A9F_tLzrWEixA1RwOM-6tw_1_5"></a><a id="Tc_Ca1CWSALtEioz_JhS01M0w_2_2"></a><a id="Tc_Fi6ZQiBz40KLFBHSNcHPHw_2_5"></a><a id="Tc_1snnbvzwEkaYhHImyVPm_w_3_0"></a><a id="Tc__MhISnsYCU63nbYOcXSzTw_4_0"></a><a id="Tc_6k10dSPJcUSKVMcDHia0gA_4_2"></a><a id="Tc__wirIS0A_UG3MkmtwPC44Q_4_5"></a><a id="Tc_5UPrY5YBr0SlLMidDyRAeQ_4_6"></a><a id="Tc_Fyghhx82qkebSlXNnJs1KQ_5_0"></a><a id="Tc_Bc4W8n4qzkW5qDd5Kg1M0w_5_2"></a><a id="Tc_K_E72MHTA0qCWvEs5zRnWQ_5_5"></a><a id="Tc_XQL4XnOk1ES4boCBxxv9lg_5_6"></a><ix:continuation id="Tb_fro2EhVtCUaJVouFtxzcGg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">by approximately <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_v9gAMp1ZXEGep6gyO5uKmA">30</ix:nonFraction>% and the discontinuation of the Company&#8217;s GMP manufacturing facility project. The Company expects the Restructuring Plan to be implemented and substantially completed by the end of the first quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the strategic considerations preceding the adoption of the Restructuring Plan, the Company assessed the recoverability of the long-lived assets relating to the GMP manufacturing project at December 31, 2023, and determined that the undiscounted cash flows of the asset group were below the carrying values, indicating impairment. The assets were written down to their estimated fair value, which was determined based on the cost approach. The resulting impairment charges were included within Impairment expense in the Consolidated Statements of Operations and Comprehensive Loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the effect of non-cash impairment charges (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="Tb_5Khy4-yiIkqW_6ht4b0AaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-cash impairment charges</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Asset write-offs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="Tc_JzvopPjVUEWPlV4xAvmKQA_4_3">12,766</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total non-cash charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="3" id="Tc_n8LXk09t6kGMbx2UnL_bCQ_5_3">12,766</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0a82675e_bbfd_430e_a516_6e393c4f9708"></a><a id="Tc_Z6lPhFtPr06tHkBTEcglZQ_1_2"></a><a id="Tc_Sj_0pIr-l0eG3eNtwz-W9A_2_2"></a><a id="Tc_fIQpIiuA1UGMUTAUmuGWaQ_2_5"></a><a id="Tc_K6myvp0u1Ey-tha3Wal7pQ_2_8"></a><a id="Tc_chTlAEZJR0i60epvO_K2vQ_2_11"></a><a id="Tc_7fxDry6u00-WHb3zFhw2mQ_3_0"></a><a id="Tc_dI4PKiSfPEG-PT6f5_xX7A_4_0"></a><a id="Tc_N959oGyaO0qEk-9EHF5z5g_4_2"></a><a id="Tc_OPhVjsXwJk-M7j29JnJy8Q_4_5"></a><a id="Tc_hDDdAAC9nEekVt0KbfGYxw_4_6"></a><a id="Tc__1t-y7jcW0-DPxCZs-am4Q_4_8"></a><a id="Tc_LzzjQfciuUuNoFJ0MHNt0g_4_9"></a><a id="Tc_Lh7YAt3ZvEiu8I9oVzTT0Q_4_11"></a><a id="Tc_jfllOqvDGU657fVD-eZipw_5_0"></a><a id="Tc_vbPlCWh4zUKj0b3FtGlwSQ_5_2"></a><a id="Tc_ET7FKeGLWEm0n2bGl43OGA_5_5"></a><a id="Tc_KjV17MvW7EyUyDapNVDa6Q_5_6"></a><a id="Tc_58zGz5U8u0yec8pr-3Y0uw_5_8"></a><a id="Tc_JGRSXVO6EEq9w_XkolLCjQ_5_9"></a><a id="Tc_VG48O_N0bUyvUTXUVBgrRw_5_11"></a><a id="_673bab4c_33f3_40ea_9ab0_de22b09266b2"></a><a id="Tc_YeCh4K9RdkKHBuXubgIO_A_1_2"></a><a id="Tc_svA6CoWnAEmYS6FKyGVV5w_2_2"></a><a id="Tc_hpkg7i8MhUiZ3w-pjLJdIw_2_5"></a><a id="Tc_SnzroV2mKUmvv2kaMxAyBw_2_8"></a><a id="Tc_YFj5tvrmCUC5ilOjD0Eu_w_2_11"></a><a id="Tc_DHB07c5_8UWd7w0zV3wbuA_3_0"></a><a id="Tc_BOU7ndObrEi7Sqq8kkVzFQ_4_0"></a><a id="Tc_MVvi71FmYkWWOIi5tUjxmQ_4_2"></a><a id="Tc_JeL0k-_B90awfU2OtNKXNA_4_5"></a><a id="Tc_3oUuFiK4202hQ3kLo4dc1w_4_6"></a><a id="Tc_uTFzWN9AZEWxdfl8ETICjQ_4_8"></a><a id="Tc_SpN8Vyqb00ugZCx_vd0_Uw_4_9"></a><a id="Tc_KCnFWt9un0-tgl4PwH-X_w_4_11"></a><a id="Tc_zdmw-eVVqEOwI06lacLP_A_5_0"></a><a id="Tc_2I0ke3YF6k-T-fTy9LYvIA_5_2"></a><a id="Tc_2H5eS6ehdUKbURTH2817rQ_5_5"></a><a id="Tc_qYKcOSnvuUmpU3OtlNVb_g_5_6"></a><a id="Tc_OBkoCAzCiUKwDdaDWuT4zg_5_8"></a><a id="Tc_TmduZmxAWU-7Vt0VhzWwkg_5_9"></a><a id="Tc_gAmqlAb1akiiw1LNwnqnoQ_5_11"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_RQfMzgR4FUS1v9yCSGWDbw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;Fair Value of Financial Assets</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Group_7Q1GzLyNo0mI2nh9_flyRQ" continuedAt="Group_7Q1GzLyNo0mI2nh9_flyRQ_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p></ix:nonNumeric><ix:continuation id="Group_7Q1GzLyNo0mI2nh9_flyRQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2023 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1LRqYYOuTkW9E0CdbjORBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_YWXNODZM7E6HpaclS8KWNw_4_3">91,084</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vp7OjZUKs0qrjBy07u3Rwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_AZf5pY4MT0GPkozsQvoGsQ_4_12">91,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_q3DFOTCJoUOMsPJyaBQ3Fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_JVOxXNF_R0-RWQZPyTGH3A_5_3">91,084</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AuBlzmENrUa8NdUXnGeaBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_m0ERaQcpukK8fRjHjQHfog_5_12">91,084</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2022 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kU5iAAu8lUOCuAzHNGZFtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_wH9T99E2sEGo_tQU77G9ug_4_3">85,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_t6cFMObpAkuRcFhZNL6fUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_TNXwL3mDpEOzI0CxuFr2DQ_4_12">85,491</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sjQ1_m16gUyGeWyA8dpSbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ApUsCY8x7UONaO_lcuFpVg_5_3">85,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_f7Evnw8lLU6TvXq4xZaF1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_tIPQMxFYMUiF1h8Ra08iOQ_5_12">85,491</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the </span><span style="-sec-ix-hidden:Hidden_Lpjoo-HNUkK1Q7dne6IAVQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">year</span></span><span style="font-weight:normal;"> ended </span><span style="-sec-ix-hidden:Hidden_9wPB5a7NckWc0o_lT7sjxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31,&#160;2023</span></span><span style="font-weight:normal;">, there were </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="3" id="Narr_T9VZEZRaI0SmaKTx9jVy0Q">no</ix:nonFraction></span><span style="font-weight:normal;"> transfers between Level&#160;1, Level&#160;2 and Level&#160;</span><span style="-sec-ix-hidden:Hidden_L0ges7xDOUOYjlazpNEvlw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span><span style="font-weight:normal;">.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_lIp7S4cK5Uaf34o-KlEKyw" continuedAt="Tb_lIp7S4cK5Uaf34o-KlEKyw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_324612f0_fbe2_4388_9704_940a5b976acb"></a><a id="Tc_l6xotpcsSUS4R87fmOEuBA_1_2"></a><a id="Tc_yV-H5VGJKEKWsJhXczFWZg_1_5"></a><a id="Tc_Iu7cKhPEm0O6QTu2pAPnQw_2_2"></a><a id="Tc_bQpuVyYkXkCxn9La_L0Ywg_2_5"></a><a id="Tc_pviQWnyKIkGYNt30A5v8aA_4_0"></a><a id="Tc_hdc27PrtN06OxxqhtVKT6w_4_2"></a><a id="Tc_RV4qoJir90OehMBbopyIaQ_4_5"></a><a id="Tc_sBs16s6bk02xi4fg_nys0A_5_0"></a><a id="Tc_TtAX4z3070uVw10tGcIotg_6_0"></a><a id="Tc_Y_e6xm-TT0ajjaq9oAq18g_7_0"></a><a id="Tc_rsWyXKQItUqUiA8ueT7ZAQ_8_0"></a><a id="Tc_aT-9Of7kIUySQ7lrWndhjQ_9_0"></a><a id="Tc_B0TolGfeN0OLQhrjxT5V1g_10_0"></a><a id="Tc_JYtM9u71p0icCGFMKramRQ_11_0"></a><a id="Tc_VneWUN0XlESmp5C3c28QHQ_12_0"></a><a id="Tc_w6ikrAfmzkKWIDHcxwxJ3g_12_2"></a><a id="Tc_xY_7pf-__EGWkRGkF7jnew_12_5"></a><ix:continuation id="Tb_lIp7S4cK5Uaf34o-KlEKyw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Property, plant and equipment, net</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_ZA2Q1VsgW0e5n-sTTFespg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_d9nAVl9o7USSeTumRsaPVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HZd0izqBr0Cth2IlXhsL9g_4_3">2,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_V0f2IgZ-pke_ekfxUL0PFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_elz07l1DBUSBlIKz2RYpsw_4_6">1,959</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_H9q5fvXIvUyymHn9HgMWCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_8dkufBQMEE2hW55wRgZFeg_5_3">3,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_2LsuutyUQE6wY7QxmZAn0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_l1ygIVOV2USp2kg3xXfVnA_5_6">3,164</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_eO8goNhRB0-aM5lXAIyMyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_isLCuklEdkKUhFae_BGf0Q_6_3">212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_pt9hTzP2p0aDdaGKrVFYZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_S0OP210EUkuCSqdRo5w_Cg_6_6">10,567</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_DTmiN0Wjdk2iaqY9dIsckQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_SEJKIY_pm02oblVTxyGc6A_7_3">8,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Dv-_4sRg6EC65tReOfjV-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_7fP_WPkAUE659pNGfi1z6g_7_6">7,403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_n75mKrZ5ykylerI6_Na9ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_B0pIsg77ykulp_tllOi_oA_8_3">654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_OVW8CCm-m0i5lry7fXD5tQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_T1dlgDlDZ0O0d35hGj1ujg_8_6">622</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_v9vy-6pd6UqP7xZfF6NTog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_zETHx5s6x0qlOgdyhujr8Q_9_3">2,652</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Pkdmu3XpuUGFFIIVvDmOsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_jvwgxSeuCUW4bxqVnxdAvA_9_6">2,034</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Id1DMPHkXEqLKBJtBKYikg_10_3">17,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_H4daVIxka0mS_0wLXTryHw_10_6">25,749</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_SHjwgR_nkkyNRTurEoZmKg_11_3">9,823</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_ahMJHLIXp0-fEPwec8814w_11_6">7,779</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_mIOsdf0R80O3YTyXqPl7XQ_12_3">7,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_TnERexT-5EmYf9e_RKIovA_12_6">17,970</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depreciation expense for the years ended December&#160;31,&#160;2023, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_KZ4Zv0G7MkaSdQg5fFigSQ">2.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_rY3KnqkWc02QMLidF5PGMQ">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_84j2cr7Y2EqE_eOS1TRrWQ">2.1</ix:nonFraction>&#160;million, respectively. Construction-in-progress as of December&#160;31,&#160;2022 mainly related to investments in connection with the Company&#8217;s GMP manufacturing facility project. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the strategic considerations preceding the adoption of the Restructuring Plan (see Note&#160;4. and Note&#160;18.) the Company determined that the estimated undiscounted future cash flows for its asset group related to the GMP manufacturing facility project were less than their carrying values. The Company therefore recognized an impairment loss of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="Narr_CVMWXLW-ekSNZPjM-_R6wg">12.8</ix:nonFraction>&#160;million related to the GMP manufacturing facility project for the year ended December&#160;31,&#160;2023, which reduced the carrying value of this asset group to <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-5" format="ixt-sec:numwordsen" name="hook:RestructuringPlanCarryingValueOfAsset" scale="6" id="Narr_CE84Va72HkWuBoA3RPOHGA">zero</ix:nonFraction>. Impairment charges are included within Impairment expense in the Consolidated Statements of Operations and Comprehensive Loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="Narr_ZdcQzm0EWUW2SoejgybL9w"><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="Narr_rgqhSyxRQEejzOO2kx4j3w">no</ix:nonFraction></ix:nonFraction> impairments in the years ended December&#160;31,&#160;2022 and 2021.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:ReceivableResearchIncentiveTextBlock" id="Tb_umcLLmQdg0OudASbCLpaSw" continuedAt="Tb_umcLLmQdg0OudASbCLpaSw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.&#160;Receivable research incentive<span style="font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company participates in a research incentive program provided by the Austrian government under which it is entitled to reimbursement of a percentage of qualifying research and development expenses and capital expenditures incurred in Austria. Submissions for reimbursement under the program are submitted annually. Incentive amounts are generally paid out during the calendar year that follows the year of the expenses but remain subject to subsequent examinations by the responsible authority. Reimbursements received in excess of the recognized receivable research incentive for a certain period are recorded within other long term liabilities for potential repayment until such time that an audit has taken place, upon expiration of the potential reclaim period, or when it is no longer probable that a reclaim will happen. The years 2018 to present remain open to examination by the authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the Company participated in the life sciences research and development program provided by the New York State government under which it was entitled to reimbursement of a percentage of qualifying research and development expenses in New York State up to $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_DNqYfPgFh0Ck9fuBQnQtWQ" decimals="-5" format="ixt:numdotdecimal" name="hook:ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" scale="6" id="Narr__IF9NI3Wi0SHcngQ7QQ8EQ">0.5</ix:nonFraction>&#160;million per year for the years 2019 to 2021. Incentive amounts are generally paid out six to nine months after amended tax returns including a certificate of tax credit issued by Empire State Development are filed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company also participates in the New York City biotechnology tax credit program, according to which certain expenses for business in the biotechnology field in New York City limited to $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_iLfkqbjLEkO8cY690Z1M_g" decimals="-4" format="ixt:numdotdecimal" name="hook:MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" scale="6" id="Narr_hFIHE_sx3UqukYZmj3AUnw">0.25</ix:nonFraction>&#160;million per year for three </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_umcLLmQdg0OudASbCLpaSw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">consecutive years from January&#160;1,&#160;2023 to December&#160;31,&#160;2025 are incentivized. The biotechnology tax credit can be refunded or applied against the next year's tax if it exceeds the current year's tax liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2023, the Company recognized receivables of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-5" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="6" id="Narr_6oI0i8fS4Eqy7GBxVnL6fg">18.8</ix:nonFraction>&#160;million from the research incentive programs, which are reported in research incentive receivables in the Company&#8217;s consolidated balance sheet. $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_AustrianResearchIncentiveProgramMember_Ocbk301LuEKBJ-hS6sdG-w" decimals="-5" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="6" id="Narr_IjbGePZxSEGb8Vs6soXqJQ">17.3</ix:nonFraction>&#160;million relate to the Austrian research incentive program, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_DNqYfPgFh0Ck9fuBQnQtWQ" decimals="-5" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="6" id="Narr_T8t2afoP0EipgrTpVs812w">1.4</ix:nonFraction>&#160;million relate to the New York State life sciences research and development program and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_0rn22fHyykOFZjGSZjx9-w" decimals="-5" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="6" id="Narr_Pfr8P31Zd0yjMh70KQaUqw">0.1</ix:nonFraction>&#160;million relate to the New York City biotechnology tax credit program. As of December&#160;31,&#160;2022, the receivables from the research incentive program were $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-5" format="ixt:numdotdecimal" name="hook:ReceivablesTaxResearchPremiumCurrent" scale="6" id="Narr_Ysy-1G7cAka55P2oyI8nbQ">15.5</ix:nonFraction>&#160;million and related to the Austrian research incentive program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December&#160;31,&#160;2023, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="hook:GrantIncomeIncentiveProgram" scale="6" id="Narr_2QoAHiEWSE-eX8rj9NJ_Jw">10.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="hook:GrantIncomeIncentiveProgram" scale="6" id="Narr_JU-e9SR930SsZlgNQW5sJA">7.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-5" format="ixt:numdotdecimal" name="hook:GrantIncomeIncentiveProgram" scale="6" id="Narr_yNwUkwaBHka94for7Le4gw">8.9</ix:nonFraction>&#160;million, respectively, of income related to the incentive programs within the Company&#8217;s consolidated statements of operations and comprehensive loss as part of the grant income. Income for the year ended December&#160;31,&#160;2023 included $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_AustrianResearchIncentiveProgramMember_b5PBJbDWP0aRQ3y6jpvjFQ" decimals="-5" format="ixt:numdotdecimal" name="hook:GrantIncomeIncentiveProgram" scale="6" id="Narr_pFbVxlUUD0K70lhKonuXag">9.4</ix:nonFraction>&#160;million related to the Austrian incentive program, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_LCk-o0XEz0Coe9Nfe-mo4g" decimals="-5" format="ixt:numdotdecimal" name="hook:GrantIncomeIncentiveProgram" scale="6" id="Narr_1aRx_4Jez0e7p8R0Whq0TA">1.4</ix:nonFraction>&#160;million related to the New York State life sciences research and development program and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_iLfkqbjLEkO8cY690Z1M_g" decimals="-5" format="ixt:numdotdecimal" name="hook:GrantIncomeIncentiveProgram" scale="6" id="Narr_A6Dy3rDiPEuJJci-pXLtYQ">0.1</ix:nonFraction>&#160;million related to the New York City biotechnology tax credit program. Income for the years ended December&#160;31,&#160;2022 and 2021 related to the Austrian incentive program. Research incentives depend on the eligible research and development expenses of the respective period.</p></ix:continuation><a id="_3b03472e_bcfb_4ea6_896a_4e1976dfb433"></a><a id="Tc_I_wVh4HupEqxlgz9ktuiRg_1_4"></a><a id="Tc_li701iOnSEuLnpjyWxwUeA_1_7"></a><a id="Tc_g90fg2TZIEmOGI8fjd_niQ_1_10"></a><a id="Tc_DWtZFZfOFEm5q_Jf2uK79w_2_2"></a><a id="Tc_4qzav04BZ0Krh1TNmXQ7lw_2_4"></a><a id="Tc_TT9qPfDtL0ixI8QG6VGDiw_2_7"></a><a id="Tc_1qzR-Eb3bESWCDoP0cP7wA_2_10"></a><a id="Tc_x9R0In9ixU2cnPLIKvfHsg_3_0"></a><a id="Tc_oeNRYY38XUCnicKkPlui0Q_3_2"></a><a id="Tc_uFy47TpCoE-zBW30ayxsbw_3_4"></a><a id="Tc_97zsVhb5HkyTSjVJfEYQ4w_3_7"></a><a id="Tc_e6tGgltHN02QOdXZeNwlUQ_4_2"></a><a id="Tc_jmGYZ0GW_kmxHWZPgf3nPQ_5_0"></a><a id="Tc___ckYvtNJkyMuOe1D_FPxw_5_2"></a><a id="Tc_3d5nJzrgeU2Ix2Ak9srXZw_5_5"></a><a id="Tc_URHWirfwnUKs91VvahNpOw_6_2"></a><a id="Tc_-ijxObEqX0uGDWP3LCjUnw_6_5"></a><a id="Tc_9b50kXAQO0-QWSL3Z-jPyg_6_8"></a><a id="Tc_cbx9WllTA0aWQl7fm5jeMg_7_0"></a><a id="Tc_4Bx3zpbY3kSQeWEW878J7g_7_2"></a><a id="Tc_YrrE_s4d_0ifX0lRR6n5IA_7_5"></a><a id="Tc_nnrvu7hkmUWPm23Pt7NF1w_8_0"></a><a id="Tc_-3SIAv8dME6n_xvD-gj33A_8_2"></a><a id="Tc_MAKVddODCE2HUK-8d_nLww_8_5"></a><a id="Tc_dsXSqV_sB0Ki4s5UoNgSXg_8_8"></a><a id="Tc_UtAxm93ZUUi2sG45BF3diQ_9_0"></a><a id="Tc_s-WY_mqEfkGBrydKJogasg_9_4"></a><a id="Tc_d1GgUq40B0ess_6iALbrMw_9_7"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:LeaseDisclosureTextBlock" id="Tb_VoC0eewv3U6mzgnejJNC9Q" continuedAt="Tb_VoC0eewv3U6mzgnejJNC9Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases real estate, including office and laboratory space and has entered into various other agreements with respect to assets used in conducting its business. The Company&#8217;s leases have remaining lease terms ranging from less than <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_t2LLWZ24bUKTQiMbE7AcJw" format="ixt-sec:duryear" name="hook:LesseeLeaseRemainingTermOfContract" id="Narr_97H5-n1hP0qmaHupb4_Aew">1</ix:nonNumeric>&#160;year to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ" format="ixt-sec:duryear" name="hook:LesseeLeaseRemainingTermOfContract" id="Narr_Shu0xCWhHEi6f-leohL5zQ">5.2</ix:nonNumeric>&#160;years. Some of the lease agreements contain rent holidays and rent escalation clauses that were included in the calculation of the right of use assets and lease liabilities. The Company&#8217;s current leases qualify as operating leases. The Company is required to maintain a cash balance of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="Narr_0du-loBsiU6JdMcOGJ2h8g">0.4</ix:nonFraction>&#160;million to secure letters of credit associated with real estate leases. This amount was classified as non-current restricted cash in the consolidated balance sheet as of December&#160;31,&#160;2023.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:LeaseCostTableTextBlock" id="Tb_fwaoK2DDgUehhQvrmeI3Tw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income&#160;statement&#160;location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b8VlOcR0O0OmF5emQANTkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_X6qRkLg7qU2bcFyG3zeJTA_3_5">1,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e9XlwwWzZUyxUx3pingkdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_VR3-lGzX7kWixJeaz88Y2w_3_8">1,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ShuqB9wIDkS3F21xuhUuPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_oYuOwMnF4UabjTx79vu1Kg_3_11">1,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3z_KZuEbyUyufSDi6RFYKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_Crm8i0rlGEaWdEGxfXvvGQ_4_5">242</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mzTecP16KUqdKJ51DcbR8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_jdeFYBM_UkOR72Zm7TOyBw_4_8">219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OgNb7067TEG0mtw4IpZ_2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_xpZuEh0mb0eeEWtb-trEaQ_4_11">203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e9XlwwWzZUyxUx3pingkdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_x1H-eH0dokWCkr-_FBJtHg_5_8">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ShuqB9wIDkS3F21xuhUuPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_qSwD1u028E6BSZn8OHCFMQ_5_11">425</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OgNb7067TEG0mtw4IpZ_2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_oHgO9hWqc0efapv7PBt3hg_6_11">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_pNxGgv4tck6OcN9EE9uBvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_T_r4URM4k0iA7YE64lYFMQ_7_8">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_xsd7nsH6k0yzM-JYdiLW2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_EtSzhQg4TkWR3g5g6Qh-7w_7_11">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_2Z7XTTCdlUG1MXSD_C6hBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="3" id="Tc_fX24b_79VE-bmyJyTIsb9g_8_11">40</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_SD7OP4Lox0C7uMzeFJoT7Q_9_5">1,589</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_UNt05vH8QE-FQVD3QJucRw_9_8">1,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_KvjWYp2uiUaq_Bu0aLN4zw_9_11">2,510</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_e48b4274_19cc_4294_ba73_67d3c36395ef"></a><a id="Tc_-Agy-zT_PUqc1rFhHvOJTA_1_2"></a><a id="Tc_n-RFhvGKeU-z3Eh8uCBVzQ_2_2"></a><a id="Tc_d7LZYYD09Ei3Jj2kyz6NHA_3_0"></a><a id="Tc_MJL4xOJXU0-suh1ANOr7rA_4_0"></a><a id="Tc_E2DCa2xemUqN58GnX3WgEQ_5_0"></a><a id="Tc_uAo0vn3W4kOdHBdqEVg-pw_6_0"></a><a id="Tc_GpxLxbug_UaVPJZA43dfFw_7_0"></a><a id="Tc_USvr2SnbVkG1FD2QqsCjNA_8_0"></a><a id="Tc_jZeqPp9GrU-qO8NPSvtNVw_9_0"></a><a id="Tc_tmqlvt0oi0uBJjNYTXMTDQ_10_0"></a><a id="Tc_JX5Kx_1p4k6auWtfqhQVxA_11_0"></a><a id="Tc_khcTJgB6_0KN-iktfCPVyg_11_2"></a><a id="_e51bb9cc_035a_4dd5_9be4_88a37cc8cb08"></a><a id="Tc_sX_NxzdDTEWvvNq9YtRFrQ_1_2"></a><a id="Tc_r81UbTjejEK6HfS_aJqgQw_1_5"></a><a id="Tc_k0tYpQoTvE-rlt-aUFHG-w_2_2"></a><a id="Tc_WgufMcNcXkS0rKChzcOXMQ_2_5"></a><a id="Tc_ruhECpVgUUi_yn9S6_idUw_3_0"></a><a id="Tc_0R_TrSIUFkK75W_qtBV_1w_4_0"></a><a id="Tc_6CPSTRJyMUWst_RBwurAHQ_4_3"></a><a id="Tc_wPXqlv2BKUmBBKyhBIMsog_4_6"></a><ix:continuation id="Tb_VoC0eewv3U6mzgnejJNC9Q_cont1" continuedAt="Tb_VoC0eewv3U6mzgnejJNC9Q_cont2"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_21n2lHt0Vk2FfVal1dNNBA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;lease</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_v2SFViH-qU-8gktpcCDEbA_3_3">1,655</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_zY3jlsizM0-7Gb8stqnhOQ_4_3">1,627</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_mHYO5dJflEeK0fSh9X7-lQ_5_3">1,351</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_ILRfqdMx70itxZtiFi7p_Q_6_3">1,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_nYBYwYtvXEemh1hK7gQeFQ_7_3">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_ZyCkHrZtpEqy3NSAaNYZgw_8_3">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_m1smKj6h5kyMPm6OvNvyhw_9_3">5,851</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_HD9OhO6aDE22NUiFfDFxgw_10_3">412</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_dpn3rIASgk2vmTKyK3Aecw_11_3">5,439</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" id="Tb_b5CTOpNFiEaGm7Of2wMEug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_sJFIB_URR0y5ug5YecjI1A_3_2"> 3.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_Ff6WMX_xM0ujMl7OnR24Sg_3_5"> 2.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_sIlPQ9y9ske640q1z_W-Dw_4_2">4.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Wz9ZQELSI0mCaH4Df39B9Q_4_5">1.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2023, the Company agreed on a lease amendment, which extended the term of the lease for its corporate headquarters in New York City by approximately <ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeaseForCorporateHeadquartersInNewYorkCityMember_O5rj1qjLx02TAFtZTvjJiQ" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_BIqyu-VDtkK1GhYK21m4HQ">2.2</ix:nonNumeric>&#160;years ending at the end of August&#160;2026. The Company also extended the estimated lease term of existing operating leases for the office and laboratory space in Vienna, Austria, by approximately <ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_rYOLLftQ0E631s3QNeZC5A" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_W5fK04DuVkOUmRC3kWdOpA">2.0</ix:nonNumeric> years ending at the end of December&#160;2027. Furthermore, the Company signed a lease amendment, which extended the term of the lease for certain parking spaces in its Vienna Office by approximately <ix:nonNumeric contextRef="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeaseForCertainParkingSpacesInViennaOfficeMember_BUA7zVRMSEmA3Ot_9-TINQ" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_q21yhxS4WE-1YvyjucBgEg">5.5</ix:nonNumeric>&#160;years ending at the end of February 2029. These lease amendments did not include additional right-of-use other than the extended lease term. There is no additional renewal term included in the lease amendments to consider in the estimate of the lease term. The respective lease liabilities were remeasured and the amounts resulting from the remeasurement of the lease liability were recognized as an adjustment to the corresponding right of use asset.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_VoC0eewv3U6mzgnejJNC9Q_cont2"></ix:continuation><a id="_50b91dcb_7572_4708_88f8_2bf223e60501"></a><a id="Tc_tau-mqtwW0eB-4KnMFe_Cw_1_2"></a><a id="Tc_YTJAJbfBkkeFkFn9CXgJaw_1_5"></a><a id="Tc_pAjgKLLtvUmfGNNWhJkO3A_2_2"></a><a id="Tc_aZ-q4QeN4EeY6m9N6bWbig_2_5"></a><a id="Tc_vpAyXhQON0GuJ4TJWJGAyg_3_0"></a><a id="Tc_1g7rE5ePL0OGsL7YCuG3Nw_4_0"></a><a id="Tc_wIiR4Z37fUig4k730tb6AQ_5_0"></a><a id="Tc_ZQlPibNOmUGYxGXN_aar0g_6_0"></a><a id="Tc_O6VkSCTnH0mMYJ5xIW6sDw_6_3"></a><a id="Tc_oxVGEuOW4kSH_BpwvzFEJw_7_0"></a><a id="Tc_egYR3bi7DEOuFlv_WJXYjw_8_0"></a><a id="Tc_gjKWD2MZ8kOP8I8vsnVbug_9_0"></a><a id="Tc_3VrRQX6-GEiUK5eY5rILeA_9_6"></a><a id="Tc_6jZBAcieT06XbPWX89CO5Q_10_0"></a><a id="Tc_uZ9Uxa2G90iy1WvVQitJpA_11_0"></a><a id="Tc_uvZe1jNoEUW-HuIQtTZhiw_12_2"></a><a id="Tc_s5nrlAlnf0WzakthoPNzFg_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_ROhKouueYUmpklUFArRpEQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;Accrued expenses and other current liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" id="Tb_og6OJgkX-0WwLaGM-2jAew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Salaries and bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_Hf0O9BkykE-VoqZem9_RQA_3_3">5,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_FnhiRBrwikqQ2WjBD2MITw_3_6">4,481</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Social security contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedSocialSecurityContributionsCurrent" scale="3" id="Tc_HcbK798ILEym-L7lgAaWYQ_4_3">340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedSocialSecurityContributionsCurrent" scale="3" id="Tc_uVAOyVPYq06-_gVg_1gEPA_4_6">267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned grant income (current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedUnearnedGrantIncomeCurrent" scale="3" id="Tc_lXVo60b7Vk-e5mkuiO1gRA_5_3">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedUnearnedGrantIncomeCurrent" scale="3" id="Tc_iuTWHvsthE6KyhYtNwtYGw_5_6">300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublicense fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedSubLicenseFees" scale="3" id="Tc_83z-ud-px0-LQNfvNWYm3A_6_6">1,220</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExternalResearchAndDevelopmentExpenses" scale="3" id="Tc__tOQn_QKk0uSt-h_Bpt7Pw_7_3">4,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExternalResearchAndDevelopmentExpenses" scale="3" id="Tc_5wgTc6omAEa_gl1nbC8nyA_7_6">3,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external general and administration expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExternalGeneralAndAdministrationExpenses" scale="3" id="Tc_4Mm_KtZrlEmdFkZQdgbfDw_8_3">292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExternalGeneralAndAdministrationExpenses" scale="3" id="Tc_a2HffsMPSUCW9UzFHiKAmw_8_6">898</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued for property and equipment acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesForPropertyAndEquipmentAcquisitions" scale="3" id="Tc_EJxL0t_QNESExBzwIK4Z0w_9_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_IXFLklKtUUCqip_ru2bshw_10_3">367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_SS02dYG0sUOXwe5D9RIzBw_10_6">230</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accruals and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="Tc_z-pFfU3mc0G2ANLvmowI-g_11_3">777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="Tc_XPN0d53DB0SfzvfkQJX8uQ_11_6">324</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_6owSIFtux0WRQZBiXBm6mA_12_3">12,101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_sGXAxgDbpkuS52EM21rfnQ_12_6">11,178</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_169030fa_6a57_4e7a_94bd_d7a0eb5e62b1"></a><a id="Tc_66JFKfvdEUiXEra80F9QdA_1_2"></a><a id="Tc_adfeUt0mgkS5-RDSz9hyVg_1_5"></a><a id="Tc_u8BjlpVyK0KFAqsxAcWw8A_2_2"></a><a id="Tc_mL_6FtQzwkaw85PeU2wdKw_2_5"></a><a id="Tc_OXQcYnsVmEemBuVQiWbRUw_3_0"></a><a id="Tc_NtoSZt1STkWnBBxFJNuQBA_3_2"></a><a id="Tc_XzmHK3vZ40mwKx_LhwsdZQ_3_5"></a><a id="Tc__mRhsfCNOEGo8LFjh-Twyw_4_0"></a><a id="Tc_SbCKGbxzKkaH3AbzGNPKwA_5_0"></a><a id="Tc_lWkuBlcMAUiK2yRuhEGFmQ_5_2"></a><a id="Tc_38Ll_rJyOkqG9knAMvopxA_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:DisclosureOfLongTermLoansPayableTextBlock" id="Tb_UF73L4KIOU6UXB9NUZOXYw" continuedAt="Tb_UF73L4KIOU6UXB9NUZOXYw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Loans payable</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="hook:DisclosureOfLongTermLoansPayableTableTextBlock" id="Tb_Ycfc14T2T0-yw8ZNFR3FTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, loans payable consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loans from FFG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:LongTermLoansPayableGross" scale="3" id="Tc_8wzL-ue72kSZ6d28zt4wUQ_3_3">1,172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:LongTermLoansPayableGross" scale="3" id="Tc_Y-IREc6Bh02LO10rhuCZ9g_3_6">2,855</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Unamortized debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" scale="3" id="Tc_fDtHgx_i9kaPYmp2CsEueA_4_3">52</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" scale="3" id="Tc_8FoXk1hDCkicrI0V3HDpYQ_4_6">350</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total loans payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_az-0FFSNnE-U87XHDY01gQ_5_3">1,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="Tc_AoV1ZIARM0SSSYFj9mUDKQ_5_6">2,505</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the funding agreements with the Austrian Research Promotion Agency, (<i style="font-style:italic;">&#214;sterreichische Forschungsf&#246;rderungsgesellschaft, </i>or &#8220;FFG&#8221;), the Company has received various loans (&#8220;FFG Loans&#8221;). The FFG Loans were made on a project-by-project basis. Amounts due under the FFG Loans bear interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Zp0I1H-Xe0G42xDHn2q5Fw">0.75</ix:nonFraction>%&#160;per annum and mature in March&#160;2024. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FFG Loans bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between an estimated market rate of interest and the rate of interest charged by FFG as grant income from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as grant income over the term of the funding agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized grant income of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_Rc5jKwDFOEqAwiZthnKExQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_CdEbyI6EekCpOk9pcXs8PQ">0.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_XWdzK47-T06jRMxyOKZ3Tw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_8_1yqtGuyUiMQhVLnRmKtQ">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_jrD8j5sy7UakHnOm30LdFQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_8JdVY55CL0KIDpN03-kuBA">0.8</ix:nonFraction>&#160;million during the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively, related to the recognition of the unearned income recorded for the imputed benefit of FFG Loans at below-market interest rates. Unearned income (current) related to the imputed benefit of FFG Loans at below-market interest rates was less than $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_RangeAxis_srt_MaximumMember_G5knO1JxEUipkKfqXVba6w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr_nwO2Pvh1CU61Z0Xj8xZfKA">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_RangeAxis_srt_MaximumMember_hy3OpU7SA0uUGHTffJQ5fw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr_nBRg7J0JPkKmPpzCy8nT6w">0.3</ix:nonFraction>&#160;million as of December&#160;31,&#160;2023 and 2022, respectively. Unearned income (non-current) presented under loans payable non-current related to such benefit was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_Oo1iK1CDRkCwVRfUUVTjbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_gv46q8Uhy0-rKTtYhzY5aw">0.1</ix:nonFraction>&#160;million as of December&#160;31,&#160;2022, and <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_iL34pNGK3UGEaXA4MINluA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_eaBLpKWH7UySGrOvUn_HaQ">no</ix:nonFraction> non-current unearned income as of December31,&#160;2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company has recorded a discount to the carrying value of each FFG Loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method. As of December&#160;31,&#160;2023 and 2022, the unamortized debt discount related to FFG Loans was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_VddLb9tnFEy11ja6LBloVw">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_vCVQ77zhb0KLZPXUnpzRCw">0.4</ix:nonFraction>&#160;million, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_92a13a5d_28a2_401f_92b3_b30b5091f1b4"></a><a id="Tc_UYUZrRSyGkOXZ8zD0Bhvtg_1_0"></a><a id="Tc_EwElGB5Rk0SRgiAv1iErQA_1_2"></a><a id="Tc_akTjZEYEN0-UvJdlmfd5LQ_2_0"></a><a id="Tc_BNB17H9lR0a_GIcemE7szw_3_0"></a><a id="Tc_kqi1GsV-SEepsUE8VDIWNw_3_3"></a><a id="Tc_-ldwIbPntEyfqS6DuFBgvA_4_0"></a><a id="Tc_SRMzSL0l80Wct0WcnO18LQ_4_3"></a><a id="Tc_4IKTvGMCCUGm1X26nFqkqg_5_0"></a><a id="Tc_1Y84QBiFQEOgR61p2Hgbww_5_3"></a><a id="Tc_TAUB0fM83kqW20pVfxPW0w_6_0"></a><a id="Tc_Nf5c-osWPEiac-kAE7pCfQ_6_3"></a><a id="Tc_iCSW735ilkavnnCSyWO_Nw_7_0"></a><a id="Tc_fhOAC8QMTEKWEhNNk7Qo-A_7_3"></a><a id="Tc_bcdZPPaswEahh7nAgTfgww_8_0"></a><a id="Tc_c19wZV-HXUCNB0kdtdCsXg_8_2"></a><ix:continuation id="Tb_UF73L4KIOU6UXB9NUZOXYw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized interest expense of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_HKfIjMZjz0CFl_iErKwxMw">0.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_soeNcajbRk-mBr4zWdkhdw">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="Narr_SyiE2wX63ECyzcHfe25tKg">0.9</ix:nonFraction>&#160;million during the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively, related to the FFG Loans, which included interest expense related to the amortization of debt discount of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_bmRZLxm2qkq5s9bXO5MShQ">0.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_A19cIqZZLESc4p7nb7HaMg">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_Wn2FHI35rEGBV2um-0pT1g">0.8</ix:nonFraction>&#160;million during the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively. Principal repayments of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_1gGRAKfBIkuryIyXSDX1aQ">1.8</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_VACYKUkRakWnjfb33E4exw">2.8</ix:nonFraction>&#160;million were made in the years ended December&#160;31,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses an estimated market rate of <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="hook:DebtInstrumentEstimatedMarketRatePercent" scale="-2" id="Narr_hgKXTbq_DEyrtNrkz0NExQ">20</ix:nonFraction>%, which was determined based on an average of the available interest rates on unsecured loans to comparable companies. A <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="hook:IncreaseDecreaseInEstimatedMarketRate" scale="-2" id="Narr_mBwpmBmY_EOcj1QRkMGc2Q">10</ix:nonFraction>% increase or decrease in the estimated market rate of interest would have no material impact on grant income or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the underlying program research results in a scientific or technical failure, the principal then outstanding under any loan may be forgiven by FFG on a project-by-project basis. The FFG Loans contain no financial covenants and are not secured by any of the Company's assets.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="Tb_9pkR01z0b0a0XkMZjBQuSQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31,&#160;2023, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments&#160;Due&#160;by&#160;Calendar&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2024</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_8qYPPMo-aUWzxj3Lb1lZEQ_2_3">1,172</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2026</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2027</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2028</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_6MMfMeth90qEIxNBMFGmlg_8_3">1,172</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_iv1sYJ1C8Ua3tUPtTruQ9w" continuedAt="Tb_iv1sYJ1C8Ua3tUPtTruQ9w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Common stock, Class A common stock and convertible preferred stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s capital structure consists of common stock, Class A common stock and preferred stock. As of December&#160;31,&#160;2023, the Company was authorized to issue&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_66FdDaQ0D0OCOx4wjP_ajQ">200,000,000</ix:nonFraction>&#160;shares of common stock,&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_n_j0ct15aEybB3d8HODfsA">3,900,000</ix:nonFraction>&#160;shares of Class&#160;A common stock and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_cryaCaF_E0WO4LHqk_UjJA">10,000,000</ix:nonFraction>&#160;shares of preferred stock. The Company has designated&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_-XqYXue810KUXAd3CdqxHg">2,978</ix:nonFraction>&#160;of the&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_KdjVu3alPEKbfr5KlgBglA">10,000,000</ix:nonFraction>&#160;authorized shares of preferred stock as non-voting Series&#160;A convertible preferred stock,&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_PuYLpht6akC73OG8Dkpoig">15,800</ix:nonFraction>&#160;of the&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_PSq1EJwVzEid0wJeYnDTBQ">10,000,000</ix:nonFraction>&#160;authorized shares of preferred stock as non-voting Series&#160;A-1 convertible preferred stock and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw" decimals="INF" format="ixt:numdotdecimal" name="hook:PreferredStockSharesDesignated" scale="0" id="Narr_jO64SPqACEiJ0660GpldTg">15,268</ix:nonFraction>&#160;of the&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_4sEXZbd6o0uIzbP1mWQ04w">10,000,000</ix:nonFraction>&#160;authorized shares of preferred stock as non-voting Series&#160;A-2 convertible preferred stock. As of December&#160;31,&#160;2023, the Company had&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_Xlt4McRef0Cq5Y88PDxyQw">96,550,590</ix:nonFraction>&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_EUaK3Tg6FEeEOqOHWmJvgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common&#160;stock</span></span>,&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_FJcxSuFNmE-kJXPZlv9Kdg">2,399,517</ix:nonFraction>&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_K3IEYYVgEkOcLQ_fmEnbgg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class&#160;A&#160;common</span></span> stock,&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_zTpYfwzfS0SWi555P9hpFQ">370</ix:nonFraction>&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_wHXhiF9z3UaARnOvYs1xow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Series&#160;A</span></span>&#160;convertible preferred stock,&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_0gKWNss0KUubxZ9W9DObVA">10,800</ix:nonFraction>&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_fN05Sy8hG0-TjqIRvTiFCg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Series&#160;A-1</span></span>&#160;convertible preferred stock and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_EcBRBFetPEGpppLUZTnmZg">15,268</ix:nonFraction>&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_HE01NwGMaUaBkBAhb5ZKIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Series&#160;A-2</span></span>&#160;convertible preferred stock outstanding and issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On June&#160;5,&#160;2023, the Company closed a public offering of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_6_5_2023_To_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_trpEIIU-tU-_tJvtabhPzw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_iEqtXuvkOECJCmM1KM3BeQ">22,900,768</ix:nonFraction>&#160;shares of its common stock and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_6_5_2023_To_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_KDCyo9xrfUm2SNyHUjgpxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_PiW6N7-O2E2m_lbtE1BjOA">15,268</ix:nonFraction>&#160;shares of Series&#160;A-2 convertible preferred stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_G59PYeJ12ECeSIQHOayjyQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_J7269GZDjk2c9jZRooNzYQ">1.31</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_9xIbJy1mtE6TWI_wKOUrpw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_HP5_hh2LP0u5p_G_CoYD8g">1,310.00</ix:nonFraction>&#160;per share, respectively, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_6_5_2023_To_6_5_2023_HDaSSSxSpUCGD9FJbOAwcw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_srZDeGl55UKVDgHBztQpyw">46.2</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In July&#160;2022 and August&#160;2022 certain of the Company&#8217;s stockholders elected to convert an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_7_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_pc7cQA2m-kOSmJHzPEfppQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_Fyu_6Pzv0kS5xYoCMNtAUA">1,420,215</ix:nonFraction>&#160;shares (<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_7_1_2022_To_7_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_igpyXqNHCkeaCiqmtmt_nQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_5PYuzQ51FUuHq6dnxvH1oQ">769,734</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_-Sb_oTNrbE67HtDm8P8UiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_FKodF781_0KgFohQS4JB6Q">650,481</ix:nonFraction>&#160;shares, respectively) of Class&#160;A common stock owned by such holders into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_7_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_qhAXDY6gbUi75WUSONZh_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_PSmZSrdkbEKPg5w8Bg6hEQ">1,420,215</ix:nonFraction>&#160;shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On February&#160;15,&#160;2022, the Company entered into a stock purchase agreement with Gilead (&#8220;Stock Purchase Agreement&#8221;), that requires Gilead, at the Company&#8217;s option, to purchase up to $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_2_15_2022_To_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_Agf-g2EmxkChN7RAIyPgCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_yoKqT1rNikCTfIGugNFVDA">35.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock. On February&#160;15,&#160;2022, Gilead purchased an initial amount of <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_2_15_2022_To_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_Agf-g2EmxkChN7RAIyPgCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_CgiEMFyEREqoIha_TS5efw">1,666,666</ix:nonFraction>&#160;shares of the Company&#8217;s common stock </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_iv1sYJ1C8Ua3tUPtTruQ9w_cont1" continuedAt="Tb_iv1sYJ1C8Ua3tUPtTruQ9w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">in exchange for $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_2_15_2022_To_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_Agf-g2EmxkChN7RAIyPgCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_uF4WQKGgn0qsyZDz2pJzTA">5.0</ix:nonFraction>&#160;million in cash at a purchase price per share equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_ob0J9wZKyk2iJVWb7ieH0A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_sqovtIHzzk-YbrQ9EERivw">3.00</ix:nonFraction>. On December&#160;20,&#160;2023, the parties amended and restated the Stock Purchase Agreement (the &#8220;Amended Stock Purchase Agreement&#8221;) and Gilead purchased <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_H8YdukywEUa5F4R0wQD4ug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_g9ysWd7xA0eW0DJwM9Hkvw">15,000,000</ix:nonFraction>&#160;shares of the Company&#8217;s common stock in exchange for approximately $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_H8YdukywEUa5F4R0wQD4ug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_BaSeUJS-PEeJBQ1C_SRJUA">21.3</ix:nonFraction>&#160;million in cash at a purchase price per share equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_9_7EqTslY0yqSx5HU_L_qA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_nuog4UKOLUGVj3N8_oxxvg">1.4167</ix:nonFraction>. Pursuant to the terms of the Amended Stock Purchase Agreement, the Company may require Gilead to purchase the balance of the $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_H8YdukywEUa5F4R0wQD4ug" decimals="-5" format="ixt:numdotdecimal" name="hook:RemainingOfCommonStockReservedForFutureIssuance" scale="6" id="Narr_mi4DIQ3lLUi0vX58pHBukg">8.7</ix:nonFraction>&#160;million of common stock as pro-rata participation in potential future equity raises. The Company&#8217;s right to sell shares of its common stock to Gilead is subject to specified limitations, including a limitation that prevents the Company from requesting purchases of shares of common stock by Gilead that would result in a beneficial ownership of more than <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_2_15_2022_srt_OwnershipAxis_hook_GileadSciencesIncMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_IJ87WrWO-k-9t1hFfOiVgA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_aQI98MbL8kOZoXNmjXoEgw">19.9</ix:nonFraction>% of the total number of outstanding shares of common stock by Gilead. The Company agreed to file a registration statement on Form S-3 to register for resale any additional shares of common stock issued to Gilead within <ix:nonNumeric contextRef="Duration_2_15_2022_To_2_15_2022_z3PV6PoxAUyoMugmqtg5lQ" format="ixt-sec:durwordsen" name="hook:RegisterForResaleOfCommonStockAdditionalIssuances" id="Narr_BxnI_QjN8k6-GZOnOMlCBA">four months</ix:nonNumeric> from issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March&#160;4,&#160;2022, the Company closed a public offering of <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_sAJY_NDjZEehCI5DuVqezg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_oonbEnrEZku929PZXiSvOA">21,700,000</ix:nonFraction>&#160;shares of its common stock and of <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_5F71-AsX2EC4M3MSefmV1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_lZCmTDtogUCBOj003CO9-Q">15,800</ix:nonFraction>&#160;shares of Series&#160;A-1 convertible preferred stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_XHb2VxbEKkeLgdecA0RSzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_fjCwK1DL30ytpIxpUmhrhQ">2.00</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4xGiuYB470aHSLaFha05pA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_xZxKChZbokiY2nHfCH1TcQ">2,000.00</ix:nonFraction> per share, respectively, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_3_4_2022_To_3_4_2022_NTQl-cLtAk6xlttcf3yn2g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_cA6mTte-mk2VyNngIpvCeA">70.2</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has three series of preferred stock authorized, issued and outstanding as of December&#160;31,&#160;2023: Series&#160;A convertible preferred stock, Series&#160;A-1 convertible preferred stock, and Series A-2 convertible preferred stock. Shares of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock may be independently converted into common stock. Holders of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock have equal rights, powers and privileges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_GQrC70uM-UyPQD7KgwAVng" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA" decimals="INF" format="ixt-sec:numwordsen" name="hook:NumberOfVotes" scale="0" id="Narr_oguliQRCwUu5jl_XWTtJAQ">one</ix:nonFraction> vote for each share held on all matters submitted to a vote of the stockholders. The holders of Class&#160;A common stock and Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock are not entitled to vote, except as required by law. The holders of common stock and Class A common stock do not have any cumulative voting rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each holder of Class&#160;A common stock has the right to convert each share of Class A common stock into <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_UsydwOHzwEWlwarT8cPtyg" decimals="INF" format="ixt-sec:numwordsen" name="hook:ConversionOfStockCommonStockIssuedForEachShareConverted" scale="0" id="Narr_QtWXM7cKQEOMcmjYNLjrag">one</ix:nonFraction> share of common stock at such holder's election. Each holder of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock has the right to convert each share of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock into <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_1Wpbg1kMJkWMHx62rdrnHA" decimals="INF" format="ixt:numdotdecimal" name="hook:ConversionOfStockCommonStockIssuedForEachShareConverted" scale="0" id="Narr_PkBuOA6g9ECOT17unkJWgg">1,000</ix:nonFraction>&#160;shares of common stock at any time at the holder&#8217;s option, provided that the holder will be prohibited, subject to certain exceptions, from converting Series&#160;A, Series&#160;A-1 and Series&#160;A-2 preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_shcM24-UD0G_87KWD0abFA" decimals="4" format="ixt:numdotdecimal" name="hook:ThresholdPercentageForConversion" scale="-2" id="Narr_dgCEuhnW9UCIv8qoPKLObQ">9.99</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock then issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of common stock and Class&#160;A common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Holders of Series&#160;A. Series&#160;A-1 and Series&#160;A-2 preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of the Company&#8217;s common stock. Holders of common stock and Class A common stock have no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the event of a liquidation, dissolution, or winding up of the Company, holders of our Series&#160;A, Series&#160;A-1 and Series&#160;A-2 preferred stock will receive a payment equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_shcM24-UD0G_87KWD0abFA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_juJZ3zph2U-LoAnp9IfQNQ">0.001</ix:nonFraction> per share of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 preferred stock before any proceeds are distributed to the holders of common stock. Then, holders of common stock and Class&#160;A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_sE5olGx9a06Mg2wMriyuaw">370</ix:nonFraction>&#160;and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember__7jEylpDhk2E7HBL-QMsuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_61FAD0fCRUm1su6s9bLcDA">1,697</ix:nonFraction>&#160;shares of Series&#160;A convertible preferred stock,&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_Yf3VW9YWMUOe4O8IioQkYg">10,800</ix:nonFraction>&#160;and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_oBjN55Dh4kWdP45kjmc_cA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_PgOASUs-6U2pUSlOEHZkmw">15,800</ix:nonFraction>&#160;shares of Series&#160;A-1 convertible preferred stock and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_eYSi82CqJU-iBv6xg7CX5w">15,268</ix:nonFraction>&#160;and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_4t0j2RLtRUim5ad7YUNdww" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_0AWJOe13_E2HACYtLfhSvQ">no</ix:nonFraction>&#160;shares of Series&#160;A-2 convertible preferred stock outstanding as of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_iv1sYJ1C8Ua3tUPtTruQ9w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively. In May&#160;2023 certain of the Company&#8217;s stockholders elected to convert an aggregate of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_f2bozshHvEqDnHPJIfLxkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_2cBgp8B5W0-Knx-y65_gnA">1,327</ix:nonFraction>&#160;shares of Series&#160;A convertible preferred stock and an aggregate of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_5OZpzWR5ZE-g65N3W9mQlg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_7GL6yxHzmEOKJtzV8rAdHA">5,000</ix:nonFraction>&#160;shares of Series&#160;A-1 convertibles preferred stock owned by such holders into an aggregate of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_VZQQp8bdV0acmmpRV4RXpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_ib5-b6yhTUqFpyfgAOW5ww">6,327,000</ix:nonFraction>&#160;shares of the Company&#8217;s common stock. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_1UfAeLclEEaGrNgqsxLasQ" continuedAt="Tb_1UfAeLclEEaGrNgqsxLasQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">2018 Stock Option and Grant Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2018, the Board of Directors approved the 2018 Stock Option and Grant Plan. Options granted under the 2018 Stock Option and Grant Plan generally vest over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_ioKeOQv4MEC7RRwFd806mw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_LNKMNSpI2UCm19xliglS_A">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aKhFceKN_063s8FrQsNE-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_aaSPCs0E4EKBaV_wO76XcA">25</ix:nonFraction>% of the options vesting upon the first anniversary of the grant date and the remaining <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pi9ns7LHMEqJa6iUqFqKqA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_n4LQxiEfWkS23ADVfSsneg">75</ix:nonFraction>% of the options vesting in <ix:nonFraction unitRef="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pi9ns7LHMEqJa6iUqFqKqA" decimals="INF" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" scale="0" id="Narr_L9mo42em_UGQ-tHdIqBM0Q">12</ix:nonFraction> equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. The options expire on the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the grant date. As of December&#160;31,&#160;2023, <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_y96X3sy35kK-JiMbzDVPjw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_EIPvpA4BBU6JgJHHsyRIsA">782,176</ix:nonFraction>&#160;options granted under the 2018 Stock Option and Grant Plan remained outstanding. Any authorization to issue new options under the 2018 Stock Option and Grant Plan was cancelled upon the effectiveness of the 2019 Stock Option and Incentive Plan and no further awards will be granted under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">2019 Stock Option and Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April&#160;1,&#160;2019, the Company&#8217;s stockholders approved the 2019 Stock Option and Incentive Plan, which became effective as of the effective date of the registration statement in connection with the Company&#8217;s IPO. The plan provides for the grant of shares of restricted stock, long term incentive awards, stock options or other equity-based awards. As of December&#160;31,&#160;2023, the maximum number of shares of the Company&#8217;s common stock that may be issued under the Company&#8217;s 2019 Stock Option and Incentive Plan was <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_vsxwLcmVd0qxvZfveKo1qw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_y-gqi-BR4kKUbvTl4ZdVPg">8,067,480</ix:nonFraction>&#160;shares which shall be cumulatively increased each year by up to <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_pT4ROzEyWkS4z3OWuisutw" decimals="3" format="ixt:numdotdecimal" name="hook:StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" scale="-2" id="Narr_elfNM7-p8EaVfMq_45pJ7A">4.0</ix:nonFraction>% of the then outstanding number of shares of common stock and Class A common stock. Options granted under the 2019 Stock Option and Incentive Plan generally vest over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_pT4ROzEyWkS4z3OWuisutw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_wKAIcnxhQEql9G8NZ4Dhbw">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_H0tCjW2DHECbxO5klnyB9A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_VpD-h1PoxkC8KWe1KXxXCQ">25</ix:nonFraction>% of the options vesting upon the first anniversary of the grant date and the remaining <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ZtdYdiFLwEqrZPGSD1c3dg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_51gDbt3HZE2mqHcc_SbCfg">75</ix:nonFraction>% of the options vesting in <ix:nonFraction unitRef="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ZtdYdiFLwEqrZPGSD1c3dg" decimals="INF" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" scale="0" id="Narr_FbdTsjp510WQnwUGm2f83A">12</ix:nonFraction> equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. Initial options granted to non-executive directors upon their election generally vest over a <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_XF87Kq4bd0-7XFTH2TZbAg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_BoSQbT0Hg0-OFdcgs2Ii4A">three-year</ix:nonNumeric> term with <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_xnILDkMs_kCjhQ1U1ADU1A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_oO3RmV1HkUyklnNymWt35A">33</ix:nonFraction>% of the options vesting upon the first anniversary of the grant date and the remaining <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iIx2YHcEt0CG7Jld-YUTtA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_YqA-4K6lNUK36ouRtYF-yw">67</ix:nonFraction>% of the options vesting in <ix:nonFraction unitRef="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iIx2YHcEt0CG7Jld-YUTtA" decimals="INF" format="ixt-sec:numwordsen" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" scale="0" id="Narr_ULJSr1djSESXsM1WvIpkuw">eight</ix:nonFraction> equal quarterly installments following the first anniversary of the grant date. Option re-grants to non-executive directors generally vest on the first anniversary of the grant date. The options expire on the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the grant date. For each option the beneficiary is entitled to receive <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="INF" format="ixt-sec:numwordsen" name="hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" scale="0" id="Narr_LW1gzEyh6k6x4Ty2m0PecA">one</ix:nonFraction> share of common stock upon the exercise of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, there were&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_InducementAwardsPlanMember_bUvp9git4U6vhtxSXzOaEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_aD8te1TVHUi1IpxIZYbfMA">500,000</ix:nonFraction>&#160;shares reserved for stock options issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On August&#160;7,&#160;2023, the Company&#8217;s board of directors approved a one-time offer to eligible non-executive, non-director employees to exchange certain outstanding stock options for new stock options with modified terms. Under the stock option exchange program (the &#8220;Offer&#8221;), the Company offered to exchange certain out-of-the-money stock options for new stock options at an exchange ratio of between&#160;<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_8_7_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember__FwCStMaU0OyzpKGLfbvNA" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" scale="0" id="Narr_XxBfyAgxyESex9G1Hed3GQ">1.75</ix:nonFraction>&#160;and&#160;<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="As_Of_8_7_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_I0qOWFNRG0m7UhyFU_5e3A" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" scale="0" id="Narr_Gf7AlsFZCUCvVizs8R1CqA">2.50</ix:nonFraction>&#160;surrendered options for one new option exercisable for shares of common stock with a lower exercise price and extended vesting terms. Pursuant to the Offer, a total of&#160;<ix:nonFraction unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg" contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg" decimals="INF" format="ixt:numdotdecimal" name="hook:NumberOfEligibleParticipants" scale="0" id="Narr_alkcR1EYVUOwoXSf4e5B_A">82</ix:nonFraction>&#160;eligible participants tendered, and the Company accepted for cancellation, stock options to purchase an aggregate of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg" decimals="INF" format="ixt:numdotdecimal" name="hook:NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" scale="0" id="Narr_gfa5gYUEl0W5RYby1bXCEw">543,228</ix:nonFraction>&#160;shares of the Company&#8217;s common stock with exercise prices between $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_8_7_2023_To_8_7_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_br4Ybr-YDUajiQqo-HL-lg" decimals="2" format="ixt:numdotdecimal" name="hook:ExercisePriceLimitConsideredForCancellationOfStockOptions" scale="0" id="Narr_kquBYPvzVUGY6yWB0bS4uw">6.90</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_8_7_2023_To_8_7_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_3at3uPhCo0ShjqrpfD4Klg" decimals="2" format="ixt:numdotdecimal" name="hook:ExercisePriceLimitConsideredForCancellationOfStockOptions" scale="0" id="Narr_-XI5FHhps0OBNMjMyfIkQg">14.00</ix:nonFraction>. The eligible options that were accepted for cancellation represented approximately&#160;<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg" decimals="3" format="ixt:numdotdecimal" name="hook:PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" scale="-2" id="Narr_uMaXQKXJ8EaGczwEXThNxA">86.6</ix:nonFraction>% of the total shares of common stock underlying all of the eligible options. In accordance with the terms and conditions of the Offer, on September&#160;12, 2023, the Company issued new options to purchase an aggregate of&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_9_12_2023_To_9_12_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_Xd8PFrmLWECYLMz00H-fVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wU-GNgyi00-PTptaTD45iw">274,485</ix:nonFraction>&#160;shares of common stock in exchange for the cancellation of the tendered eligible options. The exercise price per share of each new option granted in the Offer is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_9_12_2023_To_9_12_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_Xd8PFrmLWECYLMz00H-fVQ" decimals="2" format="ixt:numdotdecimal" name="hook:StockOptionsIssuedExercisePricePerShare" scale="0" id="Narr_TYfUAMuxKUeWDGpU43nOcQ">1.00</ix:nonFraction>. New options </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_SbyElpvti0KiJauEpcKdBA_2_2"></a><a id="Tc_X0bdg-NlbEyM3JPLX7JIwQ_3_2"></a><a id="Tc_CnOyiqn2oUiroooSjrfsLw_3_4"></a><a id="Tc_rEFktA36YUqYAdKlWXXfxw_3_6"></a><a id="Tc_6BFCXLJfNUqsJIl0Vb410Q_3_8"></a><a id="Tc_8ALksxD3EUGfuT9y0_DX2w_4_0"></a><a id="Tc_1_zJVc36WEyiWgBugzszAQ_5_0"></a><a id="Tc_DbZT4_pm-0ODYVOcMHB3oA_6_0"></a><a id="Tc_Z6r50zcehEWv2Bh_8O_jqg_1_2"></a><a id="Tc_TEUz2zaD5E6eH3mdVynTRw_2_2"></a><a id="Tc_2CzUeZ3dRkOkNaZwvn6nvg_2_4"></a><a id="Tc_rj2SYmYQBEap-GuzZD5DaA_2_6"></a><a id="Tc_G3BRaDntpk6jSka2bAfy-A_4_0"></a><a id="Tc_LleNogVSi0mltp8YSUa6jg_4_3"></a><a id="Tc_tbcKXB3jJU61RYXX5fLt8Q_4_5"></a><a id="Tc_ZvJocIoM5E6P1zgs3CWNBQ_4_7"></a><a id="Tc_sQXGIUaPgkKqQaiBEImgHg_5_0"></a><a id="Tc_WUoDFmsGc0WFwRu8NeVcDA_6_0"></a><a id="Tc_GStoJftBsESU3XCXjjiukA_6_3"></a><a id="Tc_RPq88Qva9UCQKDLk5mZgDQ_6_5"></a><a id="Tc_L1bzMf707UShFOzUd0dcKQ_6_7"></a><a id="Tc_93aILMgZFU6MpyDUg_WNDA_7_0"></a><a id="Tc_nzZ8W_9Y2UGZT6oP6z72nQ_7_2"></a><a id="Tc_bS3egQEAL02RYKzz50YhBQ_7_3"></a><a id="Tc_GKKIvIpQZE6BISyaxACvEA_7_4"></a><a id="Tc_e8Uk92h9QEe5fPwX_WL2QA_7_5"></a><a id="Tc_EglSHe40MUeuyDa9631WsA_7_6"></a><a id="Tc_FE9yHgCAJkypLkoygmoZNg_7_7"></a><ix:continuation id="Tb_1UfAeLclEEaGrNgqsxLasQ_cont1" continuedAt="Tb_1UfAeLclEEaGrNgqsxLasQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">issued for previously vested stock options vest on the first anniversary of the grant date and new options issued for previously unvested stock options vest over a&#160;<ix:nonNumeric contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_St7eTbsrmEids1JXEhIGVQ">three-year</ix:nonNumeric>&#160;term in&#160;<ix:nonFraction unitRef="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA" contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg" decimals="INF" format="ixt-sec:numwordsen" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" scale="0" id="Narr_2Ez9CXN5dEy2iSNPexyLDA">twelve</ix:nonFraction>&#160;equal quarterly installments. The stock option exchange offer resulted in incremental stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" scale="6" id="Narr_rK9AcwLy0U2HX9rUnXayFQ">0.1</ix:nonFraction>&#160;million, which will be recognized using the graded-vesting method over the remaining requisite service period of the new stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents a summary of awards outstanding:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_AXNLnHkqHkSUOozBEHbj2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inducement Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Granted and outstanding awards:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_y96X3sy35kK-JiMbzDVPjw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_pL9wJay2MEevgqgwE3LmJA_5_2">782,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_vsxwLcmVd0qxvZfveKo1qw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_j97YeP01l0S1H-qnknEO3w_5_4">7,099,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_InducementAwardsPlanMember_bUvp9git4U6vhtxSXzOaEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_pc8LX_SYzkqCPY-ObHnh8g_5_6">230,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_dfgp1X3V60OioC9XYQVraQ_5_8">8,111,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_y96X3sy35kK-JiMbzDVPjw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_rY1Sg72gnUm53uwtWEOCLQ_6_2">782,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_vsxwLcmVd0qxvZfveKo1qw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_UidvBbJD1US95lY6aIz54w_6_4">7,099,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_InducementAwardsPlanMember_bUvp9git4U6vhtxSXzOaEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_IZeYBLNiz0u8ipRy6osxtA_6_6">230,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_Ud6QeSOGmUyclYtFheLoVQ_6_8">8,111,575</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock option valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the option&#8217;s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, volatility, the risk-free interest rate, the dividend and employee exercise behavior. Forfeitures are accounted for when they occur. Expected volatilities utilized in the Black-Scholes model are based on historical volatilities of a group of comparable companies. The group of representative companies have characteristics similar to the Company, including the stage of product development and focus on the life science industry. Management believes that this represents the most accurate basis for estimating expected future volatilities under the current conditions. The risk-free interest rate is derived from the yields for U.S.&#160;Treasuries with a remaining term approximating the expected life of the options. The expected term represents the period of time that the options granted are expected to be outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options granted during:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_dBu2HGQrrkauWw4qijk3rw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Ly1gJTBnO0iqC8vpF5sQAA_4_2">3.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_DK1lsMdyake3jrckbZL70A_4_4">3.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_jw4JPWVuj0idTWWun_rN2w_4_6">1.07</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_oFi_Jb33QU6O3ZNc3dzVuw_5_2"> 5.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_xdTk7EIFkUqyIv4xKaQ-6w_5_4"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_n2kEEjuVjUW_ADtO2pVkGA_5_6"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_UspDIO3vwEmRTzbr8GvKgg_6_2">93.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_z2qYQ11COUusXCLsAxod7A_6_4">85.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_67cgzR-KQkGpzFinxSVpdg_6_6">85.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the 2021, 2022 and 2023 grants, the Company used the simplified method in developing an estimate of the expected term due to a lack of historical exercise data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_09570cce_2139_48e2_8298_f8dcd10d9816"></a><a id="Tc_yssIoGVep0uJQLqU2vGTTA_1_7"></a><a id="Tc_-rH3JJ_zgkW9C_4Is8awrQ_2_4"></a><a id="Tc_pqRbkT8Vn0qIQdQqUYVuZQ_2_7"></a><a id="Tc_pc-2IX3BaUaAU4bzS9LdIw_3_4"></a><a id="Tc_aM0ywiMyrEm2KLrk6MFMvg_3_7"></a><a id="Tc_4IAp1BUzHU-5O1iAebiiKA_3_9"></a><a id="Tc_RqWdgu3TUUOmD9PQhZq8Eg_4_2"></a><a id="Tc_mkkYhJcqOkGy4pAb6BxZqQ_4_4"></a><a id="Tc_BqtIZXGEDEqxY-gMV_Y7RA_4_7"></a><a id="Tc_gEqimlQ2E0mJLmCR8-R5nw_4_9"></a><a id="Tc_IudAxugghEe1I7_olTHCDg_5_2"></a><a id="Tc_qsL3MuE2-UyKlN-w5_07GQ_5_4"></a><a id="Tc_WYRjfupphE6mtM0_pa3wiQ_5_7"></a><a id="Tc_APYzgf1W10izW-AqRoFrWg_5_9"></a><a id="Tc_nTAANDYxdUWU_6JflE5_sg_6_7"></a><a id="Tc_n62kaCJn2UabEi-OXJM47g_7_0"></a><a id="Tc_CRQRlaMqt0-VBid8AX3zrA_7_4"></a><a id="Tc__WOzyBfEckutlsfMpI2fIw_7_9"></a><a id="Tc_phLa5uTllEG5ixQIIim66w_8_0"></a><a id="Tc_Aq6JVCZnfkOWesyOvUGekQ_9_0"></a><a id="Tc_QdufTZwwVU-lSZg7QMHk-g_10_0"></a><a id="Tc_71gU-V1RDU6Tn_yPaCixbg_11_0"></a><a id="Tc_nwLv8UCmP0KyxXtsA_kBeA_11_4"></a><a id="Tc_5lafBMlqP0OIt3ryVrfbIg_11_9"></a><a id="Tc_B2ULh_Cs3kqwH7IoGM_uUw_13_0"></a><a id="Tc_v6Ksd-_RMUqaAHRKikQPKg_13_4"></a><a id="Tc_unvlpaoto0WV3edFE_EolA_13_9"></a><a id="Tc_WgdpQsDA00Sl0vYX7fNBIQ_14_0"></a><a id="Tc_TjTioIA1ykKYgQmYEPesvA_14_4"></a><a id="Tc_VfdBxNXzZ0q_P_XuZgC4hw_14_9"></a><a id="Tc_jSxRNY4iQkyyFeNheNhlTQ_14_10"></a><ix:continuation id="Tb_1UfAeLclEEaGrNgqsxLasQ_cont2" continuedAt="Tb_1UfAeLclEEaGrNgqsxLasQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock option activity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_7p-9wBJGBEWihARYGziyMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity since January&#160;1,&#160;2023 (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_hZlPbBwUQke4chhKR8YfXA_7_2">6,532,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_OB7_ubjU3ESP0LriVlqPfA_7_5">6.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_WOGea9JmFkGA4HfJ0EFzVw_7_7"> 7.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_-XBHjba470mAZTUqBgF3kg_7_10">490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc__2RC6FNTGEyP5OHgcahbhg_8_2">2,880,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_K2mzdJ82S0CL3SkU3e5IWg_8_5">1.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Gz_K7pIJqE-EIBOIVEMgeg_9_2">5,684</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_fgjSd5dtHk2d9SHsKnDIGg_9_5">0.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_zSLgZ7_RekSNR_SnNZU3Rg_10_2">1,296,249</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_6DLaJHz6wEG5tknQrn45Ww_10_5">6.63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_xx0oLzR6W0qTTFNM-x5luw_11_2">8,111,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_mCxOGw5SlkeKD_IpulamFg_11_5">4.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_QpfysqbKHE2fMatmbZEBDQ_11_7"> 7.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_ZPcTvHE4wUSqAT1D2ewGfQ_11_10">486</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_bQqEcAnEWUStfR8eOn70cQ_13_2">4,101,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_W_Lepg2MokKHjFCb8A7vkg_13_5">6.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_ZTgSguzPCEySnwolSLSq3w_13_7"> 6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_TH7W1uXRW0WlBEL7dljvzg_13_10">486</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options unvested as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_atnzXf35ZEWPG805gJHY3Q_14_2">4,010,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_xYW8GqI1q06FxJS1DrGJCQ_14_5">1.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" format="ixt-sec:duryear" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" id="Tc_0r57yDlW6keESKLHdithIA_14_7"> 8.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options was calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The fair value per common stock used for calculating the intrinsic values as of December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021, was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" scale="0" id="Narr_iHv8rrTQIk6lP1rY0VUOlA">0.81</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" scale="0" id="Narr_JExhR3nndkOp8gt48fa2og">0.81</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" scale="0" id="Narr_yYlN9X3iL0uFjP3viayFLw">2.33</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised during the years ended December&#160;31,&#160;2023, 2022 and 2021 was less than $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_TLnzJeHBQUmVUiVn6q3pCA">0.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Cjpb3hF7IEea2TyyB2JGNg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_tTPNjobw6EaxqgniWlVq3A">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_AFyGmgyE8kiyCNQqfpXApA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_wa5UwQnjaUiUyP8pwXo-XQ">1.0</ix:nonFraction>&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant-date fair value per share of stock options granted during the years ended December&#160;31,&#160;2023, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_FfPBDqjRF0ajWVPHrLnynQ">0.55</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_F5E_Xt0U_U6mjGMcgkei8Q">1.55</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_kvFpuQWbekixTa9Dz-a64A">11.46</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total fair value of stock options vested during the years ended December&#160;31,&#160;2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_lv3r--kfEkygAJuhGjaqRA">5.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_eUp7ptfpk0q79AZJUR55GA">7.9</ix:nonFraction>&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash received from stock option exercise under share-based payment arrangements for the years ended December&#160;31,&#160;2023, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_vI9nBR7LcUyP-paCHbZw-Q">1</ix:nonFraction>&#160;thousand, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_nvk_utXs5UaToNmyEidTaQ">3</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Narr_qGiXsrYZHEayNEylk_d96g">203</ix:nonFraction>&#160;thousand, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Common Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2022 the Company issued unrestricted shares of common stock to its executive team. The Company&#8217;s executive team agreed to convert a portion of their base salaries, for the six months ended June&#160;30,&#160;2022, for shares of the Company&#8217;s fully vested common stock having a value equal to their foregone salary, determined based on a value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BcR8oItz_UOIQXNtcPyaQQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_dyExjSp-4EynTYXc54JlKQ">3.00</ix:nonFraction> per share. This resulted in the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_m8WtQLcukk2yFLSY4g5v3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_FamGlA9Nr06TjNFwvtffiQ">112,551</ix:nonFraction>&#160;shares of common stock with a total fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_m8WtQLcukk2yFLSY4g5v3Q" decimals="-5" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" scale="6" id="Narr_yL0ON4xD5UOQDb_bQios6w">0.2</ix:nonFraction>&#160;million. The grant date fair value per share of common stock was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_m8WtQLcukk2yFLSY4g5v3Q" decimals="2" format="ixt:numdotdecimal" name="hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" scale="0" id="Narr_JUhPGPQI80yTucdXwRKLFg">1.50</ix:nonFraction> and was measured at the closing price of the common stock on the date of grant. Expenses were recorded immediately and are included in stock based compensation in the year ended December&#160;31,&#160;2022. <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_6eU7lu-gYkGX1lF7SujF0A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_lnV5ouRoKEuOWcdKYuGJRg">No</ix:nonFraction> unrestricted shares of common stock were issued in the year ended December&#160;31,&#160;2023.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_98bcaf9f_3ffb_4770_908b_7a0da2118d95"></a><a id="Tc_rBT7ymyE_0C29J8GCqHElA_1_2"></a><a id="Tc_SMmVc2Br20euJFLFNYU7Kw_2_2"></a><a id="Tc_4kMI6hdBCk6wLERNYUBY4g_2_5"></a><a id="Tc_3mBZhmsM1UeiAddM6SbMSA_2_8"></a><a id="Tc_pNLdRE09PEuMt4OI2qgHZw_3_0"></a><a id="Tc_5Jawoa4sbU2Ql5Sat9HpIg_3_2"></a><a id="Tc_TBrXk6y2AkCdYLfpaVJs_Q_3_5"></a><a id="Tc_eVa699ItF0GmKKE0r7PnfA_3_8"></a><a id="Tc_dwWyX-F7FE6WOPNP9zxlbA_4_0"></a><a id="Tc_-A29kqpFwUG7SC-7gr2frg_5_2"></a><a id="Tc_12V7IArJGUq-ylKOmitbKA_5_5"></a><a id="Tc_UJEThSVjikiGHFUgnI6Wfw_5_8"></a><ix:continuation id="Tb_1UfAeLclEEaGrNgqsxLasQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock-based compensation</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_TCxiyU-p1EK4DFocUcV5AA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b8VlOcR0O0OmF5emQANTkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_rIUYWBtg_kq20jIg_qDOBQ_3_3">861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e9XlwwWzZUyxUx3pingkdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Cs4DpGk-ZkC1Z7AAPGO-HQ_3_6">2,074</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ShuqB9wIDkS3F21xuhUuPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_U8W6MUIb5UOeaRbNFMr41g_3_9">3,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3z_KZuEbyUyufSDi6RFYKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-p3S_JqWtEyxHK6dRfQUNQ_4_3">1,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mzTecP16KUqdKJ51DcbR8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_OPsib2w_LEqPYoHIrKUn6Q_4_6">2,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OgNb7067TEG0mtw4IpZ_2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_fGX4TR5waE6JBaQjceJ0MQ_4_9">4,444</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_RvEJjNal20ujvIOmDK1OhQ_5_3">2,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_8lsyUt0C0k2BuX6jqkCMGQ_5_6">5,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_K1VLgvkCPE2_m5wl1d3w4Q_5_9">7,644</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2023 total unrecognized compensation cost related to the unvested stock-based awards was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_9JVhQIGNGEiOpoFps4u8Wg">1.5</ix:nonFraction>&#160;million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_FRFArWaJd0OPmkWUN2iUFg">1.5</ix:nonNumeric>&#160;years.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ad54a640_b934_4abd_9486_d14fcfe3b977"></a><a id="Tc_u6maJ5wo0k6IGR27D14qfQ_1_2"></a><a id="Tc_FKIn2Z-n6UWE1FbHi-b7WQ_2_2"></a><a id="Tc_KItBl_eIe0CWzk0itDYnKw_2_5"></a><a id="Tc_V4sdodBLWU2EzNnalM4Z3w_2_8"></a><a id="Tc_A7YHCHHfkkOqxab-JW-tYg_3_0"></a><a id="Tc_9IcyUIqr3EKRkY7wMntdOg_3_2"></a><a id="Tc_PL7CZtO2qEOoCGzSnru9YQ_3_5"></a><a id="Tc_7IkEMKh0ckaT_e5_b5PGkw_3_8"></a><a id="Tc_GSjk42DRLkmAX4bko-0bTg_4_0"></a><a id="Tc_WnAbg80nuUSbmwHBfDqWdQ_5_0"></a><a id="Tc_s3-xV3emM0COvoO3IJmwew_5_2"></a><a id="Tc_huQF-qywtEut704F3_-JFg_5_5"></a><a id="Tc_iUBCXOzaQUWSjIOrDQ8-Cg_5_8"></a><a id="_da2e6908_6cf8_4e5d_b935_ae2e688cbae9"></a><a id="Tc_uSAtcSVfD0CJksCV-TZfxA_1_2"></a><a id="Tc_aKnJyNLWVEGA8StIvDMvMA_2_2"></a><a id="Tc_F3sP03NYJUCwrqVcrDefaQ_2_5"></a><a id="Tc_aWiv5TetIk2d9g4h1Cq8EQ_2_8"></a><a id="Tc_rR97wU1PrUGJ6cm7ChdyVg_3_0"></a><a id="Tc_gQtLPPifbE6Oh2KjX4wZOw_4_0"></a><a id="Tc_2LFEBjPrEU6yg0ElGkGsFw_4_2"></a><a id="Tc_DViG_PVJI0uoDBzwr0yHCw_4_5"></a><a id="Tc_Mxv3rN6BQ0i5BUKAmCrSwQ_4_8"></a><a id="Tc_vV0FXO2Hfk-iWmwC5BYeLQ_4_9"></a><a id="Tc_QwtCXRMKZ0i8sumOUAlR7A_5_0"></a><a id="Tc_yGMfIqmw-kGRwU050b__vg_5_9"></a><a id="Tc__2ioG1TnFU-wflEFU9leCQ_6_0"></a><a id="Tc__aR2EwXZVkea4VyFJsYi3w_7_0"></a><a id="Tc_ro7kQpJwo0ypAYG4UikT3A_8_0"></a><a id="Tc_AphpMpwKp0aflAzLGbJv_g_9_0"></a><a id="Tc_SutIatiQKUiYf29cTEwapA_9_3"></a><a id="Tc_w8i7R_6hGUahRmCpOsAnqA_9_6"></a><a id="Tc_m2TDGwWSuE6OolYNrFqzZg_9_9"></a><a id="Tc_Gj74DL6bwU237rjATPBhvQ_10_0"></a><a id="Tc_yH7y08s_IkSGXZmc9agPlQ_10_3"></a><a id="Tc_B-q3rBIfnESOQ8E9K_nXeg_10_6"></a><a id="Tc_Q4n8SAD4bkWv8-WcggpQ5w_10_9"></a><a id="Tc_d6sG30Qa6Uqk_zthPwjsdw_11_0"></a><a id="Tc_tyIpvFRM8ECSgbSvgorzLA_11_3"></a><a id="Tc_PY0JKIsngk63B-Pfup5oUg_11_6"></a><a id="Tc_mQsK6p3ECkOUWlA7GP_3sA_11_9"></a><a id="Tc_6_svSNIjSUSRUtck8Ms7Ow_12_0"></a><a id="Tc_VcQm98BCfkCXVyi09eQ0Vg_12_3"></a><a id="Tc_pz_pczHsiUitdOi5rL-IKg_12_6"></a><a id="Tc_b3JH1ysSKUuEX_CTaxEEOQ_12_9"></a><a id="Tc_BuEGiXESVUCyIyW3WMHfAg_14_0"></a><a id="Tc_Nsz3Inqfl0eUtgUDU7zz8Q_14_2"></a><a id="Tc_QZ5IY4RCC0WOOFx6Yuw92A_14_5"></a><a id="Tc_ZhSTzVbpAEKHlLwDdzEChA_14_8"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_WyHvdQ9h20yEz_b37h0OBA" continuedAt="Tb_WyHvdQ9h20yEz_b37h0OBA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income tax expense during the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 resulted from US federal and state income tax as well as minimum tax obligations in Austria. From inception through December&#160;31,&#160;2021, we have not been required to pay U.S. federal and state income taxes because of current and accumulated net operating losses. Income tax expense during the year ended December&#160;31,&#160;2021 resulted from minimum tax obligations. During the years ended December&#160;31,&#160;2023, 2022 and 2021, the Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt-sec:numwordsen" name="hook:IncomeTaxBenefitsNetOperatingLossesIncurred" scale="3" id="Narr_ADZMTpvv6UCwhWku07eM2A"><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt-sec:numwordsen" name="hook:IncomeTaxBenefitsNetOperatingLossesIncurred" scale="3" id="Narr_bZR54tKyrUyoTR8QN9PoFg"><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt-sec:numwordsen" name="hook:IncomeTaxBenefitsNetOperatingLossesIncurred" scale="3" id="Narr_e-3atmpQRkCtu-QOe7RkHg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> income tax benefits for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items. The Company's losses before income taxes were generated in the United States and Austria.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_v7_PBmpMB0ynODr5aUBoeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2023, 2022 and 2021 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="Tc_F2gO2tV-JEi1HFWIkxVDcg_3_3">1,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_5AjtMcG7m0KVQmw0HBmQKA_3_6">7,222</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_muOTRZ6-tkSyAPTebOkDWQ_3_9">11,403</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign (Austria)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_anc61ACgOkuiEPFX5Inuww_4_3">82,922</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_f3otQX5-vkacnv7glIGTvg_4_6">57,463</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_eyIipq4xoUu2XEtpSZ9Idg_4_9">64,261</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_gZ1-UbUfv0OYEOgFTwl5zg_5_3">81,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_F4Gz5fEFzEO-cNQ906K3dw_5_6">64,685</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_fjlQ80N99UeYJQsaLolmqQ_5_9">75,664</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_Qu5jlB84KEOWb6KgIl1ssw" continuedAt="Tb_Qu5jlB84KEOWb6KgIl1ssw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The components of the consolidated income tax provision for the years ended December&#160;31,&#160;2023, 2022 and 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Federal</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="Tc_Q48itgLs-UaQmNn950LrIg_4_3">145</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="Tc_ebUa4bfOVUaNaMUub-mxFg_4_6">217</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">State</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_nTfo9N51cUmVvhVXFqYF8g_5_3">222</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_umpMOYk7F0GzyCIsvreVAg_5_6">12</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Foreign (Austria)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_gKaUDGQAIkuVmUx6F5govg_6_3">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_mY1cv29Like-ntyHcF628g_6_6">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_WvXt3RMj50aPRkzhUDBZrg_6_9">1</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total current tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_0j7apgEKOEOTo044TLFGug_7_3">368</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_7cgtp0PVOEuWXIG2JEskrA_7_6">230</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_zPOWVeySwEGCkdIZbi7q-g_7_9">1</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Federal</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">State</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Foreign (Austria)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Total income tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_qZxu7SnvUU62cHSub49Ipg_14_3">368</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_K0FYFLa_8E2RVYVeC8G0YQ_14_6">230</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_qpwmn72vRECTDkGHUYQkVQ_14_9">1</ix:nonFraction></span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3beb9c49_f1b3_4147_9690_eed96b9b15f9"></a><a id="Tc_NncSHFWcxUyAS4i5iA-cMg_1_2"></a><a id="Tc_kUfKWnHJ2ESYg6TbxamYOg_2_2"></a><a id="Tc_-fu8tice2kK3ljsuToodvA_2_5"></a><a id="Tc_J8F4MhEiakGR7Dv8kPLfYw_2_8"></a><a id="Tc_RCDFQqj8wEessfa3Kuulxg_3_0"></a><a id="Tc_bMsA0KIgUESthv_MOzxjSA_3_4"></a><a id="Tc_yu4UR4EvtEq8iS1srCH3HQ_3_7"></a><a id="Tc_p5o5I2uPaUqU-Cl87oLSKw_3_10"></a><a id="Tc_bwFDyQwJ_UKNDPX9xTALpQ_4_0"></a><a id="Tc_JFPsJ5BjGU6J-FTseQ9FaA_4_6"></a><a id="Tc_ESNRwXYGbUiIWKwyhQPGLw_4_9"></a><a id="Tc_p0XfFCHKLU-RMFk3Btgj0Q_5_0"></a><a id="Tc_uUyXn7fA6k2sThGLos78fw_6_0"></a><a id="Tc_dcMe5vOgaUetsHmlTP92-A_7_0"></a><a id="Tc_lRWb0uPSAkqauamQw16hbA_8_0"></a><a id="Tc_3DaocqnfXE2Umud_DcdWCg_8_9"></a><a id="Tc_l-stGPw5r0e6Ko7mtyqylQ_9_0"></a><a id="Tc_0ooJrqt9_0a6NPwTE9rKKQ_10_0"></a><a id="Tc_WzDNYCx2vEahJ-EyRo8NLw_11_0"></a><a id="Tc_2crEaf5bsUOKSMPyoa-lgQ_11_4"></a><a id="Tc_AYpHiRg9xU2f0Rx0tnLwlA_11_7"></a><a id="Tc_gwtbxtCU3keZxl7GSUxbgQ_11_9"></a><a id="Tc_O692ajmR6U2Pn1n8VPPkpw_11_10"></a><ix:continuation id="Tb_WyHvdQ9h20yEz_b37h0OBA_cont1" continuedAt="Tb_WyHvdQ9h20yEz_b37h0OBA_cont2"><ix:continuation id="Tb_Qu5jlB84KEOWb6KgIl1ssw_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company's worldwide effective tax rate for the years ended December&#160;31,&#160;2023, 2022 and 2021 was <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Narr_bwpS_kSb70KAaaST40LFjQ">0.5</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Narr_kyrgB6amW0yVgs7pE0dG1Q">0.3</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_PrzoODvnhUOlegZIXZt8KA">0.0</ix:nonFraction>%, respectively. The tax rate is affected by recurring items, such as tax rates in foreign jurisdictions and the relative amounts of income earned in those jurisdictions, which is expected to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. The following items had the most significant impact on the difference between the statutory U.S. federal income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr__d2_QY3ewkWNmppDWmoVYw"><ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr__SOVErHKLEORWsMQ36TkHQ"><ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_Di7VUZWUWUu9wwPhgInsHA">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>% for the years ended December&#160;31,&#160;2023, 2022 and 2021 and the effective tax rate:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_yXhFmWQdFUuay_S_ru5-Ig" continuedAt="Tb_yXhFmWQdFUuay_S_ru5-Ig_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_XZLZChSLQkC2zro0CUoD5g_3_3">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_MQMFs1ez7UymyKO7mxlFZw_3_6">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_PuEqAcdkzUifSdeQTQEgvA_3_9">21.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_t4IBIkm5pEu7ZwYjC9Q5Cw_4_3">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign tax rate differential<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Tc_3ioFV0aNQkeGCeFVt5BXdA_5_3">2.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Tc_23vxKOBKZkOIonrG24l66w_5_6">4.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Tc_8aVsNy2J40y1PC1XRT5kZg_5_9">4.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Not taxable government grants<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" sign="-" scale="-2" id="Tc_V-PU4FTmnkmTLs26hK_IPw_6_3">6.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" sign="-" scale="-2" id="Tc_zZU0Qc_JbkuQNFKHBDub-A_6_6">3.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" sign="-" scale="-2" id="Tc_R_-drpK1GkCRbaV9HKgRzg_6_9">3.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_3xtx-JGGLEudaUQqAi2AHg_7_3">0.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_lFIWfpAzs0SFTZdjhK3Ghg_7_6">0.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_WxPU9XqHGk-O18dZ3jzXdg_7_9">1.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Global intangible low-taxed income</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" sign="-" scale="-2" id="Tc_P8jjP6qF2EKwpWAD7IJ1qw_8_3">2.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" sign="-" scale="-2" id="Tc_TlblhAEOrk-jGLBv4VGZ6Q_8_6">1.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_UT3zhT_TkUOXDl1kbeAhgg_9_3">0.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_M2BmzaZSAky0MUvscrPY7Q_9_6">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_kNtRI-FYpUCidR33B8DhQA_9_9">0.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Change in deferred tax asset valuation allowance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_Aajkh0bWF0ye-d9LDQBG1A_10_3">28.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_GuMxOj1Axku1bHAG9VRrNw_10_6">27.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_C4CWTsXSGk6BPG4abR2eRg_10_9">30.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_C8GYXla41kyZLBBkPrFEMA_11_3">0.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_gpv4_35mMkSvwG9iQ5YwDQ_11_6">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Narr_75lA2qR8oU28lt-DOtQD5g">2.7</ix:nonFraction>% increase for the year ended December 31, 2023, and the <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Narr_oAp5WcYBdUeJBm-lljlLYA"><ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="Narr_EFjwZVl5rUyyJibaSdGY1A">4</ix:nonFraction></ix:nonFraction>% increase for the years ended December&#160;31,&#160;2022 and 2021, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_AT_hpenzR01Xkuk5j5fUTX0jQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_GH_2iULSq02hE5piqfVBYw">24</ix:nonFraction>% for the year ended December&#160;31,&#160;2023, and <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AT_3NogJxMRLUKuio1gDYqLrg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_MLBjW8V1C0-AI3xEEDMlog"><ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AT_c4d1mu2O80qu0WCXkZuWww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_1WsfR6VtYEW-ZPN5vZCK2Q">25</ix:nonFraction></ix:nonFraction>% for the years ended December&#160;31,&#160;2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup>For the years ended December&#160;31,&#160;2023, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" sign="-" scale="-2" id="Narr_JulIgdiEk0WZc6La-nzHtA">6.8</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" sign="-" scale="-2" id="Narr_ME6iayc-vU6DVzquUbf2Ag">3.8</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" sign="-" scale="-2" id="Narr_nM3Y9gll6kaqPT4lOYKWmA">3.8</ix:nonFraction>% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3) </sup>For the years ended December&#160;31,&#160;2023, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Narr_49n0oRppuUO4PR1UBPGnnw">28.2</ix:nonFraction>% reduction, <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Narr_uAIPsP3CXUiqU0nmeps_rg">27.1</ix:nonFraction>% reduction and <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Narr_GyWLqNi-s0OqWKEarJxVYw">30.2</ix:nonFraction>% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company's research activities and the inherent uncertainties the deferred tax assets are fully offset by a valuation allowance.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b142edfd_b2f8_4850_a66a_e36f664a2589"></a><a id="Tc_5VtWf8a8PkCm4Z2Nrc9J-g_1_2"></a><a id="Tc_jM7RInmdNkiOkehbkmbjng_2_2"></a><a id="Tc_PIkI9wotMEqT_f-MtMRyTw_2_5"></a><a id="Tc_ytp9ERblo02Gbnra1iSBYw_3_0"></a><a id="Tc_GDjM6v9GV06kWJ3WvQ7-cg_4_0"></a><a id="Tc_tPnP3RoXI0CjqxvtA7sNVQ_4_2"></a><a id="Tc_BtYLs9Y6SkyOUmjsjX_Bbw_4_5"></a><a id="Tc_907kq7vgfEWv-FyB3oi-1A_5_0"></a><a id="Tc_sJ6aVs9HjU6fVUjSyji2Tg_6_0"></a><a id="Tc_flpEczv2aUKd3gMYNmk8gg_7_0"></a><a id="Tc_49wLWkfmzEO-y3ixxFhU4A_8_0"></a><a id="Tc_IJypIKbWX0ybgzxAMX7R7g_9_0"></a><a id="Tc_m0saBEKO-USR8QMQDRbyUA_10_0"></a><a id="Tc_k0tfgSuw9USZ6R99CgMv2g_11_0"></a><a id="Tc_LWgibIjZZkSi6RYu3xqoTw_12_0"></a><a id="Tc_qA6okpBrhEaE2ZkZsCwmzA_14_0"></a><a id="Tc_QfYZ3GdTCUarCXtFId-J9w_15_0"></a><a id="Tc_xnnpsw60GEOZq-YdYBoZeg_16_0"></a><a id="Tc_4CU5M-lTnU6aL-GKIeTqBw_17_0"></a><a id="Tc_kjfrfnDXqkKBEt6ef51Wvw_18_0"></a><a id="Tc_GIbRmZq1SUea79eF30zwbQ_20_0"></a><a id="Tc_J-03_PuMMUu-dHb_wrC-4A_20_2"></a><a id="Tc_wo7PYsd1L0GHVFhsupblNQ_20_3"></a><a id="Tc_oK3zY3zr50Wf1Vpr90Jg_w_20_5"></a><a id="Tc_0qZ8tWa_wUamqkhyoEVM9A_20_6"></a><ix:continuation id="Tb_WyHvdQ9h20yEz_b37h0OBA_cont2" continuedAt="Tb_WyHvdQ9h20yEz_b37h0OBA_cont3"><ix:continuation id="Tb_yXhFmWQdFUuay_S_ru5-Ig_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_csA4lYXipkGPgSkOZLhyDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_O7TXQEAU1UaOEDVPQr_96w_4_3">87,445</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_oXWFM6kMXU-GShCI13tyNA_4_6">66,201</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Capitalized R&amp;D expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="3" id="Tc_wlUCCSihEEKoFI7ERg19Zg_5_3">2,657</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="3" id="Tc_04im37Wi9EaKtQ6qk4p7YA_5_6">1,354</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Credit carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_cUkaQ4GYFkC3wUYudTYehw_6_3">1,265</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_B3VYstNA4kKHO1UF1loVIA_6_6">64</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" scale="3" id="Tc_mVfEpSZ58kuuSgfUfwyWmQ_7_3">317</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" scale="3" id="Tc_UdQC59cLZUeAf6skjkYqRw_7_6">366</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_PlS5_Sm47061B7128NWNSQ_8_3">1,421</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_YITe7q0rTUCFjoJlIWZVyg_8_6">1,251</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_UWwDlFr5c0-qozey7KwvxA_9_3">1,254</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_E1CzMebgtUSJPsYcqqSkzQ_9_6">918</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_z1yBQ66j7kqX-ZBLv3QWhg_10_3">94,359</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_8ygtbb54EEuiSpeepBiDzA_10_6">70,154</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_uZE5lyNOPUalnN2F17RWDQ_11_3">89,309</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_8_XkpGN_YkGq-wipVFzNTA_11_6">65,774</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc__YDDph-ri02isywiNE1NxA_12_3">5,050</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_4fQnMrGOwkq-3eeBgfZAFQ_12_6">4,380</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="Tc_MRfeWgD7kUeFRy2oiNgG3A_15_3">3,774</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="Tc_A2z7uB_WgkGCcLhhQGsScQ_15_6">3,450</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Fixed assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="3" id="Tc_GOEGBDxIq0SlcbBfXAOTxg_16_3">14</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="3" id="Tc_DpTdfmmRykmmfH-OJz5JzQ_16_6">10</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease right of use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="Tc_jf5UjyMoFkW_dTB8m4HdWw_17_3">1,262</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="3" id="Tc_nCXcb6kyH0Wli9DZ5vBMuA_17_6">920</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_1lJB6Zq0yE2MDFvG21pFOg_18_3">5,050</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_jRVg41LENUOTwEkZZJFdCQ_18_6">4,380</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2023, 2022 and 2021, the Company had Austrian net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_AT_yaoK_p7Sukuiq2w5N3spOA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_uPuopDNJIky8Kh_WcxqoyA">378.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_AT_3mwjH__tMUma_hkm6Ve5jg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_4ERdTKwT4kS4oDoykuv-Qw">275.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AT_nqOGXBicVESvalgSTFcbwQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_vtx84ze3MkKxFQCMsER3xw">219.7</ix:nonFraction>&#160;million, respectively, that do not expire, however these carryforwards are limited to 75% of the taxable income in any one tax period. As of December&#160;31,&#160;2023, 2022 and 2021, the Company had federal net operating loss carryforwards that were generated after December&#160;31,&#160;2017 of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_C_IAmN5vm0OXRMTCb5TGJQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_bLH82GN4p0GvLchujGCFHg">2.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6rCpmJmAUk-pthMRELXHZw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_8MSb_mJygEC-n1yC4spJzg">13.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_poFM7cMgMUmMG8tthzI0dA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_iVjNUXSxMkySv9J0j5QUlA">17.9</ix:nonFraction>&#160;million, respectively, that do not expire, however these carryforwards are limited to 80% of the taxable income in any one tax period. The Company generated US taxable income in the current year and was able to offset 80% the taxable income utilizing net operating loss carryforwards which gave rise to current taxes during 2023. The federal net operating loss carryforward as of December&#160;31,&#160;2023 were $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_C_IAmN5vm0OXRMTCb5TGJQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_aWS_mFimuUq3KYe4LLy6tg">2.2</ix:nonFraction>&#160;million, and US Federal net operating loss carryforwards as of December&#160;31,&#160;2022 were $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6rCpmJmAUk-pthMRELXHZw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_7KxZWD8fzE2OeUYR0UTATQ">13.8</ix:nonFraction>&#160;million. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets resulting from its net operating loss carryforwards. Management has considered the Company's history of cumulative net losses incurred since inception and the uncertainties related to the long period necessary to achieve profits from commercialization of any products and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December&#160;31,&#160;2023, 2022 and 2021. According to a tax reform in Austria in 2022, the corporate income tax rate will be reduced from <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_AT_hpenzR01Xkuk5j5fUTX0jQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_eEX2o0sif0yX5Wpzx8p8AQ">24.0</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_StatementGeographicalAxis_country_AT_kfxilsmFSkCesBThL4nisw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_9Qrqo6aJekOZkWFWYT-3Og">23.0</ix:nonFraction>% in 2024. The future tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2024_To_12_31_2024_srt_StatementGeographicalAxis_country_AT_kfxilsmFSkCesBThL4nisw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_tn8vJ2ek9EizPotFcer8UQ">23.0</ix:nonFraction>% was used to determine deferred taxes and the valuation allowance for the Austrian business. Management reevaluates the positive and negative evidence at each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_13248276_e6c0_415a_9005_b38b59538dbf"></a><a id="Tc_BLxgwhYMM0WX0LnZtvO70Q_1_2"></a><a id="Tc_LNXPMSvdRE6BH7xaYrMovg_2_2"></a><a id="Tc_eCs0MwdZe0uOwGLVoX-RmQ_2_5"></a><a id="Tc_fmZMv3ewIEWcbi5qEjyMnA_2_8"></a><a id="Tc_VAKPzOzsu0SG_inwP4TCRA_3_0"></a><a id="Tc_aAdKh4aF3U6clFF68gH9vw_3_2"></a><a id="Tc_axqKicE-BEq8fveXhqoJHg_3_5"></a><a id="Tc_uylvU96GhUOSM2zmBiL5SQ_3_8"></a><a id="Tc_UkK_Wlp410uubz7o-M9fUw_4_0"></a><a id="Tc_Z32K7Kmw6Ee2EkrQRuSv-g_5_0"></a><a id="Tc_8EdH0iM1jkqzXEw25ugfqA_5_2"></a><a id="Tc_eCZfnqIanEmVrpY4ot2K6A_5_5"></a><a id="Tc_bH4yZWj8oUuFQ_w4tk2PJg_5_8"></a><ix:continuation id="Tb_WyHvdQ9h20yEz_b37h0OBA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">losses is no longer present and additional weight may be given to subjective evidence. The tax years in which the tax carryforwards were generated may still be adjusted upon examination by the tax authorities.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="Tb_oLr3WtMuDUyi_wcjVzuLyw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2023, 2022 and 2021 related primarily to the increases in net operating loss carryforwards as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_i0c0fdYmPEeXl6U5C9HE7A_3_3">65,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_fJDzQ8JZHUi2MH0w156Agw_3_6">53,728</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2020_PSUqRWmVfkCw7OQN6sRoGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_S3q5Ve_UmUquL9TV2A0LOw_3_9">46,064</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Increases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Tc_ITLrGvkkv0KG2QS8jA9dkg_4_3">23,535</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Tc_Eb0G8YqswEK3IROGIcZvNQ_4_6">12,046</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Tc_sF_9pV6vq0iPVQlSQVNB7g_4_9">7,664</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_8QdwAnozP0WcBkKEpptCUQ_5_3">89,309</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_pAY6t80U7kyLZcW4Q0uViQ_5_6">65,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_TAA4UxCbcUSVX206APOJjQ_5_9">53,728</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;22,&#160;2017, the United States enacted the Tax Cuts and Jobs Act (&#8220;Tax Reform Legislation&#8221; or &#8220;TCJA&#8221;). The Tax Reform Legislation introduced section 951A, a new tax on so-called &#8220;global intangible low-taxed income&#8221;. GILTI applies to income of a controlled foreign corporation (&#8220;CFC&#8221;) that is not otherwise subpart F income, and consists of the excess "tested income" over a 10% return on the CFC's &#8220;qualified business asset investment,&#8221; or &#8220;QBAI&#8221;. QBAI is the total tax basis of the CFC's depreciable, tangible property used in the production of tested income. The full amount of GILTI is included in taxable income. The GILTI inclusion is then reduced by 50% (reduced to 37.5% after 2025). However, that reduction in GILTI may be limited based on the level of U.S. taxable income. A limited allowance for foreign tax credits is allowed that would reduce the U.S. tax cost. GILTI foreign tax credits can only reduce U.S. taxes owed on GILTI and are not eligible for carryforward. The Company's Austrian subsidiary falls under the category of a CFC and due to the nature of its business model as a technology company, there may not be a material amount of tangible assets if this subsidiary starts to generate profits. GILTI taxation therefore may be applicable. The Company estimated approximately $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" scale="6" id="Narr_PAmlf0SvqUq31dMNWmAl9w">8.8</ix:nonFraction>&#160;million of GILTI inclusion for the year ended December&#160;31,&#160;2023. The Company previously estimated $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount" scale="6" id="Narr_vH2OUVjrtEeHlG0_otMGdg">3.6</ix:nonFraction>&#160;million for the tax year ended December&#160;31,&#160;2022, but did not recognize any GILTI inclusion upon filing of the December&#160;31,&#160;2022 statements. The U.S. tax on GILTI, net of research credits, was $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="hook:UsTaxOnGiltiNetOfResearchCredits" scale="6" id="Narr_XUijoSu1WEiSouag_2PiMw">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="hook:UsTaxOnGiltiNetOfResearchCredits" scale="6" id="Narr_EYAdjM2tfUqGp7d5gdMxeA">0.2</ix:nonFraction>&#160;million for the years ended December&#160;31,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company files income tax returns in the U.S. federal jurisdiction as well as in New York. The tax years from 2018 to present remain open to examination by the jurisdictions in which the Company is subject to tax. <span style="background:#ffffff;">There are currently no pending income tax examinations in the U.S. </span>Furthermore, the Company files income tax returns in Austria. The tax years 2018 to present remain open to examination by the jurisdiction. There are currently no pending income tax examinations in Austria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company evaluates tax positions for recognition using a more likely than not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31,&#160;2023 and 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="Narr_88pT5eV9g0-Kx4zgTUQxaA"><ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="Narr_J3QCCO5p2k-_LnCFH0hMUA">no</ix:nonFraction></ix:nonFraction> unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_0LTWChXOzE2RHzApaTLGAA" continuedAt="Tb_0LTWChXOzE2RHzApaTLGAA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Commitments and contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Contract manufacturing arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into arrangements with contract manufacturing organizations (&#8220;CMOs&#8221;) for manufacturing of materials for research and development purposes, including manufacturing of clinical trial materials. These contracts generally provide for non-cancellable obligations or cancellation penalties depending on the time of cancellation. As of December&#160;31,&#160;2023, the Company&#8217;s total non-cancellable obligations under contracts with CMOs were $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="6" id="Narr_B-8JTPX6R0e7GZJk-3YO_w">7.4</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="6" id="Narr_YbVHlBZ7IUSFWJ-QuVvBbg">0.9</ix:nonFraction>&#160;million relate to 2024 deliverables and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="6" id="Narr_4ZWsjEUMqU-_VszB8vQFGA">6.5</ix:nonFraction>&#160;million relate to 2025 deliverables.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0LTWChXOzE2RHzApaTLGAA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Intellectual property licenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into certain license agreements under which it is obligated to make milestone payments upon the achievement of certain development and regulatory milestones, to pay royalties on net sales of licensed products, and to pay a percentage of the sublicense fees which the Company receives from its sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the years ended December&#160;31,&#160;2023, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="hook:LicensingFeesIntellectualPropertyLicenses" scale="6" id="Narr_hw1RAfCPQkyfclKm8_n6Kg">1.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="hook:LicensingFeesIntellectualPropertyLicenses" scale="6" id="Narr_W-Kx_yw2gUeWfBlm8KwwUw">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-5" format="ixt:numdotdecimal" name="hook:LicensingFeesIntellectualPropertyLicenses" scale="6" id="Narr_wSwqTdo31k2iOudM34KDUg">1.3</ix:nonFraction>&#160;million, respectively, in licensing fees related to intellectual property licenses as research and development expenses. The amount for the year ended December&#160;31,&#160;2021 mainly related to the upfront payment and milestone payments received by the Company under the Gilead Collaboration Agreement. The amount for the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 mainly related to the upfront payment and milestone payments received by the Company under the Gilead Collaboration Agreement and the Roche Collaboration Agreement. The amounts recognized as expenses have been agreed to by the licensors but calculation of sublicensing fees on future payments may be subject to interpretation and may change until agreed to by the receiving party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Indemnification agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31,&#160;2023 or December&#160;31,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Legal proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company was recently a party to a patent proceeding opposing European Patent No.&#160;3218504 (the &#8220;EP&#160;&#8217;504 Patent&#8221;), which was granted to the University of Geneva in July&#160;2020 and is exclusively licensed to the Company. In a decision that has become final, the Opposition Division of the European Patent Office (&#8220;EPO&#8221;) dismissed the opposition, and maintained the patent as granted. The Company expenses the costs related to this case and other such legal proceedings as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_xmB61jfi9Ey3KqPud6khgw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. 401(k) Savings Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_IxZE1dfzPEiPXPPlgJoS3Q">100</ix:nonFraction>% of the first <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_siwPTUcrj0GY_HOwR5KPyg">4</ix:nonFraction>% of each employee&#8217;s contribution. During the years ended December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021 expenses recognized for the 401(k) Plan were $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_Rp4byV-Rz0iLvfvXRJ_s6Q">0.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_4S8oJzHLCkeNGxXbrJJ2MA">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_xWTcHeQCN0-GWF_Ir3BmIw">0.4</ix:nonFraction>&#160;million, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_493064cf_9e66_417f_b4d1_f22f65596033"></a><a id="_e1d7c50e_5a8a_494d_8948_19b3593ccf55"></a><a id="Tc_MQSt666_l0q7auq2z9X1rg_1_2"></a><a id="Tc_8qirawTgoUCbBLOnVffhrw_2_2"></a><a id="Tc_IrZ8boD0-kac-0jB80pyog_2_5"></a><a id="Tc_Ms3P56nEE06YJyEJdYnbug_2_8"></a><a id="Tc_N1XXXcf_3kauei8_WgK9cQ_3_0"></a><a id="Tc_pQju0soidUSOiPH-LpeCKQ_4_0"></a><a id="Tc_pftGMSYTxkKIz-AsZgTt7Q_4_2"></a><a id="Tc_8J3cFWy6DkGZzY_3qPwrvw_4_5"></a><a id="Tc_-K4pLEzRjUCNiBuh8x8riA_4_8"></a><a id="Tc_yCr3iGf3VUqwFYQ3v88TnA_6_0"></a><a id="Tc_AHDW37ilf0eCzWJsiOkNFQ_7_0"></a><a id="Tc_8hs6aIaYtUScCR9FD3LPfg_8_0"></a><a id="Tc_yGoZxdJXhkWLW9pc-9yVuA_9_0"></a><a id="Tc_FstgtMuaVUScXln9RAGYCg_9_9"></a><a id="Tc_qKNNUuDafEmHVhEHMTp-4Q_10_0"></a><a id="Tc_kpzQk8iL4km9N9qwZE8IqQ_10_6"></a><a id="Tc_ySNE886fb0OvHoAbZULn9A_10_9"></a><a id="Tc_LqhHZbfg90q8q2xEH74V4Q_11_0"></a><a id="Tc_xoD6QtYfo0W5JSoMYCZwQg_13_0"></a><a id="Tc_4cJ0M_LwWESohjU8DGK8GQ_13_2"></a><a id="Tc_-RTa5of25kmE1fyRkbvEWQ_13_5"></a><a id="Tc_RQnZHvBoW0-E3KuJEV0P-A_13_8"></a><a id="Tc_uA9e4MOkZkCxrJ6yPDLSrQ_1_2"></a><a id="Tc_LGzTNmOGgU2IDVB2V5FkVQ_2_2"></a><a id="Tc_uhfXTtYUsUGRWTVVw17IIQ_2_4"></a><a id="Tc_AwTOxLQGsUO8brh8PQlD5g_2_6"></a><a id="Tc_CxVhJuRkJUGU4wOvDYvzXw_3_0"></a><a id="Tc_HURSp9VYg06PEg1zbVGRQQ_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:EarningsPerShareTextBlock" id="Tb_WfoHXKo9v0-dGaisz0iO7w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16. Net loss per share</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_lUvaXsuvt0WL0bcjFU52sQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__HU7m5oggEWSEq8lXtX4jQ_4_3">81,580</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VMthAYQW702bEm_JfcoqjA_4_6">64,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wJIb35J0IkS81vQwCWZCdQ_4_9">75,665</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_vxWMxth910WYNpMnH4Je_A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Qs0Yt_YpE06Hdl0zYqFzaA_7_3"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_vxWMxth910WYNpMnH4Je_A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_Qs0Yt_YpE06Hdl0zYqFzaA_7_3_2">72,422,676</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_Rai6liu0xUW1EmNBgzCqLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_BAceyx1YT02DfoSeJHJAfg_7_6"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_Rai6liu0xUW1EmNBgzCqLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_BAceyx1YT02DfoSeJHJAfg_7_6_2">50,743,080</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_7YwYjyiTDkSMl_b_qdxauw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_J0HK3XBhqEStOpvU4b_pCw_7_9"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_7YwYjyiTDkSMl_b_qdxauw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_J0HK3XBhqEStOpvU4b_pCw_7_9_2">29,945,954</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_l4B2TGYOiE-DNTqDxlQcPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Wl_4pj2yHkiZVlHaht7c3Q_8_3"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_l4B2TGYOiE-DNTqDxlQcPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_Wl_4pj2yHkiZVlHaht7c3Q_8_3_2">835,359</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_K5J3_Ady2kSe1fEoyF_eEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Ve5lwN7TqUGfp4DGg_Nm3w_8_6"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_K5J3_Ady2kSe1fEoyF_eEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_Ve5lwN7TqUGfp4DGg_Nm3w_8_6_2">1,697,000</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_UtzcBbT1wkeghno1rw2kMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EpqLWF7UqUuUFnLScOGZWg_8_9"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_UtzcBbT1wkeghno1rw2kMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_EpqLWF7UqUuUFnLScOGZWg_8_9_2">2,887,636</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_1EokcRnMHkWHJTLR_xT8tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_JM9RYTUWlEy7hbK6u15nzg_9_3"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_1EokcRnMHkWHJTLR_xT8tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_JM9RYTUWlEy7hbK6u15nzg_9_3_2">12,526,027</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4T_o5zMCE0ug338F1VQDdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_lShhh5f3_U6ZjOJlXjABDA_9_6"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4T_o5zMCE0ug338F1VQDdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_lShhh5f3_U6ZjOJlXjABDA_9_6_2">13,072,877</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A-2 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_WqKtPPVwDUSMTGed8PBTnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ZZFl1Xvy6ku2Bxm5TUbsjQ_10_3"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_WqKtPPVwDUSMTGed8PBTnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_ZZFl1Xvy6ku2Bxm5TUbsjQ_10_3_2">8,742,499</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total number of shares used to calculate net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_5OqHzogmLkCT_F3pZbqg8w_11_3"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_5OqHzogmLkCT_F3pZbqg8w_11_3_2">94,526,561</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_HYnGOpiduEmXc6Wz3CMfmQ_11_6"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_HYnGOpiduEmXc6Wz3CMfmQ_11_6_2">65,512,957</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2E216X3UbkeYKzBmq9_mmw_11_9"><ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_2E216X3UbkeYKzBmq9_mmw_11_9_2">32,833,590</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_RooOUorOv0G4Q4w0pTVThQ_13_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_RooOUorOv0G4Q4w0pTVThQ_13_3_2">0.86</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_gEbOlV7CLEy1KEZ90YAUvg_13_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_gEbOlV7CLEy1KEZ90YAUvg_13_6_2">0.99</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_OfwAxRAWwkCdLrcwK31xIQ_13_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_OfwAxRAWwkCdLrcwK31xIQ_13_9_2">2.30</ix:nonFraction></ix:nonFraction>)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#8217;s common stock. The Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is independently convertible into&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" format="ixt-sec:numwordsen" name="hook:ConversionOfCommonStockSharesIssuedUponConversion" scale="0" id="Narr_H6pKfjljHEeJgX0Je60F4A">one</ix:nonFraction>&#160;and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w" decimals="INF" format="ixt:numdotdecimal" name="hook:ConversionOfCommonStockSharesIssuedUponConversion" scale="0" id="Narr_5SGSNLg81keG5GdXNWq7ew">1,000</ix:nonFraction>&#160;<span style="-sec-ix-hidden:Hidden_Eut-pnlYxkmGfE27-Y1kbg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares</span></span>&#160;of&#160;<span style="-sec-ix-hidden:Hidden_x3Vvh87iFkeGHTZK_-BIJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common</span></span>&#160;stock, respectively.&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ" decimals="INF" format="ixt:numdotdecimal" name="hook:ConversionOfCommonStockSharesIssuable" scale="0" id="Narr_lEglqGL3j0uzlMCPMnEmlg">2,399,517</ix:nonFraction>&#160;shares of the Company&#8217;s common stock are issuable upon conversion of the Class&#160;A common stock,&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" id="Narr_zufKI2aYp0iq5YbwMf3jFQ">370,000</ix:nonFraction>&#160;shares of the Company&#8217;s common stock are issuable upon conversion of Series&#160;A convertible preferred stock,&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" id="Narr_qG6RuOmxtUWBiSDq0pXPMg">10,800,000</ix:nonFraction>&#160;shares of the Company&#8217;s common stock are issuable upon conversion of Series&#160;A-1 convertible preferred stock and&#160;<ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" id="Narr_uo-xkvFnYE2H5xZcVNhR7A">15,268,000</ix:nonFraction>&#160;shares of the Company&#8217;s common stock are issuable upon conversion of Series&#160;A-2 convertible preferred stock (see Note&#160;11).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares (common stock and Class&#160;A common stock) outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_PfPnM4te7kGl7XTD-QTX7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_4GN9LMP8E0i2s2spo0zrXg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_SpQpBUfhFU-PbBrY_XVHPw_3_2">8,111,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Eytulubnr0ySr_VAROpxiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ncZk4F3aRE-IZ4X-LKH-bQ_3_4">6,532,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nivr3y_350aPACUslx3dMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_47T4p1_qy0KCmkyTRlq_cA_3_6">4,231,178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ZVKBbdlpaE6FnmtfCoRLpw_4_2">8,111,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_xQ1kNosRy02Pmf4O_ksXPQ_4_4">6,532,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA" contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Gj7hTNg9oUuTze11J3dEDw_4_6">4,231,178</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">HOOKIPA PHARMA&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS (continued)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_jIRhUvHqJUKZq_i04iGo5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17. Related parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective September&#160;15,&#160;2023, Malte Peters, a member of the Company&#8217;s board of directors, agreed to lead the Company&#8217;s clinical activities ad interim as Senior Clinical Advisor. During the year ended December&#160;31,&#160;2023, the Company recorded expense of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_hook_MaltePetersMember_us-gaap_RelatedPartyTransactionAxis_hook_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_PWdmVxfZlkStxnW1wmGGow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="Narr_UJlKWHsyvEOlRxfWXpKfFQ">0.1</ix:nonFraction>&#160;million related to a consulting agreement entered into with Dr.&#160;Peters, effective September&#160;15,&#160;2023. In the years ended December&#160;31,&#160;2022 and December&#160;31,&#160;2021, the Company did not record any related party transactions.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q" name="us-gaap:SubsequentEventsTextBlock" id="Tb_e5O51WGvvEeGZqHtqjrxZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18. Subsequent events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Roche Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25,&#160;2024, the Company received written notice of termination from Roche of the Roche Collaboration Agreement (see Note 3.). The termination was made according to Roche&#8217;s right to terminate without cause, acknowledging that, to date, the Company had met all go-forward criteria under the agreement. The Company remains eligible for a final milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_1_25_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_c0SKflh3TEWHuSa8ZwnJiw" decimals="-5" format="ixt:numdotdecimal" name="hook:CollaborationAgreementFinalMilestonePayment" scale="6" id="Narr_kPm62SlCQUGb4sU9K3ipOw">10.0</ix:nonFraction>&#160;million associated with an IND submission for the HB-700 program. Upon the termination effective date April&#160;25,&#160;2024, the Company will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for this program. At December&#160;31,&#160;2023, $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_hxMA56zoRUiay5PFbkyb_w">26.8</ix:nonFraction>&#160;million of non-refundable upfront and milestone payments received from Roche were still recorded as deferred revenue and may be early recognized as revenue as a result of the termination in the first half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">January 2024 Restructuring Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;29,&#160;2024, the Company announced its decision to prioritize the clinical development of its HB-200 program for the treatment of HPV16+ head and neck cancers and its two Gilead-partnered infectious disease programs and to pause development activities related to HB-300 and most of its preclinical research activities. In connection with this strategic refocus, the Company&#8217;s Board of Directors approved to reduce the Company&#8217;s workforce by <ix:nonFraction unitRef="Unit_Standard_employee_JIvkuNcm3UeH8NvB6ulLsQ" contextRef="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="Narr_U9RPRhi3oE-RVr9yH_IkVQ">55</ix:nonFraction>&#160;fulltime employees, or approximately <ix:nonFraction unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA" contextRef="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_A5ZaUvS460yRsis9IeuIHg">30</ix:nonFraction>% of the Company&#8217;s then-current employee base and to rebalance the Company&#8217;s cost structure in alignment with the new prioritization of research and development programs (together, the &#8220;Restructuring Plan&#8221;). The Company expects the Restructuring Plan to be implemented and substantially completed by the end of the first quarter of 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with the Restructuring Plan, the Company estimates that it will incur cash charges of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ" contextRef="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="Narr_R0CEqe94q0KXgRqxytpf0w">1.6</ix:nonFraction>&#160;million for severance and other personnel and restructuring related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>hook-20231231xex4d3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 10:36:27 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 4.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">DESCRIPTION OF SECURITIES REGISTERED UNDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The following description of the registered capital stock of HOOKIPA Pharma Inc. (&#8220;us,&#8221; &#8220;our,&#8221; &#8220;we&#8221; or the &#8220;Company&#8221;) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our amended and restated certificate of incorporation (&#8220;Certificate of Incorporation&#8221;) and our amended and restated bylaws (&#8220;Bylaws&#8221;), which are incorporated by reference as exhibits to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, and applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). Our common stock, par value $0.0001 per share (the &#8220;common stock&#8221;) is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended. The summaries below do not purport to be complete statements of the relevant provisions of our Certificate of Incorporation, our Bylaws or the DGCL.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Our authorized capital stock consists of 200,000,000 shares of common stock, 3,900,000 shares of Class A common stock, par value $0.0001 per share (the &#8220;Class A common stock&#8221;) and 10,000,000 shares of undesignated preferred stock, par value $0.0001 per share (the &#8220;preferred stock&#8221;), of which 2,978 shares are designated as Series A convertible preferred stock (the &#8220;Series A preferred stock&#8221;), 15,800 shares are designated as Series A-1 convertible preferred stock (the &#8220;Series A-1 preferred stock&#8221;) and 15,268 shares are designated as Series A-2 convertible preferred stock (the &#8220;Series A-2 preferred stock&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Annual Meeting</i><font style="font-size:11pt;">. Annual meetings of our stockholders are held on the date designated in accordance with our Bylaws. Written notice must be mailed to each stockholder entitled to vote not less than ten (10) nor more than sixty (60) days before the date of the meeting. The presence in person or by proxy of the holders of record of a majority of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the stockholders may be called for any purpose only by the board of directors pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office. Except as may be otherwise provided by applicable law, our Certificate of Incorporation or our Bylaws, all elections of directors shall be decided by a plurality, and all other questions shall be decided by a majority, of the votes cast by stockholders entitled to vote thereon at a duly held meeting of stockholders at which a quorum is present.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Voting Rights</i><font style="font-size:11pt;">. Holders of common stock are entitled to one vote for each share held of record on all matters to be voted upon by stockholders and do not have cumulative voting rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Dividends</i><font style="font-size:11pt;">. Subject to the rights, powers and preferences of any outstanding preferred stock that we may designate and issue in the future, and except as provided by law or in our Certificate of Incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets or funds when and as declared by our board of directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Liquidation, Dissolution and Winding Up</i><font style="font-size:11pt;">. Subject to the rights, powers and preferences of any outstanding preferred stock that we may designate and issue in the future, in the event of our liquidation, dissolution or winding up, our net assets will be distributed pro rata to the holders of common stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Other Rights</i><font style="font-size:11pt;">. Our common stock has no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. Holders of common stock are not required to make additional capital contributions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#8220;HOOK.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Class A Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The rights of the holders of our common stock and class A common stock are identical, except with respect to voting and conversion. The shares of class A common stock do not have associated voting rights and each share of class A common stock is convertible at any time at the election of the holder into one share of common stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Our board of directors has the authority to designate and issue up to ten million (10,000,000) shares of preferred stock in one or more series. The authorized shares of our preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. Our board of directors may also designate the rights, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">32,820 shares of preferred stock are outstanding as of the date of our Annual Report on Form 10-K with which this Exhibit 4.3 is filed as an exhibit, consisting of 1,752 shares of Series A preferred stock, 15,800 shares of Series A-1 preferred stock and 15,268 shares of Series A-2 preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">Series A Preferred Stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Rank. </i><font style="font-size:11pt;">The Series A preferred stock will rank:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">on parity with our common stock, Class A common stock, Series A-1 preferred stock and Series A-2 preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">on parity with any class or series of capital stock hereafter created specifically ranking by its terms on parity with the Series A preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">senior to any class or series of our capital stock hereafter created specifically ranking by its terms junior to the Series A preferred stock; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">junior to any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series A preferred stock;</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">in each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily or involuntarily.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Conversion. </i><font style="font-size:11pt;">Each share of the Series A preferred stock is convertible into 1,000 shares of our common stock (subject to adjustment as provided in the related certificate of designation of preferences rights and limitations) at any time at the option of the holder, provided that the holder will be prohibited, subject to certain exceptions, from converting Series A preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">of shares of our common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to us.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Liquidation Preference. </i><font style="font-size:11pt;">In the event of our liquidation, dissolution or winding up, holders of the Series A preferred stock will receive a payment equal to $0.001 per share of Series A preferred stock </font><i style="font-size:11pt;font-style:italic;">pari passu </i><font style="font-size:11pt;">with the common stock, Class A common stock, Series A-1 preferred stock and Series A-2 preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Fundamental Transaction</i><font style="font-size:11pt;">. Upon consummation of a Fundamental Transaction (as defined below) pursuant to which holders of shares of our common stock are entitled to receive securities, cash or property, then upon any subsequent conversion of the Series A preferred stock, the holder thereof shall have the right to receive, in lieu of the right to receive the shares of our common stock underlying the Series A preferred stock, for each share of common stock that it would have otherwise been entitled to receive upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of our common stock. If holders of our common stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder of the Series A preferred stock shall be given the same choice as to the consideration it receives upon any exercise of the Series A preferred stock following such Fundamental Transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">A &#8220;Fundamental Transaction&#8221; means:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">we effect any merger or consolidation with or into another person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another person (other than such a transaction in which we are the surviving or continuing entity and our common stock is not exchanged for or converted into other securities, cash or property);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">we effect any sale of all or substantially all of our assets in one transaction or a series of related transactions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any tender offer or exchange offer (whether by us or another person) is completed pursuant to which more than 50% of the common stock not held by us or such person is exchanged for or converted into other securities, cash or property; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">we effect any reclassification of our common stock or any compulsory share exchange pursuant (other than specified dividends, subdivisions or combinations) to which our common stock is effectively converted into or exchanged for other securities, cash or property.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Voting Rights. </i><font style="font-size:11pt;">Shares of Series A preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding shares of Series A preferred stock will be required to amend the terms of the Series A preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Dividends. </i><font style="font-size:11pt;">Shares of Series A preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Redemption. </i><font style="font-size:11pt;">We are not obligated to redeem or repurchase any shares of Series A preferred stock. Shares of Series A preferred stock are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Exchange Listing. </i><font style="font-size:11pt;">We do not plan on making an application to list the Series A preferred stock on The Nasdaq Global Select Market, any national securities exchange or other nationally recognized trading system. We expect the common stock issuable upon conversion of the Series A preferred stock to be listed on the Nasdaq Global Select Market.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The transfer agent and registrar for shares of our Series A preferred stock (and the underlying shares of common stock) is Equiniti Trust Company, LLC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">Series A-1 Preferred Stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Rank. </i><font style="font-size:11pt;">The Series A-1 preferred stock will rank:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">on parity with our common stock, Class A common stock, Series A preferred stock and Series A-2 preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">on parity with any class or series of capital stock hereafter created specifically ranking by its terms on parity with the Series A-1 preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">senior to any class or series of our capital stock hereafter created specifically ranking by its terms junior to the Series A-1 preferred stock; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">junior to any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series A-1 preferred stock;</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">in each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily or involuntarily.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Conversion. </i><font style="font-size:11pt;">Each share of the Series A-1 preferred stock is convertible into 1,000 shares of our common stock (subject to adjustment as provided in the related certificate of designation of preferences rights and limitations) at any time at the option of the holder, provided that the holder will be prohibited, subject to certain exceptions, from converting Series A-1 preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to us.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Liquidation Preference. </i><font style="font-size:11pt;">In the event of our liquidation, dissolution or winding up, holders of the Series A-1 preferred stock will receive a payment equal to $0.001 per share of Series A-1 preferred stock </font><i style="font-size:11pt;font-style:italic;">pari passu </i><font style="font-size:11pt;">with the common stock, Class A common stock, Series A preferred stock and Series A-2 preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Fundamental Transaction</i><font style="font-size:11pt;">. Upon consummation of a Fundamental Transaction (as defined below) pursuant to which holders of shares of our common stock are entitled to receive securities, cash or property, then upon any subsequent conversion of the Series A-1 preferred stock, the holder thereof shall have the right to receive, in lieu of the right to receive the shares of our common stock underlying the Series A-1 preferred stock, for each share of common stock that it would have otherwise been entitled to receive upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of our common stock. If holders of our common stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder of the Series A-1 preferred stock shall be given the same choice as to the consideration it receives upon any exercise of the Series A-1 preferred stock following such Fundamental Transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">A &#8220;Fundamental Transaction&#8221; means:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">we effect any merger or consolidation with or into another person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another person (other than such a transaction in which we are the surviving or continuing entity and our common stock is not exchanged for or converted into other securities, cash or property);</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">we effect any sale of all or substantially all of our assets in one transaction or a series of related transactions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any tender offer or exchange offer (whether by us or another person) is completed pursuant to which more than 50% of the common stock not held by us or such person is exchanged for or converted into other securities, cash or property; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">we effect any reclassification of our common stock or any compulsory share exchange pursuant (other than specified dividends, subdivisions or combinations) to which our common stock is effectively converted into or exchanged for other securities, cash or property.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Voting Rights. </i><font style="font-size:11pt;">Shares of Series A-1 preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding shares of Series A-1 preferred stock will be required to amend the terms of the Series A-1 preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Dividends. </i><font style="font-size:11pt;">Shares of Series A-1 preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Redemption. </i><font style="font-size:11pt;">We are not obligated to redeem or repurchase any shares of Series A-1 preferred stock. Shares of Series A-1 preferred stock are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Exchange Listing. </i><font style="font-size:11pt;">We do not plan on making an application to list the Series A-1 preferred stock on The Nasdaq Global Select Market, any national securities exchange or other nationally recognized trading system. We expect the common stock issuable upon conversion of the Series A-1 preferred stock to be listed on the Nasdaq Global Select Market.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The transfer agent and registrar for shares of our Series A-1 preferred stock (and the underlying shares of common stock) is Equiniti Trust Company, LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">Series A-2 Preferred Stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Rank. </i><font style="font-size:11pt;">The Series A-2 preferred stock will rank:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">on parity with our common stock, Class A common stock, Series A preferred stock and Series A-1 preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">on parity with any class or series of capital stock hereafter created specifically ranking by its terms on parity with the Series A-2 preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">senior to any class or series of our capital stock hereafter created specifically ranking by its terms junior to the Series A-2 preferred stock; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">junior to any class or series of capital stock hereafter created specifically ranking by its terms senior to the Series A-2 preferred stock;</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">in each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily or involuntarily.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Conversion. </i><font style="font-size:11pt;">Each share of the Series A-2 preferred stock is convertible into 1,000 shares of our common stock (subject to adjustment as provided in the related certificate of designation of preferences rights and limitations) at any time at the option of the holder, provided that the holder will be prohibited, subject to certain exceptions, from converting Series A-2 preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">number of shares of our common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to us.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Liquidation Preference. </i><font style="font-size:11pt;">In the event of our liquidation, dissolution or winding up, holders of the Series A-2 preferred stock will receive a payment equal to $0.001 per share of Series A-2 preferred stock </font><i style="font-size:11pt;font-style:italic;">pari passu </i><font style="font-size:11pt;">with the common stock, Class A common stock, Series A preferred stock and Series A-1 preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Fundamental Transaction</i><font style="font-size:11pt;">. Upon consummation of a Fundamental Transaction (as defined below) pursuant to which holders of shares of our common stock are entitled to receive securities, cash or property, then upon any subsequent conversion of the Series A-2 preferred stock, the holder thereof shall have the right to receive, in lieu of the right to receive the shares of our common stock underlying the Series A-2 preferred stock, for each share of common stock that it would have otherwise been entitled to receive upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of our common stock. If holders of our common stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder of the Series A-2 preferred stock shall be given the same choice as to the consideration it receives upon any exercise of the Series A-2 preferred stock following such Fundamental Transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">A &#8220;Fundamental Transaction&#8221; means:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">we effect any merger or consolidation with or into another person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another person (other than such a transaction in which we are the surviving or continuing entity and our common stock is not exchanged for or converted into other securities, cash or property);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">we effect any sale of all or substantially all of our assets in one transaction or a series of related transactions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any tender offer or exchange offer (whether by us or another person) is completed pursuant to which more than 50% of the common stock not held by us or such person is exchanged for or converted into other securities, cash or property; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">we effect any reclassification of our common stock or any compulsory share exchange pursuant (other than specified dividends, subdivisions or combinations) to which our common stock is effectively converted into or exchanged for other securities, cash or property.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Voting Rights. </i><font style="font-size:11pt;">Shares of Series A-2 preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding shares of Series A-2 preferred stock will be required to amend the terms of the Series A-2 preferred stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Dividends. </i><font style="font-size:11pt;">Shares of Series A-2 preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Redemption. </i><font style="font-size:11pt;">We are not obligated to redeem or repurchase any shares of Series A-2 preferred stock. Shares of Series A-2 preferred stock are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Exchange Listing. </i><font style="font-size:11pt;">We do not plan on making an application to list the Series A-2 preferred stock on The Nasdaq Global Select Market, any national securities exchange or other nationally recognized trading system. We expect the common stock issuable upon conversion of the Series A-2 preferred stock to be listed on the Nasdaq Global Select Market.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The transfer agent and registrar for shares of our Series A-2 preferred stock (and the underlying shares of common stock) is Equiniti Trust Company, LLC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Registration Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Pursuant to the terms of our shareholders&#8217; agreement, dated as of February 15, 2019, certain of our stockholders are entitled to rights with respect to the registration of their shares under Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Demand Registration Rights.</i><font style="font-size:11pt;"> Pursuant to the terms of our shareholders&#39; agreement, certain holders of shares of our common stock are entitled to demand registration rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Short-Form Registration Rights. </i><font style="font-size:11pt;">Pursuant to the terms of our shareholders&#39; agreement, certain holders of shares of our common stock are entitled to short-form registration rights. If we are eligible to file a registration statement on Form S-3, upon the written request of a majority of our stockholders to sell securities at an anticipated aggregate price of at least $10.0 million, we will be required to use commercially reasonable efforts to effect a registration of such shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Piggyback Registration Rights.</i><font style="font-size:11pt;"> Pursuant to the terms of our shareholders&#39; agreement, certain holders of shares of our common stock are entitled to piggyback registration rights. If we register any of our securities either for our own account or for the account of other security holders, the holders of these shares are entitled to include their shares in the registration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Expiration of Registration Rights</i><font style="font-size:11pt;">. The demand registration rights and short form registration rights will terminate as to a given stockholder at such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such stockholder&#39;s shares without limitation during a three-month period without registration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have Anti-Takeover Effects</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The provisions of Delaware law and our Certificate of Incorporation and Bylaws could discourage or make it more difficult to accomplish a proxy contest or other change in our management or the acquisition of control by a holder of a substantial amount of our voting stock. It is possible that these provisions could make it more difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to be in their best interests or in our best interests. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by the board of directors and to discourage certain types of transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. Such provisions also may have the effect of preventing changes in our management.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Board of Directors</i><font style="font-size:11pt;">. Our Certificate of Incorporation and Bylaws provide for a board of directors divided into three classes. Each class is elected to a term expiring at the annual meeting of stockholders held in the third year following the year of such election. The number of directors comprising our board of directors is fixed from time to time by the board of directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Removal of Directors by Stockholders</i><font style="font-size:11pt;">. Our Certificate of Incorporation provides that members of our board of directors may only be removed for cause by a vote of the holders of at least two-thirds (2/3) of the outstanding shares entitled to vote on the election of the directors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Issuance of Preferred Stock</i><font style="font-size:11pt;">. Our board of directors is authorized, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, and to fix the designations, powers, preferences and the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The issuance of preferred stock could impede the completion of a merger, tender offer or other takeover attempt.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Stockholder Nomination of Directors</i><font style="font-size:11pt;">. Our Bylaws provide that a stockholder must notify us in writing of any stockholder nomination of a director not earlier than the close of business on the 120</font><font style="font-size:8.5pt;">th</font><font style="font-size:11pt;"> day and not later than the close of business on the 90</font><font style="font-size:8.5pt;">th</font><font style="font-size:11pt;"> day prior to the first anniversary of the preceding year&#8217;s annual meeting; provided, that if the date of the annual meeting is advanced by more than 30 days before such anniversary date, delayed by more than 60 days after such anniversary date or if no annual meeting were held in the prior year, notice by the stockholder to be timely must be so delivered not later than the close of business on the later of (x) the 90th day prior to the date of such meeting and (y) the 10th day following the day on which public announcement of the date of such annual meeting is first made by us.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">No Action By Written Consent</i><font style="font-size:11pt;">. Our Certificate of Incorporation provides that our stockholders may not act by written consent and may only act at duly called meetings of stockholders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">Exclusive Forum Selection</i><font style="font-size:11pt;">. Our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for state law claims for (1) any derivative action or proceeding brought on behalf of the Company, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to the Company or our stockholders, (3) any action asserting a claim arising against the Company or any of our current or former directors, officers, or other employees pursuant to any provision of the DGCL or our Certificate of Incorporation or Bylaws, (4) any action to interpret, apply, enforce or determine the validity of our Certificate of Incorporation or Bylaws, or (5) any action asserting a claim against the Company or any of our current or former directors, officers, or other employees that is governed by the internal affairs doctrine. In addition, our Bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Section 203 of the Delaware General Corporation Law.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">We are subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><font style="font-size:11pt;">Section 203 defines a business combination to include:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any merger or consolidation involving the corporation and the interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>hook-20231231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 10:36:27 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Georgia';font-size:11pt;font-style:italic;font-weight:bold;line-height:13pt;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;font-style:italic;font-weight:bold;line-height:13pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No.&#160;333-266084, 333-266104 and 333-276220) and Form S-8 (No.&#160;333-230995, 333-237285, 333-264587 and 333-271238) of HOOKIPA Pharma Inc. of our report dated March&#160;22,&#160;2024 relating to the financial statements, which appears in this Form&#160;10-K. </font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Vienna, Austria </font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">March&#160;22,&#160;2024</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">PwC Wirtschaftspr&#252;fung GmbH</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Gabor Kruepl</font></p><p style="font-family:'Georgia';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Austrian Certified Public Accountant</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>hook-20231231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 10:36:27 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS <a name="_Hlk34745580"></a>PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Joern Aldag, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of HOOKIPA Pharma Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:38.8pt;text-indent:-38.8pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:40.5pt;text-indent:-40.5pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 27.8pt 0pt 0pt;">Date: March&#160;22,&#160;2024</p></td><td style="vertical-align:top;width:50.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">/s/ Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 27.8pt 0pt 0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>hook-20231231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 10:36:27 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:right;text-indent:-36pt;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">CERTIFICATIONS PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.15pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">I, Reinhard Kandera, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of HOOKIPA Pharma Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:37.4pt;text-indent:-37.4pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">. JK</p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Date: March&#160;22,&#160;2024</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">/s/ Reinhard Kandera</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Reinhard Kandera</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">Chief Financial Officer </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>hook-20231231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 10:36:45 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32</b><font style="font-size:12pt;"><a name="Exhibit32_080634"></a></font><b style="font-weight:bold;">.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Annual Report of HOOKIPA Pharma Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the period ending December&#160;31,&#160;2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify that to the best of their knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:4.95pt;"><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><div style="height:4.95pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:46.29%;margin:0pt;padding:0pt;"><div style="height:4.95pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March&#160;22,&#160;2024</p></td><td style="vertical-align:top;width:46.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joern Aldag</p></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March&#160;22,&#160;2024</p></td><td style="vertical-align:top;width:46.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Reinhard Kandera</p></td></tr><tr><td style="vertical-align:top;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reinhard Kandera</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>7
<FILENAME>hook-20231231xex97d1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/22/2024 10:36:47 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 97.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">HOOKIPA PHARMA INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CLAWBACK POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Adopted on September 20, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">HOOKIPA Pharma Inc., a Delaware corporation (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-size:12pt;">&#8221;), has adopted a compensation recovery / clawback policy (this &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Policy</u><font style="font-size:12pt;">&#8221;) as described below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-size:12pt;font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance with rules issued by the United States Securities and Exchange Commission (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</u><font style="font-size:12pt;">&#8221;) under the Securities Exchange Act of 1934 (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</u><font style="font-size:12pt;">&#8221;) and the Nasdaq Stock Market. Please refer to Section 3 below for definitions of capitalized terms used and not otherwise defined herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-size:12pt;font-weight:bold;">Compensation Recovery Requirement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">In the event the Company is required to prepare a Financial Restatement, the Company shall reasonably promptly recover all Erroneously Awarded Compensation with respect to such Financial Restatement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-size:12pt;font-weight:bold;">Definitions</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Recovery Period</u><font style="font-size:12pt;">&#8221; means the three completed fiscal years immediately preceding the Restatement Date for a Financial Restatement. In addition, in the event the Company has changed its fiscal year: (i) any transition period of less than nine months occurring within or immediately following such three completed fiscal years shall also be part of such Applicable Recovery Period and (ii) any transition period of nine to 12 months will be deemed to be a completed fiscal year.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Rules</u><font style="font-size:12pt;">&#8221; means any rules or regulations adopted by the Exchange pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">c.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="font-size:12pt;">&#8221; means the Board of Directors of the Company.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">d.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee</u><font style="font-size:12pt;">&#8221; means the Compensation Committee of the Board or, in the absence of such committee, a majority of independent directors serving on the Board.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">e.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Person</u><font style="font-size:12pt;">&#8221; means any Executive Officer. A person&#8217;s status as a Covered Person with respect to Erroneously Awarded Compensation shall be determined as of the time of receipt of such Erroneously Awarded Compensation regardless of the person&#8217;s current role or status with the Company (e.g., if a person began service as an Executive Officer after the beginning of an Applicable Recovery Period, that person would not be considered a Covered Person with respect to Erroneously Awarded Compensation received before the person began service as an Executive Officer, but would be</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><font style="font-size:12pt;">considered a Covered Person with respect to Erroneously Awarded Compensation received after the person began service as an Executive Officer where such person served as an Executive Officer at any time during the performance period for such Erroneously Awarded Compensation).</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">f.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-size:12pt;">&#8221; means October 2, 2023.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">g.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Erroneously Awarded Compensation</u><font style="font-size:12pt;">&#8221; means the amount of any Incentive-Based Compensation received by a Covered Person on or after the Effective Date and during the Applicable Recovery Period that exceeds the amount that otherwise would have been received by the Covered Person had such compensation been determined based on the restated amounts in the Financial Restatement, computed without regard to any taxes paid. Calculation of Erroneously Awarded Compensation with respect to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Financial Restatement, shall be based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company shall maintain documentation of the determination of such reasonable estimate and provide such documentation to the Exchange in accordance with the Applicable Rules.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">h.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange</u><font style="font-size:12pt;">&#8221; means The Nasdaq Stock Market LLC.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">i.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">An &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Executive Officer</u><font style="font-size:12pt;">&#8221; means any person who served the Company in any of the following roles at any time during the performance period applicable to Incentive-Based Compensation such person received during service in such role: the president, principal financial officer, principal accounting officer (or if there is no such accounting officer the controller), any vice president in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy making function, or any other person who performs similar policy making functions for the Company. Executive officers of parents or subsidiaries of the Company may be deemed executive officers of the Company if they perform such policy making functions for the Company.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">j.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Reporting Measures</u><font style="font-size:12pt;">&#8221; mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, any measures that are derived wholly or in part from such measures (including, for example, a non-GAAP financial measure), and stock price and total shareholder return.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">k.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">A &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Restatement</u><font style="font-size:12pt;">&#8221; means a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required restatement to correct an error in previously-issued financial statements that is material to the previously-issued financial statements or that would result in a material</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"><font style="font-size:12pt;">misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">l.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive-Based Compensation</u><font style="font-size:12pt;">&#8221; means any compensation provided, directly or indirectly, by the Company or any of its subsidiaries that is granted, earned, or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure. &#160;Incentive-Based Compensation is deemed received, earned or vested when the Financial Reporting Measure is attained, not when the actual payment, grant or vesting occurs.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">m.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restatement Date</u><font style="font-size:12pt;">&#8221; means, with respect to a Financial Restatement, the earlier to occur of: (i) the date the Board or the Audit Committee of the Board concludes, or reasonably should have concluded, that the Company is required to prepare the Financial Restatement or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare the Financial Restatement.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-size:12pt;font-weight:bold;">Exception to Compensation Recovery Requirement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Company may elect not to recover Erroneously Awarded Compensation pursuant to this Policy if the Committee determines that recovery would be impracticable, and one or more of the following conditions, together with any further requirements set forth in the Applicable Rules, are met: (i) the direct expense paid to a third party, including outside legal counsel, to assist in enforcing this Policy would exceed the amount to be recovered, and the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-size:12pt;font-weight:bold;">Tax Considerations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">To the extent that, pursuant to this Policy, the Company is entitled to recover any Erroneously Awarded Compensation that is received by a Covered Person, the gross amount received (i.e., the amount the Covered Person received, or was entitled to receive, before any deductions for tax withholding or other payments) shall be returned by the Covered Person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-size:12pt;font-weight:bold;">Method of Compensation Recovery</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Committee shall determine, in its sole discretion, the method for recovering Erroneously Awarded Compensation hereunder, which may include, without limitation, any one or more of the following:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">a.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">requiring reimbursement of cash Incentive-Based Compensation previously paid;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">b.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">c.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">cancelling or rescinding some or all outstanding vested or unvested equity-based awards;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">d.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">adjusting or withholding from unpaid compensation or other set-off;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">e.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">cancelling or setting-off against planned future grants of equity-based awards; and/or</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">f.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">any other method permitted by applicable law or contract.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person&#8217;s obligation to return Erroneously Awarded Compensation to the Company if such Erroneously Awarded Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">7. </b></font><b style="font-size:12pt;font-weight:bold;">Policy Interpretation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law. The Committee shall take into consideration any applicable interpretations and guidance of the SEC in interpreting this Policy, including, for example, in determining whether a financial restatement qualifies as a Financial Restatement hereunder. To the extent the Applicable Rules require recovery of Incentive-Based Compensation in additional circumstances besides those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive-Based Compensation to the fullest extent required by the Applicable Rules.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-size:12pt;font-weight:bold;">Policy Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This Policy shall be administered by the Committee. The Committee shall have such powers and authorities related to the administration of this Policy as are consistent with the governing documents of the Company and applicable law. The Committee shall have full power and authority to take, or direct the taking of, all actions and to make all determinations required or provided for under this Policy and shall have full power and authority to take, or direct the taking of, all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of this Policy that the Committee deems to be necessary or appropriate to the administration of this Policy. &#160;The interpretation and construction by the Committee of any provision of this Policy and all determinations made by the Committee under this policy shall be final, binding and conclusive.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-size:12pt;font-weight:bold;">Compensation Recovery Repayments not Subject to Indemnification</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Notwithstanding anything to the contrary set forth in any agreement with, or the organizational documents of, the Company or any of its subsidiaries, Covered Persons are not entitled to indemnification for Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered under this Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">DATE APPROVED BY BOARD OF DIRECTORS: September 20, 2023</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>hook-20231231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $) [4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M("X?.#DD <\T ;5%4)=>TZ#4[33I+ZW2_NT:2WMFD DE50"S*O4@9&2/6K]
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MO4]3;C\&^+M3^%_@33=3AA_M[2=0T][\QW(*-';SKND#=RR(&QUR<=:]>HH
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MFC9VZ+$(V8!%  &>?6O3Z** "BBB@ HHHH **** "BBB@ HHHH SM(^_>_\
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M&\&:]XQUO0?L;6%K8:?>1WOVUYI/M$;+G<JQ;2CA@<9)!'->A44 (.E+110
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M>3:=_P!"5>_^!4?^-'_#R;3O^A*O?_ J/_&OA.BC_5S+OY'][_S#^W,=_/\
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M*/\ Z%V3_O\ #_&C_AL*/_H79/\ O\/\:^:J*/[1Q'\WX(/]9\S_ .?B_P#
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M0<G/)_*D;X72QR^3+J]ND\D[P0((';S"J;\DY^4$?7FCV-3L#P.(3LX_BO\
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M8=,NX;V6ZFN(+FSW1R&X $HP&! (48P<CUJEJGQ3U_583"\MO;QBXM[F);:
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M_*OO?^0?ZS83^27W+_,\/\Z/_GJG_?0H\Z/_ )ZI_P!]"O</^$KU?_H(S_\
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M_P">L?\ WV*_9W_A6GA7_H7M._\  =:/^%:>%?\ H7M._P# =:/];8_\^/\
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MOYT>8O\ >7\Z_0G_ (5_X<_Z ]I_W[H_X5_X<_Z ]I_W[H_LE_S_ (?\$/\
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MOT)_X5_X<_Z ]I_W[H_X5_X<_P"@/:?]^Z/[)?\ /^'_  0_U-G_ ,_U_P"
M_P#VQ^>WF+_>7\Z/,7^\OYU^A/\ PK_PY_T![3_OW1_PK_PY_P! >T_[]T?V
M2_Y_P_X(?ZFS_P"?Z_\  ?\ [8_/;S%_O+^='F+_ 'E_.OT)_P"%?^'/^@/:
M?]^Z/^%?^'/^@/:?]^Z/[)?\_P"'_!#_ %-G_P _U_X#_P#;'Y[>8O\ >7\Z
M/,7^\OYU^A/_  K_ ,.?] >T_P"_='_"O_#G_0'M/^_=']DO^?\ #_@A_J;/
M_G^O_ ?_ +8_/;S%_O+^='F+_>7\Z_0G_A7_ (<_Z ]I_P!^Z/\ A7_AS_H#
MVG_?NC^R7_/^'_!#_4V?_/\ 7_@/_P!L?GMYB_WE_.CS%_O+^=?H3_PK_P .
M?] >T_[]T?\ "O\ PY_T![3_ +]T?V2_Y_P_X(?ZFS_Y_K_P'_[8^9?V<F4V
MVO88'YX.A]GHKZBM?!VC66[[/IT$.[&[RP1G%%>E2PKI04+['U6"RB6$P\:+
MG>W6WG?N;-%%%>@?2!1110 4444 %%%% !1110 444E "T4F?K^5&<4 +129
MHS0 M%%% !1110!G:U_J(/\ KXB_]#%:-9VM?ZB#_KXB_P#0Q6C0 4444 %%
M%)0 M%-$BLS*&!9>H!Y%+F@!:*3.:,T +124M !1110 4444 %%%% !37^Z:
M=37^Z: /R^^)?_)0O$G_ &$;C_T8:YJNE^)?_)0O$G_81N/_ $8:3X;V\=UX
M]\/PS1I-$][$K1R*&5AN'!!X(K^A:,_9X6,^T4_P/XNQ-/VV83IIVO-K[Y'-
MTF1G&1GTS7T+IWA[2];U#PA8)I]JFH17-Q=KB%1]JB6Z99(V&/FPH##/92.]
M97FNOB3P-HL-I:S:;J%L?M=J;2(B13<2JS$[=W"C[V>,#TKC69)W2CJK]>BO
M_D>H\C<;.531V2LNKY=-^G-K]_4\0HKK?"2Z;:?$:UADL8=6L/MQBCBG=MC+
MOPI./O#&#CH:['4M)T4>&[Y[W?9E?%4T,;VEC'*Q4!OD.73"^P)'M774Q:IS
M47%ZV_'\3SJ&72KTY34UI?3TMU=EK<\AH[9R,>N:]#\76JV?QIOH+'2(=1"7
MZB'3?+VQRG"X4JO0'T%=7?7MF;#5IHTT^_\ %6CZ<[3W=I:Q>2DCS*-J*%VN
M8U+#?C'/'3-9RQME!J-^9)[[7[^7G^9O3ROFE5C*=N1M;;VWMYVNTO+5K2_B
M/Y45[W=/9>'KR6[O-,TVPT/RH9]1>2V1I;V=X 3:Q(P^7D[CMP%W9)X KG;W
MPSIUA\'+^6V73KJ\^T6UQ->17<,LD8?=B%0&W# QG@$GZ5G#,%*UX[M+?O\
MY?JC6IDTH<UIWY5)O3^7_/7739[GDU%%%>N?.!1110 4444 %%%% !7VQ^Q9
M_P B%+_U]S?^R5\3U]L?L6?\B%+_ -?<W_LE?'\5?\BY_P")'Z5X??\ (Z7^
M"7Z'TA1117XX?TV%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G:
M]_R#V_WE_G6C6=KW_(/;_>7^=:- !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &=I'W[W_ *^&_I6C6=I'W[W_ *^&_I6C0 4444 %%%%
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MC7)^/]>L]=TCPD+0VD,MO9/'-;V@*I QE) P2<<<]32I8FO.<8SA9/\ RO\
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MI45F_P!M+_SZ7O\ X#M1_;2_\^E[_P" [4 :5%9O]M+_ ,^E[_X#M1_;2_\
M/I>_^ [4 :5%9O\ ;2_\^E[_ . [4?VTO_/I>_\ @.U "Z]_R#V_WE_G6C7/
MZSJRRV++]FNU^9>6@8#K5[^VE_Y]+S_P':@#2HK-_MI?^?2]_P# =J/[:7_G
MTO?_  ':@#2HK-_MI?\ GTO?_ =J/[:7_GTO?_ =J -*BLW^VE_Y]+W_ ,!V
MH_MI?^?2]_\  =J -*BLW^VE_P"?2]_\!VH_MI?^?2]_\!VH TJ*S?[:7_GT
MO?\ P':C^VE_Y]+W_P !VH TJ*S?[:7_ )]+W_P':C^VE_Y]+W_P':@#2HK-
M_MI?^?2]_P# =J/[:7_GTO?_  ':@#2HK-_MI?\ GTO?_ =J/[:7_GTO?_ =
MJ -*BLW^VE_Y]+W_ ,!VH_MI?^?2\_\  =J %TC[][_U\-_2M&L#3-66-KL_
M9KMMTS'B!CBKO]M+_P ^E[_X#M0!I45F_P!M+_SZ7O\ X#M1_;2_\^E[_P"
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M\./HC\3K_P :?J_S"BBBM3 **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG.EM=>8RSRNI.Q0<,$#9Y((P<$?I5M-1\*3;KETM%>Q43NYCR(B0G ;&"?\
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M>R#<&8@C((.30!&/VN=!N_!6@^(=-\.ZWJAU@7]Q#I\"1+/':V;$3SOO=5
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MRLSD-1TB73KV.U++-)(B.OE@\[AD#GZU=D\,&U6XDN[Z&V@@<0M(49\R$9*
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M7@Z5\A^#O^1HTO\ Z^$_G7UX.E?*YS\</1GZ!PS_  JGJA:***^</LPHHHH
M**** "BBB@#.U[_D'M_O+_.M&L[7O^0>W^\O\ZT: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,[2/OWO_7PW]*T:SM(^_>_]?#?TK1H
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MK2HH S?LNI?\_P!!_P" Q_\ BJ/LNI?\_P!!_P" Q_\ BJTJ* ,W[+J7_/\
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M1>^T:?\ \^<__@3_ /8T?:-/_P"?.?\ \"?_ +&J-%'LH]W][_S#V\NR_P#
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MHW[&;]EU+_G^@_\  8__ !5'V74O^?Z#_P !C_\ %5I45B=)F_9=2_Y_H/\
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MNE,M_*CS^6-ZPJVYXP9,@]"._>@#VZBOD5OC]XVO=$TW2M%\1VTWB!(M7O\
M4[K6?#OV26V-BD1^Q/:B8A68RC,@=OE.0#5S3?VFO%FO^)=,UBW6PM/"R7NA
M:9=Z2]JSW$SZC DC2K-N&WRS*H"[3NP<D9% 'U=12"EH **** ,[6O\ 40?]
M?$7_ *&*T:SM:_U$'_7Q%_Z&*T: "BBB@ HI#P#7A5W\<-5M]"U=?LUV=2M_
M$G]FQ70TF4V@@^U)'AI<;,["1G/6@#W:BO!O"7QKUFST?5[_ ,2/#<1MI+ZI
MIQA@\K>T<TD,L/7D[O(([_O#7LGA4:H/#>F?VU)')JYMT-VT2;$\TC+!1DX
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MD_@)Y_L@.I/"U['.91N"*<"/9G/(W'..U9_68**E)6N[&OU&HY.$6FTK_P#
M]3SS%)7703IH^G:.+K1=*U&&^4LA*.)V ;!RP(Y],5E>,-(@T+Q)>V5L6,,3
M#:'.67*@[3[C./PK6-52ERV[_AH83H.$.>_;\5=&;8P+<WL$+$A9)%4D=<$U
MVLG@>R_M"YMI8+W3DBNT@BEN)01< M@[04&#CG(R.*XBVG-K<13* 6C8, >A
MP:N?VW+_ &^=6\J/SS/]HV<[<YSCUQ2J1G)^Z[%49TH+]Y&^OX&A+X.F^TJL
M-W;RV[F0)*N\YV-@KMV[F;D= <TM[X(OM.BGDNI88%B;8"P?#';N R%^7(/\
M6.:2T\:7-I;-;_9XGA82A@'=&(=@Q^92".1V_&I1XZGCOI;R.RMX;AU"!HY)
M%55"[0"N[##'9JS_ ']_^&-O]D:O_GVU_P"!J5+_ ,)7NG64ES(4;R@AFC4-
MNB#_ '<D@ ]1T)QFF:-I%KJ&G:I/+<ND]K 98X43[V.Y;H![=:DU7Q9<ZO9M
M%/&@=P@>7S'.X*,#"EMJ]LX'-9UAJCZ?%=H@1A=0F%BQZ ]Q[UHE4</>W,9.
MA&I[NL;?Y_\  \K^1<\,65GJ6L6]G>13.L\@0/#,$*^_*G/Z5;_X1V*\W7%N
MZ6ELMS]D6*XF9Y)'YZ%8\ 8'?I6/I>HOI6I6]W&$>6%PZH_0X]<<U:C\031P
MK$(XR%N_MG?.[GCKTYHG&?->(J<Z7(E-=_TM^IHQ^"+R<W#1M$5@9]\:%G*J
MK8.6"[0>N 2"?2O1_@I81Z7XRU^TB+-'%&JJ7.21D=:\\_X6!=$$O9V[OMD1
M6+R84.23A=VW/)^;&:[[X%7[ZIXIUN[D54>:)6*IT'(Z9KR\;[7ZO/GV_P""
MCWLK^K_7*2I;W?Y,]OHHHKXT_2@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,[7O^0>W^\O\ZT:SM>_Y![?[R_SK1H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH SM(^_>_]?#?TK1K.TC[][_U\-_2M&@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?Q7XXN
M=*UZWTVV2&("2/S7EE DD5DD;$:$<@;.6SQZ'%=Q43VT4LBR/$CNHP&902!]
M: .#_P"%HM;P7YEL5D>VMXYHP)P6EW>6"6PN% ,@SW &<4__ (6>5N-+A>QB
M#W4JQ2JMSDKNE:-64[<,I*YZ@X/3BNY^R0Y<^3'F1=K_ "CYATP?44@LX 8S
MY,>8QA#L'RCV]* //(OB\\L=N%TN-IV+&1%NAA5'E_*K%0K.?,& #CCKS7I
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M>7^OD=CJ9@L;2]MIH;6VLI3)!8P!!ND;>?W[,>5"],YYQ@=ZI>+].M;+P[I
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M?EI_US;^8KEJ /7?-3^\OYBCS4_O+^8KR*B@#UWS4_O+^8H\U/[R_F*\BHH
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MY&O::*/[8_Z=_C_P _U:7_/[_P E_P"">+>6W]UOR-'EM_=;\C7M-%']L?\
M3O\ '_@!_JTO^?W_ )+_ ,$\6\MO[K?D:/+;^ZWY&O::*/[8_P"G?X_\ /\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>hook-20231231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $+ [8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO(_VIK;4Y/@UK%QI6K:
MGI5S:207'_$J?9)< 3(/*9@"P0Y^8*02!@G!((!ZWGG% .:^./B1J^NP_$SQ
M:-#O]>/Q,2_ODM;&WEN#$-#&CNT+I#_J=OVG85?&XSG;D\K79? ;6;VUT?QI
M)\.(+OQ=X:CFL/[+CU[5KB)&N&@!O@MQ.DC\,49EP0)#(/E.X  ^DXIHYMWE
MNK[6*MM(.".H/O3Z^</A1XL^*4%MXI^R?#K0K@-XCU%I"WBLIL<R_,H_T0Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM)YVYSC/.*^6OV@/A1J'Q7_:#2RM/#_AK7!!X0!27Q3]J\FU=KR0;X?(YW\
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MC*R@AE(((X- 'SKIOQ/UWQ;^R[XMU2Y\2G69$UV?11KT-E]B=[#^T([9IO+
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MNE=6RY/EMC'LJ_E7G/[?GP!^('QA^.UI=>#_  Y<:Y;V7A^V2=XI8UV$S7!
M^=@3G!Z5X[^Q'K/B3X9_%Z02W=SX<T>8+'K$PTU[MVBC;?Y054<JS$A<X&,G
MFOL,;E^&SZG1Q4E^_IJ3BDWIS)77*M[I:)I]T?J^9YQA\7DDYN<7)I7BFFT^
M9+UT;U_$_7FBLGPKXJTOQKH-MK.C7/VS3K@N(Y?+:,DJY1@58!@0RL"" <BM
M:OAYPE3DX35FM&GNGV9^6IWU04445 PHHHH **** "O%_P!J?X$?\+M^$^OZ
M+HUEI$/B>^%NL&I7\(5D5)D<@RA2X^56 QZ^]>T45K2JRHS52&ZU-Z%:>'J1
MJTWJG?[C\N_#W_!,3XFZ9K^F7ESJ_A>6VM[J*66,7$S;D5P6&#%@\ \5^FNC
MZ#IOAZV:WTO3[33;=G,C16<"Q(6/5B% &>!S[51M/&>F7OBZ^\-Q2YU*TMTN
M)$[;6/0>X^4G_>%;M;5\VGFBNY)\K:T[IZI^::/4S/'XS&."Q:M976EM'JG_
M )'&^/?A?I7Q%U7PQ<ZQ'#>6>B7DUV;"ZMDGAN3);2P;75P1@"4MTZBO))/V
M-K".^TX6OB6=-(M(ET[^S;FR29/[,CNFN+>S4E@!Y1DDC5V5_P!V5!7<@:O9
M?B'\1-,^&FB0ZGJD-]=)/=164%MIMH]U<332'"*D: DDX/Y54\&_%KP[XUTR
MYNX)[C2Y+2\&GW5GK5L]C<V]P45UB>.4*0621&7&=P8$9KD/$/'O ?[+>KR6
M.AW7BWQ+*;O1[R2XT[3[>VB\NSC?4/M4B&1>92^R$!FQM /!8EJT=._97U/0
M?#=YX=T7XD:MI&B75K$98;:Q@\TWJ6L5MY_FGYA&RPHQB&#G.' XKV'Q-\0-
M!\):3J6HZAJ,2P:=%YURD)\R2--VW)1<M]XXZ5<TWQ-8:DMN!,+:>X:9(K:Y
MQ',_EN5<A"<D#;G([$'O0!X-HO['ATMWDD\:7$\MS>W-[>!=.C1)3--I\VQ!
MO)0*^FQX)+$AV!)(!J#QS^S1JFAZ#X=U'PE?7&J>(O#9/V&,F& EGOOM+R8D
M!1R%9TV,5#!L[U8 U[7K?Q2\+Z"EEY^L6TLM_)/#9PVSB5[F6&)I9(T"YRX1
M&X]<#J16S:>(M-O"ZQWL'FQQ>=)"95$D2>KKG*XZ'/I0!XSX5^#WB?2O@7X0
MTK498+OQ?HNKIK\J"1%CFE-[)<21%E4*"4F=<@!0V".*?:_LXZTF@W6@7'CQ
MVT:&^DU71OLVD11W>FWOVPW44OFEV64(S,I1D 96(->NZAXOT;3/#E[KTVHV
MYTBSA:XFNHG$B*BKN)^7.>,8 Y.1CK7"/^T?X4@\3RZ-<6^N6HBODTN34YM(
MG%@EVZJRP-<;=BN2ZKR0-Q"YR<4 <YKG[-&J>,DENO$WQ!U'5-::"[B@NX;.
M.WBLFDCC6%[>$$B,Q21++DEB[]3@ "34OV5],O/"6I:);:_?:>]S?6E[!?6\
M:>=;&*RCLI@.Q\Z$3!B>1Y[$=!6W>?M-^!;2/3Y5N=1N[:YL+;5+BYL]+N)X
M=.M;A=T,MVZ(1 &7GYR" "Q 49K;;XU>&/\ A&--UV.>ZGMM0U"72K:"*TD:
MX>ZC:598O* W KY$Q/LA/I0!B:C\$K#Q/X_%]JEHUOH&E:3;:9I5K97DMNV5
ME,KL3$RL%7;"@0D@[6)'2M?X5_!+PU\*;$_V?INGR:S))<R7&M+8117=QYT[
MS$/(HW, 7 Y/.T5>\6_%C0?"/@_3O$LK7>IZ=J4EO%8KI5J]U-=-/CRA'&@W
M-N!S]*Q=._:*\#W\&DB34;C3M0U/5_["ATK4+*6WO5O<*QB>%E#+A71BQ&W:
MZG/S#(!SUS^REX6\0C3+7Q4Y\3Z-IPU-K?2[N/RXA-?73SRRDHP)(1S"!TVE
MCU8UNZ?\$%M=)\ 6=SK]S?/X0@N+:"YEA7S+E)+9[9-YS]Y(V'S#[Q7GJ:ZG
M2?B1X?UOQQKOA&SOA)K^B007%[:E&&Q)@2A#$88X R 3MW+G&X9GT#QWHOB6
M_P!6LK&]5[O2[J2SN89/D=7C"EB >2HWK\PXYZT >'O^QO$^@?\ "._\)I??
M\(V84E:P^PP[C?KIPL!<^;][9L4/Y73</O;?EKI/&_[+VE^.K/5[6[UN[MX=
M1U>+5W,$*;HWCTL6"*I.0<;5ER0>1M(*FO6D\2:3)!;3)J=FT-R=L$BW"%93
MN"X4Y^;YB!QW.*</$&EM';R#4;0I<2F"%A.F)) 2"BG/+9!&!SQ0!X?=?LJ3
MZOJ%WKNJ^-[R[\77+_:6U:+3X8HTN8Y+)[:18.5VQ_88P4)._>^2/EQPWC+]
MFGQY8^(1#X<U3^T8_$UQ;7?BG6K@6T4<TL5^+C_CW*EHE6/<B^4S%LC=M(\P
M_3/AOQWHGBJRMKJPOD*W-Q=6L,<W[N262WF>&8*C8)VO&W('3GH:O-XDTE$N
MW;4[-4M"1<,;A,0X.#OY^7!]: /#7_9.GVVXC\<7B?V+('\,@Z= 1I8^VQW;
M"7H;G+0QI\Q7Y!_>)>G:!^R>^A>+O#>NCQI>2W.EW4MW<SQV$4%U>L]U/<M$
MTT97]RS3E6C97&%^782<^\#5+-NEU >4'^L7J_W._P#%V]>U&GZI9ZO"TUC=
MP7D2N8R]O(KJ&'!4D$\CN* +5%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 45Q7COXS>#?AM=V]GK^M1VU_.N^.QMXI+FY9/[_DQ*S[?]K&/>M;P
M7X]\/?$32/[3\.:M;:M9AC&[V[Y:-QU1U.&1A_=8 ^U &_1110 AZ&O.?@C_
M ,@[Q=_V-6K?^E+5Z,>AKSGX(_\ (.\7?]C5JW_I2U 'H]%%% !1110 4444
M %%%% !7(_%__DD_C3_L"7O_ *3O775R/Q?_ .23^-/^P)>_^D[T <5^QO\
M\FG_  ?_ .Q3TS_TF2O8Z\<_8W_Y-/\ @_\ ]BGIG_I,E>QT %%%% !1110
M4444 %%%% '$_&3XO>'O@7\.M6\;>*)+B+0],$9N&M83-(-\BQKA1U^9Q7F'
M[/?[='PN_:;\7WOAKP3=:I/J=G9-?RK>V#0((E=$.&)ZY=>*XG]HG_@G#\.?
MBKX'\3P>%M+A\.^--6F%RFM7=]>SQQR&822L8C*5^8;QC;@;N!Q7C7[-/_!(
MFP^&OC:_U'XDZQIOC;1)K!H(;&Q-W9O'.70B0NCJ2 JL,9_B'I0!^CX.:X'X
MQ_%D_![PX-<F\,:SXBT],FY?1_LY-L,JJEQ+*A.XN -N>ASBM;X;?#+PW\(O
M"=OX:\)Z<=+T6W>22.V-Q+/M9V+,=\C,QR2>IJK\8O MQ\2OAQK7ANTN8K.X
MOT1$GF4LB[9$?D#GHI'XT 6M ^(%CJ6D?:M5C_X1B^C,:W6EZI<P?:+1I9"D
M(D\N1U!D(^7#'=D <\57MOC-X O+B.W@\;^')IY;F.R2*/58&9IY!F.( /DN
MPY"]3VKSGXE_ OQ5XI\?ZIJ.C:SI%IH.M2Z+<:C#>VTKW2/IUWYP6)E.W;(O
M!+#*D<9SQR+?L:,/"B:;%<:+#>+X7L=#%W%9;66>&^-R\ZD#(W9X/WMPS0![
MN_Q>\"QPZO,_C/P^D.CRB#49&U2 +92$D!)CN_=L2I&&P<@CM5G7OB9X0\*I
MI[ZUXIT72$U!0]FU_J$4 N5)4 Q[F&\$LHXS]X>M?/6C_LA:U]M\.IJU]X:D
MT[PU+86]DMCIC1R:A:P7T=TSWF20TQ\E0 ,J':1\_/@>F?%WX%+\3]9O;USI
MQ63PAJOAVW6\MO,,,UVT)64<<*!%@@<G(H ZW6?BWX4TFZUC3X]>TN^UW2K<
MW-UHT&HVXNXT&,ED=UV#YEY; Y'/(K0OOB)X6TO2UU*\\2:3::<T4LZW<]]$
MD1CC8+(^XMC:C,JL>@) /)KYB\3_ +'GC7Q3X@O+FZ\2Z$;81:G%;S+;3I*X
MN[;REWH#Y:F,@98 M)]YB#P>B\:?LD:GX@U3Q%?6>OVR)'JL&J>&[&:.18K,
M?:#=WD$K(<[9KABX9.4V1\';@@'T?HNMZ=XCTJVU/2;^VU/3;I!)!>6<RRPR
MH>C*ZDAA[@U=K@O@G\.I_ACX$BTB\DMI+Z6[N;^Y^Q&4PB6>5I&"&5BQ&6ZG
M&3D[5SBN]H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y_P ;>+U\$Z,NH/I.K:RIE6+[/HUFUU,,@_,47G:,<GMD
M5SWPQ^->B?%6\U"VTNSU*TELHTDD&H6XBW!B0-N&.?NFMWXE:$WBCX>>)]'3
M._4-,N;5<2",Y>)E^\00O7J1CUKP']D+3= @\6>,Y=*%K8WL44$-WING:+!;
M00LTDLK?Z7;R20W($DD@158-$A"L,X- 'U%2-]T_2EI&^Z?I0!YY\&/^/7Q?
M_P!C1J?_ *.KT2O._@Q_QZ^+_P#L:-3_ /1U>B4 %>=_%H8U+X?_ /8SVW_H
MBXKT2O//BW_R$OA__P!C/;?^B+B@#R_]J+XM:S\#]"\;^+_#\-G/JEI8:-%&
ME_&TD6)+JX1LA64YP>.:_-O2/VE/B'=Z]J"Z3J$FEZCXAU".>XETAY;>:27A
M JE'S@_W>>37Z8_M%?!R\^/5EXT\&6&HP:5<WFGZ1,MU<HSHHCNKER"%YYQ7
MRYX=_P""<'B/X?\ Q*\#7L_C+2KH?VO',%CM90?W -P1R>XB(^I%?882.6I1
MJXF*=6*3C>^W+%_FCZKAJOE\<JQ&'Q+7-.52Z:O=)NWW.[7GJ==^P?<^)O%W
MQ+O+K6O$>O3Z78VUQ<06D]W*UO<W+2*)2X+8++YP8@CEI >HK[[KR[0?"&D>
M"?BOI6GZ+91V%G+I.JWCQ1#@RS7EM)(WXL?P  Z"O4:\S.,1'%5XUX*RE&]O
MFU^ESX3 89X2@J4G=]6%%%%>$>B%%%% !1110 5B^)-'@O+6:[-O=7=S!"WE
M06]W)#YA&2%^5E&2>,FMJBLJM*-:#A-:/T?YFM.I*E-3B_T_(^2=$^&OQ$T[
MQC#KMQH-W,S3^9<*EZJM)&3\R;Q)NZ<#GL*^IM)T>VTF-_LPG EP6$]Q)*1_
MWVQQ^%7\4M?.9+P_A\DY_93E/F=_>LVGULTEOU/>S;/*^;\GM8J/*K>[=)KI
M=-O;H>=_&SX5)\7] T;1K@Q'3[?6;/4+R*262(RPQ,69%:,A@QR,8(Z=:\!\
M6_L4:Q)IT>D:%<:+=Z)9WNI-:V^KRR^;+!>QPYDN)6BE:2X@,;1))]YH64;T
M9<GZA\<^/-&^'&@G6-=N);>R\^*V7[/;2W,CRRN$C1(XE9V9F8   ]:K>!?B
M;X=^(UI>SZ)>2R&QN!:W=O>6LUI<6\I56"O%,J.N592"1@@@C-?4'SA\MZ'^
MRSXH\0:CXJ=K+1=#1=4U1;?5[B.8:IJBR".)!</@AH"$\T-N8LR1_*""QZ2/
M]ECQ7IVI7,UJ/!.H37<4@CU36[*:ZN-)<7%Y*GV5 %!#BY7?ETPV\_O 0!]*
M>)?%.E^#]"OM9U>[2STZRB,UQ,06\M!U. "?TJUI^JV^IP"6$N%,DD8$L;1L
M2CE&^5@#C*G!Z$8(R"#0!\=:?^Q;XN32M06=?!\-S=3LT5O#YC0VJOH\^GN\
M9%N@#[WAD^5%!"X)RH)T/'O[*%]HWA+5]7L++3;S6FFU.ZO1IMFTMSJ<$Q@:
M.UD "M+&?(573=]W.W)X/U/KOC'1_#9M4O[Z.*6Z,JV\*@O).T43RNJ(H)9@
MD;G &>/6M2"ZBN8D=&R'4. PP<'U!Y'XT ?+7P[^&_B.[_9T\<0_\(E:^&[_
M %3Q%)KUEX?L[9[6-XHYK>41+$X5D\W[.XPZKDODJH.!WWAW]G+2+CQ#XC\4
M:TDU]J6I:U)K6G0R7UTMM:EH8UB9[4L(O.0J3G82#@YR./7]6UJPT+1[S5+Z
MZCMM/LX6N)[AS\L<:KN9C]!S7 -^T?X!B\22Z'+JMU;WD5U]@>6?2[I+9;G8
M'\G[08_*\S!'R[LDG;][B@#@/!_P5^)OPMTO^S?"6K^&3'JFF:;;ZC>:DD[2
M6%W;V<5I)/;HJ[9T9(498Y#'A@<DAL#I--^#MWX3^*NL>,9KA=1\.VT<^JZ=
MI%K$QN5U.>%([N0+]T[TA^0#G=<S=B*W=0_:/^'>F76G03^(5S?6UM>++':S
MR0P0W&# ]Q(J%+</D8\TIUK8D^,/A*/PSIVOG5=VF:C=/8VSI;RL\DZ&421^
M6%W!E\B;<"./+;/2@#R#2OV9=:U/X9>$=&U;Q1J92WN-,N[S17N1!;V(AD,L
MB6LL"+,K\[,F0C"\8KO-2^!&FZ;H6@:9X5ABTZ.R\1VFNW<U[/+<371CD#RE
MY7+.\C!5 +''RJ. !74^+_BGX:\#>'=.US4[V5M.U*:*WLGL+66\>Y>12Z!$
MA5F;*JQR!C S6?I/QV\"ZU:Z#-;^(8%?7+^32["UGCDAN9;J,,9(3"ZB1&4*
M2P91CC/49 ///!/[.OB#PCXXT?QP_BF:]\1W%_?3:_8RW#'3WM[OYI$ME\O<
MK(T-IM+'!$)'&ZL/QW^R/=^*KKQ)?V=QHVGZQK&L:E>2:GY+F=[2XL5@2VD8
M ,R%T3>@8#;DCYJ]\T?Q[H'B#Q1KWAS3]2BN=;T+R/[1LU#!K?SD+Q9)&#N4
M$\$X[XJ]XE\1:?X1\/:EKFK7 M-+TZVDN[J<J6\N)%+,V%!)P > ": /ER\_
M8VU#Q)9>(I=5T_P=I]QJ6EZM;V6D:;!(;#2+NYCLHXI;?=&I!_T1Y'=41@TG
MRC.6,WC#]C[4KSQ+KUQH-IX071M5,]O;V5_;2*-$66.U#7MFD:[1<[X'; V9
M(C;S 0P/O'@?XR^%?B%J-YI^E7=W%J%I EU+9ZGIUS83>2Q(654GC0LF01N7
M(!X.*[*:ZB@C9WD554%CSV R?TH ^53^R1XE3586^V^'[M)KJ*9M:N4E.IZ0
M(M4N+P/8MLP'E690^2@#@D^8N%KSKX:? 'Q7XHU2ZD7P)H>C1Z';:;;^3KVF
M3V=MXBFMY[HL;T%6+N1,LOF()4\P+\S_ ,/VQX6\::1XTTF'4](N6N;">.*6
M&X>%XEE22))49-X&X%77IT.0>00+.M>)-*\.6JW.I7T%E UQ#:AY7 'FRR+'
M$GU9W4#ZT ?,>F?LJ>--&BL=,MM2\-2:+<2:3=ZBKI<HUN]G<RR_9K9!U@"2
MJB%F5E$>,#(*^C?LR_!WQ#\'-#UG3];N=*-K/-";&STS,OV>..(1G?.T4;R9
MVK@.&9 N#(^<CUS2]7MM7LX;JW,@CESM6:-HGX.#E& 8=.XJTLJ,"0P('7!Z
M4 /HKG?"_P 0O#_C.>XAT?45O7M[>&ZDVHRCR9C((G!( *MY3D$=AGH1GAYO
MVJ_A;;6>IWDWBE(+'3[:6\DO);.X6":"-U222"0Q[9U5F7)B+ 9!Z<T >M45
MQ7B+XR^#/"OB;1O#^IZ[!;ZOK$:365N$=_,C>9(4<LH*JK22QH"Q )85H1?$
M7P]-XPF\+IJ*G6X2JO;^6X =HC*$WXV[_+!?;G.WG&* .EHKSGQ5^T'X&\%>
M)[G0=8U2YM;VT\@W4HTVYDMK7SO]49KA8S%&&]688ZG%;D'Q3\)W5SXJ@AUR
MTFD\+ '6O+8L+',9DQ(0,9"*20,D=\9H ZJBLOPQXFTOQGX=TS7M%O$U#2=2
MMX[NUN8P0LL3J&5L$ C@]" 1T(S6I0 4444 %%%% !1110 4444 ?,'QFTG^
MQOB/K&M^+/B!>?#KPI=2V:P2V6K0:?%J\"P/YMIN!29;D2JK^:&_U6$4@%Z]
M._9PG&L_"G1-=GN8-3O]0A;=J2W45Y/+ DL@@CGN8_EGDCCVHS@D%@^"<Y/
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MUR2T5!<26C@[20<$@=,X-85I\$M L_C1>?$E(_\ B<W.GK8F/:-JL#\TP/\
M?*!4/LOO7H5>UF.,P.)C%8>CRNW1I*_5-<MW;H[KT/*P.&KT.?VTW*[TOKIT
M_P"">??&WX<W'Q0\+:;HT,IABCUO3KZY=+J2VD\B&Y263RY(R'5]JG!4@Y[B
MOGCQQ^Q_XGN([C3]-:R\1:0FJ7EXAUS5)6NKT7-O''%)<S313[I;0QM'&V,^
M4X*E74[O<OVA]3U[3?#_ (8'AN_73M4N?$^EVJRS;S"5>;#"14(+H1G*Y&<
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M+SLEU]=>G8\C@[$9E@\=4>9Q5HRE.-M^5\S].FG7N?DO^P^!_P -5_#S@?\
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M'?ZG=PS^)!K-AI$6J2BP_=Q0"&26 85I%DB+X.1N56Y(&/;* "BBB@ HHHH
M**** "BBB@#YE_;5EL+BU\&:5>S6NF-?75SY>KLU\UQ;;(U<I''9$2LKX&XM
M^[78N1N*8]8^ $%K;?"'P['9R6T\ BD(FM8+F%)&,KEG*W),VYF)+-(2S,2V
M>:\^_:UM[=(?"5\WC+3/!5Y;7%P(+S4-9N--,@:-0R(T/+C@$JW' /4#';?L
MV:S>>(/@KX;OKZZ:^N9$F#7;7,UR+@+/(JR)+,JNZ, &5F RI7M0!Z;1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/BMZQ_:@\<VT/A>75I/":76I:;I&JC1XHIX[K5DOY_+\BQW2'+P* 78AMQ8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'DO[2'BB?PWX5T2+^V9_#FEZIJR6&IZM;6*WDEM;-!,YVHT<BC>\<<>
MYD8 .>,XKE/V-[[P--X$\GPWI>GZ7XC:))=<6QTR6R\V0,ZHY5U& V"P13A=
MYP #7T(1F@#% "TC?=/THR,TC'*GZ4 >>_!C_CU\7_\ 8T:G_P"CJ]$KSOX,
M?\>OB_\ [&C4_P#T=7HE !6#X\\:Z5\./!>N>*=<F,&D:-92W]W(J[F$4:EF
MP.YP.!W-;U<[\1? NF?$[P'X@\):RCOI6MV,VGW(C.'$<B%25/8C.1[@4 ?D
MM;?\%9(=:^,'B_5=1\"BQ\->)='AT#=#>E[JTCB:Z,<[ @*Y)NCN48P%&"3U
M_7_2"K:39%6#J84(93P1M'-?AM\?_P#@F7XJ^ 5S?ZE?>(+35/"<<$\]KJ%M
M ZRN45F6*1#\J.0 ?O$=<9Q7ZJ_LK_%_6_&G@C1[37M+G)4+:6VL*%$5SLAW
MD$9!W *064$'CH:]98'$2P;KV7(G?=7UT_"WJ?.RS7!0S)82[]HU;9V5K-7=
MNO-OMYW/C[]M[]F_QWXC\;^*_B58Z;!+X2L[<O-=M=QJX$3NK_NR=QP?;FOF
M+P5\5Y?!W@/Q3X7_ +'L]0AUR:UN!=SLXEM)8"^UH\'!R)&!![&OV)^)W@*^
M^)_P*\8^%=,EMX-0U:.^M89;HE8U8SO@L0"0..P-?B_\2_ 5]\+_ ![KGA34
MYK>XO])N6M9I;4DQ,P .5) ..>X%?3<,XOZU@:=&I:\%&WHDK/[S][RRK1S?
M#U<OQD5**=N776*[_,^ZOV"?B)X0\'ZU-I=S9ZG>>-/$=TEI;FVM0\,-LJ[N
M7W# SO9N.B+7Z%U^0'P \5WWPZ\'77Q"GL-0F>ZN9M#T_4=*O8[<V<RQ+(WF
M*\3AMP92.G",*_0K]F']H74OCQINH33^&Y-*L],2*W?4I+H2"ZN"N6"J%&,#
MYCSQN K+B# RG-XZEK'9W?7;3\K;GX9AH/+*TLKQ+7M(-JR3MWWM\[GNM%-#
M!NAS3J^(/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /%OVB?B%XP\ 7WA*3P:EOJM[=RW,<V@26EQ<2WJ!$/F)Y*,4$9Y+,0OS@<
MEEKN?A'XPN_'OP\T?7;\6BWUTC^?'9+,L<3K(R-&5F59%92I5E900P8=J\:_
M;*U<:;)X%BAU=?#&HW%U=BWU^)[PW-L!$I>-(K4%W608W%@478N?F*5ZA^SW
M!;6WP>\.):W$-Y$8I&-U!%<QB=S*Y>0BY)F+,Q)8N<EB3T(H M^-_BM:^"O&
M7@[P[)I6HWLWB.^-FMY#"1:VG[J60&24\;F\I@$&6/)P ,UYZ_[6-K:Q:A>W
M?A/5(='E@NYO#]Y'-$[:RUO<1VSHL>X&%FDECV>9PRDL2N"*]1\<>!1XSU#P
ME<F\-I_8&LIJX41[O.VP3P^7U&W_ %^<\_=QCFO))?V3I[VWO-/NO&<[:19V
M]Y%X;@BL$672GN+J.Y\R20N?M!C>*-4!5!L!#;B=P /3_AC\1Y?'FG:LFJ:/
M+X;UW1KXZ=J6FSW"3B*7RXY4*2I\KHT<L; \=2" 0:S_ ((D-IOBP@@@^*=6
MY'_7RU4-#^ 6EWOAK6['Q^-/\>WFMZH-8U![K3EBMC,L4<,0C@+-M5(XD RS
M$G<2>< _9ST#3O"WA3Q!I&CV,&FZ79>)=5AMK.V0)%$@N6^55'0<F@#U:BBB
M@ HHHH **** "BBB@#P?]N/Q7=^%?V7?'2Z:Q_M?6;5- L$0_,\][*MJH7W
ME)_"NM\1^%+7P)^SAJOANR4+9Z/X4FT^$ 8 2*S:,?HM>;?M._\ %:?&_P#9
M^^'P_>0S^(IO%5\@Y @TV O'N'H9Y8OQ%>R_%[_DDWC3_L"7O_I.] '%_L;_
M /)I_P '_P#L4],_])DKV.O'/V-_^33_ (/_ /8IZ9_Z3)7L= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%YL'_++[U_\ (GH^\87_  MCP3_T-^A?^#*'_P"*H_X6QX)_Z&_0O_!E#_\
M%5N_V%IW_/A:_P#?E?\ "C^PM._Y\+7_ +\K_A1S8/\ EE]Z_P#D0]XPO^%L
M>"?^AOT+_P &4/\ \51_PMCP3_T-^A?^#*'_ .*K=_L+3O\ GPM?^_*_X4?V
M%IW_ #X6O_?E?\*.;!_RR^]?_(A[QA?\+8\$_P#0WZ%_X,H?_BJ/^%L>"?\
MH;]"_P#!E#_\56[_ &%IW_/A:_\ ?E?\*/["T[_GPM?^_*_X4<V#_EE]Z_\
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MRDC(R./<4 <M\&/^/7Q?_P!C1J?_ *.KT2O._@Q_QZ^+_P#L:-3_ /1U>B4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOA^TGNKN[<O+-(T8+,Y/))/6O6J "BBB@ HHHH **** "BBB@ HHHH ****
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MLH;J]U>XOKM[^^U'5I%FN+N=@J[W(55X5$0!5 "HH IO@+P79>&[36$2>VU
M7FKWE_N2)<1F64N8^_*YQ5KXGVVJWOPV\5V^A&4:W+I-W'8&%MKBX,+B+:>Q
MW;<'UKQ?]E&ST>/7/$]SX0T2]T'P@VF:3;-;W5E+:*VIQI.+HB.0 F0(;=9'
M ^9EY)()H ^A?[.M?^?:'_OV/\*/[.M?^?:'_OV/\*LT4 5O[.M?^?:'_OV/
M\*/[.M?^?:'_ +]C_"K-% %;^SK7_GVA_P"_8_PH_LZU_P"?:'_OV/\ "K-%
M ',^.O!]KXM\&ZYH ,%G)JUA<6*SF)6V&2-EW8XSC.<>U6XM T74(;>.:SL+
M^2Q(4,\*.8G '(X.T]*\J^)_A.ZD_:#^&FO6+ZA+<_9]6M?FE=K2V!LR5;8/
MD5F?;EB,G: #CBN!_9-TF"S\8VYT?1-1T8VGA2"R\6M>6DMO]HUT3[F,AD $
MTP_T@M(N<K(GS$%0&FXNZ9,HQFN62NCZE_LZT/\ R[0_]^Q_A3)M'L+F%XIK
M*WEB<%71XE*L/0@CD5<HH3:U0VDU9E&UT/3K&W2"VL+6W@C&$BBA554>P XI
MDGAS2IKV*\DTRS>[B&V.=K="Z#T#8R*T:*?-*[=R?9P:4;:(JMI=FZE6M(&5
M@008UP1Z=*ALO#^EZ;;B"TTVTM8 21%! B*">IP!BM"H;MXX[69Y698U0EF7
M.0,<D8Y_*E=VM?0?+%OFMJ<IK_A33?$&O>'=6CN+2*/P_>SW$R"-6#%K66$J
M3_#CS0W/I6[;Z#HSW)U&#3[$W$R &ZC@3>Z]OF R1TKX7T,^"O%&G>(M5\,Z
M%+I/A5;G1H]5\+VVG7AN;C2(+\O/>7RLF9I7SED4N_E!MY8L57Z?_9ALFL_A
MW>FVM)M/\/3ZWJ-QH-I/"\!BTY[AC %C<!HT(W,BD#",N !@ 3:V8.,96NMC
MU"YT33KRWD@N+"VG@D&'CDA5E8>A!'-$&C:?:P)#!8VT,,8VI''"JJH]  .*
MNT47=K7T#ECS<UM3.;PYI37RWITRS-XJ[%N#;IY@7T#8SCVJQ_9MI_S[0_\
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MT>Q$0MM*L;<1.LD?E6R+L=8_+5A@<$)\@(Z+QTH ^<?A'^UOK7Q/\9:#:?\
M",VMII&H216,JBZ8W4,[62W33#*A&AR=@ .\C#XQD#/^,?[5/B+0/$_BSPWX
M>70SY=EJ]K8WPGE:>UO;/3FNR\JE K ;2NQ=V"5)/) ^E;/P1X=T_5H-4M=
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M$^+6@>%=(N]8\5ZQ<V^NZ38W^HW_ /84/G:(K7ZQ3FWC2+YF$+C*N'(VF3!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>hook-20231231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "B Q8# 2(  A$! Q$!_\0
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MYZ*/]6LO[/[P_M[&]U]Q^C'_  \9^&W_ $!/%7_@);?_ "11_P /&?AM_P!
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MC/PV_P"@)XJ_\!+;_P"2*_.>BC_5K+^S^\/[>QO=?<?HQ_P\9^&W_0$\5?\
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MYZ*/]6LO[/[P_M[&]U]Q^C'_  \9^&W_ $!/%7_@);?_ "11_P /&?AM_P!
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MQ*5;VB4FO^WFFW%_-6?RMW.1N/VOK>35KK4(?!8MYKS7+#7KI5U/Y7FMU"N
M/)^42;0>^TYZUYEX=^,5YX9^*FK>,;6PCDAU6:[^V:7-(2DUO<%O,A+@ ]&X
M8#J <=J['XE?#%?#/P,T^XO]/M;'Q+X>\2W?A^]FMD4?:T*"9'9@ 7*Y(!/.
MT@=J\,KKP>'P<X3=&&CO%ZMW5DEUV<4CFQ5?%TY1]K+7?9)IIR_%2<O7<]4\
M,_%_0?A[XHT76?"'@Y[">RFE:YDU/5GNYKJ*1&1H,JD2(NUC@B,MG!W'&#TO
MA_\ :>MO"$%AI>B>%)+;PY966H6\5C<:IYTS378PTK3>2 0H  0(.,Y))S7@
MU%=53+\/5_B1;Z:M^?GYNW:^AST\=7HM2IM*SOHEOIY>2OWM9Z'N%I^TP%\-
M:3X<O/#C7.B0^'F\/W\$>H>7)=+YGF+,C^4?*92. 0XY.:A\4?M)OXB\%>(O
M"\?A\6>EWUAINF:<OVTR-8V]H[,H8E/WK,6.6^3'I7BM%+^SL+?FY.M]WO?F
MOOO?\--M 6/Q*7*I=+;+:RC;;LE^>^I[G8?M)V=K?Z!J3>'-2M=8TO0H=#.H
M:5K[VDA6$CRY$41,HSR&242JW& N.?/OB]\29_BUX^U'Q/<64>GR78C7R$8.
M0$14!9@%W,=N2<#GL*XVBM*>#H4JGM81][5;O9N[W?<SGBZTZ?LI/W=.BZ*R
MZ=@HHHKM.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KT7X"6FBZY\2]!\/ZYX=L==LM8O[>T=KJ:YBD@5GPQC,,T8R<_Q
MAAP,#KGSJMGP9XKN_ WBS2/$-A'#->Z9<QW4,=RI:-G0Y 8 @D<=B*RJQ<Z<
MHQW:]"H/EDF>PZE\*?#7BJ;XEZOO@\#Z'X(O%LS;Z5:3WTMX'GDC1C]HNN'^
M11P0IST&.9?$W[(6N>'O!\^K"[O9;ZTM+2]N8)-)D2UV3MMV0W"LWFR1Y4N@
M08SP6Q7G+?&#66T?QUIIMK'R/&%U'>7[>6^Z)TE:4"+Y\ ;G(.X-QCGO6MJ'
M[0>NZG#ITUQI&A2:[8K:1IX@DLC)?E;9MT(W.Y13T!9$5F  8FO&5',(<JA/
M2ZWL].6-]7KK+FOK?:Q[3JX&;DY0U?-MIU=M%I\-NEK[GKWAC]CK2K+Q3X4D
MUW6;^^T74-4ETRXM&L%M)S*D+2KP)V9(V"-]\)(.,H-V1SGA_P#99T7Q7%X=
MFM/&MS:-XC74I=/@GT481;1V!$K"X.W*KG@-@\<]:Q9OVNO%AN[&XM=%\/:<
M]KK3Z\1;V\Y$UT\;)(7WS-E6#G(&,<8(Q6?8_M.^(=*OO#D]AHFA646@)?I9
M6L<5PT86[R90VZ8L<;CM^88[YKD5+-K-\^MO[MMI6Z?S..O9,Z?:96K14=+K
MO??7K_+?3OW.JL?V09=6TR#7=.UW4=3\-RZ3%JBO9:&9M18R2F-8EM5F(8_*
MS$B3@ \58;]CI=)EEAU_Q<^G3'Q)#X<MUMM*\_S6FB22*4[IDV@B0;AU&#@M
MTKA[3]I;Q'#X<LO#USI6BZEH-OI::3)IUU#-Y=U$DGF(\A256WJV<%&4<G(-
M16O[1GB"QLK>SM=(T&TM;?Q%%XEB@M;(P1I<1JJK&J(X4184< ;CR2V36_L\
MTYG[ZM?31;77EO:_2VW4P]IEO*O<=[=WOR^NW-YW^1M?$WX->'_AU\(X;V2[
MO+CQ6GB*\TF:00C[.X@(!5?WGRKCY@VTDDD84#)[WX:_!'1_$?PI^&NJ67@C
M2/$>IZQ>W:ZQ-J.KSVTJVL4Y!>&-;F/<53.=J/T&1SSXQXS^..L^//#NHZ/J
MVFZ5)%=ZO-K4<\4<J2VL\I'F+&?,P4.,8<,>>N<8-+^//B?1-#\$Z9IYM;(>
M$;N:\T^YB1Q,[2ON=926PRG)7  X)!S3>'QTZ"BY^_S7>NEN5Z:6=KVT$Z^"
MC7;C'W.5I::WN[/6^MNIZAIW[)=OX_O=0U+PMJE^OAZ^UBZT_0WCTQ[N,I$&
M/F7,H9?)B+#RPY5B3SBH]8_9TTO4[3P#:V4-WH][=>')=1U:6TMWO))9TFV'
MAY4BBZ]6>-..I) /%7O[26KZFM[%?>%_"]]:S7\VJ6UG=64LL%C<RIME>*-I
M2I#$EML@=0W( HL?VF?$EIHEGHTVE:+?Z1!H_P#8DEG<0S!+B#S/,#/LE4AP
MW0J5&#TK)4<S7*^;;T_E:U?VG>U[Z75U8V=;+FY>[OZ_SIZ+I[J:5M4KIW/2
MO$/[(^F>'/#M]I"ZK<ZEXPE\26>DV-VML$MBDT(D7<!*=HVMN9OF(*84$$M6
M7=?L6:JNNZ;;P:O=PZ5-<WEM=WVJ:.]I)!]G0NTL<1D;S8W4'8P9=W<"N7US
M]K3QAX@FO)[FPT5+B:]M-2@FA@E1K.ZMXQ''+%^]QDJ "KAE/]T5F)^T;K5E
MXOL_$>F>'O#>CW\4UQ/<BSL7Q?M.")1.[R-(RD$_(K*JY^4 U,*6;*.LUS6?
M9J_*K>BO?;KW03JY8VK0=E;NG\3;]=&M^GR+_P :/ 'A+PM\+/AEK/ADRW4N
MLQ7K7>HSJ\4ER8Y55=T)D=8RH)&%...IKQFN[^(?Q?U#XB:!X<T6;2-)T;2]
M 69+*WTN.50JR,&8,9)')Y'7.>3G-<)7MX.%6%*U9W=Y/771R;7EM;;1;(\C
M%2I3FO9*R2BM.Z2OOKOU>KZA1117:<84444 %%%% !1110 4444 %%%% !11
M10 4444 %364Z6MY!-+;17D<;J[6\Q8)* <E6*,K8/0[2#SP14-% 'T=KO@;
MPKKGAGX16^E^$M(T'4_';R07.HQ37\YLF%TL2O#')=%3P>0^[/8BHM*_9+BU
MW6/$<&F^(=5U'3]#U*/1I[JR\/\ G2/=LY5ML2W!/DQKAFE)!&>%/?S6+XU:
MY#'\/T6UT\CP3*TNG9C?]Z3,)3YWS_,-P ^7;Q^=7=,^/>LV=UXF-[I&BZWI
M_B#45U6ZTK4H)7M5N5<NKH%D5N"2-K,0PX8&O =#'035*?66[OISZ;WVALKI
M7W[GLQK825O:QZ1VTUY'?;O.WRO8[OPE^QWJOB&]UC3;O6)-/U2RO+NSCQIY
M:TD>!-P)F>2,G?V$22E1RP6KVI?LW^$=3T[0VTW7]1TIH_!C>)]1FN-.6<S[
M9,':!.-K')&T< (/F)8XX_PE^U1XF\'P:>EOHOAVY?39[N:QDFLY(_L@N?\
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M145BIVL<56O_ -JKP99QV<D46IW\=WH]GK$+6D,;!A=RB*UMN9!B>5R0J_=
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M5_X);G_XBOV(HH_ULK_\^E][#_5NE_S\?W(_'?\ X45\2?\ HGOBK_P2W/\
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M>S6]MWY:^FOY]40N'*5K^T>U]EY_CHS\R?\ A17Q)_Z)[XJ_\$MS_P#$4?\
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M3WQ5_P""6Y_^(H_X45\2?^B>^*O_  2W/_Q%?L112_ULK_\ /I?>P_U;I?\
M/Q_<C\=_^%%?$G_HGOBK_P $MS_\11_PHKXD_P#1/?%7_@EN?_B*_8BBC_6R
MO_SZ7WL/]6Z7_/Q_<C\=_P#A17Q)_P"B>^*O_!+<_P#Q%'_"BOB3_P!$]\5?
M^"6Y_P#B*_8BBC_6RO\ \^E][#_5NE_S\?W(_'?_ (45\2?^B>^*O_!+<_\
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MO8([F%_5'4,I_(BKM#XIQT79PC]S_P#DB5P_A))-2E;U7^1^9/\ PQQ\7_\
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M110 5%<_\>TO^X?Y5+45S_Q[2_[A_E0!@T444$!1110 4444 %%%% !1110
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M14E!1110 4444 %%%% !1110!K:3_P >S?[Y_D**-)_X]F_WS_(44%E;5O\
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MBBBI*"BBB@ HHHH **** "BBB@ HHHH *BN?^/:7_</\JEJ*Y_X]I?\ </\
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M97=YI7BG1=3M+.86US<6>H0RQP2D@"-V5B%8D@!3SDBB4>:\7VMZ*UOO\_\
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MY4@GC".) 5)/ XP1[YKF?#W[.WP]\(?$&V\8:!X6TK0M4M[*2RCCTS3[>WA
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XG8?'KQ&-
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M/ __ (3EG_\ &Z]+HH \T_X9D^#W_1*/ _\ X3EG_P#&Z/\ AF3X/?\ 1*/
M_P#X3EG_ /&Z]+HH \T_X9D^#W_1*/ __A.6?_QNC_AF3X/?]$H\#_\ A.6?
M_P ;KTNB@#S3_AF3X/?]$H\#_P#A.6?_ ,;H_P"&9/@]_P!$H\#_ /A.6?\
M\;KTNB@#S3_AF3X/?]$H\#_^$Y9__&Z/^&9/@]_T2CP/_P"$Y9__ !NO2Z*
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MW_1*/ __ (3EG_\ &Z]+HH \T_X9D^#W_1*/ _\ X3EG_P#&Z/\ AF3X/?\
M1*/ _P#X3EG_ /&Z]+HH \T_X9D^#W_1*/ __A.6?_QNC_AF3X/?]$H\#_\
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M$Y9__&Z/^&9/@]_T2CP/_P"$Y9__ !NO2Z* /-/^&9/@]_T2CP/_ .$Y9_\
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MZ<*)'81#<XW*6" C)W)):W>W^3_KT=PD^5)G>?\ #,GP>_Z)1X'_ /"<L_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>hook-20231231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  O O@# 2(  A$! Q$!_\0
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M?"/XP:=\9M#O=<T;2M3LM"BNIK6UU'41 B7_ )4CQR21*DK2*H=&'[U8V/!
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M-T_PWXTUN\74+.T\*Z]_PC=RLL2;[J])B5%@ <@JS3( SE,<EMH&:?*^W?\
M!J+_ !:7S077Y?BFU^";^1[+]MG_ .>C4?;9_P#GHU>9:?\ '#38_"_B/7/$
MV@>(/ D&@8-[%XALU&X, 5,,L#RPW&[( $,CG<0I ;BK7AGXK-K>IR6>J>#O
M$_A)/L[W<-[K5K";6:%,9<RV\LJPG!!"3F-R,_+P<3M_7S_(9Z']MG_YZ-1]
MMG_YZ-7E?ACX[6OBV]TR2P\(^*G\-:JX33O%"V,<MA=9^Z^R.5KB*,X.)984
MC(P=V&4GTVG9K<5T3_;9_P#GHU%044AA7S/J?PR\4^(_VR?%&KV&O>)_!>D-
MX0T^W36-'L;1X;N5;F<M"9+NUG0LH(8JF&&X9X(KZ8K(C\7:--XKF\,QZE;R
M:_#:+?2Z>C9EC@9BBR,!]T%@0,]<''0T+XD_7\FORU!_"UWM^:?YJQ\H_'CX
M?_$#5/'/Q?D\*V.K75S=^"]$M(+Y(S"=0\J]G:Z@CF4*GG-"6!"8(\P8 R*\
MD^(OPZMO&VN?'#P[\,?!5]H\-W\.-)^PZ&VER::[,+V5V5+:14:,D(PVE5+,
M&.#G)_0CQ?X/T7Q]X:U#P]XBTZ#5]%U"(PW5E<KE)4ZX/X@$$<@@$5B_#_X0
M^%?AA)>3:!8W*7EXD<5Q?:CJ-SJ%U)'&"(XS/<R22>6FYMJ;MJ[C@#)IQ=M^
ME[?.^_DKZ?/N4W9J2WT_#D_/EU/A3X_^#_%/Q*E^,.HZ%X*\67-IJ?@CP]96
M7FZ!>02W,T5^&EC2-XU?>@R2N 0!G&,$^D_M#?"+6--\;^%8='T"TB^&Z:#=
MQIIUKX-N->BM]9DE5_M'V2VFA,=PXR4NG.U&#[F4ONKZ\;Q?HJ^+4\,'4K<^
M('LSJ TX-F86X<)YI'9=Q !/4YQG!QL4-WBETNW]]U^%W;LT3'W-.UORC^:B
MO5-G%_"WP[?6?PC\+Z+XHFN=;U"'2K>"^EUBWC6>=U103.BR2IOX^;$CC.?F
M/6O'O@)<:M\*-"^*E_JOA+Q'<_VA\2+UK6TL=-=YYH+B6&-+E4;;N@&2S2#(
M"JQ&<5[$/BKI)^,!^''V>]_MP:+_ &]]HV)]F\CSO)V[MV[?NYQMQCOVKLZO
MG<INL_M)K_R9-_C&Q/*HP5+^5I_^2NWX2N?.'[;GARY\1>&?AOY>EZ_J=A8^
M-=/O-1_X1NWO)KRWM467S)5^Q@SKMR/FCPP)&#G%>4ZU\//&NI6GQNN_@\GB
MZPTS5_#5G!9W'BM-0BU.[U*.1_-6"742MWM%OA%W,$#R?(0=V/L[2?%VC:]K
M.L:3IVI6][J.CR1Q:A;PMN:V=UWHCXX#%<-CK@@GJ*XSXC?M!^$/AKH'B'5+
MJZEU<Z!=V=CJ5GI(26>VENI$2)6#,J@_O%8C=D*<XY .<59.*ZN_WJ,=>ZT5
MO-FKE[REV27_ (#)R^3W3\M#Y*/P@US6OAKXU@M6\0Z+X=O9=),>G:#\-I-/
ML(9HF=IY#I-S>//=QME5N%6(>;A2HE^:J\_PDUK7?@YX//B+X;VUWI/AWXD6
M]ZL&G>'+Y?M&D, )I8])G$DUO&7;#6Z(JX3<(P.3^@X.0#ZT5I&?++F\T_N<
M7_[;;T?72V/*FK>37WIK[];^O;6_S1^W0EN_@/X<+-:37=J?'FB![6W4B21/
M-.449!R1QCCTKQ?Q-\-_'5SHWBN;P/H-UH/PDF\:V%Y'X7O?#=RPDTY+8K>L
M-)'DS/;O<;6-L IDVN0"&^;V7QY\>O!7CO3]<O=>^&OB_5O"?P]\1E[[Q!%)
M91VMC>63@FX\M;Y;B1(]P; B;(_A/2NSUW]I_3M/\9:YX>T;P7XH\72:)IEM
MK%_?:+]@%O%:SJ[1N//NXG<[8V.$1CQWR*S@U&#EW?-Y6M!J_E[GDK/1]M97
M;Y>RY?G>2=O-<R^>EN_SC9?!?7=8OO@O9:MH6I>(?":^-=3NWL;KPM)IMEI^
MG26;*D1LWGG:"U+Y"1SE" ^PQKP#Z#HW@6ST3XO^*#XV\ :]XCUQO$EM/X-U
M71-/E\O3]+6&%8XX[U"D=I%&RR>9"\J>8-WR2;MI]2UO]J#P[IGAFR\46.@^
M)->\(S:5'KESXBT^Q1+&RLGY$CO/)&78 $M%"))% Y09&35/VEK*/QYJ_A70
MO!7BGQC<Z3I]IJEY>Z(+#[/';W 9HF7SKJ*20D(QVHC'C@'(K2[IRUZ:?=;7
MR?N_%_B^6;]Z/JOS;?S7OK3_  ^1\]?##X:_$.#XX6=UX@>]M_$MMXJU"]O-
M5L_"$Y>]TMC+Y,,^L/=I!):E'0);I&[QNJ?N_E+5F_!_X,ZSX=TKX ZD?!6I
M6.MCQ3K=OKUQ-ILJSIILIO2L=R67*V[$QL%?"$L"!ELG[@\&^+]*\?\ A72_
M$>AW7VS2-3@6YMIMA0LC#NK %2.A!&000:V:E7II0:VLONZ?/JO7N5)\_,U]
MK];_ )<VGHNQ\Z?L2?#_ /X5I\)]<\//X:/AC6K?Q!J?VE6TMK5)U:YD-O(C
ME%6=/),05D+  !<@K@<+\&_!::/HC6GB7P!XEN?C,MOJR:WXJAL)HX+GS/-,
M;2WA*1WL;J8UBB4S&,[1LCVDC[%/%> Z9^V+H=_X=;Q3/X*\6Z9X(CU)]+F\
M4W8T\VD,JW)MBSQI>-<!/-&W=Y/&<G R:B2=6\.K5OPM\KWVZZ(I/E]^WVK_
M (MV_P CPOX+?"KQ/\-A^S_J&A^"=1LM8;P/JUOXA:2SEM7EN1#$]K;WTVT,
MA$F5C$A!7D+C%<!HWPR\716OBB;2?!?B+2X]=^%&IVFK:?;>&;BS@FUL%3Y+
M&13-=3?.X6>5Y6ER=KM\U?8_B7]J+3M \7^--"M?!'BO7D\'0P7&MZGIBV'V
M:VBEA\Y7"RW:2R (&)"1L?E. >,W?$O[3'A[PYID&N+H?B'4O!YL;?4[GQ5:
MVD::;:6T^#'(SS21O+P066!)60?>"Y&=)2]JY/\ FNO3FY_P]YVO_*K/>ZIO
MV/*ETL_7EY?QT7_@7I;YSD^$'C7P[JTD/P_T#4?#VIZM\'#:W%[%;R6ZS:PA
MC6%9YC@?:@I=0SMO [X''(ZMX2O+GXB6NE_"?POJ?@?Q/+\)M4ABBN+"739#
M?_:( Y D"GS2VX>?C#EE8.W4?4OB[X_Z'KGB#QQX%_X5WXF\;:=HEK"FOSV,
M5A+9BWN8?,'[N6Z2693&6RL<;'@@ \9Z'X*?#+X;^&M#TSQ/X$MI)K&_TR%+
M#4;O4;J^:.P(#QPPM<R.T,/0^4FU01]W(IN7.W.6UG_Y-[2WR]_3NHZ;$Q_=
MQC&.K5OP]G^/NKTOYZ>5?L@^"]9T#Q3KVH/%=:5H\VE6=M/I<7@R?P[9-?JS
MF28)<7<DDUQAL23K&J2?(0[$''!?'3X:>)O$/BGXMBW\,ZU>6FI>,O!\\$EK
M9S$3P1>2)Y(W09*QX.YU/RX.2,5]*_#/]HOP9\7_ !UXH\,>%+J?5)?#T-O-
M<ZE'&/L4XF,B@029S)M,3 L!MSP&)!QZ=0Y/GA4:VL_NDI?=I9>1*BDI0[Z?
MA;[[:OS/C7PCX,O? W[3\]A!H4^@^$IOB)#=:1"EHUO92%_"NJ?:'MQ@(<R
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M)^OOB/\ %8?#N2-%\)>)/$H^S27MQ-HUK%Y%I!']]Y)IY8H\CJ(U9I&&2J$
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M&A\B%R@!0B,&OI3]C/X=P?#[]G/P/#-X<'A[Q#<:/:G5HYK/[/=R3JFW]^&
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M5*?,Y.V]_P 7)_=[[^Y=M7%<O+Y6_!17_MB^^7?3Y$^ W@W3]._:AM=8\*>
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M3P_]C/X=P?#[]G/P/#-X<'A[Q#<:/:G5HYK/[/=R3JFW]^& <LH^4;N0 !P
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MEP[^6!)&5:!%F!9#\JALC ^]Z*G[')Z?@[_=O_6^C=Y.7>_XW7Z_@?!G[/\
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(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>hook-20231231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %W B8# 2(  A$! Q$!_\0
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M(_+5Y'P %3<VU518T R3A!DDYH Z"BBB@ HHHH **** "BBB@ HHHH ****
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MQ<\4SZ\O@M1HX\5_V])I;:I]DE-A]G2S%V9?)$V_S-C*GE^;C=DENU:_B?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM(T.U8O;Z=:Q6J2,,,^Q0NYO<XR3ZDT :]%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIU"NWIOH2MV%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'<5VM24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MG+XZ?#/PMJD_B/QS%XSO;"6/2;K^T-(TV]ME348Q JO&'>-WB:2.%(RR<X P
M <Y^C:^7KB[^%,VL:Y8Q_LY7%[J%C,8EQX)MMMS(4WC]X5VJ#GAB<$<]* /I
M+09H[C0].EAA%O"]M&R0@Y"*5!"Y[XZ5?J"Q7;96X^SBTQ&H^SKC$7'W1CCC
MIQQQ4] !7,^,_AEX1^(WV+_A*O#&D>(_L3E[;^U+*.X\DD@G;O!P"57(Z':,
MYP*Z:B@#G=8^'7A;Q!XCTKQ!J?AS2]0US2O^/#4KFSCDN+7G/[MR,K@\C!X/
M(KHJ** .(^(/_(V_#/\ [&&;_P!-.H5^>/[1O_)T?Q?_ .PM8?\ IETZOT.^
M(/\ R-OPS_[&&;_TTZA7YX_M&_\ )T?Q?_["UA_Z9=.KR<V_W;YH_2O#O_D>
MK_#+\D=A^P[_ ,G3P_\ 8F:M_P"EVE5^BM?G5^P[_P G3P_]B9JW_I=I5>>?
M$/XA^-/$OQ-\>7-SX\\86IM_$VKZ?#;Z7XDOK"WB@MKZ>W@1(+>9(UQ%$@)"
MY8@LQ9F9CAAL3#"X*$YIVNUIZL]7/LBQ/$'%>+PN%E%248R]YM*RA!=$]=3]
M6**^*/\ @GMXCU[5?&WQ1T_5O$WB#7[2UT[1)[>/7=9NM1\AY)=260QFXD<I
MN$4>0N =B^E?:]>Q2J*M!5([,_,<QP-3+,74P=9IR@[.VWRNE^04445J><%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?$?[2XLHOC=KLCZYIZO+I(M+M]1TW5I9=)CE6
M+RY(GMK9XR%>+SE_>1XD9LGCC[<KY3^-,\6E?$GQ=;:K!XUM=%UNWMXIX_#&
MH:9#;ZE'Y 203"[D61&Q\FZ$IE<=QD@'TAX*\2Z7XN\,6.IZ-J/]K6$BF-;L
M@JSLA*/N4@%6#*P((!!!&*W*Y[P+X8TSPKH1ATI)8[:\N9M1(F<.P>>0RL,C
MC W;1C/ ').2>AH *\/_ &O_ (_:E^SU\&]8\0^'=+MM<\51V\D]E87>[R%C
MBPT]Q-M93Y<:D="-SO&@(+@U[A7SQ^U1^R_K'QQ\,^,&\.^-]4T36]9T :)'
MID_V0Z5(@D>3$C/:2SQAF?YS"ZEO+CS]P8 +'Q/^//B?PIXP\4RZ1::3)X0\
M$?V8?$"7D$S7EW]K?,GV:175(O(A:.7YDD\TL4_=8WGW^OG;QQ^SWXNUK6M=
MTZPUJPU'POXOATF+Q'J6KR&+4T:S(6:2*."$0R-<PHB''D+$P+JK@[![-XC\
M!:9XIODN[RYUJ&5(Q$%T[7;VQCP"3DI!,BD\GYB,XP,X P 9?Q!_Y&WX9_\
M8PS?^FG4*_/']HW_ ).C^+__ &%K#_TRZ=7W7KW@+3/"WCKX;7=G<ZU-*^NS
MQ%=1UV]OH\'2[\Y"3S.H/ ^8#.,C."<_"G[1O_)T?Q?_ .PM8?\ IETZO)S;
M_=ON/TKPZ_Y'J_PR_)'8?L._\G3P_P#8F:M_Z7:57C_B/_DH'Q#_ .QS\0_^
MG:[KV#]AW_DZ>'_L3-6_]+M*KQ_Q'_R4#XA_]CGXA_\ 3M=UXU;_ )%M/U_^
M2/T[+?\ DN<=_P!>E^5(^D/^"=?_ "4GXM?]@GP__P"CM5KZ:U;]IOX/:!JM
M[IFI_%?P/IVI64SVUU9W?B.SBF@E1BKQNC2 JRL""I (((-?,O\ P3K_ .2D
M_%K_ +!/A_\ ]':K7S?XC_Y*!\0_^QS\0_\ IVNZ]..*^J8*G.U^G;N?!5\@
M_P!8^*<;A/:^SY;RO;FV<5:UUW[GZE>!?BQX'^*'V[_A#?&7A_Q;]AV?:_["
MU2"]^S[]VSS/*=MN[8^,XSM;'0UU=?#7_!.O_DI/Q:_[!/A__P!':K7RGX%\
M:>,]9\$^'M0O/B/\0)KNZTZWGFD_X3355W.T2LQP+D 9)/ XKIECX4Z,*TT_
M>[?TCPZ'!V*QN9XG+<+5BW1W<KQOZ)*1^R-%?"_[//Q(\6:'^Q[^T1XA3Q/K
M&I:YX:FU:XTC4-;OY=3FM&BT*SN(P&N6D)5969]C97+'C!->1?\ #1OQM_Z*
M_KG_ (*-%_\ D"M*F-I4H0G.]I*Z_KYG#@>%,QS'$XC"X;E<J$N66ME>[6EU
MJO=?1'ZBT5\G^ ?VE_$_A3]B&W^*/B)/^$[\26^K7&F,+J6+3OM6[7GTZ$NT
M,!1-J-&25BYV'C)S7%?\/%/&'_1)=#_\+.;_ .5M;3Q-&G;GE:YYF%R+,L<Z
MBPM%SY'9VZ,^Y:*Y3X3^.O\ A:'PL\&^,OL/]F?\)%HMEJ_V+S?-^S_:($E\
MO?M7=MWXW;1G&<#I75UTG@A1110 4444 %%%% !1110 4444 %%%% !1110
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M\>.FW5W''<7/./W:$Y;G(&!R>*Z&@#B/B#_R-OPS_P"QAF_]-.H5^>/[1O\
MR='\7_\ L+6'_IETZOT.^(/_ "-OPS_[&&;_ --.H5^>/[1O_)T?Q?\ ^PM8
M?^F73J\G-O\ =OFC]*\._P#D>K_#+\D=A^P[_P G3P_]B9JW_I=I5>/^(_\
MDH'Q#_['/Q#_ .G:[KV#]AW_ ).GA_[$S5O_ $NTJO'_ !'_ ,E ^(?_ &.?
MB'_T[7=>-6_Y%M/U_P#DC].RW_DN<=_UZ7Y4CZ0_X)U_\E)^+7_8)\/_ /H[
M5:^;_$?_ "4#XA_]CGXA_P#3M=U](?\ !.O_ )*3\6O^P3X?_P#1VJU\W^(_
M^2@?$/\ ['/Q#_Z=KNM<5_R+Z7JOR9P9!_R6N/\ \,O_ $JF?2'_  3K_P"2
MD_%K_L$^'_\ T=JM?'_PR_Y)MX3_ .P3:?\ HE*^P/\ @G7_ ,E)^+7_ &"?
M#_\ Z.U6OC_X9?\ )-O"?_8)M/\ T2E98O\ W*B=_#O_ "5.9_+\SZ;^"?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]-.IU\'_ !-_Y)MXL_[!-W_Z)>C,_P#>X>B_-BX"_P"2;Q?^*?\ Z;B?6?\
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MVD7VR,?:USC=G^#CG!K>HHN!DIJ6IMJEI VCLMG+;^9-=_:4/DR<_N]G5O\
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M&:?\NO0/#_\ YC_^OK_4]V^-G_)C'[*'_<$_]1N]KYD^)O\ R3;Q9_V";O\
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M\V\#]/%O_8Y^)_\ T^7U>D_LQ?\ )=_B=_V+?AW_ -*M9HQ7^X0](_D/ ?\
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M)]X6_P#!+;?_ !%'_"C?AO\ ]$^\+?\ @EMO_B*[>BCF?<.5=CB/^%&_#?\
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MT^[<^:/A5\//"NH_M(^'],N_#.CW.FR^$]:N9+.:PB>%Y4O-)6.0H5P6599
M&QD"1@/O'/*^#O!/AVZ'BCSM TN7R?%GB*VCWV<;;(H]8O(XHURO"HB*BJ.
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M QN.[<3D 8YR/6JIZ6)6MPHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@
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M   =/W0C//4TDGAS4'M]5C7Q3JT;WL@>"58K/=8#.=D.8"",<?O1(<=\\T6
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MP7^S!\:?#G@'338+K6@ZI-:Z'X>T>SMU-P]HZB*&&WMU,C2!4BRV^0@*%8$
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M+_2O#.FQWVFS6T$;LXM8@UO.DD)=/+(*878XP=Q)YKV&O</Q0**** "BBB@
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M=$O'UV>%[C3M/AMY&0Z7?DJ6102,JIQTR!Z5ZU5/H2NH4445)04444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=RR#9N;-?4WB.Q\6W5\C:#K>BZ;9B,!XM1T>:\D+Y.6#I=1 #&T;=I.03GG
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MP>,]Z\V^$_P;N/!M[<:_XIUN3Q=XRN%,+:K<+M6&$<+'"G1,@ L1R3G\?4*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (;NS
MM]0MV@NH([F!^&CF0.I^H/%<!\$_#NDZ5X=U"XLM,L[.=M<UF(RV]NB,474[
ME57(&<!54 =@H':BB@#T6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>hook-20231231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $X S$# 2(  A$! Q$!_\0
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M\\-WVE^-[?P[&QGMM+U2-U,JL%,32H'",,\@@D>E.VMOZ[?F):VMU/5/-?\
MOM^='FO_ 'V_.N6?XG>$;?Q+8^&KKQ1HMIXHO8EF@T.;485O95()RL)8.PP#
MR!V-;&NZ_I?A?2;G5-9U*TTC3+5#)/>W\ZP0Q*.K,[$!1[DTGIJQ+WMC1\U_
M[[?G1YK_ -]OSKQ/XW_M3>%?A'X"\/>)++4M"U]/$6HP:?I4DFN16UE-YC -
M.UR!)B&,'<[HCX&..<UZC?>*+#P]X7_MSQ'J&FZ'90P+-=W<]ZJVD&0"3Y[A
M 4!Z,0N1S@=*.C?1.WSW_4?5+OK^AM^:_P#?;\Z/-?\ OM^=>?:E\7+#^U?
MXT2;1M=T'Q++<+_;$6NVT:1QQP/*)(4))NLE<$1GY1ECP#6CIGQ?\!ZUI&H:
MKI_C;P[?Z7I\*W%Y>VVK0206T39*R2.KE44[6P6(!P?2FU;<-VDNIV'FO_?;
M\Z/-?^^WYUS&F_$[P=K$6BR6'BS0[Z/6V=-*>VU*&0:@R+N<0$,?-*@$D)G
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M!UY)*3A;5?I;\/>6NVIGS+EYNG^=U]]XO3?0^@/-?^^WYT>:_P#?;\Z\HO\
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M9:S%)#%)IUQJD$=PCRG;$IC+[@7) 48^8],TEK:W4'I>_0ZSS7_OM^='FO\
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MR.,]':$-O"^Y&*4ES0=/H]/NYK_=SLKFM-3^?WV7_MOX'R5X-_9U\:^']$^
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M^&]7TR4*)[AW^SWMI>$03VS#:Q9)68'C8<9'WC11+WOZ\FOR?](2=M?ZWO\
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MM*UB_P#$/B>R\/S:?]MDN[Z-P[0->AK5V@+B(>8<>6&VD'%?9E%)>ZK+^O\
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MS0_\\D_[Y%2T4 1?9H?^>2?]\BC[-#_SR3_OD5+10!%]FA_YY)_WR*/LT/\
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MFA_YY)_WR*EHH B^S0_\\D_[Y%'V:'_GDG_?(J6B@"+[-#_SR3_OD4?9H?\
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MQ_=F[@B$GW3G9G'&<9&;FG33<NFOR(@U/X?ZO_PY7_X2+XA_]"3HW_A1O_\
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M>)_'$_Q+T'3M6T.TT?1)]/OI9FL[_P"V"29&MQ&&)@0I@/)C!YYXXX])HHH
M**** "JFK:9;ZUI=YIUVGF6MW"\$J?WD92K#\B:MT5,HJ2<7LQIN+NCQ'X6>
M OB=\*_#?AOP%I[>%)_">@)%:0>(+NXN9+^>SC("Q-9+&B)+Y?R^;]H89&[R
M^=H]NHHK24G)WEJ^Y*26VP4445(PHHHH **** "BBB@ HHHH **** "BBB@
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M  =\!_#R+48_"?@KP]X6744$=Y_8FEP67VA1G D\I%W8W-C/3<?6G?\ "G_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXV_8V\8:5'\5_'FGR?'O3OB1>>(KMM8L=*@BLD>YB\BW0WC&"-2D@\ID,(.
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M /"/U?\ ^1:[JBCFH?RO_P "7_R([5?YE]S_ ,SA?^%S:!_T#_%?_A'ZO_\
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MBBD 4444 %%%% !1110 4444 %0WEU'8VLMQ*<1Q*6;\*FKG_$LZ75S;Z<S
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MAO\ L_\ ABP\=6K:G_PB4$-ZT6F1W%XT4L)+1B-8E\R<H"%^X2^W)7FM_P"
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MKD.@**** *D>JVLNHRV"2YNHEWO'M/ X[XQW%6ZY33O^2B:I_P!>P_E'75T
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M%%% !6%X5_YC'_81F_I6[6%X5_YC'_81F_I0!NUXKX__ .3I/A/_ -@S6?\
MT"*O:J^4?VE/@9H/Q?\ VD?A[8ZS=ZC;0ZGHU[!,UC)&C*ML?,CV[D;!)G?.
M<\!<8Y)]3+HPE6:J2LN66MK_ &7TT.'&.4::<%=WCUMU1ZO\7/VG/ ?P5UBS
MTKQ'J$_]I7*++]FL[<RM%&20'?H .#QG/'2N_P##OBW2?%OABS\0Z1>I?:/=
MP?:(;F,'#)]",@C!!!&0001FOASXJ?\ !.35+75+1_AYJJ7NF.@6>+7KD+/'
M)D_,&CB"LF,<8R#ZYX[WP]_P3;\$IHED-=\0Z_-K'E#[4^GSP1VYD[^6KP,V
MWMR<GKQTKU:N#RF-"$HXA\SW]V_X75OO9PPQ&8.K)2HJW36WX]?N1Q6@_P#!
M1K6]2^)EK;W/AS3X?!]S=K $'F?;8HF;:)"^XJS ')4+@XP".M?1/QF_Y+?\
M#_\ L)ZC_P"D;5YY_P .W?AI_P!!SQ7_ .!=M_\ (]8EG^S#X6_9_P#C]\)+
MOP]?ZQ>2:E?7L4PU.:*0*$M'(V[(TP>3US795>559\V#;BU&>EGK[KZWT_&Y
MS4UCZ<>7$I-.4=;[>\NEC[(K-\2:_9^%/#NJ:WJ#M'8:;:RWEPZ*698XT+N0
M!U.%/%:5<+\>/^2'?$3_ +%S4?\ TFDKY"C!5*D8/9M(^AJ2<(2DNB.-MOVN
M?!-[;17%OI_BB>"5!)'+%H%RRNI&0P(7!!'.:\@_:C\<?#_XY?#V6!].\6V^
MN:4DUUI<XT&X13*4_P!5(63 1R$R>", YX(/TC\!_P#DAWP[_P"Q<T[_ -)H
MZ^??^"D-MKTGPU\.S6,S+X?COW&I1(V-\A4>03ZJ")./4K7T67J@LQA2IIQ:
ME9/F[?\ ;O7:WF>1BW5>#E4G9JVUO^#T,O\ 98\9_#_X%^ PJV'BVZU[6(X+
MC5)_[!N&19%3B*,JF"B%G /).2?0#V:;]K;P7;PO++IWBF**-2SN_A^Z"J!R
M225X%?/_ .P5X]L_AO\ #WQ+?^,?$=GHOAJ\OXHM*COKE5W3HC&Y**><8:#)
M'&1^?UQXTUK3_$?PB\1:GI=[!J.GW.C74D-U;2"2.1?)?D,.#5YI3IQQTU5C
M*5W;FOH]O[O3:W2PL#.<L-'V;4=-K?\ !Z[F[X5\2V/C+PWIFNZ8[R:=J-NE
MU;O(A5C&ZAE)!Z<'I6K7G7[.G_)!?A]_V [3_P!%+7HM?-5X*G5G!;)M?B>O
M2DYTXR?5(*Y[5K[Q%!>S+8V$$UH -DCD;CP,\;QWSVKH:*Q-3R+2M4U+^W$N
M+=FGOI6VD/SO]C[<?ACVKT?0KC5[CS_[4M8K;&WR_*.=W7.?F/M6@EI!',TR
M0QK*W60( Q^IJ:@ HHHH *JZIJEIHFF7>HZA<Q6=C:1//<7$S!4BC4%F9B>@
M !)/M5JN5^*^OR>%/A?XOUN*::WET[2+N[26WV>8ACA9@R;PR[AC(W C/4$5
M$Y<L7+L:4X\\U#NSP7X+3?!_QY\</&&H^%/&]CK^M75S%K4;>'O%TRO<@<.+
MBSM94B>*-F11YJ,6#?,6KWSPS_R-_C#_ *^;?_TFCKYO_8MU7P1J?B'Q!-H7
MQ9M_'?B!FE2]BOKG3[K4[Q%,;"Y::+]\T*F4HHXC7D #@5](>&?^1O\ &'_7
MS;_^DT=;2CR1BEV_K^O^&,(RYVWYF[JS^7I5X_G7%OMA<^=:1>;,GRGYD3:V
MYAU"[6R<#!Z5R'P'_P"2'?#O_L7-._\ 2:.NVG$K02"%TCF*D(\B%E5L<$@$
M9&>V1]17F'P.\:>'[7X*_#^&;7=,AFC\/Z>CQR7D:LK"VC!!!/!![5M'^!+U
MC^4B'_%CZ/\ -'J=%87_  G?AK_H8=*_\#8O_BJ/^$[\-?\ 0PZ5_P"!L7_Q
M5<QL;M><?&W_ (\_!G_8UZ9_Z.KJO^$[\-?]##I7_@;%_P#%5YW\:/&OAZ:T
M\'>7KVF2;?%.FLVV\C. )>2?FZ4 >PT5A?\ "=^&O^AATK_P-B_^*H_X3OPU
M_P!##I7_ (&Q?_%4 ;M%87_"=^&O^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\
M50!NT5A?\)WX:_Z&'2O_  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !5 &[7"_!G_
M )%#4/\ L8]>_P#3O=UN_P#"=^&O^AATK_P-B_\ BJY[X)3Q77@F\FAD2:&3
MQ!KKI)&P964ZM=D$$=01WKIC_ EZQ_*1B_XL?1_FCEM175+_ ..OEKJFJ0V5
MI<02):EG%DX, W L1A6P6(5<[_F!V@&O9Z\X^(<LC?$OX>0I>>2J37=R8#,J
M!L+''OP>6($Q08R/WV,9*D>CUS&Q4U:V^V:5>6_V6WOO-A>/[+=G$,V5(V.=
MK84]#\K<$\'I7DO[('_)OOAW_KYU'_TX7%>MM/:Z@;NS6X5Y(QY<Z0S;9(MR
MY&2IW(2#D'@]"*^/_P!G7]K+P!\/_A!HVA:U<W=KJ=M->/+"8E!3S+N:1007
M!!VN,C'6NRE"=2C)05W=;>DCFG*,*D7)VT?Z'V2Q*J2%+$#.!U->3?$3Q))I
M]C%J L+U]0T^Y>.WOK2T\^4L(74%EC5VPK/B3"8"ERN0#GEG_;D^%Q'RZE<@
MY')B0\9Y_P"6GI7">,?VS? 5[I6L3:??ZA?ZDL#K:^8J0+'."&1HOWAV@%>H
M5BQ(SO7@>EEU"<:R]I3=MM4UOIO:WWBG6IVTDOO1ZQH$EZ^HW,6IVIU&>.*6
M B&5;NW6&509-R&:0IO,3$22YR%9 K,<OF?&2Q8V_A:>*U$%W<^+;"&ZBC\L
M&0>83\K$#S0'?< 3\I:4;OX:X+P]^U]\+)4+S/\ 9W>=KN>XBMS;RSS%HYE8
MH)>!O+94NX^4 G+.JYWQ6_:V^'&N#P>UA>7D]Q8>(+"ZFN/)C+>1&QW>81)D
MC+;O3/IUKIQ3JRG94W]SM_3>O?\ (F-2DE\:^]'TY9^'MD]SM"7P,DL8FED)
M901O5!AODC5F=-H&=NT$'+,<>_\ #NH7FC/<%%L?)M9Y#;[W"&?=O5FC53ER
MQD+NH;=D8$@8UY5:?MH?#.VUE[L:A+Y3Q+"V_$DF%+X(8OQD;"1SDDGJ,M;L
M_P!M;X1PK\EQ/#(LGFOLB3F0K@MNWC<<'&X]?K7+?$PE=0;VZ,KVM)Z<R^]'
MLN@^&8[69Y"TB1_9!:V\+P(@A@))6/ 7&%P !GA=H9=V6;H+:T\H*\S">Y ;
M,Q4#&2"0H[+P./89)/-?/EM^VK\)((743R1F4?O@L49WD]<G?ENIY/7)]:M?
M\-R_"S_H(W7_ '[C_P#BZXZM/$U)-N#^XI5J2^TOO/H&BOG[_AN7X6?]!&Z_
M[]Q__%T?\-R_"S_H(W7_ '[C_P#BZY_JU?\ D?W,KVU+^9?>CZ!KQK]CS_DV
MOP/_ ->TO_H^2L/_ (;E^%G_ $$;K_OW'_\ %UL?L:3BX_9H\$,$>/$,Z8D7
M:?EN91GZ'&0>X(-:.E.G0ESQ:U6Z\I$*<9U5RN^C_-'M-%%%<1TA1110 444
M4 ?(/[7NI>.O#_Q&M[OPKX=O==AN]$MK=9+75+.V%M)'J*32DK<3)DO"KQY4
M'[V"<5]"?"OQVOB[P$FNWGAU_!*"217T^]N;:0Q!3C>SP.\>#U^]]<5E_&/X
M6_";Q?:7'B/XE>%?#VNQ:'9/*][K-BERUK;C+,1E20O#' ')%8/A#0/ /Q"^
M 6O>&OA;I>CZ)H-TES8_V9J/AZ2"UM[A@"ZW%A*L3X.Y6*L%W!@<X(-3&\:4
MH[M7?WNXY6<T]KV_"*7Z7_$\3^ WB_XS>)/V@K*3Q%K&J'0$N;VQN-.N);(V
M4L"+-*UP@B)<DRRVL<)ZF**7=S7VQ7Y]?LHZ'X?T#]H*S2"'P5;20R75C:7N
MC_#=M&:_<0R$_9KLW#_(1'*02@$@B?:2!FOT%K5VY(6[?U_F9IMSDWW_ *_R
M^04445!9\W>#?V:QX?\ C;\9[BPTRX\(^$O&&DZ<D6JZ#?+:W<MYYEV]W*KH
MWFI+F9#YA ZC:>.,3]E[P!#\-/VI?C]HEOK>O>((TTSPQ+]M\2:G+J%V=R:@
M=IFD)8J.P[5]65\Z_"?X9_%[PY^TKX_\<>)8_!(\+>*K>SM2FDWUY)>Q)9"X
M6V(22!4RXN,O\Y V_+FFW=)=M >LG+O_ )6_0^BJ***0!1110!3U;5[#0-.G
MU#4[VWTZPMUWS75W*L44:^K,Q  ^IK*O/B+X4T_0;?6[KQ-H]OHUP-T&H2W\
M2V\H_P!B0MM;\#7&_M*_"/4/C;\*;_PSI>HQ:;?O-%<1/<%A#(4;.R0J"0IZ
MY ."!Q7F_P #?V'/!_@;P]:R^-=,L?%?B@.SR2N\DEI$N?EC2-L*XP,DNF<D
M]J]6C1P;P_M:U5J5[<J5W;OJU_70X:E3$*M[.G!.-MV^OW'2ZK^V5X!%\VG>
M&(M:\>ZJ,C['X:TV2<@]LLVT$>Z[JH'QY\?OB @'A[P#HO@*RD4XO?%-\9YL
M>HBB *-[.I%>[Z-H>F^';".QTK3[73+*/[EM9PK#&OT50 *O5/UC#T_X5&_G
M)W_!67WIC]C5G_$J?^ JWYW?Y'SI)^R]XM\=+N^(WQ>\0:Q%(/WFF:$J:=:_
M[K!00X]RH-2^&?V<_AQX2\1)'X>\,VL4T,@1+VZ9KF5&7F24-(6VD< ;<#KC
MFO?=2>X2PG-I'YMSM(C7('/KSQQUKR'XE>$/&-YX&N]&\-6K+J>M2IID^H">
M-3I]DQ/GSC<P+,P+ !<D%@>,52QF(Q#5%U.6+[6C'YI60GAZ-).HH<S7?5_>
M[G@OQ/\ C':V\^O?$Y1$]G9++X;\$VK8*2$$K<W@'HS*5!X^2-@>2*[_ /9*
M^%=M\&/AKJGQ(\:S+;:]K,#:A>WEZ"'M;0_O K9YW,?G8=22HQE:YK1?V8_$
MWC?XW:/+XKT :-\,_"<"PZ3827<,_P!K$>T(&5')&\@,Q8#*H%(R379?M+^
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M_LN(L(0 OG')F)Q_$9-Y/OFO4J_,\9;ZS5MMS/\ ,^UPU_80OV7Y!1117&=
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MEG;;N6=SD#/J78<[6]_O=>L/@?IVE>*M<T**/QC)"UOX'^'T#;H]&MV&//F
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MSI].%%%% !1110 5RGPT_P"1<O/^PUJW_IQN*ZNN4^&G_(N7G_8:U;_TXW%
M&U+X<TF;5HM4DTNSDU.+/EWK6Z&9,C:</C(R !UZ<5HT44 ?//[3'PJ\;^)_
MV6-5\):!XB@NO%*P_-KNIRBT55!8O*TC%_+VJ?O DC&05/(];^$W_)*_!O\
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M7/&:^=?VA?VI-*U[]D;QEINH6'B/5-;UKPC?J^H:9X0O8=/BF:.:)DD<//'
M4=&5PT[A=I.[!!KZJ^#_ /R27P3_ -@.Q_\ 1"5I/XF*#O%-'75S&GZO?:>;
MJ*XTZ_NB;AV1U7<-F> ,GI73T5!9SMWXHN4M93'H]\LFT[2\7 /;.#7.>"]<
MN[+[2AM+F]AE;?F%=Q#]\GW&/R%>BUR?PW_Y <__ %\-_P"@K0!?_P"$EF_Z
M VH?]^Q_C4OAE[N6"]DNTGC+W3O&D^=RH0, >W6MBB@ HHHH **** "BBB@
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M"?CB_P#$^FR:QX?M](N9+W3XG*/<Q",YC5@1M)Z!LC!.>U=]7FG[2UWHME\
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M;!6,(@X3!&0" >:M^!-"T?3]<N9?#+V>N:U9J!?^+[Q,:9I$2KM$=J&)W,J
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M/W$ST_4[AD^\^$_!&E>#;9TL(6:XE.Z>\G;?/.W4EW/)Y[=*W418D5$4(BC
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M/P]_8M^)FDZ?I\=R-/\ ">J&.^OD66Z=S#+(TC28SN+LS<8 )X '%>R_!_\
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M<5U_C_X=Z!\3_#[:+XCLY+RP,JS 074MM(CKG#++$RNIP2#AAD$@Y!(KCO\
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MT2YMHO/L[>X,<$Y#VQW%T ;<ORG.0 *]%_X9$\3?]'&_%G_P/LO_ )%JQ?\
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M?,/]H?\ ".?VM]OV;3CR?._=YW;?O<8S7T/110 4444 %%%% !1110 4444
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MX[Z"2PU&YL)X9X\[)$FMY(Y%(R>C#K7'7/[+/PYG?1Y8M/UG3;S2HKF&VO\
M2O$VIV-VRW$BR3^;<0W*23M(Z*S-*S$D DT44+W=OZTM^6GH#UW-3X9_L_\
M@OX0:OJVI>%;;5[*XU6:2YO8[KQ!J%[!/-(P9YC#/.\?F$J,R!=V.,X)%>BT
M44[NR785MWW"BBBD,*\EM_V5?AG!'J\1T2^N;;5(KZ&:UO-<O[B");PL;K[/
M%).R6QD\Q]S0A#\QYHHI6&FTTUTU^94F_9#^%]Y%9QWVE:SJR6B>3$-5\4:K
M>X@.W=;GSKEMUNVQ"T!S$Q125) KV-$6-0J@*H&  , "BBJ<FU9LE)+8=111
M2&%<#\0O@;X/^*.LV.K>(+347U"SM9;&.;3M:O=/WV\K(TL,@MIHQ+&QC3*2
M!@<=***/,#*?]F+X<OKVH:J-&O(SJ*11WVFPZU?1Z7>I'"L")/8+,+:5!$BI
MM>(@@<@UT/PV^#?@?X/0ZM#X(\+:9X6@U6Z^V7<.EVXACDEVA00HX4 #A5 4
M9. ,G)13N_Z_KR$TG:_3_AOR.RHHHI#"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>hook-20231231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %M XP# 2(  A$! Q$!_\0
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MA5#Y8C S0M79;@]%=['LO]K3?W4_(_XT?VM-_=3\C_C5*B@"[_:TW]U/R/\
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M:NB[_:TW]U/R/^-']K3?W4_(_P"-4JP?%WCO0? FA:OK&N:E%96&D6;:A?,
MTDD-NN<R&- 7(X/0'..*6Q23>B.K_M:;^ZGY'_&C^UIO[J?D?\:S+*\AU&RM
M[NW?S+>>-98WP1N5AD'!Y'![U-3::=F2FFKHN_VM-_=3\C_C1_:TW]U/R/\
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MBJ&O?M+?#_PWXIUCP]>:AJDFHZ,L+ZFUCX?U&[MK%94WQO-<0P-#&I4[MS.
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M)%B>&1HY4PZJ?E=6&<8.,@D5T- %W^UIO[J?D?\ &C^UIO[J?D?\:I$@ DG
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MA[AHYD(9&!'4?0Y!(HG.]W:^_P [WT_K>W0F"LE%O:WX<J_]M?WOY_-O[/\
MXKL=0_:=\4Z/X7\;:OXM\$0^#M-N[+[;KD^J6XF>XF#R1RRN^]B ,MN8YRN0
M%"C;\,^+-(^"WQY^+UW\0==LO#MMXDNM.O-$OM6F6"&\@2T$1@AD<@/(DB/F
M)26^<''S5Z=\.O@U9?#_ %[5/$%QKVM>+/$NI6T%C<:SKLD!G-O"6,406"**
M, &1SNV;F+?,QXQZ#0W:UNS7WRYO\E]Y$5O?R_"*7XZO[GN?)OC3XL>#]"_;
M$^'?BG7/$-EX9T&^\!Z@(+SQ%)_988M=VY52MSY;*Q )"L < \5YEJ>G75I)
MHWB/4]0N?!_A+4_B?J^M67C;RDC.B6;6KQQR SHT4<=S*& >5&0JX/WF4U]_
MT5*TBDNB:^3GS_?>R_34T;YKWZV_](</R;9\4>$_!7Q7U;]C30]-^&%S:^'+
MU;J7:OV.6"^U2,:EN%\EQ]K@6 31!IG0JV\.57:"*^PO#%MK=IHEM%XBU"PU
M35USYUUIEB]E _)QMB>:9EP, YD;)!/&<#5HJG*[=NKO_7]?A8A+J_Z_K^M3
MYZ_9T_Y+S^T;_P!C'8?^FZ&LOX\>*5L?CA8Z5XY\6:GX%^&C>&Y;FPU33=5F
MTS[1JXGQY9FB93)(L6&2W.]9,M\C[<#Z9HJ/Y/[J2^Z/+?\ 5=G8O^;S=_\
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M(B"96=@/+FRHC.!'R %QBON^BA_"XQTNK?\ I=ONY_\ R5#O[RD]=;_A%?\
MMOXL^)O 7C_7KB'P-)X?\5:OX@\47^AWDWQ$L+[4YISI$RV1=':W8[;"47&$
M2.-8]X+':VW<L/[._BOQ+:^)?V:)KKQ7X@UAO&7@_4)M;35M5GNX[F2&.%XI
M!&[%$=2[#>H#,#\Q8\U]OT5ISKF<K;_AI-67E[RMZ?=FXW25_P#@ZIW?GI^/
MW_.'QM\4"R^-EGI?C;Q-?^"_AS_PCS7.GZA9:M-I27>K^?M,3W$3(6=8]I2
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MGARZBN]7N)+>33S-=J(#"7V$+Y2%6(+IC"L%P*H_"6*Y\":;9?V'J^MV8O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(+NZ4V,(A59UDR^YAFX(SW/VS13@^27-_6S7Y2?]()^]'E]?T:^YQ3"BBBD
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7Q7X]\)Z2G[6?Q/U3QGH_Q*30
MM2\/Z3;:=?>"[7Q"(;J1!.)D=]+&URNY.)20-QQU-?:E%2XWW\_QT*3LFO3\
M&G^AY'^R;X8\2>#/V>O!FB>*X?LVKV5JT0MFACB>" 2-]GC=8P%#K%Y8; Z@
MYYS7KE%%:SDYR<GU,XKE5D%%%%04%%%% !1110 4444 %%%% !1110 4444
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M]*^JZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!DLJ01/+*ZQQHI9G<X"@=23V%5],U
M6RUNR2\TZ\M[^TDSLGM95DC;'!PRD@UR7QN^'MS\5?A7X@\*V>H?V7=:C"JQ
M7)SM#+(KA6QSM;9M..S'@]*X;]E#X":Q\!/!^JZ=K6K6^H7FH78N3#8L[6\(
M"A?E+*I+, ,G Z*.U=L:-%X:55U+33LHVW7>_P#7XG+*I55=4U#W6OBOL^UC
MW&O/OB=\:=)^&6K^'M#;3=1\1>)_$+S+I>@Z0;=;FZ$*AYF#7$L42A%()W2
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M,(L/]GD&'BW==F. O11PN!Q38_A-X+BCLXH_"VDQPV5R;RVA2T01P3%0I=%
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M9%<:I>DJ64D X(./<>M:2YK+F[:>G]?AY&$%!)\FW]?T_/S/I6BBBH- HHK
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M5+2O!]O^ OS_ ,NMTJFM&2[V_5_E?^M']_(P901P",UAZEX_\,:/I.JZK?\
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MN4OVA_VFM$^$.G7&E:=J-I>>-F:%8=)$3W$BAR.2B8&=O(5F7.0>X!\P\/\
MP.\??M!SW&H>.T'PZ\#W]VVH-X4T@[+F^D8@F2Z8\ECA>7YXX1.#7JWP+_9F
M\-?"R&#7;R*;7?&MT@FO-:U5O-G65AEPF?N<DC/WCW)KVEF"J2<X SP,FO6>
M+HX)>SP2O+K-[_\ ;JZ>3=WZ'"L/4Q#YL2[+^5?J^OY>IY]HGPWT;PE=Z'X9
MT3PA86OA2SC;4#= @%+V-XQ!QG=(Y!D8NV<;%YST]"KE/A[!:7VFW'B6"RO[
M"X\1.FH30:D<31CRDCC4K_ -B*=G8LV>2:ZNO)K2E*5I.[6_KUZL[J:2CIM^
M@4445@:A7+^-OA?X2^(\,<?B;P]I^M"(@QO=0!G3V5_O >P/-=115PG*G+F@
M[/R)E%25I*Z*FEZ59:'I\%CIUI!8V4"A(K>VC$<<:CH%4< 5;HHJ6VW=E;!1
M112 **** "BBB@ HHHH **** "BBB@ HHHH **** "HKFUAO8'@N(DG@D&UX
MY5#*P]"#P:EHH \4\=_L=?"OQTS3MX=30;\Y*WFA/]D96/.[8O[LG/.2IKC/
M^%%?&OX7G?\ #_XI?\)%IZ<C2/%J&3"CHJR_-Z#IY8KZ>HKTX9EB8QY)2YX]
MI+F7X[?*QQ2P=&3YHKE?=:?EO\SYA'[5'COX;CR_BI\*-4TZWC3,FL^'B+JU
MXZL1DJ@[\R$^U>G> OVFOAG\2#%'H_BVQ6\D.U;*_;[+.6]%23&X_P"[FO3R
M,C!Y%>9>/OV:?AK\2?-DUGPG8_;)!S>V2FVGSZEX\;C_ +V:T]M@:W\2FX/O
M%W7_ (#+_P"2)]GB:?P34E_>5G]Z_P CLO$'CKPWX3B,NM^(-+T>,<EK^\CA
M'M]YA7F/B/\ ;)^$'AIBDOC""^E&<)IL$MR#_P "12O_ (]67X?_ &&?@_H3
MK))X?GU:13D-J%]*P_%595/XBO4/#GPB\$>$#NT7PCHFF28 ,MM81+(<=,OM
MR?Q-*V70ZSG]T?\ Y(+XN72,?OE_\B>*G]MN#Q I'@GX9>,O%C-Q%*EEY4+G
MM\Z^80/<CBC_ (6;^TAXN8#1?A=HOA:V?GS]>OQ,R^VU71L_5.QKZ7 P,#@4
MM'UO#P_A8=?]O-R_5+\ ^KUI?'5?R27^;_$^9Q\*/VBO%NXZ]\6M+\-1,>(-
M TX2[0>OS%8VS_P(_6E_X8>TO7F5_&?Q"\8^+\'+0W5_MB<]LJP<\'GAA7TO
M11_:F)C_  K0_P ,4OQ2O^(?4J+^.\O5M_A>QXSX<_8\^$/AD P>#+6]DQS)
MJ4LEUN_X#(Q4?@!5_6OV4_A)KZ,MSX#TJ(-U^Q(UJ?SB9<5ZO17.\=BW+G=6
M5_\ $_\ ,V6%H)<JIJWHCYQU']@;X57+B33X=9T*=>4FT[4FWH?4&0/_ )-5
MC^QWKFC8/ACXU>-='9?NK<W)N8_Q17C![_IZ5]+T5NLUQNTJC?K:7YW,OJ.&
MZ0MZ:?E8^:6^$G[16@8.C_&+3-8"](M8TI(U;ZL(Y&'4]#V%#:U^U-X>P9/#
M_@GQ2B]5M9WAD;Z%Y(U'7N.U?2U%/^T9/^)2A+_MU+_TFPOJB7PSDO\ MYO\
M[GS2W[1?QAT#']N_ 74YT'WY-'OQ<,/HB(^>W?UJQ8?ML:/'?VMEKOP_\;>'
MIKB585>ZTT>6K,<#)+*>I X'>OHZBD\5A9+WL.EZ2DOS<AJC7CM5;]4OTL%%
M%%>4=P4444 %%%% &#XZ7Q._A345\&RZ3#XF*#[%)KL<LEFK;AGS5B97(VY^
MZ1SBOS[.J>.[B]O/C1J^@_LZRZAI.N-I]SJ?]B7HU<F&Y^S22J#.2)LJ=BG+
ME=IZD+7Z15\YZW\"?!>H?M;:-XPCT;P0SV^EW$NI12VUL=4?46EA^RW."A?Y
M4$B[]PY9>#P0Z>E:+_K37\;6]6@GK2DOZUT_#1_(^BU.Y0?49I:**0!6+XST
MC5M?\+ZCI^AZ]+X7U:XCV6^KP6L5R]JV1\PCE!1CC(PP(YK:K%\9^&Y/&'A?
M4=&BUG5/#TEW'Y:ZIHLJ17=N<@[HF='4'C'*D8)XH ^?OV&M)U/0H/CC8:UK
MDOB75;?XDWR7&K3VT5N]T_V#3\N8X@$4GT4 5]-U\R?L->'I/"<'QQT>76-2
MU^2S^)-]$VIZQ(DEW<D6&G_/*R*BEO<*![5]-T %%%?*W[0?[;H^$/Q G\*:
M/X>CU>XL1&;VXNK@QJ&=0^Q  <X5E^8]SC'&:[,)@ZV-J>RH1N]SEQ&)I82'
MM*SLCZIHKPW1_P!L/X?S>!/#/B+6KF]TB;74NC#IUOIUUJ$RM; &Y&+:)SM1
M2'W$#Y#N(&#B_P"%_P!J/PGXLT3XB:U96^JR:-X,G$<]]#IES,E[&;>.82V^
MR(^8I$G\&XA0KD!74GFJ0E2<XS5G"]_*SL_Q.B$E4C"4=I;>=SV.BO$?@Q^T
MROQ;^&&N^,F\':UI:Z7.MM_9BVES)<W$GD0NZHLD$1.V61XL@;?W98E0>.]^
M#OQ#_P"%L_"SPMXR&GMI(US3XK_["TWFF#>N=A? W8]<"AP<6T^EOQ5U^0TU
M)76VOX;G8T445 PHHHH ADV_:H<_?VMC[OMGKS^7X]JFJ)S_ *1'P3PW.3@=
M.W3\_P .]2T %%%% !1110 4444 %%%% !1110 4444 %0VH 1\%3^\;[A![
M^P'/^<FIJBMSE7X(^=NI)[^__P"KTH EHHHH **** "BORR\6?M=_%.Y^(=W
MJ\.OWNCK!=,(M&7 MX5#$")XR,.0."6!.:]A^(]_\3?C%\7VLO"4GB:PO[OP
M=X<U2&*P\1/8Z=H\L]S<&YDN;?SD\Y6A5X\*DC9"?+D!E]G,,JQ&71IRJ6?/
MVZ65]?\ /8\S!9A1QSJ*%UR6W\VE^OJ?;ESXBTJRTL:G<:G9P::651>2W"+#
MEF"*-Y.,EB%'/)('6H7\7:%'X?776UK3ET-E5UU,W48MB"VT$2YVX)( YZG%
M?&OBG]F[XD:G^QQ\.OA]HNG:CI?B/0[M7U&UN]<FE\W[.LLB,DL.HQ9BDFCA
M"*7/EB12$B*97TSQA^S9>R?LD^'/AXL"^)/$/AZVL5M!'<201/-%+&2^V:=P
M=JAB-[L 1\H7Y0/)<4G+7:22\UU?R/2G>-DE>Z;^YV2^?Y=SZ4HI!2U PHHH
MH **** "BBB@ HHHH *^:_VYM/L5^'NC:C+8+<WC:I%IXE_T<.D4@9V"M<S1
M0(2T2?-*V.-H^9A7TI7@G[9-K#=?#K0%^T&UU)?$%J^G22?9A;_: LF!.USF
M%8RN\$N&R2H4;BM9S^SZK\U?\#2'VO1_DRU\,=/MW_9.6T_LJ'5+=]'O5.F:
ME=VD<5P"9<Q2S6\DD"*V<%E=@ <GD$5X5^Q!\1[WQW\5]2M]9T9AJ.EZ5+:P
M74OBNX\1BPC$L8:VCN([<6@R54M^_:4^6N0<''NGA;Q NI_LCW^K16$?B,_V
M%J#'3Y+*&.*\=1,&A\JV_=LC,I4&/AU(8?>KY\_87\06]Q\4Q8Z5X?TN#3?[
M+O5-[I?@N_T*&(1R6OEE6N&96\TR3@Q@Y7R >,\]4?>Q51>3?_I7]>:^9A:V
M'AZ__(_UTU75V/NZ^:Y2RN&LXXI;P1L88YY"D;/CY0S ,5!.,D D>AKXK\0?
M'_XF0_#;3!=>++70];E\0>*H+K6;.P@:-8],2[D@MHTF1EV-Y*@D@R%$;#*Q
MW#[;KF=4^&/@[7-';2=1\)Z'J&E->-J)L;K389(#=,Y=IRC*5\PN2Q?&[))S
MDU@T];/=?=KO_6^VUS9-62:ZW]59JWXKTWWL?-_P0^/WC?QY\:+*#5]2":7J
M5Q?V#^&5M(E73Q;6-E<+<>8%\TLSW+JP=MN'CPJD$MZ1IW[0-K>?M%7'PM'P
MV\16^KP6_P#:,FOO%:"R%HS2(ESN$WF['DB>,?)NSU '->J6O@GP[8^)[GQ)
M;:!I=OXBNH%MI]7BLXUNY8E^[&\P7>RC PI.!7BVG_\ *0'7_P#LF&G?^G6^
MK2332LK67]??_P  PA&44^9W_K]-OQ/H.O'_ (T?$#1]-\>_#KP/J7A"P\7R
M^([]I$&H%"FGB+:#<!&C?<X623&-I^5AN&:]@KY@;;X\_;\ ,;&#P7X<ZD_+
MYTHSGZE+O_QSVKOP%.,YSG/:$9/MK:RV\VCGQ4W&,8QWDTOQN_P3/I^LS4?$
M=CI6L:3I=Q(PO=4>1+:-4+;O+C+N3C[J@#&3QEE'4BM.N<T*XN=8\1ZMJ"ZC
M87VB1A;*SCM</)#-&[K=;WQP=X5-@)QY7."2!PQBFFWLOZ7]=CJ;V2.CHHHK
M,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *_/#P]^SOXK^)GC'Q3<>%;7P=>^'[W5;ZPU#QM<M<VVLK/'J:W
M/F20/ &>XMS'Y43>9LP%8$#Y:^V/C5\4+7X+_"WQ%XTN[*;4HM(MO.6R@8*\
M[E@B(&/"Y9E&3TSFOECX)_L\_"_XF_$GQRGC/X4W'@WXE:9>6VKZG'IWC/4[
MNUNA=!I8I@RS1J>4=2A3 VX&1Q3I75537V5_E]^E]+WV9-5)TG!]6OP_+6W2
MVZ/MU1M4#).!U/>EI ,#%+2&@KG_ !_X:T+QAX.U31O$V?["O(O+N\7DEH=N
MX$8FC='3D#E6!KH*Y7XHS>$(/A_K<GCX::?!RP?\3,:PBM:>5N'^M# @KG'7
MB@9X3^PAX=T7PC8?&[1_#N[^P[/XD7T5INNY+L^6+#3\?O9&9W^K,3[U]05\
MJ_\ !/Z7PG-H/QG?P(--'A!OB-?'3!HZJMIY/V"PQY07@+UZ5]54 %?,/Q\_
M8CL?C'X[F\5:?XC;0+R\5!>PR6GVA)&50@=?G7:=J@$<@GGCG/T]179A<77P
M53VM"5GM_5SFQ&&I8J'LZT;H^8M8_8T8_P#"L])T+Q/?:'HGARUU:#4M1LI(
MTU"Y>\CC4F-9(98MIVN"&&54KM.X!AVFF?LF^"](\!>-O!-M/J8\)^*[>&"X
MTJ5X98[3R[:.VWP,\18,4ABSYC. R J%.<^TT5SRJ2G*4I.[EOYZWU^>IO&*
M@HQBK*.WEZ'!?";X(>$/@EX3NO#OA'2;?2K"ZNI[N<P011/))*[,=WEHH(4,
M$7CY415[5L_#?P'I_P +_ 6@^$M*FN;C3=&LX[*WEO&5IF1!@%RJJ"?H!]*Z
M2BI<F[WZV_#;\REHK(****D HHHH B=2;B-M@( ;YMHR.G?/'Y=NU2U#( ;J
M$Y7(5L D9[=.,_J/QJ:@ HHHH *Y7Q%\5O!7A"]ELM<\7:'I%]$@D>TO=1AB
MF"D9!\MF#<CIQSVKJJPO'/@^Q^('A#5_#FIF5;'4[=[:5H&VNH8?>4D$9!P1
MD$<<@UK2]GSKVM[>1G4Y^5^SW\SC_#O[3/PK\46;W-GX\T2&-',974;D63Y
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MO:ZFNHP!Y8%F$?G*B#S4#A9$ (5NC.,$^J4-6_KOJ).X4444AA1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .-^,'PMTSXT_
M#C6_!>LW=]8:;JT:QRW.F2(EQ'M=7!1G1U!RHZJ:\6T3]AFVT'Q9=>)+;XV_
M%LZM>BW2\G?6K/-W'"6\N.0BS!*C<PQD<,:^FZ_.V[\$?&;XB^*=;ND_X2BY
M3P[J-U_9.H:?X@3[+=:K<:F/+N (I@#:VUI&BM$XX)D782:=/^*DM+]?Z^[U
MMTU2J?PVWK;IZ_\ #?):^OZ(C@4M(N0HW'+8Y(I:0(*YSXB>*-#\%^"M5UOQ
M)&\NAV40DNDCM'NV*[@.(D5F<Y(X )KHZQ?&?B23P?X7U'68M&U3Q#):1^8N
MEZ+$DMW<'(&V)7=%)YSRP& >:!GSM^P9XET;QCIOQLUKP\CQ:+>_$B^FM$DM
M'M6"&PT_&8G563Z$ U]1U\R?L->(9/%D'QQUB71]2T"2\^)-]*VF:Q&D=W;$
MV&G_ "2JC.H;V#$>]?3= !14%_>1Z=8W%W*LKQ01M*ZP0O-(0HR0J("SMQPJ
M@DG@ FN(N/C=X9M/*\^V\30^:XBC\SPGJJ[W/11FVY)]*UA2J5/@BWZ(SE4A
M#XY)'?45S7AWX@:7XHOVL[.UUN&4(9"VHZ#?64> 0/\ 63PHI//3.3SQP:Z6
MIE"4':2LRHRC-7B[A1114%!1110 4444 1./](CY(X;C!P>G?I^?X=ZEJ&3;
M]JAS]_:V/N^V>O/Y?CVJ:@ HHHH *YCXG>&=0\9_#WQ#H6E7_P#9FHZA92V\
M%WD@1LRX&2.0#T)'(!.*Z>BKA)PDIK=$RBI1<7U/F?\ 8A^#?B#X5^&O$5SK
M6HP30ZG=^7!96TC.D30/)%)(20!EB,<#HHR>@'TQ7(?"K_D35_Z_]0_]+)JZ
M^NO'5YXG$SJU-V_RT.?"T88>A&G#9(****X3J"BBB@ HHHH *BMQA7Y)^=NH
M([^__P"KTJ6H;7;L?9T\QL_=ZYYZ?UY]: )J*** "BBB@#Y/\8?L9?#[6?CO
MIFY=0MM/U>RO]7NM.MYU2'S89[-=B';N5'^TN2 <C VE1Q7K/[0GP?O?BI\*
M+?PAX>NH-$>'4]+N8YMYB$$-M=PS,(R$?#A(B$!7&[;G YK?U?\ Y+=X3_[%
MW6?_ $ITRNXKTL5B:U>-'VLV^575_*3_ ,D<.&H4J,ZKIQ2N]?N7^;/'/AE^
MR]X<^%GBO5/$>G:SKFHZGK-M+!K3:D]M(FJR23O-Y\RK H5PTL@ B\M-K8*'
M PGP?_90\!? G2M=MO!MFVD7VL6Z6TVKP6]K%>1JL2QC8Z0J/O+YOS*1O8G&
M, >R45YO2WE;Y=OQ_0[[N]WJ[W^??\#S;X#_  .L?@#X1D\-Z7XBUK7].,S7
M"-K:V9F1W):1C);V\+2L[$LSR[W)_BKTFBBFVY.[)22V"BBBD,**** "BBB@
M HHHH *^?_VP?$&CV_@RPTF^UZRTVY\_^U'T^_AO)H;ZVA^1XY$M,2,"\T05
M<C=(8UPV=I^@*\6_:)\)^ [FX\+^)?%VF:YJNHV5ZEIIMIH"SRS74I=;A4:&
M,XD5'MEF&[A3$#[&))-J^UU_P/QL7&^MNS_X/II?7IN0_LQ:?J6N_ JWL=<U
MJQ\0:1=1S6]I<Z:E[:S)"7=9(9!<-YT;QMNC )#($ )R,UY=^RA9:3X=^*5W
MH=IX2\9V-W:6=[ WBCQ3KVIW5MJZQW2H&M(IV,3< %G*Q,.-@=6+5[U\/] L
MM*^"R:=X9T_7](C>UN6AAU']SJGGR-(SR.9L@3/(S/N?C+9/%>>_LW:+XJT7
M58D\:^*OB=J7B%K*3S]-\56=E_9@(D7]Y'-9PF,28QA#<,2"Y .,CHO^_DUV
M?ST?Y=?74Q2_=)>?W?U^A]$445@^,_'WACX<Z2NJ^+/$>D^%],:40B]UF^BM
M(3(02$#R,J[B <#.>#6+:6YHDWL;U?/FG_\ *0'7_P#LF&G?^G6^KV/2OB#X
M6UW77T33?$ND:AK,=JE\^G6M_%+<+;N 4F,:L6",",-C!R,&O'-/_P"4@.O_
M /9,-._].M]56L2FGL9W[?WB/^R?@-+I@L9;N36;Z"U25&(6%E82Y('WB=A
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M)[DFO:S1J%;DC]F,8K[DWUTU=NN[//P*<J?.^K;_ !LOP1J4445X)Z@4444
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M!(( D4$9R">F.:]VK;%TJE&O*%2-G?J98>I"K2C*F[H****Y#H"BOFG]I?\
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MRZ\*_#S1]-NK^WU)8(1':2VT81%M!Q;H. 6(B"98\DY-=I66.K>WQ,ZG=O\
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MY6T9ZW17DE[^U=\+;#3X+Q_$DLT<]K:7D45KI=Y<3R)=2O%;JL,<+2&1WCD
MBV[QL8E0 377^(/BEX=\+>$K+Q'JLU]9Z?>M&EM ^EW1O9I)!E(ELQ$;@R$
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MY(&\Q<L!PL+(00<B0],<^<ZQ^Q+I^J:GIS+XDGBTB*&6VN=/5KZ%7C^U7%S
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M6_9>D^,'QEN=>U?7;NP\'77AJ'1+W3=,G5)K_;>-.\4P>%P(6!4;HW23((!
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M]R;^\]]HKP+_ (;>^&G_ #[>-?\ PA]8_P#D6D;]N#X9HI9K?QHJ@9)/@C6
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MVA>.;&QLIO&&LV-I):Z;%;27$<EQ* SI%")$:0A!(RH9$W;,%USD<S!^VO\
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MJV\036GV\?%%K;2[N1;S8UR]@(3&J-<(K.I4KO!8AL%Z(->UBI;=?R7XOO\
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M?#SQYIOQ+\)67B'2A(+*Z+A5F7:P*N5((^JFO$_B5^SY_P +V\3^)/\ B?\
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M\MY-NYU1?E0%CEF4<#O7%_ GXE^&_'OAE[30M1^W7&F8^UIY$D?E^8\A3EU
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M4/Q7^9S5=]^SI_R6>3_L7[G_ -*;:M@_LI^(2TI7Q]9[64>7_P 2$\'G)/\
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M]WH>]T5\W:;^SK\7K.\TZ]G^/^HW-['!;07LAT2/9<^5<>8Y6,RE(S)'F,D
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M^>_F8S_M[J^9JZ*Q[D"34;B[#V=CIENEYK&HSK:65O(^Q'D(+%G/4(B*\C$
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M?[4.D?&/Q_XS\+VGA_Q!I<F@7JVT-U?Z)J%NEPAMXY2TIFM8UMGS(5$4C;V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>hook-20231231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (^ UX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]09]4=)65
M%7 .,MWJ/^UIO[J?D?\ &JL_^OD_WC_.F4 7?[6F_NI^1_QH_M:;^ZGY'_&J
M5% %W^UIO[J?D?\ &C^UIO[J?D?\:I44 7?[6F_NI^1_QH_M:;^ZGY'_ !JE
M10!=_M:;^ZGY'_&C^UIO[J?D?\:I44 7?[6F_NI^1_QH_M:;^ZGY'_&J5% %
MW^UIO[J?D?\ &C^UIO[J?D?\:I44 7?[6F_NI^1_QH_M:;^ZGY'_ !JE10!=
M_M:;^ZGY'_&C^UIO[J?D?\:I44 7?[6F_NI^1_QH_M:;^ZGY'_&J5% %W^UI
MO[J?D?\ &C^UIO[J?D?\:I44 7?[6F_NI^1_QH_M:;^ZGY'_ !JE10!=_M:;
M^ZGY'_&C^UIO[J?D?\:I44 7?[6F_NI^1_QH_M:;^ZGY'_&J5% %W^UIO[J?
MD?\ &C^UIO[J?D?\:I44 7?[6F_NI^1_QH_M:;^ZGY'_ !JE10!=_M:;^ZGY
M'_&C^UIO[J?D?\:I44 7?[6F_NI^1_QH_M:;^ZGY'_&J5% %W^UIO[J?D?\
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M&" :QY/V>? ,GA2R\/#1IH;*RO&U&WNK?4KJ*_CNFSON!>K*+CS6#,&?S-S
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M_P"5;U% &#]DF_YY/^5'V2;_ )Y/^5;U% &#]DF_YY/^5'V2;_GD_P"5;U%
M&#]DF_YY/^5'V2;_ )Y/^5;U% &#]DF_YY/^5'V2;_GD_P"5;U% &#]DF_YY
M/^5'V2;_ )Y/^5;U% &#]DF_YY/^5'V2;_GD_P"5;U% &#]DF_YY/^5'V2;_
M )Y/^5;U% &#]DF_YY/^5'V2;_GD_P"5;U% &#]DF_YY/^5'V2;_ )Y/^5;U
M% &#]DF_YY/^5'V2;_GD_P"5;U% &#]DF_YY/^5'V2;_ )Y/^5;U% &#]DF_
MYY/^5'V2;_GD_P"5;U% &#]DF_YY/^5'V2;_ )Y/^5;U% &#]DF_YY/^5'V2
M;_GD_P"5;U% &#]DF_YY/^5'V2;_ )Y/^5;U% &#]DF_YY/^5'V2;_GD_P"5
M;U% &#]DF_YY/^5'V2;_ )Y/^5;U% &#]DF_YY/^5'V2;_GD_P"5;U% &#]D
MF_YY/^5'V2;_ )Y/^5;U% &#]DF_YY/^5'V2;_GD_P"5;U% &#]DF_YY/^5'
MV2;_ )Y/^5;U% &#]DF_YY/^5'V2;_GD_P"5;U% &#]DF_YY/^5'V2;_ )Y/
M^5;U% &#]DF_YY/^5'V2;_GD_P"5;U% &#]DF_YY/^5'V2;_ )Y/^5;U% &#
M]DF_YY/^5'V2;_GD_P"5;U% &#]DF_YY/^5'V2;_ )Y/^5;U% &#]DF_YY/^
M5'V2;_GD_P"5;U% &#]DF_YY/^5'V2;_ )Y/^5;U% &#]DF_YY/^5'V2;_GD
M_P"5;U% &#]DF_YY/^5'V2;_ )Y/^5;U% !1110 4444 %%%% !17S!^WAXK
M\.MX/\(?#CQ)XAL/#6D^.M;BL]4O]0OTLHX]-@_TBZS*[*%WA$B'/685J_L)
M_$2P\8_!$>'K76+77IO!&H7'AAM1L[E+B*ZA@;%M,DB$AP\!B.0>H;TIP7.I
M/M^6EW][2\W?L$_<Y;]?^#;_ -)=^VG<^BJ***0!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!SE]\._#^I>/=+\:76G^=XETNSFT^SO&FDQ!#,RM*JQ[
MMF6*+EMN[ QG'%,T#X;^'?"_B_Q+XHTO3S:ZWXD:!]5N!<2LMRT,?EQ-Y;,4
M0A.,JH)P,YP*F^(.L7OAWP'XCU731;MJ-CIMQ<VPNY!'"94B9DWLQ 5<@9)(
M '<5Y7^RYXI^*?BRP\07OQ*LI+.*:6*?2TFLH[5DB;?\@",VX>6(')8DAY)%
MR0HPXZW2Z+\WLOGJ_P#,):)-_:?Y):O\$>Z5\^_M#^._B_X=\:Z)8> O"NH7
MGAU]+U&:[UBRM[:ZS>"TG:VB,;R"1 LB(V=F'9T3=U5OH*BIZW_K;^F-.W]>
M?](^,/BC\6OVF_AS\%V^(&AP^!+SPWHVBS7VH#QO8W]MKMQY<TVUS;P"**-G
M@$#%"(R'9P57@#['TZX:[T^VG< /+$KD+TR0#Q7BW[</_)H7Q<_[%R[_ /0#
M7LFB_P#(&L/^O>/_ -!%7)\TFT1%<L4KW+M%%%24%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!S?Q+5G^'/BE5TZ75V.E70&GP/LDN3Y3?NE8="W0'MFOE__@F_K^I:
MYX.\7)J":JXM+R&"*XOM2U*YAVA7Q%''?.SQ%%V[MAVL'3H00/HGXZZ%I?B/
MX.^,;'6WU:/2FTN>2Y.AW#P7A1$+D1,A!W';C'0YP002*^??^"=GB#PEX@\*
M^*7\/Z5K%EJ-M):VM[=:KXE;7A/$B.MN$G. FU0V8@JA=RD#:RT4OBJ^D?S?
M]?TQ5?AI>K_)?U_2/KVBBB@9X=^W#_R:%\7/^Q<N_P#T U[)HO\ R!K#_KWC
M_P#017C?[</_ ":%\7/^Q<N__0#7LFB_\@:P_P"O>/\ ]!% %VBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWM,G_P F*%F%)Z*$_P#P74_^1&L/4>R_%?YGWY17Y^_\/I/@_P#]"?XW_P#
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M/X0=OM5^;X?:'<:OJFIR6]P;W4[4V5TXO9P'B*A<!0^U3A1\R@-WSDFNCHH
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M_P!*I'31V9\_>!O"-YX_\::!X8TZ2"&_UJ_@TZWDN6*Q+)+(L:ERH)"@L,D
MG'8UZKXB_9.UK3=%\8WV@^+O#7CBY\(7<5EK6EZ NH?:[622<P+A+BTA$H\T
M;<QENW8BN&^!OB/3O!WQI\!:]J]Q]DTG2]>L;V[N-C/Y4,=PCNVU06.%!. "
M3V%>VO\ M67?B'XZ7MEJ/BD^&?A5J/BW^T+Z]\&:):Z1?3VR73/#,\MM!'<2
M,H(;+EG!R<%J^@<4U!)ZMN_E9QM?[Y>MM]"I2E'FE:Z27SWO;ST7IYG!^!OV
M.?B]XW\7Q^&SX&UWP]J$MA<ZE&=>TF[M4DB@3<VW,1+$DHBX'+2(,C-8-S^S
MI\07UF/2M&\*:]XGO_[-M]3G@TG0=0:2UBF!*B1)+=&[$;U!C;!VNPYK[KLO
MVF_@3X=\/^&]!TWQK:P0IJ.O27<\<&M7JQ_;M/FB2XEFNH/-D+2L"^Q 07X5
ML-(V7-^U7\*-0^'^E>$(/%FB0W^EV_AR?^UM:L==6QFEL[;RI43[ 8;@R1./
M,3S!Y3$CH?F7'F;>W\OX\U_NT]>ZN0ISN[KO^%K??KZ>9\+:+\"_B3XDTF75
M-(^'OBK5=,B,JR7MEHMS-"AB.)075"!L/#<\'KBM7XB?LY>//ADG@3^U]$NG
MF\:6$5]I%O;6L[2R%W*K;E6C&9_N$QINXEC_ +P%?8C_ +9_@>\\:_"#4I?%
MT=O;:5X\UG7-?%AH]W9VXMYL+%<?9\S']XK2G8))&&]LXSBOGK]H;XB>"_'[
M_!O4M)UBPU==&T2'1]7T:]MKR+R&BNI9"9&54W1.DH_U,F_ ;[IQ1"4IN":M
M=I/R7*V_E>ROTL;)ZSOT3:\WS-+YV5_.ZMTOIWG_  3L^+&C>%;;Q%K@TCPS
MI<D%A/-/KTMQ8I9BZ9QMN'EA5(FBV R[F^7S(U!9F"UY=\4O@'J?PR\*>'O%
M,7B'0?%_A?7)[FUM-8\/2W#0B> @21.L\,3JPW CY<,.02*^O?VB?VD?@C\:
MM,T+P#9:CI6C^%[[Q!YFH>(1I^KM)I-E:6L5O:310[\.\B+*BIL955@60/ES
M\Z_M3>+/#.K6?ACP_P" O%>@ZEX \/++;:3HVE1:@MTA<@RWEV]S9P*\TQ"D
M["P7:% P,F'*3=TM&]/2RW^>G_ %3YG;GWMKZZK3UW].BNCY^HHHQ6NQH@'!
MI2,TE'XT]$,7;0!B@?6EJD 4$T49%,8 YHHX%(32OW$!-+NXQS3<YHI *3FD
MHZT5!(44450!1110 444 9('K0 #/:K26<AA\SRR0?:I=-L#=W&P#)';UKV"
M;P@CZ19(\]I8K+&I+1DG<0,X;/<>@[U]/E&25,T4VGLM$MWJ>GA,#4Q2E*'0
M\HT#PY+K^JQ6:N+<L>9'!VJ/4UV>FZ9IO@B\N?.2TUN<C;&TC'9'U&=O<^F>
M.*O>*;9?#VF+:VUF([B1@3J ?YBA'W00< '\ZS-,\+VSIY37[&_N<!%.#CMZ
MYSS7JX;+(X?$RHT8<\H7=Y/EMV5GU/4AAOJ;]FHIU>_17Z6>C]3HCXLNSISR
M17L:^<C1K&CC@8Q@@5Y/]ANE=D^SR;B<?<-=<FA75E%+:W"2(R$Y!3!SG_"N
MUTR^BU3PQ':R^?' JL@:(X"L1WY&?SKW*V'Q7%3A2E:%6G%I+;F\O7S+JX=X
MAWKR<;)Z/OU]#QM=*G)VM'Y;'IN.*O7/@W4K9$<QJVY0PVL.E:M[X;U"UNGD
MV^9%&V Q(PWO[TR:_P!6">9&ZHJ'[H/]#7@X7)<-1C.>90J*VB45K?OVL>#4
MA&+<.5W[G+W=C/9.$GC,;$9&X=:KC ZD5TWB"ZNM9$4DT+H%4#<RU5TJTLH8
MK@WD#SL4Q$%.,-ZFOF\;EZP^)E1I2O'O:QDJ7M)>[HO,PP2.0:0'%67M<.XY
M4=<$9J!8R3C%>,X-:&+33LQ?/<)MWMMSG&>*1B6'+9S360J2#SCTI,4M=A!2
MXR*2K%C;+=3^6TJQ#!.Y^F:UHT9XBHJ-/XI:$R:2NR%<J0<GCT-;>C>+K_1[
MJ.19I)(T_P"69<X--@\/^9&&:YCP3M.UQD?A6IK_ (%7P[HJW5S>*+F7:884
M&1(A&2V>W88KUG@L=@)>ULXM>]NOD=N&IUW&5:CM'=FDWQ73RF9=$MOM1_Y:
MN[%0/]WIFL"\\?ZY>+M;4)DC!R(T;"CZ#I7.T5.*SC,,8TZ]9O\ #\A3QV(F
MN5ST\M/RL?U(Z7_R#+3_ *XI_P"@BK55=+_Y!EI_UQ3_ -!%6J^(RG_D78?_
M  0_])1Y$_C?J%%%%>J0%%%% !1110!D>+M"L_%/A;5]%U&5X;'4K26RGDCD
M\MU21"C%6['#'!]:^=_V5?ASX=_9\UWXG^&X-9NM8FTZ.RU&^U6:WA@A,+I.
MR*L4*CYE"ON8Y+94# 4 >M_M OX+M_A#XBN_B#H)\3>$K. 75[IBV#7IF",&
M7$2@DX8*<]!C)( )'E'[.WBOX3)\/?'.M?"KP=/\-=#M[&.]NM7N/#TEG%*W
MD.^]8G"F8PC.[;E3D;6.:E.WM)+HE?\ 2_X_TPDG)TX]V[?K;\#T7PO^T;H?
MB?7K/33X9\:Z+#?2>59ZGK/AF[M;.X;L/,9/W>[^'S0F[MFO5J^4/V<-?\9?
M$#XSZKXQUW5M5DT6[L7L[6VM;:[CTJ26(HC_ +N6<BVD&TN$: ,?.;$\JC"_
M5]:-6BN[_I$IW;_KU_R/#OVX?^30OBY_V+EW_P"@&O9-%_Y UA_U[Q_^@BO&
M_P!N'_DT+XN?]BY=_P#H!KV31?\ D#6'_7O'_P"@BI*+M%%% !1110 4444
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ME=Q!1NF21%YSUP5Z5Z1I6ISQ*7F>)X9DPT0CS@GW/KT[]:PKF22ROAY:"TC
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M^C99'!8/+88B45*K-NS:T72UW?IY%_6=<3Q.46:=E@M0T\BVXV*"OW0!P
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M_'WI\UA-->JZ7"PNJA<*O/X^]9@MY!?SYP2>,TFI1W-K\D=Y(KX!R&..O?\
M2O,ISFJ,ZL.:=.$K6O9W6F]_(^FE.%./+.G;T.@ED1-/F2X9BMO@C;U8Y_\
MKU6\.7EO-82QM&N'F#)&/F;\^M8$(U4 S27&^W8%6#='(Z@BH_#<G]F:O;/+
M#OB9PQ&[J*^8QV8*>/C4E0Y(+1IKOU;UN=V'Q<I2IVUZ78>*1?-(975UMBV
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MC'.,5NW^CQ:I:SB.0/&YR/,P-OKZ8Z]?\:H'P-H5DFP7DEW<I*V6@E)B9=N
MO7J& /XFO#Q^75UBH/#TE/E2L[V<5VN>.Z?U>K"5*FDVV]]?5'3-XD6:"*>T
M1GD8A2[-\N\8]>O'H:BEL(-9OMXMY$N3B640S84MWR/RK'L]+_LFVFCG5E/#
M0;L@%N/K[<UK+82W,:322&R>1-F\'"(?<]_6OL:-*C4PD85::;71RM=W/65;
M$8JH_;*^S:LK*WF^Y:TJY:.VG@O+5Y(T?$<;-M#?CU/2HO&_PY3QE9F:2*.Q
MEMU+)YLN)0OHQYX]C6<MC;6=V\=Z6N[(,5\^9VPV>XP<XKDY0^G:K(8YIX;)
MY3Y:,QVXSQU/I6&<P=>DJ.(H)TY[]4GZ,Y)XVC&A[#%0YX[;I-:W3ORWLKF4
M/A#J,4"7,UA<+:,Q"R,P 89(S^8(_"NBTWP1:Z):8(^SW9)82+(0RC'3-;T^
MMW+6J6L-S(]HW*2,Y.?;'US2VJ0I<QQ:B\TQ!RL2@X_6NO*.%\ORZBJL:,)2
M:W45?;N?/_4\"JUJ-WT;D]$V7+V1[71+(3Q2SK&^6D>3<KG'0''&!BLJ;^S8
MK]-8N(X[^\90B))N41X &...*NZKJMW=6D=K&JQ6:.72UE<8SW-0PZ5#>W]A
M!?W$&EV$I&^1MA526 R<LH'7/+#IUK+&Y?EU*DL3F%DXN^KVM^IZ^-QLH*;H
MJ\();QOK:U_.WGJ8X%NTTDDZ8+J2%![D<5J:1"L\$\TS1:?/ A,4;,-LYP3P
M?H#SFM7XS^%+#X;V5J+;7=*U^RFC::PU*PE61;B,-M9,AFQ(IQE1D .#FO"O
M$WC>^\1I#;,WDVD/$<$9^5?QK\OSOC?"<WM,#)SNM-['C8?'X.%%5G::DKI)
M-7;[]45O$&L76L:F9-1N3<,@V@1D8 ] :AN%O;RUMXO)9+9,^4" .O)Y[]*I
MV^F7MS#)/!9S30QX$DJ(2J9Z9/09-.34IU!5Y') VC+9P/:OQZA5H5ZTJN/<
MGS==[^3;/F)UI3;Y7^)5:-P^TC!Z5>BL6M)T,DD9(^=E)R/H?6H(+.>^9A A
MD8#<0.N*['1_!R6UI'=74V+J0'%N%Y0>I/3\J]/(\GJYG64:>'E)-Z2NTDEO
M\[^=P4)U+\KVW,KPUI,.J:FT]VA:R0D[02/H![5UUM;""Z*PQQP0;.0V1^5(
MNG'38PB,' ;)*_*&'I5MF544%B-Q#$CG ]*_=,@R'#933C]8I.55N[;6FNRO
MKL=JC-0Y:<N7SZO_ (!5>/Y [R!<.-BL./>J.H^(+6*5H8&61^ 0 =I/J.AJ
M?4E!"/OQ&2 2><50DLU-T9A:B5#P' XK3B2M4E-4\+.*?,M&NEOP"C*=--)>
MKW+T,IDLW^T.HCQD9XY]!20SJB0QSJI5Y 4"':=HZY[53$8:8[HSM()!/&*&
MEB:,IO(/\+9Z"OGE.EB%*KB6DK66NKUMY7\OO-YNI&*A"_4[?XK36J:_,;+P
MP/#EK<V\,ME;F8R,T97_ %A(.T[^3A0 ., <UPJ7%U91,"ZPMT)7GZ<TUKHW
M+I'(IW(,(7)8X':I!MN$$C[P@;&Q1UKFJRITZ="AB9NR5M[I^J?^9Y^!I3IP
MDZ+]Y>OY[L;//&%C\YGD+\NYSQZ<=Z@1+MK9Y67;"I^50<?Y%.DU![B=$:W^
M4' W=13Y8Y[PB9)76!!\T8Z9^E>!B_>KQPF63E)O?2S^\]2#]I&5>MTV_P V
M1P2B^*&6WA<1],H"34LM^O),*Q1<;=I[_3\ZD22VM;Q'AC$A11E5!Y)'^--N
M(!?JTDA/F[@2DG Q7JPK>QG+V$N:K&RMRI/3S26S]3FY)2IJ]M7=^?\ 2)6N
M&\A&1I67'4C*_E7/ZEXAU*QNMH?$(/R@#AJWC-)-'((1Y,9& JU5ATJQGMKG
M[=(6D1<Q*V>#7C9FL?CY*G2KJ$VW?WGK9=3646H+V=UV>R.+NKJ2]N'FD RQ
M[5VWA"STJ;34EN[2.2;<P+.I/&!CO]:Y:^N%A'D@(PZ95<"DTC4+BWN1'#O*
ML?\ 5KDU\/ET\!@\P2QEZD=GIM+YG!1K5*-3VEDWYZG]/VE_\@RT_P"N*?\
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M9CZM"70>NP?CWX?]Y3J4?+F7K'_[6_X'-5]R<:GR?S_X-CV>BBBN Z0HHHH
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M+-RS26D]NMT([:7YF"Q\K@\9;K_^NN)\:>%;B#2YKR%&DL(@ 9\85F/''?\
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M49<Z>I_4CI?_ "#+3_KBG_H(JU572_\ D&6G_7%/_015JOG\I_Y%V'_P0_\
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MR6J0?+Y[_@.A AA$J2-YC<D9X6L.6+[3?0PN2D1^9E]:TXP%"M&CRF3.58\
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M[=/I3K3]FOXD7O\ 993PT\::CIEUK,,EQ=V\*)9V[LD\TS/(! $9&4B4J<X
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MW@Z$, 4OBJ>B^6K_ #_K="J_#3]7\]%^7_#;,^N****!GAW[</\ R:%\7/\
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MX?-,9AH^SIU9*/:[M]QZ5#,L9AX.G3JM1?0]L\*^+]*UK[-I\<20W$C8VNP
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MMTZF_<:E:Z?I-G"DL<EW&Y8NI#9/:KU]=-HZV,LVI).UV<R+C)08'?MU_G7
MK8C!#;@Z]1CD4^31[EH6EC/F1@<X8$C]:Y'BZTE*I2IV2MU>EOS,8X^K%6<;
MOIOTW.\UK4(+2*))',\;D.@B^;CUKG/$%_'=8:"%D7&!N&,4SP[I4M[&S.X_
M=_P,W;UKLM%T*:YMI8_MEE$TRG]S*I;)]1Z$#^=>ZL1F&,I7DO=FG;1=#MA3
MGF-U%6]+?JT<9$+,6L18NI7D.1QN[C'UJ'4KTVX1TR'./E]..M:"6T$%^MO<
M7(:.-\,O '7D@]ZLW4.GV=U-<+-'+:D'Y4D 8=AQ7B2H/V=J<E?KW1QNG-PD
MI626AC>';2+4KP0W-QY$6QCY@&<$ X^O/;TSR*MQZ3+J=XKV<<L$)!Q)(I <
M# )'M6.FJ2FT-O#&2N\D,#@\\&NHTS4=9OIHKB_N'2,*L:MD     'Z ?RK@
MPLI5*L8QN_0Y\/&-248-7CU+-GX?5"'0Y<?WR!5B\86<865C(\@SE><4^2,W
MCL7/FJ#Q(""!5&Y-_:7"_-YBJ=PC X-?<NM5J15&4-(_>>ZX4<+%U**LGU6H
MQK9X5$JN6##.T=<?2FPW\,D>V6)B_3<B@$#ZUGB&>YU26\F)A97W>6#\O7H*
MW+UC-#F-@MOG+[%X_,UYM&5:$_;<KC!.QS1G[6G)1W\^OGY&-<WT-@0C9"L<
M[R<M5F&_BN+;='(Q&>7*_-^-8UX&NI5$T2I$A.''?FM#3C:[72W)4X *@^@K
MJCC9UL4E2:4+]5[QY-%RO*,K;>A>6:0MY5I*H<C.?N_TZU%*ERD3^6%:8\/(
M2>/\:CGFV,B$*LH/#>M7 [0VS A2[8Q\P _*ONYNGBJLHXBNU.VC5DEY=?0Y
M(+W6XQ=EN9EU;1O"#<E/,']WO^M4Y9KDQQ+#P@/4'FK\EKYEP))8U&.0$(_7
MUJ*XC><,?*"D?=,?0U\'B5B<36E3A3M=?^!6[G0X0A#F;:]-R:WD^UR*KG<O
MHQYJ&;6[>.4VS0D%3PV>O-.TR%!'))<.PG3Y0NWJ/7-236L0NHYI(D8]ARV[
MZBN*O5G54*E**C4O9JW0[*:J*EH].[UT-<H[7$)CFW%@I&!QC'2N=\<:=(T\
M5V%QO!!&.XP*NW-M:WC*_P ZOR0D1QCVZ5#>>+KRTLTM&"36\1.!,,FO5S#%
M_6,!.CF.B;3BUKJO*^FAC65%\T=O-.YQ+#!/-)6M>Z>;BV-_'Y0B/WHUD!*_
M49S64>M?E4H\KL>)*+@)1114$G]2FE_\@RT_ZXI_Z"*M55TO_D&6G_7%/_01
M5JO"RG_D78?_  0_])1SS^-^H4445ZI 4444 %%%% 'FO[0OPOU/XO\ PTF\
M/:/J%CIFI#4+'4(9]3M6N;8M;74<X22)64NK>7M(##@UF?LT_#'QI\(/ <?A
M;Q7KF@ZW96'R:8VBZ;+9F*,L[.L@>60-RP"[0H &,&O7:*:?*FEUU_+_ "!^
M]:_0*SM7\1Z3X?\ )_M35++3?.$AC^UW"1;PB&1]NXC.U%9CCH%)/ K1KY]^
M+7[)3_%?QU%XGO/B1XB22&TO[&#2[BUL)K*V@NK:2%DB5;=)!RZL2\CLP0*3
MT*SUL-6ZDG[8^MZ=XD_8L^*.JZ1?VNJZ9>>&+F:VO;*99H9XS'E71U)5E(Z$
M'%>XZ+_R!K#_ *]X_P#T$5X:/V(OA9XDTK3&\?>%M*\;^(K6&2.75[BW> /Y
MD\L[+'&)&\N,23R;5+,0" 6/6O?(8D@B2*-=L:*%5?0#I5R24GR[$1;<4Y*S
M'T445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ&ZU;VFF7L/DL)8YAO"+)D#DC!/X?K4>X31D63/"[<A>A'T.:2XGAD0JT;<
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MK&K6HK%'<%8)#+'M&'P1G\ZJ5^=R23=CBEHV@HHHJ1']2FE_\@RT_P"N*?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.=+->;YHQQFL9Y5AY+EYJENWMJO_ ,F1]GDZ=CN#<?!XG_D2O&__ (65G_\
M*JCS_@]_T)7CC_PLK/\ ^55<-17.\DPG>?\ X-J__)F7L:?\IW0F^#Q_YDOQ
MQ_X65G_\JJL3P_!Z)59?!_C60, >/&5GQ[?\@JO/QTH+8/!XK>&38!0E&49M
MO9^VJZ?+GUN3[&%_A.W,WP>'_,E^./\ PLK/_P"55*)?@\1_R)?CC_PLK/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-S@^F,5@:AKM]/-]AANV:TW87(QD$]37N&H:OHWBOPE=:GJ MK77[>+,T6[
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_"TNB:SHE[)/<W\=Y-=VNH&(R6J #R!&1M/)=@2."JX[UNWGBGQ!\*O!L/\
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MXNUD[_HK(RQ&-C.%Z$.=Z66_XD$>@LNI?9-01].N$B$D4=Q$4>1S@HN"1MW
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M'D^WJS!KV_<+"PWG<QX P/3 %5/AMI-EHJZE)J]K+/*T+Q(58?NY0-P+<$G
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MBICURYTFWDODVC"XG*%Q@<#G@4JT;R:CIO\ UYA2E[B<M=%_7D?.B^.?'_\
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MRZ6NH[)KM?\ (SP>3TXU=9W:U5[ZV[Z&=!\.M%U>2*S5%@DN7"+<2?NUC).
M2QXV^M=/?_LK?\*U637=2N[/Q;HT2*K_ &>.6.V;S5(1XIP0K[3Z$?,N""*]
M7\0_LYQ6/PDC\3Z;<7WB#5F:"2.&Q0BV2)XVD+MD$M@(^2",' QUKP2\N+Z[
MO89)4>"WMA\UL,A3)C&[&>O%;U<'EN;N&+P=._++EE'E<;ZZ]FK'A0J87/*D
M<1E\K0I2<91Y?BMZVVN>=^)?AS=V5PW]EQ2W]H1N5U7<P]00*YK5="O=(=%N
MK=XMRA@64C(->[6LUVB2W,L&^((&9X#@Q@G )QVR0,^XJQ,EKJJQ)?SBZW*$
M2)^>/J:SS#@[#.O4C0J\O5)]+]#W_P"P\/BHN5&7*^SV7ZZGSA@BDKW?4?AY
MH5M&[QVS^7)]\F0$I],=/QKS+QAX0_X1N19$D#QS'*)GD"OB<QX=QF6T57JV
M<?)WMZ^O0\'&Y/B<"G*5FEO9F!97+17,9C=HOF^\#BOL6\\<_$?PU\+/"OEW
MTUMI,,$5[9-;PF-R%0X?>!ELX/4%>!DU\8X93@<&NFTKQKKFCVXC34;Q;7R?
M)6+S6*;020NW. ,G]:Y,IS%8*?[R-X]]^73HMOO/.P]2G&5JL+KOUB[;I;?>
M>R^*?B)9>*O%NEW-KJ^H:OJ.JPQ-?M>Q;91=.3OC5!D[1E0,9SV]*1+*"^O$
MA,\TL0W"-8@6C+8^4$=>3Q^->9>&=)LOB!I.H6('E>+HR;FS<R'%Y&!\T."<
M!A@D$=?H#71?!WQ'=ZUXVTS0KS6H?#LD\PC74KD.OER@X7)&=I)XSP/6OK,H
MXHHU)O"X^348:1=NG2]NATY7Q'1H1JX.M?\ =;N6_+;1V6Z:6GFFMTSL$G%O
M*L*21%&7$J[]LD?J!GTJK?SVK0VGDQ0PW$,DC-=(H#R!MO#'T&!@?[1IOQT\
M,^(_ FK76F:E$DVIZ7=#S)E^82*R!@^>X((//K4?@Z>QU'189M6MFLYGYWX^
M5A_L^E?>PS7 9A75&JE=).,TGRO]/(^[P^(>.J*C2=TTI)RT5FN@VVM'.HBY
M@1K=7<+(L: @=/FQ^.?SK&N]2DL=4FAFMRJNQ*S(/OKR,X[>M;MU=RR7NZVD
MVKNV@GIZ#-8FH2/'JT9NI)'D!$?+9('J,=JW^"7^R2:YG=1Z?._1F.-A[*-[
M[/?2QZ59?%>P3X/V_@9M.CU"=+V6^74+R;>;/>H&R%1RN2H)/3KP<UQ1WWEC
M.[[G#2A(U7CD=<"H?[,5KL/;A#&0=\BKM&!UR*TK26VB4P B11EE8H<@]R/:
MNO"X66$E.=6T?:-W2U3;V:Z+Y')@,#1HJ<**W;DW=ZMG+I9NE[-;3ND8D&SS
M)FX7C))Q71V?@35/#O\ 8SOI<UK9:RC/87LX"I==!\ASC^)??D>HKFY-,8S.
M9&8PM(6#@\GFO3YO&U_>^%/#.D7MT9H- DGGL;B65O.5I=F1NSGY=@V]QZ]*
MX<QIXBC/#XBA%73U;[?\/;[C@PV$QN(Q-J#BH*][[_(Y[QQINDZ1X.US2-4F
ME?Q#9W EA1 # P&%>(L"&#C)8<%?E/>OGR9MSDC('I7L&M6=UXDU<31.\UR6
M)8OSR?6O/O$&C#P]J:!P=W22-OX6]1[5\1Q!EN,KUIXJ<ER-J[[;+1=CPL=0
MJT$IUFY:VOT^1B0V%S-:W%U%;S/! 5$LR(2D>[[NX]!G!QGK4312-&7"DKW?
M!Q7T+\$_$I\9> [;X0:;#:PZGXH\1!KJ>8;5-L%B(!< D?-&0".1GCK7TMXB
M\4^%K'X8:EH\_A&*Q\.2[KB*V\/S*7$49%NLKMY91CYPY+8!))PQ %?FZI8J
MK6>'H1YO>LM4KJ]K^OD?!RSB="M[*O2LY3Y8I-7:NES6OWZ;GYRQ[HV5P61Q
MRK XYK:\+36O]L;+XY1U*B0G[K=C73>/_!L-GIR:K8;O(,AB9"!E1@$,?<X-
M>?Q1LS *#D\@U[E2CB,HQ2HU8>]%W:[^I]Q6H3P59*:OLUV:/5TL8[C35DN4
M,L<)*K*I^8'I_6N?O? ]_"IOM.B:\@?I&BEF [D@>GK[U3\-ZW<Z9>%+B0Q1
MLO1LD>Q(KV7X2>,IO"7B$:W$(;P);2P&+D$+(I4E<=#R*^]G1H9C@%B:"_?I
MNRO9Q^75'NI+,H.G2A>:CHN\EUN?LC^RO%)#^S3\+8Y8VAE3PSIZO&PP5(MT
MR"/45ZE7!? /4IM9^"?@74+AG>>[T:UGD:0 ,6:)6)..,Y/:N]K^:\O36#HJ
M6_+'\D?EM=256:FK.[OZW"BBBN\Q"BBB@ K$\:>#]*^('A35/#NMP/<Z3J4#
M6]Q%'*\3E3_=="&4CJ"""" 16W2=*32::8T[.Z/AC]D(^'?#'Q=M-(TA;R2S
MNX]3CTZ*7Q_=ZO>6H@FQ+]OTYPL5NQ8X#+N(8@$DL347[9/B74?A;\2[9SX^
MU6SMM7BDU#[#]ET"""TB10FV&2\M6>9V91D%\*&!+ %0?4_@I^U%X1^(WQJU
M;PWIG@VTT;5[M[H'4[:ZM9;JX6WQDW44>)8B3N&&W;2 &*LP6O.?^"A7B^]T
M'Q3X0LI/&>A>&]*FM)KA(-0O+:"Z\^-PX>+S8)6RQ6*,,N H,F0<C$MO]R_Z
M:U?Z>OWE12_>6_K9?U_P#[*\)7J:EX5T:[C:9H[BRAE5KB(12$,@(W(,!6YY
M X!XK6K)\)375QX4T66^N4O+U[*%I[F)"B2R&,%G"D @$Y."!C/05K5O4TG+
MU9STG>G%OL@KP+QQKVFV'[9?PZ%SJ%K;F+P;X@$@EF52A-UI9 .3QD D>H!K
MH?CQK>OVMQH>EZ'XHNO!_GV^H7\VIVEM:S.YMH-Z0D7$<B!6+%F(4-B,@,N<
MU\Q67[5'[.7QO\0SQ^.OAMY7BBW=M&U;Q+>Z/;+-#/$ C[+F&0W*1$[U!^5M
MIP5 )QIAJ$\5-PIQ;M:]M7;75+KLR:]:%!)S=KWM?:ZMO]Z/?_@Q;R_&#XB:
MK\7=1C<:3$'TGPG!*A7;:*Q$MW@_Q2MD X!"@CD$5[U7&^!?&'A&^\-:?#X1
MGCO=#M46TMO[,A>6*)$<0JN5!P <<G^$%_N@M6^GB"V=RHAO@0RK\UC,!EI&
MC')3IE22>@4JQPK F\54=2J]+):)=DMEZ]_.["C#DAO=O5ON_P"MO(TZ*R[;
MQ%;71MPL%^AG6-E\RPG3;O#D!LI\I&PY!QM)4'!9<HOB.V:!)1!?[7 (!T^<
M-S$9>1LR/E&,'^+"?>(%<AN:M%9%QXHM+:"ZE:WU%EMD=W$>FW#LP6)92$4)
MER5< !<DL&0992HEEU^VAEDC:&]+(LC$I8S,I"% <$)@D^8-H'WL,5R%; !I
M45G'7;<$#R;WES'Q93=1*(L_=Z;CG/3;E_NC=3!XAMF;:(+[.]$YL)@,M*T8
M.=G0%22>@4ACA6!(!J5'/;Q7*!9HDE4'(5U##/XU1@U^VN&B"PWR^:L;#S+&
M9  X8C.4&"-AR#RN5SC<N6IXBMI(8Y!!?@. 0&L)PPS$9>04R/E&.>C83[Q
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M^+XW:PJALJLFBV3X^OR8/Y5ZA-XFM((KB1H-098 Q8)IUPQ.V)93M 3+?*P
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ML;>S3]W.RJ\RV\@#=5(5FR"-H8+E<<C/K70>$-8M7\5Q>(G^R126]VEP;2)
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MAO\ 5].T'RPZR8P0P!+A Q. W3=3H[RJ=-OPDOSO=]4K6L[BK+W8P^?W./\
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M5?P^NI>#=9MM8\-7R1:I V5EB(9DQU^5A@C'J#UKS/PM\4M0TJ!+.95N;?A
MO1@/KC^=>H)?)&C:C#;*D4UONC()7&<9'IGK7Z)DV8Y9FV%5"K!<R2336_J?
M28:E@,=1T]YZ<U]UOMT?W%;Q#IMYX[\3C3Y-(&I:K*JP6X@18'<=A\N 3SU/
M-7?%'Q"M-8\*>$-&M8VM6T6R^R7?VC#AAN!'EC/R\YSQCIBK6G^*H/"YCU&Y
MACU$CY=DGWO9>"#^.:Z+Q5\*[-/ ,7Q!MKNRNA>1QYLX8\_9VD9@L*LYR[KC
MY@,D#KWQY.=X'#T<?2JP?+-+11TNG=:VWNC#'T,NPM:A.551E=V5GUV3MO\
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MW[.?PR+YW'PY89SZ^0E>G5_*V&:="#79?D?D^+=\14?]Y_F%%%%=!RA1110
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MW;_2&PVV0!BK]&RN,<BD\9>([G6_"-EX9U:2.YL[3S'L?+0_Z+(S#>1@A<G
M!P#P!Z56_M-!K$LEP23$FS?R>@P*]-^&?ASP)XACOE\075\-4:WD?38=/9 L
MDBJ6V.75L%R%  [DG(KRL?+"4J#J8J]6.\NOD[[M/\3SL=*G'"WK-6I^ZM+O
M72Z7?S1\WPRR_#[6=/U/3KQDUFRN$N;>>/@Q.A#*P]P0#[5Z?X&^-&CKXRFN
M?&>GPRZ1JR1BXO!9F62%E(W,B!ARV "W4=:R_% MY[CR/LUO_HTC-F,AP6'!
MR1P>G:J2II6KL+*ZC%QA2X* H4'<>G'6OCWD,Z?M*F%KJ$';E^>MFSP,3EL:
MSE2I3Y>9*S5T_OO?4FO-6TR6ZDDL&-S8EBT)F38Q3/ 9<GGIGFI7O'=V"1?9
MUV[B57A1Z 5PMS=6RM'96X8%&)$F[Y1[=/:M.'Q#<6]C<(;2Y1M@*RC)!QW^
ME>A1XCIU*+I8B*YHJW,OR\CU*5=PE9STZ]=5YFQ?63WENPCF9G*;L(.@!Y)]
M*9JUC<7>GI<QW$L=RG5E! <8&./SIFAZI"\@<W $LZ_OCC 7U7Z5?W [K==W
ME-UPW(_'M7M82&'Q]*<INUXJR;W]'Y&LK3CS1^UH[='T+&B"<Z0L]S>QHZJ"
MRN#D\\#WS6?XYUOP[J5OIUD]@PU:%P)[A)3M=.PQGKS6=JVCV.FQB2X$G3A1
M)UK$3PE=ZBZWNG0M/$3N*%AN49[CK^->#FE?&>S_ +/C1YFK-Z\^G>UOU,JN
M(K1I>QA%.]KK=Z=3K[G4H_#WEA%$2Q-G%JHPQ('?\!6XFK-=6T,P)MC,=K0Q
MD%WXZFJ5]<R3:;%:7)2*W!5FCX+;O3CFET^*)6,4H>U*?-%-G)W?W17V%.A%
M5/:UY+V:2]U::_HGM_PYWTYS@W2IO22Z]/Z^1A^.KJ]T>1!'_J2BG"J!M/&,
M^_ KFK+QYJT+9EG:89SB3D>U>@W%KN65+A'8RQLK"9<%L'U/?C/X5YW?>#M0
MA,\UO$T]LASYB]@<XS[U\9Q%@,9AL1'%X"I)P[1;?)UMIT[=-#Q\5+$0J\U)
MM7Z+MZ'?^']5;Q+HMW]LC1G.T*$Z\GD@4V72A9*)H;9Y+3)6-DYD!QP#CM7
MZ3XOO-#8QH@VY&Y&'7%;D7Q1NEM/*2R@')SN!.2>,]<U5#.,OFX5L16;J*WV
M;W.REF-&K0C"O?F2WZG5JM]:*YCCM[@(BB2,Q?-@GJ#W/3\Z],^%W@?P5XTT
M+Q=J.L>('T+5=,L))[:QN/E65P,GDCDX! 0<DLOH17":;?%="B,+K)*T8:21
MCC:>I49[^U5O$%A;2HUQ<%EWNB2..5"MP2<5]/FV'E'!_6,'/EV?FM>_2^S/
M4J8=UL/RQK-/1WTT]&[_ #*R74%M:N^E6@NI6_UTDGS)GZC\N*H-<W.J6=Q#
M=NWV6657\I.4) /4DYX'8"MO7S;^#=;33[(>4L'R.)U^<>S UK6MMHOEO>2-
M');VSQ.=,9G62XW'#[& (7 YYQ['. >WV=&KA4ZU1M.UXQM:_FO-[MO4Y:D9
MRYHN27)[MNCOV:W3//(?A!JVNW8BT.'^T,(TDFQL^6JJ7)(ZX"@D^F*P;OP)
MJ-M$9!Y4N 251P2!7TU^S_XVT_P/K'BNXU2VCLO[7TZ2QM1)#(\&'=?-B8#+
M*60':V1@]>ISR&H:7;0:I>K#)YT#2M&C2[0VTYP<>O?BOD:?#6%Q>+KTYIT[
M6<>E^^AY&$PCQN(J4_8RA&*CKT;:UL_)GC=KX<O+OPW+=B. 1I+Y8#-AR3Z#
MVQW]16-+!=Z+J1A9C%(K?>!X]J]DDU-K?2DTV58[B-#(8+I@=_S +C_=&#C(
MXSZ5QGBNVE\06J&"T?[3&Y,K8 'T KDS;A^6&@O9.4I)*UEHTF^WE;[A/".G
M2YY.TUTZG[R?LM.\G[-GPN>1Q([>&M/+.O1C]G3)KU&O*?V4(GA_9B^%$<BE
M73POIRLI[$6R9KU:OY[RZ_U*A??DC^2/S_$-NM-ON_S"BBBO1.<**** "D/2
MEKEOBGX_M/A7\./$GB^^MIKRTT2PEOI+:W($DH12=JD\ GID^M)[#2N[(^8O
MV7/[/N?B[>V%_P"%O%EEKNA2ZC%"+G7X+S0]+#S9(M[874DL+21LAPZ?('*@
MJI /V-7QG^QU\'+!_B!K_C2[N[K3-<T34;O39/#+K9S+:331QRL?ML4:/=*8
MYH\%@I)Y<,RAJ^S*MIQA!/>R_'7\5KH0FI2DUW?^05R'Q+\4:YX9T&5M \+Z
MGXBOIH9A')8/;".T<1DH\PFF1F4M@8B61O\ 9KKZ*RG'FBTG8TB^5W/@>U\>
M6]EX>$/BSXL71\+,]Q=-XCTSQ->V,*:J;-G33S.]RTOF(ZR%K<2A"^Q1!& 8
MZ]0\+>)O$FO_ +67PPA\1>&[S2)+;X>ZFRZG<SP/'J4DDFD-,4C1V>/8^5(D
M5<D_+D<U]45XAXM_Y/*^&O\ V)GB'_TKTJM;_%YV^5D_Z]$NQC&#7+=WM?YW
M:?X?JSV^BBBI- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOW"<FO2Z_E_#.]"F[6T7Y'Y;B[?6*EMN9_F%%%%=)R!1110 5F>)?#6E^,=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OP%_X*6?\GO?$W_KM
M8_\ I!;5^_5?@+_P4M_Y/=^)O_7:Q_\ 2"VK@7_(RI?]>ZG_ *52.JALSYG
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M972AIOMJ[-H^8\'U^M<7I:1R7T232%(F;!9>H]ZW9?!%U<7XCT\_:(CC$AX
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MY@Z[2R$'!Q@C.""0<@D5KT5E**G%Q?4UBW%IH^([+X+^.XM!^!G@G4/A?/\
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M .1JZ?[0J?\ 0+/[Z?\ \L-N:'\WY_Y'XU[J<IP*_9+_ (<M?!__ *'#QO\
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M8#S6K8 & !F#@>U:5A_P3A\$:?J-C<KXL\4SPV;&2*PN)K>2U#D %C$8<$G
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MK]'M0_X)/_#34(@C>+_&$('>&>U'_M"LV[_X) _"R]*F7QCXT+#^+[3:9/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>hook-20231231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %8 @D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*^=?VB
MOBQXJ\">-K*PT/5?L-I)IR3M']GBDRYDE4G+H3T5>.G%>6_\-&_$3_H8?_)*
MW_\ C=?48;A[%8JC&M"4;2UU;_R/A,=QE@,!B9X6K";E%V=E&W_I2/MRBOB/
M_AHWXB?]##_Y)6__ ,;JWIGQU^*>MW!M].U2YOYPI<Q6NF02,%]<+$3CD?G7
M0^%\9%7<X?>__D3CCQWELVHQI5&_2/\ \D?:-%?&&J?''XJZ'*D>I:C=:?(X
MW*EUI<,18>H#1#-4O^&C?B)_T,/_ ))6_P#\;I1X8QDE>,X->K_^1'/CK+H/
MEG2J)^:C_P#)'VY17Q'_ ,-&_$3_ *&'_P DK?\ ^-UH6WQJ^+5[!%-;WM[/
M#,':.2+2H65PGWR"(N=O?'2B7#&+CK*<%\W_ /(A#CK+JCM"E4;\HQ_^2/LR
MBOB/_AHWXB?]##_Y)6__ ,;H_P"&C?B)_P!##_Y)6_\ \;JO]5L;_/'[W_\
M(D?Z^Y9_S[J?='_Y(^W**^,](^-?Q9\0-(NEWUYJ31 %Q9Z5#*4'8G;$<5$W
MQV^*26UQ<-JEPMO;R>5-*=-@"QO_ '6/E8!]C4?ZLXJ_+[2%_5__ ")JN.,
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MPT;\1/\ H8?_ "2M_P#XW1_JMC?YX_>__D0_U]RS_GW4^Z/_ ,D?;E%?$?\
MPT;\1/\ H8?_ "2M_P#XW1_PT;\1/^AA_P#)*W_^-T?ZK8W^>/WO_P"1#_7W
M+/\ GW4^Z/\ \D?;E%?$?_#1OQ$_Z&'_ ,DK?_XW1_PT;\1/^AA_\DK?_P"-
MT?ZK8W^>/WO_ .1#_7W+/^?=3[H__)'VY17Q'_PT;\1/^AA_\DK?_P"-T?\
M#1OQ$_Z&'_R2M_\ XW1_JMC?YX_>_P#Y$/\ 7W+/^?=3[H__ "1]N45\1_\
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M>,M.\,:YJ-G-X9\$>(H_%.G^*_#7A;2)KBYT/39[6-D9'9E5\3AVWE$ 7Y2
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MBW"2ER-:_P##?YHCF27,]OZ?Z'U)_P )1=?\\X?^^3_C1_PE%U_SSA_[Y/\
MC7DWP7U^]U70M:TS4;B2]O/#^LW>D&[F)9YXXV#0LS'EF\J2,,W=@3WKT&IZ
M)K9I/Y-77X#OJUV;7S3LS3&O2"Y:Y%K:BX9!&9?+.\J"2%SG.,DG'N:E_P"$
MHNO^></_ 'R?\:QZ*0S3MM?ELK>."WMK:"",;4BBC*JH]  < 5+_ ,)1=?\
M/.'_ +Y/^-8]% &Q_P )1=?\\X?^^3_C1_PE%U_SSA_[Y/\ C6/10!L?\)1=
M?\\X?^^3_C1_PE%U_P \X?\ OD_XUCT4 ;'_  E%U_SSA_[Y/^-'_"477_/.
M'_OD_P"-8]% &Q_PE%U_SSA_[Y/^-'_"477_ #SA_P"^3_C6/10!L?\ "477
M_/.'_OD_XT?\)1=?\\X?^^3_ (UCT4 ;'_"477_/.'_OD_XT?\)1=?\ /.'_
M +Y/^-8]% &Q_P )1=?\\X?^^3_C1_PE%U_SSA_[Y/\ C6/10!L?\)1=?\\X
M?^^3_C1_PE%U_P \X?\ OD_XUCT4 ;'_  E%U_SSA_[Y/^-'_"477_/.'_OD
M_P"-8]% &Q_PE%U_SSA_[Y/^-'_"477_ #SA_P"^3_C6/10!L?\ "477_/.'
M_OD_XT?\)1=?\\X?^^3_ (UCT4 ;'_"477_/.'_OD_XT?\)1=?\ /.'_ +Y/
M^-8]% &Q_P )1=?\\X?^^3_C1_PE%U_SSA_[Y/\ C6/10!L?\)1=?\\X?^^3
M_C1_PE%U_P \X?\ OD_XUROB74WT7P[JFH1()9+2UEG5#_$50L!^E?&X^,?C
M/PG\-K;7KR?Q/!KOB;PW'?62SW5O>)<R23VJ230QD[+62,70*1Y,;*PW'*FD
MO>;2Z?K>W_I+';9=_P#@7^ZZ/O+_ (2BZ_YYP_\ ?)_QH_X2BZ_YYP_]\G_&
MO"O@?JE_;Z]XK\-ZO)K4.I:>+2Z_L_6+]=0,44RN%DCN1RP=HGRC?<9&Q\I%
M<%K>J^//B5X7COO#,U\\FJ^,+RUDM[?6AIK6VG67VB!523#%=\L"LY1&;]X<
MC"C%--/[OQM_G?Y,2U5_ZV;_ !M^*/JT:](+EKD6MJ+AD$9E\L[RH)(7.<XR
M2<>YHDU^66:*9[:V>6+/ER-&2R9&#@YXR*^0_#'B>_\ B!>7?ARVU[Q1X?A\
M-Z#>7,SS:EYMT=22\FA;S;@#]^D1A.T$;660;EX 'I/@KXDZ;\7_ (>Z%I>H
M:GJFC^(M4T2TU&\DTR*XM6A+PQS,8[C9L'WN@;."1ZT6O%R6R_*\M?\ R5OT
ML#TGR2W_ /V?_DE\[H]X_P"$HNO^></_ 'R?\:/^$HNO^></_?)_QKXAM-8\
M6Z7X4\-7NE:YXJURR^(7B<6NFVMQJ^;F#3(K:XDC*7$G^J,_DB1W'S*C[5&X
M UW_ (:\<:II&E^$+Z34=7EDM?%<_AC5M/U:99I$69F"(73Y9C&_D%)B-QC+
M;N2U4HZVZZ+YNR_.27D_E=2?(KOS?W<WZ1;_ "ZV^G_^$HNO^></_?)_QH_X
M2BZ_YYP_]\G_ !K'HJ!FQ_PE%U_SSA_[Y/\ C1_PE%U_SSA_[Y/^-8]% &MK
M=E<2ZG,Z02NIVX94)!^451_LZZ_Y]IO^_9KN** .'_LZZ_Y]IO\ OV:YGQA\
M)](\?7_AZ[U[1IM0ET&^&IZ>KF18XKD*RK(4!"N0&;&X$ G(YKUZN0^*OQ6\
M._!GP=<>)?$UU+!81R1V\<5M"T]Q<SR-MCAAB4%GD9B % _3-)NUG_5^GSOL
M-)O3^O/\#P_XV?LK:5\4+#Q%>V&E6UCXJU;38M,>]OK>::VDACF$R+)"DB?,
M&SME4B1,Y5N,5R'PG_8AL_#VA>-;/QI;0ZP?$U]:WA@TLWD2V1MHPD+QW$DK
MW!FSES+O#9/%>Y?";]I;P_\ %;Q)J?AM]"\2^"O$]A:+J$FB^+M-^PW+VC-M
M%PF&963/!PV0>" :],@\0Z5=627D.IV<UH[^4EQ'.C1L^<;0P."<\8JDN1/L
M_P#._P":^^_6XF^9Z]/\O\OPMT/ M _9BT+PCK7A"[T&UOM-MO#UQ?7OEM+<
M3RWMQ<QA)))Y9')D)Y)+AFR%PR@$-E_$;]G76/BC\=/ GBW6FTX^&?!SR7MA
M9)ITAOI;MUV_O)B^SRE(1PJH#N09)KZ/'B32&TQ]2&JV1TY&*M=BX3RE(.""
M^<9SQUKE? ?QK\+?$+2O$.I6%X;2PT/6;G0KNXU K"GVF!@K[6+8*DD8/&?2
MFF^9-;QU].E_O:M\A->ZT]GI]]W;YZ_B>;ZQ^R_X)UWX@KXSO/#=T^M?:(KR
M14N;A+6>YB&(IY;97$4DB ##LI(P.>!6'8?L6_#73+Q[FW\+Z@I*7L44+:E>
MM#;QW:,ES'#&9-L2.'8E4  )R,$#'TC<:_IEG+#%/J-I!+,%,:23JK.&.%V@
MGG)X&.M6;N]M]/MVGNIXK:!< R3.$49.!DGCJ:BVG+TV^_<J[O?KI^&W_ /G
MGQ/^RIX)\6:/X>TZ[T+4[6+0+#^RK";3=1N[.X2SVJIMVEBD5Y(R%7*N2#C/
M6M?PK\#;'P9XV_MW2+26PM(M#M]!M=*MXY%@@@B=F!VEBN>0 0JG .2V1CV*
M+Q1HTSPI'JUC(\TK01*MRA,DB_>1>>6'<#D5!JGC'1]*BU,R7]O+<:;;/=7-
MG#*K3I&JEB=F<]!WIRGRWFWW?X.[_%_>Q*/-:"79?BK?BE]QYK)\'=$EN8;A
MM&G,L.LG7T;?+Q>F,QF7K_=)&W[OM6-JG[./A?5+>&,:7JVG217%Y<K=:7J5
MW9W&;J4RW*&6*17*.[;BA.T$*0!M&/3_  /\4_#OC[P/X9\56-ZMIIGB*VCN
MM.74&6&6577<J[2?O8/09KKJIQ</<:M;3[M/R27IH"E=73WU_-_FV_F^Y\]:
MQ^R]X+UE+:)] O[.SAMH+0V6G7UU:6TT4&/(66*)U679CY2X)%6-1_9P\+:C
M=_:3I.J6EPTEU)+)8:A=VS3BYE\V>.0QR*7C9_FV'@=@ 2*]OM]=TV\O6LX-
M0M9[Q5+-;QSJT@ .TDJ#G ((^HKF?'?Q;T'X=RSQZJUP[6^F7&KW'V:,/Y%M
M#@%FR1RS,$4#)8Y[*Q$O7SW_ .#_ ,$-OP_X'YZ>IYW9?L[>$]/\*7_AJW\/
M7$>C7UC;:=/;>?.=UO;KMA0,6W#:.,@Y/<FM7Q]\.;WQ9#H=Q:1M:ZKHFI0Z
ME932Q,5#*&21#CG#Q22IGMNSSC%=%X7^-.D>*9M(LX]/U*RUF_NKFSETFZ6(
MW%B]NNZ8S[)&3:NZ-=R,X)FCQG/'2Z5XPL-6\3:WH""6'5-)$,DT,P WQ2J3
M'*F"<H2LBY.#NC88Z$TW)OF;\_7S\_U)5DFEYK]&CR?4/@#X>O\ 2K"P&F:E
M8I87USJ5K<:?>W-M<0SW#R-.RS1N' <RR97.,-@ 8&)/"OP$\,^"VM6T?0;F
MU-K!>V\1:>>0JEW,L]P,NQR7D16R<D=B,FO<**GOY_Y6_+0H^./'/[&G_"0M
M:Z/I,46E>%8K.RL%B26_2:."W(PKHDPBNFVKA'G#&,DGYN!7J4'P!\.VGBP>
M(H=)U 7J73W\=HU[<FQ2[8$-<"UW^4)3D_.$SEF/4DGW6BG=OKKJ_O%9'CWP
MX^'=YX(\/26LZR7>I7EW/J-_<I$P62XFD,C[<\[1D*N?X56NI_LZZ_Y]IO\
MOV:[BBD/S.'_ +.NO^?:;_OV:/[.NO\ GVF_[]FNXHH X?\ LZZ_Y]IO^_9H
M_LZZ_P"?:;_OV:[BB@#A_P"SKK_GVF_[]FC^SKK_ )]IO^_9KN** .'_ +.N
MO^?:;_OV:/[.NO\ GVF_[]FNXHH X?\ LZZ_Y]IO^_9H_LZZ_P"?:;_OV:[B
MB@#A_P"SKK_GVF_[]FC^SKK_ )]IO^_9KN** .'_ +.NO^?:;_OV:/[.NO\
MGVF_[]FNXHH X?\ LZZ_Y]IO^_9H_LZZ_P"?:;_OV:[BB@#A_P"SKK_GVF_[
M]FC^SKK_ )]IO^_9KN** .'_ +.NO^?:;_OV:/[.NO\ GVF_[]FNXHH X?\
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MK2WT^.:%'LM0N[>:>*5M\T<\J2!YUD;YG$A;<W)YYKO9?"PET=]*_L^6.P:
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MKK_GVF_[]FNXHH **P=3UZXLKZ6%$B*KC!8'/(!]:J_\)1=?\\X?^^3_ (T
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M=_GS.3];MI>B149.$U-;_P"227I:S?JV?#_B?]B34+#7_B-J/A?X:Z782_\
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MNV ,MSR< #)[ 5*=FGVO^*:_5OU)DE)-=_T:?X62]#K:*Y?_ (2BZ_YYP_\
M?)_QH_X2BZ_YYP_]\G_&D,ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\
M?)_QH ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_ .$H
MNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_ .$HNO\ GG#_ -\G_&C_
M (2BZ_YYP_\ ?)_QH ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_Q
MH ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_ .$HNO\
MGG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2B
MZ_YYP_\ ?)_QH ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH ZB
MBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_ .$HNO\ GG#_
M -\G_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YY
MP_\ ?)_QH ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_
M .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_ .$HNO\ GG#_ -\G
M_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\
M?)_QH ZBBN7_ .$HNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH ZBBN7_ .$H
MNO\ GG#_ -\G_&C_ (2BZ_YYP_\ ?)_QH Y#Q3\.KG6_BCJ5V=%@O?#][X0N
M]*F2658HIYY9U8Q/C+#<N[+!3W[\5Y]^S[\*O%=A\2[/Q-XA3Q1:6FB^'I-!
MMK?Q7>6%Q+F26"0I;FT #0QB *)9?WLA;YONBO</^$HNO^></_?)_P :/^$H
MNO\ GG#_ -\G_&BG^[MR]+_BY?\ R;7I\[S**G>_5I_<H_\ R*O_ ,-;PG5_
M!M[K6C?%W0DTN_U#Q';>,+;Q#:C3;R*UOA$R6SP75L\JF(O&(9$5)1L=H&1B
M 37+Z9\#-3B2]\3>-?AWK'Q*BU;7Y-1DTS5+VS_M>W7^SXK1)Y88Y8K-RYC?
M,:L!&KIM&0P'TR->D%RUR+6U%PR",R^6=Y4$D+G.<9)./<U+_P )1=?\\X?^
M^3_C0O=CRKLE]RBOQY5?_@*U=6^[;^]M_@V[?\%W\-\)>$?$>DZO\#/#^JRR
MKK>DWVKZU<P/<>>]EIAAN(H;624$[RGVJUCSDAC$2"=N:^FJY(:_(MRUP+:U
M%PR"-I1&=Y4$D*3G. 23CW-2_P#"477_ #SA_P"^3_C5RDY;DI6?]?UO^&AU
M%%<O_P )1=?\\X?^^3_C1_PE%U_SSA_[Y/\ C4%'445R_P#PE%U_SSA_[Y/^
M-'_"477_ #SA_P"^3_C0!7U__D+3_P# ?_016?6YJ^D7=UJ,LL46Y&Q@[@.P
M]ZI_V!?_ //#_P ?7_&@#/KYK_;P\6^(?"7PT\(GPWJFMZ7=ZCXLT_3IF\.S
M)%?30R^8'BB9_DWMQC=\N<9XKZD_L"__ .>'_CZ_XUS'COX,:;\2K?2(/$6E
M&^BTG4H-7LP+EHO+NH23&_R,,X)/RG(/<&E:[C?:Z;]$TW^!<9*-_1_>TTOQ
M/C#X)_&OQ=X5T3XJZZVLZSJN@:/<VFDV&E_%/5;:+4[?4BY6993;1L5C(=-B
M!69R/E!SFNJ\'_MJ>*?'5EIF@Z5X.TL?$#4/$5YH$45]>75KIH%M;)<R3LTE
MNLZ@JZ@1M$&SSTKWOQE^R1X)\>:WKFKZMX<D;4M:BMH[ZXM=1FMC*UNX>"7$
M<BA98R!MD&' XSCBLUOV*/A^= N=)7P]>)'/J7]L&\76KK[:EYY:Q-.ESYWF
MJ[(H#$-\W.<Y-6G=>]V7WW6OY_>EYJ+)/3N_R=ON=O6S?6QY)\1?VP_%G@J^
MT#0(O ^FOXOET6;7-4L'U*:X@C2.4Q"&WEMH)=\CE6(+A%7@,037TMX1\1+X
MN\)Z/KD=I<6"ZC9Q78M;M"DL.] VQU/(89P1ZBN(UG]BWX>ZWH.B:/)X6DM+
M+2+>2SM_[/U.>UD>WD;=+#+)'*KS([99ED+;B23R:ZCP5\#%\#>+_$>MZ>AB
MCU:"RM8["-]L%M%;1&- JER 2"<E0HPJC&0685N5I[_\%_I;[O,3O=-;6_R_
MX+_#T^7-5_X*'VGA7Q%!I'B#P]#926$FJVWB*:.Z)33;BW:86B<KS]I\G*YP
M?F&,UDZC^TK\5?"_C'QMXG_L&PO=,TKP7H_B'4_#]]JTL,>GB03-,MN!$V^4
M@ $ML'R>X%?3/B;]COX?>,+SQ3=:OX.ANY_$]U:7FK.;J1?M$MM_J6X<;<=P
MN V3NSDUM>(?V;O#7BFZ\5W&I:"9Y?%.F1:/JQ6\=!/:Q[]D8"N F/,;E<'G
MKP*F.D4W\7X;/]7]R75LJ5G)V^'\=T_R3^;/D?XR_M">.]*U[XB2>![J6*2#
M4/"D2IJM_F"&&]7YE@C$)\LNQ57.2<,67!4 ]WH?[96N:M\6G\-CP=!/H=IK
MZ^&+ZZLI;N6ZBNPJ^9<!?LWE?9UD.W+2!\?-M XKV?Q!^R+X)\36?B&WO_#D
MK+KR6"7SQ:E-&[?8@!:LC+(#&R8'*X)[YIMM^R'X)M/&EMXJB\/3?VM;RI=(
MKZG.ULURD?EK<O 9?+><*,>:RECU)SS5IQ4MKK_@1_R?WWT(E=QTWLE\[.[^
M^WR6SN=)\0_$\G@GP#XD\0Q6ZW<NDZ;<7R0.VT2&*-G"D]@=N,UQ_P -?B=X
MA\0>,;GPWXFTC3=.OO[%M-=@;2[N2=!',\B&)RZ+\RM']X<$-T&*Z3P5\ 8?
M"OPH/@*Z675M*FANH+HRSLID2X=VD0$R,ZK^\95RY8 #YB1FN@L/A5:Z9XC_
M +=MM-,>J?V=%I7G?:"?]&C=G1-I;'#.QSC)SUJ592?5?\!_K;Y(TE9QLM]?
MSC;\.;YM?+Q+5G\5?$@^.)]+NM1-I8>(8=(&F:=J#V,TEG;QHT_E2AT\N5Y9
M6^?<I*1JN153X3_%6:/7]/L/&&O3W.I0V5KH\?V9)'MI;@N8I;F9U&P&6XC>
M&-FQGR7*X$E>RZ%\)=1T'Q!XOG@;9I?B&5+QH8Y LL%UY0AE93G #+'$1W#!
MCSGBFO[./A^+4=$O8M(DA?2+>WMK>**[98G2W8O;B5 V)#&[,RELD,Q-%.T;
M)[>[?UM:5OQ\G>^A$KM2[ZV^^ZO\M_1+4Q_@]XBN]0;QAH-]<37L_AK79=-2
MZN&+/+"T45Q#N8\L52X5"3R=F3R:]$K%^'OPMU'P=I^IM<A+K5=6U&?4[Z>,
M@*TLA 51DYVI&L<8)Y(0&NJ_L"__ .>'_CZ_XT=%WLK^ME?\;CZOU?W7=OP,
M^BM#^P+_ /YX?^/K_C1_8%__ ,\/_'U_QI 9]%:']@7_ /SP_P#'U_QH_L"_
M_P">'_CZ_P"- &?16A_8%_\ \\/_ !]?\:/[ O\ _GA_X^O^- &?16A_8%__
M ,\/_'U_QH_L"_\ ^>'_ (^O^- &?16A_8%__P \/_'U_P :/[ O_P#GA_X^
MO^- &?16A_8%_P#\\/\ Q]?\:/[ O_\ GA_X^O\ C0!GT5H?V!?_ //#_P ?
M7_&C^P+_ /YX?^/K_C0!GT5H?V!?_P#/#_Q]?\:/[ O_ /GA_P"/K_C0!GT5
MH?V!?_\ /#_Q]?\ &C^P+_\ YX?^/K_C0!GT5H?V!?\ _/#_ ,?7_&C^P+__
M )X?^/K_ (T 9]%:']@7_P#SP_\ 'U_QH_L"_P#^>'_CZ_XT 9]%:']@7_\
MSP_\?7_&C^P+_P#YX?\ CZ_XT 9]%:']@7__ #P_\?7_ !H_L"__ .>'_CZ_
MXT 9]%:']@7_ /SP_P#'U_QH_L"__P">'_CZ_P"- &?16A_8%_\ \\/_ !]?
M\:/[ O\ _GA_X^O^- &?16A_8%__ ,\/_'U_QH_L"_\ ^>'_ (^O^- &?16A
M_8%__P \/_'U_P :/[ O_P#GA_X^O^- &?16A_8%_P#\\/\ Q]?\:/[ O_\
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ML:U=A(6$BV_[PG;LQP')XK;_ .%H:7%X;\-:[=6U]8Z;KT\%O!)=1*A@:?B
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M10!S>KZO=VNHRQ12[47&!M![#VJG_;]__P ]_P#QQ?\ "C7_ /D+3_\  ?\
MT$5GT :']OW_ /SW_P#'%_PH_M^__P">_P#XXO\ A6?7S5^WEXL\2>%/AGX2
M_P"$7U/6=,O]2\6:?ILAT"X2"\GBE\P-%&[_ "!FXP6^7.,\4F[-)=6E][2_
M4J,>:_DF_N5_T/J7^W[_ /Y[_P#CB_X4?V_?_P#/?_QQ?\*^#]5UOX@_#[X=
MZ9ICZI\1O#E_XO\ %VF^'GU;QSJ=A?W6GVTH<R2VK6R[(RV-@+@G<0>PKI/B
MGJ^O_LN_#+XEOX?^*M]XPOK>UL7L],\37"7^HZ(;B<0O=O,3O>$[BRJZ8!0X
M8C@79].]EYNR=O\ R9:^M[$K5I=]?E=J_P!Z>A]F?V_?_P#/?_QQ?\*/[?O_
M /GO_P".+_A7Q7XLN/$_[+OCGP#)I7C[Q-\0[?Q5%?Q7^D>);T7OF20VC3K<
MVV%!A&Y "B_)AQ@ \UQWA_QOK'ASPO\ ";XGZY\3?B)=ZOXOFM;J^^QV/V_P
MU$LTBH;%X 4CMCF0(K[M^5)^;&*<8\TK+NE\W>WKLW_P="9/ECS>5UZ+^K?\
M#4_07^W[_P#Y[_\ CB_X5F^3;_VQ_:WV*R_M7&W[=]DB\_&,8W[=W3CK7RW^
MW+XN\0>')_A78:'J?B^QAU?79;6]@\#O&NIW,0MW8)$)/D)W*#\W8&O.)KGX
MWCX*)I\^K>([2YOO%YCTK3->UBSTOQ7JFC"(LT$<X^1;C<&;Y<-M4X(XK.+Y
MKM=';\8K_P!NOZ)EM6LGU5_S_P#D?O:/OW^W[_\ Y[_^.+_A1_;]_P#\]_\
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M]_\ QQ?\*/[?O_\ GO\ ^.+_ (5GT4 :']OW_P#SW_\ '%_PH_M^_P#^>_\
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MYB6>>.-@T+,QY9O*DC#-W8$]Z]!I;V?>S^3U7X"75=FU]SLS0_M^_P#^>_\
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M!?\ _/#_ ,?7_&C^P+__ )X?^/K_ (UV%% ''_V!?_\ /#_Q]?\ &C^P+_\
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M+Q5XU\2O;7>J_#?3_"_A[7[:VMX(TN;:*_>02S.2<LJ*$9ER<!6QFO?/AO\
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M'OVMI?M<3=M_/\/\^G1^FI[-12 Y&12TAA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'FOC#X:
MZOXC\>:GJ]EJ:Z3!=^%+G0HKN%C]IMKB24.LJC&,*!G.<Y X[UQ/P#^!NL_#
MOQ;'JEUX?\,^#;6VT;^RKBU\,7#RC6[CS$87UQF&+:ZA&QGS'_?R9?@9[OXP
MW^NZ190:C;^+;#P3X7LH)Y]5U66%)KK>-H@CB21&CVL2^XGYB0BJ/F)&%/\
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M]%+LNVGW;!U;[W?S>K/0**\_HH ] HKS^B@#0U__ )"T_P#P'_T$5GUH:_\
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M8+MMM[MM_-ZL****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI^>NO_!/Q_\ LSZ-!>:=XLT;P1K7Q(\?Z'I5Q:?#O2EL],TVU,<L3_9X)Q(
M[Y#,2.JCK3_$/CWQC\*KKXYV>F>(+F*.P\6>&])U;QD=/MVO[+3Y+&$75_*4
MA DD _C=6"!L@ *!7Z#NBR8W*&P<C(S@^M(88SO^1?G^]Q][Z^M6I/6^NWW+
MDLO3W7?OS/L0[-I]OS][7U]Y6_PH_.J/XP_$3Q/<:+X4\,?%76]0\&7WQ&M/
M#VE?$.*"U:\U*RDL)9;F-7\GRI?+E7:)0G7UVU]#_M;ZSXL\$_#[X8:+X9\9
M:GHFI:MXOTGP]=Z]%'#)=R02ATD<AT*;VP&^[C/;M7T9':PQ1QQI#&D<?W$5
M0 OT':GNBR8W*&P<C(S@^M%T[)K:46_-)1T^=G?_ !=>J5TV_P"ZTO)OFU^5
MU_X#I;I^<OQ,^/\ XR\ _M#Z+X;T;XCZ[>'1/$VB^'=1TO7[JRB^VVTPA66X
M%HEJ9)5<R<W)EB57.%4\5B>'_B+K'Q"^,_P8NO%GQ!U+4?'$7Q U"/5O =Q!
M EOH*I%=I;[%6(2)F,#!=V$@8L!\I-?IDUI \IE:&-I" "Y49(!R!F@6L(E:
M00QB1B"7VC)(& <_2E%VBD]6G>__ (#^J;^>EM;N=I*26EU;\)+]5]WW?E-?
M?M$>*/#/[.G@6QT+Q=?^#]?_ +'UW6+9-.^P:587TL6HS(D8S:RF>4 9^S1(
MF_=N9QG-5OB)XRO_ +;\:O$NI>+Y;K7];\">%-6AT>^@M9K6[$LD9E987B(9
M(68[>RF8YR=N/UA:S@;R\P1GRR2F4'RYZX]*0V5NSAC;Q%@NP,4&=O7'T]JN
M$^63DU?7_/3\ON^ZY2O/F6W;YQ?Z/[SX"^-GQ\\=:!\2?'<=KX]U/P_XQT+4
M=-M?!?P[MK.%[?Q+;2K"9)'5HC)-O9I5+1NHB"<].6M\6/BA;^(]3\7O\0M6
M6UT[XR1^#5\,-#;&P;3YI(U=&/E>:SKYGRMOP-O3)S7Z O;0R31RM$C2QY".
M5!9<]<'M2^1'S^[3EM_W1U]?K2IM0E%M7M;YZP;^]1:?^)V2V>;5X./?_*2_
M!M-==-6]U\2_\%/-2!\#:%I*_%:U\%SW-U;SKX=NHK54U(1WD#-<>=-@J8 -
MX52-Q&"#D"O0?B-\3?$OAO\ 8GNO%O@CQN_Q"U=+=-OC*WT^(.\#702>Z6WC
M783%$9" %Q^[R0>:^F)K:&X(,L22$=-Z@XIZ1I&@1554' 4# K-:4W#N[_\
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MLM"LK.*&6^5I^&5H2%B(C4%(PN0!@@ @_IKY$8V_NU^4;1P.!Z"D%O$ 0(D
M*[<;1T]/I5-^ZXQT_P _WFO_ ).G_P!N^>DQTES2UV^Y.&GS46K_ -[RU_+G
M]H_Q3K7Q"\(_$W5+O4WTN0^#O!&L7D^FVL$;R^=</YPED\LNT2[BX4G"E!C
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MTO+C[U[-/)%)._J0JVT//=I&'\-:1<9-7T[_ /@+^[WDD^EV[:&#3BG;7_\
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M(Z233SHLCB2>5HHRS#:H"8"C)HI=/:=G]]YV^_W&^R5NK)G?WN7NK>EH7_\
M;UYWOT5V^-_C[J6B-XG?2;"QEMM/U[3O"MK<7S,D7V^X:/S)96!XAC%Q$N
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M6-5D.P%L*2< GH*['Q;#)<>%=9BB1I97LIE1$&68F-@ !W-?,OPX^!'B6]^
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M*C_>$17/L4]JNR=FNM_EUU^6FJ3NUTWIZ<WE^.MO^#NU97]/6J***@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH YS4/B)X;TO6M0T>XU>W&K:?IQU:ZL8\R30VH)'FL
MB@G!(( QDX. <5A>!/CWX%^)7B*?0?#NMM?:O!:_;9+22RN+=UAW!-_[V-1C
M<<?GZ&L+2O EIX=_:5N=8TO0DL;;4/#DTE]J%O;;5N+IKN,_O) /FDVCH3G
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MG^)M9TS2-6>R@LX=$BEC\RYOD1C>S)G+%%E26%!T)MIC\PY!%<RNNR^YJ_\
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B<,ZKYCML5V P*]3HHHZ)"MJWW"BBB@84444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>hook-20231231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %< 4\# 2(  A$! Q$!_\0
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MERXRJ^BJ, #Z"NF\-_M!?$;PAH=IHVC>++S3]+M%*06L<<3+&"2<#<I/4DT
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MU/XZ_$#6M:TK5K[Q7?7.HZ46:RF?9^X+##$*%VDD<9()H ]\TFXT/Q&OQ/\
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M=R 8YD8%64\''!.#V.* /K_XPV%QK7@7QJNK_#S0-3\.6R>9HNN^!VBEFM6
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M /"!?"__ **X_P#X3=Q_C1_P@7PO_P"BN/\ ^$W<?XUYAFC- 'I__"!?"_\
MZ*X__A-W'^-'_"!?"_\ Z*X__A-W'^->89HS0!Z?_P (%\+_ /HKC_\ A-W'
M^-'_  @7PO\ ^BN/_P"$W<?XUYAFC- 'I_\ P@7PO_Z*X_\ X3=Q_C1_P@7P
MO_Z*X_\ X3=Q_C7F&:,T >G_ /"!?"__ **X_P#X3=Q_C1_P@7PO_P"BN/\
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M&D7Z>7>V,[V\JCIN4XR/8]1[&O4]1^*5M\4=*\,^%;]/[*VW-HU[JVH72F"
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M +;UBQW4%@"02.<4:%\ _$>OV.G207^A0:AJ5L;RRT>YU%4OKB(9Y6+'4X.
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MFZ*** /4U_Y-ED_[&=/_ $2:\LKU-?\ DV63_L9T_P#1)KRR@ HHHH ****
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M\03VE]+"D4;*AX+#GI5;_A*+G_GC#^1KK6%J22:.*6,I1;39^2/_  C&M?\
M0'U'_P !)/\ "C_A&-:_Z ^H_P#@))_A7ZW?\)1<_P#/&'\C1_PE%S_SQA_(
MU7U2J3]=H]S\D?\ A&-:_P"@/J/_ ("2?X4?\(QK7_0'U'_P$D_PK];O^$HN
M?^>,/Y&C_A*+G_GC#^1H^J50^NT>Y^2/_",:U_T!]1_\!)/\*/\ A&-:_P"@
M/J/_ ("2?X5^MW_"47/_ #QA_(T?\)1<_P#/&'\C1]4JA]=H]S\D?^$8UK_H
M#ZC_ . DG^%'_",:U_T!]1_\!)/\*_6[_A*+G_GC#^1H_P"$HN?^>,/Y&CZI
M5#Z[1[GY(_\ ",:U_P! ?4?_  $D_P */^$8UK_H#ZC_ . DG^%?K=_PE%S_
M ,\8?R-'_"47/_/&'\C1]4JA]=H]S\D?^$8UK_H#ZC_X"2?X4?\ ",:U_P!
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M ,\8?R-'_"47/_/&'\C1]4JA]=H]S\D?^$8UK_H#ZC_X"2?X4?\ ",:U_P!
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MJ+,4<D=\)&"/]ZL/QQ:7/B;XH>+;75;_ $6UMM.M(&LDURYG@$4+(2T\/ED
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MXFC8D@.!DC?U'X5"JS>QHZ4([GJ]MXRTF\GT>*VN3<OJT33V@B0MNC R7/\
M=7MD]^*LV7B"RO\ 6+_2XI&%]8JCS1.A4[7^ZR_W@<$9'>O!-+UK4?!<-I?Z
M?+9V\<NDS2V3ZLI9C8VQ&R)1D8>5F+D_3BN^N=1>Y^+'@:^BC:WEU/1[@W,!
M'(CVJXW?[K''XU<:K9G*DD>G4445U'*71_R!C_UV_I5*KH_Y Q_Z[?TJE6<.
MOJ:U.GH0WM[!IMG/=W4JP6T*&225SA54#))KE-"^+?ASQ!?1VL$]U:O+"UQ
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MFX/4:A-:%*BKO]FK_P _UI_WT?\ "C^S5_Y_K3_OH_X57M(D^RD _P"0,?\
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M7]A<RIOC$B@@HX[HP)!QS7=:[_R%[GZC^0JA6D$I4TGV1E4DXU9-=V>,:_\
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MG_/A:_\ ?)_QJB[K&K,Q"JHR23@ 5FZ/XIT7Q#)*FE:O8ZD\7^L6TN%D*?4
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M.=(_M4:K9'2P,_;?M"^3_P!]YQ2Y8?TQ\\_Z1O\ ]I)_SX6O_?)_QH_M)/\
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M/_"C_5K,_P#GY'[W_D'^MN3_ //N7W+_ .2/T?\ ^$3M_P#GO)^E'_")V_\
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M "#_ %MR?_GW+[E_\D?H_P#\(G;_ //>3]*/^$3M_P#GO)^E?G!_PVK\6O\
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M.UU,H--MO.,2A25S*^06.[ [5Y?X0\<WG@?QQ9^)]-BA>ZM;AYXXKE=R,&W
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MF$*D>:W5)J^JOIMZNWXG+6RJI2ERWOHVG;1VUW]-?P/*:*#P:*]4\,*^W_\
M@G-_R#_&'_72'^1KX@K[?_X)S?\ (/\ &'_72'^1KYGB3_D65/E^:/L.$_\
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MH/RH]EB?^?J_\!_X(>VPG_/E_P#@7_ /5O\ AGC5?^AK\&_^#R.C_AGC5?\
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MC7Q!7V__ ,$YO^0?XP_ZZ0_R-?/\2?\ (LJ?+\T?4\)_\C>E\_R9\_?M;_\
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M<W_Z"W]\@^LY/_T!K[HGZ ?\,-?"?_H%7W_@:]'_  PU\)_^@5??^!KU^?\
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M0A2E"5XI+IT5NYZV(R#$5:TZBDK-M]>K]#\G<48K]8O^&1O@]_T(.E_^/_\
MQ5'_  R-\'O^A!TO_P ?_P#BJZ?]:L)_)+\/\S#_ %=Q/\\?Q_R/R=Q1BOUB
M_P"&1O@]_P!"#I?_ (__ /%4?\,C?![_ *$'2_\ Q_\ ^*H_UJPG\DOP_P P
M_P!7<3_/'\?\C\G<48K]8O\ AD;X/?\ 0@Z7_P"/_P#Q5'_#(WP>_P"A!TO_
M ,?_ /BJ/]:L)_)+\/\ ,/\ 5W$_SQ_'_(_)W%&*_6+_ (9&^#W_ $(.E_\
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M *$'2_\ Q_\ ^*H_UJPG\DOP_P P_P!7<3_/'\?\C\G<48K]8O\ AD;X/?\
M0@Z7_P"/_P#Q5'_#(WP>_P"A!TO_ ,?_ /BJ/]:L)_)+\/\ ,/\ 5W$_SQ_'
M_(_)W%&*_6+_ (9&^#W_ $(.E_\ C_\ \51_PR-\'O\ H0=+_P#'_P#XJC_6
MK"?R2_#_ ##_ %=Q/\\?Q_R/R=Q1BOUB_P"&1O@]_P!"#I?_ (__ /%4?\,C
M?![_ *$'2_\ Q_\ ^*H_UJPG\DOP_P P_P!7<3_/'\?\C\\T'_&+TO\ V-"?
M^B#7E.*_70?LU?#$>'CH0\&Z?_9!N!=FT^?9YN-N_P"]G..*S?\ AD;X/?\
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MXE[SC^/^1^3N*L3:C>7-G;VDMS-+:6Y9H8'<E(RWWBJ]!G'-?JU_PR-\'O\
MH0=+_P#'_P#XJC_AD;X/?]"#I?\ X_\ _%4?ZU81_P#+N7X?YA_J[B?YX_C_
M )'Y.XHQ7ZQ?\,C?![_H0=+_ /'_ /XJC_AD;X/?]"#I?_C_ /\ %4_]:L)_
M)+\/\P_U=Q/\\?Q_R/R=Q7W-_P $VABP\9_]=(?Y&O?/^&1O@]_T(.E_^/\
M_P 578> OA+X0^%R7:>%=!M=$6[(,XMMW[PCIG)->5FG$&'QV%E0IPDF[;V[
4W[GHY?DU;"8B-:<DTK[7[>A__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>hook-20231231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $9 ?P# 2(  A$! Q$!_\0
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M\93JU7:*>IY^/I3KX6I3IJ[:/R3K]B/@5_R1'X>_]B[IW_I-'7RO_P .SO\
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M):U>0-*D]O932QM!&)) RH2"JG@G(X'>DW97&E=I&Q7G'[1?_)$?&'_7D?\
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M?[/GBR>.2[9R^G9$MY-(OR7<*#Y6<CH3GCYCACD@&OSVKY'.?CAZ,_HSPO\
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M6.YUKX<_$72+:600I-?Z&D".Y!8*"TP!.%8XZX!]*Q/^&_\ P)_T+'C'_P
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M^^1I#N**J]7(&%' 'UK3'XRGB8Q4+Z&&4Y;6P,Y2JM:KI_PQ\C>%/^1?L_\
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M/?I7!_&C_DM.H_\ 8$L/_1UY2HU(U<PYX/1_Y%8JE.AE'LZBLU;_ -*.7KZ
M_9]_Y([X:_ZXO_Z->OG^OH#]GW_DCOAK_KB__HUZWS?X(>IQ\._Q*GHCYA\!
M?\B3H7_7E%_Z *W;7_D9?"O_ &'M._\ 2F.L+P%_R).A?]>47_H K=M?^1E\
M*_\ 8>T[_P!*8Z]6K_N\O3]#PL/_ +]#_$OS/1OVV?\ DC$?_85MO_9Z^%:^
MZOVV?^2,1_\ 85MO_9Z^%:][A'_<Y_XOT1\9XD?\C*C_ (/_ &Z1]3_L$?\
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M/O\ L7M/_P#2:.OQVK]<O@D->_X4CX!\IM.W?\(U;[=ZR8W^3']GSSTV_?\
M?[O%5Q;M0_[>_0]'AK>K\OU/3J*9%O\ *3S=OF;1NV=,]\>U/K\Z/N0HHHH
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M *$M:)NZN9M))V/1Z***S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OS$_;P_Y.*U7_ *\K7_T4*_3NOS$_
M;P_Y.*U7_KRM?_10KZCAO_D81]'^1\]GW^Y/U1\]5^Q/P-_Y(G\/O^Q>T_\
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M4SIOSYC\KN<X^6-\G;ZA-\8/"MNFZ6^N8WP[&%M.N1*BHJLSM'Y>Y5"NK;B
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>hook-20231231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #M 90# 2(  A$! Q$!_\0
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MQCPX!]'T5\Z^&?VM+SQ#XLTG0QX!U1W.H3:1K$^FV^H7T-E=QW\UBYCFBL3
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M3IYLIG\R$IAPTAE8@J=Q=B02QJ_X4T#6O#MY>6\DUC/I,U[<W:L XN!YLC2
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MM@$*P^8RDNFU5)R!E@#@8Q3LA:E_X??\C;\3/^QAA_\ 33I]=O7EGP)\+_\
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M/@'6M0U87\DL-C%J86 0+"(2)-J[F\M)"PZ'*C(Y+LNXKOL:?P^_Y&WXF?\
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M*BCTH/BWQ%H&1K_AJ6ZMUZZAX?8W:8]6@($P)_NQK+]:[2BM/:7^-7_/[_\
M.Y');X7;^OZV,;P]XQT3Q6)1I.IV]Y+"<30(V)H#Z21G#(>1PP!YK9K$\0^"
M]#\5&)]4TR"ZN(?]3=8V7$'O'*N'0^ZD&L<>%?$F@<Z%XD:^MATT_P 0H;@
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M00"PPIAN?@=XA\>:_I^M^._$=G=>5:F%M'TZQ800,<',;/(5?YE5CYL;@XP
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M?,V[<\>5[X_O42?\)#Y6I[/[,\W>/L&[S-NW//F^^/[M &U166G]L_;[+?\
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MYBW7+B-I!##N8!Y&53M7.34/@+XP>"_B?"C>%_$MAJTK1M,;2.79<HBOL+/
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M'IT&+D]OH/B* 12>#=/U,L>(_&OBR.XY[9VO=\_3\.U/V<Y.TZ?+\[/[GO\
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M;ZG"KY]-I;(-=?2,H=2K ,I&"#T-#4^C7W?\$<989?%"7_@2_P#D68-OX_\
M"]VY2#Q)I$S@9*QWT3''KPU5IOBGX+MX5FD\7:$D3'"NVI0@,<D8'S<\@CZ@
MUL3^']+ND"3:;9S(#D+) C#/KR*32/#NE>'X?*TO3+/38LD[+2W2(9)R3A0.
MIH]_R&GAK7<9?>OSM^ASMU\3?"5_ T0N)-8B;JEEIT]Z&_".-L]_UKEKK1_
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M?^4N]_\ C-'_  VG\&?^AR_\I=[_ /&:.278.>/<]NHKQ'_AM/X,_P#0Y?\
ME+O?_C-'_#:?P9_Z'+_REWO_ ,9HY)=@YX]SVZBO$?\ AM/X,_\ 0Y?^4N]_
M^,T?\-I_!G_H<O\ REWO_P 9HY)=@YX]SVZBO$?^&T_@S_T.7_E+O?\ XS1_
MPVG\&?\ H<O_ "EWO_QFCDEV#GCW/;J*\1_X;3^#/_0Y?^4N]_\ C-'_  VG
M\&?^AR_\I=[_ /&:.278.>/<]NHKQ'_AM/X,_P#0Y?\ E+O?_C-'_#:?P9_Z
M'+_REWO_ ,9HY)=@YX]SVZBO$?\ AM/X,_\ 0Y?^4N]_^,T?\-I_!G_H<O\
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MB.L_VM_9WE_:O]%FA\OS-VS_ %B+G.QNF<8Y[5V]2TUHRDT]4%%%%(84444
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>hook-20231231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %8 <$# 2(  A$! Q$!_\0
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MWWBSQ+<(+2+S)U$4%S]GN&G78D9P2 N%()\S- 'V!^Q__P FI?!W_L4=*_\
M22.O7J\A_8__ .34O@[_ -BCI7_I)'7KU !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD9(+8P<' !]"UXO^TI\7/&_P@\.RZ[X:\+Z)J.A:;I]UJ>KZSXAUD6-O;K$
M4MXU5'D>:4DA3M" @ G+ 5[17@?[1W[./B;XY>+/!VIZ=X[L-#TGPY(]VN@:
MMX>_M6RNKP\1W$J?:80QC'W%8,%)+#F@#@-,_;5\4_%7XQ6/PP^&?@;3U\21
M>&+3Q+K5QXNU&6U@TT3PP2BVVQ0N[R*+J$$\<EACY2:ZK]G+]K0?'&_^)?@_
MQ+H4'A+QQX%O7T[5+2&^^TVD_P TJ"6"1E1BI:)^"N0"IR<X&=J'['_B?2_C
M8/C%X0^(]GH?Q%U'18]'\12WGA[[5INK;5B7SEMQ<(\!/D1' D;[@'=MU3X9
M?\$^?AYX-'C3Q!X^L],^*_C3Q/?3:KJ&L:YHT BCE8NY6W@.\0J6=B<,2>.<
M*  #T_\ 8_\ ^34O@[_V*.E?^DD=>O5Y#^Q__P FI?!W_L4=*_\ 22.O7J "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!LDB0QM)(P1%!9F8X  ZDFO*_A_&_P 4?%S?$2[4_P!B6JR6?A>!
MQ@-">)K\@_Q38VH>T0!_Y:&G?$FYE^(WB6+X;:=*Z6#1+=^)[N%B#%9DG9:
MCH]P00>XB5SU9:]0MK:*SMXH((DA@B4)'%&H544#   Z #M73_"A_>E^"_X/
MY>IQ_P >I_=C^+_X'Y^A)1117,=@4444 %%%% !1110 4444 %%%% !1110
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MSG_5G\*]GZA%8!XJ3?-?Y6T/GWF<WFBP44N6V_6^ORZ6/MFBBBO$/HPHHHH
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MR%=P-S\\_,3SS7=4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC)ZU[%7D/['_ /R:E\'?^Q1TK_TDCKUZ@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &2RI!$\DCK'&@+,[' 4#J2>PKC?A
MEXRU'X@6>HZZUO#;>&KF?;H9V,)[FW48-S(2<;9&RR *#L"DD[L# ^(\\OQ*
M\3Q_#>PD==-$:7?BBZB8CR[1B?+LP1T>X(.>XB5_[RUZA!!%:P1PPQI##&H1
M(XU"JJ@8  '0 =JW<5"&N[_!?\'\O4Y8R=6I[K]V/XO_ "7Y^A)535M5L]"T
MN[U'4;F*RL+2)IY[B9MJ1HHRS$]@ *MU\Z_$OQ\GCW5(8K:U;6?#%GJ'V/3-
M*C;'_"3ZLAR$S_SYVY4M(Y^4LAZA,,Z-)U96Z=?Z_KOM<,175"%^KV_K^NRU
M:1T%E\8?%7B*XMK#2M*LK?5]=E%UI-E>PR%]/TI2 U]?@.,&0Y\N%=ARRJ3D
M.5]I&<#/)[XKCOAKX!?P98WEWJ=VNJ^*=6D%SJ^J;<>=+C"H@/W88Q\J)V R
M>2Q/945I0<K4UHOZ_K[^HL-&HH\U5ZO\/^#W^Y:(\9_:X\9>,O ?P1U;5O \
M4AU:.6-);B&'S9+:W)/F2JI!Y' S@X#$]LCE?V&?B+X]^)'PQU"^\<&>[$-[
MY>GZE<PB.2YCV@MT W!6X#8YR1D[:^D**U6(BL,Z'(KMWYNOH8O"S>+6)]H^
M5*W+T]?Z7S"BBBN(]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K\Y/^"H/Q#\'_#;XF>!;KQGX6M_%]K?:="+:WDBBG>T%MK%C<W)V2< 3VZ2
M0Y'7E3\I:OT;KX?_ &V_VA];_9N^.GACQ/X;^'3>.;G_ (12[@U-FF9$M[9[
MVW$)RL;;3Y^T?[1D48! - 'HO[&;6_Q)_8SMI])MH=%L/$DOB">PL8<>7I\-
MSJ5Z8X!M& (PX7 '&W Z5^:VF?M:ZUKNJ:W\+Q\/]&C\3^)?"5A\)$CMKT!;
M:>WD>!;LOL*.':Y<!5;CR8_F( )^YOV'OC5X]\5_"CQE8:S\*[SP'9::FL:E
M%K4D[&.ZU*2^N9+N%(3&IB\J=I5"%F*A IR1FOES5_VQO@2W[!6E_##3M'U2
M+QC9Z):M!.-("QQZW&$D>Y6?=U,ZN=XY(;!X)% 'Z^P1>3#''DML4+D]3@5)
M110!\A_'O]LC3Y_B)>?"'P'XW\,^#_$%MA?$'C/Q-?V]O:Z&AZQV\<SK]JN\
M=%&40XWGJ!XO^P9^VOXW\<> ?%FB>(-,\0?%OQ3#JEU-!/I^H:1'/%8+# HS
M#-=02% [,?,$93,@ 8G('Z'W/A/0[R=YY]&T^>:0[GDDM49F/J21S7#_  L_
M9[^'O[/WAG6--\ ^&XM M;Z6:]N!]HFN'>5T56.^9W8 B-/E!"\9QDF@#._8
M_P#^34O@[_V*.E?^DD=>O5Y#^Q__ ,FI?!W_ +%'2O\ TDCKUZ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y3XE>.1X"\-F[@
MMCJ.L7<JV6EZ:IPUY=OD1QY[+P69OX45F[5U$TJ6\3RRNL<:*69W. H'4D]A
M7EOP[AD^)WBM_B->HPTB%'M/"]M(,8MVXEO2#T:? "^D2K_ST:MZ45K.6R_'
MLOZZ7.:M.2M3A\4OP75_+\['4?#/P,? OAPP75R-1UR^F:^U;4L8-W=OC>X'
M91@(B_PHBCM76T5P'Q8^(LOA&S@TK1C;R>*=320V@NFQ!9PH,S7MP?X88@<G
M^\2JCEN$E.O/S8VX8:EY+^OO?XLY3XW_ !'B<:AX7M-1ETVPM(4F\2:O:9,U
MI!)Q':6^.3=W!(5 .55MW4IG8^#WPXETH1>)=:TZ'3-5>U6RTW1H<&+0M/&-
MEJF.#(<*TKC[S  ?*BUROP2^'<7B!K#Q)=BXF\/6<SWFC)?KB?5+M_\ 6ZQ<
M@]9),D1*?N1D$ ;@%]\KJK35*/L*?S?]?UT[WX</3E7G]9J_)?U^'??LD445
MRWQ ^(-EX!TV!Y()M2U:^D^SZ;I%I@W%]/C(1 >  .6<_*B@DFN&,7-\L=ST
MYSC3BY2=DCR[]M'Q?XE\+?!J2'P==RV_B+4KR.UABL\M>2Q89I1 HRQ8!025
M&0NX\=:Q_P!A74/B/J'PPU!_B#_:3A;W&F2ZP&%T\6T;\[_F*[NA;_:[8J;X
ME^*Y?V=O!-_\5?&5LGB?QS>,EA;6L$A2UL%DRPMH"02L8"DO)C=(RC.!M"]#
M^RS^T<G[1OA'4=0ETG^QM2TVX%O<P)+YD3!EW(Z,0#S@@@],=3FO9<9QP+48
M)QOK+S\NMO,^>C*$\SC*=1J?+I#I;N^E^MCVNBBBO$/I HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "O@?_ (*!>(=-TGQ]X8\03^*](L_!NF7V
MFZ/X[MI0\MY!$MY!J=I'#&@):206SY7!PI5B IW#[XK\K/VC_BUX+_9Z_:8U
M2U^*'@&_\1V<WC@^+H9DLX;FWU:PET8VD<>)6"M);3D$(WR\N<J<;@#[,_9X
MD_M#]D*77;S6],A;Q)!K7B.?5()MEG:_;KJZNR2[?<6(38;/W2C9Z5\3ZI^W
M1\)_$?[".E_!:U/V7QW/HEGX5:RN(UCL;:Y0QQ->M=D^2(@R&8.&)S@G'+#Z
ME_9+\/S?$[_@GU=:+I%C'X=D\1V_B>SL=-N]R1Z;Y^H7\<<#84D+'N"G"Y '
M3M7XQ?%7]G7Q5\*?B9K/@JX^SZ[=Z3<K9W.J:0)6T]9L0[U\^5(P-C7$*.6
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MQ_\ \FI?!W_L4=*_])(Z]>KR']C_ /Y-2^#O_8HZ5_Z21UZ]0 4444 %%%%
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M!+=<C'[>?LT?&2;]H'X'>%?B!<:(_AV;6897;3GD,GE^7-)%N5BJDH_E[U)
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MJT8+FVOU^\****YCL"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT>#P_P#"_0]-MO![> DM5EB;P^\ZW'V9Q,^\B52?-#MND$A.YQ(&8!B0.YH
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MHHKYQMMW9]>DHJR5D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
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M445Q'I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWCY)+2R=3R2<#"@DX R:[FBBOEYSE4DY3=VS[6G3A2BH4U9(****@T"BBB@
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M1\%_BLKCHLGA.\&?Q$9II_;R)C!3X-_$H-G[LGAC4!^HMC7U911[6'_/M?\
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M .1*Z_X<_&C0?BC>WEKH]CXDM)+6,2R-KGAN_P!+0@G'R-<PQAS[*217>44
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MDZ5::%I5GIMA EK8V<*6]O GW8XT4*JCV  % %NBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KX?_ &A_BAXCL_VM=2\(KXO^)6C:#;>#+75+2P^'.BIJ
M<SWK74Z%ID-M-A"JJ.2@) &X5]P5S%O\-?#EK\1[OQY%IVWQ9=Z9'H\VH>?(
M=]HDC2)'Y>[8,.S'<%W<XSCB@#XXT']M;XK^#=&T+PSXI^'UUX@\?Z1X>L]6
M\26EIIUY+=73W$TBQPQ1VEO)%!+Y$8D8S,B%V* #:2/2?%O[9-[X:^/.F>$(
M-&T[4O#=UXDL?"TMU:O=O=075S#Y@:5Q!]FC9&*@P-*92I+8&"!Z[X^_9W\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>hook-20231231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $8 EX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%5&R)9B2SJ0#C( /6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M02"X\%VL=K=!+0*FK>7;2P1.PWDQLGGRD'+<.5.>" #I=6^*/B"X\1^)=/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD+*& ) )Z GK0 M
M%%% !17A/[2?[4L'[.NH:!;3^')-=758YI-\=X(#%Y908P4;=G?ZCI7F>B_\
M%*_!URX&K>%-;L%/\5J\5QC\V2N66*HPER2E9GT&'R#,\50CB:%%R@]FFN]M
MKW_ ^PJ*\6\&?MB?";QMY:0>*H=+NG(46^K(UJP)Z#<PV'\&->QVEY!?VT=Q
M:SQW-O(-R2Q.&1AZ@C@UO"I":O%W/*Q&#Q&$ERXBFX/S37YDU%%%6<@4444
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MRKSZE2<'VK5KK33U1\Y*,H-QDK-!1113)"BBB@ HHHH **** "BBB@ HHHH
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MH:9=INBFB.>^"I]"""".Q%;5>\FFKH_')PE3DX35FMT%%%%,@**** "BBB@
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MG#^K_P#26? -%%%?(G])'H'P?U_5O!NIW_B;3=2NM._LN$.IMY2@EN'RL*,
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M %%%% !1110 4444 %%%% !1110 4444 ?.G[0O[&?A;XNVU[JVC0Q^'_%K
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M[L%=WRY @\ Z'X;N[KPKK%K\7AXOLXM7\1W&F2C[7'/?K$X^W[1'/!)%(B+
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M=5\'PSK+J<5R!#>6JC+"*1#D/OQM#(2.3G;TK](HHD@B2*-%CC10JHHP% Z
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M81YI?$_P/P#BCB#^UJOL*#_=1?\ X$^_IV^\****](^$"BBB@ HHHH ****
M"BBB@ KDO&>A>8AU"!?F4?O0.X_O5UM-=%D4JP#*1@@C((J91YE8VHU71FIH
M^<?&/CVST'3KB;[4EO;PKF6[8\+[+ZD]!C\*^0OB/\3KSQU=F*/?;:3&V8[<
MGYG/]]_4^W0>_)/O7[8'P9\0:=CQ#I3O>>%8CNEL8EYLG/\ &0/O*>F[^'IT
M-?)]?'X^K44W3DK+\S^HN#,OP$\)''T9*<G_ .2OL_[W]+35E201B60!FV(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !17E'CC]J?X7_#CQ1>^'?$7B?^
MSM9LMGGVW]GW4NS>BR+\R1,IRKJ>">OK6%_PV_\ !3_H=/\ RE7O_P 9K%UZ
M2=G-?>CU893F%2*G##S:>J:C*S7=:'NE%4-!URR\3Z'IVL:9/]ITW4+:.[MI
MMC)YD4BAT;:P!&5(." ?45?K;?5'ERBXMQDK-!1110(**** "BBB@ HKR#7/
MVMOA1X;UO4-(U'Q7]GU"PN)+6YA_LZ[;RY48JZY6(@X((R"1Z52_X;0^#?\
MT./_ )3+S_XS7.\116CFOO1[,<ES224HX6HT_P"Y+_(]LHHHKH/&"BBB@ HH
MHH ***IZSJ]IX?T>^U34)?L]A8P27-Q+M+;(T4LS8 ). "< $TF[:LJ,93DH
MQ5VRY17CW_#77PF_Z&S_ ,IUW_\ &JV/"/[1?P\\>>(K30M"\0_;M5NM_DV_
MV*XCW;49V^9XPHPJL>3VK!8BC)V4U?U1[-3(\UHPE4J82HHI7;<)))+=MVT2
M/2:***Z#Q HHHH **** "BBL[7/$%AX<M$N=1G^SP.XC5MC-EB"<84$] :3:
M6K*C"4Y*,%=LT:*Y/_A:OA;_ *"G_DO+_P#$UH:'XUT;Q'=O;:=>?:)T0R,O
ME.N%! SEE ZD5*G!Z)G3+"8B$7*=.22\F;E%%%6<@4444 %%%% !115/4-7M
M-*\O[5+Y7F9V_*3G&,]![BDW;<J,7)VBKLN45C_\)=I/_/W_ .0W_P *N:?J
M]IJOF?99?-\O&[Y2,9SCJ/8TN9/9ERI5(J\HM+T+E%%%49!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!^4?[;_\ R=#XT_[<O_2*"O"Z^]OVB_V)/'/Q=^,OB'Q;H^J^
M'K;3=0^S^5%?7,Z3+Y=O%$VX+"P^\A(P3QCZ5YO_ ,.W/B9_T'/"?_@7<_\
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MH?$/@#4_"?B+6=2\1VVHPR03WUZ+>*YVMT*F"*-%*G!4A,@@$YK1\#>#=/\
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MZOGU&]MKV/39!>RN<L9I19B9N,*,2 A0J@@   'S]#XQT1_ _B>;5==^(_\
MPG-UK^KZ9HTMA?:XMK+=_;)TLK>%P?L1/RHH1OE&TAAP:^OO"W]J?\(SI']N
M>7_;7V.'[=Y.-GVC8/,VXXQNW8Q7*Q_!3PX?AUKG@FY6YOM%U>YO+JX^T.OF
MK)<3O.S(RJ-I21\H<97:IR2,UUOAW2)-!T.QTZ;4[W69+6(1&_U%D:XGQ_%(
M455+>I"C/?F@#1KC_B#_ ,N'_;3_ -EKL*P?%.@W&M_9?(>)/*W;O,)'7'3
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MA+(+,(AG)3]TI!4*C;-P]@B^'.DKXD\4ZQ+YUU)XDM+>QOK69E,)BA655"@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>hook-20231231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (" U4# 2(  A$! Q$!_\0
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MH_X6'XO_ .ALUG_P+:L"BCDAV0<TNYO_ /"P_%__ $-FL_\ @6U'_"P_%_\
MT-FL_P#@6U8%%')#L@YI=S?_ .%A^+_^ALUG_P "VI'^(OBY%+'Q7K. ,_\
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M7ZJ>+':/PMJS(Q1Q:2D,IY!V'FOR3_83_P"3I/"'^Y<?^BS7ZU>+O^14U?\
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M,HB-V -TX0D'=^E>#UW8?FFI.K!+73TZ,YL1&--J,)-NVOD^J-__ (6'XO\
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M]+T6Q>"YA=@QWE>",X( X%4[GP/\'+;Q7XE\./\ "[3V&@:#'JIO$D<23R;
M2IY^Z:Y(9A!1YIPZ7LDM$E=]3H>"DVHPGU2NV]6[)+[V?$7_  L;Q9_T-VKX
M_P"OPUU'PW_X6'\5/%<'AW1?%^H)J$R-(IN;YE3"C)R:^G[/X0?#3QKX/B\7
MVO@JST=+WPY<W0TZ&1C%#.F=LBY.<U0_9G\$:#IOACX=>)K738H=>O;B\AN+
MX$[I$"' -;SQM-0FU"THZ;+?WOUB8?5*EZ;4[J6O7;1O\'IYGR=J/CGQAIFH
MW5E-XNU;SK>5H7VWIQN4X.*W_"A^(_BZ[TV.W\3ZK96>H7'V6'4[V]9+82>C
M-VKZO\"?!;PKK=_IFG7_ ,*[:_LM6:YDO?$^HW82Y23)V^5'D$K^%+X/LO#6
MJ?"/PEX3O?".G7.E'Q;-IS$NZN0I/[W(/WB.*S>/ARVC"[T[=79O?NMF;RP,
MDY2<O=5^_9M?@M;'QQX@\6^,O#>N7VE7'C/4II[.9H7E@OBT;D'DJ>XK//Q'
M\6#KXNU<?6\-?4^O^#_A?\$]'@U37O ]OXKD\0>()K."*ZD8+8VZOM^3!R6^
MM=1XU^$_PM^!'@K4=9U#P)9^+9+K5HH[%+UV'E0R@$*<'L#6D<=2M%<C=]%H
MM7I=;]+DSP513DE)*UW:[T6NNWEZ[:'RKX,_X6=\0)+E-#US7;T6T332.ETQ
M4!1DC/K5J/2_BW+X;O-=_M'Q$NGVDHBE9KEL@GO]*]U\0_%:S_9#^*VO67A3
M1D.BZ[80W$>GORMKO7+!3U[UP$7[7NLK\)]<\%26:RG4Y)9#?D#>FXY"CV X
MH]M6JKGH4ERNUK[[Z_=_PPE1HTVHUJCOUMVM=/YGCG_"Q/%W_0V:S_X%M1_P
ML/Q?_P!#9K/_ (%M7/J-H I:]CDAV1Y7-+N;_P#PL/Q?_P!#9K/_ (%M1_PL
M/Q?_ -#9K/\ X%M6!11R0[(.:7<W_P#A8?B__H;-9_\  MJ/^%A^+_\ H;-9
M_P# MJP**.2'9!S2[F__ ,+#\7_]#9K/_@6U'_"P_%__ $-FL_\ @6U8%%')
M#L@YI=S[1_8A\5:[JN@^*VOM<U"]9+N$(9YRQ4;&Z9HK,_82_P"0!XN_Z_(/
M_0&HKXW')+$SLOZL?48-MT(_UU/$OVI?^3DOB1_V%F_] 6O+J]1_:E_Y.2^)
M'_86;_T!:\NKZW#_ ,&'HOR/FZW\67J_S"BBBN@Q"BBB@ HHHH *;(F^-ESC
M(Q3JU_!^G6^L>+]#L+M2]K=7L,$J@X)1G (S]#32;:2)DU&+D^AUOQH^*\'Q
M;/A+R]*?3!H.D1Z4_F.'\_;U<>@/I6Y\2OVC-2\5_P#"(6OA=+WPGI'ARQBM
M8;..XR)74Y9SCL3VKV'QI\'OA5\+-$^)^NW_ (*E\1V_A_6;?3[&QDU%X D<
MB G+#KR:Q_V=_ GPH_:,^(=]I(\!GPCI]IIDDS;=5>8--D!')/3&>E>'"O0E
M3]I&#<87ETT;CS;7U=I?)L]:=*M3J<DII2E:/7924=[::Q];(QM6_:YT[5?%
MOB7Q$?"4Z7VO^'!H=X?M ^:8#'G_ $]J^;8HQ&@  X[@8KZ#\(? '3K&Z^->
MD^*;.6;4O"&G&XTZ19"@#;OED(_B!&*^>XG+11D@DLH)(4X_/M77A503:H+I
M'[G=JWWF6)==)1K/9O[TDG^"1[O\)OC!X)?X;7'PV^*.C7FH>&#=_;K._P!-
M<)<6DG<9QD@UO:G^U7HFD_$7P!=>&/#-Q#X*\$I)#9Z?-.#<70=2&<OV)S7S
M9DL/E4[B< ,".>U?4>I^!O@U\$M*\%:3X_\ #EYXH\3ZW;QWNI7$%VT*Z=#)
M]W"C[Q'6LZ]*C":G)-N3?NKJ^5INVB^'2_ZA0JU7!PBTE%;OHKK2_9M[?H-T
M?]L30?#EUX=&E^"K^*PT>\OKM89[P-))]I!!&?8G->=1?':"+X7:=X0_L64R
M6GB7_A(#=^:-K+OW>5CU]Z]+\,?!OX7:9JOQ:U*6*/XB>&O#FG0ZCI*VUXT(
M(<\QNR]QT_"J-I\'/ OQ\^'5KK_PQT6?PEK=EJ$%EJVDW%R9XPDIP)$=N3BN
M6#PL&FH/[-V^C;O&]W?=ZZ;[G7-XEIQE-?:MYZ.]M+;-V_S+FI?MA>%/%LGB
M"U\6?#Z]U;0]1U.#5K:S@O1&\$T:@89OXE..E6-6_;E@N=?\2:KIW@^6SDU4
MV7V>.6=66W%N1P1WR!BL7QS^RQX:LO#/BZ?P5XOO_$7B'PA*D.KZ==6GE*Y;
MJT1_BP>*\6^(/PR\0_#&XL8=>M! U[:QWD+)RNUQD*3_ 'AW%51I8&JUR>5D
MVUT33L][I+7JD*K5QM._/\]$[6>S[6;V/>=7_:T\"7>D^.+2P^&^I6=QXQC)
MU.ZDU$.WF]BG]U >=M0R?MBZ5'%-=V?A&^M]>F\.QZ"]V;L&(&,C9*J]NG2N
M7^)GP@\/:'X-^'=CX8L-0U3QYXCLQ>R0QC<LBDD;5'KQ7F>G?"_Q;JC_ +G0
M+N.(7HTY[B9-L<5R3@1L3T.:NGAL).+2323MJWT]W37;HODC&6(Q,>6;=^97
MV7VK2UTWT4OQ[GN6H?M?:!+;ZGK=AX#DL_B3J6DC2KCQ UP#!C;M:18^H8BL
M.W_:EMH?B9\//%C>')W7PGI/]F26OGC==-@CS >PYZ5E_&+]F#5_A!JG@?1+
MB_74/$/B10)+2, QV\A; 56'WA[UU/BG]D;1[;3?$ECX3\:3^)/'/AN..34]
M#:V"QC=C<(G'+;2:A?45%36SNNKVO%^D5S/RUN6_KDVZ;W25]NMFK]V^5>>A
M\]:[J0UG7=2U%8S"MY<R7 C)R4W,3C/MFJ-?8.A?LK^ M-U#1?#OB*>]NO$.
MIZ)+J DM\B**=%+%"?;BOD&9/+GE0=$=E'X$BN_#XBE5;IT_L_E=K3[F<M>C
M5BO;5-Y/YW:4M?DQE%%%=IQA1110 4444 %%%% 'OG["?_)TGA#_ '+C_P!%
MFOUJ\7?\BIJ__7G+_P"@&OR5_83_ .3I/"'^Y<?^BS7ZU>+O^14U?_KSE_\
M0#7PN=_[U#T7YL^LRG_=Y>K_ "1^#)_UDW_7:3_T(T4'_63?]=I/_0C17W1\
MF%%%% !1110 4444 %7_  _J@T/7]-U)HS,MG<QW!C!P7VL#C/OBJ%=[\!_"
M.E^//B]X9T#6H6N-+OKGRYXD<H67'8CI2<N5.783V(/C7\18/B[\2=6\51::
MVEQWP0"UE8.R;5 Z_A7I_@CXR?#;Q9\-]'\&_%O0]0NX] D:73=3TJ41R,IY
M\I^.16Y=?#[X8_#SX8^+?%6M>")/%4MAXHET>UMWU%[<1P@_+DCJ15[]GCX8
M_"W]I+Q+XDM(?!1\(6UCII:W0:F\P%P3A9"Q_E7BNK1>':C&7)3L[JUU9)JV
MM[V9[$Z=:&)]^2YY-KK9Z\KZ6MI^!F?$C]LZ/Q+X.U;P]X9\.W/APSI#9VE^
MESEXK2+HA[ECUS7G.J?'B;Q'\"_^%?Z]9W.K:A;WWVRQUF:;)@!^\A!Y.:W_
M  Q\$=.M?!7QF/B2RE;Q#X1"+9R!RH0EB-Q'?(Q7A"M\BY#$D Y"G'YUM0H8
M67-&FKV<7?SLFG??;?YF5>MB8-.;M\2MVW35OR/?OAM\8?A_J_PRM_AY\5]%
MOKW1]/N&N]/U+2Y!'-"3UC/&2#6Q=?M::39?%?PQK.E>%YT\'^&M.ETNRTOS
MQY\D3KM+ESW/6OG&QM9-1O;:TA!\VXE6% P(Y8X'\Z^JM?\ !/P$^%GB_1/A
M_P"*]"O=2UJ6WC_M;Q(EXT:6,TBY7"#@@9YI8BE1A.\HN3E?W5Z6D[:+9V^?
M=BH5:KARQ:2C;5]%>Z5]7OK;]#+TO]L#1-".B0Z;X-O8[#2K2]M8XYKP,["X
MSR3_ +.:X33_ (^V]CX$\#>'3HDKOX:UIM7>X$PQ< MGRP.Q]Z[/P1\+/AUH
M7A[XM:WK6FQ_$2Q\+31#37M;UH(IXW/7<M6H?@1X+^.W@_0?$7PPTZ?PK*VH
MIINL:9<SF=8"PR)$8]16,7A82NHNUXW?9OWE>[O]K73=ZG1)XEQY936TK+NE
MH[65MEIKZ$\O[87A+Q%)?1^+/A[>:Q8_VU_;>GP07JQF"3 ^5S_$.*FN/VYH
MTUS7M3L?",L$NIZC;7J)+.&$21#!0CN2._:N=\>_LP^';;PAKVK_  _\57_B
M>]\.WRZ=JMC>6GDG>3C?'_>&:\>^('PVU[X8:U%I>OVP@N)(8YU9#E&5P" #
MZ@'FBC1P-9I0^YMKI%[/NE%WZA6K8VE=S^;LGU:_!WT/<M;_ &JO ESX4\6Z
M)H_PYU+3AXEF%Y=W,VHB23[0&W Y_N _PTSQ#^U]I.J6FOR6'A*^L=9UC2;;
M3I;N2[#1I)#C;(J]@<=*P/B]\%=%T2T\'Z-X)TO4]6\6W^EIJ=_'&-RF,C)*
MCVKS'1/A9XL\02Z4MMHEQ%#JMR;.SNK@;(9)0<%<GT[U=*AA)QTNM>K?33OM
M[MEZ>1C.OB8M-N]TGLMG[VNF^M_GYGN=[^V%H,D5]KEGX"DM?B+?Z8NF7.NF
MY!@*A=I=8^H8CO6,G[5ML/C!HWCAO#4[I8:'_9#69N!ND;9M\S=V'?%4O'_[
M)^K>!_B7X,\"KJ:7NMZ]"LMQ@ 1VK?Q!3_$ .]7?&O[+FCQ^']2O?A[XNN?&
M=]H]^FG:G92VPC,<C'&Z/'WE!SS[5FHX"R:VE=+>UK\K]%=V6RUT-&\9K!]+
M/IO927J[1]=#P&]N!=WUU<!=@FE>4*>VXDX_6H:^P%_9<^'^CW-QX>U.>]NO
M$BZ ^J)<0Y$*RJN67/L:^/Q_4BO1P^)IU[QI]/\ -K3[F<E>A4I_O*G5_C9/
M7Y-!11178<84444 %%%% !1110!]+?\ !/#_ ).:TW_KPN/_ $&OTZ^+G_)+
M?%?_ &#)_P#T U^8O_!/#_DYK3?^O"X_]!K].OBY_P DM\5_]@R?_P! -?"Y
MQ_OL?1?F?6Y;_NDO5_D?A7;?ZA/Q_G4E1VW^H3\?YU)7W1\D%%%% !1110 4
M444 >B_!;XM0_"/4?$%U-I<FJC5=,ETX)'($\LN,;SGJ!Z5S_P ,/'5W\+O'
M&D^);"))I[&;S#"RC$BD\J?J*YJO6OV:_AYH7Q*\;:GIOB"VDNK.#2[BZC2.
M0H1(BDJ<CWKFJJG24Z\E]G7T5W^K-8\U3DHKJ]/5M+_(]/N/VA/A'X.;7?%?
M@7PEJEOX[\0020W$=W< VMD9!AV1>_>N3\$?M5GP5IWP\MX]"EFE\+7,TUS(
M)@!>K)U4#M^-;/B?P]\*OA1\+? NLZM\.'\5ZGKR3//-)JSVX38Q P!70?"C
MX">!/C[\(O&_B/0_#;>&=;M)BFE6OVYIE3:N2F3][->1_LU*G*I*,G&+M=N^
MUXV6M[*[Z'K_ .T591I\R4I:V[WUN]+7=NYAZ9^V18#5O$=WK7A&YU6'5M6C
MU..$7(7R5C^[&?7FN4\.?M5^(M&^--UXXO'O+_3+J60RZ(9_D\EAC8.V0*I7
M_P ,-$L/V8X?%\ME+%XJ76VT^:9I#M"+U7;ZYKQPM@XPWU"G'YUV4<-A9.2A
M';W?P2T^5M=SDK5L3&,>>7Q>]YW4I;_.^A[5\*?CIH?@GQ9XMBU7P])>^!_%
M!>.[TM7'FP(QR"K>JUK?$3XT> M%^'J^ ?A9HE_:Z'+>QW]Y?ZI-YDLS*<A!
MZ"O&?!?AJ?QKXLTC0K8E)M0N4@#$<J"<$XKZ7UCPG^SOH_Q NOAO>Z5>6-_;
M0_9Y?&,MZPC2["]X^FW/>HKPHTIQ=I-VO9=5"UF]=;=.K\QT*M6:E:22ON^C
MGH[=KZ_)=#,UO]L+0]3&KW%MX,OK?4=5TZWL;J62\#1YB(PRKV! Z5B7?[5-
MK=>-?%FO_P#"-3JFNZ*NDK!YXS"0NWS">XXZ5IV?@?X9?#OX(0^+/$7A'_A/
M;V36I=.^TP:B]O$T2GB1=O7BN@G_ &5?!GQ$31_&7A/4+OPU\/+NPEN[Y''G
MSV3QC+(N?O9[5ROZG"[E%J.JOTVO;>^VVGD=,5BWRJ,ES:-+J[2LGM9ZKOL<
MUX&_:[LO"?A[PYH5YX3GU'3+"QGT^_1+@*UU')_</\)%:X_;'\*:-%X5L?#?
MP]O=+TC03*4MI;Q7:7>",EO7FO/_ (I? *PT'3/"FN^!-9NO%6@>)':&U-U;
M^5/'(#@JR>GO7G_C;X=:U\./%/\ 8.OVX@NPR99#E&#8/RGOUKJC0PF(E?JV
M]+M.Z;O=>5W]YRRJXG#PY?LQ2[.R>VOG;\-3Z'T[]M+PN-;T/Q'JWP\O-1\4
MZ1"UI!=)?!(!"2>D?]_!ZUB^'?VL/#.AV45M)X*U&=;/79-<L2MZ!Y9?JC_W
MJP?CC\%](\.7NFZ3X%TG5-3U.VTN+4=9D"[DC1ESN'L*XWX>_ +QI\1?$.C:
M7:Z5)8)JJ^;;W=[^[CDB!PSJ3UQ44Z&#G#F6B\VULV^_>[^\UJUL6GRRUO9[
M=UUT[.WE='ING?M6^&-4L[BR\;> KCQ'9P:L^K:4L%T(VM68YV.3]X9K'^)G
M[5$WQ/\ !]SHU]HC07,NL)J4=PD@V1Q+]V$+[ =:IW/[,TX_:$N/AC;:SYL5
MH@FNM5D3;Y<87<[8]NU=2/V1M*\22Z'J/@3Q;/XH\-7&H&PU*[N[<0O:%3R<
M#^$]C4I8&+A-=;-;V6UGV5[==[#E/&2YXO?5/:[T=UY[O1;7/*OC?\58OC#X
MOM];ATR32EBLHK3R)) Y)08W9]Z\^KZ8^*/P-\ >'?AQXROM"-\VN^'+^.V>
M6?(CD5NA%?,]=V#JTJE.U%-)=_-7_4Y<52JTY)U6FWII_=]W] HHHKN.(***
M* "BBB@ HHHH ^OOV$O^0!XN_P"OR#_T!J*/V$O^0!XN_P"OR#_T!J*^,Q_^
M\S_KH?4X/^!'^NIXE^U+_P G)?$C_L+-_P"@+7EU>E_M47<"?M*?$A6F16&K
M-D$_["UY=]NMO^>\?YU]9A_X,/1?D?.5OXLO5_F345#]NMO^>\?YT?;K;_GO
M'^=;F-R:BH?MUM_SWC_.C[=;?\]X_P Z N345#]NMO\ GO'^='VZV_Y[Q_G0
M%R:N@^'8)^(/A@#D_P!IV_\ Z,%<S]NMO^>\?YU+:ZPMA=0W-M>+!<0N)(Y4
M;E&!R"/<5479ID37-%Q74_0;XN^(;#PEX/\ CEJ&J^%[+Q9:+XDLU.G:DSI$
M28AAB5YR*\F_9Q\5V'BSQ1\1=0T/PI8>"TA\)SXL]*=WCWCD29;G-?.&K_%?
MQ)X@L]2M-3\475]:ZG,MQ>PS296XE485V]2!5#0?'.H^%6O&T;6Y=,:\A-M<
MFW?'FQ'JC>QKP:>72AAYTF_>:23UM\$8[>JOL>S4QRG7A42T4KO:_P ;E_P#
M[U\$:[HWQ7_9T\6_$2ZD==8'AX:'KT5N/WK^6V5E'^T5]:\>^"/B/X9:EJ$7
MPT\*Z;JMSIWBP(M]J'B6./SK>2/YE\DKT7@YKYPT7XAZOX:TC4M*TGQ!/I^F
M:FNR]M(),1W"^C"NH^ 'C;PQX(^+.AZUXDN?+T>S\PR&,%B"4(7@>]:/ \GM
MI)NSU27DFTOE+5&2QC:I)KWHZ-OY*_W:,O?M#^+++Q3\8]8N].MH;;3["2*R
MB2! JL(<*6P/7%>N_M0_#7Q!\4?&G@7Q7X7TV?6-*\3:3:6EO-:H72*55"LK
MX^[CKS7R]K6KV5]KFI7,$Z^1/<R21[CSM+$C]*ZGPM\>_'/@;2#I7A[QQJ&C
MZ823]EMI1L!/7&1Q^%;K#SC3I.G\4._6ZUO^#)G7BZE52^&6FG2ST:^2L?3^
M@_"K2OA9X>^/'A/P[>W.OSVWANU^W%$WE+HG+QH%Z@5+^QEX*N]#^&6K-XA-
MQX<3Q-JUG:::UPOE2RM&=Q*JV#VQ7R=X4^,/BGP)J-_J'AWQ9=Z/?:@<W=Q;
MR9:?G/S9Z\U+XI^-?C#QQ=V%UX@\97VJW-@_F6DDTN# PY!7& #6#PE>2E&4
MD^;EN^ONVV6VZTUV+^LT8M.$6N7FLO565W^+TW/N+QC\3=8^('A7XV65UX:3
MP$?##K<6VL00&-[Z1&PHD)&&SUXKXQ^*_P ;?$GQE.FRZ\\2I8VB01Q0K@$J
M,>8?<]ZM>/OVGO'?Q-\.6^A>(/%+W>F18WQ A?/('!DP/F->9O>VQ0@3Q]/6
MG@L#[#6I%75K6UV5F]>_;H7B\;[;2FW9WOZ-WMYV[]3Z?^,":[+K?P%7PR)C
MKYT>W^Q^1G=O\SV[>M=W^WQ/K(\-^%YM)N(%\.I*XU5]))51JP'SER/XNN,U
MY#\3OC3X7U+P=\.=5\)>([O3O'7AZP%A+Y8*B( GYE8\9YKQ^?XBZS=:-?:/
M-XAN)M*OKC[7=6<DF4FF_P">A_VJB.&G5E"=K<DI/5;WD_PMJO,/K$*5-1WY
MJ<%H]K1MKYWT_P +?<^KO&&LQZ3JG[+VJ:I*[Q1P*TLUPQ).7QDD]:Z+PQH7
MB'X7_&3X^^,;VWETVRAL99;/4I%_=R22<Q;">&/>OBG5_'.I>(+/3;34];EO
MK73$\JQBF?(MDZ[4]!6UK_QO\9>*_#L.@:SXSO\ 4]$A"B.PGES&H'3W./>G
M4P-246HM>]SI^DI<VGFMNQ-'&0A;G5[*'WP5ON=SZ4^ O[0WC#XU_$G1+#Q1
M-;W#:5HUYBXCB5))V,9^9\#K]*^2+K_C\N?^NS_^A&O7/V7_ (C>!?AQXEUK
M7O%.J2VUVEA+;V$,"EA*SJ0=V.E>-3:C;23S.)TP\C,.>Q)-=-&C&EB9^SC:
M-ETTO>3?YF<ZLJF&7M)7?-\[**1)14/VZV_Y[Q_G1]NMO^>\?YUZ!P7)J*A^
MW6W_ #WC_.C[=;?\]X_SH"Y-14/VZV_Y[Q_G1]NMO^>\?YT!<FHJ'[=;?\]X
M_P Z/MUM_P ]X_SH"Y]!?L)_\G2>$/\ <N/_ $6:_6KQ=_R*FK_]><O_ * :
M_)#]@^[AE_:G\(*DJLVRXX!_Z9FOUO\ %Y \)ZP3P/L<O_H!KX7._P#>H>B_
M-GUF4_[O+U?Y(_!D_P"LF_Z[2?\ H1HJ$WUN)9@9TSYTG?\ VC1]NMO^>\?Y
MU]T?)DU%0_;K;_GO'^='VZV_Y[Q_G0%R:BH?MUM_SWC_ #H^W6W_ #WC_.@+
MDU%0_;K;_GO'^='VZV_Y[Q_G0%R:O5OV5@6_:$\%  D_;.@^E>1_;K;_ )[Q
M_G5S1O%-QX;U2WU/2=3;3]1MFWPW,#8>,^HJ9Q<HN*ZH3U/M#Q+XGTWP?\!_
M'][J_A'3_&%L?'4R"RU-W2)6S][*\Y%<K\ O%MOKFG?%_6M!\-V7@]8- #Q6
M.ENSQQNK9#@MSFOFB_\ B/K.JZ3<Z7>>(9[G3;JY-[/:R/E))SUD(_O5!HOC
MG4?#=O?V^E:W+I\&H1>1>1P/@3Q_W6]J\E8"2HU(7]Z5K;VVBMOD>O5QRJ8B
M-5+W4VVM+_$Y;_,^]%U3P[\1_P!F/Q9\2+AYDDU;3+>PUZ"R \T2PG!<9_B(
MQUKRSX'>(/AIXAOU^&?AG3-1ET35MM_<:EXC1/M,<L0W;4*_P$"OF/3?B'K&
MC>'K[0;#Q!/::)?X-UI\<F(IO]X5U_[/GCSPMX%^(\6K>);HIIT=E<1*8@6/
MF,A"C ]ZF6!=.-9Q;L]8I>2T7R:T^1"Q?.Z2DE=63;];7^:W+?Q \>6>N?M
MS^([>VAMM-@U2()%$@5 D;!2<#Z9KUG]H'X$^)?B'^TI:RZ5IUQ?:%XK$%Q;
MZG FZ%82HWL6Z#:,]:^5[O4;2>[N9%G3RY)7=03V))%=II?[0OC[0] &A:=X
M\U*ST8(8Q91S#8%/51W KI>'G&-)TMX)K6^S2_5+\3%UX2G5]IM)K;I9NWX-
MH^A-+\#Z7X/^%/[0/AKPI<7>OV%A):P).D?F/*X/S8"]0#GI79?L?^#KOP_\
M+[>WUXW&@W.OZY%-IT4P\N:81+N.%;G!QBOCGP9\8O%/PX-V?"WBR[T(WAW7
M/V5Q^^/JV0<U)K_QK\7^*]8L-6UGQC?:CJ>GL'M+F:7#0$=UQP*PG@ZTU*'-
M\7+=]?=26VVK7W&JQ5)24U&W+S6736_7?2_;<^T?&_Q5UKQY\*/BEJ$_AU/A
M[=>&-426TN;: QF_D#$8DW#YB1SQ7R!\5OC'X@^,VM6NI:\T2-#%'%'!",*N
MT ;OJ>M6/B/^TKXW^+.DVNE^)?$K7FGV^#Y"X59&'\3XZFO./MUL"/W\?!!Z
MU6"P/L/>G%7Z6UMHD]7WM?R'C,;[=6IMV=[_ #=TOEWZGV%XP3Q')^T'\(/^
M$6,@U4:+:$E<[1%C]YO_ -G;G.:H_MZW&J1^+?#UQI$Z1^"/*<Z;)I;%85N-
MW[[D=&W9KBOC%\<O#NI6GA'7/ OB>]T[Q1;:0FE:BL8*!8P,$ GUKQ>\\>ZI
MJ'A^WT*ZUV:XT:WE,T-C(^8XW/5A[FLJ.&G*=.HU;D<MUO=O]&K>K+J8B$:;
MA>_-""TZ6C']4T_*Q]KS:E'8_'GX!SW\I'G^'_*\ZX;DNR$ DGW-<KX)L?$_
MP.\#_'+Q#>Q3:#>M?B#3;B=,%I_,)#(#][@]:^4]5^(&K:[-ITNHZ_/>2Z:B
MQ63R2<VZ+T5/0"M3Q?\ &CQ;\0;&VLO$WC"]URSMCF&"[DRJ'UX_K5/ U&N5
M-6=T_3GY]//6Q$,7"-G)/3EMZJ'+KY=3Z9^#/Q[\5?&_Q7J \3O;R2Z7X8NH
MEEAB"-,Q0Y=L#K7R"._U/\Z]D_9P^)7@3X=6_BW4O$.J2PZQ<Z=+96%O$I9)
M-ZD98]N:\4%];G_EO'U/?WKIH452Q$U"-HVCTTO>3=OO,JE5SP\>>5WS/KK:
MT4OR)Z*A^W6W_/>/\Z/MUM_SWC_.O0.&Y-14/VZV_P">\?YT?;K;_GO'^= 7
M)J*A^W6W_/>/\Z/MUM_SWC_.@+DU%0_;K;_GO'^='VZV_P">\?YT!<^G/^">
M'_)S6F_]>%Q_Z#7Z=?%S_DEOBO\ [!D__H!K\P/^"=EU#+^TWIJI*KG[!<<
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M_A1_PI+X?_\ 0EZ%_P""^/\ PKMJ*/:U/YG]X>SA_*CB?^%)?#__ *$O0O\
MP C_ ,*/^%)?#_\ Z$O0O_!?'_A7;44>UJ?S/[P]G#^5'$_\*2^'_P#T)>A?
M^"^/_"C_ (4E\/\ _H2]"_\ !?'_ (5VU%'M:G\S^\/9P_E1Q/\ PI+X?_\
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M"_\ !?'_ (5VU%7[6I_,_O)]G#^5'$_\*2^'_P#T)>A?^"^/_"C_ (4E\/\
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M+T+_ , (_P#"C_A27P__ .A+T+_P7Q_X5VU%'M:G\S^\/9P_E1Q/_"DOA_\
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M_P"%)?#_ /Z$O0O_  7Q_P"%=M11[6I_,_O#V</Y4<3_ ,*2^'__ $)>A?\
M@OC_ ,*/^%)?#_\ Z$O0O_!?'_A7;44>UJ?S/[P]G#^5'$_\*2^'_P#T)>A?
M^"^/_"C_ (4E\/\ _H2]"_\ !?'_ (5VU%'M:G\S^\/9P_E1Q/\ PI+X?_\
M0EZ%_P" $?\ A1_PI+X?_P#0EZ%_X+X_\*[:BCVM3^9_>'LX?RHXG_A27P__
M .A+T+_P7Q_X4?\ "DOA_P#]"7H7_@OC_P *[:BCVM3^9_>'LX?RHXG_ (4E
M\/\ _H2]"_\ !?'_ (4?\*2^'_\ T)>A?^"^/_"NVHH]K4_F?WA[.'\J.)_X
M4E\/_P#H2]"_\%\?^%'_  I+X?\ _0EZ%_X+X_\ "NVHH]K4_F?WA[.'\J.)
M_P"%)?#_ /Z$O0O_  7Q_P"%'_"DOA__ -"7H7_@OC_PKMJ*/:U/YG]X>SA_
M*CB?^%)?#_\ Z$O0O_!?'_A1_P *2^'_ /T)>A?^"^/_  KMJ*/:U/YG]X>S
MA_*CB?\ A27P_P#^A+T+_P %\?\ A1_PI+X?_P#0EZ%_X+X_\*[:BCVM3^9_
M>'LX?RHYW1OAUX7\.I*FE^'M-T])2&=;:U1 Q'0G YHKHJ*ARD]6RE%+1(\X
M^-^J:C;Z)I.E:;?3:5-K.H16+:A;G$D"GDLI['C'XUYOJ&B:_#XU\/\ @I?B
M)J=W:&:[9[BVD7[6@$094G;')!.1P.*]Q\;>"].\?>'Y](U,2BWE(826\ACE
MC8'(96'(/O7#K^S;X3CMK!8YM4BN[266?^T$O6%S,\B[6,C]6XX&:F&E[^?Y
M67I9ZFK>UNWZO\U9?(\J^%/[3]YXL\>0^$XM6TV]BTB&[L[^624?:KJ[A^[M
M3KC'7UK<\"?&_P 5QV>HIK-DVKZ[O\[^SK>(Q&TMFW;)CG[R\8XKT'0_V:_A
MQX<UBPU?3_#%G;ZQ91/%'J"(!.V\89G;JS'U/-7_  -\,?#?@O6]4EL[JXU#
M5KJ(13M>W'G2)#DE8QGHO/2B-[>\];?CW^?X+0AVO=;7_#^OO?W'CUK)XEL/
MAQ%XN;X@7K7FNVTCMI]PX949FX%L/X2OXUS_ (Q^*?C'X/>);;P_9:Y<:W!J
M6F1:D9]00W%S;OCY@%49V''X5Z\/@'X T:]N[:YNKK?J$<P@M+F^)6W5OF<P
M*?N8]NE9&E_!?X9>*+&XU/2]>NKV>R_T5]8BU(O- @&#"7[+CJ*&[WY=%^2U
MT^^VOR'IS-O7_/37[DU;S-"R^*6O>*?A-XAU*?3)-&O+;2!<0W\3AHYG:,G=
M'],5YIX%\7ZIX@T?Q;-<>+]>_MVUBS;1[?\ 18_W"D'.,?>.3S7T,?#?AFP\
M#VOA/S8X-%N;4V4$?FX,D>WD*>YQDYJEX/\  'A2U\*ZEINB2_:-*U E9V2?
M?DA0A ;MP!5U;2510TNFE_70JFU&G!2W3N_33[]CP3X6_'_5['7='L?&-_>7
M&I:=X=9M1LK6$R&>;S?DGV@9&Y>]>UZ3\:8?%-IIM[X=TBZU>PN=1&GS7"?*
M(#C)<YZ@=/K4^A_#3P;8>/;S7=)"?\)-:Z7'H]P5ER1"/FC$B^OH3VK4^%'A
M&X\$>"[72KL0"YCDED<VZX4[G+ _D:TE*,GS/_+JW^7W$6M!+JK+\/T?W[G%
M:EHVIO\ 'ZSME\4ZQ%IKZ<;QM.25?)+B3&.F<8[4[Q+^T3!X<U+6F;0YYM T
MJ;[%-J_GHJ&[XQ"%/.>1STYKTF3PEI\OBJ+Q$4?^TH[8VBON^7RR<XQ]:XKQ
M%^SKX.\4ZOJM]J%O=2)J:G[39K<,+=G/_+79T#\?>KG5U%+M?\_\OQ-&X-MO
MR_+4\/\ %?[1.M7OCN*:)[S1HM-MX3J.C12K,-QF[,O#%E]*^@?A%\5/^%IZ
M3>W;Z1/H<UM<&$VEU(K2[>S$#IFN7TO]DKX?:/9I;VUI>+MC$9E-TQD8!MP)
M;N0>]=K\.OA7H?PPM[^/1Q<O)?3>=<3W<QED=NV6/8>E:WC;E_J^GX;F$N9R
M4EY+[K_\#U.QHHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /)_B__:GB#Q3X8\+V.N7GAVWO6DFGN[!PDSA%R$4D>O7VKS^1
M/$FJ:OK=H/'U[.=!TE9XKC3V"Q32*6/[SKDX !KVKXA_#'2/B79VD.IR7EM+
M:2>;!<V$YAFC.,'##G!'6N;N/V</",GE"'^T+)$MUMG2UNVC$R Y^?'WB3U/
M>I2=K==?^ _EL5=:_+\U?[SQT_M5ZWXEO_L/AVZTF:;^QT98!(&N)+X_>P@.
M=H]*ZNU^-FOM\/KQ5MY=1U&""2.\U6)?+2SN 0#&5/.X;LUW%_\ LT_#RYU<
M:O:^';;2M96'R4U'3U\F91ZAAW]ZV?"WPY\,Z#X<U/PQ9LUU%<LSWQGF\R:1
MW'+.WK[U3M*,M-7?\W]RU_!"C:,HOHK?DOU7YGCWB72?$7@[2]-TR+XC:E?-
MJUQ9LZO(IO8MS8=D..(STQBN,N?C]XU\ _%C7? T5Z-;L-%F@:.ZNXR\LRS'
M_5RR#A".Q->NS? [X;Z/I.IVEYJUWOM?*N;B]N=2)N+5(SE!O/*H#VJ'2_@/
M\,]3$6OV.J7%U;ZC.DD]R+\NFH.IR@D/\>".*T33G%]+Z^FEONLR&OW;B]_Z
MO]YK^.?'>MW7PM?5X[2Y\-ZA]K\H1NP+[0Q&<^AKQ2]\6^)[WX50:IX;\7Z[
M/XL%TA>*\0BW<"3YHUXP<CC@U]1^+=)T'Q58S:)JDZ>7&@N)(5EV,J#HQ]JS
M])\">%]0\(Z7IMA(;G2+&42V[Q3;OF4YY;OS6234W)=X_@U?\OF:2=X<O77\
MG_FCR_X5_'^WU6[\:7=_<7M\MM=*([6*$R+;;8QYD88# PV>M>@>"OBXGQ"U
MA(=*TFZ;0Y8I&36"0(RRG!4#\:G\'?#WPQX<M/%<GA18D?7+J2XO DFY/M!7
M:>.WN*U_AGX8F\&^!]+TBY$(N+:,K)]G7"%B2<C\ZUO&6K[+[[:_B$M=5W_#
M^MSS[P98WVD_%#Q7+?>*M8OM-T^)9DL[F0&) <D\ =JI7'[3<T%G;S?\(G.&
MU*1AHZ27D:?;XUY+@G[HP.AKUJV\&Z9:ZMJFHK$S7&I1B.XW-E64=L5YIJG[
M)?@'6M.FLKR#4)X&F\Z$->-FV_V8C_ OL*R5U&*?1?U^GXB7+>3?5_@>777[
M1&J67Q!BUNWDU#5-#>"=TT2WP6=PH^4?0YYKZ1^''C9/B#X3M=:6T:Q:8E7M
MGD#M$PZJ2.]<;=?LQ^")_),4%[9O#"T,;VUTR,BD '!'?CK7;^ _ >D_#CP[
M%HNBQ/'9QNTG[UR[LS')8D]2:T7*H\O;;[W^@I-R<7Y:G14445 !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YE\;;S4IK;0M#TW
M5+C1&U:^2WEOK4A943N$)Z$UPVH:7KK:MHOA8>/M0N8XY9P][92 3X"_*DK8
MY85[%X]\ Z7\1=#_ +,U0SQQ!Q+'-:RF*6)QT96'(-<I)^SSX6.F:?9Q2:E;
M-9N\JW4%XRSR.PPS._5B?>IBK;]_T7Y!+7;R^6]_O/$-)_:JU9KW3_#MGJVE
M7U]9)<VU]+-*OGSS(2L2JF<D^OK7;>#_ (V>)8_#-W%J%F^L:Y;JYO?)C,0L
M#L+(&!Y(([UV#_LM?#-I;&X7PO:1:C9 ^5J$:[;C<>KE^I;/.36_X*^'/ASP
M5_:>GVD\M[>ZA^\NY+V?S9Y5Q@9)[ <"JW4K[M?C^G_#%-KG4DM+[>7ZGB^L
MP^)O#'@'^V$^(E]/=:U:B5K2X=3+&S,#FW_NA0<'.:;XK^(OBGX3/?:-::Q<
M:SYBQ3Q75^AGN(LK\RA5^]_2N\?X _#W3GOM-N[V[DN+Z!_+CNK\M);Q [F\
MG/W!ZXJ#3_AA\./$FA74FG>()[OR[A2^JQ:B7FB<#:%\SL,<8IRU24?Z6BM\
MGU^0EHM?Z?\ P?\ @D&D_%GQ%XK^&-]>SZ?)I5U%9I,FIPL#'*Q;&%'8\<CM
M7GEWXLUC5/#WC5[?QAKUOXBMH,V:*O\ HT3;,@YQCK[U]#V_@OPUI/A"V\(*
MPBTYHR(XC+AY!G<3GOSSFJVC^ _"FH>&]5TO3Y?M6G7S%+GRI]QR!C&>U$DG
M4FUM;]?P)5XQAY/7[OQ/'?A+^T!<W/B*#2?$MY=SZW:Z3&+RRMX&=#.%R7X'
MR[AZ]:].\+?&V'QQKEK:Z)H]W=Z<\C0W&H'Y4MY N2I'KVK2\-?#_P ):)XT
MUC5]'"+K\]I#9W@67)V(,1[E]?>K?PN\(W/@S0;FSNQ )Y;R:X)MUP"&;(S[
MXJU9ZOS_ !;_  LPM9.SZK[K?YHXVWT;48_CG+&WBG6'TX6AN?[.:4>0&STQ
MC.*;KO[0[:->WW_%.3RZ7%,;2VU!KE$2YN!_RS /(YXR:]-7PIIX\2MKH1_[
M0:'R"V[Y=GTK@O$'[-7@SQ/=ZK-J$-[-'J!+26WVIA%&YZNB_P +>XK!<RC&
M/9/\]/P*5N:3?5K[K:_C^'F>1>)?V@M4U#Q;I&I6DUYI]E;I(M_H\4BR9E3J
M@8<,?I7N?P@^*H^*VCW5ZVD3Z+)!*(_LUTX:3!&0Q Z?C6#9?LM^ ].T^RL[
M:TNH8[1&2-UN6W_-U8GN?>NM^'7PKT/X86U[%HXN6:\D$L\MW,97=L8ZFM5R
MJZ^[[S*SO?\ JQV%%%%2:!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>">-M9O_"UK\3=<T>5H]<@DB6TPF\S.$!6(#W->
M]U@V'A"TT_Q#J6K))(S7X0RV[D&,,O1@/6HE%RV=BTTEJK['SQK<-[XLT;PC
MX@F^T7GB:]T.\CFD52NUC&2T87H"#QFN=T+PK/\ $"QGG\(S16?AS3[2U_M*
MTV- L]U'&?,!P!EAW[&OL-;>)<8C08Z84<51U30H-1T>\T^,FRCND9&DM@%8
M9ZD<=:MO22BM[V\KW_#7]3-)Z7?]6L?/GB2*+7/ VAVUW)>6]GI^@?;#>VBE
MI(9&.P'\LY]J\UM/B'=^'[<Z;IGB*U\)1&?+ZUI437$%^RQYCCVN/E=B/FP.
M]?9NBZ!::%HUKID";K:WA$"^8,DJ/7UJG=^!]%O+RPN'L(!]B9FBB$2[ 6ZG
M&.M5-\U24ELW_P"W7_(45:"3W2_2WY]3XXUSXN^)?"FIZIJLYU#0[K519/=W
MEA9><QF$'RQ[2. QQD]LU+XN_:(^(3:IJ-G:7.I:5K>R*(:?]@#P00/L_P!+
M#XY?D_+TK[9DL;>48>")QP?F0'ITH:QMWD+F"(N1M+%!G'IFJYDY7DM.WEV_
M3TVUU-7*\N;T_"W^77OV//O@KJ6MS6&KZ;KNJ2ZW<Z=<B%=0F@$3S*5!R5''
M?M7I%-6-4SM4+GK@8S3JAN]K]E^7ZF45RJU^X4444B@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY=^(?C'7?!.K
M:E=^';J1+V\UQ+>ZC$/FXMN TOMM_K7U%6#I/@ZSTC5]4OHF>3^T'$DD,F"B
MMCDKQQFE;WD^W^:T^95URM?UU_*]SP#QMHUKIFL^,KN*.26SFCL;O4)9%9Q-
M$&!<X],?PBN0TOPEJ.HI?>+;&Y0>#?[5/]EVB[HA&C.GSHG P?>OL=K:)U96
MB0AAM(*CD>E8OB;P=9^)]/M[&9Y+:UAF28Q6^%#[3D*?;-72E[-KR:_._P"1
MG*[A*/>_Y'D7Q#B@U32O'M_>2W>GQJT-@E[;H25C&&)/?9GKBO';?XEZAHEN
M-/TK7[?PDJ22.+C3(6N;;5)53Y(UWC*EL<X]:^V7MHI(FC>-'C88964$'ZUC
M3>"-&FU.RO38P![166%!$NQ<]3C'6H2L_N_K_@;%O76W]?UU/C#P[\;/%_AU
MM'MA%J.F7MXPNX[*WLM\6H7+-\\+L1\@[Y%:UA\:?B!XV\7'0=.U[5=(:XG(
MOYY=-4C2Y%/^HCR/G!'<U]H&RMRR,8(BR'*G8./I0ME;H[,L$2LQR2$&2?6F
MMDNW_ _R$];M=?\ @_YG'_!OQ!J7B7P#8WFK2&:^WRQ22LFPOL<J&([9 KMZ
M:D:QKM10J^BC IU7-J4FTK"2LK!1114#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OGCXL>(=4\)7GC76M"F===@
MCMTM8Q'YGG$_\L\=LU]#U@P>$+2W\376M+)(9;F-8Y(&P8SCHV/6I:NT6FDF
MK=OS1X#J5I+K.N^'=<)FO-9OO#=T+BXVD#=M!9-O12#D>^*X&Q\,-XL%UK?A
METMO#6EV<2WEH5:$27(7!8# W$>]?:PMXEQB)!@$#"CBLCQ%X3M/$6B3Z6S-
M9V\Y'F&V 0L,\CIWK5R]ZZ7]7D_N]Y_-)F*B^6U]6K?E^.GYGD_B?R=7\YIG
MO(8],\/KNGME)=?,4#<OJ1BO$=.\?3^&;7^SM+\16_AJ%Y(UD\1Z=$]PLZX^
M59$<860G@XK[9M;""TM8[=(U\M(Q&,CJH& #63?^!]&U&6S>2P@"VLIF2-8E
M"ECW(QS4OXFUM_P6_P!?\R]XVZ_\!+\U?\CXQO/C%XH\.75QJ=U+J&DW>HQ1
M&6_LK'S3-(I(C0J1P'XR>V:T-._:#^(7B.\NK,76IZ3K,UJ1=6;Z>#%IG'R2
MHV/G+>AK[5:PMG4*UO$RC& 4'&.E*+*W#L_D1[V&"VP9-5=7U6G_  ";634=
M'K^+;_#]->QYM\"-9UW4-#U&UU_4Y=8N[*Y\I;V: 1-*NT')4<=Z]/IJ1I'G
M8JKGDX&*=2D^9W&E;8****D84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% #)IDMX7ED<)&BEF9C@ #J37R;=?M':YK/BSXGW
M6G7MNN@Z=X>%QHL:L"[N)2CRD?7I[5]7W=K%?6LUO,H>&5"CJ>ZD8(KQJS_9
M-\$Z;XMU?6;2"6WBU+2#I+V*L?+12Q)<>_3\J(VYFY*ZL_O_ *V[&T)1C9ON
MON316^!]O>^$?&E_X<DUK4M:L;K3+;5%?4YS-)%*X^<!CT4D\#M7H/C+XS>!
M?AWJ,=AXF\6:3H5[)%YR07]TL3LF<;@">F>]97PH^$=Q\/;F_OM4\0W/B;5+
ME([=;JYB6,Q01C"1@+QP._>M7XB^ ?#/B71]2OM8\/:7JMY%8S(D][9QRNJ[
M&. 6!(%7)WM_75V^Y67R.=+5_+\E?[W=_,Z?2-7LM?TRVU'3;J&^L+F,2P7,
M#ATD0]&4CJ*N5Y+^R<BQ_LY> 410B+IJJJJ,  ,V *]:J"@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!#G!QUKY*^)VH:_P""/&5YJ&D>*+_5O$K&234+!)BUE8V+?*N4Z+)S
MD&OK5AE2 <$CK7BND?L\ZCI^HZ_]H\9W5[I6MSR37=G+9Q[VW# 7S?O87L*A
MIWT[/_AOG_P.I6EM>Z_K^O7H5?@I'>>$/'E[X8?6-2UNTNM*AU7SM3G,KQR,
M<,%)Z+[5Z'XC^,?@?PAXAAT+6_%>DZ5K,P4QV-W=+'*VXX7"D]STK+^%?PDG
M^'US>WNI^(+GQ+J4T:6\5U<Q+&8;=?NQ@+UQZUP_[8O@[0;SX2:QK-QHFGW&
MKQR6HCOY;9&G0"=,8<C(Q]:WFT[6_K73[E9?(PIQE&_-_6B_-W9[Z"& (.0:
M6J]AS8V__7-?Y"K%9FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 C9P<=>U?(_P 2K[Q)X*\:
M7E]I'BJ]U;Q&YEDU&R24M9V%D1B/*=%<''/>OKAAN4C.,CK7B>C_ +.VH:;>
M>($N/&EU?:3K<TLUU9RV<8=@XX7S?O87M2^U?R?_  Q:=HM?UZ_+\_0H? AK
M_P ,^.=0\-RZQJ&LV<^DV^J^9J4QF=)I/OA6/1?0=J[YOCY\.5\1'03XUT1=
M9$_V8V)O$$OF]-FW.=WM53X4?!^3X=W5[?:CKUQXDU*>)+6.ZN8EC,5NGW(@
M%ZX]>IKS_P#:E^'WA?3_  A9:M;>'-*@U5]=L9&OH[.-9BQG7+;P,Y]\UO5E
M&3]W^OZV,X_Y?DKOYN[/HFBD'2EK$84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %97BO
M_D5]7_Z\YO\ T!JU:RO%?_(KZO\ ]><W_H#4 >>?LH_\FZ^ _P#L'+_Z$U>L
M5Y/^RC_R;KX#_P"P<O\ Z$U>L4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C'[7O_
M "0G7/\ KK;?^CTKV>O&/VO?^2$ZY_UUMO\ T>E 'K^G_P#'C;_]<U_D*L57
MT_\ X\;?_KFO\A5B@ HHHH **** "BBB@ HHJ.>>.UA>:9UCB0%F=C@ >II-
MVU8TKZ(DHKF=!^)/AWQ+J,ECI^IQ3W*?P XW?3UKIJSI5J=:/-2DI+R=S6K1
MJT)<E6+B_-6"BBBM3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "O%?VL?\ DG&G_P#8:L/_ $>M>U5XK^UC_P DXT__ +#5A_Z/
M6@#VD=*6D'2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "LKQ7_P BOJ__ %YS?^@-
M6K65XK_Y%?5_^O.;_P! :@#SS]E'_DW7P'_V#E_]":O6*\G_ &4?^3=? ?\
MV#E_]":O6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQC]KW_ )(3KG_76V_]'I7L
M]>,?M>_\D)US_KK;?^CTH ]?T_\ X\;?_KFO\A5BJ^G_ /'C;_\ 7-?Y"K%
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M5BJ^G_\ 'C;_ /7-?Y"K% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O%?VL?^2<:?\
M]AJP_P#1ZU[57BO[6/\ R3C3_P#L-6'_ */6@#VD=*6D'2EH **** "BBB@
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M+2"EK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "LKQ7_R*^K_]><W_ * U:M97BO\
MY%?5_P#KSF_] :@#SS]E'_DW7P'_ -@Y?_0FKUBO)_V4?^3=? ?_ &#E_P#0
MFKUB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\8_:]_Y(3KG_ %UMO_1Z5[/7C'[7
MO_)"=<_ZZVW_ */2@#U_3_\ CQM_^N:_R%6*KZ?_ ,>-O_US7^0JQ0 4444
M%%%% !1110 4444 ,2&.-B515)ZD#%/HHHV#<**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ7]K'_DG&G_ /8:L/\ T>M>
MU5XK^UC_ ,DXT_\ [#5A_P"CUH ]I'2EI!TI: "BBB@ HHHH **** "BBB@
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MWD>Y4445[IX04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !65XK_ .17U?\ Z\YO_0&K5K*\5_\ (KZO_P!><W_H#4 >>?LH
M_P#)NO@/_L'+_P"A-7K%>3_LH_\ )NO@/_L'+_Z$U>L4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBX\-ZQ;:O#;R>5*UNV=C>AJ]XK_Y%?5_^O.;_P! :O&_@W)IDOQ1OVT$VC6
MT&Q%T;+;Y?F[>,[>-W7/>MKXV_%+Q-X.^U:9H_PTUOQA9SZ=+))J.G3PI'$V
MUAL(<@YQSQ525OZ[-K\;77D8IZM>GXI/];$_[*/_ ";KX#_[!R_^A-7K%>3?
MLGDM^SEX 8J5+:8C%3U4DL2/PZ5ZS4C"BBB@ HHHH ***0]* #-?)O[2^AW]
MO\0/[0>&62SN;=%BE5"1D=5XKFO&/[/O[6>J>+M:O-#^.]AIFC7%Y++963V6
MXP0ELHA.WL.*\N^.'P]_:Q^#/PK\0^-M;^.EEJNFZ+!]IELX; "209 PI*X!
MYKP,[RI9QA/JSERNZ:>^J\CWLES1Y1BOK"CS*S36V_F?67[*VB7UCHFJ7UPC
MPVMS*!$C@KNQU;!KW>OSX\'?!#]KWQ;X1T77++X_Z?;6FI6<5W% UAS&KJ&"
MG"XR :]O_9N^$GQ^\">-[R_^*/Q3M/&V@O9F*&P@MO+*3;@0^<#MD?C77EF!
M66X2GA8RORK?OU.7,\:\QQ<\5)6YNGX'TQ1117J'EA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !67)XHTB+4+FQ;4;<7EM%Y\T/F M''_
M 'F'85J5\L>-?".F^&_B3\5+K1+3[/J&IZ%%<7CB1F,K;\$X)X^7TK.<N7[G
M^";_ $-(1YOO7XR2_4^A/!OQ$\-_$*WN9_#FL6VKQ6TGE2M;MG8WH:\[_:]_
MY(3KG_76V_\ 1Z5E_!U]/E^*<[>'S:MI \/6PF-CM\OSL\;MO&['XUS?[9GC
M[7;/PCJ'AR'P+JM[HT[6C2>)(I8Q:P$SKD,I.XXQV'>NB4>6W];-K]+G-3GS
MZ_ULG^I]+Z?_ ,>-O_US7^0JQ4%B,64 SG]VO/X"IZS-0HHHH **** "BJ^H
M7]OI5E/>74JPVT"&221NBJ.2:\N'[57PL89'BZS89QD;B/Y4 >LT5Y/_ ,-4
M_"W_ *&VS_)O\*!^U1\+B<?\);9_DW^% 'B?[)G_ "=Q^TM_V$++_P!%FOL2
MO@/]F?XV^"?#G[3W[0>K:AK]O;:?J=]:/9SMG$P5""5X[&OJ3_AJGX6_]#;9
M_DW^% 'K%%>3_P##5/PM_P"AML_R;_"MOP=\=/ WC[6/[*T'Q!;:AJ&POY$>
M=VT=3R* .]HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*
ME\5:/#J$]@^HVZWD$)GE@\P;HXQU9AV%:M?*OC[PCI?AKXD?$>XT>T^SW>I>
M'S/>L)&9I3N&3@GCCTJ;^];R?X)L4GRQOYK\6D?0_@WXB>&_B%;W,_AS6+;5
MXK:0Q2M;MG8P[&O./VL?^2<:?_V&K#_T>M8OP0>QD^*5VVAFV;3!X<LA(;/'
ME^;WSMXW>N>:X[]H_P"*?B?68+?0+OX9ZWI>DQ^(+.)?$$\\)MF43+A]H.[!
M^E;U(<CL$7?\/Q2?X7LSZT'2EI*6LAA1110 4444 %%%% %35;J&ST^XEGE2
M&-4.7<X XKY6_P"">FC7VC>&_B6M]:R6K7'BV[N(1(,;XV/RN/8UWG[5=_>0
M:%IEO&SQV<LW[QE.,GL#7GO[-NIWEO\ $:.VAED-O/"WG1@Y4XZ$U\3BN(WA
M\WAEOL[IV3?6[VLNW<^UPW#JQ&43S'VEFKM+I9;W\SZZHHHK[8^*"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&4.I!&0>"*X[1/
M@YX)\-ZG)J.E^&-.L;V3S-\T,."V_P"_GZ]Z[*B@#G_"'@'P[X!M9[?P[H]I
MH\$\AEE2UCVAV/<U;\5<>&-7_P"O.;_T UJUE>*_^17U?_KSF_\ 0&HW \\_
M91_Y-U\!_P#8.7_T)J]8KR?]E'_DW7P'_P!@Y?\ T)J]8H **** "BBB@ HH
MHH *^=?^"A7_ "9S\3?^P;_[.M?15?.O_!0K_DSGXF_]@W_V=: /3O@+_P D
M3\!_]@.S_P#1*UWE<'\!?^2)^ _^P'9_^B5KO* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K-D\.:7+J%Q?/8P->7$7D2S%!N>
M/^Z3W%:5% &!X2\!>'? =O<0>'M'M-(BN)/-E2UCVAV]37F_[7G_ "0G7/\
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MI8ETFXW_ &6,)O\ KBOI"O"/%G_)V/@W_L$W% 'NPZ4M(.E+0 4444 %%%%
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M )+E^T[_ -C<G_HHU]A'I7Q[^Q#_ ,ER_:=_[&Y/_11KU3RC[#HHHH ****
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MH6OGK]C_ /X]?B/_ -C5=_SKZ%H **** "BBB@ HHHH **** "BBB@ HHHH
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M-:-"B6,K0G=.N,R@;%Z'J:UE%P=F1&2EL?3&G_\ 'C;_ /7-?Y"K%06(VV4
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MD_\ 11K["/2OCW]B'_DN7[3O_8W)_P"BC7:<1]AT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>,?M>_\D)US_KK;?^CTKV>O&/VO
M?^2$ZY_UUMO_ $>E 'K^G_\ 'C;_ /7-?Y"K%5]/_P"/&W_ZYK_(58H ****
M "BBB@#C/C-_R2?Q;_V#+C_T6:Y[]EG_ )-W\ ?]@J+^M=#\9O\ DD_BW_L&
M7'_HLUSW[+/_ ";OX _[!47]: /5**** "BBB@ KPCQ9_P G8^#?^P3<5[O7
MA'BS_D['P;_V";B@#W8=*6D'2EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\5_:Q_Y)QI__8:L/_1ZU[57BO[6/_).-/\ ^PU8?^CU
MH ]I'2EI!TI: "BBB@ KS']IF[FL?@1XUGMY##,FFRE77J.*].KRO]J/_D@'
MC?\ [!LO\J -SX(1+!\(?!Z(,#^S(#^)0$UW%<5\%?\ DDG@_P#[!=O_ .@"
MNUH **** "FR?ZMOI3J;)_JV^E 'SY^Q_P#\>OQ'_P"QJN_YU]"U\]?L?_\
M'K\1_P#L:KO^=?0M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5E>*_^17U?_KSF_\ 0&K5K*\5_P#(KZO_ -><W_H#4 >>?LH_
M\FZ^ _\ L'+_ .A-7K%>3_LH_P#)NO@/_L'+_P"A-7K% !1110 4AZ4M(>E
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M6K65XK_Y%?5_^O.;_P! :@#SS]E'_DW7P'_V#E_]":O6*\G_ &4?^3=? ?\
MV#E_]":O6* "BBB@ I#TI:0]* /CKX0_\I(_C7_V+>F_SK[&KXY^$/\ RDC^
M-?\ V+>F_P Z^QJ "BBB@ HHHH 0]*^/?V(?^2Y?M._]C<G_ **-?81Z5\>_
ML0_\ER_:=_[&Y/\ T4: /L.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+27RTW(KMQ][/0$\T ?1%%1V]Q'=V\<\+B2*10Z,IR"",@U)0 4444 %%%%
M!1110 4444 %%%% !1110 5XK^UC_P DXT__ +#5A_Z/6O:J\5_:Q_Y)QI__
M &&K#_T>M 'M(Z4M(.E+0 4444 %>5_M1_\ ) /&_P#V#9?Y5ZI7E?[4?_)
M/&__ &#9?Y4 ;_P5_P"22>#_ /L%V_\ Z *[6N*^"O\ R23P?_V"[?\ ] %=
MK0 4444 %-D_U;?2G4V3_5M]* /GS]C_ /X]?B/_ -C5=_SKZ%KYZ_8__P"/
M7XC_ /8U7?\ .OH6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8BX.A:U8:P+<A938W"3>63T#;2<5M9H$+129HS0 M%)FC- "T4F:6@ HHHH
M***R_$_B"W\*Z!?:M=9,%I$TC =3@=!]:4FHIMC2<G9&I7C'[7O_ "0G7/\
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MKC_L9+C_ !H_X8G\$?\ 0?\ &O\ X4EQ_C7T#10%SY^_X8G\$?\ 0?\ &O\
MX4EQ_C1_PQ/X(_Z#_C7_ ,*2X_QKZ!HH"Y\_?\,3^"/^@_XU_P#"DN/\:/\
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MD7_!.[X101K'$GB*.-!A476Y@%'H.:=_P[S^$W_4R?\ @[F_QKZ9HH ^9O\
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MX['6X]/(*FT76)A$0>HVYJC!_P $O_@%:RI+!X?U&&5#E'CU.4%3['-?6-%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\>V-5B8$_/G+$#C'O7F&A_LK7O@ _%BYT"\M]2/BEIO[&TV_G>&WTI;A0;D
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M72KFWTO6_"-KX:\0:@9KC3K35-<B$,MG&J'SY)8T;RR6<((]I.?;FHO!O[5
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,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>hook-20231231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '+ @\# 2(  A$! Q$!_\0
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BDW 4 YH 6BBB@ HHHH ****
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MZ$MV#<7*;2)4<6D:[/N_.Y')&/KV75M7O? \>I:99V\FM36*3PVEY*8HO-9
MVUF )49.,X-<MXA_9O\ AWXH.AB_\.0M%HUM'8VL$$LD,1MD8,D$B(P$L:L
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M_?DRWIBM[X/?"#P_\%/ UGX:\.6H@M81NFE8[I+F; #2NW=CC\!@#I4GQ?\
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M7(7_ 'B:]&+JUZ,ZM)6IKXTNZVU\_P -=#MBZE6G*I35J?VDN_37S/H;X1>
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M2-?W,? :)W0_\!8U]DFOE']A&87.H?&N4&_.[QG)SJ=DMG<?\>T7WHE "^V
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M18Z4M(.E&10 M%)N'K2;QGK0 ZBDW"EH **** "BBB@ HHHH **** "BBB@
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MY[1_]]"F27D.#B5"?9J\K_X9-^%7_0K'_P &5W_\=I#^R=\*P>/"W_E2N_\
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M[/Q7J8M[>YN%F9E:8LWS*3DAL@L?O$DC.:^B* "BBB@ HHHH **** "BBB@
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M5'0# KZ&DJW/-U&N7I;L?1T5B%4J>U:Y;^[;=::W^8ZBBBNHZPHHHH ****
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M(I)_$XQ7S=^P-^T9=_'/PUXKMM:F+:WI^J2W2JYY-K.Q>,#V0[D_ 5]%^/?
MVD_$?PQ?>'M=M3>Z3?($N+<2,GF*"#@D<XX%><_ K]E/P1^S_J-]?^&X+EM1
MO/-22ZN)B3Y+.'6+:.-JD#!QGWKFG&JZL7%^ZMSV\/6P,<!7I54_;2<>5I:*
MV_\ P?D>T44@I:Z3Q HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!<Y\F:.7'78P./RH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KY:_X*9ZKJND_L9^/9-)9TDD2WAN'C)!$#3().1V(.#]:^I:Q_%_A'
M2?'GAG4_#^NV4>HZ1J5N]M=6LPRLD;#!!_Q[$ T ?.6D_"CX+7/[%NA:;XDL
MM)M?A\V@6<]U?D)$5)1&,WF@9#E^^<\XKW7X06GA^P^&7AFV\*7KZCX9AL(8
M]-NGF,QDMPN(SO/+<8YKY8@_X)@>%RD&A7?Q%\:7WP]@N//C\(37O^B\'(0M
M_=![8_6OLO1](L] TNTTW3K:.SL+2%(+>WB&U(HU 554=@  * +E%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTLIVM422Y$;&))&VJSX^4$]AG'->1?VW\<B.?"G@[_P>3_\ R/7LE% 'C?\
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M%MH=R3C+$_C7TG7SW^S%_P E,_:!_P"QU/\ Z1P5]"4 %%%% !1110 4444
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MS#\%[VU\.^)-37X5PGQ59OX1TV]O+'^TR8Y-2>9QN:61B$E:+<S#C.T<5J_
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M[]: /G)/V:/$^JQ7VJ:UXIT[_A*X8M.@TB[TW33#;VXLIC+$\L9;+EF)# $
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M90>&4DE%)\SOKY>1Z&,J4*DHN@G9)7N[Z^7D+1117FG %%%% !1110 4444
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MPK[%7R;2T/(CAC0\G@*H'^%?+/@[PQ-X5_:/T3X<,$7PSX>M[WQ-HBEQD1W
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MMW'AW2/D\[4;6Y^SR1?,,8?!QDX'XUV-17%M#=Q&*>))HSU210P/X&@#X_\
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M/<&4>IKU[Q%^U_\ #SPW\;M \337-[;6VK>''L[NVDM'66(B99;9F7'(8-(
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M116-XQ\3VG@OPMJVO7Y866F6DMY-L&6*1J6( ]>,"@#9KP+X<_\ )X_QD_[
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M6$>CW$T%S X8$F,A<>^2.*^!/AGJ@\;>#YHKY[>ST986N+F;4.+>V01"%9Y
M?O%(UVPQ]W9FZ5S7[2OPZ^-W@B!(?$RQKI7B"<O-8^&BWV.2XR%!>->%9RP&
M!PQ[9KW/X%_LY^,=$\!:>^L?#+3?%OVZ!9_*UG6_)2/< 1F )PP&!ELD=!BG
M3I87*\%[55%-S>EMTEOO8N$:&7X7VG/S.3TMTM]QN?L@?%;PS\,O!&CZ3:ZC
M#=>#-1G.S4&VI=:==LV#%=J.BM@%9.G.#7 _#SX$>-_V=OCGJGCB\M[&_-[-
M=66A6\,V]K^YNR3$$'94'+D] #7KVK? G6=4T"ZTA?@+X5T^VN,[Y+'Q!Y,@
MR,'Y@N>G8Y'M7B/P[^$WQ[M/BWJEO8?:A)X<A6.UAU'5HI_L$4Z_NPCL""Q1
M"-P&<>F:RHXRC/ZQ4A/EYU[RE]I=$FNO=]C"GBJ4_;3A+EYEKS=?2W7OY'W=
M\,?!MM\.?#UIIUW?1W6O:G*]U?7LC8>]NV&Z1@.X X [*!7FGQ[\+>)OA1H7
MB#Q[\*W2#4UC^T:GH31>9;WH!^:5$'W90.I'WAUYKPCQO^SM^T;XM\9:%KT>
MI"W326#I'/KZE]YXD*%8P$W+\O0U=^,VB_M >$OA?XDOTO+K3]*MK.22Z>36
M8;N18?XMN(U;.#U%>52A35:G/VT6Y;II\N_4\^G&"J0DJJ;ENFG;Y^1Z=\.I
MO$T7AF'P3H]PDGQ#U@G5?%OB +F/3'G^8K_M3!2J(G8+D\"KWA+X!:M^R_!=
MZQX%U#4?%%A<2FXUC0K]E,EP/XIH&'24<G!^]TZTGPCM/B_\.O ^FZ7;?#?0
M[BXV"6[O9-? EO)V +S2$J268\\GCI79GQG\:SG/PUT,=\_\) /_ (BN6KC)
MPJ3A3MR-Z_WO^!VML85<2XSE"'PO?S_X'8]#\%^/]$\>:3;ZCI%\EQ#,A?RR
M=LD>#AE93RI!X(/0U6\:?%/PO\/=/BO-?UBUT^![B.V5I)!G>[;1Q]>I[5\/
M>(_AS\6->_:QDN5T*PTEM1T1M2NM$TK6VMX[B!)$A8M,H_UAD9&.!R%KJ?'_
M .ROXA^(EM917GPMM+3[*S-YMMXM+23,<<NSHV<8XH]A@HSBYU'RM7=E=KRW
M0W2PT91<JCLU?17:\CWKQE^U9X+\-Z1J.H6/V_Q"ME$7E.EVCRQJ!ZOC:.<=
MZY/X+_M8:O\ $WP5;ZLOP[U^[N4=H+QM/C4QK*.2!N(.,%>U;&F:I\7/#OAN
M'3%^&.@R6-K;K&1)KJ'>J*.6 CP3QZ5D?"CXQ_$[XD> =%\6^'OA9H=KI>LV
MXNX(WUI8G"DD#<HCX/%9RJX6--PA2N[[N73T21DZE!0<53N[Z-M_\ L_#']L
M_P ,>/\ XG^(/"%]%)X;GLG2*T_M(A&N)!D3(>P*MT&>:]/\?_![PI\4==\-
M:OKNGPZA/H,[W%J)%#(^]=I5@?O+T;'J!7E>I^&_'.L0W*7?P.\'2BX#"5O[
M6C#-GJ=PCSGWSFO%/$'Q*^.WP)^(?AKPW8>&'O=%U&5FL]+DNS?C[C[H1<!0
M=J@>9@@D!>N*Z*<85ZJ>#?LY)=7OIK9]+G1",*U1?5?<:75^6NI]Y6>C:?IU
M@;6UL;:VM2NTP0PJJ$8Z%0,5=C"JH"@ #C %?)_Q0^(?[2FC>#[UK#P/H<EQ
M<+]FB?2+UKFXA9@1Y@3: 0O7GVKTSX%>/?B?XPL--D\8^"+?PY:&V(FN'OMU
MR9EPO,.WY0Q!/7CBN&>'E"FJSDFF[;W?W''.A*-/VK::;MOJ>S4445RG,%%%
M% !1110 4444 %%%% !1110 5S_C_P *1>.O!6N^'9Y6@BU6QFLFF09,>]"N
MX#VSG\*Z"B@#Q'P7\#M6U6[UJ[^)EYINO37NEVFB);Z6)88OLT#M)O9LAM[R
M-N('   R:O)^R?\ "B&\FN(_"$"W,JJDLRW=P'=1]T,WF9(&3C/3->P5Y=\;
M_BE?_#FTT&TT73H]3\1>(M4CTC3;>>3RX1*RLQ>1NRJJD^IJ9245=FU&C.O4
M5.FKME;_ (9=^%X)'_"+KC_K^N?_ (Y1_P ,N_# ]/"ZCW^W7/\ \<KSV\_:
M%\:>'?!WC:2]TK1=?U[07MQ$^A79EA=))-DCR1X\Q/*/+#'/:NP^ 7QFO/B/
MI6KS:U=:%,+&X2&*_P!)NCY4X9<X9'PT; \88<]16<:T).R.VIEN(I4I5I6Y
M4[:-/L_U1=A_91^%=L7,/A.*/S#N?9>7"[CZG$G-3?\ #+?PP[>&%_\  ZY_
M^.5YCX0_:=\1?$GXAZ]X?\.)X>C1)=0LM-M[ZZ=;DRVQVK*ZXP4=@?E4E@,&
MCP_\6?C+K?A;QEJCQ>#;>+0+UK47[S3"UE6%6-TP.,D(<*#W(;TJ%7@]E_2-
M993B8Z5;)JV[MN['I@_9<^&!_P"977_P.N?_ (Y3U_9:^%Y&?^$77_P.N?\
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MK1[&&PT^RC$5O!$N!&H["M>BA1BG=(N>(K58J$YMI=V%%%%4<X4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$9I:* .%\4
M? [P+XT\0#6]:\-65_J>$#SR*1YH7[HD .'QVW U-K/P=\'^(+N^NK[0[>:Y
MO;B&[GE!9&::)/+CD!!&&"?)D=5X-=I10!Y]?? 'X?ZCI%II<_A>R:PM8Y8(
MH%#*HCD8L\9P>5+$G:<C-3Z1\)M,TOXD2>,=_F7L>DIHEC$(PJVEJK[R@/4Y
M8+R>PQ7=44 <]K?@#P_XDU>UU34]*M[S4+6UN+*&XE7+)#. )D'LP !K(U#X
M)^"=4TC2=,N/#]JUCI5O]DLXDW)Y4& /*!4@E#@94\&NXHH XVY^$'@^ZU^U
MUJ30;7^T+8Q&.1057,0Q$2@.UB@^Z2#C ]*MZ+\-?#?AV\TZZTW28+.XT^&:
MWMI(@04CED\R1?<%SNP>]=/10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>hook-20231231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !" 8D# 2(  A$! Q$!_\0
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MMHK&X,$IAF$2HWER  E&QT8 C@\\BBRL]&U*UCN;2&QNK:092:!4=&'L1P:
M.7_X7Y\,?^BC>$O_  >6O_QRC_A?GPQ_Z*-X2_\ !Y:__'*Z_P#L73_^?&V_
M[]+_ (4?V+I__/C;?]^E_P * .0_X7Y\,?\ HHWA+_P>6O\ \<H_X7Y\,?\
MHHWA+_P>6O\ \<KK_P"Q=/\ ^?&V_P"_2_X4?V+I_P#SXVW_ 'Z7_"@#D/\
MA?GPQ_Z*-X2_\'EK_P#'*/\ A?GPQ_Z*-X2_\'EK_P#'*Z_^Q=/_ .?&V_[]
M+_A1_8NG_P#/C;?]^E_PH Y#_A?GPQ_Z*-X2_P#!Y:__ !RC_A?GPQ_Z*-X2
M_P#!Y:__ !RNO_L73_\ GQMO^_2_X4?V+I__ #XVW_?I?\* .0_X7Y\,?^BC
M>$O_  >6O_QRC_A?GPQ_Z*-X2_\ !Y:__'*Z_P#L73_^?&V_[]+_ (5CZ]J_
MA#PJT"ZW?:+H[3@F(7\T,!DQC.W>1G&1G'J* ,C_ (7Y\,?^BC>$O_!Y:_\
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MRNX#E<CD9ZB@#E_^%^?#'_HHWA+_ ,'EK_\ '*/^%^?#'_HHWA+_ ,'EK_\
M'*Z)6\.OIT>H*VF-82%52Z!C,3%F"* W0Y8A1SR2!6?9>(?!6I:L^EV>J:#=
M:FC,C64%Q"\RLOW@4!SD8.>.,4 9O_"_/AC_ -%&\)?^#RU_^.4?\+\^&/\
MT4;PE_X/+7_XY70A_#AT;^UP^F'2O*\_[<&C\CR\9W^9]W;CG.<5>&C:<0"+
M*V(/?RE_PH Y#_A?GPQ_Z*-X2_\ !Y:__'*/^%^?#'_HHWA+_P 'EK_\<KK_
M .Q=/_Y\;;_OTO\ A1_8NG_\^-M_WZ7_  H Y#_A?GPQ_P"BC>$O_!Y:_P#Q
MRC_A?GPQ_P"BC>$O_!Y:_P#QRNO_ +%T_P#Y\;;_ +]+_A1_8NG_ //C;?\
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MA#[5Y?E>=_PC5SOV9SMS]NSC/.*@@\(>.[74[G4H=9\&1:A<J%FND\+W EE
M  #-]NR< #KZ"@#YN\.>.]0\*^"_AA\0/%*2Z7KOPVU:7P'XV6YE5WBL;@11
MI-,Z':WS?V9<%AD89R.,U['\"KK6](\-VOB"[\*:MJ6I_$'4G\0ZC=126Z+I
ML4Y1+6*822J_[FT2W0A%;F-L#)Q767/@SQQ>Q7L5QJ_@J>*^(-TDGA:=A.0
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MPI_X3ES_ /)] '=45PO]E_$O_H9_"G_A.7/_ ,GT?V7\2_\ H9_"G_A.7/\
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M:W_X6C%^QM9?V" WC_\ X1R0I_:(E6Y'^CR>5M!)<7'^JP)"3NSN.<U] ")
M,;%QZ8I] 'CGQ8_X3=O@%=_;1MUXW%F-4'A?SC+_ &=]MB^V_9_^6GF_8_.Q
MM^;=]WG%>&Z]=>#WG\4:3X%TZ'2_!USIMO->ZUX.%Q=V\)2_L\#4;15C0EU>
M?S=DAF,"3[NQ'VK31&J@@* #UP* /F?X&:]J6E6'BC3_  /X3T+4[*.[A"7_
M (:O7M=#=FB(+6T$BLL;KM4R1Q,RY=3O+%@/+/A$=,LOA]XDN_%7AG2/&TL7
M@R/5_$.FMID_F?VO"=PM=06=W2>]>0N!)M1AY9^4(8\?=BJ$&%  ]!2!%&?E
M'/7CK0!\HZ[^R]X)L/#7PR^'-WX0T&_U35+N275]732H@\,$:M=7GV<[#Y*R
M3&.%54KL28[2"BU3^%=MJ%G^TFMI8P64EW#K.NOKFIQ2W']H7%BSRFUBO(GC
M"1QQLULL&)'#HNZ,1C>M?7>!G/>@* 20 ">IH ^<OB#\8O&GA3Q%XOT-3+"O
MAZVN]?;58M+6Y$FGR0JEE$$+HI<7$EQD[U^6PRY D)/G_A?]H[Q;KAO;'5?&
M(\-:!;:C>1Q^,9=-@NS,4L[.6WMB8T$#>8\]V0Z+\PMO+4[SN/V:5!SD YXI
M/+3&-BX],4 ?'GBKXV^)]1T/6#?ZLDFKO<M;GP1<^& 1!:J\9AO)1(6>(2##
M9=G7=,L8&Y2PU[GXQ?$'POHCZYJVNO=VFI:=KDT<$&B1.=.>UU*WMK9T^=-P
M,<[,YE?:-N_Y55@?JPHI).T9/?%!12,8&/I0!\!S_&CQCXM_X2/4K_7YKJQT
M;1?%NG6=K=6MK-:ZS(FF:;=VZRJL0BF)\ZYQL #+;L!D&3=Z%XQ^/?Q TM/$
M<NDZQ'<Z_"^OPW'AEM)'_$BM[6*Y:QO6;&YQ(T-J/G8K)]KR@ 0U]=>6@'W5
M_*C8N2=HR>IQUH \]^%&I^(SK'C;0_$6JG77T;4X8;34'M$MWDBDLX)BK*@"
MG:\D@! Z8!R02?1*3 'XTM !1110!Y%\2H?&#>,;<Z3]M-IM3[/]F)\L-_%O
MQP.?[W:O68!((8Q*09=HWE>F<<XJ2BNVOB?;4Z=/E2Y5:ZZ^IUUL1[6G"GRI
M<O;KZGQ7X6U/2=%_X5W<MH::K\8WU>U@\4--<W,&O1W$EQ&ETRA8F\RR57F?
M#LL'E(NT_=(E^#-_%X9\<:!_PCNE6OB_Q!=V]T+V54FTK7K9A&SD:ZK-)'*V
M]5C$A*_O'4QH4)(^S=B[MVT;O7'- 1020H!/4XKB.0^6/$FM>%=>^/6E0A++
M0OB'87=I?:K=76J*;Q/W \O2;$$@R+,-AD  B_>,?FD8[/'_ (8ZMX6\)>&=
M1;QNMMKFBW>D:.]W8V8DM8KC5O-N/]$U4SL$FO&W!II'\M2L.7B0*H;]!S&A
M;=M7=ZXYI#$A!!1<'GI0!\ ^.M+N-&\):8FBZGHOB[6+OP_<CPO)%?7+II&H
MM?W4BIH[QQ.L[Q&>WML,8F6*VC8G89%'U;\<V^)BIX<_X5\NF-'_ &I:_;OM
MAE$GE^<N[.SCRMN=_?'2O4A&@QA1QTXZ4Z@#Q'X]H9#\/!XP3=X%-])_PDZV
MRRM:E_LK^0+@+R;7SOO;_ESY6_C->&S7.AZOH+V!L-&\/^"[3Q"\EI)<PW&J
M>#KLFR ,3JWD"*/=DH4W0K,K'EB ?M\@,,$9'H:3RUV[=HV^F.* /D^]\3^,
M;G]E_4K7POX1FL=-\B[0:C;:G<2A(%O)!(UK&46X:%H06BVX*HZA,A5)YVT\
M%>&_&/PSUKPW#X;\*^((;SQ5!H^@:U9:.?[.MUN;>W-Y<64%PTPA:*-)B?+8
MQO-'DX8N!]I@ #&./2D"*H    ]!0!\U:]\ /!M[\6;#3M"\)Z9H1\'^'(M0
MCUBRT]#?/=.DMIIX67&]Q!':SMM+<M]G.?EK,_8Z^V3:[K8T^ST[3?#R:!IL
M5PVC37$T$^I[[@RSR&>*/;=LA0S1[693Y8=W/W?JG'.>]"J%Z #Z4 ?)VN?'
MGQU8^'YI-2O)]!.F7MMX7OKZ'3X%$VIH+B2ZN%DN"(H('CCMC'(P=29R@0L5
M(J>!/VB?&/B:TT*[U;6CHMT;>V^Q:5'HPFD\23&_N;:=1G:48)#'D1E/*,AD
M<&/"U]=E%8$%00>>11L7CY1QTXZ4 ?&\_P </%5SX8T758_$,/B371;S:A=6
M;^'5C_L"^&B:K,UNKD95UDBC3RW!E"A@SE90*WO&GQ=\;_#R"ZTK6/%4TTLM
MSIKQZS%I=I!Y0N+6YDDAWRD0Q*)+9=KNLC'?Y>&9@Z_57EJ,_*.>O%!16ZJ#
M]10!\->"_BUXYUO7[7Q%?S/K&L:C8:/<6OAVZLD6,N@U2.22%&3?&YDA0,00
M09\<#8!V'AWXP>/?%&J^'='T;QJFKPZO+IPU'6$T)(SI,\L5T]Q:*I7;N A0
MA) SQ$#S"P<"OK78H.=HR/:@(J]% [\"@#BO@UKVL>(O 4,^OS+=:M;7^H:=
M-=) (?M MKV>V64H.%+K"KD#C+'&!BNWI  .G%+0!YM\!O\ D6/$/_8UZ]_Z
M<[BO2:\V^ W_ "+'B'_L:]>_].=Q7I- 'E7Q]_YIS_V.>F_^U*]5KSCXW^&=
M=\1:5X9G\/6,.IWVCZ_9ZJUI/<BW$L<6_< Y! /S#M3?^$V^(W_1-+?_ ,**
M+_XU0!\<?\%/-7^,6F^._!2_#.Y\:P6+:;,;P>%FNQ&9/-&WS/(XW8Z9YQ7T
MO^PO=>++W]ECP3-XXDUB7Q0WV[[8^O&4WIQ?7 C\SS?G_P!7LQG^';CC%=A_
MPFOQ&/\ S32W_P#"AB_^-4?\)M\1O^B:6_\ X447_P :KZO%Y['%9/1RI4(Q
M=-WYU\3^+1Z?WN_1&$:7+4<[[GDOQM\3WGPS_:%N/B#!!=ZA:Z)X9L+&[T^W
M)/GPWEQJ"(JKTWF[BL!N[*6KSGPAX\\5_!G1?$WAZ7Q5;:--83ZK>V][J%@U
MV?$.KJZ[K2/+#EF^;RH_WC^>-F AKZ@/C7XBGK\-+?\ \*&+_P"-4A\:?$4]
M?AG;_P#A0Q?_ !JOE#<^=/B1\:?%GB3P;X@M[_4;>R\3C4_);X?1VA6XL8H=
M2A6VGDNE)*),BHWF.I1O/"H,H:]NT7XC^*-5^ EYXHC*S^,-)EDFU?25M0IA
MDMY]UWIZ)DG=Y2O''(2=VZ.3)#"MW_A-/B+G/_"L[?/_ &,,7_QJE_X37XC?
M]$TM_P#PH8O_ (U0!\[_ !9_:Q\6^$_#$6OV%]':M>Z9=>(](TV6Q@5;RR\Z
M06B,TLJRR%H(ED=((R\?G9=E 7/2:K^T!XHM%UN0>*;&#58M1EM+[0/[$>5_
M#MD-5BMA?3.&R%%J[S9E&R3[Z8C1@?8SXT^(IZ_#.V/_ ',,7_QJC_A-/B+S
M_P 6SM^>O_%0Q?\ QJ@#Q:W^+OBG6?&-EIWA[Q/IVJ#4)M,L%\61:*J_:;>2
MYU0,Z G;( MN@5U/EEMS*,-BN;\9?M7>,O"4EA:2ZI#)JEA.T%Q!]@MX(]26
M/6+JRDE DF\UOW-NK,+>/$18LSX8*OT;_P )I\11_P TSM__  H8O_C5!\:?
M$4_\TSMO_"AB_P#C5 'S;X6^+7BGPK;V%G/XGMKB9;J_M-:\4:C9)/-HL8UF
M6-C+C&U0OE_ZSY4\Y'(V**Z"[^.7Q)O/"_BO6-.UVQ:Q\,:%J.M6MZ-*!37X
M[:YE6&09;Y(Y(XL%D^\<.A"D ^Y?\)I\1>?^+9VW/_4PQ?\ QJE_X33XBXQ_
MPK.WQT_Y&&+_ .-4 4?B=)KFI_$OP]HNC7<=G=CPYK>J:<\XW0C4HS9P6[R+
M_$J+=S94\'?GJH(\-\:?M1_$"?3-$\0:7:0>&?"FN3W4<-YJODP-9R6T-NK6
M\CSX0/)<O>J >66S 3EZ]PU+5_&^K7^EWMU\+;>2[TR9KBTE'B1%:)VC:-ND
M8R"KL"IR.AQD B^?&GQ%(Q_PK.WQ_P!C#%_\:H ^>+3XF?$#2]"\2^+[J:S@
M35]<L+74?#<VG.T:R3^&[&20AI<2*%EVX1E' <,"6^6'QM\9->U?X5^-=-O/
M$=II%Y_PC-Y!;^$+;2&^T2VAT(S+>)(K!HT\YCB7'E +Y6/,.:^CO^$U^(O_
M $32W_\ "AB_^-4G_":?$7/_ "3.V]/^1AB_^-4 >,>$/C/XR^(GQHUCP)XA
MM;.'0+J[U?2[[2@ZK=6%E$)EM[HA094$H2,B20B-_.S&<J ?>?@;XBU'Q=\&
M? ^MZO(9M3U#1;2YN)BNWSG>%29-O;=G=CMNQ6#K.N^._$&DWVF7WPPADL[V
M![>=$\2I&S1NI5@&6,,,@GD$&K4'B_XA6L$<,/PPM8H8U")&GB")550,  "+
M@ 4 >F45YM_PFWQ&_P"B:6__ (447_QJC_A-OB-_T32W_P#"BB_^-4 >DT5Y
MM_PFWQ&_Z)I;_P#A11?_ !JC_A-OB-_T32W_ /"BB_\ C5 'I-%>;?\ ";?$
M;_HFEO\ ^%%%_P#&J/\ A-OB-_T32W_\**+_ .-4 ?#?[9NM?&RS_:)\2Q>#
MKOQW%X>6.T^SKHC7@M0?LT6_9Y?R_>W9QWSWK]&/"C3MX7T=KHR&Z-G"93-G
M?OV#=NSSG.<YKB_^$U^(I_YII;_^%#%_\:H_X3;XC?\ 1-+?_P **+_XU7L8
MS,%BZ%&@J:C[-6NMWHEK]QZN+QRQ5&E1]FH\BM===$M?N/!=1?5M/^*?Q-T.
MVENWM?B-K!T%"I?;:2006IG="/N.UE<73@\#-DO<UD_";XW^,-%\">!=-M=2
MMI-5L].\-6.G>"Y;$O=ZW8SZ=9-<WPESO C>:XRZC8OV4J_S/7TA_P )K\1?
M^B:6_P#X4,7_ ,:I/^$T^(N0?^%9VV1_U,,7_P :KQSRCYL\3?&GQOK.F> M
M3\.ZU:?$#Q-!JD=Y-I=GI3VHTVY?0]8-Q;-A\221[0RVKE90R*'<>:K+[W\1
M_B[>>"?AWX7\=Z)(WBSP[+$HNA!"/.OA/ 1:21A0-K/<^1&1@ "=B0-HK8'C
M3XBCI\,[<?\ <PQ?_&J7_A-?B+C'_"M+?'I_PD,7_P :H \!\5?M+^//!/Q'
MM/#2W,/B+6;.:+3;S2$LK>W6ZF.F^:9(U\TW&U[GA)#&D1!V#<1N.E;?M ZO
M*NE0R?%'2AHERJ2ZGXM_L(1V^EW)@=A8%V?RA(SK]Q_WB;=C9>5,>U_\)I\1
M<Y_X5G;Y]?\ A(8O_C5'_":?$3&/^%9VV/\ L88O_C5 'B,7Q8\?:J-8.BZK
M9:))#I>L:Y/.=!,;7<UK9Z.\0:&5MT>YKR8,K$N% 7(*Y'(_$?\ :<\9Z_K&
MH^'-#U22UFU.VU"Q>TM[6!)K KHUQ<Q2Q 3-<!FFB55ED5$<,=@)VM7T[_PF
MOQ%_Z)I;_P#A0Q?_ !JD_P"$T^(N<_\ "L[;/_8PQ?\ QJ@#P/1?C=JUC(++
M_A-=(\.>')F9F\<2Z?'.EY<QZ-HLEO"Q!",\QNKEA_$PMEC3FNH^'OQ=^)?B
M+4-'UK6YK72K2X\0:;HMWX9;32KP"XT:VNI296;>'2XF8 $8"J5()Y'JG_"9
M_$3&/^%9VV/^QAB_^-4O_":_$7_HFEO_ .%#%_\ &J ./\7^,M7\/>-?B'XE
M5]T7A-=*WV;1%_\ B3L#-?3QCKO(,IROWC8HOK7ENO\ [2?Q2TOQ;X>M9+6R
MT]-4M;+4[+3KN-$EODN[J4_957!DEDA@\E&$(W*P:1P48 >Y#5O&X\0-K8^%
MMNNIO:BR>9?$J#S(0Y=5=1'M;:S,5)!*[WP1O;.@?&GQ%)!_X5G;Y'3_ (J&
M+_XU0!\\^"?&?C#PGX&\#V5WJ%KK6E:VYN8[.ZT\$V;1>(]-MQAR27)CO9&R
MW1XU9=H&*DF^,WB7Q3I_A&[EUJ'7_$0U"TU"^\)V6FM!)HMZ%F_XE\LP;ALG
M9LD&]O+,@PI KZ"_X37XB_\ 1,[?_P *&+_XU2?\)I\11_S3.W_\*&+_ .-4
M ?._@[X[>-_B#\.?%^J:O/9W-[H5CI^LV,FGE1);:EYQS9-Y8PF_ C,,A\U5
M=@^0XK[2KR76=5\;>((K:+4/A9;7,5M=17D<9\1QA?.B8/&Q CPVUPK '(#*
MIZ@$:/\ PFWQ&_Z)I;_^%%%_\:H ])HKS;_A-OB-_P!$TM__  HHO_C5'_";
M?$;_ *)I;_\ A11?_&J /2:*\V_X3;XC?]$TM_\ PHHO_C5'_";?$;_HFEO_
M .%%%_\ &J #X#?\BQXA_P"QKU[_ -.=Q7I-<%\%_#VL^'?"-XFO6<.GZE>Z
MSJ>I-:PW G6)+B\EF1=X !(61<\=<UWM !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
M(?\ !2;XB^*_ WQ%^ UMX;\3ZSX?M]1UIX[V'2]0EMDND\R ;9 C .,,PPV>
MI]:^C_VOM<U+PU^S'\2=4TC4+K2M3M-&FEM[VRF:&:%QC#(ZD%3[@T44 <I_
MP3W\4:SXR_9'\":OK^K7VN:M<1W'G7^I7+W$\F+B0#=(Y+'  ')Z 5]%T44
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>hook-20231231x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #H 8 # 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSJ7I/6S2OO????S)5&"G[1;A1117S9N%>??'GX/6/QZ^%NL^"-1OY],M-25
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M1@<8965E)!!KS_XNW>D:3X^T%O[,\7#Q'J=M):6M]X9EBB6=$S(T#^;(J,X
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M'U*3H?6%)6O8]4JK)JME#(8Y+RW1P<%6E4$?AFJ/FZ^__+KIL/\ V\R28_\
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M"[2O&'P ^&>O:QJWBV^U?5/#&F7UY=/XOU8--/+:1O(Y N0 2S$\ #FO0?\
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M_!6N067A7X?W_CJUM] A\4:Q>0ZE!8BPTZ4N$D59>9G(BD.Q<8P.>: /1O\
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M_P#X>_"O;<'2+G2Y[#4&6?$7VN\>%[>0IOVDQ_9@N6&Y1<RX!SS]CT %%%%
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M<?&7[3WP7C\*^$=8M],:UN6U2XM92P;4GBB?R;4'<J ,[ [G. R(>Q(^G:*
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+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>hook-20231231x10k019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $, 48# 2(  A$! Q$!_\0
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M.%[NX>>00Q:Q>1Q*9')9MJ(JC))PHKU>@ HHHH **** "BBB@ HHHH ****
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M[P11^40SD,<HYR1_%[5[10 4444 %%%% !1110 4444 %%%% !1110 4444
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>hook-20231231x10k020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #; ?$# 2(  A$! Q$!_\0
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MN)^,?Q3L?@U\/]1\4ZA:SWT5J41+:WP&ED=@J+D\*,GDGH/6G?!_XHZ=\8_
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MT7X?V4&LSQ9CDUF[)-L'Z'RD',F/[Q(4]LBOA/4+^?5+^ZO;J0S75S*\\TA
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M*H& !T%.KS'X9?%'7/$GB_7?"GB?1+'2M<TJWM[QVTF_:\MO+FW;49FCC*R
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MH%#.WWF..I/K5NAVZ%.UW8****0@HHHH **** "BBFR%A&Q0!G .T,< GZT
M.HKP-?C9\2K#XE7'A>^^'^B:@MO82ZC,V@^();FXBC!Q"K1R6L:AY#@ ;^.3
MT%=-\./BOXAUWQQ=^$_%?AVRT75DTZ/58QIFHM>)'$[;?*FW1H4D!],J><&F
ME?;^OZLP>G]?UW/5J***0!1110 5\&?'3Q%K?[5'[0-M\+_#UVT'AK1[AEN9
MDY3S(^)[AA_%L_U:#^]_O5]N^+=4?0_"VLZE&,O9V4UPH]2D;,/Y5\A_\$XO
M#R7.G^,_%EP!)?W5Q%9B4GD+M\V3\V=3^ ]* /J[X>_#W0_AAX5L_#_A^S6S
MT^V7ZO*Y^]([?Q,>I/\ 3 KX^_;I_:,N#?3?#;P[=M##&H_MJYA;#.2,BV!'
M;!!?UR%]:^S_ !;X@@\)^%]7UJY(%OIUI+=OGN$0L1^E?C-K6LW7B/6+[5KZ
M0RWM_/)=3NQR6=V+-^IH IT444 ?2?[(W[,&E?'*+5M9\175[;Z1ITZ6\=O:
M$)]I<J68&0@D!05Z<\]17Z#> / &B?#+PM9^'O#]I]CTRUW%$+EV+,269F/)
M))SFOD+]@KX[KYD'PPN=)@A!6>[L[^U!#2,/F<3 ]6QT8=E QT-?;] ",H92
M#T-?,5G^R3K&G> /B5I-KXAM8M9U?4$N?#-Z(FV:3#!,UQ9QL.IV322DE>H8
M5]/44K#O8^5_%7[(FIQ7.C7/AV;2KYXO"\'AJ[@U6^O[.)3$S.+A?LK RAFE
MD+1/@-QAEYS4;]C._P!+UV[MM/?0K[P[J5SI]U<O?7&H1-:FWBAB>..SCE\F
M52+="AD8&,GG>%%?6=%7S-._];W_ #_JQ'*K6_K:WY'S[\$?V<-8^"OC&YUK
M3M5LY(-=N]1F\16A,K"X,EU-/9S1%ONR1K+Y;+PK DCD GZ"HHJ>B78IZMR[
MA7B7Q3^$'B[6O%FOZMX1U'2+>/Q-HB:%J:ZMYNZV1&D*7$&P$.P$T@*-M!^4
M[A@@^VU\J_ME?$7Q-X/^)/P%TK0]:NM*L-9\700ZA%:OL^TQAD_=N1R4.XY7
MH>_2@:?]?B?2WA?0+?PIX:TG1+0LUKIMI#9Q%^I2- BY]\**U*04M-MR=V2D
MDK(****0PHHHH **** /'-<^&/C/3O$?Q,\1>$]5TFTUGQ%IUC:Z6^H1R,EK
M+")@TDH4'(_>@@#/3FK7[/WP_P#$WPZT>^L/$-GH*232"XDU#3+NYN;J_N",
M237,DR*2QP,8X X   %>9?\ !0OXA>)/AM\*/#FJ^%]:N]$O_P#A)+&-IK1]
MI=-Q)1AT93@94\'O7U% Q:%">25!/Y4)V'+WM7_70DHHHH$%%%% 'BG[0/PY
M\??$B_T6RT*;0)_",0>35-'U>XN;<Z@_'EH[PHQ,(Y+)QNX!XR#S_B/X$^.-
M6/B""QN_#>G6/C'3[6RUV)///V$Q!D+68V@.#&Y4*^S!4'D<5]"W;M';2LIP
MP4D'\*^7OV"_B%XD^(FB?$N\\2ZU=ZS<6_BZ\MX&NGR(8EPJQH.BJ !P./S-
M"TT'OJ?3^GV46FV-O:0#;#;QK$@/95  _058HHIMW=V2E9604444AGS]J7PO
M^)NJ?&:X\4:BWA36-'@E\K1X[FYNTETJ KMDDCB$9C:X;)_>$\# &!G-+X;_
M +-^O^$O&?AVZNY?#T%AH%U>7*ZQID<BZKJXFWX2[+*  -^3\S[BBX"]MW]M
M;Q+JWA#]F7QUJVAZE<Z3J=M8EX;RSD,<L;9'*L.AKMO@3X@U#Q5\&O!>L:K<
MM>:E>Z3;3W%PX ,DC1@LQP ,DTT^6UN@-<U[]3MKJ.26VE2&7R)60A)=H;8<
M<'!ZX]*^<K[X,?%6]\0/XE75?!]CXLT_3;FQLM6L[:9#J4DHVI+>($ 4(,$(
MN\;@""!Q7TE7RK^W3\1/$O@:3X3V_A_6KO1X]4\5V]O>?9'V--$ 6V$]=I(&
M1WZ'BD-'I_[/WP^\4?#K2KZR\16F@":X<7$VHZ9=W-S=7]P?ORW#S(N2<< <
M <  "O6Z:ARM.IMW)2L%%%%(84444 %%%% !1110 4444 %%%% !1110 444
M4 >5:1\-_$WAMOB1K.GZAILGBGQ#<F73I[E)&AMXUCVPI)QDA3N) XYK._9^
M^'7C/X?_ -I#Q7#X=N;N^Q/>:SIUU<SWM]<=VE,T:A4 X55X4< 5R_[?WC37
M? '[..J:SX<U:[T75(;ZT"7=G(4< RC(SZ'N.]>Z>"K^?5?!NA7MU)YMS<V$
M$TKX W.T:EC@<#))IK3[K ]?ON;5%%%( HHHH Q_&&F2:UX2UK3HN9+RQGMU
M^KQLH_G7QS_P3C\7Q61\6^#;MQ%?!X[^&)N"VT>5,!ZE2$_.OMZO@#]ICX*>
M*_@E\4)/BCX#6X33);@WLDMFF]M/G;_6!T YA<DGICYB#C@T ?5G[45G>7_[
M/WCN&P5FN#I<K80\[5PS_P#CH:OR7)!.1TK[:T3_ (*,6UUX7FMO$7@M[O4V
MA,9-C<+]EN"1@[@_* ]Q\U?%$S"2:1UB6%&8L(TSM0$Y"CV'3\* &445+:VL
ME[=0VT*EYIG6)%'=F( 'YD4 ;&A:1XA@TR]\4Z/%>0VNC2PB;4K1BAM9')\O
MY@<@DCM[9ZU^Q'A.>[NO"VCS7YS?26<+W!_Z:&-2WZYKPSQI^RK%J/@?PKX(
M\+W,.@>$TO4N/$,*C]]?A5!W%L$LY9<8) &[/\(%?0MO;QVL$<,2[(XU"*OH
M , 4 24444 %?!O[87[9OQ?^"/QGF\,>#/#6GZIHB:=;70N+C1;NZ?S',FX;
MXY%7 VKQC(S7WE2%0?7\Z!GY0?\ #RG]HG_H2=(_\)K4/_CM'_#RG]HG_H2=
M(_\ ":U#_P".U^KVP>_YFC8/?\S0.Z/RA_X>4_M$_P#0DZ1_X36H?_':\O\
MB]^V%\6?BAXG\":OXE\.6%AJ'AG5%U'2HH=&NH%GN 5(5E=R9!\H^5<&OVNV
M#W_,U\:_MV$K\8_V:R&8$>,XL<GCYHZ 3/FO_AY3^T3_ -"3I'_A-7__ ,=H
M_P"'E/[1/_0DZ1_X36H?_':_5X(/4_F:-@]_S- 71^4/_#RG]HG_ *$G2/\
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M@?\ (DZ1_P"$U?\ _P =H_X>4_M$_P#0DZ1_X36H?_':_5U%!7J?S-+L'O\
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M.D?^$UJ'_P =H_X>4_M$_P#0DZ1_X36H?_':_5[8/?\ ,T;![_F: NC\H?\
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M<:AH5O?JT4TIE(5)1A'4GY7'X@UU)^ =J#K874-1 U31(=$<M;(3&D9)\T8
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M7R\;"7*Y<#:."<&O.?$G[/'C.#Q+I&LZ=XGOM2UNZUNWO;_5'TR&*.TCBA9
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M_P"O\/\ \C^)\,>/_@3J/A74?$7A+PSI.J:_I>C^"?#ZA'AW/JD=OK,US=0
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MCXB$_P#+@/\ O]_]C0?B(1_RX#_O]_\ 8U\-?#SQ?XD\*07OB*#Q+:2:!?\
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MI[7(!5-4O"+D2.%9B4A"C:!N.6*[?IJDP,YP,TMVF^G]?U_G8%HG;K_7]?\
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M8\>_M)VK^%O@/X.UO3+.^_<WGQ"\46#V%C8Q-D,]O&_SS28Z# P2.*^PMHH
MQ0!P?P.^#NC? ?X:Z3X.T0R36]FI:>\G_P!;=SL<RSR'NS-D^W [5WM%% !7
MGOQ[^"^B?M _"O7? ^O*19ZE#M2=0"\$HYCD7W5@#^%>A44 ?S@?M%?LB_$?
M]FGQ)=6/BC0KB320["UUZTB9[*Z0'A@X&$..J-@C]:\I\.^%]8\7:K#IFAZ7
M=ZQJ,S!8[6Q@::5R3@85037]2%S:PWD+Q3Q)-$XPR2*&5A[@\&J>F^'-*T9V
M>PTVTL6889K:!(R?J5 H ^!_^"9_[ NJ_ EY?B-\0;5;7Q?=P&'3]*)#-I\3
M#YGD(Z2L., _*"<\GC]":** "N&^,_P>\/\ QT^'^I>$O$<+/97:@QSPG;-;
M2J<I-&W\+JP!!]J[FB@#Y&\/^+/VD/V>X8_#VO\ @5?CCX;M?W5EXE\/W\5K
MJGE#[HN;>8@.X P64\]R:FUWXH?M(?&5'T+P7\+!\);*X_=S^*O&.H0S3VZG
M[Q@M82V7 S@L2,XKZR(!HP!0!YK\ ?@3HOP \#KH6F3SZG?W$S7FJ:S>G-SJ
M-T_+S2'U)Z#L/Q->ET44 %<)XC^'!\237:W<=C=V<[[C;W<?F*<8QE2I!Y%=
MW16M.I*F[Q.'%X.EC8J-7H[Z:'GEW\-)[^UEM;K[%<VTJE)(9E+HZGJ"I7!'
ML:P%_9S\/+X>;01X<\.#0V?S6TT:?&+<O_>,>S&??&:]BHK;ZU49YBR+!QVO
M][/*[?X(V%G<Z?<6^F:-!<:?$8+.6*U56MHSU2,A,HI[@8%&N_ _3_%$MI+K
M.EZ+JTMF_F6SWUJLS0MZH60[3]*]4HH^M5 _L+!IWL_O9YD/@[;JA066DA#/
M]JVBW7'G?\],;?O_ .UU]ZR;/]G'PYI[3FU\,^&;<SEFE,>FQ*7+?>S^[YSW
M]:]CHH^M5!K(\(MK_>SR35/@#HVMZ?)8:CH>@7UE)-]H>VN+%'C:7 &\J4QN
MP -W7BK\?P@AA:-H[32D:.W^RH5@ *0_\\A\O"?[(X]J],HH^M5!?V%@]M?O
M9\T^,_V.(/&OB""\N=9A@TJ-8U_LM-/MF$:H<A()S%YD"' W*AP>V*[^+X%:
M9!XB;7X](T./7678=36T47)7&,>9LW=..M>KT4EB:BV-)9-A9I)WTTW/-[GX
M4B\F>:XATV>5XC;O)+%N9HCU0DKRI_N]*S=,^ >CZ+I;:;I^B:#8Z<THG:TM
M[)$B,@.0Y0)@L#T/45ZU13^M5#-9%@UI9_>SR+4OV?=#UB&VAO\ 0?#U[%:R
MF>".XL(W6*0G+.H*<$GDD=3UJ_=_!RWOY99+FQTFYDE@^S2/-;J[/#G/EDE>
M4S_">/:O3J*/K50?]AX/S^]GGG_"LYOLGV7_ $+[+L\KR-IV;,8V[=N,8XQT
MK@O$O[(WAK7]#BTF#2M$T:S%Y#=RIIUA%&)_+;<(Y!LPRD]0:^@**'B:CW'#
M),)3=XW7S9YIHGPBB\-:?'8:1:Z9I5A&24M;*'R8ER<G"JH KT>",Q01H<$J
MH!Q]*DHK*I6G5MS';A,OH8)RE23O+>[N%%%%8GI!1110 4444 %%%% !1110
M 4444 %%<=\6?B[X2^!_@F]\6>--8AT71;3 ::7+-(Y^['&@RSN<<*H)K\\_
M'/\ P6[T.QU9X?"7PQO=7T]78"ZU;5%LW=>Q$:1R8SSP6H _3VBOB3]G#_@J
MU\,/CAKUGX=UZSN?A_K]VRQVPU&=9K*>0X 19P!M8GIO50?7)Q7VW0 4444
M%%%% !1110 4444 %%<Q\1?B7X8^$OA6[\2>+M:M=!T6U'[RZNWP,GHJCJS'
MLJ@D]A7SQ%^W#K_BI#?^!/@!\1O%GA\C='JTMK%81W"_WHDE;<X.>.!GTH ^
MKJ*\'^$G[8O@SXF^*AX/U*QUKX?^.\97PUXNLC9W,X'4PMDI*/\ =.?:O>*
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MF^RP^4R$*V5'F.NXJ1P.:M:-^T?%J'[0&H_#6\T";3(H-(BU*WU:>?\ ULK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>hook-20231231x10k021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $8 :P# 2(  A$! Q$!_\0
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M0""0:0]SPZ3]J*_;P;!,GC#P^/B,GB8VLG@%;<?;I(3<&$:?Y1?S1($_>_:
MNTXSC9S7O7QH^(,'PP^&NL>(KGPWJWBZ*U55.C:)9BZN;DNX0!8SU&6R3V )
M[5\I?#ZV\<>+]4TWQ/J$?Q]TN[O+UGDMQ_8/V2&/[0P$19XEG\D*!D$9QG!/
M!/T'^UAXQN_ WP7O]0MM:F\.1RW^GV=UK%L<2V5K-=Q13RHV#M98W<AL';U[
M4Y? ELV[?DOZ_J[C\;ZK_AW_ %_PR7R[X.\9GQ-XZTG5M,M_$?P0M)-0AEFT
M3PSX7URZ^VY;!CNM]NEC$&S\S+$Q']\=:_0,5^;G_"X/"T>J>)=1TGXUZ_XB
M\4:'XCT^S\'02Z[<.EY8,;8S1O" ([H,TMPC22!FPB_,-@-?I&*T:]Q/^MD_
MUU71W^>?VG_7<;-$D\3QR*'1P593T(/45XSX9_9DT_PM?Z(\?B?7=3TCPUYS
M^'-#O)(?L^EN\;QAE=8A)+L21U3S6?8&[G!KVFBLOZ_K].Q1XC>?LWW6OZ5I
M4^I>.=>LO$[:*NA:[JVF- 'U>VR6*R;XB%8,S[9$5&&]L8S@/\0?LJ^'-5EG
MMM-U?5_#OA_4+&TTW6-"TV2(6VI6ULNR%'+HSI^[_=LT;*63@G@&O:Z*J_\
M7]>KT\P6G]>G^2^X\?U;]FK1M5\47=Z-;U:U\.W^I0:SJ'A:!H?L%Y>0[/+D
M8F,R*,Q1%D5PK%%)'7/KDT$=Q&8Y461#U5P"#^!J2BB^E@ZW/@7_ (+$6%M:
M_LW^&'AMXHF/BVT&Y(PIQY%QZ"OO2S_X]8?]Q?Y5\)?\%D/^3;/"_P#V-MG_
M .B+FONVS_X]8?\ <7^5(":BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&!_ U(JA%"@  < #M2T5N>6%%%% !1129&<9H 6BBB@ HHHH **** "BBB@
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ME0EUVG*Y&<'!Z9!Q7:445$81BVXJU]SHJXFO7C"%6;DHJT4VW9=E?9>2"BO
M_P!K[Q;\3_"7@K3;CX9V5Q<74EV$O)K.T%S-''M.,(0>"V 3@UZ;\)-3\1:Q
M\-O#U[XMM?L?B*:U5[V$IL*OSU7^$D8)'8FL8UU*M*A9W2O>VGWGJ5LIJ4<M
MI9FZD'&<G'E4O?5NKCT7S[=T=?11172>&,E+"-M@!?' /K7R!\"/$_[0]_\
MM,>(;+QM87T?@</<<SVJ):1("?(,$@&6)^7N<Y.<8K["I,52E9/0]##8M8>G
M5ING&7.K7:UCYKS%HHK#UCQOH/A_4K73]2U:TLKVY_U,,T@5FYQ_/UJ3CITY
MU7RTXMORU-RBBB@S"BBB@ HHHH **** "BN-\8>-;?P_J<-M+JEK9-L$ACFE
M521G&2#VKKH)!-#&X(8,H.5.0>.U>!@<XAC\;B<%&E.+H-)RE&T975_=?7\#
MIJ8>=*$:DEI+8DHKGO'7Q \._#/P_-KGBC5[;1=*B(5[FY8@9)P  ,DD^@&:
MF\'>--#^('A^UUSP[J=OJ^DW()BNK9LJV#@CU!'H>:^@MU,_95.3VO*^7:]M
M+]KFW1112,@HHHH *RO%.LS>'O#][J-OI-[KDUM'O73]-"&XGY^Z@=E4GV+#
MI6K6+XM\7Z3X)TN/4-:NOL=G+=6]DDGEL^9IY5BB7"@GYG=1GH,Y.!2>NB'Y
MGY\6?B'1/&U_HOAC2?"GCW1/%<UQ);2^%;W6-*BCDL)+\7!LY6>0W$<,;(TB
M[8_,"LR E2#7Z'^(?#FE^+=#O='UK3[;5=*O(S%<6=Y$)8I4/4,IX(KY8/P"
M\;MH*^ /^$*\+?91K7]H_P#"QOM_^F[?M?VC[1Y'D^9]KQ\F?,VYYW;?EKZX
MQQ6C:=-)^?Z?U^/45VI,\8T3PO\ !S_A(-"\+0>']-TG4?!MW)-H^EWED]HD
M,K YGMT<*DQ/)$B[R#DY!S7LZL'4,I!4\@CO7C4/AOP_<_&;5O"VMZ%)XJ-W
M8MXBCU'7E6[CM-\H@-K"KH0B@ D <X)'->F>$?!NA^ M#AT;P[I5KHVE0L[1
MV=G&(XD+,6;"C@9))I:N*;Z_\,_R%:S:7]=5^9M4445(PHHHH **** /@S_@
MLA_R;9X7_P"QML__ $1<U]VV?_'K#_N+_*OA+_@LA_R;9X7_ .QML_\ T1<U
M]VV?_'K#_N+_ "H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **HW&N
M:=:7\5C-?6\5Y+RD#R@.WT'6KU4XN-FUN2IQDVHN]A*6N0^)?Q<\&_!S18M7
M\:>(K+PYITLH@CGO7P'<C(50 23@$\#H*W_#_B#3?%6BV6KZ/?0:EIE[$LUO
M=VSAXY4/1E(ZBJ=.:BIM.SZ]"K]#0HHHK,!LC^7&S8+8&<#J:^8?@Y^U_JGQ
M-^/&K> KKPJNG6=N]PD5RLCF:/RB>95(P V.V,9'6OJ"JEOI%C:WLUY#96\-
MW. );B.)5DD Z;F R?QKEK4ZLY0=.?*D]5;==CW<OQ>!PU#$4\7AO:SG&T)<
MS7)+^:RW]'V\RW7EOQ"^ UAX_P#%MIKDNIW%FT:HDT"(&$BJ<C!)^4\GUKU*
MN%\8?$*Z\.>(+:PALDEB<*S,Y.YLG&%Q_P#7JJ]>GAX<]1Z'#@L5B,)5]IA9
M<LK-=-GZG<1H(D5%^ZH %.IJ-N4'!&1G![57U#4[/2;8W%[=0V< X,L\@11^
M)K9R45S-V1Q).3LM6RU14=O<17<*302)-$XW+)&P96'J".M24TTU="::=F%%
M%(>E,09I:^.O 6M_M$2_M<ZE::W:WX^'@GE'[R!!8+;8_=M&^,E^G0DYSGBO
ML0=*J4>4]#&8-X.48N<9<R3]UWM?H_,\]^('P1T+XC:W9:IJ$MU#/;@(P@8
M2H#G!R#CZBN_MK=+2WCAB7;'&H15] !@"I**DRJXNO7IPHU)MQALNQYK\?O@
M3HW[0?@1_#.LW=W81B9;B*ZLR-\;KT.&!!'L:M_ _P"#>D? CX?67A/1KBYN
M[:!WE>XNR#)+(WWF(  '0<#TKOZ*KF=N7H'UNN\/]5YW[.][=+]PHHHJ3D"B
MBB@ KRW]I+X;:G\6/AB?#NDRRV]S+JVF7#SV]S]FFBAAO8997CD_A<(C%?<"
MO4J*.J?:S^[4:=CQ73_V8;>PO[>Z'Q.^)UP895E\FX\52O&^U@=K+MY4XP1W
M%=;\<[_PQI7POUJ\\9>)[SP?X<MU26ZUBPU&2PGA =2H26,AP6;"[5Y;.W!S
M7>UY!^U/XEB\*?"N.^N6TY+!M;TFWO&U:"*6V%O)?PQR[Q*"@&QF^8_=ZC!%
M*5VE%=6OQ:0XZ._]:'S#\-=.TCXE^.=&URT^-'B+P5X,M[A);73-6^(K7FKZ
MZ=P*"6!IF6UA;CY#NE8'!$><5]^"OEGX7>,?@;X@\=>-K&X@^%EO_9.NPVFB
MR6T>GI+.AMK>4,ISEV\V1P"O=<=17U/6C^%6]?O2?W]S/[3N-=UC0LQPH&23
MV%>3^#OVD_#OC/Q#H^G0Z3KVG66NO/'HFLZC9+%9:JT09F$+!RXRB.Z^8B;E
M4E<UZM<2^1!))L:38I;8B[F.!T [FOEKX7^,M4^)?Q6M/%/CCP1XUT2ZT\72
M>'M&NM EAL-)C*L&GGG)VR7,L:[0?NH'V+DEF,)J^I;6ET>N_$KX^:+\-=:.
MDRZ3KGB"_AL&U6^AT.T6<V%D&V_:)MSK\I(;"IN=MC84X-97B3]J3P?X?OG6
M&WU;6]*M;2UO]3UO2K0366F6]R,PRSL6#89?GPBN53YF %>;ZKXLU%?%NL_$
M+3/!?B37-&\=>#;6TTZ"STXRW$%W$]P1!<HI/DAQ<*=['8-K98<9X:R^&?C#
MX6?#CQU\.Y?"NJZ]JGB_PYI>G:;?Z;;&>S2X33TLIDN)AQ"L;+OW/@%#\N2,
M526CONOQ=VK?<D_GYH6C:MMW\K1U^]M?+R9]%:K^TEX9TGQA/HKV.L3Z?::A
M!I-[XC@M5;3+.]F"F."27?NR?,C!94*J9%#,":]7SQ7QMJG@#Q-I?A?QG\)4
M\-ZS>WWB'Q5;:E9:_#:%M.%F6M7EFEN,[8WC\B0;&^8G9M!#<?2WQ>^&:_%W
MP%?^&'\2:_X36[>)_P"U?#%[]COHMDBOA)=IP&V[3QR"119<J:_K1?JVOPW3
M)3=W?^M7^:/D#_@L><_LV>%_^QMM/_1%Q7W;9_\ 'K#_ +B_RK\G/^"CW[*4
M7P/^#&@:ZGQ2^)'C5IO$5M:?8/%VO?;K5-T4S>8J>6N'&S .>C-ZU^L=G_QZ
MP_[B_P JDHFHHHH **** "BBB@ HHI* %HHHH **** "BBB@#YY^)/PK\8:[
M\78-4TZ,-IDKQ,+D2@+"%QNW#.>V> >M?0U?!W[0O_!10?!S]JW3_AH/"T]_
MIR26L5[J*W121#-@_NH@I#@!AU(R<CC%?>%?-93'$QQ&+=>G.*<[Q<IJ2:M:
M\4M8K39ZVMZ+T\775:G2BH1CRJUXQLWU]Y]7K^+?4\*_:Q_9/T7]JSPIIFE:
MEK-YH%WIMS]IMKVTC67!(VLK(Q ((/J"#CZ5Z3\)_AMIOP@^'.@>#M(EGGT_
M2+86\4MRP,C\DEFP ,DDGBOEC_@IYXW\8^!/AMX;OM U2XT?2'U QW]S;3F$
M[BO[I2P(."<_CBOH#]ES5/$.M_ #P3?^*9FN=:N+!9)9I'#M(A)\MBV3DE-I
MS7UCQLZE-81R?+'6UM-?/^OS,9X&I3PT<8W'EDVK7][3NNB\[GJE%%%8'$%%
M-=UC0LQPH&2:\%^&G[:OPZ^*OQ>U'X=Z*^I?VQ:M,D=S/;!;:Y:+/F"-@Q/&
M#]X#.#[9N,)23<5L:PI3J)R@KI;^1[Y6/JNL6=G?PQ36XED'(<J"4SZ9K8KY
MO^//QDM/ _Q3T/1KKQ1I>D3W*1M;6=S*JM,2^#N!'3H!D@=:\?,\'F6.H>RR
MJO"C4NGS5%>-ENNNK].^VZYIUG17,J4JGE!7?KZ(^CP<C-?-'[=_Q T7X>_#
M32[S5%O)[B6_$=I;6H&)'V,6WD\ !03]:^EHR6C4MC<0,[>E<[X]^'/AKXH:
M"VC>*M&M=<TQG$GV>Z7(##HP(P0?<&NO$X6AC:,L-B8\T):-;7^X]C*\9' 8
MVEB9)VB[Z;_B<=^R_P")-*\6_!#PUJFCM<FSGB8[;M0KHX<AEP., YQBO5:S
MO#WA[3?"FBV>D:/8P:;IEG&(H+6W38D:CL!6C6M&C3P].-&DK1BDDNR6B.;%
MUEB<14K+[3;UWU=PI#Q2T5J<AX3X:_:]\)>)_C5=?#JVLM02]BE>VCOW1?)D
MF3[RXSN'0C)'.*]VK@M.^#7@#3?B'<>+;/P_I\/BN3+27B$^8"1@MLS@$CN!
MFN]KEP\:\4_;M-WTMVZ'NYO4RRI4I/*Z<H1Y(\W.[WGU:\G_ $D?+/[4OQ&^
M-'A'XB^%[+X?Z7<7.AW&WS'MM/%R)I=W*2-@[!CZ=^>*^G=.DN9=/MGO(UAN
MVB4S1H<JKX&X ]P#FN+\>:WXCTW6;*+2H7:V< Y2'>';/0GM7<P,[0QF10LA
M4%E'8XYKFPSOB*OO2>VCV7H7CLPIXK!8;#0P\(.FFG*/Q3N]Y>G]6V/)/VH_
MBYKOP7^%MUXA\/Z7%J=ZDJ1%KA&>*!2>9'"D$@?4"M#]G'XFZS\7/A1I?B37
MM+72M0N"ZLD:LL<JJ>)$#<A3]3T-='\2_$<OAGPU)=1"+YG$;-,H95!]N]3_
M  ]UZ7Q)X7MKV41[B2H,0PI [X[?2M>2K]9Y[RY+6V]V_P#B[^1D\QP+RQ9>
MJ$?K"ES>TYO>Y;6Y>7M?K^!TM%%%=QX@4444 %%%% !7*_$[POJ?C+P7?:3I
M%WIEC?SE-D^L:8-1ME <$[H"RA\@$#D8.#VKJJ*35QIV=T?-.D?LW^/['5;&
MYG\2_#J6""9)&2#X>112%0P)"O\ :#M/'!QP>:^EJ**J^EB0IC1(ZE6164C!
M!'!%/HI#&101P1)%%&L<2*%5$& H'0 =A3L4M% "8I:** /@S_@LA_R;9X7_
M .QML_\ T1<U]VV?_'K#_N+_ "KX2_X+(?\ )MGA?_L;;/\ ]$7-?=MG_P >
ML/\ N+_*@":BO)/VJ?%_C+P)\$?$.M^!+<3:_:JCJYC60PQ;QYL@1N&*KD\_
M7!Q6+^QE\0/'/Q,^"=EKGCV$#4I;F1+6[\M8VN[8!=LK*O .[>O09VYQZZ<D
MN3GZ;'HK U'@WC>9<JERVOK>U]NQ[9J5S+9Z?<SPPFYFCC9TA4X+D#(7\>E?
M)O[&_P"U%\1OCEX_\6:-XP\-P:=8:?$94FMK62'[)*'"_9WW$[F()/.#\I[&
MOKNHH6A9G\ID+9^;81U]ZR]K"'N2M=[?\ 5#$4J5"K3G24I2M:7\MNWJ2T44
M4SSPKY'_ ."@'P<^,WQ:T;PDGPGU2YMULKJ1M0LK35?[/>3< (Y"^Y0RI\WR
MYSSD U]<56O=1M=.17NKF*V5CM!E<*"?3FNK#8IX*M'$12;CWV^8<KG[J.=^
M%6C^(?#_ ,-_#6F^+-276/$EKI\,.H7R\B:<* [9[\]^_7O75TBL'4,I!4C(
M([TM<\I<\G)]0V"BBBI ***^*_VZ?VN?C#^SQXQ\.Z9\-_ EEXKL;^SDGNI[
MK2;V[,3AP H:"10,@G@\T >4_M4^*/$5A_P4 \"P6WPTT?68XFLUM;NYTLRS
M7BLY#/YV<+Y9SCT(YR*^]/B[\9?"'P(\%S^*_&^JG1M!@ECADNA;2SX9V"J-
MD2LW)([5^36L_MD?%_Q5XQT[Q!K7@FUT[66\MI=.BT^ZB!8,1& KN77.!QGF
MO0/"/[2'Q9_;5\9Z!\*/C%\(K6R\!ZQ>H;ZYL=+U2PEBV9=&$S3$+\P'48KT
M,5*FZ=+V=)1:6K6\GW?F>IC*56G3I.I4<DUHF_A6FBU+O[=?Q=^%/[<'@_P_
MI_P]\<W-[>Z'>M<3H=,N(80KH5!83*F3Z;<]3FO7_P!GS]MWX!_L]?!_PG\.
M/$7Q NHM>T2T%O<Q7&CWDK*[,7QNCB9,?,,88\8SS7EW[6W[,?PX_9$\+:-J
MOP]\+WMO>:K=&WN;J[U6XFB1 I(4J6ZDXP<CIWKTSX,_\$]?@G\:/AKX<\=>
M)?">J0Z_J]LMQ=#^VKE07!*Y"AA@$*"!CH>_6E/),SH86&;U7'ZM4;C&S7-S
M+>ZWMOU^ZZOG.>">&C&G)^VOJN72VO6^O3HM_(^Z-'U:UU[2;+4[&7SK*\@2
MX@DVE=\;J&4X(!&01P:N51T/1[7P]HUAI=DC)9V5O';0JS%B$10J@D\G@#DU
M>K@//([@$P/C;G!QNZ?C7YL?LE?!SQ;X4_;5UGQ-J,V@OI]Y<:GOBM.2@9FV
M>4-HVD\9P?7UK]);IBMO(5&XA3@8Z\5^:7[)?Q6\6>(_VQ+C1-22W>Q2[U0/
M!':['A"L^P[NO&!UZYKT\)@<]Q5*K5RF$'1IJ]9SW4-?@\]W\EZ/TL+4P4*=
M58IR4FO<Y=K_ -[R_P""?IET%?!_[7OP_P# VI?'NRN/$;:4-4U2UM8K<WUZ
ML4BA9& V@L-OS,.>]=M^WC\ OC9\;F\)'X0^,G\)"P$_]H;==NM-\[=LV?ZE
M3OQANO3/O7YP_%+]B_\ :5TOQK&NOVTWC;4;6**676_[:-X70L=J*\[+(2N"
M=JCC=[UX6)PM#&4_9XC$SH1NGS0=GOMJUHS7*\?++J_MH04G9JTKVUZZ=C]T
M-.MOL5A;6^2WE1JF3SG  _I7%?&3Q7K'A#PS'>Z0JH?-"S7#H'$2^N#QR<#)
M]:_/[X*?L8_M9>&_BMX0\0^(/BE+>>%;34H+N\TY_%]_-OM@P9HS$R;6^7C:
M3BO6?^"K7AS4O%WPL\):3:Z[/H]G+JQ>Z2 ,?/58G*@X(!PV#@GW[5[V64)X
MC&TZ-.'.V]%IK]^GWGCSP5?,KX3#2:G/1-:/\;?H?8W@+5=1UOPGI][JL(AO
M9DW. NW<,\-CMD8-=!7SI_P3_M-0TW]EWPK8:EJTFLSVC3P)<3!MPC$AVH=V
M2< ^OMVKZ+KFQ=.5+$5*<H\K3:MVUV^0+#U,(OJ]5WE'1WWNM&%(:6D/ KD&
M?*7@QH#^TO<L-3N'!O)@KLAS(V#^[//0=,^U?5HZ5\^^&/'>AW?QXN;*+PA:
MVUX\\D U)7/G;@.6*_=&<=1S6]^TO^U5X._93\.:3K7C*WU:XM-3NS9P#2;9
M)W#A"_S!G3 PIYS7FX&GC:<9K'34FY-QLK6CT3\_ZNSZ?/L6L75HR47'EA%:
MVZ>G]>2,3XY_M ZA\.O&=MI-A-80Q00+=70NL;F0G'.2-J\'FO==(U!=6TJS
MO4QLN84F7:<C#*#P?QK\I/CIXHL?VV?%]G\0? '@_7-4T/3K9;2:;4UBMG#H
MVXA$,IWC'8$\]J^E?A'_ ,%-?A-XJ\5^%OAS9Z;XKM]?NIH=(3[7IL:1), $
M^9O.) R.NW/M54*$*5>K4CB95'*UX-65/39/K??I\]SCQBE]5H)T(PLOB4XM
MSOK=Q3O&R_F^1[+^UKK5]HOPQ5M+TR+4M3ENXX[<7%QY,,1[NY )( [ 9/M6
MA^RYJ]UK/PELIK_3%TN_6>6.XCBN/.C=P1\Z-@':1C@C(YJ_\?=#CU_P?#;R
MJ=@N48R+]Y,>GUZ5;^!NC1Z%X$AM8E(032,&;JV<<FLUF&.>.>!<X_5^7FMK
MS<U_NM8Y'@\K6$6*4']:O;FZ<G;^D>A4445ZAYX4444 %%%% !1110 4444
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MDCD9[\Y_"NTK\)[SX^_M6^!]=;1]&U+QFF@:=,(8+;3-(9K<1+CY8SY!!7J
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M[-/PN^#OP^N_BSIGPBTW4?B#H=C_ &Y'!;_:!--?*H<A=I<[BY/13]*X./\
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M /(-9_9LT?6/%5[?G7-7MM U'4X=:U+PQ"T/V&]O8MFR5B8S(H)BC9D5PK%
M2.N?7B,C']:6BCI;H&[N?*?_  46^#GQ$^-'P;T/2/AE93WNO6^OP7<RP:A'
M9L+813!SOD= 1N9/E!R>..*^IK>(I!&K9#!0",^U>#_$WQEX[USXD>)_#O@_
MQ!;^&H?"OA^'69&DL([HZA<3/,(X7W_<B"V[9*8<EQAACGU?X8>,A\1/AQX8
M\4>0+8ZSIEO?F '(C,D:N5![X)(_"J3<HWZ+];_G9@]';^NC_5'1R01S1LDB
MB1&&&5^01Z$&DAMHK:)8H8UAB485(QM4#V J6BI CECW1L!G)']XU\F?L(_
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,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>hook-20231231x10k022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $@ :\# 2(  A$! Q$!_\0
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M&3UKSSX0?%#Q[\0=4CEU+PO86/AX/-#+?6]SN9)4R-NTMD_,,9Q0![+1110
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M'_\ 1KT >BW/_'O)_NFO+_V;_P#D0+K_ +"U]_Z.->H7/_'O)_NFO+_V;_\
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MU:_98-S@@8,F&;KT"U@_L]^+O&OB#X?VVD>&HO#L$&DYMY)M1EF>;+$L&\M
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M>GZ=MZ-;VR(WY@9K=HH 3%>'?'?_ )*5\+_^PK7N5>&_'?\ Y*3\,/\ L*T
M>@^-?ACIGC":+4(Y)=(U^W_X]M7L3LGC/H3_ !K_ ++9%<[9?$K5_ 5W%I?Q
M!MTB@=A';^)+1#]DF/82CK$WU^6O4A4%]86VJ6DMK>01W5M*I62*90RL#V(/
M6@"2">.YA26&198G&Y70@JP]01UKCOC3_P DH\5?]>$G\JYR;P+XA^%TSWG@
M9SJ>B9W3>&+R4X7U-M(?N'_9/%0^,_B/I'CKX1^+TM'DM=1M[&1;K3+M?+N;
M=L=&0]O<<&@#O_ /_(C^'_\ KP@_] %;]8'@#_D1_#__ %X0?^@"M^@ HHI"
M<4 >7?L\_P#(J:S_ -AN\_\ 1E>I5Y;^ST"OA76<@C.MWG4'_GI7J5 !1110
M!X=:_P#)V-[_ -@5*]QKPZU_Y.QO?^P*E>C^*_BAX8\%,(M5U>"*Z;[EG%F6
MX<^BQIEC^5 '54UW5%+,P50,DDX KS(^.?&_C#Y?#'A3^Q[-NFI^)6,61ZK;
MIES_ ,"(I5^#$OB)EE\;>)=1\3'J;"-OLED#Z>5&06'^\30!X?\ M/?M+_"_
M3?&7A73Y?&VD/?Z'J?G:A:PW =X% '#8XS[9KV+PY^T?I/C;0K;6/"_AKQ-X
MBTNY7?;WMC8*895]58N 17RY^W=\&O!>C?$#X*-8>'K.R_M;Q$ME>K;QA%FA
M"CY2!_/K7W7X:\.:;X3T.TTC2;2.QTZU3RX;>)0%11V I <2OQ.\577_ !Z?
M#+6V'8W5W:P9_-SBE/B[XDW/^I\ 6%H.QO-=0G\0D9_G7I&*6F!\>_M4?M _
M$[X6>&9+/4_ATNIZ1J5G+]IU'0G>X2S0<-YC-M ..<XQBO1?V./C/>?%_P"&
M4+7?A+5_#0TU(H(IM2152]0H"LD6#RN*ZK]J4?\ &.WQ$X_Y@EUV_P!@U/\
MLTC'P#\ Y'_,&MO_ $ 4NH'IE%%%, HHHH *^/\ XR:1J=]KNJ6WCKQ-\0;3
M11>/-8P6_@G2_$&G*I8B/R7CL)I%PO&)0'&2"6')^P*:<>_X4FM;COI8\J^
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MXYZR=!^$_B6Z#['-HT*D==SX0?\ H5?-_P '_P#E)A\<_P#L7=._] M:Z_\
M;_\ &P\/_ *]M[&=7O\ 4;F.U@CB<;F=L[0,<YW;:2 XG]D+]ECX8>._@^/%
MGBCX?^'M;NM?U2]U"VDO].CE:.U,Q2%5W#A2L>_ZR&NR\<Z7%^R?\4+;X@:/
M +/X9>(#;Z9XITZVCQ#IDR@16NHHH'RJ %BD_P!G:>U>Z_"GP9%\._AIX6\,
M1*JKI.F6]F=@P"R1@,?Q;)_&MGQ'X>T_Q9H.H:-JUI%?:;?P/;W%M,N4DC88
M92/<&BP'PK^TOXK\7VOQ@\/K-\$HM1@US6QINE:A_P )A&!KJ"(LB; #]F!
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MOX/_  >\6V_B?PAX,AT;7;='CBNTO+F0JKJ58;9)67D$CI0![+1M&<X%+10
MUT5U*L-RD8(/0U^?7PS^"/@>V_X*2^,+./P[:+9Z9I,>M6=MR8H;QW&Z55)Q
MGDG'0$Y K[]U.]_LW3KJ[\F6X\B)I/*A7<[X&<*.Y/:OSB\!_'/5[7]LG7OB
M7+\(_B-%HNNZ5!I$,+^'YEEAD#KEY,KM">^:3 _0?6?A[X7\1?\ (5\.:1J?
M.?\ 3+"*7_T)37#:Y^R9\&/$<OF:A\+O"<TF,;UTF&-OS517K-%,#P27]ACX
M,KDV'AB[T-NW]CZW?6:K]%CF"C\J^ /VT_V-KWPG\=?"-AX>UJ2_L?&<\>G6
M UN^FN)[:9>"LDLFYFCP<@Y)'(K]>J^,?VV#_P 9"?LX?]C+_04F@.Z\'_L6
MQ:%X.TC2+OXJ_$KS+2UCAD33_$\MO;!E R(XP/E3/0>F*U5_8\TQ>OQ-^*<G
M^]XPN!_(5[\.E+18#YXG_8L\/W,ADE^(/Q.=SU8^,KO_ !KY^_;A_8:L4^$U
MQXN\/^*-<GN?#4$EU<P>)-6N-06>$#YA&9"=C^XX/>OT(KQ_]K__ )-A^)?_
M &!9_P"5#0'S]^R=^P!X+LO@_I5_XW-WXBU/6(TU$+9ZI>6=O!'(@*H$BE0,
M<'EB.OM7MT'[#WP)@?>WPTT6[DXS)?+)<L<>K2.Q/XUWGP/_ .2->!O^P)9_
M^B5KMZ /+-)_97^#NA_\>/PN\(P<YR-&@)S^*FKGB+]G7X:>)?#E_HEUX(T*
M&QO86@D^QZ=#!(%(ZJZ*"I'8@UZ/7/\ CGQ[X>^&OARYU_Q1J]KH>C6^!+>W
MLFR-,G R:8'QE^P#^R_\.XO#_BSQ'>Z##KFHIKE]HT?]KJMU%';PR[5VHZXW
M$=6ZGVKZ2UO]DCX+>(93+?\ PM\*2R$8+II44;?FH%>%?L"?'3X?WFAZYX4M
M_%^DS^)-1\3ZI>VFF1W&9IH&DW+(J]U(Y!K[0ZTEL!X'+^PQ\&UR=/\ #=]H
M;=O['UV_M%7Z+'.%'X"H9/V.M.M8)8]'^)_Q/T1&!"1V_BN:6-./[LH;(]B:
M^@J@O99H;.>2VA%S<+&S1PE]@=@.%R>F3QFF!^+_ (>_8[\<M^V(?AY<:B(+
M^VN/[6FUF*["RFS+;A.K 9$A';&0:_2FW_8?^%UTWF>([?7O&UP3EI/$WB"\
MO _UC,@C/TVXKPNP\-?M#Q?M57'Q;D^"MDL5UIR:.^G?\);:$)&&P9O,QDG'
M.W;[9K[N@9WA1I$\N0J"R9SM/<9J4@.$\*?L_P#PT\"J@\/^ ?#>D,ARLEKI
M<*N#Z[MN?UKO4C6-0JJ%4# "\ 4ZDZU0'QA_P4$M(9O'GP +VZ2;O%01BT8.
M1M4[>G([XK[-C 6-0!@ 8 QC%?/'Q0_86^'GQ=\97'B;Q!J'BM]0EF^T)';>
M()XH8'QC,48XC/'\.*]G^'W@:Q^&_A'3O#NG7-_=V=C'Y<<VIW;W5PPSGYY'
MY8^YI ='1113 \H_:HGCC_9Y^(2/(BNVB7.%9@"?D/2K'[,LT<GP#\!A'5RN
MCVP(5@<'8.M8/[0'[(7@#]I35-)U#QE%J<EQID+06YL+]K<!6.3D '/-:?[/
M_P"S'X*_9JT[5K+P;'J$<.IS+/<?;[QK@EE7:,$@8XI >M4444P"BBB@ KY[
M_:$UVY@\>Z'I.J:IXXT;PE-ITUP;CP+97#S/=K(N%GEAC=U3R\D*N,G<6X K
MZ$KR3XF>$/%,?Q&T7QGX=T;2O%?V33I]-;2M5OVLS;F1U8SP/Y<BY8#RW!4$
MKC!Z@R]U_71_J4MG_75&5^S%\17\2^'I]&O+'Q!'>6L]S-#?:SH$NGFZM3.1
M#)))Y:1/,R%2VSD]2,YKW"N!^"/@;4/A[X"@TK4A9P7+W5Q=_8--9FM+!996
MD6V@+ $QQAMH.%[X51@#OJTD9H**X"^^-&AVGQATOX<1K/=:Y>6,]_))$H,-
MLD84A)&_OL&R%'.!DX!&>^+ >OX"IZ)E'QG\(W\O_@I9\=6P6V^&]/.!U/R6
MU?.>E_M0:Q+^W'JGQ'7X4>,[EX]$&COX=ALRU_;YVD2NNWY4/)&>Q!KZ,^$)
M/_#RWXZ$<'_A'-/QG_<MJYKX*>%_B?XA_:'^,7BS3+_0_P"W;+58-(O)9RWE
M';:Q'"*%/1=O/'.:D#[PC?S(U;:5R <'J*=35SM&[&['.*=5 )@4M%% 'QG^
MVM^S_P#'7]H+5X=%\,7_ (2B\!V[VU]##J,DD5X+N,N6)98V!3E>/K7T1\";
M7XDVG@../XJW.B7?BH7$FZ30%9;;R>/+&& .[KGBO1** ,;6O!F@>([A9]5T
M33M2G1=BR7EG',P7K@%E)Q[59T;P]I?ARW>#2M.M--A=M[1V<"0JS8QDA0!F
MM"B@ HHHH **** "BBB@ I,?YS2T4 %%%% !7RI\:?V-O&OQA^)5CXK?XUWF
ME)H][]NT*P7P[;2C3'V@?*Y<&3D$_.#UKZKHH PO VBZOX=\)Z9IVO:])XHU
M>WBV7.KRVR6S739)WF-/E7C P/2MVBB@ KQ[]K\_\8Q?$O\ [ L_\J]AKQ#]
MHWX"^,/CG8OI.D_%*[\%>'+JS>TU'2H-&M[Q;P,1R9'(=..,*1UH [?X'?\
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M?5H@W_LU) >M4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW8#SW_1S_A9_[4W_ $13P=_X61_^,U*8SZ?HKY@_X6=^U-_T13P=_P"%D?\
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M!_PK;ZGXFN_L6FI%XJ:19)?1F$.$'N:0'VS17S!_PL_]J;_HBG@[_P +(_\
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MGNS$DUV?@[P9H_@'0H='T*S%CIT1+)")'?!/)Y<D_K6W10 4V2-)HVCD4.C
MJRL,@@]013J* //]'^ ?P_T&:_DL_"]DIOH7MYEEWRH(G.6C178K&I/)5 !6
MOX'^&/AGX;Q7,?AW2H]/^TL&FD\QY9'P,*"[LS8 X S@#H!74T4 %%%% &5K
M'AC2]?NM-N=0LX[J?39_M5H\F<PRX(W+SUP2/QK"T'X/>#O#/BBX\1:9H-M:
M:O.7+3H7(4N<N40DJA8]=H&>]=E11L#UT84444 %%%% !1110 4444 %%%%
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>hook-20231231x10k023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hook-20231231x10k023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $@ 9(# 2(  A$! Q$!_\0
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MUNUW%$LT?DOL7S8I8_,*MA6#1LI7-<!\//A'X^^#</@OQ'INA6GB+4X/#_\
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M"T;N%)&>.:ROAC^U)I_CGP3X^U_4=(DT-_"-W<Q3VK3>:9X(]WES(<#B38X
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ML=9MS<:?>6]] &*^;;2K(N1U&5)&>17@VD?L-?#/P_8K9:9#J5C:*Q988;E
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M_(T;Q[_D: '44W>/?\C1O'O^1H =13=X]_R-&\>_Y&@!U%-WCW_(T;Q[_D:
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M_P"BS?$O_P &J?\ Q-'_  ["TO\ Z+-\2_\ P:I_\37VS119 ?$W_#L+2_\
MHLWQ+_\ !JG_ ,31_P .PM+_ .BS?$O_ ,&J?_$U]LT460'Q-_P["TO_ *+-
M\2__  :I_P#$T?\ #L+2_P#HLWQ+_P#!JG_Q-?;-%%D!\3?\.PM+_P"BS?$O
M_P &J?\ Q-'_  ["TO\ Z+-\2_\ P:I_\37VS119 ?$W_#L+2_\ HLWQ+_\
M!JG_ ,31_P .PM+_ .BS?$O_ ,&J?_$U]LT460'Q-_P["TO_ *+-\2__  :I
M_P#$TV3_ ()B:6D;,/C-\2R0,X_M1?\ XFOMNBBR _)']CW]IF+]F?X[>-?"
MWQ#\07D'A>6::W?4O$$EW<7,)MY)!!MC&['F!@2=N.!CBOTK^$'[0/@#X]VV
MIW'@/Q%'X@ATUXTNVCMIH?*9PQ0?O47.0K=,]*O>(_@U\._$>I7.L:[X%\-:
MOJ,H!FOK_1[>>>3 P-SLA8X  &3T%?'O_!-KQ3X=N/BK^T#INB^7;VMQK@O;
M"VAMS#&MHLLZ#:N $ +* O'':EMH!][T4W>O]X?G1O7^\/SJ@'44W>O]X?G1
MO7^\/SH =13=Z_WA^=>4>+?VH_ASX(^+&D_#?5]:FM_%VJ& 6MFEA/(CF9RD
M>950H,E3U/'>@#UFBBB@ HHHH **** "BBB@ KPW]JKQO_PB7AO3+67Q=HOA
M>QU5I[6ZBUOPI=:]#>Q[!F/RX)$V#!.=V0P.*]RKA_B9+X6MDLI?$_BQ_"T;
MQW%O PUYM+6;S$VL>)$WLHY4\E#R,'FHDKHJ+LSY6_9L_P"$*_X7)H0TC7/A
MW>7^V?RX-!^%E[HMV?W+9V7<DK+'@9SD?,,CO7W#7A_PVT3X;VGC&PET#XI:
MMXDU51)Y6FW/CZXU-)1L.[-N\[A\#)Y4XQGM7N%:MZ(S6["BBBI*"OEKXL_\
MG^? ;_L >(?_ $7'7U+7RU\6?^3_ #X#?]@#Q#_Z+CI,#ZEHHHI@%%%% !11
M10 4444 %%%% !7(_%[Q3+X'^%7C#Q%!!%<SZ3I%W?)#.Q6-VCA9PK$<@''.
M*ZZH[BWBNX)(9XTFAD4H\<BAE93P00>HH _/C_@GA^UII&J:!XQL?%DFG>'T
MMI[6>V:%II3,71U<'@@!?+3'^\:^OO\ AI/X;?\ 0U6W_?F;_P"(K>A^#_@.
MV!\GP5X>ASU\K2X%S^2U+_PJCP5_T*.A_P#@NA_^)H YS_AI/X;?]#5;?]^9
MO_B*/^&D_AM_T-5M_P!^9O\ XBNC_P"%4>"O^A1T/_P70_\ Q-'_  JCP5_T
M*.A_^"Z'_P")H YS_AI/X;?]#5;?]^9O_B*/^&D_AM_T-5M_WYF_^(KH_P#A
M5'@K_H4=#_\ !=#_ /$T?\*H\%?]"CH?_@NA_P#B: .<_P"&D_AM_P!#5;?]
M^9O_ (BC_AI/X;?]#5;?]^9O_B*Z/_A5'@K_ *%'0_\ P70__$T?\*H\%?\
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MM .?[RT/1V9*=U<^[J***8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[1?AWXJ^.?&-O)>Z&]I+#%;VZSO/Y$I=8RQ5-@.YN0"17VQ10 4444 %%%%
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M  ?VO_QRC_AIOX0?]%3\&?\ @_M?_CE 'IE%>9_\--_"#_HJ?@S_ ,']K_\
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M\!MX2CT%+7P8=&71;9V18="\D6\3$[F 6+Y023DCWS71T6L!\Z_\.]/V>O\
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MZ?L]?]$TT_\ \"[K_P"/5]%5#>7EOIUK+<W4\=M;1*7DFF<(B*.I)/ 'N:-
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M>*KA!:6.H0F*XM;&!=D,;HP!4ES,Y!_OBKM9V[?JE;\;_)&<9.45+O\ H_\
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>31
<FILENAME>hook-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 10:36:48 AM-->
<!--Modified on: 3/22/2024 10:36:48 AM-->
<xsd:schema targetNamespace="http://www.hookipapharma.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:hook="http://www.hookipapharma.com/20231231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" id="DisclosurePropertyPlantAndEquipmentNetDetails">
        <link:definition>40601 - Disclosure - Property, plant and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2" id="DisclosureLeasesMinimumLeasePaymentsDetailsCalc2">
        <link:definition>40703 - Disclosure - Leases - Minimum lease payments (Details) calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" id="DisclosureLeasesLeaseCostsDetails">
        <link:definition>40802 - Disclosure - Leases - Lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" id="DisclosureLeasesMinimumLeasePaymentsDetails">
        <link:definition>40803 - Disclosure - Leases - Minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40901 - Disclosure - Accrued expenses and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" id="DisclosureLoansPayableDetails">
        <link:definition>41001 - Disclosure - Loans payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" id="DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails">
        <link:definition>41002 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails">
        <link:definition>41301 - Disclosure - Income taxes - Losses before income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails" id="DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails">
        <link:definition>41302 - Disclosure - Income taxes - components of the consolidated income tax provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" id="DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails">
        <link:definition>41303 - Disclosure - Income taxes - Effective income tax reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails">
        <link:definition>41304 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails">
        <link:definition>40201 - Disclosure - Summary of significant accounting policies - Going concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails">
        <link:definition>40203 - Disclosure - Summary of significant accounting policies - Others (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails">
        <link:definition>40204 - Disclosure - Summary of significant accounting policies - Comprehensive loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" id="DisclosureCollaborationAndLicensingAgreementsDetails">
        <link:definition>40301 - Disclosure - Collaboration and Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails" id="DisclosureImpairmentAdditionalInformationDetails">
        <link:definition>40401 - Disclosure - Impairment - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" id="DisclosureFairValueOfFinancialAssetsDetails">
        <link:definition>40501 - Disclosure - Fair Value of Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails" id="DisclosureReceivableResearchIncentiveDetails">
        <link:definition>40701 - Disclosure - Receivable research incentive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40801 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" id="DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails">
        <link:definition>40804 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" id="DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails">
        <link:definition>41101 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" id="DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails">
        <link:definition>41201 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" id="DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails">
        <link:definition>41202 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails" id="DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails">
        <link:definition>41203 - Disclosure - Stock-based compensation - Summary of awards outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" id="DisclosureStockBasedCompensationStockOptionValuationDetails">
        <link:definition>41204 - Disclosure - Stock-based compensation - Stock option valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>41205 - Disclosure - Stock-based compensation - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" id="DisclosureStockBasedCompensationCommonStockAwardsDetails">
        <link:definition>41206 - Disclosure - Stock-based compensation - Common Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" id="DisclosureStockBasedCompensationStockBasedCompensationDetails">
        <link:definition>41207 - Disclosure - Stock-based compensation - Stock-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>41306 - Disclosure - Income taxes -Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41401 - Disclosure - Commitments and contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" id="Disclosure401KSavingsPlanDetails">
        <link:definition>41501 - Disclosure - 401(k) Savings Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41601 - Disclosure - Net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>41602 - Disclosure - Net loss per share - Antidilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" id="DisclosureRelatedPartiesDetails">
        <link:definition>41701 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41801 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization" id="DisclosureNatureOfBusinessAndOrganization">
        <link:definition>10101 - Disclosure - Nature of the business and organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements" id="DisclosureCollaborationAndLicensingAgreements">
        <link:definition>10301 - Disclosure - Collaboration and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureImpairment" id="DisclosureImpairment">
        <link:definition>10401 - Disclosure - Impairment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets" id="DisclosureFairValueOfFinancialAssets">
        <link:definition>10501 - Disclosure - Fair Value of Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet" id="DisclosurePropertyPlantAndEquipmentNet">
        <link:definition>10601 - Disclosure - Property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive" id="DisclosureReceivableResearchIncentive">
        <link:definition>10701 - Disclosure - Receivable research incentive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10801 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10901 - Disclosure - Accrued expenses and other current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayable" id="DisclosureLoansPayable">
        <link:definition>11001 - Disclosure - Loans payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock" id="DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock">
        <link:definition>11101 - Disclosure - Common stock, Class A common stock and convertible preferred stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11201 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11301 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11401 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlan" id="Disclosure401KSavingsPlan">
        <link:definition>11501 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11601 - Disclosure - Net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureRelatedParties" id="DisclosureRelatedParties">
        <link:definition>11701 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11801 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureImpairmentTables" id="DisclosureImpairmentTables">
        <link:definition>30403 - Disclosure - Impairment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables" id="DisclosureFairValueOfFinancialAssetsTables">
        <link:definition>30503 - Disclosure - Fair Value of Financial Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables" id="DisclosurePropertyPlantAndEquipmentNetTables">
        <link:definition>30603 - Disclosure - Property, plant and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30803 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30903 - Disclosure - Accrued expenses and other current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableTables" id="DisclosureLoansPayableTables">
        <link:definition>31003 - Disclosure - Loans payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31203 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31303 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31603 - Disclosure - Net loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureImpairmentNonCashImpairmentChargesDetails" id="DisclosureImpairmentNonCashImpairmentChargesDetails">
        <link:definition>40402 - Disclosure - Impairment - Non-cash impairment charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsDetails">
        <link:definition>41305 - Disclosure - Income taxes - Changes in the valuation allowance for deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="hook-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="hook-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="hook-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="hook-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element id="hook_GoingConcernPolicyPolicyTextBlock" name="GoingConcernPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_DeferredOfferingCostsPolicyPolicyTextBlock" name="DeferredOfferingCostsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" name="ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" name="GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_EarningsPerSharePolicyPolicyTextBlock" name="EarningsPerSharePolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" name="CollaborativeArrangementNumberOfPreclinicalResearchPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_CollaborativeAndLicensingArrangementAbstract" name="CollaborativeAndLicensingArrangementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_MilestoneAxis" name="MilestoneAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_MilestoneDomain" name="MilestoneDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_CommercialMilestonesMember" name="CommercialMilestonesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ProceedsFromNonRefundableUpFrontPayment" name="ProceedsFromNonRefundableUpFrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" name="DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="hook_CollaborativeArrangementTermOfRoyaltyPayment" name="CollaborativeArrangementTermOfRoyaltyPayment" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" name="CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" name="CollaborativeArrangementContractAssetRelatingToSublicensePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_PrepaidExpensesAndOtherCurrentAssets" name="PrepaidExpensesAndOtherCurrentAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_CollaborationAndLicensingMember" name="CollaborationAndLicensingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_GrantIncome" name="GrantIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" name="IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="hook_LeaseDisclosureTextBlock" name="LeaseDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" name="ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_LesseeLeaseRemainingTermOfContract" name="LesseeLeaseRemainingTermOfContract" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" name="AccruedExpensesAndOtherLiabilitiesCurrentAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_AccruedSocialSecurityContributionsCurrent" name="AccruedSocialSecurityContributionsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_AccruedUnearnedGrantIncomeCurrent" name="AccruedUnearnedGrantIncomeCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_OtherAccruedExpensesAndLiabilitiesCurrent" name="OtherAccruedExpensesAndLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_NumberOfVotes" name="NumberOfVotes" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="hook_LicensingFeesIntellectualPropertyLicenses" name="LicensingFeesIntellectualPropertyLicenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_StockOptionAndGrant2018PlanMember" name="StockOptionAndGrant2018PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_StockOptionAndIncentive2019PlanMember" name="StockOptionAndIncentive2019PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_DisclosureOfLongTermLoansPayableTextBlock" name="DisclosureOfLongTermLoansPayableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_LongTermLoansPayableGross" name="LongTermLoansPayableGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_DisclosureOfLongTermLoansPayableTableTextBlock" name="DisclosureOfLongTermLoansPayableTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_NumberOfPreclinicalResearchPrograms" name="NumberOfPreclinicalResearchPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" name="StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_NonExecutiveDirectorsMember" name="NonExecutiveDirectorsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" name="ConversionOfStockCommonStockIssuedForEachShareConverted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_CommonStockOtherThanClassMember" name="CommonStockOtherThanClassMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_IncomeTaxBenefitsNetOperatingLossesIncurred" name="IncomeTaxBenefitsNetOperatingLossesIncurred" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree" name="DeferredRevenuePercentageOfRevenueRecognizedInYearThree" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="hook_IncreaseDecreaseInEstimatedMarketRate" name="IncreaseDecreaseInEstimatedMarketRate" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_DebtInstrumentEstimatedMarketRatePercent" name="DebtInstrumentEstimatedMarketRatePercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ReceivablesTaxResearchPremiumCurrent" name="ReceivablesTaxResearchPremiumCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_TotalMilestoneAmount" name="TotalMilestoneAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_CollaborativeArrangementRevenueFromMilestonePayments" name="CollaborativeArrangementRevenueFromMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" name="CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" name="ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_NumberOfResearchProgramPerformanceObligations" name="NumberOfResearchProgramPerformanceObligations" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" name="NumberOfCombinedPerformanceObligationForEachResearchProgram" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" name="CollaborationAgreementMilestonePaymentsRevenueRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_ProceedsFromMilestonePayment" name="ProceedsFromMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="hook_SeriesaConvertiblePreferredStockMember" name="SeriesaConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ThresholdPercentageForConversion" name="ThresholdPercentageForConversion" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" name="StockIssuedDuringPeriodValueRestrictedStockAwardVested" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVested" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_SharesGrantedValueShareBasedPaymentArrangementVested" name="SharesGrantedValueShareBasedPaymentArrangementVested" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" name="SharesIssuedSharesShareBasedPaymentArrangementVested" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_ConvertiblePreferredStocksMember" name="ConvertiblePreferredStocksMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="hook_RevenueRecognizedUpfrontPayment" name="RevenueRecognizedUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_PreferredStockSharesDesignated" name="PreferredStockSharesDesignated" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="hook_ReceivableResearchIncentiveAbstract" name="ReceivableResearchIncentiveAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="hook_ReceivableResearchIncentiveTextBlock" name="ReceivableResearchIncentiveTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="hook_GrantIncomeIncentiveProgram" name="GrantIncomeIncentiveProgram" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="hook_AccruedExternalResearchAndDevelopmentExpenses" name="AccruedExternalResearchAndDevelopmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_AccruedExternalGeneralAndAdministrationExpenses" name="AccruedExternalGeneralAndAdministrationExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" name="AccruedExpensesForPropertyAndEquipmentAcquisitions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element name="AccruedSubLicenseFees" id="hook_AccruedSubLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" id="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LeaseAssetsDerecognizedUponLeaseCancellation" id="hook_LeaseAssetsDerecognizedUponLeaseCancellation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Seriesa1ConvertiblePreferredStockMember" id="hook_Seriesa1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncreaseDecreaseInReceivableResearchIncentives" id="hook_IncreaseDecreaseInReceivableResearchIncentives" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockPurchaseAgreementMember" id="hook_StockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" id="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborativeAgreementProgramInitiationFees" id="hook_CollaborativeAgreementProgramInitiationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RemainingOfCommonStockReservedForFutureIssuance" id="hook_RemainingOfCommonStockReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="HbvProgramMember" id="hook_HbvProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HivProgramMember" id="hook_HivProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RegisterForResaleOfCommonStockAdditionalIssuances" id="hook_RegisterForResaleOfCommonStockAdditionalIssuances" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PublicOfferingMember" id="hook_PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredRevenuePercentageOfRevenueRecognizedInYearOne" id="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="GileadSciencesIncMember" id="hook_GileadSciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValueAssetsLevel1ToLevel2TransfersAmount1" id="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueAssetsLevel2ToLevel1TransfersAmount1" id="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RocheCollaborationAgreementMember" id="hook_RocheCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConversionOfCommonStockSharesIssuedUponConversion" id="hook_ConversionOfCommonStockSharesIssuedUponConversion" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ConversionOfCommonStockSharesIssuable" id="hook_ConversionOfCommonStockSharesIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfCombinedPerformanceObligation" id="hook_NumberOfCombinedPerformanceObligation" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CollaborationArrangementProgramCompletionFeeOnOptionExercise" id="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" id="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SeriesA2ConvertiblePreferredStockMember" id="hook_SeriesA2ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InducementAwardsPlanMember" id="hook_InducementAwardsPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember" id="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" id="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="StockOptionExchangeOfferMember" id="hook_StockOptionExchangeOfferMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfEligibleParticipants" id="hook_NumberOfEligibleParticipants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" id="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" id="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockOptionsIssuedExercisePricePerShare" id="hook_StockOptionsIssuedExercisePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" id="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ExercisePriceLimitConsideredForCancellationOfStockOptions" id="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaltePetersMember" id="hook_MaltePetersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConsultingAgreementMember" id="hook_ConsultingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AmendedStockPurchaseAgreementMember" id="hook_AmendedStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="January2024RestructuringPlanMember" id="hook_January2024RestructuringPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AustrianResearchIncentiveProgramMember" id="hook_AustrianResearchIncentiveProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentIncentiveProgramAxis" id="hook_ResearchAndDevelopmentIncentiveProgramAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentIncentiveProgramDomain" id="hook_ResearchAndDevelopmentIncentiveProgramDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentIncentiveProgramTable" id="hook_ResearchAndDevelopmentIncentiveProgramTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentIncentiveProgramLineItems" id="hook_ResearchAndDevelopmentIncentiveProgramLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember" id="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember" id="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeaseForCertainParkingSpacesInViennaOfficeMember" id="hook_LeaseForCertainParkingSpacesInViennaOfficeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember" id="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestructuringPlanCarryingValueOfAsset" id="hook_RestructuringPlanCarryingValueOfAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" id="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" id="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborationAgreementFinalMilestonePayment" id="hook_CollaborationAgreementFinalMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Rule10b51ArrangementModified" id="hook_Rule10b51ArrangementModified" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NonRule10b51ArrangementModified" id="hook_NonRule10b51ArrangementModified" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LeaseForCorporateHeadquartersInNewYorkCityMember" id="hook_LeaseForCorporateHeadquartersInNewYorkCityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UsTaxOnGiltiNetOfResearchCredits" id="hook_UsTaxOnGiltiNetOfResearchCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>32
<FILENAME>hook-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 10:36:48 AM-->
<!--Modified on: 3/22/2024 10:36:48 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosurePropertyPlantAndEquipmentNetDetails" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesMinimumLeasePaymentsDetailsCalc2" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesLeaseCostsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesMinimumLeasePaymentsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLoansPayableDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" />
  <calculationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638467006054826260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638467006054826260" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467006054826260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467006054826260" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467006054826260" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_638467006054826260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467006054826260" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent_638467006054826260" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638467006054826260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467006054826260" xlink:to="us-gaap_AccountsReceivableNetCurrent_638467006054826260" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_638467006054826260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467006054826260" xlink:to="hook_PrepaidExpensesAndOtherCurrentAssets_638467006054826260" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638467006054826260" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638467006054826260" xlink:to="us-gaap_RestrictedCashCurrent_638467006054826260" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_638467006054836263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_638467006054836263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638467006054836263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638467006054836263" xlink:to="us-gaap_RestrictedCashNoncurrent_638467006054836263" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638467006054836263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638467006054836263" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638467006054836263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638467006054836263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638467006054836263" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638467006054836263" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638467006054836263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_638467006054836263" xlink:to="us-gaap_OtherAssetsNoncurrent_638467006054836263" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638467006054836263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638467006054836263" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638467006054836263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638467006054836263" xlink:to="us-gaap_LiabilitiesCurrent_638467006054836263" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638467006054836263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638467006054836263" xlink:to="us-gaap_AccountsPayableCurrent_638467006054836263" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638467006054846263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638467006054836263" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638467006054846263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638467006054846263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638467006054836263" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638467006054846263" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_638467006054846263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638467006054836263" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_638467006054846263" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_638467006054846263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638467006054836263" xlink:to="us-gaap_LoansPayableCurrent_638467006054846263" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638467006054846263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638467006054836263" xlink:to="us-gaap_LiabilitiesNoncurrent_638467006054846263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable_638467006054846263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638467006054846263" xlink:to="us-gaap_LoansPayable_638467006054846263" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638467006054846263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638467006054846263" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638467006054846263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_638467006054856265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638467006054846263" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_638467006054856265" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638467006054856265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638467006054846263" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638467006054856265" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638467006054856265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638467006054856265" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638467006054856265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638467006054856265" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638467006054856265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638467006054856265" xlink:to="us-gaap_CommonStockValue_638467006054856265" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638467006054856265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638467006054856265" xlink:to="us-gaap_PreferredStockValue_638467006054856265" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638467006054856265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638467006054856265" xlink:to="us-gaap_AdditionalPaidInCapital_638467006054856265" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638467006054866265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638467006054856265" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638467006054866265" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638467006054866265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638467006054856265" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638467006054866265" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638467006054866265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638467006054866265" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638467006054866265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638467006054866265" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638467006054866265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638467006054866265" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638467006054866265" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638467006054866265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638467006054866265" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638467006054866265" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638467006054866265" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638467006054866265" xlink:to="us-gaap_NonoperatingIncomeExpense_638467006054866265" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GrantIncome" xlink:label="hook_GrantIncome_638467006054876262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638467006054866265" xlink:to="hook_GrantIncome_638467006054876262" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638467006054876262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638467006054866265" xlink:to="us-gaap_InvestmentIncomeInterest_638467006054876262" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638467006054876262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638467006054866265" xlink:to="us-gaap_InterestExpense_638467006054876262" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638467006054876262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638467006054866265" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638467006054876262" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638467006054876262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638467006054866265" xlink:to="us-gaap_OperatingIncomeLoss_638467006054876262" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467006054876262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638467006054876262" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467006054876262" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638467006054876262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638467006054876262" xlink:to="us-gaap_CostsAndExpenses_638467006054876262" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638467006054876262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638467006054876262" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638467006054876262" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638467006054876262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638467006054876262" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638467006054876262" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006054886262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638467006054876262" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006054886262" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467006054886262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467006054886262" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638467006054886262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467006054886262" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638467006054886262" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_638467006054886262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467006054886262" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_638467006054886262" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638467006054886262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467006054886262" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638467006054886262" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638467006054886262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467006054886262" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638467006054886262" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638467006054886262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467006054886262" xlink:to="us-gaap_RepaymentsOfDebt_638467006054886262" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467006054896262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467006054896262" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638467006054896262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467006054896262" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638467006054896262" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638467006054896262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_ProfitLoss_638467006054896262" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638467006054896262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_ShareBasedCompensation_638467006054896262" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638467006054896262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_OtherNoncashIncomeExpense_638467006054896262" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638467006054896262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638467006054896262" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006054896262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006054896262" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638467006054896262" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638467006054896262" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638467006054906261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638467006054906261" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInReceivableResearchIncentives" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_638467006054906261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="hook_IncreaseDecreaseInReceivableResearchIncentives_638467006054906261" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_638467006054906261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_638467006054906261" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638467006054906261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638467006054906261" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638467006054906261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638467006054906261" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638467006054906261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638467006054906261" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638467006054906261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638467006054906261" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_638467006054916263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006054896262" xlink:to="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_638467006054916263" order="14" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property, plant and equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638467006054916263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638467006054916263" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638467006054916263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638467006054916263" order="2" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2" xlink:type="extended" xlink:title="40703 - Disclosure - Leases - Minimum lease payments (Details) calc 2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638467006054916263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_OperatingLeaseLiability_638467006054916263" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638467006054916263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638467006054916263" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Leases - Lease costs (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638467006054916263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense_638467006054916263" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638467006054926263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638467006054926263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638467006054926263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638467006054926263" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_638467006054926263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome_638467006054926263" order="4" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Leases - Minimum lease payments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638467006054926263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638467006054926263" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638467006054926263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638467006054926263" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638467006054926263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638467006054926263" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638467006054926263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638467006054926263" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638467006054926263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638467006054926263" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638467006054936266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638467006054936266" order="6" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Accrued expenses and other current liabilities (Details)">
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_638467006054936266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_638467006054936266" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedSocialSecurityContributionsCurrent" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_638467006054936266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedSocialSecurityContributionsCurrent_638467006054936266" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638467006054936266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638467006054936266" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedUnearnedGrantIncomeCurrent" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_638467006054936266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedUnearnedGrantIncomeCurrent_638467006054936266" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_638467006054936266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_OtherAccruedExpensesAndLiabilitiesCurrent_638467006054936266" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_638467006054936266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedExternalResearchAndDevelopmentExpenses_638467006054936266" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExternalGeneralAndAdministrationExpenses" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_638467006054936266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedExternalGeneralAndAdministrationExpenses_638467006054936266" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_638467006054936266" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_638467006054936266" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedSubLicenseFees" xlink:label="hook_AccruedSubLicenseFees_638467006054946267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedSubLicenseFees_638467006054946267" order="9" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Loans payable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_638467006054946267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_638467006054946267" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LongTermLoansPayableGross" xlink:label="hook_LongTermLoansPayableGross_638467006054946267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="hook_LongTermLoansPayableGross_638467006054946267" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638467006054946267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638467006054946267" order="1" use="optional" weight="1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income taxes - Losses before income taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638467006054946267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638467006054946267" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638467006054946267" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638467006054946267" order="2" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income taxes - components of the consolidated income tax provision (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638467006054956263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638467006054956263" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638467006054956263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638467006054956263" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638467006054956263" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638467006054956263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638467006054956263" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638467006054956263" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_638467006054956263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638467006054956263" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_638467006054956263" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income taxes - Effective income tax reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467006054956263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467006054956263" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638467006054956263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638467006054956263" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638467006054956263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638467006054956263" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_638467006054966263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_638467006054966263" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638467006054966263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638467006054966263" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_638467006054966263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_638467006054966263" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638467006054966263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638467006054966263" order="7" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638467006054966263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638467006054966263" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638467006054966263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638467006054966263" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638467006054966263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467006054966263" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638467006054966263" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638467006054966263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638467006054966263" xlink:to="us-gaap_DeferredTaxAssetsGross_638467006054966263" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638467006054976272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638467006054966263" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638467006054976272" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638467006054976272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638467006054966263" xlink:to="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638467006054976272" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638467006054976272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638467006054966263" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638467006054976272" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_638467006054976272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638467006054966263" xlink:to="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_638467006054976272" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638467006054976272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638467006054966263" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638467006054976272" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_638467006054976272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638467006054966263" xlink:to="hook_DeferredTaxAssetsOperatingLeaseLiabilities_638467006054976272" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638467006054976272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638467006054976272" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638467006054976272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638467006054976272" xlink:to="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638467006054976272" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638467006054976272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638467006054976272" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638467006054976272" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_638467006054986263" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638467006054976272" xlink:to="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_638467006054986263" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>33
<FILENAME>hook-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 10:36:48 AM-->
<!--Modified on: 3/22/2024 10:36:48 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureCollaborationAndLicensingAgreementsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureImpairmentAdditionalInformationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureFairValueOfFinancialAssetsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosurePropertyPlantAndEquipmentNetDetails" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureReceivableResearchIncentiveDetails" roleURI="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesLeaseCostsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLoansPayableDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationCommonStockAwardsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationStockBasedCompensationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#Disclosure401KSavingsPlanDetails" roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.hookipapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="hook-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_1" xlink:title="hook_AccruedExpensesAndOtherCurrentLiabilities_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To hook_AccruedExpensesAndOtherCurrentLiabilities_1" order="1" priority="0" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_2" xlink:title="srt_ProductsAndServicesDomain_2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationAndLicensingMember" xlink:label="hook_CollaborationAndLicensingMember_1" xlink:title="hook_CollaborationAndLicensingMember_1" />
    <definitionArc xlink:type="arc" xlink:from="srt_ProductsAndServicesDomain_2" xlink:to="hook_CollaborationAndLicensingMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:srt_ProductsAndServicesDomain_2 To hook_CollaborationAndLicensingMember_1" order="1" priority="0" />
  </definitionLink>
  <link:definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MilestoneAxis" xlink:label="hook_MilestoneAxis_1" xlink:title="hook_MilestoneAxis_1" />
    <link:loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MilestoneDomain" xlink:label="hook_MilestoneDomain_1" xlink:title="hook_MilestoneDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="hook_MilestoneAxis_1" xlink:to="hook_MilestoneDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:hook_MilestoneAxis_1 To hook_MilestoneDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityNameAxis_1 To us-gaap_IncomeTaxAuthorityNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis_1" xlink:title="us-gaap_RestructuringPlanAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_1" xlink:title="us-gaap_RestructuringPlanDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringPlanAxis_1" xlink:to="us-gaap_RestructuringPlanDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringPlanAxis_1 To us-gaap_RestructuringPlanDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramAxis" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramAxis_1" xlink:title="hook_ResearchAndDevelopmentIncentiveProgramAxis_1" />
    <link:loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramDomain" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramDomain_1" xlink:title="hook_ResearchAndDevelopmentIncentiveProgramDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramAxis_1" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:hook_ResearchAndDevelopmentIncentiveProgramAxis_1 To hook_ResearchAndDevelopmentIncentiveProgramDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006054986263" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638467006054986263" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CountryRegion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006055076264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638467006055076264" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="hook_PrepaidExpensesAndOtherCurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LoansPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006055166266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638467006055166266" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_PreferredStockSharesDesignated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638467006055186266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_638467006055186266" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConvertiblePreferredStocksMember" xlink:label="hook_ConvertiblePreferredStocksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="hook_ConvertiblePreferredStocksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006055196268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638467006055196268" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638467006055206266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638467006055206266" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PublicOfferingMember" xlink:label="hook_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hook_PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockPurchaseAgreementMember" xlink:label="hook_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hook_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ConversionOfStockAmountIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:to="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="hook_SharesGrantedValueShareBasedPaymentArrangementVested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:to="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" xlink:label="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006055386270" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638467006055386270" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638467006055396267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638467006055396267" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PublicOfferingMember" xlink:label="hook_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hook_PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockPurchaseAgreementMember" xlink:label="hook_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hook_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006055406265" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006055406265" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="hook_ComputerEquipmentAndSoftwareMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006055406265" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638467006055406265" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Collaboration and Licensing Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MilestoneAxis" xlink:label="hook_MilestoneAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="hook_MilestoneAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MilestoneDomain" xlink:label="hook_MilestoneDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="hook_MilestoneAxis" xlink:to="hook_MilestoneDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MilestoneDomain" xlink:label="hook_MilestoneDomain_638467006055426267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="hook_MilestoneAxis" xlink:to="hook_MilestoneDomain_638467006055426267" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DevelopmentMilestonesMember" xlink:label="hook_DevelopmentMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="hook_MilestoneDomain" xlink:to="hook_DevelopmentMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommercialMilestonesMember" xlink:label="hook_CommercialMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="hook_MilestoneDomain" xlink:to="hook_CommercialMilestonesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006055426267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006055426267" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_HbvProgramMember" xlink:label="hook_HbvProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="hook_HbvProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_HivProgramMember" xlink:label="hook_HivProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="hook_HivProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RocheCollaborationAgreementMember" xlink:label="hook_RocheCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="hook_RocheCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006055436264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638467006055436264" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfPreclinicalResearchPrograms" xlink:label="hook_NumberOfPreclinicalResearchPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_NumberOfPreclinicalResearchPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ProceedsFromNonRefundableUpFrontPayment" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_ProceedsFromNonRefundableUpFrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeAgreementProgramInitiationFees" xlink:label="hook_CollaborativeAgreementProgramInitiationFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeAgreementProgramInitiationFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_TotalMilestoneAmount" xlink:label="hook_TotalMilestoneAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_TotalMilestoneAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise" xlink:label="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementTermOfRoyaltyPayment" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementTermOfRoyaltyPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ProceedsFromMilestonePayment" xlink:label="hook_ProceedsFromMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_ProceedsFromMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RevenueRecognizedUpfrontPayment" xlink:label="hook_RevenueRecognizedUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_RevenueRecognizedUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementRevenueFromMilestonePayments" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementRevenueFromMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Impairment - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638467006055476267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_638467006055476267" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_638467006055476267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_638467006055476267" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_January2024RestructuringPlanMember" xlink:label="hook_January2024RestructuringPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="hook_January2024RestructuringPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638467006055476267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_638467006055476267" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Financial Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638467006055486264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638467006055486264" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638467006055496264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638467006055496264" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638467006055496264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638467006055496264" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_FairValueAssetsLevel1ToLevel2TransfersAmount1" xlink:label="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_FairValueAssetsLevel2ToLevel1TransfersAmount1" xlink:label="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property, plant and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006055516266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006055516266" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="hook_ComputerEquipmentAndSoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RestructuringPlanCarryingValueOfAsset" xlink:label="hook_RestructuringPlanCarryingValueOfAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="hook_RestructuringPlanCarryingValueOfAsset" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Receivable research incentive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramTable" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramTable" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramAxis" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramTable" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramDomain" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramAxis" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramDomain" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramDomain_638467006055536272" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramAxis" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramDomain_638467006055536272" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AustrianResearchIncentiveProgramMember" xlink:label="hook_AustrianResearchIncentiveProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramDomain" xlink:to="hook_AustrianResearchIncentiveProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember" xlink:label="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramDomain" xlink:to="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember" xlink:label="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramDomain" xlink:to="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramLineItems" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GrantIncomeIncentiveProgram" xlink:label="hook_GrantIncomeIncentiveProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems" xlink:to="hook_GrantIncomeIncentiveProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" xlink:label="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems" xlink:to="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" xlink:label="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems" xlink:to="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006055546267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638467006055546267" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LesseeLeaseRemainingTermOfContract" xlink:label="hook_LesseeLeaseRemainingTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="hook_LesseeLeaseRemainingTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Leases - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638467006055556266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_638467006055556266" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SubleaseIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638467006055566265" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_638467006055566265" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseForCorporateHeadquartersInNewYorkCityMember" xlink:label="hook_LeaseForCorporateHeadquartersInNewYorkCityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="hook_LeaseForCorporateHeadquartersInNewYorkCityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember" xlink:label="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseForCertainParkingSpacesInViennaOfficeMember" xlink:label="hook_LeaseForCertainParkingSpacesInViennaOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="hook_LeaseForCertainParkingSpacesInViennaOfficeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Loans payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006055576263" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638467006055576263" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638467006055586268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_638467006055586268" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LongTermLoansPayableGross" xlink:label="hook_LongTermLoansPayableGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hook_LongTermLoansPayableGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLoansPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInEstimatedMarketRate" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hook_IncreaseDecreaseInEstimatedMarketRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DebtInstrumentEstimatedMarketRatePercent" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="hook_DebtInstrumentEstimatedMarketRatePercent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638467006055616268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638467006055616268" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockPurchaseAgreementMember" xlink:label="hook_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hook_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AmendedStockPurchaseAgreementMember" xlink:label="hook_AmendedStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hook_AmendedStockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006055616268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638467006055616268" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember" xlink:label="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638467006055626265" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_638467006055626265" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GileadSciencesIncMember" xlink:label="hook_GileadSciencesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="hook_GileadSciencesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006055636264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006055636264" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_PreferredStockSharesDesignated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RemainingOfCommonStockReservedForFutureIssuance" xlink:label="hook_RemainingOfCommonStockReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_RemainingOfCommonStockReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RegisterForResaleOfCommonStockAdditionalIssuances" xlink:label="hook_RegisterForResaleOfCommonStockAdditionalIssuances" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_RegisterForResaleOfCommonStockAdditionalIssuances" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfVotes" xlink:label="hook_NumberOfVotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_NumberOfVotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ThresholdPercentageForConversion" xlink:label="hook_ThresholdPercentageForConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="hook_ThresholdPercentageForConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638467006055686268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_638467006055686268" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndGrant2018PlanMember" xlink:label="hook_StockOptionAndGrant2018PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="hook_StockOptionAndGrant2018PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638467006055686268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_638467006055686268" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006055686268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006055686268" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="hook_NonExecutiveDirectorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638467006055706267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_638467006055706267" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndIncentive2019PlanMember" xlink:label="hook_StockOptionAndIncentive2019PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="hook_StockOptionAndIncentive2019PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_InducementAwardsPlanMember" xlink:label="hook_InducementAwardsPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="hook_InducementAwardsPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638467006055706267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_638467006055706267" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006055716264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006055716264" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="hook_NonExecutiveDirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006055716264" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006055716264" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionExchangeOfferMember" xlink:label="hook_StockOptionExchangeOfferMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="hook_StockOptionExchangeOfferMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006055726267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638467006055726267" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfEligibleParticipants" xlink:label="hook_NumberOfEligibleParticipants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_NumberOfEligibleParticipants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" xlink:label="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ExercisePriceLimitConsideredForCancellationOfStockOptions" xlink:label="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" xlink:label="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionsIssuedExercisePricePerShare" xlink:label="hook_StockOptionsIssuedExercisePricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_StockOptionsIssuedExercisePricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-based compensation - Summary of awards outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638467006055766265" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_638467006055766265" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndGrant2018PlanMember" xlink:label="hook_StockOptionAndGrant2018PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="hook_StockOptionAndGrant2018PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndIncentive2019PlanMember" xlink:label="hook_StockOptionAndIncentive2019PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="hook_StockOptionAndIncentive2019PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_InducementAwardsPlanMember" xlink:label="hook_InducementAwardsPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="hook_InducementAwardsPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Stock-based compensation - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006055776266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638467006055776266" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Stock-based compensation - Common Stock Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467006055896266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467006055896266" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xlink:type="extended" xlink:title="41207 - Disclosure - Stock-based compensation - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638467006055916269" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_638467006055916269" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income taxes - Effective income tax reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638467006055926266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_638467006055926266" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AT" xlink:label="country_AT" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_AT" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="41306 - Disclosure - Income taxes -Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638467006055936267" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_638467006055936267" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AT" xlink:label="country_AT" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_AT" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638467006055946265" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638467006055946265" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_UsTaxOnGiltiNetOfResearchCredits" xlink:label="hook_UsTaxOnGiltiNetOfResearchCredits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="hook_UsTaxOnGiltiNetOfResearchCredits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" xlink:type="extended" xlink:title="41501 - Disclosure - 401(k) Savings Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006055956274" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_638467006055956274" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006055966266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638467006055966266" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_CommonStockOtherThanClassMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesaConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConversionOfCommonStockSharesIssuedUponConversion" xlink:label="hook_ConversionOfCommonStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="hook_ConversionOfCommonStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConversionOfCommonStockSharesIssuable" xlink:label="hook_ConversionOfCommonStockSharesIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="hook_ConversionOfCommonStockSharesIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Net loss per share - Antidilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638467006055996271" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638467006055996271" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638467006056006281" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_638467006056006281" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyMember" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638467006056006281" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638467006056006281" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MaltePetersMember" xlink:label="hook_MaltePetersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="hook_MaltePetersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638467006056016271" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_638467006056016271" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConsultingAgreementMember" xlink:label="hook_ConsultingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="hook_ConsultingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638467006056026268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_638467006056026268" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056026268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056026268" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RocheCollaborationAgreementMember" xlink:label="hook_RocheCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="hook_RocheCollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RestructuringPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_638467006056026268" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanDomain_638467006056026268" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_January2024RestructuringPlanMember" xlink:label="hook_January2024RestructuringPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="hook_January2024RestructuringPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638467006056036266" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_638467006056036266" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationAgreementFinalMilestonePayment" xlink:label="hook_CollaborationAgreementFinalMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hook_CollaborationAgreementFinalMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>34
<FILENAME>hook-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 10:36:48 AM-->
<!--Modified on: 3/22/2024 10:36:48 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CommonStockOtherThanClassMember" xlink:to="hook_CommonStockOtherThanClassMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CommonStockOtherThanClassMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classification of common stock other than Class A common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CommonStockOtherThanClassMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Country Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ReceivablesTaxResearchPremiumCurrent" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables Tax Research Premium, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable research incentives</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_PrepaidExpensesAndOtherCurrentAssets" xlink:to="hook_PrepaidExpensesAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for costs and other other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash balance maintained to secure a letter of credit associated with a real estate lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenues, non-current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 14)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_SeriesaConvertiblePreferredStockMember" xlink:to="hook_SeriesaConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A Convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_SeriesaConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_Seriesa1ConvertiblePreferredStockMember" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A-1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_SeriesA2ConvertiblePreferredStockMember" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A-2 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_PreferredStockSharesDesignated" xlink:to="hook_PreferredStockSharesDesignated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_PreferredStockSharesDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares designated as preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_PreferredStockSharesDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock shares Designated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_PreferredStockSharesDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock shares designated (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from collaboration and licensing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Product and Service [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets to be Disposed of</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash impairment charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment charges of assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GrantIncome" xlink:label="hook_GrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GrantIncome" xlink:to="hook_GrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of grant income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income and (expenses), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss before tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive (loss) income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment, net of tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation (loss) gain, net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConvertiblePreferredStocksMember" xlink:label="hook_ConvertiblePreferredStocksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ConvertiblePreferredStocksMember" xlink:to="hook_ConvertiblePreferredStocksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ConvertiblePreferredStocksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to convertible preferred stocks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ConvertiblePreferredStocksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PublicOfferingMember" xlink:label="hook_PublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_PublicOfferingMember" xlink:to="hook_PublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock by a private company to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockPurchaseAgreementMember" xlink:label="hook_StockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockPurchaseAgreementMember" xlink:to="hook_StockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock into common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Class A common stock to common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Class A common stock to common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:to="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate value of stock related to Restricted Stock Awards vested during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:to="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares related to Restricted Stock Award vested during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:to="hook_SharesGrantedValueShareBasedPaymentArrangementVested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of vested shares granted under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Granted, Value, Share-based Payment Arrangement, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of equity grants</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xlink:to="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares (or other type of equity) vested during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Shares, Share-based Payment Arrangement, Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of equity grants (in shares)</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" xlink:label="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" xlink:to="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase decrease to additional paid in capital due to at the market issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, At the Market Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-cash items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInReceivableResearchIncentives" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncreaseDecreaseInReceivableResearchIncentives" xlink:to="hook_IncreaseDecreaseInReceivableResearchIncentives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in amount of receivable research incentives.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Receivable Research Incentives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable research incentives</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expenses and Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xlink:to="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments related to finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of convertible preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Financing and Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment additions in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseAssetsDerecognizedUponLeaseCancellation" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseAssetsDerecognizedUponLeaseCancellation" xlink:to="hook_LeaseAssetsDerecognizedUponLeaseCancellation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of right of use assets derecognized upon lease cancellation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Assets Derecognized Upon Lease Cancellation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease assets derecognized upon lease cancellation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the business and organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the business and organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeAndLicensingArrangementAbstract" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeAndLicensingArrangementAbstract" xlink:to="hook_CollaborativeAndLicensingArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and Licensing Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and Licensing Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivableResearchIncentiveAbstract" xlink:label="hook_ReceivableResearchIncentiveAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ReceivableResearchIncentiveAbstract" xlink:to="hook_ReceivableResearchIncentiveAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ReceivableResearchIncentiveAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ReceivableResearchIncentiveAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable research incentive</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivableResearchIncentiveTextBlock" xlink:label="hook_ReceivableResearchIncentiveTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ReceivableResearchIncentiveTextBlock" xlink:to="hook_ReceivableResearchIncentiveTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ReceivableResearchIncentiveTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for receivable research incentive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ReceivableResearchIncentiveTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable Research Incentive [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ReceivableResearchIncentiveTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable research incentive</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseDisclosureTextBlock" xlink:label="hook_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseDisclosureTextBlock" xlink:to="hook_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="us-gaap_LongTermLoansPayableAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DisclosureOfLongTermLoansPayableTextBlock" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DisclosureOfLongTermLoansPayableTextBlock" xlink:to="hook_DisclosureOfLongTermLoansPayableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of loans payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Long Term Loans Payable [Text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, Class A common stock and convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, Class A common stock and convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Savings Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">401(k) Savings Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GoingConcernPolicyPolicyTextBlock" xlink:label="hook_GoingConcernPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GoingConcernPolicyPolicyTextBlock" xlink:to="hook_GoingConcernPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GoingConcernPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for going concern.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GoingConcernPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Going Concern, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GoingConcernPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Going concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency and currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of credit risk and of significant suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredOfferingCostsPolicyPolicyTextBlock" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredOfferingCostsPolicyPolicyTextBlock" xlink:to="hook_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for deferred offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Software Development Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition from contracts with customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:to="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for research and manufacturing contract costs and accruals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Manufacturing Contract Costs and Accruals, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and manufacturing contract costs and accruals</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" xlink:to="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for government grant agreements and research incentives.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grant Agreements and Research Incentives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government grant agreements and research incentives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_EarningsPerSharePolicyPolicyTextBlock" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_EarningsPerSharePolicyPolicyTextBlock" xlink:to="hook_EarningsPerSharePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for earnings per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of estimated useful life of each asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of impairment charges were included within Impairment expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial assets measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the effect of lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of maturities of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" xlink:to="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of weighted average remaining lease term and weighted average discount rate of finance leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Weighted Average Remaining Lease Term and Discount Rate of Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average remaining lease term and weighted average discount rate of operating leases</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" xlink:to="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Expenses and Other Liabilities, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DisclosureOfLongTermLoansPayableTableTextBlock" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DisclosureOfLongTermLoansPayableTableTextBlock" xlink:to="hook_DisclosureOfLongTermLoansPayableTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of loans payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Long Term Loans Payable [Table Text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of loans payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of aggregate minimum future principal payments due in connection with the FFG Loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of awards outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of losses before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of the consolidated income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of the net deferred tax assets or liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Valuation Allowance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in the valuation allowance for deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities that were not included in the diluted per share calculations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ComputerEquipmentAndSoftwareMember" xlink:to="hook_ComputerEquipmentAndSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Computer Software, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" xlink:to="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of preclinical research programs in collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Number of Preclinical Research Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preclinical research programs</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfCombinedPerformanceObligation" xlink:label="hook_NumberOfCombinedPerformanceObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfCombinedPerformanceObligation" xlink:to="hook_NumberOfCombinedPerformanceObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfCombinedPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of combined performance obligation under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfCombinedPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Combined Performance Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfCombinedPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Combined Performance Obligation</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" xlink:to="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of combined performance obligation for each research program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Combined Performance Obligation for Each Research Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of combined performance obligation for each research program</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfResearchProgramPerformanceObligations" xlink:label="hook_NumberOfResearchProgramPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfResearchProgramPerformanceObligations" xlink:to="hook_NumberOfResearchProgramPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfResearchProgramPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of research program performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfResearchProgramPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Research Program Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfResearchProgramPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of research program performance obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Subsidiary or Equity Method Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MilestoneAxis" xlink:label="hook_MilestoneAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_MilestoneAxis" xlink:to="hook_MilestoneAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_MilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by characteristics of milestone payments recognized under the milestone method by arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_MilestoneAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Axis]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MilestoneDomain" xlink:label="hook_MilestoneDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_MilestoneDomain" xlink:to="hook_MilestoneDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_MilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of milestones that an entity engage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_MilestoneDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DevelopmentMilestonesMember" xlink:label="hook_DevelopmentMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DevelopmentMilestonesMember" xlink:to="hook_DevelopmentMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to development milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DevelopmentMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Milestones</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommercialMilestonesMember" xlink:label="hook_CommercialMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CommercialMilestonesMember" xlink:to="hook_CommercialMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CommercialMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gilead Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_HbvProgramMember" xlink:label="hook_HbvProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_HbvProgramMember" xlink:to="hook_HbvProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_HbvProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HBV program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_HbvProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HBV program</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_HivProgramMember" xlink:label="hook_HivProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_HivProgramMember" xlink:to="hook_HivProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_HivProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HIV program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_HivProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HIV program</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RocheCollaborationAgreementMember" xlink:label="hook_RocheCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_RocheCollaborationAgreementMember" xlink:to="hook_RocheCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_RocheCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_RocheCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roche collaboration agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_RocheCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roche Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and Licensing Agreements</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfPreclinicalResearchPrograms" xlink:label="hook_NumberOfPreclinicalResearchPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfPreclinicalResearchPrograms" xlink:to="hook_NumberOfPreclinicalResearchPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of preclinical research programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Preclinical Research Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfPreclinicalResearchPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preclinical research programs</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ProceedsFromNonRefundableUpFrontPayment" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ProceedsFromNonRefundableUpFrontPayment" xlink:to="hook_ProceedsFromNonRefundableUpFrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash inflow from non-refundable upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Non-Refundable, Up-front Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment received</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeAgreementProgramInitiationFees" xlink:label="hook_CollaborativeAgreementProgramInitiationFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeAgreementProgramInitiationFees" xlink:to="hook_CollaborativeAgreementProgramInitiationFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeAgreementProgramInitiationFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses relating to program initiation fees under collaborative agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeAgreementProgramInitiationFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Agreement, Program Initiation Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeAgreementProgramInitiationFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Program initiation fee</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_TotalMilestoneAmount" xlink:label="hook_TotalMilestoneAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_TotalMilestoneAmount" xlink:to="hook_TotalMilestoneAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_TotalMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total milestone amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_TotalMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Milestone Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_TotalMilestoneAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total milestone amount</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise" xlink:label="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise" xlink:to="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of program completion fee on exercise of option under collaboration arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Arrangement, Program Completion Fee on Option Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">program completion fee</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementTermOfRoyaltyPayment" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementTermOfRoyaltyPayment" xlink:to="hook_CollaborativeArrangementTermOfRoyaltyPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term for royalty payment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Term of Royalty Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment term (in days)</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ProceedsFromMilestonePayment" xlink:label="hook_ProceedsFromMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ProceedsFromMilestonePayment" xlink:to="hook_ProceedsFromMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ProceedsFromMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount received from milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ProceedsFromMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ProceedsFromMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne" xlink:to="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of revenue recognized in year one that was previously reported as deferred or unearned revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Percentage of Revenue Recognized in Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of upfront payment included in deferred revenue expected to be recognized in 2024</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" xlink:to="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of revenue recognized in year two that was previously reported as deferred or unearned revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Percentage of Revenue Recognized in Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of upfront payment included in deferred revenue expected to be recognized in 2025</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree" xlink:to="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of revenue recognized in year three that was previously reported as deferred or unearned revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Percentage of Revenue Recognized in Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of upfront payment included in deferred revenue expected to be recognized in 2026</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RevenueRecognizedUpfrontPayment" xlink:label="hook_RevenueRecognizedUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_RevenueRecognizedUpfrontPayment" xlink:to="hook_RevenueRecognizedUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_RevenueRecognizedUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payment recognized as revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_RevenueRecognizedUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognized, Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_RevenueRecognizedUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from upfront payment</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xlink:to="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments revenue recognized under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Milestone Payments, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from milestone payments</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of revenue from cost reimbursements for preparation of first human trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Revenue From Cost Reimbursements For Preparation of First Human Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement revenue from cost reimbursements for preparation of first human trial</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of revenue from cost reimbursements for research and development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Revenue from Cost Reimbursements for Research and Development Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from cost reimbursements for research and development services</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementRevenueFromMilestonePayments" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementRevenueFromMilestonePayments" xlink:to="hook_CollaborativeArrangementRevenueFromMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of revenue from milestone payments for milestones achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Revenue from Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from milestone payments for milestones achieved</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xlink:to="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of contract assets relating to sublicense payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Contract Asset Relating to Sublicense Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract asset relating to the sublicense payment</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xlink:to="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of contract liability relating to sublicense payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Contract Liability Relating to Sublicense Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liability relating to sublicense payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability in deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Restructuring and Related Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Restructuring [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Severance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Severance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Plan [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanDomain" xlink:to="us-gaap_RestructuringPlanDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringPlanDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Plan [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_January2024RestructuringPlanMember" xlink:label="hook_January2024RestructuringPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_January2024RestructuringPlanMember" xlink:to="hook_January2024RestructuringPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_January2024RestructuringPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2024 Restructuring Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_January2024RestructuringPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2024 Restructuring Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_January2024RestructuringPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">January 2024 Restructuring Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction if workforce (in percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_FairValueAssetsLevel1ToLevel2TransfersAmount1" xlink:label="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1" xlink:to="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from Level 1 to Level 2</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_FairValueAssetsLevel2ToLevel1TransfersAmount1" xlink:label="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1" xlink:to="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from Level 2 to Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from into Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers from out of Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Land</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset under construction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RestructuringPlanCarryingValueOfAsset" xlink:label="hook_RestructuringPlanCarryingValueOfAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_RestructuringPlanCarryingValueOfAsset" xlink:to="hook_RestructuringPlanCarryingValueOfAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_RestructuringPlanCarryingValueOfAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying value of the  asset after restructuring.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_RestructuringPlanCarryingValueOfAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Plan, Carrying Value of Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_RestructuringPlanCarryingValueOfAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramTable" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramTable" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Research and Development Incentive Program [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Incentive Program [Table]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramAxis" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramAxis" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by research and development program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Incentive Program [Axis]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramDomain" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramDomain" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by research and development program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Incentive Program [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AustrianResearchIncentiveProgramMember" xlink:label="hook_AustrianResearchIncentiveProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AustrianResearchIncentiveProgramMember" xlink:to="hook_AustrianResearchIncentiveProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AustrianResearchIncentiveProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to Austrian research incentive program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AustrianResearchIncentiveProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Austrian Research Incentive Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AustrianResearchIncentiveProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Austrian Research Incentive Program</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember" xlink:label="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember" xlink:to="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to New York State life sciences research and development program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New York State Life Sciences Research and Development Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New York State Life Sciences Research and Development Program</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember" xlink:label="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember" xlink:to="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to New York State
New York City Biotechnology Tax Credit Program  [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New York State New York City Biotechnology Tax Credit Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New York State New York City Biotechnology Tax Credit Program</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramLineItems" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Incentive Program [Line Items]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GrantIncomeIncentiveProgram" xlink:label="hook_GrantIncomeIncentiveProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GrantIncomeIncentiveProgram" xlink:to="hook_GrantIncomeIncentiveProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GrantIncomeIncentiveProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income recognized related to the incentive program during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GrantIncomeIncentiveProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income, Incentive Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_GrantIncomeIncentiveProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income related to the incentive program recorded as grant income</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" xlink:label="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" xlink:to="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The reimbursement amount receivable as a percentage of qualifying research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement Amount Receivable as a Percentage of Qualifying Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of research and development expenses</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" xlink:label="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" xlink:to="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum expenses eligible for incentives in Biotechnology field per year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Expenses Eligible for Incentive in Biotechnology Field Per Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum expenses eligible for incentives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LesseeLeaseRemainingTermOfContract" xlink:label="hook_LesseeLeaseRemainingTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LesseeLeaseRemainingTermOfContract" xlink:to="hook_LesseeLeaseRemainingTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LesseeLeaseRemainingTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of lessee's lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LesseeLeaseRemainingTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Remaining Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LesseeLeaseRemainingTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance lease amortization expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on finance lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net lease expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Contractual Term [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseForCorporateHeadquartersInNewYorkCityMember" xlink:label="hook_LeaseForCorporateHeadquartersInNewYorkCityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseForCorporateHeadquartersInNewYorkCityMember" xlink:to="hook_LeaseForCorporateHeadquartersInNewYorkCityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseForCorporateHeadquartersInNewYorkCityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to lease for corporate headquarters in New York.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseForCorporateHeadquartersInNewYorkCityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease for Corporate Headquarters in New York City [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LeaseForCorporateHeadquartersInNewYorkCityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">lease for corporate headquarters in New York City</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember" xlink:label="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember" xlink:to="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to Leases for Office and Laboratory Space in Vienna, Austria.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases for Office and Laboratory Space in Vienna, Austria [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases for Office and Laboratory Space in Vienna, Austria</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseForCertainParkingSpacesInViennaOfficeMember" xlink:label="hook_LeaseForCertainParkingSpacesInViennaOfficeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LeaseForCertainParkingSpacesInViennaOfficeMember" xlink:to="hook_LeaseForCertainParkingSpacesInViennaOfficeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LeaseForCertainParkingSpacesInViennaOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to lease for certain parking spaces in Vienna Office.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LeaseForCertainParkingSpacesInViennaOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease for Certain Parking Spaces in Vienna Office [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LeaseForCertainParkingSpacesInViennaOfficeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease for Certain Parking Spaces in Vienna Office</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease, Weighted average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease, Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease,</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salaries and bonuses</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedSocialSecurityContributionsCurrent" xlink:label="hook_AccruedSocialSecurityContributionsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedSocialSecurityContributionsCurrent" xlink:to="hook_AccruedSocialSecurityContributionsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount as of the balance sheet date of the unpaid sum of the social security contributions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Social Security Contributions, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Social security contributions</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedUnearnedGrantIncomeCurrent" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedUnearnedGrantIncomeCurrent" xlink:to="hook_AccruedUnearnedGrantIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount as of the balance sheet date of accrued unearned grant income (current).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Unearned Grant Income , Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned grant income (current)</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedSubLicenseFees" xlink:label="hook_AccruedSubLicenseFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedSubLicenseFees" xlink:to="hook_AccruedSubLicenseFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedSubLicenseFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued sub license fees at the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedSubLicenseFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Sub License Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedSubLicenseFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublicense fees</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExternalResearchAndDevelopmentExpenses" xlink:to="hook_AccruedExternalResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount as of balance sheet date of accrued external research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued External Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued external research and development expenses</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExternalGeneralAndAdministrationExpenses" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExternalGeneralAndAdministrationExpenses" xlink:to="hook_AccruedExternalGeneralAndAdministrationExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount as of balance sheet date of accrued external general and administration expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued External General and Administration Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued external general and administration expenses</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xlink:to="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount as of balance sheet date of accrued expenses for property and equipment acquisitions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses for Property and Equipment Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued for property and equipment acquisitions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:to="hook_OtherAccruedExpensesAndLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount as of the balance sheet date of other accruals and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Expenses and Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accruals and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans payable</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LongTermLoansPayableGross" xlink:label="hook_LongTermLoansPayableGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LongTermLoansPayableGross" xlink:to="hook_LongTermLoansPayableGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LongTermLoansPayableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of loans payable, gross.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LongTermLoansPayableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Loans Payable, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LongTermLoansPayableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans from FFG</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total loans payable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt discount</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInEstimatedMarketRate" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncreaseDecreaseInEstimatedMarketRate" xlink:to="hook_IncreaseDecreaseInEstimatedMarketRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in estimated market rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease in Estimated Market Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold for change in estimated market rate</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DebtInstrumentEstimatedMarketRatePercent" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DebtInstrumentEstimatedMarketRatePercent" xlink:to="hook_DebtInstrumentEstimatedMarketRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the estimated market rate under the debt instrument arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Estimated Market Rate Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated market rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Fiscal Year Maturity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AmendedStockPurchaseAgreementMember" xlink:label="hook_AmendedStockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_AmendedStockPurchaseAgreementMember" xlink:to="hook_AmendedStockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_AmendedStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to amended stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_AmendedStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_AmendedStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember" xlink:label="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember" xlink:to="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A, Series A-1 and Series A -2 convertible preferred stock .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SeriesA, SeriesA-1 And SeriesA-2 convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A, SeriesA-1 And SeriesA-2 convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GileadSciencesIncMember" xlink:label="hook_GileadSciencesIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_GileadSciencesIncMember" xlink:to="hook_GileadSciencesIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_GileadSciencesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining Gilead Sciences, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_GileadSciencesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gilead</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares elected to convert</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RemainingOfCommonStockReservedForFutureIssuance" xlink:label="hook_RemainingOfCommonStockReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_RemainingOfCommonStockReservedForFutureIssuance" xlink:to="hook_RemainingOfCommonStockReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_RemainingOfCommonStockReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents amount remaining common stock reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_RemainingOfCommonStockReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining of Common Stock Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_RemainingOfCommonStockReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership percentage</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RegisterForResaleOfCommonStockAdditionalIssuances" xlink:label="hook_RegisterForResaleOfCommonStockAdditionalIssuances" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_RegisterForResaleOfCommonStockAdditionalIssuances" xlink:to="hook_RegisterForResaleOfCommonStockAdditionalIssuances_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_RegisterForResaleOfCommonStockAdditionalIssuances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period to register for resale the shares of common stock from the additional issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_RegisterForResaleOfCommonStockAdditionalIssuances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Register for Resale of Common Stock, Additional Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_RegisterForResaleOfCommonStockAdditionalIssuances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Register for resale of common stock</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfVotes" xlink:label="hook_NumberOfVotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfVotes" xlink:to="hook_NumberOfVotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of votes for each share held .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xlink:to="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of new common stock issued in the conversion of each stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Common Stock Issued for Each Share Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issued upon conversion of each share</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ThresholdPercentageForConversion" xlink:label="hook_ThresholdPercentageForConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ThresholdPercentageForConversion" xlink:to="hook_ThresholdPercentageForConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ThresholdPercentageForConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percent of common stock that can be owned after conversion of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ThresholdPercentageForConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage For Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ThresholdPercentageForConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage for conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Liquidation Preference Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndGrant2018PlanMember" xlink:label="hook_StockOptionAndGrant2018PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockOptionAndGrant2018PlanMember" xlink:to="hook_StockOptionAndGrant2018PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockOptionAndGrant2018PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2018 stock option and grant plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockOptionAndGrant2018PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Stock Option and Grant Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockOptionAndGrant2018PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting upon first anniversary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting in equal quarterly installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NonExecutiveDirectorsMember" xlink:to="hook_NonExecutiveDirectorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NonExecutiveDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to non executive directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NonExecutiveDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Executive Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of options vesting</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of quarterly installments of vesting of share-based compensation awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Vesting, Number of Quarterly Installment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of quarterly installments for vesting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options outstanding</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndIncentive2019PlanMember" xlink:label="hook_StockOptionAndIncentive2019PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockOptionAndIncentive2019PlanMember" xlink:to="hook_StockOptionAndIncentive2019PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockOptionAndIncentive2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2019 stock option and incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockOptionAndIncentive2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Stock Option and Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockOptionAndIncentive2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_InducementAwardsPlanMember" xlink:label="hook_InducementAwardsPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_InducementAwardsPlanMember" xlink:to="hook_InducementAwardsPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_InducementAwardsPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to inducement awards plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_InducementAwardsPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Awards Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_InducementAwardsPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Awards</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionExchangeOfferMember" xlink:label="hook_StockOptionExchangeOfferMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockOptionExchangeOfferMember" xlink:to="hook_StockOptionExchangeOfferMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockOptionExchangeOfferMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to stock option exchange offer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockOptionExchangeOfferMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option exchange offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number stock option authorized</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xlink:to="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of the then outstanding number of shares which will be the cumulative annual increase in issuance under the stock incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Incentive Plan Arrangement, Cumulative Annual Increase In Issuance Of Percentage Of Outstanding Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding were cumulatively increased</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xlink:to="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock entitled for each option upon the exercise of the option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Number of Common Stock Entitled for Each Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock entitled for each option upon the exercise of the option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exchange ratio for option surrendered for one new option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exchange Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange ratio</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfEligibleParticipants" xlink:label="hook_NumberOfEligibleParticipants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfEligibleParticipants" xlink:to="hook_NumberOfEligibleParticipants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfEligibleParticipants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of eligible participants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfEligibleParticipants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Eligible Participants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfEligibleParticipants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible participants</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" xlink:label="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" xlink:to="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares cancelled those will be issued upon exercise of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares to be Issued Upon Exercise of Stock Options Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options cancelled</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ExercisePriceLimitConsideredForCancellationOfStockOptions" xlink:label="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions" xlink:to="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price for cancellation of stock options if exceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Limit Considered For Cancellation Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" xlink:label="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" xlink:to="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of options accepted for cancellation on total shares of common stock underlying all of the eligible options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Options Accepted for Cancellation on Total Shares Underlying Eligible Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of options accepted for cancellation</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionsIssuedExercisePricePerShare" xlink:label="hook_StockOptionsIssuedExercisePricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_StockOptionsIssuedExercisePricePerShare" xlink:to="hook_StockOptionsIssuedExercisePricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_StockOptionsIssuedExercisePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share of stock options issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_StockOptionsIssuedExercisePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options Issued, Exercise Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_StockOptionsIssuedExercisePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option exchange offer resulted in incremental stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions used in the Black-Scholes option-pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option unvested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Averaged Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option unvested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term, option exercisable</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term for non- vested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term, option unvested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, option exercisable</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value per common stock used for calculating the intrinsic values.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value used for Calculating Intrinsic Values</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value per common stock used for calculating intrinsic values</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant-date fair value per share of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of stock options vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received from option exercise under share-based payment arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based awards granted</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of share-based awards granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Total Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate fair value of share-based awards granted</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average grant date fair value price of shares issued at grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date fair value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost related to the unvested stock-based awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average periods over which expense is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncomeTaxBenefitsNetOperatingLossesIncurred" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_IncomeTaxBenefitsNetOperatingLossesIncurred" xlink:to="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of income tax benefits recorded for the net operating losses incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax benefits, Net Operating Losses Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefits for the net operating losses incurred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign (Austria)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Foreign Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign (Austria)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AT" xlink:label="country_AT" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AT" xlink:to="country_AT_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AT_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Austria</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal statutory income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign tax rate differential</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Not taxable government grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, GILTI, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Global intangible low-taxed income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in deferred tax asset valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:to="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Reserves and Accruals Accrued Liabilities and Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="hook_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:to="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from fixed assets and intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed assets</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Operating Lease Right of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right of use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, GILTI, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Global Intangible Low Taxed Income estimated</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_UsTaxOnGiltiNetOfResearchCredits" xlink:label="hook_UsTaxOnGiltiNetOfResearchCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_UsTaxOnGiltiNetOfResearchCredits" xlink:to="hook_UsTaxOnGiltiNetOfResearchCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_UsTaxOnGiltiNetOfResearchCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of U.S. tax on GILTI, net of research credits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_UsTaxOnGiltiNetOfResearchCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Tax on GILTI, net of Research Credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized income tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cancellable obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Due in Next Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 deliverables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Due in Second Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025 deliverables</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LicensingFeesIntellectualPropertyLicenses" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_LicensingFeesIntellectualPropertyLicenses" xlink:to="hook_LicensingFeesIntellectualPropertyLicenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of licensing fees from intellectual property licenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing fees, Intellectual Property Licenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing fees from intellectual property licenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Matching contribution to defined contribution savings plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer's Matching contribution to defined contribution savings plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses recognized for the 401(k) Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average Shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average Shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConversionOfCommonStockSharesIssuedUponConversion" xlink:label="hook_ConversionOfCommonStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ConversionOfCommonStockSharesIssuedUponConversion" xlink:to="hook_ConversionOfCommonStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ConversionOfCommonStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for each share of common stock that is converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ConversionOfCommonStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Common Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ConversionOfCommonStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for each share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issued upon conversion of each share of Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConversionOfCommonStockSharesIssuable" xlink:label="hook_ConversionOfCommonStockSharesIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ConversionOfCommonStockSharesIssuable" xlink:to="hook_ConversionOfCommonStockSharesIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ConversionOfCommonStockSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issuable upon conversion of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ConversionOfCommonStockSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Common Stock, Shares Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ConversionOfCommonStockSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares issuable upon conversion of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Shares Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issuable upon conversion of convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Board of directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MaltePetersMember" xlink:label="hook_MaltePetersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_MaltePetersMember" xlink:to="hook_MaltePetersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_MaltePetersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Dr. Malte Peters, a member of the Company's board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_MaltePetersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Malte Peters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_MaltePetersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Malte Peters</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConsultingAgreementMember" xlink:label="hook_ConsultingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_ConsultingAgreementMember" xlink:to="hook_ConsultingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_ConsultingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the consulting agreement about the Company's clinical activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_ConsultingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_ConsultingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense recorded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationAgreementFinalMilestonePayment" xlink:label="hook_CollaborationAgreementFinalMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_CollaborationAgreementFinalMilestonePayment" xlink:to="hook_CollaborationAgreementFinalMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_CollaborationAgreementFinalMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of final milestone payment the Company remains eligible, under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_CollaborationAgreementFinalMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Final Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hook_CollaborationAgreementFinalMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final milestone payment the Company remains eligible</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employees reduced</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance Costs</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Rule10b51ArrangementModified" xlink:label="hook_Rule10b51ArrangementModified" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_Rule10b51ArrangementModified" xlink:to="hook_Rule10b51ArrangementModified_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_Rule10b51ArrangementModified_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_Rule10b51ArrangementModified_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Modified</label>
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NonRule10b51ArrangementModified" xlink:label="hook_NonRule10b51ArrangementModified" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hook_NonRule10b51ArrangementModified" xlink:to="hook_NonRule10b51ArrangementModified_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hook_NonRule10b51ArrangementModified_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hook_NonRule10b51ArrangementModified_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Modified</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>35
<FILENAME>hook-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/22/2024 10:36:48 AM-->
<!--Modified on: 3/22/2024 10:36:48 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureNatureOfBusinessAndOrganization" roleURI="http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureCollaborationAndLicensingAgreements" roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureImpairment" roleURI="http://www.hookipapharma.com/role/DisclosureImpairment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureFairValueOfFinancialAssets" roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosurePropertyPlantAndEquipmentNet" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureReceivableResearchIncentive" roleURI="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeases" roleURI="http://www.hookipapharma.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLoansPayable" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock" roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxes" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#Disclosure401KSavingsPlan" roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureNetLossPerShare" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureRelatedParties" roleURI="http://www.hookipapharma.com/role/DisclosureRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSubsequentEvents" roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureImpairmentTables" roleURI="http://www.hookipapharma.com/role/DisclosureImpairmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureFairValueOfFinancialAssetsTables" roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosurePropertyPlantAndEquipmentNetTables" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesTables" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLoansPayableTables" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureCollaborationAndLicensingAgreementsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureImpairmentAdditionalInformationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureImpairmentNonCashImpairmentChargesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureImpairmentNonCashImpairmentChargesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureFairValueOfFinancialAssetsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosurePropertyPlantAndEquipmentNetDetails" roleURI="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureReceivableResearchIncentiveDetails" roleURI="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesLeaseCostsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesMinimumLeasePaymentsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLoansPayableDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationStockOptionValuationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationCommonStockAwardsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureStockBasedCompensationStockBasedCompensationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#Disclosure401KSavingsPlanDetails" roleURI="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="hook-20231231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_638467006056056270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable_638467006056056270" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638467006056056270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638467006056056270" xlink:to="us-gaap_StatementClassOfStockAxis_638467006056056270" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006056056270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056056270" xlink:to="us-gaap_ClassOfStockDomain_638467006056056270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_638467006056056270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056056270" xlink:to="hook_CommonStockOtherThanClassMember_638467006056056270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638467006056056270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056056270" xlink:to="us-gaap_CommonClassAMember_638467006056056270" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_638467006056056270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638467006056056270" xlink:to="dei_DocumentInformationLineItems_638467006056056270" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638467006056056270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_DocumentType_638467006056056270" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638467006056056270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_DocumentAnnualReport_638467006056056270" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_DocumentPeriodEndDate_638467006056066266" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_DocumentTransitionReport_638467006056066266" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityFileNumber_638467006056066266" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityRegistrantName_638467006056066266" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityIncorporationStateCountryCode_638467006056066266" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityTaxIdentificationNumber_638467006056066266" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityAddressAddressLine1_638467006056066266" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityAddressCityOrTown_638467006056066266" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityAddressStateOrProvince_638467006056066266" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityAddressPostalZipCode_638467006056066266" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion_638467006056066266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_CountryRegion_638467006056066266" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638467006056076275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_CityAreaCode_638467006056076275" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638467006056076275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_LocalPhoneNumber_638467006056076275" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638467006056076275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_Security12bTitle_638467006056076275" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638467006056076275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_TradingSymbol_638467006056076275" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638467006056076275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_SecurityExchangeName_638467006056076275" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638467006056076275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityWellKnownSeasonedIssuer_638467006056076275" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638467006056076275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityVoluntaryFilers_638467006056076275" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638467006056076275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityCurrentReportingStatus_638467006056076275" order="21" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638467006056076275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityInteractiveDataCurrent_638467006056076275" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638467006056086268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityFilerCategory_638467006056086268" order="23" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638467006056086268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntitySmallBusiness_638467006056086268" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638467006056086268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityEmergingGrowthCompany_638467006056086268" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638467006056086268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityExTransitionPeriod_638467006056086268" order="26" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638467006056086268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_IcfrAuditorAttestationFlag_638467006056086268" order="27" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638467006056086268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638467006056086268" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638467006056096268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityShellCompany_638467006056096268" order="29" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638467006056096268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityPublicFloat_638467006056096268" order="30" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638467006056096268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityCommonStockSharesOutstanding_638467006056096268" order="31" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638467006056096268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_AuditorName_638467006056096268" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638467006056096268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_AuditorFirmId_638467006056096268" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638467006056096268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_AuditorLocation_638467006056096268" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638467006056096268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_EntityCentralIndexKey_638467006056096268" order="35" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638467006056106266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_CurrentFiscalYearEndDate_638467006056106266" order="36" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638467006056106266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_DocumentFiscalYearFocus_638467006056106266" order="37" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638467006056106266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_DocumentFiscalPeriodFocus_638467006056106266" order="38" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638467006056106266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638467006056056270" xlink:to="dei_AmendmentFlag_638467006056106266" order="39" use="optional" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638467006056116269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056116269" xlink:to="us-gaap_StatementClassOfStockAxis_638467006056116269" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056116269" xlink:to="us-gaap_ClassOfStockDomain_638467006056116269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056116269" xlink:to="hook_CommonStockOtherThanClassMember_638467006056116269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056116269" xlink:to="us-gaap_CommonClassAMember_638467006056116269" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056116269" xlink:to="us-gaap_StatementLineItems_638467006056116269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056116269" xlink:to="us-gaap_AssetsAbstract_638467006056116269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638467006056116269" xlink:to="us-gaap_AssetsCurrentAbstract_638467006056116269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467006056116269" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638467006056116269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467006056116269" xlink:to="us-gaap_RestrictedCashCurrent_638467006056116269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467006056116269" xlink:to="us-gaap_AccountsReceivableNetCurrent_638467006056116269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467006056116269" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent_638467006056116269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_PrepaidExpensesAndOtherCurrentAssets_638467006056116269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467006056116269" xlink:to="hook_PrepaidExpensesAndOtherCurrentAssets_638467006056116269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638467006056116269" xlink:to="us-gaap_AssetsCurrent_638467006056126269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638467006056116269" xlink:to="us-gaap_AssetsNoncurrentAbstract_638467006056126269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638467006056126269" xlink:to="us-gaap_RestrictedCashNoncurrent_638467006056126269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638467006056126269" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638467006056126269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638467006056126269" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638467006056126269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638467006056126269" xlink:to="us-gaap_OtherAssetsNoncurrent_638467006056126269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638467006056126269" xlink:to="us-gaap_AssetsNoncurrent_638467006056126269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638467006056116269" xlink:to="us-gaap_Assets_638467006056126269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056116269" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467006056126269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638467006056126269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467006056126269" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638467006056126269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638467006056136268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467006056126269" xlink:to="us-gaap_AccountsPayableCurrent_638467006056136268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638467006056136268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467006056126269" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638467006056136268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638467006056136268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467006056126269" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638467006056136268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_638467006056136268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467006056126269" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_638467006056136268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent_638467006056136268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467006056126269" xlink:to="us-gaap_LoansPayableCurrent_638467006056136268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638467006056136268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638467006056126269" xlink:to="us-gaap_LiabilitiesCurrent_638467006056136268" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638467006056136268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467006056126269" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638467006056136268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable_638467006056136268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638467006056136268" xlink:to="us-gaap_LoansPayable_638467006056136268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638467006056146268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638467006056136268" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638467006056146268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_638467006056146268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638467006056136268" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_638467006056146268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638467006056146268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638467006056136268" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638467006056146268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638467006056146268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638467006056136268" xlink:to="us-gaap_LiabilitiesNoncurrent_638467006056146268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638467006056146268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467006056126269" xlink:to="us-gaap_Liabilities_638467006056146268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638467006056146268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467006056126269" xlink:to="us-gaap_CommitmentsAndContingencies_638467006056146268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638467006056146268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467006056126269" xlink:to="us-gaap_StockholdersEquityAbstract_638467006056146268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638467006056156270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467006056146268" xlink:to="us-gaap_PreferredStockValue_638467006056156270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638467006056156270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467006056146268" xlink:to="us-gaap_CommonStockValue_638467006056156270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638467006056156270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467006056146268" xlink:to="us-gaap_AdditionalPaidInCapital_638467006056156270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638467006056156270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467006056146268" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638467006056156270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638467006056156270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467006056146268" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638467006056156270" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638467006056156270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638467006056146268" xlink:to="us-gaap_StockholdersEquity_638467006056156270" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638467006056156270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638467006056126269" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638467006056156270" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638467006056166276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638467006056166276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638467006056166276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056166276" xlink:to="us-gaap_StatementClassOfStockAxis_638467006056166276" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006056166276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056166276" xlink:to="us-gaap_ClassOfStockDomain_638467006056166276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember_638467006056166276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056166276" xlink:to="hook_SeriesaConvertiblePreferredStockMember_638467006056166276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_638467006056166276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056166276" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember_638467006056166276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember_638467006056166276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056166276" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember_638467006056166276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_638467006056166276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056166276" xlink:to="hook_CommonStockOtherThanClassMember_638467006056166276" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638467006056166276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056166276" xlink:to="us-gaap_CommonClassAMember_638467006056166276" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638467006056166276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056166276" xlink:to="us-gaap_StatementLineItems_638467006056166276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638467006056176268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056166276" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638467006056176268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638467006056176268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056166276" xlink:to="us-gaap_PreferredStockSharesAuthorized_638467006056176268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated_638467006056176268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056166276" xlink:to="hook_PreferredStockSharesDesignated_638467006056176268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638467006056176268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056166276" xlink:to="us-gaap_PreferredStockSharesOutstanding_638467006056176268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638467006056176268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056166276" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638467006056176268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638467006056176268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056166276" xlink:to="us-gaap_CommonStockSharesAuthorized_638467006056176268" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638467006056176268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056166276" xlink:to="us-gaap_CommonStockSharesIssued_638467006056176268" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638467006056176268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056166276" xlink:to="us-gaap_CommonStockSharesOutstanding_638467006056176268" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467006056176268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467006056176268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_638467006056186270" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638467006056186270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638467006056186270" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638467006056186270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638467006056186270" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638467006056186270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638467006056186270" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006056186270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638467006056186270" xlink:to="us-gaap_CostsAndExpenses_638467006056186270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638467006056186270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638467006056186270" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GrantIncome" xlink:label="hook_GrantIncome_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638467006056186270" xlink:to="hook_GrantIncome_638467006056186270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638467006056186270" xlink:to="us-gaap_InvestmentIncomeInterest_638467006056186270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638467006056186270" xlink:to="us-gaap_InterestExpense_638467006056186270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638467006056186270" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638467006056186270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638467006056186270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638467006056186270" xlink:to="us-gaap_NonoperatingIncomeExpense_638467006056186270" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638467006056196267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638467006056196267" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638467006056196267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638467006056196267" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638467006056196267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638467006056196267" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638467006056196267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638467006056196267" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638467006056196267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638467006056196267" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638467006056196267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638467006056196267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638467006056196267" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638467006056196267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638467006056196267" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638467006056196267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638467006056196267" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638467006056206271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056206271" xlink:to="us-gaap_StatementEquityComponentsAxis_638467006056206271" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConvertiblePreferredStocksMember" xlink:label="hook_ConvertiblePreferredStocksMember_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467006056206271" xlink:to="hook_ConvertiblePreferredStocksMember_638467006056206271" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467006056206271" xlink:to="us-gaap_CommonStockMember_638467006056206271" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467006056206271" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638467006056206271" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467006056206271" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638467006056206271" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467006056206271" xlink:to="us-gaap_RetainedEarningsMember_638467006056206271" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638467006056206271" xlink:to="us-gaap_EquityComponentDomain_638467006056206271" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056206271" xlink:to="us-gaap_StatementClassOfStockAxis_638467006056206271" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056206271" xlink:to="hook_CommonStockOtherThanClassMember_638467006056206271" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056206271" xlink:to="us-gaap_CommonClassAMember_638467006056206271" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember_638467006056206271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056206271" xlink:to="hook_SeriesaConvertiblePreferredStockMember_638467006056206271" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056206271" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember_638467006056216348" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056206271" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember_638467006056216348" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056206271" xlink:to="us-gaap_ClassOfStockDomain_638467006056216348" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056206271" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638467006056216348" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PublicOfferingMember" xlink:label="hook_PublicOfferingMember_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638467006056216348" xlink:to="hook_PublicOfferingMember_638467006056216348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockPurchaseAgreementMember" xlink:label="hook_StockPurchaseAgreementMember_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638467006056216348" xlink:to="hook_StockPurchaseAgreementMember_638467006056216348" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638467006056216348" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056216348" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056206271" xlink:to="us-gaap_StatementLineItems_638467006056216348" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056216348" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638467006056216348" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_StockholdersEquity_638467006056216348" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638467006056226269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_SharesOutstanding_638467006056226269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638467006056226269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638467006056226269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467006056226269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638467006056226269" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467006056226269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638467006056226269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638467006056226269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638467006056226269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638467006056226269" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638467006056226269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1_638467006056226269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_ConversionOfStockAmountIssued1_638467006056226269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_638467006056226269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockAmountIssued1_638467006056226269" xlink:to="us-gaap_ConversionOfStockSharesIssued1_638467006056226269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638467006056226269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638467006056226269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638467006056226269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638467006056226269" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638467006056226269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_638467006056236268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_638467006056236268" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_638467006056236268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested_638467006056236268" xlink:to="hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_638467006056236268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SharesGrantedValueShareBasedPaymentArrangementVested" xlink:label="hook_SharesGrantedValueShareBasedPaymentArrangementVested_638467006056236268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="hook_SharesGrantedValueShareBasedPaymentArrangementVested_638467006056236268" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SharesIssuedSharesShareBasedPaymentArrangementVested" xlink:label="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_638467006056236268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_SharesGrantedValueShareBasedPaymentArrangementVested_638467006056236268" xlink:to="hook_SharesIssuedSharesShareBasedPaymentArrangementVested_638467006056236268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost" xlink:label="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost_638467006056236268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost_638467006056236268" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638467006056236268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638467006056236268" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638467006056236268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638467006056236268" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638467006056246275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638467006056246275" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638467006056246275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_NetIncomeLoss_638467006056246275" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638467006056246275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_StockholdersEquity_638467006056246275" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638467006056246275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638467006056216348" xlink:to="us-gaap_SharesOutstanding_638467006056246275" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638467006056246275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638467006056246275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056246275" xlink:to="us-gaap_StatementClassOfStockAxis_638467006056256280" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056256280" xlink:to="us-gaap_ClassOfStockDomain_638467006056256280" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056256280" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember_638467006056256280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056256280" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember_638467006056256280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056256280" xlink:to="hook_CommonStockOtherThanClassMember_638467006056256280" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056246275" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638467006056256280" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638467006056256280" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056256280" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PublicOfferingMember" xlink:label="hook_PublicOfferingMember_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056256280" xlink:to="hook_PublicOfferingMember_638467006056256280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockPurchaseAgreementMember" xlink:label="hook_StockPurchaseAgreementMember_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056256280" xlink:to="hook_StockPurchaseAgreementMember_638467006056256280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056246275" xlink:to="us-gaap_StatementLineItems_638467006056256280" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056256280" xlink:to="us-gaap_SharePrice_638467006056256280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638467006056256280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056256280" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638467006056256280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" xlink:to="us-gaap_ProfitLoss_638467006056266268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" xlink:to="us-gaap_ShareBasedCompensation_638467006056266268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638467006056266268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006056266268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" xlink:to="us-gaap_OtherNoncashIncomeExpense_638467006056266268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638467006056266268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInReceivableResearchIncentives" xlink:label="hook_IncreaseDecreaseInReceivableResearchIncentives_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" xlink:to="hook_IncreaseDecreaseInReceivableResearchIncentives_638467006056266268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_638467006056266268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" xlink:to="hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_638467006056266268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638467006056276267" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638467006056276267" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638467006056276267" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638467006056276267" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities" xlink:label="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" xlink:to="hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities_638467006056276267" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638467006056266268" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638467006056276267" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638467006056266268" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638467006056276267" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638467006056276267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638467006056276267" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638467006056276267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467006056276267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638467006056276267" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638467006056276267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467006056286270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467006056286270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638467006056286270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467006056286270" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638467006056286270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638467006056286270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467006056286270" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_638467006056286270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638467006056286270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467006056286270" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638467006056286270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_638467006056286270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467006056286270" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_638467006056286270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638467006056286270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467006056286270" xlink:to="us-gaap_RepaymentsOfDebt_638467006056286270" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467006056286270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638467006056286270" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638467006056286270" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638467006056286270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638467006056286270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467006056286270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467006056286270" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467006056296278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467006056296278" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467006056296278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638467006056296278" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638467006056296278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638467006056296278" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638467006056296278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638467006056296278" xlink:to="us-gaap_InterestPaidNet_638467006056296278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638467006056296278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638467006056296278" xlink:to="us-gaap_IncomeTaxesPaidNet_638467006056296278" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638467006056296278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638467006056296278" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638467006056296278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638467006056296278" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638467006056296278" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638467006056306271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638467006056296278" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638467006056306271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseAssetsDerecognizedUponLeaseCancellation" xlink:label="hook_LeaseAssetsDerecognizedUponLeaseCancellation_638467006056306271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638467006056296278" xlink:to="hook_LeaseAssetsDerecognizedUponLeaseCancellation_638467006056306271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of the business and organization" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638467006056306271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638467006056306271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638467006056306271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638467006056306271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements" xlink:type="extended" xlink:title="10301 - Disclosure - Collaboration and Licensing Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeAndLicensingArrangementAbstract" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638467006056316272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_CollaborativeAndLicensingArrangementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638467006056316272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureImpairment" xlink:type="extended" xlink:title="10401 - Disclosure - Impairment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_638467006056316272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_638467006056316272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets" xlink:type="extended" xlink:title="10501 - Disclosure - Fair Value of Financial Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638467006056316272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638467006056316272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet" xlink:type="extended" xlink:title="10601 - Disclosure - Property, plant and equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638467006056316272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638467006056316272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive" xlink:type="extended" xlink:title="10701 - Disclosure - Receivable research incentive" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivableResearchIncentiveAbstract" xlink:label="hook_ReceivableResearchIncentiveAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivableResearchIncentiveTextBlock" xlink:label="hook_ReceivableResearchIncentiveTextBlock_638467006056326282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ReceivableResearchIncentiveAbstract" xlink:to="hook_ReceivableResearchIncentiveTextBlock_638467006056326282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10801 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseDisclosureTextBlock" xlink:label="hook_LeaseDisclosureTextBlock_638467006056326282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="hook_LeaseDisclosureTextBlock_638467006056326282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10901 - Disclosure - Accrued expenses and other current liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638467006056326282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638467006056326282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayable" xlink:type="extended" xlink:title="11001 - Disclosure - Loans payable" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DisclosureOfLongTermLoansPayableTextBlock" xlink:label="hook_DisclosureOfLongTermLoansPayableTextBlock_638467006056376280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="hook_DisclosureOfLongTermLoansPayableTextBlock_638467006056376280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock" xlink:type="extended" xlink:title="11101 - Disclosure - Common stock, Class A common stock and convertible preferred stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638467006056376280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638467006056376280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11201 - Disclosure - Stock-based compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638467006056376280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638467006056376280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11301 - Disclosure - Income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638467006056386266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638467006056386266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11401 - Disclosure - Commitments and contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638467006056386266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638467006056386266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/Disclosure401KSavingsPlan" xlink:type="extended" xlink:title="11501 - Disclosure - 401(k) Savings Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638467006056386266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638467006056386266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11601 - Disclosure - Net loss per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638467006056386266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638467006056386266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureRelatedParties" xlink:type="extended" xlink:title="11701 - Disclosure - Related Parties" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638467006056396273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638467006056396273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11801 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638467006056396273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638467006056396273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638467006056396273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638467006056396273" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GoingConcernPolicyPolicyTextBlock" xlink:label="hook_GoingConcernPolicyPolicyTextBlock_638467006056396273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_GoingConcernPolicyPolicyTextBlock_638467006056396273" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638467006056396273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638467006056396273" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638467006056396273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638467006056396273" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638467006056406338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638467006056406338" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredOfferingCostsPolicyPolicyTextBlock" xlink:label="hook_DeferredOfferingCostsPolicyPolicyTextBlock_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_DeferredOfferingCostsPolicyPolicyTextBlock_638467006056406338" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638467006056406338" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638467006056406338" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638467006056406338" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_638467006056406338" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_638467006056406338" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638467006056406338" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638467006056406338" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638467006056406338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638467006056406338" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock" xlink:label="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_638467006056416277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock_638467006056416277" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock" xlink:label="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_638467006056416277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock_638467006056416277" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638467006056416277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638467006056416277" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638467006056416277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638467006056416277" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_EarningsPerSharePolicyPolicyTextBlock" xlink:label="hook_EarningsPerSharePolicyPolicyTextBlock_638467006056416277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_EarningsPerSharePolicyPolicyTextBlock_638467006056416277" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638467006056416277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638467006056416277" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638467006056416277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638467006056416277" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of significant accounting policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_638467006056426268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_638467006056426268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureImpairmentTables" xlink:type="extended" xlink:title="30403 - Disclosure - Impairment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_638467006056426268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_638467006056426268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Fair Value of Financial Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638467006056426268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_638467006056426268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables" xlink:type="extended" xlink:title="30603 - Disclosure - Property, plant and equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638467006056426268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638467006056426268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638467006056436267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638467006056436267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638467006056436267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638467006056436267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases" xlink:label="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_638467006056436267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases_638467006056436267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Accrued expenses and other current liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock" xlink:label="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_638467006056436267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock_638467006056436267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableTables" xlink:type="extended" xlink:title="31003 - Disclosure - Loans payable (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DisclosureOfLongTermLoansPayableTableTextBlock" xlink:label="hook_DisclosureOfLongTermLoansPayableTableTextBlock_638467006056446271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="hook_DisclosureOfLongTermLoansPayableTableTextBlock_638467006056446271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_638467006056446271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_638467006056446271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Stock-based compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_638467006056446271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_638467006056446271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638467006056446271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638467006056446271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638467006056446271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638467006056446271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638467006056446271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638467006056446271" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Income taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638467006056446271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638467006056446271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638467006056456279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638467006056456279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638467006056456279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638467006056456279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638467006056456279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638467006056456279" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_638467006056456279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_638467006056456279" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31603 - Disclosure - Net loss per share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638467006056456279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638467006056456279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638467006056456279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638467006056456279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of significant accounting policies - Going concern (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638467006056456279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss_638467006056456279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638467006056456279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638467006056456279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467006056466276" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467006056466276" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467006056466276" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467006056466276" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056466276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056466276" xlink:to="us-gaap_EquipmentMember_638467006056466276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056466276" xlink:to="us-gaap_FurnitureAndFixturesMember_638467006056466276" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056466276" xlink:to="hook_ComputerEquipmentAndSoftwareMember_638467006056466276" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467006056466276" xlink:to="srt_RangeAxis_638467006056466276" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467006056466276" xlink:to="srt_RangeMember_638467006056466276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056466276" xlink:to="srt_MinimumMember_638467006056466276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056466276" xlink:to="srt_MaximumMember_638467006056466276" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467006056466276" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056466276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638467006056466276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056466276" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638467006056466276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of significant accounting policies - Others (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="us-gaap_CapitalizedComputerSoftwareAmortization1_638467006056476276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CapitalizedComputerSoftwareAmortization1_638467006056476276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms" xlink:label="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_638467006056476276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms_638467006056476276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfCombinedPerformanceObligation" xlink:label="hook_NumberOfCombinedPerformanceObligation_638467006056476276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_NumberOfCombinedPerformanceObligation_638467006056476276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfCombinedPerformanceObligationForEachResearchProgram" xlink:label="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_638467006056476276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_NumberOfCombinedPerformanceObligationForEachResearchProgram_638467006056476276" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfResearchProgramPerformanceObligations" xlink:label="hook_NumberOfResearchProgramPerformanceObligations_638467006056476276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hook_NumberOfResearchProgramPerformanceObligations_638467006056476276" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Summary of significant accounting policies - Comprehensive loss (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637200539053968672" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638467006056476276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637200539053968672" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638467006056476276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Collaboration and Licensing Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeAndLicensingArrangementAbstract" xlink:label="hook_CollaborativeAndLicensingArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_CollaborativeAndLicensingArrangementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638467006056486270" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MilestoneAxis" xlink:label="hook_MilestoneAxis_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638467006056486270" xlink:to="hook_MilestoneAxis_638467006056486270" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MilestoneDomain" xlink:label="hook_MilestoneDomain_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_MilestoneAxis_638467006056486270" xlink:to="hook_MilestoneDomain_638467006056486270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DevelopmentMilestonesMember" xlink:label="hook_DevelopmentMilestonesMember_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_MilestoneDomain_638467006056486270" xlink:to="hook_DevelopmentMilestonesMember_638467006056486270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommercialMilestonesMember" xlink:label="hook_CommercialMilestonesMember_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_MilestoneDomain_638467006056486270" xlink:to="hook_CommercialMilestonesMember_638467006056486270" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638467006056486270" xlink:to="us-gaap_TypeOfArrangementAxis_638467006056486270" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638467006056486270" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056486270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056486270" xlink:to="us-gaap_CollaborativeArrangementMember_638467006056486270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_HbvProgramMember" xlink:label="hook_HbvProgramMember_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_638467006056486270" xlink:to="hook_HbvProgramMember_638467006056486270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_HivProgramMember" xlink:label="hook_HivProgramMember_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementMember_638467006056486270" xlink:to="hook_HivProgramMember_638467006056486270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RocheCollaborationAgreementMember" xlink:label="hook_RocheCollaborationAgreementMember_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056486270" xlink:to="hook_RocheCollaborationAgreementMember_638467006056486270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638467006056486270" xlink:to="srt_RangeAxis_638467006056486270" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467006056486270" xlink:to="srt_RangeMember_638467006056486270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467006056486270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056486270" xlink:to="srt_MaximumMember_638467006056486270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638467006056486270" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfPreclinicalResearchPrograms" xlink:label="hook_NumberOfPreclinicalResearchPrograms_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_NumberOfPreclinicalResearchPrograms_638467006056496293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ProceedsFromNonRefundableUpFrontPayment" xlink:label="hook_ProceedsFromNonRefundableUpFrontPayment_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_ProceedsFromNonRefundableUpFrontPayment_638467006056496293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeAgreementProgramInitiationFees" xlink:label="hook_CollaborativeAgreementProgramInitiationFees_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_CollaborativeAgreementProgramInitiationFees_638467006056496293" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_TotalMilestoneAmount" xlink:label="hook_TotalMilestoneAmount_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_TotalMilestoneAmount_638467006056496293" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise" xlink:label="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise_638467006056496293" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementTermOfRoyaltyPayment" xlink:label="hook_CollaborativeArrangementTermOfRoyaltyPayment_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_CollaborativeArrangementTermOfRoyaltyPayment_638467006056496293" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ProceedsFromMilestonePayment" xlink:label="hook_ProceedsFromMilestonePayment_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_ProceedsFromMilestonePayment_638467006056496293" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne_638467006056496293" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo_638467006056496293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo_638467006056496293" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree" xlink:label="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree_638467006056506279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree_638467006056506279" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RevenueRecognizedUpfrontPayment" xlink:label="hook_RevenueRecognizedUpfrontPayment_638467006056506279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_RevenueRecognizedUpfrontPayment_638467006056506279" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationAgreementMilestonePaymentsRevenueRecognized" xlink:label="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_638467006056506279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_CollaborationAgreementMilestonePaymentsRevenueRecognized_638467006056506279" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial_638467006056506279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial_638467006056506279" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices" xlink:label="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_638467006056506279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices_638467006056506279" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementRevenueFromMilestonePayments" xlink:label="hook_CollaborativeArrangementRevenueFromMilestonePayments_638467006056506279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_CollaborativeArrangementRevenueFromMilestonePayments_638467006056506279" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_638467006056506279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment_638467006056506279" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment" xlink:label="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_638467006056506279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment_638467006056506279" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638467006056516274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638467006056516274" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638467006056516274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638467006056496293" xlink:to="us-gaap_ContractWithCustomerLiability_638467006056516274" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Impairment - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467006056516274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_3" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467006056516274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638467006056516274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467006056516274" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638467006056516274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638467006056516274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638467006056516274" xlink:to="us-gaap_TypeOfRestructuringDomain_638467006056516274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638467006056516274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638467006056516274" xlink:to="us-gaap_EmployeeSeveranceMember_638467006056516274" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis_638467006056516274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467006056516274" xlink:to="us-gaap_RestructuringPlanAxis_638467006056516274" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_638467006056526277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis_638467006056516274" xlink:to="us-gaap_RestructuringPlanDomain_638467006056526277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_January2024RestructuringPlanMember" xlink:label="hook_January2024RestructuringPlanMember_638467006056526277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain_638467006056526277" xlink:to="hook_January2024RestructuringPlanMember_638467006056526277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638467006056526277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467006056516274" xlink:to="us-gaap_SubsequentEventTypeAxis_638467006056526277" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638467006056526277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638467006056526277" xlink:to="us-gaap_SubsequentEventTypeDomain_638467006056526277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638467006056526277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638467006056526277" xlink:to="us-gaap_SubsequentEventMember_638467006056526277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_638467006056526277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638467006056516274" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_638467006056526277" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638467006056526277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638467006056526277" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638467006056526277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureImpairmentNonCashImpairmentChargesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Impairment - Non-cash impairment charges (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006056526277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_2" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006056526277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Financial Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467006056536269" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467006056536269" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638467006056536269" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638467006056536269" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638467006056536269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638467006056536269" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638467006056536269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467006056536269" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638467006056536269" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638467006056536269" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638467006056536269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638467006056536269" xlink:to="us-gaap_FairValueInputsLevel1Member_638467006056536269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467006056536269" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638467006056536269" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638467006056536269" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638467006056536269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638467006056536269" xlink:to="us-gaap_MoneyMarketFundsMember_638467006056536269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638467006056536269" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467006056536269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638467006056536269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467006056536269" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638467006056536269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638467006056546270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467006056536269" xlink:to="us-gaap_AssetsFairValueDisclosure_638467006056546270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_FairValueAssetsLevel1ToLevel2TransfersAmount1" xlink:label="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1_638467006056546270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467006056536269" xlink:to="hook_FairValueAssetsLevel1ToLevel2TransfersAmount1_638467006056546270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_FairValueAssetsLevel2ToLevel1TransfersAmount1" xlink:label="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1_638467006056546270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467006056536269" xlink:to="hook_FairValueAssetsLevel2ToLevel1TransfersAmount1_638467006056546270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_638467006056546270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467006056536269" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_638467006056546270" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_638467006056546270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638467006056536269" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_638467006056546270" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property, plant and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467006056546270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467006056546270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467006056546270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467006056546270" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467006056546270" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056546270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638467006056546270" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056546270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember_638467006056546270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056546270" xlink:to="us-gaap_LandMember_638467006056546270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056546270" xlink:to="us-gaap_LeaseholdImprovementsMember_638467006056556268" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056546270" xlink:to="us-gaap_ConstructionInProgressMember_638467006056556268" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056546270" xlink:to="us-gaap_EquipmentMember_638467006056556268" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056546270" xlink:to="us-gaap_FurnitureAndFixturesMember_638467006056556268" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ComputerEquipmentAndSoftwareMember" xlink:label="hook_ComputerEquipmentAndSoftwareMember_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638467006056546270" xlink:to="hook_ComputerEquipmentAndSoftwareMember_638467006056556268" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638467006056546270" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056556268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056556268" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638467006056556268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056556268" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638467006056556268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056556268" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638467006056556268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056556268" xlink:to="us-gaap_Depreciation_638467006056556268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056556268" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006056556268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RestructuringPlanCarryingValueOfAsset" xlink:label="hook_RestructuringPlanCarryingValueOfAsset_638467006056556268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638467006056556268" xlink:to="hook_RestructuringPlanCarryingValueOfAsset_638467006056556268" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Receivable research incentive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivableResearchIncentiveAbstract" xlink:label="hook_ReceivableResearchIncentiveAbstract_1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramTable" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramTable_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ReceivableResearchIncentiveAbstract_1" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramTable_638467006056566270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramAxis" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramAxis_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramTable_638467006056566270" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramAxis_638467006056566270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramDomain" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramDomain_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramAxis_638467006056566270" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramDomain_638467006056566270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AustrianResearchIncentiveProgramMember" xlink:label="hook_AustrianResearchIncentiveProgramMember_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramDomain_638467006056566270" xlink:to="hook_AustrianResearchIncentiveProgramMember_638467006056566270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember" xlink:label="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramDomain_638467006056566270" xlink:to="hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_638467006056566270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember" xlink:label="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramDomain_638467006056566270" xlink:to="hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_638467006056566270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ResearchAndDevelopmentIncentiveProgramLineItems" xlink:label="hook_ResearchAndDevelopmentIncentiveProgramLineItems_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramTable_638467006056566270" xlink:to="hook_ResearchAndDevelopmentIncentiveProgramLineItems_638467006056566270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GrantIncomeIncentiveProgram" xlink:label="hook_GrantIncomeIncentiveProgram_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems_638467006056566270" xlink:to="hook_GrantIncomeIncentiveProgram_638467006056566270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReceivablesTaxResearchPremiumCurrent" xlink:label="hook_ReceivablesTaxResearchPremiumCurrent_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems_638467006056566270" xlink:to="hook_ReceivablesTaxResearchPremiumCurrent_638467006056566270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses" xlink:label="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems_638467006056566270" xlink:to="hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses_638467006056566270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear" xlink:label="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear_638467006056566270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_ResearchAndDevelopmentIncentiveProgramLineItems_638467006056566270" xlink:to="hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear_638467006056566270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638467006056576270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638467006056576270" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467006056576270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638467006056576270" xlink:to="srt_RangeAxis_638467006056576270" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006056576270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467006056576270" xlink:to="srt_RangeMember_638467006056576270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638467006056576270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056576270" xlink:to="srt_MinimumMember_638467006056576270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467006056576270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056576270" xlink:to="srt_MaximumMember_638467006056576270" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638467006056576270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638467006056576270" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638467006056576270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LesseeLeaseRemainingTermOfContract" xlink:label="hook_LesseeLeaseRemainingTermOfContract_638467006056576270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056576270" xlink:to="hook_LesseeLeaseRemainingTermOfContract_638467006056576270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638467006056576270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056576270" xlink:to="us-gaap_RestrictedCashNoncurrent_638467006056576270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Leases - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638467006056576270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638467006056576270" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638467006056576270" xlink:to="us-gaap_IncomeStatementLocationAxis_638467006056586268" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638467006056586268" xlink:to="us-gaap_IncomeStatementLocationDomain_638467006056586268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638467006056586268" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638467006056586268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638467006056586268" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638467006056586268" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638467006056586268" xlink:to="us-gaap_InterestExpenseMember_638467006056586268" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638467006056586268" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_638467006056586268" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638467006056576270" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638467006056586268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056586268" xlink:to="us-gaap_OperatingLeaseCost_638467006056586268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056586268" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638467006056586268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056586268" xlink:to="us-gaap_FinanceLeaseInterestExpense_638467006056586268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056586268" xlink:to="us-gaap_SubleaseIncome_638467006056586268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638467006056586268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056586268" xlink:to="us-gaap_LeaseCost_638467006056586268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Leases - Minimum lease payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638467006056596282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638467006056596282" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638467006056596282" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638467006056596282" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638467006056596282" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638467006056596282" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638467006056596282" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638467006056596282" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638467006056596282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638467006056596282" xlink:to="us-gaap_OperatingLeaseLiability_638467006056596282" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638467006056606269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638467006056606269" xlink:to="us-gaap_LeaseContractualTermAxis_638467006056606269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638467006056606269" xlink:to="us-gaap_LeaseContractualTermDomain_638467006056606269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseForCorporateHeadquartersInNewYorkCityMember" xlink:label="hook_LeaseForCorporateHeadquartersInNewYorkCityMember_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638467006056606269" xlink:to="hook_LeaseForCorporateHeadquartersInNewYorkCityMember_638467006056606269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember" xlink:label="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638467006056606269" xlink:to="hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_638467006056606269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LeaseForCertainParkingSpacesInViennaOfficeMember" xlink:label="hook_LeaseForCertainParkingSpacesInViennaOfficeMember_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638467006056606269" xlink:to="hook_LeaseForCertainParkingSpacesInViennaOfficeMember_638467006056606269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638467006056606269" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638467006056606269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056606269" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638467006056606269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056606269" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638467006056606269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638467006056606269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638467006056606269" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638467006056606269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Accrued expenses and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:label="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_638467006056616269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedSocialSecurityContributionsCurrent" xlink:label="hook_AccruedSocialSecurityContributionsCurrent_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedSocialSecurityContributionsCurrent_638467006056616269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedUnearnedGrantIncomeCurrent" xlink:label="hook_AccruedUnearnedGrantIncomeCurrent_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedUnearnedGrantIncomeCurrent_638467006056616269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedSubLicenseFees" xlink:label="hook_AccruedSubLicenseFees_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedSubLicenseFees_638467006056616269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="hook_AccruedExternalResearchAndDevelopmentExpenses_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExternalResearchAndDevelopmentExpenses_638467006056616269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExternalGeneralAndAdministrationExpenses" xlink:label="hook_AccruedExternalGeneralAndAdministrationExpenses_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExternalGeneralAndAdministrationExpenses_638467006056616269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesForPropertyAndEquipmentAcquisitions" xlink:label="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExpensesForPropertyAndEquipmentAcquisitions_638467006056616269" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638467006056616269" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:label="hook_OtherAccruedExpensesAndLiabilitiesCurrent_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_OtherAccruedExpensesAndLiabilitiesCurrent_638467006056616269" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="hook_AccruedExpensesAndOtherCurrentLiabilities_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract" xlink:to="hook_AccruedExpensesAndOtherCurrentLiabilities_638467006056616269" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Loans payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638467006056616269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="us-gaap_DebtInstrumentTable_638467006056616269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638467006056616269" xlink:to="srt_RangeAxis_638467006056626276" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467006056626276" xlink:to="srt_RangeMember_638467006056626276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056626276" xlink:to="srt_MaximumMember_638467006056626276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638467006056616269" xlink:to="srt_ProductOrServiceAxis_638467006056626276" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638467006056626276" xlink:to="srt_ProductsAndServicesDomain_638467006056626276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638467006056626276" xlink:to="us-gaap_GrantMember_638467006056626276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638467006056616269" xlink:to="us-gaap_DebtInstrumentLineItems_638467006056626276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LongTermLoansPayableGross" xlink:label="hook_LongTermLoansPayableGross_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="hook_LongTermLoansPayableGross_638467006056626276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_638467006056626276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_LongTermLoansPayable_638467006056626276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638467006056626276" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638467006056626276" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638467006056626276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638467006056626276" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_638467006056636271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_638467006056636271" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_638467006056636271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_638467006056636271" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638467006056636271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_InterestExpenseDebt_638467006056636271" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638467006056636271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_RepaymentsOfDebt_638467006056636271" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638467006056636271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638467006056636271" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncreaseDecreaseInEstimatedMarketRate" xlink:label="hook_IncreaseDecreaseInEstimatedMarketRate_638467006056636271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="hook_IncreaseDecreaseInEstimatedMarketRate_638467006056636271" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DebtInstrumentEstimatedMarketRatePercent" xlink:label="hook_DebtInstrumentEstimatedMarketRatePercent_638467006056636271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638467006056626276" xlink:to="hook_DebtInstrumentEstimatedMarketRatePercent_638467006056636271" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayableAbstract" xlink:label="us-gaap_LongTermLoansPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_638467006056636271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayableAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_638467006056636271" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638467006056636271" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638467006056646268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638467006056636271" xlink:to="us-gaap_LongTermDebt_638467006056646268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_638467006056646268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056646268" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638467006056646268" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638467006056646268" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056646268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockPurchaseAgreementMember" xlink:label="hook_StockPurchaseAgreementMember_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056646268" xlink:to="hook_StockPurchaseAgreementMember_638467006056646268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_AmendedStockPurchaseAgreementMember" xlink:label="hook_AmendedStockPurchaseAgreementMember_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638467006056646268" xlink:to="hook_AmendedStockPurchaseAgreementMember_638467006056646268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056646268" xlink:to="us-gaap_StatementClassOfStockAxis_638467006056646268" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056646268" xlink:to="us-gaap_ClassOfStockDomain_638467006056646268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056646268" xlink:to="hook_CommonStockOtherThanClassMember_638467006056646268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638467006056646268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056646268" xlink:to="us-gaap_CommonClassAMember_638467006056646268" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember" xlink:label="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056646268" xlink:to="hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_638467006056656269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056646268" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember_638467006056656269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056646268" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember_638467006056656269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056646268" xlink:to="hook_SeriesaConvertiblePreferredStockMember_638467006056656269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056646268" xlink:to="srt_OwnershipAxis_638467006056656269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638467006056656269" xlink:to="srt_OwnershipDomain_638467006056656269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_GileadSciencesIncMember" xlink:label="hook_GileadSciencesIncMember_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638467006056656269" xlink:to="hook_GileadSciencesIncMember_638467006056656269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056646268" xlink:to="us-gaap_TypeOfArrangementAxis_638467006056656269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638467006056656269" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056656269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056656269" xlink:to="us-gaap_CollaborativeArrangementMember_638467006056656269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638467006056656269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638467006056646268" xlink:to="us-gaap_StatementLineItems_638467006056656269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638467006056666271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_CommonStockSharesAuthorized_638467006056666271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638467006056666271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_CommonStockSharesIssued_638467006056666271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638467006056666271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_CommonStockSharesOutstanding_638467006056666271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638467006056666271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_PreferredStockSharesAuthorized_638467006056666271" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PreferredStockSharesDesignated" xlink:label="hook_PreferredStockSharesDesignated_638467006056666271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="hook_PreferredStockSharesDesignated_638467006056666271" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638467006056666271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_PreferredStockSharesIssued_638467006056666271" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638467006056666271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_PreferredStockSharesOutstanding_638467006056666271" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467006056666271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467006056666271" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638467006056676275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_SharePrice_638467006056676275" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638467006056676275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638467006056676275" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_638467006056676275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_ConversionOfStockSharesConverted1_638467006056676275" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638467006056676275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638467006056676275" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638467006056676275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638467006056676275" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RemainingOfCommonStockReservedForFutureIssuance" xlink:label="hook_RemainingOfCommonStockReservedForFutureIssuance_638467006056676275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="hook_RemainingOfCommonStockReservedForFutureIssuance_638467006056676275" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638467006056676275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638467006056676275" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RegisterForResaleOfCommonStockAdditionalIssuances" xlink:label="hook_RegisterForResaleOfCommonStockAdditionalIssuances_638467006056676275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="hook_RegisterForResaleOfCommonStockAdditionalIssuances_638467006056676275" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfVotes" xlink:label="hook_NumberOfVotes_638467006056686284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="hook_NumberOfVotes_638467006056686284" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConversionOfStockCommonStockIssuedForEachShareConverted" xlink:label="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_638467006056686284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="hook_ConversionOfStockCommonStockIssuedForEachShareConverted_638467006056686284" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ThresholdPercentageForConversion" xlink:label="hook_ThresholdPercentageForConversion_638467006056686284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="hook_ThresholdPercentageForConversion_638467006056686284" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_638467006056686284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638467006056656269" xlink:to="us-gaap_PreferredStockLiquidationPreference_638467006056686284" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056696282" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056696282" xlink:to="us-gaap_PlanNameAxis_638467006056696282" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638467006056696282" xlink:to="us-gaap_PlanNameDomain_638467006056696282" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndGrant2018PlanMember" xlink:label="hook_StockOptionAndGrant2018PlanMember_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638467006056696282" xlink:to="hook_StockOptionAndGrant2018PlanMember_638467006056696282" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056696282" xlink:to="us-gaap_VestingAxis_638467006056696282" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638467006056696282" xlink:to="us-gaap_VestingDomain_638467006056696282" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638467006056696282" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638467006056696282" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638467006056696282" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638467006056696282" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056696282" xlink:to="srt_TitleOfIndividualAxis_638467006056696282" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638467006056696282" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006056696282" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006056696282" xlink:to="hook_NonExecutiveDirectorsMember_638467006056696282" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056696282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056696282" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638467006056696282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056696282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638467006056696282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056696282" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638467006056706268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056696282" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_638467006056706268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056696282" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638467006056706268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056706268" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056706268" xlink:to="us-gaap_PlanNameAxis_638467006056706268" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638467006056706268" xlink:to="us-gaap_PlanNameDomain_638467006056706268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndIncentive2019PlanMember" xlink:label="hook_StockOptionAndIncentive2019PlanMember_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638467006056706268" xlink:to="hook_StockOptionAndIncentive2019PlanMember_638467006056706268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_InducementAwardsPlanMember" xlink:label="hook_InducementAwardsPlanMember_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638467006056706268" xlink:to="hook_InducementAwardsPlanMember_638467006056706268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056706268" xlink:to="us-gaap_VestingAxis_638467006056706268" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638467006056706268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638467006056706268" xlink:to="us-gaap_VestingDomain_638467006056706268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638467006056706268" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638467006056716275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638467006056706268" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638467006056716275" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056706268" xlink:to="srt_TitleOfIndividualAxis_638467006056716275" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638467006056716275" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006056716275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NonExecutiveDirectorsMember" xlink:label="hook_NonExecutiveDirectorsMember_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638467006056716275" xlink:to="hook_NonExecutiveDirectorsMember_638467006056716275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056706268" xlink:to="us-gaap_TypeOfArrangementAxis_638467006056716275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638467006056716275" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056716275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionExchangeOfferMember" xlink:label="hook_StockOptionExchangeOfferMember_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056716275" xlink:to="hook_StockOptionExchangeOfferMember_638467006056716275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056706268" xlink:to="srt_RangeAxis_638467006056716275" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467006056716275" xlink:to="srt_RangeMember_638467006056716275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638467006056716275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056716275" xlink:to="srt_MinimumMember_638467006056716275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467006056726271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056716275" xlink:to="srt_MaximumMember_638467006056726271" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056706268" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638467006056726271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638467006056726271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares" xlink:label="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_638467006056726271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares_638467006056726271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638467006056726271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638467006056726271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638467006056726271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638467006056726271" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_638467006056726271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment_638467006056726271" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption" xlink:label="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_638467006056726271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption_638467006056726271" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638467006056726271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638467006056726271" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio_638467006056736271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio_638467006056736271" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfEligibleParticipants" xlink:label="hook_NumberOfEligibleParticipants_638467006056736271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="hook_NumberOfEligibleParticipants_638467006056736271" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled" xlink:label="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled_638467006056736271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled_638467006056736271" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ExercisePriceLimitConsideredForCancellationOfStockOptions" xlink:label="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions_638467006056736271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="hook_ExercisePriceLimitConsideredForCancellationOfStockOptions_638467006056736271" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions" xlink:label="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions_638467006056736271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions_638467006056736271" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467006056736271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638467006056736271" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionsIssuedExercisePricePerShare" xlink:label="hook_StockOptionsIssuedExercisePricePerShare_638467006056736271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="hook_StockOptionsIssuedExercisePricePerShare_638467006056736271" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_638467006056736271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056726271" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_638467006056736271" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-based compensation - Summary of awards outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056746272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056746272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638467006056746272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056746272" xlink:to="us-gaap_PlanNameAxis_638467006056746272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638467006056746272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638467006056746272" xlink:to="us-gaap_PlanNameDomain_638467006056746272" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndGrant2018PlanMember" xlink:label="hook_StockOptionAndGrant2018PlanMember_638467006056746272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638467006056746272" xlink:to="hook_StockOptionAndGrant2018PlanMember_638467006056746272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_StockOptionAndIncentive2019PlanMember" xlink:label="hook_StockOptionAndIncentive2019PlanMember_638467006056746272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638467006056746272" xlink:to="hook_StockOptionAndIncentive2019PlanMember_638467006056746272" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_InducementAwardsPlanMember" xlink:label="hook_InducementAwardsPlanMember_638467006056746272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638467006056746272" xlink:to="hook_InducementAwardsPlanMember_638467006056746272" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056746272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056746272" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056746272" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638467006056746272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056746272" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638467006056746272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Stock-based compensation - Stock option valuation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007036907995380" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638467006056756284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007036907995380" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638467006056756284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638467006056756284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638467006056756284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638467006056756284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638467006056756284" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638467006056756284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638467006056756284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638467006056756284" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Stock-based compensation - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056756284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037511167838" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056756284" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467006056756284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056756284" xlink:to="srt_RangeAxis_638467006056756284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006056756284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467006056756284" xlink:to="srt_RangeMember_638467006056756284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467006056756284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056756284" xlink:to="srt_MaximumMember_638467006056756284" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467006056766270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638467006056766270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638467006056766270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467006056766270" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638467006056766270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638467006056766270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384670060567662701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384670060567662701" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638467006056766270" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638467006056766270" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638467006056766270" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467006056766270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638467006056766270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638467006056766270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638467006056766270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638467006056776266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638467006056776266" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638467006056776266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638467006056776266" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638467006056776266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638467006056776266" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638467006056776266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467006056766270" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638467006056776266" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638467006056776266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638467006056766270" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638467006056776266" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467006056776266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467006056776266" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638467006056776266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467006056776266" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638467006056776266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638467006056776266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467006056776266" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638467006056776266" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_638467006056776266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638467006056776266" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm_638467006056776266" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638467006056786269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638467006056786269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6384670060567862691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6384670060567862691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638467006056786269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638467006056786269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_638467006056786269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues_638467006056786269" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638467006056786269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638467006056786269" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638467006056786269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638467006056786269" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638467006056786269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638467006056786269" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638467006056786269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056756284" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638467006056786269" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" xlink:type="extended" xlink:title="41206 - Disclosure - Stock-based compensation - Common Stock Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037846361893" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056796268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637007037846361893" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056796268" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638467006056796268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056796268" xlink:to="us-gaap_AwardTypeAxis_638467006056796268" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467006056796268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638467006056796268" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467006056796268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638467006056796268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638467006056796268" xlink:to="us-gaap_StockCompensationPlanMember_638467006056796268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056796268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056796268" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056796268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638467006056796268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056796268" xlink:to="us-gaap_SharePrice_638467006056796268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638467006056796268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056796268" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638467006056796268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_638467006056796268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056796268" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue_638467006056796268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056796268" xlink:to="hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_638467006056806268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" xlink:type="extended" xlink:title="41207 - Disclosure - Stock-based compensation - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637502792358011410" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637502792358011410" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056806268" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056806268" xlink:to="us-gaap_IncomeStatementLocationAxis_638467006056806268" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638467006056806268" xlink:to="us-gaap_IncomeStatementLocationDomain_638467006056806268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638467006056806268" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638467006056806268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638467006056806268" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638467006056806268" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638467006056806268" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056806268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056806268" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638467006056806268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056806268" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638467006056806268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638467006056806268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638467006056806268" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638467006056806268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income taxes - Losses before income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_IncomeTaxBenefitsNetOperatingLossesIncurred" xlink:label="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_638467006056816267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="hook_IncomeTaxBenefitsNetOperatingLossesIncurred_638467006056816267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638467006056816267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638467006056816267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638467006056816267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638467006056816267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638467006056816267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638467006056816267" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income taxes - components of the consolidated income tax provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638467006056816267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638467006056816267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638467006056816267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638467006056816267" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638467006056816267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638467006056816267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638467006056816267" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638467006056816267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_638467006056816267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638467006056816267" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_638467006056816267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638467006056826268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_638467006056816267" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638467006056826268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638467006056826268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638467006056826268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638467006056826268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638467006056826268" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638467006056826268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income taxes - Effective income tax reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638467006056826268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638467006056826268" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638467006056826268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638467006056826268" xlink:to="srt_StatementGeographicalAxis_638467006056826268" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638467006056826268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638467006056826268" xlink:to="srt_SegmentGeographicalDomain_638467006056826268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AT" xlink:label="country_AT_638467006056826268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638467006056826268" xlink:to="country_AT_638467006056826268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638467006056826268" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467006056896266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467006056896266" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638467006056896266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638467006056896266" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638467006056896266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638467006056896266" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_638467006056896266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_638467006056896266" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638467006056906268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638467006056906268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_638467006056906268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_638467006056906268" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638467006056906268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638467006056906268" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638467006056906268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638467006056906268" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638467006056906268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056826268" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638467006056906268" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638467006056906268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638467006056906268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638467006056906268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" xlink:to="hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638467006056906268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638467006056906268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638467006056906268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" xlink:to="hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_638467006056916268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638467006056916268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="hook_DeferredTaxAssetsOperatingLeaseLiabilities_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" xlink:to="hook_DeferredTaxAssetsOperatingLeaseLiabilities_638467006056916268" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" xlink:to="us-gaap_DeferredTaxAssetsGross_638467006056916268" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638467006056916268" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract_638467006056906268" xlink:to="us-gaap_DeferredTaxAssetsNet_638467006056916268" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638467006056916268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638467006056916268" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_638467006056916268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:label="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638467006056916268" xlink:to="hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_638467006056916268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638467006056916268" xlink:to="hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_638467006056916268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638467006056916268" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638467006056916268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638467006056916268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638467006056916268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41305 - Disclosure - Income taxes - Changes in the valuation allowance for deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638467006056926267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638467006056926267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638467006056926267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638467006056926267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_6384670060569262671" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_6384670060569262671" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="41306 - Disclosure - Income taxes -Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638467006056926267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638467006056926267" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638467006056926267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638467006056926267" xlink:to="srt_StatementGeographicalAxis_638467006056926267" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638467006056926267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638467006056926267" xlink:to="srt_SegmentGeographicalDomain_638467006056926267" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AT" xlink:label="country_AT_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638467006056926267" xlink:to="country_AT_638467006056936268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638467006056926267" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638467006056936268" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638467006056936268" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638467006056936268" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638467006056936268" xlink:to="us-gaap_DomesticCountryMember_638467006056936268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638467006056926267" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638467006056936268" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056936268" xlink:to="us-gaap_OperatingLossCarryforwards_638467006056936268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056936268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638467006056936268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056936268" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount_638467006056936268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_UsTaxOnGiltiNetOfResearchCredits" xlink:label="hook_UsTaxOnGiltiNetOfResearchCredits_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056936268" xlink:to="hook_UsTaxOnGiltiNetOfResearchCredits_638467006056936268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638467006056936268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638467006056936268" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638467006056936268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Commitments and contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligation_638467006056946271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_638467006056946271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInSecondYear_638467006056946271" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_LicensingFeesIntellectualPropertyLicenses" xlink:label="hook_LicensingFeesIntellectualPropertyLicenses_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="hook_LicensingFeesIntellectualPropertyLicenses_638467006056946271" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails" xlink:type="extended" xlink:title="41501 - Disclosure - 401(k) Savings Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638467006056946271" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638467006056946271" xlink:to="srt_RangeAxis_638467006056946271" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638467006056946271" xlink:to="srt_RangeMember_638467006056946271" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638467006056946271" xlink:to="srt_MaximumMember_638467006056946271" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638467006056946271" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638467006056946271" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638467006056946271" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638467006056946271" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638467006056946271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638467006056946271" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638467006056946271" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638467006056946271" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638467006056956275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_638467006056956275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_638467006056956275" xlink:to="us-gaap_StatementClassOfStockAxis_638467006056956275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638467006056956275" xlink:to="us-gaap_ClassOfStockDomain_638467006056956275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056956275" xlink:to="us-gaap_CommonClassAMember_638467006056956275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CommonStockOtherThanClassMember" xlink:label="hook_CommonStockOtherThanClassMember_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056956275" xlink:to="hook_CommonStockOtherThanClassMember_638467006056956275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesaConvertiblePreferredStockMember" xlink:label="hook_SeriesaConvertiblePreferredStockMember_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056956275" xlink:to="hook_SeriesaConvertiblePreferredStockMember_638467006056956275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Seriesa1ConvertiblePreferredStockMember" xlink:label="hook_Seriesa1ConvertiblePreferredStockMember_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056956275" xlink:to="hook_Seriesa1ConvertiblePreferredStockMember_638467006056956275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_SeriesA2ConvertiblePreferredStockMember" xlink:label="hook_SeriesA2ConvertiblePreferredStockMember_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638467006056956275" xlink:to="hook_SeriesA2ConvertiblePreferredStockMember_638467006056956275" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_638467006056956275" xlink:to="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" xlink:to="us-gaap_NetIncomeLossAbstract_638467006056966272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638467006056966272" xlink:to="us-gaap_NetIncomeLoss_638467006056966272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638467006056966272" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638467006056966272" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638467006056966272" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638467006056966272" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638467006056966272" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" xlink:to="us-gaap_EarningsPerShareBasic_638467006056966272" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" xlink:to="us-gaap_EarningsPerShareDiluted_638467006056966272" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConversionOfCommonStockSharesIssuedUponConversion" xlink:label="hook_ConversionOfCommonStockSharesIssuedUponConversion_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" xlink:to="hook_ConversionOfCommonStockSharesIssuedUponConversion_638467006056966272" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638467006056966272" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConversionOfCommonStockSharesIssuable" xlink:label="hook_ConversionOfCommonStockSharesIssuable_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" xlink:to="hook_ConversionOfCommonStockSharesIssuable_638467006056966272" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_638467006056966272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_638467006056956275" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_638467006056966272" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Net loss per share - Antidilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638467006056976269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638467006056976269" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638467006056976269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638467006056976269" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638467006056976269" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638467006056976269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638467006056976269" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638467006056976269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638467006056976269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638467006056976269" xlink:to="us-gaap_EmployeeStockOptionMember_638467006056976269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638467006056976269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638467006056976269" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638467006056976269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638467006056976269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638467006056976269" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638467006056976269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467006056986270" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467006056986270" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638467006056986270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638467006056986270" xlink:to="us-gaap_RelatedPartyDomain_638467006056986270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638467006056986270" xlink:to="us-gaap_RelatedPartyMember_638467006056986270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyMember_638467006056986270" xlink:to="srt_DirectorMember_638467006056986270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467006056986270" xlink:to="srt_CounterpartyNameAxis_638467006056986270" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638467006056986270" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638467006056986270" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_MaltePetersMember" xlink:label="hook_MaltePetersMember_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638467006056986270" xlink:to="hook_MaltePetersMember_638467006056986270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467006056986270" xlink:to="us-gaap_RelatedPartyTransactionAxis_638467006056986270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638467006056986270" xlink:to="us-gaap_RelatedPartyTransactionDomain_638467006056986270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_ConsultingAgreementMember" xlink:label="hook_ConsultingAgreementMember_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638467006056986270" xlink:to="hook_ConsultingAgreementMember_638467006056986270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638467006056986270" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638467006056986270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638467006056986270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638467006056986270" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638467006056986270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638467006056996270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467006056996270" xlink:to="us-gaap_SubsequentEventTypeAxis_638467006056996270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638467006056996270" xlink:to="us-gaap_SubsequentEventTypeDomain_638467006056996270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638467006056996270" xlink:to="us-gaap_SubsequentEventMember_638467006056996270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467006056996270" xlink:to="us-gaap_TypeOfArrangementAxis_638467006056996270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638467006056996270" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056996270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_RocheCollaborationAgreementMember" xlink:label="hook_RocheCollaborationAgreementMember_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638467006056996270" xlink:to="hook_RocheCollaborationAgreementMember_638467006056996270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467006056996270" xlink:to="us-gaap_RestructuringPlanAxis_638467006056996270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain" xlink:label="us-gaap_RestructuringPlanDomain_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanAxis_638467006056996270" xlink:to="us-gaap_RestructuringPlanDomain_638467006056996270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_January2024RestructuringPlanMember" xlink:label="hook_January2024RestructuringPlanMember_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringPlanDomain_638467006056996270" xlink:to="hook_January2024RestructuringPlanMember_638467006056996270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638467006056996270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467006056996270" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638467006056996270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638467006057006276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638467006056996270" xlink:to="us-gaap_TypeOfRestructuringDomain_638467006057006276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638467006057006276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638467006057006276" xlink:to="us-gaap_EmployeeSeveranceMember_638467006057006276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638467006057006276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638467006056996270" xlink:to="us-gaap_SubsequentEventLineItems_638467006057006276" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_CollaborationAgreementFinalMilestonePayment" xlink:label="hook_CollaborationAgreementFinalMilestonePayment_638467006057006276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467006057006276" xlink:to="hook_CollaborationAgreementFinalMilestonePayment_638467006057006276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638467006057006276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467006057006276" xlink:to="us-gaap_ContractWithCustomerLiability_638467006057006276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638467006057006276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467006057006276" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638467006057006276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638467006057006276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467006057006276" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638467006057006276" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1_638467006057006276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467006057006276" xlink:to="us-gaap_SeveranceCosts1_638467006057006276" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006057006276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638467006057006276" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638467006057006276" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_Rule10b51ArrangementModified" xlink:label="hook_Rule10b51ArrangementModified_638467006057016274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="hook_Rule10b51ArrangementModified_638467006057016274" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="hook-20231231.xsd#hook_NonRule10b51ArrangementModified" xlink:label="hook_NonRule10b51ArrangementModified_638467006057016274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="hook_NonRule10b51ArrangementModified_638467006057016274" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039691568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HOOKIPA PHARMA&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5395687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">350 Fifth Avenue, 72nd Floor, Suite&#160;7240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">+43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">890 63 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HOOK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PwC Wirtschaftspr&#252;fung GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Vienna, Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001760542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,550,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039591328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 117,096<span></span>
</td>
<td class="nump">$ 112,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">6,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ReceivablesTaxResearchPremiumCurrent', window );">Receivable research incentives</a></td>
<td class="nump">18,760<span></span>
</td>
<td class="nump">15,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_PrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,749<span></span>
</td>
<td class="nump">12,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">147,116<span></span>
</td>
<td class="nump">147,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">7,742<span></span>
</td>
<td class="nump">17,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,473<span></span>
</td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">14,221<span></span>
</td>
<td class="nump">23,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">161,337<span></span>
</td>
<td class="nump">170,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,498<span></span>
</td>
<td class="nump">5,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">14,631<span></span>
</td>
<td class="nump">15,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">1,638<span></span>
</td>
<td class="nump">1,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">12,101<span></span>
</td>
<td class="nump">11,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, current</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">1,594<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">41,988<span></span>
</td>
<td class="nump">35,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">3,801<span></span>
</td>
<td class="nump">2,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">19,674<span></span>
</td>
<td class="nump">25,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">6,017<span></span>
</td>
<td class="nump">3,420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">29,492<span></span>
</td>
<td class="nump">32,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">71,480<span></span>
</td>
<td class="nump">67,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">467,041<span></span>
</td>
<td class="nump">397,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(7,933)<span></span>
</td>
<td class="num">(7,156)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(369,261)<span></span>
</td>
<td class="num">(287,681)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">89,857<span></span>
</td>
<td class="nump">102,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">161,337<span></span>
</td>
<td class="nump">170,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs and other other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReceivablesTaxResearchPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReceivablesTaxResearchPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040289248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_PreferredStockSharesDesignated', window );">Preferred stock shares designated (in shares)</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember', window );">Series A-1 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_PreferredStockSharesDesignated', window );">Preferred stock shares designated (in shares)</a></td>
<td class="nump">15,800<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">10,800<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_PreferredStockSharesDesignated', window );">Preferred stock shares designated (in shares)</a></td>
<td class="nump">15,268<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">15,268<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">96,550,590<span></span>
</td>
<td class="nump">52,317,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">96,550,590<span></span>
</td>
<td class="nump">52,317,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">2,399,517<span></span>
</td>
<td class="nump">2,399,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">2,399,517<span></span>
</td>
<td class="nump">2,399,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares designated as preferred shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040267200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration and licensing</a></td>
<td class="nump">$ 20,129<span></span>
</td>
<td class="nump">$ 14,249<span></span>
</td>
<td class="nump">$ 18,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">hook:CollaborationAndLicensingMember<span></span>
</td>
<td class="text">hook:CollaborationAndLicensingMember<span></span>
</td>
<td class="text">hook:CollaborationAndLicensingMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">$ (86,424)<span></span>
</td>
<td class="num">$ (68,645)<span></span>
</td>
<td class="num">$ (82,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(18,633)<span></span>
</td>
<td class="num">(18,759)<span></span>
</td>
<td class="num">(17,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment expense</a></td>
<td class="num">(12,766)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="num">(117,823)<span></span>
</td>
<td class="num">(87,404)<span></span>
</td>
<td class="num">(100,122)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(97,694)<span></span>
</td>
<td class="num">(73,155)<span></span>
</td>
<td class="num">(81,674)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_GrantIncome', window );">Grant income</a></td>
<td class="nump">11,193<span></span>
</td>
<td class="nump">7,916<span></span>
</td>
<td class="nump">9,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,293<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(317)<span></span>
</td>
<td class="num">(687)<span></span>
</td>
<td class="num">(898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income and (expenses), net</a></td>
<td class="nump">313<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(2,843)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">16,482<span></span>
</td>
<td class="nump">8,470<span></span>
</td>
<td class="nump">6,010<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before tax</a></td>
<td class="num">(81,212)<span></span>
</td>
<td class="num">(64,685)<span></span>
</td>
<td class="num">(75,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(368)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81,580)<span></span>
</td>
<td class="num">(64,915)<span></span>
</td>
<td class="num">(75,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation (loss) gain, net of tax</a></td>
<td class="num">(777)<span></span>
</td>
<td class="num">(2,376)<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (82,357)<span></span>
</td>
<td class="num">$ (67,291)<span></span>
</td>
<td class="num">$ (74,378)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (2.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (2.30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356026199696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A convertible preferred stock </div>
<div>Public offering</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A convertible preferred stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A-1 convertible preferred stock</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A-2 convertible preferred stock </div>
<div>Public offering</div>
</th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Common stock </div>
<div>Public offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common stock </div>
<div>Stock Purchase Agreement</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Common stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class A common stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series A convertible preferred stock </div>
<div>Public offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series A convertible preferred stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series A-1 convertible preferred stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Common stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series A convertible preferred stock </div>
<div>Public offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series A convertible preferred stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series A-1 convertible preferred stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series A-2 convertible preferred stock </div>
<div>Public offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Public offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Stock Purchase Agreement</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Common stock </div>
<div>Public offering</div>
</th>
<th class="th">
<div>Common stock </div>
<div>Stock Purchase Agreement</div>
</th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Series A-1 convertible preferred stock </div>
<div>Public offering</div>
</th>
<th class="th"><div>Series A-1 convertible preferred stock</div></th>
<th class="th">
<div>Series A-2 convertible preferred stock </div>
<div>Public offering</div>
</th>
<th class="th"><div>Public offering</div></th>
<th class="th"><div>Stock Purchase Agreement</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,288<span></span>
</td>
<td class="num">$ (6,067)<span></span>
</td>
<td class="num">$ (147,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,123<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,948,712<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested', window );">Vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,665)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,135<span></span>
</td>
<td class="num">(4,780)<span></span>
</td>
<td class="num">(222,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,592<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,383,483<span></span>
</td>
<td class="nump">3,819,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,685<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,687<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,700,000<span></span>
</td>
<td class="nump">1,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Class A common stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Class A common stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,420,215<span></span>
</td>
<td class="num">(1,420,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_SharesGrantedValueShareBasedPaymentArrangementVested', window );">Vesting of equity grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_SharesIssuedSharesShareBasedPaymentArrangementVested', window );">Vesting of equity grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost', window );">ATM costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,713)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,915)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,915)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,349<span></span>
</td>
<td class="num">(7,156)<span></span>
</td>
<td class="num">(287,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,517<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,317,138<span></span>
</td>
<td class="nump">2,399,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,530<span></span>
</td>
<td class="nump">$ 27,791<span></span>
</td>
<td class="nump">$ 21,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,530<span></span>
</td>
<td class="nump">$ 27,793<span></span>
</td>
<td class="nump">$ 21,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,900,768<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,327)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,327,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost', window );">ATM costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,207)<span></span>
</td>
<td class="num">$ (136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,580)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 467,041<span></span>
</td>
<td class="num">$ (7,933)<span></span>
</td>
<td class="num">$ (369,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,857<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,550,590<span></span>
</td>
<td class="nump">2,399,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase decrease to additional paid in capital due to at the market issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_SharesGrantedValueShareBasedPaymentArrangementVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of vested shares granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_SharesGrantedValueShareBasedPaymentArrangementVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_SharesIssuedSharesShareBasedPaymentArrangementVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) vested during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_SharesIssuedSharesShareBasedPaymentArrangementVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award vested during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards vested during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040095376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 05, 2023</div></th>
<th class="th"><div>Mar. 04, 2022</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hook_StockPurchaseAgreementMember', window );">Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember', window );">Series A-1 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember', window );">Series A-1 convertible preferred stock | Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 convertible preferred stock | Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="nump">$ 1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 1,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock | Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2,207<span></span>
</td>
<td class="nump">$ 2,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="nump">$ 1.4167<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=hook_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=hook_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=hook_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=hook_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040480400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (81,580)<span></span>
</td>
<td class="num">$ (64,915)<span></span>
</td>
<td class="num">$ (75,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,345<span></span>
</td>
<td class="nump">5,043<span></span>
</td>
<td class="nump">7,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">3,602<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment expense</a></td>
<td class="nump">12,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">6,180<span></span>
</td>
<td class="num">(341)<span></span>
</td>
<td class="num">(1,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_IncreaseDecreaseInReceivableResearchIncentives', window );">Receivable research incentives</a></td>
<td class="num">(2,726)<span></span>
</td>
<td class="num">(1,958)<span></span>
</td>
<td class="num">(295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,735<span></span>
</td>
<td class="nump">2,007<span></span>
</td>
<td class="num">(7,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,499<span></span>
</td>
<td class="num">(1,999)<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="num">(8,258)<span></span>
</td>
<td class="nump">35,508<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,622)<span></span>
</td>
<td class="num">(1,584)<span></span>
</td>
<td class="num">(1,588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">2,510<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">2,727<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(57,524)<span></span>
</td>
<td class="num">(19,997)<span></span>
</td>
<td class="num">(66,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,159)<span></span>
</td>
<td class="num">(5,017)<span></span>
</td>
<td class="num">(12,581)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,159)<span></span>
</td>
<td class="num">(5,017)<span></span>
</td>
<td class="num">(12,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments related to finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">18,530<span></span>
</td>
<td class="nump">29,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">49,043<span></span>
</td>
<td class="nump">45,691<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payments for deferred offering costs</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings</a></td>
<td class="num">(1,754)<span></span>
</td>
<td class="num">(2,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">65,670<span></span>
</td>
<td class="nump">72,271<span></span>
</td>
<td class="num">(235)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="nump">47,257<span></span>
</td>
<td class="num">(78,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">113,444<span></span>
</td>
<td class="nump">66,912<span></span>
</td>
<td class="nump">143,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">90<span></span>
</td>
<td class="num">(725)<span></span>
</td>
<td class="nump">2,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">117,521<span></span>
</td>
<td class="nump">113,444<span></span>
</td>
<td class="nump">66,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="num">(403)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment additions in accounts payable and accrued expenses</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(742)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 2,874<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">2,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_LeaseAssetsDerecognizedUponLeaseCancellation', window );">Lease assets derecognized upon lease cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncreaseDecreaseInReceivableResearchIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount of receivable research incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncreaseDecreaseInReceivableResearchIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LeaseAssetsDerecognizedUponLeaseCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of right of use assets derecognized upon lease cancellation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LeaseAssetsDerecognizedUponLeaseCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028382192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the business and organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the business and organization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the business and organization</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.&#160;Nature of the business and organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HOOKIPA Pharma&#160;Inc. (&#8220;HOOKIPA&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body&#8217;s immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the name of Hookipa Biotech,&#160;Inc. under the laws of the State of Delaware in February&#160;2017 as a fully-owned subsidiary of Hookipa Biotech AG. In June&#160;2018, the Company changed its name from Hookipa Biotech,&#160;Inc. to HOOKIPA Pharma&#160;Inc. and in order to effectuate the change of the jurisdiction of incorporation, the Company acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH. HOOKIPA is headquartered in New York, with European research and preclinical development operations headquartered in Vienna, Austria. In April&#160;2019, the Company closed its initial public offering (&#8220;IPO&#8221;) and its common stock started trading on the Nasdaq Global Select Market under the ticker symbol &#8220;HOOK&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities and may not ultimately lead to a marketing approval and commercialization of a product. Even if the Company&#8217;s drug development efforts are successful, it is uncertain if and when the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031275328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.&#160;Summary of significant accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company&#8217;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2023, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $81.6&#160;million, $64.9&#160;million and $75.7&#160;million for the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively. As of December&#160;31,&#160;2023, the Company had an accumulated deficit of $369.3&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;22,&#160;2024, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company will seek additional funding in order to reach its development and commercialization objectives. The Company may seek funds through further equity financings, debt financings, collaborations, strategic alliances and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards, the valuation of current and non-current loans payable and the impairment of long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign currency and currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency for the Company is the United States dollar and the functional currency for the Company's wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 the net proceeds from the Company&#8217;s offerings have been deposited in interest-bearing bank accounts with two of the largest investment grade U.S. financial institutions and have been partially invested in money market funds. The money market funds, held in U.S. dollars, are primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, the Company&#8217;s cash and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">cash equivalents included smaller amounts of cash balances held in accounts with regional European banks at the Company&#8217;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively, Gilead Sciences, Inc. (&#8220;Gilead&#8221;) and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together &#8220;Roche&#8221;) accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021 Gilead and Roche accounted for the majority of the Company&#8217;s revenues. Other customers accounted for less than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022 cash equivalents consisted of money market funds and short-term deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred offering costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">shorter of useful life or term of lease</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 4 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#8220;ROU&#8221;) assets and lease liabilities in the consolidated balance sheets. For leases with an initial term of 12 months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#8217;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#8220;ASC&#8221;)&#160;360.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Capitalized Software Development Cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of $0.1&#160;million associated with the Company's cloud computing arrangements has been recognized during each of the fiscal years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 (see Note&#160;6). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value (see Note 4. and Note 6.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company's resources. The majority of the Company's tangible assets are held in Austria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition from contracts with customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized revenue from collaboration and license agreements with Gilead and Roche. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the collaboration and license agreement with Gilead (as amended and restated, the &#8220;Gilead Collaboration Agreement&#8221;), the parties agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#8220;HBV&#8221;) and the human immunodeficiency virus (&#8220;HIV&#8221;). In February&#160;2022, the parties signed an amended and restated collaboration agreement (the &#8220;Restated Gilead Collaboration Agreement&#8221;), which revised the terms only for the HIV program, whereby the Company took on development responsibilities for the HIV program candidate through a Phase&#160;1b clinical trial. The Company&#8217;s performance obligations under the terms of the original agreement include one combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The terms of the Restated Gilead Collaboration Agreement added an additional performance obligation to perform research and development work for the HIV program. The licenses do not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under the Restated Gilead Collaboration Agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the research collaboration and license agreement with Roche (the &#8220;Roche Collaboration Agreement&#8221;), the Company has agreed to conduct research and early clinical development through Phase&#160;1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. The Roche Collaboration Agreement also includes an obligation of the Company to deliver a specified package of preclinical data and results with respect to a second program, targeting undisclosed cancer antigens (collectively &#8220;UCAs&#8221;) and an option for Roche to license the UCA program. The Company&#8217;s performance obligations under the terms of the Roche Collaboration Agreement include one combined performance obligation for the transfer of intellectual property rights (licenses) and providing research and development services for the HB-700 program, and a second, separate performance obligation to perform research and development services with respect to the UCA program. The UCA Option provides a right to license the program at the standalone selling price and therefore does not constitute a separate performance obligation. Payments to the Company under the Roche Collaboration Agreement include a non-refundable up-front payment, payments based upon the achievement of defined milestones, an additional payment if the option for the UCA program is exercised and royalties on product sales. In January 2024, Roche provided written notice of the termination of the collaboration and licensing agreement to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC&#160;606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC&#160;606, the Company applies significant judgement to evaluate whether the promises under the collaboration and licensing arrangements, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, the timing of revenue recognition, whether the UCA Option constitutes a material right, and the determination of when milestone payments are probable of being received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Upfront payment and program initiation fee</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-refundable upfront-payment received by the Company upon signing of the Gilead Collaboration Agreement, and milestone payments that were linked to future performance obligations, were initially recorded as deferred revenue and allocated between the two research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The non-refundable program initiation payment received from Gilead upon signing of the Restated Collaboration Agreement was also initially recorded as deferred revenue and is recognized on a percent of completion basis using total estimated research and development costs (input method) for the performance of the obligations. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer, due to the immediate benefit that it adds to the value of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the customer&#8217;s rights on the program, the short time intervals in which development results are shared and the nature of the work being performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-refundable upfront-payment received by the Company upon signing of the Roche Collaboration Agreement, was initially recorded as deferred revenue and allocated between the HB-700 program and the UCA program. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development costs (input method) for each of the obligations during the initial term of the contract. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reimbursement for services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Collaboration Agreement and the Roche Collaboration Agreement, the Company incurs employee expenses as well as external costs for research, manufacturing and clinical trial activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangements, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues as progress is achieved. Unpaid reimbursement amounts are presented as Accounts Receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development milestones</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gilead Collaboration Agreement and the Roche Collaboration Agreement include contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific uncertainties and the required commitment from Gilead and Roche. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to including the variable consideration associated with these payments within the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales-based milestones and royalty payments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gilead Collaboration Agreement and the Roche Collaboration Agreement also include certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost to fulfill contracts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and manufacturing contract costs and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government grant agreements and research incentives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes funding from grants and research incentives received from Austrian government agencies as well as from New York State and New York City government agencies in the United States as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company's common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient's payroll costs are classified or in which the recipient's service payments are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss and foreign currency translation adjustments. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 comprehensive loss included $0.8&#160;million and $2.4&#160;million, respectively, of foreign currency translation loss adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $1.3&#160;million of foreign currency translation gain adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2023, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2017 Tax Cuts and Jobs Act subjects a US shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in the future years or provide for tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize tax expense related to GILTI in the year the tax is incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Adopted as of current period</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718) to amend various SEC paragraphs in the Accounting Standards Codification to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. Staff Accounting Bulletin No. 120 provides guidance to companies issuing share-based awards shortly before announcing material, nonpublic information to consider such material nonpublic information to adjust observable market prices if the release of material nonpublic information is expected to affect the share price. The ASU does not provide any new guidance so there is no transition or effective date associated with it and therefore, the Company adopted the ASU with no impact to its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#8220;own stock&#8221; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company adopted this standard with no impact to its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028750896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeAndLicensingArrangementAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and Licensing Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Collaboration and Licensing Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gilead Collaboration and License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2018, the Company entered into the Gilead Collaboration Agreement whereby the Company and Gilead agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of HBV and HIV. In February&#160;2022, the Company signed the Amended and Restated Collaboration Agreement, which altered key aspects of the collaboration pertaining to the HIV therapeutic. Most importantly, the Amended and Restated Collaboration Agreement allocated additional research and development responsibility to the Company with respect to the Company&#8217;s HIV candidate and provided for additional funding by Gilead of such research and development activities as well as increased later stage development and commercial milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Collaboration Agreement, the Company granted Gilead an exclusive, royalty-bearing license to the Company&#8217;s technology platforms. Upon entering into the agreement in June&#160;2018, the Company received a non-refundable $10.0&#160;million upfront payment from Gilead and upon signing of the Restated Gilead Collaboration Agreement in February&#160;2022, the Company received a program initiation fee of $15.0&#160;million. Gilead is also obligated to make additional payments to the Company upon the achievement of pre-clinical, development and commercial milestones. The development milestones amount to $140.0&#160;million for the HBV program, and up to $172.5&#160;million for the HIV program, inclusive of a $10.0&#160;million program completion fee, payable upon Gilead&#8217;s exercise of the option to pursue further development activities post Phase&#160;1b. The commercial milestones amount to a total of $50.0&#160;million for the HBV program, and $65.0&#160;million for the HIV program. Additionally, Gilead is obligated to pay royalties on net sales for each program. Payments from Gilead generally have a 60&#160;day payment term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The $10.0&#160;million upfront payment, the $15.0&#160;million initiation fee and $8.0&#160;million in milestone payments were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of December&#160;31,&#160;2023, $7.5&#160;million of such payments were still recorded as a liability in deferred revenues, current and non-current. As of December&#160;31,&#160;2022, $14.3&#160;million of upfront and milestone payments were included as a liability in deferred revenues, current and non-current. Approximately 55.2% of deferred revenue is expected to be recognized as revenue in 2024, 36.8% in 2025 and the remaining 8.0% in 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2023, the Company recognized $7.1&#160;million of the milestone and initiation payments that were originally recorded as deferred revenue. Furthermore, the Company recognized $1.4&#160;million revenue from cost reimbursements for research and development services. In the year ended December&#160;31,&#160;2022, the Company recognized $3.7&#160;million of the upfront and milestone payments that were originally recorded as deferred revenue, $5.2&#160;million revenue from cost reimbursements for research and development services and $5.0&#160;million revenue from a milestone achieved in December&#160;2022. In the year ended December&#160;31,&#160;2021, the Company recognized $2.1&#160;million of the upfront and milestone payments that were originally recorded as deferred revenue and $16.3&#160;million revenue from cost reimbursements for research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the triggering payment is recognized. As of December&#160;31,&#160;2023 and 2022, the contract asset relating to the sublicense payment was $0.1&#160;million and $0.2&#160;million, respectively, and there was no liability relating to sublicense payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Roche Collaboration and License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2022, the Company entered into the Roche Collaboration Agreement whereby the Company and Roche agreed to collaborate with respect to the development of novel arenaviral immunotherapies for KRAS-mutated cancers and, potentially, a second, novel arenaviral immunotherapeutic program targeting specific undisclosed cancer antigens. In January&#160;2024, Roche provided written notice of the termination of the collaboration and licensing agreement to the Company (see Note 18. &#8220;Subsequent Events&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the terminated Roche Collaboration Agreement, the Company granted Roche an exclusive, royalty-bearing license to the Company&#8217;s technology platforms for KRAS-mutated cancers, and an option right to exclusively license a second, novel arenaviral immunotherapeutic program targeting undisclosed cancer antigens. Pursuant to the terms of the Collaboration Agreement, following the termination notice, the Collaboration Agreement will end on April&#160;25,&#160;2024. The Company remains eligible for a final milestone payment associated with an IND submission. Effective April&#160;25,&#160;2024, the Company will regain full control of the associated intellectual property portfolio and will have full collaboration and licensing rights for the KRAS program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon signing the Roche Collaboration Agreement in October&#160;2022, the Company received a non-refundable upfront payment of $25.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This upfront payment, and a $10.0&#160;million milestone payment received in the twelve months ended December&#160;31,&#160;2023 were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of December&#160;31,&#160;2023, $26.8&#160;million of such payments were still recorded as a liability in deferred revenues, current and non-current. As of December&#160;31,&#160;2022, $27.0&#160;million of the upfront payment was included as a liability in deferred revenues, current and non-current. The deferred revenues related to the $25.0&#160;million upfront payment and the $10.0&#160;million milestone payment are subject to foreign currency exchange rate fluctuations in future accounting periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2023, the Company recognized $11.1&#160;million of the upfront and milestone payments that were originally recorded as deferred revenue. Furthermore, the Company recognized $0.5&#160;million revenue from cost reimbursements for activities related to the preparation of a first in human trial. In the year ended December&#160;31,&#160;2022, the Company recognized $0.3&#160;million of the upfront payment that was originally recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from the triggering payment is recognized. As of December&#160;31,&#160;2023, the contract asset relating to the sublicense payment was $2.0&#160;million and there was no liability relating to sublicense payment. As of December&#160;31,&#160;2022 the contract asset and the liability relating to the sublicense payment was $1.5&#160;million and $1.2&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeAndLicensingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeAndLicensingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031255280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Impairment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Impairment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;Impairment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January&#160;29,&#160;2024, the Company announced its decision to prioritize the clinical development of its HB-200 program for the treatment of HPV16+ head and neck cancers and its two Gilead-partnered infectious disease programs and to pause development activities related to HB-300 and most of its preclinical research activities (see Note&#160;18. &#8220;Subsequent Events&#8221;). In connection with this strategic refocus, the Company&#8217;s board of directors approved a Restructuring Plan to rebalance the Company&#8217;s cost structure, which includes a reduction of the Company&#8217;s workforce </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">by approximately 30% and the discontinuation of the Company&#8217;s GMP manufacturing facility project. The Company expects the Restructuring Plan to be implemented and substantially completed by the end of the first quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the strategic considerations preceding the adoption of the Restructuring Plan, the Company assessed the recoverability of the long-lived assets relating to the GMP manufacturing project at December 31, 2023, and determined that the undiscounted cash flows of the asset group were below the carrying values, indicating impairment. The assets were written down to their estimated fair value, which was determined based on the cost approach. The resulting impairment charges were included within Impairment expense in the Consolidated Statements of Operations and Comprehensive Loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the effect of non-cash impairment charges (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-cash impairment charges</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Asset write-offs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,766)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total non-cash charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,766)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028714496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;Fair Value of Financial Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2023 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,084</p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,084</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2022 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,491</p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,491</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the </span><span style="-sec-ix-hidden:Hidden_Lpjoo-HNUkK1Q7dne6IAVQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">year</span></span><span style="font-weight:normal;"> ended </span><span style="-sec-ix-hidden:Hidden_9wPB5a7NckWc0o_lT7sjxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December&#160;31,&#160;2023</span></span><span style="font-weight:normal;">, there were </span><span style="font-weight:normal;">no</span><span style="font-weight:normal;"> transfers between Level&#160;1, Level&#160;2 and Level&#160;</span><span style="-sec-ix-hidden:Hidden_L0ges7xDOUOYjlazpNEvlw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3</span></span><span style="font-weight:normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039290640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Property, plant and equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,959</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,164</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,567</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,403</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 622</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,034</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,749</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,823)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,779)</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,970</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depreciation expense for the years ended December&#160;31,&#160;2023, 2022 and 2021 was $2.0&#160;million, $1.9&#160;million and $2.1&#160;million, respectively. Construction-in-progress as of December&#160;31,&#160;2022 mainly related to investments in connection with the Company&#8217;s GMP manufacturing facility project. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the strategic considerations preceding the adoption of the Restructuring Plan (see Note&#160;4. and Note&#160;18.) the Company determined that the estimated undiscounted future cash flows for its asset group related to the GMP manufacturing facility project were less than their carrying values. The Company therefore recognized an impairment loss of $12.8&#160;million related to the GMP manufacturing facility project for the year ended December&#160;31,&#160;2023, which reduced the carrying value of this asset group to zero. Impairment charges are included within Impairment expense in the Consolidated Statements of Operations and Comprehensive Loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were no impairments in the years ended December&#160;31,&#160;2022 and 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028717696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Receivable research incentive<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ReceivableResearchIncentiveAbstract', window );"><strong>Receivable research incentive</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ReceivableResearchIncentiveTextBlock', window );">Receivable research incentive</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.&#160;Receivable research incentive<span style="font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company participates in a research incentive program provided by the Austrian government under which it is entitled to reimbursement of a percentage of qualifying research and development expenses and capital expenditures incurred in Austria. Submissions for reimbursement under the program are submitted annually. Incentive amounts are generally paid out during the calendar year that follows the year of the expenses but remain subject to subsequent examinations by the responsible authority. Reimbursements received in excess of the recognized receivable research incentive for a certain period are recorded within other long term liabilities for potential repayment until such time that an audit has taken place, upon expiration of the potential reclaim period, or when it is no longer probable that a reclaim will happen. The years 2018 to present remain open to examination by the authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the Company participated in the life sciences research and development program provided by the New York State government under which it was entitled to reimbursement of a percentage of qualifying research and development expenses in New York State up to $0.5&#160;million per year for the years 2019 to 2021. Incentive amounts are generally paid out six to nine months after amended tax returns including a certificate of tax credit issued by Empire State Development are filed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company also participates in the New York City biotechnology tax credit program, according to which certain expenses for business in the biotechnology field in New York City limited to $0.25&#160;million per year for three </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">consecutive years from January&#160;1,&#160;2023 to December&#160;31,&#160;2025 are incentivized. The biotechnology tax credit can be refunded or applied against the next year's tax if it exceeds the current year's tax liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2023, the Company recognized receivables of $18.8&#160;million from the research incentive programs, which are reported in research incentive receivables in the Company&#8217;s consolidated balance sheet. $17.3&#160;million relate to the Austrian research incentive program, $1.4&#160;million relate to the New York State life sciences research and development program and $0.1&#160;million relate to the New York City biotechnology tax credit program. As of December&#160;31,&#160;2022, the receivables from the research incentive program were $15.5&#160;million and related to the Austrian research incentive program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December&#160;31,&#160;2023, 2022 and 2021, the Company recorded $10.9&#160;million, $7.3&#160;million and $8.9&#160;million, respectively, of income related to the incentive programs within the Company&#8217;s consolidated statements of operations and comprehensive loss as part of the grant income. Income for the year ended December&#160;31,&#160;2023 included $9.4&#160;million related to the Austrian incentive program, $1.4&#160;million related to the New York State life sciences research and development program and $0.1&#160;million related to the New York City biotechnology tax credit program. Income for the years ended December&#160;31,&#160;2022 and 2021 related to the Austrian incentive program. Research incentives depend on the eligible research and development expenses of the respective period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReceivableResearchIncentiveAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReceivableResearchIncentiveAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReceivableResearchIncentiveTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for receivable research incentive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReceivableResearchIncentiveTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031279792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_LeaseDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases real estate, including office and laboratory space and has entered into various other agreements with respect to assets used in conducting its business. The Company&#8217;s leases have remaining lease terms ranging from less than 1&#160;year to 5.2&#160;years. Some of the lease agreements contain rent holidays and rent escalation clauses that were included in the calculation of the right of use assets and lease liabilities. The Company&#8217;s current leases qualify as operating leases. The Company is required to maintain a cash balance of $0.4&#160;million to secure letters of credit associated with real estate leases. This amount was classified as non-current restricted cash in the consolidated balance sheet as of December&#160;31,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income&#160;statement&#160;location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,910</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40)</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,510</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;lease</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,655</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,627</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,351</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,213</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,851</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 412</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,439</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2023, the Company agreed on a lease amendment, which extended the term of the lease for its corporate headquarters in New York City by approximately 2.2&#160;years ending at the end of August&#160;2026. The Company also extended the estimated lease term of existing operating leases for the office and laboratory space in Vienna, Austria, by approximately 2.0 years ending at the end of December&#160;2027. Furthermore, the Company signed a lease amendment, which extended the term of the lease for certain parking spaces in its Vienna Office by approximately 5.5&#160;years ending at the end of February 2029. These lease amendments did not include additional right-of-use other than the extended lease term. There is no additional renewal term included in the lease amendments to consider in the estimate of the lease term. The respective lease liabilities were remeasured and the amounts resulting from the remeasurement of the lease liability were recognized as an adjustment to the corresponding right of use asset.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031245264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.&#160;Accrued expenses and other current liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Salaries and bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,481</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Social security contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned grant income (current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublicense fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,220</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,458</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external general and administration expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 898</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued for property and equipment acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accruals and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 324</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,178</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356138095504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayableAbstract', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DisclosureOfLongTermLoansPayableTextBlock', window );">Loans payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Loans payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, loans payable consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loans from FFG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,855</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Unamortized debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (350)</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total loans payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,505</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the funding agreements with the Austrian Research Promotion Agency, (<i style="font-style:italic;">&#214;sterreichische Forschungsf&#246;rderungsgesellschaft, </i>or &#8220;FFG&#8221;), the Company has received various loans (&#8220;FFG Loans&#8221;). The FFG Loans were made on a project-by-project basis. Amounts due under the FFG Loans bear interest at a rate of 0.75%&#160;per annum and mature in March&#160;2024. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FFG Loans bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between an estimated market rate of interest and the rate of interest charged by FFG as grant income from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as grant income over the term of the funding agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized grant income of $0.3&#160;million, $0.6&#160;million and $0.8&#160;million during the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively, related to the recognition of the unearned income recorded for the imputed benefit of FFG Loans at below-market interest rates. Unearned income (current) related to the imputed benefit of FFG Loans at below-market interest rates was less than $0.1&#160;million and $0.3&#160;million as of December&#160;31,&#160;2023 and 2022, respectively. Unearned income (non-current) presented under loans payable non-current related to such benefit was $0.1&#160;million as of December&#160;31,&#160;2022, and no non-current unearned income as of December31,&#160;2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company has recorded a discount to the carrying value of each FFG Loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method. As of December&#160;31,&#160;2023 and 2022, the unamortized debt discount related to FFG Loans was $0.1&#160;million and $0.4&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized interest expense of $0.3&#160;million, $0.7&#160;million and $0.9&#160;million during the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively, related to the FFG Loans, which included interest expense related to the amortization of debt discount of $0.3&#160;million, $0.7&#160;million and $0.8&#160;million during the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively. Principal repayments of $1.8&#160;million, and $2.8&#160;million were made in the years ended December&#160;31,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses an estimated market rate of 20%, which was determined based on an average of the available interest rates on unsecured loans to comparable companies. A 10% increase or decrease in the estimated market rate of interest would have no material impact on grant income or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the underlying program research results in a scientific or technical failure, the principal then outstanding under any loan may be forgiven by FFG on a project-by-project basis. The FFG Loans contain no financial covenants and are not secured by any of the Company's assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31,&#160;2023, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments&#160;Due&#160;by&#160;Calendar&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2024</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,172</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2026</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2027</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2028</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,172</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DisclosureOfLongTermLoansPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DisclosureOfLongTermLoansPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039299072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, Class A common stock and convertible preferred stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common stock, Class A common stock and convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common stock, Class A common stock and convertible preferred stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Common stock, Class A common stock and convertible preferred stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company&#8217;s capital structure consists of common stock, Class A common stock and preferred stock. As of December&#160;31,&#160;2023, the Company was authorized to issue&#160;200,000,000&#160;shares of common stock,&#160;3,900,000&#160;shares of Class&#160;A common stock and&#160;10,000,000&#160;shares of preferred stock. The Company has designated&#160;2,978&#160;of the&#160;10,000,000&#160;authorized shares of preferred stock as non-voting Series&#160;A convertible preferred stock,&#160;15,800&#160;of the&#160;10,000,000&#160;authorized shares of preferred stock as non-voting Series&#160;A-1 convertible preferred stock and&#160;15,268&#160;of the&#160;10,000,000&#160;authorized shares of preferred stock as non-voting Series&#160;A-2 convertible preferred stock. As of December&#160;31,&#160;2023, the Company had&#160;96,550,590&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_EUaK3Tg6FEeEOqOHWmJvgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common&#160;stock</span></span>,&#160;2,399,517&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_K3IEYYVgEkOcLQ_fmEnbgg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class&#160;A&#160;common</span></span> stock,&#160;370&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_wHXhiF9z3UaARnOvYs1xow;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Series&#160;A</span></span>&#160;convertible preferred stock,&#160;10,800&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_fN05Sy8hG0-TjqIRvTiFCg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Series&#160;A-1</span></span>&#160;convertible preferred stock and&#160;15,268&#160;shares of&#160;<span style="-sec-ix-hidden:Hidden_HE01NwGMaUaBkBAhb5ZKIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Series&#160;A-2</span></span>&#160;convertible preferred stock outstanding and issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On June&#160;5,&#160;2023, the Company closed a public offering of&#160;22,900,768&#160;shares of its common stock and&#160;15,268&#160;shares of Series&#160;A-2 convertible preferred stock at a public offering price of $1.31&#160;and $1,310.00&#160;per share, respectively, for net proceeds of $46.2&#160;million after deducting underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In July&#160;2022 and August&#160;2022 certain of the Company&#8217;s stockholders elected to convert an aggregate of 1,420,215&#160;shares (769,734 and 650,481&#160;shares, respectively) of Class&#160;A common stock owned by such holders into an aggregate of 1,420,215&#160;shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On February&#160;15,&#160;2022, the Company entered into a stock purchase agreement with Gilead (&#8220;Stock Purchase Agreement&#8221;), that requires Gilead, at the Company&#8217;s option, to purchase up to $35.0&#160;million of the Company&#8217;s common stock. On February&#160;15,&#160;2022, Gilead purchased an initial amount of 1,666,666&#160;shares of the Company&#8217;s common stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">in exchange for $5.0&#160;million in cash at a purchase price per share equal to $3.00. On December&#160;20,&#160;2023, the parties amended and restated the Stock Purchase Agreement (the &#8220;Amended Stock Purchase Agreement&#8221;) and Gilead purchased 15,000,000&#160;shares of the Company&#8217;s common stock in exchange for approximately $21.3&#160;million in cash at a purchase price per share equal to $1.4167. Pursuant to the terms of the Amended Stock Purchase Agreement, the Company may require Gilead to purchase the balance of the $8.7&#160;million of common stock as pro-rata participation in potential future equity raises. The Company&#8217;s right to sell shares of its common stock to Gilead is subject to specified limitations, including a limitation that prevents the Company from requesting purchases of shares of common stock by Gilead that would result in a beneficial ownership of more than 19.9% of the total number of outstanding shares of common stock by Gilead. The Company agreed to file a registration statement on Form S-3 to register for resale any additional shares of common stock issued to Gilead within four months from issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March&#160;4,&#160;2022, the Company closed a public offering of 21,700,000&#160;shares of its common stock and of 15,800&#160;shares of Series&#160;A-1 convertible preferred stock at a public offering price of $2.00 and $2,000.00 per share, respectively, for net proceeds of $70.2&#160;million after deducting underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has three series of preferred stock authorized, issued and outstanding as of December&#160;31,&#160;2023: Series&#160;A convertible preferred stock, Series&#160;A-1 convertible preferred stock, and Series A-2 convertible preferred stock. Shares of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock may be independently converted into common stock. Holders of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock have equal rights, powers and privileges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of Class&#160;A common stock and Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock are not entitled to vote, except as required by law. The holders of common stock and Class A common stock do not have any cumulative voting rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each holder of Class&#160;A common stock has the right to convert each share of Class A common stock into one share of common stock at such holder's election. Each holder of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock has the right to convert each share of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock into 1,000&#160;shares of common stock at any time at the holder&#8217;s option, provided that the holder will be prohibited, subject to certain exceptions, from converting Series&#160;A, Series&#160;A-1 and Series&#160;A-2 preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company&#8217;s common stock then issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of common stock and Class&#160;A common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Holders of Series&#160;A. Series&#160;A-1 and Series&#160;A-2 preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of the Company&#8217;s common stock. Holders of common stock and Class A common stock have no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the event of a liquidation, dissolution, or winding up of the Company, holders of our Series&#160;A, Series&#160;A-1 and Series&#160;A-2 preferred stock will receive a payment equal to $0.001 per share of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 preferred stock before any proceeds are distributed to the holders of common stock. Then, holders of common stock and Class&#160;A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There were&#160;370&#160;and&#160;1,697&#160;shares of Series&#160;A convertible preferred stock,&#160;10,800&#160;and&#160;15,800&#160;shares of Series&#160;A-1 convertible preferred stock and&#160;15,268&#160;and&#160;no&#160;shares of Series&#160;A-2 convertible preferred stock outstanding as of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively. In May&#160;2023 certain of the Company&#8217;s stockholders elected to convert an aggregate of&#160;1,327&#160;shares of Series&#160;A convertible preferred stock and an aggregate of&#160;5,000&#160;shares of Series&#160;A-1 convertibles preferred stock owned by such holders into an aggregate of&#160;6,327,000&#160;shares of the Company&#8217;s common stock. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028448000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">2018 Stock Option and Grant Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2018, the Board of Directors approved the 2018 Stock Option and Grant Plan. Options granted under the 2018 Stock Option and Grant Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. The options expire on the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the grant date. As of December&#160;31,&#160;2023, 782,176&#160;options granted under the 2018 Stock Option and Grant Plan remained outstanding. Any authorization to issue new options under the 2018 Stock Option and Grant Plan was cancelled upon the effectiveness of the 2019 Stock Option and Incentive Plan and no further awards will be granted under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">2019 Stock Option and Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April&#160;1,&#160;2019, the Company&#8217;s stockholders approved the 2019 Stock Option and Incentive Plan, which became effective as of the effective date of the registration statement in connection with the Company&#8217;s IPO. The plan provides for the grant of shares of restricted stock, long term incentive awards, stock options or other equity-based awards. As of December&#160;31,&#160;2023, the maximum number of shares of the Company&#8217;s common stock that may be issued under the Company&#8217;s 2019 Stock Option and Incentive Plan was 8,067,480&#160;shares which shall be cumulatively increased each year by up to 4.0% of the then outstanding number of shares of common stock and Class A common stock. Options granted under the 2019 Stock Option and Incentive Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. Initial options granted to non-executive directors upon their election generally vest over a three-year term with 33% of the options vesting upon the first anniversary of the grant date and the remaining 67% of the options vesting in eight equal quarterly installments following the first anniversary of the grant date. Option re-grants to non-executive directors generally vest on the first anniversary of the grant date. The options expire on the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the grant date. For each option the beneficiary is entitled to receive one share of common stock upon the exercise of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, there were&#160;500,000&#160;shares reserved for stock options issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On August&#160;7,&#160;2023, the Company&#8217;s board of directors approved a one-time offer to eligible non-executive, non-director employees to exchange certain outstanding stock options for new stock options with modified terms. Under the stock option exchange program (the &#8220;Offer&#8221;), the Company offered to exchange certain out-of-the-money stock options for new stock options at an exchange ratio of between&#160;1.75&#160;and&#160;2.50&#160;surrendered options for one new option exercisable for shares of common stock with a lower exercise price and extended vesting terms. Pursuant to the Offer, a total of&#160;82&#160;eligible participants tendered, and the Company accepted for cancellation, stock options to purchase an aggregate of&#160;543,228&#160;shares of the Company&#8217;s common stock with exercise prices between $6.90&#160;and $14.00. The eligible options that were accepted for cancellation represented approximately&#160;86.6% of the total shares of common stock underlying all of the eligible options. In accordance with the terms and conditions of the Offer, on September&#160;12, 2023, the Company issued new options to purchase an aggregate of&#160;274,485&#160;shares of common stock in exchange for the cancellation of the tendered eligible options. The exercise price per share of each new option granted in the Offer is $1.00. New options </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">issued for previously vested stock options vest on the first anniversary of the grant date and new options issued for previously unvested stock options vest over a&#160;three-year&#160;term in&#160;twelve&#160;equal quarterly installments. The stock option exchange offer resulted in incremental stock-based compensation expense of $0.1&#160;million, which will be recognized using the graded-vesting method over the remaining requisite service period of the new stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents a summary of awards outstanding:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inducement Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Granted and outstanding awards:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 782,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,099,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,111,575</p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 782,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,099,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,111,575</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock option valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the option&#8217;s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, volatility, the risk-free interest rate, the dividend and employee exercise behavior. Forfeitures are accounted for when they occur. Expected volatilities utilized in the Black-Scholes model are based on historical volatilities of a group of comparable companies. The group of representative companies have characteristics similar to the Company, including the stage of product development and focus on the life science industry. Management believes that this represents the most accurate basis for estimating expected future volatilities under the current conditions. The risk-free interest rate is derived from the yields for U.S.&#160;Treasuries with a remaining term approximating the expected life of the options. The expected term represents the period of time that the options granted are expected to be outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options granted during:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the 2021, 2022 and 2023 grants, the Company used the simplified method in developing an estimate of the expected term due to a lack of historical exercise data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock option activity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity since January&#160;1,&#160;2023 (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,532,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 490</p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,880,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,684)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,296,249)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,111,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,101,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options unvested as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,010,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options was calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The fair value per common stock used for calculating the intrinsic values as of December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021, was $0.81, $0.81 and $2.33, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised during the years ended December&#160;31,&#160;2023, 2022 and 2021 was less than $0.1&#160;million, $0.1&#160;million and $1.0&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant-date fair value per share of stock options granted during the years ended December&#160;31,&#160;2023, 2022 and 2021 was $0.55, $1.55 and $11.46, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total fair value of stock options vested during the years ended December&#160;31,&#160;2023 and 2022 was $5.1&#160;million and $7.9&#160;million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash received from stock option exercise under share-based payment arrangements for the years ended December&#160;31,&#160;2023, 2022 and 2021 was $1&#160;thousand, $3&#160;thousand and $203&#160;thousand, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Common Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the year ended December&#160;31,&#160;2022 the Company issued unrestricted shares of common stock to its executive team. The Company&#8217;s executive team agreed to convert a portion of their base salaries, for the six months ended June&#160;30,&#160;2022, for shares of the Company&#8217;s fully vested common stock having a value equal to their foregone salary, determined based on a value of $3.00 per share. This resulted in the issuance of 112,551&#160;shares of common stock with a total fair value of $0.2&#160;million. The grant date fair value per share of common stock was $1.50 and was measured at the closing price of the common stock on the date of grant. Expenses were recorded immediately and are included in stock based compensation in the year ended December&#160;31,&#160;2022. No unrestricted shares of common stock were issued in the year ended December&#160;31,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock-based compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,200</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,444</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,644</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2023 total unrecognized compensation cost related to the unvested stock-based awards was $1.5&#160;million, which is expected to be recognized over a weighted average period of 1.5&#160;years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356140406400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income tax expense during the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 resulted from US federal and state income tax as well as minimum tax obligations in Austria. From inception through December&#160;31,&#160;2021, we have not been required to pay U.S. federal and state income taxes because of current and accumulated net operating losses. Income tax expense during the year ended December&#160;31,&#160;2021 resulted from minimum tax obligations. During the years ended December&#160;31,&#160;2023, 2022 and 2021, the Company recorded no income tax benefits for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items. The Company's losses before income taxes were generated in the United States and Austria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2023, 2022 and 2021 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,222)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,403)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign (Austria)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,922)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (57,463)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,261)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (81,212)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,685)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,664)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The components of the consolidated income tax provision for the years ended December&#160;31,&#160;2023, 2022 and 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Federal</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 145</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 217</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">State</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 222</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Foreign (Austria)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total current tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 368</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 230</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Federal</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">State</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Foreign (Austria)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Total income tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 368</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 230</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company's worldwide effective tax rate for the years ended December&#160;31,&#160;2023, 2022 and 2021 was 0.5%, 0.3% and 0.0%, respectively. The tax rate is affected by recurring items, such as tax rates in foreign jurisdictions and the relative amounts of income earned in those jurisdictions, which is expected to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. The following items had the most significant impact on the difference between the statutory U.S. federal income tax rate of 21% for the years ended December&#160;31,&#160;2023, 2022 and 2021 and the effective tax rate:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign tax rate differential<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Not taxable government grants<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Global intangible low-taxed income</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Change in deferred tax asset valuation allowance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The 2.7% increase for the year ended December 31, 2023, and the 4% increase for the years ended December&#160;31,&#160;2022 and 2021, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is 24% for the year ended December&#160;31,&#160;2023, and 25% for the years ended December&#160;31,&#160;2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup>For the years ended December&#160;31,&#160;2023, 2022 and 2021, 6.8%, 3.8% and 3.8% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3) </sup>For the years ended December&#160;31,&#160;2023, 2022 and 2021, 28.2% reduction, 27.1% reduction and 30.2% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company's research activities and the inherent uncertainties the deferred tax assets are fully offset by a valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 87,445</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 66,201</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Capitalized R&amp;D expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 2,657</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,354</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Credit carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,265</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 64</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 317</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 366</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,421</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,251</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,254</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 918</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 94,359</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 70,154</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (89,309)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (65,774)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 5,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 4,380</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (3,774)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (3,450)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Fixed assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (14)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (10)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease right of use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (1,262)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (920)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (5,050)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (4,380)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2023, 2022 and 2021, the Company had Austrian net operating loss carryforwards of $378.1&#160;million, $275.3&#160;million and $219.7&#160;million, respectively, that do not expire, however these carryforwards are limited to 75% of the taxable income in any one tax period. As of December&#160;31,&#160;2023, 2022 and 2021, the Company had federal net operating loss carryforwards that were generated after December&#160;31,&#160;2017 of $2.2&#160;million, $13.8&#160;million and $17.9&#160;million, respectively, that do not expire, however these carryforwards are limited to 80% of the taxable income in any one tax period. The Company generated US taxable income in the current year and was able to offset 80% the taxable income utilizing net operating loss carryforwards which gave rise to current taxes during 2023. The federal net operating loss carryforward as of December&#160;31,&#160;2023 were $2.2&#160;million, and US Federal net operating loss carryforwards as of December&#160;31,&#160;2022 were $13.8&#160;million. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets resulting from its net operating loss carryforwards. Management has considered the Company's history of cumulative net losses incurred since inception and the uncertainties related to the long period necessary to achieve profits from commercialization of any products and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December&#160;31,&#160;2023, 2022 and 2021. According to a tax reform in Austria in 2022, the corporate income tax rate will be reduced from 24.0% to 23.0% in 2024. The future tax rate of 23.0% was used to determine deferred taxes and the valuation allowance for the Austrian business. Management reevaluates the positive and negative evidence at each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">losses is no longer present and additional weight may be given to subjective evidence. The tax years in which the tax carryforwards were generated may still be adjusted upon examination by the tax authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2023, 2022 and 2021 related primarily to the increases in net operating loss carryforwards as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (65,774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (53,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,064)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Increases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23,535)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,046)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,664)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89,309)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (65,774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (53,728)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;22,&#160;2017, the United States enacted the Tax Cuts and Jobs Act (&#8220;Tax Reform Legislation&#8221; or &#8220;TCJA&#8221;). The Tax Reform Legislation introduced section 951A, a new tax on so-called &#8220;global intangible low-taxed income&#8221;. GILTI applies to income of a controlled foreign corporation (&#8220;CFC&#8221;) that is not otherwise subpart F income, and consists of the excess "tested income" over a 10% return on the CFC's &#8220;qualified business asset investment,&#8221; or &#8220;QBAI&#8221;. QBAI is the total tax basis of the CFC's depreciable, tangible property used in the production of tested income. The full amount of GILTI is included in taxable income. The GILTI inclusion is then reduced by 50% (reduced to 37.5% after 2025). However, that reduction in GILTI may be limited based on the level of U.S. taxable income. A limited allowance for foreign tax credits is allowed that would reduce the U.S. tax cost. GILTI foreign tax credits can only reduce U.S. taxes owed on GILTI and are not eligible for carryforward. The Company's Austrian subsidiary falls under the category of a CFC and due to the nature of its business model as a technology company, there may not be a material amount of tangible assets if this subsidiary starts to generate profits. GILTI taxation therefore may be applicable. The Company estimated approximately $8.8&#160;million of GILTI inclusion for the year ended December&#160;31,&#160;2023. The Company previously estimated $3.6&#160;million for the tax year ended December&#160;31,&#160;2022, but did not recognize any GILTI inclusion upon filing of the December&#160;31,&#160;2022 statements. The U.S. tax on GILTI, net of research credits, was $0.4&#160;million and $0.2&#160;million for the years ended December&#160;31,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company files income tax returns in the U.S. federal jurisdiction as well as in New York. The tax years from 2018 to present remain open to examination by the jurisdictions in which the Company is subject to tax. <span style="background:#ffffff;">There are currently no pending income tax examinations in the U.S. </span>Furthermore, the Company files income tax returns in Austria. The tax years 2018 to present remain open to examination by the jurisdiction. There are currently no pending income tax examinations in Austria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company evaluates tax positions for recognition using a more likely than not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31,&#160;2023 and 2022, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040717520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Commitments and contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Contract manufacturing arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into arrangements with contract manufacturing organizations (&#8220;CMOs&#8221;) for manufacturing of materials for research and development purposes, including manufacturing of clinical trial materials. These contracts generally provide for non-cancellable obligations or cancellation penalties depending on the time of cancellation. As of December&#160;31,&#160;2023, the Company&#8217;s total non-cancellable obligations under contracts with CMOs were $7.4&#160;million, of which $0.9&#160;million relate to 2024 deliverables and $6.5&#160;million relate to 2025 deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Intellectual property licenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into certain license agreements under which it is obligated to make milestone payments upon the achievement of certain development and regulatory milestones, to pay royalties on net sales of licensed products, and to pay a percentage of the sublicense fees which the Company receives from its sublicensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the years ended December&#160;31,&#160;2023, 2022 and 2021, the Company recorded $1.6&#160;million, $1.0&#160;million and $1.3&#160;million, respectively, in licensing fees related to intellectual property licenses as research and development expenses. The amount for the year ended December&#160;31,&#160;2021 mainly related to the upfront payment and milestone payments received by the Company under the Gilead Collaboration Agreement. The amount for the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 mainly related to the upfront payment and milestone payments received by the Company under the Gilead Collaboration Agreement and the Roche Collaboration Agreement. The amounts recognized as expenses have been agreed to by the licensors but calculation of sublicensing fees on future payments may be subject to interpretation and may change until agreed to by the receiving party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Indemnification agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31,&#160;2023 or December&#160;31,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Legal proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company was recently a party to a patent proceeding opposing European Patent No.&#160;3218504 (the &#8220;EP&#160;&#8217;504 Patent&#8221;), which was granted to the University of Geneva in July&#160;2020 and is exclusively licensed to the Company. In a decision that has become final, the Opposition Division of the European Patent Office (&#8220;EPO&#8221;) dismissed the opposition, and maintained the patent as granted. The Company expenses the costs related to this case and other such legal proceedings as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356159458416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>401(k) Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. 401(k) Savings Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to 100% of the first 4% of each employee&#8217;s contribution. During the years ended December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021 expenses recognized for the 401(k) Plan were $0.6&#160;million, $0.6&#160;million and $0.4&#160;million, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031262240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16. Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (81,580)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64,915)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75,665)</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,422,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,743,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,945,954</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 835,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,697,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887,636</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,526,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,072,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A-2 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,742,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total number of shares used to calculate net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,526,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,512,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,833,590</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.86)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.99)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.30)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#8217;s common stock. The Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is independently convertible into&#160;one&#160;and&#160;1,000&#160;<span style="-sec-ix-hidden:Hidden_Eut-pnlYxkmGfE27-Y1kbg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares</span></span>&#160;of&#160;<span style="-sec-ix-hidden:Hidden_x3Vvh87iFkeGHTZK_-BIJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common</span></span>&#160;stock, respectively.&#160;2,399,517&#160;shares of the Company&#8217;s common stock are issuable upon conversion of the Class&#160;A common stock,&#160;370,000&#160;shares of the Company&#8217;s common stock are issuable upon conversion of Series&#160;A convertible preferred stock,&#160;10,800,000&#160;shares of the Company&#8217;s common stock are issuable upon conversion of Series&#160;A-1 convertible preferred stock and&#160;15,268,000&#160;shares of the Company&#8217;s common stock are issuable upon conversion of Series&#160;A-2 convertible preferred stock (see Note&#160;11).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares (common stock and Class&#160;A common stock) outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,111,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,532,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,111,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,532,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031187040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related parties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17. Related parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective September&#160;15,&#160;2023, Malte Peters, a member of the Company&#8217;s board of directors, agreed to lead the Company&#8217;s clinical activities ad interim as Senior Clinical Advisor. During the year ended December&#160;31,&#160;2023, the Company recorded expense of $0.1&#160;million related to a consulting agreement entered into with Dr.&#160;Peters, effective September&#160;15,&#160;2023. In the years ended December&#160;31,&#160;2022 and December&#160;31,&#160;2021, the Company did not record any related party transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031282272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18. Subsequent events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Roche Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25,&#160;2024, the Company received written notice of termination from Roche of the Roche Collaboration Agreement (see Note 3.). The termination was made according to Roche&#8217;s right to terminate without cause, acknowledging that, to date, the Company had met all go-forward criteria under the agreement. The Company remains eligible for a final milestone payment of $10.0&#160;million associated with an IND submission for the HB-700 program. Upon the termination effective date April&#160;25,&#160;2024, the Company will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for this program. At December&#160;31,&#160;2023, $26.8&#160;million of non-refundable upfront and milestone payments received from Roche were still recorded as deferred revenue and may be early recognized as revenue as a result of the termination in the first half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">January 2024 Restructuring Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;29,&#160;2024, the Company announced its decision to prioritize the clinical development of its HB-200 program for the treatment of HPV16+ head and neck cancers and its two Gilead-partnered infectious disease programs and to pause development activities related to HB-300 and most of its preclinical research activities. In connection with this strategic refocus, the Company&#8217;s Board of Directors approved to reduce the Company&#8217;s workforce by 55&#160;fulltime employees, or approximately 30% of the Company&#8217;s then-current employee base and to rebalance the Company&#8217;s cost structure in alignment with the new prioritization of research and development programs (together, the &#8220;Restructuring Plan&#8221;). The Company expects the Restructuring Plan to be implemented and substantially completed by the end of the first quarter of 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with the Restructuring Plan, the Company estimates that it will incur cash charges of approximately $1.6&#160;million for severance and other personnel and restructuring related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356160915072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_GoingConcernPolicyPolicyTextBlock', window );">Going concern</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, the Company&#8217;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2023, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $81.6&#160;million, $64.9&#160;million and $75.7&#160;million for the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively. As of December&#160;31,&#160;2023, the Company had an accumulated deficit of $369.3&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;22,&#160;2024, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company will seek additional funding in order to reach its development and commercialization objectives. The Company may seek funds through further equity financings, debt financings, collaborations, strategic alliances and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards, the valuation of current and non-current loans payable and the impairment of long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency and currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign currency and currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency for the Company is the United States dollar and the functional currency for the Company's wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk and of significant suppliers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of credit risk and of significant suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 the net proceeds from the Company&#8217;s offerings have been deposited in interest-bearing bank accounts with two of the largest investment grade U.S. financial institutions and have been partially invested in money market funds. The money market funds, held in U.S. dollars, are primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, the Company&#8217;s cash and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">cash equivalents included smaller amounts of cash balances held in accounts with regional European banks at the Company&#8217;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively, Gilead Sciences, Inc. (&#8220;Gilead&#8221;) and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together &#8220;Roche&#8221;) accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021 Gilead and Roche accounted for the majority of the Company&#8217;s revenues. Other customers accounted for less than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022 cash equivalents consisted of money market funds and short-term deposits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DeferredOfferingCostsPolicyPolicyTextBlock', window );">Deferred offering costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred offering costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;5).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">shorter of useful life or term of lease</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 4 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#8220;ROU&#8221;) assets and lease liabilities in the consolidated balance sheets. For leases with an initial term of 12 months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#8217;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#8220;ASC&#8221;)&#160;360.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Capitalized Software Development Cost</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Capitalized Software Development Cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of $0.1&#160;million associated with the Company's cloud computing arrangements has been recognized during each of the fiscal years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 (see Note&#160;6). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value (see Note 4. and Note 6.).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company's resources. The majority of the Company's tangible assets are held in Austria.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition from contracts with customers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition from contracts with customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized revenue from collaboration and license agreements with Gilead and Roche. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the collaboration and license agreement with Gilead (as amended and restated, the &#8220;Gilead Collaboration Agreement&#8221;), the parties agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#8220;HBV&#8221;) and the human immunodeficiency virus (&#8220;HIV&#8221;). In February&#160;2022, the parties signed an amended and restated collaboration agreement (the &#8220;Restated Gilead Collaboration Agreement&#8221;), which revised the terms only for the HIV program, whereby the Company took on development responsibilities for the HIV program candidate through a Phase&#160;1b clinical trial. The Company&#8217;s performance obligations under the terms of the original agreement include one combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The terms of the Restated Gilead Collaboration Agreement added an additional performance obligation to perform research and development work for the HIV program. The licenses do not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under the Restated Gilead Collaboration Agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the research collaboration and license agreement with Roche (the &#8220;Roche Collaboration Agreement&#8221;), the Company has agreed to conduct research and early clinical development through Phase&#160;1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. The Roche Collaboration Agreement also includes an obligation of the Company to deliver a specified package of preclinical data and results with respect to a second program, targeting undisclosed cancer antigens (collectively &#8220;UCAs&#8221;) and an option for Roche to license the UCA program. The Company&#8217;s performance obligations under the terms of the Roche Collaboration Agreement include one combined performance obligation for the transfer of intellectual property rights (licenses) and providing research and development services for the HB-700 program, and a second, separate performance obligation to perform research and development services with respect to the UCA program. The UCA Option provides a right to license the program at the standalone selling price and therefore does not constitute a separate performance obligation. Payments to the Company under the Roche Collaboration Agreement include a non-refundable up-front payment, payments based upon the achievement of defined milestones, an additional payment if the option for the UCA program is exercised and royalties on product sales. In January 2024, Roche provided written notice of the termination of the collaboration and licensing agreement to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC&#160;606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under ASC&#160;606, the Company applies significant judgement to evaluate whether the promises under the collaboration and licensing arrangements, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, the timing of revenue recognition, whether the UCA Option constitutes a material right, and the determination of when milestone payments are probable of being received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Upfront payment and program initiation fee</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-refundable upfront-payment received by the Company upon signing of the Gilead Collaboration Agreement, and milestone payments that were linked to future performance obligations, were initially recorded as deferred revenue and allocated between the two research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The non-refundable program initiation payment received from Gilead upon signing of the Restated Collaboration Agreement was also initially recorded as deferred revenue and is recognized on a percent of completion basis using total estimated research and development costs (input method) for the performance of the obligations. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer, due to the immediate benefit that it adds to the value of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the customer&#8217;s rights on the program, the short time intervals in which development results are shared and the nature of the work being performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The non-refundable upfront-payment received by the Company upon signing of the Roche Collaboration Agreement, was initially recorded as deferred revenue and allocated between the HB-700 program and the UCA program. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development costs (input method) for each of the obligations during the initial term of the contract. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reimbursement for services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gilead Collaboration Agreement and the Roche Collaboration Agreement, the Company incurs employee expenses as well as external costs for research, manufacturing and clinical trial activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangements, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues as progress is achieved. Unpaid reimbursement amounts are presented as Accounts Receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development milestones</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gilead Collaboration Agreement and the Roche Collaboration Agreement include contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific uncertainties and the required commitment from Gilead and Roche. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to including the variable consideration associated with these payments within the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales-based milestones and royalty payments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gilead Collaboration Agreement and the Roche Collaboration Agreement also include certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost to fulfill contracts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock', window );">Research and manufacturing contract costs and accruals</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and manufacturing contract costs and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock', window );">Government grant agreements and research incentives</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government grant agreements and research incentives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes funding from grants and research incentives received from Austrian government agencies as well as from New York State and New York City government agencies in the United States as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company's common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient's payroll costs are classified or in which the recipient's service payments are classified.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss includes net loss and foreign currency translation adjustments. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 comprehensive loss included $0.8&#160;million and $2.4&#160;million, respectively, of foreign currency translation loss adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $1.3&#160;million of foreign currency translation gain adjustments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_EarningsPerSharePolicyPolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2023, 2022 and 2021.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2017 Tax Cuts and Jobs Act subjects a US shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in the future years or provide for tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize tax expense related to GILTI in the year the tax is incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Adopted as of current period</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718) to amend various SEC paragraphs in the Accounting Standards Codification to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. Staff Accounting Bulletin No. 120 provides guidance to companies issuing share-based awards shortly before announcing material, nonpublic information to consider such material nonpublic information to adjust observable market prices if the release of material nonpublic information is expected to affect the share price. The ASU does not provide any new guidance so there is no transition or effective date associated with it and therefore, the Company adopted the ASU with no impact to its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#8220;own stock&#8221; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company adopted this standard with no impact to its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredOfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredOfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_EarningsPerSharePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_EarningsPerSharePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government grant agreements and research incentives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for research and manufacturing contract costs and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -SubTopic 50<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482610/350-50-25-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -SubTopic 40<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482633/350-40-30-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031275072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of estimated useful life of each asset</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;useful&#160;life</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">shorter of useful life or term of lease</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 10 years</p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2 - 4 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031286384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Impairment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of impairment charges were included within Impairment expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-cash impairment charges</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Asset write-offs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,766)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total non-cash charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,766)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031189888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of financial assets measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2023 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,084</p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,084</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement at December&#160;31,&#160;2022 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,491</p></td></tr><tr><td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,491</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032528304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, plant and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Property, plant and equipment, net consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Land</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,959</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,164</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,567</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,403</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 622</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,034</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,749</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,823)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,779)</p></td></tr><tr><td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,970</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028589344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of the effect of lease costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the effect of lease costs in the Company&#8217;s consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income&#160;statement&#160;location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,910</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 242</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 203</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease amortization expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 425</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest on finance lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublease income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (40)</p></td></tr><tr><td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,510</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of operating lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating&#160;lease</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,655</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,627</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,351</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,213</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,851</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 412</p></td></tr><tr><td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,439</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases', window );">Schedule of weighted average remaining lease term and weighted average discount rate of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term in years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted average remaining lease term and weighted average discount rate of finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356031204800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Salaries and bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,481</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Social security contributions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 340</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 267</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned grant income (current)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sublicense fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,220</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,458</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued external general and administration expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 898</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued for property and equipment acquisitions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accruals and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 324</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,178</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039520624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayableAbstract', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DisclosureOfLongTermLoansPayableTableTextBlock', window );">Schedule of loans payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, loans payable consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Loans from FFG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,855</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Unamortized debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (350)</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total loans payable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,505</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of aggregate minimum future principal payments due in connection with the FFG Loans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31,&#160;2023, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Payments&#160;Due&#160;by&#160;Calendar&#160;Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2024</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,172</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2025</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2026</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2027</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">2028</p></td><td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Thereafter </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,172</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DisclosureOfLongTermLoansPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DisclosureOfLongTermLoansPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (S-X 210.12-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028478032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of awards outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2018 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inducement Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Granted and outstanding awards:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 782,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,099,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,111,575</p></td></tr><tr><td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 782,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,099,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,111,575</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity since January&#160;1,&#160;2023 (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,532,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 490</p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,880,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,684)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,296,249)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,111,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,101,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options unvested as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,010,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,200</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,444</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,644</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028630704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of losses before income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2023, 2022 and 2021 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,222)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,403)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign (Austria)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,922)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (57,463)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,261)</p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss before tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (81,212)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (64,685)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75,664)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of the consolidated income tax provision</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The components of the consolidated income tax provision for the years ended December&#160;31,&#160;2023, 2022 and 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Current</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Federal</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 145</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 217</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">State</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 222</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 12</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Foreign (Austria)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total current tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 368</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 230</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Federal</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">State</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Foreign (Austria)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Total income tax expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 368</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 230</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. federal statutory income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign tax rate differential<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Not taxable government grants<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Global intangible low-taxed income</p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Change in deferred tax asset valuation allowance<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> The 2.7% increase for the year ended December 31, 2023, and the 4% increase for the years ended December&#160;31,&#160;2022 and 2021, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is 24% for the year ended December&#160;31,&#160;2023, and 25% for the years ended December&#160;31,&#160;2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup>For the years ended December&#160;31,&#160;2023, 2022 and 2021, 6.8%, 3.8% and 3.8% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3) </sup>For the years ended December&#160;31,&#160;2023, 2022 and 2021, 28.2% reduction, 27.1% reduction and 30.2% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company's research activities and the inherent uncertainties the deferred tax assets are fully offset by a valuation allowance.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of the net deferred tax assets or liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2023 and 2022 consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Net operating loss carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 87,445</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 66,201</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Capitalized R&amp;D expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 2,657</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,354</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Credit carryforwards</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,265</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 64</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 317</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 366</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Stock-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,421</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,251</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 1,254</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 918</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 94,359</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 70,154</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (89,309)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (65,774)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 5,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> 4,380</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Deferred tax liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Accrued expenses and other</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (3,774)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (3,450)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Fixed assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (14)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (10)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Operating lease right of use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (1,262)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (920)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (5,050)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';"> (4,380)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-family:'Times';">Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times';">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Times';"> &#8212;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of changes in the valuation allowance for deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2023, 2022 and 2021 related primarily to the increases in net operating loss carryforwards as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (65,774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (53,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,064)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Increases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23,535)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,046)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,664)</p></td></tr><tr><td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (89,309)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (65,774)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (53,728)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040902016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (81,580)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64,915)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (75,665)</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,422,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,743,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,945,954</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 835,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,697,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887,636</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,526,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,072,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Weighted-average Series A-2 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,742,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total number of shares used to calculate net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,526,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,512,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,833,590</p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.86)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.99)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.30)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#8217;s common stock. The Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is independently convertible into&#160;one&#160;and&#160;1,000&#160;<span style="-sec-ix-hidden:Hidden_Eut-pnlYxkmGfE27-Y1kbg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares</span></span>&#160;of&#160;<span style="-sec-ix-hidden:Hidden_x3Vvh87iFkeGHTZK_-BIJg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common</span></span>&#160;stock, respectively.&#160;2,399,517&#160;shares of the Company&#8217;s common stock are issuable upon conversion of the Class&#160;A common stock,&#160;370,000&#160;shares of the Company&#8217;s common stock are issuable upon conversion of Series&#160;A convertible preferred stock,&#160;10,800,000&#160;shares of the Company&#8217;s common stock are issuable upon conversion of Series&#160;A-1 convertible preferred stock and&#160;15,268,000&#160;shares of the Company&#8217;s common stock are issuable upon conversion of Series&#160;A-2 convertible preferred stock (see Note&#160;11).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities that were not included in the diluted per share calculations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,111,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,532,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td></tr><tr><td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,111,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,532,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,231,178</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028405808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Going concern (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="num">$ (81,580)<span></span>
</td>
<td class="num">$ (64,915)<span></span>
</td>
<td class="num">$ (75,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (369,261)<span></span>
</td>
<td class="num">$ (287,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039004416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Property and equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032862064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Others (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>Program</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Amortization expense | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms', window );">Number of preclinical research programs | Program</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_NumberOfCombinedPerformanceObligation', window );">Number of Combined Performance Obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_NumberOfCombinedPerformanceObligationForEachResearchProgram', window );">Number of combined performance obligation for each research program</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_NumberOfResearchProgramPerformanceObligations', window );">Number of research program performance obligations</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of preclinical research programs in collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfCombinedPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of combined performance obligation under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfCombinedPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfCombinedPerformanceObligationForEachResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of combined performance obligation for each research program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfCombinedPerformanceObligationForEachResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfResearchProgramPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of research program performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfResearchProgramPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -SubTopic 20<br> -Topic 985<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039591168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Comprehensive loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="num">$ (777)<span></span>
</td>
<td class="num">$ (2,376)<span></span>
</td>
<td class="nump">$ 1,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356034756464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,631<span></span>
</td>
<td class="nump">$ 15,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Gilead Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_NumberOfPreclinicalResearchPrograms', window );">Number of preclinical research programs | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ProceedsFromNonRefundableUpFrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeAgreementProgramInitiationFees', window );">Program initiation fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeArrangementTermOfRoyaltyPayment', window );">Payment term (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ProceedsFromMilestonePayment', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne', window );">Percentage of upfront payment included in deferred revenue expected to be recognized in 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo', window );">Percentage of upfront payment included in deferred revenue expected to be recognized in 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree', window );">Percentage of upfront payment included in deferred revenue expected to be recognized in 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborationAgreementMilestonePaymentsRevenueRecognized', window );">Revenue recognized from milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices', window );">Revenue recognized from cost reimbursements for research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeArrangementRevenueFromMilestonePayments', window );">Revenue recognized from milestone payments for milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment', window );">Contract asset relating to the sublicense payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment', window );">Contract liability relating to sublicense payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=hook_RocheCollaborationAgreementMember', window );">Roche collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ProceedsFromNonRefundableUpFrontPayment', window );">Upfront payment received</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ProceedsFromMilestonePayment', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_RevenueRecognizedUpfrontPayment', window );">Revenue recognized from upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborationAgreementMilestonePaymentsRevenueRecognized', window );">Revenue recognized from milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial', window );">Collaborative arrangement revenue from cost reimbursements for preparation of first human trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment', window );">Contract asset relating to the sublicense payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment', window );">Contract liability relating to sublicense payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_MilestoneAxis=hook_DevelopmentMilestonesMember', window );">Development Milestones | HBV program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_TotalMilestoneAmount', window );">Total milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_MilestoneAxis=hook_DevelopmentMilestonesMember', window );">Development Milestones | HIV program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise', window );">program completion fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_MilestoneAxis=hook_DevelopmentMilestonesMember', window );">Development Milestones | HIV program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_TotalMilestoneAmount', window );">Total milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_MilestoneAxis=hook_CommercialMilestonesMember', window );">Commercial Milestones | HBV program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_TotalMilestoneAmount', window );">Total milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_MilestoneAxis=hook_CommercialMilestonesMember', window );">Commercial Milestones | HIV program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_TotalMilestoneAmount', window );">Total milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborationAgreementMilestonePaymentsRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments revenue recognized under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborationAgreementMilestonePaymentsRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of program completion fee on exercise of option under collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeAgreementProgramInitiationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses relating to program initiation fees under collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeAgreementProgramInitiationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contract assets relating to sublicense payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contract liability relating to sublicense payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from cost reimbursements for preparation of first human trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from cost reimbursements for research and development services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementRevenueFromMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from milestone payments for milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementRevenueFromMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborativeArrangementTermOfRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term for royalty payment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborativeArrangementTermOfRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue recognized in year one that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue recognized in year three that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue recognized in year two that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfPreclinicalResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of preclinical research programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfPreclinicalResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ProceedsFromMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received from milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ProceedsFromMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ProceedsFromNonRefundableUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from non-refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ProceedsFromNonRefundableUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_RevenueRecognizedUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_RevenueRecognizedUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_TotalMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total milestone amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_TotalMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=hook_RocheCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=hook_RocheCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_MilestoneAxis=hook_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_MilestoneAxis=hook_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=hook_HbvProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=hook_HbvProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=hook_HivProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=hook_HivProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_MilestoneAxis=hook_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_MilestoneAxis=hook_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356029564032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Impairment - Additional information (Details)<br></strong></div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance | January 2024 Restructuring Plan | Subsequent events</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Impairment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction if workforce (in percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=hook_January2024RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=hook_January2024RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032672528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impairment - Non-cash impairment charges (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Impairment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Non-cash impairment charges</a></td>
<td class="num">$ (12,766)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040738816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_FairValueAssetsLevel1ToLevel2TransfersAmount1', window );">Transfers from Level 1 to Level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_FairValueAssetsLevel2ToLevel1TransfersAmount1', window );">Transfers from Level 2 to Level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers from into Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers from out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">91,084<span></span>
</td>
<td class="nump">$ 85,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">91,084<span></span>
</td>
<td class="nump">85,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">91,084<span></span>
</td>
<td class="nump">85,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 91,084<span></span>
</td>
<td class="nump">$ 85,491<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_FairValueAssetsLevel1ToLevel2TransfersAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_FairValueAssetsLevel1ToLevel2TransfersAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_FairValueAssetsLevel2ToLevel1TransfersAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_FairValueAssetsLevel2ToLevel1TransfersAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039622624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 17,565<span></span>
</td>
<td class="nump">$ 25,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(9,823)<span></span>
</td>
<td class="num">(7,779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,742<span></span>
</td>
<td class="nump">17,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charges of assets</a></td>
<td class="nump">12,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_RestructuringPlanCarryingValueOfAsset', window );">Carrying value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,025<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">10,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,722<span></span>
</td>
<td class="nump">7,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,652<span></span>
</td>
<td class="nump">$ 2,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_RestructuringPlanCarryingValueOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value of the  asset after restructuring.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_RestructuringPlanCarryingValueOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hook_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040578256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Receivable research incentive (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ResearchAndDevelopmentIncentiveProgramLineItems', window );"><strong>Research and Development Incentive Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_GrantIncomeIncentiveProgram', window );">Income related to the incentive program recorded as grant income</a></td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ReceivablesTaxResearchPremiumCurrent', window );">Receivable research incentives</a></td>
<td class="nump">18,760<span></span>
</td>
<td class="nump">$ 15,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ResearchAndDevelopmentIncentiveProgramAxis=hook_AustrianResearchIncentiveProgramMember', window );">Austrian Research Incentive Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ResearchAndDevelopmentIncentiveProgramLineItems', window );"><strong>Research and Development Incentive Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_GrantIncomeIncentiveProgram', window );">Income related to the incentive program recorded as grant income</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ReceivablesTaxResearchPremiumCurrent', window );">Receivable research incentives</a></td>
<td class="nump">17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ResearchAndDevelopmentIncentiveProgramAxis=hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember', window );">New York State Life Sciences Research and Development Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ResearchAndDevelopmentIncentiveProgramLineItems', window );"><strong>Research and Development Incentive Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_GrantIncomeIncentiveProgram', window );">Income related to the incentive program recorded as grant income</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ReceivablesTaxResearchPremiumCurrent', window );">Receivable research incentives</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses', window );">Reimbursement of research and development expenses</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ResearchAndDevelopmentIncentiveProgramAxis=hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember', window );">New York State New York City Biotechnology Tax Credit Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ResearchAndDevelopmentIncentiveProgramLineItems', window );"><strong>Research and Development Incentive Program [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_GrantIncomeIncentiveProgram', window );">Income related to the incentive program recorded as grant income</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ReceivablesTaxResearchPremiumCurrent', window );">Receivable research incentives</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear', window );">Maximum expenses eligible for incentives</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_GrantIncomeIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant income recognized related to the incentive program during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_GrantIncomeIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum expenses eligible for incentives in Biotechnology field per year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReceivablesTaxResearchPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReceivablesTaxResearchPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reimbursement amount receivable as a percentage of qualifying research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ResearchAndDevelopmentIncentiveProgramLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ResearchAndDevelopmentIncentiveProgramLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ResearchAndDevelopmentIncentiveProgramAxis=hook_AustrianResearchIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ResearchAndDevelopmentIncentiveProgramAxis=hook_AustrianResearchIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ResearchAndDevelopmentIncentiveProgramAxis=hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ResearchAndDevelopmentIncentiveProgramAxis=hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ResearchAndDevelopmentIncentiveProgramAxis=hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ResearchAndDevelopmentIncentiveProgramAxis=hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040269952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Cash balance maintained to secure a letter of credit associated with a real estate lease</a></td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_LesseeLeaseRemainingTermOfContract', window );">Remaining lease term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_LesseeLeaseRemainingTermOfContract', window );">Remaining lease term (in years)</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LesseeLeaseRemainingTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LesseeLeaseRemainingTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040543712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease expenses</a></td>
<td class="nump">$ 1,589<span></span>
</td>
<td class="nump">$ 1,738<span></span>
</td>
<td class="nump">$ 2,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses</a></td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">1,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses</a></td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040740064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum lease payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">5,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 5,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356234583104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted average remaining lease term and weighted average discount rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, Weighted average remaining lease term (in years)</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, Weighted average discount rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=hook_LeaseForCorporateHeadquartersInNewYorkCityMember', window );">lease for corporate headquarters in New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease,</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember', window );">Leases for Office and Laboratory Space in Vienna, Austria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease,</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=hook_LeaseForCertainParkingSpacesInViennaOfficeMember', window );">Lease for Certain Parking Spaces in Vienna Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease,</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=hook_LeaseForCorporateHeadquartersInNewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=hook_LeaseForCorporateHeadquartersInNewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=hook_LeaseForCertainParkingSpacesInViennaOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=hook_LeaseForCertainParkingSpacesInViennaOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356140659344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Salaries and bonuses</a></td>
<td class="nump">$ 5,665<span></span>
</td>
<td class="nump">$ 4,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedSocialSecurityContributionsCurrent', window );">Social security contributions</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedUnearnedGrantIncomeCurrent', window );">Unearned grant income (current)</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedSubLicenseFees', window );">Sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedExternalResearchAndDevelopmentExpenses', window );">Accrued external research and development expenses</a></td>
<td class="nump">4,594<span></span>
</td>
<td class="nump">3,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedExternalGeneralAndAdministrationExpenses', window );">Accrued external general and administration expenses</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedExpensesForPropertyAndEquipmentAcquisitions', window );">Accrued for property and equipment acquisitions</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_OtherAccruedExpensesAndLiabilitiesCurrent', window );">Other accruals and liabilities</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_AccruedExpensesAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">$ 12,101<span></span>
</td>
<td class="nump">$ 11,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExpensesForPropertyAndEquipmentAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of balance sheet date of accrued expenses for property and equipment acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExpensesForPropertyAndEquipmentAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExternalGeneralAndAdministrationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of balance sheet date of accrued external general and administration expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExternalGeneralAndAdministrationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of balance sheet date of accrued external research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedSocialSecurityContributionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the social security contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedSocialSecurityContributionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedSubLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued sub license fees at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedSubLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_AccruedUnearnedGrantIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of accrued unearned grant income (current).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_AccruedUnearnedGrantIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_OtherAccruedExpensesAndLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of other accruals and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_OtherAccruedExpensesAndLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356160886032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_LongTermLoansPayableGross', window );">Loans from FFG</a></td>
<td class="nump">$ 1,172<span></span>
</td>
<td class="nump">$ 2,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent', window );">Unamortized debt discount</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Total loans payable, net</a></td>
<td class="nump">$ 1,120<span></span>
</td>
<td class="nump">2,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 20,129<span></span>
</td>
<td class="nump">14,249<span></span>
</td>
<td class="nump">$ 18,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">14,631<span></span>
</td>
<td class="nump">15,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">19,674<span></span>
</td>
<td class="nump">25,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Principal payment</a></td>
<td class="nump">1,754<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_IncreaseDecreaseInEstimatedMarketRate', window );">Threshold for change in estimated market rate</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DebtInstrumentEstimatedMarketRatePercent', window );">Estimated market rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Loans payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DebtInstrumentEstimatedMarketRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated market rate under the debt instrument arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DebtInstrumentEstimatedMarketRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncreaseDecreaseInEstimatedMarketRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated market rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncreaseDecreaseInEstimatedMarketRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LongTermLoansPayableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans payable, gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LongTermLoansPayableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032089920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans payable - Schedule of aggregate minimum future principal payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039818992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common stock, Class A common stock and convertible preferred stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 20, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 05, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,200<span></span>
</td>
<td class="nump">$ 70,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,043<span></span>
</td>
<td class="nump">$ 45,691<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_RegisterForResaleOfCommonStockAdditionalIssuances', window );">Register for resale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,550,590<span></span>
</td>
<td class="nump">52,317,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,550,590<span></span>
</td>
<td class="nump">52,317,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,900,768<span></span>
</td>
<td class="nump">21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares elected to convert</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,420,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_NumberOfVotes', window );">Number of votes | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,517<span></span>
</td>
<td class="nump">2,399,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,399,517<span></span>
</td>
<td class="nump">2,399,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares elected to convert</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,481<span></span>
</td>
<td class="nump">769,734<span></span>
</td>
<td class="nump">1,420,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ConversionOfStockCommonStockIssuedForEachShareConverted', window );">Number of common stock issued upon conversion of each share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember', window );">Series A, SeriesA-1 And SeriesA-2 convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ConversionOfStockCommonStockIssuedForEachShareConverted', window );">Number of common stock issued upon conversion of each share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ThresholdPercentageForConversion', window );">Threshold percentage for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember', window );">Series A-1 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_PreferredStockSharesDesignated', window );">Preferred stock shares designated (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares elected to convert</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_PreferredStockSharesDesignated', window );">Preferred stock shares designated (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,268<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,268<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_PreferredStockSharesDesignated', window );">Preferred stock shares designated (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares elected to convert</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hook_StockPurchaseAgreementMember', window );">Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hook_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Gilead | Gilead Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hook_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4167<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hook_AmendedStockPurchaseAgreementMember', window );">Amended Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="nump">$ 1.4167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="nump">$ 21,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_RemainingOfCommonStockReservedForFutureIssuance', window );">Outstanding amount | $</a></td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ConversionOfStockCommonStockIssuedForEachShareConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new common stock issued in the conversion of each stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ConversionOfStockCommonStockIssuedForEachShareConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of votes for each share held .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares designated as preferred shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_RegisterForResaleOfCommonStockAdditionalIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period to register for resale the shares of common stock from the additional issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_RegisterForResaleOfCommonStockAdditionalIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_RemainingOfCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount remaining common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_RemainingOfCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ThresholdPercentageForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percent of common stock that can be owned after conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ThresholdPercentageForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=hook_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=hook_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=hook_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=hook_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=hook_AmendedStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=hook_AmendedStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040891632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - 2018 Stock Option and Grant Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">8,111,575<span></span>
</td>
<td class="nump">6,532,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember', window );">2018 Stock Option and Grant Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">782,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember', window );">2018 Stock Option and Grant Plan | Vesting upon first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember', window );">2018 Stock Option and Grant Plan | Vesting in equal quarterly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment', window );">Number of quarterly installments for vesting | installment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of quarterly installments of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356035262912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 12, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 07, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>installment </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption', window );">Number of common stock entitled for each option upon the exercise of the option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=hook_StockOptionExchangeOfferMember', window );">Stock option exchange offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment', window );">Number of quarterly installments for vesting | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_NumberOfEligibleParticipants', window );">Eligible participants | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled', window );">Exercise of stock options cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions', window );">Percentage of options accepted for cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">274,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_StockOptionsIssuedExercisePricePerShare', window );">Exercise price per share | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost', window );">Stock option exchange offer resulted in incremental stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=hook_StockOptionExchangeOfferMember', window );">Stock option exchange offer | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ExercisePriceLimitConsideredForCancellationOfStockOptions', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=hook_StockOptionExchangeOfferMember', window );">Stock option exchange offer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ExercisePriceLimitConsideredForCancellationOfStockOptions', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number stock option authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,067,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares', window );">Number of shares outstanding were cumulatively increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Non Executive Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Vesting upon first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Vesting upon first anniversary | Non Executive Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Vesting in equal quarterly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment', window );">Number of quarterly installments for vesting | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Stock Option and Incentive Plan | Vesting in equal quarterly installments | Non Executive Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of options vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment', window );">Number of quarterly installments for vesting | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_InducementAwardsPlanMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ExercisePriceLimitConsideredForCancellationOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price for cancellation of stock options if exceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ExercisePriceLimitConsideredForCancellationOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfEligibleParticipants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of eligible participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfEligibleParticipants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares cancelled those will be issued upon exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of options accepted for cancellation on total shares of common stock underlying all of the eligible options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the exchange ratio for option surrendered for one new option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of quarterly installments of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock entitled for each option upon the exercise of the option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the then outstanding number of shares which will be the cumulative annual increase in issuance under the stock incentive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_StockOptionsIssuedExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of stock options issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_StockOptionsIssuedExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=hook_StockOptionExchangeOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=hook_StockOptionExchangeOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=hook_NonExecutiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=hook_NonExecutiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hook_InducementAwardsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hook_InducementAwardsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028695568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-based compensation - Summary of awards outstanding (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">8,111,575<span></span>
</td>
<td class="nump">6,532,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">782,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">7,099,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hook_InducementAwardsPlanMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hook_StockOptionAndGrant2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hook_StockOptionAndIncentive2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hook_InducementAwardsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hook_InducementAwardsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040902992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Stock option valuation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used in the Black-Scholes option-pricing model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.09%<span></span>
</td>
<td class="nump">1.07%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">93.60%<span></span>
</td>
<td class="nump">85.40%<span></span>
</td>
<td class="nump">85.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040749792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance</a></td>
<td class="nump">6,532,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">2,880,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(5,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(1,296,249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance</a></td>
<td class="nump">8,111,575<span></span>
</td>
<td class="nump">6,532,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Option exercisable</a></td>
<td class="nump">4,101,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Option unvested</a></td>
<td class="nump">4,010,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Averaged Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance</a></td>
<td class="nump">$ 6.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">6.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance</a></td>
<td class="nump">4.28<span></span>
</td>
<td class="nump">$ 6.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Option exercisable</a></td>
<td class="nump">6.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Option unvested</a></td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years)</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, option exercisable</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term, option unvested</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, beginning balance</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, ending balance</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, option exercisable</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues', window );">Fair value per common stock used for calculating intrinsic values</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 2.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share of stock options granted</a></td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 11.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of stock options vested</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercise under share-based payment arrangements</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, options exercised</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value per common stock used for calculating the intrinsic values.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non- vested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028563984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Common Stock Awards (Details) - Common Stock Awards - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based awards granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue', window );">Aggregate fair value of share-based awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue', window );">Grant date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant date fair value price of shares issued at grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356234583104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Stock-based compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,345<span></span>
</td>
<td class="nump">$ 5,043<span></span>
</td>
<td class="nump">$ 7,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to the unvested stock-based awards</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average periods over which expense is expected to be recognized</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,484<span></span>
</td>
<td class="nump">$ 2,969<span></span>
</td>
<td class="nump">$ 4,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032692160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Losses before income taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_IncomeTaxBenefitsNetOperatingLossesIncurred', window );">Income tax benefits for the net operating losses incurred</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="num">(7,222)<span></span>
</td>
<td class="num">(11,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign (Austria)</a></td>
<td class="num">(82,922)<span></span>
</td>
<td class="num">(57,463)<span></span>
</td>
<td class="num">(64,261)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before tax</a></td>
<td class="num">$ (81,212)<span></span>
</td>
<td class="num">$ (64,685)<span></span>
</td>
<td class="num">$ (75,664)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_IncomeTaxBenefitsNetOperatingLossesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax benefits recorded for the net operating losses incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_IncomeTaxBenefitsNetOperatingLossesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040481104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - components of the consolidated income tax provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign (Austria)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356034911664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Effective income tax reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Not taxable government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.80%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(3.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent', window );">Global intangible low-taxed income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.20%<span></span>
</td>
<td class="nump">27.10%<span></span>
</td>
<td class="nump">30.20%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AT', window );">Austria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="num">(23.00%)<span></span>
</td>
<td class="num">(24.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039486576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Components of the net deferred tax assets or liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 87,445<span></span>
</td>
<td class="nump">$ 66,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Capitalized R&amp;D expenses</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credit carryforwards</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">94,359<span></span>
</td>
<td class="nump">70,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(89,309)<span></span>
</td>
<td class="num">(65,774)<span></span>
</td>
<td class="num">$ (53,728)<span></span>
</td>
<td class="num">$ (46,064)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">5,050<span></span>
</td>
<td class="nump">4,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Accrued expenses and other</a></td>
<td class="num">(3,774)<span></span>
</td>
<td class="num">(3,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets', window );">Fixed assets</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (5,050)<span></span>
</td>
<td class="num">$ (4,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from fixed assets and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356135988064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Changes in the valuation allowance for deferred tax assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at beginning of period</a></td>
<td class="num">$ (65,774)<span></span>
</td>
<td class="num">$ (53,728)<span></span>
</td>
<td class="num">$ (46,064)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases</a></td>
<td class="num">(23,535)<span></span>
</td>
<td class="num">(12,046)<span></span>
</td>
<td class="num">(7,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at end of period</a></td>
<td class="num">$ (89,309)<span></span>
</td>
<td class="num">$ (65,774)<span></span>
</td>
<td class="num">$ (53,728)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356039073568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes -Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount', window );">Global Intangible Low Taxed Income estimated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_UsTaxOnGiltiNetOfResearchCredits', window );">US Tax on GILTI, net of Research Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized income tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">$ 17.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AT', window );">Austria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378.1<span></span>
</td>
<td class="nump">$ 275.3<span></span>
</td>
<td class="nump">$ 219.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_UsTaxOnGiltiNetOfResearchCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of U.S. tax on GILTI, net of research credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_UsTaxOnGiltiNetOfResearchCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040009552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Non-cancellable obligations</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024 deliverables</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025 deliverables</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_LicensingFeesIntellectualPropertyLicenses', window );">Licensing fees from intellectual property licenses</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_LicensingFeesIntellectualPropertyLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of licensing fees from intellectual property licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_LicensingFeesIntellectualPropertyLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032853856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses recognized for the 401(k) Plan</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contribution to defined contribution savings plan</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer's Matching contribution to defined contribution savings plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356040158320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (81,580)<span></span>
</td>
<td class="num">$ (64,915)<span></span>
</td>
<td class="num">$ (75,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average Shares outstanding, basic</a></td>
<td class="nump">94,526,561<span></span>
</td>
<td class="nump">65,512,957<span></span>
</td>
<td class="nump">32,833,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average Shares outstanding, diluted</a></td>
<td class="nump">94,526,561<span></span>
</td>
<td class="nump">65,512,957<span></span>
</td>
<td class="nump">32,833,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (2.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (0.99)<span></span>
</td>
<td class="num">$ (2.30)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ConversionOfCommonStockSharesIssuedUponConversion', window );">Number of shares issued for each share of common stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ConversionOfCommonStockSharesIssuable', window );">Number of common shares issuable upon conversion of common stock</a></td>
<td class="nump">2,399,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average Shares outstanding, basic</a></td>
<td class="nump">72,422,676<span></span>
</td>
<td class="nump">50,743,080<span></span>
</td>
<td class="nump">29,945,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average Shares outstanding, diluted</a></td>
<td class="nump">72,422,676<span></span>
</td>
<td class="nump">50,743,080<span></span>
</td>
<td class="nump">29,945,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average Shares outstanding, basic</a></td>
<td class="nump">835,359<span></span>
</td>
<td class="nump">1,697,000<span></span>
</td>
<td class="nump">2,887,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average Shares outstanding, diluted</a></td>
<td class="nump">835,359<span></span>
</td>
<td class="nump">1,697,000<span></span>
</td>
<td class="nump">2,887,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_ConversionOfCommonStockSharesIssuedUponConversion', window );">Number of shares issued for each share of common stock</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Number of common stock issuable upon conversion of convertible preferred stock</a></td>
<td class="nump">370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember', window );">Series A-1 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average Shares outstanding, basic</a></td>
<td class="nump">12,526,027<span></span>
</td>
<td class="nump">13,072,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average Shares outstanding, diluted</a></td>
<td class="nump">12,526,027<span></span>
</td>
<td class="nump">13,072,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common stock issued upon conversion of each share of Preferred Stock</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Number of common stock issuable upon conversion of convertible preferred stock</a></td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average Shares outstanding, basic</a></td>
<td class="nump">8,742,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average Shares outstanding, diluted</a></td>
<td class="nump">8,742,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common stock issued upon conversion of each share of Preferred Stock</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Number of common stock issuable upon conversion of convertible preferred stock</a></td>
<td class="nump">15,268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ConversionOfCommonStockSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ConversionOfCommonStockSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_ConversionOfCommonStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of common stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_ConversionOfCommonStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_CommonStockOtherThanClassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesaConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_Seriesa1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hook_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032539904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per share - Antidilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">8,111,575<span></span>
</td>
<td class="nump">6,532,523<span></span>
</td>
<td class="nump">4,231,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">8,111,575<span></span>
</td>
<td class="nump">6,532,523<span></span>
</td>
<td class="nump">4,231,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032187200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Board of directors | Malte Peters | Consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Expense recorded</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hook_MaltePetersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hook_MaltePetersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=hook_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=hook_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032793680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 29, 2024 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 25, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment charges of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,766<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=hook_RocheCollaborationAgreementMember', window );">Roche Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Liability in deferred revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | January 2024 Restructuring Plan | Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees reduced | employee</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction if workforce (in percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | Roche Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_CollaborationAgreementFinalMilestonePayment', window );">Final milestone payment the Company remains eligible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_CollaborationAgreementFinalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of final milestone payment the Company remains eligible, under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_CollaborationAgreementFinalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=hook_RocheCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=hook_RocheCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=hook_January2024RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=hook_January2024RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356032668928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (81,580)<span></span>
</td>
<td class="num">$ (64,915)<span></span>
</td>
<td class="num">$ (75,665)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140356028552240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_Rule10b51ArrangementModified', window );">Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hook_NonRule10b51ArrangementModified', window );">Non-Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_NonRule10b51ArrangementModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_NonRule10b51ArrangementModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hook_Rule10b51ArrangementModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hook_Rule10b51ArrangementModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hook_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>112
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MS@N)0;3;T8=J1U[-CEP/W!',-TSL)4:Q*C 01WTX=&]_Z!\\H^(41>? =\^
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M\'143S>5YD(X*H2C%._Z#-Y*E0OAG 1 S;'_] XDF(,##O<$O*$Q"%@88BY
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MDI45^PO&_:(_I0&*HZ5J>.D:BFAAV<XMJV:[&Q,-$W<TW!V&JHW"!C$:* ]
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M:--\5--034<U ]6:J-9"-1/5VJC60;4NJO50S4(U&]4<5.NCFHMJ'JKYJ#9
MM2&JC>33VV]<UBK5:B5Q<R-TU FJ35%-Y!3OXOF+[<S/<FPE%VPI%T;^V1E/
M8,?&^]'#K 26N,]1L+S)OC>CG)K0,L<HG-!(34,U'=6,O99U@T9TP!:JF2G3
M3]ZC,?\(.^B<NJC60S4+U6Q4<U"MCVHNJGFHYJ/:8*_%[@$FUV2UDKQ =;K=
M9;E6+R7?!DS93%&46K6:##7D44Q0;8IJ(J<>%@\U*,?6/L$6/\%6/V&DG)[U
M1J6AG,DTQR[T<G8;^MQ,DW'7QO1\0S:6O48U#=5T5#/V6NPMW&JCEHPX:'=Z
M5#-3CD"IJ76U7#]).J=;IM^^$9U@%]5ZJ&:AFHUJ#JKU4<U%-0_5?%0;H-H0
MU4:H-D:U":I-44WD5.?B"8OM7\]R;/D5;/T5!L7%@]BQB;W\W)CU7[JMHTPV
MD;U&-0W5=%0S4*V):BU4,U&MC6H=5.NB6@_5+%2S4<U!M3ZJN:CFH9J/:@-4
M&Z+:"-7&J#9!M2FJ"<%R;+47;+D7;+T7;,$76,6/Y[QCAWSY[2WRSW8"RS8*
MISFT_;V<VWY=1P<T4*V9,OW$5:=6_A&:Z)S:J-9!M2ZJ]5#-0C4;U1Q4ZZ>=
MM8VJDGBORT4']5(&+9>J]<2@?LIFE9,;5 W0J0U1;81J8U2;H-H4U41.K2L>
M:]YTE@NVH(FTBK8]SQ/OO0C]32>ZP.I5/& <F\7+;^\6_[8^6&@C>%33Y)1.
MY)5Z\CG7T4$-5&NF'((BUTJEDS.GE7:PU=W_DNF#G& ;U3JHUD6U'JI9J&:C
MFH-J?51S4<U#-1_5!J@V1+41JHU1;8)J4U03.>6W>.9A&[NSG,9R;)T66*&.
M)ZUC=W<YN[U[_,;3U_>SS482\3OT).X]G1J_T+;OJ*:AFHYJ!JHU4:V%:J:<
MW_T]?Y,..J<NJO50S4(U&]4<5.NCFHMJ'JKYJ#9 M2&JC5!MC&H35)NBFLBI
MUL6#&=L0GN78RBS8TBRPVAP+9LJQ*;R2W12^>##+NT:6/6#1D(9J&JKIJ&:@
M6A/56JAF*J>]XN7R]H\D$E>OVRD;7J9NV4$GV$6U'JI9J&:CFH-J?51S4<U#
M-1_5!J@V1+41JHU1;8)J4U03.66\<&)C.;9*"[9,"[9."ZQ0QQ/;L1.\DMT)
M_IVWN$Z-:F@W>%334$U'-0/5FJC60C5SKV5=3T,'[*!:%]5ZJ&:E/+6)/_ZT
MT0$=5.NCFHMJ'JKYJ#9 M2&JC5!MC&H35)OFO_A$3ATN'KG8INTLQY9;P=9;
M@17<>.12CI$KN[G[.R-7[I4RM/\[JFFHIJ.:@6I-5&NAFJF<]L=5RXJ2;!*!
M#MI!M2ZJ]5#-0C4;U1Q4ZZ.:BVH>JOFH-D"U(:J-4&V,:A-4FZ*:R*GVQ8,=
MVP">Y=A"+MA*+K!2'@]VQT;Q2G:C^%>WQ YV_2*DV_5L&:9?+$/[Q:.:AFHZ
MJAFHUD2U%JJ9>RWS8AG:!![5NJC60S4K_ZFUT0$=5.NCFHMJ'JKYJ#9 M2&J
MC5!MC&H35)NBFLBIR<7C%]O_G>78RBS8TBRPVAR/7\<N\='#]\2OW MGF6SA
M*$9J&JKIJ&:@6A/56JAF[K781\QDI5*1DWF,'+6#:EU4ZZ&:A6HVJCFHUD<U
M%]4\5/-1;8!J0U0;H=H8U2:H-D4UD5//BT<WE&,+N6 KN6!+N<!J>3RZ'9OA
M*]G-\(7?D^:KS9E+96AC>U334$U'-0/5FJC60C43U=JHUD&U+JKU4,U"-1O5
M'%3KHYJ+:AZJ^:@V4$YO/[']"YS$?8/0,4>H-D:U":I-44WDE.SBZ8SMD,]R
M;!T7;"$71M[K)IZZCIWOE<R.J\</HIV/7FAS>U334$U'-0/5FJC60C43U=JH
MUD&U+JKU4,U"-1O5'%3KHYJ+:AZJ^:@V0+4AJHU0;;S77K^Y?ZG4Y,2G7"<I
MFR4^ S!%YR5$VL3D1BW99)4MNH*MNH(MNX*MNP(KO/%$=>PQKV3WF#=6ZV!Q
MNY3F3^MUL)S_+87KV7)S/]M^@%^:W?SYM D?@F7XF[0,PMWM'F<_4V,7VH4>
MU314TU'-0+4FJK50S42U-JIU4*V+:CU4LU#-1C4'U?JHYJ*:AVH^J@U0;;C7
MXK?*5FN)+M4C=- QJDU0;8IJ(J>Z%[_DA7)L'1=L(1=L)1=&[JD>3VC')OU*
M=I/^W6T=+[_.-L'-]H\O'X/EYCF=!3^WCX/4.(;VZ4<U#=5T5#-0K8EJ+50S
M4:V-:AU4ZZ):#]4L5+-1S4&U/JJYJ.:AFH]J ^7T1A^54EE-O@&)]OM'M3&J
M35!MBFHBIY(73V-LOW^68^NX8 NY,/)>-_$P=NSCKV3W\;>"4#*740P+I _=
MU>;,Q_/1-OVHIJ&:CFH&JC51K85J)JJU4:V#:EU4ZZ&:A6HVJCFHUD<U%]4\
M5/-1;8!J0U0;[;78]89JN9%L#3U&1YV@VA351$[Q+IZ_V+;^+,=6<L&6<F'D
MGYVQ!*8>&_:KV0W[O\SN=Y\ FX52>!=(P?)F][9D]/ Q6"]6-]MO:,'\=TF5
M?Y.4DJ*D);3L,8HF-%334$U'-6.O97P$H8D.V$(U,V7ZR9;[^4?80>?41;4>
MJEFH9J.:@VI]5'-1S4,U']4&ZND=*M1&32TW$A>H4K:[K,F5Y/N :9LI]5JU
MGOB[Y3%Z%!-4FZ*:R*F'A4,-R[&U3[#%3[#53Q@IIZ=<4BIR[4RH.?:T5[-[
MVN>&FE<-(=X6<-#.]JBFH9J.:L9>BZUPK=RH)4,.VK(>U<R40Z@HJER3U7HR
MZYQNJ:B-QNOS>9]XT*;TJ-9#-0O5;%1S4*V/:BZJ>:CFH]H U8:H-D*U,:I-
M4&V*:B*G/!?/6&RK>Y9CZZ]@"[ P*"Z>Q)1C$GONN*J>26+F<KX.9IM ^A!E
MK-VC7Z4H>^T^A'6WNK\)UIM?)'W7K"LU=Z$M[5%-0S4=U0Q4:Z):"]5,5&NC
M6@?5NJC60S4+U6Q4<U"MCVHNJGFHYJ/: -6&J#9"M3&J35!MBFI"L!Q;[05;
M[@5;[P5;\ 56\>,Y[]CY7LWN?/_ZED:[FQ:EICFTY3VJ::BFJ[G]Q0UTP&;*
M@(FN.JW\34QT3FU4ZZ!:%]5ZJ&:AFHUJ#JKU4<U-.<'E>D5-O/"\M-=!K=9(
MO"7FIVTFRW+B)3- #V&(:B-4&Z/:!-6FJ"9RBEWQ7,.VE'_;>2ZT,R=Z\L:4
M:<5J>Z:7$]MA%2L>,8[=W:.'A2)&7EOW;*]PW" U#=7TO19[FZVB5.O)R$$.
MVDP95%$:I5(M.6XK=7JEW?^2 82<81O5.JC61;4>JEFH9J.:@VI]5'-1S4,U
M']4&J#9$M1&JC5%M@FI35!,Y];=XZD$YMOX*M@ +G>6P2AV/6L=N[&IV-_;K
MU?)[L-YLNR)$82L:XENP7@<W^]BU6(:KV'VK4\,7VK-]KV5<3]'R-]'1.1FH
MUD2U%JJ9J-9&M0ZJ=?-/HE[*)HE+!Q8Z)QO5G/PC[*=L<IDX1!>=E(=J/JH-
M4&V(:B-4&Z/:!-6FJ"9RZE_QJ,.V-F<YC>78*BJP,AJ/.L<6Z&IV"_2"42?W
MFA/:+WVOQ=N^JTHM&7U2-JN<7%S1T;D9J-9$M1:JF:C61K4.JG533J3MZ79R
M*O52-DR]H&>A\[-1S4&U/JJYJ.:AFH]J U0;HMH(U<:H-D&U*:J)G*);/%^Q
M#=%93F,YMDP+K$['\]6Q(;J:W1#]];MVL2#U]+CKN1FLYXO-J_?T5H_;9IRI
M]Z+)'JEPMD*;HJ.:CFH&JC51K85JYE[+N+C11@?LH%H7U7JH9J&:C6H.JO51
MS44U#]5\5!NHIPV;Y63; G+ $:J-46V":E-4$SDENW@Z8[N<LQQ;F05;FH61
M4K'D,]T/CAW.U>P.Y^^,7+F7MM FZ*BFH9J.:@:J-5&MA6JFFM(DMEHO)Q,8
MVMP<U;JHUD,U"]5L5'-0K8]J+JIYJ.:CV@#5AJ@V0K4QJDU0;8IJ(J?8%P]K
M;!-TEF/KN& +N3#RZEL\KQV;H*O93="%WSM_ ^;L?0NG+K3Y.:KIJ&:@6A/5
M6JAFHEH;U3JHUD6U'JI9J&:CFH-J?51S4<U#-1_5!FI*"^=Z-7F%#.UICFIC
M5)N@VA351$[%+AZZV,[G+,>6<<'6<7$HY+4S+YM8YBH?VYZ7L]N>OUPC.QN\
MLH&BP0O5-%334<U M2:JM5#-1+4VJG50K8MJ/52S4,U&-0?5^JCFHIJ':CZJ
M#5!MB&HC5!N73^^V<*DHI<3GA2=IF\EJ(HI.T:F)G()<.%*QW'7J4U*NR<F>
M"NRP;.D56.V-AZICV_5R=MMU8[4.%K=+:?ZT7@?+^=]2N)XM-_?/MU>>W?SY
MM D?@F7XF[0,PEU#]MG/U.2%-EM'-0W5=%0S4*V):BU4,U&MC6H=5.NB6@_5
M+%2S4<U!M3ZJN:CFH9J/:@-4&Y9/[Z]P6:LEPLT('7.,:A-4FZ*:R"GNQ0,:
MV[2=Y=@Z+MA"+HR\,SV>SY1C/LML OIYUW7]\NML$]QL/QCV&"PWS]DL^+E]
M'*2&,;0#.ZIIJ*:CFH%J351KH9J):FU4ZZ!:%]5ZJ&:AFHUJ#JKU4<U%-0_5
M?%0;[+7X[:G*B1MV#M$Q1Z@V1K4)JDU13>14\N)AC.VLSG)L'1=L(1=&WNLF
M'L:.'=/+V1W3K2"4S&44PP+I0W>U2?_,?;91.'VA'=-134<U ]6:J-9"-1/5
MVJC60;4NJO50S4(U&]4<5.NCFHMJ'JKYJ#9 M2&JC?9:_)-I<J6>^-OI,3KJ
M!-6FJ"9RBG?Q_,5V@&<YMI(+MI0+(__LC">P8T/YZ&%6 LN]2W3BSM!J:D++
M'*-P0B,U#=5T5#/V6D:KAB8Z8 O5S)3IR\E6$_F'V$$GU46U'JI9J&:CFH-J
M?51S4<U#-1_5!BDOEW*U5BHGFTBD;'=9:ZAJ\GW E,W4:D.IRLE40Q[%!-6F
MJ"9R"F+Q5(-R;/$3;/43;/D3:?6OWJA7SKW'=VS=7LYNW9X;:EYU>7A;P$$;
MN:.:AFHZJAE[+7;9L%I6Z\F0@_9]1S4SY1 :U4JE5&F<1)V4@U4;C8I<2P8>
MM%T[JO50S4(U&]4<5.NCFHMJ'JKYJ#9 M2&JC5!MC&H35)NBFL@IS\4C%MM9
MGN78^BO8 BP,BGM.8E>;NR (M5DX^_SQ<78;]&;KV\5R(]T'WR*^]'LM&FV]
MN+U[^2)</7ZZD"^DKZLP7#WL'MX%LYM@O=T@^OZWU2H\?'$5^3]6Z[]V8WS^
M?U!+ P04    "  R/'98K:75-S0%  #G*   &    'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;*V:;9.J-AB&_TJ&GFEW9WJ4X-ON5IW9E3#'=E^LNJ?3CXA1
MF0/$D\3U=*8_O@%9$,2L3)\O"B'/E9";)X;;]/>,?Q,;2B7Z$0:1&!@;*;=W
MS:;P-C1T18-M::2NK!@/7:E.^;HIMIRZRR0H#)J6:7:;H>M'QK"?E$WXL,]V
M,O C.N%([,+0Y?\\T(#M!P8VW@NF_GHCXX+FL+]UUW1&Y>MVPM59,Z,L_9!&
MPF<1XG0U,.[QG6-9<4!2XZM/]^+H&,6WLF#L6WPR7@X,,^X1#:@G8X2KOM[H
MB 9!3%+]^)Y"C:S-./#X^)WN)#>O;F;A"CIBP5_^4FX&QHV!EG3E[@(Y9?LO
M-+VA3LSS6""23[1/ZYH&\G9"LC -5CT(_>CP[?Y(!^(H '?/!%AI@%4.:)\)
M:*4!K4L#VFE ^]* 3AK0N32@FP9TD[$_#%8RTK8KW6&?LSWB<6U%BP\2N9)H
M-<!^%#]9,\G555_%R>'HY7GV\CBV[^?$1K.Y^GHBS_,9>G&0NO253.?CAT>"
M)E/BD.DTJ?,R^@/=/Z='7UX>;3*=_8+(GZ_C^=_HRB;.>#2>7Z.KB<MI)#=4
M^IX;7*//Z'5FHZM/U^@3\B,TW["=<*.EZ#>ENH^X-TTO[?/#H<_6F3YC"STQ
M11:(1$NZ+ *::@"R4;#>1^'!TA)MZC50"_^*+--J571H='FX51%NZ\-_WT4-
M9';.MD[TX4\N5^'MLZT[^G"'+AH(=ZK""V/9RIZH5L)KG^'-)/.^H<F.>QN5
M\>A^S2E54Y&LTEE+BB?5.[%U/3HPU*PI*'^CQO#GGW#7_*U*(TB8#0DCD# '
M"%;0MIUIV]9KNU$YC;;<]RBZ4DD<9_26JA^JN/RZ2F$MKZ["D# ;$D8@8<X!
MUDM@\<K@;:AFA;<*V3J9;!V];)3[5*#[SQAY+'JC7/J+(-:1KBCG=(E$G+-5
M\FFY=>6#A-F0, ()<X!@!:6[F=)=X 35\NHJ# FS(6&D>Y)3:NUM9FEU4 ZH
MQ8)RO4RY'D".HG_5+^LB\#W$5JK<C]95FFI;JJLI),R&A!%(F ,$*VA_DVE_
M YRU6EY=A6\NR T;LD4""7. 8 7E;C/E;K7*C878N9&2S6-"5K[*:./K*G5[
MHA2^[75*2D&V2"!A#A"LH!0V\S==\[(9UJJ["M*#ZXH(2K-!:024YD#1BH(?
M61L8>%K5 VL+#4FS4UHA^5NX-$T3T#8=*%I10"L7T +(V,O61/JF:DL+2;-!
M:024YD#1BH] ;B;A#]RD^CG<NB!/1OIF:PL(:A>!TAPH6E' W#'">LOHXQ42
M/O4[<+N'RX*!FC^@- )*<Z!H1<%RKPCKS:(1"T,6:19#H)X0*,T&I1%0F@-%
M*\J:&T,8VAG2 VL+#>H-I;3;XSFCT<+EQ5"%ZU.R?*"Z550E-WVPWO4Y3K8+
MUS&@Y@XHS0:E$5": T4K"IT[/!C:XDF!^D=\A"O,FY(?H.]9;55 O1LH6E&5
MW+W!_]>^P:>6BV69O;(*%;5ZN%46 M29 :4Y4+3BW^^Y-V/IO9G2/%CG/V0]
MN>Z$"$JS06D$E.9 T8J*Y^:,!6W.I,";PH38QMUR,EJG1DDY$_5]JZT+J.<"
M12OJDGLNEMYS^7A*3 '%%^QN68332N5_%/0=J2T"J.L!13N(T#S:GQ52ODYV
MT@DUPKM('C8I9:79;KW[9(]:J?P!WXT.>^YRS&$+X)/+UWXD4$!7"FDV>NIM
M@Q]VU1U.)-LFN\ 63$H6)H<;ZBXICRNHZRO&Y/M)W$"VMW'X'U!+ P04
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M!#WGFLULQYZ[:&2;1PI!+BXYR*::A<IU?S)J#7FO1P#XC-[*\.EH<F);=#R
MO# *]5VZU#EI%1]O5?KBW>0<#Z=3"^-K3WD\6#Q6R.*-?W!'2R'@"SUKR;*Y
M[3WB%_@WXPW [%4RQ3#U0UCP#2F,NM]1B9<"3Z@#PRMP4*Q9U<&ZQ5OJ$BAQ
M CYE0-["Y;; ^7K.[$8SALFNG%//_BB9Z Z(D%=)<[9SY%3)FMWW/&&QI=P)
M,1/QI5O5I,!E9V[ID5&%"BY&U!/*^-A<A&_)]KOX"*1HG;P4A\/H7M4Y#795
M;-O:G[QRFAP5R%SACF11!IEA6%Y+=_24)+1)/TJ5V#N%F,U"S]P*;4O3 YNB
M/=W1_:*N]$6679VPZ#>AU))?]?1-&1NU)27HJ&?!K2-GQG&[0;BED:U"Q"8A
MJN),-(R,]\UFRK@\WH&#9OCN@_+4P="3 'G#)@14C%C8":^H<RBEZ"F7. C!
MQ*<C^D-0[<'D0SBU4/9^?M3]'?$9!3C+G1VBQ(TIJCV*%)_RA5)=6\?%K.C(
MUO;(BY-[---WER/$>+/JS%>^9]_=T.K\EO0RH?DK9#[R)HZ9(QG\*5Z?G"T_
M3Z^$O5@^"5?&IF?PTZH<Q5CF=0CM UB?+XXC>![N@KT3 3XW,$'@GX[<04O@
M!NTBK$/X@<_*=484(8AVY7-)VCVNSM4-WS\/U:F7#85;'!C8Y-;BK!UZ;G5G
MD]S&685E]G55\Z@?@-2?0.@@ LGYK7Z#90FDN$=$WH\NFC3A1W=]TSJ!KU/>
M!_EMC][6+)RBM_.EPI@Z6WK(;;CG>"&HC(GG2.]HZ!5%SC9LE@%PD %??NOF
M%@.QX9A@T$&L9 A7<(6:*;5EG^R,N_K3<DGFU($<9T[<G8:16NCE:MEP=V3@
M(3WY_4]=U.R#Q#Y_/PJ%$T^RBI\*M0L]$;8)J99;M21A.ZE>.ZD:-.ZN]W$$
M@3UTQ+:;E#]20+.N> 7N.SM-A0B6'LBA\8]?@]'U6G=?U2B*/W4%,%YG:.@F
MVLF&,T!UMO>9BZ1H_2%FK;O;C/<@KT>^C4V<FQD\Q8.AT>1BP_;019SJ;YE&
MDD<\$=EDX:\^BSDG%;,8'Y>##B<[\'TQPKQ!X',]DX-IZ ?C'<%WDVB2D!#&
M>_&H?_GB467IGX+^Z]H;^I<#M:_S/G_Y8F<H^'AMZIHS4DW_U<GY2?0MP5Q_
M=7)Y_N7EQ<DC>C,\_O+%GK3B/RAVP95NM5G3JV?+SYZ>2,NB^]"W>X#,5FW?
MMSO^<VO(?^KP /V^;DD_Z@<,@ Y$1N_E_P)02P,$%     @ ,CQV6#]VLA)?
M"0  _R   !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL[5II;^.X&?XK
MA#>[: &/SUR='$"R,[.3;6<;9(Y^IB7:8D<2M205Q_WU?5Y2E.1#CA=)@1;H
ME]@2R?=XWIO.Y5+I[R81PK*G+,W-52^QMG@[')HH$1DW U6('"MSI3-N\:@7
M0U-HP6-W*$N'D]'H=)AQF?>N+]V[>WU]J4J;RES<:V;*+.-Z=2M2M;SJC7OA
MQ8-<))9>#*\O"[X0GX7]6MQK/ UK*K',1&ZDRID6\ZO>S?CM[3'M=QN^2;$T
MK>^,-)DI]9T>[N*KWH@$$JF(+%'@^'@4/XLT)4(0X_>*9J]F20?;WP/U#TYW
MZ#+C1ORLTG_(V"97O?,>B\6<EZE]4,N/HM+GA.A%*C7N+UOZO=._]%A4&JNR
MZC DR&3N/_E3A4/KP/FHX\"D.C!Q<GM&3LIWW/+K2ZV63--N4*,O3E5W&L+)
MG(SRV6JL2IRSU] FY3.EN<<HC]G?9$28YPMVL]!"P #67 XM>-&)8531O?5T
M)QUTQQ/V2>4V,>Q]'HMXG< 00M:23H*DMY.]%-^):,"FXSZ;C";3/?2FM>93
M1V_ZZII[NL>[Z5(4O34%C\15#V%BA'X4O>N??AB?CB[V2'U<2WV\C_H+I-Y/
M=SI@AY%FO\@4P=^Y6S1[V5W.?BUS 8N-S_O,)@*GLH+G*X95H47,9&Z56]A)
MM:&T3+!]MEJC03RK8YPVQ@RTHIJ 0"39!(G#%,@ M&:7BL$D$727$4]I27 =
M)7BI%IIGAC:)1YZ6=+I0%IPE]CWR* )<M"TN(T" 7.@DL4B#EN3K(U2UZ+-8
M\D6NC#0,.\#JD2A $35G'V^_.8D_WGT;$# ?Q$R72(/DSI-U<(Q<Y*0-7MV
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M!W&*4IM2(& U9:>NB"PH6=TG"$0VGGE8=B+60H7CC\4B6?GD('R.3D]V;6N
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M4X93&(H(91>E0/?NMW>4=S)IC)MRW\_G/F]M\%UWBJ5OCQ=42^8EOKLDJM(
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M PI'U@D;]@5'S71:K*&R7/#/Y, JJDF+FDH%J=.DQ8:^@3=<$H:J##DQ;P_
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MD '^7VKL@-V$ C1W^_D_4$L#!!0    ( #(\=EAS&'F>&P8  $L1   9
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MS(!(4^;9@\2_>[HAK=D18'QK?0[Z+=EP\[KS_B'$CEA2Z>C&Z+]4[HN+P=E
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M"7PM A@!6<"@9/_&9@\?N$DZ5E *ERH0JERES-E3NM8JA?0<SH$#8I5OVE3
M" E:>>=E/-8CD'.4 K24<@=P8J1;(9"ZZ9$X *S('PCPD^7N2?W)X5%N=- N
MHIWUN.2S,W*E)21#< HXP[=WL4.Q["LOFBA!#*M01[;.FV^PUSGR[BB81>OD
M"JW)BJ."G%%E50)P/=AVS&[S/ZM"8._KN#OG+VCCVT/3)L7[C?O'MYN;1NXK
MR(61+V6!0D(W_3NWU-=E@ =8,K]#&:\H6%K<RWR:A(O.V:G%IZ<6SX\N(I@H
M@!Q9?'Q+N/0<N4_==]L==]X=2D+WS:\KG"FP/SY!M+/M \YU?+?8;X^O/V_1
MO"O-'5 .4@#I8B!L?%&) V\VX15C:;PW9?A<$_#,\@:LY\;X9L "VF>MJ[\!
M4$L#!!0    ( #(\=EA?,5 !2PD  +,?   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;+U9:7/;.!+]*RB-=S:IHF61LB0[L5WE9.ZJU*3&>WR&2$C$
MAB0X(&C%^^OW=8.D*.NPE&2V*H=( GVA^_5K\F9E[*<J5<J)SWE65+>#U+GR
MS<5%%:<JE]70E*K DX6QN72XM,N+JK1*)KPISRZBT6AZD4M=#.YN^-Y'>W=C
M:I?I0GVTHJKS7-JG=RHSJ]M!.&AO_*&7J:,;%W<WI5RJ!^7^67ZTN+KHI"0Z
M5T6E32&L6MP.[L,W[RYI/2_XEU:KJO=;D"=S8S[1Q:_)[6!$!JE,Q8XD2/SW
MJ-ZK+"-!,.//1N:@4TD;^[];Z3^Q[_!E+BOUWF3_UHE+;P=7 Y&HA:PS]X=9
M_:(:?R8D+S99Q?^*E5\[G0U$7%?.Y,UF6)#KPO\O/S=QZ&VX&NW9$#4;(K;;
M*V(K?Y!.WMU8LQ*65D,:_6!7>3>,TP4=RH.S>*JQS]V]-WF.X$!/_"D0[S-9
M5>)>Q+V[0A8);A2/RCH]SY3 X2^4M2KQSV\N'.P@:1=QH_.=UQGMT1E&XH,I
M7%J)'XM$)9L"+N! YT74>O$N.BCQ!Q4/Q3@,1#2*Q@?DC;NHC%G>^/\:%:_S
M<K=.JKXW52EC=3N K$K91S6X^_Z[<#IZ>\"CR\ZCRT/2_R*/#NK<[5$8#L77
M&R/^D2H24\KBZ?OOKJ)P]K82L2RUDQE6V#IVM54DH=*5JX19;(@_H/29HJ&X
MY]W(,)7/E>VR+!!N;8)8R4K(VJ7&ZO]BJS-"5U6ML'(4C/Q?4:424=@V91Q<
M;ZW8:UZX2]Z6S;WHB!2F):K2RT(ZK(B"Z]D5;2+S>])ZUN\5+""J,,7YHW&Z
M6(H'9;7R5NX]J$"$D^ *\K^IQO/P8')PH"9!-/W&CIY'A]0>F2JI3,3U-)A,
M1L'D>E]6/$^ +M2]"/2LHA(8C=^*WPOQ6UTH,=FE.,Y,!5NE*.MYIF.HA/7D
M'G1'$2?A#!%;&Z11.-L)Z..Z7G5<<(1T.S275L>*A)R%PW'(\L_"8!R.ACBH
M$B%D-0&Z?U4J[M_94R! 140!OE):$RN5L!5GE]-AA :99=SK%PZ;T5N  Z2G
M1I^Q*ZOY(M%5;.H"SGF0R7/4*G;YZ\XV]1G$IU+5L(ONKQ3=[(E"&_':^WJ)
M#NVO8S@.#M0FW'-LXB"D)H,=E6!.XF&B"1G$";E<6K5$D9*,,+B,1D$43MI(
MOYI-KX/9^)(53Y$\EU=A\VPS/J_WXH=9%5 Z?P(#BU/1&J,+F/&B^CUN]>4/
M^VGXDYK;&BR/\H4#M)F+JL !P1BOO+&OK&T,M%(PQ2H%YN= AEPJ?M89Z*9X
M1>*CT=L'7ORQ77S?+N;'X=O7I G99M6?M2;3_?: ,G"7"Z8D>AC0870&U"5=
MGHTGPU&74T=%8+?GC0.M^(3"K0MD(YJ5S"D7?<RGTRG]/2'F$(-$A=1BJ;@N
MSOHFXV$LJ[2MO<8Y7W1==0G$"7:POR@[]J&#,"1!#TE*B>*&81+A3MB-A%+/
M<6.A!?N.1KRBI\WYW3>[7SI'%K\5.D1UNP&>'"99 CP^:[!Z5(PXBP _7QRU
M<'@93F=#\J2J)9S%33((&9YWUKWD]&9YY/*IS=\V OWTI*5SF<G"@R==GET-
M9_U4W<3MBK#RW&) \&<8ZU*ZQM?2..BG5%S43)I(KX-^J1G]=C$M2[,.F83Q
M*CO4,;"DL5\# ^OY?X!2O ]PI1<: <ET#M)&Q@#'=!%G=4+H*WL/?#VCH3PJ
M0NU^H!;6Y!PI9"$WE"9$;,V>U@H ;&-*<E>FSCB-,<=1/*28JT(M$".$A"#3
M5JDN24IN+,4>Q1M>#Z__UH;>&2*=1<T%@WL8?5$2!;OQD@F;5(UQCX]Z@:>P
M!( ,^FI]%+C.N)IP02.I>#@?TV*_"LHILZ%.TEX2ER2:=LILGQU,4I/>*1'>
M(@8+4UNXRS,:AY@64KIM8/P'B6"+RUWX?I!KA,%LJX)W<@T"1<\>=]"-%RC@
M8;H1$<%@NA&1(:?3C=GH+Z<;STF\2Y$=J#CV?Q=G[8AMT!XL:^BEH]Q-4-\<
M2>6/BWW :H_ES ];)[NAYWA1#)ISA1).5$E@6SA >[.AI1J;W?J7A@)] ^6I
M?&Q[ H,CP*PT*Q+NATK]B );]H^WIWPS\0F" <@N\Y5IP.<QA_B^I20JSC>@
M5 &V*/F P.ACCF0!80&:#;64?EN#4GT"ZE$G71NP=]S\VK"0H85Q&PZ150&U
M8U4ZRLBFT3$SS>1JR[@MHW9:FQA6Q.? "%3G=2:IAD4SQ?ES&8H?9<=^]_KN
MZTVM&UW+TWL'L&\O)QJ=6K=LTP/7Y]]_;Z8! ,*695^?DT<Y\;5JV-_PP"L.
M!F,<B=.Y:EFX]W*+A -C'W6BFM:\7HC&A#2?DW*3ZKEV!'(]/M%.7SZK/)G@
MQM4:WIOB#_FYT[>U5]06-\]Z$5 *RY8_$.N@P_5J*S]8=%[0D+%4N+9^L*&F
M)Q?H]1J='19[*@+.T:,:8!K[J<8)#!@+BCUM8;@?B_95VW.0LF@I5&I$,>>
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M6[7=BU2 HO_* O0?1 P6WP^JQO8ZJB+P+\-_Z3<[_L,>/_3W1_$L8=_#1[*
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MI@%!YI!Z$3*?3J-D"(D WTB+"3J0\/%K7FQ>O@O Q70U)YI.9EV[B$:3,;N
M0X##Z]]W]VHR[5KK=,S.TU170$*]-4I/]1K3*.Z2,)I.#W<BD, F/0E!E$QB
M]O..BP)6:BE>WXRN1SB+YWWHU>MRY^TQ,.^L,SP;1C&L_6N/F7=<W?PL&@W/
M^MSQ))K-("\^G)I)-)QTTQH@<=X=/?2SI> -=CY>RQ^A(R<C=_2>\?$$@MRE
M1-]_!Q=.XKZ9,4S;UPZ-=7ST*E@M=)ZY.P]4OB]8GB7#7M'<IW$G)*"^R(TB
MZL<5A_J/^_1CE\'OOM52(7?\N (DPF&?,I8]5<8])P++'X]F<PA:A<QSL(:(
M'2>S"<0:_TR['"?QV6"V>Z69W$0.X&>*X#OHC]0B8FNU%8!KD#(07WM/A/JY
M+*1/-F:39R%X!$SD(Z-/%2"2N6J2T%)E@R=S)>#'!YE"!]JKA?(EY#S[FX*W
M1 8F$-YW[(L!?K6Y%\\&9W\3\^;#1S*OD1 W3O?YJF<Z5?9\"8?2,#P,)KST
M'FRNEDLT2Z2AAX#*2E^;?I#A+@E=87,!DE-:NU$[ F/UE7X4LT\"#Y.E!S1=
M $/2;0L.3P=\N#Q42_J73OS232UH<WT-$X4#F<(EAAMEI,O>2^Q^K%PJ+ZYE
MYM-53J>O --1$\ YL5MDDVL ")?A]G@9U_K V91-X^R'#C9@/_&2KP2E)$@L
M83Q@BJ=V5TY9 _+#](]Z.=2]0;I+7U]N]C,,-I@:7::0$N_:&>B2J8KA]!I_
MS!5V$DAO8=%4&,,U'9JG:PD&@N5EUU/!HX'.%4)C'T+^Z>(ZD(7\AK>R*K4N
MI/GSI'F5T7' ^"15,0I%AO4%C!*'2S)(^KWI1K8@4/JER?>ZMX-%%_CHD<,
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M9GQQ)2,L& /ZOC28W(<Q))T3(4PVL-ME*@LM&E92!3 @.\1>)9-S;30?#6]
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MJGDK-!TC-^Y^OI &;_ON=XW/*U!V .J7$C.C[=@%^@?;_%]02P,$%     @
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MIE7$EU=,Q ?( RT*Y8JJ<@G,$C7%M8'Y/O"N?N%6FQ06&\/5.J"^(3. OL.
M^B/RW/?(X+ N.46EC8_#5W(NBY[QESPMZ/4($:TDGA&19E!I9>D!^S)!"_F-
MHSK$#0-'3>_1M; @-OMSPA-GFL)WU?.U1PB7P-2_J\5'&36O06FWDP-1V?OE
MOH$S3%D6O,VFG_5A=N *$LTZ>!_=A]XH%PVB7^WM]2ZZRGMX].8'9M9<6;KD
MAE+S].HB 1/]+DZ<[H+'K+0CQPK#EAH"C0^@_49KMY_X OV?SO0/4$L#!!0
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M'*DK0-JXJE6BF$%5V5I5G=@B+O[8[OMX_7UT]#/-,0NDL%C.;U%I.-J']$&
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MT[LK AVG(.!QDIOA!B#*+C<TFT!'$[4>"TE: 4#P^&I7(Y#U506CV6YMB[P
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M9- 6I&2B0*Q9F5JG)=$N1R/8]?*:10\,NK>Q .K-+E.DJ!UMIZ<*Q!8+JQ6
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M@4(M'JM$24&*QLGQZO@O9*V,K!3>1)9/@;2>-[L&%98-S]!G(G%*M>,H_.%
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M6\$;4[C#2^5O?QJ]_S"XP_C;[N8::2_CNB7^<+QZXGNXP.<_G*X>Z(/^K3Q
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M55;]LWQS]UMQ:!U==.N6#]/CXR6<07$!-\5ERD%B:M%F\BU2!E6JGCP-6H4
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M=AR![@=(;UAJ0M.NR;H1$+:UF[FH?8 [+XGLQO )QBF>_0502P,$%     @
M,CQV6/.A([1C @  \P4  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
MK51M3]LP$/XK5I@02$ 2MQ0$;20*F^ #$P*V?7:32V/AE\QV2/?O=W;24*;2
M:=*^Q#[[GN>>\^5NVFKS8BL 1U92*#N+*N?JBSBV>062V1-=@\*;4AO)')IF
M&=O: "L"2(J8)LDDEHRK*)N&LP>3377C!%?P8(AMI&3FUQR$;F=1&JT/'OFR
M<OX@SJ8U6\(3N&_U@T$K'E@*+D%9KA4Q4,ZBJ_1B/O;^P>$[A]9N[(G/9*'U
MBS?NBEF4>$$@('>>@>'R"M<@A"="&3][SF@(Z8&;^S7[EY [YK)@%JZU^,$+
M5\VB\X@44+)&N$?=WD*?SZGGR[6PX4O:SO<,(^:-=5KV8+0E5]W*5OT[; #.
MDP\ M ?0H+L+%%3>,,>RJ=$M,=X;V?PFI!K0*(XK7Y0G9_"6(\YE=[)FW. K
M.W+PS!8"[.$T=DCLK^.\)YEW)/0#DI22>ZU<9<EG54#QGB!&18,LNI8UISL9
M;R _(:/TB-"$CG;PC88T1X%O]-<TMV778<?;L;XM+FS-<IA%^-];,*\09?M[
MZ22YW*%L/"@;[V+/GK#-BD8 T27A;\7(*V:68$D+!@A7N6CP8?'?<!579*-H
ML,+VM+ MJ]UQ]_?.:3*Z)/]KQ8J!7( )57MGK#U\*?V'DJ]:'>?,5ML2_M>X
M5];BZ&H-=W"LR_*-X!,Y2.G1V61RN''D=RF]),_:,4'46L>?P7=B^Y-MM8\W
M&E$"4OIQ8TFN&^6ZGAQ.AXEVU37RFWLW#N]1$5>6""@1FIR<G4;$=".F,YRN
M0ULOM,,A$;853F4PW@'O2ZW=VO !ACF?_0902P,$%     @ ,CQV6)9'IJ0%
M P  =0D  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULW59M3]LP$/XK
M5IC0D!!Y:8'2ETBT#&W2D!!O^^PFE\;"L8/MM'2_?F<GS;*M=!K3-&U?8CN^
M>^ZY\YW/XY54CSH',.2YX$)/O-R8<NC[.LFAH/I(EB!P)Y.JH :7:N'K4@%-
MG5+!_2@(3OR",N'%8_?O6L5C61G.!%PKHJNBH&H]!2Y7$R_T-C]NV"(W]H<?
MCTNZ@%LP]^6UPI7?HJ2L *&9%$1!-O'.P^&T;^6=P .#E>[,B?5D+N6C77Q(
M)UY@"0&'Q%@$BL,29L"Y!4(:3PVFUYJTBMWY!OW2^8Z^S*F&F>2?6&KRB3?P
M2 H9K;BYD:OWT/AS;/$2R;7[DE4M>]KS2%)I(XM&&1D43-0C?6[BT%$8!"\H
M1(U"Y'C7AAS+"VIH/%9R19251C0[<:XZ;23'A#V46Z-PEZ&>B2\I4^2!\@J(
MS,@E$U0DC')RKC483=[>T3D'?3#V#1JS*G[2 $]KX.@%X# B5U*87)-W(H7T
M6P ?6;94HPW5:;03\0*2(](+#TD41+T=>+W6]9[#Z[W*]6T>UWC][7BV?(:Z
MI E,/*P/#6H)7KR_%YX$HQUL^RW;_B[T^!;+,:VXXYJU7&E]3 5072E("34D
MLVXM:[<PZ[%RDDHI)A8V>]E6OW9;OLN!9))C^5H0XQ*". ^%(4S4%X.KL#E6
M/3$H/I-%2<5Z?V\0A:<C_5N$"14IFDE9@E8L <3GL 1N(V$7'?V<@:(JR=>D
M,HRSSVC 2"Q2 PIK!_#J2?*./.8W$X@A*XU&],&06,9!;_37QDY.7M4A*FR4
M,4J8_5#,0;450.ZU#<=&\Z,+2=B,43/VVOT[:3#\,ZIS D\50_\16/]YC_$2
M@#7>6.H1.TQ689C;K3?D+#P,!GV<N$R)1IW9#T*U Z_3_7>.-?H?CG5P?-@_
M"W]R-(W0]\?Z"[K;;E6_TPH+4 O7\#5)9"5,W17;O^V;XKQNI5_%ZP?)%54+
M)C1>-AFJ!D>GQQY1=9.O%T:6KK'.I<$V[:8YOHM 60'<SZ0TFX4UT+ZTXB]0
M2P,$%     @ ,CQV6/@XT/L2 P  PP<  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S N>&ULI55M;YLP$/XK%IVJ5D(%# E)ED3JRZI-ZJ1JW<MG!XY@S=C4
M-DW[[W>&A-"UC:;N"_:9N\?/O7J^4?JW*0$L>:R$- NOM+:>!8')2JB8.5,U
M2/Q3*%TQBZ)>!Z;6P/+6J!(!#<-Q4#$NO>6\/;O5R[EJK. 2;C4Q354Q_70!
M0FT67N3M#K[Q=6G=0;"<UVP-=V!_U+<:I:!'R7D%TG EB89BX9U'LXO$Z;<*
M/SELS&!/G"<KI7X[X4N^\$)'" 1DUB$P7![@$H1P0$CC?HOI]5<ZP^%^AW[=
M^HZ^K)B!2R5^\=R6"V_BD1P*U@C[36T^P]:?D</+E##MEVPZW23U2-88JZJM
M,3*HN.Q6]KB-P\!@$KYA0+<&M.7=7=2RO&*6+>=:;8AVVHCF-JVKK362X](E
MY<YJ_,O1SBYO->97VR>?U())2YC,"=PWO,; 6Y](+(N3[VPEP)S. XL7.K,@
MVX)?=.#T#?"(DJ]*VM*03S*'_#E @$Q[NG1']X(>1+R"[(S$D4]H2.,#>''O
M?MSBQ>]V_S6O.\SD=4S71C-3LPP6'O:) ?T WO+X*!J''P\P3GK&R2'TY1VV
M9=X((*H@];O8'\;_AX+(%/:DL9 [#K8$4BB!S<WEFIQPB2>J,6AF3F?D^&A"
MP_CC?Z^8=ZA6H-O</Q-V&JX@W(>^^XX;Y^I.^$"H']+10([\Z6A*;@!'0*E$
M3GB%X7\ %Q;S BOVXS!\Y30:)^02PV=UTTTEC!?"K+%.7H+0Z*4S4>B/QBER
M72G-K-)/^^3T.A,_'80A]9,P)M>-EMPV&MJ$%OS1[?=7CD?)?H_&EZJJ&XLA
MWJ,[.Z,*NV$(TE/TQR,ZD,(X(;L*^KMTUEH-G(Q2=&0?7SKRT\2%UY@9.<^R
MIFH$<R66 S91QED;K9WVR=2?T/AT+Z=^FDY/W[S:5>T^DZB<T&%F4W^:AJ_U
M9C 8K!7H=?M\&&R 1MINQO:G_0MUW@WFO7KWO'UE>LVE(0(*- W/TI%'=/=D
M=()5=3NF5\KBT&^W);ZRH)T"_B^4LCO!7="_V\L_4$L#!!0    ( #(\=E@\
M>-=-700  -\-   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;,57;6_;
M-A#^*X3:%0D06.^VD]@&FG3="K1KD&0K]I&63C912O1(RD[ZZW>D9$F.'"$M
M.NR+91[)Y]Z>.Y*SG9!?U1I DX><%VKNK+7>7+BN2M:04S42&RAP)A,RIQJ'
M<N6JC02:VDTY=P//&[LY986SF%G9C5S,1*DY*^!&$E7F.96/5\#%;N[XSEYP
MRU9K;03N8K:A*[@#_>?F1N+(;5!2ED.AF"B(A&SNO/4OKL9FO5WP%X.=ZOPG
MQI.E$%_-X$,Z=SQC$'!(M$&@^-G"-7!N@-",?VI,IU%I-G;_[]'?6]_1ER55
M<"WX%Y;J]=R9.B2%C)9<WXK=[U#[$QN\1'!E?\FN7NLY)"F5%GF]&2W(65%]
MZ4,=AY=L".H-@;6[4F2M?$<U7<RDV!%I5B.:^6-=M;O1.%:8I-QIB;,,]^G%
M1T"7%#FYITL.ZG3F:@0U4VY2 UQ5 ,$S 'Y /HE"KQ7YM4@A/01PT9K&I&!O
MTE4PB/@.DA$)_3,2>$$X@!<V+H86+QQT\9AGU;[H^#Y3#A=J0Q.8.\AW!7(+
MSN+-*W_L70Y8%35614/HB[NJ"HC(B%X#@2Q#GIH1-^:21"A]U.9AU'N$R@3'
M4F/%BFB3U+K>V#=,\[.:""OLY+7(-[1X?/-J&OB32X63A1*<I51#2I3&#Q8D
M+L?=V!<D-96E""U27)ECE-:F7+= N%!(*@LJ2H7SZO2"&%0OO/S?OW\#E00,
M6[]3]*% +Z&- [J9V! 0Y"SD2Y -;YL]3V>"9V=\\KD**6:N2@T\8.\UY7F+
M]*,R6=M(I[#%7KJQ!C0K]J"OB7\61I.#<11ZO1CX9^=^*_T-"M3,+3Q-L<TP
MI8TE6^AK"*+6A< _[R'C#WG/"EHD4+M!<R$U^U9%Z@=\LFP,6@W3OM(HB'_(
MF:?0Q\;F.\'<:\ N@(53D.S /<[HDG&F60>W67U4XY"F?JIB<E<N*U6L(N!G
M+%6Y'YS4*DZ_VZF3R#LE?^#!?\"V ^K$G5B;\22<]A-^%OO>0$>,FXX8O[0C
MXFE;RBJB;:=IRJ(3\&,=<EB+Z9"&$WF9UW ;^E@U-;SBV"98P(/&'"-?'I&A
M57LS$0>:858)E56L$M,3M2!+9+BJN^[/:WK/=Y2G70(GHTY=C^/8B.*N*)@8
MT;@C"F/?B"8=4>"'1M0F."+WK=?-.G(O-%;7D]CU2'LV10T?0:D+)&I=#+VJ
MQ<O#C3E:L>JWE)?0GDK'BNHUHD;A^0#5Q@W5QL-4P[MM6G*K;V<O;IA*NL6X
MK@"OFN8RV\87C<\M!WHK4Z824:+QF \XPM2C]!RVS-#SO[3(LK>EZ\\[E _X
M.BCL'Q@=<A^<D%]>% @LN*I.P]&D#SZ:/@]W&*T3_Y1$(Y_\TG)]%.((Y<<H
MYW8NW3G(E7U:F!L3 E;W[T;:O%[>5I?V=GGU]/E$Y8KA/8I#AEN]T01;F*R>
M$]5 BXV]PB^%Q@>!_;O&%QA(LP#G,R'T?F 4-&^ZQ;]02P,$%     @ ,CQV
M6/?U5; ] P  5 @  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULK5;;
M;MLP#/T5P1V&%@AJ6W8NS9( O6S8'H85RR[/LLW$PF3)E>2F_?M1<NRD2QI@
MV%XBB28/#RF*S&RC]"]3 ECR5 EIYD%I;3T-0Y.74#%SJ6J0^&6E=,4L'O4Z
M-+4&5GBC2H0TBD9AQ;@,%C,ON]>+F6JLX!+N-3%-53']? -";>9!''2"KWQ=
M6B<(%[.:K6$)]GM]K_$4]B@%KT :KB31L)H'U_'T)G7Z7N$'AXW9VQ,72:;4
M+W?X5,R#R!$" ;EU" R71[@%(1P0TGC88@:]2V>XO^_0/_C8,9:,&;A5XB<O
M;#D/)@$I8,4:8;^JS4?8QC-T>+D2QO^23:L[O I(WABKJJTQ,JBX;%?VM,W#
MGL$D>L6 ;@VHY]TZ\BSOF&6+F58;HITVHKF-#]5;(SDNW:4LK<:O'.WLXCK/
M=0,%@2>\9@.&,%D094O0Z%UKD)8(SC(NN.7X]?P;RP28BUEHT;F#"/.MHYO6
M$7W%44S)9R5M:<A[64#Q$B!$UCUUVE&_H2<1[R"_)$D\(#2BR0F\I$]%XO&2
M_Y**8QEH\=/C^.YY34W-<I@'^'X,Z$<(%F_/XE'T[@3[M&>?GD)?+/&Y%HT
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MH)T"?E\I9;N#<]#_D5C\!E!+ P04    "  R/'98-UW$2Q #  "("   &0
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MK$&@*E$19??16W%;^CJZ-/FL[6JH839[&FKD<?\W/6!DVTX(7RYFNA8T_]R
MMVN_U^1W^0A7K$*9,0W?D!X7PC< 17+RS++M(CI*=H*/8]^+IT.'9T.'YWL/
M[TNDT9I;RO->%=^7>UI^5_.%&]-!H"[\##3@+T [*/K=?LQ>M-/E2;V=T9^8
M+C@5J<*<3*/C,^H<W<Z]5K"J]K-FJ2Q-+O]:TJ\":J= Y[E2=BTX!_W/Q^(/
M4$L#!!0    ( #(\=ECY"3 $1 4  $81   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;,U8ZV_;-A#_5PAW*U) E:FWE(>!).VZ#N@:)%F+?62DLTU$
M$EV2LI/]]3M2LJRDMIN^AGVP25%W/]X=[T4=KX2\57, 3>ZJLE8GH[G6B\/Q
M6.5SJ)ARQ0)J?#,5LF(:'^5LK!826&&9JG+L4QJ/*\;KT>38KEW(R;%H=,EK
MN)!$-57%Y/T9E&)U,O)&ZX5+/IMKLS">'"_8#*Y _[6XD/@T[E$*7D&MN*B)
MA.G)Z-0[/$L,O27XP&&E!G-B-+D1XM8\O"U.1M0(!"7DVB P')9P#F5I@%",
M3QWFJ-_2, [G:_3?K.ZHRPU3<"[*C[S0\Y-1.B(%3%E3ZDNQ^ATZ?2*#EXM2
MV7^RZFCIB.2-TJ+JF%&"BM?MR.XZ.SR%P>\8?"MWNY&5\A73;'(LQ8I(0XUH
M9F)5M=PH'*_-H5QIB6\Y\NG)E1;Y[4NC5T%R4>%9*V;-=7#-;DI0+X['&K<Q
MQ..\@SQK(?T=D)Y/WHE:SQ5Y71=0/ 08HWR]D/Y:R#-_+^(KR%T2> [QJ1_L
MP0MZI0.+%WRETMMT;9'"[4@F9 [5@N5P,L*84""7,)H\?^;%]&B/G&$O9[@/
M?7*%(5@T)1 Q)6S%9*$(QI72K"YX/=LF[7Z\Y\]2GP9'Y/\^GBJC,9XZ5#<@
M^Y/OW_O42\E%R6HSR]K9V[IHD!YJ34Y;4UT+S4KR1K):XSFCS8;&Z^QY^-VR
M6E\B8F'\1Y$D]1TOB4GBT"QS@BS;R!Q0AU)*4L?S/"=*HDZ^K^#8XU%1[U'1
MTSU*82;NY&Y,*/":Z#F0LY)A=""EP/CO-'NYD#PW9JM$ 27!8D! :8Y9T2P:
MKBGCDBQ9V5AL-;3*-D?=*^:NL/HYWO8W,-3&I*J'+O>8SKH@_OGFS_MAVU]R
M=?MR*@'0_AI06TTDT]"_#]R$DE]QH!D.GDL3'%[?+;"LH<3(49$#/+E[U$*]
MZ+DB-R&Q2_'G;8B7HL0#*[F^[^FRP(T1+XW<L!VB(7K!E[Q TZ@'4GO^$1)M
MF^WQT+CWT/C)'MIU"H\=JBWEJ,4VQ]J/?FT\5938BEB_-26NVX7_@\YN'/D<
M"P*K[ZU2R9':OC-1O,Z!_,'JQ@BX3E '-H1$HS#)*(? 70X+3=2<2; ):(&N
MU3U5HJFU>O']">AGC1]M0X-.\,, 3I<@L='[]K+PB/\23-=I#K*GF,TDS(;1
MLQ[_;&Q<HR>M5U[?@<RYVI">8],B\8 ;S,KKM;>XQ+$#S3?YWAR?(A>8#X%<
MF^C[8)/>MRJU)78?C^^'96MK:?1)[$2![T2#(OF+B?V,))@(-DMA1ON*Z#MI
M2ITLC?KWF%SH3BG6]BK(0>3$:;B1E[K>;C;LG:? S7X'GN-GL>.'V88U=N/@
M._0.!N5TH*3KIZAW.%Q*XY\6*.^[&@JM@6Q.V25NZ'@4Q?7I@V-* YNG'XJ[
MAFWJ)=8$T\'LQ*0>=@K1T 2>&R<D==/!4I>E]Z3HI$_1R=-3]*[[ ]R9.6Q+
MT5] _P(B6:$A\A*[%S[EFZXE1UN)DA?,F K=1MM>T)H,;["2M<8T2=B 2IB;
MB^422"F4,J9MJX)ZF,+_P_3\I2[D4?=QB5T1D_G<:E3 $F_7"]O\=E92@Y-/
MXZ%O^0Y-AJ$1.'B!)V^@1B.5%HX5>-'D2ANCH84^0_2<,-T@^$X6;YK6T G#
M\#/ES*Y!.'30R*'A,%<E3AR&VWQS/+C;5B!G]@:/#F#*9WO-[5?[CP2G[=UX
M0]Y^87C'Y R3.2EABJS43; )E>VMO7W08F%ORC="X[W;3N? "I"& -]/A=#K
M![-!_^ED\B]02P,$%     @ ,CQV6-+*^)!P!@  B1H  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&ULQ5E9;]LX$/XKA'O !E1;HLY<!M*DW>U##S1M
M%_M(2[1-5!*U)!TG^^MW2%F*$]&*G>WQ8DLCSLS'N2F=KKGX+I>4*G13Y*4\
M&RR5JHXG$YDN:4'DF%>TA"=S+@JBX%8L)K(2E&2&J<@GV'6C24%8.9B>&MHG
M,3WE*Y6SDGX22*Z*@HC;US3GZ[.!-V@(G]EBJ31A,CVMR()>4?6U^B3@;M)*
MR5A!2\EXB02=GPW.O>/7B5YO%GQC="VWKI'>R8SS[_KF778V<#4@FM-4:0D$
M_J[I!<US+0A@_+.1.6A5:L;MZT;Z6[-WV,N,2'K!\[]8II9G@V2 ,CHGJUQ]
MYNL_Z68_H9:7\ER:7[2NU\:@,5U)Q8L-,]P7K*S_R<W&#EL,B;N# 6\8L,%=
M*S(H+XDBTU/!UTCHU2!-7YBM&FX QTKME"LEX"D#/C5]5Z:\H$B1&RK1\ N9
MY52.3B<*1.L%DW0CYG4M!N\0XV'TGI=J*=&;,J/9?0$3P-0"PPVPU[A7XB5-
MQ\CW'(1=[/?(\]N-^D:>O\=&;?NKN0,[MTZ-8UF1E)X-(/8E%==T,'WYS(O<
MDQYL08LMZ),^O8)4RU8Y17R.<BXEN&)&(>$H8H^@[I<+<8OFK"1ERD@.*51Q
MH5BY0-5*5!RT.#W:$%"06E)T2XF0B&JW(G *+694M(XQOQB1,M,7'DHYI*M4
ML!2VHKGG/(>\UTJ'K 0*7TE8+$?'Z.6S!+O^R4_[_QMPVV WSS7\&KU!_K5D
M&O:5(@HV_QQY3NRY\#^,'8SQ2%]YGA.X_@B!62'92S0\A_P4C(PZNH<)=HXT
M5^=!&#M!Y%L>1(&#(V^$/D AUEYI? +.T+H3S\%>#0-61DEH+N/0B:)@U!."
M81N"X=XA"$%0\9*62C9>U&[E.<N(-M%=E*!*\&NFZ[,M-OL5?C%B#U;TM+!<
M4[ DD9MHE+\\%I\8DQ<K(< Z/TS]6YI1 96@N8<H#T+XQ5X,OYKJX9,Z!3J\
MD 0=FM<E-4(>SQ%O+\H7K@!PNC&$#@5Z P.)[ +THZ0+VG<M,B_IG(*\[*?9
M]:$Q#J7;/?!4:8^[XJF2:^=DC3G[O/-4%3\Z VO(6Y7E(>#G)I">F]"!_.@I
MK5%;6J.]2RN=SZF90[<A".UM0:'VI2QG1.VHI[U:=DTHOZ:N[5O?=M2YAOQU
M?#5&\TTR24B"E>+BMF.J3N_$WM@=H1=[$.K,VIYS'%1"QP77-'IGM*1SUBVZ
M0W=LZ=O[QF^3A.TF,@:AH(N:'LV&GF4BP./80@WT1OJI'[BIE'J61PM^3459
MZ.*Y$$1WVJ%M+(G&B87J/TZ]4CS]_DJ?BS+3SB&73 !WV-QQ9*&%7?'>.+P3
M_T?.9R9?%2D73&\(^O<K[;AV/.C$UMCOUOQQ\*B'/L)4(2P0NSW.'7<[U3;M
M8@E@=93=+XT$1FV%KDF^JBU$]"P"LSD%DW;-C!.+9AQ;5/O;&-_L+# VX[_8
MNO.W[AK;;&401*B.' VUIR;&;4V,_\>XJ3.R:SIX+!#4QQD42<7LYZ%^K1=/
MU*1'QPU#[]C9#)SX=YR#]I\M+[L;/AR&/J?P"BJF.5&:$TM*A+B%^7Q-1":W
M&FH"9QXS9T:1@UT8:TG%H NS?P'"YY>DJ$XNFS8LNR'O1&'<36C'#P-T 9N
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MO8]3R;8V^OR2O'^7!E[X\7]O_P*F"%C5$M0<5"OD8G6WZ[?ZLX_ /GSRI:U
M,2/5ZPQ'J>T,/Y&SU*=1ZIWOF^(9S?SHA2F):!SOF?ZK]@9JB4?(-.W7VF_=
M^0;%!_:(GF]@C*T-F"9XWFN#$45)T2-:^1$M">@L"&B<Q ==D4>364B]U#OH
M"C*:S2*:1;-#.G>@./*X0EXUF@RW$L3\7(-22. DFI1T"5U;QDP3OMZ!X3>O
M?] S.?,/0Y2&$0VC[,#NTSA+J.<=\8FF:4+C,'[=I0_^VSKE!S0*8NH%R6$7
M!@ICF2:'7;;U@R/"&=T*WCA6J#.48788K1WUU^SWTC!!ZK8[)?!\' BW&M>V
M*S.1MX(9.')$3B5'-NOV.8K]T11'-,+MSZ+G_0UQN\.01MFAEOYM>U@=I^CB
M2>5=I/'Y2T.6O3 $%R&>=W;[ATWJPS)1**.Q4$8G%\I&&E0"9T)\[VGB30]K
M6MXJ;JS63,D,V0)6EEH:E$<NVJ+325?:=HX]UY]=!+'^Z6,%=IK9&]>FWYN.
M-^%:MS8Y,'1[J82R]WTL0TE$4&JA3>V0S&B @'Z2#M*>'C.L>RR&[MY-%"OD
MIKMOVZ!C.>\OI:-UO-)?]3?9Y^']_\!GIC8<W1"PQJG>18*;KOH[=O]A9-/=
M:U?2X"VY>RWQMP24'8#]:XFJ&#[L N./SO(?4$L#!!0    ( #(\=EA>KV#;
MH@(  *@'   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;*U5;4_;,!#^
M*U:&)I &>6O3PM)(E(QM'Y@0'=MGDUP:"\?.;*=E_WZVDX:V"Q73^)+8YWL>
MWW.7W,5K+AYE":#04T69G#FE4O6%Z\JLA K+,UX#TR<%%Q56>BN6KJP%X-R"
M*NH&GA>Y%2;,26)KNQ5)S!M%"8-;@61355C\G@/EZYGC.QO#'5F6RAC<)*[Q
M$A:@[NM;H7=NSY*3"I@DG"$!Q<RY]"_2L?&W#C\(K.76&ADE#YP_FLW7?.9X
M)B"@D"G#@/5K!5= J2'28?SJ.)W^2@/<7F_8KZUVK>4!2[CB]"?)53ESI@[*
MH< -57=\_04Z/3; C%-IGVC=^7H.RAJI>-6!=0058>T;/W5YV +XT0N H ,$
M^X#1"X"P X2O!8PZP,AFII5B\Y!BA9-8\#42QENSF85-ID5K^829LB^4T*=$
MXU2R:,N->($D63)2D PSI<N1\88IPI:HYI1D!"0Z19^Y,62<92 8.DY!84+E
MB3ZY7Z3H^.@$'2'"T/>2-Q*S7,:NTB&:B]RL"V?>AA.\$(X?H!O.5"G1)Y9#
MODO@:FV]P& C<!X<9$PA.T.A_P$%7A .!'3U>G@P $]?#_</J G[<H66+_SO
M<@WEON4>#7.;!G,A:YS!S-$=1()8@9.\?^='WL>AO+TE6?I&9#LY'?4Y'1UB
M3[[IYDJYE,,Y:[$3BS4]=)6<3OWQU(O=U78V!MRBT;D_WG5+!]PFXRAZ=MM1
M,.X5C \JN,RRIFHH5I";GJ?KKX:DC/^^/(S.@\C?TS+@%TPGT73/+ST8U+\6
MS=WJ816(I9T%$MGONOW;>VL_;BYME]VSS_48:J?&,TT[PVZP6!(F$85"4WIG
M$RU M'.AW2A>VT[YP)7NNW99ZE$*PCCH\X)SM=F8"_KAG/P!4$L#!!0    (
M #(\=E@HZ_CC 0,  .4.   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM
M;+57:VO;,!3]*\*#T<%66\Z[2PQKN]+!"J%EVV?%ODY$9<F5Y":%_?A)=FIG
M$*O%.%\2R=8].O?EPYUOA7Q4&P"-=AGC:N%MM,XO?%_%&\B(.A<Y</,F%3(C
MVFSEVE>Y!)*41AGSPR 8^QFAW(OFY;.EC.:BT(QR6$JDBBPC\N42F-@N/.R]
M/KBGZXVV#_QHGI,U/(#^E2^EV?DU2D(SX(H*CB2D"^\;OKC$,VM0GOA-8:L.
MULBZLA+BT6Y^) LOL(R 0:PM!#%_SW %C%DDP^-I#^K5=UK#P_4K^DWIO'%F
M111<"?:')GJS\*8>2B E!=/W8GL+>X=&%B\63)6_:%N=G9C#<:&TR/;&AD%&
M>?5/=OM '!C@88M!N#<(2][5127+:Z))-)=BBZ0];=#LHG2UM#;D*+=9>=#2
MO*7&3D</53:02)&B:TY3&A.N3;!B47!-^1KE@M&8@D)?T%*::I#Z!1&>('@J
M:&[RH]'9-6A"F?HT][6A9(']>'_]975]V'+]-<3G:( _HS (!_^;^\:3VIVP
M=B<L\88M>#_)2DBBA?&HX?<7W5%.LR([QL^)9WOB0N4DAH5GBEZ!? 8O^O@!
MCX.O#K:#FNV@1!^TL#T>SV,L!R=@.:Q9#ITQ_:XT->4/"2H4I 5#C*: SBA'
M+T#D\:R[$</*TL%M5',;=<HWV;7EVXG7,9+CFNVXIWR/3\!R4K.<])YO-R(.
MWDSXM"8W=4+=%))374@H8YC2G5TK=XL[$3L&<U;SG?64\MD)6.*@D8&@]Z2_
M ?EVE^,#E<(=T][>Z6[(KA%ME B'/64>GT*#<"-"V*D>W5+OAGQ'P^-&?K!;
M+:Y$EA<:Y,$7WH94B51OB:D(9^^[L;O&MI$G/.JK"$XA3+A1)NR4E&Y%X(9\
M1_\WDH3="O*.&G!\")S874/;*!:>]E4#IU JW$@5=FI,MQIP0P[;:\ _&%KL
M 'A'Y)IRA1BD!BHXGYB&D-5,56VTR,LY9B6TF8K*Y<;,H2#M ?,^%4*_;NQH
M5$^VT3]02P,$%     @ ,CQV6.[627CU @  >PD  !D   !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&ULK99M;]HP$,>_RBFKIE;:""3E01U$*K!I>]$5%75[
M;9(CL>K8F6V@F_;A9SN04192UNT-^.G^OM]=[/-P(^2#RA U/.:,JY&7:5U<
M^;Z*,\R):HD"N9E9"ID3;;HR]54AD23.*&=^T&[W_)Q0[D5#-S:3T5"L-*,<
M9Q+4*L^)_#Y&)C8CK^/M!NYHFFD[X$?#@J0X1WU?S*3I^95*0G/DB@H.$I<C
M[[IS-1G8]6[!%XH;M=<&2[(0XL%V/B4CKVT=0H:QM@K$_*UQ@HQ9(>/&MZVF
M5VUI#??;._4/CMVP+(C"B6!?::*SD3?P(,$E63%])S8?<<O3M7JQ8,K]PJ9<
MV^]Y$*^4%OG6V'B04U[^D\=M'/8,PNX1@V!K$!P8!,$1@W!K$#K0TC.'-26:
M1$,I-B#M:J-F&RXVSMK04&ZS.-?2S%)CIZ-YF3T02U TY71)8\*UB6XL5EQ3
MGD(A&(TI*G@+MSI#J>!\BII0IB[@#"B'&\J8R8@:^MHX9&7]>+OYN-P\.+)Y
M)X ;P76FX#U/,'DJX!N2"B?8X8R#1L4IQBT(.V\@: <AW,^G<'YV 51C#C,I
M4DGR&B\GIVL&.\T&7\,J]*'3#?\Y]'61+;4OZ[7MV;]2!8EQY)G#K5"NT8M>
MO^KTVN_J O"?Q)Z$X;(*PV63>G2="ZGI#^).-3Z:ZTDA_(2S.NA2J>N4[/VT
MCMJMSM!?[[,TKWGB8K=RL=OHXN=5OD!I$V7X8S-K,L7 AH+(.#.#[LM2QNOC
M']FXW**WYU=PX'FC$R_,0J]"[)V(.!'YPDPF,$/IJ@2/$6X7C*8N175HO3_0
M#I/2N/D+T?H56O]$M'B'5NRAB0H-S!@@,1D]3&T==/]9Z$:W7@@]J* ')T(?
MLAR!K[UD!L]^LXU>_"VCOU?'<I2I*^\*W'U8UH!JM'I!7+O">3 ^-B^+\B'P
M6Z9\EMP0F5*N@.'22+9;?7/H9%GJRXX6A:N6"Z%-[77-S+R.4-H%9GXIA-YU
M[ ;5>ROZ!5!+ P04    "  R/'98/QRWBI "  #>!@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6RM55U/VS 4_2M6AB8F ?DJ+6)I)-ILVAZ0$!W;
MLTEN$@_'SFRWA7^_:R<-A06$-%X2?]QS?.^Y\4FRE>I.UP"&W#=<Z+E7&].>
M^[[.:VBH/I$M"-PII6JHP:FJ?-TJH(4#-=R/@F#J-Y0)+TW<VI5*$[DVG FX
M4D2OFX:JAP5PN9U[H;=;N&95;>R"GR8MK6 %YJ:]4CCS!Y:"-2 TDX(H*.?>
M17B>36R\"_C)8*OWQL16<BOEG9U\+^9>8!,"#KFQ#!1?&U@"YY8(T_C3<WK#
MD1:X/]ZQ?W6U8RVW5,-2\E^L,/7<._-( 25=<W,MM]^@K^?4\N62:_<DVSXV
M\$B^UD8V/1@S:)CHWO2^UV$/$$Y? $0]('H.F+P B'M _%; I <XJ?VN%*=#
M1@U-$R6W1-EH9+,#)Z9#8_E,V+:OC,)=ACB3KKIV$UD2S2K!2I938; =N5P+
MPT1%6LE9SD"38[*4#7Y;M6WZ!@B76I/## QE7'_"[9M51@X//I$#P@3Y4<NU
MIJ+0B6\P3WN:G_<Y+;J<HA=R"B-R*86I-?DB"BB>$OA8X%!EM*MR$;W*F$%^
M0N+PB$1!%(\DM'P[/!J!9V^'AZ]4$P\]BQU?_-\]&].^XYZ,<UN7.=<MS6'N
M8:LUJ UXZ<</X33X/*;;>Y)E[T3V1-/)H.GD-?84300M0N"54PI$_D",HD)S
MVIE3\1MO(IJ=.2("K1B%-_1^3-SND)D[Q#KN)CV>S6:)O]D7;20HBF?3IU'9
MOU%A=/9(U57I[]W\!E3E'%03]R%TUV-8'4SZPGG3L_4%FG?GM8\TG?-?4E4Q
MH0F'$BF#D]FI1U3GIMW$R-;YRZTTZ%9N6.,/")0-P/U22K.;V .&7UKZ%U!+
M P04    "  R/'98[(]-/_$(  !=5P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T,2YX;6RUG.V3VR8"QO\5QNUTTIF;V$+R2_9V=R:[$M?>W-YEDJ;]C&5L
M:ZH75\*[R4W_^$.V5@@+$^OZ.!^RM@P_$ \@>$#<OA3E[]56"$F^9&E>W8VV
M4NYNQN,JWHJ,5V^+G<C5+^NBS+A47\O-N-J5@J\.D;)T3">3V3CC23ZZOSU<
M^U#>WQ9[F2:Y^%"2:I]EO/SZ(-+BY6[DC5XO?$PV6UE?&-_?[OA&?!+R\^Y#
MJ;Z-6\HJR41>)45.2K&^&[WW;E@PKR,<0OR:B)>J\YG4M[(LBM_K+S^O[D:3
M.D<B%;&L$5S]>1:/(DUKDLK''PUTU*991^Q^?J6SP\VKFUGR2CP6Z6_)2F[O
M1HL168DUWZ?R8_'RDVAN:%KSXB*M#O^3ER;L9$3B?26+K(FL<I E^?$O_](4
M1"<"I6<BT"8"/8TP/Q/!;R+XEZ80-!&"2R-,FPC32R/,F@BS0]D?"^M0TB&7
M_/ZV+%Y(68=6M/K#0:Y#;%7 25[7K$^R5+\F*IZ\5XJD?%F4_*ASOB+_2N*Z
MXN0;\GY3"J%JD:S(FU!(GJ35C^1[DN3DEVVQKU3@ZG8L529JU#AN$GPX)DC/
M).B1IR*7VXI$^4JL+/'#;\2G#L!8W7U;!/2U"!ZHD_B?6+XEOO<W0B>4DL^?
M0O+F^Q\M&7MT8_ZYSQ5F4F.\Q2N&)%)DMIMTLT(1MUGR'5F*+L>X[HQ=CO'L
M&*/@_;;N^0>N_Y?JGJV*';F!G5MWQC?5CL?B;J1ZVTJ4SV)T_\-WWFSR=YNL
M2%B(A$5(& /!#*6#5NG 15<U:"W*4JS4L^A9Y'MA%=6)&"HJ$A8>8?,#K'Y4
M/]][P<SW;L?/7;4LH::S16"&8J",&3),6QFF3AG^D:1J\$'.M3NA6YU-'R=[
MJ#Y(6(B$14@8 \$,M6>MVK,K=:\SI-)(6(B$14@8 \$,I>>MTG-GN_[W/EN*
MDA1KHN"Q^C6)>4KJ='@9;]7%8E/RK")_GAN./#CY0Q4_PF:=CI":G6"(3"Y"
MPA@(9LBX:&5<.&7\O%N7:FA+=OQKW325@+%0TR[;(/G!21HJV*+_Y)JH?R>B
M(9.,D# &@AFBO6M%>^<4[<.Q<:E942*38U>[%L(FF9,S5+)WEL%&7S)DDA$2
MQD P0S)OHB>]$[=H30N3HLS(&S6A7?&OE6UF]. &#57M&]F:30X9L4Z*D?F(
MH#2&HIEB=AP,SUEJ3VI46\DB%Q=UG&[88$&]7CM<])LA-,T(2F,HFBD>U>)1
M=TL4I1J32KX1]?!E?_($3/(XW:_4O+%NHB=S2"*^[$0LU059D*6H12\V>?+?
M8V@ZH8%5?F=V!LN/I(4-K6Y.;6V:O)U.3T9/$315AJ*9%4![0)[3>+AF!9A:
M*P#4.X+2PH9V4@'\V>*T D"-(13-K #:&O+<WM 5*\#,6@&@/A.4%C8TSS,J
MP*2G/S)1AJ*9^FM/RG.;4A\;,3OJJ2J0D>STL6Y?;("Z4E!:V-"Z@X.Y=SHX
MB)I0W>FR/S\-Q2PLVF69A:\M(L_I2YPM_+BHZF%4DBWW9=6L :V+4GL*M9VT
M4I'38G=HIW5A)+'=V'7G8;!&4$.IH75+WPOZ&O5#36E?HUE_4C;SSXJDW1W/
M;>]<WD(.&K67*\+C;2+.#82AG@^4%D)ID=<WI/IS989*TQ19>S^>V_QY5$^]
MDL>2\*H2==M+N:R=6O5HDUM!JOTR;4SZ1FRKIE!;"$H+&YK1TOH-K1_(TLZN
MX?=XVO#QW(Y/JU2:\&62)O*KH=:%2D'=("@M;&A=$7HZ?3,(0^7)7-/7%@]U
M>RD7+3FZ&4-5@-)"*"UJ:.9SSN\U+52BIFC:RJ%N*Z<530W[B\SJHKH)@R5#
MTL*&UBWD^;37QT'39"B:J9CV;ZC;O_E8Q.KI%)M+C:Y59#=OL'Y0 P9*BZ T
MAJ*9.FN;AEYKKPZ%&BY06@BE15 :0]%,P;4M0]VVS)#%2-K?^D+[(^Q'=XJ#
MM4/2(BB-H6BF=MI2H6Y+9=B*B!LVN(%"+13:-T<L2],1-%&&HIGJ:4^&_G^>
MS(DU:I42ZK1 :2&4%M&^(V,9S5YC4P[5O@U%^396+:'^#)06TKZCXGG]V3PT
M48:BF6IJ@X9^RZ!I1T#/@O"RY/E&-)WK46>G<ZKRM./-\*E8DW52JG#;?<9S
M(LN$I]8J +5SH+20]IT:RU0'NLT'13,K@/9]Z(6^SU]QZ-QI#)84ZOO0OJE#
M+<_:?BBOISQ#Y<Q\L4"[/[[;_8%X=.XT!K]F '6'_+Z?<RJ4)8C7-U-1V3*%
MTHZ/?Z'CX[+IW(S!0D ]'R@M\OO[B>B\OU:!2M0439L^OMOTN<"F<Q,&2P:U
M>1J:4<BS1:^C@R;*4#13LLZK5NYM-F%GK?9)+Q#^27YZ^/5U@[A51^RK5MAW
MK; O6V'?MKJ&>^-K]\8/KF37^=#M,5!:"*5%4!I#T4S!M>7CNRV?7PK)T\[,
MDF?%_LRH!FKW^!:#)K"\/ !--8+2&(IF2J?]'M_M]YSOFG]V=\U0LP=*"Z&T
M"$IC*)HIMW:%_/FUNF:H(P2EA5!:!*4Q%,T47!M'OMLX:IHP44/E72I<;PBY
M08,%MFZXZ??,T/>ZH#2&HIG*:<?'=SL^E_3,ZML3_Y)D>WL?#;5[H+002HN@
M-(:BF:<5:/LHF%RICPZ@GA&4%D)I$93&4#13<&U#!6X;ZO+ALQLT6.#^CB%O
M3GMV:@A--8+2&(IF2J?-J,!M1CT662;*.%'Z#3$VW-3!.D(-*B@M@M(8BF:J
MK7VLX%K[D *HDP6EA5!:!*4Q%,T4O'-RD'L?TH">&>I<-;33EP9Z'3/4DH+2
M&(IF*J<MJ<!M29WMF-VVAILZ6$;H=B0H+8+2&(IFJJU=K.!:IPT%4!\+2@NA
MM A*8RB:*;CVL0+W[J8!'3/4MVIHW=6[F>7H$VBB$93&4+2C<N/.Z9^JP]T<
MSFFM2%S+<3R,L;W:G@7[_G "ZLGU!^_FT;-<#[T;=CSI5>./!\\^\7*3Y!5)
MQ5HE-7D[5WU0>3S+]?A%%KO#V:/+0LHB.WS<"KX291U _;XN"OGZI4Z@/5'W
M_G]02P,$%     @ ,CQV6%YE_( P @  YP0  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#(N>&ULM51M;YLP$/XKEB=-G;0% K3=,D#JRZ9VTJ0HT;;/#AS!
MJK&I;4(K[<?O; C*I"3[M"_@L^]Y[KGSG=->Z2=3 UCRT@AI,EI;VRZ"P!0U
M-,S,5 L23RJE&V;1U-O M!I8Z4&-"*(PO H:QB7-4[^WU'FJ.BNXA*4FIFL:
MIE]O0:@^HW.ZWUCQ;6W=1I"G+=O"&NR/=JG1"B:6DC<@#5>2:*@R>C-?W";.
MWSO\Y-";@S5QF6R4>G+&8YG1T D" 85U# Q_.[@#(1P1RG@>.>D4T@$/UWOV
MKSYWS&7##-PI\8N7ML[H1TI*J%@G[$KU#S#F<^GX"B6,_Y)^\+V.*2DZ8U4S
M@E%!P^7P9R]C'0X \^0$(!H!D=<]!/(J[YEE>:I53[3S1C:W\*EZ-(KCTEW*
MVFH\Y8BS^6/3,JZQRI9\(#=ER5VMF"!<#A?N*G=Q#Y9Q8=ZE@<60#A@4(_WM
M0!^=H/_&Y(Q$G]Z3*(R2O^$!*IWD1I/<R/,E)_B^-*U0KP!D#3O03!9 ?A,,
MTF%#^1AD!<;JKK"=YG)+EH))]%AW&P//G<L2<=*:8YF<C>R&8V%:5D!&L?L-
MZ!W0_.V;^57X^4Q>\917[-GC?U[#,67Q?U"63,J2LQ5?0=D- \0K/V'8%UCU
M"RY)"[B2]FA;#*3SH>W<R[#+PUF<!KM#*<%!W[HGX#O36RX-$5 A*IQ=7U*B
MA[$:#*M:W\H;97$P_++&EPBT<\#S2BF[-]QT3&];_@=02P,$%     @ ,CQV
M6(+LHP1; @  B@8  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULK55=
M;]HP%/TKEE=-K31P/BA,+$0J9%/[T F5=7LVR8583>S,-M#]^]E.2*$+K ]]
M(;[7]QS?<QU.HIV03RH'T.BY++B:X%SK:DR(2G,HJ>J+"KC960E94FU"N2:J
MDD S!RH+$GC>D)24<1Q'+C>7<20VNF <YA*I35E2^6<*A=A-L(_WB0>VSK5-
MD#BJZ!H6H!^KN301:5DR5@)73' D837!-_XX&=AZ5_"3P4X=K)%5LA3BR09W
MV01[MB$H(-66@9K'%F90%);(M/&[X<3MD19XN-ZS?W/:C98E53 3Q2^6Z7R"
M/V.4P8IN"OT@=K?0Z+FV?*DHE/M%N[IV-,0HW2@MR@9L.B@9KY_TN9G# < _
M!0@:0/ :,#@!"!M ^%; H &X49-:BIM#0C6-(REV2-IJPV87;I@.;>0S;J]]
MH:7990:GX[NRHDR:>]2HA[X+WDNIRA%[R:8YE6M0Z#(!35FAKDS=XR)!EQ=7
MZ (QCG[D8J,HSU1$M&G(TI*T.7Q:'QZ<.-P/T+W@.E?H*\\@.R8@1DDK)]C+
MF09G&1-(^RCT/Z' "\*.AF9OAP<=\.3M</^,FK"]G-#QA?^]G*[9UMA!-];:
MQ5A5-(4)-GZ@0&X!QQ\_^$/O2]=<WI,L>2>RHYD-VID-SK''9][AKB'69"-'
M9BUR&_?\8#0<1F1[.)Y_R[SCBN1<12V$'/Q+2S -6;=3*!4;KNLWO,VVAGKC
M?.15?FJ,MO;%%YK:I>^-3L85*F!E*+W^Z!HC63M?'6A1.2]8"FV<Q2US\[$
M:0O,_DH(O0_L >WG)_X+4$L#!!0    ( #(\=E@92AHHD@,  (D2   9
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+68:V^;,!2&_XK%IFF3MH+)O4N0
MVG35)FU2U>[RV85#L IV9INDD_;C9P.%9"%N$M$O"0:?UW[,L?WBZ9J+!YD
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M=S;2<UV4YQYE0?%E<71PSY7B67&9 (E F KZ><RY>BJ8!NK3I^ ?4$L#!!0
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M;Q4-VT+KB]AY>V1>NCZ_&#5+S\%T]$K41'F3X>>AN6_G<G=/-F!3RG?51K8
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M^&!0- 3-\E?H2RH$3?+#"' (3'60UU=4[E]E0PU0?;:9_@=02P,$%     @
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M *,<8%PZP"P'F)<.Z)<#^I<.&)0#!D<#C%,#AN6 X?$ _<2 43E@=.F ZW+
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MG[</M,7G6,5)9AOCB9: 4,U"-1O5'%1S4<U#-1_5 E0+42VB-#G$50G(4)>
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M'5)_0!,L6D^4> Q:7;W,\8N/&V7/@4?-M\)6%5: WOKBU&!H[J6M"K+F:5,
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M@1>$ P'=OMT]&'!/WN[NC[ )VW4*#5YXX3H-*5TC1<-(.I%<BPJGL'14IA#
M=^"LWO_AQ]Y?0RK9!$LL@?44C%H%HS'T\SL=7G0;AI2L$:<&46?0W2H(H\G"
MW745.C6:>%'8-TI.C:9Q%+5&/4:3EM%DE-$CY9"R#26_CBFE3$B5E0LLU8QD
M2.: MG0'0O=%1PB\QWSXN$Y. O8GGG=$?32^2S>');">E'$K93PJY7=S/VA!
M=L#5?8<JX(1E C'51_N<I/EAGR B3#-MM'T"]+H,0TJ.?]E'/P%S%*/2I+^A
M(S@*<*G*EL!Z*D];E:>C7.\5(N9*2G5'J,MYIUX=E7I#R(.T@QMQ%/+2;&83
M++$$UI-RUDHYLW8?S&PJ:!,LL0364W#>*CBW?A_,3Y+B+/:/<F)M$W?O#&\:
M'5T'IT9AT,FN/4*^]_J6\T8I_0M49:_"'"^<J=<B$9)C_; >(S4.>NG^L(J6
MV$+K"]IY'/O63ED#94M&FVB)+;2^C,&KC('UH]9 ]AX@T>SH'-T.6 7S>'YT
MV@:LHNCD]>5VJJ@2^,94HT(%O*6R+CO:T;;B_6SJO*/Q&UT)F^KL%:8NH[]A
MOB%4H +6"M*[FJHW#Z\KT[HC665JM2<F5>5GFKFJYH%K S6_9DP>.OH#[?\'
M5K\!4$L#!!0    ( #(\=EALY'_,]P(  /P(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;*U6VVZ;0!#]E16-JD1JPM7@IC92;+=JI*:*XJ9]7L/8
MK *[[N[:3O^^LX I)L3U0UY@+W/.S!E&,XQV0CZI#$"3YR+G:FQE6J^O;5LE
M&11478DU<+Q9"EE0C5NYLM5: DU+4)';GN.$=D$9M^)1>78OXY'8Z)QQN)=$
M;8J"RC\3R,5N;+G6_N"!K3)M#NQXM*8KF(-^7-]+W-D-2\H*X(H)3B0LQ]:-
M>SV+C'UI\)/!3K76Q"A9"/%D-K?IV'),0)!#H@T#Q=<6II#GA@C#^%US6HU+
M VRO]^Q?2NVH94$53$7^BZ4Z&UM#BZ2PI)M</XC=5ZCU# Q?(G)5/LFNLHTB
MBR0;I451@S&"@O'J39_K/+0 ;O@*P*L!7A<0O +P:X!_*B"H 4&9F4I*F8<9
MU30>2;$CTE@CFUF4R2S1*)]Q\]GG6N(M0YR.;WDB"B":/H,BE^2;4 H7"\""
M L+:E^<ST)3EZ@+-'N<S<GYV0<[0A/S(Q$91GJJ1K3$BPVLGM?=)Y=U[Q;OK
MD3O!=:;(9YY">DA@HY1&C[?7,_&.,LX@N2*^^X%XCN?W!#0]'>[UP&>GP]TC
M:OSFZ_@EGW_"U^G+;H4.^M&F8URK-4U@;&%+4""W8,7OW[FA\ZDO,V])-GLC
MLH.L!4W6@F/LK:QA(7-8,JT(UC/1&1".G11[IJ2:\17)JW+'.M](V:V_*L65
MJZAT97KH-G9&]K:=M_]:S(Y9'"@<- H'1Q4^<J8A)7--=7]A5/"PY=&-W&[@
M+XTN(\^4_4'P/5:N&SA^OX*P41 >58!-&ULR)^<WV.,DHQ=]*L*7KH?>QVZ$
MTQZS012$?D=(CUD8>*';+R1JA$1'A7S'@C)EM.^96'5]4J(7)7 Y=#VW*Z7'
M+ S"X: CI<<L&H1AT)%BM^9" 7)5SE=%$K'ANFJIS6DSPF_*R=4YG^!HKR;Q
M/YKJO^".RA7CBN2P1$KG*L)RD=6LK39:K,OILQ :9UFYS/#W!*0QP/NE$'J_
M,0Z:'Y[X+U!+ P04    "  R/'98G^M^8A0#   *"P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6RM5N]OFS 0_5<L5DVMM)4 "4FZ!*DIJ]8/E:JF
MW3Z[X1)0P6:V\V/__<Z&L"00%E7YDF#SWN/>'9QOM.;B7<8 BFRRE,FQ%2N5
MW]BVG,6047G-<V!X9\Y%1A4NQ<*6N0 :&5*6VFZGX]L939@5C,S>DPA&?*G2
MA,&3('*9953\F4#*UV/+L;8;S\DB5GK##D8Y7< 4U&O^)'!E5RI1D@&3"6=$
MP'QLW3HWX5#C#>!G FNY<TVTDS?.W_7B(1I;'1T0I#!36H'BWPKN($VU$(;Q
MN]2TJD=JXN[U5OW>>$<O;U3"'4]_)9&*Q]; (A',Z3)5SWS] TH_/:TWXZDT
MOV1=8CL6F2VEXEE)Q@BRA!7_=%/F88?@^$<(;DEP#PG=(P2O)'BG$KHEH6LR
M4U@Q>0BIHL%(\#41&HUJ^L(DT[#1?L)TV:=*X-T$>2IX8#.> 5%T Y)\);C(
M.0.F).%SHF+ '29YFD140422"DURP5>)*?YE"(HFJ;Q"_NLT))<75^0"H>0E
MYDM)621'ML)0]0/M61G6I C+/1*6XY)'SE0LR7<60;0O8*/'RJB[-3IQ6Q5#
MF%T3S_E"W([K-01T=SK=;:"'I].=%C=>53;/Z'E'].Z60F"5FA);$+O-1-U%
M;F1.9S"VL$U($"NP@L^?'+_SK2DIYQ0+SR2VE[!NE;!NFWIP#Q$(FC8EK"#V
M#5%WR57@='LC>[6;ASK&=?K[F+ U@ _:ZU7V>JWVI@J_SR9S!<W?#5R_OWOF
MZACG !*V/OV#WOS*F]]>.BZP>V.?N<5V*!)ZU>33KWLX</E?1.C77X0*L1=Y
MOXJ\WQKY"U<TQ2YNOE73-6&#Y[5LK%2_%I_G#PX\U#&NUSEP4<<<<3&H7 Q:
M>TT(<T '45/0@W,VFW.*A6<2V\O8L,K8\(2Z[QR6+64?UEZZ>MGKF'K9ZYC#
MLML[4T(&8F&F+8D'_)*IXARM=JN![M;,,0?[$QSTBKGLGTPQ)3Y2L4B8)"G,
M4;)SW<>^(8K)JU@HGIM9Y(TKG&S,98S#*@@-P/MSSM5VH1]0C;_!7U!+ P04
M    "  R/'98/Y@S47$$  "N%@  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6RU6-MNXS80_15"10L7V%BB9#N7V@826VT#[':##;9]*/I 2V-;B$2Z
M)&TG?U]24F3+H>@+U)=$E.8<#L_0Y,P,MXR_B"6 1*]92L7(64JYNG-=$2TA
M(Z++5D#5ESGC&9%JR!>N6'$@<0[*4M?WO(&;D80ZXV'^[HF/AVPMTX3"$T=B
MG66$OSU RK8C!SOO+[XEBZ74+]SQ<$46\ SR^^J)JY%;L<1)!E0DC"(.\Y%S
MC^]"W-> W.+/!+9B[QGII<P8>]&#QWCD>-HC2"&2FH*H?QN80)IJ)N7'OR6I
M4\VI@?O/[^R_YHM7BYD1 1.6_I7$<CER;AP4PYRL4_F-;7^'<D&Y@Q%+1?X7
M;0O;@9HQ6@O)LA*LQEE"B__DM11B#X '#0"_!/B'@%X#("@!P:F 7@GHG0KH
MEX!\Z6ZQ]ERX*9%D/.1LB[BV5FSZ(5<_1RN]$JHWRK/DZFNB<'+\2".6 9+D
M%02Z0N%\#GGH4%)]4/LA8C1*TH3DL>U,09(D%3\/7:D\T#QN5,[V4,SF-\R&
M??2%4;D4**0QQ'4"5[E>^>^_^__@6QFG$'51@#\AW_-[!H<FI\,# WQZ.MPW
MP,/3X=@B1E %,\CY@@:^KRO@*D9T@3XS(="$</ZFSI(MX;% ?W]6UNA10B;^
M,46NH.Z9J?5Y=2=6)(*1HPXD 7P#SOBG'_# ^\6D>IMDTS;)PI;(:O'I5?'I
MV=C'W[O/732'6$4I14(2N9:,O]5^:D2"*3A6WG.#8W>RX^.NY_UH^G5/+T:&
MER!K&O<KC?M6JF<EZ_[I!>(3HNK"9?-*^1E0F"?2I+.5^UR=[8YVO&[0('.;
M7H0MD=6",:B",;"N4=WEZJ:FU=9&<:(N& Y4)B0UZ6^E.U=_NV\=OWO=H/\1
M8*]QEU\ K.EZ7>EZ;67Z@TFM*9FE@!9L YRJW$VB!2=4"I.N5KIS=;7[UAET
M;QIT/0(,FH#A!<":KC>5KC='#@\6O5SIQ#-&Z@!1V;C(<QZ3I%:F<R4MR+"7
ML^GD?C/VU&89#-W-OH -9OVZ66A?9 =W^W:Y;BNY;JU,OZ5LIL[3A$I"%XG>
MC*KNN-*';ER>P";AK)SG"G=K5$3G<C7AS&:X=R!<2Z[5Q,3>+A7WK')^E4O@
MQJ3:BCM7LI+MPR[R#S1KLL,'HAVWJ^NQ5YI@JQZ3I=I6^B[7E1]PKG:5ODB(
M$.H^WY!T7=0C)%6[CM#(N-GL4YPM'38MU;_Y()W9[OJ#=$:[8"\4=>G\G72^
M53IS'=>07-JYSM;(/^F0FC;9!8<:V5?:\8Y=JGA7/F%K]C^^5_4V3XA1HU;+
MHU;9IJVRA6VQU6.P*Y%P[_^K87&K=5*K;--6V<*VV.I1VA59V%Z\7%[)'B'N
M^$%3=CTY"FU,S*='H?W&G/XB:"&KN]>7RX O\H:H4)GEFLJBQ56]K9JN]WFK
M\>#]@V[&YOV^'4W1R?U"^"*A J4P5Y1>]UIYRXOF:#&0;)5W_V9,2I;ECTL@
M*G#:0'V?,R;?!WJ"JD4]_@]02P,$%     @ ,CQV6(*4.BUZ!   NA<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULM9AMC]HX$,>_BI6KJE8Z-G&>
M@"T@M4#5OKB[U6[;>^T-!JQ-8LXV"[U/?W:2#7GPND3RO8&$S/P9_SSQ>#P[
M4?;$]Q@+<,[2G,^=O1"'6]?ER1YGB-_0 \[EDRUE&1+RENU<?F 8;0JG+'5]
MSXO=#)'<6<R*W^[88D:/(B4YOF. '[,,L9^?<$I/<P<Z+S_<D]U>J!_<Q>R
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MH5P2B/AU_D5]*I)=!UW?*.Z",T8S%)PEL1:XN 87&\%]3!)VE'GWDF] UBA
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MAYRM$-?1BDT/C)D&K>03JLO^++GZ2A1.IO<T9S4@B=<@T"6:E)C.U8A0)$M
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ML6J@;;][IVF[[P/FZFP*5,%,47I7 ^4Z;SM:.Y&L,7?\E$G5,<RP5#\!P'6
M^CYC3&XF>H/^MR+]"U!+ P04    "  R/'986/L9+2H$   S%0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970V-RYX;6RU6%UOVS84_2N$5@PMT.K+\E=F&T@L
MM3.0=$'2; _#'FCIVA8JD2Y)Q^E^?4E)EB5-5NR!S4,L2O<<\IY#79&<["G[
MRC<  KVD">%38R/$]LJR>+B!%'.3;H'()RO*4BQDDZTMOF6 HPR4)I9KVP,K
MQ3$Q9I/LWCV;3>A.)#&!>X;X+DTQ^WX#"=U/#<<XW'B(UQNA;EBSR1:OX1'$
MT_:>R995LD1Q"H3'E" &JZEQ[5P%CJ< 6<2?,>QYY1JI5):4?E6-130U;#4B
M2" 4B@++GV>80Y(H)CF.;P6I4?:I@-7K _O'+'F9S!)SF-/DKS@2FZDQ,E $
M*[Q+Q /=_PY%0GW%%]*$9__1/H\=RA[#'1<T+<"RG<8D_\4OA1 5@#,X 7 +
M@-L$>"< O0+0.Q?@%0#O7$"_ &2I6WGNF7 ^%G@V872/F(J6;.HB4S]#2[UB
MHB;*HV#R:2QQ8K8@(4T!"?P"''VXCJ)8^8<3M"#Y+%1NOO5!X#CA[] ']/3H
MH[=OWJ$W*";H+DX2&< GEI!C48Q66/1[D_?KGNC7<=$=)6+#44 BB.H$EDRB
MS,0]9'+C=C+Z$)JHY[Q'KNUZ+0.:GP_OM<#]\^%N"SPX'^YTB-$K;>UE?+T3
M?']L@4GOR!K=4L[1'#/V7?JYQRSBZ.];&8T6 E+^3YMS.;773JTJUQ7?XA"F
MABQ-'-@S&+-??W$&]F]MJNLD\W62!9K(:OYXI3]>%_ML3MF62H= OD6'%Q"I
M=IL?G527^I&3.7D]4)^1YYEMJCGW7!7ZK*C@M:B:-/U2FGZG-)\2NLSJC\!D
M'2\3D%-XC[[( A6AHEH!%[$L3<VRD:O5R7ZI6CE9OY+@R!S9U;^F<O]%],Q!
M0S=-0ZS).RCE'73*^_2HM$2RJG]:W'Y9O$=$KD;H"CW(GC +-VC.0'X$6DMZ
M)_.ETN9DCE>;/%Y#S=8@MR&GIF'5Y!R6<@Z[Y20,0KHF\;]R>E;>Y2406)V0
ML9/Q4AESLD%5H(:&KT8$F@94$W!4"CCJ%/ C1/)3E;3IU F\5">=9+Y.LD 3
M64W]<:G^^.>M$\8Z_=%)YNLD"S21U?QQ[./ZW.Y\/SZK\ERZE"B7PJI+K4OO
M3LI+G2G8:D78;19AORW*Z9FC1JDIPJK?1V=HCMN7#$YE%^-TJG0M=THLQJUB
M="(O%D,GFZ^5+=#%5O? /7K@_KQ:4G#K<DDGFZ^5+=#%5G?IN#%T.O<U_Z^>
M:-T1%FRU)?)P9#87TBUA[K!O]IH%I27,&9O#$Q7EN$%S-.[0G/:=4&.L\Q-A
MS47OB;!^,_/7PO+,K<KA4 ILG9W*2=/ICHC\=*6\6Y[\76?G78W[-^I$,#MT
M.M+DQXEWF*UCPE$"*TEIFT/I!LM/Z/*&H-OL"&I)A:!I=KD!+!=^*D ^7U$J
M#@W507E..OL!4$L#!!0    ( #(\=EAF!A>GZ0(  .D)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8X+GAM;*U6;6_:,!#^*U963:VT$O)"V#J(5)I-F[1.
M5:MNGTUR!*N.G=D&VG^_<Q(RH)"V$U^([=SSW-UC<G>CE50/>@Y@R&/!A1X[
M<V/*"]?5Z1P*JGNR!(%O9E(5U.!6Y:XN%="L A7<]?O]R"TH$TX\JLYN5#R2
M"\.9@!M%]*(HJ'J: )>KL>,YZX-;EL^-/7#C44ESN -S7]XHW+DM2\8*$)I)
M013,QLZE=Y$,K7UE\(O!2F^LB<UD*N6#W7S/QD[?!@0<4F,9*#Z6< 6<6R(,
MXT_#Z;0N+7!SO6;_6N6.N4RIABO)?[/,S,?.1X=D,*,+;F[EZALT^0PL7RJY
MKG[)JK:-0H>D"VUDT8 Q@H*)^DD?&QTV %YT . W '\7<,A#T ""UP+"!A!6
MRM2I5#HDU-!XI.2**&N-;'91B5FA,7TF[+7?&85O&>),?"6+@AF\1Z,)%1E)
MI3!,Y"!2!IJ<)F HX_J,G)/[NX2<GIR1$\($N6:<X[7ID6LP"$OEIHW#2>W0
M/^#0\\DU^IAK\D5DD&T3N!A]FX*_3F'B=S(FD/9(X'T@?M\/]@1T]7JXOP>>
MO![N=603M!<25'S!_US(/KEKNG _G:T:%[JD*8P=+ L:U!*<^/T[+^I_WB?5
M,<F2(Y%MR1BV,H9=[/%/*<Y3*E(L*'3*@<@I9SDUA_ZS-=F@(K.5<AD/>^'(
M76YJT^GPK=H<B6Q+FT&KS:!3&_RGAE@;.19<9<79JTA-X84;DO1[GW8DZ?3S
M5DF.1+8E2=1*$KTDR>!%2:+GDD2]P8XDG7[>*LF1R+8D&;:2##LE^<%2V]U%
M3F: K6"F9(&5W^ 'A2U[03DI%0X?RCP17EGNUVSX[,/R>M&.9+7-<--FVR+9
MQQ*T-G5Z[D83+$#EU3"AL7XNA*F;27O:SBN759O>.9_@'%./'?]HZB'HFJJ<
M"4TXS)"RWQMB1*H>+.J-D675:J?28..NEG.<Q4!9 WP_D]*L-]9!.]W%?P%0
M2P,$%     @ ,CQV6'@ &>L, P  M@L  !D   !X;"]W;W)K<VAE971S+W-H
M965T-CDN>&ULM59M;]HP$/XK5E9MK;21%\*+.HA42*=5&A(JZO9AV@>3',2J
M$V>V>>E^_6PG9, @HU+V!>S+/<_=/8XO-]@P_BP2 (FV*<W$T$JDS&]M6T0)
MI%BT6 Z9>K)@/,52;?G2%CD''!M02FW/<;IVBDEF!0-CF_)@P%:2D@RF'(E5
MFF+^,@+*-D/+M7:&1[),I#;8P2#'2YB!?,JG7.WLBB4F*62"L QQ6 RM._<V
M[&M_X_"5P$;LK9&N9,[8L]X\Q$/+T0D!A4AJ!JS^UC &2C612N-GR6E5(35P
M?[UC_V1J5[7,L8 QH]](+).AU;=0# N\HO*1;3Y#64]'\T6,"O.+-H5OS[%0
MM!*2I25899"2K/C'VU*'/8#;/0/P2H!W#/#/ -HEH'TIP"\!OE&F*,7H$&*)
M@P%G&\2UMV+3"R.F0:OR2::/?2:Y>DH43@:^XUX_WZ 97I-L*="4X@Q=AR Q
MH>(&?4!/LQ!=7]V@*T0R-"&4JL,2 UNJT)K CLHPHR*,=R:,ZZ$)RV0BT'T6
M0WQ(8*N<J\2]7>(CKY8QA*B%VNY[Y#E>^T1"X\OAW@EX>#G<K:FF71U#V_"U
MS_(ME"5&8R42)_.5N1/F,$(B(LK$B@/Z_D7YH <)J?AQZ@B*$/[I$+I_W(H<
M1S"T5(,0P-=@!6_?N%WGXRGYFB0+&R([D-:OI/7KV(/[K6J1 H1J4A%;9N27
MDEFU2R030.7;KX4^)6A!W#'$NG^N Z?5'=CK?9TN\ E/^?B5ST%5G:JJ3FU5
M$[PEZ2H]E74M\+6O09-D84-D!X)U*\&Z__^&=9N4MDFRL"&R VE[E;2]?[R+
M,DK4YP-%^]I*IK^_1O,#NR@_-?F92U?$<MV]V^(>W;G:=%ZK7$-D!\KU*^7Z
M];TIS2E[ ?Y.H&9%[/\MHM-R_",=:Y-[K8X-D14ZVGL330I\:29#H3189;*8
M$2IK-7S>F9GKR#Y20VDQ0_ZA*2;:">9+D@E$8:$HG59/=2=>3(G%1K+<S$US
M)M449I:)&JR!:P?U?,&8W&UT@&I4#WX#4$L#!!0    ( #(\=ECJ*R6O  8
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MUDS+UN$39I;]40G=2S1/9=_TSJ)<2M2 W@P5%H NT U3I"2T-4N")!2M((J
M1.]R4)A0^5YC+%:FKM*3,%)NT0^XZ ;TCPSH^>B.,U5)](F54.X+N'KV0PC^
M-H2%?U(QA^(2!=X'Y,_\8&1"M^?3_1%Z?C[=.Q%-,"Q(8/6"(WK&^XL1\\><
M[I3"<25S85S+!A<P=_2-($&LP<G>OO'BV<<QEZ84RR<2VW,P'!P,3ZF_=O#H
M/NU48JMB;L=U=N5Y7I1$J;O>->80%T>!'YF]MHO+#W&A'WA><C7@]L*)AG"B
MD^%\;\P%*1&1LH42858B?7U+I0N$K<8".ZGWO]MB2K%\(K$]'^/!QWBR@Q5/
MZ>"48OE$8GL.)H.#R20'*SGS8!WBQ@_6(6[\8+D[SV -8F73"8D*WC+5/2=#
MZY"QW-B'^E7[0F<R7>+Q3Z9+@^ZP6!%]&"DLM>3L,M$[6G2I15=1O+&/[1-7
M^NFVQ4IG8R ,0/<O.5?;BAE@R.^ROU!+ P04    "  R/'98/4.C?TP"  !7
M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6RU5,%NVS ,_17"*X86
M&&+'2=JA<PPT38?M$"!(T>VLVHPM5)8\B4DZH!\_2DZ\#&NSTRZV*/$]/E(B
MLYVQ3ZY&)'ANE';3J"9JK^/8%34VP@U,BYI/UL8V@MBT5>Q:BZ(,H$;%:9)<
MQHV0.LJSL+>T>68VI*3&I06W:1IA?\Y0F=TT&D:'C96L:O(;<9ZUHL)[I(=V
M:=F*>Y92-JB=-!HLKJ?1S?!Z-O'^P>&;Q)T[6H//Y-&8)V]\+:=1X@6APH(\
M@^#?%F]1*4_$,G[L.:,^I <>KP_LGT/NG,NC<'AKU'=94CV-/D90XEIL%*W,
M[@ON\PD""Z-<^,*N\YU<15!L')EF#V8%C=3=7SSOZW $2-,W .D>D ;=7:"@
M<BY(Y)DU.[#>F]G\(J0:T"Q.:G\I]V3Y5#*.\A4J05C"4EB2Z.!\CB2D<A=P
M!E+#0BK%Q7-93!S,0^)B3SSKB-,WB(<I+(RFVL&=+K'\DR!FE;W4]"!UEIYD
MG&,Q@-'P Z1).H*'^SF<GUV<X!WU)1@%WO$;O#,C; EF#:6T_%:,=? ""Z$(
M88F$P;SE&O ]2UV!J"PB/TMZK28G(_D&NW:M*' :<0<YM%N,\O?OAI?)IQ-Y
MC/L\QH%]](^K;+NK?$W>^#_(F_3R)B?+?/?,@\0A=W)A[%\OHM/7,4P"@Q\G
MVSP9#+-X>QPV/GKL#=HJM+2#PFPT=>^^W^VGQDW7++_=NY&S$+:2VH'"-4.3
MP15'MET;=P:9-K3.HR%NQ+"L>?*A]0Y\OC:&#H8/T,_2_!=02P,$%     @
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M1=G1J!MB%^;&S]40E1:BTB(L6E?&HPT*UYPR:\FJ1#E95]M4:\9C(!=J^BU
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M*=VSB78UT?E>%RC>6">XYTK[BEV6^E,!PB3H\R7G:AN8 L/')_T'4$L#!!0
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M)TE@5S%OV!.,(UF&(5"+_AI-4V1U4OCX]P=[2I(DR_P(8'X'28(A\#3B".8
M/&!(DC3OP9WW4;1Z3T7K_^ .?P-02P,$%     @ ,CQV6)>*NQS     $P(
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M7UV,;R<7[._Q]7AZ/F'S+Y/)[3P C!# Z&B [&3& \@8@8S?$')^"R]?)U,
MO+ED-[/)MP R02"3HT'"J;L ,D4@TR-"?H\"R R!S(X'.9Y_"2!S!#*GA9SR
MIC6"Z25KUH(M6BN5L-8/1E!.V'$^() ?:"'G;5US\^ HK5PI"5_C;L0L"MW"
MB!E GB*0I\3-#6KB"VW\&5^!U_!%!16Z8N.5"0?R(3:2#VDQK^H-E\9=%!*A
M;B&6RR7PL#M>M?XQO)2*JT+RBHVM!?>&E)A@1L2&@4!G V'(PWNVJ?BCKL5_
MK=RX[[UG(2:FF!&Q8[Z)0L@MAQ]E1EC!3;%F4L%SZ,*?$!)3S(C8,=>"6]%I
M6<PE(V*9C(O"M ):\R<4 ER[P0^&0\.*UG0Z+F:3$;%.KC57EFWX _>_^P2%
MV6-$K(]S7=<PVME&%_?OV7G%P1UC5NR/AIB8/T;4 G%\_04\=:6#<^W\(KK&
MU#$B=L>5 BH!*<S/3K>(,%%$Q*)P32L;=]&N1Q20F8'+! S.74C,'1&Q.Y+A
MZ.3^'9OS+:!9-H.A.41#,Q)B84RAW$I#?P!M !(W8:>-,$=$Y(Z @] 39AS2
MZFY;8E:(B*TP;Q<6C.IR8;%UCUT(A@DB(A8$&GYVLHT($T1$+ @<,PXQ,65$
MQ,IX"D#9R:USF7T7HF&:B(@U@4>B88P78;:(B&V!AJ*=YS'&!!(3"V07Y1UJ
MY!A31DRL##3<Z]8>IH^86!^=<.]@):(S6<0*>2V@>@0-,3&EQ,1*">.J@W6(
M:24FULK+ .$@(J:4^*A*24),3"DQL5)PS#3$Q/02'W,:ZWL68F)ZB8GU@F/F
MX30UII>$/#]!YMLZXWB"Z28AUDT0[O39N"RENP)B"KE;XPDQ,=TDQ+KI8$ZU
MZA?<KIG<'PTQ,>\DQ-Y!([1NHZ-K*,3>P2.T,!1/, ,EQ 9")PO928B)62BA
MGOEZ#"0O1,-EU;%C@FDG(=;.(U>?^3<0!]GF%4K,.@FQ=?Y0?G4+[FW-*D\+
MD67]+,E.,.LDQ-;Y@_FOD*NUFY[@6V'XRCV:-0_7>%+,.BFQ=?#L(>S9*6:=
ME-@ZS[*' \]DBMDF?=/DIL_F4&;95GY0YZM5B(G9)J5>L,=FMSNV23';I-03
M9Z\E8WT6#?V\^Q],=,V>>AH-Q3P-,3';I-0YS^N8+C(.,3'YI-0Y#X()IT),
MS#[ID59>/&:W"V'V2:ESGM<QW2 0;BC![),1VP>OS= ^&6:?C#KG":==(#S2
MUIER(: P 0%FB(E9**/.>;J8KD*U\NM=?CM,B(E9*".VT#/,R7(I_&9&%ZK#
MB1 3LU#VEG-MOML$M=G=DX59*".VT'/,-5<K>">5WP"U#3'1O6/$%NIB!O,&
MN[VA(29FH>P-UO]?723N9) 99J&,V$('EHD/!L49YJ",V$&'YH,/,.:8@')B
M 1U@[+,QM'DIJ[:S$R_'!)03"^C9"O?A>L34DQ.KY\5:]V%$3#LYL79F_(%M
MH:\(X[^N"L$NI"V@]=O.5H8<DTY.+ATK2W@4;PTO_<2O,6X\?SZSD6/&R;UQ
M!OYB^_E3*992B7(*Y5LX7O"JF$%R#R^[/8A)ZG*595M5YW#L1D$N6^[_.;#_
MU\/GWU!+ P04    "  R/'989_Q20DP"  !H+   &@   'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QSS=I+;J- %(7AK5@L(+CNJY)6G%%/,HVR >24'XIM
M$-!*LONVG(%]4 ]Z$G%&J$!<_@F?$/#X4@[-N&]/PV[?#8O/X^$TK*K=.':_
MZGI8[\JQ&>[:KIS.1S9M?VS&\[+?UEVS?F^VI9;E,NK^=D;U]'@[<_'ZU97_
MF=AN-OMU^=VN_QS+:?S'X/JC[=^'72ECM7AM^FT95U7]>;CN'NK+)MV=)U>+
MY[=5U3^_I:J>.T@@2.8/4@C2^8,,@FS^((<@GS\H("CF#\H0E.</NH>@^_F#
M'B#H8?Z@M$09EP1)$ZP)M$[(=2+P.B'8B4#LA&0G K,3HIT(U$[(=B)P.R'<
MB4#NA'0G KL3XIT(]!;46PCT%M1;"/26R<,V@=Z">@N!WH)Z"X'>@GH+@=Z"
M>@N!WH)Z"X'>@GH+@=Z">@N!WHIZ*X'>BGHK@=Z*>BN!WCIY64*@MZ+>2J"W
MHMY*H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@MZ'>1J"WH=Y&H+>AWD:@MZ'>1J"W
M35YV$^AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H[:BW$^CMJ+<3Z.VHMQ/H
M[:BW$^CMJ+<3Z.V3CY4$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z!^H=!'H'ZAT$
M>@?J'01Z!^H=!'H'ZAT$>@?J'01ZQ^1G$P*] _4. KT#]0X"O0/U#@*],^J=
M"?3.J'<FT#NCWIE [XQZ9P*],^J="?3.J'?^2;V'\>M0AFO/]QJO_Y-4C^=S
MR_7RE^7WSLD-=<&YOJT8GOX"4$L#!!0    ( #(\=EB&IF-(# (  &$K   3
M    6T-O;G1E;G1?5'EP97-=+GAM;,W:S6[B,!0%X%=!V5;$^#?3$;"9F6V'
M15_ 32XE(HDMVVWA[<<);:56'305(_5LB,#V/3>^TK=B>7OT%&>'OAOBJMBE
MY+\S%NL=]3:6SM.05[8N]#;EK^&>>5OO[3TQL5@85KLAT9#F::Q1K)<_:6L?
MNC3[=<@_Q]8-JR)0%XO9C]/&,6M56.^[MK8IK[/'H7F7,G].*//):4_<M3Y>
MY0T%^S!A7/E[P/.YWX\40MO0;&-#NK%]WL4.'8OIV%$LSY?XH$>WW;8U-:Y^
MZ/.1,OI MHD[HM1WY:GHU?GDE&^83I_\XORIS+G O',3G(]Y8H$^'_<RDO'T
MW.="%%)[_A5?$W/IB]^/QFDWU/QC=K[>)Q?VTSPBFQZ7W_';&;_6_V0? J0/
M"=*' NE#@_1A0/JH0/KX!M+'-4@??('2"(JH'(54CF(J1T&5HZC*45CE**YR
M%%@YBJP"15:!(JM D56@R"I09!4HL@H4606*K )%5H$BJT215:+(*E%DE2BR
M2A19)8JL$D56B2*K1)%5HLBJ4&15*+(J%%D5BJP*15:%(JM"D56AR*I09%4H
MLFH4636*K!I%5HTBJT:15:/(JE%DU2BR:A19-8JL!D56@R*K09'5H,AJ4&0U
M*+(:%%D-BJP&15:#(FN%(FN%(FN%(FN%(FN%(FOUE;+>.;?_S_'3L^QM.[SD
ML^F?M>L_4$L! A0#%     @ ,CQV6 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  R/'987Q>(C>X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ,CQV6!RG*1K^ P
M,10  !@              ("!JQ<  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( #(\=E@"\/TT]04  /P9   8              " @=\;
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  R/'98 P@H
M_5@9  "_L@$ &               @($*(@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ ,CQV6*VEU3<T!0  YR@  !@
M ("!F#L  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( #(\
M=EAG=MA F@@  )<J   8              " @0)!  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    "  R/'98N]L@/[D%   [#0  &
M        @('220  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
M  @ ,CQV6,:<.4S*)@  VH4  !@              ("!P4\  'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #(\=E@_=K(27PD  /\@   9
M              " @<%V  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L!
M A0#%     @ ,CQV6&JWS'KG!   I@L  !D              ("!5X   'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  R/'98@"H CB0#
M  #5"0  &0              @(%UA0  >&PO=V]R:W-H965T<R]S:&5E=#$R
M+GAM;%!+ 0(4 Q0    ( #(\=EC2M:%FM@0  .<+   9              "
M@="(  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ,CQV
M6',8>9X;!@  2Q$  !D              ("!O8T  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    "  R/'98 A]H3<X&  !'$P  &0
M        @($/E   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( #(\=EB0NLRX+ ,  '$(   9              " @12;  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ,CQV6"P(- J.!@  XA(
M !D              ("!=YX  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    "  R/'987S%0 4L)  "S'P  &0              @($\I0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( #(\=EB9DF53
MQ0T  "8N   9              " @;ZN  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ ,CQV6*<7&+^,#@  I#   !D
M ("!NKP  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  R
M/'98(J7B IP'  "%$P  &0              @(%]RP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #(\=E@^YH>P[ (  *@&   9
M          " @5#3  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#
M%     @ ,CQV6,-(^C]_!   O T  !D              ("!<]8  'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  R/'98@G(A_<H"  "
M!@  &0              @($IVP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;%!+ 0(4 Q0    ( #(\=ECX=/<=A04  *T,   9              " @2K>
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ,CQV6/03
M_DH%+P  ?*@  !D              ("!YN,  'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6Q02P$"% ,4    "  R/'98(X$3*(8"  #1!0  &0
M    @($B$P$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M #(\=ECSH2.T8P(  /,%   9              " @=\5 0!X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ ,CQV6)9'IJ0% P  =0D  !D
M             ("!>1@! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    "  R/'98^#C0^Q(#  ##!P  &0              @(&U&P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #(\=E@\>-=-700
M -\-   9              " @?X> 0!X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ ,CQV6/?U5; ] P  5 @  !D              ("!
MDB,! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  R/'98
M-UW$2Q #  "("   &0              @($&)P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( #(\=ECY"3 $1 4  $81   9
M      " @4TJ 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ ,CQV6-+*^)!P!@  B1H  !D              ("!R"\! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  R/'980=%U&!L$  #T#
M&0              @(%O-@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( #(\=EA>KV#;H@(  *@'   9              " @<$Z 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ,CQV6"CK^.,!
M P  Y0X  !D              ("!FCT! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    "  R/'98[M9)>/4"  !["0  &0
M@('20 $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( #(\
M=E@_'+>*D (  -X&   9              " @?Y# 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ ,CQV6.R/33_Q"   75<  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( #(\=EA*61I&700  ,(9   9
M  " @>]= 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M,CQV6%$74WCT @  ' L  !D              ("!@V(! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    "  R/'98ICW^)@D$   C%@  &0
M            @(&N90$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( #(\=EC7<#?@H0(  *<'   9              " @>YI 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ,CQV6/)B#B=T P
M< \  !D              ("!QFP! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    "  R/'98EA+V0W0#  " "P  &0              @(%Q
M< $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( #(\=ECU
M5SFZU 0  )89   9              " @1QT 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ ,CQV6-'M=>\^ @  O00  !D
M     ("!)WD! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #(\=EB@T9JAZP(  + (   9              "
M@3>9 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ ,CQV
M6.5BDSA<!@  ;"8  !D              ("!69P! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    "  R/'98#ALUF<D"  !>"   &0
M        @('LH@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( #(\=E@]V![$G@,  "L0   9              " @>RE 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ ,CQV6&SD?\SW @  _ @
M !D              ("!P:D! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    "  R/'98G^M^8A0#   *"P  &0              @('OK $
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( #(\=E@_F#-1
M<00  *X6   9              " @3JP 0!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ ,CQV6(*4.BUZ!   NA<  !D
M ("!XK0! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    "  R
M/'98+GQXA- "  !B"   &0              @(&3N0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( #(\=EA8^QDM*@0  #,5   9
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M970W,2YX;6Q02P$"% ,4    "  R/'98/4.C?TP"  !7!0  &0
M    @(& T $ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    (
M #(\=EA*>_W$E 0  "<=   9              " @0/3 0!X;"]W;W)K<VAE
M971S+W-H965T-S,N>&UL4$L! A0#%     @ ,CQV6#$\QP%D @  B 8  !D
M             ("!SM<! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"
M% ,4    "  R/'98!Z; [V$"  #"!P  &0              @(%IV@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( #(\=EAW/%5!40,
M ,X5   -              "  0'= 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !3 %, O!8  &/L 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>239</ContextCount>
  <ElementCount>394</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of the business and organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization</Role>
      <ShortName>Nature of the business and organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Collaboration and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements</Role>
      <ShortName>Collaboration and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Impairment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureImpairment</Role>
      <ShortName>Impairment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Fair Value of Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets</Role>
      <ShortName>Fair Value of Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet</Role>
      <ShortName>Property, plant and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Receivable research incentive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive</Role>
      <ShortName>Receivable research incentive</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Accrued expenses and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued expenses and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Loans payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLoansPayable</Role>
      <ShortName>Loans payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Common stock, Class A common stock and convertible preferred stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock</Role>
      <ShortName>Common stock, Class A common stock and convertible preferred stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/Disclosure401KSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Impairment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureImpairmentTables</Role>
      <ShortName>Impairment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureImpairment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Fair Value of Financial Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables</Role>
      <ShortName>Fair Value of Financial Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Property, plant and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables</Role>
      <ShortName>Property, plant and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Accrued expenses and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued expenses and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Loans payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLoansPayableTables</Role>
      <ShortName>Loans payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureLoansPayable</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31603 - Disclosure - Net loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of significant accounting policies - Going concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails</Role>
      <ShortName>Summary of significant accounting policies - Going concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of significant accounting policies - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of significant accounting policies - Others (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails</Role>
      <ShortName>Summary of significant accounting policies - Others (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Summary of significant accounting policies - Comprehensive loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails</Role>
      <ShortName>Summary of significant accounting policies - Comprehensive loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Collaboration and Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails</Role>
      <ShortName>Collaboration and Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Impairment - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails</Role>
      <ShortName>Impairment - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Impairment - Non-cash impairment charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureImpairmentNonCashImpairmentChargesDetails</Role>
      <ShortName>Impairment - Non-cash impairment charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Fair Value of Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails</Role>
      <ShortName>Fair Value of Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Property, plant and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails</Role>
      <ShortName>Property, plant and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Receivable research incentive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails</Role>
      <ShortName>Receivable research incentive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureLeasesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Leases - Lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Leases - Minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails</Role>
      <ShortName>Leases - Weighted average remaining lease term and weighted average discount rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Accrued expenses and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued expenses and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Loans payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLoansPayableDetails</Role>
      <ShortName>Loans payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureLoansPayableTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails</Role>
      <ShortName>Loans payable - Schedule of aggregate minimum future principal payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails</Role>
      <ShortName>Common stock, Class A common stock and convertible preferred stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails</Role>
      <ShortName>Stock-based compensation - 2018 Stock Option and Grant Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails</Role>
      <ShortName>Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Stock-based compensation - Summary of awards outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails</Role>
      <ShortName>Stock-based compensation - Summary of awards outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Stock-based compensation - Stock option valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails</Role>
      <ShortName>Stock-based compensation - Stock option valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41205 - Disclosure - Stock-based compensation - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-based compensation - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41206 - Disclosure - Stock-based compensation - Common Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails</Role>
      <ShortName>Stock-based compensation - Common Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41207 - Disclosure - Stock-based compensation - Stock-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails</Role>
      <ShortName>Stock-based compensation - Stock-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Income taxes - Losses before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails</Role>
      <ShortName>Income taxes - Losses before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Income taxes - components of the consolidated income tax provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails</Role>
      <ShortName>Income taxes - components of the consolidated income tax provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Income taxes - Effective income tax reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails</Role>
      <ShortName>Income taxes - Effective income tax reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41304 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails</Role>
      <ShortName>Income taxes - Components of the net deferred tax assets or liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41305 - Disclosure - Income taxes - Changes in the valuation allowance for deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsDetails</Role>
      <ShortName>Income taxes - Changes in the valuation allowance for deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41306 - Disclosure - Income taxes -Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income taxes -Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Commitments and contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41501 - Disclosure - 401(k) Savings Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails</Role>
      <ShortName>401(k) Savings Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/Disclosure401KSavingsPlan</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Net loss per share - Antidilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net loss per share - Antidilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureRelatedParties</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.hookipapharma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="hook-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost in us-gaap/2023 used in 1 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. hook-20231231x10k.htm 186</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 14 fact(s) appearing in ix:hidden were eligible for transformation: hook:FairValueAssetsLevel1ToLevel2TransfersAmount1, hook:FairValueAssetsLevel2ToLevel1TransfersAmount1, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion, us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3, us-gaap:PreferredStockSharesIssued -  hook-20231231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 4 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies, us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList -  hook-20231231x10k.htm 9</Log>
    <Log type="Warning">[dq-0712-Presentation-Base-Set-Order] Role '41801 - Disclosure - Subsequent events (Details)', a level 4, Detail role, appears before '995410 - Disclosure - Pay vs Performance Disclosure', a level 1, Note role. hook-20231231.xsd 267, https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd 30</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent has a value of -0.023 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent fact are: Context: Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q, Unit: Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA, Rule Element Id: 9793. hook-20231231x10k.htm 189</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent has a value of -0.014 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent fact are: Context: Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw, Unit: Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA, Rule Element Id: 9793. hook-20231231x10k.htm 189</Log>
  </Logs>
  <InputFiles>
    <File>hook-20231231.xsd</File>
    <File>hook-20231231_cal.xml</File>
    <File>hook-20231231_def.xml</File>
    <File>hook-20231231_lab.xml</File>
    <File>hook-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="hook-20231231x10k.htm">hook-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>hook-20231231x10k001.jpg</File>
    <File>hook-20231231x10k002.jpg</File>
    <File>hook-20231231x10k003.jpg</File>
    <File>hook-20231231x10k004.jpg</File>
    <File>hook-20231231x10k005.jpg</File>
    <File>hook-20231231x10k006.jpg</File>
    <File>hook-20231231x10k007.jpg</File>
    <File>hook-20231231x10k008.jpg</File>
    <File>hook-20231231x10k009.jpg</File>
    <File>hook-20231231x10k010.jpg</File>
    <File>hook-20231231x10k011.jpg</File>
    <File>hook-20231231x10k012.jpg</File>
    <File>hook-20231231x10k013.jpg</File>
    <File>hook-20231231x10k014.jpg</File>
    <File>hook-20231231x10k015.jpg</File>
    <File>hook-20231231x10k016.jpg</File>
    <File>hook-20231231x10k017.jpg</File>
    <File>hook-20231231x10k018.jpg</File>
    <File>hook-20231231x10k019.jpg</File>
    <File>hook-20231231x10k020.jpg</File>
    <File>hook-20231231x10k021.jpg</File>
    <File>hook-20231231x10k022.jpg</File>
    <File>hook-20231231x10k023.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="799">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>119
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "hook-20231231x10k.htm": {
   "nsprefix": "hook",
   "nsuri": "http://www.hookipapharma.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "hook-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "hook-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "hook-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "hook-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hook-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "hook-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 299,
   "keyCustom": 95,
   "axisStandard": 26,
   "axisCustom": 2,
   "memberStandard": 30,
   "memberCustom": 30,
   "hidden": {
    "total": 22,
    "http://fasb.org/us-gaap/2023": 17,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://www.hookipapharma.com/20231231": 2
   },
   "contextCount": 239,
   "entityCount": 1,
   "segmentCount": 60,
   "elementCount": 682,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 799,
    "http://xbrl.sec.gov/dei/2023": 40,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_7Ko22T84I06Il1nncKM6WQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_7Ko22T84I06Il1nncKM6WQ",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "As_Of_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_ob0J9wZKyk2iJVWb7ieH0A",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_Xcsey5dkJECXYtbLisOkXA",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization",
     "longName": "10101 - Disclosure - Nature of the business and organization",
     "shortName": "Nature of the business and organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "10201 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements",
     "longName": "10301 - Disclosure - Collaboration and Licensing Agreements",
     "shortName": "Collaboration and Licensing Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.hookipapharma.com/role/DisclosureImpairment",
     "longName": "10401 - Disclosure - Impairment",
     "shortName": "Impairment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets",
     "longName": "10501 - Disclosure - Fair Value of Financial Assets",
     "shortName": "Fair Value of Financial Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet",
     "longName": "10601 - Disclosure - Property, plant and equipment, net",
     "shortName": "Property, plant and equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive",
     "longName": "10701 - Disclosure - Receivable research incentive",
     "shortName": "Receivable research incentive",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:ReceivableResearchIncentiveTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:ReceivableResearchIncentiveTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.hookipapharma.com/role/DisclosureLeases",
     "longName": "10801 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "10901 - Disclosure - Accrued expenses and other current liabilities",
     "shortName": "Accrued expenses and other current liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.hookipapharma.com/role/DisclosureLoansPayable",
     "longName": "11001 - Disclosure - Loans payable",
     "shortName": "Loans payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:DisclosureOfLongTermLoansPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:DisclosureOfLongTermLoansPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock",
     "longName": "11101 - Disclosure - Common stock, Class A common stock and convertible preferred stock",
     "shortName": "Common stock, Class A common stock and convertible preferred stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation",
     "longName": "11201 - Disclosure - Stock-based compensation",
     "shortName": "Stock-based compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxes",
     "longName": "11301 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "11401 - Disclosure - Commitments and contingencies",
     "shortName": "Commitments and contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.hookipapharma.com/role/Disclosure401KSavingsPlan",
     "longName": "11501 - Disclosure - 401(k) Savings Plan",
     "shortName": "401(k) Savings Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShare",
     "longName": "11601 - Disclosure - Net loss per share",
     "shortName": "Net loss per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.hookipapharma.com/role/DisclosureRelatedParties",
     "longName": "11701 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.hookipapharma.com/role/DisclosureSubsequentEvents",
     "longName": "11801 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20202 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "30203 - Disclosure - Summary of significant accounting policies (Tables)",
     "shortName": "Summary of significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.hookipapharma.com/role/DisclosureImpairmentTables",
     "longName": "30403 - Disclosure - Impairment (Tables)",
     "shortName": "Impairment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables",
     "longName": "30503 - Disclosure - Fair Value of Financial Assets (Tables)",
     "shortName": "Fair Value of Financial Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables",
     "longName": "30603 - Disclosure - Property, plant and equipment, net (Tables)",
     "shortName": "Property, plant and equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesTables",
     "longName": "30803 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "hook:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "hook:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "30903 - Disclosure - Accrued expenses and other current liabilities (Tables)",
     "shortName": "Accrued expenses and other current liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.hookipapharma.com/role/DisclosureLoansPayableTables",
     "longName": "31003 - Disclosure - Loans payable (Tables)",
     "shortName": "Loans payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:DisclosureOfLongTermLoansPayableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "hook:DisclosureOfLongTermLoansPayableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:DisclosureOfLongTermLoansPayableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "hook:DisclosureOfLongTermLoansPayableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables",
     "longName": "31203 - Disclosure - Stock-based compensation (Tables)",
     "shortName": "Stock-based compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables",
     "longName": "31303 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables",
     "longName": "31603 - Disclosure - Net loss per share (Tables)",
     "shortName": "Net loss per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails",
     "longName": "40201 - Disclosure - Summary of significant accounting policies - Going concern (Details)",
     "shortName": "Summary of significant accounting policies - Going concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)",
     "shortName": "Summary of significant accounting policies - Property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Kkn9Mty5DUurhtItxm046g",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Kkn9Mty5DUurhtItxm046g",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails",
     "longName": "40203 - Disclosure - Summary of significant accounting policies - Others (Details)",
     "shortName": "Summary of significant accounting policies - Others (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:CapitalizedComputerSoftwareAmortization1",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:CapitalizedComputerSoftwareAmortization1",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:CapitalizedComputerSoftwareAmortization1",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:CapitalizedComputerSoftwareAmortization1",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails",
     "longName": "40204 - Disclosure - Summary of significant accounting policies - Comprehensive loss (Details)",
     "shortName": "Summary of significant accounting policies - Comprehensive loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
     "longName": "40301 - Disclosure - Collaboration and Licensing Agreements (Details)",
     "shortName": "Collaboration and Licensing Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA",
      "name": "hook:NumberOfPreclinicalResearchPrograms",
      "unitRef": "Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
     "longName": "40401 - Disclosure - Impairment - Additional information (Details)",
     "shortName": "Impairment - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.hookipapharma.com/role/DisclosureImpairmentNonCashImpairmentChargesDetails",
     "longName": "40402 - Disclosure - Impairment - Non-cash impairment charges (Details)",
     "shortName": "Impairment - Non-cash impairment charges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails",
     "longName": "40501 - Disclosure - Fair Value of Financial Assets (Details)",
     "shortName": "Fair Value of Financial Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
     "longName": "40601 - Disclosure - Property, plant and equipment, net (Details)",
     "shortName": "Property, plant and equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails",
     "longName": "40701 - Disclosure - Receivable research incentive (Details)",
     "shortName": "Receivable research incentive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:GrantIncomeIncentiveProgram",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:GrantIncomeIncentiveProgram",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
     "longName": "40801 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_t2LLWZ24bUKTQiMbE7AcJw",
      "name": "hook:LesseeLeaseRemainingTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "hook:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
     "longName": "40802 - Disclosure - Leases - Lease costs (Details)",
     "shortName": "Leases - Lease costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:LeaseCost",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "hook:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:LeaseCost",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "hook:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails",
     "longName": "40803 - Disclosure - Leases - Minimum lease payments (Details)",
     "shortName": "Leases - Minimum lease payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails",
     "longName": "40804 - Disclosure - Leases - Weighted average remaining lease term and weighted average discount rate (Details)",
     "shortName": "Leases - Weighted average remaining lease term and weighted average discount rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "40901 - Disclosure - Accrued expenses and other current liabilities (Details)",
     "shortName": "Accrued expenses and other current liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
     "longName": "41001 - Disclosure - Loans payable (Details)",
     "shortName": "Loans payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "hook:LongTermLoansPayableGross",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:DisclosureOfLongTermLoansPayableTableTextBlock",
       "hook:DisclosureOfLongTermLoansPayableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "hook:LongTermLoansPayableGross",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "hook:DisclosureOfLongTermLoansPayableTableTextBlock",
       "hook:DisclosureOfLongTermLoansPayableTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails",
     "longName": "41002 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)",
     "shortName": "Loans payable - Schedule of aggregate minimum future principal payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
     "longName": "41101 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)",
     "shortName": "Common stock, Class A common stock and convertible preferred stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_5_2023_To_6_5_2023_HDaSSSxSpUCGD9FJbOAwcw",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
     "longName": "41201 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)",
     "shortName": "Stock-based compensation - 2018 Stock Option and Grant Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_ioKeOQv4MEC7RRwFd806mw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
     "longName": "41202 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)",
     "shortName": "Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails",
     "longName": "41203 - Disclosure - Stock-based compensation - Summary of awards outstanding (Details)",
     "shortName": "Stock-based compensation - Summary of awards outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_vsxwLcmVd0qxvZfveKo1qw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails",
     "longName": "41204 - Disclosure - Stock-based compensation - Stock option valuation (Details)",
     "shortName": "Stock-based compensation - Stock option valuation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "longName": "41205 - Disclosure - Stock-based compensation - Stock option activity (Details)",
     "shortName": "Stock-based compensation - Stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
     "longName": "41206 - Disclosure - Stock-based compensation - Common Stock Awards (Details)",
     "shortName": "Stock-based compensation - Common Stock Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BcR8oItz_UOIQXNtcPyaQQ",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BcR8oItz_UOIQXNtcPyaQQ",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
     "longName": "41207 - Disclosure - Stock-based compensation - Stock-based compensation (Details)",
     "shortName": "Stock-based compensation - Stock-based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails",
     "longName": "41301 - Disclosure - Income taxes - Losses before income taxes (Details)",
     "shortName": "Income taxes - Losses before income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
       "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
       "hook:IncomeTaxBenefitsNetOperatingLossesIncurred",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails",
     "longName": "41302 - Disclosure - Income taxes - components of the consolidated income tax provision (Details)",
     "shortName": "Income taxes - components of the consolidated income tax provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails",
     "longName": "41303 - Disclosure - Income taxes - Effective income tax reconciliation (Details)",
     "shortName": "Income taxes - Effective income tax reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails",
     "longName": "41304 - Disclosure - Income taxes - Components of the net deferred tax assets or liabilities (Details)",
     "shortName": "Income taxes - Components of the net deferred tax assets or liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsDetails",
     "longName": "41305 - Disclosure - Income taxes - Changes in the valuation allowance for deferred tax assets (Details)",
     "shortName": "Income taxes - Changes in the valuation allowance for deferred tax assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "41306 - Disclosure - Income taxes -Additional Information (Details)",
     "shortName": "Income taxes -Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "41401 - Disclosure - Commitments and contingencies (Details)",
     "shortName": "Commitments and contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails",
     "longName": "41501 - Disclosure - 401(k) Savings Plan (Details)",
     "shortName": "401(k) Savings Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
     "longName": "41601 - Disclosure - Net loss per share (Details)",
     "shortName": "Net loss per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
     "longName": "41602 - Disclosure - Net loss per share - Antidilutive securities (Details)",
     "shortName": "Net loss per share - Antidilutive securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails",
     "longName": "41701 - Disclosure - Related Parties (Details)",
     "shortName": "Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_hook_MaltePetersMember_us-gaap_RelatedPartyTransactionAxis_hook_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_PWdmVxfZlkStxnW1wmGGow",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_hook_MaltePetersMember_us-gaap_RelatedPartyTransactionAxis_hook_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_PWdmVxfZlkStxnW1wmGGow",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
     "longName": "41801 - Disclosure - Subsequent events (Details)",
     "shortName": "Subsequent events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_employee_JIvkuNcm3UeH8NvB6ulLsQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "75",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hook-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "country_AT": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AT",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Austria"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of significant accounting policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r690"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Salaries and bonuses",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "hook_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current.",
        "label": "Accrued Expenses and Other Current Liabilities.",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "hook_AccruedExpensesForPropertyAndEquipmentAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AccruedExpensesForPropertyAndEquipmentAcquisitions",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of balance sheet date of accrued expenses for property and equipment acquisitions.",
        "label": "Accrued Expenses for Property and Equipment Acquisitions",
        "terseLabel": "Accrued for property and equipment acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "hook_AccruedExternalGeneralAndAdministrationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AccruedExternalGeneralAndAdministrationExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of balance sheet date of accrued external general and administration expenses.",
        "label": "Accrued External General and Administration Expenses",
        "terseLabel": "Accrued external general and administration expenses"
       }
      }
     },
     "auth_ref": []
    },
    "hook_AccruedExternalResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AccruedExternalResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of balance sheet date of accrued external research and development expenses.",
        "label": "Accrued External Research and Development Expenses",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r127"
     ]
    },
    "hook_AccruedSocialSecurityContributionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AccruedSocialSecurityContributionsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the social security contributions.",
        "label": "Accrued Social Security Contributions, Current",
        "terseLabel": "Social security contributions"
       }
      }
     },
     "auth_ref": []
    },
    "hook_AccruedSubLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AccruedSubLicenseFees",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued sub license fees at the balance sheet date.",
        "label": "Accrued Sub License Fees",
        "terseLabel": "Sublicense fees"
       }
      }
     },
     "auth_ref": []
    },
    "hook_AccruedUnearnedGrantIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AccruedUnearnedGrantIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of accrued unearned grant income (current).",
        "label": "Accrued Unearned Grant Income , Current",
        "terseLabel": "Unearned grant income (current)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r171",
      "r523"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r93",
      "r177",
      "r519",
      "r542",
      "r543"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14",
      "r34",
      "r436",
      "r439",
      "r480",
      "r538",
      "r539",
      "r792",
      "r793",
      "r794",
      "r804",
      "r805",
      "r806"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r690",
      "r876"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r556",
      "r804",
      "r805",
      "r806",
      "r856",
      "r878"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase decrease to additional paid in capital due to at the market issuance cost.",
        "label": "Adjustments to Additional Paid in Capital, At the Market Issuance Cost",
        "negatedLabel": "ATM costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r360"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Issuance costs",
        "verboseLabel": "Issuance costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r117"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r725",
      "r735",
      "r761"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r728",
      "r738",
      "r764"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r729",
      "r739",
      "r756",
      "r765",
      "r769",
      "r777"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r397"
     ]
    },
    "hook_AmendedStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AmendedStockPurchaseAgreementMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to amended stock purchase agreement.",
        "label": "Amended Stock Purchase Agreement [Member]",
        "terseLabel": "Amended Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r101",
      "r303"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r173",
      "r198",
      "r235",
      "r250",
      "r254",
      "r262",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r429",
      "r433",
      "r453",
      "r515",
      "r593",
      "r690",
      "r703",
      "r816",
      "r817",
      "r863"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r178",
      "r198",
      "r262",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r429",
      "r433",
      "r453",
      "r690",
      "r816",
      "r817",
      "r863"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r262",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r429",
      "r433",
      "r453",
      "r816",
      "r817",
      "r863"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r721"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r721"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r721"
     ]
    },
    "hook_AustrianResearchIncentiveProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "AustrianResearchIncentiveProgramMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Austrian research incentive program.",
        "label": "Austrian Research Incentive Program [Member]",
        "terseLabel": "Austrian Research Incentive Program"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "negatedLabel": "Property and equipment additions in accounts payable and accrued expenses",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Amortization expense",
        "documentation": "Amount of expense for amortization of capitalized computer software costs."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r134"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r169",
      "r664"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r104",
      "r195"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r104"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r174",
      "r175",
      "r176",
      "r198",
      "r222",
      "r223",
      "r225",
      "r227",
      "r233",
      "r234",
      "r262",
      "r279",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r308",
      "r309",
      "r313",
      "r316",
      "r323",
      "r453",
      "r546",
      "r547",
      "r548",
      "r549",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r581",
      "r602",
      "r625",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r785",
      "r798",
      "r807"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "hook_CollaborationAgreementFinalMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborationAgreementFinalMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of final milestone payment the Company remains eligible, under the collaboration agreement.",
        "label": "Collaboration Agreement, Final Milestone Payment",
        "terseLabel": "Final milestone payment the Company remains eligible"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborationAgreementMilestonePaymentsRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborationAgreementMilestonePaymentsRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments revenue recognized under the collaboration agreement.",
        "label": "Collaboration Agreement, Milestone Payments, Revenue Recognized",
        "terseLabel": "Revenue recognized from milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborationArrangementProgramCompletionFeeOnOptionExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborationArrangementProgramCompletionFeeOnOptionExercise",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of program completion fee on exercise of option under collaboration arrangement.",
        "label": "Collaboration Arrangement, Program Completion Fee on Option Exercise",
        "terseLabel": "program completion fee"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborativeAgreementProgramInitiationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborativeAgreementProgramInitiationFees",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses relating to program initiation fees under collaborative agreement.",
        "label": "Collaborative Agreement, Program Initiation Fees",
        "terseLabel": "Program initiation fee"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborativeAndLicensingArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborativeAndLicensingArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Collaboration and Licensing Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborativeArrangementContractAssetRelatingToSublicensePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contract assets relating to sublicense payment.",
        "label": "Collaborative Arrangement, Contract Asset Relating to Sublicense Payment",
        "terseLabel": "Contract asset relating to the sublicense payment"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborativeArrangementContractLiabilityRelatingToSublicensePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborativeArrangementContractLiabilityRelatingToSublicensePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contract liability relating to sublicense payment.",
        "label": "Collaborative Arrangement, Contract Liability Relating to Sublicense Payment",
        "terseLabel": "Contract liability relating to sublicense payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and Licensing Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r141",
      "r152"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gilead Collaboration and License Agreement",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborativeArrangementNumberOfPreclinicalResearchPrograms",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of preclinical research programs in collaborative arrangement.",
        "label": "Collaborative Arrangement, Number of Preclinical Research Programs",
        "terseLabel": "Number of preclinical research programs"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue from cost reimbursements for preparation of first human trial.",
        "label": "Collaborative Arrangement Revenue From Cost Reimbursements For Preparation of First Human Trial",
        "terseLabel": "Collaborative arrangement revenue from cost reimbursements for preparation of first human trial"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue from cost reimbursements for research and development services.",
        "label": "Collaborative Arrangement, Revenue from Cost Reimbursements for Research and Development Services",
        "terseLabel": "Revenue recognized from cost reimbursements for research and development services"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborativeArrangementRevenueFromMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborativeArrangementRevenueFromMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue from milestone payments for milestones achieved.",
        "label": "Collaborative Arrangement, Revenue from Milestone Payments",
        "terseLabel": "Revenue recognized from milestone payments for milestones achieved"
       }
      }
     },
     "auth_ref": []
    },
    "hook_CollaborativeArrangementTermOfRoyaltyPayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CollaborativeArrangementTermOfRoyaltyPayment",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term for royalty payment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Collaborative Arrangement, Term of Royalty Payment",
        "terseLabel": "Payment term (in days)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaboration and Licensing Agreements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "hook_CommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CommercialMilestonesMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to commercial milestones.",
        "label": "Commercial Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 14)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r75",
      "r516",
      "r580"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r273",
      "r274",
      "r649",
      "r813"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A common stock",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r700",
      "r804",
      "r805",
      "r856",
      "r874",
      "r878"
     ]
    },
    "hook_CommonStockOtherThanClassMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "CommonStockOtherThanClassMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock other than Class A common stock.",
        "label": "Common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r581"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Common stock, issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Common stock, outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r87",
      "r581",
      "r599",
      "r878",
      "r879"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r518",
      "r690"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) Savings Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r180",
      "r182",
      "r188",
      "r511",
      "r528"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "hook_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer equipment and software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk and of significant suppliers",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r143"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in progress",
        "terseLabel": "Asset under construction",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "hook_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the consulting agreement about the Company's clinical activities.",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "terseLabel": "Liability in deferred revenues",
        "verboseLabel": "Deferred income",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r337"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r337"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r337"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "terseLabel": "Non-cancellable obligations",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, Due in Next Fiscal Year",
        "terseLabel": "2024 deliverables",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, Due in Second Year",
        "terseLabel": "2025 deliverables",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of aggregate minimum future principal payments due in connection with the FFG Loans",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "hook_ConversionOfCommonStockSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ConversionOfCommonStockSharesIssuable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of common stock.",
        "label": "Conversion of Common Stock, Shares Issuable",
        "terseLabel": "Number of common shares issuable upon conversion of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ConversionOfCommonStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ConversionOfCommonStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of common stock that is converted.",
        "label": "Conversion of Common Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of shares issued for each share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of Class A common stock to common stock",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "hook_ConversionOfStockCommonStockIssuedForEachShareConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ConversionOfStockCommonStockIssuedForEachShareConverted",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new common stock issued in the conversion of each stock.",
        "label": "Conversion of Stock, Common Stock Issued for Each Share Converted",
        "terseLabel": "Number of common stock issued upon conversion of each share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Number of shares elected to convert",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "verboseLabel": "Conversion of Class A common stock to common stock (in shares)",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of common stock issued upon conversion of each share of Preferred Stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r54",
      "r86",
      "r115",
      "r319"
     ]
    },
    "hook_ConvertiblePreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ConvertiblePreferredStocksMember",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible preferred stocks.",
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses",
        "negatedTotalLabel": "Total operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r203",
      "r204",
      "r291",
      "r311",
      "r487",
      "r665",
      "r667"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r801",
      "r854"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign (Austria)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r801"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r416",
      "r421",
      "r801"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r801",
      "r854"
     ]
    },
    "hook_DebtInstrumentEstimatedMarketRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DebtInstrumentEstimatedMarketRatePercent",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated market rate under the debt instrument arrangement.",
        "label": "Debt Instrument, Estimated Market Rate Percent",
        "terseLabel": "Estimated market rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r289"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Loans payable",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r464",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r799"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Loans payable",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r54",
      "r56",
      "r69",
      "r70",
      "r72",
      "r76",
      "r114",
      "r116",
      "r205",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r464",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r799"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount",
        "verboseLabel": "Unamortized debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72",
      "r819"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails": {
       "parentTag": "us-gaap_LongTermLoansPayable",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount, Noncurrent",
        "negatedLabel": "Unamortized debt discount",
        "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r128",
      "r410"
     ]
    },
    "hook_DeferredOfferingCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DeferredOfferingCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferred offering costs.",
        "label": "Deferred Offering Costs, Policy [Policy Text Block]",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DeferredRevenuePercentageOfRevenueRecognizedInYearOne",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue recognized in year one that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Percentage of Revenue Recognized in Year One",
        "terseLabel": "Percentage of upfront payment included in deferred revenue expected to be recognized in 2024"
       }
      }
     },
     "auth_ref": []
    },
    "hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DeferredRevenuePercentageOfRevenueRecognizedInYearThree",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue recognized in year three that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Percentage of Revenue Recognized in Year Three",
        "terseLabel": "Percentage of upfront payment included in deferred revenue expected to be recognized in 2026"
       }
      }
     },
     "auth_ref": []
    },
    "hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DeferredRevenuePercentageOfRevenueRecognizedInYearTwo",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue recognized in year two that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Percentage of Revenue Recognized in Year Two",
        "terseLabel": "Percentage of upfront payment included in deferred revenue expected to be recognized in 2025"
       }
      }
     },
     "auth_ref": []
    },
    "hook_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development expenses.",
        "label": "Deferred Tax Assets, Capitalized Research And Development Expenses",
        "terseLabel": "Capitalized R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "hook_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "verboseLabel": "Credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r853"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r853"
     ]
    },
    "hook_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other liabilities.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves and Accruals Accrued Liabilities and Other",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "negatedPeriodEndLabel": "Valuation allowance at end of period",
        "negatedPeriodStartLabel": "Valuation allowance at beginning of period",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "hook_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from fixed assets and intangible assets.",
        "label": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "auth_ref": []
    },
    "hook_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use asset.",
        "label": "Deferred Tax Liabilities Operating Lease Right of Use Asset",
        "negatedLabel": "Operating lease right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsOrLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Accrued expenses and other",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expenses recognized for the 401(k) Plan",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer's Matching contribution to defined contribution savings plan",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Matching contribution to defined contribution savings plan",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r49"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r240"
     ]
    },
    "hook_DevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DevelopmentMilestonesMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to development milestones.",
        "label": "Development Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of directors",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r875"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r362",
      "r390",
      "r391",
      "r393",
      "r685"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "hook_DisclosureOfLongTermLoansPayableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DisclosureOfLongTermLoansPayableTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of loans payable.",
        "label": "Disclosure of Long Term Loans Payable [Table Text block]",
        "terseLabel": "Schedule of loans payable"
       }
      }
     },
     "auth_ref": []
    },
    "hook_DisclosureOfLongTermLoansPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "DisclosureOfLongTermLoansPayableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of loans payable.",
        "label": "Disclosure of Long Term Loans Payable [Text block]",
        "terseLabel": "Loans payable"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r721"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r721",
      "r757"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r220",
      "r222",
      "r225",
      "r226",
      "r227",
      "r231",
      "r443",
      "r444",
      "r512",
      "r529",
      "r668"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r225"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r222",
      "r225",
      "r226",
      "r227",
      "r231",
      "r443",
      "r444",
      "r512",
      "r529",
      "r668"
     ]
    },
    "hook_EarningsPerSharePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "EarningsPerSharePolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for earnings per share.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r228",
      "r229",
      "r230"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "U.S. federal statutory income tax rate",
        "verboseLabel": "Corporate income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r404",
      "r423"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in deferred tax asset valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r855"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedLabel": "Foreign tax rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r855"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Amount",
        "terseLabel": "Global Intangible Low Taxed Income estimated",
        "documentation": "Amount of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "negatedLabel": "Global intangible low-taxed income",
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "negatedLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r855"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r855"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State income taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r855"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent",
        "verboseLabel": "Not taxable government grants",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r855"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted average periods over which expense is expected to be recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to the unvested stock-based awards",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options issued and outstanding",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r165",
      "r184",
      "r185",
      "r186",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r218",
      "r232",
      "r263",
      "r264",
      "r324",
      "r394",
      "r395",
      "r396",
      "r417",
      "r418",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r480",
      "r538",
      "r539",
      "r540",
      "r556",
      "r625"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r725",
      "r735",
      "r761"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r722",
      "r732",
      "r758"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "hook_ExercisePriceLimitConsideredForCancellationOfStockOptions": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ExercisePriceLimitConsideredForCancellationOfStockOptions",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price for cancellation of stock options if exceeds.",
        "label": "Exercise Price Limit Considered For Cancellation Of Stock Options",
        "terseLabel": "Exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value of Financial Assets",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r451"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r451"
     ]
    },
    "hook_FairValueAssetsLevel1ToLevel2TransfersAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount1",
        "terseLabel": "Transfers from Level 1 to Level 2"
       }
      }
     },
     "auth_ref": []
    },
    "hook_FairValueAssetsLevel2ToLevel1TransfersAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount1",
        "terseLabel": "Transfers from Level 2 to Level 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r125"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r447",
      "r492",
      "r493",
      "r494",
      "r674",
      "r675",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r448",
      "r449",
      "r452"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r341",
      "r346",
      "r447",
      "r492",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Transfers from into Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Transfers from out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r492",
      "r493",
      "r494",
      "r674",
      "r675",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r452"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on finance lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r472",
      "r689"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments related to finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r475"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease amortization expenses",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r472",
      "r689"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency and currency translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r729",
      "r739",
      "r765"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r729",
      "r739",
      "r765"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r729",
      "r739",
      "r765"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r729",
      "r739",
      "r765"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r729",
      "r739",
      "r765"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense.",
        "negatedLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r604"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "hook_GileadSciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "GileadSciencesIncMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining Gilead Sciences, Inc.",
        "label": "Gilead"
       }
      }
     },
     "auth_ref": []
    },
    "hook_GoingConcernPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "GoingConcernPolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for going concern.",
        "label": "Going Concern, Policy [Policy Text Block]",
        "terseLabel": "Going concern"
       }
      }
     },
     "auth_ref": []
    },
    "hook_GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government grant agreements and research incentives.",
        "label": "Government Grant Agreements and Research Incentives, Policy [Policy Text Block]",
        "terseLabel": "Government grant agreements and research incentives"
       }
      }
     },
     "auth_ref": []
    },
    "hook_GrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "GrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant income.",
        "label": "Grant Income",
        "terseLabel": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "hook_GrantIncomeIncentiveProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "GrantIncomeIncentiveProgram",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant income recognized related to the incentive program during the reporting period.",
        "label": "Grant Income, Incentive Program",
        "terseLabel": "Income related to the incentive program recorded as grant income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrantMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant",
        "documentation": "Award of money not required to be repaid."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "hook_HbvProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "HbvProgramMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HBV program.",
        "label": "HBV program"
       }
      }
     },
     "auth_ref": []
    },
    "hook_HivProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "HivProgramMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV program.",
        "label": "HIV program"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r721"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentNonCashImpairmentChargesDetails",
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "negatedLabel": "Non-cash impairment charges",
        "negatedTerseLabel": "Impairment expense",
        "terseLabel": "Impairment charges of assets",
        "verboseLabel": "Impairment expense",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r110"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r422"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before tax",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r94",
      "r131",
      "r235",
      "r249",
      "r253",
      "r255",
      "r513",
      "r525",
      "r670"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign (Austria)",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r422"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r268",
      "r609"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r609"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "hook_IncomeTaxBenefitsNetOperatingLossesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "IncomeTaxBenefitsNetOperatingLossesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesLossesBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax benefits recorded for the net operating losses incurred.",
        "label": "Income Tax benefits, Net Operating Losses Incurred",
        "terseLabel": "Income tax benefits for the net operating losses incurred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r400",
      "r405",
      "r407",
      "r414",
      "r419",
      "r424",
      "r425",
      "r426",
      "r551"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesComponentsOfConsolidatedIncomeTaxProvisionDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Total income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r149",
      "r217",
      "r218",
      "r241",
      "r403",
      "r420",
      "r530"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r401",
      "r402",
      "r407",
      "r408",
      "r413",
      "r415",
      "r545"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "negatedLabel": "Cash paid for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other liabilities.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r796"
     ]
    },
    "hook_IncreaseDecreaseInEstimatedMarketRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "IncreaseDecreaseInEstimatedMarketRate",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in estimated market rate",
        "label": "Increase Decrease in Estimated Market Rate",
        "terseLabel": "Threshold for change in estimated market rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r796"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and other current assets.",
        "label": "Increase (Decrease) in Prepaid Expenses and Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "hook_IncreaseDecreaseInReceivableResearchIncentives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "IncreaseDecreaseInReceivableResearchIncentives",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount of receivable research incentives.",
        "label": "Increase (Decrease) in Receivable Research Incentives",
        "negatedLabel": "Receivable research incentives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r729",
      "r739",
      "r756",
      "r765",
      "r769",
      "r777"
     ]
    },
    "hook_InducementAwardsPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "InducementAwardsPlanMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to inducement awards plan.",
        "label": "Inducement Awards Plan [Member]",
        "terseLabel": "Inducement Awards"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r781"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r781"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r781"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r133",
      "r187",
      "r239",
      "r463",
      "r610",
      "r701",
      "r877"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r301",
      "r306",
      "r676",
      "r677"
     ]
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expenses",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r193",
      "r194"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r238"
     ]
    },
    "hook_January2024RestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "January2024RestructuringPlanMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 2024 Restructuring Plan",
        "label": "January 2024 Restructuring Plan [Member]",
        "terseLabel": "January 2024 Restructuring Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "hook_LeaseAssetsDerecognizedUponLeaseCancellation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "LeaseAssetsDerecognizedUponLeaseCancellation",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of right of use assets derecognized upon lease cancellation.",
        "label": "Lease Assets Derecognized Upon Lease Cancellation",
        "terseLabel": "Lease assets derecognized upon lease cancellation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Net lease expenses",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r689"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of the effect of lease costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "hook_LeaseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "LeaseDisclosureTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "hook_LeaseForCertainParkingSpacesInViennaOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "LeaseForCertainParkingSpacesInViennaOfficeMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to lease for certain parking spaces in Vienna Office.",
        "label": "Lease for Certain Parking Spaces in Vienna Office [Member]",
        "terseLabel": "Lease for Certain Parking Spaces in Vienna Office"
       }
      }
     },
     "auth_ref": []
    },
    "hook_LeaseForCorporateHeadquartersInNewYorkCityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "LeaseForCorporateHeadquartersInNewYorkCityMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to lease for corporate headquarters in New York.",
        "label": "Lease for Corporate Headquarters in New York City [Member]",
        "terseLabel": "lease for corporate headquarters in New York City"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Leases for Office and Laboratory Space in Vienna, Austria.",
        "label": "Leases for Office and Laboratory Space in Vienna, Austria [Member]",
        "terseLabel": "Leases for Office and Laboratory Space in Vienna, Austria"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "hook_LesseeLeaseRemainingTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "LesseeLeaseRemainingTermOfContract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Lease, Remaining Term of Contract",
        "terseLabel": "Remaining lease term (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of operating lease liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "verboseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease,",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r198",
      "r262",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r430",
      "r433",
      "r434",
      "r453",
      "r579",
      "r669",
      "r703",
      "r816",
      "r863",
      "r864"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r130",
      "r521",
      "r690",
      "r800",
      "r811",
      "r857"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r168",
      "r198",
      "r262",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r430",
      "r433",
      "r434",
      "r453",
      "r690",
      "r816",
      "r863",
      "r864"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r79",
      "r80",
      "r81",
      "r83",
      "r198",
      "r262",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r430",
      "r433",
      "r434",
      "r453",
      "r816",
      "r863",
      "r864"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "hook_LicensingFeesIntellectualPropertyLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "LicensingFeesIntellectualPropertyLicenses",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of licensing fees from intellectual property licenses.",
        "label": "Licensing fees, Intellectual Property Licenses",
        "terseLabel": "Licensing fees from intellectual property licenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable.",
        "terseLabel": "Loans payable, non-current",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r129",
      "r872"
     ]
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Current",
        "terseLabel": "Loans payable, current",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt",
        "totalLabel": "Total",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r129",
      "r295",
      "r305",
      "r674",
      "r675",
      "r872"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2024",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r205",
      "r299"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable, Noncurrent",
        "totalLabel": "Total loans payable, net",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_LongTermLoansPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLoansPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans payable"
       }
      }
     },
     "auth_ref": []
    },
    "hook_LongTermLoansPayableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "LongTermLoansPayableGross",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails": {
       "parentTag": "us-gaap_LongTermLoansPayable",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loans payable, gross.",
        "label": "Long Term Loans Payable, Gross",
        "terseLabel": "Loans from FFG"
       }
      }
     },
     "auth_ref": []
    },
    "hook_MaltePetersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "MaltePetersMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Dr. Malte Peters, a member of the Company's board of directors.",
        "label": "Malte Peters [Member]",
        "terseLabel": "Malte Peters"
       }
      }
     },
     "auth_ref": []
    },
    "hook_MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum expenses eligible for incentives in Biotechnology field per year.",
        "label": "Maximum Expenses Eligible for Incentive in Biotechnology Field Per Year",
        "terseLabel": "Maximum expenses eligible for incentives"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r357",
      "r496",
      "r537",
      "r571",
      "r572",
      "r633",
      "r635",
      "r637",
      "r638",
      "r640",
      "r659",
      "r660",
      "r672",
      "r678",
      "r684",
      "r692",
      "r818",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "hook_MilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "MilestoneAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by characteristics of milestone payments recognized under the milestone method by arrangement.",
        "label": "Milestone [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "hook_MilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "MilestoneDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of milestones that an entity engage.",
        "label": "Milestone [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r357",
      "r496",
      "r537",
      "r571",
      "r572",
      "r633",
      "r635",
      "r637",
      "r638",
      "r640",
      "r659",
      "r660",
      "r672",
      "r678",
      "r684",
      "r692",
      "r818",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of the business and organization",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net losses",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r106",
      "r132",
      "r166",
      "r179",
      "r181",
      "r186",
      "r198",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r224",
      "r235",
      "r249",
      "r253",
      "r255",
      "r262",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r444",
      "r453",
      "r527",
      "r601",
      "r623",
      "r624",
      "r670",
      "r701",
      "r816"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to New York State life sciences research and development program.",
        "label": "New York State Life Sciences Research and Development Program [Member]",
        "terseLabel": "New York State Life Sciences Research and Development Program"
       }
      }
     },
     "auth_ref": []
    },
    "hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to New York State \nNew York City Biotechnology Tax Credit Program  [Member]",
        "label": "New York State New York City Biotechnology Tax Credit Program [Member]",
        "terseLabel": "New York State New York City Biotechnology Tax Credit Program"
       }
      }
     },
     "auth_ref": []
    },
    "hook_NonExecutiveDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NonExecutiveDirectorsMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to non executive directors.",
        "label": "Non Executive Directors"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r729",
      "r739",
      "r756",
      "r765"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "hook_NonRule10b51ArrangementModified": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NonRule10b51ArrangementModified",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "hook_NumberOfCombinedPerformanceObligation": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NumberOfCombinedPerformanceObligation",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of combined performance obligation under collaboration agreement.",
        "label": "Number of Combined Performance Obligation",
        "terseLabel": "Number of Combined Performance Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "hook_NumberOfCombinedPerformanceObligationForEachResearchProgram": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NumberOfCombinedPerformanceObligationForEachResearchProgram",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of combined performance obligation for each research program.",
        "label": "Number of Combined Performance Obligation for Each Research Program",
        "terseLabel": "Number of combined performance obligation for each research program"
       }
      }
     },
     "auth_ref": []
    },
    "hook_NumberOfEligibleParticipants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NumberOfEligibleParticipants",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of eligible participants.",
        "label": "Number of Eligible Participants",
        "terseLabel": "Eligible participants"
       }
      }
     },
     "auth_ref": []
    },
    "hook_NumberOfPreclinicalResearchPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NumberOfPreclinicalResearchPrograms",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of preclinical research programs.",
        "label": "Number of Preclinical Research Programs",
        "terseLabel": "Number of preclinical research programs"
       }
      }
     },
     "auth_ref": []
    },
    "hook_NumberOfResearchProgramPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NumberOfResearchProgramPerformanceObligations",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of research program performance obligations.",
        "label": "Number of Research Program Performance Obligations",
        "terseLabel": "Number of research program performance obligations"
       }
      }
     },
     "auth_ref": []
    },
    "hook_NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares cancelled those will be issued upon exercise of stock options.",
        "label": "Number of Shares to be Issued Upon Exercise of Stock Options Cancelled",
        "terseLabel": "Exercise of stock options cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "hook_NumberOfVotes": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "NumberOfVotes",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of votes for each share held .",
        "label": "Number of Votes",
        "terseLabel": "Number of votes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r249",
      "r253",
      "r255",
      "r670"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expenses",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r689"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r689"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, Weighted average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r689"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the business and organization"
       }
      }
     },
     "auth_ref": []
    },
    "hook_OtherAccruedExpensesAndLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "OtherAccruedExpensesAndLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of other accruals and liabilities.",
        "label": "Other Accrued Expenses and Liabilities, Current",
        "terseLabel": "Other accruals and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesComprehensiveLossDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment, net of tax",
        "verboseLabel": "Foreign currency translation (loss) gain, net of tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r13",
      "r124"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income and (expenses), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r727",
      "r737",
      "r763"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r730",
      "r740",
      "r766"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r730",
      "r740",
      "r766"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Financing and Stock Issuance Costs",
        "negatedLabel": "Payments for deferred offering costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "401(k) Savings Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r683"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "hook_PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of options accepted for cancellation on total shares of common stock underlying all of the eligible options.",
        "label": "Percentage of Options Accepted for Cancellation on Total Shares Underlying Eligible Options",
        "terseLabel": "Percentage of options accepted for cancellation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "terseLabel": "Number of common stock issuable upon conversion of convertible preferred stock",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r86",
      "r798",
      "r820"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r308"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r581"
     ]
    },
    "hook_PreferredStockSharesDesignated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "PreferredStockSharesDesignated",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares designated as preferred shares",
        "label": "Preferred stock shares Designated",
        "terseLabel": "Preferred stock shares designated (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r308"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r581",
      "r599",
      "r878",
      "r879"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred Stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r517",
      "r690"
     ]
    },
    "hook_PrepaidExpensesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs and other other current assets.",
        "label": "Prepaid Expenses and Other Current Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "verboseLabel": "Net proceeds from public offering",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r546"
     ]
    },
    "hook_ProceedsFromMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ProceedsFromMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount received from milestone payment.",
        "label": "Proceeds From Milestone Payment",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ProceedsFromNonRefundableUpFrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ProceedsFromNonRefundableUpFrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from non-refundable upfront payment.",
        "label": "Proceeds from Non-Refundable, Up-front Payment",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from option exercise under share-based payment arrangements",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r18"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r498",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r662",
      "r679",
      "r691",
      "r788",
      "r814",
      "r815",
      "r821",
      "r873"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r498",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r662",
      "r679",
      "r691",
      "r788",
      "r814",
      "r815",
      "r821",
      "r873"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r179",
      "r181",
      "r191",
      "r198",
      "r209",
      "r217",
      "r218",
      "r235",
      "r249",
      "r253",
      "r255",
      "r262",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r428",
      "r431",
      "r432",
      "r444",
      "r453",
      "r513",
      "r526",
      "r555",
      "r601",
      "r623",
      "r624",
      "r670",
      "r687",
      "r688",
      "r702",
      "r794",
      "r816"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, plant and equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r144",
      "r147",
      "r148"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r170",
      "r524"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r514",
      "r524",
      "r690"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r144",
      "r147",
      "r522"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life (in years)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "hook_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock by a private company to the public.",
        "label": "Public offering",
        "terseLabel": "Public offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r339",
      "r357",
      "r385",
      "r386",
      "r387",
      "r495",
      "r496",
      "r537",
      "r571",
      "r572",
      "r633",
      "r635",
      "r637",
      "r638",
      "r640",
      "r659",
      "r660",
      "r672",
      "r678",
      "r684",
      "r692",
      "r695",
      "r812",
      "r818",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.hookipapharma.com/role/Disclosure401KSavingsPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r339",
      "r357",
      "r385",
      "r386",
      "r387",
      "r495",
      "r496",
      "r537",
      "r571",
      "r572",
      "r633",
      "r635",
      "r637",
      "r638",
      "r640",
      "r659",
      "r660",
      "r672",
      "r678",
      "r684",
      "r692",
      "r695",
      "r812",
      "r818",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "hook_ReceivableResearchIncentiveAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ReceivableResearchIncentiveAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a.",
        "label": "Receivable research incentive"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ReceivableResearchIncentiveTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ReceivableResearchIncentiveTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for receivable research incentive.",
        "label": "Receivable Research Incentive [Text Block]",
        "terseLabel": "Receivable research incentive"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ReceivablesTaxResearchPremiumCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ReceivablesTaxResearchPremiumCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Receivables Tax Research Premium, Current",
        "terseLabel": "Receivable research incentives"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r722",
      "r732",
      "r758"
     ]
    },
    "hook_RegisterForResaleOfCommonStockAdditionalIssuances": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "RegisterForResaleOfCommonStockAdditionalIssuances",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period to register for resale the shares of common stock from the additional issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Register for Resale of Common Stock, Additional Issuances",
        "terseLabel": "Register for resale of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reimbursement amount receivable as a percentage of qualifying research and development expenses.",
        "label": "Reimbursement Amount Receivable as a Percentage of Qualifying Research and Development Expenses",
        "terseLabel": "Reimbursement of research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r484",
      "r485",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r598",
      "r600",
      "r632"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r484",
      "r485",
      "r486",
      "r487",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r598",
      "r600",
      "r632"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Expense recorded",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r484"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r485",
      "r862"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related parties",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r609"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r484",
      "r485",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r598",
      "r600",
      "r632",
      "r862"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related parties",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r485",
      "r488",
      "r552",
      "r553",
      "r554",
      "r607",
      "r608",
      "r609",
      "r629",
      "r631"
     ]
    },
    "hook_RemainingOfCommonStockReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "RemainingOfCommonStockReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount remaining common stock reserved for future issuance.",
        "label": "Remaining of Common Stock Reserved for Future Issuance",
        "terseLabel": "Outstanding amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of borrowings",
        "terseLabel": "Principal payment",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r291",
      "r311",
      "r487",
      "r666",
      "r667"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense.",
        "negatedLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r399",
      "r871"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "hook_ResearchAndDevelopmentIncentiveProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ResearchAndDevelopmentIncentiveProgramAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by research and development program.",
        "label": "Research and Development Incentive Program [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ResearchAndDevelopmentIncentiveProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ResearchAndDevelopmentIncentiveProgramDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by research and development program.",
        "label": "Research and Development Incentive Program [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ResearchAndDevelopmentIncentiveProgramLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ResearchAndDevelopmentIncentiveProgramLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table",
        "label": "Research and Development Incentive Program [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ResearchAndDevelopmentIncentiveProgramTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ResearchAndDevelopmentIncentiveProgramTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Research and Development Incentive Program [Table]",
        "label": "Research and Development Incentive Program [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for research and manufacturing contract costs and accruals.",
        "label": "Research and Manufacturing Contract Costs and Accruals, Policy [Policy Text Block]",
        "terseLabel": "Research and manufacturing contract costs and accruals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Capitalized Software Development Cost",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r78"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r723",
      "r733",
      "r759"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r724",
      "r734",
      "r760"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r731",
      "r741",
      "r767"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r797"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Cash balance maintained to secure a letter of credit associated with a real estate lease",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r791",
      "r797"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of employees reduced",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Reduction if workforce (in percent)",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r270",
      "r271"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Impairment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Impairment",
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "hook_RestructuringPlanCarryingValueOfAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "RestructuringPlanCarryingValueOfAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value of the  asset after restructuring.",
        "label": "Restructuring Plan, Carrying Value of Asset",
        "terseLabel": "Carrying value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r117",
      "r520",
      "r541",
      "r543",
      "r550",
      "r582",
      "r690"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r218",
      "r263",
      "r264",
      "r394",
      "r395",
      "r396",
      "r417",
      "r418",
      "r435",
      "r437",
      "r438",
      "r440",
      "r442",
      "r538",
      "r540",
      "r556",
      "r878"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from collaboration and licensing",
        "verboseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r248",
      "r251",
      "r252",
      "r256",
      "r257",
      "r259",
      "r335",
      "r336",
      "r498"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition from contracts with customers",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r661"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Product and Service [Extensible List]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "hook_RevenueRecognizedUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "RevenueRecognizedUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payment recognized as revenue.",
        "label": "Revenue Recognized, Upfront Payment",
        "terseLabel": "Revenue recognized from upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Lease assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r689"
     ]
    },
    "hook_RocheCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "RocheCollaborationAgreementMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.",
        "label": "Roche collaboration agreement",
        "terseLabel": "Roche Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "hook_Rule10b51ArrangementModified": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "Rule10b51ArrangementModified",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accrued expenses and other current liabilities.",
        "label": "Schedule of Accrued Expenses and Other Liabilities, Current [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities that were not included in the diluted per share calculations",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of the consolidated income tax provision",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of the net deferred tax assets or liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r45",
      "r222",
      "r223",
      "r225"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation",
        "terseLabel": "Schedule of effective income tax rate reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of losses before income taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails",
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property and equipment, net",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "terseLabel": "Schedule of estimated useful life of each asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureRelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r605",
      "r606",
      "r609"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of impairment charges were included within Impairment expense",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Activity [Table Text Block]",
        "terseLabel": "Schedule of awards outstanding",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r60"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of summary of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r59"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "hook_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted average remaining lease term and weighted average discount rate of finance leases.",
        "label": "Schedule of Weighted Average Remaining Lease Term and Discount Rate of Operating Leases",
        "terseLabel": "Schedule of weighted average remaining lease term and weighted average discount rate of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r257",
      "r258",
      "r568",
      "r569",
      "r570",
      "r634",
      "r636",
      "r639",
      "r641",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r663",
      "r680",
      "r695",
      "r821",
      "r873"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r257",
      "r671"
     ]
    },
    "hook_SeriesA2ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "SeriesA2ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A-2 convertible preferred stock.",
        "label": "Series A2 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-2 convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "hook_Seriesa1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "Seriesa1ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A-1 convertible preferred stock.",
        "label": "Series A-1 convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "hook_SeriesaConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "SeriesaConvertiblePreferredStockMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A Convertible preferred stock.",
        "label": "Series A convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A, Series A-1 and Series A -2 convertible preferred stock .",
        "label": "SeriesA, SeriesA-1 And SeriesA-2 convertible Preferred Stock [Member]",
        "terseLabel": "Series A, SeriesA-1 And SeriesA-2 convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Total Fair Value",
        "terseLabel": "Aggregate fair value of share-based awards granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Share-based awards granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used in the Black-Scholes option-pricing model"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number stock option authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exchange ratio for option surrendered for one new option.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Option exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Option exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value per common stock used for calculating the intrinsic values.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value used for Calculating Intrinsic Values",
        "terseLabel": "Fair value per common stock used for calculating intrinsic values"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant-date fair value per share of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for non- vested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, option unvested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, beginning balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Averaged Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of quarterly installments of vesting of share-based compensation awards.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Vesting, Number of Quarterly Installment",
        "terseLabel": "Number of quarterly installments for vesting"
       }
      }
     },
     "auth_ref": []
    },
    "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant date fair value price of shares issued at grant date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting upon first anniversary",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting in equal quarterly installments",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost",
        "terseLabel": "Stock option exchange offer resulted in incremental stock-based compensation expense",
        "documentation": "The excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock entitled for each option upon the exercise of the option.",
        "label": "Share-based Payment Arrangement, Option, Number of Common Stock Entitled for Each Option",
        "terseLabel": "Number of common stock entitled for each option upon the exercise of the option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "verboseLabel": "Share price (in USD per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of options vesting",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, option exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, option exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Option unvested",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Option unvested",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "verboseLabel": "Total fair value of stock options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "hook_SharesGrantedValueShareBasedPaymentArrangementVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "SharesGrantedValueShareBasedPaymentArrangementVested",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of vested shares granted under share-based payment arrangement.",
        "label": "Shares Granted, Value, Share-based Payment Arrangement, Vested",
        "terseLabel": "Vesting of equity grants"
       }
      }
     },
     "auth_ref": []
    },
    "hook_SharesIssuedSharesShareBasedPaymentArrangementVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "SharesIssuedSharesShareBasedPaymentArrangementVested",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) vested during the period.",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, Vested",
        "terseLabel": "Vesting of equity grants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r196"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails",
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r174",
      "r175",
      "r176",
      "r198",
      "r222",
      "r223",
      "r225",
      "r227",
      "r233",
      "r234",
      "r262",
      "r279",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r308",
      "r309",
      "r313",
      "r316",
      "r323",
      "r453",
      "r546",
      "r547",
      "r548",
      "r549",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r581",
      "r602",
      "r625",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r785",
      "r798",
      "r807"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32",
      "r165",
      "r184",
      "r185",
      "r186",
      "r206",
      "r207",
      "r208",
      "r210",
      "r216",
      "r218",
      "r232",
      "r263",
      "r264",
      "r324",
      "r394",
      "r395",
      "r396",
      "r417",
      "r418",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r480",
      "r538",
      "r539",
      "r540",
      "r556",
      "r625"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r163",
      "r257",
      "r258",
      "r568",
      "r569",
      "r570",
      "r634",
      "r636",
      "r639",
      "r641",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r663",
      "r680",
      "r695",
      "r821",
      "r873"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r232",
      "r498",
      "r544",
      "r567",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r603",
      "r604",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r625",
      "r696"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r232",
      "r498",
      "r544",
      "r567",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r581",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r603",
      "r604",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r625",
      "r696"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r726",
      "r736",
      "r762"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Awards",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of the then outstanding number of shares which will be the cumulative annual increase in issuance under the stock incentive plan.",
        "label": "Stock Incentive Plan Arrangement, Cumulative Annual Increase In Issuance Of Percentage Of Outstanding Shares",
        "terseLabel": "Number of shares outstanding were cumulatively increased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r54",
      "r117",
      "r298"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock (in shares)",
        "verboseLabel": "Issuance of common stock",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r86",
      "r87",
      "r117",
      "r546",
      "r625",
      "r643"
     ]
    },
    "hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award vested during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Vested",
        "terseLabel": "Vesting of restricted stock (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r86",
      "r87",
      "r117",
      "r371"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32",
      "r117"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r86",
      "r87",
      "r117",
      "r556",
      "r625",
      "r643",
      "r702"
     ]
    },
    "hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardVested",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards vested during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Vested",
        "terseLabel": "Vesting of restricted stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32",
      "r117"
     ]
    },
    "hook_StockOptionAndGrant2018PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "StockOptionAndGrant2018PlanMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2018 stock option and grant plan.",
        "label": "2018 Stock Option and Grant Plan",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "hook_StockOptionAndIncentive2019PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "StockOptionAndIncentive2019PlanMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationSummaryOfAwardsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2019 stock option and incentive plan.",
        "label": "2019 Stock Option and Incentive Plan",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "hook_StockOptionExchangeOfferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "StockOptionExchangeOfferMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to stock option exchange offer.",
        "label": "Stock option exchange offer"
       }
      }
     },
     "auth_ref": []
    },
    "hook_StockOptionsIssuedExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "StockOptionsIssuedExercisePricePerShare",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of stock options issued.",
        "label": "Stock Options Issued, Exercise Price Per Share",
        "terseLabel": "Exercise price per share"
       }
      }
     },
     "auth_ref": []
    },
    "hook_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to stock purchase agreement.",
        "label": "Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r90",
      "r91",
      "r108",
      "r583",
      "r599",
      "r626",
      "r627",
      "r690",
      "r703",
      "r800",
      "r811",
      "r857",
      "r878"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, Class A common stock and convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common stock, Class A common stock and convertible preferred stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r197",
      "r307",
      "r309",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r324",
      "r441",
      "r628",
      "r630",
      "r647"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureLeasesLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease Income",
        "negatedLabel": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r689"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r490"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent event",
        "terseLabel": "Subsequent events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r490"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r490"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r490"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r490"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r491"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of changes in the valuation allowance for deferred tax assets",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "hook_ThresholdPercentageForConversion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "ThresholdPercentageForConversion",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percent of common stock that can be owned after conversion of preferred stock.",
        "label": "Threshold Percentage For Conversion",
        "terseLabel": "Threshold percentage for conversion"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r861"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "hook_TotalMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "TotalMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total milestone amount.",
        "label": "Total Milestone Amount",
        "terseLabel": "Total milestone amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails",
      "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureImpairmentAdditionalInformationDetails",
      "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r270",
      "r271"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized income tax benefits",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "hook_UsTaxOnGiltiNetOfResearchCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.hookipapharma.com/20231231",
     "localname": "UsTaxOnGiltiNetOfResearchCredits",
     "crdr": "debit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of U.S. tax on GILTI, net of research credits.",
        "label": "US Tax on GILTI, net of Research Credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r140",
      "r142",
      "r145",
      "r146"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureIncomeTaxesChangesInValuationAllowanceForDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Increases",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails",
      "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average Shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r227"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average Shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r227"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "SubTopic": "50",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-4"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "SubTopic": "40",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "SubTopic": "20",
   "Topic": "985",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "(m)",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(S-X 210.12-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>120
<FILENAME>0001558370-24-003738-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-003738-xbrl.zip
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MW-C&M?>3N);67#KPD,[)$]A$K@>3Y"E=NKG'-:JA7E"*_W%Y[(<L#!]Y"'5
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MJ VGRLXIF\@RLT0*JTDFE02K/G>!5<?MUQAYCH3*<];LC;K-GG_H>!3="&7
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M3,Q_^Z['0CA*J,@ZJ7U4$R$>R,7MJVE6AG/=GD&!$0)7T$$F% I>UOI-M_Q
MJI9%7FD>R!(J)='*/FI;6?84O$*PG;-D]L3(&LYQ_"$5V:W+DYRMR^'&<3)]
M@L0,^\ V,G76"^!C)9D5RH>7K[$GQAS^0R6YM1H/DE_KCT37H:AZ=D!0+,D(
M>$%@JJ='+CX][*3)%Y:;@,CE;'A]EQTJ5X&L-X?2"[=;T'R(JB?2V)R/5PF<
M -)0=YSW*7%>=<<4EC>?0I)#9Z>]LYYJ2L"7I( :2"*O^VPH_8[31J^'^A)[
MND5O9\G?]B].K27*4 <7% PTV4 (OPSA;^P5LA'IM5NB$E6@KOO\1= VP"_1
M9Z'&4G5V7MA-:W:#6K=<_AN90A:C9!LM49KF>%-WZJ Z3,T:$^);_X U2EHG
M?4Q31U,MT<?&653W28V@Q4M/8,K)>BE>NR5:407JNA,=565_5IN8^6^J9U79
M <F+[V8) Y1\ +6J! XQ:+$>)O5S[3VKG'$M2D9=,0O+C#_,2S%AAS8X8S@?
M'+34L<E9^TK5;95JE$=>P^I6QAA<XS=D!G8/G)4;V]/M&8TO"3X2MP;9=)+(
MSQ7:[ZS6'!3@0KD[%5^. OG CV<P0#__#U!+ P04    "  U/'98PJ">"$!(
M  "1V00 %0   &AO;VLM,C R,S$R,S%?9&5F+GAM;.U]6W/<.++F^XG8_U#K
M?=@Y$>.V)-NRW=$])THWM\[(*HTD=Y_9EPZ*1*DXS2*J05)6S:]? *P++[CR
MABRY(CK:DHA+9GX)()%()'[ZK^=Y-'I") EQ_/.KPQ\.7HU0[.,@C!]_?I6E
MT]<?7_W7W_[7?_STOU^__I^3VZM1@/ULCN)TY!/DI2@8?0O3V>@>+Q9>//J"
M" FC:'1"PN 1C4:'!S^\_^'@AX^CUZ__QILX\1):!<<CWM;1#X?K#Z>KUG#\
MX^CMFZ.C-T<'1^]H_1_?'O_X[N-H_&5=\ LE;1IJ2T9A_,>/['\/M,<1Y3%.
M?GQ.PI]?S=)T\>.;-]^^??OAV]L?,'FD]0\.W_S/EZL[?X;FWNLP3E(O]M&K
M$2W_8\+_>(5]+^4"*E1_?B#1NH&W;S9]24NPWUZOB[UF?WI]>/3Z[>$/STGP
M:D4B^VS0R;HX^QJDFPK%PN_?Y!^+14-%TP6V\_(U4E;B.OSTZ=,;_O75W_YC
M-/J)X C=HNF(_^G'=+E /[]*PODB8DWQO\T(FM*6,/Z#<GWT]O HY_G_G*U4
M:?WO. [.XS1,EY?Q%),YE_BK$6O_Z^UEB1365KCP%C./%OO!Q_,WK-0;LP8Y
M?T9"?M.2P;N4ZC0CY!3'"8["@*GXB1<Q.=_-$$H3*_9,FH/$W(U'Z.<92D/?
MBSKFM-*V8[8W?TPF4_IW.IVFX4.$;F@;=$9DW['_!]5&_N\,1P&=;\__S*AF
MGJ%IZ(=I>^ET0,*N"[%C?>N:GN'$>Q8F?H23C*"[;#[WR'(RO0L?8[IN^AZ=
M%7T?9W1:C!]O**M^B)(;@A>4NR6;+RD#"SZ'HM0+([L)JM-^78CK%$>1]X )
M7RDH55>AC^*$4CQ^)"C7A79RL>G A0 NYPLO)'SM#(*0$>E%A<6S'?.FC;M@
M_()2]JL796@RO0ACNLZ$7C1.$M06<(-V7;"['GDWD9>;2>OA=XU:CGRCEEVP
M?(M\%#YY#ZRE!'G$GUU2:X+.1T^H'<<F#;M@^ K1!ENJ;Z4-=VSP_Y_BI.UX
ME+;FCK7?4/@XH_;&F%H8WB-M=.Z%,5T2^-=[1.9T%%7*L";86GI++90NY-$5
M"4Z$B+V8;@>6; "VE(6H)3=FR'R.8VY7GD9>DA1^IT!(;=&VIDF[3IV8MXP"
M[E.BU"ZH)<4-B:.#PX_\RV2Q,K,^$[H8L16II57;N#M0POE4IG:S6O4H(*,N
MX0AILWT9?_-(D$RRE#G'F$^T#_D8] 9(- 4@?0HAW^[V(!-%-W"$49PC.79]
MB$+>"1Q!B/_:FV+(>W*R:8XI]>C>>T;)^72*F+IN_T9W!YCN^J*PBPUT@XX<
M"Z0/-X)IZRY8?W=P^/<[[XG.W4G[Y536F O&Z/;]"B?)#2)WE-Z6EK:L,0",
MC:E=$H11QL;6'?(S0A6L[2[:K@LWSI&(N;QO/-*>6TE;;MS?#PGZ,Z.VYOE3
M>^>MM#5;UCCU'O'7+*Y^K!*$$DH'R@A>L'_X>>X;E*#IFU7Y-]_" )'7L4<(
M_H;(*[VH! 1&A&S:8QV^7OWRFFUK7A\>OC[*A5KMJ\#)FHV&JSPU=:E5P_:8
M69+B^?@Y3,XP<T"<H:F71?Q4T]@X,6ZL+"5+E:/\)>OS]JF7/'!)9LGK1\];
ML'B$MV\0[8K]A369<'(YJ0@%\[KVU9K(T:!EWYP_I^R @&Z[S^-LCO*#@ZLP
M:7+6:Z!VFP;".'T3A/.-:GA1U$R_"J$(+.;A/1<#;ZT]4?1G)AP<OPXXQAU2
M6&^Z W)Y2Z_G:/[0=+2*:2VWVY[0&:6)^-D#>KT10X?D"EOO5!GRH=Z/-JS;
MS@FFOX9QF(_)^(]5XXR<UF.[0#IBY0(4;/X:IJR#;?51H?XHG^Y&7[@VV,P2
MC"&& ?9+O4<L]@F3QC,@^\MV ES]X?>KT'N@>Q5F(9QFA)V3CQ^2E'C^!K;(
M>T#1SZ_T%7X_K C&K,H;*WYKBP[[R^]CWR<9"LZ?V4:4;D?B8)+.$%GU5NB_
MPI1=Y1J#]M77S&[U=4S*;--AM.YE2O#<4O"X"5%90OO%BWP#MVYJ-9R;SJ:Y
M@+9L_FC"QN@>C^S)QX1:1#^_HC\M2(BI$;_\^=6!K5X)QU%"TL(8HK]MQP_]
MY?<;@H/,3QEY=X@\A3Y:V3@5+5.6_?VH(C-MZ2X&C#3^X4L)QN(PT501#PZ#
M2@V&A*E L3D5@XP!#=T;]3>@5Z7T/[TI+X?;)5V_3':]5U"NG)\^?3HX&+T>
M;5NFOZP;']'61WGS(];^>D'=]+ >!EQ1K0=Y@OP?'O$3%568CW'ZPW9XTU]^
MOT*/7I3'K;+^*V-"4*(V!"1EWO1->=Z=<"ZJ?A;27"U0(MABG*IEA,6=M1R)
M4NNS-AJ%U+$Q**)J.]Y:HM?$2-N&1;(#X<DT/X.HZZ2VO-1$4]9PP'&1#*$>
MRPM*>107;:K;-K+&.B(&TWD#JMD(4%/;_5C0&%H;:N_H.NC1]4Z@^])R-7U0
MEAR*HU6W7^-D@7Q^D49J.DK+BCE3E6ZJ[";"Q0;]#Z;G"H*9?FL)'5S%5V;A
MA*R,0HF&BXH)U4!6<%AV6FZ-%(R)2[?1;XUHL4'W@ZJWF-ZU=BOIA&',Y'<T
M6/0 CMDQCHE!(ZJC-VIDM1QP7R%%:=L(RTJYE9;NS,+1"!\;T.+.T!$37S1V
MI$0['2ZGF,?HY;Z VS#YXV1Y3[M3#!9%#;EMK*X#@6]&CWHK(*]ASG>Y3MNA
M8P8%-J9G\.&C9*"T4U 3#FT(G:#8G\T]HMI%ZZK9#*9:11!B6!-E-ZPJU2S$
M4*_8PP"38:0:90+*( RU"BO*\29@P>F@D]X_TZY?!C6E.F=8%Y(\M.N:04U[
M>72[SME!AJWI&WPP&C%4'(^&C SN5[CUXD>9,V'S3;C1+GT=DEKA$63EJYSB
M^L%B$V> 2#18V,N@>_X"6>N-?H6<P17L-)MGD<=":/-0^!M$0AQ,IN,@%XI$
M]TRJ"4$VK0B$?:G7RZQB(Q%TXP^S1 C;TC;HP#%C9CVFS)EP:F*-@W]E2<J3
M55Q@<HV^%3)[$!S3'_T\E87"V+)J0VIF6+?B0%IL(=Y"*%QD5$6EO,L*M[6I
MFB*#]:0-;DY9\E(TK&0\#&])H63M2Y394^428ANE7F9X^J6+4JV,CH=NEAJY
MX+"BQV$MKRJ)&_M+1)K392&_E[=Q?*]S)BH6 44-Z;2GJ0.';^7>6EG'EO?N
M]M-F@& +B@:?\I4L%"=X+>FM!I,X_/5+&-%ABV/1SKA>0!S:6BO2/75"U145
MT5#87C&50L'R_@93.Q&!FWA: 6%.9^B534,(V[M+# IE69TQ6B_M8GNRI8*%
M(5QC=FEQ_9=[^E/B^0R[1&F+6[8BWZ+8M]-V%M=!AUM1-_B,+F&G.)<W8,/I
M0-QD!3Q9?D$>"T!GA%X0?KO8%X5]6]24JJ)A79?R$-&E-*0,:NKEH:[;=CC:
M08:MZ1M\0!HQ5!R>AHQ &9*;'W\)$6'Y')=7Z E%9J-24=ED8&JJ QF;29U,
MZU$J;<-JO"I;Z7#DFL&J&;Q*8ET.8R5WNI&LY,IM (Z7S-A=,?H/.Q=]\B*-
M5UI>01YMHJSB@&GF&"*AGZ) 3)KXKTI;N$V34L&U;;1U"(\)UK@[>H</[%$P
M6!S3;1ES&]6=/21A$'ID>4?I,KBB)BLOC^96U7#!\9:*:V].?RSL;Y2+L+ZB
M7 9&55L'?!M@@VV)&C[R6\Y%<=294>]T;/$TMHB[2#/5JEDK)]4C84G7G"D'
MC:"D&7?=#0N5>+&V]\'U7T!N4>\E9+J-&8V\F U"57!HH8@\ZK%2R"$KZLC.
M4B$M.QW&:XJEB%5]#A^#62*R%&Q9(\ZIVOY*#3?V=(Q<:PLEI"A7RKCC0ZFR
MI3(Z7KI36+$ L:+'P=6U1&)16VND#1ZZ<L^(GDPOXR!\"H/,$[G0I.6$(2#2
MDJXX^BU,9SSA*3M=F(6+>WPN3X+2H 4S*>C;:!,FHX,'-Z9JT% :"1OK@)H&
MY+O=^;)4PO7TZ.ROR3A+9YB$_T;!UYB26$BFSY:PY&1Y_HR('R;HAF[\D2Q6
MO\>>Y#O-?OK:+7SJ?*@W]MWWU <^JKY:NPYZ55'<.__#>RGZ$%C)O]&/H-P&
MOK/G-S2W"$MEY%$AU5)@)JAB*,7)<EOFQEORV M&^);Z.##:</;1E>44U;ZS
MUH'U$LW0SB[M21\^\+[,JWYB:,^CVYE!^*3#^;,?90$*+J@>,&:SE/,ZF9Y[
M).:O>JQ>A#A9BAM0S3/]]2B?M?KM$PQNVOE,5\U2@AW/,X-H!K9C:O@9J$\I
ME&(/#;@?_G8LN^6$R,(CZ5+BV=85JQW7;UYU618C*D^6Q2^#WRU:9,2?T85B
M\WYVE27%G2/+N@J!='3S584&MJ9Z\"%GHR+E  21)'=IS(BO2TL*OJ2Q(;FG
M9U%[Z%2NGQ%^)-YB%OI2=[2TK)!;9>FAN$./50KD:5UE9<7<J4IWDM95(61L
M0(.;U*YUHC?I757$ KB?>>\]K]POTEE.7T%S0U%6!0S3!G<SQ54L&>_Z9J8&
MB]K%3#D]CNYEBAFH7\N4$PYL"%D-'\NA VK86 X9Z^'2YU"Q&2:@AHC)\  R
M-"J/8VJ\Y)+2RB!<27D8O*K=W[+R-OQV&V>K%CXVI,1)<*V0])*'647RX-O*
MR;<8$18_(-EME+X+;?!:B:$IE^XE*B74U'>S;Y")"TM[&W2'4"%OO2L0D.5T
MMC9WU4BF-#MW(""/8D,A*>=WL0-K *]A*S2PCJJ] ['S 68_HIH,(2!CQO1B
MDK*.+>^]#RJS403C+I*2!=D(@G<1B=]0S/PT(RQQ7^2IAY&@K/H2JJ@T!"XU
M@T98VIS3+@>*6N352[1B*AP,#B'9M:NQ8G+A#(A3G+#,W_1OB#RI-MV:6F:J
M(Z[G+)E5B3;E@)&6E_*MK-'IH%&"44NL*J'([0 2L5#/IRHAO8=4>XP0EHN"
MTG3&<EE@GA7_DK]>$3ZA&\+.9^:R/'SFM6O:TZ#^P$S+T_O9U&_#>$>) 1NA
MA!M2.FQ*01O6-OD&;5ERNH9=(2]!IYB])4/G R^Z1T0T''7%I;.WJ@(0=I7K
ME;R"%<O=K5@&"&!36@9?J^3$%Q<I-=&5X?+3FXHDK\+5F_?MGKO'?I9G=<[_
M98^Z\'MGE_$4TY*LV5<EQ"2OW!\<''SBK]RO&BK^Z,7!*&]U5&YV'L5)B<H-
M"$<'!V\YQP]41J_6NM3#*_)K(@N$W7L/$:J,$W71-XT)=/I0^I9PHP%J/&)F
MM";QLP?T>C-VBOI<'.XF$)0.B.2\5$;YL)BT>,J]+Q0*\]:J'S$$QFJE?N%]
M=P'X_?CMQW?''PX.C@_>O_OT\?CH^.T F*S7DEY!$;+6"B?Q5N 4S^<XSJ_6
MI3-$[F=>S*D19GHSJ](3 EPNK^>K3M32ERO5QK#7LK$@(8^<X)VX'2*<5$[<
M6)F!3U1P2#2.FJ"A(KXSL3>R)ZA9AB[I**ZNS_KB_0C=BR++Y;C& 1.X>NFN
MVMR4F"#]T:?6+C4@SR,^I_W\*LGC5[??(YR@X.=7*<E:F57F.#%/D0*7_+-#
MY6^*2$YX/Y./N73'<4PW-K=H@4FJD'*YV)#2?MN-M,L,N)9Z_I+;>1R<4>-!
M(?9*N2'E_JX;N5<X<"UX?IC)):=5^7K1(<7_OJ-)IL:$*P1R]\)%&*'K3&#9
MB(L,*?'C=A*O$^]6TK?H,4Q2EEV1!<Q+I5TM-J3$/W0A\2H#;J7.XK$)'6AY
M=A.V->17W<CR% =R$#2UAL3D8Q>8:/AQ"]&]]WP9L!.0:9@_\:69CZ3EAX3E
M4Q>P2#EQ"\@X" BB>\'\'\;#H10,8=E!_1 '72 A9 ,$"J?TQPFYQ]^JWCEE
MR4$1:+DCEC(!0OY\MIR0&X*?PMB7+QFRXH,BT7(GK.8$!!PW.$F]Z/^%"^7Z
M+2X\*!0MM\DJ/EP!L;(9F(&'1;-1Y?N@XFZY.ZZ0[DS"#'."/(ERES\/*M^6
MV]\RY:[$>T7;B&YF.)9O>>M%!A5SRSUOG7I7HEYE6EH>'CWPQ+T"4=>+#"KJ
MEIO=.O6N1'U/O"",'^^6\P<<">1<^3ZHD%ON7BNDNU;F\V=_QK(@2APXXF*#
MRKOEME3,@5O#[S<417^/Z8;@#GD)G=F"RR3)%.X!:?E!CZ0ZV95*67&+R*\X
MHM:21[ASE8C.:"7E!D6@DUUIC06WDC_-"*'TYT<';&+DK_1( 9 5'Q2'3O:D
M,DY<.Y=3Q")1PR=TYJ7>BDB%5UE<?% X.MF7RCAQ?Y9%3KT4/6*R5!YG%4H-
M*OR6NU0A VYE?C?WHN@D2RC)B7PBJI0:5.8M=ZY"!MS*_'R.R".=!#\3_"V=
ML32Y7BS7=TGI03'HY"A7PHAC+)ZW)_IY:(4<"$'105'HY'A7Q(4K""[]*1EG
M04C;&:<I2O)DT1>1]R@ 055X4!A:[HE5?+B.YKD(X[MTGIX3@LDIID:!KP#$
MI-*@P+3</)OPXWBQGM$-I6Z]*!<:-+*PDTUSF7ZW K_)'J+0OXBP)]\5E,H,
M*NY.=L@E\AWOCK<7"_)WC"992J?'F+D0Y7MD9:5!\>AFIZSDQQ5 JP5+XC@M
M?1U4Y"UWPR7"'<OV(B3S2Y'U6?D^J'Q;;G@KI#N6,#M=2\5'W[42@TJYY1:W
M1KSC:1RQ^]W191R@Y[\CN:%2*S>HS#O9TM98<!9XD'OP+L+$]Z)_(H_(KT+(
MBPXJ_Y:;63D7[O=0:Y(NZ%]4-^!J)0<%H.4V5LH$#/GGK@TS!$IE!\6@LQUK
MC0UG2RVE)^ TB9T&E>^#7L!JN3VMD*Z5\$]ONDY=LKT:C^,$1V' <DJ>>)$7
M^XANFU&ZI5F=N.3P@"4NV31'?SZ=7-]-KB[/QO?G9Z.3\=7X^O1\=/?+^?G]
MW:L!LI:T2@HBREXB*[3/6](T;XE:[/N,)?N,)4-E+'E_\.'XZ/C=2\Q8LF%M
MG[%DR(PE^R0ENYVDI-7:7#/X9(MRH>#@:4KT5 M78!"I21H]')TDU)P=/R0\
M5: $F6HA (/!#)\JX7 R)N64K;PK1N*OE06P)HBUIXY C78X0)QZ"<LSR_XY
M_S,+G[R($IJ,TU./D&48/_[J19ELTV-8%PQ0$G4K+1]F+,'!CV?B#GVZ06<T
MBT-+-64!3&?&^$A8@(/'V/?9'<'D%OF(J@]=%J]1JH9%7<5ASB9K=-2<= >2
M+&OZNM?DWGM>)]&^(6@>9G,Q!!;U'.9P,L;!@IV^P:#]+;PP.']>T$TN2NB<
MRK=$:^(Y)R(PS.HYS.AD!X89.X"FKR)7)O:8TUQ/]A-4F71H<K_&L6]A$HN*
M@UG,]3"(R(>#2-G2V-)J9%L5BX,Q?^7:);>PBHS P>:&X 4BZ9(]Y<03ZU-3
MG;^10<T-"3[J*F!&C1E&:F;@X#2A5'KL'AY_D.$V?)RED^G7!'%>)4!IZH Q
MA\V0TG #""IFEE0YDT$D+@O&0C:$1LP%'$@,T7 +A-(Z-@,"/@9*R0.:D_12
MAB3;J]!["",J+[XOXN<Z,QQ1+A.VGJ5+C0UL7AT /F;^>G.60*)HYLY750!@
M*]MJI00_P"[_M9?NQELR+Y&9<[):&!92%K[)*B-P<%D_6/9;F,Y.LR3%<T36
M/"[5*)E5!;#+L</,C"TX"):M?4/L=)4 K%YVJ.D8ZMOU3$<ZR9#,YUK@1>1_
MMJ@,8+]C!HPM8W &U!7V8K-U2E@2P$;(;N@(N0 $1XT98QL/Q#F!)1@")D!B
M87QLH*D#RSYH8WW#/EHHCG*#Z0R:L6WFU2ES $?X$NM$[_34UX,U?IHXJ(5L
MP<%.N1_0(FA<&Y;%;8:C,7-PT.3VIY!1U;F#I (L8]SB!$+"#QR8;! " ([>
M#C=<OW8(%ST:T":U-L8=)!#8=9,PG?,@X3A@DS!=2E'LRT%1UH UBUF#I.0-
M#FC61TU0#I?T<YLU9+MQR'1#FT%T!LZ94]U)$)8$L'^R0T7(!1PX"A<=E?=#
M:L4 [)#L9[0R"W!0& =!F/=\XX7!97SJ+<+4JS[MH2T-P#"PPT3*"2!H?#^;
M9Q'+FY%[V?%\0=",W?=^0NR5S3FZPDERC=+)]-Y[EI^]VK4"P'RPA-*60S@0
MWZ*42@4%YQZ)J963%%@YH^+W0WFDL+XB */"#D@3IN!@5^?-V/ #<8[1UL2#
MA(7.>&T8_04"IXXVO!(&06:&NO&8GV2&TM#?FB+:-%'OS=-$C?Y2ZN(_7^W3
M1NW31NW31NW31H%)&W5X?'QT?/PBTT:M6>LA:NL.$;K4>71A>4(D#>G@+3M!
MY-FC3&L"\ (9))$RY:8_" Z;8Z"O"L #9 Z"GIU]_C13'X_S_&DJG1\?-=9Y
M@ZH W#+&.F_ #@#7\PYDL9.X5?99[/99['H^'J/[XPGA3 7\S.(&$?[$B]&)
MF;PR@)7;#$]3AN#XP,H4Y^_QC+-T1LG[-ZJ^U6):"<":WP2O.B,#I"JJ]7^&
MDO Q9DHC6OEU-0 L^&K1&W$!>WS('^TRK@7 '&@^0@9XKZME:(#E.F14$X!3
MWPPR(VY PF:X_"AK# G3AXY@ZG/AZ1R>RR3)S*%9EQX2EH^=PK+F # D^@4)
MSAN2GSH%QVXI&NA4<O-'NMN6NC2$)ZN5\ W-X>5;]1LW=_?TGR_GU_=WH\D%
M^_3K^>W]Y<G5^>CF]OSB_/:6EYF<_GTTOE[]],ODZNS\]N[_CL[_\?7R_I^C
MOYR=7UR>7M[OCSH[(#&'F,49X9C'*1L<=XKK[.*1IYB3[9 ]<CRI5NA3GL))
MR@(["57I6Q$B"3>[C4;Y[/ CS&/15@@).>SE4$BR@BE/A71U )R(*G6L<#*D
M8P6*+6AP)@'M/%0+@8)\B 'P2@@T=0 X38WAT+ "/0!>#9-Y?0#.5G/(S-D"
M%=RNQ$I6&(![U1@8&0\P#EUW,3Y3=X37)#X3SD9E'ZRYNP"4;?9/U&;_"&]7
MTD6PYHJU?8S:_HU/:-%1C4(S>XN.^AXBDIN'9>XCDL%$9[J)2'YI,;*-0C-W
M*$;V+GM(PB#TR/+.BY#!OD%>?OA]@RZ43+YOD'/A%HTM-=?>G/YX3[PX\7Q&
MC=)R-:D(9"NA4[@23@9LO53 2O;YT0&L Y%N012RVD?T9O80A?YD2B?A,'Z4
MKT3B<@ V'>;JMHW<%/+2Q\K/X]<RXL^\!(T?">)3L&*Y5Y8'L,%H(&PU3S <
MA%?[6QGP;F5<QCYA277/4/[O95R/-;K%472!R3>/R(+YK%N!,,J,$+;F#$[P
MW\XDD)$,P8:JN3M994Q#,AW'84K&3Q?P0+XDP+G)0WK/,F;"W%!#!N?1\=?H
M&_\B7\J,Z@)PK74UR/3,@D<VU\:&T-8J YA K338 -$:C^ AY:SF?C"VRRP%
M6=\AGY949*9NV28 EVW/@]M ". U)-?ICE7$N%'@DX2Q6(PGCYU2F2*QN:-I
MSEYGS'D[E*B$KA* ,X0.I@4=EX!!+-[5,@:Q4@G N#533B5F%:;@8*::D_*H
M!DY8<OZ,B!\FTCN&#=H!<'>WYU5;PCAX]'-M[0!^94, 1G9C[3=>A7M7 86C
M7L+8+4I2$OKI^LXCT^Q?Z=_$N2V:M@3@RG>+T=V*=4?@Y@K7";KZIAP.W@X4
M7 >QGO_>,>84?"9>O$X3P?]R0M4XN/&6S)D^)O3K(_>K*P!NU Z Q "M!V\C
MQH>!-5>XU0+1 E;;=IP/VA9*70'6EO7>'QD/_I4E^5-7]UAR$VN<?O'('XAO
M'%B&]%.<5!^%:-D6@)P1;<=M<^;AF-4F/!16GB(;,O=7NR8''?@'O>VUV@D!
MCG[([OI1UE'X&.>OB_O+0BS*. [X;Y''?]O(8?T2S@TF_$-*#9:'+&4A$O<X
M?QA!HE #TS"H!O9WRCVPU."HK-'08^LP2S<3, E1\7"6;Q$5;!*FZ Z1I]!'
MN85]BWS\F"N"ZLFX_KL=5#'[.]_O7U!P=)$.G>U;8!+%J909%.7^SO\K7+V8
MW%I-7@EZJWXEJ,M$6_LWAO9WV/=O#.VOK8,"H'2AXNW'XZ,/!W#NCG1X;7W-
MVOXZ:?^O#.VODW: 0J.[[ ->)WV9*1R@/C/T75_>;9[T9W]Y=W]Y%SA@92N%
M)=?Y ,< Z_'R[IK5_>5=@=SWEW>'LZCVEW?WEW<'O4!X0T)?ZE8K%( P-LQP
M*1 -Q[__71^?MWHZK><#\NZ/$\["A(WJC*"[;#ZGY@J=S\/'.)R&OA>G8]]G
M@?8L+ _3-9+NC6\(IKN-=#F. W: L&"LGK%<K=%6'JIC@W<'5-M&KT?;?MD9
M0M[U"$]'R;;SD;?I?;18=4\+KRD8>7$P0FL:1G]940'W;,"?H2!C"^::@YN(
MB;@@2.6I@7'UH9^"DU!SLKRGW2HVRD8UX9PQ6,)7?B[.@%/'#_K)>**=*K=I
M1C5A;*PM5-4(O2*'+Q>]TM;S'<L;]1[,+KL_1(5<.W_\92'=,$I+ =B36ZAG
M]7V7$BM.Q7^1$2H^:J]0!B["9_:3.@N_J@* _4E#4%1<]7,HLLA21#;4L2 6
M/$V_T6V3\EQ$6PO EL(2 F/6>MY()B0M#!CZVW:PT%]^OV61_P*SK_(-SEE(
M \.NPHL;&0OUO_;5K>DE5(B2!/N;W+N2(40#R%2N YDQ&E%_H2*:9W.IL"O?
M'9HL$L582[9"Z/""])[5@BQ_=VAFZ 19)A3F[DEW#F!2T=FY@#E7)7^T\6*X
M>R<(4HZ^)FB:15?A5.9[,ZH)V:978F[$G5/7]"F.*"*8>*O[/%>ASY;)^'%S
M@)C8^:#?'AQ6?="E/KAO>=/+:-O-+KF9"QP]H<*-W(1*\!K'ON1SX0PW,7-(
M=]=1%UO&+V&$DA3'HCV(J ! #W/7R&UVCQ76>]BP;WH0NAW%1=QN4>1*4Q=;
M)][>K@17MNV/0(0_V0M3R$4/\CU#3RC"N3]Q38$BM%99W'4:!XFN;$2L)+[O
M1 PLFI>E6?(B$SFK2CNTJ(S$K*(=3C '<R9.IH5E0G$D*RD+T%?7QQ*ID8+;
MD)P:BYZ8*_4KSK:MP#BX5:IP*?S&EK_O#U.(5D/?.'=O8[3/U"J>GS1OA*HK
M 3CJ;:C2Y=2M:BY[,%E^>7BZ(?B1>&+/JJ0, '&;J='&8*GST(<P0P-AULH
M\)[9"K/&0P_"O,74XBF[O_3W!@PJ 1!WBZG"E,O]V;<NJ+E7>WI_2O[=GI*_
MI3;6.^=V9;-3\A7M^\/=QJ?D@ YW.YC7:H=GAF9YLRZ<'1CW(2GQT7)W:\WP
MA]!B,^TZ8ZK.#LV13TNS'%6W*$%4^K.5C2@\B3*J!L!4ZTLUS(70M].:]N0C
M%"07E.]KEI)OFL4!T[&O"_JG.%WE-1:!:%P50,1IKT :"Z+_$X@B&^M-P4J9
M+IGH^7;A M7>NK*O#N#ELUY!M1)&W\#>X[1PUI(_ B1"4%P.P&M4O4(EYGK
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M041SOLS_8ES+64BH(3_E*R"*90^*8Z5 Y"UB*DBW(_>(S"?3]0/V(O/>I!:
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M;V_N7^U>L/KF6/-F0$RK+5W')GS"\:LH:2]NZ5>WZ9I +6P&Q)3<+=1"/N%
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M28+2A 6 Y[NL*,+?O%AZL:WS7@#DE>I18:Q$ 5V76'[?,,ZHH%824QSW6S0
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M!"BN40H*N<Y?9:MHFQ , 2]@[*7"[&R_IW2U_DB"\OO>1 +;-18H,]ZN".J
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MZP7*K\'9NN&L!I%TA!?"VXW@ %9/-W;OCI0YO.&62$-[Q !JHFGCYL=Q8^0
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M4E_,P]C/$84?F G.=DF:A__D?]>:1W?\9CSRN)%A;#O6CIB-1!LOVHRNH?4
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M=5Q;@+@*:10P._W*1&RR\&"*B$>7<:Q5#B3#R"$?,T92;LCPX)7E;G="F#*
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M3B;ZE;F@IAWR3*]+ZNGR.,&9%*SAAHD_;UXVE>Z"KHL5W7I.=+_UF+VNL^Q
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MSZI?0&2N503C);YUS5<1I77R9JEA\\D+4(W]-26O-"65=AMRMH^.86J$:.W
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MHR>V[1YWIZJ.;3[1H;GBCKTA(,/H0UO%65,^"[@]@-,//K8U5!YWEQZUM':
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ML@ 9HM"\([I,(SP#N8/."_1ATGY$D&A_$-Q")T +I7=,I;;H59H89F1;+L.
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M,-Y!J[&\29!)H;(%M)V, J@>]8UJ^<6O0GRTS("S7M 4'-N!40=34$(FBG+
MU686^)O?2]N?Y C[&2U%R7M]!<L7$.U@(U+%-)0$M;R%I[60BH#JW,/(JY.7
MG5)19!<</7:2HN6('2E$K-4D!$TKP2VR);M#6U-Q4_#J,+*U$I&)FZ*!31S$
M9]0B!S3\L^$@\35-!XHIEL",X[ ?8*9!D#K^(UB%$6W102MF(5"-XIG3DQX
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M)?0I$%5^MPB?9KD*< ;<]"A(=/WFD@L*C#U(6C&+H!(6KT!L\*V-WX#O_S-
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MRJ[W$&;'&8QX?')5!XH'1PO91R]4I>DAHNFY&1'#!!"AAGUC2\6)O"*S>$A
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MYN+>/5(_TG6F^^LW;/)9>Y+,\A\,:ZFCKH%#&ZZ"G@R?[V&CT>+R-G\!(=Z
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MANP_0^;:9@6X$&.,:/5Q$Z:3E!HR=0S(ESL0QR"/.B!&$4Z-<;-"5K!B1^O
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M6Q<<V(B& ;;&A;:0AO*CA#P#HR3CI%NLZOL+TO?Y.-FF1G*MBX(!KQA<S^<
M3SRW'1$?<./!.G"A#[=;<!*S*NDFK>&:(M%MG=\70:J17C+_:V3L=UT(Q'DF
MU9HU%.LNM=9I=>\WJS<W8[>[/6C5\=T)W&8J"50=.V_:BMA+]HB>\S9+K;\H
MUQKJV9N-7X6--(US:43=>2-\/<<E[GA^FF K*#<UD6G-M*XODP):I<B]>!\-
M0*UID$ /:P'-UY[P]2\R@%Z_X;"^P,L"?.(HU/D&EFQJ<?4/LH.06K5AAR.$
M4+"/<H[!*Y XT!<;VCX?'-$R(0M'_O@T(4^>N-FC)W_)'V[L&#CBQ*IHQI%-
M^/ TAO&VE3*FF0C9@#]-HB@:B]8@>@DW/;SO<,FHNP3 *PP;4E&Z3,F)#%K;
M(1VQ0U8T51PW^BWETV#R#;+RQ:W4\H5466O?)6_V]C)W]1;WA]GO98[*OI2,
MY^V-,T]^]6IW.D'=Z61$YJ*3E)QQ9+!4#$PQ+MZ?T6.G;Y U!1"H:1K6G="K
MDZ&M!D;% RS)58CO)LKR8%O3-!ZT!4Z" @W",RG0+^J;U_T*EB\@8B"\4VHT
M:#9@4$=31%!#D+M)T7PUP1OQ@7<#W_!?,1=$=@5[\924F3FI5W'UK4@NMY$&
MO5.1:(X*G& M^]#K(CCS$%O_3;5')UC0YDN5WTQ#2]&,J%E&SH)9[9Q'!"5J
M?]OYU12DFE5+@6&@\:M!]U]A )?IDJG]RN_&Z9_S6E4$FL48$@/GC8]!^?<1
M8] HAJ+!7MNZZPX&X#8!2^GE]Z:B*>CUO?KF*\ N-S>!B.2R_-G6-(U +1&7
MH$Z#[%:$1!$[ B!Q8V+93?\NR1T^3;)G?FSRZTP>YJQ@XOCX1M1NMO/I$N<6
M_C<AV"%#$-'JU=YS.KCED$P>UD5*#39"S?:#C[ ,<?RX-9A&$9Y-D?BT*9XA
MX2$9N*@5U#W](C,CLI*+R*E-0+HV-TYN:)%:URER1ZX4XB#RO^"S\0<0S4,T
MF@0NV(:.H;%"J.*(\6\OGX999V](WX31M>.^[C"Z-?[TYFQGA834&JY*J.3*
MC@A4::ECAE0#%O"AO9P:[D$8M+2HY&;%3G>RJXS/G589E<=G5ROV:<6!"'>*
M)/ER?([__^3LY+1W7X,LF&\]0V]^!3L+4>J^/Z/Y58S>&'?RP".?_*S+>_^=
MQDF>76$V)\D](_)#DD3P)4W(]8+P@71JAH)Z?8?Q&#,J.^HKI.&UIVN9I=M$
MEI801"EWT,4*#!;3102R-*-RYO"X[E=?>0;QH-P\9;)]C'ZK)[(2+6M@NZ#B
M1;*6JS]<, 7Z4A'?G+T/46>A_USJ,;&8MZ6J!U5[V1GJ90?#Q<1NPQ%6( :-
MZM'AR$?O-%^A#^(D#&@.!O4"IF#9,QP[\_!FE0R ']65DE;$% P%5<G2/4<8
M1:?@C$CC8 W\,'/F*]Z%[B#75-Q,(#AZW8%"5C2ML* YXQ)$.&6G""KLTF,'
M15(R0YP5L O?;%X>@]G7 ZAE38%ML(%)7CN].<[);$?4]./05<+U2)9LQ33N
MB$-8AU^%Z(8XHK,Z#A=Z?B73D%:!%N6465X'6H?F7U[6^4XU>T#>+6,:4BUT
MNC,P"TFH://)5W<X\PL4  ]:#YZ(A(H.W16"]QBB:4AU8[#8I6.CV5C)-'C5
M6M$..AB2 #U=+!D>[=YGULW:X/A@C.$*RG"8-JN6 L- ,U=]UQ\,T+^09103
MP_#5@X1QN&NX**'R$555GI\<G1_OEY7M3:E:X\4J2I+=TG=6VEMT>)YIAWMG
M8M=616;ENZ2S!@G@ N#%..C@/<Z+,D\##W>];ROT59#D*5%HS!&LNN_LZ:(F
MK;$<I>..BGA0%"N>O&/<!C#)8K[? "#@N\^MON],ZJHJK9<-%=FCYS IG4)-
ME]@SC$8;6KE]YX>P3L8PG:ENI&RUD],=N_OY(*?[+,@2R%V_X5/,>-=-J7-[
M^TXLY;K3&EI?D25B*1FGN)[-'\-WQT_>.=,CF?H?!.NHJYQ0)R9;M/)$<&.E
M!>?7N^7WG3#2NLD)<FKR3+K(:_,(UB!(P0,RH!C&!<"W=\A7VPR2M\&_T )T
M%E#'NE8-[3NEU"DMY]J9R:.;O+3/WT,U7$,-?7!-E=)RKIV;D<E*&==0>XHL
M&VFJHKHO!X-'A1\!WYAJ*W8U#TRF7$VJ;ZMYPW9F0Y5]IU ;]114,21ODLA&
MP\9C8V=2&=?D;]YD$&]KW\FE5&\%ZT:T:[Y582YBE@,J1A_A\B5%[T'DOPFC
MAP@@^(B>9O,;&,7)+^G2"9XCB 44WX7H\IP/MO:DTX+)1N_8M]5&<82*$_%M
M+P4]@6@-79&C(E5/^F!S;UHM^#R6@P>6/FH#4TNVUMKYX*(BG15,TW/"<*:7
M:9=H6HWODI/DUH\ !ZD(%L_A4_KBDYOGO$WCKFU^,%"#_@HVZCF>T#PC+20O
M,JR_*V:D2+L?K-2DPX*9AIR+='?@S?3Q&TQ>+U,T3"Q!M-%-%@>(%8))I&I5
MA8=(A9_WA8:=U50PS9!3$:U,:T.Q#VZUT$]!JJ['']5DN'5:Z8[#=;M<.3 B
MU[8]#V8RW 8D0"/^(!>#ZW,]!M>V??1A^X@)W#[#_+"#:,&91*F;I!$.O11X
M9*P#WA21;4T2J#=$(12N_WOOX];VY@3C)?$*7# $5V,+IED:*5SJ5J.KY$->
MGU;:);"<1.H81&M>KM2&6J;QHRO =<JT4<"8:9(%!ZE(S4VBRBQO&C7: %FG
M@YRX8R;"]7+EA^\ / $TX\&QG_F95NFE32.!''QU^&7$'#R?AM(1 V<<$ATG
MBK*FH:]Y=."*;5SLABY$X(X(C-)5K1PAK9R:,QYPH1. G2.B>2%W_K<3I$[T
MCG[X7!.$';:EN9;Q"'-0VME$;2GLZ$W^4_H2@S]3I-CK-<@R'W.,/J.T:3Q0
M;_9E!%=TDW(0PT^1DVOZF>6-HX0$@$+P&SH *"8 =PE +3L"X(5&!7DA1S\6
M<!;,=PV1:T2J&L>,/K>.^%H8/(^6INUWK(--@)0P)B<+\;4/ES# /S^ "(9>
M?N% ;F->IF73B->:)@V,4ZB=7J+3]'=P=A\&ET[\NOWB$E5: ,G\-9\/CKAG
M9^@IGUSTF G<?NMF#_HX0-L>U/0> WP+TFQ^%P:+.[A&+X9]M>+G\ (@0%=A
M#+S9G"&:<'VC#4T3)G7CTDWNKB;D/.O. 5C@=ZX9D:.>C,@-4L&OCI\"[)4?
M. %.A)#I0,YX?*D?O..F)Z1MG YPT_HD:]Y\D[%1S5:J)BO!K]*O6=B\2Z9O
MDKLI\R>!.,.%@U_.FP6/P$VCO ,A"Q\5'R^<&')/W96U7^U>QR=')\,Z.(K@
M7K8C>A6A(S.2,FI=O.?R82MZ$Y&%I/O.V6$3J&DL';3 RZ&3I(J,)@I-$N[.
MFT!-8XDB"1R' I+"&Q)*F/;Z\:9_</?<1*H:B[LD6F*X"TEO&O 7[YL_?X$@
MPE?EWN_P13FQH8%3V5CP^Q\=9+5D8OXJ*N/K@DD/%<PVC.6//)Z"]D-*$Z89
MDMM@E28QT<.AV,!1KV$LY*U1XB O*+XA..-=2V01\3_7?Z9P[?CDE@5[D&!7
M,!;EG@8&2<WTEH)%=H\6NGB#GRH,_5NN6>C2I&F,DD28<9JB4AF&6)&O80#>
MOSK1'R"Y20./SPAZ8=.P5@Y5G0T2BC $9Q4FM>FD7^DS3&/58(L5;<HT*YJ[
MGND093]::G9$J6\C,?E$$9TPB2I+JP=![W<P,[6+$XU9OJJKSX,G/QR"6'+*
MT9KF1E%8J!TM9JO+YY#\>T1NO:,WC;.D&X<T7WNI!O:90XJTI37;C492'>52
M'K8E%;.!#U)UUI9=<RW:+AP.OO$M"%^PKR*>YF:;:3CD:N B: @_'BL0$&5N
MM'<;))E"CYM6%UH>NL\<'U##6A/Z6-$O9BEVL>N[8Y2>^M$SAE%Q+ZF)=+M(
M/D3A"D3).[XKB7W9\6J1Q'N]!XF<D^1)W4FR:/RODQ5N?N($W@04#_CK) ")
M^8Z2/ 4U.$R*51TJ(!'S[<2B$?&KFV:39%"DQR!J(:_6;923OIG#5,#%>\/-
M8X&:IO&E$^YU&K75@(ENCVR%-%TX%JAI&@_: B=!@0;A#3F>ND-C-_?H<5M@
M-!@V:+Z.88.,8[X[?H?FS> U]+W;Y2H*UYG?#A]P=HVJ=KZ@2?N9+0R0%)JY
M =Y[4-OL-AEZ^FU LON"F \OKXJ]^$I+S=R,[CG^6R$Q/^Y;M92],(H(RMSQ
M[7E+*HT"F*#U,A+X!K[AO_@=DUW!7CPE969N6JI)I[!<I6A-MI$&O=-3.$^^
M(WVP W(UU[(/O2Z",S?7#%GLW#6X6C57- WOOI:\? 68Y3&@C3X_1V$L31U2
MR33:M,19@C!LL;5NL/5.EJGKILN41'FX D@"%^8Y E8^(( &WG091@G\-_F>
MJ2^66Y.BYJTEH%8%=;5K#1$US-D-O@=MCD.L)96TT*J\F\+$\8?WO2QW) 8M
MRD6LI4&CD';Y'PT4M<DBPG33@%:O'47IA6NAFB^=*'I'?^<1FXBPM*6T4$7K
MB-%1=*W.*GT%!7P$+H#$EZ?(47P;X#"(J&_(^:J<UGU5MFU/HKSQ"2Q:U^^F
MPNHC3($9OB>BU7Y7UXLIR:(WCR,[Z,Z2YE(B6[U*ZY/!CA5E-%SOOIVD-2\[
M@9A$%-\0R=J&@=\-QE:L8&IAK*2@NHI(UQ\A,9A(MN(%1PWF,6.:XIO?3E S
MFKDP[/,3L9HC9 ,'OQT^=%#!X.'MZ72X!]__%49_/"%,P!V<@R<7 B143-=<
M(T<Z-&<U<53K1<,9C6HVY7]?HN7)!0P3X+X&H1\NWI^=MTOT?E".3'*M[0V7
M%*A%PUW._F8PK#/@-DV,D#2*)[A\50R9D8_.D9\CAP@1+L&N*#0^<(J/$'L^
M6#OXRXK>2P(+93LS,3)WA=(>(K"$Z?(RC:+Z0:QP/=OYT%H'6IU#E!$#+E]2
M] #BZT1NG&_EG<9YXA9G 6;S_TH='\[Q]BU=R==O*Q#$@#&\*'^,_;3K1V5:
MXU,H8NE7YPTNTV4AQ[4/%Q!IX2:,-BJ^#2J3NAL(?)QVZ%]('31"=FO1=NYI
MT([6$^.^3G3(?0K);"QG]<.;K!GS+Q-G[]EP;7BW4-\7@>(89+A<@=B-(.$5
M[TXPIT:5N*>#7P6CZ[]ZP4=.F-YN:,914H(/?=I"AS[\_N@$"]H=W,IOYL$A
MI^PM7,UB&04,=9MIYU=3P&E6+04&C@@Z+[ VZ/XK#/"HR]1^Y7?C],]YK2H"
MS6(,B4$V\V%C4/Y]Q!@TBF'(55"ZS65M90K6,@6W[@-+%X&U;D](#U;TA5])
MKD> -_W1&O<91,O9_#(,F Y%S;7&P0 ^?CMKMI9"VQ4\MQJK_3X,7.K>9E-Q
MN^C12EI%UF$-HI=PP(!AV1**_)?D6)==N]?2,.=K]_R/B8L;_5C)?ZSDK5W)
MR]RC((=FY+"=^(KCAV =LV-M<6I4I3X;W"6^^R1-5M@10<P-I,6M8QK,LB )
MP\P1UY"@6=S#HZ;43DTU1X(S!R7JA*J5V(;@_3,(0.3X^**PMT3K!3PXX:,=
M$<2%ZMJ(>7O!#=E1N0W06@VM!$10II:U$55Q00V)H#5+7D&$EG#XFAX2-UAD
M6A !5:2JC1BWEMN0T%L];(4.#W3/6Z%-IGF0K=#.MJ$@^&;;@V4):@7'00<^
MF)2>+R:G7?%Y;F#@!&Z^(0P7K\EL_BW.DAR4X\(PJ"%8VTZ^=!'>KHA@94WL
MS)$$B+-3PWZRB AL5CZPS@D:4C0R$\GQ7(K!B6HA.VD@(&-7%TC3@FHU32\L
MGU4(328ZQ[2A!L;J]_0L=]@A'QZ<=Q)$7/8<[9AYCI:W/B&]9[+*V_\X4E.^
M$"BEM=J@F+("L[1IHMH/SD^.SHX,/W3K+)U=2X;,+M*5\EY2R3WJZ,_?@;\&
M7\,@>>5O/<@W9QJ/.K.$M4FA2#6*2-CDJF$<#?%=D^?O84?VY:U\D$Y((W8M
M;Z4T@I[)]T21:.>#;8(ZL6NU+*.3FS!EYS*2:^:#;6(JL2NJK91*X%J%;</-
M?)!-3"5VI:H65<ETGF27A!4PKM+6!^TD]*(HO.[H5@P="??!,;XJ<EJ=:MWS
M-(-4WP(/QBX.R@&\ZS<7%<U"=+1A&*NM?:>;E%YR[IW9D;V:H1&I3=KW/>"/
MC.0Y0\XU#7HGO9[)_ :P7P+PINAUG,7VQA_Y%5_[FP;>3IFKO#,].HED_/FS
M@\_,XYOB(1,G>\HD*EXE/]%!/6HY<0)O\GVW9-&[)PC"'F+6[\&!C[X[5"<'
M)T<GYX8?Y\@*,_H,V,7-WM3Q29]G7[1B%3</9#D(F<?R8I+:Q@#N/2QV!?-8
M((&A& 4X@IH7>)X(<!-&EV&T"O'H^ MPO#]3)\+3T]N@%,F8'1%:MHTQ<( #
MXI8%ZJ0W- Y]-A BX6;S.71QDFG4.!8RC-Z?5HX+;H-?(0@")P_!W\ 1Z98L
M9(H:'1@::7[3%T"$9MC!@Q/]@:;G1+:X$"X37L":"+9A(4>Z2C]X\'CS+R 9
M093N$U!Y@8>,%Z]VKZIQ8^*0P1/99L9!'#[L31M:+;5@5D1ZK?PJ;VKE(;';
M\(O2S![R2U0+9@6VUW'.\P@"\#V;)4B<Z)1JV<F>-D+W$E]>]Z;[U'6C%)]"
M90'1T2*!W";/LS^4CC+D-M;/Z['!\R=-0/XHLG4>XH=-\G!M$W_[N*$RO3+T
M45)$KAI>WM<6C?1K&8H77*[\\!V "\3T.4QB>KX4L4K5+G(XF%WHAF+9)K20
MUZQ;$UR&/X4N=/PG@/H>:ITL(.%+BM^700.YRO;008'<6J<5TJ%(N;3X%@ G
M"H!7RA753 =V)3MI("FOUHF"6OB?TI<[Z&+UW !ZPB-J03MA%I"QE^0OJJ8T
MZ"GHW>1S7$DU8"<5.LBNU1U:;>\OI*2'@@L#"9(T-6$W35I)K\AWN1^B9'+<
MA-%#A,..)>](UNL_4TCZP]1%?\60S(L$UD<"K=A*EVX*4.66;$:(^UPIV7SJ
MV7D#8NO1>GE[R-).5*T>PXHF)40)==W4U4*S'\*5[6&" KD5N0GW.;ZPMR,E
MMMWJE2VC13>YBSVK@W$'] F= +O;X^-LJ:WJPP-*&DO<&([8@UL;@?]VF"7$
M*>N@R9N;6Z7?<?\*O"2W 7IVBB<]/)]N2DE3NK(,%N61750DLW:6J9 KSXR)
M)#\Z/1D43E%XML VBS/NC)@#@M*L6@H,'!%&F8W1!/US7JN*0+,8 V* EMQ>
MZB:SZ E$:^P@2[=-M&*F(-+-3 E+QCF_ZM5BY2^,9[CY*\?4>R'<LJ9@)X4
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M:G9"WE;PP9,=*)N"D4FRP.#,*F\<+UH-SE+2]7;53<8#J?3BW,&X7M!8!(7
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M81KB*E!C[X&**L"X?+,-,\%'+!1CHK_YS32H^YS<\Y6@*)M,OW!3>_S.KZ9
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M1J8Q1\GP)RZIYL3B@_,A[QJ"C,A+[P4G>+(JVC%3Q@K680C>%8K1J\WFI0.
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MR7D&I073N-4*?_$IAJ@&M!X*]N4'_92^Q.#/%+5UO<99N^2.!<_JQX+;!B>
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M Q.QWV$V&4?\#;O<WGQ8\[0./7D#DL=&"5A)W;2@B8/?05+M\YY5IXKN -
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M? !,[^_V]22D9]2]J6C*P3,W1U^@)Q6I\+2<*5!<AN4[3+B4*RMVX)S=+[M
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M[,#A''O82$G1>KH;W,MWC@+-41._:=B<4ESM&$T#XAUEL6BO>IRSY);4%%H
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M/OWDN+KNC"A*J#5>J?*2F-.2_%2RH'[W +(2QA07ILDR%Y6 5LX6:\2R$5B
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M=[5<I=^BNB,Y(\Y96\RIK2$3V/578.1Y=XWUA97]+W\US]/[3U+U53T2;^
MEPA'DO)]<U"H!L[ !_!JG@M>@++5/4_Q=;[J&2\%ADY2/JOA*E9<UJHYV8[&
M3+,:[^=![:Y\ A_@.0T<1SHBG4ATQMLL0\NAN!5GTD5+$X,;! B,(Q(X<+RO
MX,J1FJ.=D4I2/%<>XN2HQK0J"Q(?9Z[-2_UBS1&$:CPOW1IQ$CC,1G(RBG&J
MQ3DA/"E'9BV:NH/C?>#XBKP-?T';)]V2*N&]VCM@9L.QLW/XG^>UNO9_/]Z[
M?=L("7BC,%3&5)-M9^T&'^LMM+P4.'=WMV;/ 4+M%/TZ1*G+.KY?M0H/(P"3
MF_(UE_>$SU'87B:R=*^;+YE<B,#I0=4@]64DL YQH.O*!]GU.0=4A$XUO>)X
MI< 65@M)3/ )K5X(K)$+-%2"X @]A0I%KX;CW*19YAR*#K>$AJ14DQ<W/-=
MN6<;5\E0 N2YOLIST8*3S,UJX5 S>7%)",JN3DU)=6N5E9Z69W/%)BT.G[;G
M%S<97QT17]?R>99?'R9J*3)<C; 5PYK(E?B"Y.J!2XJFCB]T<^:D'#]@#"DU
MJPO--).?CKB&5JX3;:HVKL^#H&#V:P&?)YKI39[RBS6&3\M. 8J4$GM159)#
M1#%9(&0F6IH%-C 5I.P4Z)-3.R4E/Y.?1YWVQQV&FM!58+(-4.E7]=Z,E:?!
M]ZD"==K_;#Q^:]W%MB81J;X:=MAVMU&;MZ4<W0@%4-5_SC+$UB2/;!S\ \F!
M)O*&V#?1%15F7TZ&N%BCV2OA;6TQ'AC2H+/BMDZ""GC3-L ??XSN.^M^UK^M
M/Z..WNB4:Z3Z]5P<4&I7H_!*J]-0K923#I=JSWJ43#U,$O0C?.6$#OV=M7ZE
MU5K5Y((6QAL=3=$&'4!SUO-INM+AOW-"KU/X?#\'QD(AIV2KK(/WM/H\E*X3
MTDN416^\O\,4NA<+N%3UV9E7A[UR",P,N3U960YIAA)<<]NI>Y$6V&VL;*L
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MI!S]C$[I8B+\51NYCT(G3@!NE(8@,;?RA8G]!=N#ZP;,M(4Q9HYU=.@-\RK
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M(T/LI&2L-T7NW+LG$]NTI*&SK^Z*AY7_GF=RO"?QO#C9.W8Q7X?S9^PE,=^
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MES03U=I8\(884G1=1C,PM\>8%F-)&&.\ 3"5%P$VM0T3G4O$+!VSQ@ S^2'
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M6K+Q#5 0R%+=/<A8(J:/#-<]6..ZU[CNK\1UKS7R'THCPV&,1Z,Y67:;P7>
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M]/ JAG"[D=T@;4H+NS'RZS]/&4@SO<XY/.\L*Z[%#-SAN/"B)B3W9!1P=,@
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MD%''UKB2PT$/UC'.&MIIZ!R1BXS4JX8_L32K0<FPEX3S)C"YCG2CJ^+Q/E>
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M'C*ROO B1MO2 _Q^60*P;D'D=)AY%H8)@($QFW-VYSK1\XY)'!*&+B6R@Q;
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M_O8VNR^N2B?,A(KZ(4'&7;F_S>CDD[<OK,E7YBI\="M!(QCGG:#W'7&I1HQ
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M0KK/\ML]D$@H]GZ/X#?-E#? HT=DM8('X:PB/#($?N!0-*AK^4A>1%E<600
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M[*U"\(CQ6#4Q(5.JNL*H'&EWN:'S0/MJ*HT243)B=,H,R^0/)_$5^4HI.VX
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M\?M3VP[5C8ZB%^7\(GH3PRV/7F+ #AL_=.V9-9G-]SH>N&Y. 024;,RC*J1
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M ?*0&>R8&"' +A:E_2O86RCJDL=RE4B#NY6<#V-!;3&QF@_1=#)Q\ FI?[5
M!59D-T]R[EF 27BALS%/3:+BE9U.O"(0#ZL+6$K7=ZE>W8W)GM7\$FY_-AW/
MMCVB243+'J2!QZ::(Q+(#>BG-=$H%EB+ 1'"_,1%?L"17]YD*/N,3&78IN'G
MW @JR<#4;;&.'ZT"DG4S<MLONS>_XQ7*-5=B>B^\6<[>J?K-JG, @H6])KR@
M?Z:FI&H:7\_)1]=6:M!?Z5&X+ LHM5?/!?[SZN2C?7C6/)8>D@%<@ 2[47#X
M5<M.^9DV)L_F[0Y:W8K&HL,&&==)NH%WK<9=GVE!\XJU^_[SI\B9Y@DSZ#%
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M3--B+IF&80& P*9T0YKZ.E.FSDP:I;TK0+6P;*4W7IL5B$ 5SD@2Y7N,40]
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MPHVP\L\8&>;'@^<GY+1"!H;$7<?NM0Z2NP9#R7S2[DZR:&\:<G0]>/KZ?-W
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MG#Y_<ZP<->I4;2N#UZ ?$-X]BT9I.6(.#@G0/V_%G]/* CDT N<T@:]49;8
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ME!P@8L+LGO^?O7=M;MO*TD;_"NL]F2FI#J18LIU+^Y,BVXG[M!.5[737.=]
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MW?W'U/07E96**N0#UFP_5_+7%7L:DU;S+G>YF&JRY^64;9!@?1P1&*)=!?V
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M,8B8N(J<4UO!3;RBT-6_6RY8_.KI\9,G-)FN6,^Z64A*\Q5US"YVY=/6L^5
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M5C.[CLO3<HXZGTF1E#='4R Q%7M;P_YIV!UJ;F]=3,!Y%ZVB=(M68@%LTYR
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M/:O-C;%XMRSM(+$ZEY4ZTR5L0AJJ9 ]V(*67IQ:,G H?X-X?4)R7JXL3OR=
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MU#(Z#[KO!S45L]&;]V>CB\1LK$<_'/_S.!O]O*GPO(N7[_%]'()L].'\77@
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MC^<P,/':@XX$WM.#2GG/Q&<2.4D8O\L-D!%/_+JI?B^E&E[>M2\@/Z6F1M1
M RE^Y*88\:> ;*(XL%*-WAH!K')94'RU4R,A%%>$-N0C$/9BPZ6QL'<SUF/6
M%=Z>3,9P&$SPM6"N:&L)[F0U7(8YA">/H37/D$CS!6J%YMV'0S!R4<K(K?\
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M#SI]"F,?T_MO<NJ_/2+76W@1I=K7L.5E#")-RO6D75@@R3L)_"0]!)Z&+PS
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MC2;EY&"0!<T< 3N<59,5%')NE_IW-OH049@7T8[@M=%UB3EV%9YA+%/JFB7
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M3_=84@E1R7%RFF6<.JLSE*%5E'</#[L.NZJF59SQ+/+-(^=;,;UN]\YD?7H
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MS*IKZ_/RK72UC'20]FXF$T4)FJ1'\.6(73O0M@6-M;%&S08WC2#56",J4ZV
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M+N#IZ!=0!])1>,-EIF$V/TI,X#SZBFJ6_F@TFTP$Y5_9*\G]6JS>SO>,$9$
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M'X-Q#ANE6B_+7!J@V;]]+S1^3LQY?3=$&.A^JK\061,]K2>Q =S%NS/K"GZ
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M,$N$*#&>&#WG+&AS%7H9L?F[5SREXJ!#)5\5O"FT[J*R2,G3\\*U3#7J26*
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MD>B525:&<ZMEJI1=] %O7KVPF6LB*ZS!X/E!]IF>S7VFN<_TGO:9REHD:E3
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MN"]\>/GM]Z\B%OE\(1*$.K'3QPV/+) ;B0S7Z\^AIO#"=[E9+NW[V^4-;<M
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MF0R34H6]91;UVB2P=%;*XI_>GW6L+QJI[24S ^YFRR$B4%@\!B9<E70U&TC
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M4$P6]^MIAZ.JU%%%C<=O/4+[V%IZSR7;&D[LR,)&21]<J"K57Q"+=<XTT7A
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MSM2(=0"S7MH/;2U]2V<*3@0R&+R%Q;_P+;RT/4R^;O@5BF7W39S@<NG0J0X
MRNY%HSJDH1@/9HQD"$&[1+Q@OPTY)8$MQ?#I-9)_,WI*__JAYVR8+Z.F&ADR
M0.U4)VI7Q0;E:\R-:946L#<BQP!(:V'3F8R0VQWXG1/X@A JHY._F*/E+#NI
MO=Y"22::,I0(=>7U78R-#5L#@'PB0[AV,G76DM/>BYBC/B]8$X'08/ED'5P+
M;P7#SFZAA99$7'P$GU!=F1O.&NZ&OPA+(X>TF%(672IU&!APHLQT\NHDKMWE
M/S'O0.'L=&^HS+[L6(J-2R;F.N1B&,RMI".T*P =VO,[#V9+TW+DP@RW EH*
M&N*B!D;8SH?L(>@F/[FG7)->-.(N5FG4%?C79;Y*G(Y2OHBJ'[LK/AJ59L"@
M -_(/!2[HOOZ(4\8188"TYTF>05KLK-[I!7]]^?/SJ5[&-Q2I8?+OW]V<?X\
M^3$69\N0C^J@[ Q'VC&&=.,ML]\(0\0*Q":( ?[]Z?//SY\F7]-ST+&SI,YZ
MQ,?KG!B%8EU1<+J]WT'(EEQA;=P7UIB![^B4AB'":Y)=4*ZYV)!#'.G_3W(5
MSV?6YX>U'E .Z@'LCZ(3UDG?#S@T6.*(V_KB/2(7GZWLE%96%4HR%VS'3ZZ@
MK+^Z11EI:$ ,D?"FF!R;SBZ/F-J'UN=],O=YYS[O+^SSSF[U#^56P>$Q)D3I
MY^V]/T5X*$!J+7@R*FJHN%RB9C>?X;.QB=R0S@+<E(0^DW&''@I+K2A;R-"#
MD3L@G8Y:@#8^,!O8;&!L8$Q]R%!!K563)<5R?VXZJ3PT+@/M#".5#-<,*U%-
MB<,JC2E/(H\9B26S'H:3JRE:G5+NZ&*]YIYR_Y8[UF\0+@TI&LU6/ENY6+DR
MC,-J4DM;YMLXCQ3'JLJ6QQZ!;6UIX@E (VYNPJWFX>7MM[VK>7IRK?22[5?,
M;-VO/HZ:^6RWL]TFWEEH)'; O*.*.U:')O^Z;JJRF>UGMI^^W\NY5Y-%ZO-,
MM4X7^7J=E]*&7)4TZ7*UEQ[!NLUMVI\KY]%7%4?X:JF;*>,"0ZYUFPU6TC=_
M38$P41->B5"J]^HD?SP;] GS(1[,9/Z],T%J"QIH)/4&FL=5/C\T&<6OB<"-
M)W500& 4M=\P# %GL$#3]M7<DW:F3O2,=+]</WRZ66D V:1%CO8V<[=RI@ \
MC\M.)UZ+. F&/&BKV;K,-FCG^G*$%0?*M:@Y1FL,*I'"(Z@]!PI(:&#53'C>
M+O:UM/)J:]1EP=]1&YX(F'5X4IF3Z)=%1<PV\<GW-<.#UB)>;X*+^0J< M3D
M9B$ZCP)B9%8'[\:O1[HWVC+5CN&JH(7-6-*@);JK6A@X>;!:_BRJ6"9-1TV*
M'%]K?UUYNG3;EHWA4QC+3)W1PKI*\BNTEKG7NAJ:#GY+75A^=%7@$__M* 5,
M74YH#W UH4Z2UOV)$"TOA1)WW(YLD$%YMV4,KMMW.-C@@S0!3CD_:6+D'X9/
M!\ #J$2P?YTO+I4;DMAW8 ]Y6<D)JP/WJ/1L//:'B($5#-?*)'0A? T]?@9.
M*^BS#I3F[(*0$T7$31C,2* 9XPY DN]LX6H&$>C61N-(,W-B9U7XGDQ>CM\S
M[5;/YT\X/^(9?0#,[ST"JF&?Z%BE=ZQ^;)*+*U+FR/WKEZ )4%93H#=PTAV1
MO=$H)V.]'68(,Y9@V,DQCZJRH" X(2PC_'1P9QFCKC+5B"64 T0<X&/<T>%?
M?91ZG:[)$( %3C+!/)YB6[\9PETB-(FM!HB5"2YU.%57:(JEL(A:>AAGD:%Z
M2)*F+>1H,2[&^-])=U;WULC!&;PIQK)U# JTY"Z\(3FV!Z&>F+@[0F,?\"R3
MALT:J!S(HZTQG%H>"STXBNC''K*^T^ ;#H#J6J9H3$#E"%YB(@*)1DWN9Q)0
MH:? \J8A3\1S]=V^R'@WWM&C7I>U#X0T@3E2:(HQA=&Y$'%OI],S28RE<")(
MB(UK%#CDV0.1;YGX&@:X#=M9.D#8K\IR-2M!Y+L4CSX0?LK_/DS #BD5Y5#$
M@A<YK?0\O2H.C6P#?8L<I*C:U-HBL@C$6NG:M-#-,NF3;[ZZ% [T[R^SZ*<>
MK/@1Q8GW";?1V*;B2^NRNSX-3T@U73$"*8^/<+[XLHAJ-HX(EA<S?;&BY.9O
MPF%@#>0.WQ?LF=7V;,B+IC@V#%\CMFK4DE1"*9X\/-TVTKKL[[GQ@GUO)S;M
M]#X[7W XQE(:&FPED4IZ_K7C1^"=ADE7!9]^*W?V31UZDP[0ZVO)K4\>@;_?
MX.G#89+_?G'QZ?DG*123/&C>W63XOXC*PWZWZ1?E_H=8;W<3+%*EG8XO%(NY
MWT6<941%JGXY?1WL9/"]N^,/LVNN>0+&W+VJX]QY7*>J)'&"(R.)^J+=-/;K
M9GE#$W2J#\)<K\J<0I1"X0K50I@5R?E^D.053V=0TPQJ>D_YT@OV\'R@4@3I
ML\;@*Y*JQLAL1JJ=,CYD<_%$_%ZXJ1N5=;!C+_S;1.N(T'<CHBA6TV']$.;V
MO&L;B/MQX8J#%>@L4%YM<\U#:DT:KE:93W-5YXL7&.QF+0Q,["4!3Z,B*!0G
MN(1X+U$VB:1-?;6,#C+)-M@88D-^*=\JG)(XVARYXT3<CQ<0_[(U>FRA*I-#
MT1[=O1:N9]$";Q!B<]7,W=*,?O\#UO!!IK@,6STS$XR3I!Q&BMZO!AN:68B%
MVFS00_#P@U1OQ9K*[YHNO4\MJ-E^3VV_]1[TA?T@./%^S7JZ,:4Y(,X9*2=X
M!I)4(/&>8L;P8K.QSL;*QMHK_&NC0S473.?36D!0D31U[6ZLW,9YX)(E9" /
M42[##];-<C^[R=GR_#$?>VG RS%_0UE4JZ[7"NVQB(JJ&FJ,_*?[K;H^G285
MF6A?9QIQCFNTC7<HRN773.!\;]UJMN+9BJ,5ASR*V?6C5 Z'J([:;JJ:;I (
M#X#JQJ)9YZ4C; N@K=Y5?!]!)T:R09QP/"B^L^(M76!0R&X+5_6=-\.\&9Q+
M[RM"N")JQ_'!MV55Y*O9;&:S&8U!'2C5,93V+"ESH27#_. GM7>7R%RI4XZ-
M>K2"P @/QBDM[7<]761B@@UQ!_6YJ-8O?8&ZH6FI8@4&*)4LB?ROC6L=[42H
MWC<2(@4[-L,<$L\;P?M/Y%>H0/6[B".XD8<=YC[_EU,],\ZXO!)X**PQ=\;:
MM+-ESI:96F82TU)I=)NWF!58EQ7^EPC]H.." 0+QW?@/1@7BGZMB7=0KK=H6
MA+L%VDWHIYG3V7<F'".T0#C$I3L$!%QY_.!LN[/M]E.TC!$ 6W:8#&:!Z2"+
MHOR-9#B;0UZ)9$7F2Q!1ME>F\.DJ[Y&5S8,G)S:R$-6UUTJMRE+8/'ZQ9*%J
M'FM:HU0:8L=5V2E*.SQP"OI3T+R,2WA*U@]M1N4'IJ:E#C>KP!%KZRN5'HJP
MFMS:VZ/1<I([9H++)\B:S!D >@;&ZQ6DH5IHU:#-SJ,1!$*U_$#'S360&L&Q
MOS>@\=="8^@9':2;#MPI>O^KLMHKC+ _7Y$99JL_% _584;L,GB@)=KR\(,.
MU+S;MBQVE/TPA>&)X-H_UKNR$HQBG%CI]B8+K2$OT&GPWI&.DM C)3.BP[@(
M6>:[<%DZD\CC1JLF2X%C_A(&: A7@FJ2#853\+RY<E@RH1L [0N)818ZXM*L
MUQ"WP@S1U2X"_H&@G\IS\ZHJZ3:ZS*6\@TR7#3R6 XG1V0]M#OX 4A_8(.'C
MOQ]&D=&<C-\<,6U=U(>LH<+X-!^'IISI)(![6<#151G^>&7:(MI_#?$H.+$E
M5QJ=UAJ;6))]H1)@F6(*H4VWL\3KWH=DW?-*#X[(;DU@Z/@DRZ;&"0IL%]4I
M&'>#0 .L;/YO,YZ"^2"1B<]F9.*,3'Q/D8DD0=M"Z;N$9F2W,R$\',(DFM2O
M(BIX&<2X0[G)>G&Y86)=X?[?85IA,E1RD5 B'6-'6=EU>[E:%SP6R76&_4'_
MS\G4[NLV'"L=WTCB=<*EY.I#=<U_#[;XY).%\?.Z65T-)>1OO<+D?@MT07JE
MSX()ZX4PP^!$!NDN^]Z0I;96*BY0FLCE4P9=JI2D\?SH$4$?G5R;)T^RS\/:
M?/K\,[<VR7+01TGP-/G$&Q(-[Q:79T\2M\QG"6CAV0GS][+&?/S8P%OS3.@%
M7A&%<'7!PZ"IQ"W.H9NB(N@;O3H)DDV?PO0LWIP]73SZ)KP'5DQ[^O3LR?/G
M%X^??80W6A>FML9TS,^>GS_5-Z%S%O<>6FGDD@Y6='L(=7/L]#,QNPL>OPDO
MYMKI0+ 0F/\\L6+3T$['@X@2PF@$.](-W>4_%6!T!X<9"[]3W(32?B?<U[T
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MLXQ\TAW+G:YX\$6+'X-B"TD4QB_DV?P;OI3F/\-MP5\;!X+IR<C4":F[W\E
M2__/2.!\66Y)ZQL3N3WH)E@]:SZ0)ZG^99L%RV)6NF(PP9L8UG&2L:CL9O!0
M^[H04VW#K2AYJ$>+>D^9U+82'"EBHW(M-@=1<[8JNO>BA4)YUX2S8W>< <CK
M<>,,96<03Z@AWS.37&$L^52ZL_7A^(@SCZD_1/!-0K+8:W""<2SHSEK7/#21
MEQR0C0G\B<)=DC2MVOVUS)&[\K)2:0\C2R=!NDA=G\YW\^VB+-N%%&%'-&.4
M\H4E;5:=GC96): WBQP4=ONS6C7J47+<N7'P8XQYQF5&>1?-)W%;BRE<4,*&
M KR6W"49T^/#.=0K$PM<-1K.\5.-+_"1\?6ILU*FWT;:.%&DQAH([U-O9RIM
MQ(!A]%"CYK[*>DW&'"0#9"'=OJ/23"DE>)H*5-:*B(GL)#;,JT.GHHMWIGQ\
MO<^A_5XDI?@'%4ZR7])B17'#;C!QYGFGQH,73<9DE28RHRL/LC=C$RWF(ZFS
M]6"=X/.O>.Q?_-1H\TR9-DI*HI+(AU A-L)%T5NW3L@T@@W>BD\?IFKGB[=R
MI/V\XZ9.ONL?G#W; \.%#OHT'$C]'G,,6B,"%C(YE%3BQ\V^'X=>IM%9V$)R
M\+&,M!V'GI( N4,J6.D."I.Y2A12N=*5WX;86YM?I/OK(&CN$K+"%!W&!XU4
M)_<_V?D'V?#Y?&[XS V?DS9\?G7URT>9ID$.'?=(U!/)>8XAPI&1YZO;7)*C
M03G4U[Z$\),Z2RB,],.FZ>06]S'@ >I&A]H;QTETE7=EEU 2N=M!D$DZ1<I#
M*C=5_\M(@MZEBG OY 6A3V7NM0[7ULA>R*?&"C(A8ZL,%^_MP"<8J-1$:$2_
M)--3FHTJ]AU*.%Y<FRH+2CDSR%P1P8RQ-&@AS](BG/5'"W4JPSAJ1MBE:J+A
MCW>48RYN]ANZN[[%QK)#L)X":LP0[)L4Q.YE]8F"7_@C#BA\A!:.6(=HV@F?
M4(R+->20*IZ9P/$GEPHA?8%@UC0,MSCG%\!V'] ]%?MD1-/0*BSI?]<'PG<X
M,BD_::)*$ ]2@3A?7%)YD0/$S&4(Z.JU$BBGPRMXY6Y>)7FK(M>N^?>O7>-W
MH.A2*J=!73HDLD5P)2?R5HKN4[^24Y-.<UKY(=<7B)!P26PS]-PWX7D*+;1)
M#Q<-V%W8K1V];+4)Y'C_3)[\JFH:*I+2ENG2K)S+TO$$TZ9+TL<6<T&]XSWL
M4KVD)2HW%'QO%^&9A14@1!/!(FLJ!T_(\?7*SF3I>[0P"6D!Q2"!.E"IGS(A
M^E]'YQ/R-22H6AC%UUP5V+DQ,\!+05YO.,?$9D.6@,\0W?=:-HXOV^+V^H4L
M[3(F!5\RG;*6"L&)[/N;_H)9#5*7M!R\+K:[A[TMG Z8 BV6P)JZA*O6:TNA
MH[04ETLFE#80_[6<*/4>/H:^/01+!/7CIHN2^?-&O:**/0N":H$,UVEJBLY0
MF;:F\+ZJA-^'],^X; ?2.:E4I$*BEGN?+]ZP[ZP.MEIMP1Y\8HU<"K\-#YQ+
MT?&GXD"B+&%!Z">Q#BW?'RTD!63G\=Z*U?GB5?RBWJ;2]3V^H>[;(@!W<"5J
ML%VFOKUI'_CE6L;09E!9'?24%R GKX ]^W![6B3'/<P!K6?\3CFG^9%=YS\^
MO3ZXDY15_G5"5]SK/JQ4%P[<?6%:W-406T_V JA7I_9.=>2V((Y;_W1'_4P*
MS4\]2K@W[AG88\9&EK$X#C;R'2L;E,V^J\P)D)4ED<;6O_2XBU?1 '"Q[D:+
M@%1'T^9'.,3P,.&L+*O^34,\+5K7]^HX-9>9=* 2;'")B'Z5V-_R(9,%)R\Q
M?\/!7\;A4Y<BSN,9=,V38@XM)/&J*.'U)NW%>8_Y)=O7 NZ)15Y4WTH9+B!4
M?VOC %A0LR4XP5[C8,D120A&]JX=23W!/86<$D%G/FS1*91VI!,S>H5>LQ6
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M3&'\A?QG4 I6,6Q!R<M%DM&CD7YJ)'880HZ.:/Z^G$ZD'5P 2'ZZ9Z\D^/M
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M:2,O\(J)NFC-4)&;FK?+)@G3(X(KI?L 8YQ0,DR]P:A3F59E!O($3FM!WLI
M%<&VU-5A<G^V'E&"6M?1^;"$9^ETL@ H%%(-C!4T=KR<<KB.,Q$/]X-SWX(D
MZM.42_3MZOG@)$S(<:-O3N<V?X5C1&-R#)&GD,'[SH^QQS5JWGT]>41)<Y:C
M\;!K0$](^"FN/0R/H5/U)M>_U1$DSZI%9T&VI)Y2#B@NK;IC*A-UAWN.FFQX
MUL13AFO^_%74-[YI&HZ)S;"GWN4Q _"EG+UQ+ZIZX[_@W?VJB/DOXO(\)YW!
M5==E$;P?)?P$5VW.3#2!/.N0'J*TDWR5;ZC/Q4!GIZ"M7!-'1F#!C&YRP4X.
MQD$C?Z=&U]L;'^3I^0GNS^&-)TRK$TCQ"12?+%,*>MY%\D'5.L!+<*'0I30)
M(+EC+ZT7\ZO>Q51@_9#[1K0RP(G32V1T<\RWS!\DN,(84-!'#/Z>L.["+'"3
M]2\R25,(; A&D*9\ODS(>C4U<PKSCHZJ9SXR[\=>)#/&0DKT7ZN"4 ;3:)2'
M+:R'ZLG3&A_OK;"4(0"AXS;>"JIA^R[848>8#3 'I \R+N=%#V\:7C <MRO$
M::8\/PQ<@*H?[MNRZ]7FEE5>;EQ&<M14Z<_W-;GJS HFAC7EVXB?-<F H29=
M=HP"EXZ2#[(=]GQNA\WML/>T'795)"RTP(IQ 5B=A <&^,F65&ECH/;(";>A
MMQBHU0(*C&21,RQQV.-^RF>MP3=N20,;O0OKM+ ([,[CVSJ&Z<L),W1TJ70>
MX?FKXKKL!*7;6* KH/-\)QZ:QY=ZN!^K:K6+/BAQ[,C(-$I$9B,2WZ-LSG*>
MWU$D.TI^S4*:!DNA9T7_!]<)ER1SR#SZK3?:TE\A.MQQ7HZB% J)TNHD4,N<
M)AJQ9<NK"O=)G1P;.> * 3G[;=$JT;>0(D-U#.''9IN7;&E]\F2_LOG_9>]M
MF^0VCBWAO])Q-YX-*18<D;)LV=:-&T&1U(MM60R1LB*>;YAN] Q$-- &&C-J
M__JM//E264"A9RC)&G+='_:NQ>E& X6LK'PY><[I!)JNE#^XA]DI_)1G^NCN
MBK0&[B:1I&0GE.MDQW3#6C,S53RZ&W_;#XPO_#:_.$[0J910H9(P/\::TYAL
M*2A,0@"WS!85X;IDA$W]IF(YMB,A\NS?TYU8DHL  *S'YD9J;%8J!J@=^;9K
M'_F(2P"Q\PBL9M(=3RB0!,J9L'/&\LT=AEPTJO6QZ3,3IA7%DI.1[F7=3?J(
MX>V. S4FLT'A%14ZPZTG<REQ6Q<K=@6D(Z2L5PEP+_77SNUL3&H4]=2*"WA=
M3,=G: /N2T7=T6'=AT=H]<;CKI9/3*9)C*\_4WH_@0)]5U+J'Q)GX:JN<I()
MD0!DO70\!Z""Y:Z?:RD]&/)S^I@O!<0!O@3,_%[1.[_I&A*<TR>CE]=V!*W/
MPX[Y+'%(W=6^WE<JCK)0(,#\$';K?NR'T9&*3\1A3ZZ;FP9_6Z?!* >%D(20
M0W2RJ_A&%[(4'40^PJ$L=!&RC\-@UZ@_(N#@.02&8JEQ&*SA/W#[R+C]@3X.
MON-,P?\?2'F2CV0(\+2#'9@$G].MQ=P\B]]2 $6A.LBJ3VVN,]?3V>+8XES]
M)FGU.^:F04>_VHV*C%@@DHOB+X>.E)[)&M'9+ _02*:<^&QV9[-CGN%3%N3:
M=:8B%4Y*&-.E3"1IQ8.4.\%R70T8TOWT,VHJ5S)4ILB.< 1#ZQ5%K[/W.YOA
M?<PPV!X&[+<\XACN:]S00'ZPCVN">1Q$#I#20$H@/']/$?[Z$[51I&8N7733
M]:;Q-O&K@C2)G#Q0AER-+:7>S5$01Q$JCJ:$!S-F\C $D4MD.F?S/YO__<Q?
M ]'(!44Y"U4R!"1$13\5V#99-:KK'G?[\'K/GO9L:H[,43P1I\HG;,^K@0Y=
M[&)J17<S+22H5OGD,BP-WG3M%3J:E)#3^SX;Y=DHV2COMD)Q@.MRK[U"AFSR
MIPU^JR"4?XY$W(-#OV1,-I^Z]%VJH#*1VH&F3#X+__,=,L3'9SM\6.?H2OHA
M@;F^59ZLDR8:/-QUN!17I/=-]1,BOTU-92)J/% WM;PA]&V5%K!IM%Y&YH R
M_F6TN;]Y=?NY&R&YAX#PI ^)4/ED[5GB:ZZJ.4(N_[6ML'VBY TB@+9*!P*"
MMU VSKJEP38&)$_(=OQAYGEWE%D@;+\(;9S,P^E<DRL6)J\9VG;K2E%]7&X^
M_>B'ZQZ\K--FKI33+]Y+$,^G9Q#/&<3SH"">7Z-G26+U1' W]B8GG[0!I-U6
M.MFW_!A0'&Z!]]*N5XAR<&]$=-EF2[OI7(R!.H/[P:Q '#W4,1HC4V%NGM+Z
MX"ANU-==MQ&FXO5O!QY>6-Z(,-]VZW%(NL&R4C0=O&9:(-]^.7E&8Y7<Q #@
M]#8RUT9_S7RX(6&I@T-C%LGP1D,>!*X6Y<6Q7Y"!!!J,":?%KJH8X!11/60N
MZX.2=N80,_D7?U-+O!KI5+7XQ&IP^HYUCFE/L ^"E0&9.^%(()Z?JXZQ/00L
M@)'6W)OV7_236'G3D]D#+3.8]34P*)E2D)J<FIE_"'U'0D/9U&VXR^%ZA7$"
MS'JC.BR'Z/6IPS&R< &[P6],<!<B@M<=RX9P=GY*G)(%W'OX'[PSPD(XT!:/
MT*@>;3?JU!H// )P1KV5>X"L^%&8VI:0R,Q[U>HP)F][I6D,"]H3JUR[R>*@
M9.H]VPNWJ7_O%S1QXBZZL'O91)O:5X2C?+W5&;,XD6%#'H<4YA]W6J>UITE=
MX83O*WX.I(.LU=]P @D\T!S@[60,36DG'-HN8C!*\>!QG^JI\RY!9+;E.ITY
M-[D6*HACZA!F?EEW#C /0TE14<9D6=B3"Y(0 3O#"Q'#4G.[ZF6FTSP3DUS$
M"B1RE8<X)%Z?!GW5@ZON_XN[4P#"#%6R=L"M!'=+E8,V9"AX\=BFTTZLB^FS
M\]>,E\1XE.'9##$@M7^=]\"H*08_9<GY)QT V/TX(U;(O?](T$G,A2AF=_GM
M&IDS/7MB%>Y#<!?PBTL7P@*%(P&Z"@?]!Q46%4]%!&3U8923[1LWL^2? RXU
M85.V8\$V7\' (=-VL!_BTSWR;0I1S:*S##^RW0HI-;&/\2B&:\T ,YN.63MJ
M9)EY;II'?AV9W#/XM74UA53ODI3./S;LP*KU1,Z(@A6:HF0[!QFNH5^,!]?T
MG*(E6]=[@^S2B5<Q7I:/MMK-5--]3,9FT,=*T6,7JU<[8J*%.895;([!0]$@
M6GSY-KQJI_EEW@WQ,+&Y>FJ3S8]F@D'[QT*$@1>9FJO]_L7JA?OG11.UN^3A
M9J(,NJFY4T?UOH89.Q2)<YS92E@N!MTY"J-!@K^0D6G\E_F,@[3ORC?**;3(
M,6Y^0R 98:]49,:",B/4$!\]'M9ZVI^+P]-EB #7"O1* FN7V)AKI>NNI0R]
MQT"1S@O$]PC2 /./S"\HP%/MO)8Q=F7<(*H:=M-^3%NX.".[8 (F)H8<<0$S
M8GF.@67XG]ZK#I#S%HL//G/7P9IJOL]&)J=E<,U;(AEK"RD2XY#AY4CH4-;*
M!4W@F1A5TGYT,(;+<@CG#9@U.YS!]'Q1^CN>!W@?=G86F,?M"_GG<)%IW+,Q
MT Y5J[&KRO8$7-\CA@C^W1/O%G$S381IAFJ-\?.9$_(C=FWEB"$F^P5#:--7
M&2/('RAV;G#DT9??5,=$7TZQE;%W+I.KIR<6_$SI"2F;.-RLX\Z'CGP VU:!
M5,/^PTOJA<L&[UD(J].,?>OAV*VG>'EZ*5^]_,>3/_P?&2%D:A0$B;/ ,/I)
M/3L_K[N_T\M;/?VR6#T;*_H'=BM%.-36%^'_OGJZ>IDXFO"MBW]<",^/2[9X
M:WU78<XI_.?D6WK!O];! [^4WRA77]8-$98*S2B'HB^?OZ(;<>[N6=?OY6<B
M(TUX3N,7S,SZ++-!'*;J%4H>EIN=-.R2;F$_M\16BL$8G=?EZTC69!,O8'0_
M2<6<Q!!^%"2^;!>*)61-/&D!'K(IX-JAG L(.E'VIR6J0U>$K=U10!%>&A4(
M:LL:Z1\ONPT'D,107P'9M::I8T<?0P\][GRZJ5=#J$*'A><R2$WU88M*$RAO
M35T:=FH^.]PW9:O<+O=1U^*)7U [<:JA''AQ+XH?#<XG?%6OYNA7J,H1]E+8
ME3S1I]0ON^IPW6U2A9-E7FLE>G 7EJO:L Y-Z2T?582GM[H;1=?],@&,H_!1
MXUK7_7K<#7C ]Y5P]X_GYL2Y.?'^-B>^CH- %N= [64D+G8Z0RZ1F87HZJJD
MS#WL8:M AW.#*I2NPZK74,>?H=WE4_$M)DL?[@A B 2>7>G_8M:GRRW9),E!
M8F/CFSK6=Y*9!9&M_B+R,4UV\*L<S"R..@\3QOW(DS,0Y*I>_.EU.7*W N(<
M0N+%_,@EN^L?Q_ZH']B2*Y/,/HY)4Q]$RJP;+H],GWU&'11K*QU+ O-<8U*Z
MCZLKC!AB<ZAO42WB2H>JMR'28>5-L#DEO^3^LJFH&D$AI7;VB46W[&%\&RHU
MH( 6F_TN0Z<PZ*JAL(6DM421(-XAJM?DN</]DP A2A<'9M7CFW>#I112#,%
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M,J;'9UMZT#"Z6H._4X"XPS6ZM@0?>M^&P+^('=C(S*UC4I$I<=[%=)LF1]*
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M1\)?S9$/Y.$ DKUM$AIO4X*&&YW1ED/?DR[HPQ.FGO/A$@/@BB%&GD(2$.X
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M)Z)-V<4>!P;SF&M@@3'1$C$3YO_?"BX*"KBBADW:!HGZ-Q^LO_SFY8>S;99
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M?D8CV4)<A_PR9FCE-VWX>V&H4S8SJ;J)*HP3>6'STU*+S;F;/4Z4J<.1C)$
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MNSR* KH_UZK^IA8:=$QUUM(8AYB$$/,DW\@%#_\/P8'1H3FWB.ZIO[NI=D(
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MSZ(02]*?16U>4&FI,@:[[3KO&Z/?,W&1=5/6.\*A6.TR=:!.7$38)B<MOT3
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M,@S6QV\E?P 3(GEPJ?DH18:G[E@ZV.1V^&PK%^\C6:"X+B*"'K7>Y76%USC
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MPQ^#]Z;2=0@D)$,I!UV<>+C+?\0J\5]7S^D4>!E/ 7N(H2(XSF&Z --3@ZF
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M(Y,!5+K:?'V7;EQ@\L,X[%%@#+NQ[#F'M RF+V'^0[S%L-*PL4INDZ/6>?!
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MO5HYS-5=(@.;_\6&0&?BOO7;TQ.?'HV\Z?PD$QA=B%06'D-B*_R#RO+N9,8
M'^5R.7_WLCIV!-(+CWU@3_WD$WUT9<WAOODV/JGIG'_;0E+('D^=-'Y:*<0P
MH"$]4"ZRV3KBD->%)#EWHH^4RN\6A3;$7@?6:/!_B0PL_(GI3SMI)1=@*U]-
MV;KU2EFFA*"Q)LT'3WR\"3E:PW3#Z4<-PXKPP*(SDXYR-908)NLE=);6_9!G
M&O:E?]0X+#D\*(/H$*'REZ+9B,+!+5\I'&D*F$USA*1_/=L)O=%WL42R4 B[
M11NROY5$*K,(A9:=:WZ9<N]6&U9J9MJ00I1%F:F-A$XQNPK\U7@C5O#DDW&C
MA9"_ZP#O3(K8#&]W'+#NA<Q+C!(E.;9CK@!$)J=\)<#RH(=);E_5H))^&Y#P
M#OC82<V0 ULWP2%.,HU/.2@F9G$*&F\7FZR4Q*&N0B#UNA\.#NE[S-SMW>G4
MI#I&=\?TBY-'-O$W]4LL'Q(,JY%8CS<WU2W@ R7R_X;8%GG^ZLD?2%'WR>\*
M[O&%)X;*YMJWW;6R1<;9O>$BCLA)/F(F,-0U0_9R& ].%Y$:O@5759BWJH*R
MQ*U$H+96/$ZMG5W?RY'.\X2#2@\S?F;E@'=K$QP&>F?(U$TVEO?G9)(+[ZF[
M#*9YXTD+M*@Z:52+0W WX=^K'6S_T&^3\?&(F#_[&,L0"<VP[+BI:M /HC V
M^_IR57QOI7L/EY#N^8N7X3V0;90WP6V7NABTX/CM:F -9EV;HTARN9;,K!"L
M'7GN1#D@$9@0+U:OXNS((,:T 4LHMU,:[42T\K!B8V,K6'5NQ22%;WZ4E>C
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M%*SIKVF+2^!T'BY>[H?;15 [Y'NAS =QSJUQ_2PJEDSMOX5N 4?C\]E:F]Z
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MXTA$V!1#07YV3,6[F%LWY)-PUU6S6<=0[:U1:WD2&H)W)>^^DS+I*P7-/CR
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M4#9:_6Z4DX6[X[Z8'!'=E1)&(D6^J&9=8T%$WC25W'A75?V!F37K0H5C2 6
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M [4!TM%JX05= R7_ZLISIX?RW*$\]Y'EN8,Q_A<SQN%6OBBGW%*L'IFV6W.
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MAY; -;4V[]EMET\+>* _KY:% $I&%A-?!7QAF9<KSIB8EY[C"*+] \ I.UW
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M9M"?+6I!6PF5-%K-YBRT6U9SV5VN8TC6.)'4J)8FS:*FR!^>/Y64D=+N"##
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M':65*)C'6Q*)?_-[/4SX"^/VR[6@N;]<G]'UAYQ+W5O'<OX_% 6$T'BMMD'
ML)S"X @&]+?O@4*=&CQ<R;-I)/H\;63>L!PI74$"ZORW[1)$ -@E$PES"IR<
MF,MH/-;<[X!;4A( "[(/;WX/^+TT%Y/6[%>2IM2IB@1!3FA3\$UI;!U)!L$L
M!5H>Y;>T?3=6O3*I"(F& N0V?Q3613@+G'62Z'P_*8S,,1F0RORIV8%3VR)-
M,8C[\;!G)M="BOM\F >.FJ?U<3W,9^H%/U>\SU.-'<D9.:@AL_]NU3<)3X$6
MJI/&X*@S0;:.,HTLE0F\,4,?8:,5@0>N9O DMK^#0P'C-,^4I.=0R)\*0*(%
MSXR&E) VY1]3#LJ29N"2>(K7#MT2A#"E$QT%S0,F4BA>]N8:[DAUDLUVT.Q.
M'=#!;M=;V0+5(7FP5R83(*B HU/"Y&)0(1=CFK"-([[:<9^Q.4C.;4H(SKNM
M@T RP4 !2$<+YLQ01+!:M^T Y0]3N%X0R&PTHK;]9LLU,*I&@B&GPH=JA%"K
M<VFRD*::'C,UI\X$L&;!]1(\*4:9Q]8%2/]5P<;-,IJP<'FMO13P#S2@1L7G
MR HH.509+^2$WVKK#V-Y?$>S*?:[;(HNF^(+LREJR6N'!\>;2EX[LU*C5:1Y
MMR0EJ8D/914J4BA>E9#AVS3 6VGEE2OS7.%"V#]232*NFY'"(E/"@M.E)!H,
M#C58#L+R*X1>V";&65B-%&R"OC)P3=ZEH5=!W5MZP??\V30"+?I";P"[V+08
M9XE/G\ ^55>"M(U8D"5J7* %LZB[RI8A\I'CBA+!<VLA2O,A^)%5]FRM]EXV
M2OCSV[(.[[7L&+2G#&]4+.:I="^I,3KCW%.R"*/T;"E>;8G;:]SV+!>P"JW@
ME%R^Z4S4PDUF>0W0W;ZJM_@Y]HDE>*9S24VDI=#EY8'$ZTF1PBCW>^0,V)@!
M3PS.F#\M5(V\X! (%5*;:[Q.(D[%C)T:@APNHW2]V^3]GW'9B[T*:R&#-Q;E
M,/13/'60@M,]QY7 7E%/W;S*S-YS%J;9&83,,E]:UHN)4-S;+VT[2URW:,I2
MQK$YE= 2H%.SKC4].I%2*0JXH-[=,"^X;9\NIL966&HTUQ5H9%@4NCT%RR/;
MT<]1TDFQ+^NI)3=2YLXT<J8V#Q#U#)5=E'?<U(N%7D7>;&R?/)M;:$LJ=&+M
M$T@'E=0))\JRO='ZC@:[=\:_NE 9D; (- V_:<K2D71;S-<:'1N:8^4QC1:A
M?I"B7&-X%%@MK$D]7\_&(=L4SX>" FOD>9N@@P2Y3SVX&<_IPG/7:("Y:>/R
M7]Z =NSIUH!$NSMF51J43IO&2-!-0AE<QY-S',:;F15+;N= B001@B J!D:-
ML'X>:T3X@JUN<%!PQ^;02RPG7-;W2-^Y*(;DQG7($#M)L%P?+8+#0SXCK&TB
MY4)W Q>.J4%U_UFGR,#_LCT-)&DZB&/]6:CWJ5"C*.5+@RI82^KF0TB^?*6@
M)<&]+717"ZQO,Z1@7,'7FEH"H=EX<4G\:NGAVY/&YA6VJJ<=.!F'N1Y,F+0
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MV:9<&(Z OWND86)!6"]X49ND;6 I<?T4\]L*@30NE![+02C1Q*7WC#8"J:M
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MG39Y(U[=7-++5FR"</B&=^&NV3W<']SY;?;8*:%CA\?+#J<MT=/=,\U,1;A
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MR=0@4A7ZPGC.Z[R8!A_V]H.G?*#.<Q_T<]^RPHP/?'CU0KL7KBA1>)R2H:N
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M!=&J0H9BGD;X8#*E_A "[FMH90RFEP#PHQ]MG!)M" 4A S+6_N_1&,QN:B#
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MH<;<I(]EU&(:6W"S:H9^273":H\!6"7H,Q'KR#BKK(-_G!3C:@I;P$UTI=I
M7RA\):#:0'^AB9+Y+3T*[8JB45[Q)H^CHEC@'W$CU KQR)*U4-2/$R878VYI
M-,-;![ON4MX6MT3F?G:] "_.B+4./4ETB<0)9G*9"(37-I97RD\(@1C1GA?V
M*MV4ZQ27--8JBGLKNBH*)<ZH^44>2T_4QBV%!M9L!OMG3G;*USCNK78'F/;@
M^&XMCSPO#5?QG2^W[L]-/>6EKZ><.7K*:\-4+SP=Y;TEJ;=61]D+5BEG<M?K
M2K(S=C6\)Z9#PG^-5#GH[_V#"/(FML<D2=T6Z!]L.U/2!Z6'*2QA.DUXG5H'
M 95&JR X!2=K<'#HV%M;DW'\'DRL\RS1&I+NH,L)W&A:1V/=SA>.%!00,.@W
MUC6=Z-5S'=Z@T[4A@KH[N-7!I1THHEHW6Q"SK %2)9.)^IP[+6*M^'0B5< !
MUC^GN_NBCYL[H*,#N74XZ_JNEQ$1BQ9)R66M]+DBRLH)A^O:C6%Q=3[51O&W
MG!=/J;?(74L-9#C!RX2D[#OMDQ\M]*:SNU,ONVVEL;@>03N!Q_B2F>UQ*9VX
MDT+?V[]T)C8C.#3->/5^FA'8N%D6&]#.+71TF>ZRRRFC'BCP?(.:.-@KF%CB
MT5WOS15"EQG(Z0U=)<M9:%6+]QUGG ?B"O.M'[_?.^[W-8=J2(I2(16$\/]D
MD*IE,T;W*?]EC4]*R"H&%>Y28<1#NDE3W^KQ)TE5PN)N0^$1^E\=GP!)=BDP
MXZ;4Q3GWB<=.T/JV'^,T,< Z3T")MA;W;R_.]$*MX>U*!R8L>ZBK">V+),5Z
M?&[YE\,2UNFE$^83%J#YS*,<9X4<ZD&"QP_>A10(F@F_PX-0-LD40U1R2HA$
M-,<>W/D<JYNTP)?FVDY@IE9Q3$JU=D<:/MJ<"/+LGY5S+3!U2'PR,R<&[NB"
M'\ NB:,B+H&H8FRDS@,=]8^"IV<?7O"VPD_H$$).X>U28L8LUWV\;Y,=,@'U
MF Y"1Z-TAW/W,^2VU@P\][IS3S#J4L[5K'P6/$V^#; Q^SR9+.3(6-5Z"H*'
M#CLRZM9S>+K^^#+I*5/3H]&K\*Z_;!*&W&X>76MCA8]=@L"#F8[Q7%H?TKD'
M:W\:S_(I#"N[_%]E-A@[R8=H6T4E[1>"4Y03#$VV#\Z14A2'%-N3DGQ14=<D
M'RUW=7&B9S<ZI[\AMCB;NB@%7 %54;RB(0@].>B*UC758&TNKA;%CINCK,:P
M1SHEJR4S8UWQ#G2$4C77!Z[=)/#LI:4.ERO1[D7#5+P3$@V*R@9"@[8!/=_N
M*$J)DLH+I:C4WWJ!6E;AQ/Z=:]2Y.TGE:5,57=U0G!6,"\'8 $+^L2L\FNS%
M_B3*@9/<&UP+/$?7E]WB\RIA/SN,!)(')5TO^%"AFB TI/=*ODHQ+]XD!'QH
M,#&[IO3=86O-K9J!G*4#S.Q-F\Y217.W_AZR3V001RYP7%M%Y(F;7P@L!9 3
M[/,5R&T]F)8"T=B]R98)&Q.XH+W,YQ3R*&ER- ]?+,C]C2$!F"R[2?!1GA9'
M&&126BUB!!/:0M;^#)6AQHA./=;56.25I+I41)".^^\_<+%CYB0-EAK]CN>+
M?KKQ7 D.G58WG.VW"B3%5FC0O/Z0O]!1%9^C6O'>1;7C$RO%ID(F,0=[;\*C
M,/+:)T#&U)A+6IE.CK21UU_O?BJ83:%-!JV1D8K6D&=6HULXL@WU2I& P);M
M-D_4S$DSH3+4F;%H=ZX\BDHF]#V\"D5C%+S)QDB1@1J!3=E1=+K3+EK418LV
M&BVZE9/T)\[_WHQJR'@O-3,/Y 8IL&C*6C47+52X=%+674#N1H+Z@]=>! (0
MS!BMH!-2U(S5Z[<U_*%E,;*:8B'1')2(&N[(C9_Q6#7S7*OQ)O3CPQ)9%85_
MC\O&;#^5F3W0MZM]@(P(XQ;24?F<D3]B-#3T[BGG31*]">V9B7LMS!5!)I_C
M#[A*0!D>*>L (,4&,[SQH62*B:)838/?H)%UN,H<G<''J@JN*< %@R( HJI@
M"]&^W!PS*;T@F#=J;8O=+!Z;5K[TM)+FUC8.R>Z:3?S[E3ZU=!U):<U.]&&0
M189N,"J*J#VLU1_*\.3DL3%#N> (.M8*9)DC3"&\3Y/A.=0(J)+D6VOSUM&U
MA+I=I[%PB<%>"P/100IQ2Q':$G.$*D'_Y]T=IU&%OP:CX!-_M>"(+'H9)_+0
ME4N\A@J:2OJ2:>;&KEYAV/@^5\_P17['O\F@ FK&/Z'N#9J/J5V; <61:ZL1
M9\2X8"Y> ./"S NB2?=7M</0YRK."Y9*M"Q336!G8]YR$^5<GP)!7.#KN/%E
MV9!;6D)-4M:L6Y#5-'+=S3$>&>W/QY)<#=MVK3WZ$[VE\34I:"ZIMO4-*5U:
M(7.,+$.XNO92)'$VP]IDYV92ZI8I$G+U8MC1\6V_=&SI%VBIW'WC@!O<M^^7
MN=W9B$(2DR,CMM6&7R]8^J*A, &HL1:9L1K1L&1;=V6PP0U\,9?@XV _1(6F
MT5&>H4Q:CB,?!@INEGRA,/<C4Y,$^4'0MA*:9(F_<2"URHH$0^DCQ88UP"Z/
MC_#J+3(QRTD@@@$8YX2C=QZ=L[!$CSA:.%Z HG6UON]ESK63M4P<[0"P#D"G
M1BLX8TQ&7S2=YWE,21[&(H99C93UPHD $@\^OE)I>--K3ZCALZH#:SHIBDGL
M>6]<^F*#GUU3/%]\0D(^BK6;"\=90[8WDY(V%Q^<A7[SG91 ."W^-LY@I90-
M\SM24O6E80\2-1!;?F,-8O22N7NU]%3D',75E61BGAN'FV7B-XY&TRBR G/O
MG#9]M%B:'$'C"?0=7^U9O-XD;6L*QTU7GZ]XDER?E'LY;*N\_T#"Z'L21B\<
M8;112>]X)C&VPTA;VGZPVH K2*,KBC6=@X(EOF(M3/F-."GJ1<XD0**DT-IT
MUD@TI-$D*JMC)1YLMP/!S7E8,@U#*)2P#+:SD0-".J$MM+(<@R]H&,>ESE_Z
M FF%I&MAX&DIJKB>7IO.XV15^^GGDD  XN\"N1RK\A"/W2WU@N/.V'UJR9_F
MA?N4S! 8Z_]0!461IZES/<N,$^3G'_2RV4@LRTKY!QTR_\J^[>6(&Z=WQPW9
MRND4AIG%II$#!!F_IU]C#_.F*I+^99,;&[0G[G%W V1'[6*^3R,XY@^@[U.-
M&SVTAS$*6EH.-X^FJDI*:I)L5LW+EH\U8.Q:DA(QN1ZNY]*4%= )C)2BH /C
M\%$B(M@*)5IHP; _..4B4G>9QI_.7[K,44P2@*C'B<[O98+YE9F=KU X2;7^
M6WI>R$MT\@':))AIH50ADTW(O0[OH//X G&HE4FYI67">_^A*+CS&<K.P#)#
M<?<OG:_^+$V;XD<]S'8TPLLC:0VE4*?IT-\WLK3E&[XHO( -H0-Q#7J<U'_U
M+"4=I"2?!3*>3LV48 O5X[+,HDU@)Q5:<_K560I&ZA[H:$F:1OIMF0 K2D52
M?MJ;%$I1!@]V=6IS-(PPXD:9O#9D_5OO PQ1D*A?!(M$I3&:>)?*%HAJ]PB=
M$VP"BV01B\PAI);@GR67&\WE(O],%(AZ"*Y)?[&QJ6:87O!*_RU.,+\#.()G
ME#3N#*HG<4@F4RCO25LDN$P]@%P].5GC_&E3[8O@$/ZS6J?-41%17/!'^BU)
M>SV*9BWB6,H;IJKJB2+47=[YR#*M$I,;J[G9=4#[9=\H38 S'\/>]W:S[.6@
MWP4RND#&Y@,9=^:%\1*@6-V%.Q8,&8D-VQX16DLU19LZC;#>MV+3*KW5H64E
MY&JDV9=A:Z,-'4F&VZLB/QV[14"73$H/N$H7B8S1=3*_(ATE,[(2\Y"+3TJN
M)<DTI7M*?T#;C!75VKJ7&!P HSC[,*0MO3K@!& "B?+\'XPQ!!OZ1UY\XK)(
M^JCYU0M4(-H&:2NH)"NXMG/B_S1[YKLD??M:4B!J-BL\)M>^[RURS._0)CV:
M^(NC@S-)VF%E9GG1Z)IBAJ'+B707RK=$'4G>XL$PK\I+BRPMB+\&9^(GEW=8
M*4VM.I.=->?LHT**"1&,H!YX&D/;UKC>0=+;97^GV *17?6"+T*>^[%TVW%S
M/QR B<TPY ^T&;)\3YMQG6S2,869!A>-^]"Z):5UJ2771D:\3#&> UB$RX_'
MH6B*IETS%V_>M)S9W"J/FK1<4B*&6N&EJK/7#=:Y=MN>#=<>F&-G>;>4#8E6
M$+#+2DH&4'&$K(2M'(7S+L6X+Z&U#&\5W]R/C51W,O=X;1B MWGFYPXGA*X_
MP0SE1H+( <JCP KJ4^H%;QTW$FT50;T;0A/?,^UT33R1H)8,-AW:]=^5/&#2
MYGU:II0"+ N@#=?Y;XUR3C,FV_MPR'".F>%!QRM55J,2Y""<N)\JN7SKK-/+
MM:T:!+0A1RAH5+R6-^AIBKVJQ2+/X-\<>M]0#=T9R)MR7"0SF_,N\TUXOA[J
M@CM?)C*,F<]RU(XYN158#:U4'WQ"*[^KL2>\4M)?8$RI@+!MTZY#:8!+3_#\
M2$+"F*T5H%)]V=_[QX9HXM54%02 ^D.17\TOR/^-=CDJ6Q7+Z0]@@J1 UN]-
MP;@\M"$RP5EISXS2TS_GZ8LS+M1.&F2_OU?3&9P,;#K6=FDL&%QA,:]F)3:O
M00H8]@=#$B]7&EHC!LUP :R>&XK,8$%4^W?)93:6($M3ZN&H.^CG<)V$-;^;
M\TZA) ?*?[E(+DF"Z[=[P8_Y%3I:0J.I)'!]7N9CR@_2C@Y)?*#\&J374J72
MUY HD5./4(1BHC>S@VAODYQ]A"G)3/+4K;5FK![#ZURAYX8FIW.2'-PNXSM?
M:TB-"=#80:_POIT DHUAB;K8BI%Q/0H'6<@%H5/KB8PDOTD,"[E2/6<U^STO
MT!TGC5^CR21)$\KJ@6--*7'] ICCR7&_ADBE<[LTD*PN=HF\UP;]?J#?$#O)
M0,H:8:QSXE'P8;:1!KUC?$<&L^#F?G#Z4;!T[9AEK!(Z8JPXNH-5#P]KJ\X+
M+D]::^7^JTZF_!K+MS '=WMN8.Q.-#K@JJUT'<17F$H>E>8$LB4\PD&G^ID5
MZ"ZFL)G2<1"N9=)PI1:Z1("(G!N8IFF2^C#U:LF,292AO5LBJBCK;J0'(C3B
MJI4:K,09^M3G<PEA$SYD?,/Y6QMDR4H\6;R.,%JU7!)'49#$?_WF#2@)QV?_
MQ(+!9$X>.)C*/]&(XY]>RAR_8??>PS="@ODQ&1Z?"3CNZO^Z2Z%M=183O#0[
M#E<MP:S\S$SR/BD_/5S[&A',8,;DDH2I;368AM"(;7KJ65"8@@37&N(_*HVN
M41A8')-,V0O.X,HS2%[.\"69>08JE IF$%)\3'<SOC(2K40@?$RD@_*1\#V,
M?5?LKJ4 F]][C(-0MIS3@*^)KZE<!J3GQ?-*CF,]8$\ASPGLQU20'I^#?I!0
MUN+BV442PR#P#MZ9_?WGKB=WYR(U@RY2TT5J-A^I\2(N*X$X2?B]<'/?#<X0
MBO&'EN(UHX)$./9*2RMT@)F:;RVU3=*^+[Y#74L[)G]! VT"8^55D3,FR*3*
MQB) S7!):4/X,=;X646P[7'1!Z\N<NJ,>(5.)SU%]#4E<0*W0@@V7OXIF5%3
M#LPL#'Z8CK"M15F;$8;.I3<EZB^@<[J1KWF1< 4G_CTBXV]5ZV&3UDXZC(L.
M20.(2[<T:FS;'"D40-,[:Z_1@=%:W\,C)5N4(S&$_.)LJ@' \X[/R8^0I 3/
M[TS>1Q,L2D"ET<F_3FS'^:A\ DSJ J_<99]R[ (VF7O!;QG(7DZGU./AU4J
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MC;'[.,UV*WU143D:QV:YA+3//#DBED0LXR>6ATK%WRB64K'$.(J2?NE-)_1
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MU<K-QY9:3]-3UV;LEY>K^WQ#4;F@GB,K)WAY4Z8L 0$" @0$8FOV; T"34>
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M(/7"9JF/76K7&YY^DP&P@;_#@R^V-7=O(Z;>](O#Y ]L:;B&PP\^# JFU;O
M"JZ,#%90O*SV*O6'8L.XEJXLB;D1^>?*[[L&"\_[U-[[M/5XXZI*>D"S_-"Z
MTMLOPLW'X=(=Y2#LB);/R3'(3R9/;(/E;[W\\))IN9,_"!S]+BVKTN3%NLST
M_*P@M%]D0;IN\3UE^SR&;9A\*==AB^OCX\I]H41LE57@]>N=MIE)TC1@NYE)
MX<HN7CW':F?Y"^5@*PKV6>:F,'4*O=[-K50J56\8^<I#%&3I3R1F;"4$^T[>
MB(5D'0]?%%S7?X<G7+I(7[9UK=!+:N,[[?8F-[F_1CPA"XE4BDZDY'4L\0D.
MP-&J."S6\<#@1U&LWEV>&66SF2OZRNDS=U6:2]$*TF(IW+I&3##<NNR0[5=L
MW;4X%I<T)LG0E?F9#_Y1NUX>=OT),\X:@O-8[LOUZ>U(66LW_J:C$;[#]T'3
M0?0TPT_&$'L=LX^^_3("]I[[55O,]3VV7#_1O*27U:$HW#2&9J<.*\\MF^U\
MQ407HI&?FNU. Y>[/<!U5@X[R;,_DL#" 57[)]N+S!_W7G#B9G2?E+O/%MV;
M7HG3/IJZ</>HJ'S0='!C:S,BR4223TZ2#VCW[5J2KYL/T&^IO-Y@RXI=?A"G
M29ZM8$D6D+5WY&7E-AX]"N@>I.8OQACC$C^<71$N8?"U$C')73Y7N'WV;[0&
MN"VRUU;R6KGL_L'AB]^-=-T/!@^73+:ITH!)Y=2JGL\]I ]U<NF/*-@9C,=2
M*G7WT#.&3.=NU,SD.X4OB+OVH?V03]_R.EVZN1W14M&_+VB?B!4>^,Q37+EV
MJ[C4R_/ <O7'K$D#BZZ).6W"P*</N?5 $9ROX=6MZ&:VZW=#(4G3#=!J:C6^
MV7->,OAH0D*.S3&KLU_#C\(YPPY7:_F#4:I1,R>YICIP"ZQ[B'SXN(/&AJ#E
M;?.I_U!/L736OY:;8_.Y8(LU A@;:?9,%UN#LCKD&X92G-!/:7EL,$K0\%J6
M$ZFUC=NV18\P !=  TF8.PK/E72P/1'_=N^(M&NOMGI7N.^.DU.O<24U.M[+
MM6;4K\<JSY"4.2+W1.YW&=?Z(^MMUW*OC'DH]:>C8N]*S\FZ6(5*^D[!<G]L
M27,;0U<*>A:> #"I 3#TI&%1&A@8'C!)H)T$VD\8D':>@?\J264D2 4K'8K1
M&FBY-*Y <OC$FKUA2WJN#YULOYWOJ'S0E)H7Q 3-KXO8$7$DXGBRXKCSU/CM
MQ;$ZD;3&V-/TWK1M5F3WLJTUL84?]I26Q03'RZ>\>Z5HFM_W3;S/0-EX*Q'O
M8PT<V(66:XP@9=HNZ2U-W)HC<6LP5'T_-M/A50*#O?STHOP5+"2.\!8)81%Z
MI78=3!"&H9FC9ZP!,U9IW N#EYS<Z]^S3QVC^>@_>,AM"7I&X_YNW J4[:[9
M"Q%N(MS'+MR[-T1V)]R%J]R@+[ZTKGL"W;^L%;@:<W<YQL(M8.%F4L(FX3ZR
MP,2"5:+#MJ$9'G&!_@"42"O9DX2KG=LB5>@!PX)Z%C@6(I6[((>94 PW(=0U
M>T-GKQMYA4Y.NFWSQJT-N#Y"J*!#-"?("598#6V0;G-$L(E@[]L.^3/!?NP)
MQ2S7ZCETO^84_8;FC/.##A9L9'JPDI@0I(V"?<11$H8-[E^W/6"&N;UK>\D0
M+VK?7M0I0UWL9AN;R/#.+9S%=E#90'37X-USONBV.PS@&\GT ^MWA#OX;"%#
M)H4-&4E.2*EU"6@$ 0@"$ 2(O2FT%0(4\DG[<<0^]FE(OUQG+\?YC-,,$$#
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MT]UYP?2#QV9#$54L/?,JH-G0X5CC@V6-^Z>!U'[H9V^4?IXMJ".!G> 3K[B
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M[RFR!HA/\)W; /()I>Y; \2GNS<! (1TD2H5 " $7G %#9"?R#O7 + !@(3
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M2!?-\KP=<P&@<AE0H6]JZ3DSJ)3%2LXTX%-.U^U8PYUBQ@5P@OJ$ YPHOV6
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M^<*:HB+D^2,BJW*0ZD<TT/DARWG5-DDU(B&-B! X@<A;0L;S>O E+N2!&W]
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MF.7':\(<')=3?C(;BKN)V:2&T&5XOF\-0!<;!JGS%('RYG8[UV<]!-M)^S0
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M 0?73;UM<TM]:F%&*IO?SVY%<^2K[8HA16M?6G2M)<TM3K+Y^Y@J9^X4>KV
M)S68BS54FV/!2?;+?C8C:'R]AC\1<U3/MI5-H/_UY8OO+YC3>^SG.^ST-E<]
MW0*_O"W_CKCS?%V>)R&$_I=/?6X-.=U0%Z7FVGL99<C'$>L+2N?], V<RJS=
MLP: #9R*>MVS!DXY;?>L@8^I,U5D#61EI>Y9 0 (3QF^]ZP! (3 "TY5*.Y9
M \ & !("+P!> +P Q / "T[5)^Y9 Z?"$_>L > %I[H']ZR!4\F#>]9 85/P
M/_*H^+X5<,J^OP$-%.Z!IL*7GRCL&GB]YV ^YO;PIUGR=VPFY=+)Q]PPEDLG
M'[.U+I=./ORUFQ+HY$/N)<NEDD*OQ/=],@G@$_C%%37P,;<VP"K*914 +8%?
M +\ ?@&BB'OS"]6STQ_^]Q%]?*<VJ$_P98\NJ-\WD%_54OVNB#NH>7[K=W\?
MB9,?</=7.IPLYFW@QQ;DOF<%?,QMX%7< MP/WM0Z">X'"ZNDDET87D=));M!
MO):[E6HW>RUW*]4=XY\JZ>L.F'GO#AAE/E&Y%Q^1S>$A\&Q3N\*#(W^Z13Z]
MXWIZ93Q[R@-LE"]P<$)\HB^[]I_[X.3KJYO ', YVN?L!41@"> $#9R@@1.T
M#T%(\M-E+^/.#) C+_QQJ01G1C>U,IQMZX&_UR40]!.#W]+6H^_K2]WW=>T2
MNX_[W-?^B7'18%\+0.J/[8CX1* W94>V$@0G,V)/_P&6]2>6=3='*'W%U*"F
M"XP#'*B\NCIM?'VENX&YT^_!1*X %\QEM5$&JAHX4"CK@<+WKZJG>D&H?X/C
MA8+C(_5W"OC5A)_BR?R_9P*#$_GD=L+RX4KQ]: L*^?'6,99%DWZEJR$=;S(
M#4MUIE0J^DB6CGT[Y@) Y3*@0M_4TG-F4"F+E9QIP*?DR]NQACO%C O@!/4)
M!SA1?LL J\GOG00J&S/''0!F<IX#X=LQDZ:K>HY^4M>_.EX0_"^PF$L<&-^.
MQ53UI:F:9UQ_+GN87!8SR<Z1;\=*^&UDAO$YCI87BFH9?A+R:'_]0U5U?;DL
MK+E4%%MQU>2CE.#!6SZT%#=2_/@!>7I 810Y*[!^K%;*>(*4G4OGM?32Q;#$
MQ30O2I\6_>)CSP*AM[FJ V;/D7ZO<_032OR6-3[\QSPD2G%KOJ*F.1</D6N&
M WWYWT<I^4(>AHJK*;XF!]E.4[8X2**'HWD7GKC[U<(W%].CQ#X^9 ^G'DY_
MR :RL)015,80.3%I6(X"R%"43=I8J#L)9IS\/KV&]MSDVX ]F(&\\CQ+YCPW
MF\-$UU\)>MEM5-#5G87NRU3;0]$1C3=ALFDCKJNVN^1$?'S0=-5T%#OX[V.S
M5WM\6'J^HX3_?30/X5]NY&A>^"SP^. J3J**YS[]==I!"U$8I"--IBJ!YL2
M$@GX\<O#LX>:CNUP=&_R* PO1X8FL(RPEXGT%63TB:'H__S?2R5^+KL7_\K$
MBN_6IPS56W+KWUMA_GFV:SOX=?,KK1XO!H_2L"H/FHR..3,7@X7Q=.B$U;B&
M=\5"82.$_0XT?L<"./7J*S9B7[&1F=3Q;FA!+:DNR54L0E?]T=)(L)%X_ Q?
M#A?3RS" B^^Z, /N_,'13D;B%9:9.WWOS2F1-_MAEN X6BEN)OGLS&\#AB]2
MW[7V_/?US;XZK/<,!R;#H\)$'6H6+-G+!DITB^[PC::"2DX-$=C%J,YSJIB
M 94$2L03@]-/%(*":*E0J' J/7E+L "BI8+#Z_FBI:)BZ_D#K;DZ&"Q:RX,@
M.94%:=&3=F-.LPFV(O#C9^R6,/6\[GT)_@#P\6N'4"]],_LU>R;GGAZ[HQ$;
M]"!+">&!B#N=\3#87S9PFC1<3A.-YI ?>JW(<(CVDEUGSHTFSOU$(\P3A8'
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ME>M34LX;=.$#3D>ZTY$'0])P/#YZL2XI1AIT@9HFH*;)U=DF8 F^HRD'-4U
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M6GOOT):"-D-['@\-T=[+C(PBIP=D*5#LY+JW[$!+H%H#J-;PWNMYH"10K:$
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MR*'@OEB.P(&SE2 0EJ?'<;]S1L?QW.R'65FUT4IQ,\EG7_R]<Y?O6GO^^\K
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MYVDXZ5O\KEL18853ZK!(NT3%S? RI=F!:LQ7YAR5  + #A:LH,73$G ?8!C
M?4  6G[ZWR^CR.UL3^Y&@W$/CA;J(9K,XA&S_,.G"-\11>J4-7?;:C"$E4J$
M+G;HI+G0C2R*I!\_$Y=-3 .^#$KF@9)YP'U R;RKDPSOS7U R3Q0,@^4S+LZ
M8?&7(7)4V_*XZ5>E)%37'-<SUEJP_'CBXLZE,4=OA($%[7<TZ]O&?CICTQ Y
M)2[^78A<NC)YI^J%06HCWO(A.WQ_8%_2%4/OQ?>ER8<HV>T[J-IU9XM)N8IT
MW7'J*JC)!6IRW2OI:#4V:E@T&TTDR+-(I8Z'+HJ+[R<,?8LWGH=RH@J= C7D
M%:*0PJV68S=B.'CB;)O5?4=JUW>&C) GHA".PD\H G*7K\;*+5/YA6M2<$N*
M:#?&"/I[./NM368.S5C'B]SP1S3[MKL<1M)LH2ZGEK6=;$))86,%,C,TNS"-
MIZ";K?LH"Y33R,._BAA0O'2;[-?LF?R.Y<257L76NA6'W98E23J/4\8%PXAD
M'A)??B6>$"N1XAR:QA1NA_YL1*KR,JB)F0>BOPHH_A>X8FGBA2)KH,1@]'&Q
MP%61Z+(10--H!+M#XPC#];KL(^JAU>$F)_PA7HL  .X W+G=74C9#IB+/,,?
M4UBLR!H =<1N?88_IFQ8D34 JH3=^@Q_2%&P(BN@F#7 <B9^^S6J](/NJV:0
M_?;T8V^3;DI ?1Q0'P>PG:^]2)2[' Y(CP+5;PH%M.4PE"+>&Q7DYO:,E6M.
MPSC%.OQS$*2]<ID$RRU_S?JQ:D&#NGR8+0?+ZD&4$2HEIV#X$XI>\-5;X./W
MEE)\3?[*[6 CH+2\-V_BU[#X[8Z+'/>]56TMN;P2J:K2'6RZ*I+!(BA64RS?
M+DOYC?\L7GSJ]WKZ/GI> %,"JVNYU 8\$'@@\$ 0WX+X]@VE>!B9X$EDS6W@
MK35HTYMILS*87J88XUMCW18>+0]56^WSIL]",T*7)7&PSV)=^O$SV/X7Q\]+
M7U_G6O ("NZ4S5) P9W": D4W"F?85PK?"]W!9YK+4^@),\%H_>!8I*V&<$'
M:8+P3J]B'+GMA<J?OS7B'H0;MG>LX;AD*D-L.>P2S0AFTX@[K=#SJXB[=-5Y
MQGH0)I^7\J_T;-?T8/B*>\;WR0#9"M3@*>AR FKP@$2ARQ&DRC+E5V1#%<T$
M /7I#ZE/:6?_^CY1_IGLE/Y;49)@JZ_$:?=8/PDRC*RG:0#R*O-I(<&]U8[N
M<Q9*UNIRP]^RW,J0$3HKRX.@3P2!E+>:1;F]%Q3E*>LJ5\X]8D$83-_!6SW=
M)>G/V\JWP]NW/:9?K4R"FKII261WH0TJ<: 3DWT*;R6OTU-NK[UZ\0RP0[NZ
M#8#5#?@)\!/@)S<1!>945,!B3&5E^?S_['UI4^K*NO#W^RM2Z]QA[RKP, ]K
MGW=5(: BR(RH7ZB0-! )"68 \=>__71W)@BH:XF ]JVZ^[@@=+J??N;Q(_5!
MY3)WM6BNYNE8YG;RV"Q9O69\7"#Z8.ZTNS:=-@%_3L^;TX81[XIS3#CPA=KD
MG!1(>-^<8[KR V;8<!#QWCM'T7NGT+W!FKKY@=D<O)L.[Z9S+(AQ4LH![Z;S
MI0JE>#>=ST:,[X<7G*U^@X)4SE8Y^1P.,4ZE-0!'#,Y7CQ!*G'PX8G#R^5)J
MR0:0#A\N_X,XMW37O'CIB6JU7'W!,#\7S[5V]?VCB$B<NR _VJ8%&S*[^I;7
M%JP;T9@BRVGZ7=1-*R36+5_6)X-DO?4P726[A<Y=-W]?;+4&\3R)=<=3B3U&
MNSE1?O$>%KQE!9?\AXZ+<RCQEA5?K64%[U!Q+$ ZQH84A]>;D]F7T:3RV*WW
M5LELZE;J*&JSN#RXKGNK-RLQ2VI;T\QUJ_N0S:ZN5_=+T'6AE\0KNN[)M9.X
MT V$MR5(MF$@35H)EB%JIDHN3A!=J$8$#5G0<\(2GT\F/^\$$Q&^M#CE*9F\
MT\2Q5U_P3A,'R13XRC?.^=Y)EZ%QOO?MJ. P&B"OT#TF'."<\) A>DX%QW'E
MARK*.26R.)2_X @UAL^?",.1A-="GW@M].$]\>_,8)$D>V:K^%&9]'V QPPT
M09JI+%!%D_09<CI :)V+X?/C<V+:.>_)N<8D%:L.WY_-XG2*WO8VYL,N,A=V
M%SS8%' %3>YZ_FPO2%!'5F/4%9^;ND&^L"Q#&=J6.%115V^*>!F(#. U\0Y#
M0@23R>TXGSM_,6/5]LN#WAI,4Y=W!0S+02+^XU<BDLQF>/L'7M9^T%C]D6D&
MO*R=E[4?%X@.7M9^>+G_01'XHY//H\XB<7MQNRKU&EE#R36ETMBNM8A\SKY!
M/G^%3@*D+5=T"#VM,$K,YO@^:$P?/</?Z)3S"T^,S? & SPIC#<8^$(E)[S!
MP%$@QO?#"\Y6>24?9ZO?E7P.F97 ,>64,(4SVJ.!$B>?TT.,0R8]<+!]54WF
MN&.ZG]&5P/$3OZ58B[3D)^[+HL][V8:1MR;&A XR%HJ$Z*C@-I+TL496(>W\
M0SS"M:DV3N74'"JO<K>HK]TV#*FZ'"3BI(%!.A)+[1H2S%GA(=)6.-AXCX,O
M3V"\Q\'10(GW.#@]Q#A@=@6'VA?H@G ,FOH'9V$<0+LV>N</>@])]7(QF1"1
MU!4[U\,Q:->0;_&:=OUZNH6ESX.Y%@=,K*@C2U!U\^,F-/!LB<UL"=V0D1&E
M#_^,SY\%4U<56?A7C/S?T3&,[UH=])EY$H=#B=,#&?.)?6,JXET60M,EOC%&
M<+X:'F_@?)7SU:])10?-E^ X<A(XPCGM<8*,4]$I4=%!$R:^"%D=-'OBM.B,
M=YDX+B1BX7I.B'\>NS\M0ORV N\SH_9?A*P^,X1_O%2T ;$C[_721I:H:$@N
MBX:&X62RA,"GAV:^8:321B]QT;_44'(X*V5;OQVRK".+5HK7=-/<5=B=Z,7P
MZ99V8GI9J-JZE+V^O=): WRL1.K'KTPJDH^G]]5YA?><>%-6Q!=A5P=-D>#\
MZ].R)=[,>AZO'L_UETFE-15;MU?E6=R<#:XHZ\F^A?5\A:82.PVO<U&%J1JF
M()HP***$)"(K_O=?\4SLGV0\0O^ ._Q0TXSWG_C-_A-!+I/$7$;6[:&*CH'-
MO-_J?R,7,B'QR1Q,B]%>KM-]N(GUM>5D:"C#NY=>(<B("N:@,7J_Y@3C: 9%
M72/7A,'9-- (&0:224<61X'*K% F)_5O;LK18;5\.]9*W8=QP<_%*O6+=[ Q
MDM!E-FS+A)/BJW(Y6,SE8,\=:U@J]%2I%S5&XTZU.BU<*85!(CE(_/@5ST92
M^6Q(EM9ID^IIJP-;6X0<,^V^3VK\]P=AV-8RL&,&U=[8W%N5K0/SN'=I:F3M
M"88#,DRZJQ MK:+>YM(OI4HN9J>UZ7/[\B%;B"V!QZ5__(KMC[V=>,>60ZDF
MG&3WHYD45=$T&R-",GZ*G<UTC7Q(6O5U)Z)&GG3:];[+->1;C?V^+=_/SXW+
M0G/:>=#BT7&JGET5]JS4Q,]'O?KC]*E03AA7_5XO-6G=@UF6'$#F>2*2Q(I-
M/)GCBLU14?[66O=C)GVNV!R>2WZ<8G.L+/+C=:)Z&1]AV3.E6-^L=96'V'S<
M5L; (N,QS"._$FO\6!*F'JL/ L?61C#?DH[WJ^T$Z8]\7?@@ GX:=K+GE81Z
M$\L\7?8NI4EN8*?'^]5QVO5QH7]^?:.6B]7^8CR[5A(3G>@X\01I9YS/1])Q
M[KSA.LZ)ZCB<-WZ2CG-0QOCQFHVHC>?%4?/^N7P9MRZ+4GX6:Z2)MR>^7W</
M9XB<(7*C[_08XA_T0)OG2^FN*)G=GFT_)^Q&L5BNQ_9LN96B8NLY/^_48D_R
MY#R7B,?OB\^4O^5^_$KFLY%D*L^YW%%QN:V]RXZ9= _%Y;;T*_LZH/KP]*@_
MY7%OGMTWL>*5J9Y$TVFUFAKVKJ^+CYG;#];GMB9;G9LCNY:7;W*Q1%)Y&D>3
MC=N&15Q6,& O&XFG0P?X<+YW4.TN/ ;Z=8CY [4[SO<^E^]MRV,WBR_WA8HD
MEAOF2SN'YJ6*_O#!2MU6)I>+JSGK/+FT>HFK9+(EE>^UJDGSL5(_?B5RV4@F
M%]\GF^.M_WXWR?TKD^['<;DM[?Z.&53'9\.VU-)]J_&B7TR?%JJ=L'JQ>7^Q
M9[M3K8G=ZV$I?37M:*:I%+KYAADG 0?(=8_'$F\(-Y!\]W^3D8U[X!P2YO#(
MH)\H&J9UZV<R$TC-7F<>]!NWJ"(Q?W-)VF$VWYT@091@=*.HK3 )")IN07*]
M@3_6! 6O,#9$59B+A@7I]EB9-Q%@$BD5 ?U>&"F:J$D*?LAT9*09/)"LF'-5
M7,$MHG_>=SH52]/HA)*">SQVF-C.B_#@XCWW.]?R;UE9_/H/_H^SL*0BT0"V
M-%E;-0DO8E(O%ON?O8@R=J?LV(F4PW9=+G(13?NV3?[[7_[=>XPR*NFJ;OQT
MN*'O6 S>"<(8QR@Z-) XC8HC_.:?HKH45R8[9B[E5!']=-DI0$'(_8_ _A>@
ML '"F?@<]0&*<=^HBD86_N0LF?8^(ZS3_5 WB>OLIX%@E.L"P>J!=<E]6/K\
M9R)^1G =_Y,=)Q4_RZ;W=$-K4C#IW<=_1&%B ,?]5[=1#$51^!N3!F:L:D#9
M8!]A$@7F!L17! 9.J(NAI_@6% V".@R"(F'(6!2,<BEIF!B@V"@U2.6R\D#,
M)H>#N)B1\XET/"XFDS_H6S\&:AMR;BNB.X#UI.55HU&M- M"\ZK0OBG0%(I*
MO7A& $(/5"QTKBYJC7YG$,]F<OG,@?>><O=>;-0[C5JE5.B62T*GB__GIESO
M=H3&A0![%LBF/TTF;++178K(7Q4-"P'=-K'"87I& D.A82:?C,DQ<9 >(8Q"
M&8P]0Y05!W(LCU)Q-)0R^2&[!M'1 NQ,\>&BU"A>QU;%>WE124SOEID"5.6M
M/SE*)>R7^WPR76X\J->YQV(_;3]B2V;SR:*40XW$*%DK7SZ4"N5R*MZ?7"SQ
MD^GU)Y?U,EJ\I,_EF%U[?*E?WJ@7%^=C_&1N_<FG!_%Z?"[?C7N907R$LM)Y
MZ6Y0&"0'L?4G[]6[6F(QD>YB=NNI?][0L\EQJ3!(;3XY[=YHQGG4,J<-^:7W
MTAR9M:O[)7YR\T08WS64[EV5$[EF32O>5&[3]V/\Y,:)U(=6=;ZZ2 RF]J5V
MUT]VQ$ZO!V_?.-'B46Y9"W3=*W?2Y4?M_OI)JO4+@_3F/N4;A*+S<B\7$YO#
M<M&^4[)/Z=8@L_ED\^D60[-^WBRO>JEQP;:5E_A#89#=?')Q7N@HBRD:QC*K
M='F2[JG)U=5RD-M\LAK/7UW5$_(D9J=S=O+J)E82DRW\9&;]23%CIMJ&;I3+
MC5%F=E%NS!8/K0)^,K_^9'8IV>?U>%<L1Y6V]5B,]JR$W1KD0]ZN)>Z>9B]#
MA/781?1:O\XVN\\8/V.;CPZK"7%YD5T^Q#)7:"P/KM7G5'PYB,<W'QW4R_-2
MXC[;GJ*E$D5/#?VB-QF#1K[Q:#)3?8C?7A03TU6S63;R_6I\LL"/AF">O,P^
MJT9AF2@CJ;#,Q5.=YKV,-Q"">LVVE;E/9+5T&=G5W%,[76UUIOA8(;<OF5$[
MN93GN9@]:=QIII1\BG?Q!D*N7QW<+Q_FT>PJAIJ/[<?*>46+R7C5D/LO=Y14
M7T*MZK0375R-V_?G4GR$5PU!@'O4JB^K^:=*KY-,6.7\M56;I/"C(;=5*CZ:
M^=M2L5/.#%JEY8N:O<S!!)Z0VXK6KK%%F(YKL5FQ.VG'ZE:K?C>&4MN-1Q\S
MW?M![&K8[%6K-\^5ZVZT7ET02V7CT<S3^.'F[O+BN5R=M/K&?-6>9);XT1"X
M]B_G"3$=O9WT9MVN:2?,RQ62\%Y#@!6KE.OGLR**3QNEH5Z45\KS^1 _&@*L
M6/GJJH%FV6CYLI7*QI\O7I3<(WDTN7&QY:79R%J9;D\YG[=3XU)/OA?Q7D/@
MFDK:YCAU)^;*=O>ZH:(:%C7])3RZ05IQ5)$J^5;Y/!8MKCIWC\-VV;Q;#I(A
M5]!O/M?NYVJS7,ZT1;7TG'EZK%POP2C=>!1UAV:W,#4JO<N!AIY*R?I<;Y!'
M-S8PKBF#^N5(ZI43\Y=LXK;3JZYFXT$RY&)O+^7RQ+@UY%CU;HF:2GUQ&[]=
MPJ,;JU:>[D;I@:U=3,7%9)AJWG27C2Q^-(2VQL.9FG^.EON]HMI?7K<N9ZI:
MQ!L((9CQ8/4R>NG-!]/H_:6ZNK93B_P,KQK&!DNQ<:]63S2G_=[L/'EQ/[UM
MGV,!%');L_E=-GTS&91C2BYMWEWIO50%Y$K(%127K6'%FJ<NIO;=Z&;U8&J+
MW*@%CV[(H'+3EK/S<6(XS40KUT])M;><)<?PZ(80:EZ7[XJF<M,J5\^?Q^G2
M4RS5L\@&-J10(U/MMA0D/TY%4;-O5]-I-K' \BKDMN:W:OIQ.$0OY4YK]/A\
M:<IY!>-K*H0,\]/*^:1^7IK%+L5XNILWTY<H5X!'-XYE+@;YRW;I]JXW>XA+
MG=+S=>HBO81'-X[UD-'+%]'4PVB::3=:\HU^;];KY-&-8QGC>/&V?64U>M6:
MFFO7^DHAT\0;"$&71JI]6\E.E6@OT[[KG+^T$\6DU()'-_;:?JY&)P,K,RTC
MO=UXT:+EF]L&>71CK^</^J0E=MNS7B(WK9@9J[E<%<;PZ,9>K[HZ2@ZSY66L
M\XQ0N74;:U_'\%Y#\+7[5$BI4N6E&2NFNG9"*W<RTRN\@1">E5J\Q"NV/LC%
MBD\OHVRZ5QSTE3$\NG&LBUQ[7NQGU6CO22IBDHUVS7:J (]N'.LEF5"DFWYU
MVGL:B@_]VRM1-))+>'3C6+=ML;AZN)_?EHOE='&V,L9WJHY7#:&MVUA%RN6[
MV>$419<7UJBJM=M]\NC&7@<YO3Z:U-MR;-;HG<^OQLK5& LC_.C&7MOS2O?\
M28R-IT^-]*H:UU0Y\]*"1S?VFFX\I,O144V<HLPB4[&KEZ,K%3\:0MSJ6.W?
M2 ^M\YZX6#4FT6[MLE4BCV[L]5:]+]617(Z7Q<4B6KA9O6"-8PR/;LB"VJ!^
M+E87E[,RJC>F ^MJU+D>%N#1C6/=YOK1M&+KF9X=OZM4AYA;IL_)HQL*66HR
M:C3N['ZB;+>+#Q7CHO7PD"1[=2! 7'>N=X+Z;"5=5<6YB7XZ?_@M&C#KF4D/
MQJU$C6+'%T-\"*)MZ<X'U(% /@GX&7QN7_;,IOO&,IR-L1?&J8'TMMX:F?19
M;&=_>)_%[EM?QVN.5'WI>*6<?T?!Z?V3^F*6&$ZO>D.86XJ\V'E4')JZ:EOH
M,[P@;XFPQ-_KB&/__:.00>(L%N?W<GSW$C]+I/F]'-^]Y,YR.YLF\GOA?(S?
M"^=CQWXOG(\=Y[UP/G:<]\+YV''>2_8LR>W*_=W+.UMHOFKF'PP(N7< 8:\,
M_* 0^-,$3DE7X</_]R/WXS?!DTP<N&5Q;E<2T?M3-^^1: A(DY&\K?UJ2(X>
M)ZAC(JC<:P!XO6')YG\W,GI=TDG\+NG$8V?QPXYE_6#:2<02R0_*?.9(\H61
MY*.Z5Y\"DNP!)7)GF>07PXCX1PC5SRW$R?\);C3F"%KT:V,!$O\7V,Y YL\/
MI8K3Z.F>_RRE@YK['"@A/L,3K5_[-"AQ>N+TQ.F)TQ.GI\\&"O4%?Q-Z.CI'
MTG8%-T/>4$>6H.JF>0J&W-&C^FOAJ+V;*__]8?)OSX<XKM%JR<!HM>2@?/N8
M5MHOH[MR_[[36O252K83_?VICDU#'RG6:W/5*NG5W?6T$E5[G7ZCGTI</Q2Z
MD&,-B;"Y>"2=VVSC^!$#'3G5<JH]3:K=\T#$MU'M]3#Z.(HKHTJOH=\\S6_J
M4JZ9@:K'S%['L'*J_1)4^UJ>Q!>DVGB :N.#:O7ZNI#-U>KERT1QU#J/OJSJ
MU7W+6AME4BVMK_?+U:29,5MB_++Z#%2;__$KFXYD,A\YP?3('-M4[R_(C[9I
MD58H@J4+!L)W)BDJ$C1F$,"G\+<DFA/!-I$L*)J@AWN\N3>!>Q.X=^Z(H,3I
MB=,3IR=.3YR>N+>;>[OAW*2AWH]?I.MC="B"/@LM!9%F$NM$0,_P-^*F^5<P
MS9VDK=/WJB4W[//3=H63*6_G0'Y%'_6%6.A/]H-Y>U,J&65D-/(WT<3]5:I0
M&&3 &YZ()%-ATQHYZ7+2_<:DNV=_^)M)MZ4]UE97J9;1FXVMN+ZZLOJ3&;3B
MR_SXE8[$4DE.NB=)ND</@8-[TS^=Y/?L3'^[M)Z4E7YQI,JQS/!F6M [\T3;
M&F.2!W]Z))-*[2#YT_:F,[NBA.8&AB&U)?"E"N),QV=XV8]QP6WN@SLB/EF/
M^?S#'16?V[-5XJ=>_+>*X(^")A=\1!S"]6ZO&[?&--,1I[-6[+XQ3J?U97L\
MR(*-DHRDTXG]*3J< W .\*TXP)Z-F]_D %=+K:M4X_ENK!.[U'.MWC+>>6EA
M#I !#I")<0[PE3G T0/E$,&(H^,<>[:1?I-SE*Z[E:)MK:R8:&JEQ^?QY6/&
M@"D$V&)*88LI;&;[Z89=*K.YJ!B0;<0#+=SE\^'I"]^)G>W9%/(HM3&JZ=JX
MIBR07#!-9)E=_1R5%'.NFTANC,+F>$KYR]PL]Y2?1K5F?9%=WJ=N:N,!&>L0
M3T2RF<U9Q9P-<#;P-=D G#&>^ C[CR,X1_ C#&UL(/B7<.0WK DR!"RBHB3Q
M'5_'[.-J8[EY>G";G7OMOI"R2HBUKFM JA5-TF>H3*W+7;4_Y4IAENW)ZJ1L
M#QJ5I[Y6&-R0N7I)J-CC#CM._)SX3\%E_UO$_S2PE,9S8V!/;52]K3YGNA>W
MW<* S(7"=\^I_PM3_]$#A;OK]^^N_RVN4;F^O'^:9)^,:2=CM>OF>3V3N!@/
MR&31>"21V.77.B%G/:T,+DY$;8P7"Y;[$@\@R6Q2%9%0PH>6_GYGLN?>C;V[
M[TZUXO [(P4G"TX6G"PX67R^+_S$ZFF/Q8?"/.@%2<)[P<JB@22D+&!X,K>B
MOXX5S7UH7\B!CBU@ XDF*B'ZOQ7-H=ZV2[R[#.-E+-H=Y_NY>>^I57V\.G]8
MU97A>!"/$V=Z)![2LY+S LX+O@0OV#CMJ3>\?",SV(BGO9CG_:PFZ]-JU+J0
MQ59J</.T!!X 2?"I^![[7W(6<' 6</1 .4:G^N>SCCU[U7^3=9Q+Q?)0;R<&
MY>)@F2M6XQWM62H ZR".]7Q(JX _;L-Y2-/( P8VCDPD&M)$4#28O*4L$&_!
MS]TC)^$U/#[NMB<K::+KTQ#6YE%QFQ%QQ:7A$"97O$[<-!?M83?V%&_&2V+>
M7#UD6F2[T,HH&Q(]Y!W".2O@K."8;*2/806%S+A;0GJW46[4'^\ZUOPIT^TL
M8;L9HN^D<YP5<%9PFD&3XV,%>[)Y/H85H+0Z7=FHEBLC]=):/27';7-1@.UB
MTR>1_\+S!Y@MU#307%1DIQZ8YA;II/I"L@T#2H5ITA'W%GT=;]&W=AA_E>#1
M%@;(")JE4YH%32:YED5*S+2$>%<L:1PKI\>6W3=B#4G*Q^['J^ZJC#EBDI0/
M1[+)/;9\Y:R!LX9OQ1H^UTSZ4]9P-Z_&IJ6'V%49I>^JXVCJ\JXFM8 U9,"%
M$HME.6OXPJSAZ('"8TR?;V^]D:=LN&#LU:4R,Y:=7L8N/51[6FW>SQ-60EK5
MQO([X]6G%W+RU;/OQZKZSG3/N^6?K@;TZ9EU;N796[6>;"8MUEJ]=*G<?XK>
M1&=/_<F#/![$R43H9&R/I>J<ICE-GR)-?WJ"W+MI^LYZ25_+S?BRMTK=J-/E
MX_FT=]T"FL:63"K!:?HT:?KH(7#P\,]7JR/_ %[0CF9NI.G FL3Z9J)>;C\4
MV[U6 7@!]("-?WQ1^;$X]-8+A>;BBE<)?2V7#??F?FE;QB'=)J7<$.8VBZ:*
M%^G!A12SK?G=M+F\SPW36-%)T\J@5#[/7;:<_K\F_7^^Z_5@E4$> ]BJYC3*
M^K*0:O7D:?\N]ZS(H_.K\D4!. %->@OA!+Q"Z NQ@J,'RC%&;[Z^N?2Z"B$^
M:V.IF6_DRL5I-?9P,9V@^_LE, YL'^5"<F5/.4Y30B.$[499,- ":3:O!CH-
MQ\_W<>9^OE+SZ59-$6\&SM)7K$G1-O%](*/&NMVM=JDX*"O&<_.96)UFEO';
M>2JN/_<@=8U,*\]%$CROG]/WL=/WUP_6O$;>&RZ,TFU/CLF*/D5&L7=QL6AJ
MZ@6A:FALD(ZD8[M4$$[5QTO51P\!'J[9N_WQ7FX@/6969735R)03=YUZ)3<:
MSR_%)7 #TJL@E=@UZ_-+Q&L:;C=@%4#H;P3,_37<7_/)5<W'Y:_Y!M:12_XU
M^/>;["*IF'JYNXZJ\_+35>QFW!OW8D8*:U!96M*3">&9W/7+60EG)5\\>O0;
MK"25%:^-VD-'*Q=O+\_'UU6[?==> BLA4:1T;C-UCK,2SDJ^=Q3I\UG)YV?=
MO9^5/"<U\S[='!EE>S[-39"L]B2H)LQ22RZ=V^FM/;W04D&2#!N%=EK8APGW
MG9D ]UQ]/S_VYW998,1<\PC7J7ST?12F/U7+_>4XH<W*1;.0OU&LUGWV C,]
M,IP]E=]CG^[O3 V<'WP_?O"YK15^EQ](TOW5>6U6-'K%V^MD/=<R+NTHX0>D
MI4(ZSCD"YP@\MG7,1M$'<X3T>=ZT&[GJT[2AK1K3^F*60O$Q< 0H1XIDLU^^
M(&FS5P(/<1W.F334#1D94?K[G_'YLV#JJB(+_XJ1__M"63_'Y33Z*@;4FRLU
M=[/%G)ROEL;E:;5\>?G4:;:UC*Z5,5O,.^V[>>\ISBH.R2H.?/BC8B6';@"Q
MFY6T[Z7YR.Z)5^6G@G9GM_M:O:L5@)70&%9JEX;%60D/81TJA'7$+.8[A+AV
M\9BM4:ZG\HW<O,HFK5@Q.WVL+9:5Q/R9,)LMW25.,\:5(6^H(TN01',BV":2
M!443=#=7$4ZWX!&N#V:<WT?AXJSOTRPU3,5%3,1-0U\H,I+/5SU,S;X0?\$E
MY5V,[V%J+<OZ<#&,]:NSJ]3U_6._^-3"&P:#+9V-I$.Z;/%J+,X;.&\X9M/K
M8WB#FGY,C=LE.Q/KBZ/*?;JP7!5GA#> !9:/Y/.;WAS.&[X$;SAZ"#'KB_.4
M3S.U/H:GW(Y?>C4Q]3(JB_;#12\^+/<Z]X2G8$,KDXG$]F%K<<\%]W%Q']>)
M1-P(4-[%60\-)4Y/G)XX/7%ZXO1T-#&8KTA/)Q1G8&\8!MZP1  IO$E5QE]6
MM 4RUV(./__S[R%/G.6)LR>12G^J<O4[(P4G"TX6G"PX67Q^F<6):8W'4FM
M$U::MB%-1"C&UD?"W(!T%6M%"K/1DZW,9TBSN-GY=<S.PV<)?ZNXT9[S5)KB
M"@C4[.H%"5.K@9J,@)NJJ%D%32X[-!PV#N'N[FYZMXS%>[/TC1*_F6GW<4A/
M(6/N4Y%XFH]#X*R LX(324OY(U;PK#^DSA]>[I1IWT"KBVJL-<M5"L *,C]^
MI2.Q^#Z343@K.#@K.'J@\)Y6GY"%\D<L)&^^M.6XD2_V+L]3M[<MNSVP7\;
M0J"752*2SIW6//NC)PGN6N&9?$>?'<P]EJ>'-)RL.%EQLN)D]?WRSGD@X2,K
M7Y60+!3N-. -23[/O\A+6 Y>,NNFHKVMA*6DW8R7Z"E[-U7LX: I->58[K$U
M2*1Y3(+S%,Y3CHVG'*;4]IT\)?'P7!M7GA/%7J>?*ZG))RLC4I["@QN<IYP
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M2R2#5A^\ =1E9OGY+$K"7H@.CF23JCE$O2%S<WW&7L3_L4:BMN#HQ4P+6XW
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M[]W(',#<S]_\*]A*\MAHBGC <C!(_S&WP\B?(N7G8B!ML :C>8+VXY$SUP]
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M2W1:N['Q".%IL,'7XS7^8AO01(MU\=X %G!4Z+#K])JDUS37%2T 2-I4A#X
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MQ%Q+;W'!0KHZV*R/LD.%;+<N>PSSS8^\U;8F?VQTS/#Q0^"!+C4'?N#)+"%
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M+KV<1_GY#A!UW.3\0K-[[\[%3D T[>1P_*CACM0YGZCC3#LQ<,+5FV7':=;
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M!&@NP_,9?__^E)F[37$"C4<%MY9\4< :IZZ>:'&RC82W<GZV[/*QB1D9$JS
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MA<M2*:F>#.^VE>)MM(KB:MKM+RA+;@M+/FD10JD2V2$)@EN'/$4O=[?\MRE
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M^U>.VQ%>;%)D!2-:@_)Z'<,&DS2\\F!%^7*YN"CJS2$53Q?;#K,B,PL*/OU
MEO@D/4L1DU23XF-"8]D?]2I$$UYYL'9*E-L%/HI5:=YVLDPJ'L%[)KSR0.IR
M5,HIB!FR-'/TRDQS1$4;UD1PI4^E$W"%[Z,2?0##Z!;@AONVW8O"H ,/8OV%
MI-FF5V#RAG*V52[U@:H3MW=WRUD\_BA;?>=AJ)1W)_1[MY[WSGF#AQ?EMJT$
MWQF;AD))G(F7^M2DF <!Q#M%N2XMO:[5CQV#?+;T[6E2YD]5=T90ZU2F7XMQ
ME$-([5J#7SD5. + 6O+RXK!@QSM2>:?ZS(VFCQ_#NW4#[APV-WQ&;:#P>S!3
M= *CS!]J?=.1X@^3C@\-)7_C?5[3.)-4N9JF^O45;;<%PH2ED:9+GBJJDV"]
MA&X')LV*;Q3?%C&(B7=TH+E13I'LLN)@-%'HIPQ:[3-.#HW5.1RJLS//W&^I
M]T$2#)[51!7V&H=LTR].!&::X[FP?W"J\-9$XUQ[NUM+C8;& I^<WW1ZZ,@,
M^?;^H.;B045B4/BWZB\9#WC51(693,BT%<7;I3P,B:WZES]W 4=LLQ.>LV&I
M[PEC T$.),M!$>LA)B+9KU74PFQ>F+7INK9.4X7QE&C>".5P*_+'7M]'HWS[
M)G8Y$*7+'S^_@I(A,+<B,[K)__%_V'XIR'SOA6#$R+K!_&[R ].MO<S'87K)
M,ORG^E6M[HHLSO]\K[+5S51Y=XE&7B/)?VT3PWN>3YBM&'?K_E"M!""9/DG\
MW\-+ \B%FRJ"F]+9%(V7-D,/]B]EQFC.&G^/U R0A=@[2"?N]RZ7@JV$V__]
MK\5=P(4),$1A< ,6)GT@]?Q5O\:C 5^>D"_X:XH(&/.$C D4YCGY0KQB@<(\
M(V,"A7E.OD1?(P%CGI$Q@<(\)U_PUT0D8,S-&/._E@'#S*N%E \C0O(#1+BI
MI7@H!0X.SN]#DG-QTXW+9 (Y>4X*G(L.GDPL'J0\@9R<<XJ?3$X"L;C7KO*^
MZ_>-Q2)PNWZ4/GQUYV U&7[X__V5^.N3Y(E%7U-QOU)W,VQ-7X5 J")Q(;\&
M^(;T2WY<E\;O(,^?Q1G_O_\=!PKUS J5/$> ]]CO\OGPO[M<_VK$\G/493-)
MXEH$^M72X08N/THZ4H%T7&OQ;KCR<Z3C#1<JY )#!5)RM>CEYT@)Z@N^AM/U
MUJ#VY[]9EN<%X6EE).]U<,+:\&T$*K<H[\]5]>2^9/FV2>8'D.E')!@#\;K,
MYPO$*Q"OV^6X _$*Q.N&N?)?*U[?+_W7WNY"^0[!UMD5^>'3#TC.[4LVZL_8
M7GQD?_'/-%WR1TP>[K CO9):EAB'J%+\0IR+2RI244KD* 9[M$_-'@XTZ;D2
MF=];DYY^3NL'M&F:2@SX!H;+6!LOA.?J3*7JD270IBC0IA<LE7J)I%(_4Y]V
MO(Z[NON!XCWA<(*[[%ULLM(?M0?KV3S3&(3KXX(Z24)LE?A?_Q"1X^,+?H2N
M7=,+?' "_3E5*!-.\R5ZI#!TO.QDBO-F--S)? )\^9[:P FBCO<CW3A6E[1,
MJC]H=@T&HD$EX91P',=?8D?@]+_70<-9S? .4'YF1N3JP=_A\G8M0018 DZS
M86/^KS4%ORT@- 9X6TP0HDHKL8B]M'I4/5.!0&#W" A_K,*=//@(%"Z(&]D1
M+7&+]+B4Q>EV*B8/XDQQ'8LN@=+=)VY\,K5[7"@9Z&<07FZ4LCCD!^E*35IC
M=E+26TY<,U<6A-F\1WCY9"IY]8@ST+2?&8727+S)M^MYA798>6#E)GQ%ZT+W
M\2-1Z/\B,+!_#F#D[S&H<6?SV<6FA]AREYZ87A&C&]WH#YSO*;'OP-T='OON
MUMEM'X:&%HSL(M1>_YT_B-#GS_Z L(-PDHRY-5UV,QM*8"0#O?-F2#'GS@#Q
MP&7?4 S3,K LX38[T60XH +=)@SG2"!,0XWCY=>]:VP+<',-?F!,TU8\K%F$
M5."/G=1YUO(&7+Z$%AK$,(#\=V>7&)(Y"PL&SX<D>#(/,6H-\%7WCVA^-Z^Z
MQ8T^..3;?(LQ/V$6DF:@^<<"+\%AK> ]W $\P#CZ$WB6$QZMV@EI+&N#RRG_
MG39O([VM9#,,8W>=:/'HYBZN)R#D1#(MS8#6>_=&$!(Q!,VS[HWXT!D#P?.A
M'U5PB0LMNKED,Q4(P3N\718"ZP._ J,"%!U("^ Q:X9,"4@68_BS^#P)>($(
MI++-^9PTX2@=>'/=T(!?80&SM^!E34<UU)">@L;:IB\/LB2 K[ 2#V?3P(FS
MIF4XKZ$JHS*N;0/$EB5P!V_,D076_O;:KM I&@0PAA2&P@6H)+FC"CW1A"^V
M$08!3=;=H_]F]"F+AAY:6Q-Q7(*=$!8XL 1\54*3= U-0?=P)%[FW!>@7]NO
M'MB^P3.F;<"G>:,0WW Y$83OVTPFGXZ;5T8DVIUW[\];V9+P?:)L87L"M?>)
M]S8TRA_  @7K[48:A!G=JN:]WZ#=8ZB?+M0G5'(TBX@)N981OC5P7Z"8(6:[
M.KMM!FSSE#8=LRS[PH)0L;<LEQ#:!;3V2<>AF3V/@QS=WNJWI\9T_4V"?"/)
M"2A2+FT3A7S3,&:,W5M&Y])T%C&6MX(B/;E?WQEKU',/$-1H&+B'.!;!$A&<
MV!O!LN6QW@B%-!YYC?]2C+C3!6\/PKA*_5*,JR=C1/(U$6C$,S"">$W$ D8\
M 2,"C7@21@0:\22,"#3B21@1:,1U&?'!6IZSX</]5GU':);W'?7;=^Y<E0@;
M=*/89]&-(OAK//'4S?3G.LD'/&.$X&AA[A2FT96:R<^9J^=5E\ P/-XP)/=7
M?!HEX\N+<3V<;ZS3ARADSZNU 6,_QE@B8.S/9"S^71@;[+-WK;*[B\O]X$6>
MRRG<O%;I(:M^M*8&K U8^_RL#3AYXPWTH56SX)ZMX_4]5]L['[V^1RGF8S%W
MCE<#?[@46+<-?E3D)VRY*!<:E(,-U=8BG&OATJDYZ1^L]'FK"X[>HRHXQT@&
M+!'BM\J#H +D@/P7/?%O >G?5 F'B4V9<,7!Q5(GK=8Q:9Y)+O1<S&R2Y"@*
MN\PBKXF;%-:[YN_1*O2OV\2+OUI!B!T% ?\FUL*D..W4:">2B';9MB0W,LMO
MI2#9,BZ;5<YA9GQD:K"S\;"2P*""1*&"8#=I!@L4Y*<J"+ZC(/BH7"Z5R$2R
M4J/R1$9HIL-KIU;^7CO(=!DM-7I=>XI)7*?7L]6142.60$'B?_V#OV*)'ZP@
MWRK-1.T4E_\MJ2&'9PSSWT$^Z9DBT\MMU0TJU+<,3=CDV3^<;4 9.6IFQN?-
MS/@2,^.+90=();XQ*EI.&I7&D4B3CM<CPQH;X=9=>^FBX85BKXF#CK1O&91?
M>6O]EK)YJ<OX/+*YXCJS!%7,S>BY4UQ$5V6F&8Y[V'*A^"L6R.9/D<U+O;7G
MD4V5F%'4U.Y.Z=Z(S%IU0N_.\J2+Q 9D$_^9LOD]<Y2'O:-.D)\,HLN[YB<C
MCXHN?>'O;F3_5'Q)FWJV6(\LEI32ZJS'1C*_*(NBBX.5 IK\@^/+( 'S!!G*
M;Z B:V(^:.)XID[;9C]3,<F5QB5(%[4J&7N-!BH2J,@M<Y3?0$7B"59<M\+E
MYBROKW.2NFIW=4YT,:2 BKR'A//=5>1[9BE]Q);KC L)\I/WMU,(-(BXAE5^
M0(AYFXTEX$[ G5_+G3L@RGW9!-_@-7*:"T4%?:D7^%\"@6;! -T%'O+@CGS\
M-01UA'"W)$67)4$"ORJ\-=$0 )*'O87FLJH;K#8?36H70(JS>0@ Q80@8!*\
M9 MF; -]QC$6<TU0J*_O@D RH'LJJ2[FD=]/N]4FS,H\8T#)G_C(/SY8)7SL
M+?J$3_9A$-$WQ?64-Q<F$OO=P/^UT^6\\0@AV)%F_/&;2;;6Y757$TAA13[L
M-E$S GCT'T9>,H[IK3.1>MT,COBSZ4>!A CAV&LD]J_0UL^0( ?4A$!*6S3;
M04SROK8+FN1_>*:9VV.-I>E_"/P5X8.!7[V%17%@EV[$K"VSBDSK5NZ?"4T,
M&//\=Z>>.=IC G\&A@D$,_+.D#[OH[_^0;A;4)DR&L*>,C>RRUS3A!ST\YP=
M/;@%YUBHU\O%!AEJ%,A6E73M<+&6N:::?^G]:O4.U?9P].JA3+W6KE>*6;)#
M94.Y8HVL98ID)=3N@ ^J5*W3#OWMV0.>^_>68ITR"+O2?$Q(&105CK!4+(&!
MD&Q$X)'4*)KDB5&22"5'0I)C.1SC4DD\_I?+6,:/(QW3+&KY+J]C=JE9F=/$
M(M_ID"!P3NQ?&38*D5)IM!9GO51F%"V:269I-$<$3,KL7JG/6^-9)]E5L7FQ
MR37G]*!K#^&5!_?4V3!1[$?2#,V0='2\;J<J7'$YBAS>DZEBSE*J.@:E$.6*
M,8M7<]6%"*X\N&>T2.IXFEX7Z'"LCDLD/Y:D,@FN3.U?V9KW.-&.=&BZKF13
MC>9D.$]2HELKNGNE,IL-)B5V7I_EG:A.CN/IU7#>=(OF=J],SZWBL)^GLM1\
M-0B+U>YHD&C!\KJ#]Q2IN:3(38+"E%)%R;22X59,A75&!^]9M#ER98OBA.+Q
M8F*DR9U")BNZQ0.[5\[-2J1J4T28=LIR+;R,C;!$OND>Y>Y>V1NTIH*MZQ,J
MKEA5;*0SD:4$KSQX3[(Q6(L"WL,Q:=T+D_.6EC-Z\.D'[ZEV2+*6':PXND>/
MXB5!IF(C$^8D#NZIQHD9DRFI!,V,*2E<[Y>JT80X2HRP_2LSK69+9JIS"PMW
MTQ*7)/N1M4&"*P]6-.K5UTY:H-B9;<FF4-6+A !D*7'XGOJDPL3LCBQ3^9BT
M:A:+DA*/+T?)PZ>3\WBIFQFJPJS>XTVGOJ#S_*PY2AU>V>1LH3-<+KMT6&X/
MQ42S6IB%Q1&.'5Z:P$4ZW,5;63K>44=.@\E(JS&X%#^\5%U6%DDZHS2PLK/J
M6R8YFJ5Y$EYZL/R8S CIJCQO8/6B%3&<KB&,B^BN!^M/$W1E,LJ8D=E\64@
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MQV:Y_K)5KN1$E'H[8IBA+PO9H_",:1LP^VTA@\S*F@FWSIW:F!VF:J[E1E(
M_HYDXC5$K> *@3U8\D 00% (,<. F5<4GI/ I6"C1BZT 0]*6=GFW#W O:6[
MZ;);5/+WA\M<H-<'S#C_O(C%>3HAVV%Q,,OW<3F7:-O3'$:^MW>@,DL@:$M
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M@1O98:>C+?VY[H4/V!<AHOC65?!-@1MM*^M9-S<GL"VSXP0R,\?:>9J#0_'
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MI-H7DA'R#Y,1_#L8&;^UU_Z:U1&STC!'*5=/F5C/DJ]^S3^)S5+/U-\XS!_
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M E>E%ZWT>H&UQ[WFH""D!^7:IXF>T*ADB7(KM<3*ZX8X=Q_+A5)% :+W<)H
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MHO4 0_V_'-)="#NTPQ?"_YSA ["D1=&T8 0(;DU\0G;!@]:GC9?\"0J29"2
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MJ&)8>% UUN!YL++B_2DGNGFZNJ<%_ 7.W2_M8SJ @I#  @\F&4TQ>.5,6EH
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MA3@->-L)QK3,AU#L"#R;QE*)O^%4P],\IA/5.?</I^"?@Z]%1WSWH9</IZ(
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M$7A3\ [TFUY,R S_Q=%07K!-*(M7]E[.GG@' S_J/(?__F:I4]C^&3$B!HS
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MN=%LR=PB/NP58Q;%*J_HH,0O$+ZZ#E8?L^"SD]G80:)#+!T+D70\6+T/P#T
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MA3E'X.(;[$&XR-"A!,.$V.11Z3?7OD)[(>S[,2'"[T[D65*++DUD(*[?A<A
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MCK';W(H U[F?8"T%X.(I 7XJWK_UV-XBX=GY(<B UY'Z#M=:95 O/F/KQ\Y
M/SJJ=WG(E,V#;)B)KF_P^)^#ZC1XZ'(VS- 84P8@;.^+X47XZ5M>GO$+PZ$S
MGHPLSU:[76(18@1!D1&&_8OP_+TJW.#I#MJ=[>&9;_>U\YI_ [9[<<_^'$]I
M"YJ*8%%95;>(0FQE/VFP//"((7(U-/_RQ%!'J/:_C4IZJ[3NS:IMX'WPJ*2
MO:%]E2_,GS*=96/!Z*VE)DPFTBB'S'RE4BQ44T0UGZJ54O9\6"BG(]?2OW*E
MP=7M;C4J1+I2KE<>"IE4@\L0V4(Y54X74@]$O0$OE+ARHX[27N"LH%B@_^L
M0/!+\S8A_>S$DAKZ%NA7>=U<-'1>,>S9Q,A(AB"KAK4M8^2E4!LVI_G)?;/8
MF70E,BKE5#;U21DC&Z.W!\3]2G#I5*\W>K\N:50\0CBC81=D0?G]9\HYXT31
MSJXGZD S/3N;*-;9V81$*D24>-D$1!5 G3%"!$^,@5LJ95MF84^%!ARZV9=T
MV+R*WQGHP#[!$.I!?WM"HBPIR/0ED"A.[:PN'I_W#BD;H]2K.E D52?2[H.I
M/AQ458\04"=PD1;8ZF+O9BV;)&^B'>PEFISZ!)AK0#$P=O[G0#L5E:FJ%9*
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MLFD4=75,V,0[5L V3BRI7Q4%()C(+[L.G+<YE.H^YOL SOT(LYR*:[C)I7V
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MW;@Z5:7^]GVKJQ/%>FI_ 7\-S;'\Y[]02P,$%     @ -3QV6# -:1#960
M"WX  !@   !H;V]K+3(P,C,Q,C,Q>#$P:S P,2YJ<&?LO =45,V6-GQ((J#D
M'%6BDG.4%I4L68)$$9 D(!D4: 2)$@0$)"-94DMH<I"<<\Y1<FAR TWWW[XW
MO+[WWF_NG?F_;];,K#E0:YVN/GO7?I[:M6M7]3D'-8E:!(B5Y!3E  Q, ,!
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MH%-TX+?>-JT0*,;C)9NMXDXVZ\OSZI9>0I*#-7.<U+M1OY9Z;V%9P$/ 2_1
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MMGF[4$![V'_CVO43TZ_G?.>!(XQ>'M-,Q4NA]>$&E^,F,2@@G >*S""Z@']
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MB>YDU#M=+DH2C+^WK="IU)HU-)A^UF$G6%#.SQ6>0%/J&_B=W7'@E38$SV?
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M++1M!"C 2&H E%&/@P M'3EP+V_&ASVOCU&+:)]W<W9E [DI,R5XGR*I"RI
MA.6U^Y2*9(5#UHZ/*?5,/W;K;+3K-;/LD4>HV<<JO4\-'GM^KRN;,F7:Z VB
M<?&<T4Q6XNGA#]<F.KTPIB*1Z@&AO_RZ<KH_U8.\#]T_6T2JR3*5Q2/>VB[L
M-R%20R^D>&%F5ZX@#?0:9M8:O5X6\78U- D15B.9@:=.,XC,ZY9,2_4VT]!Q
MLJGNO'Z$O1@UX>O)7)[5]C9W(RC)$ 4TZ[T<J3NMKL*_-&3!T#B3)_-:>H/C
M((0U0[U>K^!EL&Q[6AO1;R8>LG2T&C%ET#G[\@;S-'7-#S.:6\FDWHY;GW/D
ML5_O3='FK%17Y-%(Y_B*>?(@C$M4^,6<Z6Z%2JIWAW$/^;]+Z3BKG:"1<O23
MO\\;8.]@?\QI+4R]&K&S1\BJ7OBZ%2OLAOGS0XP3X$!_,OOWZ%)U&Q:D1IO;
MRKGD[;[FT<^146L20[DLZ0SP'XQ^'>A+]2ZHS_"5NC-PJF]W8Y;MW0%NJ_Y-
MZ'RL6=9<DQW.)[]E3@-';/.$VR\*=<6GY;F\"PQ:0:5G[UU!6)5!Y6F2+?&\
M.8\RI6MSLRPUHOOY,KNL$Q3O-0',5<OU@:' P4WYT^?^NK"UR%PC>(_!Y<M8
MBK;8BDQ;!TN'.Y-]M!W<.9V+),&=LK<"9HENYQ\B>XUI*P_<D@JF36QTWKAF
MQ8D2?>FX0V<0LK-RN&OA]+3KDWK=-8P*'IFVMS=_WZ7_0U(][O:';>N?BPZ\
M\6HVN&E&0XAG-HGCJ4&1\J6.V@+#O'MR*<RQ>4^C(Y=B0N,!C3$=;"XWH'S$
MS&+-\YIG,3_GOF1V;):/MZCX]]UGTZ"6/KJ'!X%ERP8*YD9JV@K#B^7OTZ?Y
M8XU##0AJ&=P@V2ZCZKB<8-B,PB@(FH(<8FC/=*<XKXHPE")K#R[IHNGHEFN[
M?UUJE=A1Q\4$<U-?))'[AHJ/RF!C]-MAEF@#7QG2DN]T[[3; 2RK[]3%:.9Z
M#D!!=E(&2Y=7C"B@5\3]6SGIN1JT(LK??W*</01)N9'*7?4,$K?B479)M9?#
M(=4H(GY?8B_$\WB@R/58'1>W$$$)&Z\LWI9H+3&2R;,ID:$?F9XMEV6D6B ?
M6MGK+(K\#'8QIXWU(=T4F#;YL%TOKS7*2\OFK;FV3J7Q.<3*JT)6/8DZCNZI
MDZJS43TY1DL;[(/<6SOEW3/:P((\DW-C^UQW9^2G5(TYXO"/'&',%H&#XN+B
M1;P$'O@]+:)GB3%&\UO3]=-<FEL2GS(4ZZ _S(SR\_/QV/$S65;70S?S_N2:
M/_/ED:_HS!GP$44\1P'112M$EP1&X(WV8KF:_;_=>-^?!"^V#/G(KU"@@ \@
MW?.4]R;D4%-/\/V^XB2?RG'BS4IB(X.2\*4/]DT!KK<;9%<9;6D'6D<V?=B@
M$T*7RI($2<^B/9[[B1R2?/*3UGG)8NY$H"-+H?2)V25NM2;&K59$*(W21H(I
M5"V8*Y7#E5FROZ/[F@B/XO.GL*=[S(R!%:SPW *ZNUQ%14+U$FWO]:"E98=#
M7M5>8[?BN!3MLT,6 3[.R(P0S5QVSUO:[!3F_7M,X8RWPN9#3$=XENKCMFR#
M>5Z=R=^N I3XJ(FO:X311^IGYWMI39SH/>'EKJ][L3R_QEKA>\OW>\ =O7,Q
M=;S%=?9HVZB,;---=E=RK2*- G'!QI@5< C1-#;_9IRUTXBR,T-17%M5G/;T
M8=6LTZHE]7<:,?H1U\:P1$CPCFQQ=K:5^[U* 6.N-/,H^B?P:VIQZ@3/ 0(L
M7_YM0PH*SINR0J/:'2>A1<\ZC^\B)3RBK=:U@Y3>%9M[%K,$]A!)A>,%I'29
M=<G=YQ/LOU<<?Q#?.BUTH&(M7*C9@5-46CG5U/Q@)G-_XKZ:XZ;A?7)O_?"B
M3O]M"@>?E^Z9*W)0NJE@ESG"^>DAGDQEA4*BZ)[7_"*+AG$#7\49"CX?\(9
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M(%F>(6C0&Q?M'&"V"2-L+VH[F&G]>-=J<5AG%]G+5G]):)G4V1%;_\$L/#,
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M"+HJ.=_]32CSSUT/^I6E7TVXBD8SA9ZG_)C^I_36O^:F3%.\YRB "'X;F3.
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MT/FCU-NJZZ0X]P_-1,)UI%E10/IKM/;@1GB-B4$+>*#S:@,\5;5_?@!"X*"
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M_&EB0PI7C5J0RWGAR2;4&3+9N8;TF/9D)8Y:S1'E#)X10+L2$?4F@AV6O_T
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M_ \0J]D!H,Z(5[8513:91LYF[0>+W]VV$\<7I>_Z%I8XB\^_MG9V],C6=&4
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M(3WHAM</TWP_K6X*\/TK5;R5P_?"%Q1\GB8,FZ<3 ",^4L*7_P!02P,$%
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M$V_X]@D9M'P'_5T<L_[P4@)*UJ<L*EG^S*5$Y)!GW:@DJ7;B/,V,T#0_SZ[
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M,L?>SL4JK&@[&*ZAQP;1X: J\D#77(GN9,Y[XF6;O83KPT+;-?$B\'X$X%E
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M2>FIJ?X X%P)A!SN&.++9&@ZGFVJ^J*R@:S>_3*YVM#8:.B#/D<O?T[YA\0
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M=\\X<PNJL(5>9'XE2Z<,P)<[?#'SCBAVYVB1,*[.B)[G]:\G?+$FF\??#!\
MX4(:U M[*<E-W&'PI71VB>8T!5P7TE(ZNQ42K2"\>#Z=JV_H2EMGG9?%;, Q
MZ:<^4G/2Y""OM9#C6N&YFJ29G9:I"H>GN($D**C^MM(DD<K8*7@1,#_$RV<:
M\S\H7O\(4Z<%AQ*.A?OW; C+>_I [?;&R9UFHRM)B7P#6X\Z.T&<[9)>UR4B
M>@?E1>-#XX\.XX6WU#-MD^M?Q8?VX8>UWC;U)D:V[G47*94.'O-6]?423 ,T
M%H64!]#-=AL[L^"ZZC\IOOR([=7*XN7!"V^0JU6RQ'S6:@1SC* &-2>V58R[
M$>47?^5>=S/,LP< ]@*$=54#\\]P-BA!E2UYX7!$(&Q*(5I3^OCG0'ED;N7+
M[7T%-F 4JFR#('25"Y7RJS4C,\NVG>!LKKX%+'ZLGS%D4*%ELFH_E'R"H\5
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MJ]$GPQL0Y/?IVME8Q%:*;I-%Q3!I?_)6O%\8R7KA[6FT;S0RY-MCQCMLAF,
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M\-?;>*9<3*E=KH4,/9/Z,!RMR/MY):/PD@4_D7D^048K)\ICHVZ=GK6S5"Y
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M?)#T72)0739E/R5#ZQ,.'U=0CU'C!1EE9)5V?/EAGH-(W/>>F(;LT4>*G+>
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M?^C^HAM7QMC]UO\J"M88=B,4)WL3\3FI,: ]AR1#BD(6+G/3[/]XS^"$%TT
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M*A0BN#?TU'Z_V4RY3>'X:P3MR3%<3N8XS?-@TC6VJJ*$@<30TZS]D3.)E%Z
M_QBT*0[-3OXRX?+[;/LRRY3K@L6C;YQ36F(6P/A =LM8 X 6\>N8G@^^@DCJ
M;A<DFV+#M'#S=1F.YNR9'V.MBE##=VAM7>#2C_KDC^]),I$'B\-UP5]Q FQP
M=E(3V+AI U,DWY-'9S4P)^3O >E\59&%47]0 _:SJ?XL67LOD8P'P]FAKC<X
M(U CFM/TBAH3)3'-316V*OJW7ZW Z>\+0)(=$&8,JTT;(U(IPO&,4;T[C3G,
MX70A )J"+>ZXUAQH\S&"QJB3>;#IF'Y#&TK<_-45<&V[Q*8UTO'>646L<';
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MWS/V?M[S[.\[XYQQSAC/2N:/K*RL>UUKSC6O:][W"/X7?A&XH:&BK@)<N@P
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MSP+9.K??][%XH(:C8GS/@X*H;46C<?QX%N)G),G\KEXSV0JR?4MSK3R!R77
MU1P[_P8H.X%=]V;OR""MZ8]D'FNODS&,6=)\J$)J?:!2D!*NCOM4=X4D%6SG
M0'7PR:C_MR,5N<Y7]$:KY774"R0LY/TG[SX*(?V:(/7P29[=M4C=%T_Z68)O
M1YS%UAX[!1&)M^6^UUV+9+!O=#J?F3K+S9XNVP45ECR]V#2 BSC;3M=#:?S
MQ68"=]%6&$.T]FQG@T'-29!0<+5P&0)\ZG6(>'A&,PSA?_4P['):8PY _=-:
M>JUXN!0/V,_+/I&A3,U&.YYT*XZD']@KMS3R&X4L+U6^4A\5)ZL&Z-@D]7)"
M*+Y,I6*-D25LU]"IRY&7)R)F-F<^3B+CIEZXU<FC._V^(*IT@G*01PX0G[*[
MC??>J48TG3E92?1S$+G+&W\0UE-O72#I1ME%<BL)93(N,WNF&$Z<.&$0K\[/
M':F+HXOUO&VFQ,Q:(J VI34U24D6[E+E'V",6 64*Z(CI?R#NZ'.C;PT:ZLL
M\X>SO6^8I:E2^0?";KF*WI;FS[YF;[ :$[F$!Z(9<%1H*]LE 3*-BMID#\GQ
M?:']W=+]SH'4QUWTO)FVT2_8O6G<?D8I.V)YD.MA8*1;-TYH4@Q=(U%;/W;4
MD^T],<.S]EEL+[5E.]ZBJ)W89O'C5(EW$,%!Z 1GMV+T_5FEX/2N\TF6Y.K3
MFLHH\9@<AX''K(-<]+NTRI,2=]7C0UX&%VWI4(0ZA58Y42>5/-?5\J_1F=SK
MTE_YT)%K-L-]%[Z[GNH"$[<[J'.+^7Y17KHZ459#XD\OL-XTQ2^^G6NAL^93
M.L[W5BXC7KV:#:/M.Y7L[;5"MQ$"O>^X(%SS+4K-PZ0,-YT[>)M7O+G5681F
MD6CD^PN9MRXSC>QA('*C=@4B,4S$A?QD=T<+&TH $;K_JE:9'?PXT,;SQ277
M>HZ;0Z/7')%]VZU+2+?W\XSV^PS%7H;J'M.=G*ET( 9MW9/*J8!8AWRA3O7^
M*;<).5$43!'MMQS)8((,#4IO\^/-!2>+/S396V\(?V)C+U)(<V?7.I!3X MK
M-^-#H5 \X+#M3*)HE?L[G39VMCW1T#2XR5"2.3]-5,OSP6CU@AHQ#T!,(C6D
M?D]\<=S(X"F<R@@=XYQ7>G9VUNC9$OI0SL-70"-58^B<NR7=4N-BURYSCSZC
M^@>(PD'^5A-RQ?SW)[1/DP*,V#<TB7OT+/WE0/0:.V]\U"5*:>D"?UV,.OQ#
M$]VR$%GW$LHN%V'LT/#J"QPB(A[9G%W%\_+Y:4EGE-EJ=ZYW*2V\ZEO=^NIV
MP,+I>@L&@1R#7+)&\;H6NM?V@WEFG7JA?EM^::&[]^S L*^.6DN#&E/&HT<\
M[J(%#J:8&35#&KEZZB=/L^5"U)\4S;T0E#[<CT#0V*%K5G95.T[I=3</+#Y,
M]:A0/GJB?^7SE;EN)_4?&]_*),)'TRF#[Z=/4I_6F#6G-LZ?BJ8+5F]B>!6\
MM".R*C=_\62%[TI?#N?Y^K>MF6&1.R^BS%_SI[]"F;=GMT7EI-#N+FM97GVX
M&ET&N?6#0<;>853(+7+*^L.B::1=^!Z68GF0LT."NEU\+]F-=5QXKM!^^N?J
M52!0E?5#25'GT)=LUIFC^U2)ZNGMA?Z\R*GP/'12\7[0CW/V0"'Z@=E-PSB$
MIC>;#Z>*@GW#$D[YUHW\AU>EDSH0E?3U2_O7AHO)&J>=2P4$A)Q>Q*G'"'AJ
MSWHJO2E9>!VSIOE5\2/2C&Y# !5D F'O-G6HK3B0L_)@7</X.#?<4S=]=N<,
M>76#8X^B2WK?="9T]UK9UIO-,7,'9MJ4W? 9E72.V)Y>J.%TW6-)V?CG/^F?
M&+X 7H*[]-U(7 MT-$MWCM8BCWVW!<'; 25^VF57G;2?31Q"\HT@]!D4#::8
M].:EZ%_;&I4HG6"N*8]4S"[#LPGN,4$!YE;(/9$<@?O(>Z_4?G$&(&,I18(\
M5:4)663:3AEE;LF:,M95)Q&Y+#Z>.[:8H<RH7.U)K-&VN-M7YDT1U/T03.\\
ML]T9LM>U/*6,//ERTC"VW6$V._1D2H>%*_AT8-J0TO6J<!=)I]TOW%C+[='R
M)NF'(6&9)LI?N<]-3+OIVE7H]^\^F\WC=_F^>Q8BNUY/QS\S>+CMO#?K8)9_
M*+4]+9H_8^LXHCNZW7PZ57Z T+X8*NH^44PR'..8<M_UTAW'2@K&T1>4VV8F
MU]"+:%@;)TZ\NAW=-Z 6]Y:*S@ING3MJF\@*ZQS.?^JO3A4J,#FK<8B=3.&*
MY=7>C+._H_C=@U%*8/2[G\Z,6<<;M&M_^Y2,842AO<2YJ8.(P]2SP;7Y)[$^
M'PYH$\Q\:]_HQKNZ4BB#,2K>@5U]"T-3:C\A A"L,D/8R\#)GE9F<Y6B8N8L
M*5UZVC=75WH%XLPP<F/)F*VI,>6:J<03N"9DO'W&MJEXSJO."RY4-K?@=<8"
MN@FE\(8M3;5).=LT-GU'F7J''ZJG*))@9#^07#$ZS;B_LDY1':O.^$S$#Q$"
M)W:'46-YT> B$V].-11;?HGE?%F%1';Q,.3^3*?TE:5()^LY ]&T@HNKJG+H
M[H\XJ6UY.>1>=O;6C%,"EY%OT\RX6^>M0H&2@YAU?KN!5J6/5NULOAN,8O!H
M^7LC8@K$FRD^-95LU(TIASKU8;>>[O+M><0GMO/VF@-27+?&O/W=?_/48[!3
MOIM.1GF)GLW5-\L#(SU7V-T2<O/J&JLFSV<+MYB]=I*<5S#S2GK(VD)H"UO+
MI&#U!<7*&-N>2,Q5>=N!S*3>#]\.VA->ZD@5'$=/CVF.[\H1@6TI%J+]/)9Z
M/5A-S32]FF)-1B&AH0EW(LH-O<>B<CY1T?EAU!W/4Q8Z Y9@9 C309A$(<3.
MPY;_F_%<7ZJM=[:#QJ>.Q%D.#XJ>RQ'L,W8=B2G<Z9$2"5F(S1OV>.!7K,F<
MT@/-#W+##T1W$M3>S%]/8'S(QZTJ:EZ>ZJRS!C8Z2=OUV_3PL+8S$W2RW,/!
MA](C\AL(K,R7[S;:I(3AW$R_A=P]^=10.I2[0NJO;I?S:[[TF^;+N,=<%C\T
M/"-+ZU/7.?)H;V@:6DSMF!25->;-MA;/M^=JN?E O **[/<=N-CM'N_RNS"Q
M#$:.LWYD\O*Z7!_@=E*-"OUPMRE]O5U9,ZP<(LYS-X14MV2O=(6ZFQ_4W*7Q
M]OIW6X5YNL\9U4XUMLL8!>K-=#;D0C2,=NKF7(0L0R=&FR1>>Y]3K4]1X4YE
MT<8:,-Z6^#J[9$H\XU5Y7^GO\H"&4T69>FO'GYZ&>QD=L\<CI>?^$7B 6>[2
MDA"9/S_:M@1MT^\A6$6W;;$E6MS)W1ME8#!/&C,I\C4F6&JEL)RI;'^9O?-"
M:?GNNZ5!>@BG^DAU\Z57FGP!@M+Z]WM:/PO'JMZ+F9)>W1!O,ZH+"C;6J['S
M\GGH,=);LU93._(ZFI/N_O.4$XU>GE+9G/*6QF/?EDQE6B.'+EI=9>"_,SKQ
M^$VP#_'HK++/+:>RR4-Z4IYKW,;9?"^.9-7DD,I*RD  :QF:I:V!( 2HS3:A
M-*-BK#K=SEP,,A^?@X9>?[;@UT!V<X\\;UV5WSFYDS4*M_E>,V_=\<:AY?:$
M!ZN"TGCV2'Y#)1(/I''.5R5 *@1:Y9^"0QS4B>V"'V(GA2)-5X6Q"LHU8SW(
MIZ6":9\1ISD#W/)>PX<4/ZB2G-G3+,;D'VY+>%G>E6Q0B2C=Q'$0V+MAM(:'
MV\^@WDBP[)V-X6*L1-6-]I"K3=>46(DG>(\3]\[=-IM/0OHV0="-*N9?ZF8S
MW3F>8Y:J 8U#"+Y?>UAN#.M6R^WF2;'9YI=:"OJ538U5T<P^8'4VXCG2Y-6/
M:1?OU7EU^Z\4SR3M()98=;1_SFI-';/R9B.MO3-T4U:T308P-JTSQ"O@6S'5
M;RY3?4Z46B',J>^=VHITV'3.0GNN'4WOK5?$@J4Y,1SU>,#BE@/MAW>4WBRN
M,D3A^==VN9<9Q8C'*..R>N_\%D$[[^[2MKG9[#8Z=&1*\OZ>E:\OL=44=X7+
MSYK.YZ0>H2W2%SP;MX*?5@B%0D]G4X3V*QVWH8W3'@W=.\DTQJ TJLY8QYEX
M&8O$BBLYYZ#I2;!?$BESTF'&Z^3A_NHRX4.WKD9<^WFL=Y#66%2C%[&(8Y!&
M4U/#B"7CR,!578$66SR@%G'_N>>SC1J?543U</A:;5.80'6_9_T(1(Q33%B#
M30J2ZN[*>R@5]U"=V)>G,'17NJQ[14"A4]?;N?W&]LEI",[ON.)3OY_P^\YD
M\QX3(^*T&%J]N1BML4$/#7"Y\II3Q/#&/"3>T;:I+I[U: L#GCBNZ[OP.E(@
M@O;+TQ,2W_BQ$#4(;$HQ+E/R4JH:!>&HKS*\I@#GRN\;R+FA_9/$/%8*-)WT
M@XT5=1J)U;4KVD1M>QK*T*T=QWL=-J>(553Z0#A5[^\RWN-HN:HC]ZK8'E1#
M%=ZD8)UKTIK_>\S,X53R]++T8GP8;JIQ2%V8XPSJ%MFH]F-U2@"YL=QYVDY%
M#68N2\C9C,LKM)7/$ _^E?;5F)NCDM?$4/'MU\OF7[SNI=0HL2V9:/M^GY')
M+5V;F?0$@YI<2]\:\$HI*?/UJ^PUSXLC[/+34ZL:1G$T9OZ/)CSLG3*1B$#(
MD07-ADFB#AF"U=Z<Z_7;;%B^!G6+=71R0.N6N$?TM C7-[@,>P371 V/>Z/
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MG;I(N<''^VO7:S%?> T%'^SU?+\2=EU2+RIQ#8$:-0T8=>#S(2Z;1^3C-/%
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M0;W5N>I+D)M]1*>< Y=Z'43K%+1GT$;*%<C]DRNUT5;.F3Y79S&"?#9F()Y
M<N@S%L]/:GP?W0S$]T,7Z%'/'39,D0LQ):S20=,L&))\#!_YB^YF[;8'TN;N
MF?LPG=YM2$V#Y\&WN_5Z=;#.O*3>NRU>\O:H\H]RBBN-]N):.AW@W%;;E5(R
M3=#U3M:J-AC,0>)0<(Q333/QBLU!G]!UZ+%.*?0GCA]YV@:_[KA=J%C@'0*1
M[6 P\BPE5QWR$TMZM?9(XKW'T]U6J=;! )8"K!0RO:*\LPR!!JFT3"Y1E_@F
M#&60)_%0!WVEH>.7^$;^P)N#>I [H]V99'-FL*O"80E"/V58[Q7KAW;_K>=C
MD@0656-PH\D)5%^]]0Q1WTM0>@?&Y9W%\,:!X)SX]-JZ=<2V\\/IQ1;.ZDE;
ME%';++@\? R=8H/B>MY@-O-+64SS;K(;ATF@<F!TQ8G_!T^-N<8K'FM-PBA0
M9R2R7'="0$X+LF2UQ$XZ[7AR;L/LD66V5:D6*TQS+RG^0_5+;F.Y2L9TG<LM
M:57HYXMILNI:]\=:SZ^4)29I^B<^V_S$Q?<FG^_!H\8G;X_\;7S']J",:)D#
M"S;-:-+?;KW9D0W@WKRVK@X[J?<)%PC%4Y?1PI8(^"8Z,=<FOJ:RKJP46PY-
M96-8BO[0(M<RP0!J1(GEZSBSPMH>7KR=E-B^/B.E&^+"&-_S<9JBB9S\@5/-
MT81M>;#[$W(&U6_/IC)FB,GTU[>E#\]A)3T$_>VW4'/?\)/N-AZ8Z80ZP),3
M,D0)*MC(^<#!/W+;&7T2<='Z1PD^BWN8]0?-W4^,*?AG-[[_,(.'K\C,2N^<
ML&P^E=![M"D7(?M(3R1'F(;WR@/1P\LD6R3%"69Z8Q#Q-/GU-MPDRS9+P0S3
M;IDUC3+_ZP<]?8KD.30D<LS)?'GA$55/40KOH)0_[Z!J"Y<S+CO<0/O]<'-
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MC6-YI(NKBMV7<RHKJ1$M^3Q9&78)&_%RV@+]!KQW?)C+AP8\3IUR3N^E TZ
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M2EY K760R=<NCQC][W&?F:M\"/N;APJW4(J]^P?I--V*",B"PX>NSF:JC4!
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MT/GK^,!PIFK3 0;Y7^@ ZMT'= "Y?KM>AK%?EYBAPXH:DB'I'G&FH6A>B?]
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M/.8V]'DG(Q3)77?+^.^^FOO_W43H$_\%4$L#!!0    ( #4\=EA#V9)]@SD
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M![K:&S(:^3^N,(C1[15)T@_70XD3D=77B_2<$)V(WLU_5:"#U58JJ*:I=3W
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MR$B9@\J6V+M'F1K)9\UN?P?Q7BAC8"8BFEUREN)<9J @O]3%687QE:Y2X(L
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M ^4R;COJXS8PRXA[U<.RZ1P(^%X=MI=3A9:#3OHK#=KM6H=T%X47J3*:VP#
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M--(E("#=W3)##C!QQN^/?;[8>W_[6^?\>Z]USLL\B[5FWN=][^>.Z[KNYQW
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M*5%EEX<D?-QP!9:& *-#FEW0M_K1HJ(YD74!<FO\1QXFC&DKTE9A6\P9>-P
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M4_EY5 3^JUC<)OOPU(U'M8BRX'75_&Z@^<P4*TS3Y8I_?@4578L![&G4O\,
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MY$,Y'R[AISML(19/,(!.*0Q@LP!IC %\T\+>[LRSW$(<$8]6)>@!WC AY3&
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MJ YS08GLTUQMW"ABJ7(<:8&ME?IP=)K[/HH4$8(!L+MT V_H;#& 2<VO%MG
M.A=D%FLO!G!#9 C>2]6$<(MA )Y7^6<0+-%N^G9T"PXRA_\-O6Z@V;%U'83%
M@WX@%AGVYG^WA5Q@JSRI.!S=,V*" :C5E<$Q  KL[9_] 07KG CPV9&7N:C+
MU;W)<^QEXR=K5JX$7%?.]P)?Q1< 5[/ )SJ!_.!9;BS.7TOK03*02EB@P%MG
M1<4%WL<:6K\4@/V%?X"]:Q(<A.Z49<4 QN<K_5?^%IRP21J]YPL9S*0G0*8T
M8@"P80Q M>@?3P;#AM$JT(_8R50.&$">3OMW;!EY8&U60=1C *]SR#" W2/]
M=B#B#0; L= %OKA;AYWXT,@* U@LR4)B7<*I:7>"'"M"W\5.B@F<P@ NL?+E
ME_-0*U?;PFH.\DO_$=;WKATHQ</R+OL?P*#P,Q3Y.SMDG'#.]0T& -5[NH!V
M=<, W.S0OSW61'^OG$;GW&0 +]T@=_-%,(!4\Z U# #9CP',S%SG%()KO)#I
M_9T=-U0B+JC[86WZ[;B(>LB!%.OAPQM!KMBJ P8\\^ZO"Z8C>8ZZLQJ/Y+LO
M=7QLE9E9G1$;3DV=/,(3[2#X3*R,7;XW=X]4:$X/.()\:7YOAJJ;&\F57N[D
M$9FF23)(@$]*1G,\TS?9_>M50=;*^2(2Q+.F[NP67!K?/4I([B3*=9RGXUEG
M/'<)M+&'9'0X@R.S!1%O5@5OC:VND(_]^6)&SV#QXO*"\8*I\FOT6'MFKDE$
MP?/48.&LIN_?V;G:1>#A1RKPL6XTY?2Y&C@ZO7O1<';,C6$X?[>7B./M=_)'
MS_N4K'@/K!^^3"]^.C>6\F[4,L.2.[:K</#V9$OM.-?9F=W^%LTI[5'DC8+W
MQFIJI,S= H2HC"P0RB\J7=Y4OW#W]P4J[3#YGA!-C\38?&:B6L!4GR2$%M9_
MU $/.^AKIY@\%UKUBQ5_!;^=6FC&613J0[RL-W4H]GO@*'#-\%%!L%[8LP%1
MW5[M8FV=SVT[![^VN]]=V$5WJ@E]53VSRG!)YQV2:F-LS\X.W^6G6<UA['BK
M1>I/ D<&DO^2>;@>3^ZH4?2\K*Z9PU.1;CW%:%V!RZ\D[FAZ@@GPC&XG4U^K
M&[B0W[5"%<CN[=?YS5NPCX'SHDGDI_'2?L(>!F!'QEPW0\S4[<,>4T 63!ZS
MRF0G6ENNH98P:%%_+K.[U3AGB88R4+EW9"2?[!ZB#DP"Q!>O%:-X*K4D_A_?
M@]T2C&XF"?:WAHND=X0A+0/3LS+?S76$"YR=1SWGN.LBDR'P1HGR\P_&5+[Z
M4=R.'X&5D%"TX%6[+*)V?7B)3 '.5 3B'C\G\L-6GKF9:L9:A.WR,SGB.]W]
MVY^UV6GQR_&>L;KLC?>3YH"87M;7J5"6R6$ OH\!7=E:[,6Z^HX-7RK2G?(:
M/S^.Q*$E:7[V3A;^>[EXNN(GCCG9C1+H@F&3H;_KZ/:,9DZ_[)-QEJ&3DQ.1
M$Y$1_A^?,LH;..[IG7*3=P\F:JS>TN8K;C407@>&L9#"PW(%ZX_OVOLNP9Z3
M-_URGW7FN'/WOI=4T@>5C<6?!(,=-$?N([?0(KLN;DS-R)1E,B@,EJYP\V*_
MILR0KJ6:MER8V-U*(P"T+GU\;W[EP:X45W2IT9=.'P]F*Y DWN:6'&=%;HR3
M-!0O45%BL'F9ZN?R@7J3$Z,6*(N?V).*\=6*?>-" WM,'W:1&T'&OW VS(6G
M99S;'R'>7Z>&B;R)]=B3J9OTF.-.F-V#?@_FJ(]\1FA6VYA90K?#OG8\+X[6
MC%_' %"A%<"SD6*#7?#_O-WV,8+>0$=8"[VQH,8^A:8/5-X#6BUDE+O,%VO=
MF[:%V\"RRYEZ5$LW^US<6P?'ECL!K]W&ZGT,(CHV<_VQX:@>ZP%>>[9 +%'A
MX,T]+!95"V.EW<01;RNX!WSR4A:+JK,[6(R6-IN)-D$KU*' 5^QGAU"T6J87
MRM<BF7U7"\&=-?7+XEX@=S=-0OJT&:N\L&FDGG\BYY18;''*4M)DD>2!A=3^
MR3 PUM^' Q:0[@4/CV!05KM],KL/-3*-(R6CISF#_IWT.@5'8#DDUU_^/TVL
M=+4X$2S<[^#RN?HKW"?"9M]54Q,4$0WW7IC+:&!@"=O/4] 8Y9H2*WXJ;G/Z
MTSK]BF\M%9GD@H7P6:Y)#.!%84#0/T,6-5C&;-)^2HIEO<1BX:M NPE6 @%G
M*U0X$'0KZL=H[O[WQPD&]UN?VC"=HGJOVDZ#1KP+_:"=P"NA^/D.] ;X.G;.
MX./X%S >V=XUV^K8%9,=\/P2 W N\S,Q78Q'<!'FUG*Q;_"'60AY:R'4+EWZ
M+=I.K"&!R>O)_T.:R)Z!9V]O89MCUCE1EA_]% PJ#NI1GLFP\]7G08.+!="&
MQSZBI^">E2NNY4=86:"Q@H[TO7;9L,-RU>%7#."=%DKQ&+2M%=EQHM%JA"7!
MC X4Y7F5'?J23.&J-N1#QV8&=MU1X&MG[H45F+;:P97_?5@[O7OWK7+O0BZ_
M)*F&P8Z:^ON;1TS93[S<U]OO(S+^<&=OSL7=%JP?!2V\P9U*X,T<)-;NZA'P
MV63I3"<&0 7>S/"N17>*@Z\Y=W]@ ,MKNQUB KA8S[K0HA]B]45C#M:63KFJ
M8RX$%#9$7Z'15B"EV+1I1J_7BAPNO'>EQ%>WZC8C>KH3#L2FA<R?M.A>N?:L
M@V"E15X.5EI08J/+W<-Z+:V*E1:2?Z3%V@Y66K#\D1:%=!U7=/+3P"_O5I )
MAA#8-#;%C?;!#0%+6S-'6B6HJI[9""1W83_I&R.9W=[?I9$2-TV#5UKL-"/H
M4?")N\4=\"$_-B^+G!1;6!>BT9K9+EB&SD$)3('B4)G8/-U%DX-GC;%\KSX?
M2P/<M#NU2"2F17X2_"/5)A-E?\.+CVC7XL.&G1S64=;=YM1P_$-.,T83^-/D
MS+Y?M3R-%D(S[Q-C\O'*OHW=KD1(7P3#O'KB*1WGQ4-:U=9R[BW.S3$.Y(_+
M*-EYB0R)A7S)][3_)5QV;!GS[9P>P?KOW6+;OW6+P@Y3,^CNE;_J[^I<D;.0
M\O?^QUL!\:,'L/#J@7L^Y]%[M,/#RZI 6O&L"]FK>,-I(Y'$958;4,H#>. <
M_0W=& $ZW0Z5KB*:Y>14;Z!%6COBPF:BW#Y'=V.\PUB+9'(+L:#VOEP+#_$'
MW3Q'VK;#R3[6/?6] )(;R:5*96>0_(BF^WE60RY<>O^YK<1>8@ H%Y7EC[,&
MQ@O\-2^(9 ]DG) !7D!N@\#VZ*'JJ(71A8#\HY5JQ4/GMW9%&P<6&H^8\L.O
M>\^P>BU0GFF4LB] *WG%+(!F##*I\VOA55U0G:>:I!-RL H]$3Z8E+-TN+]R
M3"I9)F\Z$Y?$W D;)IIN/)D?.QKWKP:/::#(;MI W[6.+#?:E%[-6(^W,R(\
M=S0FZ[/4E*.P@-M[NC B/B?(5>_ (#II<[?IZR-JZ=<4(UY@W':I@Q7J5I/U
M#C+O\*YTKS"(NQJS+(IC4K14E.<W>W/B$8#SZ#7/T-N%6ERF]T*F-5]UR/4X
MF4EWK4I>E>SV>27N[?JZIV>70*]CU/)J%YZ3I3FY7GQF=4BB/[DXU_0>W(B*
M>FIM9#.AYAV04&48W7MC8W=H+<-Z[9!S ?*,^G[PV&;:H[YARDQ&:DRT-<CI
MP8V-]1$HTWD,YCI*8JBAINND,W%[?.[1%O24J^5&E95+$^Q56PYNE=BN+\DE
M=0>EPR>L&V7I+7V=91IJ;]PM'EF<3H+ET<?&4*[B,GYT/N5NQ<5/^6T3TX!"
M@GF;/O^V-MWL)][K];MYJY9*%:!'Z2HN9#6BPQ3>'6]C4#&>P+-)X.&$2L4!
MR*FLV=LG&^2#.Z]P,= _/R.QE+.ZD<FPG!<=E)B>4C1?6$"27S,W[+*MX77Q
M658]$WULAV45;]<178;M5O<OO\G"#,TSXODKT$NTP[3(LY6?&$#+=#,O3R,]
MI:-OWLJ^D$#4F!.^[)OZ_OF7 47J=L,+4Y(;W'&\=.>Q;Y)4^-<N%)NL!&F/
M$G*JX_K_DJ5+>1_^TU<R_R-?O?T_SE=9F23Y3XR&"=)$5^9?7CUQNVG+,D&M
M]8LJ__=-VL7>U'JP=+\<7/*BF>]I';E/R@RKP_.+-*$<09=7.S'9$B7YTZ(I
M&AS0\#F&K8A6BP;%P#[I_T@K0&>2T?3T@IX[[%1F^N167?110GQ]E6L+L+-?
M0M12E%^C7EJ"4=&F-H7L":BC[NN)S<ZEGQ3TICL.9!P%V+G=!&'FD@Y92Z$M
MVA@& :$*)UBV>"I^!OQ]7O[>T;=L99_B+\%C^=O@\5E%"=RF]NVK&2Q(@=VP
MFU;31E\,C,WV6V, &L+H$>=QA?NA?_<P1_=&9<R-M0]EYN0RHRW.8#%K6B%5
M46,?]B(R_QT_?X%I^?VL9^Y6$\RS *J+>O]0.!2;9A^U-K0B?A^?^U6*+5\3
M:=42D;',[G(&*X2=LB5,98:-<CB_>R>!Q\9J[%#LF>6H#GFGKG(S1P4"XFVS
MG7%7\8Z\FN"D<M#7P?W!@O_:[#(IF=D$$=_A"_TWBVA.5WI9XP+Y81W1_M9N
M^?*%K(3>M#=\-U;+OY>5FCMN7J4UGMA0\O9NFM2]%]#1$OH"&8Z9^?D9YV^?
MLT+&6/]*[@UCY9[7/R'W)/]=[GG]A]P[_)]MU1VR?CM&9F&QELMQY=JLT"#^
M;[?2X.7@@88<");$ [-2L%VN6QP& %$[*?@GV_$],@2W!?)S3K3%Q5TLYZ#C
MID#;?[\O8+S>L6FA-A6HOCH W*S'"IDPBVL]X7\P=^//1UAEPOU'F6BA*),O
M"/Y.',(Q@&Y!K+RA^B-OBM&1JL.TZ*T7QVLK5[QNP-3M '&8%EK=^@*[I,85
M=+ZGWI^^^\_?@O<!'3& &RQ=[HN_,:=2M$02 XMW0T* FZY8$I]90367_M^%
M%\03 \@TQ0 6Y[#HE.6M05^,;#XC(\, MH'H]HY?ERZQ.2?6K#7AJ$[@.6,;
M)$V6"[MF,;@=*M@9 SA3FYD$,P*QMWQ#=A,,WA?WLWCBKX%UIM/ZV W^$@:P
MFUKI!KQL]!4<R62ZA?7]LB!2%RL67&6Q?@C&1F 0B,"*4.MTK#0JUH6$H/_F
MXLNL,.V5*ZR32("';A8HD7T/V-](/N%_NWHX#GA0/!H#H,9.6]3Z]L^(I3^!
MOT7])_"P5&S@V?X$7L]_96T,&W@R[.U@E^BL2AYLV0]TL50C>[O!)PKK'=TF
M&("*W;? 18L3]U/P;%H!UG#/<E.OPYT_3WM@(>BNF95KVU^@:E1CQ^;>]I]&
M0^5/HZ'?>#PWABV$-0)4**3C;*1D7!>M"!:]8NL$#V+E83<0)7D?;(]-<6#T
MRL6];U@#Q;+,P(=/_VJS:N#?-[T[_FW/VTFJ&;L^/ZQ.8[VA$G5!"4R4%&/K
M!9B!_ )?.7D&@6&+2?/%68 )6JVX#W)#C_7966^A?G_G\964"\D?W03!ZJ98
MPVLH,E4KUN+B"5::[D6K5L:'8'75,N,?V\W_V,[0H5V* 3Q8242.([W4T$HN
M4]CS'FT@R29[.[#UEX,!:*5.[0%K:9&IX,B5"WX$MFI5Z]-/7?#.X"Y8=V/#
M-[EU[JMUB/4EY\JZ%RHZ$-MK3%3:QAC<?'S*?D6&@[7:-[L&^2/^3N LF,(?
MM/:4JD<,2.0O2)-2:7T+2;'H/;^I7#W,T!R&I\KVF%@X6-$O_0+X 4CGH17#
M8!%E800[+PX[Y\<S0@^D+'?K.LG1N]F!W&L>Q>)S^$.?JWY>_;JYW:Z#P,,F
M(/=:/RK:UP6=V&_&E84!<$%OL*Y<Q$95VTFV$?Y%]96]8H&X)S)>C?\'W[JK
M6[YV.<>UIP.K/+C;$(F%@[Q!;.)B (31K&AI,PP@M-7H*V)'KGX:*5ZQAV8;
M=X;Z,,2ENJ>*G3I9Q=:\X#0AKB@F""[PH#E)]B4X[%_/$OR. =22EJX_=3XX
M-!:(K_"&O&QO.IG7XKI37RFGPNJ(.Q*J\RXW*0Y'-$SPUKEAJ9LYV@*FV=HB
M<HW<8M$T$;A$49PQTZP#87- 8O .)!H,^S@#OB)L,^AB$1Q'^JT-\_L];S.3
M5VO5%U*G20CAH_9>HKL=]\+#QGN10$E?'^=ST':CJG0YRP]'.3"1^EQ>%*_&
MO_R/+-HE$./%>^:/X55Y*>U,<"=(9#WPX>*"B8,X)6]]SB=8Q%:KP2*5-:[L
M9L)O'="A[Q4Q J]' Y9]TPT%XPBX( U<G:2!V/ZW3B1'\GC%C7\ET]G_9Y<<
MG9@\,;$UX"7!=+IO\K<&@M&!R.<WSV]KAAQ3]!U;^%:_.@MM,N,:,-\Y"L:G
ML@GV.F)L=IUYRKL%H-96 '@K]>1\D+J,1AJL!Q4=, 1 0OW?H%)1+20_=!A+
MVONY;$X(LRIWNDKO+D&'%UI=1L?WL]D1+FN"=!:<VVUK ;0FK<H]#UU+]F"+
MRB5W[\M+)=XVBI.RR<%JD?S7B_!X)B0C[%9Q))I%@2"H59S8P/CPVVC"WKW]
M6K9)P4R^#SF/ER-F9=Z\.L=M(4-H=V!K;#?'&YM;^ TK2(6_^7H*'[3\O:^C
MG.JQ/-8%H8PP+)A=AG; U)PP@!YM;(:)KW6@J(Z)P*LI"QA 1-5RE.E8XY6!
M]3]YLF3.NRVS.'8TM4LW^)I[^1ZVZ>2'8OE*"<FS$H;% :U6?BP F[B@'[3X
M\FP'="=[2L3_O<6P_$ L#(S+PJ#HNTX=B*BCW?RT2U*]V77@FB)2'%L- 6LN
M2,H%,)P:W!6+<,$ 7MQTK2 X&S" =3YH7IS=HN3_;_#_5PVFV>J@ ]LP _NN
M+\/K@;>AH3*TJ"PGGS]/=M<4VJ#MI^E+B8K*5?PPN \I3:0S]R=BFYW=](=]
M[Z.;;88RN6GI^<D^'6&;_2S;C5?C*[IP@V";22=1:;Z#\@#Q[_$@T5\O3?N%
M%ZYB2Y1IWAC^</K\6F^6W UK)C/XS7"66V\V]50[B[?X]_(WUF]*C/>-G8MV
MU.-\N!+'<[_XB+E%,@CA'YSRL*F_\[&TT!PW]O/-'/*:HD/I1Q7M\>RBP&MC
MD>&'R1LHDU<_\]M@%MT:[!HA1I,0P:JWHAG1D>G31 .VC9'64C:6R(%\[Z':
MLH3[^*L)YI(W+OVK8V$==5%[$<VTH>YS_MQ%B[VV>8P2YKH^)16)O/ZYU:\B
MA'$R>?%^&NQMT8Q%>PB]<\VLW*X[" RO3I@I3%A?BRQ6T5!$'U9--H,J45J#
M6G-0'9A7'- !''K-86#,&L'O7,^X4K\WR"'^4$2MT$+BE'V0.$\AMHF.N,PW
M"$O79=Y$W4)(6T2353OSA/Y0OT5]V/2L80\[-&9W_FTHNUFCGB!'W+/OBX>^
M21:>!CF(X@L_A-%&EN>."9R[6XL $6+<O+"S+U44 G)S%9NZT[+I/2Q&HZ>H
MA?-LE_?D\IS18F4%O!<=60T\H#'0?_S*Q>E!W>3OQ:O\-8/N,<)]8%U\^-EP
M!_'NI=3;=JKI*IO:]"[NT"VU$4[K3U]-[^FE/&.DQU7$.V8Z:2>%:84[AT?)
M'.&II0["[2(J\U?L&-]&/;4ZD<@WA1!&1$7E?R@#?,=M'X89=)*% TD\C#R
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ML1RH%.A7DH&XUSJI6]&L$P*;BS$12M1KY,Q)A6BVZG@'=*%WS(CT_-N-#%H
M8/7H/>MR$I3$.Z8MN2,]?'JM AD#A\X2E'':%>:;'UDQ/9X7+M%U;]V)Y-@9
M,$.H->KJ]:VL3X6W>9 F\R5KN'U_T$RSY<#-L7" H4OQ/:J^4*;F&=Y^^'J8
M>?"4@0KZC0(ALP;23<OJ/0- -(^DTZJ^\9\!"!^6TOD6U]A>]!'##1* KR%%
M9<SR'H)#'TDS6&^F"<_1WRK7G^EFO(!4>ZBQ,*/"/6Q$S#5)+'U=O3EDX73,
MD%EE!P!P*'GQ0+9U>;/81T%SQO&!AB7J^Y6D8<8Q@_!0C/?MUV37$I3\>66V
MLJ ?@:,F=_V%L:[>IAK6HR *7\@;H?3SX;[C0@*X:+=H,(_C2KIG/MS^N[,N
M(LG-J>0=$N6\-RIBVLD6]_A;VW<U:,6TGTE\*.1K[_,Z=V)BYM/@39DB>]SF
MNT07P4"#$LWQNQ8^T+);P>28R0H @#J[GB[+CS]4&EK*"I$M4F@N82,6FL1O
M.=!<*F'*6K_P]F?D35IUF9.5EXO-?B5T*ZCHXDDKCH![OL+SVPZ5T'-<IK6=
M_'Q^NU%)MET<R>D=*EE4_MC7QI!-=?(,T/ZP#/CLR3+'[=[*G;Z007K%@>\_
M]R=;3C[4\4?['D:\?UI_FLLN?=//P$+(>]8XU_XW +]WN8GI!6<D_%*LUFUL
MO(5ZI=U(@YI+!D[/>R * / Z^1*W,SJLM3"@LK%G-H&6J_8(N.;+9U:Z;T:Y
M[" ;&B;V5X@PD_C']/YG,%GYT\4V//5-)'B(.C>?$WCC'JF&FH-6CK7B^Z('
M"%I7L0Y/TA2FG&ZW[Q928C^Z[O+U^W3&K2?O/T'?_LN<#?]LSE\N;S"%_SDI
MNSF;Z-E]!B7M%)CQY[%8+M*5YI=&T-U4W7,6/24J-;V,\HE<SOG'EQKR6SIV
M_X/ WI-(\O6\%Q!D(HG7*P/.]H#(3< *XR2RD]2VU^*>' UQ=0?NJ(7.YE3:
M#WDP&%;6RQ'>X2S;EGH=AJ;]3$7#CR;)(GV#_7D$\?NN+W'-!1(OJGXMR+:0
MOKB(D8M,=EQ^=0;(X@W*Z)_<J@HY,KHP-&1._UL1M/N/(MCR5XP8B?T=]5,&
M5IM0_EU&NG;^E8TVH]9_PL9W5*[@MR#FT:Z7M2&XUS#U^0=^W?>V'S5N_YO^
M$7[5O_(_!@A@QYZ?_GL#5AW>>_0)&RJY4GK]6+Z(UT([F]%U6#*9.7,*?'<N
MS+/VD3* I'#SN7-609(^M2N-QX>NYAMCN0&3)&V":.?Z5F=YKL^7:#7^ A )
M,Q$/ W.QOTO(8AJ*-7M-2R7B7<G<QR*0Q2(_*6L__0.LQF1C4];1>711H_Q@
M97V>YF_]Q9W_@B R+3TY16>3T2O<L&P-9O*N?#K2,\LPA'(%O/0>B+W)^*NV
M9-^'M9#''):^+0LX U@A!,1:@X+I$-+"V;#3(GR\]*FN)Z'C#/ )>9HS%10X
M+W?E*!<[T3J@U!921=J53>U+JBM%40:5RQNOYXRL#I"'2]- U[@C@ %P<8EG
M]X5J#\BN,#T#3'2$:^)%2(\MSP!1G,0[YS[D.-X&UG&UC_&#G8"%*_N I'?:
MCD_-AN<V!M(O!E^U+7[HHEW(G118X7% WX2$?=V;_&UT\CZ?&()%G5LT]^9T
M"7U&*N=3^N0/(>U*)_&BT_&H8]Y3[[G* \7@.? )#]!G'S.8VLAP2C=X[JN&
M(,1GY[@V*3L#](P1"4%Z\ H1(^Q2.6&B^*1DP>EA>/]VW4B72;QL0+VVMJ@F
MP8TS]PSPEU3-P2,&+X\3[H@FB\8 @CLNN";O%#-WN5222L=\2'072;E:,>=2
M9:D"K(HU"[?$)*E:02JO//26:?NF]:,IHJD#K_P[UYIU;%!P3$OT$X@^%@[Q
M>6+_I+2;?LU$*FEV1HNCSON5\GOI ]HZ%ZUX[V)ZU%7NYN?(=(CSO$>T3[/T
M&'R#5!\/BH-#-[(VJ030<EXW67FB#9^G=JGWD/R"\GSV!0 @'99*4A,N%05<
MO*P&;;7*=9=91'%\<$7:5N;'UP\T8.B*@GZRHNS?O@0(*+0RV9V'74>$,>("
M5C1L[K+D^M8EONIFL81V-U6!^GMX\RE5P\$ZN%( <%C2>DO0^3NE1MVZ/U]D
MM$1&F:A1=<090*_^-CMAI'PI,8AL$]P>+'':%<Q(3)X7I8<&<]8WX1Q_%.?&
M@Z1&D"+T73*IYH[W"-'<W=?F()]5UA[\"!4\-B&B%X5)T(H*H[NP:9@-M2_)
M$>>&OT-M+(]K-O0)W^PJA;MNZA9G"HJS\9NE_W'NRAHN^^KI@+3_:4-1?F3,
M4C6NMH4YA29*XFC:IZ&A@9DF1>Q;=2Y,_ZIF@0NS:M^[L%(MI"&>LR.$W+?]
M0%1RBV*E?@:KSJ43KZ$?@553UKK".OI2_/.3$=[#+[\K?=M8[X5O19S2XT(2
MFH'64$66(2^=[@GG%YL2&XI /U;JM&#M5+5+<1_>>O6 4M:-]=^#BPS4F/Z?
M:B)S\7/=P?)?@D7G5@^=\HO*,KO2'PX_'!%]E!-!D5-QU6+!\;'&UIV,_K "
M_GNYLLB2DL4S **9$S5VRD\<'M3[(MQHZ/G!W&+:9B:DG4<QWR<'E?+BIMYS
M_HT,1V->VDYZS58 YP,S[9VOTSH\:"$$6Y5"W>='FJR"(0VK&R;@.*+6O-DI
MAZ^L5X"/DOV1X]A8-<@F5?A]JG,B%]E-%NAC,@# ,_0RN.K7W/D7Q$A\2?L<
MQ9;;HYKB/7*/PMI4HOFJG!4F%^)=P43_#>*-;Q!R-5>QD^6]D(P&^!B99L/.
M *!&N@4D_>H4!Z$<N[TGS$O?X2)12UB'<\5\&93C2J"14[O!^;J_Z=G%ILN_
MSZ*?GOB]Z?=X#_9F-%#C#OMG&IK_M[\?73_)WVL8I#B^AQ<I<R3$TW\ELVL8
M!:)1AW96FJG!7M *Y;XW#N8\"('E1&V<'FS#_P#<E24_?FR./;%>-AD)YG>Q
MN&AE^=6EUH(/$^\>_91E60O2V^NBL_#*'4,&5!=75BP>FLS0K!#Y_-E65<>]
M5U[#ZMOR^F#9@P\$0"SP\2S40]B3$$:9J13+[K[7[5^AS A'C>8.NV=H1(PO
M&I(%#S+MEC$*S837E] JM&?G![[!>^^@K>F([Y&^V9T@GGH<=6[(? !4HA]!
M,4VE#6Q2'R:<JD#+%$H\G"P;#)>>F[[:)-.,CP\*5P,$ZB].[C5DA$1-L41)
MQ,9ZL!,/.]JW75(_3FOV\K71H>746V]>''=(,CUH\8YC?TD-6[>A^TJL73L
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MFJ(-IXD>G7(S^9EIS]WW2J#'X(>PD/H#_DD&U\MF<[TU7&:DGZ'>@\UJ8N4
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MNHU#5M.:*/3PV? )83DMO#SI3VC_0/;? Q;Q?X3LWX']!RXLX"0S$\-YS'P
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MJ'@BRH<:G'WZ,V&>W16H=-'IWJ$3<3^CV=OC>V-P$R('@X.UZOXX9/Y;A5%
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MU;Q?HI_"?E@AJ:QADLU5U,8^.@".DI7=B\DFV*80K6[7DFU*C!OF@POC^K#
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MXG"+.L1/,8T%.Y@O5'"#/#BNH1%U<8DYJ\U$VI"+#N#TQN _DJ,&*""_4CK
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M/P)W^.@%T2D3BBR#88V,CZ_C']\60H0<4;[V_W$@-+,ZRT:R2H)#B)L=@70
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MUY8(1^N/NV:GS",M1W%S.[.\&;Z&9R[6"2O5\'^<BI'1FV9R;=D&N0S;Z:R
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M]/6!G&Z:E5!_P;'9AZUY?P0)]QR5(*<+JG(8W#>Q3D-%;#?=Z,-A&+2T8$>
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MP=S=W?4";4PJ*U;I9C64)'K]SF[(K;(=BC96#N_-6K,%U7*_G;.*/H1D1!/
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M8H#M= #?W+KVWH 0GX^2/-4IC:'Z5=U]&+7@^L-_Q-RO9.(VJEN:FYI-<2F
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M2PB\UG>NBM&N5A2@]L:H0._E2CI@28UF67654'6<PD:.S&\CVJ#MC+F\HE_
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MSC!$G$.DP^20WQ]*.<N@F!1P<\'SBU;DZ\C3=,"/M$($WHP.H,2;4^1 O'3
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MS4&PI2'U' ]];RUY3JUYS6A^WZCO>DTZ F'\R#7_ G+JX0M2]Y<XVF8Z..F
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M8VGIH:_U]ZX33'Y4KK.X%&%>AF_X%>1$8ZW=^&+V>A/N>DI4R<F@H;0MLDT
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M0/MF/;B;HB+C>Y?%V)6ZY-_J+J+KU&"E+"-MP\>V5.D_,_)9Y0]["B%][B3
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MN5Z+'9Q"M7 I[\'"+OFPOP"FW63E$G+0,QM&1A7UWC:34K=9KM7OGLI^ZGT
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MWSHJ'@DT4OZ1".2B'R-R$SAPL6$RW[;?C4DWJB@:6U9AEG_JAY@5%55>;_Y
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MI/?1LT?$T6!JM*N7UD#2/]JGU+NK<PY_@+.]B/:Q)<9D_Z_?IK656(6%G;+
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M3=SXY2=WFC%7L:QYBF%P02JF&KUM$U;\P^>O:2&XN#O5"F+9#!"8*"$\K_L
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M',8W^XD0BRIRHG?& APF:@G?'MTJD/XM198HI;E?Y&F/5MX'*8*@>3"KX_@
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M2C=+ZR.V:"UU?+I+[S)YWF_IYD*I_EB?]T5Q_TK@@\WS46K0C-^$XKAIY[2
M99"[2T^YC0(M"Z78BV(?QA[#K1GA/DXZIECNIK0W="KM>#;D9CV]F3-@@S^N
M-17*70A4P*D!/'5^7J.0F)E2-E^"0]N=+3PY/H(2QRMI@<*3A@;Y_':1!<&/
M;\![<E?N#5!U!%-VLI^6=LT$[\7 U.A#:K@"Y7LC,CE?5I:G=/T&;PCP[#-/
MM69Q,1H7G;#STV(L8+=C[9^SFVC]SO@>G0)16*APGP3^:;E4SLL0WFDQ+Y:.
M^W%FB@QD+^@(X^2&<,RSE!BXM;@5IL[=EWBF:F[(W=R\/U#T$'I'&*CR$XGU
M"_+K'3\(3SFDE6 CWH__5N=&C*]C5F*.D6-5E>+)TG&LHN0]Z7)V=;DH566-
M"+67,,__B>M9$!;VZTQT"\18&VT5UI$0_)NX'R&;Q^,^,E:J03%<2XOSZTFG
MZ\HLV[T1!BV5Z0DM>$.+D]/UO%.C\O$!NQ'1ASK:SN)37*8VR[OO)4[4J7]I
M+-DCQ+L,#4SRPMF=5 ]%IA!*.7[#5 LN-?Z'+>H,@B[?=;F+/M*I=<T3@LN#
M(,6U0]-:(E#7S.;C\1ZS"QDQ"-E;S..V*NWR^04+DU+VX>SZ?I8?/BE/!DI3
MKWN&?@DL<0@F#7VP"%R#D%>C OLQXPVJ.?SI/$J*UR^4W^+I?J)F5WUP[V2A
MKSSK>7A>"['W+6OQL)D2KW/F2\AZ6Z5D72UK,G\IQ$,K-&!,H)<J,_N\QR/!
M4XZP:PG\!'EAXMU7'WJ?I=Y__<1:Y7&22IY<!G=UEUPSF0&W$*WA[U7K%VD:
M1VD5RY59_D5+_5#A7/"X@?2+]?:KNL;*&J7EKJFZBREQL7J3F 7I=!YA,;O8
M(9T488K2/ES5K>>L+X8WOT"=4%XK^]=E%;)[&"ZFBF^MZA\.1.ETC"=CBPG@
MAS:/_-]S>/:(L+'R.WW5(FRW+L=ULY:IR]NJ&)J^-Z7S^WT9)I]"@2V^09%.
MRGTU&B<T.R CHF:S/G!7MI,J-C8CSM\@E)PE05R +4V:>2'4_U[]L->N9F@X
M55K-<F6BZ;$]U(ES)N:9-YV7MUB%RQP>SH+47;V!$NWW<LW9)%X3=?B.N9DQ
M>F^J@E7[>Z&:,I*Z9:=B1T<!_U^T[N__BJC$@1#6.UB 2"#??R#FO[.S89C9
MX^_S8-K<?8-:>,54#O$&GQ<PYESP>T$/R5KZQ5U&MNZTIP^2.MV/DV-7Y!*K
MT2XH^35:-!,\UF+\G)!/?*CF-]BX@-"<Y[54],F;3S]B;-\4X9'!A%+CIK,@
M[2^#N1UR<?](L[^190'Y>74;OADLV.F8T!)C>6.L>-@]O$!!0(4KM$FR)D2E
M*GH,^AD,A52"*7X?G8,^&("H1<7]%4<_O)M95_=G6QQ2(0.\"%I8H8Q+DM3Y
MWK@JX8\%_,) =UO']DR$0O?=4'+3RS\;H^#"Z\M=H.BFUN\9:] PDZ(PI5F-
MI0+9$IO?\RY\FY'UQB8>#7<!:>TCRH-A%M<@#C#335:+X<IR?%W X7$D6+R@
MN\ALCX:F362B]C[['[1F!@.ZH=)2,#Y$O2!G9$6$FPQG8E^RE='JJO8&8A)
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MU"ZD+71B\YZ,6!5 G<-NT7H6\JEBK@.>@0Y8Q@*F#V!#!O=Z_J-"+?T,,=9
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M5%C BGD]%L ZQ9YWT+GJ-HL%K%]TJ,-(0?LT*8Z&TU6O1"6^)CU15V9U[9O
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MVJ^QW[KJ\MIDN0_E^IF!VFY/XZB,9G_;<6V*1/_L&J9OM*7@>H-#=:OU.@W
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MKY;^R\;E,M2'XN8DL$>6Q3S:-+L3>HDS@@58W&;S7\L!%EC AQ3P%:XC\.(
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M^ -9%%FR;X?BOWP,_-M9S=>1N!;UB,+W4LKEQNPZ9@Z-+D,;W (<M.N1F?(
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MG]<A+<+.S!X>;L;-Z%2G#-M]>+>7R*+$H\+,\" FY'<%O2X*=_5&;94SK!D
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M2JJK#;7T@&M$Q,372(C_.O75TZ"KYP 2!M(;-V\_O,ZH;T/&[\YTYWU"+KG
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MW_(S;PM(=)XM6%UI>O_QV4F&<9KW]T$2P4_"Z5+?/G6Q&$6D\QDM'6J?$(\
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MR'4^ .60U;8:[^X]&Y<*%L=^6PSLG!2I#A'QKX@1[Q(THCX0_SHLE?@E0CP
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M=I<N'BXRK<*[[]C- 0N7RUSP[$QP'BM,MRF:N]\Y-M\PP\) )'C]E=8?(A&
MR2\$=3 '1!O+B-%;*CO$2CRKNY*K)Q)^LF8-^U-%WJ4#?+-N?,U-AG;D8<;>
M23*-X6[DPYXG@TQ+9T*#EV^F5T4N^7):>:RM1V&-7;>^18G]OT):)EW!]_>S
M$W-J<SHO#;L#@)WY([4R=)L*L]ZG(3N01S>;$DA0]KYCW=,2C7>3/RER><N?
M%#!+*R*',2/Y?S*.<!S0W!5H%3A<16MI>&:[/4,D:OE" >;@,DKU.OQN-CE)
M[(G?@AW1XS*KEV]HOZY_F:[05P<I*?7U'<M&K1H_5&=ZP<2DKP[X7VXF*=O
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M)IS)LAXQ1'5:?H]+A<'O60?=/?W 3..F6#MJ):>4EPC!MTPC)(O7L&G+P*@
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MPW%IFJQ.9OWR93#/$Z8SNW+5RWL$@'5\^I%D!G?^]XV!VR:F"1&S@BO:'@1
MU_;X12LKL\R)$2)GW?:A2.:Z_=,EU@-<"_IN]^*"[)#LH/FWJE7+N'B0X5D.
M$NGQP4PH7XNCI._#RV2W]-\HV>0^D>R6I&FXD[)0KFZ8@T1-(?4!#Y4;L&OZ
M_OG)9I?UMSBCW_?+=<]R%@V">"8'$JNNX5_O5-\=VB?V4OW)DU6IW614I5U%
M&K3-E\PHD?-9N"W@\. $%W!H(C$0?!LTBLV80B]WQZN4HVA<6::642$F<1U3
M1I]:QI671,68HDI;9&6E[RJ5%^N?5.M?(!V0*X[*AQ_ O_"7.+C#W1T5>0*
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M?U4Z\VT)Y5T1HJ0++]A6827 +J/1&UW.,[9M7.?O9H76CAANBN-D7W%X2GQ
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M/^M\6'X[2=1PF(N#G9E$7#C^UV7GQWQQI5V@^)![GWK O7#X+[S"X/]'J=U
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M5CN'-Y0.MK,I_K-C[%'QQ$VHM3_II4$8M>R/>*2L;?0U(R:FFQER5O#9YY<
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M1NPW@WYM>\!FZ%Y9@#6B<N?)#RW[<.V1TG -_>2/]\+/*[_O8:-ZR,2534,
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M74X87BQ0-_<YQJP%?K711N/]VU99[M0+[VK)_TK"<7I8?V*\N?>P>FN>#5Z
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MQA4?6CLAM67G7\NH^NN?RD0]Z?'47&-B;+9G84@_/GZ\KLS>#O++6P GWQ7
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ME?NGQORR$VIA\'J@/M3 Q!5'^53C 4W$UM_BH'3NO/KG X_U/OGI_KAR+8Y
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M;#96Z$M P(F?=B<SK17O;.E;<02(>I&0Y)(.)4TUK$N0B*&4974OAQ$9B>-
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M91\@65%7-4H0LFN@E'M<&U<VN$.IS?FMV@39.U=,MD*XNC6>Y5":ACWH#GB
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MNH7U(&18AL@%]#-L+!Q'-FX%.(+PR>#UEJE6W*-SPSYLPUCWF)=G:T-3HE?
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M^?)?<JSV&[X&JK+X3)F97TH8/*/5D@C5X0"YDRB=5F/&C&WCA_T!X0.%4N-
MDM.O'WL $F3#3<X&F$77XMGAH[);?FJ8J9 FC>R_;/DE5/GEQ:RDR3E"DAJK
MW?OU#Z_Q!,<JUX>3V0-)75Z+;> HQ'5%[K^F:B$*TNCS@97)H\93D>O?;3[P
M.V9D)'Q #<<'W1M8>,;K?:6HN!QBNT ^C3M?!EUB&SV!RDZ17UM36\UXLC1[
MK*63+#YVDIE6O$Y>8_I9WA.] @$/CQPC613--#MJ[^->DY!KWF;+G0@_V1\R
M.39D&0[EU^]RW#.HY7K9U?0FBUM40PDFO7+ [:Z<FN:ZL[I5MG1_,75N\8B
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M_WAJU3\:P>"5\1QC&^;.Z6G::,8I\.+CKE.IA=:-9=W$#]^2#H&D::,P)-X
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MB@=<\+^KK7E-[22S]9W?\[.8^UZ.LG@>'1NV7>%J&8'!/O6ZVJ'Y[1Z;30U
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M)JL\_#%N+OV_A$>E'&"P@1LK-\VB$[Z*?E 4DRP43+914&P,L+1=M&;XE>#
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MX>W=)*3;A\V/,U;J/-E>2)GJ$!D;>R9\^TU TUGK?MW9%E_!O1K=U8Y4.QV
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MS\U5J69<<,^YMK(V](,_^1 I^?O[[M)O^X]TU[A[8!:,*16T\: ,N5F.G):
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MVU<ZP;5(9U[[[!$4J^ORG'F<FXID>E_2IB(RQ%QC@X\::/E6#+/-29K9V,$
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M[N'I%1@4'!(:%AX1G_ M,2GY>TIJ3FY>?D%A47%)36U=?4-C4W-+=T]O7__
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M>%QEL-@NR#V/XPFEQKGSFZ@]M3IA;6&ZX+'$4;*:8(]Y#U9%8?XBHM:J3J)
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M5; WU\FO,:AR)PAD%&:O? 7>N_ES-4]*8/] F/:*P9L+='S3-!;T\&8YSO+
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M8*)]K_'*K6_01&3-7B,\8%4X^/<J/(%_!*<35TK74YN1X7CX0-]OEHF3KF_
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MP'1&$ XS"$=#2[7&(LV,]MG)5>[2DYQJH2P&#^>>EOR&E!)$H/*,$/UWMI:
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M4Q3W#(\2O]L!_PGE%'Y/])W%+9E,<?TO[!$AXN0+,XU)A44?C<G!G9?:*K*
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MTT1:!"-=G].C)'!RU3'W2!R[YCW 1KM6S(!D]P4(J9D31O/S"KFP!Q1O3QD
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MQOX A\D&$!F&'@6-6.=R)GFZ:]P4Y5MBOG^E7:BUT"_(0ZYL-*35  RRP*.
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MC.^'1S 3QS 37!2JUV"S@$Z[3J7\S/\ZR]38X_/XYY84)<%Y[1='0YI].6V
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M.9X2>[/855\F^=$2-M?J<! :XON*B3A-KZMP2H@PRC_AI<3(/S*IWRJ$O/9
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M9);6)]LBB?5M 55L4:/$H]T?!Z"6=XWGA! J[!_@\\GYGCKT\JRDB-3D%"3
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M*%K+@:_T \711:L31,8^)BJ31XU/S:;V04=>;?Q_?8U_R-X#Z$>WQK;MC@>
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MLH^:ZMK3; >'%NJ<YZ3B*L5 .3ZQ3S,3?])HS1A7 2MF4[,83M]F\46J12_
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M5LR*U>_1D]RJ&/(F23L"Z-(D-/J:X<"J^[9U[SB"'#=-)\K@^N&WFXODL>N
M<Z/0@ )]Z0)IUPCS9!W?_GFIC958KDD*39VJ!':TM+GG&==Y]P47+USWC;'"
M5ANT>IFS)Y<\:IMFCW=WG$Q_\W[17M!6.H(-&16H*Q,V! ]&5/7HK,=7]?UY
M##"JL_D8O:9KF3'TAQ4]7O:BW".55B-2$9:RQ9F';D)$"4 !#F8Y\KKW%#=$
M2<V)MC-_TI2A,(DFN_?\1.I+A$VH5CNKZ#@WW@<_ER^*<9ULE@%7[L((5*29
M"R:'ZM<B<M(T J4%CUX79/=L_@[KM::-($)(0(>!V/4N*E-L]8H*!O-_]MFG
M_Z1\&@D$//,$F& ^FWNF)JHRQ"A YK7H=4X9R#>BG:[FNNAF<S:N>WO-VS46
M(S.8[]TJ?&#11P.WMG]N]#.=#;8E@FS_P(.HK5LG@KQO3/)RD/F -A#@>S<-
M_KVK5PZSYY:9%,!@-"UKR\*1*_VUBTUFAD(K@;_Z(S/Z' :VH:G6\;7@TU_Z
M-7WALS-K6+G9N#WU<!X5I*97;M@JYX%X119X_J4Q5NB'WX @,)M+D]=]IK+*
M-W(]1=ZS39.!CO'R5;T;\(VA]?7S]R&R';#4F3I[/ETW%L5\V#<2"\MG2LH.
M]=OCV=K:O%<-9&?Y=(=TJ3VWF:!.]1L\WR&U\Q%,!]#P6V<E@7 2AE@9I*0J
M^EMI<RX8FB^W%!+DLW)5A(!7X,GD4>$SHL,+43R$ (^B,W),LF8?&P:5EF*"
M<GZ"U7F&J;"8-0@+*0N: SJ$?VVJ>92T29V/V(L5=O-PU4>L0O#T'43(AI,O
M?K)UNV_(W;>=F:#D;#$SKLHW6L3J;'KFJV^%CO90%8\%J#%GCOV=D4VI@^!-
M3;K- +(SYG4;C;Q+&]&:L*-]A.*5^WRH+)1/3]5@:*D=^<RU46O0XYV):5^>
MZN[W$6O$'-SH$TX&^:+$#$VC:B),[%07.L/B\.?RK!][/?=RJQ"T:K\H9Q$1
MJ>2OFH@L3PE5P!(.T%*LS[>M73[G-)IWD:K3K$?*01G5M;X6*K]E%S>'B08P
M!VVP:E/;A-0PGXQ?"EU5"IE#6UFX&CZ[K=NB-%,G:VE;OZ<1B%ZQLL767VC<
MIF M@1%MVHS<5T.58FS'1C6*T<JX9B@G9]86I-GKR16YABL'@YREMZ7RO!RQ
M<FNA<:5:'B@ W 70>G=1GT*ZR$ZR[AG-ZU<NV6W3WZW\'.S)U&GQL$5KO.YF
M$W]NJ^:'ZXB*R;1YWA\M0.YL:R_>BX\HRK;[&")_: ML%B<8/B_'-/L*#!0K
MC=>A[Y+2I\W<./^^P[RH5Q@-H=?LE/LF[M1_1Y;^2OXUZ>87VIPTPENZV?#0
MC@Z@O5;--[VZ[+:P2:=R%L?MN515+OW%MZ /P8'/CE7Z:8.$3".)OFY0=\#C
M;/*=7#QH2=G'['L_6!PJ5S=%6;A0[0R>.8T]O/3Y'<,\E"Z,0)97-O-D>V9[
M5]H_N-+5Q[+H^!9"%A^4I&D*DS>")%FH>FF/H)^8<K[>B\WL&CR>"I>M3)T)
M_R3$YRZ+Y8F.T[LPB] L&7K]\*CI\#G)WKY>RP%AJ5H\8!/OV^;SB)+WG.1S
M*:U7S #IJBVV3MND'R:[W&=_2V.]R>B7Z./Y@^:CFG& >].*)=OGBL*(+HLZ
M(XG:M!G"<YW,YP+K[J\$*86 >LQJ'2WBY.GI43^NI^'*L[.*1.'T7EJE3'1'
M300* ?8):['<-!%FJ!,%M="P^9#7,00A)K<_X%.:*2#$*,>%:4]$!]O 0!FQ
M>Q7T@Z%#!(7 0/2CV[9E'.YE@VD9(V3ID'IS!S*QG#<O1;"KMAFSF!+36D]T
M-;%Y:!7&$E#G^/;]*_^&*GW-"7;>2$UV8C/A,)2YV3J# <=<3Z%CFA@\34E<
MN0_TD4^ ]RW:&M/L;C]*V=E)>*IAZ 0XN80G+9\KM;/+'1PMBB+VAT^2OB7M
M]AZ.E-\2YB9U,,L [ LH*[AQIK1"LT9*H<WG9IIICUNH&!<5N=8>KE?@]$Y3
M(SQP?;2Z=[F85BEXZK:WJB) 3<\8&<P&W(\*V*&IU#3\#]H>Y9LU_Y[:3?+?
M@L-=2+O30FB@..%-HE[3;S]-TUK/]6I]TN.7W57\TN0]Z"))EB8DH8)JLBMD
MI\ Y#;C!5Z/WK;'+"G6M3?R.;H[%GOQ/@"Z$_&NY"/BA \)_C#\L#IU3=K/6
MJ/1>]JL1_2E.I\^^,8:TCXLWU#UQ<6X7:FS1U%H;NR;0" TS'*J1I=%6\>!@
M( ]ST5FNG3L5+P5[WG=[5X6O4:-[!NBU!?EQ?#H5&Y3W0*D0<:![#1K\W7M
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M[_"UUSU>#XWUQA1"%;T ?P;Q)J,+ATMT:)&^:JRT70T(;I$JL&G#'^=[Z_T
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M[V!OI^7!(0M9H\%K6+R^"J>9^#;0)X#]#]4H?5R7HJK#92O(^ZG<'Q Z;;L
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M8]83$VEUY1L4,?ADEN%D4F#B%.U:Y=%'YAHCJOW%J>6-E$@T>K.+O:WGX!-
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M1)C[-4>,3FF9Q7Z7%44?!^?XL_D/*)\:]ZEZ9I^O24> 9.PY#DPFCMCLWM=
M@O869'1I-*&RJ.P5\OT''<\3QRHN?T\W@?SG[A!9:\ISM6NQY07&"WM-%MMA
M[):0UIHTRS#/82]M:37-I-@0"NV&G?]X5\R(#&C*$9I--U'7>WH=6@<FOXF:
M(:5-U6Z >J+<)@Z)L#I%D@]%RXIF:-2^>?TR3N^ZWU2&1B;?L/I7J.8%2J$!
M2,VW&9=H41U42_UW&I+^IYM<_]M&^"\H(V#C1OS?4,;.\_:<)\ -4QPR![7[
M^.[0[ E00#2]-?3OAV*.RJL!'%,KCYA(RPEQ\AOWL\['T:LMZZ/HU<ID]-"Y
M\E@=EV2^Y;^SKNGI^/A=#_QP2OT$(#;F4 N.>J!]V>,%,0Z/)<;29)2V&"*>
MN:_WF]^8&>3\&15;*=/<SN^137+3 48*W226W/1U7/\HLL$?<"^YUOIFB()Y
MGSR^EF;$CQG]\055?>5:W(+5FD"TJ$# ZJ&$(53Q^=4$.2EO*U"NMJ9>AB8#
M)K,6]5K5E,IJ&*%CN($%_\VU.;_V?:)-33D+83Q[Z7&=/4R3=_*/BB>@^X0=
M<>:;Z_5V<D\,A1.C^BJ,9:S=4GO*RK1:J)0D5%8-8*[3'5-M&8\U[.G@\CW6
M1^L4T5AU(__A9.3R.B=O1]GE?9;M1F^;A-+@)&6'!/]:E+^I4RR7#H'*I7TK
M CQ5!Y)E2T'\!0DJS_X!%/[N#?0#QE]1$@WET><3\>.2F![HC+]"6$)).PK1
M]7-'!/.ENISOSR5S/D;%; Z2IGX;==HW9,]9]XFA&:D\4/DPC)YZ:2P':YV1
M1"1BY=9!/H%(12\4Y)P!"\K7GJ-BLA4[7\YEAT+%:@T3,G]/.N4#TZ:5ZN7P
M6DEUVXJ5<_>O] RNL<IT_:H=:$4P/[/D>^?,U)JVG6U;4^H)ZH  E"RD<^6X
MF>NM-FUM-=;&YK9?A]:IOHS:0E*X1_@/\LN:6A]\4LH'"X2L6/2N)MO3)JR-
MW[!>^.%H3,YVW2GEL=W,-25?.%P3=0F]?]="D^-<$/O-EFJ_6YEPP]Z>"\3W
M,3G@IT.?X*N\DY3$+^6(P?10I)XO$ZD37;!(7.X?T1FM? *B:U"?/4<..H1(
M64^32R=-&B[T%3&[L(2W$VVMGD)&A<!>A+4BL@V)5]RX/1/EJ"T\)J$R#=R,
MCLDPEZ@QKAWQ]XVLU7X@:9%DW,@^" OL8P=A7N[SN_H&XE=PEY?<05*+V2TN
MFM)4M[<VDVIJCU"1TO5B(48EIJ*K&B1,NG'BPI[I2_K"R]!> ?UA64L@8KOD
M3L,[VGMA=]_UBNBX8. =[B'*)O [[*-N-OTI3NK:O4S/ --7(EJN9[&H+^[(
M#BI\/[G^$%I+7S3@-*&Q<WYVMQV;G7R']5J]MU&M@UU3\:C2_0"JO;#=+N5J
MJU&JY+(A7S.I]%B<T[RD_.P9$=S6MXP;PX]'.<I0BGN79H!3\Q;J$M<+X9 -
M.\GXDQ!FMHGI6]J'<JLEP38I=][9[?$VT[+16$P8<A6KZ 9!%"<(^U:*^8FV
M8GC[5N]]J-LTL2 QS-W(V90<:Q1I=*%6?5CTF;0S\<B$,:?8.;S3IICNS;C_
M&/L1RB7E;]^@XF(L]_MB.Z7*ZUS#W@WR8&=!*COR/GW9Z+%(1*\NL'LL\W?_
M=JLX!E$UWKMG!F 1$M>[F22ETX+0;=U>3Y:$&Y>H(('SHZ *UK*^("G;#)24
M7@B_Z*67T=]U.P >4HKCCH'/#=<21>M*C(YF'GX3O#S67HU%7.UQU/'PFD3;
MT[UA2N5OYB!)BN:D(!0:*,<@X" 1_R+[80"=!99MK,Q1,7T[_3 [GAJ6M->7
M(LN^XU#O:%UDU+7Q.T4H[.3'^P\;T?@W_O54J[SFNCR=A_U&(7[8UNP,89^9
MQZ& C3#1G-[R7?=:N"3=HZHSVC.QYLGBJ')MW .;<H$;&IM.9@>-U(9[5[J4
M(UO=!$?">9DC9Z9C][%WYC$4WT.IVHULS"CN0IBSM4?[ E%I"3.> %3. 04#
M]9Q]M'3;A"G\(:O:^SQ9N[T##07I!,S"JE=.;4WE*77-^\VEFWAPQFA A<8Z
M8+K]S8W[@KZS6<P[TV=:?ZUI'KY!]4Q5W5;&H,F0@)3K!H[JKH;:H^YF3T]W
MMGYF^[!2 /K9WG9CP+0162&IIL/=0*'5^$Z[>HRFM:#&=/PB7*RVZ=VYZNNA
MW,&H"IN97]72W[30,*L/27QQ<T;+M+>=907,HO3X@Z(82W$?Y/Y'P7:,_ZCY
M!@/&W/UE-D:ES_[9:/W_TXQA3P D0=^C<O":Q[]6,WH,9+G]AY<*^OF7O9_X
M_ON%3;OV?\WEE+IX)#Y[D#>NL:C3ID*;1LZ!%&P8R*<H_'=9%H&UE<#_0]M;
M!<7A1&&^DP A>""X)[B[6PC!@[N[!PW.P! (D. , 8('UV%P=W>"!P;7X#/(
M,/CFO[556_?E/NS=^]!/_=!=W5W?.;_J[W3O+]#=(3GV-):.MKHB.^E0)EIU
M"]"<Y:V@/O:W[\Z!;:\<V%\>$NR:ESP!\-@VZ&ZQ)YX H5Y/ (10%7<.NT]F
MX3I7F@73'DC*4UHO:TL@\,JCOGACN<Z@J;=+9R"$\IZC&M6!N#:;$<I6<:7K
M0ZJ5'=Y"3NJM]N)GEFPS++@T,(;-"B2?+]%ODQS0OD!)P>F&'@D0?C'UF;E4
MR@21EUA7$NO8:F6PH2#J$1]<+1%82*^UXXZR\G*-FWYL>**LM"+\;)L/I8.H
MO1XD-0;2TL^R9"#7CM1:N:C]D ;/E7:^Q_.W)4WB\^/CBPX$@B)!SO]Y\5_!
MBYLV:>@VT6]!D3YQ[,'BY_Y >0+D^ 17OTY 0N "(W\)F(2!STJ.;X0Q ^G2
M-G+NZ_LO2G=4G*-<]V&?;Y]G@+4TVMT?:;C;UH-.BCH([%%O[JB!8HM7217%
M,3+?[T4@!ZW,><5&_E ]E]=6-!/WJ4TU(YYNORN;"'^:C)KRI.<P6+=I#%D0
MAA ?2E,D][?N1D2,HKB'^IO,:1O;V^V4[_^.B0\QJGTG:?^%Q03 9 @?"(J
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MNZT%3SK'XQN$_O< Q_^A)] @$6B-6H3Z8VZ)]/WK1[GT+OM]:T@@>V@>X*Z
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M1/QA>S>9OKOM[?<-M!$(BW^P_!KDLAYY4.RL7W=$&O)LWLU'C9]"3M5RD?]
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M9$#*^,)W#D806<$I$,G.II SH8+L4K\^:NXCR+2N32%[%?4F.TILFV3@:,%
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MX:MWPO&#R_&@N^@_ZL62+D/6W>4RC-UI+ //6$9O)+,?S64B:X!R#OBY=Q9
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M;4Z( KS&B-/C2X^!CL@)J*K;4H?ZX2ZL$6<+WD3&UY:U1J3_J,M_\;(_%L"
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MS+5$N.!SJ5%O[\(*%@FZ^O@S(N'C+[&O(%/$BNN^\5UPDB? &]55@[0K2)?
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M:%2/=.WLFC@;]:<%;VN"_8Z('PJ*;TC'U.@,]C2K]3(V]RZH31UX7M>Q;M<
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MFAZRV9"3TLV0:*;!Z:T4G$=&+IPFEL.1S7+2=B5K\:#4A9M/NA_@P/X5SQ>
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MMT0KI&S1T <?RW+RYEB@FV:[8S#\C=G3DFJ;X_IEJY^O6/"^2"M[#R+1##G
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M7.H7_5'";A1"9KZN^E3,H\_R?"&8&'3GN=_P,"F*KYEE[5#=<C;/N538N!K
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M&/F*2<]0S2]:S[L:Q-YE!:A=685*T\ZFD;6JKV)(XOZ"+V$5VNKEPY[>6ED
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M=5T+90\6L.3W,S2:WHX\EDGCQ@F\WOC! C1*UU=X 2 !MR7-:79# L1RYEX
M=HA=7 ^2GL7?@!VZ%,WXQ&(F_> T"US+K4UA^S;!=:7OR!=R928,;ZYY"$Q_
M!:HXU(SMKGWNDP(CJV>E1/U;!,>[#EWDN)W:+[N:*"E'\S<GW'8N1B,&E,<U
M/VM?O_/>"+;PB4,:-:_)KHR VY\I2WH\D::A-61U7#\K$)S7F2*RRX]:KDQ%
MS^>3\NRKHSKK"F=<<$YX:.]"[\,&&=^)F+<D*E4,P%%K&W $^TZM-@<L>&NC
M)L\]1_\3O?J?Z%K !F\SN@X4D6(!/J04EBB:YAGW9'6I N$[18>=<GY-XQ%6
M"167@=WSV*^.*T^JK&PB'-ZKMO&Z%'^L"+[_IV+PL57:%@6>QW].WL@F'ZK^
M?S7S0!YX 3AR\"G,2]I,4AF"6C(/1$"+I:"O4$&Y+.4(H;;OTJF*&Y;O,99I
MR,@@Z9WKN1TTTYXN":9L33-7B$<:W--,/PY()(V4$058HU1$C2F-T3.D[E,\
M^6\:L' ^NA#I??%-G;W6C2=\5'8C;PL3-9&<-L$6!,EV+Z%[6G>;4_XN"W#G
M,95\(+9;P[Z"O 7A;G @;^I HO9J[*NX.N@,5O,2F'^()<E</N9[5IF$;]>0
M,6[Q:[.7*=U)#K\ ]$Z@/W3G8Q)OTXOB0U3&[B]BWI<"(#V=2Z-]7!N=2UN;
M'--TWF_^AI:YY5YA.T,?2H%AN>>:]I^ #;=]#9JR[/.,!"\ 4^*Y!/*VZL5^
MK#\K,L7/:8I7U?S6\L7UL76JY'K3QOT@W-&#J8&%6%*"-Y<R?59U/E1'F6VS
MA4WS7.8!?:#)I"T[X]J2 0Q@\$"S2V3(&[H'T?X*4>/ELX&[=/_CI5# -<V&
MD;]>S-4B9Y%1$.&B[3?,@)\F$7-4ZH%9-Y"#$3^HV$=71)F6NDI3!WAJOR'(
M2]+B^4_O[MM\A^7HT^RSO4;3\6//EA08<[B1HCW%@S((<0K;_T1&142E3(1>
M8BL[J9Z)7E(Q7%^Z.\, LF_;T?X<H8?QE<NT_:D\$\1V=-3*HE/Y/':QRY^X
MLRSR2HK2_P)4#Q[ +A?%W 5K$29'JGE:X\[<YF>9G9(.&E/>3/YY!Q?R>3]C
M/^=_--/2\O?252.\7"_GV;"SLRJV*B/-4[ZNIK%.?65B!,*[-(3LI4F421N?
M%[[C-C19Z4G]>IX#V._F&_T\_!9\:^_J1"]E$3TO]1?+(\XM-"BRW2-B33GC
M!7#R_MO'+\/Q/TY>KZ_OY:JA!04YL,6:B.Y$3+TS )MIT$EI;R=/C*E+?WU\
MT/6-(3K7?MJO,G*'G6E?+<%? !$"%7F&;V"&0HN2'&*)'H@Z^)HTG"CR[^YY
M?V*4LS.GV*6?'YD2Z:O#SZ%M60"?O7P<=SY3Z<T@ZH&UG@S.0I? &5-@UZ8J
M[^JKX,&:D7>[*]U>%*&#LG<=V$)X&38_F?WREP/GS<H37@ "_EY%(58'_AD&
MRZ.E!,6U:6FO'Z=^#>QB&3%>=]/B)+0?I:"F_AD]'TG $JM=6=(]J5T >=9<
M(APCR/@Q/O>JIXD;&JZI:K5?7>A>L.P+MN3#E.SNC>UY:GQ?B9E:16,">0J%
M'R*=U8*>CACZR MSOR;E1VP]&(?M#/323<I>YNVX9043P1 C5()]N[I3^8GJ
MM?$^?,ICB:[Y6+6\Z68%6Z):6/@,TTW],^Q.F9;0MCIB]NFV,/U$TP ]]GW^
MX?=S-SH<9R- HB<!YWEQ8X9^$;SR\-CDHYV=9XM]P^SY2A02PY$1 OTH)YN)
M.9I$Z7']F:L'GM(>CA-S"?F3$TI+,G1AY@Y_K+"]UKF]AH09?,P0CL_GE9-B
M>[D09;W.\)YI(S^243\*SMX&$9R%(";2/]]85+0SW9-5EUI.0AC^Q"L[&,\$
M+C?8MSH,'*94B,2EU\K?[##<Y?VLZ638H?/=0M%>I6P!F[QB\_6R=+%;>.7G
M6&!#4!%JQL<EXZHN-(%)I >$XWVASO\)WL@S^\48AU,:BC8M+SWHXJAIJ&+=
M BH7[EAL"JQN,:\Y>^;OE3-[KBXO@W>TV ?Y'S3F39*<@$;RZU/F%Q"FMRJ/
M":.J<.A VN\C& HQ.-J^5 &'A,2,O4I7&"=&HVDI97"ZNGANJW9^=H7>6)9'
MPBH9,"#3FPLQW.,W4LJ9@]37X;:"L<5<ALA.^6"5N'Q:T CTMOH$E2;7$@&B
MX#U&@K,#%6RMVSGNJ_QQ3<-F05]H42>'./9-3:].Z@:>@4 !S&AI9RE(7%&"
M\Y$XL=MM$41.7(,?]2%S.35YGH%, 4!B$KG; T9FY/H31[[1QK)E=(8-^F[Z
MT8W1-GX1U8@41WS ';_2/\[_9/=WM:'^*2@^1R-=DI5+,W\&(M&9;8E([.J$
M+1B$8P3_*5,9?6/%9]E$A1?$ML=CS!7=K9' C S,;O1.G@FZ;1RZ&]J9<S"M
M9/$0O:GUV8?N-^[[IQAD>W0;AL3%/\7MZ>8>GV%:,!/^HI<YE*;HT+'PH;PK
M<>4;T(44=J,.PI*V7,&=[*QX5(W?>D)%+K.R<)#7B/:>D46*TO@'$GW$UBQT
MD[4;>*EB&5A+7?')Z%Z_6<!BJ^J89P8C<M]7-T;)D_@,O4V6&AI TU]8.']^
MUR"0>#;CK@8[V*\(RB%NC3#.BU;FO-$U<L_FO\DM0N0^B$RJ+FVT"GE>&;4.
MV_ .W&*-M\AF.>*FH7!*+>6 )KG:5/&2W!IV=][9D9:S?Z)4.<5@)!C4R(!%
M]FOV;M"\MKN!&QJ9."15! ?&=UJ9[3F\Z>&QWKYPE1KW/3_O@'#6MEA5-[=X
MZ^@/"G/$MSWLMF4MB?1;UWJ^UW00IU@]>-J_>[0Q/RXJEFXU,FJ7I%FX$.?K
MIJD/B6OCQ[^QCB@,L2^PCOO,.'@K5XOYZ6D5\R#L\U_03:X]+__(VTS22ZMM
MGF,/0Y5U<4'9<]'VT[12*B<N'0I-/VT#C$5LC)M0M4MH,[N(YU94_5JD",=I
MIL>'(^Y97=\XQ0IB+O9R$HO![,7%>J0$-7^/R:00.\VO\,\[6=O'L_7@3H>C
MFO&P>/^D#BS,AJ46Y?&[BRL6!^IW-0ERT9RI'T-?'RII>LSPMQ(7F_O99?ZR
MYT5F?T*_J HQ/G>$06)V6]IG<S8-=BYM[']KKRI1"9Q+LNLI^#G<Z(HF!983
ML9;B(9_C?U8-*B(LXB+RM>%6%EA2?<PX^'O_":?F_ ;JT,UYL^ R,^D>W:Q$
M1OUQS ^ID<>DBV=2W1$OC2DGWAYB*F,#YE>,J?/;\_;;E\0J+U\[)&ZXJ/<.
M]DUR1_M#0"#OKB[] E@@"K/U*K'G4>(;?/,/0T1Q'J>V<U;N]7*CQ\\1CNIS
M<)Z6F#KO3B[0\HA#'&OCAYT @>QG7:%X2R7S3;8C7PL;]?K:GJ%,G06W;D".
MT&Z[EM:Y9PK"4JVAJ5[_:W3J )*FA.X]Y7INI>72\J$$]T+]B6#O#:]#1I('
M:QSJ&E2%>W@=\"M9B8JMT0Z*C^^@);>)S6+1J=KAJ,F &Y9F9(Z"W$38E9!K
MB'B,B#")'-#-QWPPNG*;*JYZ8G\!,(QU3?=ZS/8*'W&L-"BD=)\_&$QQYL^R
M<VJ/@Y@SR:)[1EP55B9"THP1T64'IL)S[&=7)A*J@IIVQFM&M:A,O;;!"CAJ
MZ@SH88/*5QS*,P]\P&22&-<H006<FV<M1[$OH>K.=_QCB*(!%B\=/\^]+SQ^
MY5S)4JX><7K4]MT(&B?U-S*UX4Z5)K<'Q2ZJ^!1$W\T<9@L3"IDG\>P*0V*X
M%(+CO?06'_O2!TE$&A+Y5RO+J-2UP!@GH\9CIGI8821N8H^_D"8=!J<>?5 ;
MHOV*33_6EI=^7/[[UV-6CVXSB.-J])*5+@$S83],F-:KWZ*&?5'LF7]S?J+F
M!U8YOI")C%C#(O_4XRW'+G^)>T_RSH[N'1_,<^!!M9ZS+\V*#&7[S=GDS&5Y
MQNJW=Z5%$U,8>=EIG[",T&1XIIM? -_NFYJF(!5?V?BG !^/=[  76 4@DG2
M[J&]0N?1(FYH4\)^';L"=W4@T5X)9/:<M,QO0O<I92=#B>WZK#)G\(]YT:&F
M\>QR'N-U)[ _30Q[X\3]P;1AFLORBT) *9EY1T>K(OWRVVK-XRZ/.#P_1KSK
M>01D8S#VD3U2HVW:I+Y/9T7,AV?(]07@X<["07V<0":/^:KMPD3$Q'W:21B*
ML=VDM=N5\#4+Z=;?4DPG0#TVAZFN>K8^,UM-J0*237V*.;'!EH^F*TPVQ" Y
MT2'08!_;,ZM=K'$A5Z4[[?SDO+#1O+$ 9L/6S<AC+!4%_C0YZ"@MO*U4ZU3Y
ML;1:FD,+)T0?'Z*\+?4B,4KB3D)A9V+#%R-X=C,^R:FCNGH%"HAD!_#VH)-1
M?[VY*??!@A6/4QZ2/JX:7C!0%W5*]6S:;Q:2#;=706PRSYPCI]F-\R,]#QY&
MG@V+]YHK\^U;&AK]GC(+%HU-'0A3&MXSL%]0$OHB5Q.Y]*UA<EXGHM8GR?',
M7]UM)U^)A;1$()$Q9;>4.VN&4A>'8I;-$U1%$I (V@N[I2L.LTMO4<\=YJ#,
M;,'U>B%OC("(Y".%F>,SVI6WRHP&'V,02$BX#/A,0HRL<3G7FVXHMF)O63:I
M4I*-!$Z"CAN?\"D$=-Y/W505LQ,U@V\61OXETAV:5Q(XH%5V>$VF?+**"@BD
M5)7YV76'P<Z"4$@W7GT\F5OD<00/'Z@T]RPTNHD?<5\466&@0%SSX0]3)<R@
MP)J6T"5#T*IK)[P1.=F(<3X^H7P3?_%^=T\Y2-4FYA2FZ/BM7$R%L)-P*(O-
MN@&5,2R\ F-H:]R1PZ7-@..I@L49_&?P)V.+62AEZ%OJ@IPN[V$Q9"!'RHX+
MN*!,66*"DQ,_2+?111X*G=HS=[_G+WD"T=BB,K'JUN=DK+3/7>D^C(VKRPD:
M>O5@%Q#6@A7?.B]W/OE/3G=0R 9832N:DFAS89V,;!/JTZBE_0$:KB#<#RG\
M?BVZD06XCJ"1H*/OT@10-_>##OBH9-#TOM^]'XLK;*ASE7[T&P\"<[$6_IC5
M'SX2@%C772KL"Y$+B5F=, 7_ ^*SRWUW;@.[5?KS/X(0%)(>^261K(U76>%-
MAQA4+X H-^/@\!? HDCV5$.R03Z6#/>0\6Y#0C;:S])1:YRBU0&W77EF,[53
M9-R_5^.&#:%R;UDLA_!D66CC<MJ" ! N)'"0<ZK#^T&87.OA;/UBX+7/G/Z=
M0TR%&^7TM$;(7%O+29#Z<NYBC&W34]8SF0KS6@B>/E_0)PQ5?R>_W..AUA!;
M8$1HU;28J(7 ?? &VPS;W1>,+-?9S7NY8(6=OXV!<O(O@)_/_[5O,1CYGZI(
MD84<=/OVXJ&/DPB/\]J;RYOHCA!TWT&5+YNH'84?8'/CD7WYOO<9L?M+'&9E
M!I81^/PXO-NONOUHA4X['=:B;CKXX'O1GG_;4)F66U!\#'UN-GUK57F5B*=A
M'#(''S7Z$/3",A\'1>.22V%XRL%#+X#7TD^_F<_[LU>;J2.V-)(')K55"2Q9
MF2R\.>I#'(Q?;Q%R8T/3.LP;VA6V_CE4 GOQ41ZW(A"I%9&_Q6&!7&(RFK<_
MO\!7H:Q+QS@I-H7WZST@99 61Q.(^OY.U/_>C_%J9K[?Q&,VV.$YIZ/2H/7>
M^%ZTVV8,(2HC$JB.&E8=NM3/0&R5.&I2IG0HU37N."=.1I^H6*,2H%<=9A:G
M *+_9J=GU_,:$Q VP.NOO="H8FDK/EI0R\A3'_=]8%H4P/=-!Z7F"D 8H NU
M:B[DTB+7<"!(3.8)M#U_Z%DCJ-]W%#/8J&3H)^;^Q$D/G7>D;XT1EJ(5J8CI
MXD:)2_#CW^G@"A=\@G10&'YPF*]<[WS-$EKR5ZIE.A35WY/YLMPGMWZE,DZS
MESDTT/RI_0TX18I _ZF&XZN\EJ>'UP[&#7[KKM]/NL#V0:*?98<-L-L3V_-<
MS=J4\;JV<\YV-YS<587F:0/U38Q2/;W&ZY"C<U">GMI:Y/#1DU_Q[!J<YKAU
MG</B"2K..K+7G;&([ERZ 0+/[&BJ>4 E9"?+,D9=\ (=$0'@J4>Y@D"EF3>,
M^D?G3Q&/G$+:.9))2T_%&O/M'3$G^K#YG=*SJNF%TP!(BCP^OMIM9,MC_0L@
M]-GN_(GAIK"N >[];4.=#"':)X$!1X,(01M(J@OFW15= 2I?7;*(69NQNZTG
MT!F6V5(0^>=+R@C(>NL9OL/(,.6Z&(F&&T?%Z)B'? !O3M =>CCH.P(?3J,]
M_T;S7"%.,7$PAVP)=\N3_%OG*[:A)]DXYT'YJR&B0D7-2A78GT2VQ#Y(B#RD
MLD7\I-C=G&4FMZ[D-&?R*CA(;[+FR%-#SJ]8___TT/[_,9"V.^L;NP2??@=3
M2T;0PQ.@ZXWVQ+(^!4)LO.&8"7:)A)Q2#-^E 5_BONP!:X$]Z="%ZS4J4 <=
M?!ZZR69P]LCC1!-W_?Y4V:#7)U&$%GR^8</#$!<!<,6<4)=]<$:\48(7=SG9
MJ+H,W/^SO^>X$$??;0;6SXQUY\_5XIV/#<L/KTIH3Y?^/7Y7LI;C-MP+F&#*
M%*!.%J@*CXSQ?!)P$IF_'1PG6=QI2-@@/CK.,:039<9(;'N%L6Z6HI8(9P3?
MA("/=O(OG.[+UGI5;X$Y:T$9ETHT-O]F%D&$>/,"0&65A&?FOI$\@B8^?S?2
M.X,&([\ NI5? -NWP>_^ 2*(YHFVH8KH'VV) *]/_SN;.>Z]EO"<MM'GI["G
M$$6),7(QMM*K5>&*.'9>;XO9U7<J8H)1I$[<TDC?*EU#\.1IP_$PA,M)!.M,
MFGF%Q;NH4(,CP;8TBZD[1*I*#1F=LFO=EL0$DFY*^]<7$E&SP:R^+HHJ/ 52
M24,3L7PJ%+A9\>-IPK3^^".-O^!4]3'\WO-SYCX>[,FTWFE6,G%8DJNBOJ:^
M6TDQ=\;-9GQ@Y$;_G$U0% ].LNV.;H\B*4YH '5'/C3HK5!+7>ISG:HRAP%'
M\@L@4B(B4%6D2AGZOGX^VMY%'-\8+C@0*WE"1YUMEJX;S3MBW29%]=?*%4V*
M\FJW48QLJ_)-_QLU+S+RB0/O.V)XWB(+HS..TKKE8\8=@G P16MI60G$JH+\
MUFO/];K*D%(GT3?1/BK3S<D4)NJM*T278Y&Z7'":J\)T2Z,F70[3+[RRMW$^
M=7;"+0!??)_"N,#L&D1GK2"EW [V3Y?$<JP,ICE89:[O>-HYF:U6+ZR/*4R3
M2:+'*Q)++B[B;F;,.$]$]DTTF&M3<DA>4S93LW&-I=-/!Z^?^VZV^_29LHNL
M)"]#RP_NM7FSR\6'O#%DRL)?A66Q)@!(J=A.\S,WZ@QS#7I99MQ6VC/$,X@D
MZ\MF2G[/6@8<Y#]^"B$TB)<=:4K7?]!)=6.YL[CXY&[Y9,KKLP5P?F++J3^_
MKI5#2:]A9&, &]BX&PPZ<A4?&.H]OYD74\=LGSGAK)IFEHL0_8A+,K9!H)YG
MPXK>3#1U*('<.7528.)Q(N+<_+9.ZKMQ'V,$'\7[BUXOCDM"/($M4N%Q,0DN
M3)77^WKY)ZSMSBNW2^?<?3J_RQ_PRF"&)VOM#3+V0 )ZA$>)@\@8N5=-4_AR
MOT.C]Q&CK0>K ++5*TL;0*A;J[B<7Q;YHP0G. 1*5-,8EPX@5*)*!8A@7<6J
M1V1,1GOAOO-K$Q:?)<_WT]7%8GPE\SJ,6Y>]7P5WL(8IM(O27S Q$/-\8;VC
M;OT%T&!0U$EGZZ0[/:\3([03GRK&R;T(R$)*2L93W)<P[3#G3_#U6U#C !&=
MF7#D3S%-#^</#=CZVEMHV_&S3#QOKJJQK)X><''Q[69"CD\$WG@5G;;\!)X*
MJ &Z'U%UZF:+9EU,+R@@M2;T/U&"&A*4;L],H^'8?3D4"UY/AF<?I](_S2S3
M);S_)36V]);'G+PL[OMXUX 1<J'](S6<^=N)F)&3BP_US^)L><G:T2 _.T85
MNP0? 7Q=(4H\Q>M]/YZY9XB<Q<'%(ML%6SG__)$11$OL?['V7F]-0,V_;Q05
M4*1($92B J*$(KV#B'0! 2% "(AT0J^A-T%Z"4VZ2"\AE(02>N\@'4+O'1*D
MU^W[[M_%OCC/N=CG7,P?L)[US)KO9V;6C(O'U">"#E9+EDSN+]=:)SNU+;J/
MC=MIL TW29X,75.<C</N=VO#V77>  =U;&T]'M9)=5S> JCGI)E"2UEK,0K:
MXP<AC%ZI<N.\%&-^@"'-*$6DW&3)@==;O*28W9D<V.!)W]-T^BIYM:?XW@4.
MZP\1B2WZ7P]S /;0#'QT&X)/&<\[X)"E\IN R,F<)??0_?EA,T6:]PB?/HQ>
M$$@9$:1$_267M7^^2G$__52D8M?4RXPW7<E)PS%R5'6+DWL'">> L5Z)V?S>
MB9F3.-);+7ZT57W7U-/HK_^+!-'#H#)'^_>T&\R@5LRVE\@$XKB&K;IV+%OQ
MGD,/ $[UC8A4QH6Y8#'B1*!;)J\#:L1!\PX%TN ML\CII++MMKZ6_R#J2*8W
M4HNCR2*-M"M<V(HSF%;A&N6L%3-B/@/3=>X^X8M87&[2ROY1^(P)E/9M7+XR
M3OGJPF;VXLR37=VYJ+C6QG4W(T4.>[3Y=9M1JE*T)&!?M[2O>X"U+X^NQ]:#
M_@8]G)P%)UHIU^4VMJCNV'A[YP(?^X<4&G@6:_,X<_HJH&!?B/;NXJ^>'0BR
M385,!<\86&HEY!&Y5CZ*6L\0SHI<#:DQ47].<2IC)YYQY8;DNQ]5[-^IU?S!
M:[CJ4G<O[[2<LI_=:!NC\SV]!#4_='"^Y<1PO*,<?EP]OA(KCIR3J'__H-,=
MZ^'CB_ @;%UXPN9_92Y9O=0'%=LRJ\X0$[.1@ZQ/$S.3JB4B7KR7IV>8XVM>
M%9=>NN:](*P9X^I_OG*7.^XT#$;(AB\4)U[<4]-(^HS"K:>Z(&2M D">TK4K
M)#YXNA.I)#0T4AT61-+I8*^\8H=,CN*;4H^X:7CCR99=!W'%-!E</+V27X$B
M% 9/^:Y_TY6&"T=Q_K8\B6UH4)AUET3WR;\NSN*;DZ=M&$W+G$T+J'<Z!\D7
MG<THU."H+KRR5>L3P:@&OJ^Y_9S/$J9RHC$M%?*.V2.UT&A*5)6]@<[F9!VU
MDG?ASY!DO\&G$8PBXJ<E1=_*G!"[5MJ*^?O"G ;I23(&5CJTN2H%7&$2=HVA
MNA=\KDQ4K[/SP#W66QODH-W+G^12C%)Z$W^\S"VMFZ&"AQ"]DG*A&+5$^,?G
M3[*L&7*0@(C%R<?YL,:1D^GU,2YC=)MQ#\5J]9DWM &GUFY:<>9=O#5Q89 .
MPT;< @3S16U3)CALWO"UWB4^+[\RGZ$&BRHEB-):]>8438L9"#9&[E1=/VI?
MIPTK4XVK<]53E)^;;I@9=IZM0QAN8G;U4!X2.2D^Z1ZZWU"*>IIW;;NU7 %I
M)"0IJ\Y J5T9SLC5X?@(ZNB!07M8%Y/>* I,!'_[RB^DM%$NQ4R,HD'*(*]V
M@=(@DXQR7:?#@=PA_.?%VQOY?(]CAS,/83WU=FW%WH<CE3;H#>]K-=V)?%7R
M$O2:=B,"//3W+:P7>PMH*V]YG::/E7,3'RY\(3+DM*>;9/@4/6?^Q;-!PQD#
M-^2$3+#*?'\.NO.>@*#!.86FF!%MS+*BS@N!,T.]'@^^\R#Y^PG/W08%(\3U
M/YBB&HEHV[^V\@@OTE][RWKE>N7EZOEB13C-BYJXP9R[!V;UT7?1[,=0T3,;
M1/6FH1HY=B?%VJ'#^0407OFI2[CKH:J$AW9_$XU I,^EW!^7NAD+SJ\1X)F&
MF5P4SYM9N?.[JQ%Q\&DD4<JC2-[-MC<F[!Z"[Q&^%-Z%"!O31$UQ+EY$=))
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M=S">6/\J1Y#00)HIFOY06$P,^!.)Q4X5Z6_83<LO&%J[E>YC#PDC9,0X^BA
M;#!6>;I!=D]+9XC=Y_$\,"N*MZL,TL:=Q$[N<R@IO!+ TRU1/-1IQ*9,<;R+
M]CF</VQ 3AWC80]UBK541*-Z@*BYZAE9XY/ $X.Y6P#) J[-H<^W5<@H;MOK
M.U(-R7/]D[,C?W<-UPN8:3>@+WL_/>APEV0R'W3H^KA7QTH5?%A\W;5"F]L7
M4L@X\-_TC-%_TS/42<N19KZD9V[J8WNHX@''Y9$'B1)"JD2V7 KT+)[3((>]
M6K]3ZD)]4&?F_6U#"A]*6&6;J,39J( $2#5E8GZS[E5VQ>(#D_. C._(%Y1A
MH0L)4P73/?KG?T^LXI8ET7C38^3SS7G!4=8,[&;\.+_WP\>\]]R5N^B=P'P0
MMVZ2?N)9G;@!^UL [K,OR4[CJ[.D)<4K"=R_@-!$^?S3L"T76D6JO6I$C339
M=..M9W<SQN_IN=(NI+_%\ZOYU,T_G.R8E*+EYZ:RNGD\TOA\:O.&P9L8P;_G
MMK=7#!C^";+Z_2884$'%^7==XUVV"%X-V[;BYH=&1E5YD.::+I(](2.;UM=;
ML/01GN@,P^G3O?RJ8?=:AL7VN]GK<S!@9:VGEG5(B<?3$+>^<  Z1D\LAWM5
MQF.P-\@DV;/KR<HSM1KQYTYV[DN/29?'VFU,R_V7!;?[Z&2>)6"?KS^*^,KH
M,%%TUM2RM1R/RA"[W)/2&)W.*T_!WFS3TMC4:(J3#SR;[20E#M,OW,ASTDNA
M;C6P2/'"=]U3Y*RW+9\1AL53W[OW]<$75V$Z:H_2HOH%Y#%RVU1907[TXL_Y
M.MGTRO*33;SX+8#"2TPJ;$(YEJO>B_F=D(/^AU>I@^&7']?5X*\B(D("WOU^
M54/ K'JFM909O% EWS;M+,&.'?W<@'N-M//UI?^JXL&9._(M*-=NF3V0X \(
M<_9C.2G@BMF<<[YN^9I0%A6&LSQ4*]BV;PYU_O+.K[+L[H<<P:&& %+@P-67
M';:]:-S <" 0QMW.PIL6(#F9ZZ3IS8"9P>GYD.$Y<UV\QV\!3Y'+303_:<V5
M>7C(%,U$BH9('PTQGO%\@!VTZ<+GQ?<@2F-_.=,RLH)=-[*=.QTE/,+F(RT_
MIZ3Y+DU^N4I.5[(JT3<\7G=<(+EYM65(+?XT_RQ:P8Q<OY2U.N[:%)7](UAZ
M.GZ5J=]>UD7@[T;DJ[@3A[,XMBCK;+LS4"-+C4*](I3VW'FGZJ5QDQ8#=12-
M6H$X''!QERZ[)H@U=$(G788YJ[=,/(#,06_9HO/QEUR<LAW7UCFR0_>8+UN]
M%Y?97OWO4<R\(@W<_!VV(GKW/V,7_S\8&=-U*=+91NS$ =]^<9+PNC(O7$#3
MDGH8;<RL$$YYWO8S0$&]/U#L0]P@L$7JVP*AOA?[6:W+$A/E5@93:OL"+B*U
M04H+U]C@4@B6_V;W2"F.L_D^6Z*NMER,PUL-.<'E!LJ3AK/D90@3&.?6=D"Z
MS4@[#.K03LDYO?@1SGE_+BL 2_5ZH9<K;-XR_BU+&@ FX';"&KZ4/MG*0-@N
M^1 W%'3%6@K[H1)\"P"-HI@X1'LBR)N?+!%0^LT):6;7%SG/X.!7!V[C0+W!
MY9*&J;:-4^%;@/+$*48R['?86Q(@CNGFH>XM@*T6+W13IW,+V+J/]KD"+4I=
M457>J#DMVUV[EM\"1AY9+1D>\N7> @S^.XT>\YQOW71+=4!>J0&ZJ=K>DYV0
M/<C3W:7T@6^ GS$>K3\X89KEU/EV,R?J#G.#/$3-CU_W>,[T!=I9MY,6N$)R
MIX=ZYGN;,IT>_\LZH6PEK6VY>+>XJA\(+S;<8"+FG@<:T3!5-X6;5:S9>]SY
M +!*[R]7=.!M>F*Y&/8.SH#+)BE:?-RU<+6,OF&%5M]0CV8-'XF8HS7\5%BK
M-OLH>^:J"SAX)0/#5B2I+)Z20^5.VWEZJRBS/Q2M)23\C)XW9GI'O^JY@?:I
MU:AWO+!O'?ZUT?=TH+<>C=G9<CJR;J.M*(+>5XK/[:'9Z$9['VU/0G?^'"_\
M6*#ADGP^M3"S.=)C5\#+WK+Q1L=U[T4R]8^!ZA?(%R9PZ1)N1BO,0A1ZJ,I2
M76"NX2I8UI"+F5>)6;M&HS FM,FA\VX"(.,L#I(R^G$\,B>%,9L#2.[]5YFA
M'^3'^+ Z\5V.\1M>Z7U9W6H\8B.XQ(:#7T+4FW?V/$[1@=_AO!/4S,Y .$M<
M^P&NRA+'\N.%N9]]Y[>5B&9IQ1[@@D(.YAQ<#7):V0AJ,Z/V1;_[,INKQ3J$
MJ+7)/:T8YM8$2D^(*RZJ4>@LZ"Y =*#JX-UJSP(G*AY>G/_SR" =<D G41?M
M0#'L6"K$-6L?PE4O+YG-\H$.]$W)S+NCVO8AD9E(:\$JHWN!)/-9T497!LNS
M@>M5[4*6SZW#NC-^?BQ0Q@]D)Y\=1B5XM% S!27.YRP!TT88S_@$MD[[WT(:
M=62T8FWFI5^,J;=E.*->88J#VXI<;,R63Q=6)S 9:^*E5/H.I"F1L*[<QIUC
MQ9UU]1I<5=T2DAIB>8J%- 2U^G%1Y!*R 2+H8V;?B3M #-NVG.T>G5T,Z6!&
M6"<UAO7DJ@+N,#^X4Y7P01">0[@1P>4T7YO:=]HX>F!: Q18=8N4PCX/?E%*
M-.O.[-_I#4-P!V>\]+T'^]O6R!P].+:"2LY)[/E)9!91.BG7+?&E;*OK 0JA
MFO?\L3@AGHFK^"-:#WL).4\9(@MI-]7(#?E=]"5]'P52D^^;Z5V?K\/+Z(W1
MH3D_G$?E)4$]J5N?F*)-+V,[X!^*' $MG>L2B@)]5P9GH63M330SL%00>#,1
M6E,_913#EV-%)2@,* =D!+*,#U%#4WRRD5 05B[S?AH(G#@RG.,NV1EQ_I"N
M\9P@(G.B7$#YT3678-3R;) _)/UU]#HO1<#=E:@N;&5Q[%*1NDM#9D5J,!9B
M,VQ8[10<!0[.%1*E-54=7E/1K;/,BYI[ "M61TVX!&">=!E_8W4G,=/F+JON
M);(E5C]<=>E"0_7/*ML=-YD54.,FS^2Q]_NFX8)T#I&KQVQ(3?^X'1U1^1.&
M;B;3]-<-+B+<C \S/]T"@CS,0V]HY1=O 8 S4'N%(6)\/8?%R?+1S4'?'84A
M>DSYUZE%(\^4(WL8AI:=OW!0*2<?J-FP,'^BPN#31ZR:*_S-_$!E<W]&!9KM
MYE9ALU.X)$6)F']>)_'!<)[.>!J816MV[X+I SNRC>R9RA*2 AN/"1XD3O^6
MHOSS'IX]D8Z;;JEYGV@+DAE6^N12Y>D=YJC]D2\I<\_NQYC0'SX_X/X40"2P
MULC6=&G[Z]2.Q&%>C5D%V%S\[,G4DO%G:GNG/VXG2+]E$AIN@LATLTGV2HRW
MZ9]#/J6H8#'LYPG>G7&!QA^8LX6/$,..I),!3U+$8U0G[?%SL .)Y@LV4JH[
M?NXO&!VTKB0Q28$NJ3;&;: >FD("4].08),NPX1@HJX""6C_%2=>^?/(+V61
M!%N;L_<-M&2E4ND> 88L%M@(P=Y8%3L,+[&^.1UC\H[A;Y/I*-U4(ZV'9?H]
M+*/@BTS%X%R_+O71>0\G0Y?&.:99;3QIJOM*$V6DI,H+*[V2HC)P",57-X8?
M?7YJ$FH";AU,Y B!Z(<P&3ET) (L6W')NH!]MQ2\*)_(=_@W#1_ULUC/-^P7
MKC9:O398XF-TDDFFYS3LQ8U(:7B'X</=T68>+^FJN@K,T]BN5&'CH6FLW->R
M8I$^S,HZ 0MI WYU T8O0>_-7N95J2S+P)4^436_V<8DP]4ZD26BI9XPEY )
MB:NZ!4B09=3++GD+:"M/<9D$S_U%O5M(W):3 ^;B2'-.4L#RU&5!MI2[A^+)
M[=TZ@O,28XP-09;Z.O)%ENS&'W570"Y1M@^.Z3H)D1)0/SQ#9ACJD03[@5:8
M)UALG$^W26'UH;UK;*?T8M3<SII#6)1FQ D^*#&5J]'MFE1<5D]7"S8VNJ '
M1GH/*>(9>L'@J3Z3 L(7(;S=_43')9.89P,EB9."8?CR\V3''/JCH@62*U/H
M==UO-7<Q.H1=5M+N %D*ZYVQO4<UMFRTG7).8Z#<*[5)E!W5MKJ5GGGP-]S:
M;J42-D"WYT68I6YE0F@HQ:(#BO&LZVYC5;"EID"[7(1++A?&<G5Y;N[Z'WJ5
MBA[7%K;BX:=H%:Y4NU-&8J0%Y9G5P9XKE/U5C RCZ\TKC!KIV?&Q C.J"7/Y
M3MVOKR:9>/?]C4MM@67L8,?K>ND'@C%RCL*KU\ '#(Q="AF*B)+!7\E+88?9
M$D'NF5\ZUD2^%R]Z]]HY'VM[;J;O.M5S?N*X!;@!I1M 5SRY!6?<"GBU='XW
M)K/ZZN>Y06X\AWT V@N2S(G:)NHS,T\5WNF7E*JQ+M_>:^TT,VS/XF=D>2FA
M+M1[?<6I26+W"#@3'O(U2;V<=5T,;"E-/&A+(LXS9)\O"7KPT=11H>N>[T5Q
MT$BKL3$8J^&0"9OSL+A,4@WOZBP.8M1&-7FZ+!2NJ%?*OVBYS!=&>IZ!\8*&
M#Y5-2RUC=+V+L,1&SK6:KTQ7+ ZW:FR7AC;T73(#G'N<N\#QL-*A?E;--(?F
MKJ8&HX]<XO<=J-MC9%RH<ORI<C*[J#>,<#_[H[C0,#:Y'#UO&^^,:#GWF#9E
M,F+-]N+1%%338DHFI0N#9H?>]Z3)Q')%\5+&?VBM,\90\S#K_1U[0L9Y=%(6
MC  T?A1>-Q;E7F)-I>QV8H'5M*$3GE\D>;-XS)SK0N/S"ETS+#E*]< R5 Q!
M3;PQ*;P%=C,@C^MB(E$MA"Z#:04*S!WGZ95EJ) T?Z@.Z/DHAQ6NH.)=C[Z'
M1W%%U,Y.Q"KF-*B*NW!P@155([$C/:_',SWIU].]?TM#JX#3N>CO>Y2*+6R%
MYPX+.WJNDN)E#;7_;F(M[,EEME/+[)WSQIH!>P^U0"08+.B1CL*ZQ;WN^U[[
MH>0[HS1AVJ2;PQ*G %*5,[+V2[\=S?L3*;V+3P_X^#K_?,\E*@!R@?E7ZY&^
M2<G[IN/E6F\]/XD;TQ[_E0?9+=J U''C^^7WHS.A%LH]0'+I'LWJ:[C,VR%Z
M@@%]O%TD*UXR/5NGN:JJ%3O/;\%YU?KG9]N=TYK'P:OYCSL] .^NN)?G-%M]
M:":.=$I-:)Z%/'(U>>^8%1_Y_7K$%:"P+9QG<8K3/_AK%#V@T-G#]S<VQI=Q
M!8_,:ONCT5Y0(PO91")2=DHCW7BR_'7ZY:OZGZVKS59-_)/G_5TC]S>P&23
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M/79R*M*=E7'=.]$U!1W&Q;,0C,5E$'X%VAD*WCR>&%6K8-1H.11.]W'8;9Y
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M14N<L%?1! 1U,"9!86O*(0',/.VXN.]R..R7+QJ:$E'\--E=<.[P:T22L1^
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MMYG)U/Z=R6-0?Q:9Y+@"W8;Y_I""VFAVSC-%;;0QTOP1V%-?33%D'^U@W9W
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MI41J5=_0I(SX <?%,>=75"/&XA;PR+"PLA@J=[KB56'8(2ZJ.[82W^%@?2]
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M<Z;VWG"2H%_JJ)@[0-@= +.@3&12V!W4BJ+SMD<R_AP&Q6+X(S4Z9ZT<G5F
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MQZG0KNZF) 6N=AKV%YWD#G7M6RYZZF6$;O$\3?FDLS?W/770*_.MM#?J'H)
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M'KIPY:V7+,DX+KACS$QF[D>3/B&/J!B%IXM;9K;SU,KAOGDOG@456QX),)-
M&#3\P#,K2AA<SN,B+4C;%[0</&K&@] R[3?U*.;P@^BM XC@?G:<W;0HO3%$
MM:0A_(RH]74$_+<$]U,*-EE!HGO/\UNMYJK4+9^<W6Y>_G"^5UC9??I.VAZ(
M+USP>M/1H609#>N9MJZ+F('K-/,W?*4HS%&M;AMAQ^W;+.B[J,WOA1::H")5
M6WYQG)S9V\HXVJ7O+!XHBXZ8/1"Z)NXY5C./?%)9-"3-!0#-.KIB!"9M]V6.
M58XB:5.0HZM"R&II8Y>W$?MSCZ77_NQT1Y=%&1B)FEO+XVM.=%6 ;T<#O3W1
M=&4O9K,U5!?4='>RC8)'=DT/9F$URWE&JRQB\1()W);B5@@G1D6E&IW@YP2J
M_0>FG3*+A:]$6]+V?'%3OO2]EQM[JKS[7>C:WO4.@-5[3-!5#KD#A(\,S2C%
M,@DZ:ADO8^ %V1A<\^/VX*'F-=(CT:O!XX=B4/1)=17R@HQ"1=$OH$K7V\%9
M!EWN&/7S9+^IX+'F1"I?M/C:5L($$TK>:X*&0]G*;L=GL'ZT8YX%E_HI[NBP
M&(4#\/,E50A# Y*<P&:>;'7,AO1^]_+[$4WS6:.H?)?B.A,'34;62WGLSPV_
M U V!7V0G*_YA V@"?N,,-)C.M9@PK*_CHL;1S4.O1JP&5:NYGT.29H3 U *
M4+NI]'(L/!*CUT^,@B]WESQ^(RIVLM(3D6]\<%NZFZO-E"*J,-115MG8*,-Y
M!JVW1\6K\_IXF70J#[,L;M;BW@KHG8&P_N;Q!<Y/G:F AZJQ XM#I>!L?6(?
M<.H1YB6)]VCA"J$K!C]#@F(9EK<S:YT;0"2/G?^L':L# 7:)4'+IY\BWWTS\
M/^[0\#Y[N$$<2C(^2+@<[R:W=6I6W"E7\"8\C0Q72$MUH5DF]P[@OV3)==5-
M6<,M5WSDE6/:[3.'3CK&&4H@0_$9IP'Q]K7V3M3H.)]\#JLPTZDX4/#)8T>"
MO@8I610[,#[SSG_OEPK/\U9PIQE58'K1[W[R>:D,)W]Z11^#*W]<IIM9(KX0
M5<,FV+E4PPB3I!3K'93"<>"X#V-:00*M#910.(B2N)+"BHIR(U7)XB8GP.>
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MW%T8S?WJ_?^/LK__A^?1W>)_ 5!+ P04    "  U/'98 N[SX;&I  ":PP
M&    &AO;VLM,C R,S$R,S%X,3!K,# Y+FIP9^RY9UB3W;8N'*2)=.E=!:2#
M(+U%1$I$0%1 :E1 @1@BO1,;O7<I$J7W2 D=@O0B(%UZ!^D)-4!(/MY]=GG7
M6OO]KKW/N4[YL6:>^6N.,9_1QSV>$'\1YP$,][5!V@"22P  R<4/0)P": )(
M+UWZX[E89!</^65R<C(R\BN4E!27::[0T%!?H::FI;O*0$O'2$=-S<#*P,C$
MS,+"0D//QL[*S'Z5F87YCTM(2"]XR,BIR,FIF&FI:9G_VXO8#&"\3/+T$A4I
MR0W )4824D828AN [T).<I)_68!_7227+F2DH+Q,=87Z@@#% +A$0DIZB8ST
M#ZDO3OTOS@%DC.17KTMK4# 9/:>\X<PL\R[VZV7^NV7?61X-8@1NOW!Y3W6%
ME8V=@U/PII"PB*BLG+R"HI*RYCTM;1U=T/W'3XQ-3)^:F=O8VKU\9>_@Z.KF
M[N'IY>WSX6-@4'!(:%A<?$)B4O*GE-3,K.R<W+S\@L+RBDI4575-;5U+:UM[
M1V=7=\_0\,CHV/BOB<F%Q:7EE=6UW^L;V+W]@\.C8]S)Z1]ZD0!(2?YM_:=Z
M,5[H=8F,C)2,\@^]2"YY_D' 2$9^79KBJH81Y7-GIALR[RXSWXW]6O:=BO_V
M(PS+"Y?!*ZP"L@N"V#]4^Q?-_FN*O?^?TNS?%?L/O28!-*0D%\XC900  >>/
M,YO<SS.;Q+V*FC/DR[_]/ 1_FP3E"6SS32S&2]HF@GJ_JK%XK;=[P_"RL#;#
M4W;XWOTY(B!R?.1YC2]+6!;GSP2HA#L,'_VQTSF)E"0T@[7XY@K;*SLN^+KN
MF4L8+IK J; H=$X#/!&$$0$=&[,IV/'%C.HWT(/M1ZN$-SD_3.ILK]X"6XK?
M6XH]&==<\+,UGEXX1A/N+47SK%0X2N<8H76)@#V=25G3#LZ\3KZP.NX"WIS\
M&8<]Q>D"]YQ6QN<;I/=N/T$O9 7<@/]L)0+B3(@ O%."EPV'H%<_K<_%3:Y+
MQ77T26Z%0JM91$ WGY,1F)$(:-7&WR,"O@83 0(E1 !NQM["SQ&'\B5[;#$[
M.T#S?5+IQM!7NS<(O_<WUF!^;IF6TN%1Y>EL?1>B7*=3[BU4N9NHC<_B(^B>
MR?R#CK^)@*!(7"@1H$E/ %D0 =@ZY*$%%QY[=F&W&SJG9TGP@3J$&_R$?[M'
M;$F-?PG<CF"0#<^9LW;49R!OSTBDR:%\X='F;*30"0L#09W?3.:T3$UUK^B+
M##^CYB("W*,3W_I'ZIQ6A*&E*@//P1>7.M8L 19S\T>J YX>S&V[J0]F-O'_
M@Q# OS,1\MRD@PA0#3@F KI2X,C:5_BS@F.=BU/UZ?^,W0]>J= 6:J*M[_[9
MABN])+#VRNT(Q Q&1F=-Y[0DDN#EOTL$Q'(N_2C;-LB;^<,P+__1^2U^?CB$
M1$1U0=&/(^=;($DV@[<=$3Z79DU(U!,0U$NL^\&S1, )8ZE*KQU*]'^8Z+[8
MHCW<'A;*)E-L!"D1CWB3G\2ZC/C".%*!]\-]AD!AKO)ELO+'@$\OXPW>/7I(
M1S=D\_W[_&+T(9C]<^V_!!(;STJ?U:,"V!]A9&U_]NB_X"_X1I7"R=(?S(C#
M8W$B .&N_ON/()Q*,&V#8P;1C,#?SR]"20Q.4-#YV[08)!39P#. OD3 LN:Y
M?R]P;<:P#HB//5IAP?+]'2410,N%92($\>'CJHF )3=XX:^YM>@_#,! !(!=
M!DZ.'^]$7X2G?ZV6G\X_$/]]_/+]N\C \>D*@O_(V?]/L//]G0[_XL#S/QQ(
M_T]]_ZGO_WY]_>>)@.@ E5%W2(@3:DY><!B91WVD2,&K K+5;/-/85[ZVJEJ
M(O2W+QB19.]04G35T5.;NTA2SZY1;+]Y06%&OP>T)&MH;G;_/R];_XM5[^_9
MH_^CDO-M[I@1 >H;_A>:+T=7"R-#B("_I\;9SX4@#FY=$"2BB0"NK#^]//AO
M&\$B\.]I_Z%(&9>A!_@:_^A A*85Q/[._RBS_]AC_[&> 4=?P_8[=^'XD/]7
M-,X^+P4N9SN@CZ@N0D)'WYH?;(9WQ7$@_?2QT-R"G)GUGQ:M+Y)^5,?IECX%
M\5^]E$7SO!-NOH_$V<+9X3_U-(D ]#X<6WAJB93];O3]4=ZC0GT)(RS'CE;*
MHJOR8?Y/)XG? XS(9^>?C!&=G.69NCMNOF]9V7XM[T0'.G7^'-W]NWO\P.6P
MR&O^@XYULM!A$==;P%/1.F?O*%*FNV[^=98]G73@N-5?W%:J>BW=>[+;J"V?
MF\@%,$YW"6.<5& G<),Z/%?9!.WA5'KSDLS4<='5>09U@]N=ST%$P)7A5FFO
M,)&I5D;5"@>0V(U))N9'WH%FD7EIZ-@HYJIIUVXD$%B>'/FC5WI,UE5TOCAH
MP[]UF+(G3VBK9.G3BIFI^9")<3>=Y!K-[7'*GEUKRC,9DR@YP=*P<PM__.G<
M0-F1Y:\)^;4D)36Y"Y4ST4DSO&-S>BH599C=%C2-5BGN,T5:WH:GD:.1QI'B
MDO?0[$R6B:+^AE&HN,+5N[&_15=#L]:/4E^&VKP8"J=V'V?E?J!)3G>'/&$_
MZK.!LR49^$*T^=A9-1N=R&F&']6/WS<?DIU8#IL>&6(+R:F+?O>P*5Y:#;@]
M3C S-MQ J:M"CW;QI6KX'=';G0_C$E5+\CP.(*_DQ* KL+@#^5)5B86"@PFW
MYPN;PME$P$<U.<0V,^U::#/IM36 IZKK+ *KLC 7Z 8/&D^6Y_0#L52R#CW=
M>)/+^>JUT\SU^*M! W?04GLM%Q%KB$6>DU?"ZBL(ZJ_.FA ;=;Z/JK>^+ID&
M7H>"=>P?QI6EI?04J+U1+15S-[V2QR'^,G2FQ!T?H$-?UJG\.$^\?+N]74UV
MJ#?/WW>N<!I,.04Y[?Q>(CK<7*''6T97N%N0D[XH\LUUI8+[_6-VWG1?SM_/
MFVJ'5566V+"7U@-$&@BS%4'SA2\F?GVT#F,3U.@<<4TW5:&\$ !B*D6!S&II
M8Y'@^;&A>[ H^NP\#O\R_Z%CJO!=ER>6^N_ANZ-6]S]=B8_W"IFHWRY=1_7Y
M5Y9/86YGZ<AGW6=\JK0OO(>WWFT5SNN%@&?K&X]\K3(B%RY,Q<O]H8VSO?ZW
MAX*Y7UU6L\*]_6Z:@/M5,U-O/U*H\GU*?Q>EK7C&=^6W_%$ Q>#CUCIH7S_*
MU2W>VKH^*S#(-7!:)9'+'\>2#K0SY);$0Y3OS&K*2^:=A/PVW*EMOT7HGI5]
MD;TQ*2WJ4EN+^# >/6-R*X,'".?RK]_)'#W>&3[A<;\>X5!H]DJ2".@Y2%BZ
MV<2W8J!NBD9Z%N)O8>:.DE(\FOA0A&%E_ZT8AR *5-#.HDR&>:56]^^G2ZI1
M!LI73M5C8G"N'9SN X&R?9S>V\6O&BJJ/O6667[SY.=_V9S3XOIA>K7F^#Q1
MU5D@4WNL,BA&'K.ZX:+IL]:SN:L+M -R4PG&G[W2G1.^H7WVY.2-SWN_4D>F
MEAJ7 ?:,F5.]M,:281MM;$]>95Y2S6ZU9'6PU-[LN9O'Z.P:9!$1I,Y4T?!S
M29]U]K)VF0/T-;;#R.DYM#[Q5Y??5L3G>7I#RY\5%8/N?4#K;V#Z5DB>&2YN
MSA#")?;ARK1HE_;J]'<]QJCL5^P4M4GG"0U.FPQ0&YWG;*??G/)4U!%UBY_@
MMG.<+,_<K=B#5#[YYSH9%IR//K$+7#;*D-EV'Z_SQZ.9E(I]\U?T)%;T98=6
M-CFD5M;=]T"\67DX"Q!F+MH-DD;+9U"9=#2V1P*H]O4N+XH]*V_C);%:*EW:
MMJQ*6["@M=##U&TH/WBT\?"7X_#D;Y>>%M9:O7<A=Y-^R\P);T;YF"H2 >75
M4=F?A: PD$,\EZV":Y*EV_>]FEQXJS!NR@=XU!3=2+<"JQQ(5.K7V:E1RH\>
MM7F)#3L_;!JV(@(:<6[RZ65[4'%4_AS,8VH8EDL$U!^,/]GRX&7$4"1Z%CE2
MFF",@Q#Y#?(YVPNP:DTGL,=6<S&2\37]+GFG=>W);N?D V6V2+DT:CA_5W6=
MF\;KE26CC+<97NL#.3[E 3U-2E&>G^5*!&_Z[<0ZY=%,;,:ON#Z\ "W\N&8B
MX(?>O7^MP0=O/C7<Y"TN-&1.=1"#V!U7>:5$@3_9O!G\:@A8$KQYTCA5N=N8
M8 INW<%>$9M"+\3B+S"+A@0]@0BX&,LZ\B_J@@XV^)RL$GA&!"@0 9Q(\)D-
M"1$ C-T';\Q>-,8[>ZK:84=_7_J!_W 1X5<S?&"9[Y\\_^3YO\$SM7",#RY%
M;S$5$ 'K-(=]IC^;V,Z3&XPS'5TM#?/M=Z)MO%^3N=XW6(?FA!I*TY$J"DVI
M^9CHX&6 $<#?@E^)@+D3-&[T184?)2JAL1"5O-I?\&;G-083/;KB+A(@"ESV
MBF39GL-T$2Y VI>DBYD!OGH!UY_ +_*QE?#>G.^<"$B[@-LF<U/L]"?X*/ A
M["*9OGCS\FOY>O[=2_C^\9;7SX!K>_3_Y/EW'CY+(RT67,&Y*LOR7&5T9RCP
M%1% 9>^#0@<YJ5K BS<]ZE@R4J">/$4@U;./\(;X%5*7=]VDZ7'2UA763&?6
MA(%Q1"7\@RK_0A>;89IA&=8 4;B1=)J Y#2T8W16=30"B??@2-_MB,A.A5E9
MPM;= \ZE!I/IK+SK@4W]<Y%AO&3GY7@E?]A22). PQRF0 Y&,3TYY3B6NIH#
M4P4=)4B1@!9>1#TEW8O2%BM'GQ<T,3JD\@87S_AI8[:4K6M7X2^MY/9>-P@O
M<.L,_##^=(GR6@:DOXD_H,>FA8].=H9RWB RT^N.3JE&P8:'GK-@^,:MPO)R
MB8U.\6^Z,MFZ6==$ !'C+!CZ(UFL9RN,"Z\\ZJ<A'^QKLU"/N-JGG+-\[%)]
M]#&V@=S<OE5%V)2NW].SUW8L=B4]=0*>8$PXKLI]W&#C?C'3FIS+HV8_F]1G
M!%Y,CE.^W_FNROGZ\E&QN[^8%>=E2^_+GYHJ?ZG$XQ3+42&J%-HBBM]B3@?0
M*3=Z'A7B7&$V2[H-P,4^RK99?@PJL.]P-AA6I$'SZ2//QI#2K[>,02_>9.-_
M(1F&B !;>(@\X996!HQ>9V'3,.PV;I&Z2^HFVZ-)0YH-+#O^<]$-#O[F:8V3
M*&T*1P=@N6>[A=2'5&1++5.S_E<' N^8+)0/;)MX*#9>/[,B^[&=$$:Q.YL@
M [OF; 9<L/(SP7O?( (.BHHLP+&9(),*' SGV@U?EP_0^>D3O:V#:6WE!U5A
M=2(KZ6DVE0-+<KJ&I=R%\>UL5'6JW L)\Y%+*TM*)5"]H_<X2!;^+@HCL1LE
MJP)CFV%^ZN8@]=!219&<S2E@_])EZSS^2TU K%3S;F@J$=!N&$*@QA!BO_1"
MB_Q4?N)OYT,XIPRY;_G%ZXA7%9?=2HDOB-C:^!@;83(0AK8Q#*NKCG+3LO+4
M&_63^K)9=[,@;WIZXU@>>>0K%R@0I*?X55I/>F_FXYY*]77MZ3AE)1O14.M!
M&&:U>AXU[F^R:7EC^6LI'ATM"@^'FD$A6P>G$+WSO "FS0!!&/U3O[N8\]6Z
M I4J!.V>;,_UF=7WM5UB97O*"Z .L2B,PO8@QK4C@,20S7")1Z7UU#8ULC^-
MVZ?DA\-M57$7CP)59FJA<N7XB''J^8$)OG9U[C*<=;SAU_.\5FNUT0;#?!!-
M^4L+O2SWLH<GSRH_I5[[_DW]\3[WE?WZZ%_(Q0@^^@,K5C%#&E"^%]QTS&[X
M4.UVFT]0?+Y_ZI&-3%>U]+V>&@G4O%<V#8NN\\_%RLC9TP#$&BS>U[ZZ?-7!
M$Z^V<BJTKS>^7:*WJ!!X$'UYRBMWU_I;<*OG#=9@D]L%5;$O[9Z&Q+S19'U(
MKUEC8I*%K6@^]3Q*ARU&BD^O3W[TT6KC<W@X.*=;GUD% [&[L72AF[<MVM#E
MQ0CJ!G!)>S%DW)S4H=J\0?IRS/26BJ QP :R?6V>J5J1;+P?2 F<1\S*8V!M
MT51>66T$T;+1! WG8J_4626KP.,04-U3R<?2]+'\=?Q *6EDCZ]2=HYB^^\J
M_U,""#_M8QFBTB+CVSA^N#K>K==U1$T_A?Q.#WQ_T*=UXQM6*$Q6[[/3G&&X
MT?L-X;$;WV_L+[THW4MX5D_"Q[^_MS^!OW1>@"<]NVL_:6.O?)2J"G+.;2^P
MPKFH+*?NM'.3HIH[[N\ YM_H]HNUX 7/;OAI8:R3,2^YO%7E_)T7$%<V9CG&
M_*:Z8TVW[<Q>OCT1Z*YVNO5=>=P! SMZCI5J13+YT8Y(K@VV\5[!6,T%HXQ>
MB>VDKCXF,0F7CNS^-!TW9: [OSQ6H-$#VO:$X0M@C<+^Y[M^4\FB'F.]1,!K
M])I4?1]OS%RE>C04BVA'T\.@2\-K/V4A4)OM8X604)>;DF2.V9<N[_4;&!I9
MJ^419GW0X788*^0'=49':[$1O,Y",M;PU^*XA(1^3KFE*@W'ZF2QAK$J-WY&
M46X05W0$'"0(! PVR6''(_U4%M#,]LK)P<4',Z*T!O25^E!7IONV+L5I#QDV
MWQ>#.C6L33%G!*J1ZKK=5EE<3B[.\R)",>CW?!HUY5&K'C>)@.T2&3WV7RD:
M7-^ZKRV?SQX.D"W'.0V >_(VON;E%FZGU0M)C@V/'\/7@'N#O-V8\*,?/P,D
M<-'?Y>5/>59C\W#UK<?F8Y_SK7]\NFW>MV)E+D._](!UFHK<FZ7?$5U] 8 /
M$$'F"N'+F*82Q7&49]G0Z^U67:%*B^^.4CF?;G;9O%1ZV"F12*JT>+QM>":\
MP<?0Q(+3T\:!U)/GX0PX@^5(WD<T\D='Y2T8RS9Y?L8Z)2INEQX9W['C=B)@
MHFD-?)[B!@[,H/45 VZER+I50]8Y^/=*))_%[AD_W1%CLHEZNJ=C/N&B!+;[
MD5SHM'UB)L>GHEZ78IBB/3C3CM9.C-NO'\\S2*7#OMJV@V3B[6MPOIFX1\=M
MX\JOJ]XXCIM4CV'5BJ;Q764:_)0UHHB&-Q]6'BEGB(V\)@AY^1 !BY)?Y[U@
MU%Y!G8;!CU-Y@I\%F?'*7C]EJE,XT>'G/=P;[S#\E=>6<1LWL-CG>^=B:H;*
M(CAF[8^/ZU9.8MW]Z2PH[\[9M+WFZGLZXG\P">K7\@%?].SGB,  +MR**U9R
MN#6)RF_P[M'8^[E+DX<WO3FQ8(\'T0VDG9@KG\PZN&<]=\OQ4F[H^1ECO3Q)
MZYZY '30.9IRR@NYU)%\T96B>#EP[OD6XK2E#@H^A8X5,^+.]ZZY/>8PX4Z:
MO>7Z:SS**X]PA6\!2.[EJS-^&'EE=4X3C<W9_;#<&+7- R7TKYAOX=&RK[B^
MT=W9@2!QW\^DGN)?G6?ZL2S.,?V>I _!LV79>XZQ*;]$LJ5ONXK'5AJ4E3-?
M(W\=UQR!H?5&!,*?]QGJ5F&BPKUA"^.8W,2E2$^+FJ&OGGM1R=YD/ULO"250
MS L\- T$<$NW:ZE,2EIL$@%Y+,A)#%YNVG5F"D98G44<G3?YO/8@ AB( .@V
M7S,"D][1Q!-OA&B=W$E9.-,A#(910]9WGYEEQJXYEU]^ZV15#E3^%/"KFE.J
M-6T;T@ZD<__,UE90-&5O[A0(<>69YIR9::9@M/.YU"[[*F:@HZ\D-D.L&T]_
M1H^_CWL^OQMRRAN[R$?G%=5KC"5/7 E*6PQ1GX 6.LAC/B6U'/\(C+@GE%0D
MX!NREX"-$_&3/J/VZC7 =-3F3_0M(,B\PH#,ZP0QS'A@96BII)N:O._3"0Z>
M%&.LHL>L$0"<\-8YK&;O/"^O?A/FFF9P.M!4.#:Y"48T_IYK[$7"@JNBCAN'
MCKR CB6:+;PTV"84UG2AHPRS [LRI>5YHU-YP\1S763JJH75C4+5G*J"B+=/
MO@U0RE5CTI:"(_UL%K%?< ,+K!7S_.ZV[CQ H[/7/HG9L9>^=*J6";/NXYM/
MH.GS"U&TSKQ".#:LS=%;G"N6]!X.L<A#W[I9HN&8RANY\'/<9-+R:(_*9!6T
M'*4D^"KVL4A+H+62P%C4I[G*EVETU8N&3'T+PH^U?PJ%&V &@MO;EWTZO@!$
M5'=^4F6!DZFYS8!*W8K,5F*U'N=\2P&I!\.^M%:"O$1 (5YA'#N55G^>0U"9
M(/3!*=VC0]A.GYR.YJ8)UJE];LA4@,O;AE\/X8\\P8LI- ,K=X.;;OKI8B[J
MAY^:T_$8Y]S'X'"H>V#"Z[W(YN!ND8A@LOT!,L8PY-E=O"06V E[:]+$\T[V
M_'9;LH*R_OF(J4OY=R9-5YK]+W:F0B3<4I1"'&J;@3C@V;4-( 41 ($Q>Q$!
MH)$2P]9M0ZW4R4YM&?3G/"M]M_@?L;DSF5<W=FY-<UR>BG(8!NEWY(XG+]"J
MG[S&EXP\2I95^MJ8O"01\+ND8??G:6J8<+ZP<&88X+^SQ3YAU\(.I:C-UI=T
M,=MSH7)B9ZC*H-E+-D$WC--[5:>>:K%?UEZD>UKX5N_*^F:?NKH#FA&%I-#,
MP\M!97CNKZY?)?AK&L6U#PV0=5U+O)9F6](2).SQ7G?Y2HI#]>&Y^YZH_.:J
M*R=\6\)UD2)8;U"51_WK8LV4T5E PNE'Y_;728_%;\M,0\5NKL5>HJ%9WIFH
M?+?11(Z-^HRE_YXJ%'H0[#DLYZN(A/X(1U7I?GW[_%?$?+0YID]J =8&I-9;
M&&# ^;:H,PRAPFEO'K?NVU,O4J=(F%#91=GO! Y6TNU1\;_8&%QI:/&,4SHR
M_#A+SD<3P.$%;H%#%/JR''Y.R VR[Z<P4/AY='=W-KZ.6ZZ?,^P'YXG-3%25
M'E9Y0IMFU&3G^E1*D^\?C?+8,1N9)3 ;:0'^O/EO:8FWB;Z+ S5?JMV]@M?!
M)$?EH3^T6@L/^FG*?<PPGO8Q^4K;:P$\MF4L$_:/$@L_SS_8-C3&\2.GUI..
MV9YU.QZ/584-B!]1NS)9:Q>B;[-67XW,2NJG--]#,^ &FM55<;&8(=A'SHS
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M#2D$PV]\;EK[LCB2N["&<U4DI"*^NIGV6HN-^KEB6MOK#-]N^YF5>@49\FI
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M1=I7S:F$ZJ/>W]M36YZ,G8[/]RZUU1LK'"A-:UO(_<)]>(+-^X@B GC;Z=O
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M4QHHME-[!LQ%CO\VCM=^%=+@>V&(X+KQZ,-]:+[EP"O:C\H_/*2+RP:<KT_
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M+P/JK,W4#S![&?:JJLK[Q4 RO[;>36TZ.J\N9 Q>>M&7" AA2P[@KAIO,%K
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M%%=D,OQBF/?H=-:A)#M(Z6-7^=TXH1]<*G:/!!ZL6$287L<@CJY78(X"ERR
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M<<'!N?N$@205BK=3WM+\UYX>;4_6="C.V^08+B(B,[@Q":<C"G?W5O5%+?1
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M>?/R[4>FT^(<>]TH9OM!=+MX?2ND7;;'\/+)\U;<31,'F89[W<!;@]ZY.E+
MA/S O-MOGY6R!\=]WD78-M5KC3";;!KD[G41[[8$Z\OTO_LQ O&-_#+6(_C
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M1O^K!1%6K\.@PV[ JI3])6.U+N3U\[$T2KLK.O=*:T)6[/JE-R4)U[%K)W%
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MRD91W"R$?GS-TQP<C-H@JBS\!1Q$Y/D+$J! Q.N</N#PIM#(K\\TCW+;B)&
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MN7<AV0RG2(!ILV\^H,*EK&Q%WYWJ(7CMDVFBB"]5\SC,;<N,#3Q9KC]4DVX
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M9X*0X2$),*LI9C-]3XGSGH85O"[<HDV,EQ"$VYYZ:#C(:>N11GW-U'$PX<&
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M3%R=W9[2GAWAS/"(XI"C^&^NCKIMI\_JPH9X.90\/"_4HGFQF0P)T#*V#\L
M)T\3KQ2T^+L0GN-)@!4Q /''J5CH(2S\= <]"M3.Q7OJCAV=E0H@YZ /0JR;
M&",<K))-^X?Z4W@-Y5X##?C#B/>V.&\A)0G,+3C;;@XM75PW^);T]2/8I?G'
MET&_!./-"I ]1N\C/G[M\'S+9?'5-W_Z=Z+)H_TT$^;9)P#15U8!+M?L&*LB
M3!Y36JAQI<Y*:#"3*S_3]8C4,<C<N^ CQ&)45LK4KD="@HD9")MP;KAPXJ\/
M]A^](X =V?Z]#.*@Z)DFTEPHP^JC!8O_5MIY1C75O6T^*E@H(D*HTA'$"#Q2
M1=HC*%6J2@LD2I$20Y ::A2E$YH" M*K0$ D(5)#1^D=J8'012"A!@AA_+]K
M9M8[\W'FP_7]K'WOLZ_K=^ZS]YY4V/[J:L$]W%'2&\735U[D_R_OB8)>QJ&[
M,V^?!35J$70&J*&Y460*24?NN%-$<Q;G6.[0=@XN??R/H?A+"RN(**_(2]5
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M40&TCOX6"A@P( \(K$W%5<T/Q!S G(.]OK )6=NY<:R/8UZCG.UCG,0M?:L
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M^=K Z0?9MS[^#2\58^ WJ ',]?8=%<(I2&<.7H:7HE]_7!&_9M8$N>C:@9D
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M-0?_&M&U:T349"1DU/_'![8=H"3$,</1QL-A!W I<? H<;#= .@*YS6<OQS
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M;+346=C9CZO,Q'@FPVQ>\_E./()BP*4/WU"^(.)$XY+O3*]FK+Q<?$[ /_^
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M7D,V:=I5&,MK!J[-6&.!BH_@8W68 $S/\I>D,7C/5ON2"O*=%RC/6FGKVM>
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MHQB:I%N7I?8%PJ*A63,V:JJ>WVBY^(%K(2.FW5W^FLYH +W%%=_*;%E)6*9
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M*JRB=E7UXWP:=U9"T4>;JL"-^@2?,S>\XOHUM6-EMR"<4T*V0<HD;()R"L9
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M@@V:7-DA/[TB*?3A1AFUCJ&2>^#7W_ZEW7E;OWCK=Q7PU>X.1*\@6T=9?^*
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MZZ*QBXHH37I40*0C13I1$1 1$*0'@HK4""B]1T10J0("TA)I(B5$!(+2(EU
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MU3)]/49W*AJNBU(S'-:<6 J-7"R5,4HP:Y +7?";J$WC4W\WD'?B30&O?-K
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MVV5(!UR#KKS>/?!7.!NP1N8@AAO>FS*RHC8$1@<T7J?>H0.R9L&,T7-TJ/+
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MAC'U+X.N-*A=@<*(P\T%N ,Q26.T*%RLZ*RBSV0[$K^;&8/UNEC\MF1U#"]
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M+O/+&!^PV'L/4[,*W$$*HOZJ]H]F_V.*1?PO:?;?%?O_])H!KI"2$)U'R@"
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MW3"V+W-UL? J]]E?L9W^\<NRE8N249"#MZY,MF 7'*POO&45!^GMM'CH\Y,
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M'M=H O AK<LBT1;_]#7O;] JY,#M2\#3[JLA\QJ1[H%C%>#5V#_@WH<$H(L
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M?T._2MRR?TSZJ?]?7'7*R".6^S9 ;U\GG<D-?WGI:F2^W#IQEV1MZUHHI*+
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M:];A9U7-KL$<3[V$9NVHJ3X!%$.Z_)2YJK<--6W%"4!;1S,7>(BM W1&XT8
M>EBFIO 3K#,%:4VKD-;!6)B?/T/9T)PZ<A'U)UZZ[*_[KJI?N^J<0UTSLO[>
MIDF;\W@]3/=F<#F+]KUQ$.R. <CX0G "@NX-V%/K"65+\Z(XH:VZWS.SG<V0
M2W4#:DJ!U&1^1!EUYOIH".N$>FBY^_!\8F1?S:T\K:)0[L\F*+WTSGVG?@HJ
M2^J[BY?HI-W#ACEYBK[GW#ALR66NB;,3&-9<JUL/B+C5OYWKO1S9Y\"NZK^#
MU6W&SSY18QC].K0G2^+$^BV#VH,LVD-$P#GDRZ6:3RLZYI<N<]_]@T*T].MW
M\$C6CR]:7UI2#+#=U9=/?V+B;B>U1[D7H?\&MYQ5D7P(1^"D) 0E94:/N?QJ
MAXXW>/AINMPX[SQ?MZ,FX4"7GAAJ5X<JZU;5I-LJF?/I9!GNISVZC/4RL9YO
MLW.1'>\K)F\DIG0+.A;F*RF&S\B5$A3EO5T*\UGL"\N1_6(V*1,&^@8U\&"S
MHV>NGTPUF%!'M[0IWXP.F3%=:!*-SX"*P07RXBZ[NH6)G%GGQ0X4K6)2V.OT
M/415GI,)U*?1<B[I#*!)/+<';U2"G.&8&VJW"0"4GX@^"08#64^W.SM!JLQ&
MC\S_[;M-_V:2K()KH-C4ZT1>;4VL?GKYT*O0LI-]>I<PD5&!T=H<I5'3T551
MFPDT2Y807X1T&94"'V_K+]LS(Q M? -R1BP19&@"@-4,FGK@W=K2T7GJ-+BF
M:-(U%C^&>55>2P!,>@F $P(C,H/ O5GZR^,?AQ$S>L_+>@)0&=9&/-"C=+Y1
M]F"[M?G*KZSE-CSGR&O=-<-;NJ^WA1>=K-;)\N+CT16V1.20WME_QR/">5R/
MA^4OA":*L289N((E1N33QI+%I;FG,\^O2B4J%%RQ"H.=Q(I)GK&*5MB"=@A
M<:MN\X4O/'-Q?!]2#<<FX^AQ%U"<:/JOP3/'>65\C <+ 4"8\F)C;=(6>2DL
M0U0/<A+?./G[@SV<GXMYA3SJNUAQH5N**QWO9C?ZS?MTE#>^*#;^L>37:)/T
MB=\#QB43I458J4/Y*-"*;34!>$T -K1JN/ :/)Q$_6)T",#(F=CW8;@3_%W]
MB\^TU?W(&.=#>8G5 :H>8B+X7HJ&D*CXS72^EQU;X-:W-##]<^Y .[:S>OU7
MHBGU%3[6ZU0<?,]/6#9[N6)>7U.LK:U'J^@X!M2^?V)U9ZUYVS5G<E>2  B<
M]^+;6&W/I1N-FZ/.QA<3;+L6Z&(>#@M6Q9V+701_\9@?N5'9;.[(\DYALR/0
M$"L,>6=[--H&.N,@]IV=8DF2'49?=3OSJW]MK"M<T1*M<=*2U_6W[D40K?41
MS 2>NCE( +2M3,TZDS 22DFX-^*@8]]5?PB%&FM 1@N/R*2L09";2%YC-:PN
M0E7)XODSH]47$DULI.M6#JKG9I2H?+S^0R*Q?:9/C^,.U$O0&>]37#P&KYB*
M?MQPY!G(JR8VM".)-LWA. AX)?',%?\3CD\(PN#_W06$_-GU+:^#?91H$/\:
M+PFX._4K>/*C[3E0/FN+X0@1(X;OKC(QFAS*)/^+FU!3Z$5C$TBCE1AX< VL
M_I$J%WJ: *1(\>*BW.#HH#/3YBU<'7@EGDC_["P]<+G-+-#@M^"Y=;SD,"_'
MDC8V_CL!('8C[LDGH!T& G =R@N>;";RBZ_69@P7+XAQ[9.!;Y&#GS/7SN);
M> \Y4:>XX$W$.<NX%V^=!S9#$;S#Y$I\6M_&G0NO9X$E ,>I\YW$9;2&(Z!S
M"^3)N<8%L</IH3[0QD4LX9]@FFR_@:HAV ]0,O#4+<E52U32P490[[$"5@9_
M2VP$E)W4;R")5T^'G'2 CAFL3UM &/%<*@+PHY'WG,53R18;*0':C@-OW&C8
MCP ?6J@01;8+ !V+GF<[8>.VP&\(P*;0[U7PX2,B&8<2&V ]-2CN)WCEPR8!
M0',2]=3LMZ4SFP/#Z+$IW"!\VR/PQJ]2Y)^#,VW<'_ 2.$6MM!V,X30FKB4J
MI9=\8K9#0[0)Z)WM2:\!WM]W'5['ALT(U<8W2H"/6:'W<&_ *T(H&OPO%_C
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MD M&AQ]B^W;G*U'9/O&3X\2N;<7,!,O[%8,V)$I)SGM^#C_.W]R?A>-U_6-
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M-=&.KW,T,&XOMY^(-VY?^7V_(,OTS'.DG4II_#K;/:$1*53.'BOS6$8^*<9
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MD/*[JZU_!IKM!/<6)=[\+@Y?ER/;8YGF,(++>I:8.**G#L7FFT7X@>*9?L\
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M7I,R?9?*F<HMP-YT:=:%ROVX,.&RF..'_4Z66S1"F%[S"YIW#2CO-5!V6T7
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MK'Y6\7;HU3P0#.[E65;+]C='AEO@?)QG8*YMN.@GS!%1LLNP6KQX1#IZO@<
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M8Y?"5",$U9,\]E1D3/9U]?K_0==3]9 R:!Q5%+:_HL4E)B63ODC.E8Q73Y_
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MN8#F.9,MW_+-3]^6BZAHD%'" D-E]#\>%_>I1/9MFJ60YV6Q%<GPJ'155C*
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M]4W%YOK$5N^-_NDYXM5KXWJP0%;\M1U.(DS\<-2!V[VHJ9BF32].7'XV[YF
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MYV@.#. ?X5K[2N[=82[35*N:$_2F*@=4\J;8C:]''B'V-R6OV8<ISJ>* @-
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M;1J6DRGI,Y7C!-.Y$>"Z\<0TQ&T;I_R9_SMLOZU!1>]TQ5P@]B*7!A3"6!"
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M[OGP.Q,MN"3]&$-<V(^ ;?-GHQ9FW<X?>1=G(KXE&K[ZRFM%*0#P_N1*]#K
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MT;<0YIZ\46MH^636C0%5&7=._!LB9STB&6F8ZI"CO()5O;=[J:%'\>\+,R5
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MHI%M69%PFN5T4TJ\I#:V>K_CI[%FFB/?S<'87BMO); ZH6M_R/_A?U;@DJW
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M! ?>W:X&_\%G\8P1;EV92EP%2<^9J^S=>O=4$_N@ &EXJG1$5S_ZY/QCLT9
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M$:PP"'H7 =#H8:G0](.?'PRFGC>EFZJPXT1,O;AB5YZ.Z:W%9=9L62R#*T@
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MOS'TOBI4XV&]QD.?:0KIS/(Y_?.M%@AI2[+&S8^F,QZ5693KS!)6%G*#7\/
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M:&Z876LYV?3V!>_<X-:\AB\D"B\(,THHSX]W'(TQ>-1ZBK1</0C *AZS2)"
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M25P$@"> 9&Y.\]J25<\<:'$XC.WXR<*F_]#R>OI=D<]E*XM,@(BXR+-0TZO
M8']^PHV,P%2;OLRX/"-ZHW23T>A"G"3&+K]S]A++$]4?+<$-\MO7KI-K=(H/
MJ-W *+^'C4C"BEIS0V&.[8TA=4N??<$L>J6QO.[U45.:5UE6J.L>5U2/<9@>
M6O8->]KN\OUD\!Z@"0]AG]](165UF<;[XQ[9&'-EKAG5/XEZ^J!1>4=.W_KA
M8FE1,CULC)L/'4QC@MW)QA4%>6AW^=W\2R2K<_I@@NU:7QDH\%@1:S%%QSUA
MJ]/L,?&.71<U>6<3B_ ?'_4G-+:FXO(DZ@L+#6RK_4(JMT\.[+QBT;*7+@3L
M:/:8O!HW3 $;<TVZ1@GIC]$5D]I!KMGZJ:<YKAIGZFOOGV6DI+1F.%/EY;*@
M4&UOE+^%DXNX4),7)0 4H51Z!1N*@=<R-+8/!Q45%4<_B]9G=+WL"GU6=6,1
MD!S07"B'^9S(]\E>D/63UJ/<[&\3OA\/0OD4FFF(@7SZ2SOA-"^7/"T. W7@
M$$424"S=<JG@:<ODKO$1L3J&6#;?++M]'[6 A%!O+#"W\B)E"@ML'PMO'"?=
MJWC4<YGU2/?C5_626=IXGSJO8:O0%\3.!1J8(]8'W9KOB#DZDY].FP^N_;Q&
M&]*?K>7XWO -\BNY'G!<FH6ZA0FNVZK ZG(3KN>Y3NW3?A\_F.7D?1KW\[FS
M^"79T-S,5P9]&FYI6^YGMS>SJFG"#H-&+O^>M=VPL5NL=8]5N,ZV,5#/G_M5
M[F\ 4C@O4'KJ]%V#4$O*\:9/GQ'S>2&GI?'4R@SLNA^QY?4HZ+:9#CL:=(_-
M3 ?XCXS])!''N^B!B$6XREXF.$W7!!RN5S/'!BJ]W2: B^^F68*>9+RPU!)^
MKSC&N+/2 XB;W+P-RF<_T3E[ 6_7:-;#>*'H1KK?0_=0J&D,.-9A7+J49\IX
MRESA:V4T7P19*,<[;[*3M$QQBH/$I=PT/SA%B*!FFDCJ- [J<]_=JLXAD>\-
MRCC\TO+EEV]4K18YW\&,L60UL]N0[DQVW #'I/%D64J.FV7T\UJ$\"61FUUC
MK$V#E!&@ZX^?+$_O3&^58^_L+])LG:'+(U5[BIFC=JIKFA[MI@H5*J=ON(:B
MNKY2?905JPEY =,_C]F54K?%P3&)$?)P&K%."+!9=\WTDOW,JM&FNTM.^C;E
M%X.X%\\O420\7/*\?17T\^,#H:3GT2(/4KRY@ADU0]7]E_2VW;'(1=ZY=LR0
MW\/6JABUV&)IQ9Z@&8\</[KD>T*Z+))7@)OLPUK<(E;!:#BW*YPEA'\]\_JH
M:$!UL+MQXOVJY LAIRWU]%>*^MN:2.I6Z'G3!5]'<! 9H;/HQ#>M'!NHK<9!
MQ4S=UO0?G[V>/Y(1_/Q6:OJZC%9<F9^C,I)O^M89F #"MS-WQO-V:@KC.+L2
M(V[\U0155[*(S/,T_4S6?Z*?KJRHHW[V*J_J^M_ M1C@&/R_:ZZBS!0#28"C
M*;!K*.E21+5O\4PJTG#\=GM3$VSKWI'9F\&%CBADC>^M$?[JF\;RL6QFA?Y)
MP^P/&9(-_E(%>'5^$KG@\&GX1#BO3&I22W[X=B[EBQK'LX$Q9KVO877UT59G
MV[9C,5,^,R$::8=C:PJN X;>^#R\3/G*^##R 7:\;>$?V; US0E&J4XN#P47
M;=Q],C?7JH[\KS2^J*4X$[^&\Y.-L*%)<I:GZ.*L4+,-_L81,R;:EKSS1.7&
MCQ4RO9MJ0K+22%,<,[(1WIG(8%H"B;QXPXJUWDM#3?6>PA%R@56@-L"@C3*1
M"2^V**V-*8]^AD_"8-(LQ^Y5_>ZZZ="81+N7JP5?0?']? <Z3+#W6_G@92Q^
M?8'%%@V)W7II5;"^AY9;8"5P^I_#VS? SKOOS/^^%(M5O\V(/)KL3=K:WNUU
MW38WYWGT8\LS_ZI\)![03Z/[>A;,O@AA![O8W5EZ#*$@2%<G=@G(-OB%E<^N
M5E5(A@ES_%VYJ01J?!<Z^[7$(Z-H24(1L2A*U)W^GC9J0 +:O0[A4T@?G-X2
M%2*L[,4!OU WP6@IP]A@O!GLMJC&E/EZ:(SKX:'?P55G&KZ0,.RQ ?[>,8*U
M]=HF"_0MDI/,;+?KWJ@-1Z^1AB:3;8-%F\SRAQZ,!)P.;ZMUGMZLH%E<,F\'
MS4>J'O376<W"YK2MFX17WE"*"=(X]5J8-40!Z>LPT"*CJ?5T-BXMH?DS02N4
M!#B[7D9\=LWIZ:1R!.^-O5(.B#I\V'$XC\WC^'8^7U[2G.9TKAFU6F,X;N*^
M8)/7&/EE5W;=-8!=GIG&;8&EY@N8#;\Z,8.RZ14;;1;?XI;Z'3P;6_)2%)FS
M5^$WX%3\$X=,K(9'GC[S#\RME*_J6Y[YC>IQ:FSY=!##%2FS]LN;1B24M@3"
M"S/QD+02X,8.1>% <7E:F/9G,U0?G7./7X7""LZIZ5OEB@*$9!F@3"/MYO;0
MSFY4EPTB&A:A%+B](_BF7Z"4O9&U]I)>B+_BS2WD#VD?&PMYNRO$:OM@V'!4
MJU%'0OFV ;%E(7DTP.7Y>BO9E*:(&\?I0I?R]X@>6DH4_"WFO8&'9]N*4]/3
M[J[.-YSG-@)AB2-&N%M+*8GO[,_NC<;_^%[ZZ%O0S,[:WNMS4=.YH#[$NRQT
MM(\P+AS8$7B DSU*;<9]@*R'T"7;J6G7Q&D<->[16]W(C%^MEW1E94J6<\T2
M[H]:5CXY,T),AXBZ<Q#Y\0'Y(T4:Q2=]P92,#!QYK0<_A>MVC)R_-$4J,0]/
MZ?(R%^M12+2>!U]9K[1'3"X\Z.QZ?O_[6;/"RG7?N;J5A3U;Z?$;),"-!/#.
MXA/O[*TE+SV:6FZ*+U,8,E>,6?QF*<0;9+8W,[O')9RE>D_RYA)#\ <B;6 G
MD04LP-B5%.1F> 1J"H&/?,O'%Q]YX(.Q#]#7LC&@6"NEP"7ERWD)B<*Z'/XB
M!7HG]RJ=?3B"*\Y7]]I%LAZ>1]>81J0G=JJMX%_F+[A6Z$!UOW,4M>_$=>M.
M^5.^:=(;J .>8)E\YF*Z'@3 "D>-B_."7,=/4<C/81U3">YTD\L?2Q:DS[?3
M2<#;EK,L[5$==MS:WW^YM1N2 L&::8 Q\(A6];^FCIB%:%1JTLOBF0V4!B*2
MH'04RR^SDNIB*>GZKG.PD>R9D)2,Y8.AD*+I3D3M;@=S!)P/[B)+!H5C]!(\
M"63.KNC9[3OT?VO$I5(W=.K#+>4#/GYSHM;3,.#J 1RU0(;$P5.O*'E$*)'>
ME&TS?22JYBR6)<@W&,,+KMC@SDAWBH'Z*_8)/>(04@(=PL.AB=T+OZ\=8YR[
MMZWL*O&%97@?]'&TY[<6G%Y82>?YEP>I"G=?R+V7B+848?[HV+[YGG,$L9C>
M^#QC<0AN.:I^:XG1JEN3;_(U>-LU9Z*,LH]J4#5C+OF/=BBYG@^?P!/M#^'<
MSP&>L[U0UCSIETH('@)5/DRW#LLX$EL=I>[LG?U]5&!;9\#)J& VJ_DA!_U$
M@E:W;%=YO"8E7HWQ7:LB[OD'=#C"SPBR+9D2-?B0O/OV<GAOW]^;-W5U +\:
M),P8G[^X$-XH\0>/[%8%AY?N4G1ZR)0'\5<.HE]9T"=]2/"6O(7,JM;KE(V0
M_$$".LR62NGU@@U9?)S8C@N>-;P[2)4W?_2>!$ 9@J86WJC#%W=CB2!CYX[&
MU0^8H:L-B=LVL/67//44XK_%W '=AXM[XA2]B*<C,2&,N,2M;>QL)XHSYG6P
MH]UH\_4?>H6NM4H50R^?#WCQR*4JB+Z/H/+66G9HC2A*#_G@F-OV_O?,[$PG
MSZ4Q-6BJ@@4_&Z!,,5;ZZU^-'IH4V-UTT^A6"=-(19-.@^@KN]V<-[XZS#3$
M]+*,YK=+KU^I.YYJX7TP4;U+_S=-:;JJ/=_5[S*W4TJO/CJ:VN (H$M&ZE>,
M+3<E#_?/CQGUQ7</M%_)SC0G3WM%,_C;@EM]D=G0V%;OYW1)^LB#BMJ)%S,I
MJ/D=]M2;_>T?4Y[H:@-ZV<#46#JLXDSR],5JO(I>.MSU0M/!LS)&T@[LU,S/
MBX@BIL5NWB-.B\:BZ7/2S_JKKE/X-ARDFKU5X4-R6[_B7D6.IR?D_8!:W4W?
M.\+,&HZ]>#HG,E;9S<!2L&-"'BIA+*;W\Y>4<,6XE$?UIGBE.6J,/4:^3\J[
M". 6^;!C?,OZE_S(Y78&U;(,U\).AH&7;/[OI8J2K_<W1M P,-]182]UZR])
MKOE6"YE^P*?)_2LN+VC8IFZ-J'^RBP%U);+ C--'M'])RTK)SSTR^#G>65.6
M77*7B0?S'*20$CHBVU6)+>+T'C'X]K<1M+62C5H_LG3L:M6<FM"A2HES9TAS
MHJ'E.9\-TJ^:(!30BE35#6U9GE[+<"VRV[AO;=-9,%<D.K3L731T\\<=&N^;
M[:^\:9?4S76RUW]NLKJ-KA]5;%1U_32"_2S(U)](+AB)[[XM$FI"[:X7G2CQ
MX[O+T0YAP6O36#JYPS1C\F.Y9F+EGAT)D-7P0N(YT9,]GXN,,.7L\SHE^/[5
M6[R/OPG-FK[;/PJR +^ZT;,&EG_GE*AU8[?9IX3PH#E+'P]7KAK-\6$D 7$9
M%%VY?/*6$M!TDV^]/CSPVA"S=51"AFOQ[Q&G8'?&[8P.KM6Z^C@#OBBH1/^K
M2YH1J?T]L_>JWHP-STL:Z5_68[M\]6Z\5IN%61O@QYY8T[26W+0^ T,8MYAD
M/1F[_[8Z\!@.'MK]&^ ?!;-89)[Q:@_]TSMJY'_]=9CU'S>;EKXV&2/^L=ZN
M4+L$:JU>+O8]$M #BE9=B-TMV=$4;EE-\E"+?@V)"&3UFI09(50%)3!_^!"G
M5AC2^MAEH/Z\Y>5B%M,</@%TV?2;JX_[KP+]0P.I)?=<X#)YOY4WEUCVCAN_
M&GHWO#HX9,GN)W8JT;'T#\<M-\LI%CT?04_KZC!MON.^U29QAT(SV%[LJUVB
M78O_MN-P]Y-B!\ZJN(]/:BT)$+AHSJX/IMCK;;([RWI:%M=AK"D9])G^V#J8
M^>!QRT07">#\V+2<;+GV^IW!]3\!<3&GMSH4YT43=6+U\ &+Q;*1]OR4207X
MF)O3-UFG=*KBZVYE-N4GV6H\G"Y8;V7Z)1]LOVOQ\]?!++_Y+E'3RZ-4.,$5
ML>!-H81Q=TB!^90^FQ[(.?$]]/@#?5&K[(<*;&V!C.3LQ5BJ.W9G52Y$AHBX
M<%K:*TW5++"[L89:W6]HWFOM/QG>A J3<YUKHD6\#<K>+GJUP1D)9-CF4]G(
MD'&YAJQM3B7_!![7+US<5P&  @!H'LRW",0LIUZKSM[ZVC(_QX1?Q&(+BG7I
MO[@?GG7$B)<Y_OS7&[@ECP[P+-@SC%>WWY@@+C&1*$RPFA05,\!R?"ZUK<W*
MH;&>S/W81U_ZD>;%B]N"7Y/"WM:'I$^CX=O&2[(1\SSG>2'7D46/8;>K<(*X
M+4XK9O2V+GV0[L^HCC'V!_O!A;;;U&)@B=5;T_)DI]UG@B$CIF<J!';L0L2A
M>ZRQ;7=MK="XV93T) (6J[ZO#3P_B?..C;P[K-S7L48Q6]P)=I"]XB(@<_Y)
MG;,8:K_95=?(CIP-&0''R8QM/O2HJRH^&<OO_^W[I/YO&(W;L2J 9^UII<*Y
MP1QPG!$/.E3/=_(*"3:CS5[.&-Y@1;V?QM?FYRDD>4M>6,5I2]T1:H]^#UQZ
M,0TY,R483S1[?<.KCM_!0Y88;Q @>7:V;O,2<(H_;CSED0=]FH]*.<27_!(P
M,$=W.0M A<%O::M?G&+_2YL  ^(\$^Q!@T_Q781PN\'I:N#DO__.\S=6__(L
M+Y=_R=CRT9UJJ%(PG6;6XZK*[<'F0YA+2!\)H"'><FU5PN-P])T5LS"I7\V.
M&.K6L0,$E\O-$?7:C6/955Z+^K#2WR=]Q]$C@S=":<]IBU")A+<[B,T/<&$M
M ="9@!OH2K,1UKT]1 0W'7.0R(+:%.#_V5QG9'?-R+TK0%!/^J7:8]7!+@%#
MI(")"8WA<?I_=J6%943=[Z>!_)B(7$_>O-Z3HB)J Y$#P(H6V]05.)((>H"[
MMZ^!B)#][/BK^BC:(G/N%O'3EBYAT,3")XQ+.ZZB)"OJ%>(BSMCS.XO%GGYO
MBP[ ?(D:!H_.?BJY#>K6I(7K?R0!(SI%)*":N>>3)A/> =6I'R[3;%7$7.7*
M\]IL%P6%R']#]N<6T/>L2C0 R2W5?QM$323VTA81BT3[_ S+9H>Y1VIW0+';
M:Q[-"]F1N*8ES2;FV -$9!93G ^T9^-A4'&J3K*:<@^O.S4E0R'#\MN*2\@1
M$:U#GLC$&F,J*0)GCC$)H%WHNK0]OIUV2^*VAVL]O+SI1H'UQSU+4:K? *#>
M EUH,R7?]&\,WH<&'GZ?4'!^CJ/IHKUQJT'*"+7>'2$J&+WP2B\5(JK]U$+C
M%?&H$VU7DQ^F"7+U7H#6$A3ZN]6J2@03!(C$QVG"&GT+PHS%?\J=;%XO3HKG
MH@A!M:<R ZLCFO$VDVS%0]47^C1&LB3K$2SEU+@(BK##6L1'ADO7D"TE1IW&
M5(]&/S%R#[+NZWQ\KR)QSE80?5M:^*OX<Q4AR5TNZ)LN6RAKYVDROASI2E>;
M7SHWF^N7;H/0?-%WV:R>! PHTPRVD0_%-:S)JZGU>AU"Z/"\]X/UNOQ9J7'.
M7?3UDX3/%8-FS(WC$E]%A(^]RY2>$4K3,)!8(B]>N1.-[(RUG&ZV'QZS^Y23
M?+Z8@I@R]5U96<U(%'VEYN4R39UGO@JKB)\_"Y&MW&K<.17*L^M0'T^3\ILG
M :*$L5V9+S(EAZ8LT!WFB'3-E+QY.WM\4[>5V8FEGYS>Y9:)7(K5X"AVX=N3
M7\-U^$U>?@T@!,EV0!@6H/F8NI@M>?3KV>PQ#S-8[#TFP=#M_3(1X53']JTH
M*E@\9A=E:H4//(Y&?WP#8G6+7X% TQY"#_G-5]J%':0"WLA%AD<(2URGLOZ>
M&0 /A].$B(:,"D@0YQL037I6]. 8WP >5VEO(Z[M!C([ PJ6Q4)[&]843[Q3
M11R_X9Y9HM7DZ6NCL=V![)41Y8\;$M8N#:8Y?UL"Z^:/C! /?JE;G'E"+Y+>
MPN6MUUED4+_3?M:K9S+OK\88;6L+"Y8I%4<)]4RAOEW)S9)GTIL TZBKX30%
M96IPPMW>?^SMR$?Q7@9585(EMXFL,IU2<<I$=:: $$8(7@4+ZH!0'#BZHL^D
MIZO$.0-+AP4V_AZ>+/ Q[%<_\>\Q$!N5'.YV<#$(4M>0_SY7"CD)@2=M+OZ$
M?D)XQ!:MB(VJZ01/(596)B[ ?2_1^S]3'2>YWWE4>AY*I'6?5YT,N;H96-ZE
M8=4E(#&)8O\%XY#VS$W>NCNF7]'SZTJVN9B?S"*#[S+=.7/Y\ CJT0$D"B&P
M(R_-VMG('O$C4[AZ;-=\M_L.[6'L5#B'2MX8FMX[V]SCS1&WI45L@*2(X?W0
M8+LS$%2O(X3\/(,@C=ZE'"DU16^K[#Z-@R8(<F0S+'A\_:.M2JE5SM=CW4M/
MX#=]L%73";LRNHB]X/?GS,:UV" HK;2E]9?.7=4_P9^[1IJC'V;)JWF^US=9
MNT+]A.N]6CIP$@LY+SN,%\.T[&31A)<XXX-_X'LZV])030N-"_%W-L1_&[X/
M"%+_&)"C.["C(D5-+5ES_D-3!1JY:!^;O9&N]\YQ^F"VU&1LX#ZB 6$+W9H*
M*O#X)0&,"']0U +$+W75^D4L$_3.!/ZXP]F\:IK@/,&1[:C(&"F"JS]Z9*LF
MV6K2(^=N?.IR[PUZ>3/]T4]]HG)<U)B+(2,[LX01Z]X-S^3%AJ]U&RM*?KE>
M6JY@9P.GHP69-=35)_Q#4W84PK1U*:XNO(=*:@EXX,J/#B<T>4/&5>LZ8M7
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M*E@R#1[JM<^_NGEAXY_ZS?OO,S!CXC\ 4$L#!!0    ( #4\=E@ H3^PPU4
M "Y<   8    :&]O:RTR,#(S,3(S,7@Q,&LP,30N:G!GS+IW/%QON"\Z>B=Z
M-Q*=(((HP201+2(3O9N(WJ.W883H+0BB]]ZBMV&BMX@@"**,WLVHHPS7;Y^S
M]]GW[G/.WO?>/^Y]UWK^6FO6YWW6/.^W/.N]_7.[#+CW2EE-&8"#"P#@W!V
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MOP9-57DL.%Q9"V6T,K"ZVR&Q+PX$UJRL#294WWG8=(O](7$46($C>G,H;AY
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M2)74-=U);QP=W9Q^-&=P8),R5=7[))^9/8:S76'[I<I:_/K/%VBSQQC&5:=
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MC1RMD/MAS3-A\GDA8<[PN3EQU")/))'5H?:XDB=0;MYY[P[2\'W#^V&S=US
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M9<>N_K=FT^'13>-DF%<5T48\F4)Q^;IT*6(MZ2K)9D?WKI*=85S_= 0(_GL
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M1'7&^"U_X\APK9&EI_6$9[4-\,8 +OW\_=%(+>M>.O#J5">>YM@$HP. (QW
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MW8P&3BXS!8<8KH^0 5=XE<PGSMGV3W[?3'3&-*N(C:^D!74<P*]1)E*?X_D
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M=-)M/(UZ+<P;/=<89H$.6?IH9-5N?ETC+G<(,FD^OGZER*9?0#K89=.@?FP
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MX0D,,*;IH"O!L9OD)! EB*C#GH%6SS=XR=1D/YY./IG^[!'X!6;&F05XA;I
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M7S0X-<Q0?= ;(-JC1CPYORF?^.M)WR1V^];@JZH1XB;Z"8%R/2[W/#:&^.;
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M5J(&;L ^X4AZLAO[44?1/9,^M"G6N7\J@W\#%7%P%7<74NN=W:DX^HO-JH0
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M;YR^"T2>?7XB-8=EHF+WXE'3AGTS7\USIM.K,C^MYYFW?>/'9AU>EE;H[M_
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M6,&&HV]#-H[#"Q;IH4U@Z@@%? /_WT54+II$>O8I\ZC=/?&Y]D#PQ -X@(8
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MLO%/EPM,DSD(RD@1Y$$F\"+B._/+==9EN*TI(EU)@8QK6F0LH[Y2:8/0TPG
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MOI_VP_T'[G.?>\^96PY2?7Q?1=&1.1\NOY[QIGKN-YIFG#H?V0.,^[ZG0>/
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M-0]V$4?+;O'SJ?F61LD;'![^69#N*9E[,Q"U1ALQ<"B:?",ABJVE0.&0GZ>
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M^B9#M.6%:E%YI'.'BQW?6<\!<'LFQ9O4646F'\E;K0HDQ$V+FK=4<]8FH$'
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MWAN8$-0?1MZ<.P5P0/X5-AMC4D7Y<4UA,@5V9P#32VM?I/<U?%Y@K$0!D*>
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MG3W[_=KK[/U^KUGG;OYN#4"NJJ2B!,!Z  !@W7\ =XL !0#V@P=_'_<-Y_[
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M8/CT1Q#A_]I@,C>Y<MR+?H_1PNMD#$L)L4"-%.\O=X!AE<HZ=HS)US=X_&O
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M;/\8RCA&@O]"^WM6YH_#BQU_X1*,/'(K2K388<$D@DF]]\#E#B!!M0E^? >
M:H:V$\%K[3 *3N4CH)^?%I5<7/<:L;XGR[PHEMI/FJ<_/!T+#B0]U<D X^R0
MUYOT=4F ,[#-9&_' ZN/0JZ5_""3?AS60N-\(.&B09<2$[M95*@*%]O 9P'
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M7.S#>K_T^QG ?]W,8OP?PME4]%K702+%C)AU"@9CK:R9.3/BI=M.Z_JAL$W
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M$?&1AA.A\;_I'_;< >QVVW$4[[>A*<:YN4W1I8GJE2 Y+;1,KG>2X31&V*G
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MFXQN<#UPH:A7,A$=:("$1W<N?'BQ:E1+?=)^!?V]E.<R]"?F*N0Y4#'N[QI
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MF4'JQ>CM];K0M7C2UY"W4X=F0\D^U*F2/'IJA7> "NKF^<!ZD,=&=G5VWQV
MZ';X'$@#];/;MDN/]EYX2?]2[NV%*OTRK;!^G 2C/[P?],=D]2!DW0EGN1<!
MBY+C1)DF."#&J/>\2,Y]]^?7$X<FV!<9G^A_$J%2D46V)1^8<TN_M8G]ZFZH
MK+YX!^!PF^K6<=\=?OQLM^J/$R:^%,, 5Y?IN*6?<N?G 5;O7OD1X7"OVA[Y
MJTBQ7[#/?;V=O^6I1;9WW&@>)N+4M3?75B?)KMOIYIOU4H2OFPRBUY'(P%\H
M^#&&KOL.T OI6ZVM[W?"\G-%!Z\YA3D[9)G&.B'8H0[::X:71D(2PYEE12ZX
M3:2G54L@%&W#D$I-Z^Y'?OV_Q*R-R LXW&L#(LYA\_$=%^W(4'LP^=E.U/ZM
M<(/O# 0H)A'+!G(X;*BT/*R?;/MF_.E9K\]L,JH:'I9J35)0']LBZ@3%<:#4
MXBS!QX\2HO1;#GI0'MAU@X;> 12VP\%(.[([ )7QL_1C*D/=K%0,C>*)L@!K
M=8]N,F3N9*=MO>U' Q!MUD[2ON.'W+XE>7('0)1H]H^%==_:C)$&KDT";WD:
MX]Q:_XW7ZBV)^;U7,1 HQP"\S 9)W0%"7@6B?P*.BROP,7[H#^"M?^T*# _
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MK]&EA9Y)5W!4XX_-8-CCN0P>H:5-$X.###>)@_JV,%SQ?.6C)ZF'GT,F'.\
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MI7O-\@HU00F6ZWM]<P^K"-G\+RNK._3M)G[Z&@<_HT'2K+]Z2=O=Q5)3QP!
MC'+W'>#AF9G-\^EZMX= \_14BCX?(FGJ%&WF2;*,-RWX''D!NVOK77W%XY"'
M\$]W '=@R"U[.\NZ>G0[/AH?295;!O]:#R4QW4F7:?5-*H+U;*ZN%@Y' F,P
M#PUXGW!0#'G8QB,Z<Q8DM4+(G6@"?!:_@:H*Q30W7DUUSBP0%9$/N7L]9Q;[
M@67$R+]#1&"2?6SA6D$4:UH9ZG8IO5,N,@P1MGR@YA-<-0,T>UL0#]RM=\5/
MNW%6\@@?_.IV$([W>7G)R7B",3: ZNU7]DZC3E3?SOWT=)+WG$>AUL)/\VCW
MOM_N_(DKKH[[W:'E3^1*T.WY43[T:;6MS3^WH\R!$(9JD\9$ :..#NH,,?.@
MS]9+-P78MCR>),%A)4\ ;O9'G'Q"V$+$+2'&S;1VVD<;OX?>M13RO+&^I;H^
MT2Q&EL&P2E?!1!%ULG[O]]:B?,UE^EHJ('SEX-#Q/X>QM[V3:SHM'U9_-?&$
M73ZYK^(D0@XF-$8?+GP2>3]=GV"@WU2?88$6+B"Q;VHPDU&E:F%-_[J.Q,,;
M1XX_?+OG]':-K($8]X DF-,2HM,P+\0C73'#).HOM/VXYK;(0C YUYW$I"R?
MM,0.(X7:XLU41XE$3#VE%H2I5@-(MC>@4JT8'I0;DB4:*U*!"5CK72"$*[[2
M*CNL#V30M&UVB$"0ZS8$[ZPT!_Z ?D GC*?9KQ\Z!WG@[M0L_K[X89@SB<<U
MB,^S.?&@4PUE$KV!SH'&MNNAZK1G0.VJ@26+N]1*#-.9\DX'W@-?_[9D5Q.X
MB@XYWP'P1QXK3.)/F^OVL41D'NC_*L4H]YK4]$DLO4(Y&8]3&,IZ<_(0E8;*
MTZ],*=&#5?ID]H,*,2;_3$,-J2RRF.1H[0!G.&DO>J",-W&"T/H0/$R;5BMJ
M;B(2=( U*8L+#,R*^/;-_/W8"=\SMEI"EG9-CF?0[_^EBL A5;'V0H\BLO,>
M8UFH"QW>^H"LKZ[6M&8J7N>:CWE)',;+KQ_J_>*9-"D4'9;JQYIB+$JQ9JCX
M3.8"+R^[?4D3WXSY\,>5KNQOIT:^(?G5568I^.W]:$9;9B*]T\"!/F ;&Y5?
MPDI*X*->F%\"?%X2A&\S7R\D:V/1!Z_\9[3C(@)L'YTD]LI.C)5,70=<V;5X
M[Y>J2M':/@VS?Q44/:BB4M!K.QGQPUK;WOJJO&8<]AS-/1-42?@'7Q8R&[NJ
M]H-E9ETAVC]W[P"+OW[N&K_9/7+];I3QNS]DG[%66(M935W%_);^)MU[<!;[
MXB=XVTA)=E8J*S!0LWU4LC9J)&)TZ/B?8(?E_G0>6,N[PU3M@\ &^_177[YW
M"DF]LM@-Y#X$G;7.7SE7_K:XG:5OBKF5W%LEF42BCGL<@CR*5*@+(>B5"0]&
M^?;--VVO X>M\O^R4LCI8[00#H.58#!L^0^8^QE64="XY-3*DE M#^<O^=>J
M$#\ZNN[U;%^I#MMK;B=ZW7ZM(,]1TY8&U"E]?S";+NF0:Y;Q#?MQ6O_0]F(3
M7JG7:JNB\KK33"<Q.*F[!I@:<]87?$'?'>U?\+?(SW<I-U]I:L*9@WX"&73^
M9*[V#^</546.U@#YO8O#F8D@4K*.FRIL2#Y&IN\JO;(([#I^8EH_*Q7G_]>U
M.'(>* ]JXXBO_I7IDOXF) J?<6%VC13[CB8)\AA^!Z"PX.A[!+5]>*QV\T;C
M4V->B8=U"-K@/$29#"N6OV,<S)'QHGH&E)#:GRZZ7%']-=Q?C_5F^9/ZR)ZG
MQ&J'1&\P;2TJ).(T!U]'+;'O=4/L^(KI1GC"RRI=KT_F^@D:HZM^YHS@O6;^
M>G84:C-GY3"HZO"DH5%6F1&B,5^)M96)/,4M@?VR+4W0?3/K\^$=D5@=E2J.
M/^=Z2L"3+:F)A$[V>M1%E-N[N-<--)'>G;/8H;;:3TA9H]_/D[NJ='7.EC +
M<$@PYWQDR[L*[?R]WME%;04/SIJ)1UHN*3*TLL]8SZO4^[J()!_.5%9"6)!E
MH"/OP>SE9?,QJMX1>]"T?_7-U##R4RQ:0(5E0DGMX'P.Y ,48E[H[%*LO-QT
M?E:T9^B]M'GD\[VU5DLGHP/6I?ZSR>%^T!CVF-E05"5E>-(2^QG44$YI=VL!
M=<$P^9==%YJXN6MZUOX^Z-(!<\7T&N)C)UTO^Q]F?SI+7<?G/W_[)$QP_7MJ
M_0'-=5^Q&]@$WA1FCT(ZK3+.'@HW!!+8-R59?)H&ECND?6TC+GWB.?8)5EMY
M2_8'XSKT&K5YD?AG=<"/Z3R9L>8%PY"X@R!E15L3X_9)J;'L-BVO&\AJ#FK?
M"5MK<LWP-?JQ-7/NKEG&>SWOO-!D9'<QOZ]-E=GF)!(L!NZ'*%2CK2K34ZF^
M-J5HPK9\N??T^/Z)?,HB*OQ(+< !SX#U)E_*&!,%*K2"+2[")LJJTL[Q?:\]
MQ:)EL^-!B\V'%8%Y>&!CW8.!&27^)7.EA.V5:N.F+_Y_-XN;[7F>O)!EA!06
M>R<[KE+.8K5(XT04 H$_S7;KAI13.5'^>I:7@529+\9).=ED?W&WM$@0#DX[
M+[<UUY\NU&&5%26N2GPWF;@89*W/ZV96#R]\UBQV%\#[2.ZP=28_S1DI^=G8
MK6.K% $-FN'X0M&TKL41Y!ZPJSY'N/)]IC0I8RR=J3?K,;'7%33L5)=ZV4DN
MXK>3][E!T,]5(]9(>3HU\&4&$7C7BM.1(\'0&_=!9V1*Y82,7I5U^D$0$U6T
M$7^@<8O;WR6?DJ;+Q']_ZNW_9UR6CL?%!\J"SNA7]+1AV+NB3@@I<?0-X KW
M@T66_1202]@X?(-#2TLGJ!V +05X9)YTT4+X[@#A8?TA2S#7&A_XC;&%!]!#
MJ-Z)?8+LV9N=]= 7.\ P.IWV7:CMFH6\=,-^:8:AOW^XP'B*:?!5T0&L2=UG
M?L+GNZR0'Y(GIN#>&J#O4U\W-K52EA14+*IS%P"?_G#_@0?YN.(9X U]B8I*
M%/8YPC6U[AA/\ZA8L6A[F;[ VB<9QN:;.OZ8,=[.NX)!]^-G1SG?[$S\:!\0
M\]6P;NN>M*;2U%;CKLR@VKA%\J>A%^:M)CU!A&JHS:H\($'0RT4NZJMV=/ER
M'V=XG4;'I^5^9+'_%[:D^.6?SA7U719"74SS-^9+PWTSO^%&K:U5A@WI&;5+
M0<$\/U=A]:?K(L'"F(F^QER>R"MM'KT\+2T.KL-,Y50GP>F(% J)ZT%5^8^,
M>:^ZWJ$E!F#;'S?F0=!Z($.@?/GPWP:+61_C6)$S.Y7L\F?K9<]8$FRFNAQ2
M2\'!5O1N3_?\TH-=_(P7([FD+_AXOG*/BQ]H;/MZZ<XK.\S/5K#&W5+DO%SU
MF>6<<W4@&^S=VD1'V7&X/B5YI'BUP%_XM3C(-\!+8/7F7O*0M%8F<JE+Z[FM
M M-V?T,#+[I*?^XUREKIGB>@I3/.+7+4IOO4CT$559PSPN38?;C\.QCW3L$C
M4N5$@5TG:&%M=<J>'[D*XP=U7]DG^79Y(^U]AA@!GNB-FB1CM'1YF=E@LM!<
M?1F95B'#$?ZG+[\&7V8SFN2#L_JJP:5]%S#5Q320VWM'KF,;6Q?%YXH= M.]
M!H/ZY[F+)Z#1$/7%+I'CO1O+SG2EC :?S;'OFQU-"X$VO[Q/][ 9Y^Z8>27>
M,<0/X0=%YTV'BO5O<6[CMS>O/JOSK';,2WRA@[)A;*YE=UB>G(UV6&BGGUN4
MO8[.M>OB?ZG!+JX<AQ>$G)#:_YS"_F;E^5;#*$=<)+W88%>0C5OW[@A'0FEX
MO 1AH&I0SE5XC>!/%<"+]5!QOO6W.!K3_$@>N@)+L?6M#@/8TU.I36MBS.@[
M1$A<IQ J'D=FUV/0-@TL(1?_6F+-B5]9[HQOJBA25?UXN>P)9GPFD1ARAKH#
MG)NTH$3ZDS"O,OIG5C09(Y^7 )B18"7G8:_E['B3Y(1<82G'"DDW9K? 7R'F
MV"12T;+$"!>Y7I5,QM7;<GA3UN7NTN\K9HDO>#/67'Y$AA2/<#@R33^9SC(W
M%SL8,F:;5 7:B?VQZ+U&AO*N70]_9!DO46"[>E,KP(@[1B(>+Y;+R[R=#%Y
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MMLYIG+1<%G03&Z9]HZOP69G>I?/9Y#LT8P#NWCE?9>M?*\6JISIJ$KT.BH^
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MMUDL2_'>+?M4P^@/A3%=#<K*[*7HX_X1:ATYQ@C<S$T%^6ME,$MOZWA9V6Z
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M]A4?7MH?0%T;6W8RA>/L\Q>''$H7>VP=:-F$#B?9A77 N,7^#OU=B]>WE'>
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MY1:HLO4F #?CS)<9S)Q&WX/R=/KDYBCW_Q)]":'.V8@][D *&3:/XTGL N_
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MVP1WH)O8?X$F(,62M=CT6@(=.!U"?RESY*3W(G;745,LSDO<>/'Y)"P,]<#
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M65?A,U_[+8O9/3[,SJI?Z&,-R,OJRG3T_:%A6U3>LFWJZA-E\&R$ _]=$K)
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M&I8I(/).Q9;+ZCYPYP]MTR>["5%M+3;-:L2-Q"&R/'1_<X%X ;1[!-.C:+E
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M]OK05?"I[&-3-#$G.AQ6-:RVZ;*Q',96YVU-$_QT.^L>YJ0]9X]\:DA.\IG
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M[ )/)L?_[RO!_!\:V_7<_P-02P,$%     @ -3QV6%P9-']5)   R"D  !@
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M(@Y$<1:@9*, L5&04( PV4]JBM\+^,>BH"3[>(J&EHZ>@;RA@16@I "!**E
MO[PF7PTE7P>HV*C91>1U3G&8WZ,YZ\.I\#3U%:WHE9HNKIO#6#%%)]\(.GIN
M'EZ^T^?$)23/2RDIJZA>NJRF>U5/W\#0Z-JMVQ9W+*VL;9SONSQP=7/W\/-_
M'! (#7H2&14=$_LL+CXM/2,S*_N/G-S71<5O2DK+RM_6UM4W-#8UM[1V(U$]
MO7T?^C^.C(Z-3TQ.3<^@,<M?OWU?^;&ZAMO9W?NY?X _//J%BP( 4?QS_9>X
MV,BX**FH0%0TOW!14 ;^VL!&12TB?XI=QYSFG@_'686GM)Q74E_5=-&)*M[$
M<CGY#M-SBRFAS^%^0?N-[%\#%O%O(?L/8/\3UPS "*(@)P_$!F@!)]HXEK@]
M&.UJ59EG:T-RPMU*UGD/U?-4.BDZ'1_X-'.J;8D\*TCA(\D%=A+0]0U. @0J
M36=.*>5JQ1J=C=7'9>72O_L@>I"YZCC5"B/@9V&+;T@ /?!5"QT6(D\"7B>A
MY0A"-B0 ]_'OEG424.-/ @YQC20 84SDA#FMDH#=92\2$)9-D 0])P'1A]@^
M8KQJ% (;Y$D"^B3_9I&&$WM&2<!*[RSQ1 YO(6.'#T;NFP2]%50UJ;_).>?
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MJ,2NDADK\ N*:>$A:"%SY/^#2(9>F;TZ<J&DO3.Y^^,(UZ),SWO#Y:10ZV1
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M4S^[CKX8,"S0QQ-\M!U9DC^>,-LO$>/-]UKL;J;X\3<Q]DN;=V!_%S'I:.(
M/IL$Z&I%:V%?MI" KT=:_\4N$%(E7[(QRP\C:&DXYGPF2+K$/6V&"[SB$QP7
M&/"#9MEV#S#7XP3,[>1'B.?N+Z,6./L0L;]N3C^6PSB>,!(YR17KNT("TG^
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MR;*[;B- \FMVS'VT.[R#D@;MW8^K.U=MGK^VNR_C]=?A<X6\?<9GY* 7I44
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M5D/VQ"#PH^.*EM0=G-XQ@\?BZ 0B?FK8A8_1:,CRI+EYQ -.CPE!HS;HA%N
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MJ=5A(:J%L^_LTG\\$5MJ%#ZC<+C/V=]:,9FX7?BK*13TQ^O99P<I#H>JTUL
M][?I\U5YX]2BAJZ(K1D/0=KH^S[CMA R-"]'%_Y:P8-\7,^&ATO[AJ=*L%.
MN#HPUY_^(.+2/.7&(\OS_GE+YZAR)-<M0&Y_>&..I:&$^&%6CIR8F?&SJC+F
MNY]2NQ N]%>4J27R5X6;BY/#!5O9E^TMX['3WU0OH0?6O\+A'7EV+^J[W#D0
M]OF\GRJCEM/D(LP^[.7$?R&9*1]NK'%QK^0*D&O<&ZYJ*MGV^6PB-5<7)%PJ
MMCL?U4^C%!#SY!80VND-VQFDI'%5DHQ>.K'L./ $_VS6$P_#G?"(87<M=S@7
MH]LQ$ Z.O[X%V,89O3>L(1Z7.OJ;_U?5 =2O^@Y\4-@>B6VW5#XCJ.]41XD^
M0ZY^:LTY0(A8.K>TW/\!VN!)#)4:)5-T3=/_:/EN.XDEW54LP3W/F#X5YDEG
MAN[1L'[6]V70K$@P4?SQ/F4/]VE-T(_W&;)/M,V+9-7TTA,S<NY"3,&G_ZU4
MP)U0=K:-]L;8HSDW4_"6QMF;MEM*=%W<A09CY]X6#YN%O;2&>8<%3!!T@OO$
M@(;H))3;"]1Q$I8-$OD-:1LCBA!^1VL4O>]NJ-?^F!E8 Q9XP3"#+Z+R4&7W
MP]DJ'<ZI;A(G'!2!Y>M#"?8KDT_$IP]B&9NGFQ0)M U8+6M$+AC3S/P[V%,X
MKYX/;VGTO4I,Q)T#,M^ N9%EO1.X 5J#EUF(JCV&Y,LTYZ#QK41M7_GL,D ?
MCZ,JC3R^T!-VP"C$]5N8PM*=T?==7/HSZBO'O6UO77J8IV!919CEW'_DV62_
M09MX-FYV"XABAH'_8E"V6 :YGEL KVG!Y%,.1E013"D%!OFH)#G;.&XXE)F3
ME)SB[^TIAQXP>2A+\]#A-?DH&Q6EU.(MH#\1.8'!!D!N :3LMG?QKHIQTW9X
MU0ZV5E<4X-FOA->%3H"OFC!#:#6;NZ-_/'%_*\"3J5'R(]GZ62WQVP]#ONLD
MH=SF0',TJ#B@MG\.WL]Z]O["-(RXIC19+=[9%B]IE$N.C4:\4X_ %L,_078+
MF-B)OP4@ZV9O 7\%4M#Z^<RW / $_2T 9E=U"S@Q#B*GP]E91Q8I2-P"E/,%
M[_B#FMX"_E0JP]0"G+ @A;N3J.0[9D>-=Z7^7"HWZB0J*3FODQR>'2QW/;N8
M.X%O&O+;-;6X^<;E\+Y5#D)G$Y.\+\SBXZ/#^8&=X"1MA# ! 6@GB!M+2X)G
M4XCA (O#^=8TNL>$7/)D2>U$]MX?@):8 D 6HO(O@C51'Z)<HM5 NZ (>[O)
MM*4WS68[M2H&WO M)B\T+A2;+DJ.1^#8,1/E,BS]H:*;K]8C!(/^LW#+_\_J
M"KD%D$@,*)_^A?=@A'Q!6,U:=1BHKTO>X"[MMX\?)VHO'01UBOW%"L].=O_*
M2>JWW @I!G9K0B-77O_9D?KG=2>"#\X9P\$W6R.I'&6QGMA(26D!#8:S>ZV=
ML)H=?K,7I\;SPLSKU"7]K @3)_#^Q \TOJD^PM#7JCC ;&,NL7)-+;\?H-3J
M BE*\&._3Y>(T*B:!V:/Q#^O^Y!($5A J?8O?.O_"\L] T$W9?$8^9(#/_PE
MJ'Y3_!$N%\*.+9[92YZ->LCEORJ.>494)#PS&^D)PU;!\W0>U4[]>OC8;)EL
MW%]ZRH0)>OF5<!='$1_P/N=.0'*Z"7+GGUNZQ; #"2^F2UL(A]I;$Q#DBKM?
MR2_R+5U54O,)U@@"#WK^Q7;Z7)4;YV,]L9P8F5D,([+#$%46BW$J5(%3%_65
MJ[IYEBTKZ(W +4>-'FXX&1N39@VP\=/OV1*&\IL#[=&!I0&U/_I/-2V+A"3V
MKB*B\J?@CRP>%0)IB,VY?4<V-B5QOGHC<?M-8VG@GK0ZD7GU 1TF;ZY6#2Q#
M)[#4]<^:3] Y^(HO;$1F/X=F&>^>&7O+6UQ1',TI7&/IG*)!.Z=#(+397?>/
MR;!RBL/2[EXHTP!IRU0J ^KE!?_TR#Q.87)=2+=_::B\)[N1/M7>D[+.*-)-
M%D"CZ*;SFS!>*KCFV;)VW12KGA;U!R%(LM-[D\?E[*-OPJC^A(_ W$$NZU0+
M0)[((25NM LO.,Y7V]HGA1+M]'P>X>M=)?^M_F6+_EO^:24/^.)2'</.?:/8
M,]%_=5+.?_7/+!AA"D9C<Y7B0I<A@%(?'5QK;A62[RY]LB_86HQO_/&3E>K)
M#[ T<>^#C'!VXN.[^/PO6C'Z%_NH^NV6C4Z"!*0,V%!USR@\@H'0KYH6FF_
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M$QUO_W>&N94:OW004?2;(.8F<LM>,$TH>\"O=>/.E(&D "S'O.2 ?$A&48>
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MX\'/NK7*GQ'2:V_D%U[&,[+JD(?LV5!>2X7.R7$BN.$]\2S2&:YS WU+\Q=
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M0*\*!S%=$9MLL'E4 G"09;-V1I6"9QEGN$U\7&/71*>K]1\X<P<]8'D;2IX
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M&])3%VME@T\[,1RK5BB-O?PPVG2"42S16GIJQN!Q'5GJG=IY4KT%N1Z%J:R
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MSTU$=W*>\MGG 21F?U&.0H@S_PM02P,$%     @ -3QV6!?[\$N&3P  EE4
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M!.!?Z\Y*G=0_]_O8SE_'SA-/^@;Z9UW]JWC[&["C?QT[N DL#/__PD;_(LF
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M]U0&O?C)]UH7VD_C;O]YMNQX.%"#U:F JOSVEKB"TT$W1'B_"[XIFMF=47]
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M2RKR,LDO,Q\^4:ZHD<P!9^MQ5LE>J.?'BKP]N?]O;?Y_)EIR _3O^276(P)
M;LJZ%CK],-5L4N#U?*\L7)!B.H?J;G+,41RHIY<N!.SL3HM319/%E3B?Z36[
MNU9>5+\>,CP8M:MOAAC;WE9KJ5<Q5&.B[/HXP@2.QI%_ZD/G05/UKE/ING>-
M.;$T&)"*V?.[C5OHUB8WPOWN?/"].<>OLXP(D>6FFE2B\V(NDIE084#A,KF*
M6I*%:<=888/I?-D[/+WD($4CC2F30P(PAUP.7!%;:$'JX.7.6ZFL>; #@B&K
M9K6>RQ+L+A"&3W GYS-S;9=3X+?EMZO$=X6X$EZ!:Y&]"?HKNB,1E:XRBB Z
MLZW*UVXR 4.RKKKY3K:'UV7J(M+F@FAMWGST^QWA8TX =LY1<STJ?%DVDSB&
M_"V%B>$OVH&>3@B1.\&,Z<< W;=\;!+J,N/V6 N/MABL+-$3@$ZI5>4[4^L=
M;H*?+68$ZC]\3&87?,'3H,Y!1BT92G%CM<!"G !,;U\HQQJO!R(1V[@&^24:
MF/U4U4X0_3;[4%%V=E*"6$3=4&M-#&G=8;MC=$'HJWB^9(]7JO9_PG*=ME3J
M5IES205^5*DP0?7U+&)P,BLB,=YQE7J_WRJ=$/&;CE,EFNM$O0F^4OJ(-K^U
MQ4-$VVRA:G\/CSBHSFSZ$IBQ=&&*6[HH@LE([/P\U]S"WYR@_XCU0E_7>N&J
M0_YMO.ZI580 ?NM;WFV[)?!")73!/H%?@XXCOKSLV^=C$@_UP-^K2Q1.;4JH
M74S8JICXM-DHHD#2<F:QFS_62#DV=T0YZ>&IX3G^:M9R,\> 12<W&$T 0HY^
M2A& ZPD2)MJNO'_P9A6CS1(71RZ42E*K)MT)BBOUD>)5#58N)J(WQFM+B0+B
M-N?"$Z4Y/Z3($\>>+6'XL4*?8(Q8 7?RZ-$G/;,7OV;WOL2")RWU5 ]JEIY'
M/-EO>H]2PW!AG5%@&WWZ.;4R;$U/_^T<7K3N2FMS7!6L)3CYN-=(M<__C/(_
MIC8L'68!9;_4L11_YMOK)":8VW'6FN+4)IA"(O[RO87LR2-RQ5<^U;LAVS9!
M1E;Z.C53M>=9-/>G..9$WLW>K-SCH^.,UJ#\DD/!5YU'-Y*M@I\SJ@[%?%L5
M:9:?4#*Y=A?ZZ\F/2$[V?G1?HK1[5!#WURGOP>Z:VFC8QZ01$9\'UA7=* #A
M-DT EC/A=!8FZ><=04+HI"[3]>=CSHL<D\ 7_F,1ZM(5^#(_G<N&"A.\ QS$
MAI-'RS3$U)G5(:.#!.I=,6=)<?M!TQB'_AL]UXP2M/K(G2^%H49BA2Y]T,J]
MLXT:S9*$,WD^ZQZCY W-C)JQ9TV9&F!QK77?F--^KMP'FYZL_7L@<'+NCF.:
M5+F#8WD#]9%)[<GA;HZS&*-'_BY$?7B'KRK*V()L/!0F/A19:>A.D%NUCL+,
MW9DZ04G&/1X7XA 7+>%4>L7SZ]D?\E;O5]_>=!_T;W-J44DU=I8>"]4%TJ#+
M,1Q89W1YM\2J6?X$CF_UCQ5BE8[*FD.D#+R=!Q3F&AMZ+GZE >.OOE^.&\06
MH:.2E +66E5$X=TEQI,IBMK@[?PN=F;<!O$ TL&&<N1<'3_J;Q*WLWH'IX2B
MTN97B)/8JZ/1C9RDOZYBRRH_?W=DPF3C]PNL16<F.%2:2HSNWKC8ZT#>;Y),
MK6D?[M_--Y@1)@""=:4 XBW<+3<DZ 8Z,7=E/QI/6LV>%-_"?:#U^O=*'940
MJ"TDT(+XEF)RXO&Q-R/1:<*R1)P*&S;.$:DS89=X!D[_H]-LR[10GM22\F#F
MF2J)(^MJ1A^2"2>#VNH;FI1AS3G03U_2K;<5FQS,;8IA_Y6B7R^RZQZ;^X6N
M8RE!(7FBQ6:92^3))*MM'<5D997-Q>9S>X?+,&'01B$P*EAYE,53*_U.;J*Q
MHP4C#9;':=;K*^"%%&,'&^Q51J)UT&=$^P*\<VJ1!YNU%B<X#K-:W8VCS1!:
M&G_)\.ZCNZ8;6Y2;<D^@O3HC8!(&L\7ZY-(+Z<BO-]8FCC]MF#!:"5?!Q'1%
MR*^1LPJVKJ<T%)C\5)S]D_;N65 K:X]^^O"Y35%2C@H/3@G.[2Q;O^GE7;!D
MNM 'MPMT=^._K1=UZ^'MV>V9LBW%Z9QM4(W,<*-M &:)?A!>MN4K^.=)AL&/
MRKV*O>&A:-)R-'?'"9O%C5\?IG_>+6#Z@=9>1./TF=E(R@H++-SW$(<JNJC<
MG=T2J/7>TTPS[UWVP%M+CQK'ZK)5%-^M'^@POJDAOEB574Y\MZG?@J67R:GS
M]5QQ=3OL:++.>],'+W8V?^U2Q3<\3K7L1Q*J.DNK^0RRA3.(=6>!UV"C,"3[
M<'<"D((X/)@_Y2( CAPFJ.+DCS0V1K%B"JN8%7';</X*-[5?CO4+?TB\^V0&
M-Y>J%^KRZ<4;11UWWOS<&7_-$7#W6\\MK:IO[\5XA.6D&#ZDAMAX/(\W."X*
M., +QO%_JD=<\J\ZV9_'5NUC=&K-[)K&CQVB#(;&!CU+G8Q/MD9U;[Z-T-:@
MG\A-ZUNE\19:YBI5F+%2,R!^.LHSREGWA8%=0_M0 R"-48HGVK0Q6HU_7*TM
M\@K/Z\>E[;)- 'Z5-P6>%QR>6V)YUD2R@\!4FTU!#9 5C2FQ.K9?J3L(VUL:
MUY1R'!YL#35<:-V7&MXQ*< 28SRC5@A C.M^I0RQ8);#H7+16W^!%BEB'B$&
MJUNG*1'S'BK6/X68CJ>$>ZB87/V\C_'-3$HI7DE"=5\( !V.:R0=YHBZ V*%
M*!1_\N92TT<VZ3QQ%V7>6K)/7QC4O$&M DO]ED-1409WE)VDLH:PXS^6;GMM
M>6R9F&P_?U,1R?]"*YWG330Q]Z\_K8&^L9*:4QF7NH+P?#!*@^/2_'U5I&HO
M,HI'C]Y+5_+U^!?G%B^9:=I]ZKG(9DSR8V>^40 Z%E5CXB=CW<V,ZL[]0AN!
M6(",]96ZS+YR\33O8_30H*@Y\$R/SWFU<L_E7(?Q>5*E$ 9^?4K;2/'3&0&(
M\/,[!8EC$<MTD3"=E;DA%2[F)2UD#L4R^U!.-FNSC03'U5>-'K*)5SL0\FBA
M'?3:726=0HB";\Q^G9C;MD5#*W(2]"A2>)<OEOF>,?7*VS]I RK')QK"/70L
MOD$V?>NW_#@WRV]-F^]S[%7.GYZL-'1A4-PYF-[5[2>MS2V0N<'-Y8/OX_(<
M6<]1!<%7$H.]98ZN7XP>%3#61;@L3LV:]Y5DV"\]]G*##5L;7U:@QJ07POFQ
M@'#^FP^/KXP^7K#JLG,5&^HN(VT1?I%BQGJ+-R2E.P< O&7^< M=% 6Q014-
M$[N,T8G9$%^!#^:AO50#^*0;@O+:ZC?X2/D9ILE"9HYF1=+JL"4K5#\%395T
MBOIYQM:F?B6[90Q:L(A>_]7F<^IHA_O9]PV2.09W1D2R+^04>4/6N,#]X\LZ
MY9&Y,,5GCA0UP%91OFB[7US:+R^]88S@MM?X1D6V28^Y7DR9LT(@YB-IW5ZE
M5(>=.Q_LA+:Z-OZ:;R>?)(9)**I%O01:KM4P*9U5V#J^)^=G0A]6AZDVU-!\
M5/:GE2?SJ1&7OL7G4?5J9$OHR*Y442TW+$3II\5>_I]R;@]R&;HH)8,B:+.6
MKHDF,LQ@//MW@MLSUWYS.:=YQXL,C2=[-("+@;7OROXLP\IT;(N>$K@06Z/?
M.LE6J%6@\2R#AAO6$WG_RD,3<AZVZ(Z1AZ/C>$FLD!$6[KT6I\^P68-]."GH
M=QS^(3!'DEZ$QV&W-I2&2YSKI<]K$^65W&AN+G3\R>.-IIZJ K$*V1,&?KJ4
MY.&<%^*:)U9^Y&UT15:HI9@C!,NFG<$HXN-$Q:,O[>)B<Z]8$F;E@).N\ILG
M9%FZBK</982+FRM<S-[="DG1;F=:49&X:%:Y F4QS=*9Q L[>2[=QULFF_>?
M6'",QC]LIU_*N4FTSVA"A^I;\PUNDYK1\5M.8MY4$8R4."XOF2\?8"G&X@_P
M-TP\_].9@N%U8&#YTE.L!=#$F$DL"(4TS=)&"W5G7Q\T#-]-'V-C7]<:*:!(
MJ\^U&_*&4X&=)*) '+QI.+HU9;[N!(KO;\SFZ10DMT9E.>E>"1/_*/V'[UU2
M%<LJO \,P%B^Q&[WXL7'6F0XD5OI9\NB*?!&UD&Y91J/(-J+1CPQ],0X[M%H
MF]#&JZ6'<WR16YIUXH&,WSY=Q3D1+Y06%U1$LVG9V[[1O']SXK]_."S:#<CS
M_[@R:B,/[</L80,^8C]M=W&SCK?HH-6Z99-^+YA!0=JNJJY9.?P9(JQ*G,%]
M7%M5,><P+ 4T=$X=71^V>AG2+--Z?/5PCHTA>U<I[F"]B@VZ\^['Y&-'3SWT
MN;Y+#E''B1H*OWY]H_PF&PG]!'O*OWX__W]%I]N8+]/BHL4HZTQ;I*[LV?K:
MKESH&69:7\.TMW^/)H5M8:9:,N^%8?\K;4JZ'[7A#FE5TCNPJ\LVY-"&U9-(
M@3IT_*+LUW.6KN8DWF\ZK??;=8.:(G!: H^_C0W^YA>IOW\9T V.,LWG*EB^
MWDQDC Y6J$<**Z7%38KZ75NS-4O2L.]YBZHNF6F/_WX2AQNIWHZ;-0" &JKO
ML9:[*FXB"8 K 1@( A8(  )%  [ ,:B^)#S)E@K3!$Q]18)Z4Z$86;2!OXHZ
M"X?ZJI1QM=7(#$T P?2%*9=C:+,EW0=Q@+>US88=RX>)F8J*DMZG6H)@O#9.
MIIJBHL5K!UY.:T>^?@H)'.^M>)$1W_L!D9'>2Q:XQD@4JWNHF6X-3[C<%ON*
MMQ$D[3N.:C@%<6+-3WK](V.JH%&6XS(2NTM1>!"<W#G2PH0FL%QK5=Z=E\1^
M-%GL]EK2HLX(V=>1^'%H6/O9[E3(2NWT#@)WT[5@;M-!)/NAMCA?O/KZD"/$
M+72^6_7-P\/:\+1G3X&\B\-8BOTA\ZQUPR"DLLWZTI+M3_/!L[DC+:Q%-YPV
M]W'=>(OCJIF2E9^W*]K:WB?K\<0CV<Q7UM_?U/ILS!G>H'Q^+YMC_]FT+:JA
M!Y/9T$[CM>)=U%M4#,4?03#I4R?L1K]XY8L:FYWFAB4IVGG2PMSZ^)B.^J)P
MWD70M#H[9Q$J5X73HU/QHDY-_GZB-QK:IZ$I3W/W16@G:]P#(=Y.&1[S/3+E
M5;_?\U/'*ZL1AXK(.=+JY:*N7T@<2KP_/!3;/Y4E !:PI \P&K1.Y]E21! W
M5'"P?3:G8%59S-4V5ZMI]'<#-Q>4YZ= UX#H<YD#E-%#R3MN''=H(7^05['D
MW3ZY9'983P) @:EHXT*+Q\(,_&GB0WC3*8HLXHQ)7BC5"&21]&KYW46,FKKE
M?17Z]IZ?+X6^R^X (4T (J-0[>@,#'W]%//<^2.GW+GBGLALS.'8W-"P[XN(
MA0:WM08?Z*=4;\X,,[A-=JL/HYBN^. 9#K'9N,I]HP:MW^5^%:> UH]\'7=>
MZ=C-35N'2OC=(CL\1+IV+\%>:3 ^OX_GO5D6QX,/JVTYV(#E07"4-=D/G(SM
M4%6:(]>G1LY^(X_AP)G?28TR81*]^]2Y'-",3N-7EEO^!""JMGO2?5?TXZ*A
M+/\MXC?446P_ITG\8W>DN?S[NL^8(JN+AQO,O8^;+.>^9W/+/?X&YS.Z*6]U
MY$8 XB[<+WC%'#*,\#I'#4<CWT!8$=!N5I5<O"-69H5&SU7J876,A<W7NM07
M&89-D1:!7<GL9:11:.:.%3]<[WP@9 'N%L<Q!,9\Q98P'7SY/CO_)6$POK?#
MC&[<V1R5^;V@%.N*ENI&7E6R*\$6=&;6]295FO9SBV3Y=B@=5"C<R8G04^6"
MG+%?)".=%-UG'9<=PM:>1HAY7U4SWS*NOIAQ*VA_(W$NQ!-50S2+S)J]R"<
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MA1MC3]<X]BFV\+QQ/>PF4>+268%*Q<EB;PVI,!^N'-@/HZ[VW_M /"V#6"8
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M3&<H1\MFO>MMJ )O"?_^[(H3P,^6:;"/L8XP0=U%XI?"HK'-&$>38/QTJE3
MH$ DS7LD0:_N;9OXC#0]G49,;9>]($AZ%XY.9FOW.'2Y*#:H1Z@\(G5.7)$Y
M!(0M4C[._O=>IBQP<EQU!5I75V$6XW/K*[BAWLZ("YP3?<3U0N0HFT_3+:K6
MQ9?*JW.D9M_Z3(9[GB/\[U'LQ[DJZ#Q/_V[-W% ^8$\VC97\S[I;UO*T:)&F
MWI5]L3$=\=)&>IRW,<E]3('>P;YB)^SD0$KP7W4]'MEKR-Q.EN<H;X'EAY2>
MS+AS+Z9_#7?U7BPV6%D6E&#X<'G]A_&2_[4]>\UE=C-:-/R-8&<Q2Q;=6^C
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M9&+\ZR1$Q%=]2$@I2$DI&*DIJ1G_K]ME.X">G(B5J(*8Z [@&CT1,3W193>
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MMUT,7[GPQXOS:1!%O9M6G]-"%?EM48:*="[\F&!%(I$KYOF1Y-W.L=<!)AP
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M1#O-D[1#1:*>PX_HOW'](5NOEP')!=F9.;1WKWV1=.^0TMW5DT93C(!P\J\
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M*9GQDZ1.<0#F7H'\D\RS;UWZ=:/;GZJK7XDA;1]R/.V6*Q-B!1#-5+S(B5%
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M.2]OG$0M>_9=&&# .XJ,7OCP?AAI*=1U<T5]]$6F--\.T[B0^*_U@ V3[+R
M^&L:YBL;6\U:$CL.=8V12G%!;_OXI$KL_7E)M93I'O92!VD@SL1@"MCU;EU/
M=FA(9Y/&*^2,2ZK+47_A1EW=B(:]@Z>R>]P=PWIG+ZCI\XC,027=#SNH7Y>
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MZ-AXZVU=R/A,@S[.0V1R[G=Y#,KFWAN+1J%R=;GY#(?0C)0;HE>J$K+'?&Z
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M>OMLGWS/1I8V\ASHB\LRQ=;5YVIC\@-?+-Q),IQ,\UBI611Z.=-9^?K.2PJ
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MGI62IIJ5D!XE^7Q=L"#JZT467A$3 F<Y%\>BJZ_)T"^XX'17M99C4Q39]G[
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M;:%P_F?Z_'TP;O-,-"QU!$P,[QJ7 /Y>(/#!EZXDY8K?__;9_]4OCL4=S4L
M21<.U>>92!#&[6;A*/5&*F1=7J2("G]JD*#3,B3GUU<4,N"J[=N\8N2>.T@F
M&4[NWE1+?"PNK$_L8BJ@/H!#DB@,QEG,'0D9+[BBHT7S7^.CCJXB._P>?(3V
M$L".0JARA$TW.;T.$]<M ^'),#:M)1;:*OW8+@'+=AUM*F.2E77.9_Z,A%(#
MANQU\/3^%D1^:-7OX*?8P5:3"HR99Z304J18;&*B]=CTW*"D[3EP2K0'^ 7>
MK0+OOK\7OPW3=B_9<.P1VWG^@8U]4'-.-]N.7!,ENPZN]Y^,VVESN03< +G8
M2$1HU;34UX,@\)V''CQPF<@@8]Z(Y/"'/\@K\PE<N5#@VO^Z,4O<; 15J.Y*
M5'>H?&_P9'M2W(1E6IXFQ^>I1W%,WS1ZWLK]UF;EBR_EN'6FRO#=2]'QQ=8*
M@49;S+:XW-02./3KP V[*:PP(_B[?H>G O8(&]5.[?AGN;4FLSC1W3V/V7MF
M&CFF=?*TYX4'>WSF^0(.& N\&F4LFC.3-MZ&&V%07?7!Z3-+D_)]OP0!<CMV
MZL+/!;]\[FFC<E>N[F_AO#I#+Z)ZJ-LK]MJK([5V[J,?+6I'Y1<5RQ>%+<)%
M&S,977M,Y[*UH[MZLZXY/)_?3J.?5?;9)_W:>FO 839HZ_4.AR^#NK[/B(K/
MJ64(3,K41NF=YJP9OQ\2Z3/J>Y3MJJ"T/[ <5F )[O:<.5N>+TI:O@1$AMUJ
M0F-#6W0>-\&CEEO5D[-K8L=LTST>*BH[,9W6+BO%G:$H-VZZEMB-_ZI^LYN<
M^MQ"1]C+K'XP1\EL#;%]<A;(_:J-2F:1PN+\#FXR00SYX5<2:*R"36Q7+7OM
MWDAJ_6=!9+#!N<JC/X2$/0R0<(V;(&^%CZ7O,OU(;GI4)E:H8B:+Z$$N-&_^
ML K@7Y$T\9:*C<O.KJ@S"_RR;TV+AG2@):Y A!1-@N\_%UV!L\HE5!8(*UDF
MB._#>-==%AF?M"P=HQ#_/PPZ65_1O!*["&Z8#T$,E[3=@3,] T'MZJ4?^BI3
M5DG7N*D3-U;0\%9@P3O3H<_/-.>@"#!VO,FLHU]"<!]FY'>6MZ;,^25;^%O]
M\2/B(:O)B6!@]^)T/>$&Z=T<UOJ42<Q-9\A%@;N$W]:L0P2P>8$JAE5PO9=(
M)=ALK>6^E0MF8/8"U(D6G% 6EGFLMPS2^. O4"/ZNMZ-*CR?.$#)L35DB7:'
M KMWY#19*V;7#J\6[%&Y?_:TCCF#UEOF6&1DC_9E90%Q&L<A"HE1SK-0<:5+
M\S?+R7;PYP+9$'9WCWY?);?\2RBM_YC7VJ192/'D.O[C\8X$=PS0D3;:$OA:
ME0&O/_L(Z_]+UYNI-CWG6%AY>]:>]'V5<4(K.0J&8]D>PS8O[75MM<7==^H4
MDS?$1^1.70(\-$G;9DC&P")1/ $92G&I(P:C#0I77X/IS]5C!XS'SME*\.+L
M+K%R'S%Z2OX]730^KTN6XI-2,Y&^EP!2[9;Z'"W-=MKHZM<O<MQ,W9BPW@V.
MRDMGD\S FY'EX5U&^1$)PAVJ+H5(W<WLFHD%5%AD=1=&6-VD7&9%+&4>U+BJ
M*G&5!N'GZOCF7+W<S47*6G#D44^Z6BG%+K%N!*&"C2>>ZKC+B;,,3 GO>(SF
M.Q<?=O>CEEX6+\?13'!\V>+R_[%K,*=JQ4"<9-T](;%C?.8X3Q@!T^0-&W0:
MW,(_%!-//SQ4>?&3\"/ZTRY5Q_4%6J,'J*JVI8\SU$<)9Y+.27#B=D\/I^8(
M[P[H^Y?( R5]E7(+KUXSCG3EQV7P6L4S51 J<K*U'HWPKI\4;N(V^06;_0,V
MT 4=GG#M8=>[CVUDL5RO4&"7H0(;5U-#:]WG/"\FMC<IU!J(>[V_<NO\WKAO
M-#G(\?R?_7E0>R(]%K!/[73D-G*8Q&2S^-'7K&Y8EE.?$V*$[1:CG?+T?#']
MQ51 ^D[XBX0/3)U5#[2V$#:\O-Q7W>Z#/GGLPHJO9H 9KXB[N:+9T4JKA7=P
M4-EM]41U!$IUE&@Z=DZIW_-%:S[06#-XQY&C@$$7U4<7T)?;WWM*/E0+O0IM
M-NB>%3X9 Z?! [N9";>B.M'<41;)!9\3?V^RW%3N5 ##YZ+%FNV+.#)8GR>&
M@I>CXJ.Z#:*X6'&:;\42JXM B^^)OL;WWVI\&K*4 KQ1,)<?%G?8MNY(J^FY
ME7]A.-)/XJO1?R>&/I(-_%8S]WH*NS,RSSPWX7F,!A,O^S-:6Q%+D0>)YL<:
M[4Y\<.AD/^)S4CN"XYP-1]8;AV#;(-.)Z+812C4<8[51!R(\;%YPTS>[+T]&
M=JP7AEJ7NLK-J")\0T.4 R;21VJ^#(J2/E-GNZO]&\"TO$BL*@DMQH![4)R6
MKG7)&VBV"(,QU &[&O-LA*>T/MJO.SXR]=O<3?PSE(\+TOJM_+?*(>B4RB5
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MPD+&F':ZQ9,';H;Q[-E*D$"PP\IU,/@_E;5S4O=.;_+9$[\\I:_26E7J0G+
M#2;KMW)HT=5QG4)]4'9=J<9HP3:Q+M$+HS\+!1(?VT]W4A,^DH"5/"1?NS:6
M<LAD7+%2"_V-^\:&QUQ)G;\[S505_8F@3\+Z0:HI^\REEU1'MR5>E":))M^!
M+9Q[](A:5IU.O4\/<@FO3$@.$\-!NT[/1\_L,*X:J.CKP\8-E SUS1MB <<K
MLZO2#_T&%8]R7K% G:CE[O^1TXE/4GBSL,;$=7,W>(+RJ;=EYR7LY6R4^B5W
MPT>MUA)TWC_OKZ2VW!2D4#> EY^9PJ"V6,-$_S=N>#'_( 6K>PB'3?K"1=<4
MA?DXAR:'U\)U_I_%?GAX+%ZWT+B,8_%=/<^(9NY LYQ;WK+:M'9Q+R74THN]
M;NSN1*0_WS_YXL;TLD]TMPIR]= P#NF<=QX'Z9V+B9/.0:O?7GV0)-:1=^][
ME>?%1EWJR#V^U)O41,[J$KPGQK'<Z2/$>LM(4-6@-N%A<X>#0]R35+9$GN1@
M(96H?GD[K7RXZ$R[.5:\W_R1U5Z<&CVJ?.N\!L_CVD^1K+X\<5'23G%O>6_-
MW5Y)G%:*(U*Y9F00U;ZWRQ?9)JE,C^JY*UY6@X3FO%U+O/N#:>#=KY:2]D.Y
MCKF:38DS$YPT]>L&'O]%UCL0YZ@S:YWFAC,;96"(^8A_\AE[LN8OGBH2\ C[
M,Z70U8KF^0S3'Y6U&%6.&#FB(W>0?7(\][M<B1&3_GW\D[8FS+8=,.VNT):@
M]])L4DV[5#VU=B'ZCK<GJ,/'$./@/0*-Q(7FP\:7!'T?S1RJ:]KAM/1>]IQ>
M4KO3L<6F._>4ZL/5&M]M9R*RNF>O>1HY<_0SE!?ER?D#UF,00KCY=;I<(94V
M72[[+3^4-;?PXL&."2RAM]7I^6'3I#^TH;96Q]3E'1O%4\ID"K5T"?1HPC*S
MVBT!EL(YF,XNFCAPIY$O]-3YC]6[N@7V3DC=E]J*&VX5#RR2AO?&JV"E*VK$
M:V-X!%HJI"OS=+HYD\^M\?+FG)ZC<X;" ?[-X$FR;^HYO8*C?1*@BK"-O_=K
M)I<+6Y6Y2J]H.B$69'V_/80_!_MJ_EKX7=Y-98%X=,/RG&[7W+F&0(?K4U5N
M%8YGZL0ZIV+#&SD.ES7G%;NK^D1$U#5';U:KX^17Y5<,H'U\BJ.1[?90YK(J
MM6.36ZBAEVZ?5"[>MI&^P.3[SIXCEP%[N0&#Z YNBBS%<'6@SX?Z,\;6WC@-
MT2_=I%>(SM!M 8H>4QUX7DST4Y#.3=@;_ZUZ2N3;#&&)#9/%6?=IJ$[#0:6N
M0F$M1?-]_KXL&;=/C)D*"P^?'%8@Z(AC8738_C:AUT6;QJ/>8CLC>0));EOL
MH\"W%P*);+2&=E,H.VF,>;("&(1+Z \6CZY:F_K5''7?N6)5C&\IQ"OY]P_^
M=/%?&E/@V$XFJ!TK1B8!8C F<ZX&M<=ZN;KH4K?6LIOV@5H[84]>6GWD2E)E
M4 #!?.TMF[LBSQ$)$#\MW%B4[V^UJT;G6/<<IP]*%Q07>0:^&,T$O9$K1Q:X
M^29/==@Y8%AZ@F,R41(Y4)NZ](%>C4NMH<:G2_[SDF+$M?OJ1IH\IS,E$ZYS
MZOTY1[>T.8QYC+0Y@/]I?U5OI$G#8:1)'W]=7QNX?*5/ZM_'C.T5ZA]2:',\
MI'R:\<\YFN*ZSE7G?.H^GN+WX>Q4XXG&8^0;R5<HXZ_\'_K] WWR.L9"SE29
M(':X MP4KJ9H :Y_#G+N1ZVO#N\WGN0%AATDO5W<L36 61#2X9(:<BDO?M03
MQ\^<\HYEMILUAM>W-YI 6_#EI1,2@%!SXMQ])1,-\0II<_-5^=6;PHSSM?XT
M[GET\W%'>]JJ]L@CN1J%TF\>:4DO>KGZO?O\TKZ\U*G5Z1H+=W!0IA9ZSH<A
M 0F0VM@8HA3L>+0O<-S:&C);H7.E_RUUF41YY(YW,Z)(0D?M4TIJ?KIRM4<D
MW<[C9![[NP5)MT6="\Q,F0#@-U#@'MBL?O@CG<P@,Z(_5W5,C:+(L QJ7NY.
M???9E?SVBD+>:U$_W9XY =,=R870LL^.]<WQFQ?[&+M1GQ][Z>AZ!<<?(),1
M% HR*<&*,9E5V\ES2PC%=?UGT)C[OGSW='Y'".M=N771OL,/R82GA6(FNO@@
ML>X:(QL.%W2RYD94C>0#4P=X&'B.1/W5OC<&TH[W+U57S#H_<O=%^'+6BX0_
M>ZP$NI5;=$SUTA0NLBHE,J"BV%A6:"<V58\5_:JQ'5\EU_8=_^7N+VHJ2S!7
M)Y\%W@JC3@)B]KZQ#O@!UG$5JRVR[PAKEA04V'=*1N_BO^%$,(;:.&Y4=A++
M'=:.\@6%LJN-R<IXY(K>,Z/6I^WA>QE= Z[<UE$;]FV3_A*VE\=V/3TN-339
M4(F.L/K J,1;*O)H<5O:V*6LS%;US06=>61 S[./G+/TS\"R_&GAHK[)5_,N
MP'FA6-JNTY*(@,:?$C_N/]FM%&F].X^##*5R/F414>_S7J8$.PW3KG!EEUG\
MCA:/V35+<\R85FPQFY-+D>4OLIU_<^ZL[87 T^BV9O77*?\);%8Y]8)9V]51
MH>:&$PV"]ZYX[#GNBV@&NKD7UPF#O)X82D7T^4VA03Q(!T-FN#TV.N5% _W%
M^H[:)'A.EA];4/HY6K_UV+U,#_,A^(?%W/K6@D.G1BV%0-FB&I4A]@_/_"Z6
M4WV/5(D/O>7@Q)SG=+ZAW:B+^HI(\I742Y<BPCEU 99;)E-RC^:B.8SN/B%[
M%<5_TVF5T(8O<D&8W((G]F6NU[O\@V0C;PY\,XO/H,'^X0;PPQ&V-!V]YEZB
MW^^]O+WJH\=_[I%0?G+#*HB/!#A4L\#=L8(Q#67ZYXL7$^V_/IM I0Y>?*QU
M_YO\-9JO)^ZO?ZE#?_AUJ B*&#36-L9?N=B49']WY85./-#/J<N@'LWH'DC;
M&?WQROOPZW#+U?/B72IW3C.J81F-W_O'6?_D="?FO%!^J@XH>NK,2*II/<T,
M#ITT?RA+>_V3F!YO#_- ;FR:C5,_,O)4:0#$I%T O:W0P%Z1<J4Q62\2P::S
M+<_JH>'_*QZ)>8E*SL.D=#T*$YC QUUJ&G&*&5%US,SE[09X:\(M]KU?WM[R
M"I4,\#/2!CC^M3]?,1YG38L'3E2[$9QX\T#LRP<9JQ;3_#J3:B:(0OZWJ!>P
ML!"+\5M,-[YQ?SLS?!,1R![C]\I#Q+G:##=XIN\,HFY(.*]D_M?I_8,\+RK1
MB\?6\Q[1I9Z;CW7&/3I6_[CT]DP-%J*/Y2S)SXJID<ZT+].KL(0%6W_RV[(>
M9)2_%]>$6 KT*OY:?EU8E^>(+?^4Z"<3(8W$<.,O(-A#P2O(\8%(.!/A$UX)
MNX<V?Z$F6(@+Z;527TIYFCEN4#6;(+?YK;QIT/& 8[WKY!6ELJ!VR#K<!1.2
M@KL:.R!SQNVW1Z"<[OPJ<BD=&):";U7!Y6-65T.K(D@ /7=<X<31>95?QJ^?
M3HL9U\9I4B!:F^W[U=4E?DLP:D]LN^\8K:4]2;)GD? ( "@RQ,M67]YG_#?!
MF9,-*DZ(&Q.Z'9"UA"S="#06?Y.Z:'--7MH[E<5M:O0\#*F-32K*M!(J<_DX
MWT^T'G*YDF96\XY-=24>F!'G>"9TU 5W'%>4&*6SA6QT7IJLIZ__X=!" N)"
MKAQ@8AG.(E:1G-%G*K-;?+%1DG#]<EB>Z73QY,I@?8>_<[[P#P=9BC7FG^'J
M'O&_X"%EL"@]S%3?:(Q?LW^2):]:F^4Z:Z$TJCE#U(]7'3JJ<0'^$+O7*VBL
M["_#^,,"!U/[/A3JZ=N2;OIEOK[1\-OU=P]I:\?^0_(RS]U"@MII4)5V6_J3
M#>N-G8VAZ;WN3NZ5B:O"=.HA?(?7,*/)FTA,;2</O##')%?E.VVML\I.2EQ]
M@JV)0=[.#:6KG5<#:G=M5F\^IMM8,#O5!I@H(G;(F<I'2!Y7AS*,;?*RPD4]
MXH,?%*0KR.I?7J>E7N>(W]J*PTW&AW'@BE+IN=A\4UR!"0RD5X8%?[N^N05#
MS%>DN^@MD'P)=ES#.S#ROE7E%Q'T 4+UFP=P[&:.(I ]&.!\B49P;(2='_LY
MY9]0X/2$6>F;41[OBE=^WGA#&4,,ST76W\Y4SS$S V J7(]E[+UQQ:X@Q UX
MLW;]X#NF7$N  &VOEB#D&B%07-,/QO)VVD:\B8O!Q0"GP$%QO9R^B'NRHN1P
MX@K%2V,C32$'T(XX!FT='0'7*7GDS0.I60C=7@5M$J#C8]-WS$U>/TF%]NR0
M257(Z(RE;)NN<NZ:_I4NQ2_B1=S1BB$CE%OE45E5926AS3V#'2KO#C:[S;("
MK<+LO3C<XW(^GJMZ[7U<SAB]R#'/J\12".BB)09(@/,Z!'>W4\!+>5IYM9JR
MHTO3# !H\_-I_Q(>A$V@JZ,[A6RL;Z'/F[KL+UR%O>H2S0Z_*;YFDM)? 9-!
M*\6&"7?Y*L4>L7[0]>@2>\*4MB/ZC"5'!W;X,8_[%2C&[K(HI?;S]C3BL#ZF
M[#9>!;-+CAT)^23@V4-:\W\-IS:EB9T2.'G4?'^N./914K[>Q86T3:6QS[OR
MB=%/Z85P554M'1*HT1@%U;.M,W7F047&#2MH^<QS/;5O ^)^21DBWYT +X C
M_#MF+UX!P;T1]^&W565&76F+L$>%-!LL3E!G7=1IKD&B&R]8!&T%]RE[5N(%
M78K4UWL;YZ)F-Z#N% TTB3[9K[/96[J%GBX>R)YH7NX8+W__I*Z.X<K[5! ?
M7(@$O'H#]R4!-8$/2,!W*>AV*VYBY0^^J&<UCY#0&DB,@$(<A')?I0JI5VP&
MI!(GYJA9O/F^G9[OO<7HVU'$5+AYNP9T[_@:;J+OV.I<)3:O][08V4O@FK&8
MX)(8"O(X8G2>V1%^PX@X>LL0J2:TDJL="L9,H&GR>B%,/1\^<_$7:9@M?GC<
M3Q^^[J,2-67A=8O:A*KB_4N%>N M50?O,$Q\1S;K3XSD3KM6$:[)<N+Y'UG+
M;$87L\</]1T&>!=QJ_%D$'L.%O"KA^_:K"TT\!3?-DN<+9.K+Q* (Z]048;?
MW)OCUOW4C+-$6\^Z51:WQ_3U!K(PU,<1MUC3<.:V*P9RH_<Q)1F- :E6<5)/
MTGI9KYVSYUM/IA5?:EE.(0'[NNUF),#.T-;I.7+MT1@)V!H!$;CJ*7*P8*+>
M\@OR[VY/ C"C?'83,<B.:2)X(0A\1V-X0Q*0'H@&GV*R28"FXDC8"&C_#EZ*
M!-B 2(!.!Q L-8H/&21N5,L0R!/6-%M)P*>&/\1DQ4UN,'9/_*RD'7GL20+2
M*+>(W3/+IS>_TWX<T\NR F(.1L]$EQWGCY-BAY;_!-HGGCEV^HYU7L3;=^*B
ME*)%A?C._(OT?'T;E>C7N8 =]X4\-_-Q\6)88 QR;;-=GP0\AI& 0V%-H75M
MQ1PC_>L,A>F&E"U2@>@_46H*ZXHL;!O?OX+7XQ^(OMRHD4/< [:V>L)42<"@
M'@Y" IY8;:3T3T[10YAQ^KW!Q =<SVK/%,2)M-<AZW;LV&ITY@O#7A!39RGJ
M^82T0D)T:_*T:I37.#M>[/7M7X*9"A3'=,55^I_!['[@%QDZMC<"DG=E-<:>
M^'3:]M(2BM16%[R@E?F4S=5)X/U[:G]ESH:XM@.-QTV0 -'"/L@12GP__[PG
M0 *^I*!(P"DFBBQ93J2%$ 593J >$G"$HB6&2X2%DPT[7*WI.(A\V<22+-?%
M7\3$:N-J*4(N8LUT&K&M1!XIE)C\\!>/4?54(M:V/1';#*]W%5'3R/T )>0Q
MS;T_?,"5]_$ 9F].E:@C$T,"CGF(D1V?_:I9"(7(M:<XLFJ>I/R66*"]!UB1
M5U-F24#NWV\W^+MG$O!;4:8;>2)N)T@"JGF0AZQ&<%NR,3B@/4\QF23@5ED8
M)UF@*I@] JR/!.3' YL?R$O]74[B:^=%^&WLZ[S>'*5N(::Q0ZE[/]VE;8TW
M;:$/,R;O)%SK+Z"\L[YO\:MD@>F(]\CJ9/3XY?A.V$7<5D\G4\O+[BSV!,:D
M!X*!O<=2?FOE'Q4[:N,*UJ):#9="%Y%7-\5V*PG.)( L.LJ,T=,M@DSO5T*N
MC-\>*_QV>_.,&FNI\]+EY@P28!1) AY,.TR*L-WR/=8O.ID*H!"A;%ZH$*RI
MCRS<Y-MGF6U=UIELY^6J<RAP5@G%"WG$$@I0N!M6MO-SHY=TCM?67EAD/&ZY
MR.5A779T.O8[?8<0]DC8=9Z(+(_FU/9?5#YR')\F3FY"05G33QT.(A&PDD#[
M99[R*1$-!1P9^U^5Q?TB 4]W<\C"L9J9E4DJ59=8]8Q:WG_)DHPXEMY8/J6I
M#(WZ:*=;ZM)D;OQ.E\E !*1)(7YBK!DF"YNPQ+';GSW#Q:EIK<0=02@$=7:_
MGEZ17C?V6$+D;MSU6C=K_Y;_Y-T[9J!ZTI,5]D2#0[\4A^R^D>@78GW7[<A
MFM)ZI#:)<N":DVB[*ZUX>N$YI)0B.&:)"Q=[I@M-W<B:SG[BDZ4/>Y[S:%_L
M4]L4O.MZ0Z CA5'/\XL",8N_M<,:X>=Q385X7YQ#"2Q;/]&ZZ/?CMHF%R.-
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MJ0*)49.,E%(U?"TBRBN:RMWBYJ"GJCGXN0IZ?)$0CV=%>X8+"6"_G9;&U9,
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M(=>2>SLEFNBR&(0[]3-P-!4H*LB)&MX*4]J :8\\"[);*N6]=YBS>'5DHVW
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M6]#WFXY3C/\C#HOGB/(?4$L#!!0    ( #4\=EAYNS1XVS8  -]!   8
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MH1&^88;A>/Q\@I931 $MBOW3M;]Y]J\Y]N+_EF?_T['_Y1<*H*<@(RT>!0L
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M,.A'J-@MQ'>8!I;/@<-;,$;0),_WAPB]R8?='B^R\3^@8S<&;A,X[31%?=9
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M\'\RLX=!M#829-<U+EP2>)$1"_P>.AX#H %]H&,6R#G[S*%&)CZPA[!"!*Z
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M$RJ)U\'8!9W$'59;2C./!)3I%>)LS>O.? <7]3OFGK: 9118V@ND&;FC?W\
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MG&$);/*.7\E6BJXQ,?#(8->3V8#%TA4E#GY-EK?Q>OWUR]&_Z4T1:$$O*$9
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M9!7-\S^?,6*7!; L'@'JR,99<"1>MABG=B?N[M>&=@U!X_C4C";26E5H&,\
M3TYG2Y6_OF8W)1'4/]XW^V?&3V)-]7T[W-'R/B-4;2!4;%IVO7D2+Q=T&EHV
M./<EQ;A=TT)+?NX7<[P?O9QM,DS_:TV']MO-V1,C[^#J!P;OK:.+KU5[Y-P0
M5M:A'M6Z,9V-D>6",IEWGI<A^QSOMN;T:E[.1PX$(!^S>EK:JCAP1LSS!JB=
MIWPPUK^UY>!7#E5>8<4KXK)1(8D5KM4X<Y.HGNR[O=R42$M3NX:I4:J+ 0L4
M?[PMI'PS;)Y[KY.W:_OS*$FAV 0Q5'MT5;:7$H&PG>V0J7PU@D54%73*\"M>
M[^UF@(]Z4&+3+]'7C^5OO2F6US31Z7T1N .FL=\DB!"Z9\8C9-/QM$@4^'BT
M*0N]8,F@<%O 1+'_N1UOC+%ZH6I?@R>%M_BSBF(,)*FQ8%<"3U?187!>6]&4
MZ<.8$.CLZ,DRI9^A9JZ>:L#W7-/"Z3&'_9NWPNR^D&8\TR_6F?G3.1(WG5(7
M(-:U51#A>#</L-F$7P*=UFQ 6=;C)@&V60]%J>#ATD2]7\)3B$+'.O@-(7-Y
MYGXI3HE^Y$?";*;-<ZACMYZ][;?#0)C%XV:,-??=!!:FUHM1&TX$C-W:TQQP
M7A<O.?)G%]IGR6>("-C$KR(/$%$*YYH#,,NZ'51H ]SYQS2"5[\Q.+B>_*[G
M\L7)V]1OI+^\V/@\_.W2!H6477F,0K7#O,&']AGIH[B&Q,5=:+ .EB&QN--6
MMDE_MM(UP&O1Z>-^AC!XL5"-/G#3Q5Z="##)@F504?"=4X>00\VS276C,G>D
M36EC!.K[:)E=2.K>?<$%PUKP(Q$_U#:4@$&H84%[BLL(&ESDR=T.S\>VGJHF
MXF:SG@K!68<+JG<IZE:VF(>XR5[G%F0*J]28'S^=O.9KPHLW,_"5RJ-SZ)S>
M.Z(I;(TT&J7,2$XYFU32O]WY3-3@]TMG/JL<_!\SCS"+7:O^7_<[')?!W./!
M4D/HVY,%#R;PNKN%CEF.U^7)KM,BZFY+:B]-B6KP=+GC#PD-TYP5IP1!Y/"I
M OX9)AD+"^55/H"[&+P3RZA>4T[U$EC:NYCOO/"[^!-UH3"_.YS EB""6X")
MU:OM@!^IIOV1DEI!A0G/:B-_L,Q83CW9Z:$)8)GB?)?B,L4-0F0'E)"GNHVE
M1;J]BIW-M2^,4N0 ^1B.XN'A'J&/RL<!D2<#KBLF,38U.0$E2]#WZ NEB84T
ML2NS@Q?FZ+WBR<SLOJP)[L>V6\\W;Z=W\>)3<I^L<\@0@6(B(-M_?/7I \<
M6(36@UQ_CI3E):ZM3G7,8 %BB[4#Y8EW\& UX(ZO6TN\?Z!J]26H,?]U%ZNZ
MS:+T)-X$CB4[PN7TU;D:/N,] SUQ *==/O_<RY3W(U(8I+2[[AX] :/SPXR@
MA_H0S"X./%CV[)F?294Z5?.N]?:W?)YW.6>MZJK_OJU:T]<LU6V:]C+O?-%Y
M_3>80+'WP]W3\QQNW_Y;T!DW/HBR"O,U?;_#IL[Y=(7.?HOMYB_1%$?M\.VQ
M8HUW&$1" X);Z4.;W;C<)&1MRJM9]U.=K\53T_QBQH[$FX@PZ<,$,_L[+KX:
M"I\*%VU<;^AG,Z97E!;;Z;R?9VO]:<C]]/8UZ]Z*GIO4N7X.RE\[=+BB%6^%
M4'_#<X@G^+DBQBI+%[_/Z?^8_6:K7FNKJJ:KGRSUY*V'<Y-"<WO !DX%,7.Z
MJ9"6< YB7SKZI7DPCCQXFPL_K5PQB>JB$\<.5CA[KHR$.-M.2N.EX&+Y2']D
MDUP9!#[1G;#N_+G\M$LN/EPIEW8%KRM(X%".;F2*SG"0:,'&8-9)Q\&MX#>.
MM@]%!!X_>NPMMBK[YA:S[G-)@9BN'?_.<R7Q]V"D29_Y(4A]$ME]^C1]Y5.H
MF-HVUZ0U[BLNEJLVE8')M*53-=1Q;GU,W-;4[?%W/OEEV%FXA]7B:JFYI16A
M#9YU=>&;C411R?^3V]ED<J.72HO"V-@?9\0"=T/@J@-8V9<-!5P&)9T5'EZ\
M=SJ33!N$+$UD?,=F?^N/*0LPZC5Z3NB]H8F5,]0!Q"0&I-F!UXQ77=Y2#OQM
M&$'P6+S9A!9-[*]]-A@5!A*'U_:NW/;G,C/Q?ZS<-.'&Q6*S=(D(S.3$^7KS
MS0=#S(>H8P\E)7Z1D8?'/Z-VL_D7'G\ASOTW4$L#!!0    ( #4\=EB0!Z?
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MKX?W#T></;J_99!SRC2L!B+/\O[/PT(=4Y* YGKS+I@;C!F$>#&3RS9DKF
MH 7HTD@V0(JE=ARLO2UI2I7KN!L*@!E%NK&,^WK!@_ D!\H"NF@I>&AO_.A\
MK'G(J>*X .Z2(LN^4APIUYBH6)35-JNQU$1J!@H9H$+8*:-X]7-!D5+!LJP2
MRX0'>KCTJ9KUP:<Q0T$@/= ?G'C+20XI?\OX>1HX%4UV+G\'5L\>K,;;#58;
M,XP'F+4Y-]D8N@#NICQ$1*):IM:CJ08TPP(+PA1580D9 &*<NKC Y.FQ:1%
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M(4#"5DD.]YBSPE9)\,@=<BP59(Y/4#_!D*!&,P[V:,NC!XK7!HIA()SG)OF
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MH\[ @:9YEB>*A5(5NL-5%2#P*/VH8ZX-!WR[9*M]0)0#F1B%'TOMXZ=2A8/
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MA*>"P,3"Q>]I+#W[N\T2<+3M14$@XU0=VQ].[B##81,&SA5,!1"-<;K]0*Y
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M4]T'=C$8OM&V_KIA)[;F]X[LUG%K?N^H<&0\QE@F* $F>1YK?E^"(TH5F*X
MLW4^GT9L)JWT[TCZ'T#O;6) / 4#S3K':8ZEOF#;@WYUWW%SOU,S7]XN%:4S
MJZVOJ:F4R:CM46MRE.2@B;M(B+A!(;U?E60YWVC*;]']$TWBG'O9(&_*XS)H
M57%$=];\XA$Q[0-4VF6,8T^ "6&P>ZIS<. BM,8H\-Z<AXRF ^W2_ Y$..<R
M[K$SGD0^=X,+_^@JG;5/J>3!4'E<KM'F4%@29X%D,^5:3%6"Z28M;*&SCC<\
MFL+P($W2D.-LBM$?GJJ4PQ#P Z$,'T>-21<$Q!0WEG?B3#(C&\4-E=U?\U1&
M+TJV>%7U)!A<*E.4+Q^#$"1UX:^58X;'N^'RL"+')U#6M:Y=^QDWI2!VRG+%
M9LU6RF5FX5_94U7* 5X;A+%\DX1V%<>^_O86[%=W47,\>""-/-^*@ME%1<3,
M8KLG/LUF,FWWQ-V6$C]V[[M>74?,/GPX:W7@:81'?ALZ,,R>147]0G1@F]1$
M"(M/50@]-,J5,[K(;U15L1H&^,TC@A&U8I:';)EZ,*0T\/SH(9PB_65(QL#-
M"::2C,E\@.T=#( <=O9Q:0NH$&*O/L2=$0P?ET%PP94]+,XC5L$V(F/'3;/B
M4NJ-@=4%"A*A7W=H(8BVDA*D$GN,)V2I\-K4H\+ TS780".!X%AB, [+$F'^
M<9&YPIT]-[5AAL-:PP0QF C26"<*[EKB3_C9R4XN"<0'ZA\$9I1\)UO*;Y"+
M, F-4MU;DX7R5B-![;B^9P!J%6H44]1B5IX42A9AE3O:TQ24&L$"2:ZQ8Z59
MB@'#SVMUAV+E4 WYI#_G@5PO/!N2VD+^DV#E']\&Y']]O*^[-KG2A$<?P4O
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MQ_LEQX=MB4-;XO!B2QSP8(,2V*2/DA.BS80[R@5QSEEJY,CZLKW0$J89/G<
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MR=O_ U!+ 0(4 Q0    ( #4\=EA:ZOD;)AH  &@> 0 1              "
M 0    !H;V]K+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( #4\=EBZ;1VMZQ(
M $0< 0 5              "  54:  !H;V]K+3(P,C,Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    "  U/'98PJ">"$!(  "1V00 %0              @ %S+0
M:&]O:RTR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ -3QV6#/>0S"8DP
MGH ) !4              ( !YG4  &AO;VLM,C R,S$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( #4\=E@Z,N9_,&,  / P!P 5              "  ;$) 0!H
M;V]K+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    "  U/'98/8/-+Y1/!0!
M*"X %0              @ $4;0$ :&]O:RTR,#(S,3(S,7@Q,&LN:'1M4$L!
M A0#%     @ -3QV6# -:1#960  "WX  !@              ( !V[P& &AO
M;VLM,C R,S$R,S%X,3!K,# Q+FIP9U!+ 0(4 Q0    ( #4\=EB./+&9%H$
M #".   8              "  >H6!P!H;V]K+3(P,C,Q,C,Q>#$P:S P,BYJ
M<&=02P$"% ,4    "  U/'98"EK-+-Y:  !F=   &               @ $V
MF < :&]O:RTR,#(S,3(S,7@Q,&LP,#,N:G!G4$L! A0#%     @ -3QV6$/9
MDGV#.0  VCP  !@              ( !2O,' &AO;VLM,C R,S$R,S%X,3!K
M,# T+FIP9U!+ 0(4 Q0    ( #4\=EB)I.V3NUH  (QK   8
M  "  0,M" !H;V]K+3(P,C,Q,C,Q>#$P:S P-2YJ<&=02P$"% ,4    "  U
M/'98U&G\MZ?S   5!0$ &               @ 'TAP@ :&]O:RTR,#(S,3(S
M,7@Q,&LP,#8N:G!G4$L! A0#%     @ -3QV6"LU]'"S[P  G0,! !@
M         ( !T7L) &AO;VLM,C R,S$R,S%X,3!K,# W+FIP9U!+ 0(4 Q0
M   ( #4\=EB"O'O'JK4! %O. 0 8              "  ;IK"@!H;V]K+3(P
M,C,Q,C,Q>#$P:S P."YJ<&=02P$"% ,4    "  U/'98 N[SX;&I  ":PP
M&               @ &:(0P :&]O:RTR,#(S,3(S,7@Q,&LP,#DN:G!G4$L!
M A0#%     @ -3QV6-NH:"+P=P  T(X  !@              ( !@<L, &AO
M;VLM,C R,S$R,S%X,3!K,#$P+FIP9U!+ 0(4 Q0    ( #4\=E@XC'#YVFX
M (QV   8              "  :=##0!H;V]K+3(P,C,Q,C,Q>#$P:S Q,2YJ
M<&=02P$"% ,4    "  U/'98#%-F^%)9  "37@  &               @ &W
ML@T :&]O:RTR,#(S,3(S,7@Q,&LP,3(N:G!G4$L! A0#%     @ -3QV6/4:
MP?E25   1EX  !@              ( !/PP. &AO;VLM,C R,S$R,S%X,3!K
M,#$S+FIP9U!+ 0(4 Q0    ( #4\=E@ H3^PPU4  "Y<   8
M  "  <=@#@!H;V]K+3(P,C,Q,C,Q>#$P:S Q-"YJ<&=02P$"% ,4    "  U
M/'98[UY_6^&V  "%X   &               @ ' M@X :&]O:RTR,#(S,3(S
M,7@Q,&LP,34N:G!G4$L! A0#%     @ -3QV6-C'?A1IP@  ?LD  !@
M         ( !UVT/ &AO;VLM,C R,S$R,S%X,3!K,#$V+FIP9U!+ 0(4 Q0
M   ( #4\=EA<&31_520  ,@I   8              "  78P$ !H;V]K+3(P
M,C,Q,C,Q>#$P:S Q-RYJ<&=02P$"% ,4    "  U/'98\B7\P\Y*  !Q3@
M&               @ $!51  :&]O:RTR,#(S,3(S,7@Q,&LP,3@N:G!G4$L!
M A0#%     @ -3QV6")QK:0-*@  52\  !@              ( !!: 0 &AO
M;VLM,C R,S$R,S%X,3!K,#$Y+FIP9U!+ 0(4 Q0    ( #4\=E@7^_!+AD\
M )95   8              "  4C*$ !H;V]K+3(P,C,Q,C,Q>#$P:S R,"YJ
M<&=02P$"% ,4    "  U/'98M/*(!VQ2   \5P  &               @ $$
M&A$ :&]O:RTR,#(S,3(S,7@Q,&LP,C$N:G!G4$L! A0#%     @ -3QV6%[$
MRZ0H4   _U0  !@              ( !IFP1 &AO;VLM,C R,S$R,S%X,3!K
M,#(R+FIP9U!+ 0(4 Q0    ( #4\=EAYNS1XVS8  -]!   8
M  "  02]$0!H;V]K+3(P,C,Q,C,Q>#$P:S R,RYJ<&=02P$"% ,4    "  U
M/'98D >GP,,#   \#@  &               @ $5]!$ :&]O:RTR,#(S,3(S
M,7AE>#(S9#$N:'1M4$L! A0#%     @ -3QV6&Y+/-#\"0  T$,  !@
M         ( !#O@1 &AO;VLM,C R,S$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0
M   ( #4\=EC6'9+3M@D  .U"   8              "  4 "$@!H;V]K+3(P
M,C,Q,C,Q>&5X,S%D,BYH=&U02P$"% ,4    "  U/'985YO!1^X%  "C(
M&               @ $L#!( :&]O:RTR,#(S,3(S,7AE>#,R9#$N:'1M4$L!
M A0#%     @ -3QV6&0GC\!6'P  A \! !<              ( !4!(2 &AO
M;VLM,C R,S$R,S%X97@T9#,N:'1M4$L! A0#%     @ -3QV6*N<9"@C$P
M[84  !@              ( !VS$2 &AO;VLM,C R,S$R,S%X97@Y-V0Q+FAT
7;5!+!08     (P C 'L)   T11(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>hook-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:hook="http://www.hookipapharma.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="hook-20231231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_l4B2TGYOiE-DNTqDxlQcPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_WqKtPPVwDUSMTGed8PBTnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_1EokcRnMHkWHJTLR_xT8tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_vxWMxth910WYNpMnH4Je_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_K5J3_Ady2kSe1fEoyF_eEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_UtzcBbT1wkeghno1rw2kMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_7YwYjyiTDkSMl_b_qdxauw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_2Z7XTTCdlUG1MXSD_C6hBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_Rai6liu0xUW1EmNBgzCqLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_7xv9iHlOIkCLF2rL0Aa76g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_XsAClSmPLkGgxcjtrxYK8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_b7J_k05VpUCTEauHSsAOvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_cvCbnPylgUKTRN7F1GF4qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_eDyYJl1mAEWF4gZrS_YyCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_qYw6vTRVN0ubcxuWYyT9fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kQUzEzJS40CQZoM-Toa5sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOSFNmfs3EOqv4WZIP0Bvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_uFqE4irDUEqudmnogjdsfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4T_o5zMCE0ug338F1VQDdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_2yyWaG6qFEu8WStCSjJPqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7iTqTo5Mc0yU0G14JpKP1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_klU7bfgmHkO3j4OIlzDcCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_QKv2gv1YAkqr34O2n2MLMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cwRIsmcBbUqKd9OfVFboQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_5_2023_To_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_KDCyo9xrfUm2SNyHUjgpxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-05</startDate>
            <endDate>2023-06-05</endDate>
        </period>
    </context>
    <context id="Duration_6_5_2023_To_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_trpEIIU-tU-_tJvtabhPzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-05</startDate>
            <endDate>2023-06-05</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_SUI_rRcgM0yn74er9fveIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_f2cWQ1nLsU6e2ugzoaWBEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_BAyUBYYE_0qxHktu111vWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_4_2022_To_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_5F71-AsX2EC4M3MSefmV1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-04</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="Duration_3_4_2022_To_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_sAJY_NDjZEehCI5DuVqezg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-04</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_2mnDHSaTCU-2dD6XGhTvLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_nXIctgCoNU-Gzk42kRTkKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_Lt7jkjnIqEmsokc68MGWDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_VZQQp8bdV0acmmpRV4RXpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CQ02v_YunkKcjWHZFY_DeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_ySK9Z-Ny_k23tpFuUhWeZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbReoX6pl0ebta1Mqf9EfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_4h3ktrQRFk21oF_BuLPDMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_PCu4S2Tjlkac9CaMTmb6UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kkhUGeXDzk62-3EYlJzDVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eADOfy2zHkGdzANuuDMnKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hawa35VgPkm-hhsVFZrIwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy8iNx1CQU-KWT7AIRWsZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qsCzYAIcaEOszR8epDIoZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_p9D5TacsTUuux2uOCCEN0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ht1Iko3ekkKK4bUJJCj6Vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_50aQNcU1rESa1A_NH0ITtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HPm7mnaUk0OFlLY3NbuqlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LfPs5RT700ypYFvEtpSSxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GguYoNHqi02T3cZxSRd0nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lkdWE0tsUkWi1RgazRbc0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CmfM8R1qc0ia9PJJbDvGQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TB8nJkfO206JH4IgeDIJYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eavcYujje0qBEWD0ZLFF4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_cp2qFIiDmE2EuFHtMEm6eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3sxrr_m_10WVU9FJBClJ1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BRiLG2VnwEyMWEgoQSDszQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_tQFbE_DcHkOkMLytg817wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XzMTTAsN-kat0RQ4mLVSsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GpwDSGNgm06tza9uL7YsfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_7Ko22T84I06Il1nncKM6WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hook:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_wdQcSZ0gGUG6oC7D9nz3PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_kh4lFA0HYkm_8ou4RKPQ4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kANAvXPJ_0a7gsAvkRIetA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_9_7EqTslY0yqSx5HU_L_qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="As_Of_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_9xIbJy1mtE6TWI_wKOUrpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-05</instant>
        </period>
    </context>
    <context id="As_Of_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_G59PYeJ12ECeSIQHOayjyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-05</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_Xcsey5dkJECXYtbLisOkXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_ZM4WJ3Ojn0quhH4Pn5CYdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_EcSzpwdfREKHNIcL7hVs2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BcR8oItz_UOIQXNtcPyaQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4xGiuYB470aHSLaFha05pA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_XHb2VxbEKkeLgdecA0RSzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="As_Of_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_ob0J9wZKyk2iJVWb7ieH0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_y96X3sy35kK-JiMbzDVPjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Cjpb3hF7IEea2TyyB2JGNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_AFyGmgyE8kiyCNQqfpXApA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_vsxwLcmVd0qxvZfveKo1qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_6eU7lu-gYkGX1lF7SujF0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_xnILDkMs_kCjhQ1U1ADU1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_H0tCjW2DHECbxO5klnyB9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aKhFceKN_063s8FrQsNE-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_XF87Kq4bd0-7XFTH2TZbAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_ioKeOQv4MEC7RRwFd806mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_Rc5jKwDFOEqAwiZthnKExQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_XWdzK47-T06jRMxyOKZ3Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_jrD8j5sy7UakHnOm30LdFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">hook:January2024RestructuringPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_hook_MaltePetersMember_us-gaap_RelatedPartyTransactionAxis_hook_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_PWdmVxfZlkStxnW1wmGGow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hook:MaltePetersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">hook:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_X3TmsbLhFku7xpVyRcYkrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Kkn9Mty5DUurhtItxm046g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Y740NWFhXUaA_KiLwpYS-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_oSbIwYv_yE-SfbOG9eEVMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_W1jTBgF7KU6w3PAGk_NZLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_fTi5jMBdM0qbHxQohSMwDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_H9q5fvXIvUyymHn9HgMWCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_d9nAVl9o7USSeTumRsaPVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_n75mKrZ5ykylerI6_Na9ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_DTmiN0Wjdk2iaqY9dIsckQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_eO8goNhRB0-aM5lXAIyMyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_v9vy-6pd6UqP7xZfF6NTog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_2LsuutyUQE6wY7QxmZAn0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_V0f2IgZ-pke_ekfxUL0PFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_OVW8CCm-m0i5lry7fXD5tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Dv-_4sRg6EC65tReOfjV-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_pt9hTzP2p0aDdaGKrVFYZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Pkdmu3XpuUGFFIIVvDmOsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hook:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_5_2023_To_6_5_2023_HDaSSSxSpUCGD9FJbOAwcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2023-06-05</startDate>
            <endDate>2023-06-05</endDate>
        </period>
    </context>
    <context id="Duration_3_4_2022_To_3_4_2022_NTQl-cLtAk6xlttcf3yn2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2022-03-04</startDate>
            <endDate>2022-03-04</endDate>
        </period>
    </context>
    <context id="Duration_2_15_2022_To_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_Agf-g2EmxkChN7RAIyPgCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HHVctDOtV0C6dlcgQy1LxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_unSFbxjx2kSBUd8Oh40Kbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pSYi6VRiEEWiQxkyw445Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_C_IAmN5vm0OXRMTCb5TGJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_AT_yaoK_p7Sukuiq2w5N3spOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6rCpmJmAUk-pthMRELXHZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_AT_3mwjH__tMUma_hkm6Ve5jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_poFM7cMgMUmMG8tthzI0dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AT_nqOGXBicVESvalgSTFcbwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MrV6NCzS0UKVJ_8-CMc7bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qZP9Or45rU2FWGne3bmD7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Yto5HIXmyEG1TJnAO6oOwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_15_2022_srt_OwnershipAxis_hook_GileadSciencesIncMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_IJ87WrWO-k-9t1hFfOiVgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">hook:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_rYOLLftQ0E631s3QNeZC5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">hook:LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeaseForCorporateHeadquartersInNewYorkCityMember_O5rj1qjLx02TAFtZTvjJiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">hook:LeaseForCorporateHeadquartersInNewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeaseForCertainParkingSpacesInViennaOfficeMember_BUA7zVRMSEmA3Ot_9-TINQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">hook:LeaseForCertainParkingSpacesInViennaOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_pNxGgv4tck6OcN9EE9uBvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_xsd7nsH6k0yzM-JYdiLW2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_StatementGeographicalAxis_country_AT_kfxilsmFSkCesBThL4nisw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_AT_hpenzR01Xkuk5j5fUTX0jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AT_c4d1mu2O80qu0WCXkZuWww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AT_3NogJxMRLUKuio1gDYqLrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_f2bozshHvEqDnHPJIfLxkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_5OZpzWR5ZE-g65N3W9mQlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_-Sb_oTNrbE67HtDm8P8UiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_pc7cQA2m-kOSmJHzPEfppQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_qhAXDY6gbUi75WUSONZh_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_igpyXqNHCkeaCiqmtmt_nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACQheD3jekytMJkUUeE47g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_iL34pNGK3UGEaXA4MINluA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_Oo1iK1CDRkCwVRfUUVTjbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_RangeAxis_srt_MaximumMember_G5knO1JxEUipkKfqXVba6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_RangeAxis_srt_MaximumMember_hy3OpU7SA0uUGHTffJQ5fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_InducementAwardsPlanMember_bUvp9git4U6vhtxSXzOaEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:InducementAwardsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_PSUqRWmVfkCw7OQN6sRoGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1LRqYYOuTkW9E0CdbjORBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vp7OjZUKs0qrjBy07u3Rwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kU5iAAu8lUOCuAzHNGZFtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_t6cFMObpAkuRcFhZNL6fUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_q3DFOTCJoUOMsPJyaBQ3Fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AuBlzmENrUa8NdUXnGeaBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sjQ1_m16gUyGeWyA8dpSbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_f7Evnw8lLU6TvXq4xZaF1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_4GN9LMP8E0i2s2spo0zrXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Eytulubnr0ySr_VAROpxiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nivr3y_350aPACUslx3dMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b8VlOcR0O0OmF5emQANTkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3z_KZuEbyUyufSDi6RFYKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e9XlwwWzZUyxUx3pingkdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mzTecP16KUqdKJ51DcbR8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ShuqB9wIDkS3F21xuhUuPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OgNb7067TEG0mtw4IpZ_2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_NoPDm3BqIEaimDdH7xzzAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_qjK-CNSWD0-cN7Yfpf-UAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_lBtbfJCmPUmNKH1HpAUlxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_OohY4lRPq0yPekG2Wk5KZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_37LOdjtI8EWZBGW9I5pzGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_VChA_ldFhkWxOYuQUqtGHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_eFFXVBkbrEeySJMxE-8wLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HivProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HbvProgramMember_3dT06FX4VkCwkIjTV8mikA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HbvProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_eTvVFL_Gb0ihVkFmAe5Ybg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HivProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HbvProgramMember_u76tVQD6oU2TjpnsvGjXJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HbvProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_shcM24-UD0G_87KWD0abFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_12_2023_To_9_12_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_Xd8PFrmLWECYLMz00H-fVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-12</startDate>
            <endDate>2023-09-12</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zch3U472NU6ienNHLQ1xSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_pT4ROzEyWkS4z3OWuisutw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9_5E61jCp0qkRK8pXIBRXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iIx2YHcEt0CG7Jld-YUTtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">hook:NonExecutiveDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ZtdYdiFLwEqrZPGSD1c3dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndIncentive2019PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pi9ns7LHMEqJa6iUqFqKqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hook:StockOptionAndGrant2018PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_7_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember__FwCStMaU0OyzpKGLfbvNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="As_Of_8_7_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_I0qOWFNRG0m7UhyFU_5e3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_m8WtQLcukk2yFLSY4g5v3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_IuERzRWMYUO5kK8uAkmuTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_20_2023_To_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_H8YdukywEUa5F4R0wQD4ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hook:AmendedStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="Duration_2_15_2022_To_2_15_2022_z3PV6PoxAUyoMugmqtg5lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_0rn22fHyykOFZjGSZjx9-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_DNqYfPgFh0Ck9fuBQnQtWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_AustrianResearchIncentiveProgramMember_Ocbk301LuEKBJ-hS6sdG-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:AustrianResearchIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_r-zd0dtsfkWw5mLU7UMv4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember__7jEylpDhk2E7HBL-QMsuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_4t0j2RLtRUim5ad7YUNdww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_oBjN55Dh4kWdP45kjmc_cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:Seriesa1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_t2LLWZ24bUKTQiMbE7AcJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_iLfkqbjLEkO8cY690Z1M_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_LCk-o0XEz0Coe9Nfe-mo4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_AustrianResearchIncentiveProgramMember_b5PBJbDWP0aRQ3y6jpvjFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hook:ResearchAndDevelopmentIncentiveProgramAxis">hook:AustrianResearchIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_7_2023_To_8_7_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_br4Ybr-YDUajiQqo-HL-lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="Duration_8_7_2023_To_8_7_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_3at3uPhCo0ShjqrpfD4Klg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:StockOptionExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_UsydwOHzwEWlwarT8cPtyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_1Wpbg1kMJkWMHx62rdrnHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:SeriesaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4qOs21ojTUO-rUJpz1kUcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6fTsmB6TxUSozaWhvhJ6_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_DRzR59S0e0i1yiiJ_sbKPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:HivProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hook:MilestoneAxis">hook:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_zfz8LxQPIku68ssP9_JeQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_X56qauEA7k-9t9AFLtndIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_WGiMi9INf02gQAVOw20hGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sSCjg8UmtUy-0Ck5qV73Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_25_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_c0SKflh3TEWHuSa8ZwnJiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hook:RocheCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k1H7ZYJMsU-107bPr2ox5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cXPFzUalKEKzwidBaBnRKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_qRcTFAJpgUSnNR1W3QhRvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_15_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_eliDdZ6mik-1LCK1kA6MqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-15</instant>
        </period>
    </context>
    <context id="As_Of_3_15_2024_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_0yA3j7PesESeO_PoZqEkpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hook:CommonStockOtherThanClassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-15</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760542</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_Program_OVVzQkKn40SXnlnbXe7UtA">
        <measure>hook:Program</measure>
    </unit>
    <unit id="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg">
        <measure>hook:item</measure>
    </unit>
    <unit id="Unit_Standard_Vote_GQrC70uM-UyPQD7KgwAVng">
        <measure>hook:Vote</measure>
    </unit>
    <unit id="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA">
        <measure>hook:installment</measure>
    </unit>
    <unit id="Unit_Standard_employee_JIvkuNcm3UeH8NvB6ulLsQ">
        <measure>hook:employee</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      id="Hidden_T7Md-c8SK0aUrChrCIRLXw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      id="Hidden_iMb9OcFSKUijcU0WDSX4sw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      id="Hidden_P9wzsTrqDEqqB-FUp3dy7w">http://www.hookipapharma.com/20231231#CollaborationAndLicensingMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Hidden_GQ5TUkl_kUi7iAqvXtlLgQ">http://www.hookipapharma.com/20231231#CollaborationAndLicensingMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg"
      decimals="INF"
      id="Hidden_xaQq4UotwEeS_tUhTmB-jQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Hidden_NoZMJdxkzkmTujJyjYptbQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:CommonStockSharesOutstanding>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_CKcMMs4Hy0qFoZwt02j2QQ_3_1">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ"
      decimals="INF"
      id="Hidden_htHehux1wEi6rYPm9TyLvA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">52317138</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"
      decimals="INF"
      id="Hidden_H8dP_q76KUqlgTeQjbo2gA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">96550590</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      id="Hidden_Gv7XN7EYJUGrVUI8-0DE1w">http://www.hookipapharma.com/20231231#CollaborationAndLicensingMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <hook:FairValueAssetsLevel1ToLevel2TransfersAmount1
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Hidden_Lpjoo-HNUkK1Q7dne6IAVQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:FairValueAssetsLevel1ToLevel2TransfersAmount1>
    <hook:FairValueAssetsLevel2ToLevel1TransfersAmount1
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Hidden_9wPB5a7NckWc0o_lT7sjxw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:FairValueAssetsLevel2ToLevel1TransfersAmount1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Hidden_L0ges7xDOUOYjlazpNEvlw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"
      decimals="INF"
      id="Hidden_EUaK3Tg6FEeEOqOHWmJvgA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">96550590</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Hidden_K3IEYYVgEkOcLQ_fmEnbgg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w"
      decimals="INF"
      id="Hidden_wHXhiF9z3UaARnOvYs1xow"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">370</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA"
      decimals="INF"
      id="Hidden_fN05Sy8hG0-TjqIRvTiFCg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10800</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw"
      decimals="INF"
      id="Hidden_HE01NwGMaUaBkBAhb5ZKIA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15268</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA"
      decimals="INF"
      id="Hidden_Eut-pnlYxkmGfE27-Y1kbg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw"
      decimals="INF"
      id="Hidden_x3Vvh87iFkeGHTZK_-BIJg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_9blnaQpz6U-5VAFAajUEpg">0001760542</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_SRTD79RQL0GOg73FbDkU0g">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_kghkEG-k8Emlw3X7Z5XJRw">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_AwZnrK7N2Em3ia00mQ0CTQ">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_lhZ-LaUadUKICoYzxMLpbQ">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_ScvIZVjUUkCNNXzHOSUKtA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_T2HX96T6eUWZlHyX3bM4kA">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_42ZnrQeKuEKCD46TviIK3g">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_WZH4S0wzpk-DSwoQ9ycsjw">001-38869</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_2sfQ4DTZ20uYsx3qbkE64A">HOOKIPA PHARMA&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_CO6JS18iMkuVbjoh5J4i_Q_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_CvVm7IKO-UGE1pb1hRStrQ_1_1">81-5395687</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_QFeNvQuMNUaAx0l2cJXOFw">350 Fifth Avenue, 72nd Floor, Suite&#160;7240</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_KJduekKwCk-s7xe8kpDNEQ">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_PfKTXVJgiEq12L1FZg0ylA">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_ro8ATnvK1ketO2Ts-objfA_4_1">10118</dei:EntityAddressPostalZipCode>
    <dei:CountryRegion
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_ExuuUyTJ6UaJZbPU3tB7cA">+43</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_gVaTcuSHBkSlq6PgsrT9Gw">1</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_BLtql_mUwEmgxIXN95Lr6Q">890 63 60</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_Z4tV6j8FYUSDMVrWiuqfTw_3_0">Common Stock, $0.0001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc__85SdwO-2UaOw_TGbAW1JA_3_1">HOOK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_c5A-M0f_MUCOaW-dmjNCXw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_qBrlFqYwP0aLTtlRnKg7Dg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr__lZ20y7MFEuNZc0PJxK71Q">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_B5r5LTNS80yQ82n3sO_JHg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_zwhSP7aHZkij4aRm8pi-jA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_yzPnYmEVtUWuLXfs1jBpfQ">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_xTc_bzZQ5ku932xlcpo6hA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_n8s6aJSMk0ekWwAQER3XZg">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_i9MJYi-6-EeB9M3t72clpQ">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_hXhi1N54lkOW2K5PugG78A">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_a962A2hJsk6zT8hoqBoq8w">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_36JB9oYcmEizlIVvtAW-ig">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_qRcTFAJpgUSnNR1W3QhRvw"
      decimals="-5"
      id="Narr_hyly7TQHv0Goa_DIQ5YxHA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">71700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_15_2024_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_0yA3j7PesESeO_PoZqEkpg"
      decimals="INF"
      id="Narr_58U-0IRNqUeCr3JWDEmfhg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">96550590</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_15_2024_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_eliDdZ6mik-1LCK1kA6MqQ"
      decimals="INF"
      id="Narr_zlv8sxr4AU2TlEB7knEqdg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_d7PT_zuNW0Cp5tyMk0vgwg_1_1">1259</dei:AuditorFirmId>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ"
      id="Narr_NEy4PleY-EKyp5VZmhghpQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ"
      id="Narr_0dH-VAXUMkmMVOseA69efQ">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ"
      id="Narr_jSsGL3cvTEGrqix2UYZyiA">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ"
      id="Narr_02VT2QD-L0aYgYnIXATUQA">false</ecd:NonRule10b51ArrTrmntdFlag>
    <hook:Rule10b51ArrangementModified
      contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ"
      id="Narr_aFwhrdPbI0iKlBhVEEYDnQ">false</hook:Rule10b51ArrangementModified>
    <hook:NonRule10b51ArrangementModified
      contextRef="Duration_10_1_2023_To_12_31_2023_h41QD24P5EOrtjkO9w2URQ"
      id="Narr_QYpDExDQdk-namKWDUT3NA">false</hook:NonRule10b51ArrangementModified>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr__KPdqg4jaUS8T_DgwPb_Wg">Vienna, Austria</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_XWdlar86R0WFn_z0kjCQeA">PwC Wirtschaftspr&#xfc;fung GmbH</dei:AuditorName>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_DST_D3uIVESNaN2sa6G5WQ_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">117096000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_hPNgVUHlbkmAYXpeqSR6fw_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">112488000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_oS9tR_rU80es2y4sQLVetQ_6_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">537000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_QkW7ksOsj0iA-HwL2MRUrA_7_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">511000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_Dq9uPhIRZkWvHwS58-zNDg_7_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">6533000</us-gaap:AccountsReceivableNetCurrent>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_3YZwXvcvLEiIApIIaF9nqw_8_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">18760000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_NlRnuVDitE6vMTJtux6XxA_8_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">15479000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:PrepaidExpensesAndOtherCurrentAssets
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc__6N_FSVeskWr_qEj0wCSmw_9_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10749000</hook:PrepaidExpensesAndOtherCurrentAssets>
    <hook:PrepaidExpensesAndOtherCurrentAssets
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_R_b8FkQRNUaOg3ZM7d-oHg_9_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12159000</hook:PrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_OAVqJU9UB0aDuIJg_QZM4A_10_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">147116000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_V_9mZ1wI60K_d_OzxaU0TA_10_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">147196000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_FHL1zHp8x0KTQczdlaszWw_12_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">425000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_SG-K1VvMlUuw2MK2ZezgQw_12_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">419000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_utCYo6D3P0GqO2YIvmiFeA_13_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7742000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_QlrMPRHsREuIjRCRjwwDLg_13_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">17970000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_pi-IERVj7kGwWqu1hzxqTQ_14_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5473000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_i9jjh52Xkk-LQGpaewPfMA_14_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4006000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_E8MgY-8bHUCD9PmBjoRdZw_15_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">581000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_unncAv_yj0y66lf9fw3EoA_15_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">863000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_-4d7Qpo0okS0aJIkyPvAvg_16_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">14221000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_Xu_BsbcfgkCREHQZmxL7gA_16_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">23258000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_e9m3pduNEkq48iiFU2eJuQ_18_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">161337000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_KnkyI5DqSkWrnyo8WRFrRA_18_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">170454000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_42FdwMcU4EaV8fOoE7aX0Q_22_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12498000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_4qVC1GLn80ag3BQQTfGWCQ_22_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5488000</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_eDj38OkKvUOXqlohQCGrGA_23_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">14631000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_XHbu6W7Fn0SyvZgontneIQ_23_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">15684000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_qWID4AfJOEq8ysvrgSWAKQ_24_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1638000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_ovOJGOahU0-fdgySo5Q1qg_24_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1688000</us-gaap:OperatingLeaseLiabilityCurrent>
    <hook:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_GdTN3r0SDE-jlIcyFGNUfg_25_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12101000</hook:AccruedExpensesAndOtherCurrentLiabilities>
    <hook:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_eg6mt7MIrkC3lG2wwB2aoA_25_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">11178000</hook:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LoansPayableCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_5hP5oMRlu0e6hzPEX46eMQ_26_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1120000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_8Ayig_GBPEeznCcOgALjog_26_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1594000</us-gaap:LoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_NaS_bP-kHECMZJqYhYFk_w_27_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">41988000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_cCuGFNOCz0itBfQOOIZqGA_27_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">35632000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LoansPayable
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_9Vk4nMa4mE-4Yj2opc26rg_29_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">911000</us-gaap:LoansPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc__8prs3pp60qUwsYyEhQm7A_30_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3801000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_8NO1rAACzkyx0p6ZkfGHZA_30_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2310000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_Xm68LceA4kOYf5uN_Xz1dg_31_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">19674000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_1r7CJNZp_0C6XDlfV4YAdw_31_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">25664000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_Knv6lZDXYUeUJEYPqve6Mg_32_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">6017000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_YN5Nt2s-skSpAnJS1ZESOg_32_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3420000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_8cPWYb_TC0yso1ozzGVHUA_33_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">29492000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_8Wr6egrLvUqoTmfWcFwZIw_33_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">32305000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_oHhjLm-uiUKj2QbNlijCvQ_34_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">71480000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_tfawF3Y2q0mU_tvW8kTFRg_34_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">67937000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="INF"
      id="Narr_KyMXhV4bBEmrQ_ZGwhAUpA"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Narr_ru1Uub22tUKjAXc7NM5kvg"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="INF"
      id="Narr_n6sjXuiTdUqYUwHnhyWTxw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Narr_Tqpo4d--hketzZ6xJoVulQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember__7jEylpDhk2E7HBL-QMsuA"
      decimals="INF"
      id="Narr_wtTuu5gegUy_e14v34m52g"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2978</hook:PreferredStockSharesDesignated>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w"
      decimals="INF"
      id="Narr_msd8byN0mEqXRB3xnVScgw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2978</hook:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w"
      decimals="INF"
      id="Narr_8pdzFNCCkUGtkMDvnCH6iQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">370</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember__7jEylpDhk2E7HBL-QMsuA"
      decimals="INF"
      id="Narr_uV2HIE-GnEyldEvD7FDygQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1697</us-gaap:PreferredStockSharesOutstanding>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_oBjN55Dh4kWdP45kjmc_cA"
      decimals="INF"
      id="Narr_NvkUVhKBhkW9_9y-W2P_Rw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15800</hook:PreferredStockSharesDesignated>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA"
      decimals="INF"
      id="Narr_3LmZVPmqhEagqrD7c6wgUQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15800</hook:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA"
      decimals="INF"
      id="Narr_fZFEVlnlUUeR6n9l-LUr_Q"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10800</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_oBjN55Dh4kWdP45kjmc_cA"
      decimals="INF"
      id="Narr_z7YM83TrOEayjv67KpZL0A"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15800</us-gaap:PreferredStockSharesOutstanding>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw"
      decimals="INF"
      id="Narr_eVFr5tkuoU-HkiBpI6yo8Q"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15268</hook:PreferredStockSharesDesignated>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_4t0j2RLtRUim5ad7YUNdww"
      decimals="INF"
      id="Narr_c4x112QAg0mj3cfdsDQbsQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">0</hook:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw"
      decimals="INF"
      id="Narr_dSXz4I9ZhU-qcWINoF6bjw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15268</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_4t0j2RLtRUim5ad7YUNdww"
      decimals="INF"
      id="Narr_3ESBU0HX6kyMy7AbH0qlGg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_x9EhvWpDTkCVOaGm8OUqEw_39_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_GFUcUxw25UOJ0ghRBPj5jw_39_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ"
      decimals="INF"
      id="Narr_ybYKs_ACp024qnGdfz6KRw"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"
      decimals="INF"
      id="Narr_R8xznBDkuE66fz968Jb4kA"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ"
      decimals="INF"
      id="Narr_tmTgflD-00a2hDxIGoNGjg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"
      decimals="INF"
      id="Narr_m21KIyrIkkKL8OORK19Gtg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"
      decimals="INF"
      id="Narr_s0N0BfdcIk-cwMcLKFxVJg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">96550590</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ"
      decimals="INF"
      id="Narr_kMH1vEEDG0Grm1MR0350AA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">52317138</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"
      decimals="-3"
      id="Tc_KvV-9hjn0kyG7ym9e36MYA_40_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_aNBRkQTXNUiJ8Gn81K74jQ"
      decimals="-3"
      id="Tc_JWXeub_4dU2PAoPX7y-42Q_40_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg"
      decimals="INF"
      id="Narr_VppXB1EW_0a15F_RdHFXCA"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Narr_meoXHCL4d0OKLv08NuVIcA"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg"
      decimals="INF"
      id="Narr_zjpnsdYEl0an0S7Fcx1eZA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">3900000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Narr_lfTMq6-00UabWcS4WkrzDQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">3900000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Narr_qg3Sbupv5USlxFW_psI2sw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg"
      decimals="INF"
      id="Narr_LWZmXT520EuJ9WwljIo7SA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Narr_j0NbpP_q4UiANx0ZC9wi1A"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="-3"
      id="Tc_RMIVhw-ytUG8UgtzJciTJw_41_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_MHFILjuKcUaLN2Jn-JABhg"
      decimals="-3"
      id="Tc_Aw4e8myvNkGdF9d7ReACMA_41_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_BiGa-qZ2lkqb8jTqrEmfHg_42_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">467041000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_Rx8cUwtcdkyflQ9sBfcWJw_42_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">397349000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_2AUV6pzF9kmV2ZgiWYuXtA_43_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-7933000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_IGFpm7zbJk60mBSI3S1MBw_43_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-7156000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_J2K0EJUHA0-xhflKsSp3mw_44_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-369261000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_Yk6NE3bkr0mSrNuUcrwHpg_44_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-287681000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_jHNsfg1a4U-CX2ug6Mejnw_45_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">89857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_IH-oYv2Ym0e0zJEBwHDrWw_45_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">102517000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_xw1Z-6_XqEeS8TTgRCm8gw_47_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">161337000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_sL49_84dkUykFBH_-PrNSA_47_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">170454000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_F4pMqNDERk-J-g_0IPc4SQ_3_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">20129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_VOA1yNLhpkeCvRwsXYFWGg_3_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">14249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_JabPlhAN_EikqnIntHpyqg_3_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">18448000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_EiVZp8fXmEKAmH2I_v62xQ_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">86424000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_Ddhi4o6wREu6IFSa5EJpJw_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">68645000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_eOtfB1GXxE6_FpbuQHeuvQ_5_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">82853000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_JSrAM117SUuy8j5ivLRjAg_6_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">18633000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_xxTinr9b7ESUKWcTfmDyXA_6_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">18759000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_FuSfuk-PwkKlV4GdaGbKcA_6_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">17269000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_b00pHIlZe0ehARTrXR8BxA_7_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12766000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_xjOc_8wAgE-12Hxyi27zbw_8_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">117823000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_DoAadr1r30CTYie0iUf6mw_8_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">87404000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_zE55SOs2HUuhl5J-erRFZg_8_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100122000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_rxIC3pDHSEuT6Zd4ynosfg_9_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-97694000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_S_R7LruLjUq_QYQfze1TuQ_9_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-73155000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_AO-xajjuekKzKTyauXCiJw_9_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-81674000</us-gaap:OperatingIncomeLoss>
    <hook:GrantIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_SOmXON56NkSfPpUaSchz_w_11_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">11193000</hook:GrantIncome>
    <hook:GrantIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_spW_G3dNWUGE7B-igLUhFw_11_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7916000</hook:GrantIncome>
    <hook:GrantIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_QuQRIjwPkkOfA_a93-xkdw_11_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">9724000</hook:GrantIncome>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_FyxkQICIvkyv6_cJmKQ-SA_12_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5293000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_TRXfdRuKUkyoRXSEn0EcAA_12_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1633000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_LhR_BDfLZkKVrFHfpKD0Qw_12_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">27000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_-dfPmHvfzEqsssoq5hPYxw_13_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">317000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_YTECRrUHp0Ki1UUISID8lA_13_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">687000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_ml6sHYmFc0W8yfIQUdfJog_13_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">898000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_SwJf71ZI1kqV-VypIWBaqQ_14_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">313000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_6GNDPA6sE0q8EPsMsVcXVA_14_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-392000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_BCodCMF760eV89iCxc3GfQ_14_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-2843000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_4FK-2Qmmxk2VHjIMPbcpRA_16_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">16482000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_8AkpB8tDrkqs-0p6_3h19A_16_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">8470000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_ivhG5I_Eqkud5b_pJY-aMw_16_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">6010000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_IM7RF3X6zU-kBNA3-wdZZg_18_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-81212000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_ECiIIcAX3UG9Ki0e3rY8bA_18_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64685000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_p_QJk_R_eEqDsx-SyqHI1Q_18_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-75664000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_kZTxCEeO40m3FdU2e6eRiw_20_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">368000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_ZEG75uK2xkSO0se0jPB-oA_20_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_gRQlPDrbyUW8hY4ucso_Ag_20_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_Gnebx4HOc0WNd6Zy_QPvew_22_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-81580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_XnvPUk4ljkOf_Qf6i41yVQ_22_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_ZLxu_Xe9aU2aAWKxW9NgXg_22_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-75665000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_o6nEWjtwlk2nhWDXbrKhKA_26_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-777000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_P6rbcbwTR0Wk2VAPfEik4w_26_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-2376000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_havv8U0eYU-zqCM4wq4bzg_26_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1287000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_hjv7lBZ0QUKMkr7guoX_Hg_27_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-82357000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_UUfV6SFyekGa28QgzVwZ4Q_27_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-67291000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_Q70H0Ol_VEm77zxNcwedVA_27_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-74378000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Tc_JjLrPxauRk2JJadJCUSgrg_29_3"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Tc_JjLrPxauRk2JJadJCUSgrg_29_3_2"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="2"
      id="Tc_RyHUr6WGikCO21r-_irpnw_29_6"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-0.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="2"
      id="Tc_RyHUr6WGikCO21r-_irpnw_29_6_2"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="2"
      id="Tc_bPqVXYLNnkiulId2NkTwFw_29_9"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-2.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="2"
      id="Tc_bPqVXYLNnkiulId2NkTwFw_29_9_2"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-2.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA"
      decimals="INF"
      id="Tc_yIF4oRKHIkCrbNmRPsNdEA_5_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">17497</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA"
      decimals="-3"
      id="Tc_OyInEuyrfU2zJp0WCD5w0w_5_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA"
      decimals="INF"
      id="Tc_87LveTVC10qUkiTwyixEpQ_5_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">52317138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA"
      decimals="-3"
      id="Tc_kBxUGz2seESACoDK67HuOw_5_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g"
      decimals="INF"
      id="Tc_2M_rNwGl20SqrEf5ovd1bw_5_12"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g"
      decimals="-3"
      id="Tc_8eH62hbPP0GyEcozl3_lxg_5_15"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_p9D5TacsTUuux2uOCCEN0A"
      decimals="-3"
      id="Tc_Zmtda8ayQkuwcNjAXouU1w_5_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">397349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ht1Iko3ekkKK4bUJJCj6Vg"
      decimals="-3"
      id="Tc_dZ31jebrWU-HZyLvqx2pog_5_21"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-7156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qsCzYAIcaEOszR8epDIoZA"
      decimals="-3"
      id="Tc_sPlxubkqOUKsACtwM0duaA_5_24"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-287681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_0-VssoLJOE2NV2NbuShr9w_5_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">102517000</us-gaap:StockholdersEquity>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_wdQcSZ0gGUG6oC7D9nz3PQ"
      decimals="0"
      id="Narr_vYyDdd1ETEiSIcEegp_0kw"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1310</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_NoPDm3BqIEaimDdH7xzzAw"
      decimals="-3"
      id="Narr_pqR1_49ePUqs6uplRyJcWg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1471000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_SUI_rRcgM0yn74er9fveIA"
      decimals="INF"
      id="Tc_bgXPLstu4UKl9ZmFcO3O3w_6_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15268</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_SUI_rRcgM0yn74er9fveIA"
      decimals="-3"
      id="Tc_1inJhOpq3U2RZRluYVE10Q_6_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_7xv9iHlOIkCLF2rL0Aa76g"
      decimals="-3"
      id="Tc__uS9vmpQQU2tnNcoFn8X0Q_6_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">18530000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_NoPDm3BqIEaimDdH7xzzAw"
      decimals="-3"
      id="Tc_u9fOqoLAuUWn7x1rjYKjkQ_6_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">18530000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kANAvXPJ_0a7gsAvkRIetA"
      decimals="2"
      id="Narr_8GbOO7Wb70i1aHBWK2icdg"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1.31</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_lBtbfJCmPUmNKH1HpAUlxQ"
      decimals="-3"
      id="Narr_dnpQ4YXrz0uEdm46jlyMcA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2207000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_BAyUBYYE_0qxHktu111vWw"
      decimals="INF"
      id="Tc_UkHTNdDEOkiwFIiPTGpvLQ_7_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">22900768</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_BAyUBYYE_0qxHktu111vWw"
      decimals="-3"
      id="Tc_nKGnCJA-cE-ap7r2dgvwuw_7_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_b7J_k05VpUCTEauHSsAOvw"
      decimals="-3"
      id="Tc_g9X638BcL0azLylsXk8j4g_7_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">27791000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_eDyYJl1mAEWF4gZrS_YyCA"
      decimals="-3"
      id="Tc_y7udfl-aMkGJOsBOI3J5rg_7_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">27793000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_kh4lFA0HYkm_8ou4RKPQ4w"
      decimals="4"
      id="Narr_3rWuHRcTtkWrs2uviLaJkg"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1.4167</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_qjK-CNSWD0-cN7Yfpf-UAQ"
      decimals="-3"
      id="Narr_Peg_K4I2IkiliRSPJt9rWA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_f2cWQ1nLsU6e2ugzoaWBEg"
      decimals="INF"
      id="Tc_CM-h4-uRCEKIDG03lAtJ4g_8_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_f2cWQ1nLsU6e2ugzoaWBEg"
      decimals="-3"
      id="Tc_OwJUCk7tbUSU_DUc-TUHjw_8_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_XsAClSmPLkGgxcjtrxYK8w"
      decimals="-3"
      id="Tc_mpWZx_cSY0O_FJzcA1zQPw_8_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">21112000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_cvCbnPylgUKTRN7F1GF4qQ"
      decimals="-3"
      id="Tc_JBSVQQEO7kKrjTkitotBjA_8_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">21114000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_ySK9Z-Ny_k23tpFuUhWeZA"
      decimals="INF"
      id="Tc_JWVkZ7lhSkW0EiEKpc8KcA_9_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">-1327</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_ySK9Z-Ny_k23tpFuUhWeZA"
      decimals="-3"
      id="Tc_0U9a4pLks0G8wGi9UCFXGQ_9_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CQ02v_YunkKcjWHZFY_DeQ"
      decimals="INF"
      id="Tc_FqpKzO263UerByhYacyRHQ_9_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1327000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CQ02v_YunkKcjWHZFY_DeQ"
      decimals="-3"
      id="Tc_2t9_I_ONkkqLteQgcokM7A_9_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7iTqTo5Mc0yU0G14JpKP1A"
      decimals="-3"
      id="Tc_gBWL9oUcBkWG_4k2jq5W-Q_9_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_4h3ktrQRFk21oF_BuLPDMA"
      decimals="INF"
      id="Tc_FQk6Jpi37kGfZ-mXYLWucQ_10_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">-5000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_4h3ktrQRFk21oF_BuLPDMA"
      decimals="-3"
      id="Tc_dEL1Yn28gkGG3c7_TbInpg_10_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbReoX6pl0ebta1Mqf9EfQ"
      decimals="INF"
      id="Tc_4OUCnpGdrEG6cnvZf3xaUA_10_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">5000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dbReoX6pl0ebta1Mqf9EfQ"
      decimals="-3"
      id="Tc_OjI4axyZO0WR9B3u8sXn_w_10_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_klU7bfgmHkO3j4OIlzDcCQ"
      decimals="-3"
      id="Tc_W13bHMKlOkisyfMhVqwJAw_10_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cwRIsmcBbUqKd9OfVFboQA"
      decimals="INF"
      id="Tc_qF5rU01eSE-AIVAHQYIlGQ_11_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">5684</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cwRIsmcBbUqKd9OfVFboQA"
      decimals="-3"
      id="Tc_6utyp8f_IU6u0n2TKsb1WA_11_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k1H7ZYJMsU-107bPr2ox5A"
      decimals="-3"
      id="Tc_gC4IwDDGx0ukMdbXyKwryQ_11_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_bp91GE752EiqqZeYN13vUw_11_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k1H7ZYJMsU-107bPr2ox5A"
      decimals="-3"
      id="Tc_TPkzcEdB3Ey9kl9sOivpcg_12_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">86000</hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost>
    <hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_mXqdAT4By0eRUl5vnt2iuw_12_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">86000</hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_HHVctDOtV0C6dlcgQy1LxA"
      decimals="-3"
      id="Tc_I0wTzVzaeEO2x_gHKovDpw_13_21"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-777000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_7BxzSlxicEi8ERTTbJ_I8w_13_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-777000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_k1H7ZYJMsU-107bPr2ox5A"
      decimals="-3"
      id="Tc_LQ0fI3arhkS5rCntYnQ9Bg_14_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2345000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_jnPtlHKoYEu8SxvTnzQRUg_14_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2345000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MrV6NCzS0UKVJ_8-CMc7bw"
      decimals="-3"
      id="Tc_mJ--wKk9YEKFsDDvyd-Wxg_15_24"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-81580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_s95m_8JZAEmxAl5MiWXuxQ_15_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-81580000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_cp2qFIiDmE2EuFHtMEm6eA"
      decimals="INF"
      id="Tc_zivUeMsOg0eqtjm00ETRww_16_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">26438</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_cp2qFIiDmE2EuFHtMEm6eA"
      decimals="-3"
      id="Tc_PPXtofEPBU66g9A1tPNEVw_16_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eavcYujje0qBEWD0ZLFF4g"
      decimals="INF"
      id="Tc_o9P_zYaXs0-qGAOW6qMZsw_16_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">96550590</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_eavcYujje0qBEWD0ZLFF4g"
      decimals="-3"
      id="Tc_CY2YjWmyLUut5CVdhjoMOA_16_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TB8nJkfO206JH4IgeDIJYw"
      decimals="INF"
      id="Tc_uvRvF45IPUG8MyvQHs4W1Q_16_12"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TB8nJkfO206JH4IgeDIJYw"
      decimals="-3"
      id="Tc_hrFVBrXeLUq2EwXSK8Tf0A_16_15"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hawa35VgPkm-hhsVFZrIwA"
      decimals="-3"
      id="Tc_iuGPNdI3ckK0JqsdptnXtg_16_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">467041000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_gy8iNx1CQU-KWT7AIRWsZg"
      decimals="-3"
      id="Tc_nYEVCRCshk2hhyu5aGZ8gQ_16_21"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-7933000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eADOfy2zHkGdzANuuDMnKw"
      decimals="-3"
      id="Tc_DUlm38LKFkSLfZv9YBA-vg_16_24"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-369261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_paB0WL4wTUmxAdTPmTNxnQ_16_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">89857000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_7Ko22T84I06Il1nncKM6WQ"
      decimals="INF"
      id="Tc_xFe3v42wiE200fTgdOA9Ow_5_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2978</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_7Ko22T84I06Il1nncKM6WQ"
      decimals="-3"
      id="Tc_9WG4Mtk-JUGU_D3u2hPTfg_5_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GpwDSGNgm06tza9uL7YsfA"
      decimals="INF"
      id="Tc_8J8LEHIa2UmF1OAbTGECcQ_5_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">25948712</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GpwDSGNgm06tza9uL7YsfA"
      decimals="-3"
      id="Tc_ZcRRbJfxOUmBb6k8WKHZ8A_5_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XzMTTAsN-kat0RQ4mLVSsw"
      decimals="INF"
      id="Tc_WHnCdQgISESoJugm5KfAjA_5_12"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">3819732</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XzMTTAsN-kat0RQ4mLVSsw"
      decimals="-3"
      id="Tc_FVcj6YeSekCpZjDNjyMGvw_5_15"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lkdWE0tsUkWi1RgazRbc0w"
      decimals="-3"
      id="Tc_7eQ7Qr_sSE28oIgG6bzf6w_5_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">309288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_CmfM8R1qc0ia9PJJbDvGQg"
      decimals="-3"
      id="Tc_EaVeJMLCFUeFMe9wqr3amg_5_21"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-6067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GguYoNHqi02T3cZxSRd0nw"
      decimals="-3"
      id="Tc_jLPcpT9v10u8GPopiHXKuQ_5_24"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-147101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_PSUqRWmVfkCw7OQN6sRoGw"
      decimals="-3"
      id="Tc_FChepbkUlEijOMDAVOpF8A_5_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">156123000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kkhUGeXDzk62-3EYlJzDVQ"
      decimals="INF"
      id="Tc_Jn_TJbcNLEy27HNJi8AUcA_6_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">-1281</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kkhUGeXDzk62-3EYlJzDVQ"
      decimals="-3"
      id="Tc_9N96tKp1L0OQKvo6PYyxaA_6_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_PCu4S2Tjlkac9CaMTmb6UA"
      decimals="INF"
      id="Tc_rifbOpYJP0-ncCDYDLljiQ_6_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1281000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_PCu4S2Tjlkac9CaMTmb6UA"
      decimals="-3"
      id="Tc_HyGKD4V5AU6LHBspNKqcog_6_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_QKv2gv1YAkqr34O2n2MLMA"
      decimals="-3"
      id="Tc_aLqt0G4k_UO8lAKoUPEhuA_6_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw"
      decimals="INF"
      id="Tc_EmP6GXB1EUWfZ7zOkYfMjw_7_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">110071</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw"
      decimals="-3"
      id="Tc_oB9AL5P8QkS5-nV0u0YRZw_7_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zch3U472NU6ienNHLQ1xSQ"
      decimals="-3"
      id="Tc_nng59nWmvU6LuUzwGmPT6w_7_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">203000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_XSCI1_1F3kyZsait2Dy8hQ_7_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">203000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <hook:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw"
      decimals="INF"
      id="Tc_9kG7BoSMiEKba0Ws1NPtpQ_8_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">43700</hook:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_O-dEreEP9ES0moUWNhqWHw"
      decimals="-3"
      id="Tc_nHAM4ZTzREqFjdlk4b_WVA_8_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested>
    <hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zch3U472NU6ienNHLQ1xSQ"
      decimals="-3"
      id="Tc_4RCe1MXTo0-USVVzoyeUag_8_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:StockIssuedDuringPeriodValueRestrictedStockAwardVested>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pSYi6VRiEEWiQxkyw445Kw"
      decimals="-3"
      id="Tc_jZ38dKwm8ka2ItlZySgQlw_9_21"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1287000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_7mqnAg9WXU-VYd4fZWKdSA_9_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1287000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zch3U472NU6ienNHLQ1xSQ"
      decimals="-3"
      id="Tc_nXi0Cjg_LkemRfPGu4XUtQ_10_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_IBiMI77Yj0CLmlB6wclqzw_10_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7644000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Yto5HIXmyEG1TJnAO6oOwQ"
      decimals="-3"
      id="Tc_RRhEBDfEw0yXDNpcv9QcEg_11_24"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-75665000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_tJG9m9DPoEOn6LqRAQf9Nw_11_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-75665000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_tQFbE_DcHkOkMLytg817wQ"
      decimals="INF"
      id="Tc_Bj5KVu7cpki2XTV5XCcJUQ_12_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1697</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_tQFbE_DcHkOkMLytg817wQ"
      decimals="-3"
      id="Tc_lsLah2EX-ES_QF1YPrL6AA_12_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BRiLG2VnwEyMWEgoQSDszQ"
      decimals="INF"
      id="Tc_oqtqyajkUUCTck28jdeaEQ_12_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">27383483</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BRiLG2VnwEyMWEgoQSDszQ"
      decimals="-3"
      id="Tc_NV9T3RFaXkah2KnBUY1Kfw_12_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3sxrr_m_10WVU9FJBClJ1g"
      decimals="INF"
      id="Tc_HTZUo9yMFEyHSrV_Q23AQA_12_12"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">3819732</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3sxrr_m_10WVU9FJBClJ1g"
      decimals="-3"
      id="Tc_TsKcNxKY00GaLUZari39Ig_12_15"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HPm7mnaUk0OFlLY3NbuqlQ"
      decimals="-3"
      id="Tc_v5Ih3fO3JE-uGbiPpGGMgw_12_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">317135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LfPs5RT700ypYFvEtpSSxg"
      decimals="-3"
      id="Tc_M6-ZrOt8Y02myKqFD0_TZg_12_21"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-4780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_50aQNcU1rESa1A_NH0ITtQ"
      decimals="-3"
      id="Tc_diAI_5ZIfEWf9JMQor-yeA_12_24"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-222766000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw"
      decimals="-3"
      id="Tc_ZCUK2TacsUiMUGQTTMgPZQ_12_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">89592000</us-gaap:StockholdersEquity>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_Xcsey5dkJECXYtbLisOkXA"
      decimals="0"
      id="Narr_uxIpDy3QzEi-KsifyjtZ0A"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">2000</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_OohY4lRPq0yPekG2Wk5KZQ"
      decimals="-3"
      id="Narr_9mzZ4w3u30yE9mXjPV2nyg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_Lt7jkjnIqEmsokc68MGWDw"
      decimals="INF"
      id="Tc_ZrybZflSBUeRmqfcgYYugQ_13_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_Lt7jkjnIqEmsokc68MGWDw"
      decimals="-3"
      id="Tc_uK0-rG4EhkChHNvIRwG_CQ_13_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YOSFNmfs3EOqv4WZIP0Bvg"
      decimals="-3"
      id="Tc_pyTeFP-mEkqlQ5QWJVVibg_13_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">29625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4T_o5zMCE0ug338F1VQDdA"
      decimals="-3"
      id="Tc_Cfy5HAteAkOhFCUUTGGQDA_13_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">29625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_EcSzpwdfREKHNIcL7hVs2g"
      decimals="2"
      id="Narr_rLzC8hKH_0G8dOLPyojNBQ"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">2.00</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_VChA_ldFhkWxOYuQUqtGHw"
      decimals="-3"
      id="Narr_aMMFv0YPlEyXK-jJVDPGqA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2713000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_nXIctgCoNU-Gzk42kRTkKA"
      decimals="INF"
      id="Tc_e-ryeT2cV0Gt5ilaPCb0Iw_14_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">21700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_nXIctgCoNU-Gzk42kRTkKA"
      decimals="-3"
      id="Tc_kvd_FiQffk-jEjyE3nv8bQ_14_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_kQUzEzJS40CQZoM-Toa5sw"
      decimals="-3"
      id="Tc_cz72siGDDkSoaWEqAcoKWA_14_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">40685000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_PublicOfferingMember_2yyWaG6qFEu8WStCSjJPqg"
      decimals="-3"
      id="Tc_C1_ayEsvU0qVCUI4E5qNZg_14_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">40687000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_ZM4WJ3Ojn0quhH4Pn5CYdA"
      decimals="2"
      id="Narr_PIB7NXLBqEKINHtqcjttCA"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">3.00</us-gaap:SharePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_37LOdjtI8EWZBGW9I5pzGQ"
      decimals="-3"
      id="Narr_uwyRGVVKOUCYWpiqsH7Vsw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_2mnDHSaTCU-2dD6XGhTvLA"
      decimals="INF"
      id="Tc_qY-y-5Yt-0qfRr6kvWKEoQ_15_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1666666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_2mnDHSaTCU-2dD6XGhTvLA"
      decimals="-3"
      id="Tc_46rkEvMBQ0aCaG0Q8n5BnQ_15_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_qYw6vTRVN0ubcxuWYyT9fQ"
      decimals="-3"
      id="Tc_e7kZnKcsS0aBu2bv2WIbeg_15_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_uFqE4irDUEqudmnogjdsfg"
      decimals="-3"
      id="Tc_vn83meHtsk-wv8ArlgwXYA_15_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q"
      decimals="INF"
      id="Tc_aChfVnu9C0WmqIDwLUKGvg_16_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1420215</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q"
      decimals="-3"
      id="Tc_SuUYbcfXkkqWptUaAya-ig_16_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACQheD3jekytMJkUUeE47g"
      decimals="INF"
      id="Tc_QBuamxIgX0KtrYT6c_fsFQ_16_12"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">-1420215</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ACQheD3jekytMJkUUeE47g"
      decimals="-3"
      id="Tc_IgHsvxHz00GG_r1cxJLCWQ_16_15"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q"
      decimals="INF"
      id="Tc_0_JrjAryck-RG_xYfRfDxQ_17_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">34223</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q"
      decimals="-3"
      id="Tc_6VPohFjUnEauccaMRpMc1Q_17_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9_5E61jCp0qkRK8pXIBRXA"
      decimals="-3"
      id="Tc_J4ufxDlcPEirA-Y5e_UQRw_17_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_Rai6liu0xUW1EmNBgzCqLA"
      decimals="-3"
      id="Tc_RtpANzF44UiaS3fSM5Iu0A_17_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <hook:SharesIssuedSharesShareBasedPaymentArrangementVested
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q"
      decimals="INF"
      id="Tc_bU0Nhv8PCk26FG_HrqAChg_18_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">112551</hook:SharesIssuedSharesShareBasedPaymentArrangementVested>
    <hook:SharesGrantedValueShareBasedPaymentArrangementVested
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVgF3uYTWU-ok6aG4tn24Q"
      decimals="-3"
      id="Tc_rDBWsFcpJU6MbdRByse5Ww_18_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:SharesGrantedValueShareBasedPaymentArrangementVested>
    <hook:SharesGrantedValueShareBasedPaymentArrangementVested
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9_5E61jCp0qkRK8pXIBRXA"
      decimals="-3"
      id="Tc_iG8HvPyp506VhjPDtUP1gA_18_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:SharesGrantedValueShareBasedPaymentArrangementVested>
    <hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cXPFzUalKEKzwidBaBnRKg"
      decimals="-3"
      id="Tc_dGNh_3NQZky3TASXT9YCQQ_19_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">142000</hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost>
    <hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_VoPI0tcRtk6JQTZ77yJyYw_19_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">142000</hook:AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_unSFbxjx2kSBUd8Oh40Kbg"
      decimals="-3"
      id="Tc_hhVg98Bzs0KRzZoQ_k4GXA_20_21"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-2376000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_fSv2VFVyDUO7ri8PcDguLQ_20_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-2376000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cXPFzUalKEKzwidBaBnRKg"
      decimals="-3"
      id="Tc_Lkng48l8eEy8VeWnVOrcKw_21_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5043000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_rUBZoUecNEC32aecTaSJbg_21_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5043000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qZP9Or45rU2FWGne3bmD7Q"
      decimals="-3"
      id="Tc_2U0ratwu2kGAKuoc7JVHnQ_22_24"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_jHjBozhIQkaQVHEm1sm_HQ_22_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64915000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA"
      decimals="INF"
      id="Tc_xStbDAUlcU-rfgSKKkAHiA_23_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">17497</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_6ye68cWMME-bKEVgnDTZgA"
      decimals="-3"
      id="Tc_IlV85zDI80u5nkxRGZ7A0w_23_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA"
      decimals="INF"
      id="Tc_1BfUNjkqAE2rHWUU4hQYHQ_23_7"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">52317138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RdYpBrGAPkSZn1-g4N7yAA"
      decimals="-3"
      id="Tc_NEnClwUsc0WsLTiZ0pgRig_23_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g"
      decimals="INF"
      id="Tc_RNgAWBJMlECKWvgmJi2hoQ_23_12"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qbS7BI2lM06qGUGch8_u5g"
      decimals="-3"
      id="Tc_angpCfPYxEG1tGCc9m0O5w_23_15"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_p9D5TacsTUuux2uOCCEN0A"
      decimals="-3"
      id="Tc_D-aQx9pSL0qdhB8211YCxw_23_18"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">397349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ht1Iko3ekkKK4bUJJCj6Vg"
      decimals="-3"
      id="Tc_BsfuL9dM8023iqg-3OVOtg_23_21"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-7156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_qsCzYAIcaEOszR8epDIoZA"
      decimals="-3"
      id="Tc_81l8tB3wtU2H33QcEYnKsA_23_24"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-287681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_lLaTJbD5HkSnssiAT9Os1Q_23_27"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">102517000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_I5yXJkI-lUSWOW42JZATcQ_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-81580000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_Jb-jf1ifIUOoMqpMNc8P6g_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64915000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_ue64QnWoWEK3s6sQa1GKxg_4_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-75665000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_quZsVMDDrEerO9M-2YH4AA_6_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2345000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_QnjLyH4QrUmgt1oyHtWhmQ_6_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5043000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_qhEiWCfld06bMkAoSp2Rtg_6_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7644000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_VJOVrk6SakmQ0YOg55owRg_7_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3552000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_HwnTiK19T0S0Go8QUw1SzQ_7_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3602000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_DJTICutyt0asnDjxgGj6rA_7_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4640000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_8c9G8m8q9k-nPNv7wY4MLg_8_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12766000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_EIAm7UdlhEu_OIqWnA_MuQ_9_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_q_tiOxO_ukueKVKx6TFVTA_9_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-160000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_IJGYqh7qrkS6tRNsBN62Fg_9_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-1226000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_w0-Tg9W8pUqQKjHBZyNibg_11_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-6180000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_EzsBW7ndokK-tFdaQ4_Mqw_11_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">341000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_BcCEboR2_EC_w8CK1SnxcA_11_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1943000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <hook:IncreaseDecreaseInReceivableResearchIncentives
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_CJ2MPvRbT0q1P1Da9syZ6Q_12_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2726000</hook:IncreaseDecreaseInReceivableResearchIncentives>
    <hook:IncreaseDecreaseInReceivableResearchIncentives
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_A6gTDeoTOEONjXStpq6TSw_12_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1958000</hook:IncreaseDecreaseInReceivableResearchIncentives>
    <hook:IncreaseDecreaseInReceivableResearchIncentives
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_e5lkyueL8EelGtyq3gRsvA_12_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">295000</hook:IncreaseDecreaseInReceivableResearchIncentives>
    <hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_g0E5gtuWr0Occ90YgyTyEA_13_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-1735000</hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_XpK0kDZ0HEe5XKg-4GXLcQ_13_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-2007000</hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_AuyGimrwSU6uDZKUnLpW9Q_13_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7091000</hook:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_765aLQU5DEWq-M-mqWhZdg_14_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-304000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_Xtz5JdP1wUy4MlkwjBkUJQ_14_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-424000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_R-6Mck_th0Ws2NERZCRUQA_14_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-416000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_m-4CF5_Fc0utpXkPwY8b5Q_15_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">6499000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_OEowA4QUdkWX8xidfBHEFA_15_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-1999000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_axngcP9O8ECkK0ZFkheYYw_15_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">858000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_e7a18pmaKk6w1Vp41oxUEA_16_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-8258000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_mDVUd0diokerCUFFvPnlFA_16_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">35508000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_cj6yEeHO6E2XSNI8fgpGaw_16_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1422000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_cC4zXJ-lpEqH0MgUgU0r4A_17_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-1622000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_47aJrLZSnECVGBgJKuRXRw_17_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-1584000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_x3nsY5PfrEupk8hedlUccQ_17_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-1588000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_4KEWwg2nmECsA9MitQY7FQ_18_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">490000</hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities>
    <hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_ccYHBLmCrUCVJ3N8QrGu-Q_18_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2510000</hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities>
    <hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_5B9suO8KqkOnyOkNvm4e1g_18_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4776000</hook:IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_8d9KDgEkKEGGqSPRn6onEg_19_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2727000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_RYcpfuUaHEqAnXuRWnNTnA_19_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1546000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_qEMdPH73t0C7kjLvwI2pxA_19_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-416000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_ZktwEobvb0WKmH4JYjWCqQ_20_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-57524000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_l5j4gRDu60WafIY5AwyCmQ_20_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-19997000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_VgzULa4zfEauZFU1bEUSYQ_20_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-66016000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_OXXXkXw01Um5Mi1MmnY1qQ_23_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4159000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_xoZ4BZzXikWreyFK0Qm8IA_23_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5017000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_9szRd1r9CUGB4VVQuR_uzg_23_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12581000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_DnMgweq7Xkiub_PcPd08jQ_25_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-4159000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_2ZxLgIx2CUSW8Dl3qt6ajQ_25_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-5017000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_cgpLiPQ21UaXCJuDDpah0A_25_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-12581000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_UcCjc56IZUyr1yP4tnsnog_28_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">25000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_dvo147Ls70aPSR8Lq14kSA_28_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">438000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_CfpCWR_QSkqLVTAt6nNyzw_29_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">18530000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_l87TKpctrEqi1nTgVuJw4A_29_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">29625000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_xFfrDvy6yU2o0rW9dexUQw_30_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">49043000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_ZdXg3Wvrj0uemZej7tKwPA_30_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">45691000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_hWReKAa99kyWnqfUoXVdxg_30_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">203000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_tdp2Xup-rEC_1Di1ys2p1Q_31_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">149000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_kBUQZK3KvUK7zTywlbfE5w_31_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">195000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_pOeFSdL36kapp47YAwZjKw_32_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1754000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_nNPRrKlygUuFJ7Fw56Doxw_32_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2825000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_INOmb49Ao0aCDP-oLeETuw_34_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">65670000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_GhlzAUUSMU-wGGeJhi6L6w_34_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">72271000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_gV8vVGMQjE6RyDAow7KH9g_34_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-235000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_-0c-PlREkESjujNF0OK_Zw_36_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_wweVdrb3jEKlamV7PhCM0g_36_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">47257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_Y0aJpm-y-U6ko9bPh5p4Iw_36_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-78832000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_Q2FQvlFY20WV2Q7YOks-Dw_38_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">113444000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw"
      decimals="-3"
      id="Tc_gU97CZ91skeklvjMZDcskQ_38_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">66912000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_PSUqRWmVfkCw7OQN6sRoGw"
      decimals="-3"
      id="Tc_LgBhbmW0SEOs_-elW4O6IQ_38_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">143177000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_zgCosuqVb06DQKrSMyIo5w_39_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">90000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_9KwkwSEcgUGeaaW-Hhbw9Q_39_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-725000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_Q2NLjDbl10ey4MeoeYfadQ_39_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2567000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_Tre6XGb4U0CPp2mc0asChg_40_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">117521000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_oZUdVAL5ZkG51480xy-Kvw_40_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">113444000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw"
      decimals="-3"
      id="Tc_JwRvmpy7yk2JBm3IHd9nkg_40_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">66912000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_3UJiTkbctUi_3y6ZAK5N3A_43_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">14000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_4HJsoIcS9kaNYLfORfxXHg_43_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">32000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_4ql3tslo0kmJO7od4I-qAQ_43_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">48000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_awqZpsTxr0mDpn8kg6UcMg_44_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">403000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_cVcTPiitb0-8Vu7l7Mxwww_44_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_wyAZ2nL6XE6MI8nN2uigEw_44_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_IO_ez6knZU2_hkr7r30T_w_47_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">34000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_nymgSQ4RCEC_lNJWsznhoA_47_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">56000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_8IcY1O_t_U6wSHzDWBJCFA_47_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">742000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc__gZLLBN23kqqA5rKa-e5NA_48_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2874000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_avEMQ-5OBEGl_wZVCI--qw_48_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">225000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_WhGqOvrCgEWMOVfX1z4xcg_48_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2727000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <hook:LeaseAssetsDerecognizedUponLeaseCancellation
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_qik5bQL83k-RmuC88QwKvA_49_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1061000</hook:LeaseAssetsDerecognizedUponLeaseCancellation>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_uHfLEoOoPk6CBdL3XO0Zyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1.&#160;Nature of the business and organization&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;HOOKIPA Pharma&#160;Inc. (&#x201c;HOOKIPA&#x201d; or the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body&#x2019;s immune system.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company was incorporated under the name of Hookipa Biotech,&#160;Inc. under the laws of the State of Delaware in February&#160;2017 as a fully-owned subsidiary of Hookipa Biotech AG. In June&#160;2018, the Company changed its name from Hookipa Biotech,&#160;Inc. to HOOKIPA Pharma&#160;Inc. and in order to effectuate the change of the jurisdiction of incorporation, the Company acquired all of the shares of Hookipa Biotech AG, now Hookipa Biotech GmbH. HOOKIPA is headquartered in New York, with European research and preclinical development operations headquartered in Vienna, Austria. In April&#160;2019, the Company closed its initial public offering (&#x201c;IPO&#x201d;) and its common stock started trading on the Nasdaq Global Select Market under the ticker symbol &#x201c;HOOK&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, the ability to establish clinical- and commercial-scale manufacturing processes and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities and may not ultimately lead to a marketing approval and commercialization of a product. Even if the Company&#x2019;s drug development efforts are successful, it is uncertain if and when the Company will realize significant revenue from product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_zUxLtDPaKUGDlNlpoDWYiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2.&#160;Summary of significant accounting policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Going concern&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Since inception, the Company&#x2019;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2023, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $81.6&#160;million, $64.9&#160;million and $75.7&#160;million for the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively. As of December&#160;31,&#160;2023, the Company had an accumulated deficit of $369.3&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;22,&#160;2024, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company will seek additional funding in order to reach its development and commercialization objectives. The Company may seek funds through further equity financings, debt financings, collaborations, strategic alliances and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards, the valuation of current and non-current loans payable and the impairment of long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency and currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency for the Company is the United States dollar and the functional currency for the Company's wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of credit risk and of significant suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 the net proceeds from the Company&#x2019;s offerings have been deposited in interest-bearing bank accounts with two of the largest investment grade U.S. financial institutions and have been partially invested in money market funds. The money market funds, held in U.S. dollars, are primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, the Company&#x2019;s cash and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;cash equivalents included smaller amounts of cash balances held in accounts with regional European banks at the Company&#x2019;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively, Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;) and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together &#x201c;Roche&#x201d;) accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021 Gilead and Roche accounted for the majority of the Company&#x2019;s revenues. Other customers accounted for less than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022 cash equivalents consisted of money market funds and short-term deposits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred offering costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;5).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;useful&#160;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;shorter of useful life or term of lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#x201c;ROU&#x201d;) assets and lease liabilities in the consolidated balance sheets. For leases with an initial term of 12 months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#x2019;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#x201c;ASC&#x201d;)&#160;360.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Capitalized Software Development Cost&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of $0.1&#160;million associated with the Company's cloud computing arrangements has been recognized during each of the fiscal years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 (see Note&#160;6). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value (see Note 4. and Note 6.).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company's resources. The majority of the Company's tangible assets are held in Austria.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition from contracts with customers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized revenue from collaboration and license agreements with Gilead and Roche. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Under the collaboration and license agreement with Gilead (as amended and restated, the &#x201c;Gilead Collaboration Agreement&#x201d;), the parties agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#x201c;HBV&#x201d;) and the human immunodeficiency virus (&#x201c;HIV&#x201d;). In February&#160;2022, the parties signed an amended and restated collaboration agreement (the &#x201c;Restated Gilead Collaboration Agreement&#x201d;), which revised the terms only for the HIV program, whereby the Company took on development responsibilities for the HIV program candidate through a Phase&#160;1b clinical trial. The Company&#x2019;s performance obligations under the terms of the original agreement include one combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The terms of the Restated Gilead Collaboration Agreement added an additional performance obligation to perform research and development work for the HIV program. The licenses do not &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under the Restated Gilead Collaboration Agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the research collaboration and license agreement with Roche (the &#x201c;Roche Collaboration Agreement&#x201d;), the Company has agreed to conduct research and early clinical development through Phase&#160;1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. The Roche Collaboration Agreement also includes an obligation of the Company to deliver a specified package of preclinical data and results with respect to a second program, targeting undisclosed cancer antigens (collectively &#x201c;UCAs&#x201d;) and an option for Roche to license the UCA program. The Company&#x2019;s performance obligations under the terms of the Roche Collaboration Agreement include one combined performance obligation for the transfer of intellectual property rights (licenses) and providing research and development services for the HB-700 program, and a second, separate performance obligation to perform research and development services with respect to the UCA program. The UCA Option provides a right to license the program at the standalone selling price and therefore does not constitute a separate performance obligation. Payments to the Company under the Roche Collaboration Agreement include a non-refundable up-front payment, payments based upon the achievement of defined milestones, an additional payment if the option for the UCA program is exercised and royalties on product sales. In January 2024, Roche provided written notice of the termination of the collaboration and licensing agreement to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC&#160;606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC&#160;606, the Company applies significant judgement to evaluate whether the promises under the collaboration and licensing arrangements, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, the timing of revenue recognition, whether the UCA Option constitutes a material right, and the determination of when milestone payments are probable of being received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Upfront payment and program initiation fee&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The non-refundable upfront-payment received by the Company upon signing of the Gilead Collaboration Agreement, and milestone payments that were linked to future performance obligations, were initially recorded as deferred revenue and allocated between the two research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The non-refundable program initiation payment received from Gilead upon signing of the Restated Collaboration Agreement was also initially recorded as deferred revenue and is recognized on a percent of completion basis using total estimated research and development costs (input method) for the performance of the obligations. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer, due to the immediate benefit that it adds to the value of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;the customer&#x2019;s rights on the program, the short time intervals in which development results are shared and the nature of the work being performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The non-refundable upfront-payment received by the Company upon signing of the Roche Collaboration Agreement, was initially recorded as deferred revenue and allocated between the HB-700 program and the UCA program. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development costs (input method) for each of the obligations during the initial term of the contract. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reimbursement for services&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Gilead Collaboration Agreement and the Roche Collaboration Agreement, the Company incurs employee expenses as well as external costs for research, manufacturing and clinical trial activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangements, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues as progress is achieved. Unpaid reimbursement amounts are presented as Accounts Receivable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and development milestones&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gilead Collaboration Agreement and the Roche Collaboration Agreement include contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific uncertainties and the required commitment from Gilead and Roche. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to including the variable consideration associated with these payments within the transaction price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Sales-based milestones and royalty payments&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gilead Collaboration Agreement and the Roche Collaboration Agreement also include certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Cost to fulfill contracts&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and manufacturing contract costs and accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Government grant agreements and research incentives&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes funding from grants and research incentives received from Austrian government agencies as well as from New York State and New York City government agencies in the United States as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company's common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient's payroll costs are classified or in which the recipient's service payments are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss and foreign currency translation adjustments. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 comprehensive loss included $0.8&#160;million and $2.4&#160;million, respectively, of foreign currency translation loss adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $1.3&#160;million of foreign currency translation gain adjustments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2023, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2017 Tax Cuts and Jobs Act subjects a US shareholder to tax on global intangible low-taxed income (&#x201c;GILTI&#x201d;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in the future years or provide for tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize tax expense related to GILTI in the year the tax is incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Adopted as of current period&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718) to amend various SEC paragraphs in the Accounting Standards Codification to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. Staff Accounting Bulletin No. 120 provides guidance to companies issuing share-based awards shortly before announcing material, nonpublic information to consider such material nonpublic information to adjust observable market prices if the release of material nonpublic information is expected to affect the share price. The ASU does not provide any new guidance so there is no transition or effective date associated with it and therefore, the Company adopted the ASU with no impact to its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#x201c;own stock&#x201d; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company adopted this standard with no impact to its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_K-iM1PahdUuot_zG6JtbcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <hook:GoingConcernPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_24i2poVYSEe3sQxnA2S8tA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Going concern&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Since inception, the Company&#x2019;s activities have consisted primarily of performing research and development to advance its technologies. The Company is still in the development phase and has not been marketing its technologies to date. Through December&#160;31,&#160;2023, the Company has funded its operations with proceeds from sales of common stock, sales of convertible preferred stock, sales of redeemable convertible preferred stock, collaboration and licensing agreements, grants and borrowings under various agreements with foreign public funding agencies. Since inception, the Company has incurred recurring losses, including net losses of $81.6&#160;million, $64.9&#160;million and $75.7&#160;million for the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively. As of December&#160;31,&#160;2023, the Company had an accumulated deficit of $369.3&#160;million. The Company expects to continue to generate operating losses in the foreseeable future. As of March&#160;22,&#160;2024, the filing date of this Annual Report on Form&#160;10-K, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12&#160;months from the issuance date of the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company will seek additional funding in order to reach its development and commercialization objectives. The Company may seek funds through further equity financings, debt financings, collaborations, strategic alliances and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt;</hook:GoingConcernPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_QsvcaFqJUEeNYgyeoqoiGA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-81600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_ja2R6ir1YEmfi2q0b1IooQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-5"
      id="Narr_nWoCfJjLh06sM32VsWhgrg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-75700000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-5"
      id="Narr_tMYPLLZQZEik8ZXXNcb_IQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-369300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_k-vjCcVw4Ua5V2gG8YFxpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue and income, the accrual of research and development expenses and general and administrative expenses, the present value of lease right of use assets and corresponding liabilities, the valuation of stock-based awards, the valuation of current and non-current loans payable and the impairment of long-lived assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from those estimates or assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_Hdbcl-psr0SOG-_ziBpPDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency and currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency for the Company is the United States dollar and the functional currency for the Company's wholly owned foreign subsidiary, Hookipa Biotech GmbH, is the euro.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities of Hookipa Biotech GmbH are translated into United States dollars at the exchange rate in effect on the balance sheet date. Income items and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) as a component of Accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expenses, net in the Consolidated Statements of Operations and Comprehensive Loss as incurred.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_5px0XzcdHkSdZWdFmipnMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of credit risk and of significant suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term bank deposits held with banks in excess of publicly insured limits. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 the net proceeds from the Company&#x2019;s offerings have been deposited in interest-bearing bank accounts with two of the largest investment grade U.S. financial institutions and have been partially invested in money market funds. The money market funds, held in U.S. dollars, are primarily invested in U.S. and foreign short-term debt obligations. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, the Company&#x2019;s cash and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;cash equivalents included smaller amounts of cash balances held in accounts with regional European banks at the Company&#x2019;s Austrian subsidiary, partially in euros. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and raw materials for its development programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively, Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;) and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together &#x201c;Roche&#x201d;) accounted for the majority of the accounts receivable balance. For the years ended December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021 Gilead and Roche accounted for the majority of the Company&#x2019;s revenues. Other customers accounted for less than 10.0% of accounts receivable or net sales. The Company monitors the financial performance of its customers so that it can appropriately respond to changes in their credit worthiness. To date, the Company has not experienced any significant losses with respect to collection of its accounts receivable.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_ko-ixCQC9UST2ygDxcw3xQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022 cash equivalents consisted of money market funds and short-term deposits.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <hook:DeferredOfferingCostsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_wrmaUWtz9ESnu1c4AlwEjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred offering costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#x2019; equity as a reduction of the additional paid-in capital on a pro-rata basis generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</hook:DeferredOfferingCostsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_EMcRpuTekUebnVbWb4xURA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 - Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;5).&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_DA_TpH1MwUCBxnWPpw77Vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;useful&#160;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;shorter of useful life or term of lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Expenditures for repairs and maintenance are charged to expense as incurred. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_gJaePAoZikamlGMNYZCkQQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;useful&#160;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;shorter of useful life or term of lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 10 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2 - 4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Kkn9Mty5DUurhtItxm046g"
      id="Narr_ljmwRFk7uUy-7Ha8khHDaA">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_W1jTBgF7KU6w3PAGk_NZLA"
      id="Narr_wGRfmUGNKUKCsuqfVPXVhg">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_X3TmsbLhFku7xpVyRcYkrQ"
      id="Narr_jINFXzY_Dkya9Bv6dViwsg">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_oSbIwYv_yE-SfbOG9eEVMQ"
      id="Narr_H4A-ee7zIEOWUOo6F9h7JQ">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Y740NWFhXUaA_KiLwpYS-Q"
      id="Narr_k98d4ForMkiUF-AhPsrglw">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_fTi5jMBdM0qbHxQohSMwDw"
      id="Narr_lx4EAyvipUCgAOz6SP6G8A">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_U0N1iec4B0m9UnTH88bSVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The determination whether an arrangement qualifies as a lease is made at contract inception. A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases and are included in right of use (&#x201c;ROU&#x201d;) assets and lease liabilities in the consolidated balance sheets. For leases with an initial term of 12 months or less, the Company does not recognize a right of use asset or lease liability. These short-term leases are expensed on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. The lease payments used to determine ROU assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized as ROU asset on the consolidated balance sheet. In addition, certain of the Company&#x2019;s arrangements contain lease and non-lease components. The Company generally separates lease payments from non-lease payments. Operating leases are reflected in operating lease assets, in current operating lease liabilities and non-current operating lease liabilities in the consolidated balance sheets. Finance leases are reflected in finance lease assets, in accrued expenses and other current liabilities and in other non-current operating lease liabilities in the consolidated balance sheets. The ROU asset is tested for impairment in accordance with Accounting Standards Codification&#160;(&#x201c;ASC&#x201d;)&#160;360.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_UxaEGXYxXkenJZcLyn3cwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Capitalized Software Development Cost&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company capitalizes certain implementation costs for internal-use software incurred in a cloud computing agreement that is a service contract. Eligible costs associated with cloud computing arrangements, such as software business applications used in the normal course of business, are capitalized in accordance with ASC&#160;350. These costs are recognized on a straight-line basis in the same line item in the statement of operations and comprehensive loss as the expense for fees for the associated cloud computing arrangement, over the term of the arrangement, plus reasonably certain renewals. Amortization expense of $0.1&#160;million associated with the Company's cloud computing arrangements has been recognized during each of the fiscal years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 (see Note&#160;6). The Company tests for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_w7lQTu68vE-easOWEWnUsA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_DdbPOR9mY0qHUd7ZT1UsBA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_m0Am1ThASUqfIV_MdrnsCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-lived assets, including operating and finance lease right of use assets, consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative technological, scientific or economic trends and significant changes or planned changes in the use of the assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value (see Note 4. and Note 6.).&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_irR8dE7k9k-uAAv1HMsL-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company's singular focus is on developing pharmaceutical products to prevent and cure infectious diseases and cancer. The Chief Executive Officer is the chief operating decision maker, and regularly reviews the consolidated operating results to make decisions about the allocation of the Company's resources. The majority of the Company's tangible assets are held in Austria.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_RfIRCYRSc02nmX3FPjF0vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition from contracts with customers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized revenue from collaboration and license agreements with Gilead and Roche. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Under the collaboration and license agreement with Gilead (as amended and restated, the &#x201c;Gilead Collaboration Agreement&#x201d;), the parties agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of the hepatitis B virus (&#x201c;HBV&#x201d;) and the human immunodeficiency virus (&#x201c;HIV&#x201d;). In February&#160;2022, the parties signed an amended and restated collaboration agreement (the &#x201c;Restated Gilead Collaboration Agreement&#x201d;), which revised the terms only for the HIV program, whereby the Company took on development responsibilities for the HIV program candidate through a Phase&#160;1b clinical trial. The Company&#x2019;s performance obligations under the terms of the original agreement include one combined performance obligation for each research program (HBV and HIV) comprised of the transfer of intellectual property rights (licenses) and providing research and development services. The terms of the Restated Gilead Collaboration Agreement added an additional performance obligation to perform research and development work for the HIV program. The licenses do not &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;represent distinct performance obligations, because they cannot be used without the research and development services. Payments to the Company under the Restated Gilead Collaboration Agreement include a non-refundable up-front payment, payments for research and development activities, payments based upon the achievement of defined milestones, and if certain future conditions are met, payments for manufacturing services, commercial milestones and royalties on product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the research collaboration and license agreement with Roche (the &#x201c;Roche Collaboration Agreement&#x201d;), the Company has agreed to conduct research and early clinical development through Phase&#160;1b for HB-700, a novel investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. The Roche Collaboration Agreement also includes an obligation of the Company to deliver a specified package of preclinical data and results with respect to a second program, targeting undisclosed cancer antigens (collectively &#x201c;UCAs&#x201d;) and an option for Roche to license the UCA program. The Company&#x2019;s performance obligations under the terms of the Roche Collaboration Agreement include one combined performance obligation for the transfer of intellectual property rights (licenses) and providing research and development services for the HB-700 program, and a second, separate performance obligation to perform research and development services with respect to the UCA program. The UCA Option provides a right to license the program at the standalone selling price and therefore does not constitute a separate performance obligation. Payments to the Company under the Roche Collaboration Agreement include a non-refundable up-front payment, payments based upon the achievement of defined milestones, an additional payment if the option for the UCA program is exercised and royalties on product sales. In January 2024, Roche provided written notice of the termination of the collaboration and licensing agreement to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates its collaboration and licensing arrangements pursuant to ASC&#160;606 Revenue from Contracts with Customers. To determine the recognition of revenue from arrangements that fall within the scope of ASC&#160;606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC&#160;606, the Company applies significant judgement to evaluate whether the promises under the collaboration and licensing arrangements, represent separate or one or more combined performance obligations, the allocation of the transaction price to identified performance obligations, the timing of revenue recognition, whether the UCA Option constitutes a material right, and the determination of when milestone payments are probable of being received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Upfront payment and program initiation fee&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The non-refundable upfront-payment received by the Company upon signing of the Gilead Collaboration Agreement, and milestone payments that were linked to future performance obligations, were initially recorded as deferred revenue and allocated between the two research program performance obligations. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development labor hours (input method) for each of the obligations. The percent of completion basis using labor hours was considered the best measure of progress in which control of the combined performance obligations transfers to the customer, due to the short time intervals in which research results are shared with the collaboration partner and the nature of the work being performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The non-refundable program initiation payment received from Gilead upon signing of the Restated Collaboration Agreement was also initially recorded as deferred revenue and is recognized on a percent of completion basis using total estimated research and development costs (input method) for the performance of the obligations. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer, due to the immediate benefit that it adds to the value of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;the customer&#x2019;s rights on the program, the short time intervals in which development results are shared and the nature of the work being performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The non-refundable upfront-payment received by the Company upon signing of the Roche Collaboration Agreement, was initially recorded as deferred revenue and allocated between the HB-700 program and the UCA program. Such amounts are recognized as revenue over the performance period of the respective services on a percent of completion basis using total estimated research and development costs (input method) for each of the obligations during the initial term of the contract. The percent of completion basis using research and development costs was considered the best measure of progress in which control of the performance obligations transfers to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reimbursement for services&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Gilead Collaboration Agreement and the Roche Collaboration Agreement, the Company incurs employee expenses as well as external costs for research, manufacturing and clinical trial activities presented as operating expenses or prepaid expenses. Based on the nature of the Company's responsibilities under the collaboration arrangements, reimbursement of those costs are presented as revenue and not deducted from expenses, as the Company controls the research activities. Amounts of consideration allocated to the performance of research or manufacturing services are recognized over the period in which services are performed. Reimbursements for external costs are recognized as revenues as progress is achieved. Unpaid reimbursement amounts are presented as Accounts Receivable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and development milestones&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gilead Collaboration Agreement and the Roche Collaboration Agreement include contingent milestone payments related to specified preclinical and clinical development milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC&#160;606, due to the scientific uncertainties and the required commitment from Gilead and Roche. The Company will continue to assess the probability of significant reversals for any amounts that become likely to be realized prior to including the variable consideration associated with these payments within the transaction price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Sales-based milestones and royalty payments&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gilead Collaboration Agreement and the Roche Collaboration Agreement also include certain sales-based milestone and royalty payments upon successful commercialization of a licensed product. In accordance with ASC&#160;606-10-55-65 Sales Based or Usage Based Royalties, the Company recognizes revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale; or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Cost to fulfill contracts&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. Sublicense fees triggered by the receipt of payments are capitalized as an asset when the obligation to pay the fee arises. The capitalized asset is amortized over the period in which the revenue from the triggering payment is recognized.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <hook:CollaborativeArrangementNumberOfPreclinicalResearchPrograms
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="INF"
      id="Narr_Hd55lHAEJUuDdusP_eWLAQ"
      unitRef="Unit_Standard_Program_OVVzQkKn40SXnlnbXe7UtA">2</hook:CollaborativeArrangementNumberOfPreclinicalResearchPrograms>
    <hook:NumberOfCombinedPerformanceObligationForEachResearchProgram
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="INF"
      id="Narr_kCyOmayJ8E64ob81RrFfWA"
      unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg">1</hook:NumberOfCombinedPerformanceObligationForEachResearchProgram>
    <hook:NumberOfCombinedPerformanceObligation
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="INF"
      id="Narr_z07lUc0MzUihimEoDpCReQ"
      unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg">1</hook:NumberOfCombinedPerformanceObligation>
    <hook:NumberOfResearchProgramPerformanceObligations
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="INF"
      id="Narr_aXPo9u7_lEOu979MgBUncg"
      unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg">2</hook:NumberOfResearchProgramPerformanceObligations>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_0LfErrppRESk9V2f8iaS8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments, milestone payments and annual payments made for the licensing of technology are generally expensed as research and development in the period in which they are incurred. Incremental sublicense fees triggered by contracts with customers are capitalized and expensed as research and development expenses over the period in which the related revenue is recognized.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <hook:ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_lV_ieuLyLEaWeP_ue5Ua6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and manufacturing contract costs and accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into various research and development and manufacturing contracts. Related payments are recorded as the corresponding expenses are incurred. The Company records accruals for estimated ongoing costs and prepaid expenses for advance payments. When evaluating the adequacy of the accrued liabilities and prepaid expenses, the Company analyzes progress of the research studies or clinical trials and manufacturing activities, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs.&lt;/p&gt;</hook:ResearchAndManufacturingContractCostsAndAccrualsPolicyPolicyTextBlock>
    <hook:GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_aEgBYL24_k-B5nr4nIMtqg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Government grant agreements and research incentives&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes funding from grants and research incentives received from Austrian government agencies as well as from New York State and New York City government agencies in the United States as other income. Income from grants and incentives is recognized in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grant funding that has been received by the Company in advance of incurring qualifying expenses is recorded as deferred income. Grant and incentive income recognized upon incurring qualifying expenses in advance of receipt of grant funding or proceeds from research and development incentives is recorded in the consolidated balance sheets as prepaid expenses and other current assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received loans under funding agreements that bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged as additional grant funding, and records interest expense for the loans at a market rate of interest. On the date that loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as other liability, which is subsequently recognized as additional grant income over the term of the funding agreement.&lt;/p&gt;</hook:GovernmentGrantAgreementsAndResearchIncentivesPolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_1X53pN3ZBE6QvKzfy5O0hA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of the Company's common stock for restricted common stock awards. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company uses the graded-vesting method to record the expense of awards with service-based vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies stock-based compensation expense in its Consolidated Statements of Operations and Comprehensive Loss in the same manner in which the recipient's payroll costs are classified or in which the recipient's service payments are classified.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_2oXwA53DU0yWdsPh4PWZjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss includes net loss and foreign currency translation adjustments. For the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 comprehensive loss included $0.8&#160;million and $2.4&#160;million, respectively, of foreign currency translation loss adjustments. For the year ended December&#160;31,&#160;2021, comprehensive loss included $1.3&#160;million of foreign currency translation gain adjustments.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_I2-HeT-WVk6KpgL-a7nUcA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-800000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_vYSDTuR_pkONNpUPF8AiuA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-2400000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-5"
      id="Narr_2BadKWuDlECPJu0xeeIxXg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1300000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <hook:EarningsPerSharePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_k8gig923ukqfwpLt2N9rHw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding for the period, including potential dilutive shares assuming the dilutive effect of outstanding stock options and of convertible preferred stock. For periods in which the Company has reported net losses, diluted net loss per common share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their affect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reported a net loss attributable to common stockholders for the years ended December&#160;31,&#160;2023, 2022 and 2021.&lt;/p&gt;</hook:EarningsPerSharePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_DvsGYyvFakaLlO7Ff7esdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in income tax expense. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2017 Tax Cuts and Jobs Act subjects a US shareholder to tax on global intangible low-taxed income (&#x201c;GILTI&#x201d;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in the future years or provide for tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize tax expense related to GILTI in the year the tax is incurred.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_K8G3SBroOEqCyQN5inW0JA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Adopted as of current period&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement - Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation - Stock Compensation (Topic 718) to amend various SEC paragraphs in the Accounting Standards Codification to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. Staff Accounting Bulletin No. 120 provides guidance to companies issuing share-based awards shortly before announcing material, nonpublic information to consider such material nonpublic information to adjust observable market prices if the release of material nonpublic information is expected to affect the share price. The ASU does not provide any new guidance so there is no transition or effective date associated with it and therefore, the Company adopted the ASU with no impact to its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2020, the FASB issued ASU&#160;2020-06, Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40). The ASU provides guidance that simplified the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the &#x201c;own stock&#x201d; scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. This guidance is effective for fiscal years beginning after December&#160;15,&#160;2023, including interim periods within those fiscal years with early adoption permitted. The Company adopted this standard with no impact to its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In November&#160;2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December&#160;15,&#160;2024. The Company is not early adopting, and therefore this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_M95CQoxRb02QT_2bnDKkUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Collaboration and Licensing Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Gilead Collaboration and License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2018, the Company entered into the Gilead Collaboration Agreement whereby the Company and Gilead agreed to collaborate with respect to two preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis or prevention of HBV and HIV. In February&#160;2022, the Company signed the Amended and Restated Collaboration Agreement, which altered key aspects of the collaboration pertaining to the HIV therapeutic. Most importantly, the Amended and Restated Collaboration Agreement allocated additional research and development responsibility to the Company with respect to the Company&#x2019;s HIV candidate and provided for additional funding by Gilead of such research and development activities as well as increased later stage development and commercial milestone payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Gilead Collaboration Agreement, the Company granted Gilead an exclusive, royalty-bearing license to the Company&#x2019;s technology platforms. Upon entering into the agreement in June&#160;2018, the Company received a non-refundable $10.0&#160;million upfront payment from Gilead and upon signing of the Restated Gilead Collaboration Agreement in February&#160;2022, the Company received a program initiation fee of $15.0&#160;million. Gilead is also obligated to make additional payments to the Company upon the achievement of pre-clinical, development and commercial milestones. The development milestones amount to $140.0&#160;million for the HBV program, and up to $172.5&#160;million for the HIV program, inclusive of a $10.0&#160;million program completion fee, payable upon Gilead&#x2019;s exercise of the option to pursue further development activities post Phase&#160;1b. The commercial milestones amount to a total of $50.0&#160;million for the HBV program, and $65.0&#160;million for the HIV program. Additionally, Gilead is obligated to pay royalties on net sales for each program. Payments from Gilead generally have a 60&#160;day payment term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The $10.0&#160;million upfront payment, the $15.0&#160;million initiation fee and $8.0&#160;million in milestone payments were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of December&#160;31,&#160;2023, $7.5&#160;million of such payments were still recorded as a liability in deferred revenues, current and non-current. As of December&#160;31,&#160;2022, $14.3&#160;million of upfront and milestone payments were included as a liability in deferred revenues, current and non-current. Approximately 55.2% of deferred revenue is expected to be recognized as revenue in 2024, 36.8% in 2025 and the remaining 8.0% in 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the year ended December&#160;31,&#160;2023, the Company recognized $7.1&#160;million of the milestone and initiation payments that were originally recorded as deferred revenue. Furthermore, the Company recognized $1.4&#160;million revenue from cost reimbursements for research and development services. In the year ended December&#160;31,&#160;2022, the Company recognized $3.7&#160;million of the upfront and milestone payments that were originally recorded as deferred revenue, $5.2&#160;million revenue from cost reimbursements for research and development services and $5.0&#160;million revenue from a milestone achieved in December&#160;2022. In the year ended December&#160;31,&#160;2021, the Company recognized $2.1&#160;million of the upfront and milestone payments that were originally recorded as deferred revenue and $16.3&#160;million revenue from cost reimbursements for research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;the triggering payment is recognized. As of December&#160;31,&#160;2023 and 2022, the contract asset relating to the sublicense payment was $0.1&#160;million and $0.2&#160;million, respectively, and there was no liability relating to sublicense payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Roche Collaboration and License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October&#160;2022, the Company entered into the Roche Collaboration Agreement whereby the Company and Roche agreed to collaborate with respect to the development of novel arenaviral immunotherapies for KRAS-mutated cancers and, potentially, a second, novel arenaviral immunotherapeutic program targeting specific undisclosed cancer antigens. In January&#160;2024, Roche provided written notice of the termination of the collaboration and licensing agreement to the Company (see Note 18. &#x201c;Subsequent Events&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the terminated Roche Collaboration Agreement, the Company granted Roche an exclusive, royalty-bearing license to the Company&#x2019;s technology platforms for KRAS-mutated cancers, and an option right to exclusively license a second, novel arenaviral immunotherapeutic program targeting undisclosed cancer antigens. Pursuant to the terms of the Collaboration Agreement, following the termination notice, the Collaboration Agreement will end on April&#160;25,&#160;2024. The Company remains eligible for a final milestone payment associated with an IND submission. Effective April&#160;25,&#160;2024, the Company will regain full control of the associated intellectual property portfolio and will have full collaboration and licensing rights for the KRAS program.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon signing the Roche Collaboration Agreement in October&#160;2022, the Company received a non-refundable upfront payment of $25.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;This upfront payment, and a $10.0&#160;million milestone payment received in the twelve months ended December&#160;31,&#160;2023 were initially recorded as deferred revenue in the consolidated balance sheet and are recognized as revenue when revenue recognition criteria are met. As of December&#160;31,&#160;2023, $26.8&#160;million of such payments were still recorded as a liability in deferred revenues, current and non-current. As of December&#160;31,&#160;2022, $27.0&#160;million of the upfront payment was included as a liability in deferred revenues, current and non-current. The deferred revenues related to the $25.0&#160;million upfront payment and the $10.0&#160;million milestone payment are subject to foreign currency exchange rate fluctuations in future accounting periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the year ended December&#160;31,&#160;2023, the Company recognized $11.1&#160;million of the upfront and milestone payments that were originally recorded as deferred revenue. Furthermore, the Company recognized $0.5&#160;million revenue from cost reimbursements for activities related to the preparation of a first in human trial. In the year ended December&#160;31,&#160;2022, the Company recognized $0.3&#160;million of the upfront payment that was originally recorded as deferred revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Sublicense fees payable to certain licensors of technologies upon the receipt of the deferred upfront and milestone payments, were capitalized as a contract asset and will be amortized over the period in which the revenue from the triggering payment is recognized. As of December&#160;31,&#160;2023, the contract asset relating to the sublicense payment was $2.0&#160;million and there was no liability relating to sublicense payment. As of December&#160;31,&#160;2022 the contract asset and the liability relating to the sublicense payment was $1.5&#160;million and $1.2&#160;million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <hook:NumberOfPreclinicalResearchPrograms
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA"
      decimals="INF"
      id="Narr_-uwJqYvwn0qiRAIC5328Qg"
      unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg">2</hook:NumberOfPreclinicalResearchPrograms>
    <hook:ProceedsFromNonRefundableUpFrontPayment
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA"
      decimals="-5"
      id="Narr_x9Gk1mcGhk2JxDjkb8dWdQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10000000.0</hook:ProceedsFromNonRefundableUpFrontPayment>
    <hook:CollaborativeAgreementProgramInitiationFees
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA"
      decimals="-5"
      id="Narr_jIA8fdMLT0W0zdibpGqD3w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">15000000.0</hook:CollaborativeAgreementProgramInitiationFees>
    <hook:TotalMilestoneAmount
      contextRef="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HbvProgramMember_3dT06FX4VkCwkIjTV8mikA"
      decimals="-6"
      id="Narr_JQdT3tdhF0S1h3GmtxJ1tw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">140000000.0</hook:TotalMilestoneAmount>
    <hook:TotalMilestoneAmount
      contextRef="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_eFFXVBkbrEeySJMxE-8wLQ"
      decimals="-5"
      id="Narr_Kcv6cSDjTkipW-47pVuzhw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">172500000</hook:TotalMilestoneAmount>
    <hook:CollaborationArrangementProgramCompletionFeeOnOptionExercise
      contextRef="As_Of_6_30_2018_hook_MilestoneAxis_hook_DevelopmentMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_DRzR59S0e0i1yiiJ_sbKPw"
      decimals="-5"
      id="Narr_v91eOO82Oky6o1RN05p4yA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10000000.0</hook:CollaborationArrangementProgramCompletionFeeOnOptionExercise>
    <hook:TotalMilestoneAmount
      contextRef="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HbvProgramMember_u76tVQD6oU2TjpnsvGjXJw"
      decimals="-5"
      id="Narr__HhAs6P_TEaEHweIypxSng"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">50000000.0</hook:TotalMilestoneAmount>
    <hook:TotalMilestoneAmount
      contextRef="Duration_6_1_2018_To_6_30_2018_hook_MilestoneAxis_hook_CommercialMilestonesMember_us-gaap_TypeOfArrangementAxis_hook_HivProgramMember_eTvVFL_Gb0ihVkFmAe5Ybg"
      decimals="-5"
      id="Narr_7X4jgN-j3EehjXHrFISW5w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">65000000.0</hook:TotalMilestoneAmount>
    <hook:CollaborativeArrangementTermOfRoyaltyPayment
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA"
      id="Narr_l_899bm0IEmJnt3fZDdeEQ">P60D</hook:CollaborativeArrangementTermOfRoyaltyPayment>
    <hook:ProceedsFromNonRefundableUpFrontPayment
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA"
      decimals="-5"
      id="Narr_CZTHnZI9nU-jnXaDlZ9guw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10000000.0</hook:ProceedsFromNonRefundableUpFrontPayment>
    <hook:CollaborativeAgreementProgramInitiationFees
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA"
      decimals="-5"
      id="Narr_USH4f4JWKUu2uEfYzf7cAQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">15000000.0</hook:CollaborativeAgreementProgramInitiationFees>
    <hook:ProceedsFromMilestonePayment
      contextRef="Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_YnIO_V3YgkGdvEudImVfAA"
      decimals="-5"
      id="Narr_MpxCLfE4zEel3wAwvYcc8w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">8000000.0</hook:ProceedsFromMilestonePayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg"
      decimals="-5"
      id="Narr_qgezqEplwESt0S26-K-s-A"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4qOs21ojTUO-rUJpz1kUcg"
      decimals="-5"
      id="Narr_EtFKa7nobkOhlH6Q7GkoJg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">14300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <hook:DeferredRevenuePercentageOfRevenueRecognizedInYearOne
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg"
      decimals="3"
      id="Narr_bUFmZFzgOke_91zwJTE8_g"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.552</hook:DeferredRevenuePercentageOfRevenueRecognizedInYearOne>
    <hook:DeferredRevenuePercentageOfRevenueRecognizedInYearTwo
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg"
      decimals="3"
      id="Narr_wBLEB78Z90GSGsoY7rTxtQ"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.368</hook:DeferredRevenuePercentageOfRevenueRecognizedInYearTwo>
    <hook:DeferredRevenuePercentageOfRevenueRecognizedInYearThree
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg"
      decimals="3"
      id="Narr_arO3HLkjN0eL0ldy8r-6zw"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.080</hook:DeferredRevenuePercentageOfRevenueRecognizedInYearThree>
    <hook:CollaborationAgreementMilestonePaymentsRevenueRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_zfz8LxQPIku68ssP9_JeQA"
      decimals="-5"
      id="Narr_3SoktZlhwEOaFEO0p0384Q"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7100000</hook:CollaborationAgreementMilestonePaymentsRevenueRecognized>
    <hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_zfz8LxQPIku68ssP9_JeQA"
      decimals="-5"
      id="Narr_claJokb5DkW3qm5_mze0Qg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1400000</hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices>
    <hook:CollaborationAgreementMilestonePaymentsRevenueRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_WGiMi9INf02gQAVOw20hGg"
      decimals="-5"
      id="Narr_CqjMzI4sBUe54qb6w71q3w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3700000</hook:CollaborationAgreementMilestonePaymentsRevenueRecognized>
    <hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_WGiMi9INf02gQAVOw20hGg"
      decimals="-5"
      id="Narr_WXn3eAFWPUW5v-OR6tIRwQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5200000</hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices>
    <hook:CollaborativeArrangementRevenueFromMilestonePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_WGiMi9INf02gQAVOw20hGg"
      decimals="-5"
      id="Narr_lBiXa8xdM0egJjVBeIl-Kw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5000000.0</hook:CollaborativeArrangementRevenueFromMilestonePayments>
    <hook:CollaborationAgreementMilestonePaymentsRevenueRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sSCjg8UmtUy-0Ck5qV73Gg"
      decimals="-5"
      id="Narr_y4w8HFvGu0KMKWeneYwSfQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2100000</hook:CollaborationAgreementMilestonePaymentsRevenueRecognized>
    <hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_sSCjg8UmtUy-0Ck5qV73Gg"
      decimals="-5"
      id="Narr_PDI9KVwDrU2UGSaA0QcgVg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">16300000</hook:CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices>
    <hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg"
      decimals="-5"
      id="Narr_xrD11VVi8kyKBE5HH4GkrQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment>
    <hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4qOs21ojTUO-rUJpz1kUcg"
      decimals="-5"
      id="Narr_M_pZ70LEi0yeVXWM8OTZ2w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">200000</hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment>
    <hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_4qOs21ojTUO-rUJpz1kUcg"
      decimals="-5"
      id="Narr_HjPqrjRqX0-RdRdzHcvpdg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment>
    <hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_cKgoWc-1KkGWL2K39AtJRg"
      decimals="-5"
      id="Narr_ima8rb9idEWGFOGpEpNLvQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment>
    <hook:ProceedsFromNonRefundableUpFrontPayment
      contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_r-zd0dtsfkWw5mLU7UMv4g"
      decimals="-5"
      id="Narr_74i_nDwl1022TE3mE0dkDg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">25000000.0</hook:ProceedsFromNonRefundableUpFrontPayment>
    <hook:ProceedsFromMilestonePayment
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_X56qauEA7k-9t9AFLtndIQ"
      decimals="-5"
      id="Narr_8MG7LB38eUaQEke6CgJWpw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10000000.0</hook:ProceedsFromMilestonePayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww"
      decimals="-5"
      id="Narr_8zSgY1ZsqkikJgqlf-tCqA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">26800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6fTsmB6TxUSozaWhvhJ6_g"
      decimals="-5"
      id="Narr__-eVjCempkOWCbjw3wvSMw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">27000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <hook:ProceedsFromNonRefundableUpFrontPayment
      contextRef="Duration_10_1_2022_To_10_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_r-zd0dtsfkWw5mLU7UMv4g"
      decimals="-5"
      id="Narr_yN-wAESy4US062m0SrcDQQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">25000000.0</hook:ProceedsFromNonRefundableUpFrontPayment>
    <hook:ProceedsFromMilestonePayment
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_X56qauEA7k-9t9AFLtndIQ"
      decimals="-5"
      id="Narr_O7Xq9WI1pkKtCridMCgREw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10000000.0</hook:ProceedsFromMilestonePayment>
    <hook:CollaborationAgreementMilestonePaymentsRevenueRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_X56qauEA7k-9t9AFLtndIQ"
      decimals="-5"
      id="Narr_1EYA5r4ohkmzjXI2e4AX-A"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">11100000</hook:CollaborationAgreementMilestonePaymentsRevenueRecognized>
    <hook:CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww"
      decimals="-5"
      id="Narr_slUGazWMWU23YAK2rRo-1w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">500000</hook:CollaborativeArrangementRevenueFromCostReimbursementsForPreparationOfFirstHumanTrial>
    <hook:RevenueRecognizedUpfrontPayment
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_IuERzRWMYUO5kK8uAkmuTQ"
      decimals="-5"
      id="Narr_-xVGNcdmuU6cO8pDtRGHTQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">300000</hook:RevenueRecognizedUpfrontPayment>
    <hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww"
      decimals="-5"
      id="Narr_fC3l7Y5gsE2lb8nRVWYQfA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2000000.0</hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment>
    <hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww"
      decimals="-5"
      id="Narr_NDAQ3BHcukmU6Qh_bdyHww"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment>
    <hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6fTsmB6TxUSozaWhvhJ6_g"
      decimals="-5"
      id="Narr_JPrlqvSc3kCKeInfUZ-pGw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1500000</hook:CollaborativeArrangementContractAssetRelatingToSublicensePayment>
    <hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6fTsmB6TxUSozaWhvhJ6_g"
      decimals="-5"
      id="Narr_1N6qNl-XjE-5DE3WD9_oSg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1200000</hook:CollaborativeArrangementContractLiabilityRelatingToSublicensePayment>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_fro2EhVtCUaJVouFtxzcGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4.&#160;Impairment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On January&#160;29,&#160;2024, the Company announced its decision to prioritize the clinical development of its HB-200 program for the treatment of HPV16+ head and neck cancers and its two Gilead-partnered infectious disease programs and to pause development activities related to HB-300 and most of its preclinical research activities (see Note&#160;18. &#x201c;Subsequent Events&#x201d;). In connection with this strategic refocus, the Company&#x2019;s board of directors approved a Restructuring Plan to rebalance the Company&#x2019;s cost structure, which includes a reduction of the Company&#x2019;s workforce &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;by approximately 30% and the discontinuation of the Company&#x2019;s GMP manufacturing facility project. The Company expects the Restructuring Plan to be implemented and substantially completed by the end of the first quarter of 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a result of the strategic considerations preceding the adoption of the Restructuring Plan, the Company assessed the recoverability of the long-lived assets relating to the GMP manufacturing project at December 31, 2023, and determined that the undiscounted cash flows of the asset group were below the carrying values, indicating impairment. The assets were written down to their estimated fair value, which was determined based on the cost approach. The resulting impairment charges were included within Impairment expense in the Consolidated Statements of Operations and Comprehensive Loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the effect of non-cash impairment charges (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-cash impairment charges&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Asset write-offs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,766)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total non-cash charges&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,766)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A"
      decimals="2"
      id="Narr_v9gAMp1ZXEGep6gyO5uKmA"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.30</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_5Khy4-yiIkqW_6ht4b0AaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-cash impairment charges&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Asset write-offs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,766)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total non-cash charges&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,766)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_JzvopPjVUEWPlV4xAvmKQA_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12766000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_n8LXk09t6kGMbx2UnL_bCQ_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12766000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_RQfMzgR4FUS1v9yCSGWDbw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5.&#160;Fair Value of Financial Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at December&#160;31,&#160;2023 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at December&#160;31,&#160;2022 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;During the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Lpjoo-HNUkK1Q7dne6IAVQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; ended &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_9wPB5a7NckWc0o_lT7sjxw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;December&#160;31,&#160;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, there were &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; transfers between Level&#160;1, Level&#160;2 and Level&#160;&lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_L0ges7xDOUOYjlazpNEvlw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Group_7Q1GzLyNo0mI2nh9_flyRQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicating the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at December&#160;31,&#160;2023 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at December&#160;31,&#160;2022 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1LRqYYOuTkW9E0CdbjORBA"
      decimals="-3"
      id="Tc_YWXNODZM7E6HpaclS8KWNw_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">91084000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vp7OjZUKs0qrjBy07u3Rwg"
      decimals="-3"
      id="Tc_AZf5pY4MT0GPkozsQvoGsQ_4_12"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">91084000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_q3DFOTCJoUOMsPJyaBQ3Fg"
      decimals="-3"
      id="Tc_JVOxXNF_R0-RWQZPyTGH3A_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">91084000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_AuBlzmENrUa8NdUXnGeaBA"
      decimals="-3"
      id="Tc_m0ERaQcpukK8fRjHjQHfog_5_12"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">91084000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kU5iAAu8lUOCuAzHNGZFtQ"
      decimals="-3"
      id="Tc_wH9T99E2sEGo_tQU77G9ug_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">85491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_t6cFMObpAkuRcFhZNL6fUg"
      decimals="-3"
      id="Tc_TNXwL3mDpEOzI0CxuFr2DQ_4_12"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">85491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_sjQ1_m16gUyGeWyA8dpSbQ"
      decimals="-3"
      id="Tc_ApUsCY8x7UONaO_lcuFpVg_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">85491000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_f7Evnw8lLU6TvXq4xZaF1A"
      decimals="-3"
      id="Tc_tIPQMxFYMUiF1h8Ra08iOQ_5_12"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">85491000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Narr_T9VZEZRaI0SmaKTx9jVy0Q"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_lIp7S4cK5Uaf34o-KlEKyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Property, plant and equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Property, plant and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,749&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,823)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,779)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Depreciation expense for the years ended December&#160;31,&#160;2023, 2022 and 2021 was $2.0&#160;million, $1.9&#160;million and $2.1&#160;million, respectively. Construction-in-progress as of December&#160;31,&#160;2022 mainly related to investments in connection with the Company&#x2019;s GMP manufacturing facility project. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a result of the strategic considerations preceding the adoption of the Restructuring Plan (see Note&#160;4. and Note&#160;18.) the Company determined that the estimated undiscounted future cash flows for its asset group related to the GMP manufacturing facility project were less than their carrying values. The Company therefore recognized an impairment loss of $12.8&#160;million related to the GMP manufacturing facility project for the year ended December&#160;31,&#160;2023, which reduced the carrying value of this asset group to zero. Impairment charges are included within Impairment expense in the Consolidated Statements of Operations and Comprehensive Loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;There were no impairments in the years ended December&#160;31,&#160;2022 and 2021.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_ZA2Q1VsgW0e5n-sTTFespg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Property, plant and equipment, net consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Land&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,034&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,749&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,823)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,779)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_d9nAVl9o7USSeTumRsaPVQ"
      decimals="-3"
      id="Tc_HZd0izqBr0Cth2IlXhsL9g_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2025000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember_V0f2IgZ-pke_ekfxUL0PFw"
      decimals="-3"
      id="Tc_elz07l1DBUSBlIKz2RYpsw_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1959000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_H9q5fvXIvUyymHn9HgMWCA"
      decimals="-3"
      id="Tc_8dkufBQMEE2hW55wRgZFeg_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_2LsuutyUQE6wY7QxmZAn0A"
      decimals="-3"
      id="Tc_l1ygIVOV2USp2kg3xXfVnA_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3164000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_eO8goNhRB0-aM5lXAIyMyw"
      decimals="-3"
      id="Tc_isLCuklEdkKUhFae_BGf0Q_6_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">212000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_pt9hTzP2p0aDdaGKrVFYZw"
      decimals="-3"
      id="Tc_S0OP210EUkuCSqdRo5w_Cg_6_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_DTmiN0Wjdk2iaqY9dIsckQ"
      decimals="-3"
      id="Tc_SEJKIY_pm02oblVTxyGc6A_7_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">8722000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Dv-_4sRg6EC65tReOfjV-w"
      decimals="-3"
      id="Tc_7fP_WPkAUE659pNGfi1z6g_7_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_n75mKrZ5ykylerI6_Na9ZQ"
      decimals="-3"
      id="Tc_B0pIsg77ykulp_tllOi_oA_8_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">654000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_OVW8CCm-m0i5lry7fXD5tQ"
      decimals="-3"
      id="Tc_T1dlgDlDZ0O0d35hGj1ujg_8_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">622000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_v9vy-6pd6UqP7xZfF6NTog"
      decimals="-3"
      id="Tc_zETHx5s6x0qlOgdyhujr8Q_9_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2652000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_hook_ComputerEquipmentAndSoftwareMember_Pkdmu3XpuUGFFIIVvDmOsw"
      decimals="-3"
      id="Tc_jvwgxSeuCUW4bxqVnxdAvA_9_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2034000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_Id1DMPHkXEqLKBJtBKYikg_10_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">17565000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_H4daVIxka0mS_0wLXTryHw_10_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">25749000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_SHjwgR_nkkyNRTurEoZmKg_11_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">9823000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_ahMJHLIXp0-fEPwec8814w_11_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7779000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_mIOsdf0R80O3YTyXqPl7XQ_12_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7742000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_TnERexT-5EmYf9e_RKIovA_12_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">17970000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_KZ4Zv0G7MkaSdQg5fFigSQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_rY3KnqkWc02QMLidF5PGMQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-5"
      id="Narr_84j2cr7Y2EqE_eOS1TRrWQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2100000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_CVMWXLW-ekSNZPjM-_R6wg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12800000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <hook:RestructuringPlanCarryingValueOfAsset
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-5"
      id="Narr_CE84Va72HkWuBoA3RPOHGA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:RestructuringPlanCarryingValueOfAsset>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-5"
      id="Narr_ZdcQzm0EWUW2SoejgybL9w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_rgqhSyxRQEejzOO2kx4j3w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <hook:ReceivableResearchIncentiveTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_umcLLmQdg0OudASbCLpaSw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7.&#160;Receivable research incentive&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company participates in a research incentive program provided by the Austrian government under which it is entitled to reimbursement of a percentage of qualifying research and development expenses and capital expenditures incurred in Austria. Submissions for reimbursement under the program are submitted annually. Incentive amounts are generally paid out during the calendar year that follows the year of the expenses but remain subject to subsequent examinations by the responsible authority. Reimbursements received in excess of the recognized receivable research incentive for a certain period are recorded within other long term liabilities for potential repayment until such time that an audit has taken place, upon expiration of the potential reclaim period, or when it is no longer probable that a reclaim will happen. The years 2018 to present remain open to examination by the authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Furthermore, the Company participated in the life sciences research and development program provided by the New York State government under which it was entitled to reimbursement of a percentage of qualifying research and development expenses in New York State up to $0.5&#160;million per year for the years 2019 to 2021. Incentive amounts are generally paid out six to nine months after amended tax returns including a certificate of tax credit issued by Empire State Development are filed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company also participates in the New York City biotechnology tax credit program, according to which certain expenses for business in the biotechnology field in New York City limited to $0.25&#160;million per year for three &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;consecutive years from January&#160;1,&#160;2023 to December&#160;31,&#160;2025 are incentivized. The biotechnology tax credit can be refunded or applied against the next year's tax if it exceeds the current year's tax liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2023, the Company recognized receivables of $18.8&#160;million from the research incentive programs, which are reported in research incentive receivables in the Company&#x2019;s consolidated balance sheet. $17.3&#160;million relate to the Austrian research incentive program, $1.4&#160;million relate to the New York State life sciences research and development program and $0.1&#160;million relate to the New York City biotechnology tax credit program. As of December&#160;31,&#160;2022, the receivables from the research incentive program were $15.5&#160;million and related to the Austrian research incentive program. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the years ended December&#160;31,&#160;2023, 2022 and 2021, the Company recorded $10.9&#160;million, $7.3&#160;million and $8.9&#160;million, respectively, of income related to the incentive programs within the Company&#x2019;s consolidated statements of operations and comprehensive loss as part of the grant income. Income for the year ended December&#160;31,&#160;2023 included $9.4&#160;million related to the Austrian incentive program, $1.4&#160;million related to the New York State life sciences research and development program and $0.1&#160;million related to the New York City biotechnology tax credit program. Income for the years ended December&#160;31,&#160;2022 and 2021 related to the Austrian incentive program. Research incentives depend on the eligible research and development expenses of the respective period.&lt;/p&gt;</hook:ReceivableResearchIncentiveTextBlock>
    <hook:ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_DNqYfPgFh0Ck9fuBQnQtWQ"
      decimals="-5"
      id="Narr__IF9NI3Wi0SHcngQ7QQ8EQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">500000</hook:ReimbursementAmountReceivableAsPercentageOfQualifyingResearchAndDevelopmentExpenses>
    <hook:MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear
      contextRef="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_iLfkqbjLEkO8cY690Z1M_g"
      decimals="-4"
      id="Narr_hFIHE_sx3UqukYZmj3AUnw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">250000</hook:MaximumExpensesEligibleForIncentiveInBiotechnologyFieldPerYear>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-5"
      id="Narr_6oI0i8fS4Eqy7GBxVnL6fg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">18800000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_AustrianResearchIncentiveProgramMember_Ocbk301LuEKBJ-hS6sdG-w"
      decimals="-5"
      id="Narr_IjbGePZxSEGb8Vs6soXqJQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">17300000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_DNqYfPgFh0Ck9fuBQnQtWQ"
      decimals="-5"
      id="Narr_T8t2afoP0EipgrTpVs812w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1400000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_0rn22fHyykOFZjGSZjx9-w"
      decimals="-5"
      id="Narr_Pfr8P31Zd0yjMh70KQaUqw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:ReceivablesTaxResearchPremiumCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-5"
      id="Narr_Ysy-1G7cAka55P2oyI8nbQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">15500000</hook:ReceivablesTaxResearchPremiumCurrent>
    <hook:GrantIncomeIncentiveProgram
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_2QoAHiEWSE-eX8rj9NJ_Jw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10900000</hook:GrantIncomeIncentiveProgram>
    <hook:GrantIncomeIncentiveProgram
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_JU-e9SR930SsZlgNQW5sJA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7300000</hook:GrantIncomeIncentiveProgram>
    <hook:GrantIncomeIncentiveProgram
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-5"
      id="Narr_yNwUkwaBHka94for7Le4gw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">8900000</hook:GrantIncomeIncentiveProgram>
    <hook:GrantIncomeIncentiveProgram
      contextRef="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_AustrianResearchIncentiveProgramMember_b5PBJbDWP0aRQ3y6jpvjFQ"
      decimals="-5"
      id="Narr_pFbVxlUUD0K70lhKonuXag"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">9400000</hook:GrantIncomeIncentiveProgram>
    <hook:GrantIncomeIncentiveProgram
      contextRef="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateLifeSciencesResearchAndDevelopmentProgramMember_LCk-o0XEz0Coe9Nfe-mo4g"
      decimals="-5"
      id="Narr_1aRx_4Jez0e7p8R0Whq0TA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1400000</hook:GrantIncomeIncentiveProgram>
    <hook:GrantIncomeIncentiveProgram
      contextRef="Duration_1_1_2023_To_12_31_2023_hook_ResearchAndDevelopmentIncentiveProgramAxis_hook_NewYorkStateNewYorkCityBiotechnologyTaxCreditProgramMember_iLfkqbjLEkO8cY690Z1M_g"
      decimals="-5"
      id="Narr_A6Dy3rDiPEuJJci-pXLtYQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</hook:GrantIncomeIncentiveProgram>
    <hook:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_VoC0eewv3U6mzgnejJNC9Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases real estate, including office and laboratory space and has entered into various other agreements with respect to assets used in conducting its business. The Company&#x2019;s leases have remaining lease terms ranging from less than 1&#160;year to 5.2&#160;years. Some of the lease agreements contain rent holidays and rent escalation clauses that were included in the calculation of the right of use assets and lease liabilities. The Company&#x2019;s current leases qualify as operating leases. The Company is required to maintain a cash balance of $0.4&#160;million to secure letters of credit associated with real estate leases. This amount was classified as non-current restricted cash in the consolidated balance sheet as of December&#160;31,&#160;2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the effect of lease costs in the Company&#x2019;s consolidated statements of operations and comprehensive loss (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income&#160;statement&#160;location&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest on finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expense)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,510&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,655&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,851&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,439&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December&#160;31,&#160;2023, the Company agreed on a lease amendment, which extended the term of the lease for its corporate headquarters in New York City by approximately 2.2&#160;years ending at the end of August&#160;2026. The Company also extended the estimated lease term of existing operating leases for the office and laboratory space in Vienna, Austria, by approximately 2.0 years ending at the end of December&#160;2027. Furthermore, the Company signed a lease amendment, which extended the term of the lease for certain parking spaces in its Vienna Office by approximately 5.5&#160;years ending at the end of February 2029. These lease amendments did not include additional right-of-use other than the extended lease term. There is no additional renewal term included in the lease amendments to consider in the estimate of the lease term. The respective lease liabilities were remeasured and the amounts resulting from the remeasurement of the lease liability were recognized as an adjustment to the corresponding right of use asset.&lt;/p&gt;</hook:LeaseDisclosureTextBlock>
    <hook:LesseeLeaseRemainingTermOfContract
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_t2LLWZ24bUKTQiMbE7AcJw"
      id="Narr_97H5-n1hP0qmaHupb4_Aew">P1Y</hook:LesseeLeaseRemainingTermOfContract>
    <hook:LesseeLeaseRemainingTermOfContract
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ"
      id="Narr_Shu0xCWhHEi6f-leohL5zQ">P5Y2M12D</hook:LesseeLeaseRemainingTermOfContract>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-5"
      id="Narr_0du-loBsiU6JdMcOGJ2h8g"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_fwaoK2DDgUehhQvrmeI3Tw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the effect of lease costs in the Company&#x2019;s consolidated statements of operations and comprehensive loss (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income&#160;statement&#160;location&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease amortization expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 425&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest on finance lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:26.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expense)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (40)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net lease expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,510&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b8VlOcR0O0OmF5emQANTkw"
      decimals="-3"
      id="Tc_X6qRkLg7qU2bcFyG3zeJTA_3_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1347000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e9XlwwWzZUyxUx3pingkdQ"
      decimals="-3"
      id="Tc_VR3-lGzX7kWixJeaz88Y2w_3_8"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1430000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ShuqB9wIDkS3F21xuhUuPQ"
      decimals="-3"
      id="Tc_oYuOwMnF4UabjTx79vu1Kg_3_11"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1910000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3z_KZuEbyUyufSDi6RFYKw"
      decimals="-3"
      id="Tc_Crm8i0rlGEaWdEGxfXvvGQ_4_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">242000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mzTecP16KUqdKJ51DcbR8w"
      decimals="-3"
      id="Tc_jdeFYBM_UkOR72Zm7TOyBw_4_8"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">219000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OgNb7067TEG0mtw4IpZ_2g"
      decimals="-3"
      id="Tc_xpZuEh0mb0eeEWtb-trEaQ_4_11"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">203000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e9XlwwWzZUyxUx3pingkdQ"
      decimals="-3"
      id="Tc_x1H-eH0dokWCkr-_FBJtHg_5_8"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">89000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ShuqB9wIDkS3F21xuhUuPQ"
      decimals="-3"
      id="Tc_qSwD1u028E6BSZn8OHCFMQ_5_11"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">425000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OgNb7067TEG0mtw4IpZ_2g"
      decimals="-3"
      id="Tc_oHgO9hWqc0efapv7PBt3hg_6_11"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_pNxGgv4tck6OcN9EE9uBvQ"
      decimals="-3"
      id="Tc_T_r4URM4k0iA7YE64lYFMQ_7_8"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_xsd7nsH6k0yzM-JYdiLW2A"
      decimals="-3"
      id="Tc_EtSzhQg4TkWR3g5g6Qh-7w_7_11"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_2Z7XTTCdlUG1MXSD_C6hBg"
      decimals="-3"
      id="Tc_fX24b_79VE-bmyJyTIsb9g_8_11"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">40000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_SD7OP4Lox0C7uMzeFJoT7Q_9_5"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1589000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_UNt05vH8QE-FQVD3QJucRw_9_8"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1738000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_KvjWYp2uiUaq_Bu0aLN4zw_9_11"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2510000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_21n2lHt0Vk2FfVal1dNNBA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The minimum lease payments for the next five&#160;years and thereafter are expected to be as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&#160;lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,655&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,851&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,439&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_v2SFViH-qU-8gktpcCDEbA_3_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1655000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_zY3jlsizM0-7Gb8stqnhOQ_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1627000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_mHYO5dJflEeK0fSh9X7-lQ_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1351000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_ILRfqdMx70itxZtiFi7p_Q_6_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1213000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_nYBYwYtvXEemh1hK7gQeFQ_7_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_ZyCkHrZtpEqy3NSAaNYZgw_8_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_m1smKj6h5kyMPm6OvNvyhw_9_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5851000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_HD9OhO6aDE22NUiFfDFxgw_10_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">412000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_dpn3rIASgk2vmTKyK3Aecw_11_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5439000</us-gaap:OperatingLeaseLiability>
    <hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_b5CTOpNFiEaGm7Of2wMEug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average remaining lease term and weighted average discount rate of operating leases are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term in years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The majority of the contracts are denominated in euros. The discount rate was determined on a currency-equivalent basis.&lt;/p&gt;</hook:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateOfOperatingLeases>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      id="Tc_sJFIB_URR0y5ug5YecjI1A_3_2">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      id="Tc_Ff6WMX_xM0ujMl7OnR24Sg_3_5">P2Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="3"
      id="Tc_sIlPQ9y9ske640q1z_W-Dw_4_2"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="3"
      id="Tc_Wz9ZQELSI0mCaH4Df39B9Q_4_5"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.013</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeaseForCorporateHeadquartersInNewYorkCityMember_O5rj1qjLx02TAFtZTvjJiQ"
      id="Narr_BIqyu-VDtkK1GhYK21m4HQ">P2Y2M12D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeasesForOfficeAndLaboratorySpaceInViennaAustriaMember_rYOLLftQ0E631s3QNeZC5A"
      id="Narr_W5fK04DuVkOUmRC3kWdOpA">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_us-gaap_LeaseContractualTermAxis_hook_LeaseForCertainParkingSpacesInViennaOfficeMember_BUA7zVRMSEmA3Ot_9-TINQ"
      id="Narr_q21yhxS4WE-1YvyjucBgEg">P5Y6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_ROhKouueYUmpklUFArRpEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9.&#160;Accrued expenses and other current liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Salaries and bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Social security contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unearned grant income (current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sublicense fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,220&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external general and administration expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 898&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued for property and equipment acquisitions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accruals and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_og6OJgkX-0WwLaGM-2jAew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Salaries and bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,481&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Social security contributions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 340&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unearned grant income (current)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sublicense fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,220&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,594&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued external general and administration expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 898&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued for property and equipment acquisitions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accruals and liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_Hf0O9BkykE-VoqZem9_RQA_3_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5665000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_FnhiRBrwikqQ2WjBD2MITw_3_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4481000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <hook:AccruedSocialSecurityContributionsCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_HcbK798ILEym-L7lgAaWYQ_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">340000</hook:AccruedSocialSecurityContributionsCurrent>
    <hook:AccruedSocialSecurityContributionsCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_uVAOyVPYq06-_gVg_1gEPA_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">267000</hook:AccruedSocialSecurityContributionsCurrent>
    <hook:AccruedUnearnedGrantIncomeCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_lXVo60b7Vk-e5mkuiO1gRA_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">52000</hook:AccruedUnearnedGrantIncomeCurrent>
    <hook:AccruedUnearnedGrantIncomeCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_iuTWHvsthE6KyhYtNwtYGw_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">300000</hook:AccruedUnearnedGrantIncomeCurrent>
    <hook:AccruedSubLicenseFees
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_83z-ud-px0-LQNfvNWYm3A_6_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1220000</hook:AccruedSubLicenseFees>
    <hook:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc__tOQn_QKk0uSt-h_Bpt7Pw_7_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4594000</hook:AccruedExternalResearchAndDevelopmentExpenses>
    <hook:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_5wgTc6omAEa_gl1nbC8nyA_7_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3458000</hook:AccruedExternalResearchAndDevelopmentExpenses>
    <hook:AccruedExternalGeneralAndAdministrationExpenses
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_4Mm_KtZrlEmdFkZQdgbfDw_8_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">292000</hook:AccruedExternalGeneralAndAdministrationExpenses>
    <hook:AccruedExternalGeneralAndAdministrationExpenses
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_a2HffsMPSUCW9UzFHiKAmw_8_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">898000</hook:AccruedExternalGeneralAndAdministrationExpenses>
    <hook:AccruedExpensesForPropertyAndEquipmentAcquisitions
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_EJxL0t_QNESExBzwIK4Z0w_9_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">14000</hook:AccruedExpensesForPropertyAndEquipmentAcquisitions>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_IXFLklKtUUCqip_ru2bshw_10_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">367000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_SS02dYG0sUOXwe5D9RIzBw_10_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">230000</us-gaap:AccruedIncomeTaxesCurrent>
    <hook:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_z-pFfU3mc0G2ANLvmowI-g_11_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">777000</hook:OtherAccruedExpensesAndLiabilitiesCurrent>
    <hook:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_XPN0d53DB0SfzvfkQJX8uQ_11_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">324000</hook:OtherAccruedExpensesAndLiabilitiesCurrent>
    <hook:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_6owSIFtux0WRQZBiXBm6mA_12_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12101000</hook:AccruedExpensesAndOtherCurrentLiabilities>
    <hook:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_sGXAxgDbpkuS52EM21rfnQ_12_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">11178000</hook:AccruedExpensesAndOtherCurrentLiabilities>
    <hook:DisclosureOfLongTermLoansPayableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_UF73L4KIOU6UXB9NUZOXYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Loans payable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, loans payable consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Loans from FFG&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Unamortized debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (350)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total loans payable, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,505&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the funding agreements with the Austrian Research Promotion Agency, (&lt;i style="font-style:italic;"&gt;&#xd6;sterreichische Forschungsf&#xf6;rderungsgesellschaft, &lt;/i&gt;or &#x201c;FFG&#x201d;), the Company has received various loans (&#x201c;FFG Loans&#x201d;). The FFG Loans were made on a project-by-project basis. Amounts due under the FFG Loans bear interest at a rate of 0.75%&#160;per annum and mature in March&#160;2024. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The FFG Loans bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between an estimated market rate of interest and the rate of interest charged by FFG as grant income from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as grant income over the term of the funding agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized grant income of $0.3&#160;million, $0.6&#160;million and $0.8&#160;million during the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively, related to the recognition of the unearned income recorded for the imputed benefit of FFG Loans at below-market interest rates. Unearned income (current) related to the imputed benefit of FFG Loans at below-market interest rates was less than $0.1&#160;million and $0.3&#160;million as of December&#160;31,&#160;2023 and 2022, respectively. Unearned income (non-current) presented under loans payable non-current related to such benefit was $0.1&#160;million as of December&#160;31,&#160;2022, and no non-current unearned income as of December31,&#160;2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company has recorded a discount to the carrying value of each FFG Loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method. As of December&#160;31,&#160;2023 and 2022, the unamortized debt discount related to FFG Loans was $0.1&#160;million and $0.4&#160;million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized interest expense of $0.3&#160;million, $0.7&#160;million and $0.9&#160;million during the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively, related to the FFG Loans, which included interest expense related to the amortization of debt discount of $0.3&#160;million, $0.7&#160;million and $0.8&#160;million during the years ended December&#160;31,&#160;2023, 2022 and 2021, respectively. Principal repayments of $1.8&#160;million, and $2.8&#160;million were made in the years ended December&#160;31,&#160;2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses an estimated market rate of 20%, which was determined based on an average of the available interest rates on unsecured loans to comparable companies. A 10% increase or decrease in the estimated market rate of interest would have no material impact on grant income or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event that the underlying program research results in a scientific or technical failure, the principal then outstanding under any loan may be forgiven by FFG on a project-by-project basis. The FFG Loans contain no financial covenants and are not secured by any of the Company's assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December&#160;31,&#160;2023, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payments&#160;Due&#160;by&#160;Calendar&#160;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</hook:DisclosureOfLongTermLoansPayableTextBlock>
    <hook:DisclosureOfLongTermLoansPayableTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_Ycfc14T2T0-yw8ZNFR3FTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31,&#160;2023 and December&#160;31,&#160;2022, loans payable consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Loans from FFG&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,855&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Unamortized debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (350)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total loans payable, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,505&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</hook:DisclosureOfLongTermLoansPayableTableTextBlock>
    <hook:LongTermLoansPayableGross
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_8wzL-ue72kSZ6d28zt4wUQ_3_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1172000</hook:LongTermLoansPayableGross>
    <hook:LongTermLoansPayableGross
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_Y-IREc6Bh02LO10rhuCZ9g_3_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2855000</hook:LongTermLoansPayableGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_fDtHgx_i9kaPYmp2CsEueA_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">52000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_8FoXk1hDCkicrI0V3HDpYQ_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">350000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_az-0FFSNnE-U87XHDY01gQ_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1120000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_AoV1ZIARM0SSSYFj9mUDKQ_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2505000</us-gaap:LongTermLoansPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="4"
      id="Narr_Zp0I1H-Xe0G42xDHn2q5Fw"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_Rc5jKwDFOEqAwiZthnKExQ"
      decimals="-5"
      id="Narr_CdEbyI6EekCpOk9pcXs8PQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_XWdzK47-T06jRMxyOKZ3Tw"
      decimals="-5"
      id="Narr_8_1yqtGuyUiMQhVLnRmKtQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_jrD8j5sy7UakHnOm30LdFQ"
      decimals="-5"
      id="Narr_8JdVY55CL0KIDpN03-kuBA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_RangeAxis_srt_MaximumMember_G5knO1JxEUipkKfqXVba6w"
      decimals="-5"
      id="Narr_nwO2Pvh1CU61Z0Xj8xZfKA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_RangeAxis_srt_MaximumMember_hy3OpU7SA0uUGHTffJQ5fw"
      decimals="-5"
      id="Narr_nBRg7J0JPkKmPpzCy8nT6w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_Oo1iK1CDRkCwVRfUUVTjbQ"
      decimals="-5"
      id="Narr_gv46q8Uhy0-rKTtYhzY5aw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_srt_ProductOrServiceAxis_us-gaap_GrantMember_iL34pNGK3UGEaXA4MINluA"
      decimals="-5"
      id="Narr_eaBLpKWH7UySGrOvUn_HaQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-5"
      id="Narr_VddLb9tnFEy11ja6LBloVw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-5"
      id="Narr_vCVQ77zhb0KLZPXUnpzRCw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_HKfIjMZjz0CFl_iErKwxMw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_soeNcajbRk-mBr4zWdkhdw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-5"
      id="Narr_SyiE2wX63ECyzcHfe25tKg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">900000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_bmRZLxm2qkq5s9bXO5MShQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">300000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_A19cIqZZLESc4p7nb7HaMg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">700000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-5"
      id="Narr_Wn2FHI35rEGBV2um-0pT1g"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">800000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_1gGRAKfBIkuryIyXSDX1aQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_VACYKUkRakWnjfb33E4exw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2800000</us-gaap:RepaymentsOfDebt>
    <hook:DebtInstrumentEstimatedMarketRatePercent
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Narr_hgKXTbq_DEyrtNrkz0NExQ"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.20</hook:DebtInstrumentEstimatedMarketRatePercent>
    <hook:IncreaseDecreaseInEstimatedMarketRate
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Narr_mBwpmBmY_EOcj1QRkMGc2Q"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.10</hook:IncreaseDecreaseInEstimatedMarketRate>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_9pkR01z0b0a0XkMZjBQuSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;As of December&#160;31,&#160;2023, the aggregate minimum future principal payments due in connection with the FFG Loans are summarized as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Payments&#160;Due&#160;by&#160;Calendar&#160;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Thereafter &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_8qYPPMo-aUWzxj3Lb1lZEQ_2_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1172000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_6MMfMeth90qEIxNBMFGmlg_8_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1172000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_iv1sYJ1C8Ua3tUPtTruQ9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Common stock, Class A common stock and convertible preferred stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s capital structure consists of common stock, Class A common stock and preferred stock. As of December&#160;31,&#160;2023, the Company was authorized to issue&#160;200,000,000&#160;shares of common stock,&#160;3,900,000&#160;shares of Class&#160;A common stock and&#160;10,000,000&#160;shares of preferred stock. The Company has designated&#160;2,978&#160;of the&#160;10,000,000&#160;authorized shares of preferred stock as non-voting Series&#160;A convertible preferred stock,&#160;15,800&#160;of the&#160;10,000,000&#160;authorized shares of preferred stock as non-voting Series&#160;A-1 convertible preferred stock and&#160;15,268&#160;of the&#160;10,000,000&#160;authorized shares of preferred stock as non-voting Series&#160;A-2 convertible preferred stock. As of December&#160;31,&#160;2023, the Company had&#160;96,550,590&#160;shares of&#160;&lt;span style="-sec-ix-hidden:Hidden_EUaK3Tg6FEeEOqOHWmJvgA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;common&#160;stock&lt;/span&gt;&lt;/span&gt;,&#160;2,399,517&#160;shares of&#160;&lt;span style="-sec-ix-hidden:Hidden_K3IEYYVgEkOcLQ_fmEnbgg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Class&#160;A&#160;common&lt;/span&gt;&lt;/span&gt; stock,&#160;370&#160;shares of&#160;&lt;span style="-sec-ix-hidden:Hidden_wHXhiF9z3UaARnOvYs1xow;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Series&#160;A&lt;/span&gt;&lt;/span&gt;&#160;convertible preferred stock,&#160;10,800&#160;shares of&#160;&lt;span style="-sec-ix-hidden:Hidden_fN05Sy8hG0-TjqIRvTiFCg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Series&#160;A-1&lt;/span&gt;&lt;/span&gt;&#160;convertible preferred stock and&#160;15,268&#160;shares of&#160;&lt;span style="-sec-ix-hidden:Hidden_HE01NwGMaUaBkBAhb5ZKIA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Series&#160;A-2&lt;/span&gt;&lt;/span&gt;&#160;convertible preferred stock outstanding and issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On June&#160;5,&#160;2023, the Company closed a public offering of&#160;22,900,768&#160;shares of its common stock and&#160;15,268&#160;shares of Series&#160;A-2 convertible preferred stock at a public offering price of $1.31&#160;and $1,310.00&#160;per share, respectively, for net proceeds of $46.2&#160;million after deducting underwriting discounts and commissions and offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In July&#160;2022 and August&#160;2022 certain of the Company&#x2019;s stockholders elected to convert an aggregate of 1,420,215&#160;shares (769,734 and 650,481&#160;shares, respectively) of Class&#160;A common stock owned by such holders into an aggregate of 1,420,215&#160;shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On February&#160;15,&#160;2022, the Company entered into a stock purchase agreement with Gilead (&#x201c;Stock Purchase Agreement&#x201d;), that requires Gilead, at the Company&#x2019;s option, to purchase up to $35.0&#160;million of the Company&#x2019;s common stock. On February&#160;15,&#160;2022, Gilead purchased an initial amount of 1,666,666&#160;shares of the Company&#x2019;s common stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;in exchange for $5.0&#160;million in cash at a purchase price per share equal to $3.00. On December&#160;20,&#160;2023, the parties amended and restated the Stock Purchase Agreement (the &#x201c;Amended Stock Purchase Agreement&#x201d;) and Gilead purchased 15,000,000&#160;shares of the Company&#x2019;s common stock in exchange for approximately $21.3&#160;million in cash at a purchase price per share equal to $1.4167. Pursuant to the terms of the Amended Stock Purchase Agreement, the Company may require Gilead to purchase the balance of the $8.7&#160;million of common stock as pro-rata participation in potential future equity raises. The Company&#x2019;s right to sell shares of its common stock to Gilead is subject to specified limitations, including a limitation that prevents the Company from requesting purchases of shares of common stock by Gilead that would result in a beneficial ownership of more than 19.9% of the total number of outstanding shares of common stock by Gilead. The Company agreed to file a registration statement on Form S-3 to register for resale any additional shares of common stock issued to Gilead within four months from issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On March&#160;4,&#160;2022, the Company closed a public offering of 21,700,000&#160;shares of its common stock and of 15,800&#160;shares of Series&#160;A-1 convertible preferred stock at a public offering price of $2.00 and $2,000.00 per share, respectively, for net proceeds of $70.2&#160;million after deducting underwriting discounts and commissions and offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company has three series of preferred stock authorized, issued and outstanding as of December&#160;31,&#160;2023: Series&#160;A convertible preferred stock, Series&#160;A-1 convertible preferred stock, and Series A-2 convertible preferred stock. Shares of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock may be independently converted into common stock. Holders of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock have equal rights, powers and privileges.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of Class&#160;A common stock and Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock are not entitled to vote, except as required by law. The holders of common stock and Class A common stock do not have any cumulative voting rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Each holder of Class&#160;A common stock has the right to convert each share of Class A common stock into one share of common stock at such holder's election. Each holder of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock has the right to convert each share of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock into 1,000&#160;shares of common stock at any time at the holder&#x2019;s option, provided that the holder will be prohibited, subject to certain exceptions, from converting Series&#160;A, Series&#160;A-1 and Series&#160;A-2 preferred stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company&#x2019;s common stock then issued and outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Holders of common stock and Class&#160;A common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Holders of Series&#160;A. Series&#160;A-1 and Series&#160;A-2 preferred stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of the Company&#x2019;s common stock. Holders of common stock and Class A common stock have no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In the event of a liquidation, dissolution, or winding up of the Company, holders of our Series&#160;A, Series&#160;A-1 and Series&#160;A-2 preferred stock will receive a payment equal to $0.001 per share of Series&#160;A, Series&#160;A-1 and Series&#160;A-2 preferred stock before any proceeds are distributed to the holders of common stock. Then, holders of common stock and Class&#160;A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;There were&#160;370&#160;and&#160;1,697&#160;shares of Series&#160;A convertible preferred stock,&#160;10,800&#160;and&#160;15,800&#160;shares of Series&#160;A-1 convertible preferred stock and&#160;15,268&#160;and&#160;no&#160;shares of Series&#160;A-2 convertible preferred stock outstanding as of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;December&#160;31,&#160;2023 and December&#160;31,&#160;2022, respectively. In May&#160;2023 certain of the Company&#x2019;s stockholders elected to convert an aggregate of&#160;1,327&#160;shares of Series&#160;A convertible preferred stock and an aggregate of&#160;5,000&#160;shares of Series&#160;A-1 convertibles preferred stock owned by such holders into an aggregate of&#160;6,327,000&#160;shares of the Company&#x2019;s common stock. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"
      decimals="INF"
      id="Narr_66FdDaQ0D0OCOx4wjP_ajQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Narr_n_j0ct15aEybB3d8HODfsA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">3900000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Narr_cryaCaF_E0WO4LHqk_UjJA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w"
      decimals="INF"
      id="Narr_-XqYXue810KUXAd3CdqxHg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2978</hook:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Narr_KdjVu3alPEKbfr5KlgBglA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA"
      decimals="INF"
      id="Narr_PuYLpht6akC73OG8Dkpoig"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15800</hook:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Narr_PSq1EJwVzEid0wJeYnDTBQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <hook:PreferredStockSharesDesignated
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw"
      decimals="INF"
      id="Narr_jO64SPqACEiJ0660GpldTg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15268</hook:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Narr_4sEXZbd6o0uIzbP1mWQ04w"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"
      decimals="INF"
      id="Narr_Xlt4McRef0Cq5Y88PDxyQw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">96550590</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Narr_FJcxSuFNmE-kJXPZlv9Kdg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w"
      decimals="INF"
      id="Narr_zTpYfwzfS0SWi555P9hpFQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">370</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA"
      decimals="INF"
      id="Narr_0gKWNss0KUubxZ9W9DObVA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10800</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw"
      decimals="INF"
      id="Narr_EcBRBFetPEGpppLUZTnmZg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15268</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_5_2023_To_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_trpEIIU-tU-_tJvtabhPzw"
      decimals="INF"
      id="Narr_iEqtXuvkOECJCmM1KM3BeQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">22900768</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_5_2023_To_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_KDCyo9xrfUm2SNyHUjgpxQ"
      decimals="INF"
      id="Narr_PiW6N7-O2E2m_lbtE1BjOA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15268</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_G59PYeJ12ECeSIQHOayjyQ"
      decimals="2"
      id="Narr_J7269GZDjk2c9jZRooNzYQ"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1.31</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_6_5_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_9xIbJy1mtE6TWI_wKOUrpw"
      decimals="2"
      id="Narr_HP5_hh2LP0u5p_G_CoYD8g"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1310.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_6_5_2023_To_6_5_2023_HDaSSSxSpUCGD9FJbOAwcw"
      decimals="-5"
      id="Narr_srZDeGl55UKVDgHBztQpyw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">46200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_7_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_pc7cQA2m-kOSmJHzPEfppQ"
      decimals="INF"
      id="Narr_Fyu_6Pzv0kS5xYoCMNtAUA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1420215</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_7_1_2022_To_7_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_igpyXqNHCkeaCiqmtmt_nQ"
      decimals="INF"
      id="Narr_5PYuzQ51FUuHq6dnxvH1oQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">769734</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_8_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_-Sb_oTNrbE67HtDm8P8UiA"
      decimals="INF"
      id="Narr_FKodF781_0KgFohQS4JB6Q"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">650481</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_7_1_2022_To_8_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_qhAXDY6gbUi75WUSONZh_g"
      decimals="INF"
      id="Narr_PSmZSrdkbEKPg5w8Bg6hEQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1420215</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_2_15_2022_To_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_Agf-g2EmxkChN7RAIyPgCw"
      decimals="-5"
      id="Narr_yoKqT1rNikCTfIGugNFVDA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">35000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_15_2022_To_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_Agf-g2EmxkChN7RAIyPgCw"
      decimals="INF"
      id="Narr_CgiEMFyEREqoIha_TS5efw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1666666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_15_2022_To_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_Agf-g2EmxkChN7RAIyPgCw"
      decimals="-5"
      id="Narr_uF4WQKGgn0qsyZDz2pJzTA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharePrice
      contextRef="As_Of_2_15_2022_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_ob0J9wZKyk2iJVWb7ieH0A"
      decimals="2"
      id="Narr_sqovtIHzzk-YbrQ9EERivw"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">3.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_H8YdukywEUa5F4R0wQD4ug"
      decimals="INF"
      id="Narr_g9ysWd7xA0eW0DJwM9Hkvw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_H8YdukywEUa5F4R0wQD4ug"
      decimals="-5"
      id="Narr_BaSeUJS-PEeJBQ1C_SRJUA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">21300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharePrice
      contextRef="As_Of_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_9_7EqTslY0yqSx5HU_L_qA"
      decimals="4"
      id="Narr_nuog4UKOLUGVj3N8_oxxvg"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1.4167</us-gaap:SharePrice>
    <hook:RemainingOfCommonStockReservedForFutureIssuance
      contextRef="Duration_12_20_2023_To_12_20_2023_us-gaap_SubsidiarySaleOfStockAxis_hook_AmendedStockPurchaseAgreementMember_H8YdukywEUa5F4R0wQD4ug"
      decimals="-5"
      id="Narr_mi4DIQ3lLUi0vX58pHBukg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">8700000</hook:RemainingOfCommonStockReservedForFutureIssuance>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_2_15_2022_srt_OwnershipAxis_hook_GileadSciencesIncMember_us-gaap_SubsidiarySaleOfStockAxis_hook_StockPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_IJ87WrWO-k-9t1hFfOiVgA"
      decimals="3"
      id="Narr_aQI98MbL8kOZoXNmjXoEgw"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.199</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <hook:RegisterForResaleOfCommonStockAdditionalIssuances
      contextRef="Duration_2_15_2022_To_2_15_2022_z3PV6PoxAUyoMugmqtg5lQ"
      id="Narr_BxnI_QjN8k6-GZOnOMlCBA">P4M</hook:RegisterForResaleOfCommonStockAdditionalIssuances>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_sAJY_NDjZEehCI5DuVqezg"
      decimals="INF"
      id="Narr_oonbEnrEZku929PZXiSvOA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">21700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_4_2022_To_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_5F71-AsX2EC4M3MSefmV1A"
      decimals="INF"
      id="Narr_lZCmTDtogUCBOj003CO9-Q"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_XHb2VxbEKkeLgdecA0RSzA"
      decimals="2"
      id="Narr_fjCwK1DL30ytpIxpUmhrhQ"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">2.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_3_4_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4xGiuYB470aHSLaFha05pA"
      decimals="2"
      id="Narr_xZxKChZbokiY2nHfCH1TcQ"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">2000.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_3_4_2022_To_3_4_2022_NTQl-cLtAk6xlttcf3yn2g"
      decimals="-5"
      id="Narr_cA6mTte-mk2VyNngIpvCeA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">70200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <hook:NumberOfVotes
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_j-waHxxZ2U24LtHqB1bsxA"
      decimals="INF"
      id="Narr_oguliQRCwUu5jl_XWTtJAQ"
      unitRef="Unit_Standard_Vote_GQrC70uM-UyPQD7KgwAVng">1</hook:NumberOfVotes>
    <hook:ConversionOfStockCommonStockIssuedForEachShareConverted
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_UsydwOHzwEWlwarT8cPtyg"
      decimals="INF"
      id="Narr_QtWXM7cKQEOMcmjYNLjrag"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1</hook:ConversionOfStockCommonStockIssuedForEachShareConverted>
    <hook:ConversionOfStockCommonStockIssuedForEachShareConverted
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_1Wpbg1kMJkWMHx62rdrnHA"
      decimals="INF"
      id="Narr_PkBuOA6g9ECOT17unkJWgg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1000</hook:ConversionOfStockCommonStockIssuedForEachShareConverted>
    <hook:ThresholdPercentageForConversion
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_shcM24-UD0G_87KWD0abFA"
      decimals="4"
      id="Narr_dgCEuhnW9UCIv8qoPKLObQ"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.0999</hook:ThresholdPercentageForConversion>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaSeriesa1AndSeriesa2ConvertiblePreferredStockMember_shcM24-UD0G_87KWD0abFA"
      decimals="3"
      id="Narr_juJZ3zph2U-LoAnp9IfQNQ"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.001</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w"
      decimals="INF"
      id="Narr_sE5olGx9a06Mg2wMriyuaw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">370</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember__7jEylpDhk2E7HBL-QMsuA"
      decimals="INF"
      id="Narr_61FAD0fCRUm1su6s9bLcDA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1697</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA"
      decimals="INF"
      id="Narr_Yf3VW9YWMUOe4O8IioQkYg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10800</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_oBjN55Dh4kWdP45kjmc_cA"
      decimals="INF"
      id="Narr_PgOASUs-6U2pUSlOEHZkmw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15800</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw"
      decimals="INF"
      id="Narr_eYSi82CqJU-iBv6xg7CX5w"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15268</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_4t0j2RLtRUim5ad7YUNdww"
      decimals="INF"
      id="Narr_0AWJOe13_E2HACYtLfhSvQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_f2bozshHvEqDnHPJIfLxkw"
      decimals="INF"
      id="Narr_2cBgp8B5W0-Knx-y65_gnA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1327</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_5OZpzWR5ZE-g65N3W9mQlg"
      decimals="INF"
      id="Narr_7GL6yxHzmEOKJtzV8rAdHA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">5000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_VZQQp8bdV0acmmpRV4RXpw"
      decimals="INF"
      id="Narr_ib5-b6yhTUqFpyfgAOW5ww"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">6327000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_1UfAeLclEEaGrNgqsxLasQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Stock-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;2018 Stock Option and Grant Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2018, the Board of Directors approved the 2018 Stock Option and Grant Plan. Options granted under the 2018 Stock Option and Grant Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. The options expire on the 10&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; anniversary of the grant date. As of December&#160;31,&#160;2023, 782,176&#160;options granted under the 2018 Stock Option and Grant Plan remained outstanding. Any authorization to issue new options under the 2018 Stock Option and Grant Plan was cancelled upon the effectiveness of the 2019 Stock Option and Incentive Plan and no further awards will be granted under the 2018 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;2019 Stock Option and Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April&#160;1,&#160;2019, the Company&#x2019;s stockholders approved the 2019 Stock Option and Incentive Plan, which became effective as of the effective date of the registration statement in connection with the Company&#x2019;s IPO. The plan provides for the grant of shares of restricted stock, long term incentive awards, stock options or other equity-based awards. As of December&#160;31,&#160;2023, the maximum number of shares of the Company&#x2019;s common stock that may be issued under the Company&#x2019;s 2019 Stock Option and Incentive Plan was 8,067,480&#160;shares which shall be cumulatively increased each year by up to 4.0% of the then outstanding number of shares of common stock and Class A common stock. Options granted under the 2019 Stock Option and Incentive Plan generally vest over four years, with 25% of the options vesting upon the first anniversary of the grant date and the remaining 75% of the options vesting in 12 equal quarterly installments following the first anniversary of the grant date, provided the option holder continues to have an employment or service relationship with the Company on each vesting date. Initial options granted to non-executive directors upon their election generally vest over a three-year term with 33% of the options vesting upon the first anniversary of the grant date and the remaining 67% of the options vesting in eight equal quarterly installments following the first anniversary of the grant date. Option re-grants to non-executive directors generally vest on the first anniversary of the grant date. The options expire on the 10&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; anniversary of the grant date. For each option the beneficiary is entitled to receive one share of common stock upon the exercise of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, there were&#160;500,000&#160;shares reserved for stock options issued as inducement grants to new employees granted outside of the Company&#x2019;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On August&#160;7,&#160;2023, the Company&#x2019;s board of directors approved a one-time offer to eligible non-executive, non-director employees to exchange certain outstanding stock options for new stock options with modified terms. Under the stock option exchange program (the &#x201c;Offer&#x201d;), the Company offered to exchange certain out-of-the-money stock options for new stock options at an exchange ratio of between&#160;1.75&#160;and&#160;2.50&#160;surrendered options for one new option exercisable for shares of common stock with a lower exercise price and extended vesting terms. Pursuant to the Offer, a total of&#160;82&#160;eligible participants tendered, and the Company accepted for cancellation, stock options to purchase an aggregate of&#160;543,228&#160;shares of the Company&#x2019;s common stock with exercise prices between $6.90&#160;and $14.00. The eligible options that were accepted for cancellation represented approximately&#160;86.6% of the total shares of common stock underlying all of the eligible options. In accordance with the terms and conditions of the Offer, on September&#160;12, 2023, the Company issued new options to purchase an aggregate of&#160;274,485&#160;shares of common stock in exchange for the cancellation of the tendered eligible options. The exercise price per share of each new option granted in the Offer is $1.00. New options &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;issued for previously vested stock options vest on the first anniversary of the grant date and new options issued for previously unvested stock options vest over a&#160;three-year&#160;term in&#160;twelve&#160;equal quarterly installments. The stock option exchange offer resulted in incremental stock-based compensation expense of $0.1&#160;million, which will be recognized using the graded-vesting method over the remaining requisite service period of the new stock options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents a summary of awards outstanding:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018 Plan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019 Plan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inducement Awards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Granted and outstanding awards:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 782,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,099,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 782,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,099,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Stock option valuation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the option&#x2019;s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, volatility, the risk-free interest rate, the dividend and employee exercise behavior. Forfeitures are accounted for when they occur. Expected volatilities utilized in the Black-Scholes model are based on historical volatilities of a group of comparable companies. The group of representative companies have characteristics similar to the Company, including the stage of product development and focus on the life science industry. Management believes that this represents the most accurate basis for estimating expected future volatilities under the current conditions. The risk-free interest rate is derived from the yields for U.S.&#160;Treasuries with a remaining term approximating the expected life of the options. The expected term represents the period of time that the options granted are expected to be outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options granted during:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;For the 2021, 2022 and 2023 grants, the Company used the simplified method in developing an estimate of the expected term due to a lack of historical exercise data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock option activity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity since January&#160;1,&#160;2023 (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,532,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,880,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,684)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,296,249)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,101,520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options unvested as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,010,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of stock options was calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. The fair value per common stock used for calculating the intrinsic values as of December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021, was $0.81, $0.81 and $2.33, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of options exercised during the years ended December&#160;31,&#160;2023, 2022 and 2021 was less than $0.1&#160;million, $0.1&#160;million and $1.0&#160;million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average grant-date fair value per share of stock options granted during the years ended December&#160;31,&#160;2023, 2022 and 2021 was $0.55, $1.55 and $11.46, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The total fair value of stock options vested during the years ended December&#160;31,&#160;2023 and 2022 was $5.1&#160;million and $7.9&#160;million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash received from stock option exercise under share-based payment arrangements for the years ended December&#160;31,&#160;2023, 2022 and 2021 was $1&#160;thousand, $3&#160;thousand and $203&#160;thousand, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Common Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the year ended December&#160;31,&#160;2022 the Company issued unrestricted shares of common stock to its executive team. The Company&#x2019;s executive team agreed to convert a portion of their base salaries, for the six months ended June&#160;30,&#160;2022, for shares of the Company&#x2019;s fully vested common stock having a value equal to their foregone salary, determined based on a value of $3.00 per share. This resulted in the issuance of 112,551&#160;shares of common stock with a total fair value of $0.2&#160;million. The grant date fair value per share of common stock was $1.50 and was measured at the closing price of the common stock on the date of grant. Expenses were recorded immediately and are included in stock based compensation in the year ended December&#160;31,&#160;2022. No unrestricted shares of common stock were issued in the year ended December&#160;31,&#160;2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,074&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,444&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31,&#160;2023 total unrecognized compensation cost related to the unvested stock-based awards was $1.5&#160;million, which is expected to be recognized over a weighted average period of 1.5&#160;years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_ioKeOQv4MEC7RRwFd806mw"
      id="Narr_LNKMNSpI2UCm19xliglS_A">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_aKhFceKN_063s8FrQsNE-g"
      decimals="2"
      id="Narr_aaSPCs0E4EKBaV_wO76XcA"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pi9ns7LHMEqJa6iUqFqKqA"
      decimals="2"
      id="Narr_n4LQxiEfWkS23ADVfSsneg"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_Pi9ns7LHMEqJa6iUqFqKqA"
      decimals="INF"
      id="Narr_L9mo42em_UGQ-tHdIqBM0Q"
      unitRef="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA">12</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_y96X3sy35kK-JiMbzDVPjw"
      decimals="INF"
      id="Narr_EIPvpA4BBU6JgJHHsyRIsA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">782176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_vsxwLcmVd0qxvZfveKo1qw"
      decimals="INF"
      id="Narr_y-gqi-BR4kKUbvTl4ZdVPg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">8067480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <hook:StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_pT4ROzEyWkS4z3OWuisutw"
      decimals="3"
      id="Narr_elfNM7-p8EaVfMq_45pJ7A"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.040</hook:StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_pT4ROzEyWkS4z3OWuisutw"
      id="Narr_wKAIcnxhQEql9G8NZ4Dhbw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_H0tCjW2DHECbxO5klnyB9A"
      decimals="2"
      id="Narr_VpD-h1PoxkC8KWe1KXxXCQ"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ZtdYdiFLwEqrZPGSD1c3dg"
      decimals="2"
      id="Narr_51gDbt3HZE2mqHcc_SbCfg"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ZtdYdiFLwEqrZPGSD1c3dg"
      decimals="INF"
      id="Narr_FbdTsjp510WQnwUGm2f83A"
      unitRef="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA">12</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_XF87Kq4bd0-7XFTH2TZbAg"
      id="Narr_BoSQbT0Hg0-OFdcgs2Ii4A">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_xnILDkMs_kCjhQ1U1ADU1A"
      decimals="2"
      id="Narr_oO3RmV1HkUyklnNymWt35A"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iIx2YHcEt0CG7Jld-YUTtA"
      decimals="2"
      id="Narr_YqA-4K6lNUK36ouRtYF-yw"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_TitleOfIndividualAxis_hook_NonExecutiveDirectorsMember_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iIx2YHcEt0CG7Jld-YUTtA"
      decimals="INF"
      id="Narr_ULJSr1djSESXsM1WvIpkuw"
      unitRef="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA">8</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment>
    <hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="INF"
      id="Narr_LW1gzEyh6k6x4Ty2m0PecA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1</hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_InducementAwardsPlanMember_bUvp9git4U6vhtxSXzOaEA"
      decimals="INF"
      id="Narr_aD8te1TVHUi1IpxIZYbfMA"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio
      contextRef="As_Of_8_7_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember__FwCStMaU0OyzpKGLfbvNA"
      decimals="2"
      id="Narr_XxBfyAgxyESex9G1Hed3GQ"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">1.75</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio
      contextRef="As_Of_8_7_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_I0qOWFNRG0m7UhyFU_5e3A"
      decimals="2"
      id="Narr_Gf7AlsFZCUCvVizs8R1CqA"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">2.50</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeRatio>
    <hook:NumberOfEligibleParticipants
      contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg"
      decimals="INF"
      id="Narr_alkcR1EYVUOwoXSf4e5B_A"
      unitRef="Unit_Standard_item_UFkQASyViEyzhA9dw1cdpg">82</hook:NumberOfEligibleParticipants>
    <hook:NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled
      contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg"
      decimals="INF"
      id="Narr_gfa5gYUEl0W5RYby1bXCEw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">543228</hook:NumberOfSharesToBeIssuedUponExerciseOfStockOptionsCancelled>
    <hook:ExercisePriceLimitConsideredForCancellationOfStockOptions
      contextRef="Duration_8_7_2023_To_8_7_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_br4Ybr-YDUajiQqo-HL-lg"
      decimals="2"
      id="Narr_kquBYPvzVUGY6yWB0bS4uw"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">6.90</hook:ExercisePriceLimitConsideredForCancellationOfStockOptions>
    <hook:ExercisePriceLimitConsideredForCancellationOfStockOptions
      contextRef="Duration_8_7_2023_To_8_7_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_3at3uPhCo0ShjqrpfD4Klg"
      decimals="2"
      id="Narr_-XI5FHhps0OBNMjMyfIkQg"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">14.00</hook:ExercisePriceLimitConsideredForCancellationOfStockOptions>
    <hook:PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions
      contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg"
      decimals="3"
      id="Narr_uMaXQKXJ8EaGczwEXThNxA"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.866</hook:PercentageOfOptionsAcceptedForCancellationOnTotalSharesUnderlyingEligibleOptions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_12_2023_To_9_12_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_Xd8PFrmLWECYLMz00H-fVQ"
      decimals="INF"
      id="Narr_wU-GNgyi00-PTptaTD45iw"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">274485</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <hook:StockOptionsIssuedExercisePricePerShare
      contextRef="Duration_9_12_2023_To_9_12_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_Xd8PFrmLWECYLMz00H-fVQ"
      decimals="2"
      id="Narr_TYfUAMuxKUeWDGpU43nOcQ"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1.00</hook:StockOptionsIssuedExercisePricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg"
      id="Narr_St7eTbsrmEids1JXEhIGVQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment
      contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg"
      decimals="INF"
      id="Narr_2Ez9CXN5dEy2iSNPexyLDA"
      unitRef="Unit_Standard_installment_FyfnG8C_o0iwjo7jyH89wA">12</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost
      contextRef="Duration_8_7_2023_To_8_7_2023_us-gaap_TypeOfArrangementAxis_hook_StockOptionExchangeOfferMember_AcWFtGOm6U6ZPmp8ScSBjg"
      decimals="-5"
      id="Narr_rK9AcwLy0U2HX9rUnXayFQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_AXNLnHkqHkSUOozBEHbj2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018 Plan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019 Plan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inducement Awards&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Granted and outstanding awards:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 782,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,099,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 782,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,099,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_y96X3sy35kK-JiMbzDVPjw"
      decimals="INF"
      id="Tc_pL9wJay2MEevgqgwE3LmJA_5_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">782176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_vsxwLcmVd0qxvZfveKo1qw"
      decimals="INF"
      id="Tc_j97YeP01l0S1H-qnknEO3w_5_4"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">7099399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_InducementAwardsPlanMember_bUvp9git4U6vhtxSXzOaEA"
      decimals="INF"
      id="Tc_pc8LX_SYzkqCPY-ObHnh8g_5_6"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Tc_dfgp1X3V60OioC9XYQVraQ_5_8"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">8111575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_y96X3sy35kK-JiMbzDVPjw"
      decimals="INF"
      id="Tc_rY1Sg72gnUm53uwtWEOCLQ_6_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">782176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_StockOptionAndIncentive2019PlanMember_vsxwLcmVd0qxvZfveKo1qw"
      decimals="INF"
      id="Tc_UidvBbJD1US95lY6aIz54w_6_4"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">7099399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_hook_InducementAwardsPlanMember_bUvp9git4U6vhtxSXzOaEA"
      decimals="INF"
      id="Tc_IZeYBLNiz0u8ipRy6osxtA_6_6"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Tc_Ud6QeSOGmUyclYtFheLoVQ_6_8"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">8111575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_dBu2HGQrrkauWw4qijk3rw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="4"
      id="Tc_Ly1gJTBnO0iqC8vpF5sQAA_4_2"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.0370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="4"
      id="Tc_DK1lsMdyake3jrckbZL70A_4_4"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.0309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="4"
      id="Tc_jw4JPWVuj0idTWWun_rN2w_4_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.0107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_oFi_Jb33QU6O3ZNc3dzVuw_5_2">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      id="Tc_xdTk7EIFkUqyIv4xKaQ-6w_5_4">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      id="Tc_n2kEEjuVjUW_ADtO2pVkGA_5_6">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_UspDIO3vwEmRTzbr8GvKgg_6_2"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Tc_z2qYQ11COUusXCLsAxod7A_6_4"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Tc_67cgzR-KQkGpzFinxSVpdg_6_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_7p-9wBJGBEWihARYGziyMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity since January&#160;1,&#160;2023 (in thousands, except share and per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,532,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,880,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,684)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,296,249)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,101,520&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options unvested as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,010,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="INF"
      id="Tc_hZlPbBwUQke4chhKR8YfXA_7_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">6532523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="2"
      id="Tc_OB7_ubjU3ESP0LriVlqPfA_7_5"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">6.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      id="Tc_WOGea9JmFkGA4HfJ0EFzVw_7_7">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_-XBHjba470mAZTUqBgF3kg_7_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="INF"
      id="Tc__2RC6FNTGEyP5OHgcahbhg_8_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2880985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Tc_K2mzdJ82S0CL3SkU3e5IWg_8_5"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="INF"
      id="Tc_Gz_K7pIJqE-EIBOIVEMgeg_9_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">5684</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Tc_fgjSd5dtHk2d9SHsKnDIGg_9_5"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="INF"
      id="Tc_zSLgZ7_RekSNR_SnNZU3Rg_10_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1296249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Tc_6DLaJHz6wEG5tknQrn45Ww_10_5"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">6.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Tc_xx0oLzR6W0qTTFNM-x5luw_11_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">8111575</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="2"
      id="Tc_mCxOGw5SlkeKD_IpulamFg_11_5"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">4.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_QpfysqbKHE2fMatmbZEBDQ_11_7">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_ZPcTvHE4wUSqAT1D2ewGfQ_11_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">486000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Tc_bQqEcAnEWUStfR8eOn70cQ_13_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">4101520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="2"
      id="Tc_W_Lepg2MokKHjFCb8A7vkg_13_5"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">6.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_ZTgSguzPCEySnwolSLSq3w_13_7">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_TH7W1uXRW0WlBEL7dljvzg_13_10"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">486000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="INF"
      id="Tc_atnzXf35ZEWPG805gJHY3Q_14_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">4010055</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="2"
      id="Tc_xYW8GqI1q06FxJS1DrGJCQ_14_5"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tc_0r57yDlW6keESKLHdithIA_14_7">P8Y9M18D</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Narr_iHv8rrTQIk6lP1rY0VUOlA"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.81</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="2"
      id="Narr_JExhR3nndkOp8gt48fa2og"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.81</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="2"
      id="Narr_yYlN9X3iL0uFjP3viayFLw"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">2.33</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ"
      decimals="-5"
      id="Narr_TLnzJeHBQUmVUiVn6q3pCA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Cjpb3hF7IEea2TyyB2JGNg"
      decimals="-5"
      id="Narr_tTPNjobw6EaxqgniWlVq3A"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_AFyGmgyE8kiyCNQqfpXApA"
      decimals="-5"
      id="Narr_wa5UwQnjaUiUyP8pwXo-XQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Narr_FfPBDqjRF0ajWVPHrLnynQ"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="2"
      id="Narr_F5E_Xt0U_U6mjGMcgkei8Q"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="2"
      id="Narr_kvFpuQWbekixTa9Dz-a64A"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">11.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_lv3r--kfEkygAJuhGjaqRA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_eUp7ptfpk0q79AZJUR55GA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Narr_vI9nBR7LcUyP-paCHbZw-Q"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Narr_nvk_utXs5UaToNmyEidTaQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Narr_qGiXsrYZHEayNEylk_d96g"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">203000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_BcR8oItz_UOIQXNtcPyaQQ"
      decimals="2"
      id="Narr_dyExjSp-4EynTYXc54JlKQ"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">3.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_m8WtQLcukk2yFLSY4g5v3Q"
      decimals="INF"
      id="Narr_FamGlA9Nr06TjNFwvtffiQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">112551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_m8WtQLcukk2yFLSY4g5v3Q"
      decimals="-5"
      id="Narr_yL0ON4xD5UOQDb_bQios6w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">200000</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue>
    <hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_m8WtQLcukk2yFLSY4g5v3Q"
      decimals="2"
      id="Narr_JUhPGPQI80yTucdXwRKLFg"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">1.50</hook:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_6eU7lu-gYkGX1lF7SujF0A"
      decimals="INF"
      id="Narr_lnV5ouRoKEuOWcdKYuGJRg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_TCxiyU-p1EK4DFocUcV5AA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation expense was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,074&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,444&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b8VlOcR0O0OmF5emQANTkw"
      decimals="-3"
      id="Tc_rIUYWBtg_kq20jIg_qDOBQ_3_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">861000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_e9XlwwWzZUyxUx3pingkdQ"
      decimals="-3"
      id="Tc_Cs4DpGk-ZkC1Z7AAPGO-HQ_3_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ShuqB9wIDkS3F21xuhUuPQ"
      decimals="-3"
      id="Tc_U8W6MUIb5UOeaRbNFMr41g_3_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_3z_KZuEbyUyufSDi6RFYKw"
      decimals="-3"
      id="Tc_-p3S_JqWtEyxHK6dRfQUNQ_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1484000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_mzTecP16KUqdKJ51DcbR8w"
      decimals="-3"
      id="Tc_OPsib2w_LEqPYoHIrKUn6Q_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2969000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_OgNb7067TEG0mtw4IpZ_2g"
      decimals="-3"
      id="Tc_fGX4TR5waE6JBaQjceJ0MQ_4_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4444000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_RvEJjNal20ujvIOmDK1OhQ_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2345000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_8lsyUt0C0k2BuX6jqkCMGQ_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5043000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_K1VLgvkCPE2_m5wl1d3w4Q_5_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7644000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-5"
      id="Narr_9JVhQIGNGEiOpoFps4u8Wg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Narr_FRFArWaJd0OPmkWUN2iUFg">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_WyHvdQ9h20yEz_b37h0OBA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income tax expense during the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 resulted from US federal and state income tax as well as minimum tax obligations in Austria. From inception through December&#160;31,&#160;2021, we have not been required to pay U.S. federal and state income taxes because of current and accumulated net operating losses. Income tax expense during the year ended December&#160;31,&#160;2021 resulted from minimum tax obligations. During the years ended December&#160;31,&#160;2023, 2022 and 2021, the Company recorded no income tax benefits for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items. The Company's losses before income taxes were generated in the United States and Austria.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2023, 2022 and 2021 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,222)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,403)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign (Austria)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,922)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (57,463)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,261)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss before tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (81,212)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,685)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,664)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The components of the consolidated income tax provision for the years ended December&#160;31,&#160;2023, 2022 and 2021 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Foreign (Austria)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total current tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Foreign (Austria)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company's worldwide effective tax rate for the years ended December&#160;31,&#160;2023, 2022 and 2021 was 0.5%, 0.3% and 0.0%, respectively. The tax rate is affected by recurring items, such as tax rates in foreign jurisdictions and the relative amounts of income earned in those jurisdictions, which is expected to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. The following items had the most significant impact on the difference between the statutory U.S. federal income tax rate of 21% for the years ended December&#160;31,&#160;2023, 2022 and 2021 and the effective tax rate:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Foreign tax rate differential&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Not taxable government grants&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Global intangible low-taxed income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Change in deferred tax asset valuation allowance&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The 2.7% increase for the year ended December 31, 2023, and the 4% increase for the years ended December&#160;31,&#160;2022 and 2021, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is 24% for the year ended December&#160;31,&#160;2023, and 25% for the years ended December&#160;31,&#160;2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2) &lt;/sup&gt;For the years ended December&#160;31,&#160;2023, 2022 and 2021, 6.8%, 3.8% and 3.8% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3) &lt;/sup&gt;For the years ended December&#160;31,&#160;2023, 2022 and 2021, 28.2% reduction, 27.1% reduction and 30.2% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company's research activities and the inherent uncertainties the deferred tax assets are fully offset by a valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2023 and 2022 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 87,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 66,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 94,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 70,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (89,309)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (65,774)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 5,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 4,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (3,774)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (3,450)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (14)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (10)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Operating lease right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (1,262)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (920)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (5,050)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (4,380)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31,&#160;2023, 2022 and 2021, the Company had Austrian net operating loss carryforwards of $378.1&#160;million, $275.3&#160;million and $219.7&#160;million, respectively, that do not expire, however these carryforwards are limited to 75% of the taxable income in any one tax period. As of December&#160;31,&#160;2023, 2022 and 2021, the Company had federal net operating loss carryforwards that were generated after December&#160;31,&#160;2017 of $2.2&#160;million, $13.8&#160;million and $17.9&#160;million, respectively, that do not expire, however these carryforwards are limited to 80% of the taxable income in any one tax period. The Company generated US taxable income in the current year and was able to offset 80% the taxable income utilizing net operating loss carryforwards which gave rise to current taxes during 2023. The federal net operating loss carryforward as of December&#160;31,&#160;2023 were $2.2&#160;million, and US Federal net operating loss carryforwards as of December&#160;31,&#160;2022 were $13.8&#160;million. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets resulting from its net operating loss carryforwards. Management has considered the Company's history of cumulative net losses incurred since inception and the uncertainties related to the long period necessary to achieve profits from commercialization of any products and has concluded that it is more likely than not that the Company will not realize the benefits of its deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December&#160;31,&#160;2023, 2022 and 2021. According to a tax reform in Austria in 2022, the corporate income tax rate will be reduced from 24.0% to 23.0% in 2024. The future tax rate of 23.0% was used to determine deferred taxes and the valuation allowance for the Austrian business. Management reevaluates the positive and negative evidence at each reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;losses is no longer present and additional weight may be given to subjective evidence. The tax years in which the tax carryforwards were generated may still be adjusted upon examination by the tax authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2023, 2022 and 2021 related primarily to the increases in net operating loss carryforwards as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance at beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (65,774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (53,728)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,064)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Increases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23,535)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,046)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,664)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89,309)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (65,774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (53,728)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;22,&#160;2017, the United States enacted the Tax Cuts and Jobs Act (&#x201c;Tax Reform Legislation&#x201d; or &#x201c;TCJA&#x201d;). The Tax Reform Legislation introduced section 951A, a new tax on so-called &#x201c;global intangible low-taxed income&#x201d;. GILTI applies to income of a controlled foreign corporation (&#x201c;CFC&#x201d;) that is not otherwise subpart F income, and consists of the excess "tested income" over a 10% return on the CFC's &#x201c;qualified business asset investment,&#x201d; or &#x201c;QBAI&#x201d;. QBAI is the total tax basis of the CFC's depreciable, tangible property used in the production of tested income. The full amount of GILTI is included in taxable income. The GILTI inclusion is then reduced by 50% (reduced to 37.5% after 2025). However, that reduction in GILTI may be limited based on the level of U.S. taxable income. A limited allowance for foreign tax credits is allowed that would reduce the U.S. tax cost. GILTI foreign tax credits can only reduce U.S. taxes owed on GILTI and are not eligible for carryforward. The Company's Austrian subsidiary falls under the category of a CFC and due to the nature of its business model as a technology company, there may not be a material amount of tangible assets if this subsidiary starts to generate profits. GILTI taxation therefore may be applicable. The Company estimated approximately $8.8&#160;million of GILTI inclusion for the year ended December&#160;31,&#160;2023. The Company previously estimated $3.6&#160;million for the tax year ended December&#160;31,&#160;2022, but did not recognize any GILTI inclusion upon filing of the December&#160;31,&#160;2022 statements. The U.S. tax on GILTI, net of research credits, was $0.4&#160;million and $0.2&#160;million for the years ended December&#160;31,&#160;2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction as well as in New York. The tax years from 2018 to present remain open to examination by the jurisdictions in which the Company is subject to tax. &lt;span style="background:#ffffff;"&gt;There are currently no pending income tax examinations in the U.S. &lt;/span&gt;Furthermore, the Company files income tax returns in Austria. The tax years 2018 to present remain open to examination by the jurisdiction. There are currently no pending income tax examinations in Austria.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company evaluates tax positions for recognition using a more likely than not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31,&#160;2023 and 2022, the Company had no unrecognized income tax benefits that would affect the Company&#x2019;s effective tax rate if recognized.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <hook:IncomeTaxBenefitsNetOperatingLossesIncurred
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Narr_ADZMTpvv6UCwhWku07eM2A"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:IncomeTaxBenefitsNetOperatingLossesIncurred>
    <hook:IncomeTaxBenefitsNetOperatingLossesIncurred
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Narr_bZR54tKyrUyoTR8QN9PoFg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:IncomeTaxBenefitsNetOperatingLossesIncurred>
    <hook:IncomeTaxBenefitsNetOperatingLossesIncurred
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Narr_e-3atmpQRkCtu-QOe7RkHg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</hook:IncomeTaxBenefitsNetOperatingLossesIncurred>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_v7_PBmpMB0ynODr5aUBoeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;For financial reporting purposes, losses before income taxes for the years ended December&#160;31,&#160;2023, 2022 and 2021 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,710&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,222)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,403)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign (Austria)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,922)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (57,463)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,261)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss before tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (81,212)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (64,685)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75,664)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_F2gO2tV-JEi1HFWIkxVDcg_3_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1710000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_5AjtMcG7m0KVQmw0HBmQKA_3_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-7222000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_muOTRZ6-tkSyAPTebOkDWQ_3_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-11403000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_anc61ACgOkuiEPFX5Inuww_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-82922000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_f3otQX5-vkacnv7glIGTvg_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-57463000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_eyIipq4xoUu2XEtpSZ9Idg_4_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64261000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_gZ1-UbUfv0OYEOgFTwl5zg_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-81212000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_F4Gz5fEFzEO-cNQ906K3dw_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64685000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_fjlQ80N99UeYJQsaLolmqQ_5_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-75664000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_Qu5jlB84KEOWb6KgIl1ssw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The components of the consolidated income tax provision for the years ended December&#160;31,&#160;2023, 2022 and 2021 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 145&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Foreign (Austria)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total current tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Foreign (Austria)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total income tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_Q48itgLs-UaQmNn950LrIg_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">145000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_ebUa4bfOVUaNaMUub-mxFg_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">217000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_nTfo9N51cUmVvhVXFqYF8g_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">222000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_umpMOYk7F0GzyCIsvreVAg_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_gKaUDGQAIkuVmUx6F5govg_6_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_mY1cv29Like-ntyHcF628g_6_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_WvXt3RMj50aPRkzhUDBZrg_6_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_0j7apgEKOEOTo044TLFGug_7_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">368000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_7cgtp0PVOEuWXIG2JEskrA_7_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">230000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_zPOWVeySwEGCkdIZbi7q-g_7_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_qZxu7SnvUU62cHSub49Ipg_14_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">368000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_K0FYFLa_8E2RVYVeC8G0YQ_14_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_qpwmn72vRECTDkGHUYQkVQ_14_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Narr_bwpS_kSb70KAaaST40LFjQ"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Narr_kyrgB6amW0yVgs7pE0dG1Q"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Narr_PrzoODvnhUOlegZIXZt8KA"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="2"
      id="Narr__d2_QY3ewkWNmppDWmoVYw"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="2"
      id="Narr__SOVErHKLEORWsMQ36TkHQ"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Narr_Di7VUZWUWUu9wwPhgInsHA"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_yXhFmWQdFUuay_S_ru5-Ig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S. federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Foreign tax rate differential&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Not taxable government grants&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Global intangible low-taxed income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Change in deferred tax asset valuation allowance&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; The 2.7% increase for the year ended December 31, 2023, and the 4% increase for the years ended December&#160;31,&#160;2022 and 2021, respectively, resulted from tax rate differences between U.S. and non-U.S. jurisdictions. Net loss before tax was principally generated in Austria, where the statutory tax rate is 24% for the year ended December&#160;31,&#160;2023, and 25% for the years ended December&#160;31,&#160;2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2) &lt;/sup&gt;For the years ended December&#160;31,&#160;2023, 2022 and 2021, 6.8%, 3.8% and 3.8% increase, respectively, resulted from non-taxable research subsidies received from Austrian government agencies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3) &lt;/sup&gt;For the years ended December&#160;31,&#160;2023, 2022 and 2021, 28.2% reduction, 27.1% reduction and 30.2% reduction, respectively, resulted from changes in valuation allowance on deferred tax assets. Deferred tax assets will only be recovered when the generation of future taxable income is more likely than not. Due to the nature of the Company's research activities and the inherent uncertainties the deferred tax assets are fully offset by a valuation allowance.&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_XZLZChSLQkC2zro0CUoD5g_3_3"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Tc_MQMFs1ez7UymyKO7mxlFZw_3_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Tc_PuEqAcdkzUifSdeQTQEgvA_3_9"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_t4IBIkm5pEu7ZwYjC9Q5Cw_4_3"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_3ioFV0aNQkeGCeFVt5BXdA_5_3"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Tc_23vxKOBKZkOIonrG24l66w_5_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Tc_8aVsNy2J40y1PC1XRT5kZg_5_9"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_V-PU4FTmnkmTLs26hK_IPw_6_3"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.068</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Tc_zZU0Qc_JbkuQNFKHBDub-A_6_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Tc_R_-drpK1GkCRbaV9HKgRzg_6_9"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_3xtx-JGGLEudaUQqAi2AHg_7_3"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Tc_lFIWfpAzs0SFTZdjhK3Ghg_7_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Tc_WxPU9XqHGk-O18dZ3jzXdg_7_9"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_P8jjP6qF2EKwpWAD7IJ1qw_8_3"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Tc_TlblhAEOrk-jGLBv4VGZ6Q_8_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_UT3zhT_TkUOXDl1kbeAhgg_9_3"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Tc_M2BmzaZSAky0MUvscrPY7Q_9_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Tc_kNtRI-FYpUCidR33B8DhQA_9_9"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_Aajkh0bWF0ye-d9LDQBG1A_10_3"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.282</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Tc_GuMxOj1Axku1bHAG9VRrNw_10_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.271</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Tc_C4CWTsXSGk6BPG4abR2eRg_10_9"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.302</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Tc_C8GYXla41kyZLBBkPrFEMA_11_3"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Tc_gpv4_35mMkSvwG9iQ5YwDQ_11_6"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Narr_75lA2qR8oU28lt-DOtQD5g"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="2"
      id="Narr_oAp5WcYBdUeJBm-lljlLYA"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="2"
      id="Narr_EFjwZVl5rUyyJibaSdGY1A"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_AT_hpenzR01Xkuk5j5fUTX0jQ"
      decimals="2"
      id="Narr_GH_2iULSq02hE5piqfVBYw"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AT_3NogJxMRLUKuio1gDYqLrg"
      decimals="2"
      id="Narr_MLBjW8V1C0-AI3xEEDMlog"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AT_c4d1mu2O80qu0WCXkZuWww"
      decimals="2"
      id="Narr_1WsfR6VtYEW-ZPN5vZCK2Q"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Narr_JulIgdiEk0WZc6La-nzHtA"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.068</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Narr_ME6iayc-vU6DVzquUbf2Ag"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Narr_nM3Y9gll6kaqPT4lOYKWmA"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="3"
      id="Narr_49n0oRppuUO4PR1UBPGnnw"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.282</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="3"
      id="Narr_uAIPsP3CXUiqU0nmeps_rg"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.271</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="3"
      id="Narr_GyWLqNi-s0OqWKEarJxVYw"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">-0.302</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_csA4lYXipkGPgSkOZLhyDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Components of the net deferred tax assets or liabilities as of the years ended December&#160;31,&#160;2023 and 2022 consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';font-size:7.5pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 87,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 66,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 1,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 94,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 70,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (89,309)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (65,774)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 5,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; 4,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (3,774)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (3,450)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (14)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (10)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Operating lease right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (1,262)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (920)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (5,050)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; (4,380)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-family:'Times';"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Times';"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_O7TXQEAU1UaOEDVPQr_96w_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">87445000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_oXWFM6kMXU-GShCI13tyNA_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">66201000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <hook:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_wlUCCSihEEKoFI7ERg19Zg_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2657000</hook:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <hook:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_04im37Wi9EaKtQ6qk4p7YA_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1354000</hook:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_cUkaQ4GYFkC3wUYudTYehw_6_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1265000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_B3VYstNA4kKHO1UF1loVIA_6_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">64000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_mVfEpSZ58kuuSgfUfwyWmQ_7_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">317000</hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_UdQC59cLZUeAf6skjkYqRw_7_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">366000</hook:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_PlS5_Sm47061B7128NWNSQ_8_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1421000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_YITe7q0rTUCFjoJlIWZVyg_8_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1251000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <hook:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_UWwDlFr5c0-qozey7KwvxA_9_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1254000</hook:DeferredTaxAssetsOperatingLeaseLiabilities>
    <hook:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_E1CzMebgtUSJPsYcqqSkzQ_9_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">918000</hook:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_z1yBQ66j7kqX-ZBLv3QWhg_10_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">94359000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_8ygtbb54EEuiSpeepBiDzA_10_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">70154000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_uZE5lyNOPUalnN2F17RWDQ_11_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">89309000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_8_XkpGN_YkGq-wipVFzNTA_11_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">65774000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc__YDDph-ri02isywiNE1NxA_12_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5050000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_4fQnMrGOwkq-3eeBgfZAFQ_12_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4380000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_MRfeWgD7kUeFRy2oiNgG3A_15_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3774000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_A2z7uB_WgkGCcLhhQGsScQ_15_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3450000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <hook:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_GOEGBDxIq0SlcbBfXAOTxg_16_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">14000</hook:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <hook:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_DpTdfmmRykmmfH-OJz5JzQ_16_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10000</hook:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_jf5UjyMoFkW_dTB8m4HdWw_17_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1262000</hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_nCXcb6kyH0Wli9DZ5vBMuA_17_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">920000</hook:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_1lJB6Zq0yE2MDFvG21pFOg_18_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">5050000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_jRVg41LENUOTwEkZZJFdCQ_18_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">4380000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_srt_StatementGeographicalAxis_country_AT_yaoK_p7Sukuiq2w5N3spOA"
      decimals="-5"
      id="Narr_uPuopDNJIky8Kh_WcxqoyA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">378100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_AT_3mwjH__tMUma_hkm6Ve5jg"
      decimals="-5"
      id="Narr_4ERdTKwT4kS4oDoykuv-Qw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">275300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AT_nqOGXBicVESvalgSTFcbwQ"
      decimals="-5"
      id="Narr_vtx84ze3MkKxFQCMsER3xw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">219700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_C_IAmN5vm0OXRMTCb5TGJQ"
      decimals="-5"
      id="Narr_bLH82GN4p0GvLchujGCFHg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6rCpmJmAUk-pthMRELXHZw"
      decimals="-5"
      id="Narr_8MSb_mJygEC-n1yC4spJzg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">13800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_poFM7cMgMUmMG8tthzI0dA"
      decimals="-5"
      id="Narr_iVjNUXSxMkySv9J0j5QUlA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">17900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_C_IAmN5vm0OXRMTCb5TGJQ"
      decimals="-5"
      id="Narr_aWS_mFimuUq3KYe4LLy6tg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">2200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_6rCpmJmAUk-pthMRELXHZw"
      decimals="-5"
      id="Narr_7KxZWD8fzE2OeUYR0UTATQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">13800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_AT_hpenzR01Xkuk5j5fUTX0jQ"
      decimals="3"
      id="Narr_eEX2o0sif0yX5Wpzx8p8AQ"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.240</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_StatementGeographicalAxis_country_AT_kfxilsmFSkCesBThL4nisw"
      decimals="3"
      id="Narr_9Qrqo6aJekOZkWFWYT-3Og"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.230</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_StatementGeographicalAxis_country_AT_kfxilsmFSkCesBThL4nisw"
      decimals="3"
      id="Narr_tn8vJ2ek9EizPotFcer8UQ"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.230</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_oLr3WtMuDUyi_wcjVzuLyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31,&#160;2023, 2022 and 2021 related primarily to the increases in net operating loss carryforwards as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance at beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (65,774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (53,728)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,064)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Increases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (23,535)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,046)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,664)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (89,309)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (65,774)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (53,728)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_i0c0fdYmPEeXl6U5C9HE7A_3_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">65774000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw"
      decimals="-3"
      id="Tc_fJDzQ8JZHUi2MH0w156Agw_3_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">53728000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_PSUqRWmVfkCw7OQN6sRoGw"
      decimals="-3"
      id="Tc_S3q5Ve_UmUquL9TV2A0LOw_3_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">46064000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc_ITLrGvkkv0KG2QS8jA9dkg_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">23535000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_Eb0G8YqswEK3IROGIcZvNQ_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">12046000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_sF_9pV6vq0iPVQlSQVNB7g_4_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7664000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-3"
      id="Tc_8QdwAnozP0WcBkKEpptCUQ_5_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">89309000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-3"
      id="Tc_pAY6t80U7kyLZcW4Q0uViQ_5_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">65774000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_FmXlllaV1EGLGCVfs0ymmw"
      decimals="-3"
      id="Tc_TAA4UxCbcUSVX206APOJjQ_5_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">53728000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_PAmlf0SvqUq31dMNWmAl9w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">8800000</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_vH2OUVjrtEeHlG0_otMGdg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">3600000</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiAmount>
    <hook:UsTaxOnGiltiNetOfResearchCredits
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_XUijoSu1WEiSouag_2PiMw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">400000</hook:UsTaxOnGiltiNetOfResearchCredits>
    <hook:UsTaxOnGiltiNetOfResearchCredits
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_EYAdjM2tfUqGp7d5gdMxeA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">200000</hook:UsTaxOnGiltiNetOfResearchCredits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="As_Of_12_31_2022_QlDYQOzoFkqvlu2tU0pWvA"
      decimals="-6"
      id="Narr_88pT5eV9g0-Kx4zgTUQxaA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-6"
      id="Narr_J3QCCO5p2k-_LnCFH0hMUA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_0LTWChXOzE2RHzApaTLGAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. Commitments and contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Contract manufacturing arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into arrangements with contract manufacturing organizations (&#x201c;CMOs&#x201d;) for manufacturing of materials for research and development purposes, including manufacturing of clinical trial materials. These contracts generally provide for non-cancellable obligations or cancellation penalties depending on the time of cancellation. As of December&#160;31,&#160;2023, the Company&#x2019;s total non-cancellable obligations under contracts with CMOs were $7.4&#160;million, of which $0.9&#160;million relate to 2024 deliverables and $6.5&#160;million relate to 2025 deliverables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Intellectual property licenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into certain license agreements under which it is obligated to make milestone payments upon the achievement of certain development and regulatory milestones, to pay royalties on net sales of licensed products, and to pay a percentage of the sublicense fees which the Company receives from its sublicensees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the years ended December&#160;31,&#160;2023, 2022 and 2021, the Company recorded $1.6&#160;million, $1.0&#160;million and $1.3&#160;million, respectively, in licensing fees related to intellectual property licenses as research and development expenses. The amount for the year ended December&#160;31,&#160;2021 mainly related to the upfront payment and milestone payments received by the Company under the Gilead Collaboration Agreement. The amount for the years ended December&#160;31,&#160;2023 and December&#160;31,&#160;2022 mainly related to the upfront payment and milestone payments received by the Company under the Gilead Collaboration Agreement and the Roche Collaboration Agreement. The amounts recognized as expenses have been agreed to by the licensors but calculation of sublicensing fees on future payments may be subject to interpretation and may change until agreed to by the receiving party.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Indemnification agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and senior management that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31,&#160;2023 or December&#160;31,&#160;2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Legal proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company was recently a party to a patent proceeding opposing European Patent No.&#160;3218504 (the &#x201c;EP&#160;&#x2019;504 Patent&#x201d;), which was granted to the University of Geneva in July&#160;2020 and is exclusively licensed to the Company. In a decision that has become final, the Opposition Division of the European Patent Office (&#x201c;EPO&#x201d;) dismissed the opposition, and maintained the patent as granted. The Company expenses the costs related to this case and other such legal proceedings as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-5"
      id="Narr_B-8JTPX6R0e7GZJk-3YO_w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">7400000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-5"
      id="Narr_YbVHlBZ7IUSFWJ-QuVvBbg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">900000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_12_31_2023_C-BeJU_maU6KyCIqQ4-TCg"
      decimals="-5"
      id="Narr_4ZWsjEUMqU-_VszB8vQFGA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">6500000</us-gaap:ContractualObligationDueInSecondYear>
    <hook:LicensingFeesIntellectualPropertyLicenses
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_hw1RAfCPQkyfclKm8_n6Kg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1600000</hook:LicensingFeesIntellectualPropertyLicenses>
    <hook:LicensingFeesIntellectualPropertyLicenses
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_W-Kx_yw2gUeWfBlm8KwwUw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1000000.0</hook:LicensingFeesIntellectualPropertyLicenses>
    <hook:LicensingFeesIntellectualPropertyLicenses
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-5"
      id="Narr_wSwqTdo31k2iOudM34KDUg"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1300000</hook:LicensingFeesIntellectualPropertyLicenses>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_xmB61jfi9Ey3KqPud6khgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;15. 401(k) Savings Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to 100% of the first 4% of each employee&#x2019;s contribution. During the years ended December&#160;31,&#160;2023, December&#160;31,&#160;2022 and December&#160;31,&#160;2021 expenses recognized for the 401(k) Plan were $0.6&#160;million, $0.6&#160;million and $0.4&#160;million, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ"
      decimals="2"
      id="Narr_IxZE1dfzPEiPXPPlgJoS3Q"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_u0G4IMPCe0iINErkH9RTTQ"
      decimals="2"
      id="Narr_siwPTUcrj0GY_HOwR5KPyg"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-5"
      id="Narr_Rp4byV-Rz0iLvfvXRJ_s6Q"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-5"
      id="Narr_4S8oJzHLCkeNGxXbrJJ2MA"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-5"
      id="Narr_xWTcHeQCN0-GWF_Ir3BmIw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_WfoHXKo9v0-dGaisz0iO7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16. Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (81,580)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (64,915)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (75,665)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,422,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,743,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,945,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 835,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,697,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887,636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,526,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,072,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average Series A-2 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,742,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total number of shares used to calculate net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94,526,561&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,512,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,833,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.86)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.99)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.30)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#x2019;s common stock. The Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is independently convertible into&#160;one&#160;and&#160;1,000&#160;&lt;span style="-sec-ix-hidden:Hidden_Eut-pnlYxkmGfE27-Y1kbg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;shares&lt;/span&gt;&lt;/span&gt;&#160;of&#160;&lt;span style="-sec-ix-hidden:Hidden_x3Vvh87iFkeGHTZK_-BIJg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;common&lt;/span&gt;&lt;/span&gt;&#160;stock, respectively.&#160;2,399,517&#160;shares of the Company&#x2019;s common stock are issuable upon conversion of the Class&#160;A common stock,&#160;370,000&#160;shares of the Company&#x2019;s common stock are issuable upon conversion of Series&#160;A convertible preferred stock,&#160;10,800,000&#160;shares of the Company&#x2019;s common stock are issuable upon conversion of Series&#160;A-1 convertible preferred stock and&#160;15,268,000&#160;shares of the Company&#x2019;s common stock are issuable upon conversion of Series&#160;A-2 convertible preferred stock (see Note&#160;11).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods as the inclusion of all potential common shares (common stock and Class&#160;A common stock) outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,532,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,532,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_lUvaXsuvt0WL0bcjFU52sQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except for per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (81,580)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (64,915)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (75,665)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,422,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,743,080&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,945,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 835,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,697,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887,636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,526,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,072,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"&gt;Weighted-average Series A-2 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,742,499&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total number of shares used to calculate net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 94,526,561&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,512,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,833,590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.86)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.99)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.30)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt; Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock are participating securities that have substantially the same terms and features as the Company&#x2019;s common stock. The Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is therefore included in the weighted-average number of shares outstanding to calculate net loss per share, basic and diluted as if converted in common stock. Each share of Class&#160;A common stock, Series&#160;A, Series&#160;A-1 and Series&#160;A-2 convertible preferred stock is independently convertible into&#160;one&#160;and&#160;1,000&#160;&lt;span style="-sec-ix-hidden:Hidden_Eut-pnlYxkmGfE27-Y1kbg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;shares&lt;/span&gt;&lt;/span&gt;&#160;of&#160;&lt;span style="-sec-ix-hidden:Hidden_x3Vvh87iFkeGHTZK_-BIJg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;common&lt;/span&gt;&lt;/span&gt;&#160;stock, respectively.&#160;2,399,517&#160;shares of the Company&#x2019;s common stock are issuable upon conversion of the Class&#160;A common stock,&#160;370,000&#160;shares of the Company&#x2019;s common stock are issuable upon conversion of Series&#160;A convertible preferred stock,&#160;10,800,000&#160;shares of the Company&#x2019;s common stock are issuable upon conversion of Series&#160;A-1 convertible preferred stock and&#160;15,268,000&#160;shares of the Company&#x2019;s common stock are issuable upon conversion of Series&#160;A-2 convertible preferred stock (see Note&#160;11).&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="-3"
      id="Tc__HU7m5oggEWSEq8lXtX4jQ_4_3"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-81580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="-3"
      id="Tc_VMthAYQW702bEm_JfcoqjA_4_6"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-64915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="-3"
      id="Tc_wJIb35J0IkS81vQwCWZCdQ_4_9"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">-75665000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_vxWMxth910WYNpMnH4Je_A"
      decimals="0"
      id="Tc_Qs0Yt_YpE06Hdl0zYqFzaA_7_3"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">72422676</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_vxWMxth910WYNpMnH4Je_A"
      decimals="0"
      id="Tc_Qs0Yt_YpE06Hdl0zYqFzaA_7_3_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">72422676</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_Rai6liu0xUW1EmNBgzCqLA"
      decimals="0"
      id="Tc_BAceyx1YT02DfoSeJHJAfg_7_6"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">50743080</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_Rai6liu0xUW1EmNBgzCqLA"
      decimals="0"
      id="Tc_BAceyx1YT02DfoSeJHJAfg_7_6_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">50743080</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_7YwYjyiTDkSMl_b_qdxauw"
      decimals="0"
      id="Tc_J0HK3XBhqEStOpvU4b_pCw_7_9"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">29945954</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_7YwYjyiTDkSMl_b_qdxauw"
      decimals="0"
      id="Tc_J0HK3XBhqEStOpvU4b_pCw_7_9_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">29945954</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_l4B2TGYOiE-DNTqDxlQcPw"
      decimals="0"
      id="Tc_Wl_4pj2yHkiZVlHaht7c3Q_8_3"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">835359</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_l4B2TGYOiE-DNTqDxlQcPw"
      decimals="0"
      id="Tc_Wl_4pj2yHkiZVlHaht7c3Q_8_3_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">835359</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_K5J3_Ady2kSe1fEoyF_eEw"
      decimals="0"
      id="Tc_Ve5lwN7TqUGfp4DGg_Nm3w_8_6"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1697000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_K5J3_Ady2kSe1fEoyF_eEw"
      decimals="0"
      id="Tc_Ve5lwN7TqUGfp4DGg_Nm3w_8_6_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1697000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_UtzcBbT1wkeghno1rw2kMw"
      decimals="0"
      id="Tc_EpqLWF7UqUuUFnLScOGZWg_8_9"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2887636</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_UtzcBbT1wkeghno1rw2kMw"
      decimals="0"
      id="Tc_EpqLWF7UqUuUFnLScOGZWg_8_9_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2887636</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_1EokcRnMHkWHJTLR_xT8tw"
      decimals="0"
      id="Tc_JM9RYTUWlEy7hbK6u15nzg_9_3"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">12526027</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_1EokcRnMHkWHJTLR_xT8tw"
      decimals="0"
      id="Tc_JM9RYTUWlEy7hbK6u15nzg_9_3_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">12526027</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4T_o5zMCE0ug338F1VQDdA"
      decimals="0"
      id="Tc_lShhh5f3_U6ZjOJlXjABDA_9_6"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">13072877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_4T_o5zMCE0ug338F1VQDdA"
      decimals="0"
      id="Tc_lShhh5f3_U6ZjOJlXjABDA_9_6_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">13072877</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_WqKtPPVwDUSMTGed8PBTnQ"
      decimals="0"
      id="Tc_ZZFl1Xvy6ku2Bxm5TUbsjQ_10_3"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">8742499</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_WqKtPPVwDUSMTGed8PBTnQ"
      decimals="0"
      id="Tc_ZZFl1Xvy6ku2Bxm5TUbsjQ_10_3_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">8742499</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="0"
      id="Tc_5OqHzogmLkCT_F3pZbqg8w_11_3"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">94526561</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="0"
      id="Tc_5OqHzogmLkCT_F3pZbqg8w_11_3_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">94526561</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="0"
      id="Tc_HYnGOpiduEmXc6Wz3CMfmQ_11_6"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">65512957</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="0"
      id="Tc_HYnGOpiduEmXc6Wz3CMfmQ_11_6_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">65512957</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="0"
      id="Tc_2E216X3UbkeYKzBmq9_mmw_11_9"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">32833590</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="0"
      id="Tc_2E216X3UbkeYKzBmq9_mmw_11_9_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">32833590</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Tc_RooOUorOv0G4Q4w0pTVThQ_13_3"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="2"
      id="Tc_RooOUorOv0G4Q4w0pTVThQ_13_3_2"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="2"
      id="Tc_gEbOlV7CLEy1KEZ90YAUvg_13_6"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-0.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="2"
      id="Tc_gEbOlV7CLEy1KEZ90YAUvg_13_6_2"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="2"
      id="Tc_OfwAxRAWwkCdLrcwK31xIQ_13_9"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-2.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="2"
      id="Tc_OfwAxRAWwkCdLrcwK31xIQ_13_9_2"
      unitRef="Unit_Divide_USD_shares_JmfZN-eqrkWjzty2s-BUTA">-2.30</us-gaap:EarningsPerShareDiluted>
    <hook:ConversionOfCommonStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Narr_H6pKfjljHEeJgX0Je60F4A"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1</hook:ConversionOfCommonStockSharesIssuedUponConversion>
    <hook:ConversionOfCommonStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w"
      decimals="INF"
      id="Narr_5SGSNLg81keG5GdXNWq7ew"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">1000</hook:ConversionOfCommonStockSharesIssuedUponConversion>
    <hook:ConversionOfCommonStockSharesIssuable
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_gpww855MXkiq1gMvWDHgIQ"
      decimals="INF"
      id="Narr_lEglqGL3j0uzlMCPMnEmlg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">2399517</hook:ConversionOfCommonStockSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesaConvertiblePreferredStockMember_-q8ZKW8eyESMF3p5ly9o6w"
      decimals="INF"
      id="Narr_zufKI2aYp0iq5YbwMf3jFQ"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">370000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_BeNLD4vujEaNtOo2lXDXbA"
      decimals="INF"
      id="Narr_qG6RuOmxtUWBiSDq0pXPMg"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">10800000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_hook_SeriesA2ConvertiblePreferredStockMember_Xrfw7RKjl0-6-rPnCHjPZw"
      decimals="INF"
      id="Narr_uo-xkvFnYE2H5xZcVNhR7A"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">15268000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_PfPnM4te7kGl7XTD-QTX7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,532,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,111,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,532,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,231,178&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_4GN9LMP8E0i2s2spo0zrXg"
      decimals="INF"
      id="Tc_SpQpBUfhFU-PbBrY_XVHPw_3_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">8111575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Eytulubnr0ySr_VAROpxiQ"
      decimals="INF"
      id="Tc_ncZk4F3aRE-IZ4X-LKH-bQ_3_4"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">6532523</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_nivr3y_350aPACUslx3dMw"
      decimals="INF"
      id="Tc_47T4p1_qy0KCmkyTRlq_cA_3_6"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">4231178</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      decimals="INF"
      id="Tc_ZVKBbdlpaE6FnmtfCoRLpw_4_2"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">8111575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_37zfhIjTNUy374VcSilPCw"
      decimals="INF"
      id="Tc_xQ1kNosRy02Pmf4O_ksXPQ_4_4"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">6532523</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_KKJJA78LNEG2CfQB-zyNKQ"
      decimals="INF"
      id="Tc_Gj7hTNg9oUuTze11J3dEDw_4_6"
      unitRef="Unit_Standard_shares_kC-U8STZM0WnwhbribXzUA">4231178</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_jIRhUvHqJUKZq_i04iGo5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;17. Related parties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Effective September&#160;15,&#160;2023, Malte Peters, a member of the Company&#x2019;s board of directors, agreed to lead the Company&#x2019;s clinical activities ad interim as Senior Clinical Advisor. During the year ended December&#160;31,&#160;2023, the Company recorded expense of $0.1&#160;million related to a consulting agreement entered into with Dr.&#160;Peters, effective September&#160;15,&#160;2023. In the years ended December&#160;31,&#160;2022 and December&#160;31,&#160;2021, the Company did not record any related party transactions.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_hook_MaltePetersMember_us-gaap_RelatedPartyTransactionAxis_hook_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_PWdmVxfZlkStxnW1wmGGow"
      decimals="-5"
      id="Narr_UJlKWHsyvEOlRxfWXpKfFQ"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_EVj5iRzfXEWYSQvWiI7S-Q"
      id="Tb_e5O51WGvvEeGZqHtqjrxZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;18. Subsequent events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Roche Collaboration and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;25,&#160;2024, the Company received written notice of termination from Roche of the Roche Collaboration Agreement (see Note 3.). The termination was made according to Roche&#x2019;s right to terminate without cause, acknowledging that, to date, the Company had met all go-forward criteria under the agreement. The Company remains eligible for a final milestone payment of $10.0&#160;million associated with an IND submission for the HB-700 program. Upon the termination effective date April&#160;25,&#160;2024, the Company will regain full control of the associated intellectual property portfolio and have full collaboration and licensing rights for this program. At December&#160;31,&#160;2023, $26.8&#160;million of non-refundable upfront and milestone payments received from Roche were still recorded as deferred revenue and may be early recognized as revenue as a result of the termination in the first half of 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;January 2024 Restructuring Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;29,&#160;2024, the Company announced its decision to prioritize the clinical development of its HB-200 program for the treatment of HPV16+ head and neck cancers and its two Gilead-partnered infectious disease programs and to pause development activities related to HB-300 and most of its preclinical research activities. In connection with this strategic refocus, the Company&#x2019;s Board of Directors approved to reduce the Company&#x2019;s workforce by 55&#160;fulltime employees, or approximately 30% of the Company&#x2019;s then-current employee base and to rebalance the Company&#x2019;s cost structure in alignment with the new prioritization of research and development programs (together, the &#x201c;Restructuring Plan&#x201d;). The Company expects the Restructuring Plan to be implemented and substantially completed by the end of the first quarter of 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In connection with the Restructuring Plan, the Company estimates that it will incur cash charges of approximately $1.6&#160;million for severance and other personnel and restructuring related costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <hook:CollaborationAgreementFinalMilestonePayment
      contextRef="As_Of_1_25_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_c0SKflh3TEWHuSa8ZwnJiw"
      decimals="-5"
      id="Narr_kPm62SlCQUGb4sU9K3ipOw"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">10000000.0</hook:CollaborationAgreementFinalMilestonePayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_hook_RocheCollaborationAgreementMember_6BpZOY3D6EiLXCcraWW-Ww"
      decimals="-5"
      id="Narr_hxMA56zoRUiay5PFbkyb_w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">26800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A"
      decimals="INF"
      id="Narr_U9RPRhi3oE-RVr9yH_IkVQ"
      unitRef="Unit_Standard_employee_JIvkuNcm3UeH8NvB6ulLsQ">55</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A"
      decimals="2"
      id="Narr_A5ZaUvS460yRsis9IeuIHg"
      unitRef="Unit_Standard_pure_IehcKIlHPEy0ZnRv-FR1iA">0.30</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="Duration_1_29_2024_To_1_29_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_us-gaap_RestructuringPlanAxis_hook_January2024RestructuringPlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_EB-ZAy2wKEGQUAcr45-Z6A"
      decimals="-5"
      id="Narr_R0CEqe94q0KXgRqxytpf0w"
      unitRef="Unit_Standard_USD_RI9e3mYn30OVXSmtDyF4MQ">1600000</us-gaap:SeveranceCosts1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
